PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bonfoco, E; Li, E; Kolbinger, F; Cooper, NR				Bonfoco, E; Li, E; Kolbinger, F; Cooper, NR			Characterization of a novel proapoptotic caspase-2-and caspase-9-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; ACTIVATION; DEATH; GENE; PROCASPASE-9; RECRUITMENT; ENCODES; COMPLEX; FAMILY; MEMBER	Caspases play important roles in regulating apoptotic signaling pathways. Here we report the cloning, by the yeast two hybrid system with dominant negative caspase-2 as "bait," of a proapoptotic molecule named proapoptotic caspase adaptor protein (PACA-P), encoded by a 372-base pair open reading frame. Binding of this novel protein to caspase-2 (casp-2) was confirmed in yeast two hybrid, in vitro, and in vivo assays. The deduced amino acid sequence revealed homology to functional motifs, including ATP and cytochrome c binding sites. PACAP mRNA was widely expressed in most human tissues; in transfected cells, PACAP was diffusely expressed in the cytoplasm. Bindings studies with the PACAP recombinant protein demonstrated specific binding to casp-2 and casp-9 but not to casp-3, -4, -7, or -8 in cell extracts. Cotransfection experiments showed that PACAP binds to casp-2 and -9 in 293T cells. In addition, studies with truncated PACAP demonstrated a requirement for residues 39-72 of PACAP for specific binding to casp-2 and -9. Transient transfection of PACAP into 293T human kidney cells and rat-1 fibroblasts triggered apoptosis at 24 h, which was at least in part prevented by an inhibitor of casp-3-like enzymes. Transfection of PACAP into human B cell lines using a retroviral system also triggered apoptotic cell death. In addition, transcription of PACAP in primary human B cells was dramatically down-regulated early after cellular activation by CD40L and Staphylococcus aureus and markedly up-regulated as the cells apoptose. These findings identify a novel proapoptotic caspase adaptor protein.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Novartis Pharma AG, CH-4002 Basel, Switzerland	Scripps Research Institute; Novartis	Cooper, NR (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ebonfoco@scripps.edu	Li, Erguang/N-7676-2019; Li, Erguang/C-2782-2013	Li, Erguang/0000-0002-3065-1336; Li, Erguang/0000-0002-3065-1336				Ahmad M, 1997, CANCER RES, V57, P615; ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chen WP, 1999, J IMMUNOL, V163, P2483; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grignani F, 1998, CANCER RES, V58, P14; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Hlaing T, 2001, J BIOL CHEM, V276, P9230, DOI 10.1074/jbc.M009853200; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRISTIANSEN SV, 1994, J IMMUNOL, V153, P2974; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; MCGEOCH DJ, 1985, VIRUS RES, V3, P271, DOI 10.1016/0168-1702(85)90051-6; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rothstein TL, 1996, CURR OPIN IMMUNOL, V8, P362, DOI 10.1016/S0952-7915(96)80126-9; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Troy CM, 2000, J NEUROSCI, V20, P1386; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	39	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29242	29250		10.1074/jbc.M100684200	http://dx.doi.org/10.1074/jbc.M100684200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11350957	hybrid			2022-12-27	WOS:000170346000082
J	Moroni, A; Gorza, L; Beltrame, M; Gravante, B; Vaccari, T; Bianchi, ME; Altomare, C; Longhi, R; Heurteaux, C; Vitadello, M; Malgaroli, A; DiFrancesco, D				Moroni, A; Gorza, L; Beltrame, M; Gravante, B; Vaccari, T; Bianchi, ME; Altomare, C; Longhi, R; Heurteaux, C; Vitadello, M; Malgaroli, A; DiFrancesco, D			Hyperpolarization-activated cyclic nucleotide-gated channel 1 is a molecular determinant of the cardiac pacemaker current I-f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SINOATRIAL NODE; MESSENGER-RNA; CATION CHANNEL; INWARD CURRENT; CURRENT I(F); CELLS; HEART; MODULATION; EXPRESSION; HOMOLOGY	The pacemaker current If of the sinoatrial node (SAN) is a major determinant of cardiac diastolic depolarization and plays a key role in controlling heart rate and its modulation by neurotransmitters. Substantial expression of two different mRNAs (HCN4, HCN1) of the family of pacemaker channels (HCN) is found in rabbit SAN, suggesting that the native channels may be formed by different isoforms. Here we report the cloning and heterologous expression of HCN1 from rabbit SAN and its specific localization in pacemaker myocytes. rbHCN1 is an 822-amino acid protein that, in human embryonic kidney 293 cells, displayed electrophysiological properties similar to those of I-f suggesting that HCN1 can form a pacemaker channel. The presence of HCN1 in the SAN myocytes but not in nearby heart regions, and the electrophysiological properties of the channels formed by it, suggest that HCN1 plays a central and specific role in the formation of SAN pacemaker currents.	Univ Milan, Dipartimento Fisiol & Biochim Gen, Sez Fisiol Mol & Neurobiol, I-20133 Milan, Italy; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy; Univ Padua, Ctr Studio Biol & Fisiopatol Muscolare, CNR, I-35121 Padua, Italy; Univ Padua, Dipartimento Sci Biomed Sperimentali, I-35121 Padua, Italy; Ist Sci San Raffaele, HSR, DIBIT, Dipartimento Ric Sci & Tecnol, I-20123 Milan, Italy; CNR, Ist Biocatalisi & Riconoscimento Mol, I-20131 Milan, Italy; Univ Nice, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	University of Milan; University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); UDICE-French Research Universities; Universite Cote d'Azur	Moroni, A (corresponding author), Univ Milan, Dipartimento Fisiol & Biochim Gen, Sez Fisiol Mol & Neurobiol, Via Celoria 26, I-20133 Milan, Italy.	anna.moroni@unimi.it	HEURTEAUX, Catherine/M-4947-2016; Beltrame, Monica/D-8093-2017; Malgaroli, Antonio/I-5090-2013; Bianchi, Marco Emilio/K-3417-2018; DiFrancesco, Dario/G-8408-2017; Vaccari, Thomas/B-1945-2015; moroni, anna/H-2097-2014	HEURTEAUX, Catherine/0000-0002-9741-9777; Malgaroli, Antonio/0000-0003-3758-7477; Bianchi, Marco Emilio/0000-0002-5329-6445; DiFrancesco, Dario/0000-0002-7322-1790; Vaccari, Thomas/0000-0002-6231-7105; moroni, anna/0000-0002-1860-406X; GORZA, LUISA/0000-0003-4897-400X; Beltrame, Monica/0000-0001-5094-3494; Altomare, Claudia/0000-0001-8743-9080	Telethon [971] Funding Source: Medline	Telethon(Fondazione Telethon)		Accili EA, 1996, PFLUG ARCH EUR J PHY, V431, P757; Baker K, 1997, P NATL ACAD SCI USA, V94, P4554, DOI 10.1073/pnas.94.9.4554; Baruscotti M, 1997, J PHYSIOL-LONDON, V498, P641, DOI 10.1113/jphysiol.1997.sp021889; Bois P, 1997, J PHYSIOL-LONDON, V501, P565, DOI 10.1111/j.1469-7793.1997.565bm.x; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; DAMIANI RD, 1993, P NATL ACAD SCI USA, V90, P8244, DOI 10.1073/pnas.90.17.8244; DENYER JC, 1990, J PHYSIOL-LONDON, V428, P405, DOI 10.1113/jphysiol.1990.sp018219; DIFRANCESCO D, 1986, J PHYSIOL-LONDON, V377, P61, DOI 10.1113/jphysiol.1986.sp016177; DIFRANCESCO D, 1988, J PHYSIOL-LONDON, V405, P493, DOI 10.1113/jphysiol.1988.sp017344; DIFRANCESCO D, 1986, NATURE, V324, P470, DOI 10.1038/324470a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P377, DOI 10.1113/jphysiol.1981.sp013714; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DiFrancesco D., 1989, NEURONAL CELLULAR OS, P31; EARM YE, 1983, J PHYSIOL-LONDON, V342, P569, DOI 10.1113/jphysiol.1983.sp014869; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; GORZA L, 1989, CIRC RES, V65, P360, DOI 10.1161/01.RES.65.2.360; HAGIWARA N, 1989, J PHYSIOL-LONDON, V409, P121, DOI 10.1113/jphysiol.1989.sp017488; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Luthi A, 1998, NEURON, V21, P9, DOI 10.1016/S0896-6273(00)80509-7; MASSONPEVET M, 1979, J MOL CELL CARDIOL, V11, P555, DOI 10.1016/0022-2828(79)90430-9; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Moroni A, 2000, PFLUG ARCH EUR J PHY, V439, P618, DOI 10.1007/s004240050985; Moroni A, 1999, BIOPHYS J, V76, pA210; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Shi WM, 1999, CIRC RES, V85, pE1; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; Vaccari T, 1999, BBA-GENE STRUCT EXPR, V1446, P419, DOI 10.1016/S0167-4781(99)00092-5; VANGINNEKEN ACG, 1991, J PHYSIOL-LONDON, V434, P57, DOI 10.1113/jphysiol.1991.sp018459; Verheijck EE, 1998, CIRCULATION, V97, P1623, DOI 10.1161/01.CIR.97.16.1623; Vitadello M, 1996, J MOL CELL CARDIOL, V28, P1833, DOI 10.1006/jmcc.1996.0176; YU HG, 1995, J PHYSIOL-LONDON, V485, P469, DOI 10.1113/jphysiol.1995.sp020743; Zaza A, 1996, J PHYSIOL-LONDON, V491, P347, DOI 10.1113/jphysiol.1996.sp021220	45	77	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29233	29241		10.1074/jbc.M100830200	http://dx.doi.org/10.1074/jbc.M100830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11328811	hybrid, Green Published			2022-12-27	WOS:000170346000081
J	Chang, CS; Mooser, A; Pluckthun, A; Wlodawer, A				Chang, CS; Mooser, A; Pluckthun, A; Wlodawer, A			Crystal structure of the dimeric C-terminal domain of TonB reveals a novel fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TONB; OUTER-MEMBRANE; ENERGY TRANSDUCTION; CYTOPLASMIC MEMBRANE; LIGAND-BINDING; BTUB AFFECT; IN-VIVO; PROTEIN; TRANSPORT; RECEPTOR	The TonB-dependent complex of Gram-negative bacteria couples the inner membrane proton motive force to the active transport of iron siderophore and vitamin B-12 across the outer membrane. The structural basis of that process has not been described so far in full detail. The crystal structure of the C-terminal domain of TonB from Escherichia coli has now been solved by multi-wavelength anomalous diffraction and refined at 1.55-Angstrom resolution, providing the first evidence that this region of TonB (residues 164-239) dimerizes. Moreover, the structure shows a novel architecture that has no structural homologs among any known proteins. The dimer of the C-terminal domain of TonB is cylinder-shaped with a length of 65 Angstrom and a diameter of 25 Angstrom. Each monomer contains three beta strands and a single alpha helix. The two monomers are intertwined with each other, and all six beta -strands of the dimer make a large antiparallel beta -sheet. We propose a plausible model of binding of TonB to FhuA and FepA, two TonB-dependent outer-membrane receptors.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; NCI, Mol Crystallog Lab, NIH, Frederick, MD 21702 USA	University of Zurich; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pluckthun, A (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@biocfebs.unizh.ch	Plückthun, Andreas/C-2746-2009; Chang, Changsoo/X-3271-2018	Plückthun, Andreas/0000-0003-4191-5306; Chang, Changsoo/0000-0003-1860-2969				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; Braun M, 1999, MOL MICROBIOL, V33, P1037, DOI 10.1046/j.1365-2958.1999.01546.x; Braun V, 1998, MET IONS BIOL SYST, V35, P67; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; Buchanan SK, 2001, TRENDS BIOCHEM SCI, V26, P3, DOI 10.1016/S0968-0004(00)01733-3; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Cadieux N, 1999, P NATL ACAD SCI USA, V96, P10673, DOI 10.1073/pnas.96.19.10673; Cadieux N, 2000, J BACTERIOL, V182, P5954, DOI 10.1128/JB.182.21.5954-5961.2000; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Dauter Z, 2001, ACTA CRYSTALLOGR D, V57, P239, DOI 10.1107/S0907444900015249; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; EICKHELMERICH K, 1989, J BACTERIOL, V171, P5117, DOI 10.1128/jb.171.9.5117-5126.1989; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Forrer P, 1998, GENE, V224, P45, DOI 10.1016/S0378-1119(98)00538-1; Groeger W, 1998, MICROBIOL-SGM, V144, P2759, DOI 10.1099/00221287-144-10-2759; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; HANCOCK REW, 1976, J BACTERIOL, V125, P409, DOI 10.1128/JB.125.2.409-415.1976; Higgs PI, 1998, J BACTERIOL, V180, P6031, DOI 10.1128/JB.180.22.6031-6038.1998; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jiang XQ, 1997, SCIENCE, V276, P1261, DOI 10.1126/science.276.5316.1261; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KARLSSON M, 1993, MOL MICROBIOL, V8, P379, DOI 10.1111/j.1365-2958.1993.tb01581.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARSEN RA, 1994, MOL MICROBIOL, V13, P627, DOI 10.1111/j.1365-2958.1994.tb00457.x; LARSEN RA, 1993, MOL MICROBIOL, V10, P943, DOI 10.1111/j.1365-2958.1993.tb00966.x; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1996, J BACTERIOL, V178, P1363, DOI 10.1128/jb.178.5.1363-1373.1996; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Larsen RA, 2001, J BIOL CHEM, V276, P8111, DOI 10.1074/jbc.M007479200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Lubkowski J, 1999, STRUCTURE, V7, P711, DOI 10.1016/S0969-2126(99)80092-6; Merianos HJ, 2000, NAT STRUCT BIOL, V7, P205; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 2001, J BACTERIOL, V183, P2755, DOI 10.1128/JB.183.9.2755-2764.2001; Newton SMC, 1997, P NATL ACAD SCI USA, V94, P4560, DOI 10.1073/pnas.94.9.4560; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; POSTLE K, 1988, J BIOL CHEM, V263, P11000; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; Schirmer T, 1998, J STRUCT BIOL, V121, P101, DOI 10.1006/jsbi.1997.3946; SCHRAMM E, 1987, J BACTERIOL, V169, P3350, DOI 10.1128/jb.169.7.3350-3357.1987; Scott DC, 2001, J BIOL CHEM, V276, P13025, DOI 10.1074/jbc.M011282200; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; SKARE JT, 1993, J BIOL CHEM, V268, P16302; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; WOOLDRIDGE KG, 1992, J GEN MICROBIOL, V138, P597, DOI 10.1099/00221287-138-3-597	60	102	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27535	27540		10.1074/jbc.M102778200	http://dx.doi.org/10.1074/jbc.M102778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328822	hybrid			2022-12-27	WOS:000169966900105
J	Tosaka, A; Ogawa, M; Yoshida, S; Suzuki, M				Tosaka, A; Ogawa, M; Yoshida, S; Suzuki, M			O-helix mutant T664P of Thermus aquaticus DNA polymerase I - Altered catalytic properties for incorporation of incorrect nucleotides but not correct nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FIDELITY; CRYSTAL-STRUCTURES; KLENOW FRAGMENT; ALPHA-HELICES; EXTENSION	Previous studies:indicate that the O-helix of Thermus aquaticus (Taq) DNA polymerase I (pol I) plays an important role in the replication fidelity of the enzyme. This study examines the role of Thr-664, which lies in the middle of the O-helix of Tag pol I. A mutant of Tag Pol I with a proline substitution of Thr-664 (T664P) exhibits much lower replication fidelity than the wildtype enzyme in a forward mutation assay. T664P produces base substitution, single-base deletion, and single-base insertion errors at 20-, 5, and 50-fold higher rates than mild type, respectively. In specific activity and steady-state kinetic experiments, T664P was catalytically robust for insertion of correct nucleotides. In contrast, it incorporated incorrect nucleotides 6.1- to 10-fold more efficiently than wild type at a template dC. Mismatched primer termini were extended by T664P 4.2- to 9.5 fold more efficiently than wild type. These data imply that the O-helix with a proline at position 664 functions like wild type Tag pol I for correct nucleotide incorporations, but bends and enlarges the catalytic pocket of the enzyme and increases the rate of nucleotide misincorporation.	Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Sch Med, Nagoya, Aichi 4668550, Japan	Nagoya University	Suzuki, M (corresponding author), Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Sch Med, Nagoya, Aichi 4668550, Japan.	msuzuki@tsuru.med.nagoya-u.ac.jp	Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006				Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRANDEN C, 1998, INTRO PROTEIN STRUCT, P16; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; HUANG MM, 1992, NUCLEIC ACIDS RES, V20, P4567, DOI 10.1093/nar/20.17.4567; Kim MK, 1999, PROTEIN SCI, V8, P1492, DOI 10.1110/ps.8.7.1492; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, PROTEIN SCI, V7, P1116, DOI 10.1002/pro.5560070505; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; YOSHIDA S, 1974, BIOCHIM BIOPHYS ACTA, V353, P463, DOI 10.1016/0005-2787(74)90052-5	22	20	23	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27562	27567		10.1074/jbc.M010635200	http://dx.doi.org/10.1074/jbc.M010635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346641	hybrid			2022-12-27	WOS:000169966900109
J	Faulkner, NE; Hilfinger, JM; Markovitz, DM				Faulkner, NE; Hilfinger, JM; Markovitz, DM			Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NF-KAPPA-B; DEK ONCOPROTEIN; OKADAIC ACID; DIFFERENTIAL REGULATION; SP1 PHOSPHORYLATION; TRANSLOCATION 6-9; EXPRESSION; ANTIGEN	Human immunodeficiency virus type 2 (HIV-2) gene expression is regulated by upstream promoter elements, including the peri-Ets (pets) site, which mediate enhancer stimulation following treatment with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), We previously showed that the oncoprotein DEK binds to the pets site in a site-specific manner. In this report, we show that binding to the HIV-2 pets site is modulated by treatment of U937 monocytic cells with TPA, an activator of protein kinase C, TPA treatment resulted in a reduction in the levels of DEK and the formation of a faster migrating pets complex in gel shift assays. We show further that the actions of TPA on pets binding can be duplicated by phosphatase treatment of nuclear proteins and is blocked with okadaic acid, a protein phospatase-2A (PP2A) inhibitor. Finally, we demonstrate that ectopic expression of the catalytic domain of PP2A can activate the HIV-2 enhancer/promoter alone or in synergy with TPA, an effect mediated in part through the pets site. These results suggest that, through an interaction with the protein kinase C pathway, PP2A is strongly involved in regulating HIV-2 enhancer-mediated transcription. This is a consequence of its effects on DEK expression and binding to the pets site, as well as its effects on other promoter elements. These findings have implications not only for HIV-2 transcription but also for multiple cellular processes involving DEK or PP2A.	Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Therapeut Syst Res Labs, Ann Arbor, MI 48108 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markovitz, DM (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, 5220 MSRB3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dmarkov@umich.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036685] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36685] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnaudo JP, 1998, J RHEUMATOL, V25, P1861; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; CLARK NM, 1995, J VIROL, V69, P4854, DOI 10.1128/JVI.69.8.4854-4862.1995; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong XW, 1998, ARTHRITIS RHEUM-US, V41, P1505, DOI 10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N; Dong XW, 2000, ARTHRITIS RHEUM-US, V43, P85, DOI 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Fu GK, 1996, J BIOL CHEM, V271, P19599, DOI 10.1074/jbc.271.32.19599; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HANNIBAL MC, 1994, BLOOD, V83, P1839; HILFINGER JM, 1993, J VIROL, V67, P4448, DOI 10.1128/JVI.67.7.4448-4453.1993; KILEY SC, 1995, J CELL SCI, V108, P1003; LI M, 1994, BIOCHEM BIOPH RES CO, V202, P1023, DOI 10.1006/bbrc.1994.2031; MARKOVITZ DM, 1993, ANN INTERN MED, V118, P211, DOI 10.7326/0003-4819-118-3-199302010-00010; MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MEYN MS, 1993, AM J HUM GENET, V53, P1206; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Murray KJ, 1997, J RHEUMATOL, V24, P560; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; Oshevski S, 1999, BIOCHEM BIOPH RES CO, V263, P603, DOI 10.1006/bbrc.1999.1425; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Popper SJ, 1999, J INFECT DIS, V180, P1116, DOI 10.1086/315010; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; RIECKMANN P, 1992, BIOCHEM BIOPH RES CO, V187, P51, DOI 10.1016/S0006-291X(05)81457-3; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; SEIBENHENER ML, 1993, EXP CELL RES, V207, P183, DOI 10.1006/excr.1993.1178; Slosberg ED, 2000, MOL CARCINOGEN, V27, P166, DOI 10.1002/(SICI)1098-2744(200003)27:3<166::AID-MC3>3.0.CO;2-Z; SOEKARMAN D, 1992, BLOOD, V79, P2990; THEVENIN C, 1990, New Biologist, V2, P793; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wichmann I, 1999, HUM IMMUNOL, V60, P57, DOI 10.1016/S0198-8859(98)00085-8; Wichmann I, 2000, CLIN EXP IMMUNOL, V119, P530, DOI 10.1046/j.1365-2249.2000.01154.x; Wooten Marie W., 1993, Cytobios, V76, P19; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	46	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25804	25812		10.1074/jbc.M006454200	http://dx.doi.org/10.1074/jbc.M006454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11320078	hybrid			2022-12-27	WOS:000169823300024
J	Foschi, M; Franchi, F; Han, JH; La Villa, G; Sorokin, A				Foschi, M; Franchi, F; Han, JH; La Villa, G; Sorokin, A			Endothelin-1 induces serine phosphorylation of the adaptor protein p66(Shc) and its association with 14-3-3 protein in glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; KINASE; SHC; SIGNAL; PATHWAY; RECOGNITION; ACTIVATION; EXPRESSION; APOPTOSIS; P21(RAS)	Endothelin-1 (ET-1) is a vasoconstrictor peptide known to be a potent mitogen for glomerular mesangial cells (GMC). In the current study, it is demonstrated that ET-1 treatment of GMC results in serine phosphorylation of the 66-kDa isoform of the adapter protein She (p66(Shc)). ET-l-induced serine phosphorylation of p66(Shc) requires activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling module and is efficiently inhibited by both a MAPK/ERK kinase (MEK)-selective inhibitor and adenovirus-mediated transfer of a dominant interfering MEK1 mutant. Furthermore, adenovirus-mediated transfer of a constitutively active MEK1 mutant was found to markedly increase p66(Shc) serine phosphorylation. Adenoviruses encoding constitutively active mutants of MAPK kinases 3 and 6 (upstream kinases of p38(MAPK)) and 7 (upstream kinase of c-Jun NH2-terminal kinase) failed to induce serine phosphorylation of this adaptor protein. Serine phosphorylation of p66(Sh)c resulted in its association with the serine binding motif-containing protein 14-3-3. ET-l-induced phosphorylation of a serine encompassed in the 14-3-3 binding motif of p66(Shc) Was confirmed in experiments employing anti-phospho-14-3-3 binding motif antibodies. These studies are the first to demonstrate that G protein-coupled receptors stimulate serine phosphorylation of p66(Shc) and the first to report the formation of a signaling complex between p66(Shc) and 14-3-3.	Univ Florence, Dept Internal Med, I-50141 Florence, Italy; Scripps Res Inst, La Jolla, CA 92037 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	University of Florence; Scripps Research Institute; Medical College of Wisconsin; Medical College of Wisconsin	Foschi, M (corresponding author), Univ Florence, Dept Internal Med, V Le Morgagni 85, I-50141 Florence, Italy.	m.foschi@dfc.unifi.it; sorokin@mcw.edu	Han, J/G-4671-2010	Sorokin, Andrey/0000-0002-5660-0190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki S, 1997, KIDNEY INT, V51, P631, DOI 10.1038/ki.1997.92; Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; COBB MH, 1995, PROTEIN KINASE FACTS, P214; Decker ER, 1998, CONT BIOMED, P93; Denhardt DT, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P225; Dudley DT, 2000, CANC DRUG DISC DEV, V5, P467; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; ERIKSON RL, 1995, PROTEIN KINASE FACTS, P275; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Force T, 1998, CONT BIOMED, P121; Foschi M, 2001, J AM SOC NEPHROL, V12, P1137, DOI 10.1681/ASN.V1261137; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HABIB T, 1994, J BIOL CHEM, V269, P25243; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; Kelly K, 2000, CANC DRUG DISC DEV, V5, P165; Lee CH, 1998, METH MOL B, V84, P3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; McGinty A, 2000, BIOCHEM J, V352, P419, DOI 10.1042/0264-6021:3520419; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Muda M, 1996, J BIOL CHEM, V271, P4319; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nissenson AR, 1998, KIDNEY INT, V53, pS7; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SCHRAMEK H, 1997, ENDOTHELINS BIOL MED, P81; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; Skulachev VP, 2000, IUBMB LIFE, V49, P177; Sraer JD, 1996, KIDNEY INT, V49, P267, DOI 10.1038/ki.1996.38; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Young PR, 2000, CANC DRUG DISC DEV, V5, P483	52	41	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26640	26647		10.1074/jbc.M102008200	http://dx.doi.org/10.1074/jbc.M102008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342545	hybrid			2022-12-27	WOS:000169823300129
J	Hamilton, MH; Tcherepanova, I; Huibregtse, JM; McDonnell, DP				Hamilton, MH; Tcherepanova, I; Huibregtse, JM; McDonnell, DP			Nuclear import/export of hRPF1/Nedd4 regulates the ubiquitin-dependent degradation of its nuclear substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; EPITHELIAL NA+ CHANNEL; PROTEIN LIGASE NEDD4; WW DOMAINS; LARGE SUBUNIT; SUBCELLULAR-LOCALIZATION; COVALENT MODIFICATION; PROTEASOME PATHWAY; LIDDLES-SYNDROME; EXPORT SIGNALS	The ubiquitin-protein ligase (E3), hRPF1/Nedd4, is a component of the ubiquitin-proteasome pathway responsible for substrate recognition and specificity, Although previously characterized as a regulator of the stability of cytoplasmic proteins, hRPF1/Nedd4 has also been suggested to have a role in the nucleus. However, in light of the cytoplasmic localization of hRPF1/Nedd4, it is unclear whether bona fide nuclear substrates of hRPF1/Nedd4 exist, and if so, what mechanism may allow a cytoplasmic ubiquitin ligase to manifest nuclear activity. Our search for nuclear substrates led to the identification of the human proline-rich transcript, brain-expressed (hPRTB) protein, the ubiquitination and degradation of which is regulated by hRPF1/Nedd4. interestingly; hPRTB colocalizes with the splicing factor SC35 in nuclear speckles. Finally, we demonstrate that hRPF1/Nedd4 is indeed capable of entering the nucleus; however, the presence of a functional Rev-like nuclear export sequence in hRPF1/Nedd4 ensures a predominant cytoplasmic localization, Cumulatively, these findings highlight a nuclear role for the ubiquitin ligase hRPF1/Nedd4 and underscore cytoplasmic/nuclear localization as an important regulatory component of hRPF1/Nedd4-substrate recognition.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	Duke University; University of Texas System; University of Texas Austin	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813, Durham, NC 27710 USA.				NIDDK NIH HHS [DK50494] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050494] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FUKADA M, 1997, NATURE, V390, P308; Gavva NR, 1997, J BIOL CHEM, V272, P24105, DOI 10.1074/jbc.272.39.24105; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yang W, 1999, DEV DYNAM, V215, P108, DOI 10.1002/(SICI)1097-0177(199906)215:2<108::AID-DVDY3>3.3.CO;2-9; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	43	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26324	26331		10.1074/jbc.M101205200	http://dx.doi.org/10.1074/jbc.M101205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342538	hybrid			2022-12-27	WOS:000169823300091
J	Mooney, RA; Senn, J; Cameron, S; Inamdar, N; Boivin, LM; Shang, Y; Furlanetto, RW				Mooney, RA; Senn, J; Cameron, S; Inamdar, N; Boivin, LM; Shang, Y; Furlanetto, RW			Suppressors of cytokine signaling-1 and-6 associate with and inhibit the insulin receptor - A potential mechanism for cytokine-mediated insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED STAT INHIBITOR; TUMOR-NECROSIS-FACTOR; FACTOR-I RECEPTOR; SOCS-BOX MOTIF; MOLECULAR MECHANISMS; PROTEIN; FAMILY; GENE; TRANSCRIPTION; PROLIFERATION	Insulin resistance contributes to a number of metabolic disorders, including type II diabetes, hypertension, and atherosclerosis. Cytokines, such as tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6, and hormones, such as growth hormone, are known to cause insulin resistance, but the mechanisms by which they inhibit the cellular response to insulin have not been elucidated. One mechanism by which these agents could cause insulin resistance is by inducing the expression of cellular proteins that inhibit insulin receptor (IR) signaling. Suppressors of cytokine signaling (SOCS) proteins are negative regulators of cytokine signaling pathways, the expression of which is regulated by certain cytokines, SOCS proteins are therefore attractive candidates as mediators of cytokine-induced insulin resistance. We have found that SOCS-1 and SOCS-6 interact with the IR when expressed in human hepatoma cells (HepG2) or in rat hepatoma cells overexpressing the human IR In SOCS-1-expressing cells, insulin treatment increases the extent of interaction with the IR, whereas in SOCS-6-expressing cells the association with the IR appears to require insulin treatment. SOCS-1 and SOCS-6 do not inhibit insulin-dependent IR autophosphorylation, but both proteins inhibit insulin-dependent activation of ERK1/2 and protein kinase B in vivo and IR-directed phosphorylation of IRS-1 in vitro. These results suggest that SOCS proteins may be inhibitors of IR signaling and could mediate cytokine-induced insulin resistance and contribute to the pathogenesis of type II diabetes.	Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Grad Program Cell Regulat & Mol Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Grad Program Biol & Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Furlanetto, RW (corresponding author), Univ Rochester, Sch Med, Dept Pediat, Box 777,601 Elmwood Ave, Rochester, NY 14642 USA.	richard_furlanetto@URMC.rochester.edu						Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boisclair YR, 2000, J BIOL CHEM, V275, P3841, DOI 10.1074/jbc.275.6.3841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Colson A, 2000, ENDOCRINOLOGY, V141, P3687, DOI 10.1210/en.141.10.3687; De Sepulveda P, 1999, EMBO J, V18, P904; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GOLEMIS EA, 1995, CURRENT PROTOCOLS MO, V2; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Krebs DL, 2000, J CELL SCI, V113, P2813; Kruszynska YT, 1996, J INVEST MED, V44, P413; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING PR, 1994, METABOLISM, V43, P279, DOI 10.1016/0026-0495(94)90093-0; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Minamoto S, 1997, BIOCHEM BIOPH RES CO, V237, P79, DOI 10.1006/bbrc.1997.7080; Mora-Garcia P, 1998, BLOOD, V92, p193A; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	39	200	212	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25889	25893		10.1074/jbc.M010579200	http://dx.doi.org/10.1074/jbc.M010579200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342531	hybrid			2022-12-27	WOS:000169823300035
J	Schotte, P; Van Loo, G; Carpentier, I; Vandenabeele, P; Beyaert, R				Schotte, P; Van Loo, G; Carpentier, I; Vandenabeele, P; Beyaert, R			Lithium sensitizes tumor cells in an NF-kappa B-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF) - Evidence for a role of the TNF receptor-associated death domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CYTOCHROME-C; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; INHIBITION; PATHWAYS; COMPLEX; COMBINATION; EXPRESSION; INDUCTION	We have previously shown that lithium salts can considerably increase the direct cytotoxic effect of tumor necrosis factor (TNF) on various tumor cells in vitro and in vivo. However, the underlying mechanism has remained largely unknown. Here we show that the TNF-sensitizing effect of lithium chloride (LiCl) is independent of the type of cell death, either necrosis or apoptosis. In the case of apoptosis, TNF-lithium synergism is associated with an enhanced activation of caspases and mitochondrial cytochrome c release. Sensitization to apoptosis is specific for TNF-induced apoptosis, whereas Fas-mediated or etoposide-induced apoptosis remains unaffected. LiCl also potentiates cell death induced by artificial oligomerization of a fusion protein between FKBP and the TNF receptor-associated death domain protein. TNF-induced activation of NF-KB-dependent gene expression is not modulated by LiCl treatment. These results indicate that LiCl enhances TNF-induced cell death in an NF-KB-independent way, and suggest that the TNF receptor-associated death domain protein plays a crucial role in the TNF-sensitizing effect of LiCl.	Flanders Interuniv Inst Biotechnol, Unit Mol Signal Transduct Inflammat, Dept Mol Biol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Unit Mol Signal Transduct Inflammat, Dept Mol Biol, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		van Loo, Geert/C-1505-2009; Vandenabeele, Peter/C-8597-2009; Beyaert, Rudi/B-2589-2009; Vandenabeele, Peter/AAD-5793-2022; , van Loo Geert/AAD-1220-2019	Vandenabeele, Peter/0000-0002-6669-8822; , van Loo Geert/0000-0002-8427-4775; Beyaert, Rudi/0000-0002-5704-582X				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BALKWILL FR, 1986, CANCER RES, V46, P3990; BEYAERT R, 1991, CYTOKINE, V3, P284, DOI 10.1016/1043-4666(91)90496-Z; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BEYAERT R, 1989, P NATL ACAD SCI USA, V86, P9494, DOI 10.1073/pnas.86.23.9494; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chcialowski A, 1997, Pol Merkur Lekarski, V2, P392; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENECKER G, 2001, IN PRESS CELL DEATH, V8; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KETTELHUT IC, 1987, P NATL ACAD SCI USA, V84, P4273, DOI 10.1073/pnas.84.12.4273; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; RUFF MR, 1981, INFECT IMMUN, V31, P380, DOI 10.1128/IAI.31.1.380-385.1981; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Spencer DM, 1996, CURR BIOL, V6, P839, DOI 10.1016/S0960-9822(02)00607-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tondo L, 2000, J CLIN PSYCHIAT, V61, P97; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VANHOENACKER P, 1999, GENE THER MOL BIOL, V3, P301; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	48	37	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25939	25945		10.1074/jbc.M104014200	http://dx.doi.org/10.1074/jbc.M104014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342564	hybrid			2022-12-27	WOS:000169823300041
J	Cohen, CJ; Graetz, J; Ohman, T; Bergelson, JM				Cohen, CJ; Graetz, J; Ohman, T; Bergelson, JM			Multiple regions within the coxsackievirus and adenovirus receptor cytoplasmic domain are required for basolateral sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STRUCTURAL REQUIREMENTS; APICAL SURFACE; FC-RECEPTORS; B VIRUSES; LOCALIZATION; PROTEIN; MOTIFS; ENDOCYTOSIS; EXPRESSION	The coxsackievirus and adenovirus receptor (CAR) mediates attachment and infection by coxsackie B viruses and many adenoviruses. In human airway epithelia, as well as in transfected Madin-Darby canine kidney cells, CAR is expressed exclusively on the basolateral surface. Variants of CAR that lack the cytoplasmic domain or are attached to the cell membrane by a glycosylphosphatidylinositol anchor are expressed on both the apical and basolateral surfaces, We have examined the localization of CAR variants with progressive truncations of the cytoplasmic domain, as well as with mutations that ablate a potential PDZ (PSD95/dlg/ZO-1) interaction motif and a putative tyrosine-based sorting signal. In addition, we have examined the targeting of two murine CAR isoforms, with different C-terminal sequences. The results suggest that multiple regions within the CAR cytoplasmic domain contain information that is necessary for basolateral targeting.	Childrens Hosp Philadelphia, Div Immunol & Infect Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Cohen, CJ (corresponding author), Childrens Hosp Philadelphia, Div Immunol & Infect Dis, Abramson 1202,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Cohenc@email.chop.edu		Gaetz, Jedidiah/0000-0002-7103-6241	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54734] Funding Source: Medline; NIAID NIH HHS [T32 AI07278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Boucher RC, 1999, J CLIN INVEST, V103, P441, DOI 10.1172/JCI6330; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Keller P, 1997, J CELL SCI, V110, P3001; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Pickles RJ, 2000, J VIROL, V74, P6050, DOI 10.1128/JVI.74.13.6050-6057.2000; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Walters RW, 1999, J BIOL CHEM, V274, P10219, DOI 10.1074/jbc.274.15.10219; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	33	55	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25392	25398		10.1074/jbc.M009531200	http://dx.doi.org/10.1074/jbc.M009531200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316797	hybrid			2022-12-27	WOS:000169800700128
J	Luo, Y; Liang, CP; Tall, AR				Luo, Y; Liang, CP; Tall, AR			The orphan nuclear receptor LRH-1 potentiates the sterol-mediated induction of the human CETP gene by liver X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER TRANSFER PROTEIN; MESSENGER-RNA LEVELS; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; DENSITY-LIPOPROTEIN RECEPTOR; BILE-ACID; LXR-ALPHA; DIETARY-CHOLESTEROL; TANGIER-DISEASE; TRANSGENIC MICE; PLASMA-MEMBRANE	The human cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from high density lipoproteins to triglyceride-rich lipoproteins, indirectly facilitating cholesteryl esters uptake by the liver. Hepatic CETP gene expression is increased in response to dietary hypercholesterolemia, an effect that is mediated by the activity of liver X receptor/retinoid X receptor (LXR/RXR) on a direct repeat 4 element in the CETP promoter. In this study we show that the orphan nuclear receptor LRH-1 also transactivates the CETP promoter by binding to a proximal promoter element distinct from the DR4 site. LRH-1 potentiates the sterol-dependent regulation of the wild type CETP promoter by LXR/RXR. Small heterodimer partner, a repressor of LRH-1, abolishes the potentiation effect of LRH-1 but not its basal transactivation of the CETP promoter. Since this mode of regulation of CETP is very similar to that recently reported for the bile salt-mediated repression of Cyp7a (encoding the rate-limiting enzyme for conversion of cholesterol into bile acid in the liver), we examined the effects of bile salt feeding on CETP mRNA expression in human CETP transgenic mice. Hepatic CETP mRNA expression was repressed by a diet containing 1% cholic acid in male mice but was induced by the same diet in female mice. Microarray analysis of hepatic mRNA showed that about 1.5% of genes were repressed, and 2.5% were induced by the bile acid diet. However, the sexually dimorphic regulatory pattern of the CETP gene was an unusual response. Our data provide further evidence for the regulation of CETP and Cyp7a genes by similar molecular mechanisms, consistent with coordinate transcriptional regulation of sequential steps of reverse cholesterol transport. However, differential effects of the bile salt diet indicate additional complexity in the response of these two genes.	Columbia Univ, Coll Phys & Surg, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Luo, Y (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Med, Div Mol Med, 8-401, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021					Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Chouinard RA, 1998, J BIOL CHEM, V273, P22409, DOI 10.1074/jbc.273.35.22409; Costet P, 2000, J BIOL CHEM, V275, P28240; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Feingold KR, 1996, J LIPID RES, V37, P223; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hardardottir I, 1996, J CLIN INVEST, V97, P2585, DOI 10.1172/JCI118707; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MasucciMagoulas L, 1996, J CLIN INVEST, V97, P154, DOI 10.1172/JCI118384; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; NELSON JA, 1981, J BIOL CHEM, V256, P1067; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Oliveira HCF, 1996, J BIOL CHEM, V271, P31831, DOI 10.1074/jbc.271.50.31831; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Parker KL, 1999, ANNU REV PHYSIOL, V61, P417, DOI 10.1146/annurev.physiol.61.1.417; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wiebel FF, 1999, MOL ENDOCRINOL, V13, P1105, DOI 10.1210/me.13.7.1105	46	121	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24767	24773		10.1074/jbc.M100912200	http://dx.doi.org/10.1074/jbc.M100912200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331284	hybrid			2022-12-27	WOS:000169800700048
J	Tom, S; Henricksen, LA; Park, MS; Bambara, RA				Tom, S; Henricksen, LA; Park, MS; Bambara, RA			DNA ligase I and proliferating cell nuclear antigen form a functional complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; REPLICATION-FACTOR-C; PURIFIED HUMAN PROTEINS; DOUBLE-STRANDED DNA; ENDONUCLEASE ACTIVITY; FLAP ENDONUCLEASE-1; POLYMERASES DELTA; MAMMALIAN-CELLS; PCNA; BINDING	DNA ligase I is responsible for joining Okazaki fragments during DNA replication. An additional proposed role for DNA ligase I is sealing nicks generated during excision repair, Previous studies have shown that there is a physical interaction between DNA ligase I and proliferating cell nuclear antigen (PCNA), another important component of DNA replication and repair. The results shown here indicate that human PCNA enhances the reaction rate of human DNA ligase I up to 5-fold. The stimulation is specific to DNA ligase I because T4 DNA ligase is not affected. Electrophoretic mobility shift assays indicate that PCNA improves the binding of DNA ligase I to the ligation site. Increasing the DNA ligase I concentration leads to a reduction in PCNA stimulation, consistent with PCNA-directed improvement of DNA ligase I binding to its DNA substrate. Two experiments show that PCNA is required to encircle duplex DNA to enhance DNA ligase I activity. Biotin-streptavidin conjugations at the ends of a linear substrate inhibit PCNA stimulation. PCNA cannot enhance ligation on a circular substrate without the addition of replication factor C, which is the protein responsible for loading PCNA onto duplex DNA. These results show that PCNA is responsible for the stable association of DNA ligase I to nicked duplex DNA.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, Rochester, NY 14642 USA; Univ Calif Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA	University of Rochester; United States Department of Energy (DOE); Los Alamos National Laboratory	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med & Dent, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.		Park, Min Sung/HCH-2207-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441, R01GM059301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24441, GM59301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kang HY, 2000, GENETICS, V155, P1055; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Kim CY, 2001, BIOCHEMISTRY-US, V40, P3208, DOI 10.1021/bi002100n; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LASKO DD, 1990, J BIOL CHEM, V265, P12618; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LEE SH, 1991, J BIOL CHEM, V266, P594; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; Liu QQ, 2000, J BIOL CHEM, V275, P1615, DOI 10.1074/jbc.275.3.1615; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MONTECUCCO A, 1992, NUCLEIC ACIDS RES, V20, P6209, DOI 10.1093/nar/20.23.6209; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; PETRINI JH, 1995, MOL CELL BIOL, V14, P4303; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; WU Y, 1994, J CELL BIOCHEM, V54, P32, DOI 10.1002/jcb.240540105; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zhang G, 1999, P NATL ACAD SCI USA, V96, P1869, DOI 10.1073/pnas.96.5.1869	62	83	86	34	168	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24817	24825		10.1074/jbc.M101673200	http://dx.doi.org/10.1074/jbc.M101673200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331287	hybrid			2022-12-27	WOS:000169800700054
J	Turner, J; Anderson, R; Guo, J; Beraud, C; Fletterick, R; Sakowicz, R				Turner, J; Anderson, R; Guo, J; Beraud, C; Fletterick, R; Sakowicz, R			Crystal structure of the mitotic spindle kinesin Eg5 reveals a novel conformation of the neck-linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITOR; MOTOR DOMAIN; BIPOLAR KINESIN; PROTEIN; MOTILITY; GENE; NCD; ENCODES	Success of mitosis depends upon the coordinated and regulated activity of many cellular factors, including kinesin motor proteins, which are required for the assembly and function of the mitotic spindle. Eg5 is a kinesin implicated in the formation of the bipolar spindle and its movement prior to and during anaphase. We have determined the crystal structure of the Eg5 motor domain with ADP-Mg bound. This structure revealed a new intramolecular binding site of the neck-linker. In other kinesins, the neck-linker has been shown to be a critical mechanical element for force generation. The neck-linker of conventional kinesin is believed to undergo an ordered-to-disordered transition as it translocates along a microtubule. The structure of Eg5 showed an ordered neck-linker conformation in a position never observed previously. The docking of the neck-linker relies upon residues conserved only in the Eg5 subfamily of kinesin motors. Based on this new information, we suggest that the neck-linker of Eg5 may undergo an ordered-to-ordered transition during force production. This ratchet-like mechanism is consistent with the biological activity of Eg5.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Cytokinet Inc, S San Francisco, CA 94080 USA	University of California System; University of California San Francisco	Turner, J (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Box 0448, San Francisco, CA 94143 USA.							Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; Heald R, 2000, CELL, V102, P399, DOI 10.1016/S0092-8674(00)00044-1; HECK MM, 1993, J CELL BIOL, V123, P655; Hirose K, 2000, EMBO J, V19, P5308, DOI 10.1093/emboj/19.20.5308; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; Lockhart A, 1996, BIOCHEMISTRY-US, V35, P2365, DOI 10.1021/bi952318n; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sharp DJ, 1999, NAT CELL BIOL, V1, P51, DOI 10.1038/9025; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; SWAIN KE, 1995, P NATL ACAD SCI USA, V92, P4289; SWAIN KE, 1992, NATURE, V359, P540; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3	29	188	198	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25496	25502		10.1074/jbc.M100395200	http://dx.doi.org/10.1074/jbc.M100395200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328809	hybrid			2022-12-27	WOS:000169800700140
J	Aiston, S; Hampson, L; Gomez-Foix, AM; Guinovart, JJ; Agius, L				Aiston, S; Hampson, L; Gomez-Foix, AM; Guinovart, JJ; Agius, L			Hepatic glycogen synthesis is highly sensitive to phosphorylase activity - Evidence from metabolic control analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; GLUCOSE DISPOSAL; RAT-LIVER; GLUCOKINASE; TRANSLOCATION; HEPATOCYTES; INHIBITION; SYNTHASE; GLUCOSE-6-PHOSPHATE; MECHANISM	We used metabolic control analysis to determine the flux control coefficient of phosphorylase on glycogen synthesis in hepatocytes by titration with a specific phosphorylase inhibitor (CP-91149) or by expression of muscle phosphorylase using recombinant adenovirus. The muscle isoform was used because it is catalytically active in the b-state. CP-91149 inactivated phosphorylase with sequential activation of glycogen synthase, It increased glycogen synthesis by 7-fold at 5 mM glucose and by 2-fold at 20 mM glucose with a decrease in the concentration of glucose causing half-maximal rate (S-0.5) from 26 to 19 mM. Muscle phosphorylase was expressed in hepatocytes mainly in the b-state, Low levels of phosphorylase expression inhibited glycogen synthesis by 50%, with little further inhibition at higher enzyme expression, and caused inactivation of glycogen synthase that, was reversed by CP-91149. At endogenous activity, phosphorylase has a very high (greater than unity) negative control coefficient on glycogen synthesis, regardless of whether it is determined by enzyme inactivation or overexpression, This high control is attenuated by glucokinase overexpression, indicating dependence on other enzymes with high control. The high control coefficient of phosphorylase on glycogen synthesis affirms that phosphorylase is a strong candidate target for controlling hyperglycemia in type 2 diabetes in both the absorptive and postabsorptive states.	Newcastle Univ, Sch Med, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona 08028, Spain	Newcastle University - UK; University of Barcelona	Agius, L (corresponding author), Newcastle Univ, Sch Med, Dept Diabet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Loranne.Agius@ncl.ac.uk						Agius L, 1998, ADV ENZYME REGUL, V38, P303, DOI 10.1016/S0065-2571(97)00001-0; Agius L, 1997, BIOCHEM J, V325, P667, DOI 10.1042/bj3250667; AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; Aiston S, 1999, DIABETES, V48, P15, DOI 10.2337/diabetes.48.1.15; Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; Aiston S, 2000, DIABETOLOGIA, V43, P589, DOI 10.1007/s001250051348; ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Baque S, 1996, J BIOL CHEM, V271, P2594, DOI 10.1074/jbc.271.5.2594; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bergans N, 2000, DIABETES, V49, P1419, DOI 10.2337/diabetes.49.9.1419; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOARD M, 1995, EUR J BIOCHEM, V228, P753, DOI 10.1111/j.1432-1033.1995.0753m.x; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; CAO YJ, 1993, J BIOL CHEM, V268, P21717; de la Iglesia N, 2000, J BIOL CHEM, V275, P10597, DOI 10.1074/jbc.275.14.10597; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; Fosgerau K, 2000, ARCH BIOCHEM BIOPHYS, V380, P274, DOI 10.1006/abbi.2000.1930; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Guinovart JJ, 1997, BIOCHEM SOC T, V25, P157, DOI 10.1042/bst0250157; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; Hoover DJ, 1998, J MED CHEM, V41, P2934, DOI 10.1021/jm980264k; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; Jucker BM, 1999, AM J PHYSIOL-ENDOC M, V277, pE505, DOI 10.1152/ajpendo.1999.277.3.E505; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Oikonomakos NG, 1999, PROTEIN SCI, V8, P1930, DOI 10.1110/ps.8.10.1930; Rath VL, 2000, CHEM BIOL, V7, P677, DOI 10.1016/S1074-5521(00)00004-1; Schulz AR, 1998, ARCH BIOCHEM BIOPHYS, V353, P172, DOI 10.1006/abbi.1998.0643; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SOLLING H, 1979, EUR J BIOCHEM, V94, P231, DOI 10.1111/j.1432-1033.1979.tb12890.x; STALMANS W, 1974, EUR J BIOCHEM, V41, P127, DOI 10.1111/j.1432-1033.1974.tb03252.x; STALMANS W, 1981, BIOCHEM J, V200, P327, DOI 10.1042/bj2000327; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANSCHAFTINGEN E, 1989, EUR J BIOCHEM, V179, P179	46	66	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23858	23866		10.1074/jbc.M101454200	http://dx.doi.org/10.1074/jbc.M101454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309391	hybrid			2022-12-27	WOS:000169531100085
J	List, HJ; Lauritsen, KJ; Reiter, R; Powers, C; Wellstein, A; Riegel, AT				List, HJ; Lauritsen, KJ; Reiter, R; Powers, C; Wellstein, A; Riegel, AT			Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR; GENE-EXPRESSION; BINDING PROTEIN; IN-VIVO; AMPLIFICATION; ACTIVATION; COMPLEX; TRANSACTIVATION; FAMILY; SRC-1	Human breast tumorigenesis is promoted by the estro gen receptor pathway, and nuclear receptor coactivators are thought to participate in this process. Here we studied whether one of these coactivators, AIB1 (amplified in breast cancer (1) under bar), was rate-limiting for hormone-dependent growth of human MCF-7 breast cancer cells. We developed MCF-7 breast cancer cell lines in which the expression of AIB1 can be modulated by regulatable ribozymes directed against AIB1 mRNA, We found that depletion of endogenous AIB1 levels reduced steroid hormone signaling via the estrogen receptor Lu or progesterone receptor p on transiently transfected reporter templates. Down-regulation of AIB1 levels in MCF-7 cells did not affect estrogen-stimulated cell cycle progression but reduced estrogen-mediated inhibition of apoptosis and cell growth. Finally, upon reduction of endogenous AIB1 expression, estrogen-dependent colony formation in soft agar and tumor growth of MCF-7 cells in nude mice was decreased. From these findings we conclude that, despite the presence of different estrogen receptor coactivators in breast cancer cells, AIB1 exerts a rate-limiting role for hormone-dependent hu. man breast tumor growth.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Bldg E307,3970 Reservoir Rd, Washington, DC 20007 USA.		Powers, Ciaran/E-3890-2011	Wellstein, Anton/0000-0002-0570-4950				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Berns EMJJ, 1998, BREAST CANCER RES TR, V48, P87, DOI 10.1023/A:1005903226483; Bouras T, 2001, CANCER RES, V61, P903; CATHERINO WH, 1995, CANCER LETT, V92, P39, DOI 10.1016/0304-3835(95)03755-L; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dilworth FJ, 1999, P NATL ACAD SCI USA, V96, P1995, DOI 10.1073/pnas.96.5.1995; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Glass CK, 2000, GENE DEV, V14, P121; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; HOERLEIN AJ, 1995, NATURE, V377, P397; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Leygue E, 1999, CANCER RES, V59, P4190; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; LIST HJ, 2001, IN PRESS BREAST CANC; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Murphy LC, 2000, CANCER RES, V60, P6266; ONATE SA, 1995, SCIENCE, V270, P1354; OSBORNE CK, 1984, CANCER RES, V44, P1433; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Sakakura C, 2000, INT J CANCER, V89, P217; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Shim WS, 1999, P NATL ACAD SCI USA, V96, P208, DOI 10.1073/pnas.96.1.208; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P615, DOI 10.1016/0277-5379(83)90177-3; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG TTY, 1995, CANCER RES, V55, P2487; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Werbajh S, 2000, FEBS LETT, V485, P195, DOI 10.1016/S0014-5793(00)02223-7; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	49	115	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23763	23768		10.1074/jbc.M102397200	http://dx.doi.org/10.1074/jbc.M102397200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328819	hybrid			2022-12-27	WOS:000169531100073
J	Wang, N; Silver, DL; Thiele, C; Tall, AR				Wang, N; Silver, DL; Thiele, C; Tall, AR			ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CELLULAR CHOLESTEROL; TANGIER-DISEASE; SCAVENGER RECEPTOR; APOPTOTIC CELLS; DENSITY; LIPOPROTEINS; MUTATIONS; IDENTIFICATION; MECHANISM	ABCA1, an ATP-binding cassette transporter mutated in Tangier disease, promotes cellular phospholipid and cholesterol efflux by loading free apoA-I with these lipids. This process involves binding of apoA-I to the cell surface and phospholipid translocation by ABCA1, The goals of this study were to examine the relationship between ABCA1-mediated lipid efflux and apolipoprotein binding and to determine whether phospholipid and cholesterol efflux are coupled. Inhibition of lipid efflux by glybenclamide treatment or by mutation of the ATP-binding cassette of ABCA1 showed a close correlation between lipid efflux, the binding of apoA-I to cells, and cross-linking of apoA-I to ABCA1, The data suggest that a functionally important apoA-I binding site exists on ABCA1 and that the binding site could also involve lipids. After using cyclodextrin preincubation to deplete cellular cholesterol, ABCA1-mediated cholesterol efflux was abolished but phospholipid efflux and the binding of apoA-I were unaffected, The conditioned media hom cyclodextrin-pretreated, ABCA1-expressing cells readily promoted cholesterol efflux when added to fresh cells not expressing ABCA1, indicating that cholesterol efflux can be dissociated from phospholipid efflux, Further, using a photoactivatable cholesterol analog, we showed that ABCA1 did not bind cholesterol directly, even though several other cholesterol-binding proteins specifically bound the cholesterol analog. The data suggest that the binding of apoA-I to ABCA1 leads to the formation of phospholipid-apoA-I complexes, which subsequently promote cholesterol efflux in an autocrine or paracrine fashion.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA; Max Planck Inst Mol Biol & Genet, D-01307 Dresden, Germany	Columbia University; Max Planck Society	Wang, N (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.	nw30@columbia.edu	Tall, Alan/AAT-8528-2021	Silver, David/0000-0002-7289-9890	NHLBI NIH HHS [HL 58948] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Choi JY, 2001, NATURE, V410, P94, DOI 10.1038/35065099; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Glomset J A, 1980, Adv Intern Med, V25, P91; Golstein PE, 1999, PFLUG ARCH EUR J PHY, V437, P652, DOI 10.1007/s004240050829; GREEN PHR, 1978, J CLIN INVEST, V61, P528, DOI 10.1172/JCI108963; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARA H, 1991, J BIOL CHEM, V266, P3080; IRIE T, 1982, J PHARMACOBIO-DYNAM, V5, P741; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Lawn RM, 2001, ARTERIOSCL THROM VAS, V21, P378, DOI 10.1161/01.ATV.21.3.378; Li QQ, 1997, BIOCHEMISTRY-US, V36, P12045, DOI 10.1021/bi970079t; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Vankeerberghen A, 1998, HUM MOL GENET, V7, P1761, DOI 10.1093/hmg/7.11.1761; VAUGHAN DJ, 1980, CAN J BIOCHEM CELL B, V58, P581, DOI 10.1139/o80-080; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WINKLER KE, 1989, J LIPID RES, V30, P979	37	377	391	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23742	23747		10.1074/jbc.M102348200	http://dx.doi.org/10.1074/jbc.M102348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309399	hybrid			2022-12-27	WOS:000169531100070
J	Laing, JG; Manley-Markowski, RN; Koval, M; Civitelli, R; Steinberg, TH				Laing, JG; Manley-Markowski, RN; Koval, M; Civitelli, R; Steinberg, TH			Connexin45 interacts with zonula occludens-1 and connexin43 in osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION PROTEIN; TIGHT JUNCTION; ZO-1	The relative expression of connexin43 and connexin45 modulates gap junctional communication and production of bone matrix proteins in osteoblastic cells, It is likely that changes in gap junction permeability are determined by the interaction between these two proteins. Cx43 interacts with ZO-1, which may be involved in trafficking of Cx43 or facilitating interactions between Cx43 and other proteins. In this study we sought to identify proteins that associate with Cx45 by coprecipitation in non-denaturing conditions. Cx45 was isolated with a 220-kDa protein that we identified as ZO-1. Under the same conditions, Cx43 also was isolated with anti-Cx45 antiserum from Cx45-transfected ROS cells (ROS/Cx45 cells). Cx43 antiserum could also coprecipitate ZO-1 in the transfected and untransfected ROS cells. Double label immunofluorescence studies showed that ZO-1, Cx43, and Cx45 colocalized at appositional membranes in ROS/Cx45 cells suggesting that all three proteins are normally associated in the cells, Additionally, we found that in vitro translated ZO-1 binds to the carboxyl-terminal of Cx45 indicating that there is a direct interaction between the carboxyl-terminal of Cx45 and ZO-1. These studies demonstrate that ZO-1 interacts with Cx45 as well as with Cx43, and suggest that the interaction of connexins with ZO-1 may play a role in regulating the composition of the gap junction and may modulate connexin-connexin interactions.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Washington University (WUSTL); University of Pennsylvania	Laing, JG (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Campus Box 8051,660 S Euclid Ave, St Louis, MO 63110 USA.	laing@id.wustl.edu	Civitelli, Roberto/AAA-8260-2019; Koval, Michael/C-6366-2015	Civitelli, Roberto/0000-0003-4076-4315; Koval, Michael/0000-0002-5422-5614	NIAMS NIH HHS [AR41255] Funding Source: Medline; NIDDK NIH HHS [DK-46686] Funding Source: Medline; NIGMS NIH HHS [GM-54660] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041255, R29AR041255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054660] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUERRIER A, 1995, J CELL SCI, V108, P2609; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987; Koval M, 1997, J CELL BIOL, V137, P847, DOI 10.1083/jcb.137.4.847; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Lecanda F, 1998, MOL BIOL CELL, V9, P2249, DOI 10.1091/mbc.9.8.2249; Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; STEINBERG TH, 1993, MOL BIOL CELL, V4, P329; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200	18	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23051	23055		10.1074/jbc.M100303200	http://dx.doi.org/10.1074/jbc.M100303200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11313345	hybrid			2022-12-27	WOS:000169412700142
J	Ollagnier-de-Choudens, S; Mattioli, T; Tagahashi, Y; Fontecave, M				Ollagnier-de-Choudens, S; Mattioli, T; Tagahashi, Y; Fontecave, M			Iron-sulfur cluster assembly - Characterization of IscA and evidence for a specific and functional complex with ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; 2FE-2S FERREDOXIN; CLOSTRIDIUM-PASTEURIANUM; AZOTOBACTER-VINELANDII; GENE-CLUSTER; PROTEINS; BIOSYNTHESIS; BIOGENESIS	The synthesis of iron-sulfur clusters in Escherichia coli is believed to require a complex protein machinery encoded by the ise (iron-sulfur cluster) operon. The product of one member of this operon, IscA, has been overexpressed, purified, and characterized. It can assemble an air-sensitive [2Fe-2S] cluster as shown by UV-visible and resonance Raman spectroscopy. The metal form but not the apoform of IscA binds ferredoxin, another member of the ise operon, selectively, allowing transfer of iron and sulfide from IscA to ferredoxin and formation of the [2Fe-2S] holoferredoxin. These results thus suggest that IscA is involved in ferredoxin cluster assembly and activation. This is an important function because a functional ferredoxin is required for maturation of other cellular Fe-S proteins.	Univ Grenoble 1, CEA, CNRS,UMR 5047, DBMS,CB,Lab Chim & Biochim, F-38054 Grenoble 09, France; Univ Grenoble 1, CEA, CNRS,UMR 5047, DBMS,CB,Ctr Redox Biol, F-38054 Grenoble, France; CEA, DBCM, Sect Bioenerget, F-91191 Gif Sur Yvette, France; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; UDICE-French Research Universities; Universite Paris Saclay; Osaka University	Fontecave, M (corresponding author), Univ Grenoble 1, CEA, CNRS,UMR 5047, DBMS,CB,Lab Chim & Biochim, 17 Ave Martyrs, F-38054 Grenoble 09, France.		Takahashi, Yasuhiro/F-1119-2011	Takahashi, Yasuhiro/0000-0002-0588-6045; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEAN DR, 1993, J BACTERIOL, V175, P6735; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Flint DH, 1996, J BIOL CHEM, V271, P16068; Foster MW, 2000, J AM CHEM SOC, V122, P6805, DOI 10.1021/ja000800+; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; MEYER J, 1984, BIOCHEM BIOPH RES CO, V119, P828, DOI 10.1016/0006-291X(84)90848-9; MEYER J, 1994, BIOCHEMISTRY-US, V33, P13642, DOI 10.1021/bi00250a014; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Pelzer W, 2000, FEBS LETT, V476, P134, DOI 10.1016/S0014-5793(00)01711-7; Spiro T. G., 1988, RESONANCE RAMAN SPEC, P523; SPIRO TG, 2000, PHYSICAL METHODS BIO, P97; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TA DT, 1992, J BIOL CHEM, V267, P11120; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	31	168	172	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22604	22607		10.1074/jbc.M102902200	http://dx.doi.org/10.1074/jbc.M102902200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11319236	hybrid			2022-12-27	WOS:000169412700085
J	Uzel, MI; Scott, IC; Babakhaniou-Chase, H; Palamakumbura, AH; Pappano, WN; Hong, HH; Greenspan, DS; Trackman, PC				Uzel, MI; Scott, IC; Babakhaniou-Chase, H; Palamakumbura, AH; Pappano, WN; Hong, HH; Greenspan, DS; Trackman, PC			Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN C-PROTEINASE; AMINO-ACID-SEQUENCE; GENE; COLLAGEN; ENZYME; IDENTIFICATION; EXPRESSION; PRECURSOR; ENCODES; TISSUES	Lysyl oxidase catalyzes the final enzymatic step required for collagen and elastin cross-linking in extracellular matrix biosynthesis, Pro-lysyl oxidase is processed by procollagen C-proteinase activity, which also removes the C-propeptides of procollagens I-III. The Bmp1 gene encodes two procollagen C-proteinases: bone morphogenetic protein 1 (BMP-1) and mammalian Tolloid (mTLD), Mammalian Tolloid-like (mTLL)-1 and -2 are two genetically distinct BMP-l-related proteinases, and mTLL-1 has been shown to have procollagen C-proteinase activity. The present study is the first to directly compare pro-lysyl oxidase processing by these four related proteinases. In vitro assays with purified recombinant enzymes show that all four proteinases productively cleave pro-lysyl oxidase at the correct physiological site but that BMP-1 is 3-, 15, and 20-fold more efficient than mTLL-1, mTLL-2, and mTLD, respectively. To more directly assess the roles of BMP-1 and mTLL-1 in lysyl oxidase activation by connective tissue cells, fibroblasts cultured from Bmp1-null, Till-null, and Bmp2/Tll1 double null mouse embryos, thus lacking BMP-1/mTLD, mTLL I, or all three enzymes, respectively, were assayed for lysyl oxidase enzyme activity and for accumulation of pro-lysyl oxidase and mature similar to 30-kDa lysyl oxidase, Wild type cells or cells singly null for Bmp1 or Till all produced both pro-lysyl oxidase and processed lysyl oxidase at similar levels, indicating apparently normal levels of processing, consistent with enzyme activity data, In contrast, double null Bmp1/Tll1 cells produced predominantly unprocessed 50-kDa prolysyl oxidase and had lysyl oxidase enzyme activity diminished by 70% compared with wild type, Bmp1-null, and Tll1-null cells. Thus, the combination of BMP-1/mTLD and mTLL-1 is shown to be responsible for the majority of processing leading to activation of lysyl oxidase by murine embryonic fibroblasts, whereas in vitro studies identify pro-lysyl oxidase as the first known substrate for mTLL-2.	Boston Univ, Goldman Sch Dent Med, Div Oral Biol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	Boston University; Boston University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Trackman, PC (corresponding author), Boston Univ, Goldman Sch Dent Med, Div Oral Biol, 100 E Newton St,Rm G-07, Boston, MA 02118 USA.		Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Pappano, William/0000-0003-2848-2219; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR43621] Funding Source: Medline; NIDCR NIH HHS [DE12425, DE11004, DE12209] Funding Source: Medline; NIGMS NIH HHS [GM46846] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011004, R29DE011004, R03DE012425, R01DE012209] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALMASSIAN B, 1991, CONNECT TISSUE RES, V25, P197, DOI 10.3109/03008209109029156; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; Clark TG, 1999, DEVELOPMENT, V126, P2631; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Jang W, 1999, GENOME RES, V9, P53; Jourdan-Le Saux C, 1998, GENOMICS, V51, P305, DOI 10.1006/geno.1998.5356; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; KAGAN HM, 1995, METHOD ENZYMOL, V258, P122; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1993, J BIOL CHEM, V268, P18435; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kessler E., 1998, HDB PROTEOLYTIC ENZY, P1236; Lathyrism Selye H, 1957, REV CAN BIOL, V16, P3; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Liu GM, 1997, J BIOL CHEM, V272, P32370, DOI 10.1074/jbc.272.51.32370; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Prockop DJ, 1998, MATRIX BIOL, V16, P399, DOI 10.1016/S0945-053X(98)90013-0; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Siegel R C, 1979, Int Rev Connect Tissue Res, V8, P73; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; Uzel MI, 2000, J BONE MINER RES, V15, P1189, DOI 10.1359/jbmr.2000.15.6.1189; VYTASEK R, 1982, ANAL BIOCHEM, V120, P243, DOI 10.1016/0003-2697(82)90342-6	40	189	205	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22537	22543		10.1074/jbc.M102352200	http://dx.doi.org/10.1074/jbc.M102352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11313359	hybrid			2022-12-27	WOS:000169412700076
J	Berjukow, S; Marksteiner, R; Sokolov, S; Weiss, RG; Margreiter, E; Hering, S				Berjukow, S; Marksteiner, R; Sokolov, S; Weiss, RG; Margreiter, E; Hering, S			Amino acids in segment IVS6 and beta-subunit interaction support distinct conformational changes during Ca(v)2.1 inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HEMIPLEGIC MIGRAINE; ISOFORM-SPECIFIC INTERACTION; CHANNEL ALPHA(1A) SUBUNIT; CARBOXYL-TERMINAL REGION; BI CALCIUM CHANNELS; CA2+ CHANNEL; MOLECULAR DETERMINANTS; PHARMACOLOGICAL PROPERTIES; VOLTAGE; SENSITIVITY	Ca(v)2.1 mediates voltage-gated Ca2+ entry into neurons and the release of neurotransmitters at synapses of the central nervous system. An inactivation process that is modulated by the auxiliary beta -subunits regulates Ca2+ entry through Ca(v)2.1. However, the molecular mechanism of this alpha (1)-beta -subunit interaction remains unknown. Herein we report the identification of new determinants within segment IVS6 of the alpha (1)2.1-subunit that markedly influence channel inactivation. Systematic substitution of residues within IVS6 with amino acids of different size, charge, and polarity resulted in mutant channels with rates of fast inactivation (k(inact)) ranging from a 1.5-fold slowing in V1818I (k(inact) = 0.98 +/- 0.09 s(-1) compared with wild type alpha (1)2.1/alpha (2)-delta/beta (1a) k(inact) = 1.35 +/- 0.25 -1) to a 75-fold acceleration in mutant M1811Q (k(inact) 102 +/- 3 s(-1)). Coexpression of mutant alpha (1)2.1-subunits with beta (2a) resulted in two different phenotypes of current inactivation: 1) a pronounced reduction in the rate of channel inactivation or 2) an attenuation of a slow component in I-Ba inactivation. Simulations revealed that these two distinct inactivation phenotypes arise from a beta (2a)-subunit-induced destabilization of the fast-inactivated state. The IVS6- and beta (2a)-subunit-mediated effects on Ca(v)2.1 inactivation are likely to occur via independent mechanisms.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria		Hering, S (corresponding author), Inst Biochem Pharmakol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.							Berjukow S, 1999, J BIOL CHEM, V274, P6154, DOI 10.1074/jbc.274.10.6154; Berjukow S, 2000, J BIOL CHEM, V275, P22114, DOI 10.1074/jbc.M908836199; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; Hans M, 1999, J NEUROSCI, V19, P1610; Hans M, 1999, BIOPHYS J, V76, P1384, DOI 10.1016/S0006-3495(99)77300-5; Hering S, 2000, J PHYSIOL-LONDON, V528, P237, DOI 10.1111/j.1469-7793.2000.t01-1-00237.x; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jen J, 1999, CURR OPIN NEUROBIOL, V9, P274, DOI 10.1016/S0959-4388(99)80040-3; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Perez-Reyes E, 1999, ANN NY ACAD SCI, V868, P131, DOI 10.1111/j.1749-6632.1999.tb11283.x; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Sokolov S, 2000, J PHYSIOL-LONDON, V527, P445, DOI 10.1111/j.1469-7793.2000.t01-1-00445.x; Sokolov S, 1999, J PHYSIOL-LONDON, V519, P315, DOI 10.1111/j.1469-7793.1999.0315m.x; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; Stotz SC, 2000, J BIOL CHEM, V275, P24575, DOI 10.1074/jbc.M000399200; TANAKA O, 1995, BRAIN RES MOL BRAIN, V30, P10; Walker D, 1999, J BIOL CHEM, V274, P12383, DOI 10.1074/jbc.274.18.12383; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Wu LG, 1999, J NEUROSCI, V19, P726; Yellen G, 1999, CURR OPIN NEUROBIOL, V9, P267, DOI 10.1016/S0959-4388(99)80039-7; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	47	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17076	17082		10.1074/jbc.M010491200	http://dx.doi.org/10.1074/jbc.M010491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350979	hybrid			2022-12-27	WOS:000168730400064
J	He, CY; Striepen, B; Pletcher, CH; Murray, JM; Roos, DS				He, CY; Striepen, B; Pletcher, CH; Murray, JM; Roos, DS			Targeting and processing of nuclear-encoded apicoplast proteins in plastid segregation mutants of Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; HOST-CELL PENETRATION; PLASMODIUM-FALCIPARUM; APICOMPLEXAN PARASITES; ENDOPLASMIC-RETICULUM; FLUORESCENT PROTEIN; RHOPTRY PROTEIN; TRITON X-114; LOCALIZATION; CHLOROPLASTS	The apicoplast is a distinctive organelle associated with apicomplexan parasites, including Plasmodium sp. (which cause malaria) and Toxoplasma gondii (the causative agent of toxoplasmosis). This unusual structure (acquired by the engulfment of an ancestral alga and retention of the algal plastid) is essential for long-term parasite survival. Similar to other endosymbiotic organelles (mitochondria, chloroplasts), the apicoplast contains proteins that are encoded in the nucleus and post-translationally imported. Translocation across the four membranes surrounding the apicoplast is mediated by an N-terminal bipartite targeting sequence. Previous studies have described a recombinant "poison" that blocks plastid segregation during mitosis, producing parasites that lack an apicoplast and siblings containing a gigantic, nonsegregating plastid. To learn more about this remarkable phenomenon, we examined the localization and processing of the protein produced by this construct. Taking advantage of the ability to isolate apicoplast segregation mutants, we also demonstrated that processing of the transit peptide of nuclear-encoded apicoplast proteins requires plastid-associated activity.	Univ Penn, Dept Biol, Godard Labs 305, Philadelphia, PA 19104 USA; Univ Penn, Ctr Canc, Flow Cytometry Shared Resource, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Roos, DS (corresponding author), Univ Penn, Dept Biol, Godard Labs 305, Philadelphia, PA 19104 USA.		He, Cynthia/H-9789-2012	Roos, David Siker/0000-0001-6725-4089; Striepen, Boris/0000-0002-7426-432X				Ajioka JW, 1998, INT J PARASITOL, V28, P1025, DOI 10.1016/S0020-7519(98)00030-7; Baird GS, 2000, P NATL ACAD SCI USA, V97, P11984, DOI 10.1073/pnas.97.22.11984; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; DeRocher A, 2000, J CELL SCI, V113, P3969; DUBEY JP, 1988, J AM VET MED ASSOC, V193, P697; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Hager KM, 1999, J CELL SCI, V112, P2631; He CY, 2001, EMBO J, V20, P330, DOI 10.1093/emboj/20.3.330; Jelenska J, 2001, P NATL ACAD SCI USA, V98, P2723, DOI 10.1073/pnas.051629998; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kausch AP, 1999, BIOTECHNIQUES, V26, P336, DOI 10.2144/99262rr04; KELEMEN MV, 1979, J CELL SCI, V35, P431; Kissinger JC, 2001, NUCLEIC ACIDS RES, V29, P66; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; LUBLIN DM, 1988, J EXP MED, V168, P181, DOI 10.1084/jem.168.1.181; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MANIATIS T, 1989, MOL CLONING LAB MANU, P18; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; Morrissette NS, 1997, J CELL SCI, V110, P35; NAGEL SD, 1989, J BIOL CHEM, V264, P5569; OSSORIO PN, 1992, MOL BIOCHEM PARASIT, V50, P1, DOI 10.1016/0166-6851(92)90239-G; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; ROIZEN N, 1995, PEDIATRICS, V95, P11; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; SAFFER LD, 1992, J PROTOZOOL, V39, P526, DOI 10.1111/j.1550-7408.1992.tb04844.x; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; Seeber F, 1998, J CELL SCI, V111, P23; Soldati D, 1998, MOL BIOCHEM PARASIT, V96, P37, DOI 10.1016/S0166-6851(98)00090-5; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Striepen B, 1998, MOL BIOCHEM PARASIT, V92, P325, DOI 10.1016/S0166-6851(98)00011-5; Striepen B, 2000, J CELL BIOL, V151, P1423, DOI 10.1083/jcb.151.7.1423; Sulli C, 1999, J BIOL CHEM, V274, P457, DOI 10.1074/jbc.274.1.457; Sulli C, 1996, PLANT CELL, V8, P43; Sullivan M, 2000, MOL BIOCHEM PARASIT, V109, P17, DOI 10.1016/S0166-6851(00)00226-7; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1997, MICROBIOL MOL BIOL R, V61, P1; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Zhu G, 2000, MOL BIOCHEM PARASIT, V105, P253, DOI 10.1016/S0166-6851(99)00183-8; Zuther E, 1999, P NATL ACAD SCI USA, V96, P13387, DOI 10.1073/pnas.96.23.13387	46	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28436	28442		10.1074/jbc.M102000200	http://dx.doi.org/10.1074/jbc.M102000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11319231	hybrid			2022-12-27	WOS:000170093400092
J	MacKinnon, AC; Waters, C; Jodrell, D; Haslett, C; Sethi, T				MacKinnon, AC; Waters, C; Jodrell, D; Haslett, C; Sethi, T			Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor - Direct evidence for biased agonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LUNG-CANCER; SWISS 3T3 CELLS; GASTRIN-RELEASING PEPTIDE; STRESS FIBER FORMATION; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; GROWTH-FACTORS; INDEPENDENT PATHWAY; AP-1 TRANSCRIPTION	Substance P analogues including [D-Arg(1),D-Phe(5),D-Trp(7,) (9),Leu(11)] substance P (SpD) act as "broad spectrum neuropeptide antagonists" and are potential anticancer agents that inhibit the growth of small cell lung cancer cells in vitro and in vivo. However, their mechanism of action is controversial and not fully understood. Although these compounds block bombesin-induced mitogenesis and signal transduction, they also have agonist activity. The mechanism underlying this agonist activity was examined. SpD binds to the ligand-binding site of the bombesin/gastrin-releasing peptide receptor and blocks the bombesin-stimulated increase in [Ca2+](i) within the same concentration range that causes sustained activation of c-Jun N-terminal kinase and extracellular signal-regulated protein kinase (ERK). The activation of e-Jun N-terminal kinase by SpD and bombesin is blocked by dominant negative inhibition of G(alpha 12). The ERK activation by SpD is pertussis toxin-sensitive in contrast to ERK activation by bombesin, which is pertussis toxin-insensitive but dependent on epidermal growth factor receptor phosphorylation. Spl) does not simply act as a partial agonist but differentially modulates the activation of the G-proteins G(alpha 12), G(i), and G(q) compared with bombesin. This unique ability allows the bombesin receptor to couple to Gi and at the same time block receptor activation of G(q). Our results provide direct evidence that Spl) is acting as a "biased agonist" and that this has physiological relevance in small cell lung cancer cells. This validation of the concept of biased agonism has important implications in the development of novel pharmacological agents to dissect receptor-mediated signal transduction and of highly selective drugs to treat human disease.	Univ Edinburgh, Sch Med, Resp Med Unit, Ctr Inflammat Res,Rayne Lab, Edinburgh EH8 9AG, Midlothian, Scotland; Western Gen Hosp, Imperial Canc Res Fund, Med Oncol Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Sethi, T (corresponding author), Univ Edinburgh, Sch Med, Resp Med Unit, Ctr Inflammat Res,Rayne Lab, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.							Akeson M, 1997, J BIOL CHEM, V272, P17405, DOI 10.1074/jbc.272.28.17405; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Charlesworth A, 1997, ONCOGENE, V14, P2323, DOI 10.1038/sj.onc.1201075; Charlesworth A, 1996, ONCOGENE, V12, P1337; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Donohue PJ, 1999, BIOCHEMISTRY-US, V38, P9366, DOI 10.1021/bi990544h; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hedin KE, 1999, J BIOL CHEM, V274, P19992, DOI 10.1074/jbc.274.28.19992; Jarpe MB, 1998, J BIOL CHEM, V273, P3097, DOI 10.1074/jbc.273.5.3097; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; Kelley MJ, 1997, CHEST, V112, P256, DOI 10.1378/chest.112.1.256; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Koppan M, 1998, CANCER, V83, P1335, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1335::AID-CNCR10>3.0.CO;2-5; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MacKinnon AC, 1999, BRIT J CANCER, V80, P1026, DOI 10.1038/sj.bjc.6690458; MacKinnon AC, 2000, BRIT J CANCER, V83, P941, DOI 10.1054/bjoc.2000.1362; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; MOODY TW, 1993, LIFE SCI, V52, P1161, DOI 10.1016/0024-3205(93)90098-N; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Perez DM, 1996, MOL PHARMACOL, V49, P112; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; REEVE JG, 1994, BIOCHEM BIOPH RES CO, V199, P1313, DOI 10.1006/bbrc.1994.1374; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; Seckl MJ, 1997, CANCER RES, V57, P51; SECKL MJ, 1995, J CELL PHYSIOL, V163, P87, DOI 10.1002/jcp.1041630110; SETHI T, 1991, CANCER RES, V51, P3621; SETHI T, 1992, CANCER RES, V52, pS2737; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Sinnett-Smith J, 2000, J BIOL CHEM, V275, P30644, DOI 10.1074/jbc.M003702200; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; Tsuda T, 1997, MOL PHARMACOL, V51, P721, DOI 10.1124/mol.51.5.721; Wang QMJ, 1996, INT J CANCER, V68, P528, DOI 10.1002/(SICI)1097-0215(19961115)68:4<528::AID-IJC20>3.3.CO;2-Q; Watson C, 2000, MOL PHARMACOL, V58, P1230, DOI 10.1124/mol.58.6.1230; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211	52	48	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28083	28091		10.1074/jbc.M009772200	http://dx.doi.org/10.1074/jbc.M009772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11323408	hybrid			2022-12-27	WOS:000170093400046
J	Wang, Y; Dulubova, I; Rizo, J; Sudhof, TC				Wang, Y; Dulubova, I; Rizo, J; Sudhof, TC			Functional analysis of conserved structural elements in yeast syntaxin Vam3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNARE COMPLEX; SACCHAROMYCES-CEREVISIAE; MEMBRANE-FUSION; 3-DIMENSIONAL STRUCTURE; VACUOLAR MEMBRANE; PROTEIN-TRANSPORT; VESICLE FUSION; IN-VITRO; T-SNARE; HOMOLOG	Vam3p, a syntaxin-like SNARE protein involved in yeast vacuole fusion, is composed of a three-helical N-terminal domain, a canonical SNARE motif, and a C-terminal transmembrane region (TMR). Surprisingly, we find that the N-terminal domain of Vam3p is not essential for fusion, although analogous domains in other syntaxins are indispensible for fusion and/or protein-protein interactions. In contrast to the N-terminal domain, mutations in the SNARE motif of Vam3p or replacement of the SNARE motif of Vam3p with the SNARE motif from other syntaxins inhibited fusion. Furthermore, the precise distance between the SNARE motif and the TMR was critical for fusion. Insertion of only three residues after the SNARE motif significantly impaired fusion and insertion of 12 residues abolished fusion. As judged by co-immunoprecipitation experiments, the SNARE motif mutations and the insertions did not alter the association of Vam3p with Vam7p, Vti1p, Nyv-1p, and Ykt6p, other vacuolar SNARE proteins implicated in fusion. In contrast, the SNARE motif substitutions interfered with the stable formation of Vam3p complexes with Nyv1p and Vti1p, although Vam3p complexes with Vam7p and Ykt6p were still present. Our data suggest that in contrast to previously characterized syntaxins, Vam3p contains only two domains essential for fusion, the SNARE motif and the TMR, and these domains have to be closely coupled to function in fusion.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestem.edu			NINDS NIH HHS [NS372000] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; Gerrard SR, 2000, TRAFFIC, V1, P45, DOI 10.1034/j.1600-0854.2000.010108.x; Gotte M, 1997, FEBS LETT, V411, P48, DOI 10.1016/S0014-5793(97)00575-9; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Katz L, 2000, MOL BIOL CELL, V11, P3849, DOI 10.1091/mbc.11.11.3849; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Ossig R, 2000, EMBO J, V19, P6000, DOI 10.1093/emboj/19.22.6000; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Piper RC, 1997, J CELL BIOL, V138, P531, DOI 10.1083/jcb.138.3.531; ROBINSON JS, 1998, MOL CELL BIOL, V12, P5813; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Srivastava A, 1998, GENETICS, V148, P85; Sudhof TC, 2001, SYNAPSES, P177; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wada Y, 1997, J CELL SCI, V110, P1299; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	48	45	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28598	28605		10.1074/jbc.M101644200	http://dx.doi.org/10.1074/jbc.M101644200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11349128	hybrid			2022-12-27	WOS:000170093400113
J	Tremeau-Bravard, A; Perez, C; Egly, JM				Tremeau-Bravard, A; Perez, C; Egly, JM			A role of the C-terminal part of p44 in the promoter escape activity of transcription factor IIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; FACTOR TFIIH; SSL1 GENES; DNA-REPAIR; HELICASE; CDK7; INITIATION; YEAST; XPD	The p44 subunit plays a crucial role in the overall activity of the transcription/DNA repair factor TFIIH: on the one hand its N-terminal domain interacts with and regulates the XPD helicase (1, 2); on the other hand, as shown in the present study, it participates with the promoter escape reaction. Mutagenesis along with recombinant technology using the baculovirus/insect cells expression system allowed us to define the function of the two structural motifs of the C-terminal moiety of p44: mutations within the C4 zinc finger motif (residues 291-308) prevent incorporation of the p62 subunit within the core TFIIH. Double mutations in the RING finger motif (residues 345-385) allow the synthesis of the first phosphodiester bond by RNA polymerase II, but prevent its escape from the promoter. This highlights the role of transcription factor IIH in the various steps of the transcription initiation process.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Egly, JM (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch, France.							BARDWELL L, 1994, P NATL ACAD SCI USA, V91, P3926, DOI 10.1073/pnas.91.9.3926; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Fribourg S, 2000, J BIOL CHEM, V275, P31963, DOI 10.1074/jbc.M004960200; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; GERARD M, 1991, J BIOL CHEM, V266, P20940; Guzman E, 1999, MOL CELL BIOL, V19, P5652; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Maines S, 1998, GENETICS, V150, P963; MATSUI P, 1995, NUCLEIC ACIDS RES, V23, P767, DOI 10.1093/nar/23.5.767; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; Seroz T, 2000, J BIOL CHEM, V275, P33260, DOI 10.1074/jbc.M004764200; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	34	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27693	27697		10.1074/jbc.M102457200	http://dx.doi.org/10.1074/jbc.M102457200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11319235	hybrid			2022-12-27	WOS:000169966900126
J	Cheng, A; Bal, GS; Kennedy, BP; Tremblay, ML				Cheng, A; Bal, GS; Kennedy, BP; Tremblay, ML			Attenuation of adhesion-dependent signaling and cell spreading in transformed fibroblasts lacking protein tyrosine phosphate-1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; FOCAL ADHESION; C-SRC; INSULIN SENSITIVITY; HUMAN-PLACENTA; PTP-PEST; INTEGRIN; PHOSPHORYLATION; P130(CAS); GROWTH	Previous biochemical evidence has yielded conflicting models for the role of protein tyrosine phosphatase-1B (PTP-1B) in the regulation of integrin signaling, Thus, to establish the physiological relevance for such a role, we employed a genetic approach by generating embryonic fibroblasts from PTP-1B knockout mice. Both primary fibroblasts and their derived cell lines were used in this study. Immortalization of wild-type primary cells with the SV40 Large T antigen resulted in a dramatic increase in the endogenous expression of PTP-1B, suggesting a role during transformation. Moreover, the absence of PTP-1B in the transformed cell lines led to a more pronounced effect on different pathways of fibronectin-mediated signaling compared with the untransformed state. Specifically, p130(Cas) phosphorylation, Erk activation as well as cell spreading were delayed in PTP-1B-deficient cells, compared with their wild-type counterparts. Interestingly, this attenuation in integrin-mediated events closely resembles that of Src-deficient fibroblasts, Indeed, PTP-1B deficient, transformed fibroblasts held in suspension do exhibit a hyperphosphorylation of the inhibitory site (Tyr-527) of Src, compared with their wild-type counterparts. These results establish PTP-1B as a positive physiological regulator of integrin signaling in transformed cells, acting upstream of Src Tyr-527 dephosphorylation that leads to several adhesion-dependent events.	McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada	McGill University; McGill University; Merck & Company			Cheng, Alan/M-9319-2013	Cheng, Alan/0000-0001-7897-4751				Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Angers-Loustau A, 1999, BIOCHEM CELL BIOL, V77, P493, DOI 10.1139/bcb-77-6-493; Aplin AE, 1999, J CELL SCI, V112, P695; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; ILIE D, 1995, NATURE, V377, P539; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	54	92	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25848	25855		10.1074/jbc.M009734200	http://dx.doi.org/10.1074/jbc.M009734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346638	hybrid			2022-12-27	WOS:000169823300029
J	Kroger, N; Deutzmann, R; Sumper, M				Kroger, N; Deutzmann, R; Sumper, M			Silica-precipitating peptides from diatoms - The chemical structure of silaffin-1A from Cylindrotheca fusiformis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY	Two silica-precipitating peptides, silaffin-1A(1) and-1A(2), both encoded by the sill gene from the diatom Cylin-drotheca fusiformis, were extracted from cell walls and purified to homogeneity, The chemical structures were determined by protein chemical methods combined with mass spectrometry, Silaffin-1A(1) and -1A(2) consist of 15 and 18 amino acid residues, respectively. Each peptide contains a total of four lysine residues, which are all found to be post-translationally modified. In silaffin-1A(2) the lysine residues are clustered in two pairs in which the e-amino group of the first residue is linked to a linear polyamine consisting of 5 to 11 N-methylated propylamine units, whereas the second lysine is converted to epsilon -N,N-dimethyllysine. Silaffin-1A(1) contains only a single lysine pair exhibiting the same structural features. One of the two remaining lysine residues was identified as epsilon -N,N,N-trimethyl-delta -hydroxylysine, a lysine derivative containing a quaternary ammonium group. The fourth lysine residue again is linked to a long-chain polyamine, Silaffin-1A(1) is the first peptide shown to contain epsilon -N,N,N-trimethyl-delta -hydroxylysine. In vitro, both peptides precipitate silica nanospheres within seconds when added to a monosilicic acid solution.	Univ Regensburg, Lehrstuhl Biochem 1, D-95053 Regensburg, Germany	University of Regensburg	Sumper, M (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, D-95053 Regensburg, Germany.							BURKETT SL, 1996, COMPREHENSIVE SUPRAM, V7, P465; Cha JN, 2000, NATURE, V403, P289, DOI 10.1038/35002038; Hildebrand M, 1998, MOL GEN GENET, V260, P480, DOI 10.1007/s004380050920; Hildebrand M, 1997, NATURE, V385, P688, DOI 10.1038/385688b0; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2000, P NATL ACAD SCI USA, V97, P14133, DOI 10.1073/pnas.260496497; KROGER N, 1994, EMBO J, V13, P4676, DOI 10.1002/j.1460-2075.1994.tb06791.x; Kroger N, 1996, EUR J BIOCHEM, V239, P259, DOI 10.1111/j.1432-1033.1996.0259u.x; Kroger N., 2000, BIOMINERALISATION, P151; LOWENSTAM HA, 1981, SCIENCE, V211, P1126, DOI 10.1126/science.7008198; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; NACHBAUR E, 1971, MONATSH CHEM, V102, P1718, DOI 10.1007/BF00905645; NAKAJIMA T, 1970, BIOCHEM BIOPH RES CO, V39, P28, DOI 10.1016/0006-291X(70)90752-7; NARITA K, 1975, PROTEIN SEQUENCE DET, P30; Parkinson J, 1999, TRENDS BIOTECHNOL, V17, P190, DOI 10.1016/S0167-7799(99)01321-9; ROBINSON DH, 1987, TRENDS BIOCHEM SCI, V12, P151, DOI 10.1016/0968-0004(87)90072-7; Round F.E., 1990, DIATOMS; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TREGUER P, 1995, SCIENCE, V268, P375, DOI 10.1126/science.268.5209.375; VOLCANI B E, 1978, P177; Vrieling EG, 1999, J PHYCOL, V35, P548, DOI 10.1046/j.1529-8817.1999.3530548.x	23	245	257	1	83	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26066	26070		10.1074/jbc.M102093200	http://dx.doi.org/10.1074/jbc.M102093200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11349130	hybrid			2022-12-27	WOS:000169823300058
J	Shin, D; Lim, S; Seok, Y; Ryu, S				Shin, D; Lim, S; Seok, Y; Ryu, S			Heat shock RNA polymerase (E sigma(32)) is involved in the transcription of mlc and crucial for induction of the Mlc regulon by glucose in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR GLUCOSE; SIGMA-FACTOR; EXPRESSION; GENE; TRANSPORTER; REPRESSOR; PROTEIN; CAMP; REGULATOR; PROMOTER	Mlc is a global regulator of carbohydrate metabolism. Recent studies have revealed that Mlc is depressed by protein-protein interaction with enzyme IICBGlc, a glucose-specific permease, which is encoded by ptsG, The mlc gene has been previously known to be transcribed by two promoters, P1(+1) and P2(+13), and have a binding site of its own gene product at +16, However, the mechanism of transcriptional regulation of the gene has not yet been established. In vitro transcription assays of the mlc gene showed that Pa promoter could be recognized by RNA polymerase containing the heat shock sigma factor sigma (32) (E sigma (32)) as well as E sigma (70), while P1 promoter is only recognized by E sigma (70). The cyclic AMP receptor protein and cyclic AMP complex (CRP cAMP) increased expression from P2 but showed negative effect on transcription from P1 by E sigma (70), although it had little effect on transcription from P2 by E sigma (32) in vitro, Purified Mlc repressed transcription from both promoters, but with different degrees of inhibition. In vivo transcription assays using wild type and mlc strains indicated that the level of mlc expression was modulated less than 2-fold by glucose in the medium with concerted action of CRP cAMP and Mlc. A dramatic increase in mlc expression was observed upon heat shock or in cells overexpressing sigma (32), confirming that E sigma (32) is involved in the expression of mlc. Induction of ptsG P1 and pts P0 transcription by glucose was also dependent on E sigma (32). These results indicate that E sigma (32) plays an important role in balancing the relative concentration of Mlc and EIICBGlc in response to availability of glucose in order to maintain inducibility of the Mle regulon at high growth temperature.	Seoul Natl Univ, Dept Food Sci & Technol, Res Ctr New Bio Mat Agr, Suwon 441744, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Ryu, S (corresponding author), Seoul Natl Univ, Dept Food Sci & Technol, Res Ctr New Bio Mat Agr, Suwon 441744, South Korea.	sangryu@snu.ac.kr		Seok, Yeong-Jae/0000-0003-0379-3619				Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHARPENTIER B, 1994, J BACTERIOL, V176, P830, DOI 10.1128/jb.176.3.830-839.1994; CHUANG SE, 1993, J BACTERIOL, V175, P5242, DOI 10.1128/JB.175.16.5242-5252.1993; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; HARGER DA, 1990, BIOCHEMISTRY-US, V29, P7890; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; HOSONO K, 1995, BIOSCI BIOTECH BIOCH, V59, P256, DOI 10.1271/bbb.59.256; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; KELLEY RL, 1982, P NATL ACAD SCI-BIOL, V79, P3120, DOI 10.1073/pnas.79.10.3120; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; MENG LM, 1990, EUR J BIOCHEM, V187, P373, DOI 10.1111/j.1432-1033.1990.tb15314.x; MORRIS PW, 1985, J BACTERIOL, V163, P785, DOI 10.1128/JB.163.2.785-786.1985; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; NEWLANDS JT, 1993, J BACTERIOL, V175, P661, DOI 10.1128/JB.175.3.661-668.1993; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; Plumbridge J, 1996, J BACTERIOL, V178, P2629, DOI 10.1128/jb.178.9.2629-2636.1996; ROEHL RA, 1980, J BACTERIOL, V142, P120, DOI 10.1128/JB.142.1.120-130.1980; RYU S, 1994, J BIOL CHEM, V269, P4767; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; Ryu S, 1998, MOL CELLS, V8, P614; RYU S, 1995, J BIOL CHEM, V270, P2489, DOI 10.1074/jbc.270.6.2489; Sambrook J., 2001, MOL CLONING LAB MANU; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; WEICKERT MJ, 1993, J BACTERIOL, V175, P251, DOI 10.1128/JB.175.1.251-258.1993; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541	38	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25871	25875		10.1074/jbc.M101757200	http://dx.doi.org/10.1074/jbc.M101757200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340070	hybrid			2022-12-27	WOS:000169823300032
J	Choi, YH; Kim, KB; Kim, HH; Hong, GS; Kwon, YK; Chung, CW; Park, YM; Shen, ZJ; Kim, BJ; Lee, SY; Jung, YK				Choi, YH; Kim, KB; Kim, HH; Hong, GS; Kwon, YK; Chung, CW; Park, YM; Shen, ZJ; Kim, BJ; Lee, SY; Jung, YK			FLASH coordinates NF-kappa B activity via TRAF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; TNF RECEPTOR; INTERLEUKIN-1-BETA-CONVERTING ENZYME; SIGNALING COMPLEX; ACTIVATION; PROTEIN; APOPTOSIS; KINASE; CASPASE-8; ALPHA	FLASH is a protein recently shown to interact with the death effector domain of caspase-8 and is likely to be a component of the death-inducing signaling complex in receptor-mediated apoptosis, Here we show that antisense oligonucleotide-induced inhibition of FLASH expression abolished TNF-ru-induced activation of NF-KB in HEK293 cells, as determined by luciferase reporter gene expression driven by a NF-KB responsive promoter. Conversely, overexpression of FLASH dose-dependently activated NF-KB, an effect suppressed by dominant negative mutants of TRAF2, NIK, and IKK alpha, and partially by those of TRAF5 and TRAF6, TRAF2 was co-immunoprecipitated with FLASH from the cell extracts of HEK293 cells or HeLa cells stably expressing exogenous FLASH (HeLa/HA-FLASH), Furthermore, serial deletion mapping demonstrated that a domain spanning the residues 856-1191 of FLASH activated NF-KB as efficiently as the full-length and could directly bind to TRAF2 in vitro and in the transfected cells. Taken together, these results suggest that FLASH coordinates downstream NF-KB activity via a TRAF2-dependent pathway in the TNF-alpha signaling.	Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	Gwangju Institute of Science & Technology (GIST); Ewha Womans University	Jung, YK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.			Jung, Yong-Keun/0000-0002-9686-3120				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Chung CW, 2001, NEUROBIOL DIS, V8, P162, DOI 10.1006/nbdi.2000.0335; COA Z, 1996, NATURE, V383, P443; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 2000, J BIOL CHEM, V275, P27823; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Ling L, 2000, P NATL ACAD SCI USA, V97, P9567, DOI 10.1073/pnas.170279097; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Medema JP, 1999, NATURE, V398, P756, DOI 10.1038/19638; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Serfas MS, 1997, CELL GROWTH DIFFER, V8, P951; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	38	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25073	25077		10.1074/jbc.M102941200	http://dx.doi.org/10.1074/jbc.M102941200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340079	hybrid			2022-12-27	WOS:000169800700086
J	Ellerbroek, SM; Wu, YI; Overall, CM; Stack, MS				Ellerbroek, SM; Wu, YI; Overall, CM; Stack, MS			Functional interplay between type I collagen and cell surface matrix metalloproteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GELATINASE-A; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; FOCAL CONTACTS; CONCANAVALIN-A; ACTIVATION; INTEGRIN; CLEAVAGE; EXPRESSION; INVASION	Type I collagen stimulation of pro-matrix metalloproteinase (pro-MMP)-2 activation by ovarian cancer cells involves beta (1) integrin receptor clustering; however, the specific cellular and biochemical events that accompany MMP processing are not well characterized. Collagenolysis is not required for stimulation of pro-MMP-2 activation, and denatured collagen does not elicit an MMP-2 activation response. Similarly, DOV13 cells bind to intact collagen utilizing both alpha (2)beta (1) and alpha (3)beta (1) integrins but interact poorly with collagenase-treated or thermally denatured collagen. Antibody-induced clustering of alpha (3)beta (1) strongly promotes activation of pro-MMP-2, whereas alpha (2)beta (1) integrin clustering has only marginal effects. Membrane-type 1 (MT1)-MMP is present on the DOV13 cell surface as both an active 55-kDa TIMP-2-binding species and a stable catalytically inactive 43-kDa form. Integrin clustering stimulates cell surface expression of MT1-MMP and co-localization of the proteinase to aggregated integrin complexes. Furthermore, cell surface proteolysis of the 55-kDa MT1-MMP species occurs in the absence of active MMP-2, suggesting MT1-MMP autolysis, Cellular invasion of type I collagen matrices requires collagenase activity, is blocked by tissue inhibitor of metalloproteinases-2 (TIMP-2) and collagenase-resistant collagen, is unaffected by TIMP-1, and is accompanied by pro-MMP-2 activation. Together, these data indicate that integrin stimulation of MT1-MMP activity is a rate-limiting step for type I collagen invasion and provide a mechanism by which this activity can be down-regulated following collagen clearance.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada	Northwestern University; Northwestern University; University of British Columbia; University of British Columbia	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu			NCI NIH HHS [R01 CA86984] Funding Source: Medline; NIGMS NIH HHS [5T32 GM08061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cockett MI, 1998, BIOCHEM SOC SYMP, P295; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DANIELSEN CC, 1987, BIOCHEM J, V247, P725, DOI 10.1042/bj2470725; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 1998, INT J CANCER, V78, P331, DOI 10.1002/(SICI)1097-0215(19981029)78:3<331::AID-IJC13>3.0.CO;2-9; GRENZ H, 1993, J CELL SCI, V105, P739; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lichtner RB, 1998, EXP CELL RES, V240, P368, DOI 10.1006/excr.1998.4012; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; Messent AJ, 1998, J CELL SCI, V111, P1127; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; Nagase H, 1997, BIOL CHEM, V378, P151; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PineiroSanchez ML, 1997, J BIOL CHEM, V272, P7595, DOI 10.1074/jbc.272.12.7595; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Urena JM, 1999, J CELL SCI, V112, P773; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119	45	140	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24833	24842		10.1074/jbc.M005631200	http://dx.doi.org/10.1074/jbc.M005631200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331272	hybrid			2022-12-27	WOS:000169800700056
J	Hoffmeister, KM; Falet, H; Toker, A; Barkalow, KL; Stossel, TP; Hartwig, JH				Hoffmeister, KM; Falet, H; Toker, A; Barkalow, KL; Stossel, TP; Hartwig, JH			Mechanisms of cold-induced platelet actin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; FILAMENT BARBED ENDS; ARP2/3 COMPLEX; N-WASP; CAPPING PROTEIN; KINASE-C; GELSOLIN; CALCIUM; CDC42; NUCLEATION	Various agonists but also chilling cause blood platelets to increase cytosolic calcium, polymerize actin, and change shape. We report that cold increases barbed end nucleation sites in octyl glucoside-permeabilized platelets by 3-fold, enabling analysis of the intermediates of this response. Although chilling does not change polyphosphoinositide (ppI) levels, a ppI-binding peptide completely inhibits cold-induced nucleation. The C terminus of N-WASp, which inhibits the Arp2/3 complex, blocks nucleation by 40%; GDP betaS, N17Rac and N17Cdc42 have no effects. Some gelsolin translocates to the detergent-insoluble cytoskeleton after cooling. Chilled platelets from gelsolin-deficient mice have similar to 50% fewer new actin nuclei compared with platelets from wild-type mice. EGTA completely inhibits gelsolin translocation into the cytoskeleton, and the small amount of gelsolin initially there becomes soluble. Chilling releases adducin from the detergent-resistant cytoskeleton. We conclude that platelet actin filament assembly induced by cooling involves ppI-mediated actin filament barbed end uncapping and de novo nucleation independently of surface receptors or downstream signaling intermediates besides calcium, The actin-related changes occur in platelets at temperatures below 37 degreesC, suggesting that the platelet may be more activable at temperatures at the body surface than at core temperature, thereby favoring superficial hemostasis over internal thrombosis.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Hartwig, JH (corresponding author), Brigham & Womens Hosp, Div Hematol, LMRC 301,221 Longwood Ave, Boston, MA 02115 USA.	hartwig@calvin.bwh.harvard.edu		Falet, Herve/0000-0003-0788-9204	NHLBI NIH HHS [HL56993, HL56949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993, P01HL056949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; BENNETT WF, 1980, J CELL BIOL, V86, P280, DOI 10.1083/jcb.86.1.280; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHERNOFF A, 1992, TRANSFUSION, V32, P386, DOI 10.1046/j.1537-2995.1992.32492263456.x; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Eddy RJ, 1997, J CELL BIOL, V139, P1243, DOI 10.1083/jcb.139.5.1243; Falet H, 2000, BLOOD, V96, P3786, DOI 10.1182/blood.V96.12.3786.h8003786_3786_3792; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Gross BS, 1999, BLOOD, V94, P4166, DOI 10.1182/blood.V94.12.4166.424k36_4166_4176; HARTWIG J H, 1992, P23; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Matsuoka Y, 2000, CELL MOL LIFE SCI, V57, P884, DOI 10.1007/PL00000731; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; MOROFF G, 1994, TRANSFUSION, V34, P317, DOI 10.1046/j.1537-2995.1994.34494233579.x; Mullins RD, 1999, CURR BIOL, V9, P405, DOI 10.1016/S0960-9822(99)80187-0; Nachmias VT, 1996, FEBS LETT, V378, P258, DOI 10.1016/0014-5793(95)01474-8; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tablin F, 1996, J CELL PHYSIOL, V168, P305, DOI 10.1002/(SICI)1097-4652(199608)168:2<305::AID-JCP9>3.0.CO;2-T; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; WHITE JG, 1967, BLOOD-J HEMATOL, V30, P625, DOI 10.1182/blood.V30.5.625.625; WHITE JG, 1968, AM J PATHOL, V53, P281; WINOKUR R, 1995, BLOOD, V85, P1796, DOI 10.1182/blood.V85.7.1796.bloodjournal8571796; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0	50	66	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24751	24759		10.1074/jbc.M011642200	http://dx.doi.org/10.1074/jbc.M011642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328807	hybrid			2022-12-27	WOS:000169800700046
J	Zhang, F; Romano, PR; Nagamura-Inoue, T; Tian, B; Devert, TE; Mathews, MB; Ozato, K; Hinnebusch, AG				Zhang, F; Romano, PR; Nagamura-Inoue, T; Tian, B; Devert, TE; Mathews, MB; Ozato, K; Hinnebusch, AG			Binding of double-stranded RNA to protein kinase PKR is required for dimerization and promotes critical autophosphorylation events in the activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-2-ALPHA; PHOSPHORYLATION SITES; TRANSLATIONAL CONTROL; INTERFERON ACTION; MOLECULAR-BASIS; IN-VIVO; DOMAIN; MECHANISM; YEAST; INHIBITION	Protein kinase PKR is activated by double-stranded RNA (dsRNA) and phosphorylates translation initiation factor 2 alpha to inhibit protein synthesis in virus-infected mammalian cells. PKR contains two dsRNA binding motifs (DRBMs I and II) required for activation by dsRNA, There is strong evidence that PKR activation requires dimerization, but the role of dsRNA in dimer formation is controversial. By making alanine substitutions predicted to remove increasing numbers of side chain contacts between the DRBMs and dsRNA we found that dimerization of full-length PKR in yeast was impaired by the minimal combinations of mutations required to impair dsRNA binding in vitro. Mutation of Ala-67 to Glu in DRBM-I, reported to abolish dimerization without affecting dsRNA binding, destroyed both activities in our assays. By contrast, deletion of a second dimerization region that overlaps the kinase domain had no effect on PKR dimerization in yeast, Human PKR contains at least 15 autophosphorylation sites, but only Thr-446 and Thr-451 in the activation loop were found here to be critical for kinase activity in yeast. Using an antibody specific for phosphorylated Thr-451, we showed that Thr-451 phosphorylation is stimulated by dsRNA binding, Our results provide strong evidence that dsRNA binding is required for dimerization of full-length PKR molecules in vivo, leading to autophosphorylation in the activation loop and stimulation of the eIF2 alpha kinase function of PKR.	NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Thomas Jefferson Univ, Jefferson Ctr Biomed Res, Doylestown, PA 18901 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Hinnebusch, AG (corresponding author), NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov	Dever, Thomas/GSE-0966-2022	Dever, Thomas/0000-0001-7120-9678; Tian, Bin/0000-0001-8903-8256	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001310, Z01HD001004, Z01HD001010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI34552] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHIU YS, 1978, J BIOL CHEM, V253, P7145; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Craig AWB, 1996, J BIOL CHEM, V271, P24526, DOI 10.1074/jbc.271.40.24526; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HUNTER T, 1975, J BIOL CHEM, V250, P409; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Patel RC, 1998, MOL CELL BIOL, V18, P7009, DOI 10.1128/MCB.18.12.7009; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Romano PR, 1998, MOL CELL BIOL, V18, P7304, DOI 10.1128/MCB.18.12.7304; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Sherman F., 1974, METHODS YEAST GENETI; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SIKORSKI RS, 1989, GENETICS, V122, P19; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Taylor DR, 2001, J VIROL, V75, P1265, DOI 10.1128/JVI.75.3.1265-1273.2001; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434	56	152	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24946	24958		10.1074/jbc.M102108200	http://dx.doi.org/10.1074/jbc.M102108200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337501	hybrid			2022-12-27	WOS:000169800700069
J	Blanpain, C; Wittamer, V; Vanderwinden, JM; Boom, A; Renneboog, B; Lee, B; Le Poul, E; El Asmar, L; Govaerts, C; Vassart, G; Doms, RW; Parmentier, M				Blanpain, C; Wittamer, V; Vanderwinden, JM; Boom, A; Renneboog, B; Lee, B; Le Poul, E; El Asmar, L; Govaerts, C; Vassart, G; Doms, RW; Parmentier, M			Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 CORECEPTOR ACTIVITY; PROTEIN-COUPLED RECEPTOR; 4TH CYTOPLASMIC LOOP; G-BETA-GAMMA; CHEMOKINE RECEPTORS; T-CELLS; POSTTRANSLATIONAL MODIFICATION; BETA(2)-ADRENERGIC RECEPTOR; THYROTROPIN RECEPTOR	CCR5 is a CC chemokine receptor expressed on memory lymphocytes, macrophages, and dendritic cells and also constitutes the main coreceptor for macrophage-tropic (or R5) strains of human immunodeficiency viruses. In the present study, we investigated whether CCR5 as palmitoylated in its carboxyl-terminal do. main by generating alanine substitution mutants for the three cysteine residues present in this region, individually or in combination. We found that wild-type CCR5 was palmitoylated, but a mutant lacking all three Cys residues was not. Through the use of green fluorescent fusion proteins and immunofluorescence studies, we found that the absence of receptor palmitoylation resulted in sequestration of CCR5 in intracellular biosynthetic compartments. By using the fluorescence recovery after photobleaching technique, we showed that the non-palmitoylated mutant had impaired diffusion properties within the endoplasmic reticulum. We next stud led the ability of the mutants to bind and signal in response to chemokines, Chemokines binding and activation of G(i)-mediated signaling pathways, such as calcium mobilization and inhibition of adenylate cyclase, were not affected. However, the duration of the functional response, as measured by a microphysiometer, and the ability to increase [S-35]guanosine 5 ' -3-O(thio)triphosphate binding to membranes were severely affected for the non-palmitoylated mutant. The ability of RANTES (regulated on activation normal T cell expressed and secreted) and aminooxypentane-RANTES to promote CCR5 endocytosis was not altered by cysteine replacements. Finally, we found that the absence of receptor palmitoylation reduced the human immunodeficiency viruses coreceptor function of CCR5, but this effect was secondary to the reduction in surface expression. In conclusion, we found that palmitoylated cysteines play an important role in the intracellular trafficking of CCR5 and are likely necessary for efficient coupling of the receptor to part of its repertoire of signaling cascades.	Euroscreen SA, B-1070 Brussels, Belgium; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium; Free Univ Brussels, Lab Histol Neuroanat & Neuropathol, B-1070 Brussels, Belgium; Free Univ Brussels, Inst Interdisciplianary Res, B-1070 Brussels, Belgium	University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), IRIBHN, ULB Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.		Lee, Benhur/A-8554-2016; Blanpain, Cedric/ABD-8392-2021	Lee, Benhur/0000-0003-0760-1709; Parmentier, Marc/0000-0001-8081-4685; Wittamer, Valerie/0000-0003-0003-2646	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003923] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL03923] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Arni S, 1998, J BIOL CHEM, V273, P28478, DOI 10.1074/jbc.273.43.28478; AXELROD D, 1976, P NATL ACAD SCI USA, V73, P4594, DOI 10.1073/pnas.73.12.4594; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 2000, BLOOD, V96, P1638, DOI 10.1182/blood.V96.5.1638.h8001638_1638_1645; Blanpain C, 1999, BLOOD, V94, P1899; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Carroll RG, 1997, SCIENCE, V276, P273, DOI 10.1126/science.276.5310.273; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; CRISE B, 1992, J BIOL CHEM, V267, P13593; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Faussner A, 1998, J BIOL CHEM, V273, P2617, DOI 10.1074/jbc.273.5.2617; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Gao ZH, 1999, BIOCHEM J, V342, P387, DOI 10.1042/0264-6021:3420387; Garred P, 1998, J RHEUMATOL, V25, P1462; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Hall IP, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03425-X; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; Kawate N, 1997, MOL CELL ENDOCRINOL, V127, P211, DOI 10.1016/S0303-7207(97)04010-0; Kosugi S, 1996, BIOCHEM BIOPH RES CO, V221, P636, DOI 10.1006/bbrc.1996.0648; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mack M, 1999, ARTHRITIS RHEUM, V42, P981, DOI 10.1002/1529-0131(199905)42:5<981::AID-ANR17>3.0.CO;2-4; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nelson S, 1999, ENDOCRINOLOGY, V140, P950, DOI 10.1210/en.140.2.950; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Reynes J, 2000, J INFECT DIS, V181, P927, DOI 10.1086/315315; Sadeghi HM, 1997, MOL PHARMACOL, V52, P21, DOI 10.1124/mol.52.1.21; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; YEUNG DE, 1991, VIROLOGY, V181, P35, DOI 10.1016/0042-6822(91)90467-P; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	76	114	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23795	23804		10.1074/jbc.M100583200	http://dx.doi.org/10.1074/jbc.M100583200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323418	hybrid, Green Submitted			2022-12-27	WOS:000169531100078
J	Craigie, R				Craigie, R			HIV integrase, a brief overview from chemistry to therapeutics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; TARGET SITE SELECTION; PHOTO-CROSS-LINKING; DNA STRAND TRANSFER; CATALYTIC DOMAIN; CRYSTAL-STRUCTURE; RETROVIRAL INTEGRASES; TERMINAL DOMAIN; ACTIVE-SITE; CORE DOMAIN		NIDDK, NIH, Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Craigie, R (corresponding author), NIDDK, NIH, Mol Biol Lab, Bldg 5,Rm 301,5 Ctr Dr,MSC 0560, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036108] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Brin E, 2000, J BIOL CHEM, V275, P39287, DOI 10.1074/jbc.M006929200; Brown P. O., 1997, P161; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BURKE CJ, 1992, J BIOL CHEM, V267, P9639; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; GOODARZI G, 1995, J VIROL, V69, P6090, DOI 10.1128/JVI.69.10.6090-6097.1995; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; HENER TS, 1997, BIOCHEMISTRY-US, V36, P10655; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; Hindmarsh P, 1999, ADV VIRUS RES, V52, P397, DOI 10.1016/S0065-3527(08)60308-5; JENKINS TM, 1995, P NATL ACAD SCI USA, V92, P6057, DOI 10.1073/pnas.92.13.6057; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; KATZMAN M, 1995, J VIROL, V69, P5687, DOI 10.1128/JVI.69.9.5687-5696.1995; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; Leschziner AE, 1998, P NATL ACAD SCI USA, V95, P7345, DOI 10.1073/pnas.95.13.7345; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; Shibagaki Y, 1997, J BIOL CHEM, V272, P8361, DOI 10.1074/jbc.272.13.8361; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	48	232	247	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23213	23216		10.1074/jbc.R100027200	http://dx.doi.org/10.1074/jbc.R100027200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11346660	hybrid			2022-12-27	WOS:000169531100001
J	Ludlam, AV; McNatt, MW; Carr, KM; Kaguni, JM				Ludlam, AV; McNatt, MW; Carr, KM; Kaguni, JM			Essential amino acids of Escherichia coli DnaC protein in an N-terminal domain interact with DnaB helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN; CHROMOSOMAL ORIGIN; GENE-PRODUCT; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE COFACTORS; COMPLEX; BINDING; INITIATION; EXPRESSION; SEQUENCES	Escherichia coli DnaC protein bound to ATP forms a complex with DnaB protein. To identify the domain of DnaC that interacts with DnaB, a genetic selection was used based on the lethal effect of induced dnaC expression and a model that inviability arises by the binding of DnaC to DnaB to inhibit replication fork movement, The analysis of dnaC alleles that preserved viability under elevated expression revealed an N-terminal domain of DnaC involved in binding to DnaB, Mutant proteins bearing single amino acid substitutions (R10P, L11Q, L29Q, S41P, W32G, and L44P) that reside in regions of predicted secondary structure were inert in DNA replication activity because of their inability to bind to DnaB, but they retained ATP binding activity, as indicated by UV cross-linking to [alpha-P-32]ATP. These alleles also failed to complement a dnaC28 mutant. Other selected mutations that map to regions carrying Walker A and B boxes are expected to be defective in ATP binding, a required step in DnaB-DnaC complex formation. Lastly, we found that the sixth codon from the N terminus encodes aspartate, resolving a reported discrepancy between the predicted amino acid sequence based on DNA sequencing data and the results from N-terminal amino acid sequencing.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.			Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1991, J BIOL CHEM, V266, P22096; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5253; BISWAS SB, 1987, J BIOL CHEM, V262, P7831; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Galletto R, 2000, BIOCHEMISTRY-US, V39, P12959, DOI 10.1021/bi0012484; HWANG DS, 1988, J BIOL CHEM, V263, P10633; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jezewska MJ, 1997, BIOPHYS CHEM, V64, P253, DOI 10.1016/S0301-4622(96)02221-1; Jezewska MJ, 1996, BIOPHYS J, V71, P2075, DOI 10.1016/S0006-3495(96)79406-7; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; Kaguni J. M., 1997, EXPT MOL BIOL BIOCH; Kaguni JM, 1997, MOL CELLS, V7, P145; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13757; LANKA E, 1982, NUCLEIC ACIDS RES, V11, P257; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MASAI H, 1990, J BIOL CHEM, V265, P15134; MAURER R, 1984, GENETICS, V108, P1; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; NAKAYAMA N, 1987, J BIOL CHEM, V262, P10475; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; San Martin C, 1998, STRUCTURE, V6, P501; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHUBACH WH, 1973, J MOL BIOL, V74, P205, DOI 10.1016/0022-2836(73)90107-1; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; UEDA K, 1978, J BIOL CHEM, V253, P261; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WECHSLER JA, 1975, J BACTERIOL, V121, P594, DOI 10.1128/JB.121.2.594-599.1975; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	50	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27345	27353		10.1074/jbc.M101940200	http://dx.doi.org/10.1074/jbc.M101940200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11333269	hybrid			2022-12-27	WOS:000169966900082
J	Wu, CG; Stojanov, T; Chami, O; Ishii, S; Shimuzu, T; Li, AG; O'Neill, C				Wu, CG; Stojanov, T; Chami, O; Ishii, S; Shimuzu, T; Li, AG; O'Neill, C			Evidence for the autocrine induction of capacitation of mammalian spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; PROTEIN-TYROSINE PHOSPHORYLATION; MOUSE PREIMPLANTATION EMBRYOS; BOVINE SEMINAL PLASMA; FACTOR-ACETYLHYDROLASE; FACTOR RECEPTOR; IN-VITRO; INVITRO FERTILIZATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE A(2)	Mammalian spermatozoa require a maturational event after ejaculation that allows them to acquire the capacity for fertilization. This process, known as capacitation, occurs spontaneously in simple defined medium implicating a potential role of autocrine induction. This study shows that the ether phospholipid 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphocholine (PAF) meets the criteria for an autocrine mediator of capacitation. Sperm released PAF after their dilution into capacitation medium and expressed a receptor for PAF on their membranes. PAF stimulated changes in the motility of sperm and enhanced fertilization in vitro. These actions were inhibited by a PAF receptor antagonist (UR-12519) and by extracellular recombinant PAF:acetylhydrolase (an enzyme that degrades PAF to a biologically inert form). Seminal plasma contained an acid-labile PAF: acetylhydrolase, whereas capacitation was inhibited by an acid-labile factor within seminal plasma, implicating this factor as a potential decapacitation factor within seminal plasma. Sperm from a PAF receptor knock-out mouse strain failed to express the receptor and displayed a significantly (p < 0.01) reduced rate of capacitation, as assessed by the spontaneous onset of the acrosome reaction in vitro. When used for in vitro fertilization, sperm from PAF receptor knock-out mice gave a significantly lower rate of fertilization (21.5%) than did wild-type sperm (66.7%). The study shows for the first time the operation of an autocrine Poop that induces capacitation in sperm in vitro and shows that this loop acts in concert with other mediators of capacitation to promote efficient fertilization.	Univ Sydney, Human Reprod Unit, Dept Physiol, Royal N Shore Hosp, St Leonards, NSW 2065, Australia; Univ Tokyo, CREST, Japan Sci & Technol Corp, Dept Biochem & Mol Biol,Fac Med,Bunkyo Ku, Tokyo 1130033, Japan	Royal North Shore Hospital; University of Sydney; Japan Science & Technology Agency (JST); University of Tokyo	O'Neill, C (corresponding author), Univ Sydney, Human Reprod Unit, Dept Physiol, Royal N Shore Hosp, St Leonards, NSW 2065, Australia.			O'Neill, Christopher/0000-0003-4003-8727				AITKEN RJ, 1977, J REPROD FERTIL, V50, P29; Ammit AJ, 1997, J REPROD FERTIL, V109, P309, DOI 10.1530/jrf.0.1090309; Ammit AJ, 1997, J BIOL CHEM, V272, P18772, DOI 10.1074/jbc.272.30.18772; Ammit AJ, 1997, HUM REPROD, V12, P785, DOI 10.1093/humrep/12.4.785; AMMIT AJ, 1995, PLATELET ACTIVATING, P263; ANGLE MJ, 1991, FERTIL STERIL, V56, P314; BEDFORD JM, 1962, AM J PHYSIOL, V202, P179, DOI 10.1152/ajplegacy.1962.202.1.179; Cahana A, 1999, FEBS LETT, V451, P99, DOI 10.1016/S0014-5793(99)00548-7; CLAY KL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P309, DOI 10.1016/0005-2760(90)90246-T; COLLIER M, 1990, HUM REPROD, V5, P323, DOI 10.1093/oxfordjournals.humrep.a137098; DAVIS BK, 1979, BIOCHIM BIOPHYS ACTA, V558, P257, DOI 10.1016/0005-2736(79)90260-8; DAVIS BK, 1980, ARCH ANDROLOGY, V5, P249, DOI 10.3109/01485018008986993; DOHERTY AS, 1994, MOL REPROD DEV, V37, P21, DOI 10.1002/mrd.1080370104; EISENBACH M, 1992, AM J PHYSIOL, V262, pC1095, DOI 10.1152/ajpcell.1992.262.5.C1095; Emerson M, 2000, J BIOL CHEM, V275, P21905, DOI 10.1074/jbc.M001719200; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Ishii S, 1996, BIOCHEM J, V314, P671, DOI 10.1042/bj3140671; Jones RE, 1997, ARCH ANDROLOGY, V38, P181; KUMAR R, 1988, ARCH BIOCHEM BIOPHYS, V260, P497, DOI 10.1016/0003-9861(88)90474-2; KUZAN FB, 1990, PROSTAGLANDINS, V39, P61, DOI 10.1016/0090-6980(90)90095-D; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; Luconi M, 1998, BIOL REPROD, V58, P1476, DOI 10.1095/biolreprod58.6.1476; LUDWIG JC, 1985, ARCH BIOCHEM BIOPHYS, V241, P337, DOI 10.1016/0003-9861(85)90555-7; Muguruma K, 1997, BIOL REPROD, V56, P529, DOI 10.1095/biolreprod56.2.529; ONeill C, 1997, BIOL REPROD, V56, P229, DOI 10.1095/biolreprod56.1.229; ONEILL C, 1995, BIOL REPROD, V52, P965, DOI 10.1095/biolreprod52.5.965; Osheroff JE, 1999, MOL HUM REPROD, V5, P1017, DOI 10.1093/molehr/5.11.1017; PARKS JE, 1993, J ANDROL, V14, P335; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; Reinhardt JC, 1999, FERTIL STERIL, V71, P941, DOI 10.1016/S0015-0282(99)00096-5; Roudebush WE, 2000, FERTIL STERIL, V73, P967, DOI 10.1016/S0015-0282(00)00485-4; ROUDEBUSH WE, 1993, J ASSIST REPROD GEN, V10, P91, DOI 10.1007/BF01204447; ROUDEBUSH WE, 1990, AM J OBSTET GYNECOL, V163, P1670, DOI 10.1016/0002-9378(90)90648-Q; SENGOKU K, 1993, HUM REPROD, V8, P1443, DOI 10.1093/oxfordjournals.humrep.a138276; SINGH J, 1995, ENDOCRINOLOGY, V136, P5311, DOI 10.1210/en.136.12.5311; Soubeyrand S, 1998, BIOCHEM J, V329, P41, DOI 10.1042/bj3290041; Stojanov T, 1999, BIOL REPROD, V60, P674, DOI 10.1095/biolreprod60.3.674; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Yanagimachi R., 1994, P189	44	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26962	26968		10.1074/jbc.M103107200	http://dx.doi.org/10.1074/jbc.M103107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350972	hybrid			2022-12-27	WOS:000169966900032
J	Swaminathan, GJ; Weaver, AJ; Loegering, DA; Checkel, JL; Leonidas, DD; Gleich, GJ; Acharya, KR				Swaminathan, GJ; Weaver, AJ; Loegering, DA; Checkel, JL; Leonidas, DD; Gleich, GJ; Acharya, KR			Crystal structure of the eosinophil major basic protein at 1.8 angstrom - An atypical lectin with a paradigm shift in specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; C-TYPE LECTIN; CARBOHYDRATE-RECOGNITION DOMAIN; HELICAL COILED-COIL; GRANULE PROTEINS; ANIMAL LECTINS; ACTIVATION; PRECURSOR; TOXICITY; PROFORM	The eosinophil major basic protein (EMBP) is the predominant constituent of the crystalline core of the eosinophil primary granule. EMBP is directly implicated in epithelial cell damage, exfoliation, and bronchospasm in allergic diseases such as asthma, Here we report the crystal structure of EMBP at 1.8 Angstrom resolution, and show that it is similar to that of members of the C-type lectin superfamily with which it shares minimal amino acid sequence identity (similar to 15-28%). However, this protein lacks a Ca2+/carbohydrate-binding site. Our analysis suggests that EMBP specifically binds heparin, Based on our results, we propose a possible new function for this protein, which is likely to have implications for EMBP function.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA	University of Bath; Mayo Clinic; Mayo Clinic	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.		Leonidas, Demetres/F-7228-2013; Leonidas, Demetres/AAE-9296-2021	Leonidas, Demetres/0000-0002-3874-2523; Leonidas, Demetres/0000-0002-3874-2523; Swaminathan, Jawahar/0000-0002-0215-4084; Acharya, K. Ravi/0000-0002-3009-4058	NIAID NIH HHS [AI 25230, AI 09728] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230, R37AI009728, R01AI009728] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abu-Ghazaleh R I, 1992, Immunol Ser, V57, P137; ABUGHAZALEH RI, 1992, J MEMBRANE BIOL, V128, P153; ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; BARKER RL, 1991, J CLIN INVEST, V88, P798, DOI 10.1172/JCI115379; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUTTERWORTH AE, 1979, J IMMUNOL, V122, P221; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P456, DOI 10.1042/bst0210456; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1998, TRENDS BIOCHEM SCI, V23, P321, DOI 10.1016/S0968-0004(98)01246-8; Fischer D, 1996, PROTEIN SCI, V5, P947; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Gleich G.J., 1995, SAMTERS IMMUNOLOGIC, P205; GLEICH GJ, 1974, J EXP MED, V140, P313, DOI 10.1084/jem.140.2.313; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1976, J CLIN INVEST, V57, P633, DOI 10.1172/JCI108319; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Gronwald W, 1998, BIOCHEMISTRY-US, V37, P4712, DOI 10.1021/bi972788c; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HAMANN KJ, 1987, J PARASITOL, V73, P523, DOI 10.2307/3282130; HAMANN KJ, 1990, J IMMUNOL, V144, P3166; Harp JM, 1998, ACTA CRYSTALLOGR D, V54, P622, DOI 10.1107/S0907444997019008; HASTIE AT, 1987, AM REV RESPIR DIS, V135, P848, DOI 10.1164/arrd.1987.135.4.848; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; JACOBY DB, 1988, AM REV RESPIR DIS, V137, P13, DOI 10.1164/ajrccm/137.1.13; Kastrup JS, 1998, ACTA CRYSTALLOGR D, V54, P757, DOI 10.1107/S0907444997016806; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Llera AS, 2001, J BIOL CHEM, V276, P7312, DOI 10.1074/jbc.M008573200; MCGROGAN M, 1988, J EXP MED, V168, P2295, DOI 10.1084/jem.168.6.2295; MOY JN, 1990, J IMMUNOL, V145, P2626; Natarajan K, 2000, BIOCHEMISTRY-US, V39, P14779, DOI 10.1021/bi0018180; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ODONNELL MC, 1983, J EXP MED, V157, P1981, DOI 10.1084/jem.157.6.1981; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; OXVIG C, 1994, FEBS LETT, V341, P213, DOI 10.1016/0014-5793(94)80459-1; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; PATTHY L, 1989, MOL IMMUNOL, V26, P1151, DOI 10.1016/0161-5890(89)90059-X; PETERS MS, 1986, LAB INVEST, V54, P656; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; Popken-Harris P, 1998, BLOOD, V92, P623, DOI 10.1182/blood.V92.2.623.414k32_623_631; POPKENHARRIS P, 1995, J IMMUNOL, V155, P1472; Rochester CL, 1996, J IMMUNOL, V156, P4449; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Tormo J, 1999, NATURE, V402, P623, DOI 10.1038/45170; WASSOM DL, 1981, J CLIN INVEST, V67, P651, DOI 10.1172/JCI110080; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	61	47	51	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26197	26203		10.1074/jbc.M100848200	http://dx.doi.org/10.1074/jbc.M100848200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319227	hybrid			2022-12-27	WOS:000169823300075
J	van Dijk, TH; van der Sluijs, FH; Wiegman, CH; Baller, JFW; Gustafson, LA; Burger, HJ; Herling, AW; Kuipers, F; Meijer, AJ; Reijngoud, DJ				van Dijk, TH; van der Sluijs, FH; Wiegman, CH; Baller, JFW; Gustafson, LA; Burger, HJ; Herling, AW; Kuipers, F; Meijer, AJ; Reijngoud, DJ			Acute inhibition of hepatic glucose-6-phosphatase does not affect gluconeogenesis but directs gluconeogenic flux toward glycogen in fasted rats - A pharmacological study with the chlorogenic acid derivative S4048	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOTOPOMER DISTRIBUTION ANALYSIS; REQUIRES GLUCOSE-METABOLISM; IN-VIVO; GENE-EXPRESSION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; SECRETED GLUCURONATE; LIVER-GLYCOGEN; DIABETIC RATS; SUBSTRATE; TURNOVER	Effects of acute inhibition of glucose-6-phosphatase activity by the chlorogenic acid derivative S4048 on hepatic carbohydrate fluxes were examined in isolated rat hepatocytes and in vivo in rats. Fluxes were calculated using tracer dilution techniques and mass isotopomer distribution analysis in plasma glucose and urinary paracetamol-glucuronide after infusion of [U-C-13]glucose, [2-C-13]glycerol, [1-H-2]galactose, and paracetamol, In hepatocytes, glucose-g-phosphate (Glc-6-P) content, net glycogen synthesis, and lactate production from glucose and dihydroxyacetone increased strongly in the presence of S4048 (10 muM) In livers of S4048-treated rats (0.5 mg kg(-1) min(-1); 8 h) Glc-6-P content increased strongly (+440%), and massive glycogen accumulation (+1260%) was observed in periportal areas. Total glucose production was diminished by 50%, The gluconeogenic flux to Glc-6-P was unaffected (i,e, 33.3 +/- 2.0 versus 33.2 +/- 2.9 mu mol kg(-1) min(-1) in control and S4048-treated rats, respectively). Newly synthesized Glc-6-P was redistributed from glucose production (62 +/- 1 Dersus 38 +/- 1%; p < 0.001) to glycogen synthesis (35 +/- 5% versus 65 +/- 5%; p < 0.005) by S4048, This was associated with a strong inhibition (-82%) of the flux through glucokinase and an increase (+83%) of the flux through glycogen synthase, while the flux through glycogen phosphorylase remained unaffected. In livers from S4048-treated rats, mRNA levels of genes encoding Glc-6-P hydrolase (similar to4-fold), Glc-6-P translocase (similar to4-fold), glycogen synthase (similar to7-fold) and L-type pyruvate kinase (similar to4-fold) were increased, whereas glucokinase expression was almost abolished. In accordance with unaltered gluconeogenic flux, expression of the gene encoding phosphoenolpyruvate carboxykinase was unaffected in the S4048-treated rats. Thus, acute inhibition of glucose-6-phosphatase activity by S4048 elicited 1) a repartitioning of newly synthesized Glc-6-P from glucose production into glycogen synthesis without affecting the gluconeogenic flux to Glc-6-P and 2) a cellular response aimed at maintaining cellular Glc-6-P homeostasis.	Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, NL-9700 RB Groningen, Netherlands; Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Aventis Pharma Deutschland GmbH, D-65926 Frankfurt, Germany	University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam; Sanofi-Aventis	Reijngoud, DJ (corresponding author), Univ Groningen Hosp, Ctr Liver Digest & Metab Dis, Pediat Lab, NL-9700 RB Groningen, Netherlands.	d.j.reijngoud@med.rug.nl		Kuipers, Folkert/0000-0003-2518-737X; Reijngoud, Dirk-Jan/0000-0003-1157-4491; Wiegman, Coen/0000-0001-9161-0581				Ackermans MT, 2001, J CLIN ENDOCR METAB, V86, P2220, DOI 10.1210/jc.86.5.2220; Aiston S, 1999, J BIOL CHEM, V274, P24559, DOI 10.1074/jbc.274.35.24559; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; Christiansen MP, 2000, DIABETES, V49, P1691, DOI 10.2337/diabetes.49.10.1691; Clore JN, 2000, DIABETES, V49, P969, DOI 10.2337/diabetes.49.6.969; CONSOLI A, 1987, J CLIN INVEST, V80, P1303, DOI 10.1172/JCI113206; Cournarie F, 1999, FEBS LETT, V460, P527, DOI 10.1016/S0014-5793(99)01407-6; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; EKBERG K, 1995, J BIOL CHEM, V270, P21715, DOI 10.1074/jbc.270.37.21715; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GROEN AK, 1983, J BIOL CHEM, V258, P4346; Guillam MT, 1998, P NATL ACAD SCI USA, V95, P12317, DOI 10.1073/pnas.95.21.12317; Hellerstein M, 2000, METABOLISM, V49, P1375; Hellerstein M, 2000, DIABETES NUTR METAB, V13, P46; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; Hellerstein MK, 1997, AM J PHYSIOL-ENDOC M, V272, pE155, DOI 10.1152/ajpendo.1997.272.1.E155; Hellerstein MK, 1997, METABOLISM, V46, P1390, DOI 10.1016/S0026-0495(97)90137-2; Hellerstein MK, 1997, J CLIN INVEST, V100, P1305, DOI 10.1172/JCI119644; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; Hellerstein MK, 1997, AM J PHYSIOL-ENDOC M, V272, pE163, DOI 10.1152/ajpendo.1997.272.1.E163; Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; Herling AW, 1999, EUR J PHARMACOL, V386, P75, DOI 10.1016/S0014-2999(99)00748-7; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; KACSER H, 1993, EUR J BIOCHEM, V216, P361, DOI 10.1111/j.1432-1033.1993.tb18153.x; KATZ J, 1984, J CLIN INVEST, V74, P1901, DOI 10.1172/JCI111610; KUIPERS F, 1985, GASTROENTEROLOGY, V88, P403, DOI 10.1016/0016-5085(85)90499-8; Kurland IJ, 2000, J BIOL CHEM, V275, P36787, DOI 10.1074/jbc.M004739200; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; LANDAU BR, 1995, AM J PHYSIOL-ENDOC M, V269, pE18, DOI 10.1152/ajpendo.1995.269.1.E18; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; Lei KJ, 1996, NAT GENET, V13, P203, DOI 10.1038/ng0696-203; MAGNUSSON I, 1994, AM J PHYSIOL, V266, pE796, DOI 10.1152/ajpendo.1994.266.5.E796; MEIJER AJ, 1985, EUR J BIOCHEM, V148, P189, DOI 10.1111/j.1432-1033.1985.tb08824.x; NEESE RA, 1995, J BIOL CHEM, V270, P14452, DOI 10.1074/jbc.270.24.14452; Newsholme E A, 1976, Biochem Soc Symp, P61; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; PERONI O, 1995, AM J PHYSIOL-ENDOC M, V269, pE516, DOI 10.1152/ajpendo.1995.269.3.E516; Peroni O, 1997, METABOLISM, V46, P1358, DOI 10.1016/S0026-0495(97)90244-4; Peroni O, 1996, METABOLISM, V45, P897, DOI 10.1016/S0026-0495(96)90166-3; Previs SF, 1998, J BIOL CHEM, V273, P16853, DOI 10.1074/jbc.273.27.16853; PREVIS SF, 1995, J BIOL CHEM, V270, P19806, DOI 10.1074/jbc.270.34.19806; Previs SF, 1999, AM J PHYSIOL-ENDOC M, V277, pE154, DOI 10.1152/ajpendo.1999.277.1.E154; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Shulman RG, 1996, P NATL ACAD SCI USA, V93, P7491, DOI 10.1073/pnas.93.15.7491; Siler SQ, 1998, AM J PHYSIOL-ENDOC M, V275, pE897, DOI 10.1152/ajpendo.1998.275.5.E897; Simon C, 2000, ARCH BIOCHEM BIOPHYS, V373, P418, DOI 10.1006/abbi.1999.1560; Sunehag AL, 1999, DIABETES, V48, P791, DOI 10.2337/diabetes.48.4.791; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; WANG W, 1999, AM J PHYSIOL, V279, pE50; WOLFE RR, 1992, PRINCIPLES PRACTICE, P117	58	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25727	25735		10.1074/jbc.M101223200	http://dx.doi.org/10.1074/jbc.M101223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346646	hybrid			2022-12-27	WOS:000169823300014
J	Danilczyk, UG; Williams, DB				Danilczyk, UG; Williams, DB			The lectin chaperone calnexin utilizes polypeptide-based interactions to associate with many of its substrates in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; HISTOCOMPATIBILITY COMPLEX-MOLECULES; NICOTINIC ACETYLCHOLINE-RECEPTOR; N-LINKED OLIGOSACCHARIDES; TCR-ALPHA-PROTEINS; ENDOPLASMIC-RETICULUM; CALRETICULIN FUNCTIONS; RIBONUCLEASE-B; LIVING CELLS; GLYCOPROTEIN	Calnexin and calreticulin are molecular chaperones of the endoplasmic reticulum that bind to newly synthesized glycoproteins in part through a lectin site specific for monoglucosylated (Glc(1)Man(7-9)GlcNAc(2)) oligosaccharides. In addition to this lectin-oligosaccharide interaction, in vitro studies have demonstrated that calnexin and calreticulin can bind to polypeptide segments of both glycosylated and nonglycosylated proteins. However, the in vivo relevance of this latter interaction has been questioned. We examined whether polypeptide-based interactions occur between calnexin and its substrates in vivo using the glucosidase inhibitor castanospermine or glucosidase-deficient cells to prevent the formation of monoglucosylated oligosaccharides. We show that if care is taken to preserve weak interactions, the block in lectin-oligosaccharide binding leads to the loss of some calnexin-substrate complexes, but many others remain readily detectable. Furthermore, we demonstrate that calnexin is capable of associating in vivo with a substrate that completely lacks Asn-linked oligosaccharides. The binding of calnexin to proteins that lack monoglucosylated oligosaccharides could not be attributed to nonspecific adsorption nor to its inclusion in protein aggregates. We conclude that both lectin-oligosaccharide and polypeptide-based interactions occur between calnexin and diverse proteins in vivo and that the strength of the latter interaction varies substantially between protein substrates.	Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Williams, DB (corresponding author), Univ Toronto, Dept Biochem, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.							ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CARRENO BM, 1995, J IMMUNOL, V154, P5173; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Christodoulou S, 1997, GENE, V191, P143, DOI 10.1016/S0378-1119(97)00025-5; Danilczyk UG, 2000, J BIOL CHEM, V275, P13089, DOI 10.1074/jbc.275.17.13089; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; Jannatipour M, 1998, BIOCHEMISTRY-US, V37, P17253, DOI 10.1021/bi981785c; Jorgensen CS, 2000, EUR J BIOCHEM, V267, P2945, DOI 10.1046/j.1432-1033.2000.01309.x; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Nair S, 1999, J IMMUNOL, V162, P6426; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Popov M, 1999, J BIOL CHEM, V274, P17635, DOI 10.1074/jbc.274.25.17635; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RAY MK, 1991, J BIOL CHEM, V266, P22818; REITMAN ML, 1982, J BIOL CHEM, V257, P357; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; Smith M J, 1992, DNA Seq, V3, P247, DOI 10.3109/10425179209034025; Spee P, 1999, BIOCHEMISTRY-US, V38, P10559, DOI 10.1021/bi990321r; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Suh WK, 1999, J IMMUNOL, V162, P1530; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Van der Wal FJ, 1998, EUR J BIOCHEM, V256, P51, DOI 10.1046/j.1432-1327.1998.2560051.x; vanLeeuwen JEM, 1996, J BIOL CHEM, V271, P9660, DOI 10.1074/jbc.271.16.9660; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; Wada I, 1997, EMBO J, V16, P5420, DOI 10.1093/emboj/16.17.5420; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang Q, 1998, J IMMUNOL, V160, P831; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	60	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25532	25540		10.1074/jbc.M100270200	http://dx.doi.org/10.1074/jbc.M100270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337494	hybrid			2022-12-27	WOS:000169800700144
J	Peraldi, P; Filloux, C; Emanuelli, B; Hilton, DJ; Van Obberghen, E				Peraldi, P; Filloux, C; Emanuelli, B; Hilton, DJ; Van Obberghen, E			Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; MICE LACKING SUPPRESSOR; SOCS-BOX MOTIF; DOCKING PROTEINS; STAT3 ACTIVATION; MEDIATE INSULIN; RECEPTOR; BINDS; INHIBITION; MECHANISMS	Suppressor of cytokine signaling (SOCS) proteins were originally described as cytokine-induced molecules involved in negative feedback loops. We have shown that SOCS-3 is also a component of the insulin signaling network (1), Indeed, insulin leads to SOCS-3 expression in 3T3-L1 adipocytes. Once produced, SOCS-3 binds to phosphorylated tyrosine 960 of the insulin receptor and inhibits insulin signaling. Now we show that in 3T3-L1 adipocytes and in transfected COS-7 cells insulin leads to SOCS-3 tyrosine phosphorylation. This phosphorylation takes place on Tyr(204) and is dependent upon a functional SOCS-3 SH2 domain. Purified insulin receptor directly phosphorylates SOCS-3, However, in intact cells, a mutant of the insulin receptor, IRY960F, unable to bind SOCS-3, was as efficient as the wild type insulin receptor to phosphorylate SOCS-3, Importantly, IRY960F is as potent as the wild type insulin receptor to activate janus-activated kinase (Jak) 1 and Jak2, Furthermore, expression of a dominant negative form of Jak2 inhibits insulin-induced SOCS-3 tyrosine phosphorylation, ks transfected Jaks have been shown to cause SOCS-3 phosphorylation, we propose that insulin induces SOCS-3 phosphorylation through Jak activation. Our data indicate that SOCS-3 belongs to a class of tyrosine-phosphorylated insulin signaling molecules, the phosphorylation of which is not dependent upon a direct coupling with the insulin receptor but relies on the Jacks.	Fac Med, INSERM U145, IFR 50, F-06107 Nice 2, France; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factor, Parkville, Vic 3050, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Walter & Eliza Hall Institute	Peraldi, P (corresponding author), Fac Med, INSERM U145, IFR 50, F-06107 Nice 2, France.	peraldi@unice.fr	Peraldi, Pascal/O-4592-2016; Emanuelli, Brice/M-2097-2016; Hilton, Douglas J/C-7250-2013	Peraldi, Pascal/0000-0003-0205-9252; Emanuelli, Brice/0000-0001-5795-5666; Hilton, Douglas J/0000-0002-7698-2392				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; Burks DJ, 1997, J BIOL CHEM, V272, P27716, DOI 10.1074/jbc.272.44.27716; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GIORGETTI-PERALDI S, 1995, EUR J BIOCHEM, V234, P656, DOI 10.1111/j.1432-1033.1995.656_b.x; Gual P, 1998, ENDOCRINOLOGY, V139, P884, DOI 10.1210/en.139.3.884; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Krebs DL, 2000, J CELL SCI, V113, P2813; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MANIATIS T, 1989, MOL CLONING LAB MANU, P1642; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Saad MJA, 1996, J BIOL CHEM, V271, P22100, DOI 10.1074/jbc.271.36.22100; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; VANOBBERGHEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1052; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; White MF, 1998, RECENT PROG HORM RES, V53, P119; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	41	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24614	24620		10.1074/jbc.M102209200	http://dx.doi.org/10.1074/jbc.M102209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325969	hybrid			2022-12-27	WOS:000169800700028
J	Sloane, V; Blanchard, CZ; Guillot, F; Waldrop, GL				Sloane, V; Blanchard, CZ; Guillot, F; Waldrop, GL			Site-directed mutagenesis of ATP binding residues of biotin carboxylase - Insight into the mechanism of catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ENZYME CATALYSIS; B-DOMAIN; LIGASE; SUPERFAMILY; RESOLUTION; SUBSTRATE	Acetyl-CoA carboxylase catalyzes the first committed step in fatty acid synthesis in all plants, animals, and bacteria. The Escherichia coli form is a multimeric protein complex consisting of three distinct and separate components: biotin carboxylase, carboxyltransferase, and the biotin carboxyl carrier protein. The biotin carboxylase component catalyzes the ATP-dependent carboxylation of biotin using bicarbonate as the carboxylate source and has a distinct architecture that is characteristic of the ATP-grasp superfamily of enzymes. Included in this superfamily are D-Ala D-Ala ligase, glutathione synthetase, carbamyl phosphate synthetase, N-5-carboxyaminoimidazole ribonucleotide synthetase, and glycinamide ribonucleotide transformylase, all of which have known three-dimensional structures and contain a number of highly conserved residues between them. Four of these residues of biotin carboxylase, Lys-116, Lys-159, His-209, and Glu-276, were selected for site-directed mutagenesis studies based on their structural homology with conserved residues of other ATP-grasp enzymes. These mutants were subjected to kinetic analysis to characterize their roles in substrate binding and catalysis, In all four mutants, the K-m value for ATP was significantly increased, implicating these residues in the binding of ATP, This result is consistent with the crystal structures of several other ATP-grasp enzymes, which have shown specific interactions between the corresponding homologous residues and cocrystallized ADP or nucleotide analogs. In addition, the maximal velocity of the reaction was significantly reduced (between 30- and 260-fold) in the 4 mutants relative to wild type. The data suggest that the mutations have misaligned the reactants for optimal catalysis.	Louisiana State Univ, Dept Sci Biol, Div Biochem & Mol Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Waldrop, GL (corresponding author), Louisiana State Univ, Dept Sci Biol, Div Biochem & Mol Biol, Rm 508,Life Sci Bldg, Baton Rouge, LA 70803 USA.	gwaldro@lsu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51261] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1996, NAT STRUCT BIOL, V3, P128, DOI 10.1038/nsb0296-128; Blanchard CZ, 1999, BIOCHEMISTRY-US, V38, P3393, DOI 10.1021/bi982660a; Blanchard CZ, 1999, BIOCHEM BIOPH RES CO, V266, P466, DOI 10.1006/bbrc.1999.1844; Bruice TC, 1999, ACCOUNTS CHEM RES, V32, P127, DOI 10.1021/ar960131y; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Galperin MY, 1997, PROTEIN SCI, V6, P2639; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; Kanai S, 1999, J MOL EVOL, V48, P482, DOI 10.1007/PL00006492; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Kohen A, 2000, J AM CHEM SOC, V122, P10738, DOI 10.1021/ja002229k; KOSHLAND DE, 1994, ANGEW CHEM INT EDIT, V33, P2375; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Levert KL, 2000, BIOCHEMISTRY-US, V39, P4122, DOI 10.1021/bi992662a; OGITA T, 1988, BIOCHEMISTRY-US, V27, P8028, DOI 10.1021/bi00421a009; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; SHI Y, 1995, BIOCHEMISTRY-US, V34, P2768, DOI 10.1021/bi00009a005; Stapleton MA, 1996, BIOCHEMISTRY-US, V35, P14352, DOI 10.1021/bi961183y; Sutcliffe MJ, 2000, TRENDS BIOCHEM SCI, V25, P405, DOI 10.1016/S0968-0004(00)01642-X; Thoden JB, 2000, J BIOL CHEM, V275, P16183, DOI 10.1074/jbc.275.21.16183; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P15480, DOI 10.1021/bi991618s; Thoden JB, 1999, BIOCHEMISTRY-US, V38, P2347, DOI 10.1021/bi982517h; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106	27	29	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24991	24996		10.1074/jbc.M101472200	http://dx.doi.org/10.1074/jbc.M101472200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11346647	hybrid			2022-12-27	WOS:000169800700075
J	Takagi, M; Sueishi, M; Saiwaki, T; Kametaka, A; Yoneda, Y				Takagi, M; Sueishi, M; Saiwaki, T; Kametaka, A; Yoneda, Y			A novel nucleolar protein, NIFK, interacts with the forkhead associated domain of Ki-67 antigen in mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; FHA DOMAIN; FACTOR SL1; GENE; SPECIFICITY; RAD53; IDENTIFICATION; TRANSCRIPTION; PHOSPHATASE; MUTATIONS	In a previous study, we demonstrated that the fork-head associated (FHA) domain of pKi-67 interacts with the novel kinesin-like protein, Hklp2 (Sueishi, M., Takagi, M., and Yoneda, Y. (2000) J. Biol. Chem. 275, 28888-28892), In this study, we report on the identification of a putative RNA-binding protein of 293 residues as another binding partner of the FHA domain of pKi-67 (referred to as NIFK for nucleolar protein interacting with the FHA domain of pKi-67), Human NIFK (hNIFK) interacted with the FHA domain of pKi-67 (Ki-FHA) efficiently in vitro when hNIFK was derived from mitotically arrested cells. In addition, a moiety of hNIFK was co-localized with pKi-67 at the peripheral region of mitotic chromosomes. The hNIFK domain that interacts with Ki-FHA was mapped in the yeast two-hybrid system to a portion encompassed by residues 226-269, In a binding assay utilizing Xenopus egg extracts, it was found that the mitosis-specific environment and two threonine residues within this portion of hNIFK (Thr-234 and Thr238) were crucial for the efficient interaction of hNIFK and Ki-FHA, suggesting that hNIFK interacts with KiFHA in a mitosis-specific and phosphorylation-dependent manner. These findings provide a new clue to our understanding of the cellular function of pKi-67.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Yoneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yyoneda@anat3.med.osaka-u.ac.jp	Kametaka, Ai/AAA-6869-2020	Kametaka, Ai/0000-0002-5648-9373				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Kuhn A, 1998, J MOL BIOL, V284, P1, DOI 10.1006/jmbi.1998.2164; Li J, 2000, J CELL SCI, V113, P4143; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Sueishi M, 2000, J BIOL CHEM, V275, P28888, DOI 10.1074/jbc.M003879200; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Takagi M, 1999, J CELL SCI, V112, P2463; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	31	51	56	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25386	25391		10.1074/jbc.M102227200	http://dx.doi.org/10.1074/jbc.M102227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342549	hybrid			2022-12-27	WOS:000169800700127
J	Henao, F; Delavoie, F; Lacapere, JJ; McIntosh, DB; Champeil, P				Henao, F; Delavoie, F; Lacapere, JJ; McIntosh, DB; Champeil, P			Phosphorylated Ca2+-ATPase stable enough for structural studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; ATPASE	The atomic structure of sarcoplasmic reticulum Ca2+-ATPase, in a Ca2+-bound conformation, has recently been elucidated (Toyoshima, C., Nakasako, M, Nomura, H. & Ogawa, H, (2000) Nature 405, 647-655). Important steps for further understanding the mechanism of ion pumps will be the atomic structural characterization of different key conformational intermediates of the transport cycle, including phosphorylated intermediates. Following our previous report (Champeil, P., Henao, F., Lacapere, J.-J, & McIntosh, D. B, (2000) J. Biol. Chem, 276, 5795-5803), we show here that it is possible to prepare a phosphorylated form of sarcoplasmic reticulum Ca2+-ATPase (labeled with fluorescein isothiocyanate) with a meek-long stability both in membranes anal in mixed lipid-detergent micelles. We show that this phosphorylated fluorescein isothiocyanate-ATPase can form two-dimensional arrays in membranes, similar to those that were used previously to reconstruct from cryoelectron microscopy images the three-dimensional structure of Ca2+-free unphosphorylated ATPase. The results also provide hope that crystals of phosphorylated Ca2+- ATPase suitable for x-ray crystallography will be achieved.	Ctr Etud Saclay, Dept Biol Cellulaire & Mol, Sect Biophys Prot & Membranes, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, CEA, F-91191 Gif Sur Yvette, France; Univ Extremadura, Dept Bioquim & Biol Mol, E-06080 Badajoz, Spain; Fac Xavier Bichat, INSERM, Unite U410, F-75870 Paris 18, France; Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa	Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Universidad de Extremadura; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cape Town	Champeil, P (corresponding author), Ctr Etud Saclay, Dept Biol Cellulaire & Mol, Sect Biophys Prot & Membranes, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	DELAVOIE, Franck/AAP-3126-2021; Henao, Fernando/F-6694-2016	DELAVOIE, Franck/0000-0001-9692-0386; Henao, Fernando/0000-0003-1117-8544				Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; DUX L, 1983, J BIOL CHEM, V258, P2599; HARDWICKE PMD, 1989, J MUSCLE RES CELL M, V10, P245, DOI 10.1007/BF01739814; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; Lacapere JJ, 2001, BIOPHYS J, V80, p35A; MacLennan DH, 2000, NATURE, V405, P633, DOI 10.1038/35015206; McIntosh DB, 2000, NAT STRUCT BIOL, V7, P532, DOI 10.1038/76735; PICK U, 1981, FEBS LETT, V123, P131, DOI 10.1016/0014-5793(81)80036-1; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; STOKES DL, 1994, J BIOL CHEM, V269, P11606; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	12	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24284	24285		10.1074/jbc.M103905200	http://dx.doi.org/10.1074/jbc.M103905200			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11337512	hybrid, Green Published			2022-12-27	WOS:000169531100138
J	Marbach, I; Licht, R; Frohnmeyer, H; Engelberg, D				Marbach, I; Licht, R; Frohnmeyer, H; Engelberg, D			Gcn2 mediates Gcn4 activation in response to glucose stimulation or UV radiation not via GCN4 translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN GENES; RAS/CYCLIC AMP PATHWAY; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; DNA-REPAIR; C-JUN; CELLULAR STRESS; YEAST; KINASE	In mammalian cells transcription factors of the AP-1 family are activated by either stress signals such as W radiation, or mitogenic signals such as growth factors. Here we show that a similar situation exists in the yeast Saccharomyces cerevisiae, The AP-1 transcriptional activator Gcn4, known to be activated by stress signals such as UV radiation and amino acids starvation, is also induced by growth stimulation such as glucose. We show that glucose-dependent Gcn4 activation is mediated through the Ras/cAMP pathway. This pathway is also responsible for UV-dependent Gcn4 activation but is not involved in Gcn4 activation by amino acid starvation. Thus, the unusual phenomenon of activation of mitogenic pathways and AP-1 factors by contradictory stimuli through Has is conserved from yeast to mammals. We also show that activation of Gcn4 by glucose and W requires Gcn2 activity. However, in contrast to its role in amino acid starvation, Gcn2 does not increase eIF2 alpha phosphorylation or translation of GCN4 mRNA in response to glucose or UV. These findings suggest a novel mechanism of action for Gcn2, The finding that Gcn4 is activated in response to glucose via the Ras/cAMP pathway suggests that this cascade coordinates glucose metabolism with amino acids and purine biosynthesis and thereby ensures availability of both energy and essential building blocks for continuation of the cell cycle.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Hebrew University of Jerusalem; University of Freiburg	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Broach JR, 1991, CURR OPIN GENET DEV, V1, P370, DOI 10.1016/S0959-437X(05)80302-8; COFFER PJ, 1995, ONCOGENE, V11, P561; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; ERASO P, 1985, FEBS LETT, V191, P51, DOI 10.1016/0014-5793(85)80991-1; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; Hoffmann B, 1999, MOL MICROBIOL, V31, P807, DOI 10.1046/j.1365-2958.1999.01219.x; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; KAIBUCHI K, 1986, P NATL ACAD SCI USA, V83, P8172, DOI 10.1073/pnas.83.21.8172; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MBYONI K, 1988, MOL CELL BIOL, V8, P3051; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; Takemaru K, 1998, MOL CELL BIOL, V18, P4971, DOI 10.1128/MCB.18.9.4971; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000	54	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16944	16951		10.1074/jbc.M100383200	http://dx.doi.org/10.1074/jbc.M100383200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350978	hybrid			2022-12-27	WOS:000168730400046
J	O'Callaghan, BL; Koo, SH; Wu, Y; Freake, HC; Towle, HC				O'Callaghan, BL; Koo, SH; Wu, Y; Freake, HC; Towle, HC			Glucose regulation of the acetyl-CoA carboxylase promoter PI in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; COENZYME-A CARBOXYLASE; CARBOHYDRATE RESPONSE ELEMENT; FATTY-ACID BIOSYNTHESIS; LIPOGENIC ENZYME GENES; STEROL REGULATION; TRANSCRIPTION FACTOR; DIFFERENTIATION FACTOR-1; SYNTHASE PROMOTER; INSULIN ACTION	The rat acetyl-CoA carboxylase (ACC) alpha gene is transcribed from two promoters, denoted PI and PII, that direct regulated expression in a tissue-specific manner. Induction of ACC, the rate-controlling enzyme of fatty acid biosynthesis, occurs in the liver in response to feeding of a high carbohydrate, low fat diet, conditions that favor enhanced lipogenesis. This induction is mainly due to increases in PI promoter activity. We have used primary cultured hepatocytes from the rat to investigate glucose regulation of ACC expression. Glucose and insulin synergistically activated expression of ACC mRNAs transcribed from the PI promoter with little or no effect on PII mRNAs. Glucose treatment stimulated PI promoter activity in transfection assays and a glucose-regulated element was identified (-126/-102), homologous to those previously described in other responsive genes, including L-type pyruvate kinase, S-14 and fatty acid synthase. Mutation of this element eliminated the response to glucose. This region of the ACC PI promoter was able to bind a liver nuclear factor designated ChoRF that interacts with other conserved glucose-regulated elements. This ACC PI element is also capable of conferring a strong response to glucose when linked to a heterologous promoter. We conclude that induction of ACC gene expression under lipogenic conditions in hepatocytes is mediated in part by the activation of a glucose-regulated transcription factor, ChoRF, which stimulates transcription from the PI promoter. Similar mechanisms operate on related genes permitting the coordinate induction of the lipogenic pathway.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Connecticut, Dept Nutr Sci, Storrs, CT 06269 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Connecticut	Towle, HC (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.		Koo, Seung-Hoi/E-2763-2015	Koo, Seung-Hoi/0000-0001-8769-2879; O'Callaghan, Brennon L/0000-0002-0800-5856	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26919] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cunningham BA, 1998, THYROID, V8, P815, DOI 10.1089/thy.1998.8.815; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; HARDIE DG, 1989, PROG LIPID RES, V28, P117, DOI 10.1016/0163-7827(89)90010-6; Hillgartner FB, 1996, BIOCHEM J, V319, P263, DOI 10.1042/bj3190263; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Huang CL, 1998, BIOCHEM BIOPH RES CO, V249, P704, DOI 10.1006/bbrc.1998.9217; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Kim TS, 1996, J NUTR, V126, P611, DOI 10.1093/jn/126.3.611; Kim TS, 1996, BIOCHEM BIOPH RES CO, V225, P647, DOI 10.1006/bbrc.1996.1224; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Tabor DE, 1998, J BIOL CHEM, V273, P22052, DOI 10.1074/jbc.273.34.22052; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Yin LY, 2000, BBA-GENE STRUCT EXPR, V1517, P91, DOI 10.1016/S0167-4781(00)00267-0	44	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16033	16039		10.1074/jbc.M101557200	http://dx.doi.org/10.1074/jbc.M101557200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340083	hybrid			2022-12-27	WOS:000168623100063
J	Fitzgerald, ML; Mendez, AJ; Moore, KJ; Andersson, LP; Panjeton, HA; Freeman, MW				Fitzgerald, ML; Mendez, AJ; Moore, KJ; Andersson, LP; Panjeton, HA; Freeman, MW			ATP-binding cassette transporter A1 contains an NH2-terminal signal anchor sequence that translocates the protein's first hydrophilic domain to the exoplasmic space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; CHOLESTEROL EFFLUX; MONOCLONAL-ANTIBODIES; CELLULAR CHOLESTEROL; HDL CHOLESTEROL; ABCA1 GENE; MUTATIONS; RECEPTOR; PROMOTER; CLONING	Mutations in the ATP-binding cassette transporter A1 (ABCA1) transporter are associated with Tangier disease and a defect in cellular cholesterol efflux, The amino terminus of the ABCA1 transporter has two putative in-frame translation initiation sites, 60 amino acids apart. A cluster of hydrophobic amino acids form a potentially cleavable signal sequence in this 60-residue extension. We investigated the functional role of this extension and found that it was required for stable protein expression of transporter constructs containing any downstream transmembrane domains. The extension directed transporter translocation across the ER membrane with an orientation that resulted in glycosylation of amino acids immediately distal to the signal sequence. Neither the native signal sequence nor a green fluorescent protein tag, fused at the amino terminus, was cleaved from ABCA1. The green fluorescent protein fusion protein had efflux activity comparable with wild type ABCA1 and demonstrated a predominantly plasma membrane distribution in transfected cells. These data establish a requirement for the upstream 60 amino acids of ABCA1. This region contains an uncleaved signal anchor sequence that positions the amino terminus in a type II orientation leading to the extracellular presentation of an similar to 600-amino acid loop in which loss-of-function mutations cluster in Tangier disease patients.	Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Miami, Sch Med, Diabet Res Inst, Miami, FL 33101 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Miami	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA.		Moore, Kathryn/ABE-6416-2020	Moore, Kathryn/0000-0003-2505-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066678, P50HL056985, R01HL045098, R29HL053451, F32HL010398] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53451, UO1-HL-66678, HL10398, HL56985, HL45098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson L, 1998, J BIOL CHEM, V273, P19592, DOI 10.1074/jbc.273.31.19592; ARTISS JD, 1980, MICROCHEM J, V25, P535, DOI 10.1016/0026-265X(80)90219-2; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; CHAMBENOIT O, 2001, J BIOL CHEM     0109; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HODGES RS, 1988, J BIOL CHEM, V263, P11768; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Mendez AJ, 1997, J LIPID RES, V38, P1807; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Mott S, 2000, ATHEROSCLEROSIS, V152, P457, DOI 10.1016/S0021-9150(99)00498-0; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8; Pullinger CR, 2000, BIOCHEM BIOPH RES CO, V271, P451, DOI 10.1006/bbrc.2000.2652; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Wang J, 2000, ARTERIOSCL THROM VAS, V20, P1983, DOI 10.1161/01.ATV.20.8.1983; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Zhao LX, 2000, BIOCHEM J, V350, P865, DOI 10.1042/0264-6021:3500865	39	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15137	15145		10.1074/jbc.M100474200	http://dx.doi.org/10.1074/jbc.M100474200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11328826	hybrid			2022-12-27	WOS:000168528800082
J	Tsai, HF; Fujii, I; Watanabe, A; Wheeler, AH; Chang, YC; Yasuoka, Y; Ebizuka, Y; Kwon-Chung, KJ				Tsai, HF; Fujii, I; Watanabe, A; Wheeler, AH; Chang, YC; Yasuoka, Y; Ebizuka, Y; Kwon-Chung, KJ			Pentaketide melanin biosynthesis in Aspergillus fumigatus requires chain-length shortening of a heptaketide precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYKETIDE SYNTHASE GENE; NIDULANS WA GENE; COLLETOTRICHUM-LAGENARIUM; HETEROLOGOUS EXPRESSION; VIRULENCE; CLONING; ORYZAE; PKS1; IDENTIFICATION; TRANSFORMATION	Chain lengths and cyclization patterns of microbial polyketides are generally determined by polyketide synthases alone. Fungal polyketide melanins are often derived from a pentaketide 1,8-dihydroxynaphthalene, and pentaketide synthases are used for synthesis of the upstream pentaketide precursor, 1,3,6,8-tetrahydroxynaphthalene (1,3,6,8-THN). However, Aspergillus fumigatus, a human fungal pathogen, uses a heptaketide synthase (Alb1p) to synthesize its conidial pigment through a pentaketide pathway similar to that which produces 1,8-dihydroxynaphthalene-melanin. In this study we demonstrate that a novel protein, Ayg1p, is involved in the formation of 1,3,6,8-THN by chain-length shortening of a heptaketide precursor in A. fumigatus. Deletion of the ayg1 gene prevented the accumulation of 1,3,6,8-THN suggesting the involvement of ayg1 in 1,3,6,8-THN production. Genetic analyses of double-gene deletants suggested that Ayg1p catalyzes a novel biosynthetic step downstream of Alb1p and upstream of Arp2p (1,3,6,8-THN reductase). Further genetic and biochemical analyses of the reconstituted strains carrying alb1, ayg1, or alb1 + ayg1 indicated that Ayg1p is essential for synthesis of 1,3,6,8-THN in addition to Alb1p. Cell-free enzyme assays, using the crude Ayg1p protein extract, revealed that Ayg1p enzymatically shortened the heptaketide product of Alb1p to 1,3,6,8-THN. Thus, the protein Ayg1p facilitates the participation of a heptaketide synthase in a pentaketide pathway via a novel polyketide-shortening mechanism in A fumigatus.	NIAID, Clin Invest Lab, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; USDA ARS, Cotton Pathol Res Unit, College Stn, TX 77845 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Tokyo; United States Department of Agriculture (USDA)	Kwon-Chung, KJ (corresponding author), NIAID, Clin Invest Lab, NIH, Bldg 10,Rm 11C304,10 Ctr Dr,MSC 1882, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000657, Z01AI000057, ZIAAI000657, ZIAAI000057] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; Butler MJ, 1998, CAN J MICROBIOL, V44, P1115, DOI 10.1139/cjm-44-12-1115; CHANG PK, 1995, MOL GEN GENET, V248, P270, DOI 10.1007/BF02191593; DIXON DM, 1987, J MED VET MYCOL, V25, P97; FENG GH, 1995, J BACTERIOL, V177, P6246, DOI 10.1128/jb.177.21.6246-6254.1995; Fujii I, 1996, MOL GEN GENET, V253, P1, DOI 10.1007/s004380050289; Fujii I, 1999, BIOSCI BIOTECH BIOCH, V63, P1445, DOI 10.1271/bbb.63.1445; Fujii I, 2000, BIOCHEMISTRY-US, V39, P8853, DOI 10.1021/bi000644j; Fujii I., 1999, COMPREHENSIVE NATURA, V1, P409, DOI [10.1016/B978-0-08-091283-7.00016-3, DOI 10.1016/B978-0-08-091283-7.00016-3]; FUJII T, 1995, BIOSCI BIOTECH BIOCH, V59, P1869, DOI 10.1271/bbb.59.1869; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; GOMI K, 1987, AGR BIOL CHEM TOKYO, V51, P2549; Hendrickson L, 1999, CHEM BIOL, V6, P429, DOI 10.1016/S1074-5521(99)80061-1; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Kafer E, 1977, Adv Genet, V19, P33, DOI 10.1016/S0065-2660(08)60245-X; Keller NP, 1997, FUNGAL GENET BIOL, V21, P17, DOI 10.1006/fgbi.1997.0970; Kennedy J, 1999, SCIENCE, V284, P1368, DOI 10.1126/science.284.5418.1368; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; MAYORGA ME, 1992, MOL GEN GENET, V235, P205, DOI 10.1007/BF00279362; Perpetua NS, 1996, MOL PLANT MICROBE IN, V9, P323, DOI 10.1094/MPMI-9-0323; Proctor RH, 1999, FUNGAL GENET BIOL, V27, P100, DOI 10.1006/fgbi.1999.1141; RAPER KB, 1965, GENUS ASPERGILLUS, P36; Sambrook J., 2002, MOL CLONING LAB MANU; TAKANO Y, 1995, MOL GEN GENET, V249, P162, DOI 10.1007/BF00290362; Thompson JE, 2000, J BIOL CHEM, V275, P34867, DOI 10.1074/jbc.M006659200; TIMBERLAKE WE, 1986, ANNU REV GENET, V24, P5; Tsai HF, 1999, J BACTERIOL, V181, P6469, DOI 10.1128/JB.181.20.6469-6477.1999; Tsai HF, 1997, MOL MICROBIOL, V26, P175, DOI 10.1046/j.1365-2958.1997.5681921.x; Tsai HF, 1998, J BACTERIOL, V180, P3031, DOI 10.1128/JB.180.12.3031-3038.1998; Watanabe A, 1999, TETRAHEDRON LETT, V40, P91, DOI 10.1016/S0040-4039(98)80027-0; Watanabe A, 2000, FEMS MICROBIOL LETT, V192, P39, DOI 10.1111/j.1574-6968.2000.tb09356.x; Wheeler M H, 1988, Curr Top Med Mycol, V2, P338; WHEELER MH, 1979, EXP MYCOL, V3, P340, DOI 10.1016/S0147-5975(79)80037-7; WHEELER MH, 1995, PESTIC BIOCHEM PHYS, V52, P125, DOI 10.1006/pest.1995.1037; Yang G, 1996, PLANT CELL, V8, P2139, DOI 10.1105/tpc.8.11.2139; YELTON MM, 1984, P NATL ACAD SCI-BIOL, V81, P1470, DOI 10.1073/pnas.81.5.1470; YU JH, 1995, J BACTERIOL, V177, P4792, DOI 10.1128/jb.177.16.4792-4800.1995	37	109	118	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29292	29298		10.1074/jbc.M101998200	http://dx.doi.org/10.1074/jbc.M101998200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11350964	hybrid			2022-12-27	WOS:000170346000088
J	Breton, C; Chellil, H; Kabbaj-Benmansour, M; Carnazzi, E; Seyer, R; Phalipou, S; Morin, D; Durroux, T; Zingg, H; Barberis, C; Mouillac, B				Breton, C; Chellil, H; Kabbaj-Benmansour, M; Carnazzi, E; Seyer, R; Phalipou, S; Morin, D; Durroux, T; Zingg, H; Barberis, C; Mouillac, B			Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist - Comparison with the human V-1a vasopressin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PRETERM LABOR; EXPRESSION; AGONIST; PROTEINS; LIGAND; SITE; RHODOPSIN; BUTYRATE; CLEAVAGE	Understanding of the molecular determinants responsible for antagonist binding to the oxytocin receptor should provide important insights that facilitate rational design of potential therapeutic agents for the treatment of preterm labor. To study ligand/receptor interactions, we used a novel photosensitive radioiodinated antagonist of the human oxytocin receptor, d(CH2)(5) [Tyr(Me)(2),Thr(4),Orn(8),Phe(3(125)I,4N(3))-NH29]vasotocin. This ligand had an equivalent high affinity for human oxytocin and V-1a vasopressin receptors expressed in Chinese hamster ovary cells. Taking advantage of this dual specificity, we conducted photoaffinity labeling experiments on both receptors, Photolabeled oxytocin and V-1a receptors appeared as a unique protein band at 70-75 kDa and two labeled protein bands at 85-90 and 46 kDa, respectively. To identify contact sites between the antagonist and the receptors, the labeled 70-75- and the 46-kDa proteins were cleaved with CNBr and digested with Lys-C and Arg-C endoproteinases, The fragmentation patterns allowed the identification of a covalently labeled region in the oxytocin receptor transmembrane domain III consisting of the residues Leu(114)-Val(115)- Lys(116). Analysis of contact sites in the V-1a receptor led to the identification of the homologous region consisting of the residues Val(126)-Val(127)-Lys(128). Binding domains were confirmed by mutation of several CNBr cleavage sites in the oxytocin receptor and of one Lys-C cleavage site in the V-1a receptor. The results are in agreement with previous experimental data and three-dimensional models of agonist and antagonist binding to members of the oxytocin/vasopressin receptor family.	INSERM, U469, F-34094 Montpellier 5, France; CNRS, UPR 9023, F-34094 Montpellier 5, France; McGill Univ, Mol Endocrinol Lab, Ctr Hlth, Montreal, PQ H3A 1A1, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); McGill University	Mouillac, B (corresponding author), INSERM, U469, 141 Rue Cardonille, F-34094 Montpellier 5, France.	mouillac@u469.montp.inserm.fr	Zingg, Hans/GPS-9984-2022; MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673; Durroux, Thierry/0000-0003-1091-6066				Andersson K E, 1983, Clin Obstet Gynecol, V26, P56, DOI 10.1097/00003081-198303000-00010; Barberis C, 1998, J ENDOCRINOL, V156, P223, DOI 10.1677/joe.0.1560223; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Bathgate R, 1995, DNA CELL BIOL, V14, P1037, DOI 10.1089/dna.1995.14.1037; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Carnazzi E, 1997, EUR J BIOCHEM, V247, P906, DOI 10.1111/j.1432-1033.1997.00906.x; Chan WY, 2000, EXP PHYSIOL, V85, p7S, DOI 10.1111/j.1469-445X.2000.tb00003.x; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; COTTE N, 2000, EUR J BIOCHEM, V267, P1; ELANDS J, 1988, EUR J PHARMACOL, V147, P197, DOI 10.1016/0014-2999(88)90778-9; FAHRENHOLZ F, 1988, EUR J BIOCHEM, V174, P81, DOI 10.1111/j.1432-1033.1988.tb14065.x; Fuchs AR., 1985, OXYTOCIN CLIN LABORA, P207; GAINER H, 1994, PHYSL REPROD, V2, P1099; Goodwin TM, 1996, AM J PERINAT, V13, P143, DOI 10.1055/s-2007-994312; Goodwin TM, 1998, CLIN PERINATOL, V25, P859, DOI 10.1016/S0095-5108(18)30087-3; GORBULEV V, 1993, EUR J BIOCHEM, V215, P1, DOI 10.1111/j.1432-1033.1993.tb18000.x; HINKO A, 1992, ENDOCRINOLOGY, V130, P3554, DOI 10.1210/en.130.6.3554; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KASSIS S, 1984, J BIOL CHEM, V259, P4910; Kimura T, 1997, MOL HUM REPROD, V3, P957, DOI 10.1093/molehr/3.11.957; KIMURA T, 1992, NATURE, V356, P526, DOI 10.1038/356526a0; KOJRO E, 1991, J BIOL CHEM, V266, P21416; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; Kojro E, 1999, EUR J BIOCHEM, V266, P538, DOI 10.1046/j.1432-1327.1999.00892.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARC S, 1986, FEBS LETT, V201, P9, DOI 10.1016/0014-5793(86)80561-0; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MULLER M, 1989, FEBS LETT, V242, P333, DOI 10.1016/0014-5793(89)80496-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Park C, 1996, BIOCHEMISTRY-US, V35, P9807, DOI 10.1021/bi9602223; Phalipou S, 1999, J BIOL CHEM, V274, P23316, DOI 10.1074/jbc.274.33.23316; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Postina R, 1996, J BIOL CHEM, V271, P31593, DOI 10.1074/jbc.271.49.31593; ROZEN F, 1995, P NATL ACAD SCI USA, V92, P200, DOI 10.1073/pnas.92.1.200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; STRADER CD, 1988, J BIOL CHEM, V263, P10267; Strakova Z, 1997, AM J PHYSIOL-ENDOC M, V272, pE870, DOI 10.1152/ajpendo.1997.272.5.E870; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; Thibonnier M, 1998, ADV EXP MED BIOL, V449, P251; Valenzuela GJ, 2000, AM J OBSTET GYNECOL, V182, P1184, DOI 10.1067/mob.2000.105816; Williams PD, 1998, ADV EXP MED BIOL, V449, P473; Yarwood NJ, 1995, ADV EXP MED BIOL, V395, P343	47	46	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26931	26941		10.1074/jbc.M102073200	http://dx.doi.org/10.1074/jbc.M102073200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11337500	hybrid			2022-12-27	WOS:000169966900028
J	Delmolino, LM; Saha, P; Dutta, A				Delmolino, LM; Saha, P; Dutta, A			Multiple mechanisms regulate subcellular localization of human CDC6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; FISSION YEAST; S-PHASE; INITIATION; PROTEINS	CDC6 is a protein essential for DNA replication, the expression and abundance of which are cell cycle-regulated in Saccharomyces cerevisiae. We have demonstrated previously that the subcellular localization of the human CDC6 homolog, HsCDC6, is cell cycle-dependent: nuclear during G(1) phase and cytoplasmic during S phase. Here we demonstrate that endogenous HsCDC6 is phosphorylated during the G(1)/S transition. The N-terminal region contains putative cyclin-dependent kinase phosphorylation sites adjoining nuclear localization sequences (NLSs) and a cyclin-docking motif, whereas the C-terminal region contains a nuclear export signal (NES). In addition, we show that the observed regulated subcellular localization depends on phosphorylation status, NLS, and NES. When the four putative substrate sites (serines 45, 54, 74, and 106) for cyclin-dependent kinases are mutated to alanines, the resulting HsCDC6A4 protein is localized predominantly to the nucleus. This localization depends upon two functional NLSs, because expression of HsCDC6 containing mutations in the two putative NLSs results in predominantly cytoplasmic distribution. Furthermore, mutation of the four serines to phosphate-mimicking aspartates (HsCDC6D4) results in strictly cytoplasmic localization. This cytoplasmic localization depends upon the C-terminal NES. Together these results demonstrate that HsCDC6 is phosphorylated at the G(1)/S phase of the cell cycle and that the phosphorylation status determines the subcellular localization.	Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Saha, Partha/0000-0002-4514-6391	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Herbig U, 2000, MOL BIOL CELL, V11, P4117, DOI 10.1091/mbc.11.12.4117; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Takahara K, 1996, GENOMICS, V31, P119, DOI 10.1006/geno.1996.0018; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	30	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26947	26954		10.1074/jbc.M101870200	http://dx.doi.org/10.1074/jbc.M101870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346650	hybrid			2022-12-27	WOS:000169966900030
J	Hu, MC; Fan, LZ; Crowder, LA; Karim-Jimenez, Z; Murer, H; Moe, OW				Hu, MC; Fan, LZ; Crowder, LA; Karim-Jimenez, Z; Murer, H; Moe, OW			Dopamine acutely stimulates Na+/H+ exchanger (NHE3) endocytosis via clathrin-coated vesicles - Dependence on protein kinase A-mediated NHE3 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RENAL BRUSH-BORDER; PROXIMAL CONVOLUTED TUBULE; K+-ATPASE ACTIVITY; SPONTANEOUSLY HYPERTENSIVE RATS; SODIUM-EXCRETION; NA+,K+-ATPASE ACTIVITY; PARATHYROID-HORMONE; VOLUME EXPANSION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSPORT VESICLES	Dopamine (DA) is a key hormone in mammalian sodium homeostasis. DA induces natriuresis via acute inhibition of the renal proximal tubule apical membrane Na+/H+ exchanger NHE3. We examined the mechanism by which DA inhibits MHE3 in a renal cell line. DA acutely decreases surface NHE3 antigen in dose- and time-dependent fashion without altering total cellular NHE3. Although DA, receptor agonist alone decreases surface NHE3, simultaneous DA, agonist synergistically enhances the effect of DA,, Decreased surface NHE3 antigen, caused by stimulation of NHE3 endocytosis, is dependent on intact functioning of the GTPase dynamin and involves increased binding of NHE3 to the adaptor protein AP2, DA-stimulated NHE3 endocytosis can be blocked by pharmacologic or genetic protein kinase A inhibition or by mutation of two protein kinase A target serines (Ser-560 and Ser-613) on NRE3, We conclude that one mechanism by which DA induces natriuresis is via protein kinase A-mediated phosphorylation of proximal tubule NHE3 leading to endocytosis of NHE3 via clathrin-coated vesicles.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Dept Vet Affairs Med Ctr, Med Serv, Dallas, TX 75216 USA; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Zurich	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			KARIM, Zoubida/0000-0002-3724-5592	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048482, R01DK048482, R01DK054396] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-48482, DK-54396] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter S, 2000, BIOCHEMISTRY-US, V39, P1990, DOI 10.1021/bi991739s; Albrecht FE, 2000, AM J PHYSIOL-REG I, V278, pR1064, DOI 10.1152/ajpregu.2000.278.4.R1064; ALEXANDER RW, 1974, J CLIN INVEST, V54, P194, DOI 10.1172/JCI107743; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; Amenta F, 1997, CLIN EXP HYPERTENS, V19, P27, DOI 10.3109/10641969709080802; APERIA A, 1987, AM J PHYSIOL, V252, pF39, DOI 10.1152/ajprenal.1987.252.1.F39; BAINES AD, 1980, LIFE SCI, V26, P253, DOI 10.1016/0024-3205(80)90334-3; Baines AD, 1998, J AM SOC NEPHROL, V9, P1604; BALL SG, 1977, BRIT J CLIN PHARMACO, V4, P115, DOI 10.1111/j.1365-2125.1977.tb00681.x; BARBEAU A, 1970, CAN MED ASSOC J, V103, P824; Baum M, 1998, KIDNEY INT, V54, P1593, DOI 10.1046/j.1523-1755.1998.00156.x; BELLOREUSS E, 1977, AM J PHYSIOL, V232, pF26, DOI 10.1152/ajprenal.1977.232.1.F26; BERTORELLO A, 1988, AM J PHYSIOL, V254, pF795, DOI 10.1152/ajprenal.1988.254.6.F795; BERTORELLO A, 1990, AM J HYPERTENS, V3, pS51, DOI 10.1093/ajh/3.6.51S; BERTORELLO A, 1990, AM J PHYSIOL, V259, pF924, DOI 10.1152/ajprenal.1990.259.6.F924; BERTORELLO A, 1988, ACTA PHYSIOL SCAND, V132, P441, DOI 10.1111/j.1748-1716.1988.tb08350.x; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHAN YL, 1976, J PHARMACOL EXP THER, V199, P17; CHAPMAN BJ, 1980, J PHYSIOL-LONDON, V298, P437, DOI 10.1113/jphysiol.1980.sp013093; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Collazo R, 2000, J BIOL CHEM, V275, P31601, DOI 10.1074/jbc.M000600200; CORRUZI P, 1986, CLIN SCI, V70, P523; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVIS BB, 1968, P SOC EXP BIOL MED, V129, P210; DEFEO ML, 1987, CLIN EXP HYPERTENS A, V9, P2049, DOI 10.3109/10641968709159074; Fan LZ, 1999, J BIOL CHEM, V274, P11289, DOI 10.1074/jbc.274.16.11289; FELDER CC, 1989, KIDNEY INT, V36, P183, DOI 10.1038/ki.1989.178; FELDER CC, 1990, AM J PHYSIOL, V259, pF297, DOI 10.1152/ajprenal.1990.259.2.F297; FELDER CC, 1993, AM J PHYSIOL, V263, pF1031; FELDER RA, 1993, AM J PHYSIOL, V264, pR726, DOI 10.1152/ajpregu.1993.264.4.R726; FELDER RA, 1990, AM J HYPERTENS, V3, pS96, DOI 10.1093/ajh/3.6.96S; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; GESEK FA, 1990, AM J PHYSIOL, V258, pF514, DOI 10.1152/ajprenal.1990.258.3.F514; GLAHN RP, 1993, AM J PHYSIOL, V264, pF614; GOLDSTEIN DS, 1989, CLIN SCI, V76, P517, DOI 10.1042/cs0760517; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; HAGIWARA N, 1990, JPN J PHYSIOL, V40, P351, DOI 10.2170/jjphysiol.40.351; HANSELL P, 1991, KIDNEY INT, V39, P253, DOI 10.1038/ki.1991.30; HAYASHI M, 1991, AM J PHYSIOL, V260, pE675, DOI 10.1152/ajpendo.1991.260.5.E675; HAYASHI M, 1990, AM J PHYSIOL, V258, pF28, DOI 10.1152/ajprenal.1990.258.1.F28; HEDGE SS, 1989, HYPERTENSION, V13, P828; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOLLENBERG NK, 1980, KIDNEY INT, V17, P423, DOI 10.1038/ki.1980.50; HOLLENBERG NK, 1973, CLIN SCI MOL MED, V45, P733, DOI 10.1042/cs0450733; HORIUCHI A, 1992, AM J PHYSIOL, V263, pF1105, DOI 10.1152/ajprenal.1992.263.6.F1105; IMURA O, 1996, JPN HEART J, V37, P815; JADHAV AL, 1992, CLIN EXP HYPERTENS A, V14, P653, DOI 10.3109/10641969209036213; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Janecki AJ, 1998, J BIOL CHEM, V273, P8790, DOI 10.1074/jbc.273.15.8790; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; JOSE PA, 1988, NEPHRON, V48, P54, DOI 10.1159/000184869; JOSE PA, 1986, AM J PHYSIOL, V250, P1033, DOI 10.1152/ajprenal.1986.250.6.F1033; Jose PA, 1996, AM J HYPERTENS, V9, P400, DOI 10.1016/0895-7061(95)00351-7; JOSE PA, 1992, J AM SOC NEPHROL, V2, P1265; Karim-Jimenez Z, 2000, P NATL ACAD SCI USA, V97, P12896, DOI 10.1073/pnas.220394197; KINOSHITA S, 1989, J CLIN INVEST, V84, P1849, DOI 10.1172/JCI114371; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KRISHNA GG, 1985, J LAB CLIN MED, V105, P214; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LARADI A, 1986, MINER ELECTROL METAB, V12, P303; Lederer ED, 1998, J AM SOC NEPHROL, V9, P975; LEE MR, 1993, CLIN SCI, V84, P357, DOI 10.1042/cs0840357; LEE MR, 1989, CLIN EXP HYPERTENS A, V11, P149, DOI 10.3109/10641968909045420; LOKHANDWALA MF, 1991, FASEB J, V5, P3023, DOI 10.1096/fasebj.5.15.1683844; Magyar CE, 2000, AM J PHYSIOL-RENAL, V279, pF358, DOI 10.1152/ajprenal.2000.279.2.F358; MCDONALD RH, 1964, J CLIN INVEST, V43, P1116, DOI 10.1172/JCI104996; Moe OW, 1997, CURR OPIN NEPHROL HY, V6, P440, DOI 10.1097/00041552-199709000-00006; Moe OW, 1999, J AM SOC NEPHROL, V10, P2412; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; NISHI A, 1993, HYPERTENSION, V21, P767, DOI 10.1161/01.HYP.21.6.767; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; OHBU K, 1995, AM J PHYSIOL-REG I, V268, pR231, DOI 10.1152/ajpregu.1995.268.1.R231; PELAYO JC, 1983, AM J PHYSIOL, V245, pF247, DOI 10.1152/ajprenal.1983.245.2.F247; Peng Y, 1999, AM J PHYSIOL-CELL PH, V276, pC938, DOI 10.1152/ajpcell.1999.276.4.C938; PERRICHOT R, 1995, BIOCHEM J, V312, P433, DOI 10.1042/bj3120433; RACZ K, 1986, CIRC RES, V58, P889; RECTOR FC, 1983, AM J PHYSIOL, V244, pF461, DOI 10.1152/ajprenal.1983.244.5.F461; ROBINSON MS, 1998, BIOCHIM BIOPHYS ACTA, V1404, P173; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SHEIKHHAMAD D, 1993, AM J PHYSIOL, V264, pF737, DOI 10.1152/ajprenal.1993.264.4.F737; SIDHU A, 1992, J CLIN INVEST, V89, P789, DOI 10.1172/JCI115657; SIMPSON FO, 1988, LANCET, V2, P25; SIRAGY HM, 1989, AM J PHYSIOL, V257, pF469, DOI 10.1152/ajprenal.1989.257.3.F469; SOWERS JR, 1984, ENDOCRINOLOGY, V115, P2085, DOI 10.1210/endo-115-6-2085; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEMOTO F, 1991, PFLUG ARCH EUR J PHY, V419, P243, DOI 10.1007/BF00371102; VALLEE RB, 1993, CIBA F SYMP, V176, P185; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; Wiederkehr MR, 2001, KIDNEY INT, V59, P197, DOI 10.1046/j.1523-1755.2001.00480.x; Wiederkehr MR, 1999, AM J PHYSIOL-CELL PH, V276, pC1205, DOI 10.1152/ajpcell.1999.276.5.C1205; WILLIAMS GH, 1990, AM J HYPERTENS, V3, pS112, DOI 10.1093/ajh/3.6.112S; WINAVER J, 1990, KIDNEY INT, V38, P1133, DOI 10.1038/ki.1990.323; Yang XJ, 2000, AM J PHYSIOL-CELL PH, V279, pC410, DOI 10.1152/ajpcell.2000.279.2.C410; Yip KP, 1998, AM J PHYSIOL-RENAL, V275, pF565, DOI 10.1152/ajprenal.1998.275.4.F565; YOSHIDA Y, 1990, CHIRALITY, V2, P10, DOI 10.1002/chir.530020103; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004; Zhang YB, 1999, AM J PHYSIOL-RENAL, V276, pF711, DOI 10.1152/ajprenal.1999.276.5.F711; Zhang YB, 1998, AM J PHYSIOL-CELL PH, V274, pC1090, DOI 10.1152/ajpcell.1998.274.4.C1090; Zhang YBB, 1998, J AM SOC NEPHROL, V9, P531; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978; Zhu YX, 1999, MOL BIOL CELL, V10, P537, DOI 10.1091/mbc.10.3.537	114	120	119	4	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26906	26915		10.1074/jbc.M011338200	http://dx.doi.org/10.1074/jbc.M011338200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328806	hybrid, Green Accepted			2022-12-27	WOS:000169966900025
J	Sakamoto, N; Ohshima, K; Montermini, L; Pandolfo, M; Wells, RD				Sakamoto, N; Ohshima, K; Montermini, L; Pandolfo, M; Wells, RD			Sticky DNA, a self-associated complex formed at long GAA center dot TTC repeats in intron 1 of the frataxin gene, inhibits transcriptions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICH ATAXIA GENE; ELONGATION IN-VITRO; RNA-POLYMERASE; BINDING PROTEIN; STRANDED DNA; CIRCULAR DNA; EXPRESSION; EXPANSION; SEQUENCES; PATHOGENESIS	Friedreich's ataxia (FRDA) is an autosomal recessive neurodegenerative disease caused by the expansion of GAA.TTC repeats in the first intron of the frataxin (X25) gene. FRDA patients carrying two expanded GAA.TTC repeats show very low levels of mature frataxin mRNA and protein. A novel type of unusual DNA structure, sticky DNA, was previously found in the expanded GAA.TTC repeats from FRDA patients, To evaluate the effect of sticky DNA on transcription, in vitro transcription studies of (GAA.TTC), repeats (where n = 9-150) were carried out using T7 or SP6 RNA polymerase, When a gel-isolated sticky DNA template was transcribed, the amount of full-length RNA synthesized was significantly reduced compared with the transcription of the linear template, Surprisingly, transcriptional inhibition was observed not only for the sticky DNA template but also another DNA molecule used as an internal control in an orientation-independent manner. The molecular mechanism of transcriptional inhibition by sticky DNA was a sequestration of the RNA polymerases by direct binding to the complex DNA structure. Moreover, plasmids containing the (GAAGGA.TCCTTC)(65) repeat, which does not form sticky DNA, did not inhibit in vitro transcription, as expected. These results suggest that the role of sticky DNA in FRDA may be the sequestration of transcription factors.	Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr, Houston, TX 77030 USA; Ctr Hosp Univ Montreal, Montreal, PQ H2L 4M1, Canada	Baylor College of Medicine; Texas A&M University System; Universite de Montreal	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	Pandolfo, Massimo/B-2853-2010		NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554, NS34192] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034192, R01NS037554] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashley C, 2000, DNA CELL BIOL, V19, P235, DOI 10.1089/104454900314500; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; BUTLER ET, 1982, J BIOL CHEM, V257, P5772; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Delatycki MB, 2000, J MED GENET, V37, P1, DOI 10.1136/jmg.37.1.1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Epplen C, 1997, HUM GENET, V99, P834, DOI 10.1007/s004390050458; Filla A, 1996, AM J HUM GENET, V59, P554; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FUJITA R, 1989, GENOMICS, V4, P110, DOI 10.1016/0888-7543(89)90323-6; Giovannangeli C, 1996, J MOL BIOL, V261, P386, DOI 10.1006/jmbi.1996.0471; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; Gray JV, 1997, NAT GENET, V16, P323, DOI 10.1038/ng0897-323; GRIGORIEV M, 1993, P NATL ACAD SCI USA, V90, P3501, DOI 10.1073/pnas.90.8.3501; HAMPEL KJ, 1993, BIOCHEMISTRY-US, V32, P1072, DOI 10.1021/bi00055a012; HANAUER A, 1990, AM J HUM GENET, V46, P133; Jimenez-Garcia E, 1998, J BIOL CHEM, V273, P24640, DOI 10.1074/jbc.273.38.24640; Kaplan J, 1999, P NATL ACAD SCI USA, V96, P10948, DOI 10.1073/pnas.96.20.10948; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Kovacs A, 1996, J BIOL CHEM, V271, P1805, DOI 10.1074/jbc.271.3.1805; LEE JS, 1995, J MOL BIOL, V252, P283, DOI 10.1006/jmbi.1995.0495; Mariappan SVS, 1999, J MOL BIOL, V285, P2035, DOI 10.1006/jmbi.1998.2435; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; Nelson LD, 2000, J BIOL CHEM, V275, P5573, DOI 10.1074/jbc.275.8.5573; NISHIMURA S, 1965, J MOL BIOL, V13, P302, DOI 10.1016/S0022-2836(65)80098-5; OAKLEY JL, 1975, BIOCHEMISTRY-US, V14, P4684, DOI 10.1021/bi00692a019; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Pandolfo M, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P373; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR PS, 1992, NUCLEIC ACIDS RES, V20, P5713, DOI 10.1093/nar/20.21.5713; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Wells R.D., 1998, GENETIC INSTABILITIE; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	48	141	146	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27171	27177		10.1074/jbc.M101879200	http://dx.doi.org/10.1074/jbc.M101879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11340071	hybrid			2022-12-27	WOS:000169966900060
J	Cavaille, J; Vitali, P; Basyuk, E; Huttenhofer, A; Bachellerie, JP				Cavaille, J; Vitali, P; Basyuk, E; Huttenhofer, A; Bachellerie, JP			A novel brain-specific box C/D small nucleolar RNA processed from tandemly repeated introns of a noncoding RNA gene in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNORNA HOST GENE; 2'-O-RIBOSE METHYLATION; RIBOSE METHYLATION; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; ENCODED U16; GUIDE RNA; COMPLEMENTARITIES; TRANSCRIPT; LONG	Antisense box C/D small nucleolar RNAs (snoRNAs) guide the 2 ' -O-ribose methylations of eukaryotic rRNAs and small nuclear RNAs (snRNAs) through formation of a specific base pairing at each RNA methylation site. By analysis of a box C/D snoRNA cDNA library constructed from rat brain RNAs, we have identified a novel box C/D snoRNA, RBII-36, which is devoid of complementarity to rRNA or an snRNA and exhibits a brain-specific expression pattern. It is uniformly expressed in all major areas of adult rat brain (except for choroid plexus) and throughout rat brain ontogeny but exclusively detected in neurons in which it exhibits a nucleolar localization. In vertebrates, known methylation guide snoRNAs are intron-encoded and processed from transcripts of housekeeping genes. In contrast, RBII-36 snoRNA is intron-encoded in a gene preferentially expressed in the rat central nervous system and not in proliferating cells. Remarkably, this host gene, which encodes a previously reported noncoding RNA, Bar, spans tandemly repeated 0.9-kilobase units including the snoRNA-containing intron. The novel brain-specific snoRNA appears to result not only from processing of the debranched lariat but also from endonucleolytic cleavages of unspliced Bar RNA (i.e. an alternative splicing-independent pathway unreported so far for mammalian intronic snoRNAs), Sequences homologous to RBII-36 snoRNA were exclusively detected in the Rattus genus of rodents, suggesting a very recent origin of this brain-specific snoRNA.	Univ Toulouse 3, UMR5099, Lab Biol Mol Eucaryote, CNRS, F-31062 Toulouse, France; CNRS, UPR 9023, F-34094 Montpellier 05, France; Zentrum Mol Biol Entzundung, Inst Expt Pathol, D-48149 Munster, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	Cavaille, J (corresponding author), Univ Toulouse 3, UMR5099, Lab Biol Mol Eucaryote, CNRS, 118 Route de Narbonne, F-31062 Toulouse, France.	cavaille@ibcg.biotoul.fr; bachel@ibcg.biotoul.fr	cavaille, jerome/AAM-8047-2020	vitali, patrice/0000-0001-8178-9004; CAVAILLE, Jerome/0000-0003-2833-6836; Basyuk, Eugenia/0000-0001-9768-4557				Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; ARMOFONSECA M, 2000, NAT CELL BIOL, V2, pE107; Bachellerie JP, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P191; BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; Bachellerie JP, 1997, TRENDS BIOCHEM SCI, V22, P257, DOI 10.1016/S0968-0004(97)01057-8; Balakin AG, 1996, CELL, V86, P823, DOI 10.1016/S0092-8674(00)80156-7; Basyuk E, 2000, Nucleic Acids Res, V28, pE46, DOI 10.1093/nar/28.10.e46; Bortolin ML, 1998, RNA, V4, P445; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CAFFARELLI E, 1994, MOL CELL BIOL, V14, P2966, DOI 10.1128/MCB.14.5.2966; Cavaille J, 1996, NATURE, V383, P732, DOI 10.1038/383732a0; Cavaille J, 1998, NUCLEIC ACIDS RES, V26, P1576, DOI 10.1093/nar/26.7.1576; Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; de los Santos T, 2000, AM J HUM GENET, V67, P1067, DOI 10.1086/303106; Dunbar DA, 2000, NUCLEIC ACIDS RES, V28, P2855, DOI 10.1093/nar/28.15.2855; Dunbar DA, 2000, J BIOL CHEM, V275, P14767, DOI 10.1074/jbc.M001180200; Fatica A, 2000, EMBO J, V19, P6218, DOI 10.1093/emboj/19.22.6218; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; Ganot P, 1999, MOL CELL BIOL, V19, P6906; Gaspin C, 2000, J MOL BIOL, V297, P895, DOI 10.1006/jmbi.2000.3593; Huttenhofer A, 2001, EMBO J, V20, P2943, DOI 10.1093/emboj/20.11.2943; Jady BE, 2000, NUCLEIC ACIDS RES, V28, P1348, DOI 10.1093/nar/28.6.1348; Jady BE, 2001, EMBO J, V20, P541, DOI 10.1093/emboj/20.3.541; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; Komine Y, 1999, MOL BRAIN RES, V66, P1, DOI 10.1016/S0169-328X(98)00343-X; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Leader DJ, 1999, PLANT MOL BIOL, V39, P1091, DOI 10.1023/A:1006157022319; Liang-Hu Qu, 2001, Nucleic Acids Research, V29, P1623, DOI 10.1093/nar/29.7.1623; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; Ooi SL, 1998, RNA, V4, P1096, DOI 10.1017/S1355838298980785; Paul MS, 1998, EMBO J, V17, P1120, DOI 10.1093/emboj/17.4.1120; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pelczar P, 1998, MOL CELL BIOL, V18, P4509, DOI 10.1128/MCB.18.8.4509; QU LH, 1995, NUCLEIC ACIDS RES, V23, P2669, DOI 10.1093/nar/23.14.2669; QU LH, 1994, NUCLEIC ACIDS RES, V22, P4073, DOI 10.1093/nar/22.20.4073; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Roberts TG, 1998, MOL CELL BIOL, V18, P4409, DOI 10.1128/MCB.18.8.4409; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Smith CM, 1998, MOL CELL BIOL, V18, P6897, DOI 10.1128/MCB.18.12.6897; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; SOLLNERWEBB B, 1993, CELL, V75, P403, DOI 10.1016/0092-8674(93)90374-Y; Tanaka R, 2000, GENES CELLS, V5, P277, DOI 10.1046/j.1365-2443.2000.00325.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; Tycowski KT, 1998, MOL CELL, V2, P629, DOI 10.1016/S1097-2765(00)80161-6; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Van Hoof A, 2000, MOL CELL BIOL, V20, P441, DOI 10.1128/MCB.20.2.441-452.2000; Verneau O, 1997, J MOL EVOL, V45, P424, DOI 10.1007/PL00006247; Villa T, 2000, MOL CELL BIOL, V20, P1311, DOI 10.1128/MCB.20.4.1311-1320.2000; Villa T, 1998, MOL CELL BIOL, V18, P3376, DOI 10.1128/MCB.18.6.3376; Wevrick R, 1997, HUM MOL GENET, V6, P325, DOI 10.1093/hmg/6.2.325; Yi-Brunozzi HY, 1999, NUCLEIC ACIDS RES, V27, P2912, DOI 10.1093/nar/27.14.2912	66	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26374	26383		10.1074/jbc.M103544200	http://dx.doi.org/10.1074/jbc.M103544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346658	hybrid			2022-12-27	WOS:000169823300097
J	Dong, H; Light, PE; French, RJ; Lytton, J				Dong, H; Light, PE; French, RJ; Lytton, J			Electrophysiological characterization and ionic stoichiometry of the rat brain K+-dependent Na+/Ca2+ exchanger, NCKX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; ROD OUTER SEGMENTS; NA-CA EXCHANGER; FUNCTIONAL EXPRESSION; NA+-CA2+ EXCHANGE; DYNAMIC PROPERTIES; MOLECULAR-CLONING; RETINAL CONE; STEADY-STATE; TRANSPORT	We have recently described a novel K+-dependent Na+/Ca2+ exchanger, NCKX2, that is abundantly expressed in brain neurons (Tsoi, M,, Rhee, IL-H., Bungard, D,, Li, X-F,, Lee, S,-L,, Auer, R, N,, and Lytton, J, (1998) J, Biol, Chem, 273, 4115-4162), The precise role for NCKX2 in neuronal Ca2+ homeostasis is not yet clearly understood but will depend upon the functional properties of the molecule. Here, we have performed whole-cell patch clamp analysis to characterize cation dependences and ion stoichiometry for rat brain NCKX2, heterologously expressed in HEK293 cells. Outward currents generated by reverse NCKX2 exchange depended on external Ca2+ with a K-1/2 of 1.4 or 101 muM without or with 1 mM Mg2+, and on external K+ with a K-1/2 of about 12 or 36 mM with choline or Li+ as counter ion, respectively. Na+ inhibited outward currents with a K-1/2 of about 60 mM, Inward currents generated by forward NCKX2 exchange depended upon external Na+ with a K-1/2 of 30 mM and a Hill coefficient of 2.8. K+ inhibited the inward currents by a maximum of 40%, with a K-1/2 of 2 mM or less, depending upon the conditions. The transport stoichiometry of NCKX2 was determined by observing the change in reversal potential as individual ion gradients were altered. Our data support a stoichiometry for rat brain NCKX2 of 4 Na+:(1 Ca2+ + 1 K+), These findings provide the first electrophysiological characterization of rat brain NCKX2, and the first evidence that a single recombinantly expressed NCKX polypeptide encodes a K+-transporting Na+/Ca2+ exchanger with a transport stoichiometry of 4 Na+:(1 Ca2+ + 1 K+).	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca		Lytton, Jonathan/0000-0003-4770-2512				Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; COOK NJ, 1988, J BIOL CHEM, V263, P11382; Cooper CB, 1999, BIOCHEMISTRY-US, V38, P6276, DOI 10.1021/bi983068o; DAHAN D, 1991, J BIOL CHEM, V266, P2067; EHARA T, 1989, J PHYSIOL-LONDON, V410, P227, DOI 10.1113/jphysiol.1989.sp017530; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FONTANA G, 1995, J PHYSIOL-LONDON, V485, P349, DOI 10.1113/jphysiol.1995.sp020734; FRIEDEL U, 1991, BIOCHIM BIOPHYS ACTA, V1061, P247, DOI 10.1016/0005-2736(91)90290-O; Fujioka Y, 2000, J PHYSIOL-LONDON, V523, P339, DOI 10.1111/j.1469-7793.2000.t01-2-00339.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Haug-Collet K, 1999, J CELL BIOL, V147, P659, DOI 10.1083/jcb.147.3.659; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KIMURA M, 1993, J BIOL CHEM, V268, P6874; Kimura M, 1999, AM J PHYSIOL-HEART C, V277, pH911, DOI 10.1152/ajpheart.1999.277.3.H911; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KRAEV A, 2001, IN PRESS J BIOL CHEM, V276; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; Lytton J, 2001, BIOPHYS J, V80, p18A; MARLIER LNJL, 1993, MOL BRAIN RES, V20, P21, DOI 10.1016/0169-328X(93)90107-Z; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; Navangione A, 1997, BIOPHYS J, V73, P45, DOI 10.1016/S0006-3495(97)78046-9; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Ransom CB, 2000, J PHYSIOL-LONDON, V522, P427, DOI 10.1111/j.1469-7793.2000.00427.x; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SCHNETKAMP PPM, 1991, J GEN PHYSIOL, V98, P555, DOI 10.1085/jgp.98.3.555; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P189; SCHNETKAMP PPM, 1995, AM J PHYSIOL-CELL PH, V269, pC1153, DOI 10.1152/ajpcell.1995.269.5.C1153; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; SCHNETKAMP PPM, 1986, J PHYSIOL-LONDON, V373, P25, DOI 10.1113/jphysiol.1986.sp016033; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Seiler EP, 2000, EUR J BIOCHEM, V267, P2461, DOI 10.1046/j.1432-1327.2000.01279.x; Sheng JZ, 2000, BIOPHYS J, V79, P1945, DOI 10.1016/S0006-3495(00)76443-5; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Yu L, 1997, MOL BRAIN RES, V50, P285, DOI 10.1016/S0169-328X(97)00202-7	47	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25919	25928		10.1074/jbc.M103401200	http://dx.doi.org/10.1074/jbc.M103401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342562	hybrid			2022-12-27	WOS:000169823300039
J	Eguchi, A; Akuta, T; Okuyama, H; Senda, T; Yokoi, H; Inokuchi, H; Fujita, S; Hayakawa, T; Takeda, K; Hasegawa, M; Nakanishi, M				Eguchi, A; Akuta, T; Okuyama, H; Senda, T; Yokoi, H; Inokuchi, H; Fujita, S; Hayakawa, T; Takeda, K; Hasegawa, M; Nakanishi, M			Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; BASIC DOMAIN; BACTERIOPHAGE; BINDING; PHAGE; MEMBRANE; PEPTIDE; DISPLAY; SURFACE; INTERNALIZATION	The plasma membrane of mammalian cells is one of the tight barriers against gene transfer by synthetic delivery systems. Various agents have been used to facilitate gene transfer by destabilizing the endosomal membrane under acidic conditions, but their utility is limited, especially for gene transfer in vivo, In this article, we report that the protein transduction domain of human immunodeficiency virus type 1 Tat protein (Tat peptide) greatly facilitates gene transfer via membrane destabilization, We constructed recombinant h phage particles displaying Tat peptide on their surfaces and carrying mammalian marker genes as part of their genomes (Tat-phage), We demonstrate that, when animal cells are briefly exposed to Tat-phage, significant expression of phage marker genes is induced with no harmful effects to the cells. In contrast, recombinant phage displaying other functional peptides, such as the integrin-binding domain or a nuclear localization signal, could not induce detectable marker gene expression. The expression of marker genes induced by Tat-phage is not affected by endosomotropic agents but is partially impaired by inhibitors of caveolae formation. These data suggest that Tat peptide will become a useful component of synthetic delivery vehicles that promote gene transfer independently of the classical endocytic pathway.	Osaka Univ, Dept Neurovirol, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki 3050856, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Osaka 5328505, Japan; Sumitomo Pharmaceut Co Ltd, Osaka 5540022, Japan; Fujita Hlth Univ, Sch Med, Dept Anat 1, Toyoake, Aichi 47011, Japan; Kyowa Hakko Kogyo Co Ltd, Machida, Tokyo 1940023, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Sakyo Ku, Kyoto 6068502, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 5650871, Japan; Natl Inst Hlth Sci, Dept Biochem & Biol, Tokyo 1588501, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 3058566, Japan	Osaka University; DNAVEC Corporation; Mitsubishi Tanabe Pharma Corporation; Fujita Health University; Kyowa Kirin Ltd; Kyoto University; Osaka University; National Institute of Health Sciences - Japan; National Institute of Advanced Industrial Science & Technology (AIST)	Nakanishi, M (corresponding author), Osaka Univ, Dept Neurovirol, Res Inst Microbial Dis, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	mahito@biken.osaka-u.ac.jp	Eguchi, Akiko/E-3086-2010; Nakanishi, Mahito/I-9888-2018	Nakanishi, Mahito/0000-0002-7068-7587				ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Arber W., 1983, LAMBDA, P433; CAMPBELL A, 1961, VIROLOGY, V14, P22, DOI 10.1016/0042-6822(61)90128-3; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1999, COLD SPRING HARBOR M, V36, P261; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DANG CV, 1989, J BIOL CHEM, V264, P18019; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dunn IS, 1996, GENE, V183, P15, DOI 10.1016/S0378-1119(96)00400-3; Dunn IS, 1996, BIOCHIMIE, V78, P856, DOI 10.1016/S0300-9084(97)84338-6; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Eguchi A, 2000, J BIOL CHEM, V275, P17549, DOI 10.1074/jbc.M910004199; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Georgopoulos C., 1983, LAMBDA 2, P279; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Harbottle RP, 1998, HUM GENE THER, V9, P1037, DOI 10.1089/hum.1998.9.7-1037; HART SL, 1994, J BIOL CHEM, V269, P12468; Houshmand H, 1999, ANAL BIOCHEM, V268, P363, DOI 10.1006/abio.1998.3076; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Kasamatsu H, 1998, ANNU REV MICROBIOL, V52, P627, DOI 10.1146/annurev.micro.52.1.627; Kassner PD, 1999, BIOCHEM BIOPH RES CO, V264, P921, DOI 10.1006/bbrc.1999.1603; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Larocca D, 1998, HUM GENE THER, V9, P2393, DOI 10.1089/hum.1998.9.16-2393; Larocca D, 1999, FASEB J, V13, P727, DOI 10.1096/fasebj.13.6.727; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; Lin JT, 1999, MOL CELL BIOL, V19, P3237; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MARUYAMA IN, 1994, P NATL ACAD SCI USA, V91, P8273, DOI 10.1073/pnas.91.17.8273; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mikawa YG, 1996, J MOL BIOL, V262, P21; Mizuguchi H, 1996, BIOCHEM BIOPH RES CO, V218, P402, DOI 10.1006/bbrc.1996.0070; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Okabe J, 2000, HUM MOL GENET, V9, P2639, DOI 10.1093/hmg/9.18.2639; OKAYAMA H, 1985, MOL CELL BIOL, V5, P1136, DOI 10.1128/MCB.5.5.1136; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pouton CW, 1998, J CONTROL RELEASE, V53, P289, DOI 10.1016/S0168-3659(98)00015-7; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Simpson JC, 1998, EXP CELL RES, V239, P293, DOI 10.1006/excr.1997.3921; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STERNBERG N, 1977, J MOL BIOL, V117, P733, DOI 10.1016/0022-2836(77)90067-5; STERNBERG N, 1995, P NATL ACAD SCI USA, V92, P1609, DOI 10.1073/pnas.92.5.1609; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; Yang F, 2000, NAT STRUCT BIOL, V7, P230; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	61	254	290	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26204	26210		10.1074/jbc.M010625200	http://dx.doi.org/10.1074/jbc.M010625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346640	hybrid			2022-12-27	WOS:000169823300076
J	Seko, A; Hara-Kuge, S; Yamashita, K				Seko, A; Hara-Kuge, S; Yamashita, K			Molecular cloning and characterization of a novel human galactose 3-O-sulfotransferase that transfers sulfate to Gal beta 1 -> 3GalNAc residue in O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; HUMAN COLONIC ADENOCARCINOMAS; RESPIRATORY MUCINS; CYSTIC-FIBROSIS; CANCER-CELLS; PORCINE THYROGLOBULIN; H-1-NMR SPECTROSCOPY; OLIGOSACCHARIDES; EXPRESSION; PATIENT	We have identified a novel galactose 3-O-sulfotransferase, termed Gal3ST-4, by analysis of an expression sequence tag using the amino acid sequence of human cerebroside 3 ' -sulfotransferase (Gal3ST-1), The isolated cDNA contains a single open reading frame coding for a protein of 486 amino acids with a type II transmembrane topology. The amino acid sequence of Gal3ST-4 revealed 33%, 39%, and 30% identity to human Gal3ST-1, Gal beta1 -->3/ 4GlcNAc -->3 ' -sulfotransferase (Gal3ST-2) and Gal beta1 --> 4GlcNAc -->3 ' -sulfotransferase (Gal3ST-3), respectively. The Gal3ST-4 gene comprised at least four exons and was located on human chromosome 7q22, Expression of Gal3ST-4 in COS-7 cells produced a sulfotransferase activity that catalyzes the transfer of [S-35]sulfate to the C-3 ' position of Gal beta1 --> 3GalNAc alpha1-O-Bn. Gal3ST-4 recognizes Gal beta1 --> 3GalNAc and Gal beta1 -->3 (GlcNAc beta1 -->6)GalNAc as good substrates, but not Gal beta1 --> 3GalNAc(OH) or Gal beta1 -->3/4GlcNAc. Asialofetuin is also a good substrate, and the sulfation was found exclusively in O-linked glycans that consist of the Gal beta1 --> 3GalNAc moiety, suggesting that the enzyme is specific for O-linked glycans, Northern blot analysis revealed that 2.5-kilobase mRNA for the enzyme is expressed extensively in various tissues. These results suggest that Gal3ST-4 is the fourth member of a Gal:-->3-sulfotransferase family and that the four members, Gal3ST-1, GalST-2, Gal3ST-3, and Gal3ST-4, are responsible for sulfation of different acceptor substrates.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan	Japan Science & Technology Agency (JST)	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	yamashita@sasaki.or.jp						Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; Chance DL, 1996, CARBOHYD RES, V295, P157, DOI 10.1016/S0008-6215(96)90136-6; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; Coppin A, 1999, EUR J BIOCHEM, V266, P370, DOI 10.1046/j.1432-1327.1999.00862.x; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; EDGE ASB, 1987, J BIOL CHEM, V262, P16135; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Honke K, 1996, J BIOCHEM-TOKYO, V119, P421; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Hooper LV, 1996, FASEB J, V10, P1137, DOI 10.1096/fasebj.10.10.8751716; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; KAWANO M, 1989, ANAL BIOCHEM, V182, P9, DOI 10.1016/0003-2697(89)90709-4; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LoGuidice JM, 1997, GLYCOCONJUGATE J, V14, P113, DOI 10.1023/A:1018525318185; LOTAN R, 1975, J BIOL CHEM, V250, P8518; Loveless RW, 1998, GLYCOBIOLOGY, V8, P1237, DOI 10.1093/glycob/8.12.1237; Okamura A, 2000, CLIN EXP METASTAS, V18, P37, DOI 10.1023/A:1026526829010; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; Roussel P, 1996, GLYCOPROTEINS DIS, P351; Seko A, 1996, CANCER RES, V56, P3468; Seko A, 2000, GLYCOBIOLOGY, V10, P919, DOI 10.1093/glycob/10.9.919; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; Suzuki A, 2001, J BIOL CHEM, V276, P24388, DOI 10.1074/jbc.M103135200; Tsuda M, 2000, EUR J BIOCHEM, V267, P2672, DOI 10.1046/j.1432-1327.2000.01281.x; Van Rooijen JJM, 1998, EUR J BIOCHEM, V256, P471, DOI 10.1046/j.1432-1327.1998.2560471.x; YAMASHITA K, 1981, J BIOL CHEM, V256, P4789; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	42	35	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25697	25704		10.1074/jbc.M101558200	http://dx.doi.org/10.1074/jbc.M101558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333265	hybrid			2022-12-27	WOS:000169823300011
J	Tang, HB; Sun, ZX; Goldman, D				Tang, HB; Sun, ZX; Goldman, D			CaM kinase II-dependent suppression of nicotinic acetylcholine receptor delta-subunit promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASES; ELEMENT-BINDING PROTEIN; E-BOX ELEMENTS; GENE-EXPRESSION; ELECTRICAL-ACTIVITY; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; RESPONSE ELEMENT; EPSILON-SUBUNIT	Nerve-induced muscle activity suppresses nicotinic acetylcholine receptor (nAChR) gene expression by increasing intracellular calcium levels. This suppression is mediated by nAChR promoter sequences harboring at least 1 E-box (CANNTG) that bind myogenic helix-loop-helix transcription factors, How muscle depolarization or increased calcium mediates changes in nAChR promoter activity is not well understood. In chick muscle, protein kinase C (PKC) activation is necessary for activity-dependent nAChR gene suppression. Similar effects of PKC activation have not been found in mammalian skeletal muscle. Therefore, we used rat primary muscle cultures to screen for other calcium-regulated enzymatic activities that may mediate the effects of muscle activity and calcium on nAChR promoter activity. We report here that calcium/calmodulin-dependent protein kinase II (CaM kinase II) can specifically suppress nAChR promoter activity in mammalian muscle. This regulation was mediated by a single E-box sequence residing in the previously characterized nAChR delta -subunit genes 47-base pair activity-dependent enhancer. In vitro protein/DNA interaction studies suggest that CaM kinase ii inhibits binding of the myogenic factor, myogenin, to the delta -promoter 47-base pair activity-dependent enhancer, CaM kinase activity is increased in active muscle and inhibition of this enzymatic activity results in increased nAChR delta -promoter activity. Therefore, CaM kinase II may represent a previously unappreciated activity that participates in coupling muscle depolarization to nAChR gene expression.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldman, D (corresponding author), Univ Michigan, Mental Hlth Res Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010821] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG10821] Funding Source: Medline; NINDS NIH HHS [R01 NS25153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABMAYR SM, 1990, CURRENT PROTOCOLS MO; Adams L, 1998, J NEUROBIOL, V35, P245, DOI 10.1002/(SICI)1097-4695(19980605)35:3<245::AID-NEU2>3.0.CO;2-Z; ADAMS L, 1995, J CELL BIOL, V131, P1341, DOI 10.1083/jcb.131.5.1341; Altiok N, 2001, FEBS LETT, V487, P333, DOI 10.1016/S0014-5793(00)02311-5; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Antipenko A, 1999, INT J BIOCHEM CELL B, V31, P303, DOI 10.1016/S1357-2725(98)00112-5; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHODOSH LA, 1990, CURRENT PROTOCOLS MO; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; FLUCK M, 2000, BIOCHEM BIOPH RES CO, V274, P803; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; Goldman D, 1998, CAN J APPL PHYSIOL, V23, P390, DOI 10.1139/h98-023; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; Heist EK, 1998, CELL CALCIUM, V23, P103; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; Kostrominova TY, 2000, AM J PHYSIOL-REG I, V279, pR179, DOI 10.1152/ajpregu.2000.279.1.R179; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MENDELZON D, 1994, BIOCHEMISTRY-US, V33, P2568, DOI 10.1021/bi00175a028; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1999, J NEUROSCI, V19, P8498; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Takeuchi Y, 2000, J NEUROCHEM, V74, P1913, DOI 10.1046/j.1471-4159.2000.0741913.x; TANG JC, 1994, DEVELOPMENT, V120, P1799; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WALKE W, 1994, J BIOL CHEM, V269, P19447; Walke W, 1996, J NEUROSCI, V16, P3641; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	58	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26057	26065		10.1074/jbc.M101670200	http://dx.doi.org/10.1074/jbc.M101670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350961	hybrid			2022-12-27	WOS:000169823300057
J	Lavrik, OI; Prasad, R; Sobol, RW; Horton, JK; Ackermann, EJ; Wilson, SH				Lavrik, OI; Prasad, R; Sobol, RW; Horton, JK; Ackermann, EJ; Wilson, SH			Photoaffinity labeling of mouse fibroblast enzymes by a base excision repair intermediate - Evidence for the role of poly(ADP-ribose) polymerase-1 in DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR NICK-SENSOR; REVERSE-TRANSCRIPTASE; INDUCED CYTOTOXICITY; MAMMALIAN-CELLS; BOVINE TESTIS; SITE REPAIR; BETA; PROTEIN; DAMAGE; STEP	To examine the interaction of mammalian base excision repair (BER) enzymes with DNA intermediates formed during BER, we used a novel photoaffinity labeling probe and mouse embryonic fibroblast cellular extracts. The probe was formed in situ, using an end-labeled oligonucleotide containing a synthetic abasic site; this site was incised by apurinic/apyrimidinic endonuclease creating a nick with 3 ' -hydroxyl and 5 ' -reduced sugar phosphate groups at the margins, and then a dNMP carrying a photoreactive adduct was added to the 3 ' -hydroxyl group. With near-UV light (312 nm) exposure of the extract/probe mixture, six proteins were strongly labeled. Four of these include poly(ADP-ribose) polymerase-1 (PARP-1) and the BER participants flap endonuclease-1, DNA polymerase beta, and apurinic/apyrimidinic endonuclease, The amount of the probe cross-linked to PARP-1 was greater than that cross-linked to the other proteins. The specificity of PARP-1 labeling was examined using various competitor oligonucleotides and DNA probes with alternate structures. PARP-1 labeling was stronger with a DNA representing a BER intermediate than with a nick in double-stranded DNA, These results indicate that proteins interacting preferentially with a photoreactive BER intermediate can be selected from the crude cellular extract.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Russian Acad Sci, Siberian Div, Novosibirsk Bioorgan Chem Inst, Novosibirsk 630090, Russia; Pacific NW Natl Lab, Richland, WA 99352 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; United States Department of Energy (DOE); Pacific Northwest National Laboratory	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 TW Alexandra Dr, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019; Sobol, Robert W./E-4125-2013; Lavrik, Olga I/G-4641-2013	Wilson, Samuel H/0000-0002-1702-5293; Sobol, Robert W./0000-0001-7385-3563; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050158, ZIAES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Berghammer H, 1999, FEBS LETT, V449, P259, DOI 10.1016/S0014-5793(99)00448-2; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DORONIN SV, 1994, FEBS LETT, V354, P200, DOI 10.1016/0014-5793(94)01110-9; DORONIN SV, 1992, FEBS LETT, V313, P31, DOI 10.1016/0014-5793(92)81177-N; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Maniatis T., 1989, MOL CLONING LAB MANU; MARSISCHKY GT, 1995, J BIOL CHEM, V270, P3247, DOI 10.1074/jbc.270.7.3247; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Ochs K, 1999, CANCER RES, V59, P1544; Oei SL, 2000, J BIOL CHEM, V275, P23234, DOI 10.1074/jbc.M002429200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003	52	161	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25541	25548		10.1074/jbc.M102125200	http://dx.doi.org/10.1074/jbc.M102125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340072	hybrid			2022-12-27	WOS:000169800700145
J	Mongay, L; Plaza, S; Vigorito, E; Serra-Pages, C; Vives, J				Mongay, L; Plaza, S; Vigorito, E; Serra-Pages, C; Vives, J			Association of the cell cycle regulatory proteins p45(SKP2) and CksHs1 - Functional effect on CDK2 complex formation and kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS SUC1/CKS PROTEIN; F-BOX PROTEIN; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; DEPENDENT-KINASE; HUMAN CUL-1; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; MUTATIONAL ANALYSIS; YEAST	In mammalian cells, CDK2 is part of a multiprotein complex that includes Cyclin A or E and cell cycle regulatory proteins such as p21(Cip1), PCNA, p27(Kip1), p45(SKP2) p19(SKP1), and CksHs1/CksHs2. While the role of some of these proteins has been well studied, the function of other proteins in the complex remains unclear. In this study, we showed that the carboxyl-terminal region of p45(SKP2) associates directly with CksHs1 and that CksHs1 negatively regulated the interaction between p45(SKP2) and CDK2, Moreover, we showed that overexpression of CksHs1 inhibits CDK2 kinase activity and that additional expression of p45(SKP2) overcame this inhibition and restored CDK2 kinase activity. We proposed that the association of CksHs1 and p45(SKP2) prevented CksHs1 from binding CDK2 and negatively regulating the CDK2 kinase activity.	Hosp Clin & Prov Barcelona, Serv Immunol, ICII, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona	Serra-Pages, C (corresponding author), Hosp Clin & Prov Barcelona, Serv Immunol, ICII, Villarroel 170, Barcelona 08036, Spain.							ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Medley QG, 2000, J BIOL CHEM, V275, P36116, DOI 10.1074/jbc.M003775200; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TANG Y, 1993, GENE DEV, V7, P822, DOI 10.1101/gad.7.5.822; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	38	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25030	25036		10.1074/jbc.M102184200	http://dx.doi.org/10.1074/jbc.M102184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11349131	hybrid			2022-12-27	WOS:000169800700080
J	Myles, T; Yun, TH; Hall, SW; Leung, LLK				Myles, T; Yun, TH; Hall, SW; Leung, LLK			An extensive interaction interface between thrombin and factor V is required for factor V activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; DYSTHROMBINS QUICK-I; HUMAN ALPHA-THROMBIN; BINDING EXOSITE-I; CLEAVAGE REQUIREMENTS; CRYSTAL-STRUCTURE; PROTEIN-C; THROMBOMODULIN; HIRUDIN; SITE	The interaction interface between human thrombin and human factor V (FV), necessary for complex formation and cleavage to generate factor Va, was investigated using a site-directed mutagenesis strategy. Fifty-three recombinant thrombins, with a total of 78 solvent-exposed basic and polar residues substituted with alanine, were used in a two-stage clotting assay with human FV, Seventeen mutants with less than 50% of wild-type (WT) thrombin FV activation were identified and mapped to anion-binding exosite I (ABE-I), anion-binding exosite II (ABE-II), the Leu(45)-Asn(57) insertion loop, and the Na+ binding loop of thrombin, Three ABE-I mutants (R68A, R70A, and Y71A) and the ABE-II mutant R98A had less than 30% of WT activity. The thrombin Na+ binding loop mutants, E229A and R233A, and the Leu45-Asn57 insertion loop mutant, W50A, had a major effect on FV activation with 5, 15, and 29% of WT activity, respectively. The K52A mutant, which maps to the S' specificity pocket, had 29% of WT activity. SDS-polyacrylamide gel electrophoresis analysis of cleavage reactions using the thrombin ABE mutants R68A, Y71A, and R98A, the Na+ binding loop mutant E229A, and the Leu(45)-Asn(57) insertion loop mutant W50A showed a requirement for both ABEs and the Na+-bound form of thrombin for efficient cleavage at the FV residue Arg(709) Several basic residues in both ABEs have moderate decreases in FV activation (40-60% of WT activity), indicating a role for the positive electrostatic fields generated by both ABEs in enhancing complex formation with complementary negative electrostatic fields generated by FV, The data show that thrombin activation of FV requires an extensive interaction interface with thrombin, Both ABE-I and ABE-II and the S' subsite are required for optimal cleavage, and the Na+-bound form of thrombin is important for its procoagulant activity.	Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA	Stanford University	Myles, T (corresponding author), Stanford Univ, Sch Med, Div Hematol, CCSR,Rm 1155, Stanford, CA 94305 USA.	tmyles@stanford.edu; lawrence.leung@stanford.edu			NHLBI NIH HHS [R01 HL57530] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BETZ A, 1991, BIOCHEM J, V275, P801, DOI 10.1042/bj2750801; BINNIE CG, 1993, BLOOD, V81, P3186; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Dharmawardana KR, 1999, J BIOL CHEM, V274, P18635, DOI 10.1074/jbc.274.26.18635; Dharmawardana KR, 1998, BIOCHEMISTRY-US, V37, P13143, DOI 10.1021/bi9812165; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; ESMON CT, 1979, J BIOL CHEM, V254, P964; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HENRIKSEN RA, 1988, BIOCHEMISTRY-US, V27, P9160, DOI 10.1021/bi00426a013; HOFSTEENGE J, 1987, EUR J BIOCHEM, V168, P49, DOI 10.1111/j.1432-1033.1987.tb13385.x; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; Lai MT, 1997, J BIOL CHEM, V272, P30275, DOI 10.1074/jbc.272.48.30275; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; Li CQ, 2001, J BIOL CHEM, V276, P6161, DOI 10.1074/jbc.M004164200; LIU LW, 1991, J BIOL CHEM, V266, P16977; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MANN KG, 1990, BLOOD, V76, P1; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; Myles T, 2001, EUR J BIOCHEM, V268, P70, DOI 10.1046/j.1432-1327.2001.01844.x; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; PHILLIPS JE, 1993, J BIOL CHEM, V268, P3321; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P1026, DOI 10.1021/bi9620823; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; STONE SR, 1991, BIOCHEMISTRY-US, V30, P6392, DOI 10.1021/bi00240a007; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; WALLACE A, 1989, BIOCHEM J, V257, P191, DOI 10.1042/bj2570191; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1994, J BIOL CHEM, V269, P17965	46	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25143	25149		10.1074/jbc.M011324200	http://dx.doi.org/10.1074/jbc.M011324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312264	hybrid			2022-12-27	WOS:000169800700096
J	Ramandeep; Hwang, KW; Raje, M; Kim, KJ; Stark, BC; Dikshit, KL; Webster, DA				Ramandeep; Hwang, KW; Raje, M; Kim, KJ; Stark, BC; Dikshit, KL; Webster, DA			Vitreoscilla hemoglobin - Intracellular localization and binding to membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMERIC BACTERIAL HEMOGLOBIN; ESCHERICHIA-COLI; GLOBIN GENE; PRIMARY SEQUENCE; EXPRESSION; CYTOCHROME; CLONING; IMPROVES; FLAVOHEMOGLOBIN; IDENTIFICATION	The obligate aerobic bacterium, Vitreoscilla, synthesizes elevated quantities of a homodimeric hemoglobin (VHb) under hypoxic growth conditions, Expression of VHb in heterologous hosts often enhances growth and product formation. A role in facilitating oxygen transfer to the respiratory membranes is one explanation of its cellular function. Immunogold labeling of VHb in both Vitreoscilla and recombinant Escherichia coli bearing the VHb gene clearly indicated that VHb has a cytoplasmic (not periplasmic) localization and is concentrated near the periphery of the cytosolic face of the cell membrane. OmpA signal-peptide VHb fusions were transported into the periplasm in E. coli, but this did not confer any additional growth advantage. The interaction of VHb with respiratory membranes was also studied. The K-d values for the binding of VHb to Vitreoscilla and E. coli cell membranes were similar to5-6 muM, a 4-8-fold higher affinity than those of horse myoglobin and hemoglobin for these same membranes. VHb stimulated the ubiquinol-l oxidase activity of inverted Vitreoscilla membranes by 68%. The inclusion of Vitreoscilla cytochrome bo in proteoliposomes led to 2.4- and 8-fold increases in VHb binding affinity and binding site number, respectively, relative to control liposomes, suggesting a direct interaction between VHb and cytochrome bo.	Inst Microbial Technol, Sector 39, Chandigarh 160014, India; IIT, Dept Biol Chem & Phys Sci, Chicago, IL 60616 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Illinois Institute of Technology	Webster, DA (corresponding author), Inst Microbial Technol, Sector 39, Chandigarh 160014, India.	kanak@imtech.res.in; dale.webster@iit.edu						ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; BOERMAN SJ, 1982, J GEN APPL MICROBIOL, V28, P35, DOI 10.2323/jgam.28.35; CLARK JM, 1977, EXPT BIOCH, P159; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; CRAMM R, 1994, J BIOL CHEM, V269, P7349; DEMODENA JA, 1993, BIO-TECHNOL, V11, P926, DOI 10.1038/nbt0893-926; DENG T, 1994, GENE, V93, P224; DIKSHIT KL, 1990, NUCLEIC ACIDS RES, V18, P4149, DOI 10.1093/nar/18.14.4149; DIKSHIT KL, 1989, J GEN MICROBIOL, V135, P2601; DIKSHIT KL, 1988, GENE, V70, P377, DOI 10.1016/0378-1119(88)90209-0; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; FUNG LWM, 1981, BIOCHEMISTRY-US, V20, P7162, DOI 10.1021/bi00528a017; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GEORGIOU CD, 1987, BIOCHEMISTRY-US, V26, P6521, DOI 10.1021/bi00394a035; GEORGIOU CD, 1987, ARCH MICROBIOL, V148, P328, DOI 10.1007/BF00456712; HIROSE M, 1971, BIOCHIM BIOPHYS ACTA, V251, P376, DOI 10.1016/0005-2795(71)90125-5; HOCKNEY RC, 1994, TRENDS BIOTECHNOL, V12, P456, DOI 10.1016/0167-7799(94)90021-3; Iijima M, 2000, CELL STRUCT FUNCT, V25, P47, DOI 10.1247/csf.25.47; JOSHI M, 1994, BIOCHEM BIOPH RES CO, V202, P535, DOI 10.1006/bbrc.1994.1961; Joshi M, 1998, APPL ENVIRON MICROB, V64, P2220; KALLIO PT, 1994, EUR J BIOCHEM, V219, P201, DOI 10.1111/j.1432-1033.1994.tb19931.x; KHOSLA C, 1989, J MOL BIOL, V210, P79, DOI 10.1016/0022-2836(89)90292-1; KHOSLA C, 1989, J BACTERIOL, V171, P5995, DOI 10.1128/jb.171.11.5995-6004.1989; KHOSLA C, 1990, BIO-TECHNOL, V8, P849, DOI 10.1038/nbt0990-849; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; KHOSRAVI M, 1990, PLASMID, V24, P190, DOI 10.1016/0147-619X(90)90002-T; Liu SC, 1996, BIOTECHNOL BIOENG, V49, P101, DOI 10.1002/(SICI)1097-0290(19960105)49:1&lt;101::AID-BIT13&gt;3.0.CO;2-L; Liu SC, 1995, APPL MICROBIOL BIOT, V44, P419; NARRO ML, 1990, J BACTERIOL, V172, P4549, DOI 10.1128/jb.172.8.4549-4554.1990; ORII Y, 1986, J BIOL CHEM, V261, P3544; Park C, 1996, BIOCHEMISTRY-US, V35, P11895, DOI 10.1021/bi9530503; Patel SM, 2000, BIOTECHNOL PROGR, V16, P26, DOI 10.1021/bp9901421; Ramandeep, 2001, J HISTOCHEM CYTOCHEM, V49, P355; Riistama S, 1996, BBA-BIOENERGETICS, V1275, P1, DOI 10.1016/0005-2728(96)00040-0; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TYREE B, 1978, J BIOL CHEM, V253, P7635; VASUDEVAN SG, 1995, FEMS MICROBIOL LETT, V125, P219, DOI 10.1016/0378-1097(94)00501-H; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WEBSTER DA, 1988, ADV INORG BIOCHEM, V7, P245; WITTENBERG JB, 1974, J BIOL CHEM, V249, P4057; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	42	114	120	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24781	24789		10.1074/jbc.M009808200	http://dx.doi.org/10.1074/jbc.M009808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331274	hybrid			2022-12-27	WOS:000169800700050
J	Walker, LA; MacDonald, JA; Liu, XP; Nakamoto, RK; Haystead, TAJ; Somlyo, AV; Somlyo, AP				Walker, LA; MacDonald, JA; Liu, XP; Nakamoto, RK; Haystead, TAJ; Somlyo, AV; Somlyo, AP			Site-specific phosphorylation and point mutations of telokin modulate its Ca2+-desensitizing effect in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SIGNAL-TRANSDUCTION; CA2+ SENSITIZATION; PROTEIN; MYOSIN; PHOSPHATASE; PURIFICATION; INHIBITION; IDENTIFICATION; GIZZARD	Forskolin and 8-bromoguanosine 3 ' -5 ' -cyclic monophosphate (8-Br-cGMP) induce phosphorylation of Ser-13 of telokin and relaxation of smooth muscle at constant calcium. Comparison with the effect of wild type with aspartate (D; to mimic phosphorylation) and alanine (A; non-phosphorylatable) mutants of telokin showed that the S13D mutant was more effective than wild type in relaxing smooth muscle at constant calcium. The efficacy of the Ser-13A, S12A, and S12D mutants was not significantly different from that of wildtype telokin, The effect of neither S13D nor Ser-13A was affected by 8-Br-cGMP, whereas the effect of wild type, S12A, and S12D was enhanced by 8-Br-cGMP, indicating the specificity of Ser-13 charge modification. Mutation of Ser-19 (a mitogen-activated protein kinase site) showed the S19A to be more effective than, and S19D to be not different from, wild-type telokin, The effect of both mutants was slightly enhanced by 8-Br-cGMP, A truncated (residues 1-142) form lacking the acidic C terminus had the same relaxant effect as wild-type telokin, whereas the C-terminal peptide (residues 142-155) had no effect. We conclude that site-specific modification of the N terminus modulates the Ca2+-desensitizing effect of telokin on force.	Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Dept Pathol, Charlottesville, VA 22908 USA; Dept Med, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Somlyo, AP (corresponding author), Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	aps2n@virginia.edu	Walker, Lori/J-7098-2013	Walker, Lori/0000-0003-2556-8076; MacDonald, Justin/0000-0002-9238-8473	NHLBI NIH HHS [P01 HL048807, HL 48807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIALOJAN C, 1985, P SOC EXP BIOL MED, V178, P648; Brophy CM, 1999, J VASC SURG, V29, P326, DOI 10.1016/S0741-5214(99)70385-X; Brophy CM, 1999, J BIOL CHEM, V274, P6324, DOI 10.1074/jbc.274.10.6324; Di Salvo J, 1987, Prog Clin Biol Res, V245, P195; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; GONG MC, 1995, J PHYSIOL-LONDON, V486, P113, DOI 10.1113/jphysiol.1995.sp020795; Gong MC, 1996, P NATL ACAD SCI USA, V93, P1340, DOI 10.1073/pnas.93.3.1340; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; ITO M, 1989, J BIOL CHEM, V264, P13971; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; MacDonald JA, 2000, FEBS LETT, V479, P83, DOI 10.1016/S0014-5793(00)01884-6; Masato T, 1997, J BIOCHEM, V121, P225; Mullis K.B, 1994, POLYM CHAIN REACTION; NISHIMURA J, 1989, BIOCHEM BIOPH RES CO, V163, P929, DOI 10.1016/0006-291X(89)92311-5; PALFREY HC, 1980, J EXP BIOL, V89, P103; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; Rusconi F, 1997, BIOCHEMISTRY-US, V36, P11021, DOI 10.1021/bi970752e; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; Silver DL, 1997, J BIOL CHEM, V272, P25353, DOI 10.1074/jbc.272.40.25353; Sobieszek A, 1997, J BIOL CHEM, V272, P7034, DOI 10.1074/jbc.272.11.7034; Sobieszek A, 1997, BIOCHEM J, V328, P425, DOI 10.1042/bj3280425; Somlyo A P, 1999, Rev Physiol Biochem Pharmacol, V134, P201; Somlyo AP, 1999, J PHYSIOL-LONDON, V516, P630, DOI 10.1111/j.1469-7793.1999.0630u.x; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vorotnikov A V, 2000, Tsitologiia, V42, P378; WALTER U, 1980, J BIOL CHEM, V255, P3757; WEEKS G, 1988, SYNAPSE, V2, P89, DOI 10.1002/syn.890020112; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362	38	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24519	24524		10.1074/jbc.M103560200	http://dx.doi.org/10.1074/jbc.M103560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11346659	hybrid			2022-12-27	WOS:000169800700015
J	Adak, S; Aulak, KS; Stuehr, DJ				Adak, S; Aulak, KS; Stuehr, DJ			Chimeras of nitric-oxide synthase types I and III establish fundamental correlates between heme reduction, heme-NO complex formation, and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; ESCHERICHIA-COLI; CALMODULIN; BINDING; DOMAIN; DIMERIZATION; ARGININE; ISOFORMS	Neuronal nitric-oxide synthase (nNOS or NOS I) and endothelial NOS (eNOS or NOS III) differ widely in their reductase and nitric oxide (NO) synthesis activities, electron transfer rates, and propensities to form a heme-NO complex during catalysis. We generated chimeras by swapping eNOS and nNOS oxygenase domains to understand the basis for these differences and to identify structural elements that determine their catalytic behaviors. Swapping oxygenase domains did not alter domain-specific catalytic functions (cytochrome c reduction or H2O2-supported N-omega-hydroxy-L-arginine oxidation) but markedly affected steady-state NO synthesis and NADPH oxidation compared with native eNOS and nNOS. Stopped-flow analysis showed that reductase domains either maintained (nNOS) or slightly exceeded (eNOS) their native rates of heme reduction in each chimera. Heme reduction rates were found to correlate with the initial rates of NADPH oxidation and heme-NO complex formation, with the percentage of heme-NO complex attained during the steady state, and with NO synthesis activity. Oxygenase domain identity influenced these parameters to a lesser degree. We conclude: 1) Heme reduction rates in nNOS and eNOS are controlled primarily by their reductase domains and are almost independent of oxygenase domain identity. 2) Heme reduction rate is the dominant parameter controlling the kinetics and extent of heme-NO complex formation in both eNOS and nNOS, and thus it determines to what degree heme-NO complex formation influences their steady-state NO synthesis, whereas oxygenase domains provide minor but important influences. 3) General principles that relate heme reduction rate, heme-NO complex formation, and NO synthesis are not specific for nNOS but apply to eNOS as well.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst NB3, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Adak, S (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst NB3, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 2001, J INORG BIOCHEM, V83, P301, DOI 10.1016/S0162-0134(00)00176-8; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; HEMMENS B, 1997, METHOD MOL BIOL, V100, P1; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Miller RT, 1999, BIOCHEM BIOPH RES CO, V265, P184, DOI 10.1006/bbrc.1999.1643; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; PRESTA A, 1997, NITRIC OXIDE, V1, P174; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X	30	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23246	23252		10.1074/jbc.M102509200	http://dx.doi.org/10.1074/jbc.M102509200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313363	hybrid			2022-12-27	WOS:000169531100006
J	Manalo, DJ; Liu, AYC				Manalo, DJ; Liu, AYC			Resolution, detection, and characterization of redox conformers of human HSF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; DNA-BINDING ACTIVITY; NITRIC-OXIDE; IN-VITRO; HEAT; ACTIVATION; PROTEIN; OLIGOMERIZATION; THIOREDOXIN; GLUTATHIONE	We describe here an experimental protocol for the resolution, detection, and quantitation of the reduced and oxidized conformers of human heat shock factor 1 (hHSF1) and report on the effects in vitro and in vivo of redox-active agents on the redox status, structure, and function of hHSF1. We showed that diamide, a reagent that promotes disulfide bond formation, caused a loss of immunorecognition of the monomeric hHSF1 protein in a standard Western blot detection procedure. Modification of the Western blot procedure to include dithiothreitol in the equilibration and transfer buffers after gel electrophoresis allowed for the detection of a compact, intramolecularly disulfide cross-linked oxidized hHSF1 (ox-hHSF1) in the diamide-treated sample. The effect of diamide was blocked by pretreatment with N-ethylmaleimide and was reversed by dithiothreitol added to the sample prior to gel electrophoresis. Incubation with nitrosoglutathione at 42 degreesC also promoted the conversion of HSF1 to ox-HSF1; at 25 degreesC, however, nitrosoglutathione was by itself without effect but blocked the formation of ox-hHSF1 in the presence of diamide. The disulfide cross-linked ox-hFPSF1 was monomeric and resistant to the in vitro heat-induced trimerization and activation. The possibility that ox-HSF1 may occur in oxidatively stressed cells was evaluated. Treatment of HeLa cells with 2 mM L-buthionine sulfoximine promoted the formation of ox-HSF1 and blocked the heat-induced activation of HSF DNA binding activity. Our result suggests that hHSF1 may have integrated redox chemistry of cysteine sulfhydryl into its functional responses.	Rutgers State Univ, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; Rutgers State Univ, Grad Program Cell & Dev Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Liu, AYC (corresponding author), Rutgers State Univ, Dept Neurosci & Cell Biol, 604 Allison Rd, Piscataway, NJ 08854 USA.	liu@biology.rutgers.edu		Liu, Alice Y./0000-0002-6984-1671				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; AUSUBEL J, 1990, CURRENT PROTOCOLS MO; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BRANDON C, 1998, INTRO PROTEIN STRUCT, P353; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; FREEMAN ML, 1987, BIOCHEM PHARMACOL, V36, P21; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HUANG LE, 1994, J BIOL CHEM, V269, P30718; JAENICKE R, 1991, CIBA F SYMP, V161, P206; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE KJ, 1988, J CELL PHYSIOL, V136, P411, DOI 10.1002/jcp.1041360304; Lee YK, 1996, BIOL SIGNAL, V5, P180; Lipton SA, 1996, NEUROCHEM INT, V29, P111, DOI 10.1016/0197-0186(95)00150-6; Liu A Y, 1996, EXS, V77, P393; LIU AYC, 1991, J CELL PHYSIOL, V149, P560, DOI 10.1002/jcp.1041490327; LUNBLAD RL, 1995, TECHNIQUES PROTEIN M, P63; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Mercier PA, 1999, J CELL SCI, V112, P2765; Mercier PA, 1997, J BIOL CHEM, V272, P14147, DOI 10.1074/jbc.272.22.14147; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; Park J, 2000, J CELL PHYSIOL, V185, P348, DOI 10.1002/1097-4652(200012)185:3<348::AID-JCP5>3.0.CO;2-3; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PURI PL, 1995, J BIOL CHEM, V270, P22129, DOI 10.1074/jbc.270.38.22129; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Yang F, 1997, CLIN CHEM, V43, P657; Zandi E, 1997, GENE DEV, V11, P1299, DOI 10.1101/gad.11.10.1299; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	51	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23554	23561		10.1074/jbc.M011300200	http://dx.doi.org/10.1074/jbc.M011300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320084	hybrid			2022-12-27	WOS:000169531100046
J	Shetzline, SE; Suhadolnik, RJ				Shetzline, SE; Suhadolnik, RJ			Characterization of a 2 ',5 '-oligoadenylate (2-5A)-dependent 37-kDa RNase L - Azido photoaffinity labeling and 2-5A-dependent activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC-FATIGUE-SYNDROME; L ANTIVIRAL PATHWAY; ATP-BINDING DOMAIN; SYNTHETASE FAMILY; IDENTIFICATION; SITE; PEPTIDE; PROTEIN	Upregulation of key components of the 2 ' ,5 ' -oligoadenylate (2-5A) synthetase/RNase L pathway have been identified in extracts of peripheral blood mononuclear cells hom individuals with chronic syndrome, including the presence of a low molecular weight form of RNase L. In this study, analysis of 2 ' ,5 ' -Oligoadenylate (2-5A) binding and activation of the 80- and 37-kDa forms of RNase L has been completed utilizing photolabeling/immunoprecipitation and affinity assays, respectively. Saturation of photolabeling of the 80- and the 37-kDa RNase L with the 2-5A azido photoprobe, [P-32]pApAp(8-azidoA), was achieved. Half-maximal photoinsertion of [P-32]pApAp(8-azidoA) occurred at 3.7 x 10(-8) M for the 80-kDa RNase L and at 6.3 x 10(-8) M for the 37-kDa RNase L. Competition experiments using 100-fold excess unlabeled 2-5A photoaffinity probe, pApAp(8-azidoA), and authentic 2-5A (p(3)A(3)) resulted in complete protection against photolabeling, demonstrating that [P-32]pApAp(8-azidoA) binds specifically to the 2-5A-binding site of the 80 and 37-kDa RNase L. The rate of RNA hydrolysis by the 37-kDa RNase L was three times faster than the 80 M)a RNase L. The data obtained from these 2-5A binding and 2-5A-dependent activation studies demonstrate the utility of [P-32]pApAp(8-azidoA) for the detection of the 37-kDa RNase L in peripheral blood mononuclear cell extracts.	Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Suhadolnik, RJ (corresponding author), Temple Univ, Sch Med, Dept Biochem, 3420 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038378] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00349] Funding Source: Medline; NIAID NIH HHS [R01 AI38378] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAYARD B, 1994, EUR J BIOCHEM, V223, P403, DOI 10.1111/j.1432-1033.1994.tb19007.x; BISBAL C, 1989, EUR J BIOCHEM, V179, P595, DOI 10.1111/j.1432-1033.1989.tb14588.x; CHARUBALA R, 1989, HELV CHIM ACTA, V72, P1354, DOI 10.1002/hlca.19890720624; CHAVAN AJ, 1992, J BIOL CHEM, V267, P14866; De Meirleir K, 2000, AM J MED, V108, P99, DOI 10.1016/S0002-9343(99)00300-9; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; Justesen J, 2000, CELL MOL LIFE SCI, V57, P1593, DOI 10.1007/PL00000644; Kon N, 1996, J BIOL CHEM, V271, P19983, DOI 10.1074/jbc.271.33.19983; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; NOLANSORDEN NL, 1990, ANAL BIOCHEM, V184, P298, DOI 10.1016/0003-2697(90)90684-2; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P11935, DOI 10.1021/bi00205a032; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; Rebouillat D, 1999, J INTERF CYTOK RES, V19, P295, DOI 10.1089/107999099313992; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHETZLINE SE, 2001, AM ASS CHRON FAT SYN; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; SILVERMAN RH, 1985, ANAL BIOCHEM, V144, P450, DOI 10.1016/0003-2697(85)90141-1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suhadolnik R J, 1994, In Vivo, V8, P599; SUHADOLNIK RJ, 1994, CLIN INFECT DIS, V18, pS96, DOI 10.1093/clinids/18.Supplement_1.S96; Suhadolnik RJ, 1997, J INTERF CYTOK RES, V17, P377, DOI 10.1089/jir.1997.17.377; SUHADOLNIK RJ, 1988, BIOCHEMISTRY-US, V27, P8840, DOI 10.1021/bi00424a023; SUHADOLNIK RJ, 1999, J CHRONIC FATIGUE SY, V5, P223; TRAD CH, 1993, ARCH BIOCHEM BIOPHYS, V304, P58, DOI 10.1006/abbi.1993.1321	27	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23707	23711		10.1074/jbc.M101243200	http://dx.doi.org/10.1074/jbc.M101243200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323422	hybrid			2022-12-27	WOS:000169531100065
J	Tomasini-Johansson, BR; Kaufman, NR; Ensenberger, MG; Ozeri, V; Hanski, E; Mosher, DF				Tomasini-Johansson, BR; Kaufman, NR; Ensenberger, MG; Ozeri, V; Hanski, E; Mosher, DF			A 49-residue peptide front adhesin F1 of Streptococcus pyogenes inhibits fibronectin matrix assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; PROTEIN-F; STAPHYLOCOCCUS-AUREUS; LYSOPHOSPHATIDIC ACID; PLASMA FIBRONECTIN; BINDING PROTEIN; CROSS-LINKING; FIBROBLASTS	F1 is an adhesin of Streptococcus pyogenes which binds the N-terminal 70-kDa region of fibronectin with high affinity. The fibronectin binding region of F1 is comprised of a 43-residue upstream domain and a repeat domain comprised of five tandem 37-residue sequences. We investigated the effects of these domains on the assembly of fibronectin matrix by human dermal fibroblasts, MG63 osteosarcoma cells, or fibroblasts derived from fibronectin-null stem cells. Subequimolar or equimolar concentrations of recombinant proteins containing both the upstream and repeat domains or just the repeat domain enhanced binding of fibronectin or its N-terminal 70-kDa fragment to cell layers; higher concentrations of these recombinant proteins inhibited binding. The enhanced binding did not result in greater matrix assembly and was caused by increased ligand binding to substratum. In contrast, recombinant or synthetic protein containing the 43 residues of the upstream domain and the first 6 residues from the repeat domain exhibited monophasic inhibition with an IC50 of similar to 10 nM. Truncation of the 49-residue sequence at its N or C terminus caused loss of inhibitory activity. The 49-residue upstream sequence blocked incorporation of both endogenous cellular fibronectin and exogenous plasma fibronectin into extracellular matrix and inhibited binding of 70-kDa fragment to fibronectin-null cells in a fibronectin-free system. Inhibition of matrix assembly by the 49-mer had no effect on cell adhesion to substratum, cell growth, formation of focal contacts, or formation of stress fibers. These results indicate that the 49-residue upstream sequence of F1 binds in an inhibitory mode to N-terminal parts of exogenous and endogenous fibronectin which are critical for fibronectin fibrillogenesis.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Dana Coll, Dept Biol, Blair, NE 68008 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Clin Microbiol, IL-91010 Jerusalem, Israel	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Hebrew University of Jerusalem	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, 4285 MSC,1300 Univ Ave, Madison, WI 53706 USA.		hanski, emanuel/M-2696-2018	hanski, emanuel/0000-0001-5054-0628	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CHERNOUSOV MA, 1985, FEBS LETT, V183, P365, DOI 10.1016/0014-5793(85)80811-5; Cue D, 1998, INFECT IMMUN, V66, P4593, DOI 10.1128/IAI.66.10.4593-4601.1998; GRINNELL F, 1982, EXP CELL RES, V142, P499, DOI 10.1016/0014-4827(82)90398-6; Guzman CA, 1999, J INFECT DIS, V179, P901, DOI 10.1086/314655; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes RO, 1999, P NATL ACAD SCI USA, V96, P2588, DOI 10.1073/pnas.96.6.2588; Jadoun J, 1998, J INFECT DIS, V178, P147, DOI 10.1086/515589; Joh D, 1998, EUR J BIOCHEM, V258, P897, DOI 10.1046/j.1432-1327.1998.2580897.x; Joh D, 1999, MATRIX BIOL, V18, P211, DOI 10.1016/S0945-053X(99)00025-6; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; Ozeri V, 1996, EMBO J, V15, P989, DOI 10.1002/j.1460-2075.1996.tb00435.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PEARLSTEIN E, 1978, INT J CANCER, V22, P32, DOI 10.1002/ijc.2910220108; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; Sottile J, 1998, J CELL SCI, V111, P2933; SOTTILE J, 1994, J BIOL CHEM, V269, P17192; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Zhang QH, 1996, J BIOL CHEM, V271, P33284, DOI 10.1074/jbc.271.52.33284; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	44	94	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23430	23439		10.1074/jbc.M103467200	http://dx.doi.org/10.1074/jbc.M103467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323441	hybrid			2022-12-27	WOS:000169531100029
J	Fukushi, S; Okada, M; Stahl, J; Kageyama, T; Hoshino, FB; Katayama, K				Fukushi, S; Okada, M; Stahl, J; Kageyama, T; Hoshino, FB; Katayama, K			Ribosomal protein S5 interacts with the internal ribosomal entry site of hepatitis C virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; 25-KILODALTON CELLULAR PROTEIN; ESCHERICHIA-COLI RIBOSOME; DIRECTED CROSS-LINKING; MESSENGER-RNA ANALOGS; TRANSLATION INITIATION; MEDIATED TRANSLATION; POLIOVIRUS RNA; DECODING SITE; REGION	Translational initiation of hepatitis C virus (HCV) genome RNA occurs via its highly structured 5' noncoding region called the internal ribosome entry site (IRES), Recent studies indicate that HCV IRES and 40 S ribosomal subunit form a stable binary complex that is believed to be important for the subsequent assembly of the 48 S initiation complex. Ribosomal protein (rp) S9 has been suggested as the prime candidate protein for binding of the HCV IRES to the 40 S subunit. RpS9 has a molecular mass of similar to 25 kDa in UV cross-linking experiments. In the present study, we examined the similar to 25-kDa proteins of the 40 S ribosome that form complexes with the HCV IRES upon UV cross-linking. Immunoprecipitation with specific antibodies against two 25-kDa 40 S proteins, rpS5 and rpS9, clearly identified rpS5 as the protein bound to the IRES. Thus, our results support rpS5 as the critical element in positioning the HCV RNA on the 40 S ribosomal subunit during translation initiation.	Biomed Labs, Ctr Res & Dev, Kawagoe, Saitama 3501101, Japan; Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Osaka University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Fukushi, S (corresponding author), Biomed Labs, Ctr Res & Dev, 1361-1 Matoba, Kawagoe, Saitama 3501101, Japan.			Katayama, Kazuhiko/0000-0002-7692-1151				Ali N, 2000, J BIOL CHEM, V275, P27531; Anwar A, 2000, J BIOL CHEM, V275, P34231, DOI 10.1074/jbc.M006343200; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; Fukushi S, 1997, J VIROL, V71, P1662, DOI 10.1128/JVI.71.2.1662-1666.1997; FUKUSHI S, 1994, BIOCHEM BIOPH RES CO, V199, P425, DOI 10.1006/bbrc.1994.1246; Fukushi S, 1999, VIRUS GENES, V19, P153, DOI 10.1023/A:1008131325056; Fukushi S, 2001, VIRUS RES, V73, P67, DOI 10.1016/S0168-1702(00)00228-8; GIMAUTDINOVA OI, 1981, NUCLEIC ACIDS RES, V9, P3465, DOI 10.1093/nar/9.14.3465; HARTZ D, 1991, J MOL BIOL, V218, P99, DOI 10.1016/0022-2836(91)90876-8; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Jackson RJ, 1995, RNA, V1, P985; Kaminski A, 1995, RNA, V1, P924; Kamoshita N, 1997, VIROLOGY, V233, P9, DOI 10.1006/viro.1997.8600; Kolupaeva VG, 2000, J VIROL, V74, P6242, DOI 10.1128/JVI.74.14.6242-6250.2000; KUWANO Y, 1992, J BIOL CHEM, V267, P25304; LUTSCH G, 1983, BIOMED BIOCHIM ACTA, V42, P705; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Niepmann M, 1997, J VIROL, V71, P8330, DOI 10.1128/JVI.71.11.8330-8339.1997; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; ROJASEISENRING IA, 1995, J VIROL, V69, P6819, DOI 10.1128/JVI.69.11.6819-6824.1995; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Spiridonova VA, 1999, FEBS LETT, V460, P353, DOI 10.1016/S0014-5793(99)01351-4; STADE K, 1989, NUCLEIC ACIDS RES, V17, P9889, DOI 10.1093/nar/17.23.9889; THEISE H, 1978, ACTA BIOL MED GER, V37, P1353; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VLADIMIROV SN, 1990, BIOCHIM BIOPHYS ACTA, V1048, P245, DOI 10.1016/0167-4781(90)90063-8; Wang C, 1995, CURR TOP MICROBIOL, V203, P99	32	95	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20824	20826		10.1074/jbc.C100206200	http://dx.doi.org/10.1074/jbc.C100206200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11331271	hybrid			2022-12-27	WOS:000169297900006
J	Lee, BC; Croonquist, PA; Sosnick, TR; Hoff, WD				Lee, BC; Croonquist, PA; Sosnick, TR; Hoff, WD			PAS domain receptor photoactive yellow protein is converted to a molten globule state upon activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-COUMARIC ACID; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOCYCLE; CHROMOPHORE; PHOTORECEPTOR; INTERMEDIATE; RHODOPSIN; FOLD	Biological signaling generally involves the activation of a receptor protein by an external stimulus followed by protein-protein interactions between the activated receptor and its downstream signal transducer. The current paradigm for the relay of signals along a signal transduction chain is that it occurs by highly specific interactions between fully folded proteins. However, recent results indicate that many regulatory proteins are intrinsically unstructured, providing a serious challenge to this paradigm and to the nature of structure-function relationships in signaling. Here we study the structural changes that occur upon activation of the blue light receptor photoactive yellow protein (PYP). Activation greatly reduces the tertiary structure of PYP but leaves the level secondary structure largely unperturbed. In addition, activated PYP exposes previously buried hydrophobic patches and allows significant solvent penetration into the core of the protein. These traits are the distinguishing hallmarks of molten globule states, which have been intensively studied for their role in protein folding. Our results show that receptor activation by light converts PYP to a molten globule and indicate stimulus-induced unfolding to a partially unstructured molten globule as a novel theme in signaling.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Hoff, WD (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.		Freed, Karl F/J-7764-2018	Freed, Karl F/0000-0001-6240-2599				Arai M, 2000, ADV PROTEIN CHEM, V53, P209; BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Craven CJ, 2000, BIOCHEMISTRY-US, V39, P14392, DOI 10.1021/bi001628p; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; FINK AL, 1994, BIOCHEMISTRY-US, V33, P12504, DOI 10.1021/bi00207a018; France RM, 2000, BIOCHEM BIOPH RES CO, V269, P709, DOI 10.1006/bbrc.2000.2346; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Ptitsyn Oleg B., 1992, P243; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a	25	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20821	20823		10.1074/jbc.C100106200	http://dx.doi.org/10.1074/jbc.C100106200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11319215	hybrid			2022-12-27	WOS:000169297900005
J	Pirok, EW; Henry, J; Schwartz, NB				Pirok, EW; Henry, J; Schwartz, NB			cis elements that control the expression of chick aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; GENE; IDENTIFICATION; DEGRADATION; PROMOTER; OPERON	Aggrecan is a large chondroitin sulfate proteoglycan whose expression is both cell-specific and developmentally regulated. Cloning and sequencing of the 1.8-kilo-base genomic 5'-flanking sequence of the chick aggrecan gene revealed the presence of potential tissue-specific control elements including a consensus sequence found in the cartilage-associated silencers, CSIIS1 and CSIIS2, that were first characterized in the type II collagen promoter sequences, as well as numerous other cis elements. Transient transfections of chick sternal chondrocytes and fibroblasts with reporter plasmids bearing progressively deleted portions of the chick aggrecan promoter and enhancer region demonstrated cell type-specific promoter activity and identified a 420-base pair region in the genomic Fi-flanking region responsible for negative regulation of the aggrecan gene. In this report, three complementary methods, DNase I footprinting assays, transient transfections, and electrophoretic mobility shift assays (EMSA), provided an integral approach to better understand the regulation of the aggrecan gene. DNase I footprinting revealed that six regions of this genomic sequence bind to nuclear proteins in a tissue-specific manner. Transient transfection of reporter constructs bearing ablations of these protected sequences showed that four of the six protected sequences, which contain the sequence TCCTCC or TCCCCT, had repressor activities in transfected chick chondrocytes, Cross-competition EMSA using nuclear protein extracted from chondrocytes or fibroblasts explored the contributions of the different sequence elements in formation of DNA-protein complexes specific to cell type. This is the first parallel examination of the EMSA patterns for six functionally defined cis elements with highly similar sequences, using protein from primary cultured cells.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA.				NHLBI NIH HHS [HL-07237] Funding Source: Medline; NIAMS NIH HHS [AR-19622] Funding Source: Medline; NICHD NIH HHS [HD-09402] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019622, R37AR019622] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; CAHN RD, 1967, METHODS DEVELOPMENTA, P493; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; DANOT O, 1994, MOL MICROBIOL, V14, P335, DOI 10.1111/j.1365-2958.1994.tb01294.x; EWULONU UK, 1991, P NATL ACAD SCI USA, V88, P4675, DOI 10.1073/pnas.88.11.4675; GEETHAHABIB M, 1984, J BIOL CHEM, V259, P7300; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HOUGHTON M J, 1989, Pediatric Pathology, V9, P501; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; KLEIN W, 1993, J BACTERIOL, V175, P1682, DOI 10.1128/JB.175.6.1682-1686.1993; Krueger RC, 1999, MAMM GENOME, V10, P1119, DOI 10.1007/s003359901176; Lark MW, 1995, ACTA ORTHOP SCAND, V66, P92, DOI 10.3109/17453679509157660; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; Li H, 1995, J MOL EVOL, V41, P878; LI H, 1993, J BIOL CHEM, V268, P23504; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; PLUMBRIDGE J, 1995, EMBO J, V14, P3958, DOI 10.1002/j.1460-2075.1995.tb00067.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; Schwartz NB, 2000, FRONT BIOSCI, V5, pD649; Schwartz NB, 1999, PROG NUCLEIC ACID RE, V62, P177; Schwartz NB, 1998, SKELETAL GROWTH AND DEVELOPMENT: CLINICAL ISSUES AND BASIC SCIENCE ADVANCES, P413; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1	24	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16894	16903		10.1074/jbc.M009944200	http://dx.doi.org/10.1074/jbc.M009944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350977	hybrid			2022-12-27	WOS:000168730400040
J	Odermatt, A; Arnold, P; Frey, FJ				Odermatt, A; Arnold, P; Frey, FJ			The intracellular localization of the mineralocorticoid receptor is regulated by 11 ss-hydroxysteroid dehydrogenase type 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; HUMAN KIDNEY; CORTICOSTEROID 11-BETA-DEHYDROGENASE; HIGH-AFFINITY; GUINEA-PIG; BILE-ACID; RAT; ALDOSTERONE; INHIBITION	11 beta -Hydroxysteroid dehydrogenase (11 beta -HSD) type 2 has been considered to protect the mineralocorticoid receptor (MR) by converting 11 beta -hydroxyglucocorticoids into their inactive 11-keto forms, thereby providing specificity to the TMR for aldosterone. To investigate the functional protection of the MR by 11 beta -HSD2, we coexpressed epitope-tagged MR and 11 beta -HSD2 in HEK-293 cells lacking 11 beta -HSD2 activity and analyzed their subcellular localization by fluorescence microscopy. When expressed alone in the absence of hormones, the MR was both cytoplasmic and nuclear. However, when coexpressed with 11 beta -HSD2, the MR displayed a reticular distribution pattern, suggesting association with 11 beta -HSD2 at the endoplasmic reticulum membrane. The endoplasmic reticulim membrane localization of the AM was observed upon coexpression only with 11 beta -HSD2, but not with 11 beta -HSD1 or other steroid-metabolizing enzymes. Aldosterone induced rapid nuclear translocation of the AM whereas moderate cortisol concentrations (10-200 nM) did not activate the, receptor, due to 11 beta -HSD2-dependent oxidation to cortisone. Compromised 11 beta -HSD2 activity (due to genetic mutations, the presence of inhibitors, or saturating cortisol concentrations) led to cortisol-induced nuclear accumulation of the MR. Surprisingly, the 11 beta -HSD2 product cortisone blocked the aldosterone-induced MR activation by a strictly 11 beta -HSD2-dependent mechanism. Our results provide evidence that 11 beta -HSD2, besides inactivating 11 beta -hydroxyglucocorticoids, functionally interacts with the MR and directly regulates the magnitude of aldosterone-induced MR activation.	Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern	Odermatt, A (corresponding author), Univ Bern, Dept Clin Res, Div Nephrol & Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.			Odermatt, Alex/0000-0002-6820-2712				Ackermann D, 1999, HEPATOLOGY, V30, P623, DOI 10.1002/hep.510300303; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BEAUMONT K, 1983, ENDOCRINOLOGY, V113, P2043, DOI 10.1210/endo-113-6-2043; BINART N, 1991, P NATL ACAD SCI USA, V88, P10681, DOI 10.1073/pnas.88.23.10681; BREM AS, 1991, AM J PHYSIOL, V261, pF873, DOI 10.1152/ajprenal.1991.261.5.F873; BUHLER H, 1994, STEROIDS, V59, P131, DOI 10.1016/0039-128X(94)90090-6; Couette B, 1996, BIOCHEM J, V315, P421, DOI 10.1042/bj3150421; ESCHER G, 1995, ENDOCRINOLOGY, V136, P1759, DOI 10.1210/en.136.4.1759; Escher G, 1998, GASTROENTEROLOGY, V114, P175, DOI 10.1016/S0016-5085(98)70645-6; FARMAN N, 1991, AM J PHYSIOL, V260, pC226, DOI 10.1152/ajpcell.1991.260.2.C226; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Funder JW, 2000, KIDNEY INT, V57, P1358, DOI 10.1046/j.1523-1755.2000.00975.x; FUNDER JW, 1990, FASEB J, V4, P3234, DOI 10.1096/fasebj.4.14.2172062; Fuster D, 1998, ENDOCRINOLOGY, V139, P3849, DOI 10.1210/en.139.9.3849; Gao HB, 1997, ENDOCRINOLOGY, V138, P156, DOI 10.1210/en.138.1.156; GOMEZSANCHEZ EP, 1992, AM J PHYSIOL, V263, pE1125; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; HOLBROOK MM, 1980, J STEROID BIOCHEM, V13, P1355, DOI 10.1016/0022-4731(80)90097-7; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; KENYON CJ, 1984, CLIN SCI, V67, P329, DOI 10.1042/cs0670329; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; Kotelevtsev Y, 1999, J CLIN INVEST, V103, P683, DOI 10.1172/JCI4445; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; KROZOWSKI ZS, 1989, ENDOCRINOLOGY, V125, P192, DOI 10.1210/endo-125-1-192; Kyossev Z, 1996, KIDNEY INT, V49, P271, DOI 10.1038/ki.1996.39; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200; LOMBES M, 1994, BIOCHEM J, V302, P191, DOI 10.1042/bj3020191; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; MONDER C, 1989, ENDOCRINOLOGY, V125, P1046, DOI 10.1210/endo-125-2-1046; Morris DJ, 2000, KIDNEY INT, V57, P1370, DOI 10.1046/j.1523-1755.2000.00977.x; MYLES K, 1994, AM J PHYSIOL, V267, pE268, DOI 10.1152/ajpendo.1994.267.2.E268; Mziaut H, 1999, J BIOL CHEM, V274, P14122, DOI 10.1074/jbc.274.20.14122; Naray-Fejes-Toth A, 1998, ENDOCRINOLOGY, V139, P2955, DOI 10.1210/en.139.6.2955; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Odermatt A, 2001, J CLIN ENDOCR METAB, V86, P1247, DOI 10.1210/jc.86.3.1247; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Quinkler M, 1999, J CLIN ENDOCR METAB, V84, P4165, DOI 10.1210/jc.84.11.4165; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; SASANO H, 1992, J ENDOCRINOL, V132, P305, DOI 10.1677/joe.0.1320305; SATOH K, 1993, NUCLEIC ACIDS RES, V21, P4429, DOI 10.1093/nar/21.18.4429; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SOUNESS GW, 1989, ENDOCRINOLOGY, V124, P1588, DOI 10.1210/endo-124-3-1588; SOUNESS GW, 1995, ENDOCRINOLOGY, V136, P1809, DOI 10.1210/en.136.4.1809; Stewart PM, 1999, VITAM HORM, V57, P249; STEWART PM, 1994, J CLIN ENDOCR METAB, V79, P480, DOI 10.1210/jc.79.2.480; Trapp T, 1996, TRENDS PHARMACOL SCI, V17, P145, DOI 10.1016/0165-6147(96)81590-2; Voice MW, 1996, BIOCHEM J, V317, P621, DOI 10.1042/bj3170621; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263; Windle RJ, 1998, ENDOCRINOLOGY, V139, P4044, DOI 10.1210/en.139.10.4044; YOUNG M, 1994, J CLIN INVEST, V93, P2578, DOI 10.1172/JCI117269; Young MJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE883, DOI 10.1152/ajpendo.1996.271.5.E883; ZHANG YD, 1994, J STEROID BIOCHEM, V49, P81, DOI 10.1016/0960-0760(94)90304-2	60	109	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28484	28492		10.1074/jbc.M100374200	http://dx.doi.org/10.1074/jbc.M100374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350956	hybrid			2022-12-27	WOS:000170093400099
J	Zhou, AW; Carrell, RW; Huntington, JA				Zhou, AW; Carrell, RW; Huntington, JA			The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INHIBITORS; C1 INHIBITOR; COWPOX VIRUS; COMPLEXES; TRYPSIN; SERINE; ENZYME; ALPHA-2-ANTIPLASMIN; ALPHA-1-ANTITRYPSIN; INSERTION	The recent crystallographic structure of a serpin-protease complex revealed that protease inactivation results from a disruption of the catalytic site architecture caused by the displacement of the catalytic serine, We hypothesize that inhibition depends on the length of the N-terminal portion of the reactive center loop, to which the active serine is covalently attached, To test this, alpha (1)-antitrypsin Pittsburgh variants were prepared with lengthened and shortened reactive center loops. The rates of inhibition of factor Xa and of complex dissociation were measured. The addition of one residue reduced the stability of the complex more than 200,000-fold, and the addition of two residues reduced it by more than 1,000,000-fold, whereas the deletion of one or two residues lowered the efficiency of inhibition and increased the stability of the complex (a-fold), The deletion of more than two residues completely converted the serpin into a substrate. Similar results were obtained for the alpha (1)-antitrypsin variants with thrombin and for PAI-1 and PAI-2 with their common target tissue plasminogen activator. We conclude that the length of the serpin reactive center loop is critical for its mechanism of inhibition and is precisely regulated to balance the efficiency of inhibition and stability of the final complex.	Univ Cambridge, Dept Haematol, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge	Huntington, JA (corresponding author), Univ Cambridge, Dept Haematol, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.			ZHOU, Aiwu/0000-0002-2555-5091				Bottomley SP, 1998, PROTEIN ENG, V11, P1243, DOI 10.1093/protein/11.12.1243; CARTER PE, 1988, EUR J BIOCHEM, V173, P163, DOI 10.1111/j.1432-1033.1988.tb13980.x; ChaillanHuntington CE, 1997, BIOCHEMISTRY-US, V36, P9562, DOI 10.1021/bi970651g; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HOLMES WE, 1987, J BIOL CHEM, V262, P1659; HOLMES WE, 1987, SCIENCE, V238, P209, DOI 10.1126/science.2958938; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JESTY J, 1979, J BIOL CHEM, V254, P44; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; OLSON ST, 1995, J BIOL CHEM, V270, P30007; Olson ST, 1997, J BIOL CHEM, V272, P13338, DOI 10.1074/jbc.272.20.13338; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PANNELL R, 1974, BIOCHEMISTRY-US, V13, P5439, DOI 10.1021/bi00723a031; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200; Zhou AW, 1997, J BIOCHEM, V121, P930	28	121	127	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27541	27547		10.1074/jbc.M102594200	http://dx.doi.org/10.1074/jbc.M102594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11325972	hybrid			2022-12-27	WOS:000169966900106
J	Canobbio, I; Bertoni, A; Lova, P; Paganini, S; Hirsch, E; Sinigaglia, F; Balduini, C; Torti, M				Canobbio, I; Bertoni, A; Lova, P; Paganini, S; Hirsch, E; Sinigaglia, F; Balduini, C; Torti, M			Platelet activation by von Willebrand Factor requires coordinated signaling through thromboxane A(2) and Fc gamma IIA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; GLYCOPROTEIN-IB; PHOSPHOLIPASE C-GAMMA-2; COLLAGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IX; SYK; CYTOSKELETON; ASSOCIATION; ALPHA	Interaction of von Willebrand Factor with glycoprotein Ib-M-V induces platelet activation through a still poorly defined mechanism. Previous studies have suggested a possible role for the low affinity receptor for immunoglobulin, Fc gamma RIIA, in GPIb-IX-V signaling. Here we show that binding of VWF to platelets induces the tyrosine phosphorylation of Fc gamma RIIA by a Src kinase, Treatment of platelets with the anti-Fc gamma RIIA monoclonal antibody IV.3 specifically inhibits vWF-induced but not thrombin-induced pleckstrin phosphorylation and serotonin secretion. Moreover, VWF fails to induce pleckstrin phosphorylation in mouse platelets, lacking Fc gamma RIIA, and serotonin secretion is impaired. Pleckstrin phosphorylation and serotonin secretion in human platelets stimulated with vWF are blocked by the cyclooxygenase inhibitor acetylsalicylic acid. However, release of arachidonic acid and synthesis of TxA(2) induced by vWF are not affected by the anti-Fc gamma RIIA monoclonal antibody IV.3, Similarly, vWF-induced tyrosine phosphorylation of Fc gamma RIIA, as well as of Syk and PLC gamma2, occurs normally in aspirinized platelets. Inhibition of the tyrosine kinase Syk by piceatannol does not affect vWF-induced tyrosine phosphorylation of Fc gamma RIIA but prevents phosphorylation of PLC gamma2, Pleckstrin phosphorylation and platelet secretion induced by VWF, but not by thrombin, are also inhibited by piceatannol, Pleckstrin phosphorylation is also sensitive to the phosphatidylinositol 3-kinase inhibitor wortmannin. These results indicate that PLC gamma2 plays a central role in platelet activation by vWF and that the stimulation of this enzyme requires coordinated signals through endogenous TxA(2) and Fc gamma RIIA.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ A Avogadro, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy	University of Pavia; University of Eastern Piedmont Amedeo Avogadro; University of Turin	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Via Bassi 21, I-27100 Pavia, Italy.		Canobbio, Ilaria/L-7414-2013; Hirsch, Emilio/F-4848-2013	Canobbio, Ilaria/0000-0002-9643-3403; Hirsch, Emilio/0000-0002-9073-6024				ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DU XP, 1994, J BIOL CHEM, V269, P18287; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; Law DA, 1999, BLOOD, V93, P2645, DOI 10.1182/blood.V93.8.2645.408k13_2645_2652; MEYER D, 1993, THROMB HAEMOSTASIS, V70, P99; OZAKI Y, 1995, BBA-GEN SUBJECTS, V1243, P482, DOI 10.1016/0304-4165(94)00178-Z; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; Sun B, 1999, BIOCHEM BIOPH RES CO, V266, P24, DOI 10.1006/bbrc.1999.1761; Torti M, 1999, J BIOL CHEM, V274, P13690, DOI 10.1074/jbc.274.19.13690; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Tsakiris DA, 1999, THROMB HAEMOSTASIS, V81, P177, DOI 10.1055/s-0037-1614439; WARE J, 1993, J BIOL CHEM, V268, P8376; Ware J, 1998, THROMB HAEMOSTASIS, V79, P466; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779	28	65	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26022	26029		10.1074/jbc.M102639200	http://dx.doi.org/10.1074/jbc.M102639200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344169	hybrid			2022-12-27	WOS:000169823300052
J	Carretero, J; Obrador, E; Esteve, JM; Ortega, A; Pellicer, JA; Sempere, FV; Estrela, JM				Carretero, J; Obrador, E; Esteve, JM; Ortega, A; Pellicer, JA; Sempere, FV; Estrela, JM			Tumoricidal activity of endothelial cells - Inhibition of endothelial nitric oxide production abrogates tumor cytotoxicity induced by hepatic sinusoidal endothelium in response to B16 melanoma adhesion in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; EXPERIMENTAL METASTASIS; GENE-TRANSCRIPTION; OXIDATIVE STRESS; H2O2 PRODUCTION; CANCER-CELLS; GLUTATHIONE; OXYGEN; SUPEROXIDE; RELEASE	The mechanism of NO- and H2O2-induced tumor cytotoxicity was examined during B16 melanoma (B16M) adhesion to the hepatic sinusoidal endothelium (HSE) in vitro. We used endothelial nitric-oxide synthetase gene disruption and NO-nitro-L-arginine methyl ester-induced inhibition of nitric-oxide synthetase activity to study the effect of HSE-derived NO on B16M cell viability. Extracellular H2O2 was removed by exogenous catalase, H2O2 was not cytotoxic in the absence of NO, However, NO-induced tumor cytotoxicity was increased by H2O2 due to the formation of potent oxidants, likely (OH)-O-. and -OONO radicals, via a trace metal-dependent process. B16M cells cultured to low density (LD cells), with high GSH content, were more resistant to NO and H2O2 than B16M cells cultured to high density (HD cells; with similar to 25% of the GSH content found in LD cells). Resistance of LD cells decreased using buthionine sulfoximine, a specific GSH synthesis inhibitor, whereas resistance increased in HD cells using GSH ester, which delivers free intracellular GSH, Because NO and H2O2 were particularly cytotoxic in HD cells, we investigated the enzyme activities that degrade H2O2, NO and H2O2 caused an similar to 75% (LD cells) and a 60% (HD cells) decrease in catalase activity without affecting the GSH peroxidase/GSH reductase system. Therefore, B16M resistance to the HSE-induced cytotoxicity appears highly dependent on GSH and GSH peroxidase, which are both required to eliminate H2O2, In agreement with this fact, ebselen, a GSH peroxidase mimic, abrogated the increase in NO toxicity induced by H2O2.	Univ Valencia, Fac Med & Odontol, Dept Fisiol, Valencia 46010, Spain; Univ Valencia, Hosp La Fe, Serv Anat Patol, Valencia, Spain	University of Valencia; Hospital Universitari i Politecnic La Fe; University of Valencia	Estrela, JM (corresponding author), Univ Valencia, Fac Med & Odontol, Dept Fisiol, Av Blasco Ibanez 17, Valencia 46010, Spain.	jose.m.estrela@uv.es	MARTINEZ, ANTONIO PELLICER/C-4832-2015; Carretero, Julian/N-5214-2014; OBRADOR, ELENA/H-4069-2015; Estrela, Jose/H-4449-2015; Vera-Sempere, Francisco/AAG-4726-2019; Ortega, Angel L./A-4113-2014	Carretero, Julian/0000-0001-7269-8506; OBRADOR, ELENA/0000-0002-5934-5543; Estrela, Jose/0000-0002-2540-9190; Vera-Sempere, Francisco/0000-0003-1838-5466; Ortega, Angel L./0000-0002-9901-3383				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Ahmed A, 1997, LAB INVEST, V76, P779; Akerboom T P, 1981, Methods Enzymol, V77, P373; ALBERTSSON PA, 1995, CLIN EXP METASTAS, V13, P269, DOI 10.1007/BF00133482; Anasagasti MJ, 1997, HEPATOLOGY, V25, P840, DOI 10.1002/hep.510250410; Anasagasti MJ, 1996, J CELL PHYSIOL, V167, P314, DOI 10.1002/(SICI)1097-4652(199605)167:2<314::AID-JCP16>3.0.CO;2-7; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; ARRICK BA, 1984, CANCER RES, V44, P4224; ASENSI M, 1994, ANAL BIOCHEM, V217, P323, DOI 10.1006/abio.1994.1126; Bayon LG, 1996, HEPATOLOGY, V23, P1224, DOI 10.1002/hep.510230542; Bergmeyer HU., 1974, METHODS ENZYMATIC AN, P574, DOI [10.1016/B978-0-12-091302-2.50010-4, DOI 10.1016/B978-0-12-091302-2.50010-4]; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BUTTERY LDK, 1993, J PATHOL, V171, P311, DOI 10.1002/path.1711710412; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; Chiang KT, 2000, TOXICOL APPL PHARM, V167, P30, DOI 10.1006/taap.2000.8970; CLANCY RM, 1990, ANAL BIOCHEM, V191, P138, DOI 10.1016/0003-2697(90)90400-4; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DONG ZY, 1994, CANCER RES, V54, P789; ESKENAZI AE, 1993, J NATL CANCER I, V85, P711, DOI 10.1093/jnci/85.9.711; FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FIDLER IJ, 1990, CANCER RES, V50, P6130; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GIAVAZZI R, 1990, CANCER RES, V50, P4771; GLAVES D, 1986, INVAS METAST, V6, P101; Gupta MP, 1997, AM J PHYSIOL-LUNG C, V272, pL1133, DOI 10.1152/ajplung.1997.272.6.L1133; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; Hogg N, 2000, FREE RADICAL BIO MED, V28, P1478, DOI 10.1016/S0891-5849(00)00248-3; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; Jessup JM, 1999, CANCER RES, V59, P1825; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAFRENIE R, 1992, CANCER METAST REV, V11, P377, DOI 10.1007/BF01307188; LI L, 1991, CANCER RES, V51, P245; LI LM, 1991, CANCER RES, V51, P2531; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MCCLOSKEY TW, 1992, HEPATOLOGY, V16, P191, DOI 10.1002/hep.1840160130; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Nishikawa M, 1998, HEPATOLOGY, V27, P422, DOI 10.1002/hep.510270216; NORONHADUTRA AA, 1993, FEBS LETT, V321, P59, DOI 10.1016/0014-5793(93)80621-Z; OROSZ P, 1993, J EXP MED, V177, P1391, DOI 10.1084/jem.177.5.1391; PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; RICE GE, 1988, AM J PATHOL, V133, P204; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; SELLAK H, 1994, BLOOD, V83, P2669; Sharpe MA, 1998, J BIOL CHEM, V273, P30961, DOI 10.1074/jbc.273.47.30961; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Sies H, 2000, FREE RADICAL BIO MED, V28, P1451, DOI 10.1016/S0891-5849(00)00253-7; Uppu RM, 1996, METHOD ENZYMOL, V269, P322; VIDALVANACLOCHA F, 1993, HEPATOLOGY, V18, P328; WALKER MW, 1995, PEDIATR RES, V37, P41, DOI 10.1203/00006450-199501000-00010; Wang HM, 2000, CANCER RES, V60, P5862; WEISS L, 1988, FASEB J, V2, P12, DOI 10.1096/fasebj.2.1.3275560; Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813	68	43	45	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25775	25782		10.1074/jbc.M101148200	http://dx.doi.org/10.1074/jbc.M101148200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313348	hybrid			2022-12-27	WOS:000169823300020
J	Murnion, ME; Adams, RR; Callister, DM; Allis, CD; Earnshaw, WC; Swedlow, JR				Murnion, ME; Adams, RR; Callister, DM; Allis, CD; Earnshaw, WC; Swedlow, JR			Chromatin-associated protein phosphatase 1 regulates aurora-B and histone H3 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; CHROMOSOME CONDENSATION; STRUCTURAL-CHANGES; MITOTIC CHROMOSOMES; CENTRAL SPINDLE; OKADAIC ACID; KINASE; XENOPUS; MITOSIS; INTERPHASE	Proper chromosome condensation requires the phosphorylation of histone and nonhistone chromatin proteins. We have used an in vitro chromosome assembly system based on Xenopus egg cytoplasmic extracts to study mitotic histone H3 phosphorylation, We identified a histone H3 Ser(10) kinase activity associated with isolated mitotic chromosomes. The histone H3 kinase was not affected by inhibitors of cyclin-dependent kinases, DNA-dependent protein kinase, p90(rsk), or cAMP-dependent protein kinase, The activity could be selectively eluted from mitotic chromosomes and immunoprecipitated by specific anti-X aurora-B/AIRK2 antibodies. This activity was regulated by phosphorylation. Treatment of X aurora-B immunoprecipitates with recombinant protein phosphatase 1 (PP1) inhibited kinase activity. The presence of PP1 on chromatin suggested that PP1 might directly regulate the X aurora-B associated kinase activity. Indeed, incubation of isolated interphase chromatin with the PP1-specific inhibitor I2 and ATP generated an H3 kinase activity that was also specifically immunoprecipitated by anti-X aurora-B antibodies. Nonetheless, we found that stimulation of histone H3 phosphorylation in interphase cytosol does not drive chromosome condensation or targeting of 13 S condensin to chromatin, In summary, the chromosome-associated mitotic histone H3 Ser(10) kinase is associated with X aurora-B and is inhibited directly in interphase chromatin by PP1.	Univ Dundee, Sch Life Sci, Div Mol Cell Biol, Dundee DD1 5EH, Scotland; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Inst Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Virginia, Charlottesville, VA 22908 USA	University of Dundee; University of Edinburgh; University of Virginia	Swedlow, JR (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Cell Biol, MSI-WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	j.swedlow@dundee.ac.uk	Earnshaw, William/AAY-7438-2020	Adams, Richard/0000-0003-1501-0941; Swedlow, Jason/0000-0002-2198-1958; Earnshaw, William/0000-0002-7191-0621	Wellcome Trust [073915] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CARDENAS ME, 1993, J CELL SCI, V104, P219; CHAN CSM, 1993, GENETICS, V135, P677; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; EARNSHAW WC, 1991, J CELL SCI, V98, P443; Field CM, 1998, METHOD ENZYMOL, V298, P525, DOI 10.1016/S0076-6879(98)98043-0; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1973, BIOCHEM BIOPH RES CO, V50, P744, DOI 10.1016/0006-291X(73)91307-7; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hardie DG, 1999, PROTEIN PHOSPHORYLAT, P201; HECK MMS, 1989, J BIOL CHEM, V264, P15161; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Jin Y, 2000, J CELL BIOL, V149, P1005, DOI 10.1083/jcb.149.5.1005; Kaitna S, 2000, CURR BIOL, V10, P1172, DOI 10.1016/S0960-9822(00)00721-1; Kaszas E, 2000, J CELL SCI, V113, P3217; Kim JH, 1999, J CELL BIOL, V145, P1381, DOI 10.1083/jcb.145.7.1381; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARION C, 1985, J MOL BIOL, V186, P367, DOI 10.1016/0022-2836(85)90111-1; MAZEN A, 1987, J MOL BIOL, V194, P741, DOI 10.1016/0022-2836(87)90251-8; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Roghi C, 1998, J CELL SCI, V111, P557; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Swedlow JR, 1999, PRACT APPROACH SER, P165; Tate P, 1998, J CELL SCI, V111, P2575; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	74	202	206	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26656	26665		10.1074/jbc.M102288200	http://dx.doi.org/10.1074/jbc.M102288200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350965	hybrid			2022-12-27	WOS:000169823300131
J	Schaerer, MT; Kannenberg, K; Hunziker, P; Baumann, SW; Sigel, E				Schaerer, MT; Kannenberg, K; Hunziker, P; Baumann, SW; Sigel, E			Interaction between GABA(A) receptor beta subunits and the multifunctional protein gC1q-R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C PHOSPHORYLATION; A-RECEPTOR; BENZODIAZEPINE RECEPTOR; MITOCHONDRIAL MATRIX; INTRACELLULAR DOMAINS; P-32 PROTEIN; ACID; BRAIN; EXPRESSION; CELLS	gamma -Aminobutyric acid type A (GABA,) receptors were immunopurified from bovine brain using a monoclonal antibody directed against the alpha1 subunit, Of the several proteins that copurified, a 34-kDa protein was analyzed further. After enrichment and tryptic proteolysis, the resulting fragments were sequenced, and the protein was identified as gC1q-R. Using anti-gC1q-R and anti-GABA(A) receptor antibodies, mutual coimmunoprecipitation could be demonstrated from solubilized rat brain membranes. The stability of this interaction was estimated to be very high, Using the yeast two-hybrid system, various GABAA receptor subunit intracellular loop constructs were tested for an interaction with gC1q-R. All beta subunits, but not alpha1 and gamma2 subunits, were found to bind to gC1q-R, NH2- and COOH-terminally truncated beta2 subunit loops were used to find the region responsible for the interaction with gC1q-R, A stretch of 15 amino acids containing 7 positively charged residues was identified (amino acids 399-413), This region contains residue Ser-410, which is a protein kinase substrate, and it is known that phosphorylation of this residue leads to an alteration in receptor activity. Localization studies suggested a predominantly intracellular localization. Our observations therefore suggest a tight interaction between gC1q-R and the GABA(A) receptor which might be involved in receptor biosynthesis or modulation of the mature function.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland	University of Bern; University of Zurich	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	Erwin.Sigel@pki.unibe.ch	Sigel, Erwin/F-7736-2015					Barnard EA, 1998, PHARMACOL REV, V50, P291; BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brandon NJ, 1999, J NEUROSCI, V19, P9228; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Dedio J, 1998, J IMMUNOL, V160, P3534; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; Kannenberg K, 1999, EUR J NEUROSCI, V11, P1256, DOI 10.1046/j.1460-9568.1999.00533.x; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; Lin YF, 1996, MOL PHARMACOL, V50, P185; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; Lynch NJ, 1997, FEBS LETT, V418, P111, DOI 10.1016/S0014-5793(97)01348-3; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; MALHERBE P, 1990, J NEUROSCI, V10, P2330; MALHERBE P, 1990, MOL BRAIN RES, V8, P199, DOI 10.1016/0169-328X(90)90017-8; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; McDonald BJ, 1998, NAT NEUROSCI, V1, P23, DOI 10.1038/223; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; NUSSER Z, 1995, J NEUROSCI, V15, P2948; NUSSER Z, 1995, EUR J NEUROSCI, V7, P630, DOI 10.1111/j.1460-9568.1995.tb00667.x; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; Scotti AL, 1999, PHILOS T ROY SOC B, V354, P357, DOI 10.1098/rstb.1999.0387; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; SIGEL E, 1983, J BIOL CHEM, V258, P6965; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; Sinkkonen ST, 2000, J NEUROSCI, V20, P3588, DOI 10.1523/JNEUROSCI.20-10-03588.2000; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Tretter V, 1997, J NEUROSCI, V17, P2728; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	52	20	26	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26597	26604		10.1074/jbc.M102534200	http://dx.doi.org/10.1074/jbc.M102534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350968	hybrid			2022-12-27	WOS:000169823300124
J	Bartoli, M; Ramarao, MK; Cohen, JB				Bartoli, M; Ramarao, MK; Cohen, JB			Interactions of the rapsyn RING-H2 domain with dystroglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR CLUSTERS; BETA-DYSTROGLYCAN; NEUROMUSCULAR-JUNCTIONS; FINGER DOMAIN; 43-KD PROTEIN; 43K PROTEIN; DYSTROPHIN; ASSOCIATION; LINKING; COMPLEX	Rapsyn, a peripheral membrane protein of skeletal muscle, is necessary for the formation of the highly organized structure of the vertebrate neuromuscular junction. For mice lacking rapsyn, there is a failure of postsynaptic specialization characterized by an absence of nicotinic acetylcholine receptors (nAChRs) and other integral and peripheral membrane proteins such as beta -dystroglycan and utrophin, Dystroglycan is necessary for the formation of the mature neuromuscular junction and has been shown to interact directly with rapsyn, Previous studies with rapsyn fragments and mutants, expressed in 293T cells along with nAChRs, establish that the rapsyn tetratricopeptide repeat (TPR) domain is involved in self-association and its coiled-coil domain is necessary for nAChR clustering, The function of the rapsyn RING-MS domain, which is not necessary for rapsyn self-association or nAChR clustering, is unknown. To further characterize these domains, we have used a yeast two-hybrid assay to test for interactions at the plasma membrane between rapsyn domains and a nAChR beta -subunit fragment, the beta -dystroglycan cytoplasmic domain, or rapsyn domains. The rapsyn coiled-coil domain interacts with the nAChR beta -subunit cytoplasmic domain, but not with itself, other rapsyn domains, or beta -dystroglycan, The RING-MS domain interacts only with the beta -dystroglycan cytoplasmic domain. Furthermore, when expressed in 293T cells, a rapsyn construct containing as few as two TPRs and the RING-MS domain self-associates and clusters dystroglycan, but not nAChRs, These results emphasize the modular character of the rapsyn structural domains.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu	Bartoli, Marc/O-8893-2016; Bartoli, Marc/Q-5979-2017	Bartoli, Marc/0000-0003-3339-9858; Bartoli, Marc/0000-0003-3339-9858	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018458] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 18458] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bewick GS, 1996, J NEUROCYTOL, V25, P367; Bezakova G, 1998, MOL CELL NEUROSCI, V11, P274, DOI 10.1006/mcne.1998.0688; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; Grady RM, 2000, NEURON, V25, P279, DOI 10.1016/S0896-6273(00)80894-6; Henry MD, 1999, CURR OPIN CELL BIOL, V11, P602, DOI 10.1016/S0955-0674(99)00024-1; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; James M, 2000, J CELL SCI, V113, P1717; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kentsis A, 2000, CURR PROTEIN PEPT SC, V1, P49, DOI 10.2174/1389203003381478; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; Maimone MM, 1999, MOL CELL NEUROSCI, V14, P340, DOI 10.1006/mcne.1999.0779; Moukhles H, 2000, J COMP NEUROL, V420, P182, DOI 10.1002/(SICI)1096-9861(20000501)420:2<182::AID-CNE3>3.0.CO;2-2; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Ponting CCP, 1996, BIOCHEM J, V314, P1053, DOI 10.1042/bj3141053; Ramarao MK, 2001, J BIOL CHEM, V276, P7475, DOI 10.1074/jbc.M009888200; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; Russo K, 2000, BIOCHEM BIOPH RES CO, V274, P93, DOI 10.1006/bbrc.2000.3103; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	39	79	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24911	24917		10.1074/jbc.M103258200	http://dx.doi.org/10.1074/jbc.M103258200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342559	hybrid			2022-12-27	WOS:000169800700064
J	Cao, MY; Shinjo, F; Heinrichs, S; Soh, JW; Jongstra-Bilen, J; Jongstra, J				Cao, MY; Shinjo, F; Heinrichs, S; Soh, JW; Jongstra-Bilen, J; Jongstra, J			Inhibition of anti-IgM-induced translocation of protein kinase C beta I inhibits ERK2 activation and increases apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; JUN NH2-TERMINAL KINASE; LYMPHOCYTE-SPECIFIC PROTEIN-1; CA-2+-BINDING PROTEIN; WEHI-231 CELLS; CROSS-LINKING; B-LYMPHOCYTES; RECEPTOR; LSP1; TRANSDUCTION	Expression of the COOH-terminal residues 179-330 of the LSP1 protein in the LSP1(+) B-cell line W10 increases anti-IgM- or ionomycin-induced apoptosis, suggesting that expression of this LSP1 truncate (B-LSP1) interferes with a Ca2+-dependent step in anti-IglM signaling. Here we show that inhibition of Ca2+-dependent conventional protein kinase C (cPKC) isoforms with Go6976 increases anti-IgM-induced apoptosis of W10 cells and that expression of B-LSP1 inhibits translocation of PKC betaI but not of PKC beta II or PKC alpha to the plasma membrane. The increased anti-IgM-induced apoptosis is partially reversed by overexpression of PKC betaI, This shows that the B-LSP1-mediated inhibition of PKC betaI leads to increased anti-IgM-induced apoptosis, Expression of constitutively active PKC betaI protein in W10 cells activates the mitogen-activated protein kinase ERK2, whereas expression of B-LSP1 inhibits anti-IgM-induced activation of ERK2, suggesting that anti-IgM-activated PKC betaI is involved in the activation of ERK2 and that inhibition of ERK2 activation contributes to the increased anti-IgM-induced apoptosis, Pull-down assays show that LSP1 interacts with PKC betaI but not with PKC beta II or PKC alpha in W10 cell lysates, while in vitro LSP1 and B-LSP1 bind directly to PKC betaI, Thus, B-LSP1 is a unique reagent that binds PKC betaI and inhibits anti-IgM-induced PKC betaI translocation, leading to inhibition of ERK2 activation and increased apoptosis.	Univ Toronto, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5T 2S8, Canada; Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Columbia University	Jongstra, J (corresponding author), Toronto Western Hosp, Rm 13-419,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	jongstra@uhnres.utoronto.ca						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andjelic S, 1998, EUR J IMMUNOL, V28, P570, DOI 10.1002/(SICI)1521-4141(199802)28:02<570::AID-IMMU570>3.0.CO;2-M; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Davis TA, 1998, BLOOD, V92, P1184, DOI 10.1182/blood.V92.4.1184.416k05_1184_1190; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FANG W, 1995, J IMMUNOL, V155, P66; GENESTIER L, 1995, INT IMMUNOL, V7, P533, DOI 10.1093/intimm/7.4.533; GIMBLE JM, 1993, J IMMUNOL, V150, P115; Gold MR, 1999, J IMMUNOL, V163, P1894; Graves JD, 1998, J IMMUNOL, V161, P168; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; Hsu FJ, 1997, BLOOD, V89, P3129, DOI 10.1182/blood.V89.9.3129; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; JONGSTRA J, 1994, MOL IMMUNOL, V31, P1125, DOI 10.1016/0161-5890(94)90026-4; JONGSTRA J, 1988, J IMMUNOL, V141, P3999; Jongstra-Bilen J, 1999, MOL IMMUNOL, V36, P349, DOI 10.1016/S0161-5890(99)00055-3; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; King LB, 1999, J IMMUNOL, V162, P2655; KLEIN DP, 1989, MOL CELL BIOL, V9, P3043, DOI 10.1128/MCB.9.7.3043; KLEIN DP, 1990, J IMMUNOL, V145, P2967; KNOX KA, 1992, INT J CANCER, V52, P959, DOI 10.1002/ijc.2910520622; Lee JR, 1998, J IMMUNOL, V161, P1637; LI Y, 1995, J IMMUNOL, V155, P3563; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pulford K, 1999, IMMUNOLOGY, V96, P262; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TSUTSUMI A, 1992, CELL IMMUNOL, V142, P303, DOI 10.1016/0008-8749(92)90292-W; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	42	19	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24506	24510		10.1074/jbc.M103883200	http://dx.doi.org/10.1074/jbc.M103883200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333276	hybrid			2022-12-27	WOS:000169800700013
J	Kim, CH; Ardayfio, P; Kim, KS				Kim, CH; Ardayfio, P; Kim, KS			An E-box motif residing in the exon/intron 1 junction regulates both transcriptional activation and splicing of the human norepinephrine transporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYLASE GENE; MAJOR LATE PROMOTER; SPONTANEOUSLY HYPERTENSIVE RAT; LOOP-HELIX PROTEINS; RNA POLYMERASE-II; HEAVY-CHAIN GENE; TYROSINE-HYDROXYLASE; MESSENGER-RNA; FIRST INTRON; UPSTREAM ELEMENT	The norepinephrine transporter (NET) is responsible for the rapid NaCl-dependent uptake of norepinephrine into presynaptic noradrenergic nerve endings, Recently, we have characterized the structural organization of the 5 ' upstream promoter region of the human NET (hNET) gene. A new intron of 476 base pairs was found in the middle of the 5 ' -untranslated leader sequence and was shown to robustly enhance the promoter activity. Here, we show that the first hNET intron enhances both the homologous hNET and the heterologous thymidine kinase promoter activities in an orientation- and position-dependent manner. The first hNET intron exhibited a similar promoter-enhancing effect in both SK-N-BE(2)C (NET-positive) and HeLa (NET-negative) cell lines, showing that its function is not cell-specific. Transient transfection assays of a series of deletional constructs show that the first hNET intron contains subdomains with either positive or negative regulatory functions. Furthermore, DNase I footprinting analysis demonstrated that the 5 ' side of the intron, encompassing the splice donor site, is prominently protected by nuclear proteins isolated from both SK-N-BE(B)C and HeLa cells. The protected nucleotide sequence contains a consensus E-box motif, known to regulate diverse eukaryotic genes, which overlaps with the splice donor site of the first intron, We demonstrate that two basic helix-loop-helix proteins, upstream stimulatory factors 1 and 2, are major proteins interacting at this site and that the E-box is at least in part responsible for the promoter-enhancing activity of the first intron, Furthermore, site-directed mutagenesis of the splice donor site of the first intron affects both correct splicing and transcriptional activity. Taken together, our results indicate that a cis-element residing at the first exon/intron junction, encompassing an E-box motif, has a unique dual role in basal transcriptional activation and splicing of hNET mRNA.	Harvard Univ, Sch Med, McLean Hosp, Mol Neurobiol Lab, Belmont, MA 02478 USA; Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA	Harvard University; McLean Hospital; University of Tennessee System; University of Tennessee Health Science Center	Kim, KS (corresponding author), Harvard Univ, Sch Med, McLean Hosp, Mol Neurobiol Lab, 115 Mill St, Belmont, MA 02478 USA.	kskim@mclean.harvard.edu			NIMH NIH HHS [MH48866] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048866, R29MH048866] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Axelrod J, 1969, Prog Brain Res, V31, P21; Bengzon J, 1999, BRAIN RES, V842, P239, DOI 10.1016/S0006-8993(99)01874-0; BORNSTEIN P, 1988, MOL CELL BIOL, V8, P4851, DOI 10.1128/MCB.8.11.4851; Bradford MM, 1976, ANAL BIOCHEM, V112, P195; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Charron G, 1995, J BIOL CHEM, V270, P30604, DOI 10.1074/jbc.270.51.30604; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; CUBELLS JF, 1995, J NEUROCHEM, V65, P502; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Figlewicz DP, 1999, EPILEPSY RES, V37, P203, DOI 10.1016/S0920-1211(99)00072-8; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; Gemel J, 1999, J BIOL CHEM, V274, P6020, DOI 10.1074/jbc.274.9.6020; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Gregori C, 1998, J BIOL CHEM, V273, P25237, DOI 10.1074/jbc.273.39.25237; GREMKE L, 1993, DEV BIOL, V159, P513, DOI 10.1006/dbio.1993.1260; Handen JS, 1997, J BIOL CHEM, V272, P1665, DOI 10.1074/jbc.272.3.1665; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101; Kim CH, 1999, J BIOL CHEM, V274, P6507, DOI 10.1074/jbc.274.10.6507; Kim HS, 1998, J NEUROSCI, V18, P8247; KIM KS, 1994, J NEUROSCI, V14, P7200; KIM KS, 1995, PRACTICAL APPROACH G, V2, P151; Klimek V, 1997, J NEUROSCI, V17, P8451; Lambert G, 2000, ARCH GEN PSYCHIAT, V57, P787, DOI 10.1001/archpsyc.57.8.787; LEFRANC G, 1990, BIOCHIMIE, V72, P7, DOI 10.1016/0300-9084(90)90167-F; Lu D, 1996, ENDOCRINOLOGY, V137, P763, DOI 10.1210/en.137.2.763; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Matsuoka I, 1997, BRAIN RES, V776, P181, DOI 10.1016/S0006-8993(97)01016-0; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Oskouian B, 1997, BIOCHEM J, V324, P113, DOI 10.1042/bj3240113; PORZGEN P, 1995, BIOCHEM BIOPH RES CO, V215, P1145, DOI 10.1006/bbrc.1995.2582; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; SCHLOKAT U, 1986, ONCOGENES GROWTH CON, P226; Seo HM, 1996, J NEUROSCI, V16, P4102; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; SUN ZM, 1995, J BIOL CHEM, V270, P20962, DOI 10.1074/jbc.270.36.20962; Szot P, 1997, MOL BRAIN RES, V44, P46, DOI 10.1016/S0169-328X(96)00217-3; TEJANIBUTT SM, 1994, NEUROENDOCRINOLOGY, V59, P235, DOI 10.1159/000126664; TELLIEZ JB, 1995, MOL CARCINOGEN, V12, P137, DOI 10.1002/mc.2940120305; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; Wakade AR, 1996, J PHYSIOL-LONDON, V494, P67, DOI 10.1113/jphysiol.1996.sp021476; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yang H, 1999, J NEUROSCI, V19, P2413; Yang SP, 1997, J NEUROENDOCRINOL, V9, P763, DOI 10.1046/j.1365-2826.1997.00641.x	53	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24797	24805		10.1074/jbc.M101279200	http://dx.doi.org/10.1074/jbc.M101279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333263	hybrid			2022-12-27	WOS:000169800700052
J	Poser, I; Dominguez, D; de Herreros, AG; Varnai, A; Buettner, R; Bosserhoff, AK				Poser, I; Dominguez, D; de Herreros, AG; Varnai, A; Buettner, R; Bosserhoff, AK			Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor snail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVASION-SUPPRESSOR GENE; EPITHELIAL TUMOR-CELLS; LOBULAR BREAST CANCERS; GASTRIC CARCINOMAS; ADHESION MOLECULE; DOWN-REGULATION; MALIGNANT-MELANOMA; FACTOR AP-2; MUTATIONS; METASTASIS	Malignant transformation of melanocytes frequently coincides with loss of E-cadherin expression. Here we show that loss of E-cadherin in melanoma cell lines does not involve mutations in the E-cadherin gene, promoter methylation, or alterations in expression of AP-2 transcription factors as suggested previously. In a panel of different melanoma cell lines, E-cadherin expression was negatively regulated by up-regulation of the transcription factor Snail. In comparison with primary human melanocytes, where Snail expression was not detected by reverse transcription-polymerase chain reaction, significant expression was found in all eight melanoma cell lines. In parallel, Western blot and reverse transcription-polymerase chain reaction analysis revealed strong reduction of E-cadherin expression in the melanoma cells. Consistently, transient transfection of a Snail expression plasmid into human primary melanocytes led to significant down-regulation of E-cadherin, whereas transient and stable transfection of an antisense Snail construct induced reexpression of E-cadherin in Mel Ju and Mel Im melanomas. In summary, we conclude that activation of Snail expression plays an important role in down-regulation of E-cadherin and tumorigenesis of malignant melanomas.	Rhein Westfal TH Aachen, Inst Pathol, Sch Med, D-52074 Aachen, Germany; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, Barcelona 08003, Spain	RWTH Aachen University; Pompeu Fabra University	Bosserhoff, AK (corresponding author), Rhein Westfal TH Aachen, Inst Pathol, Sch Med, Pauwelsstr 30, D-52074 Aachen, Germany.	bosserhoff@pat.rwth-aachen.de	Bosserhoff, Anja/GNH-4801-2022; de Herreros, A Garcia/H-3104-2014	de Herreros, A Garcia/0000-0001-5270-0808; Bosserhoff, Anja/0000-0001-8147-394X				Bar-Eli M, 1999, CANCER METAST REV, V18, P377, DOI 10.1023/A:1006377309524; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1998, CELL ADHES COMMUN, V6, P171, DOI 10.3109/15419069809004474; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; Danen EHJ, 1996, EUR J CELL BIOL, V70, P69; Danen EHJ, 1996, MELANOMA RES, V6, P127, DOI 10.1097/00008390-199604000-00007; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gayther SA, 1998, CANCER RES, V58, P4086; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; GRAFF JR, 1995, CANCER RES, V55, P5195; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MAREEL MM, 1991, INT J CANCER, V47, P922, DOI 10.1002/ijc.2910470623; Mbalaviele G, 1996, CANCER RES, V56, P4063; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Melki JR, 2000, BLOOD, V95, P3208; Mintz-Weber CS, 2000, J BIOL CHEM, V275, P34672, DOI 10.1074/jbc.M003812200; MOLL R, 1993, AM J PATHOL, V143, P1731; MOSER M, 1995, DEVELOPMENT, V121, P2779; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; Seline PC, 1996, J INVEST DERMATOL, V106, P1320, DOI 10.1111/1523-1747.ep12349048; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Tamura G, 1996, JPN J CANCER RES, V87, P1153, DOI 10.1111/j.1349-7006.1996.tb03125.x; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tamura S, 1996, BRIT J SURG, V83, P1608, DOI 10.1002/bjs.1800831138; VANDENBOSSCHE GMR, 1994, INT J CANCER, V57, P73, DOI 10.1002/ijc.2910570114; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	56	225	237	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24661	24666		10.1074/jbc.M011224200	http://dx.doi.org/10.1074/jbc.M011224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323412	hybrid			2022-12-27	WOS:000169800700034
J	Ruban, AV; Pascal, AA; Robert, B; Horton, P				Ruban, AV; Pascal, AA; Robert, B; Horton, P			Configuration and dynamics of xanthophylls in light-harvesting antennae of higher plants - Spectroscopic analysis of isolated light-harvesting complex of photosystem II and thylakoid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL FLUORESCENCE; EXCITATION TRANSFER; ENERGY-DISSIPATION; BINDING-PROTEINS; BETA-CAROTENE; PHOTOPROTECTION; STATE; RAMAN; OLIGOMERIZATION; IDENTIFICATION	Resonance Raman excitation spectroscopy combined with ultra low temperature absorption spectral analysis of the major xanthophylls of higher plants in isolated antenna and intact thylakoid membranes was used to identify carotenoid absorption regions and study their molecular configuration. The major electronic transitions of the light-harvesting complex of photosystem II (LHCIIb) xanthophylls have been identified for both the monomeric and trimeric states of the complex. One long wavelength state of lutein with a 0-0 transition at 510 nm was detected in LHCIIb trimers, The short wavelength 0-0 transitions of lutein and neoxanthin were located at 495 and 486 nm, respectively. In monomeric LHCIIb, both luteins absorb around 495 nm, but slight differences in their protein environments give rise to a broadening of this band. The resonance Raman spectra of violaxanthin and zeaxanthin in intact thylakoid membranes was determined. The broad 0-0 absorption transition for zeaxanthin was found to be located in the 503-511 nm region. Violaxanthin exhibited heterogeneity, having two populations with one absorbing at 497 nm (0-0), 460 nm (0-1), and 429 nm (0-2), and the other major pool absorbing at 488 nm (0-0), 452 nm (0-1), and 423 nm (0-2), The origin of this heterogeneity is discussed. The configuration of zeaxanthin and violaxanthin in thylakoid membranes was different from that of free pigments, and both xanthophylls (notably, zeaxanthin) were found to be well coordinated within the antenna proteins in vivo, arguing against the possibility of their free diffusion in the membrane and supporting our recent biochemical evidence of their association with intact oligomeric light-harvesting complexes.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Verona, Fac Sci MM FF NN, I-37134 Verona, Italy; CE Saclay, Sect Biophys Prot & Membranes, Dept Biol, Cellulaire & Mol Sect Biophys Prot & Mol, F-91191 Gif Sur Yvette, France; CE Saclay, CNRS, Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France	University of Sheffield; University of Verona; CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Ruban, AV (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	a.ruban@sheffield.ac.uk	pascal, andrew a/B-6186-2014; Horton, Peter/A-3958-2012; Robert, Bruno/D-1264-2012	pascal, andrew a/0000-0002-1844-6065; Horton, Peter/0000-0002-6095-1460; Robert, Bruno/0000-0001-5999-4538				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Connelly JP, 1997, J PHYS CHEM B, V101, P1902, DOI 10.1021/jp9619651; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; DAVIDOV AS, 1962, THEORY MOL EXCITONS; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; Farber A, 1997, PLANT PHYSIOL, V115, P1609, DOI 10.1104/pp.115.4.1609; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gradinaru CC, 2000, J PHYS CHEM B, V104, P9330, DOI 10.1021/jp001752i; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; KENKRE VM, 1974, PHYS REV LETT, V33, P803, DOI 10.1103/PhysRevLett.33.803; Koyama Y, 1999, ADV PHOTOSYNTH, V8, P161; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; LEE AL, 1995, PLANT PHYSIOL, V85, P495; NOGUCHI T, 1991, J PHYS CHEM-US, V95, P3167, DOI 10.1021/j100161a040; Paulsen H, 1999, ADV PHOTOSYNTH, V8, P123; PETER GF, 1991, J BIOL CHEM, V266, P16745; Peterman EJG, 1997, CHEM PHYS LETT, V264, P279, DOI 10.1016/S0009-2614(96)01334-6; Peterman EJG, 1997, BIOCHEMISTRY-US, V36, P12208, DOI 10.1021/bi9711689; Phillip D, 1996, P NATL ACAD SCI USA, V93, P1492, DOI 10.1073/pnas.93.4.1492; RIMAI L, 1973, J AM CHEM SOC, V95, P4493, DOI 10.1021/ja00795a005; Robert B, 1999, ADV PHOTOSYNTH, V8, P189; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; Ruban AV, 1997, BIOCHEMISTRY-US, V36, P7855, DOI 10.1021/bi9630725; RUBAN AV, 1993, PLANT PHYSIOL, V102, P741, DOI 10.1104/pp.102.3.741; Ruban AV, 1997, BBA-BIOENERGETICS, V1321, P61, DOI 10.1016/S0005-2728(97)00047-9; SAITO S, 1983, J RAMAN SPECTROSC, V14, P310, DOI 10.1002/jrs.1250140504; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; STURGIS JN, 1994, J MOL BIOL, V238, P445, DOI 10.1006/jmbi.1994.1303; Verhoeven AS, 1999, PLANT PHYSIOL, V120, P727, DOI 10.1104/pp.120.3.727; Wentworth M, 2000, FEBS LETT, V471, P71, DOI 10.1016/S0014-5793(00)01369-7; YAMAMOTO HY, 1972, PLANT PHYSIOL, V49, P224, DOI 10.1104/pp.49.2.224	38	100	101	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24862	24870		10.1074/jbc.M103263200	http://dx.doi.org/10.1074/jbc.M103263200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331293	hybrid			2022-12-27	WOS:000169800700059
J	Svergun, DI; Zaccai, G; Malfois, M; Wade, RH; Koch, MHJ; Kozielski, F				Svergun, DI; Zaccai, G; Malfois, M; Wade, RH; Koch, MHJ; Kozielski, F			Conformation of the Drosophila motor protein non-claret disjunctional in solution from x-ray and neutron scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE-SCATTERING; SINGLE KINESIN MOLECULES; CRYSTAL-STRUCTURE; DIMERIC KINESIN; SYNCHROTRON RADIATION; NCD; DOMAINS; MICROTUBULES; RESOLUTION; MOVEMENT	The quaternary structures of monomeric and dimeric Drosophila non-claret disjunctional (ncd) constructs were investigated using synchrotron x-ray and neutron solution scattering, and their low resolution shapes were restored ab initio from the scattering data, The experimental curves were further compared with those computed from crystallographic models of one monomeric and three available dimeric ncd structures in the microtubule-independent ADP-bound state, These comparisons indicate that accounting for the missing parts in the crystal structures for all these constructs is indispensable to obtain reasonable fits to the scattering patterns. A ncd construct (MC6) lacking the coiled-coil region is monomeric in solution, but the calculated scattering from the crystallographic monomer yields a poor fit to the data. A tentative configuration of the missing C-terminal residues in the form of an antiparallel beta -sheet was found that significantly improves the fit. The atomic model of a short dimeric ncd construct (MC5) without 2-fold symmetry is found to fit the data better than the symmetric models, Addition of the C-terminal residues to both head domains gives an excellent fit to the x-ray and neutron experimental data, although the orientation of the beta -sheet differs from that of the monomer, The solution structure of the long ncd construct (MC1) including complete N-terminal coiled-coil and motor domains is modeled by adding a straight coiled-coil section to the model of MC5.	DESY, European Mol Biol Lab, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; CEA, CNRS, Inst Biol Struct, Lab Mol Biophys, F-38000 Grenoble 01, France; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Institut Laue-Langevin (ILL)	Svergun, DI (corresponding author), DESY, European Mol Biol Lab, Notkestr 85, D-22603 Hamburg, Germany.	Svergun@EMBL-Hamburg.DE	Malfois, Marc/L-2974-2014	Malfois, Marc/0000-0001-5231-1896; Svergun, Dmitri/0000-0003-0830-5696				Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; BUTTNER HG, 1996, YELLOW BOOK GUIDE NE, P76; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; deCastro MJ, 1999, BIOCHEMISTRY-US, V38, P5076, DOI 10.1021/bi9829175; FEIGIN LA, 1987, STRUCTURE ANAL XRAY; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JACROT B, 1981, BIOPOLYMERS, V20, P2413, DOI 10.1002/bip.1981.360201110; Kim AJ, 2000, J CELL SCI, V113, P3681; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; KOCH MHJ, 1983, NUCL INSTRUM METHODS, V208, P461, DOI 10.1016/0167-5087(83)91169-9; Kozielski F, 1999, STRUCTURE, V7, P1407, DOI 10.1016/S0969-2126(00)80030-1; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kozielski F, 2001, J BIOL CHEM, V276, P1267, DOI 10.1074/jbc.M007169200; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Stone DB, 1999, BIOCHEMISTRY-US, V38, P4938, DOI 10.1021/bi982374z; STUHRMAN.HB, 1970, ACTA CRYSTALL A-CRYS, VA 26, P297, DOI 10.1107/S0567739470000748; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P297, DOI 10.1074/jbc.275.1.297; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, PROTEINS, V27, P110; SVERGUN DI, 1993, J APPL CRYSTALLOGR, V26, P258, DOI 10.1107/S0021889892011828; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; Trewhella J, 1997, CURR OPIN STRUC BIOL, V7, P702, DOI 10.1016/S0959-440X(97)80081-4; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; ZACCAI G, 1983, ANNU REV BIOPHYS BIO, V12, P139, DOI 10.1146/annurev.bb.12.060183.001035	43	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24826	24832		10.1074/jbc.M103618200	http://dx.doi.org/10.1074/jbc.M103618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335729	hybrid			2022-12-27	WOS:000169800700055
J	Gu, SM; Roderick, HL; Camacho, P; Jiang, JX				Gu, SM; Roderick, HL; Camacho, P; Jiang, JX			Characterization of an N-system amino acid transporter expressed in retina and its involvement in glutamine transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; FUNCTIONAL-CHARACTERIZATION; NITROGEN-METABOLISM; RAT-LIVER; CLONING; IDENTIFICATION; CALRETICULIN; ORGANIZATION; ASC	We report here on the characterization of a mouse N-system amino acid transporter protein, which is involved in the transport of glutamine. This protein of 485 amino acids shares 52% sequence homology with an N-system amino acid transporter, mouse N-system amino acid transporter (mNAT) and its orthologs. Because this protein shares a high degree of sequence homology and functional similarity to mNAT, we named it mNAT2. mNAT2 is predominately expressed in the retina and to a slightly lesser extent in the brain. In the retina, it is located in the axons of ganglion cells in the nerve fiber layer and in the bundles of the optic nerve. Functional analysis of mNAT2 expressed in Xenopus oocytes revealed that the strongest transport activities were specific for L-glutamine. In addition, mNAT2 is a Na+- and pH-dependent, high affinity transporter and partially tolerates substitution of Na+ by Li+. Additionally, mNAT2 functions as a carrier-mediated transporter that facilitates efflux. The unique expression pattern and selective glutamine transport properties of mNAT2 suggest that it plays a specific role in the uptake of glutamine involved in the generation of the neurotransmitter glutamate in retina.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Mail Code,7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Jiang, Jean/0000-0002-2185-5716; Roderick, Hywel/0000-0001-7065-3523				BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BENDER DA, 1975, AMINO ACID METABOLIS, P1; Broer A, 1999, J NEUROCHEM, V73, P2184; BURGER HJ, 1989, HEPATOLOGY, V9, P22, DOI 10.1002/hep.1840090105; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Castagna M, 1997, J EXP BIOL, V200, P269; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; Derouiche A, 1996, VISION RES, V36, P3875, DOI 10.1016/S0042-6989(96)00140-X; Fei YJ, 2000, J BIOL CHEM, V275, P23707, DOI 10.1074/jbc.M002282200; FISHMAN RA, 1992, CEREBROSPINAL FLUID, P233; Gu SM, 2000, P NATL ACAD SCI USA, V97, P3230, DOI 10.1073/pnas.050318197; GUIDOTTI GG, 1992, MAMMALIAN AMINO ACID TRANSPORT, P3; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; Imamura Y, 1998, GENOMICS, V51, P293, DOI 10.1006/geno.1998.5357; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; Kalloniatis M, 1999, PROG RETIN EYE RES, V18, P811, DOI 10.1016/S1350-9462(98)00036-6; KENNEDY AJ, 1974, NATURE, V252, P50, DOI 10.1038/252050a0; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1979, BIOCHEM BIOPH RES CO, V88, P744, DOI 10.1016/0006-291X(79)92110-7; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MARC RE, 1995, J NEUROSCI, V15, P5106; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MCDONNELL JM, 1994, RETINA, P5; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Poitry S, 2000, J NEUROSCI, V20, P1809; Rauen T, 1996, CELL TISSUE RES, V286, P325, DOI 10.1007/s004410050702; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; TAYLOR PM, 1992, J BIOL CHEM, V267, P3873; THANKI CM, 1983, J NEUROCHEM, V41, P611, DOI 10.1111/j.1471-4159.1983.tb04785.x; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VANDENBE.CJ, 1971, BIOCHEM J, V123, P211, DOI 10.1042/bj1230211; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; VOADEN MJ, 1978, J NEUROCHEM, V31, P1069, DOI 10.1111/j.1471-4159.1978.tb00149.x; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200	43	38	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24137	24144		10.1074/jbc.M009003200	http://dx.doi.org/10.1074/jbc.M009003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11325958	Green Published, hybrid			2022-12-27	WOS:000169531100121
J	Hajri, T; Ibrahimi, A; Coburn, CT; Knapp, FF; Kurtz, T; Pravenec, M; Abumrad, NA				Hajri, T; Ibrahimi, A; Coburn, CT; Knapp, FF; Kurtz, T; Pravenec, M; Abumrad, NA			Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESISTANCE; MEMBRANE-PROTEINS; CD36; TRANSPORT; MUSCLE; OXIDATION; HEARTS; MICE; TRIGLYCERIDES; INVOLVEMENT	Genetic linkage studies implicated deficiency of CD36, a membrane fatty acid (FA) transporter, in the hypertriglyceridemia and hyperinsulinemia of the spontaneously hypertensive rat (SHR), In this study we determined whether loss of CD36 function in FA uptake is a primary determinant of the SHR phenotype. In vivo, tissue distribution of iodinated, poorly oxidized beta -methyliodophenyl pentadecanoic acid (BMIPP) was examined 2 h after its intravenous injection, Fatty acid transport was also measured in vitro over 20 to 120 s in isolated adipocytes and cardiomyocytes obtained from SHR and from a congenic line (SHRchr4) that incorporates a piece of chromosome 4 containing wild-type CD36, SHR heart and adipose tissue exhibited defects in FA uptake and in conversion of diglycerides to triglycerides that are similar to those observed in the CD36 null mouse. However, a key difference in SHR tissues is that fatty acid oxidation is much more severely impaired than fatty acid esterification, which may underlie the 4-5-fold accumulation of free BMIPP measured in SHR muscle. Studies with isolated adipocytes and cardiomyocytes directly confirmed both the defect in FA transport and the fact that it is underestimated by BMIPP, Heart, oxidative muscle, and adipose tissue in the SHR exhibited a large increase in glucose uptake measured in vivo using [F-18]fluorodeoxyglucose. Supplementation of the diet with short-chain fatty acids, which do not require CD36-facilitated transport, eliminated the increase in glucose uptake, the hyperinsulinemia, and the heart hypertrophy in the SHR, This indicated that lack of metabolic energy consequent to deficient FA uptake is the primary defect responsible for these abnormalities. Hypertension was not alleviated by the supplemented diet suggesting it is unrelated to fuel supply and any contribution of CD36 deficiency to this trait may be more complex to determine. It may be worth exploring whether short-chain FA supplementation can reverse some of the deleterious effects of CD36 deficiency in humans, which may include hypertrophic cardiomyopathy.	SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Oak Ridge Natl Lab, Nucl Med Program, Oak Ridge, TN 37831 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; University of California System; University of California San Francisco; United States Department of Energy (DOE); Oak Ridge National Laboratory	Abumrad, NA (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.		Hajri, Tahar/AAQ-6499-2020; Pravenec, Michal/B-1666-2012	Hajri, Tahar/0000-0003-3805-3717; Pravenec, Michal/0000-0001-9197-5871; Ibrahimi, Azeddine/0000-0003-3226-3836	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033301] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK33301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Aitman TJ, 1997, NAT GENET, V16, P197, DOI 10.1038/ng0697-197; AMBROSE KR, 1987, EUR J NUCL MED, V12, P486, DOI 10.1007/BF00620471; Bavenholm PN, 2000, DIABETES, V49, P1078, DOI 10.2337/diabetes.49.7.1078; CHRISTE ME, 1994, J MOL CELL CARDIOL, V26, P1371, DOI 10.1006/jmcc.1994.1155; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Collison M, 2000, DIABETES, V49, P2222, DOI 10.2337/diabetes.49.12.2222; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gotoda T, 1999, NAT GENET, V22, P226, DOI 10.1038/10285; GREENWALT DE, 1992, BLOOD, V80, P1105; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HARMON CM, 1993, J MEMBRANE BIOL, V133, P43; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Knapp F F Jr, 1996, Q J Nucl Med, V40, P252; KNAPP FF, 1986, J NUCL MED, V27, P521; KROPP J, 1992, NUCL MED BIOL, V19, P283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luiken JJFP, 1997, J LIPID RES, V38, P745; MENAHAN LA, 1983, COMP BIOCHEM PHYS B, V74, P859, DOI 10.1016/0305-0491(83)90157-8; Pravenec M, 1999, J CLIN INVEST, V103, P1651, DOI 10.1172/JCI6691; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; TANDON NN, 1989, J BIOL CHEM, V264, P7570; Torizuka K., 1991, JPN J NUCL MED, V28, P681; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; WILSON DE, 1983, J CLIN ENDOCR METAB, V57, P517, DOI 10.1210/jcem-57-3-517	35	150	155	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23661	23666		10.1074/jbc.M100942200	http://dx.doi.org/10.1074/jbc.M100942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323420	hybrid			2022-12-27	WOS:000169531100059
J	Ono, K; Ohtomo, T; Sato, S; Sugamata, Y; Suzuki, M; Hisamoto, N; Ninomiya-Tsuji, J; Tsuchiya, M; Matsumoto, K				Ono, K; Ohtomo, T; Sato, S; Sugamata, Y; Suzuki, M; Hisamoto, N; Ninomiya-Tsuji, J; Tsuchiya, M; Matsumoto, K			An evolutionarily conserved motif in the TAB1 C-terminal region is necessary for interaction with and activation of TAK1 MAPKKK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE KINASE KINASE; BETA SIGNAL-TRANSDUCTION; PROTEIN-KINASES; PATHWAY; SPECTROSCOPY; JNK; PHOSPHORYLATION; INHIBITOR; EXCHANGE; MEDIATOR	TAK1, a member of the MAPKKK family, is involved in the intracellular signaling pathways mediated by transforming growth factor beta, interleukin 1, and Wnt, TAK1 kinase activity is specifically activated by the TAK1-binding protein TAB1. The C-terminal 68-amino acid sequence of TAB1 (TAB1-C68) is sufficient for TAX1 interaction and activation Analysis of various truncated versions of TAB1-C68 defined a C-terminal 30-amino acid sequence (TAB1-C30) necessary for TAK1 binding and activation. NMR studies revealed that the TAB1-C30 region has a unique cu-helical structure. We identified a conserved sequence motif, PYVDXA/TXF, in the C-terminal domain of mammalian TAB1, Xenopus TAB1, and its Caenorhabditis elegans homolog TAP-I, suggesting that this motif constitutes a specific TAK1 docking site. Alanine substitution mutagenesis showed that, TAB1 Phe484, located in the conserved motif, is crucial for TAK1 binding and activation. The C, elegans homolog of TAB1, TAP-1, was able to interact with and activate the C. elegans homolog of TAK1, MOM-4. However, the site in TAP-1 corresponding to Phe-484 of TAB1 is an alanine residue (Ala-364), and changing this residue to Phe abrogates the ability of TAP-1 to interact with and activate MOM-4. These results suggest that the Phe or Ala residue within the conserved motif of the TAB1-related proteins is important for interaction with and activation of specific TAK1 MAPKKK family members in vivo.	Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Shizuoka 4128513, Japan; Nagoya Univ, Dept Mol Biol, Grad Sch Sci, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Nagoya, Aichi 4648602, Japan	Chugai Pharmaceutical Co., Ltd.; Roche Holding; Nagoya University; Japan Science & Technology Agency (JST)	Tsuchiya, M (corresponding author), Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, 1-135 Komakado, Shizuoka 4128513, Japan.			Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Bartel P. L., 1993, CELLULAR INTERACTION, P153; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRUENGER AT, 1992, X POLAR MANUAL VERSI; BRUENGER AT, 1986, P NATL ACAD SCI USA, V74, P4130; CLORE G, 1986, J MOL BIOL, V205, P201; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miller J.H., 1972, EXPT MOL GENETICS; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REDFIELD AG, 1975, J MAGN RESON, V19, P250, DOI 10.1016/0022-2364(75)90073-6; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WUTHICH K, 1983, J MOL BIOL, V1369, P949; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	36	58	62	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24396	24400		10.1074/jbc.M102631200	http://dx.doi.org/10.1074/jbc.M102631200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323434	hybrid			2022-12-27	WOS:000169531100154
J	Doan, TN; Ali, MS; Bernstein, KE				Doan, TN; Ali, MS; Bernstein, KE			Tyrosine kinase activation by the angiotensin II receptor in the absence of calcium signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PROTEIN; CELLS; PHOSPHORYLATION; TRANSDUCTION; PATHWAY; DOMAIN	The angiotensin II type 1 (AT(1)) receptor signals via heterotrimeric G-proteins and intracellular tyrosine kinases, Here, we investigate a modified AT(1) receptor, termed M5, where the last five tyrosines (residues 292, 302, 312, 319, and 339) within the intracellular carboxyl tail have been mutated to phenylalanine. This receptor did not elevate cytosolic free calcium or inositol phosphate production in response to angiotensin II, suggesting an uncoupling of the receptor from G-protein activation. Despite this, the M5 receptor still activated tyrosine kinases, induced STAT1 tyrosine phosphorylation, and stimulated cell proliferation. We also studied another AT(1) mutant receptor, D74E, stably expressed in Chinese hamster ovarian cells and a fibroblast cell line from mice with a genetic inactivation of G alpha (q/11). Both cell lines have a deficit in calcium signaling and in G-protein activation, and yet in both cell lines, angiotensin II induced the time-dependent tyrosine phosphorylation of STAT1, These studies are the first to show the ability of a seven-transmembrane receptor to activate intracellular tyrosine kinase pathways in the absence of a G-protein-coupled rise in intracellular calcium.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University	Bernstein, KE (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Woodruff Mem Bldg,Rm 7107A,1639 Pierce Dr, Atlanta, GA 30322 USA.			Bernstein, Kenneth/0000-0001-8097-3272	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010269, R01HL061710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039777, R01DK044280, R01DK051445, R01DK039777] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61710, F32 HL10269] Funding Source: Medline; NIDDK NIH HHS [DK39777, DK51445, DK44280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI MS, 1997, J BIOL CHEM, V272, P5592; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BODART V, 1995, J STEROID BIOCHEM, V54, P55, DOI 10.1016/0960-0760(95)00077-D; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Harp JB, 1997, BIOCHEM BIOPH RES CO, V232, P540, DOI 10.1006/bbrc.1997.6322; MARIE J, 1994, J BIOL CHEM, V269, P20815; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marrero MB, 1996, AM J PHYSIOL-CELL PH, V270, pC1834, DOI 10.1152/ajpcell.1996.270.6.C1834; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Offermanns S, 1998, ONCOGENE, V17, P1375, DOI 10.1038/sj.onc.1202173; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; SADOSHIMA J, 1995, CIRC RES, V76, P1; Sayeski PP, 1998, REGUL PEPTIDES, V78, P19, DOI 10.1016/S0167-0115(98)00137-2; SCHORB W, 1994, J BIOL CHEM, V269, P19626; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677	19	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20954	20958		10.1074/jbc.C100199200	http://dx.doi.org/10.1074/jbc.C100199200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11319216	hybrid			2022-12-27	WOS:000169297900022
J	Matharu, AL; Mundell, SJ; Benovic, JL; Kelly, E				Matharu, AL; Mundell, SJ; Benovic, JL; Kelly, E			Rapid agonist-induced desensitization and internalization of the A(2B) adenosine receptor is mediated by a serine residue close to the COOH terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC TAIL; NG108-15 CELLS; PHOSPHORYLATION; ENDOCYTOSIS; TRAFFICKING; EXPRESSION; BINDING; KINASES	The G.-coupled rat A(2B) adenosine receptor (A(2B)-AR) was epitope-tagged at the NH2 terminus with hemagglutinin (HA) and subjected to progressive deletions or point mutations of the COOH terminus in order to determine regions of the receptor that contribute to agonist-induced desensitization and internalization. When expressed stably in Chinese hamster ovary cells, a mutant receptor in which the final 2 amino acids were deleted, the Leu(330)-stop mutant, underwent rapid agonist-induced desensitization and internalization as did the wild type (WT) receptor. However, the Phe(328) and the Gln(325)-stop mutants were resistant to rapid agonist-induced desensitization and internalization. Co-expression of arrestin-2-green fluorescent protein (arrestin-2-GFP) with WT receptor or Leu(330)-stop mutant resulted in rapid translocation of arrestin-2-GFP from cytosol to membrane upon agonist addition. On the other hand, agonist activation of the Phe(328)-stop or Gln(325)-stop mutant did not result in translocation of arrestin-2-GFP from cytosol. A COOH terminus point mutant, S329G, was also unable to undergo rapid agonist-induced desensitization and internalization, indicating that Ser(329) is a critical residue for these processes. A further deletion mutant (Ser(326)- stop) unexpectedly underwent rapid agonist-induced desensitization and internalization. However, activation of this mutant did not promote translocation of arrestin-2-GFP from cytosol to membrane. In addition, whereas WT receptor internalization was markedly inhibited by co-expression of dominant negative mutants of arrestin-2 (arrestin-2-(319-418)), dynamin (dynamin K44A), or Eps-15 (E Delta 95-295), Ser(326)-stop receptor internalization was only inhibited by dominant negative mutant dynamin. Taken together these results indicate that Ser(329), close to the COOH terminus of the rat A2B-AR, is critical for the rapid agonist-induced desensitization and internalization of the receptor. However, deletion of the COOH terminus also uncovers a motif that is able to redirect internalization of the receptor to an arrestin- and clathrin-independent pathway.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Bristol; Jefferson University	Kelly, E (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England.							Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; Feoktistov I, 1997, PHARMACOL REV, V49, P381; FERGUSON SSG, 1996, SCIENCE, V271, P383; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; Haynes J, 1999, AM J PHYSIOL-HEART C, V276, pH1877, DOI 10.1152/ajpheart.1999.276.6.H1877; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Ji X D, 1999, Drug Des Discov, V16, P217; KOJRO E, 1995, J BIOL CHEM, V270, P6476, DOI 10.1074/jbc.270.12.6476; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Mundell SJ, 1998, BIOCHEM PHARMACOL, V55, P595, DOI 10.1016/S0006-2952(97)00466-8; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Palmer TM, 1997, BIOCHEMISTRY-US, V36, P832, DOI 10.1021/bi962290v; Peters DM, 1998, BIOCHEM PHARMACOL, V55, P873, DOI 10.1016/S0006-2952(97)00560-1; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Schulte G, 2000, MOL PHARMACOL, V58, P477, DOI 10.1124/mol.58.3.477; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Sitaraman SV, 2000, AM J PHYSIOL-CELL PH, V278, pC1230, DOI 10.1152/ajpcell.2000.278.6.C1230; Smith RD, 1998, MOL PHARMACOL, V54, P935, DOI 10.1124/mol.54.6.935; Tsao P, 2000, CURR OPIN NEUROBIOL, V10, P365, DOI 10.1016/S0959-4388(00)00096-9	35	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30199	30207		10.1074/jbc.M010650200	http://dx.doi.org/10.1074/jbc.M010650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11333255	hybrid			2022-12-27	WOS:000170558000080
J	Coussen, F; Ayon, A; Le Goff, A; Leroy, J; Massoulie, J; Bon, S				Coussen, F; Ayon, A; Le Goff, A; Leroy, J; Massoulie, J; Bon, S			Addition of a glycophosphatidylinositol to acetylcholinesterase - Processing, degradation, and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; MEMBRANE ANCHOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHOR; ENDOPLASMIC-RETICULUM; TORPEDO-CALIFORNICA; MUTATIONAL ANALYSIS; PHOSPHOLIPASE-C; MAMMALIAN-CELLS; SIGNAL PEPTIDE	We introduced various mutations and modifications in the GPI anchoring signal of rat acetylcholinesterase (AChE). 1) The resulting mutants, expressed in transiently transfected COS cells, were initially produced at the same rate, in an active form, but the fraction of GPI-anchored ACNE and the steady state level of ACNE activity varied over a wide range. 2) Productive interaction with the GPI addition machinery led to GPI anchoring, secretion of uncleaved protein, and secretion of a cleaved protein, in variable proportions. Unproductive interaction led to degradation; poorly processed molecules were degraded rather than retained intracellularly or secreted. 3) An efficient glypiation appeared necessary but not sufficient for a high level of secretion; the cleaved, secreted protein was possibly generated as a by-product of transamidation. 4) Glypiation was influenced by a wider context than the triplet omega/omega + 1/omega + 2, particularly omega - 1. 5) Glypiation was not affected by the closeness of the w site to the alo helix of the catalytic domain. 6) A cysteine could simultaneously form a disulfide bond and serve as an co site; however, there was a mutual interference between glypiation and the formation of an intercatenary disulfide bond, at a short distance upstream of omega. 7) Glypiation was not affected by the presence of an N-glycosylation site at co or in its vicinity or by the addition of a short hydrophilic, highly charged peptide (FLAG; DYKDDDDK) at the C terminus of the hydrophobic region.	Ecole Normale Super, Mol & Cellular Neurobiol Lab, CNRS, UMR 8544, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Bon, S (corresponding author), Ecole Normale Super, Mol & Cellular Neurobiol Lab, CNRS, UMR 8544, 46 Rue Ulm, F-75005 Paris, France.	jean.massoulie@biologie.ens.fr						Bon S, 1997, J BIOL CHEM, V272, P3007, DOI 10.1074/jbc.272.5.3007; BON S, 1988, J NEUROCHEM, V51, P786, DOI 10.1111/j.1471-4159.1988.tb01813.x; Bucht C, 1996, BBA-PROTEIN STRUCT M, V1292, P223, DOI 10.1016/0167-4838(95)00205-7; Bucht G, 1999, BBA-PROTEIN STRUCT M, V1431, P471, DOI 10.1016/S0167-4838(99)00079-5; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; DUVAL N, 1992, EMBO J, V11, P3255, DOI 10.1002/j.1460-2075.1992.tb05403.x; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Furukawa Y, 1997, BBA-BIOMEMBRANES, V1328, P185, DOI 10.1016/S0005-2736(97)00084-9; FUTERMAN AH, 1983, NEUROSCI LETT, V40, P85, DOI 10.1016/0304-3940(83)90097-6; FUTERMAN AH, 1985, BIOCHEM BIOPH RES CO, V129, P312, DOI 10.1016/0006-291X(85)91439-1; Haas R, 1996, BIOCHEM J, V314, P817, DOI 10.1042/bj3140817; HAAS R, 1986, BIOCHEMISTRY-US, V25, P3098, DOI 10.1021/bi00359a005; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; LI Y, 1991, J BIOL CHEM, V266, P23083; LOW MG, 1987, BIOCHEM J, V244, P1; MARSH D, 1984, J NEUROCHEM, V43, P204, DOI 10.1111/j.1471-4159.1984.tb06698.x; Massoulie J, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P3; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MAXWELL SE, 1995, P NATL ACAD SCI USA, V92, P1550, DOI 10.1073/pnas.92.5.1550; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; MORAN P, 1991, J CELL BIOL, V115, P1595, DOI 10.1083/jcb.115.6.1595; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Ramalingam S, 1996, P NATL ACAD SCI USA, V93, P7528, DOI 10.1073/pnas.93.15.7528; RIEZMAN H, 1998, HDB PROTEOLYTIC ENZY, P756; ROBERTS WL, 1986, BIOCHEMISTRY-US, V25, P3091, DOI 10.1021/bi00359a004; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Tomassetti A, 1999, J CELL BIOCHEM, V72, P111, DOI 10.1002/(SICI)1097-4644(19990101)72:1<111::AID-JCB12>3.0.CO;2-1; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; YAN W, 1995, BIOCHEMISTRY-US, V34, P14594, DOI 10.1021/bi00044a039	48	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27881	27892		10.1074/jbc.M010817200	http://dx.doi.org/10.1074/jbc.M010817200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11337488	hybrid			2022-12-27	WOS:000170093400020
J	Huang, CF; De Sanctis, GT; O'Brien, PJ; Mizgerd, JP; Friend, DS; Drazen, JM; Brass, LF; Stevens, RL				Huang, CF; De Sanctis, GT; O'Brien, PJ; Mizgerd, JP; Friend, DS; Drazen, JM; Brass, LF; Stevens, RL			Evaluation of the substrate specificity of human mast cell tryptase beta I and demonstration of its importance in bacterial infections of the lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-ACTIVATED RECEPTOR-2; VEIN ENDOTHELIAL-CELLS; CHONDROITIN SULFATE-E; MOLECULAR-CLONING; AIRWAY HYPERRESPONSIVENESS; FUNCTIONAL EXPRESSION; THROMBIN RECEPTORS; GRANULE PROTEASES; COMPLEMENTARY-DNA; SERINE PROTEASES	Human pulmonary mast cells (MCs) express tryptases alpha and betaI, and both granule serine proteases are exocytosed during inflammatory events. Recombinant forms of these tryptases were generated for the first time to evaluate their substrate specificities at the biochemical level and then to address their physiologic roles in pulmonary inflammation. Analysis of a tryptase-specific, phage display peptide library revealed that tryptase betaI prefers to cleave peptides with 1 or more Pro residues flanked by 2 positively charged residues. Although recombinant tryptase betaI was unable to activate cultured cells that express different types of protease-activated receptors, the numbers of neutrophils increased > 100-fold when enzymatically active tryptase betaI was instilled into the lungs of mice, In contrast, the numbers of lymphocytes and eosinophils in the airspaces did not change significantly. More important, the tryptase betaI-treated mice exhibited normal airway responsiveness. Neutrophils did not extravasate into the lungs of tryptase alpha -treated mice, Thus, this is the first study to demonstrate that the two nearly identical human MC tryptases are functionally distinct in vivo. When MC-deficient W/W-nu mice were given enzymatically active tryptase betaI or its inactive zymogen before pulmonary infection with Klebsiella prteumoniae, tryptase betaI-treated W/W-nu mice had fewer viable bacteria in their lungs relative to zymogen-treated W/W-nu mice, Because neutrophils are required to combat bacterial infections, human tryptase betaI plays a critical role in the antibacterial host defenses of the lung by recruiting neutrophils in a manner that does not alter airway reactivity,	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Combined Program Pulm & Crit Care Med, Boston, MA 02115 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Pennsylvania; Harvard University; Harvard T.H. Chan School of Public Health	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.	rstevens@rics.bwh.harvard.edu	Drazen, Jeffrey M/E-5841-2012; Mizgerd, Joseph/GRY-6369-2022; O'Brien, Peter J/B-5182-2013	O'Brien, Peter J/0000-0003-4127-2718; Mizgerd, Joseph/0000-0002-4042-3169	NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063284, R01HL052132, R29HL052132, P01HL040387, P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16520] Funding Source: Medline; NHLBI NIH HHS [HL-63284, HL-52132, HL-40387, HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline; NIDDK NIH HHS [DK-19525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASS LF, 1991, J BIOL CHEM, V266, P958; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; Cairns JA, 1996, J IMMUNOL, V156, P275; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; Compton SJ, 1998, J IMMUNOL, V161, P1939; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; de Sanctis GT, 1999, J CLIN INVEST, V103, P507, DOI 10.1172/JCI4017; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; GREENBERG SM, 1988, BLOOD, V72, P1968; GURISH MF, 1991, J IMMUNOL, V146, P1527; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; HARTMANN T, 1994, AM J PHYSIOL, V267, pL113, DOI 10.1152/ajplung.1994.267.2.L113; He SH, 1997, J IMMUNOL, V159, P6216; Hollenberg MD, 1999, CAN J PHYSIOL PHARM, V77, P458, DOI 10.1139/cjpp-77-6-458; Howells GL, 1997, J CELL SCI, V110, P881; Huang C, 2000, J BIOL CHEM, V275, P351, DOI 10.1074/jbc.275.1.351; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Inoue M, 1999, BIOCHEM BIOPH RES CO, V266, P564, DOI 10.1006/bbrc.1999.1870; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Lukacs NW, 1996, PATHOBIOLOGY, V64, P308, DOI 10.1159/000164065; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; Mirza H, 1997, BLOOD, V90, P3914, DOI 10.1182/blood.V90.10.3914; Mizgerd JP, 1999, J IMMUNOL, V163, P995; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NAGAI H, 1991, INFLAMMATION, V15, P317, DOI 10.1007/BF00917316; NILSSON G, 1994, SCAND J IMMUNOL, V39, P489, DOI 10.1111/j.1365-3083.1994.tb03404.x; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; SHUSTER DE, 1995, SCIENCE, V269, P1590, DOI 10.1126/science.7667641; STACK MS, 1994, J BIOL CHEM, V269, P9416; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; THOMPSON HL, 1988, J IMMUNOL, V140, P2708; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; Wang HW, 2000, FASEB J, V14, pA1239; WONG GW, J BIOL CHEM, V276, P20464; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868	72	120	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26276	26284		10.1074/jbc.M102356200	http://dx.doi.org/10.1074/jbc.M102356200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335723	hybrid			2022-12-27	WOS:000169823300085
J	Carter, RS; Geyer, BC; Xie, MH; Acevedo-Suarez, CA; Ballard, DW				Carter, RS; Geyer, BC; Xie, MH; Acevedo-Suarez, CA; Ballard, DW			Persistent activation of NF-kappa B by the tax transforming protein involves chronic phosphorylation of I kappa B kinase subunits IKK beta and IKK gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; COMPLEX; ALPHA; EXPRESSION; INHIBITION; TYPE-1	The Tax transforming protein encoded by human T-cell leukemia virus type 1 (HTLV1) persistently activates transcription factor NF-kappaB and deregulates the expression of downstream genes that mediate cell cycle entry. We recently found that Tax binds to and chronically stimulates the catalytic function of I kappaB kinase (IKK), a cellular enzyme complex that phosphorylates and inactivates the I kappaB inhibitory subunit of NF-kappaB, We now demonstrate that the IKK beta catalytic subunit and IKK gamma regulatory subunit of IKK are chronically phosphorylated in HTLV1-infected and Tax-transfected cells. Alanine substitutions at Ser-177 and Ser-181 in the T loop of IKK beta protect both of these IKK subunits from Tax-directed phosphorylation and prevent the induction of I kappaB kinase activity. Each of these inhibitory effects is recapitulated in Tax transfectants expressing the bacterial protein YopJ, a potent in vivo agonist of T loop phosphorylation, Moreover, ectopically expressed forms of IKK beta that contain glutamic acid substitutions at Ser-177 and Ser-181 have the capacity to phosphorylate a recombinant lKK gamma substrate in vitro, We conclude that Tax-induced phosphorylation of IKK beta is required for IKK beta activation, phosphoryl group transfer to IKK gamma, and acquisition of the deregulated IKK phenotype.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, A4301 Med Ctr N, Nashville, TN 37232 USA.				NCI NIH HHS [R01 CA 82556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	19	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24445	24448		10.1074/jbc.C000777200	http://dx.doi.org/10.1074/jbc.C000777200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325957	hybrid			2022-12-27	WOS:000169800700004
J	Maroney, AC; Finn, JP; Connors, TJ; Durkin, JT; Angeles, T; Gessner, G; Xu, ZH; Meyer, SL; Savage, MJ; Greene, LA; Scott, RW; Vaught, JL				Maroney, AC; Finn, JP; Connors, TJ; Durkin, JT; Angeles, T; Gessner, G; Xu, ZH; Meyer, SL; Savage, MJ; Greene, LA; Scott, RW; Vaught, JL			CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; PROGRAMMED CELL-DEATH; PROTEIN-KINASE; C-JUN; JNK PATHWAY; SYMPATHETIC NEURONS; MOLECULAR-CLONING; INDUCED APOPTOSIS; ACTIVATION; IDENTIFICATION	CEP-1347 (KT7515) promotes neuronal survival at dosages that inhibit activation of the c-Jun amino-terminal kinases (JNKs) in primary embryonic cultures and differentiated PC12 cells after trophic withdrawal and in mice treated with 1-methyl-4-phenyl tetrahydropyridine. In an effort to identify molecular target(s) of CEP-1347 in the JNK cascade, JNK1 and known upstream regulators of JNK1 were co-expressed in Cos-7 cells to determine whether CEP-1347 could modulate JNK1 activation. CEP-1347 blocked JNK1 activation induced by members of the mixed lineage kinase (MLK) family (MLK3, MLK2, MLK1, dual leucine zipper kinase, and leucine zipper kinase), The response was selective because CEP-1347 did not inhibit JNK1 activation in cells induced by kinases independent of the MLK cascade. CEP-1347 inhibition of recombinant MLK members in vitro was competitive with ATP, resulting in IC,, values ranging from 23 to 51 nM, comparable to inhibitory potencies observed in intact cells. In addition, overexpression of MLK3 led to death in Chinese hamster ovary cells, and CEP-1347 blocked this death at doses comparable to those that inhibited MLK3 kinase activity. These results identify MLKs as targets of CEP-1347 in the JNK signaling cascade and demonstrate that CEP-1347 can block MLK-induced cell death.	Cephalon Inc, W Chester, PA 19380 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Teva Pharmaceutical Industries; Cephalon Inc.; Columbia University; Columbia University	Maroney, AC (corresponding author), Cephalon Inc, 145 Brandywine Pkwy, W Chester, PA 19380 USA.	amaroney@cephalon.com		Xu, Zhiheng/0000-0002-4809-2851				Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bergeron P, 1997, BIOCHEM BIOPH RES CO, V231, P153, DOI 10.1006/bbrc.1997.6073; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Borasio GD, 1998, NEUROREPORT, V9, P1435, DOI 10.1097/00001756-199805110-00034; Cleland W W, 1979, Methods Enzymol, V63, P103; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEIJARD B, 1995, SCIENCE, V267, P682; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Eilers A, 1998, J NEUROSCI, V18, P1713; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; EZOE K, 1994, ONCOGENE, V9, P935; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Glicksman MA, 1998, J NEUROBIOL, V35, P361, DOI 10.1002/(SICI)1097-4695(19980615)35:4<361::AID-NEU3>3.3.CO;2-G; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hartkamp J, 1999, CANCER RES, V59, P2195; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ING YL, 1994, ONCOGENE, V9, P1745; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kaneko M, 1997, J MED CHEM, V40, P1863, DOI 10.1021/jm970031d; KATOH M, 1995, ONCOGENE, V10, P1447; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; KOIDE K, 1995, CHEM BIOL, V2, P601, DOI 10.1016/1074-5521(95)90124-8; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 1998, J NEUROSCI, V18, P104; MARONEY AC, 1995, J NEUROCHEM, V64, P540; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; MEYER SL, 1994, J NEUROCHEM, V62, P825; Michel PP, 1999, CLIN NEUROPHARMACOL, V22, P137; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Pitt A.M., 1996, J BIOMOL SCREEN, V1, P47, DOI [10.1177/108705719600100115, DOI 10.1177/108705719600100115]; Rasmussen RK, 1998, BIOCHEM J, V335, P119, DOI 10.1042/bj3350119; Rasmussen RK, 1998, ELECTROPHORESIS, V19, P809, DOI 10.1002/elps.1150190535; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 1998, NEUROSCIENCE, V86, P461, DOI 10.1016/S0306-4522(98)00059-1; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; SCHLINGENSIEPEN KH, 1994, CELL MOL NEUROBIOL, V14, P487, DOI 10.1007/BF02088833; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; Waggie KS, 1999, LAB ANIM SCI, V49, P358; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	75	184	191	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25302	25308		10.1074/jbc.M011601200	http://dx.doi.org/10.1074/jbc.M011601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325962	hybrid			2022-12-27	WOS:000169800700116
J	Agarwal-Mawal, A; Paudel, HK				Agarwal-Mawal, A; Paudel, HK			Neuronal Cdc2-like protein kinase (Cdk5/p25) is associated with protein phosphatase 1 and phosphorylates inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CYCLIN-DEPENDENT KINASE-5; CATALYTIC SUBUNIT; GLYCOGEN-SYNTHASE; SYNERGISTIC PHOSPHORYLATION; MOLECULAR MECHANISM; BRAIN; TAU; IDENTIFICATION; PURIFICATION	Protein phosphatase 1 (PP1) is complexed with inhibitor 2 (I-2) in the cytosol,In rabbit muscle extract PP1 .I-2 is activated upon preincubation with ATP/Mg. This activation is caused by phosphorylation of I-2 on Thr(72) by glycogen synthase kinase 3 (GSK3). We have found that PP1 LB in bovine brain extract is also activated upon preincubation with ATP/Mg. However, blocking GSK3 action by LiCl inhibited only similar to 29% of PP1 activity and indicated that GSI(3 is not the sole PP1 .I-2 activator in the brain. When bovine brain extract was analyzed by gel filtration PPI .I-2 and neuronal CdcS-like protein kinase (NCLK), a heterodimer of Cdk5 and the regulatory p25 subunit, co-eluted as a similar to 450-kDa size species. The NCLK. from the eluted column fractions bound to PP1-specific microcystin-Sepharose and glutathione S-transferase (GST)-I-2-coated glutathione-agarose beads. Similarly, PPI from the eluted column fractions was pulled down with GST-Cdk5-coated glutathione-agarose beads. In vitro, NCLK( phosphorylated I-2 on Thr72 and activated PPI I-S in an ATP/Mg-dependent manner. NCLK bound to PP1 through its CdkS subunit and the PP1 binding region was localized to CdkS residues 28-41. Our data demonstrate that in brain extract PP1 .I-2 and NCLK are associated within a complex of similar to 450 kDa and suggest that NCLK is one of the PPI I-8-activating kinases in the mammalian brain.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Paudel, HK (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca						Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; Chou KC, 1999, BIOCHEM BIOPH RES CO, V259, P420, DOI 10.1006/bbrc.1999.0792; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; GERVASI C, 1995, MOL BRAIN RES, V33, P192, DOI 10.1016/0169-328X(95)00109-6; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HELLMICH MR, 1994, FEBS LETT, V356, P317, DOI 10.1016/0014-5793(94)01298-9; HELPS NR, 1994, FEBS LETT, V340, P93, DOI 10.1016/0014-5793(94)80179-7; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HOLMES CFB, 1987, BIOCHIM BIOPHYS ACTA, V929, P208, DOI 10.1016/0167-4889(87)90178-9; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Huang KX, 2000, P NATL ACAD SCI USA, V97, P5824, DOI 10.1073/pnas.100460897; INO H, 1994, BRAIN RES, V661, P196, DOI 10.1016/0006-8993(94)91197-5; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LEE EYC, 1999, FRONT BIOSCI, V4, P270; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, NEUROBIOL AGING, V16, P263, DOI 10.1016/0197-4580(95)00014-6; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; PARK IK, 1994, J BIOL CHEM, V269, P944; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PICKING WD, 1991, BIOCHEMISTRY-US, V30, P10280, DOI 10.1021/bi00106a028; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; RESINK TJ, 1983, EUR J BIOCHEM, V133, P455, DOI 10.1111/j.1432-1033.1983.tb07485.x; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; WANG QM, 1994, J BIOL CHEM, V269, P14566; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANG SD, 1981, J BIOL CHEM, V256, P231; YANG SD, 1985, J BIOL CHEM, V260, P3464; YANG SD, 1980, J BIOL CHEM, V255, P1759; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	46	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23712	23718		10.1074/jbc.M010002200	http://dx.doi.org/10.1074/jbc.M010002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320080	hybrid			2022-12-27	WOS:000169531100066
J	Chang, JW; Mechling, DE; Bachinger, HP; Burrows, GG				Chang, JW; Mechling, DE; Bachinger, HP; Burrows, GG			Design, engineering, and production of human recombinant T cell receptor ligands derived from human leukocyte antigen DR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BOUND SINGLE PEPTIDES; MULTIPLE-SCLEROSIS; ANGSTROM RESOLUTION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; STRUCTURAL BASIS	Major histocompatibility complex (MHC) class II molecules are membrane-anchored heterodimers on the surface of antigen-presenting cells that bind the T cell receptor, initiating a cascade of interactions that results in antigen-specific activation of clonal populations of T cells. Susceptibility to multiple sclerosis is associated with certain MHC class II haplotypes, including human leukocyte antigen (HLA) DR2. Two DRB chains, DRB5*0101 and DRB1*1501, are co-expressed in the HLA-DR2 haplotype, resulting in the formation of two functional cell surface heterodimers, HLA-DR2a (DRA*0101, DRB5*0101) and HLA-DR2b (DRA*0101(al, DRB1*1501). Both isotypes can present an immunodominant peptide of myelin basic protein (MBP-(84-102)) to MBP-specific T cells from multiple sclerosis patients. We have previously demonstrated that the peptide binding/T cell recognition domains of rat MHC class II (alpha1 and pi domains) could be expressed as a single exon for structural and functional characterization; Burrows, G. G., Chang, J. m,, Bachinger, H.-P., Bourdette, D. N., Wegmann, K, W, Offner H, and Vandenbark A. A. (1999) Protein Eng. 12, 711-778; Burrows, G. G., Adlard, K. L., Bebo, B. F., Jr., Chang, J. W., Tenditnyy, K., Vandenbark, A. A, and Offner, H. (2000) J. Immunol 164, 6366-6371). Single-chain human recombinant T cell receptor ligands (RTLs) of similar to 200 amino acid residues derived from HLA-DR2b were designed using the same principles and have been produced in Escherichia coli with and without amino-terminal extensions containing antigenic peptides. Structural characterization using circular dichroism predicted that these molecules retained the antiparallel beta -sheet platform and antiparallel alpha -helices observed in the native HLA-DR2 heterodimer. The proteins exhibited a cooperative two-state thermal unfolding transition, and DR2-derived RTLs with a covalently linked MBP peptide (MBP-(85-99)) showed increased stability to thermal unfolding relative to the empty DR2-derived RTLs. These novel molecules represent a new class of small soluble ligands for modulating the behavior of T cells and provide a platform technology for developing potent and selective human diagnostic and therapeutic agents for treatment of autoimmune disease.	Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Burrows, GG (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, L-219,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	ggb@ohsu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010554] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43960] Funding Source: Medline; NIEHS NIH HHS [ES10554] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Burrows GG, 2000, J IMMUNOL, V164, P6366, DOI 10.4049/jimmunol.164.12.6366; Burrows GG, 1998, J IMMUNOL, V161, P5987; Burrows GG, 1999, PROTEIN ENG, V12, P771, DOI 10.1093/protein/12.9.771; Chen G C, 1973, Biophys Chem, V1, P62; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; CONNOLLY ML, 1986, BIOPOLYMERS, V25, P1229, DOI 10.1002/bip.360250705; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; CUSH JJ, 1988, ARTHRITIS RHEUM-US, V31, P1230, DOI 10.1002/art.1780311003; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; HEIDEN W, 1993, J COMPUT AID MOL DES, V7, P503, DOI 10.1007/BF00124359; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; Li YL, 2000, J MOL BIOL, V304, P177, DOI 10.1006/jmbi.2000.4198; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; OKSENBERG JR, 1993, NATURE, V362, P68, DOI 10.1038/362068a0; PATERSON PY, 1973, J CHRON DIS, V26, P119, DOI 10.1016/0021-9681(73)90085-4; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; QUILL H, 1987, J IMMUNOL, V138, P3704; Schafer P H, 1995, Semin Immunol, V7, P389, DOI 10.1006/smim.1995.0043; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; SWANBORG RH, 1983, J IMMUNOL, V130, P1503; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; VANDENBARK AA, 1994, J IMMUNOL, V153, P852; WEINBERG AD, 1992, J IMMUNOL, V148, P2109; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; ZHAO BG, 1992, J MOL BIOL, V227, P239, DOI 10.1016/0022-2836(92)90694-F; ZinnJustin S, 1996, BIOCHEMISTRY-US, V35, P8535, DOI 10.1021/bi960466n	37	30	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24170	24176		10.1074/jbc.M101808200	http://dx.doi.org/10.1074/jbc.M101808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319230	hybrid			2022-12-27	WOS:000169531100125
J	De Ferrari, GV; Mallender, WD; Inestrosa, NC; Rosenberry, TL				De Ferrari, GV; Mallender, WD; Inestrosa, NC; Rosenberry, TL			Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORSIONAL RELAXATION; SUBSTRATE-BINDING; ANIONIC SITE; INHIBITION; PROPIDIUM; LIGANDS; PROTEIN; GORGE; SPECIFICITY; TRANSITION	Three-dimensional structures of acetylcholinesterase (AChE) reveal a narrow and deep active site gorge with two sites of ligand binding, an acylation site at the base of the gorge, and a peripheral site near the gorge entrance. Recent studies have shown that the peripheral site contributes to catalytic efficiency by transiently binding substrates on their way to the acylation site, but the question of whether the peripheral site makes other contributions to the catalytic process remains open. A possible role for ligand binding to the peripheral site that has long been considered is the initiation of a conformational change that is transmitted allosterically to the acylation site to alter catalysis, However, evidence for conformational interactions between these sites has been difficult to obtain, Here we report that thioflavin T, a fluorophore widely used to detect amyloid structure in proteins, binds selectively to the AChE peripheral site with an equilibrium dissociation constant of 1.0 mum. The fluorescence of the bound thioflavin T is increased more than 1000-fold over that of unbound thioflavin T, the greatest enhancement of fluorescence for the binding of a fluorophore to AChE yet observed. Furthermore, when the acylation site ligands edrophonium or m-(N, N,N-trimethylammonio)trifluoroacetophenone form ternary complexes with AChE and thioflavin T, the fluorescence is quenched by factors of 2.7-4.2. The observation of this partial quenching of thioflavin T fluorescence is a major advance in the study of AChE, for two reasons. First, it allows thioflavin T to be used as a reporter for ligand reactions at the acylation site. Second, it indicates that ligand binding to the acylation site initiates a change in the local AChE conformation at the peripheral site that quenches the fluorescence of bound thioflavin T, The data provide strong evidence in support of a conformational interaction between the two AChE sites.	Mayo Clin Jacksonville, Dept Pharmacol, Mayo Fdn Med Educ & Res, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Program Neurosci, Mayo Fdn Med Educ & Res, Jacksonville, FL 32224 USA; Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Regulac Celular & Patol, Dept Biol Celular & Mol, Santiago 114D, Chile	Mayo Clinic; Mayo Clinic; Pontificia Universidad Catolica de Chile	Rosenberry, TL (corresponding author), Mayo Clin Jacksonville, Dept Pharmacol, Mayo Fdn Med Educ & Res, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.			De Ferrari, Giancarlo/0000-0003-0932-125X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-16577] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; BERMAN HA, 1981, BIOCHEMISTRY-US, V20, P4803, DOI 10.1021/bi00519a043; BRODBECK U, 1979, BIOCHIM BIOPHYS ACTA, V567, P357, DOI 10.1016/0005-2744(79)90122-0; Camps P, 2000, MOL PHARMACOL, V57, P409; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HUCHO F, 1991, TRENDS PHARMACOL SCI, V12, P422; KITZ RJ, 1970, MOL PHARMACOL, V6, P108; KUNG CE, 1986, BIOCHEMISTRY-US, V25, P6114, DOI 10.1021/bi00368a042; LeVine H, 1999, METHOD ENZYMOL, V309, P274; LOUTFY RO, 1982, J PHYS CHEM-US, V86, P4205, DOI 10.1021/j100218a023; Mallender WD, 2000, BIOCHEMISTRY-US, V39, P7753, DOI 10.1021/bi000210o; Mallender WD, 1999, J BIOL CHEM, V274, P8491, DOI 10.1074/jbc.274.13.8491; NAIR HK, 1993, J AM CHEM SOC, V115, P9939, DOI 10.1021/ja00075a009; Radic Z, 1999, CHEM-BIOL INTERACT, V119, P111, DOI 10.1016/S0009-2797(99)00019-8; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; Sentjurc M, 1999, BBA-PROTEIN STRUCT M, V1430, P349, DOI 10.1016/S0167-4838(99)00018-7; SHARP TR, 1982, J BIOCHEM BIOPH METH, V6, P159, DOI 10.1016/0165-022X(82)90062-8; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; Tara S, 1998, BIOPOLYMERS, V46, P465; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; TAYLOR P, 1974, MOL PHARMACOL, V10, P703	31	117	122	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23282	23287		10.1074/jbc.M009596200	http://dx.doi.org/10.1074/jbc.M009596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313335	hybrid			2022-12-27	WOS:000169531100011
J	El Nemer, W; Gane, P; Colin, Y; D'Ambrosio, AM; Callebaut, I; Cartron, JP; Le van Kim, C				El Nemer, W; Gane, P; Colin, Y; D'Ambrosio, AM; Callebaut, I; Cartron, JP; Le van Kim, C			Characterization of the laminin binding domains of the Lutheran blood group glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL ADHESION; LU-A/LU-B; GROUP ANTIGENS; IMMUNOGLOBULIN SUPERFAMILY; MOLECULAR-BASIS; GROUP PROTEIN; IDENTIFICATION; EXPRESSION; RECEPTOR; INTEGRINS	Lutheran (Lu) blood group antigens and the basal cell adhesion molecule antigen reside on two glycoproteins that belong to the Ig superfamily (IgSF) and carry five Ig-like extracellular domains. These glycoproteins act as widely expressed adhesion molecules and represent the unique receptors for laminin-10/11 in erythroid cells. Here, we report the mapping of IgSF domains responsible for binding to laminin, In plasmonic resonance surface experiments, only recombinant Lu proteins containing the N-terminal IgSF domains 1-3 were able to bind laminin-10/11 and to inhibit binding of laminin to Lu-expressing K562 cells. Mutant recombinant proteins containing only IgSF domain 1, domains 1 + 2, domains 1 + 3, domains 2 + 3, domain 3, domain 4, domain 5, and domains 4 + 5 failed to bind laminin as well as a construct containing all of the extracellular domains except domain 3, Altogether, these results indicate that IgSF domains 1-3 are involved in laminin binding and that a specific spatial arrangement of these three first domains is most probably necessary for interaction. Nei ther the RGD nor the N-glycosylation motifs present in IgSF domain 3 were involved in laminin binding.	Inst Natl Transfus Sanguine, INSERM U76, F-75015 Paris, France; Univ Paris 06, CNRS UMR7590, F-75005 Paris, France; Univ Paris 07, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite	Le van Kim, C (corresponding author), Inst Natl Transfus Sanguine, INSERM U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.		colin, yves/O-1910-2017; Nemer, Wassim El/N-4247-2017	colin, yves/0000-0001-5196-4254; Nemer, Wassim El/0000-0001-8184-427X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bailly P, 1995, EUR J IMMUNOL, V25, P3316, DOI 10.1002/eji.1830251217; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; CHESAGARIN P, 1994, INT J ONCOL, V5, P1261; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; El Nemer W, 1998, J BIOL CHEM, V273, P16686; El Nemer W, 1999, J BIOL CHEM, V274, P31903, DOI 10.1074/jbc.274.45.31903; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; Ferletta M, 1999, J CELL SCI, V112, P1; Freigang J, 2000, CELL, V101, P425, DOI 10.1016/S0092-8674(00)80852-1; GANE P, 2001, IN PRESS BR J HAEMAT, V113; Gu YC, 1999, BLOOD, V93, P2533, DOI 10.1182/blood.V93.8.2533.408k22_2533_2542; Hebbel RP, 1997, J CLIN INVEST, V99, P2561, DOI 10.1172/JCI119442; Hermand P, 2000, J BIOL CHEM, V275, P26002, DOI 10.1074/jbc.M002823200; JOHNSON JP, 1993, MELANOMA RES, V3, P337, DOI 10.1097/00008390-199310000-00006; Lee SP, 1998, BLOOD, V92, P2951, DOI 10.1182/blood.V92.8.2951.420k30_2951_2958; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Parsons SF, 1997, BLOOD, V89, P4219, DOI 10.1182/blood.V89.11.4219; PARSONS SF, 1995, P NATL ACAD SCI USA, V92, P5496, DOI 10.1073/pnas.92.12.5496; Parsons SF, 2001, BLOOD, V97, P312, DOI 10.1182/blood.V97.1.312; Rahuel C, 1996, BLOOD, V88, P1865; Rahuel C, 1999, IMMUNOGENETICS, V50, P271, DOI 10.1007/s002510050602; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435; TERRANOVA VP, 1982, CANCER RES, V42, P2265; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; Wick T M, 1996, Curr Opin Hematol, V3, P118; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YURCHENKO PD, 1993, MOL CELLULAR ASPECTS, P121; Zen Q, 1999, J BIOL CHEM, V274, P728, DOI 10.1074/jbc.274.2.728; Zen Q, 1999, FASEB J, V13, pA1360	38	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23757	23762		10.1074/jbc.M102978200	http://dx.doi.org/10.1074/jbc.M102978200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319237	hybrid			2022-12-27	WOS:000169531100072
J	Gonzalez, LC; Weis, WI; Scheller, RH				Gonzalez, LC; Weis, WI; Scheller, RH			A novel SNARE N-terminal domain revealed by the crystal structure of Sec22b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; GOLGI-APPARATUS; ENDOPLASMIC-RETICULUM; SYNAPTIC EXOCYTOSIS; GAF DOMAIN; PROTEIN; PROFILIN; COMPLEX; TRANSPORT; SYNTAXIN	Intra-cellular membrane fusion is facilitated by the association of SNAREs from opposite membranes into stable alpha -helical bundles. Many SNAREs, in addition to their alpha -helical regions, contain N-terminal domains that likely have essential regulatory functions. To better understand this regulation, we have determined the 2.4-Angstrom crystal structure of the 130-amino acid N-terminal domain of mouse Sec22b (mSec22b), a SNARE involved in endoplasmic reticulum/Golgi membrane trafficking. The domain consists of a mixed alpha -helical/beta -sheet fold that resembles a circular permutation of the actin/polyproline binding protein, profilin, and the GAF/PAS family of regulatory modules. The structure is distinct from the previously characterized N-terminal domain of syn taxin 1A, and, unlike syntaxin 1A, the N-terminal domain of mSec22b has no effect on the rate of SNARE assembly in vitro. An analysis of surface conserved residues reveals a potential protein interaction site. Key residues in this site are distinct in two mammalian Sec22 variants that lack SNARE domains, Finally, sequence analysis indicates that a similar domain is likely present in the endosomal/lysosomal SNARE VAMP7.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Fairchild Bldg, Stanford, CA 94305 USA.	bill.weis@stanford.edu	Weis, William I/G-1437-2011; Gonzalez, Lino/E-4102-2012	Weis, William I/0000-0002-5583-6150; Gonzalez, Lino/0000-0003-3817-6450	NIMH NIH HHS [MH58570] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; Grosse-Kunstleve RW, 1999, ACTA CRYSTALLOGR D, V55, P1568, DOI 10.1107/S0907444999007763; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Neiman AM, 2000, GENETICS, V155, P1643; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pevsner J, 1996, GENE, V183, P7, DOI 10.1016/S0378-1119(96)00367-8; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SOHN RH, 1995, J BIOL CHEM, V270, P21114, DOI 10.1074/jbc.270.36.21114; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tang BL, 1998, BIOCHEM BIOPH RES CO, V243, P885, DOI 10.1006/bbrc.1998.8194; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Womble D D, 2000, Methods Mol Biol, V132, P3; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843	53	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24203	24211		10.1074/jbc.M101584200	http://dx.doi.org/10.1074/jbc.M101584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309394	hybrid			2022-12-27	WOS:000169531100129
J	Methot, N; Ritchie, BD; Blanton, MP; Baenziger, JE				Methot, N; Ritchie, BD; Blanton, MP; Baenziger, JE			Structure of the pore-farming transmembrane domain of a ligand-gated ion channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; TRANSFORM INFRARED-SPECTROSCOPY; EXCHANGE-RESISTANT CORE; SECONDARY STRUCTURE; TORPEDO-CALIFORNICA; ALPHA-SUBUNIT; SPATIAL STRUCTURE; GLYCINE RECEPTOR; GAMMA-SUBUNIT; PROTEINS	The structure of the pore-forming transmembrane domain of the nicotinic acetylcholine receptor from Torpedo has been investigated by infrared spectroscopy. Treatment of affinity-purified receptor with either Pronase or proteinase K digests the extramembranous domains (roughly 75% of the protein mass), leaving hydrophobic membrane-imbedded peptides 3-6 kDa in size that are resistant to peptide H-1/H-2 exchange, Infrared spectra of the transmembrane domain preparations exhibit relatively sharp and symmetric amide I and amide II band contours centered near 1655 and 1545 cm(-1) respectively, in both (H2O)-H-1 and (H2O)-H-2. The amide I band is very similar to the amide I bands observed in the spectra of alpha -helical proteins, such as myoglobin and bacteriorhodopsin, that lack P structure and exhibit much less p-sheet character than is observed in proteins with as little as 20% P sheet. Curve-fitting estimates 75-80% cy-helical character, with the remaining peptides likely adopting extended and/or turn structures at the bilayer surface. Infrared dichroism spectra are consistent with transmembrane alpha -helices oriented perpendicular to the bilayer surface. The evidence strongly suggests that the transmembrane domain of the nicotinic receptor, the most intensively studied ligand-gated ion channel, is composed of five bundles of four transmembrane alpha-helices.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA	University of Ottawa; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Baenziger, JE (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jebaenz@uottawa.ca		Baenziger, John/0000-0002-2888-5328	NINDS NIH HHS [NS35786] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Baenziger JE, 1997, BIOCHEMISTRY-US, V36, P3617, DOI 10.1021/bi962845m; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; Barrantes FJ, 2000, J BIOL CHEM, V275, P37333, DOI 10.1074/jbc.M005246200; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BLANTON MP, 2001, IN PRESS BIOCH BIOPH; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Cascio M, 2001, J BIOL CHEM, V276, P20981, DOI 10.1074/jbc.M010968200; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; Corbin J, 1998, J BIOL CHEM, V273, P771, DOI 10.1074/jbc.273.2.771; DOUSSEAU F, 1990, BIOCHEMISTRY-US, V29, P8771, DOI 10.1021/bi00489a038; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; GUNTHARD HH, 1981, MEMBRANE SPECTROSCOP, P270; HUBNER W, 1991, BIOPHYS J, V59, P1261, DOI 10.1016/S0006-3495(91)82341-4; HUCHO F, 1994, TRENDS BIOCHEM SCI, V19, P383, DOI 10.1016/0968-0004(94)90116-3; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; Leite JF, 2000, J BIOL CHEM, V275, P13683, DOI 10.1074/jbc.275.18.13683; Lugovskoy AA, 1998, EUR J BIOCHEM, V255, P455, DOI 10.1046/j.1432-1327.1998.2550455.x; Marsh D, 1997, BIOPHYS J, V72, P2710, DOI 10.1016/S0006-3495(97)78914-8; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; Methot N, 1998, BIOCHEMISTRY-US, V37, P14815, DOI 10.1021/bi980848o; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; NAUMANN D, 1993, BIOCHEMISTRY-US, V32, P3162, DOI 10.1021/bi00063a031; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; Ortells MO, 1996, PROTEIN ENG, V9, P51, DOI 10.1093/protein/9.1.51; Pashkov VS, 1999, FEBS LETT, V457, P117, DOI 10.1016/S0014-5793(99)01023-6; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Tamamizu S, 2000, BIOCHEMISTRY-US, V39, P4666, DOI 10.1021/bi992835w; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107	39	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23726	23732		10.1074/jbc.M102101200	http://dx.doi.org/10.1074/jbc.M102101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328815	hybrid			2022-12-27	WOS:000169531100068
J	Xiao, WH; Wang, LH; Yang, XY; Chen, TS; Hodge, D; Johnson, PF; Farrar, W				Xiao, WH; Wang, LH; Yang, XY; Chen, TS; Hodge, D; Johnson, PF; Farrar, W			CCAAT/enhancer-binding protein beta mediates interferon-gamma-induced p48 (ISGF3-gamma) gene transcription in human monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED DISRUPTION; ISGF3 COMPONENTS; MELANOMA-CELLS; DNA-BINDING; IFN-BETA; ACTIVATION; EXPRESSION; INDUCTION; RESISTANT; FAMILY	Previous studies have identified a novel interferon-stimulated response element-like element, termed gamma -interferon-activating transcription element, within the interferon-stimulating gene factor-3 gamma (p48) promoter region that is bound by novel transcription factors in response to stimulation with interferons (IFNs) (Weihua, X,, Kolla, V., and Kalvakolanu, D, V. (1997) Proc. Natl. Acad, Sci. U. S. A. 94, 103-108), In the present study, we have identified CCAAT/enhancer-binding protein beta (C/EBP-beta) as one of the gamma -interferon-activating transcription element cognate transcription factors by screening a human monophage-derived cDNA library in a yeast one-hybrid system. Electrophoretic mobility shift assay studies suggest that C/EBP-beta dynamically regulates p48 gene expression upon IFN-gamma stimulation by undergoing changes in its heterodimerization partners. Transient transfection studies demonstrate that overexpression of C/EBP-beta strongly enhanced IFN-gamma -induced transcription from the p48 promoter. However, deletion mutants of C/EBP-beta that lack the N-terminal transactivation domain were unable to stimulate the p48 promoter. Western blotting revealed that C/EBP-beta is induced by IFN-gamma stimulation in THP-1-derived macrophages. Collectively, these results suggest that C/EBP-beta plays an important role in the human IFN-gamma signaling pathway by transcriptional regulation of p48 gene expression, an essential component in the IFN signaling pathway.	NCI, Frederick Canc Res & Dev Ctr, Intramural Res Program, SAIC Frederick,NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Cytokine Mol Mech Sect,NIH, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Regulat Cell Growth Lab, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Xiao, WH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Intramural Res Program, SAIC Frederick,NIH, POB B,Bldg 560,Rm 31-76, Frederick, MD 21702 USA.	xiaow@mail.ncifcrf.gov	Xiao, Weihua/N-2775-2013; Chen, Taosheng/I-6351-2013; Johnson, Peter/A-1940-2012	Xiao, Weihua/0000-0001-9102-6326; Chen, Taosheng/0000-0001-6420-3809; Johnson, Peter/0000-0002-4145-4725	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N0 1-CO-56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Baer M, 1998, BLOOD, V92, P4353, DOI 10.1182/blood.V92.11.4353.423k21_4353_4365; Berger LC, 1997, J INTERF CYTOK RES, V17, P757, DOI 10.1089/jir.1997.17.757; Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Cross JC, 1999, BIOL REPROD, V60, P312, DOI 10.1095/biolreprod60.2.312; Dai WJ, 1997, J IMMUNOL, V158, P5297; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dlaska M, 1999, J IMMUNOL, V162, P6171; GAO PQ, 1993, J BIOL CHEM, V268, P12380; Harada H, 1996, GENES CELLS, V1, P995, DOI 10.1046/j.1365-2443.1996.870287.x; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leonard GT, 1997, J VIROL, V71, P5095, DOI 10.1128/JVI.71.7.5095-5101.1997; Masumoto M, 1999, J IMMUNOL, V163, P5039; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Nakao K, 1999, J BIOL CHEM, V274, P28075, DOI 10.1074/jbc.274.40.28075; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nishiya T, 1997, FEBS LETT, V408, P33, DOI 10.1016/S0014-5793(97)00383-9; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Roy SK, 2000, J BIOL CHEM, V275, P12626, DOI 10.1074/jbc.275.17.12626; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Suzuki Y, 1997, INFECT IMMUN, V65, P2339, DOI 10.1128/IAI.65.6.2339-2345.1997; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; Wang LH, 1999, J IMMUNOL, V162, P3897; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wong LH, 1998, J IMMUNOL, V160, P5475; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Xiao WH, 1999, ANTIVIR RES, V40, P145, DOI 10.1016/S0166-3542(98)00056-4; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P103, DOI 10.1073/pnas.94.1.103; XU B, 1994, BLOOD, V84, P1942	40	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23275	23281		10.1074/jbc.M010047200	http://dx.doi.org/10.1074/jbc.M010047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312260	hybrid			2022-12-27	WOS:000169531100010
J	Nielsen, MS; Vorum, H; Lindersson, E; Jensen, PH				Nielsen, MS; Vorum, H; Lindersson, E; Jensen, PH			Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; AXONAL-TRANSPORT; LEWY BODIES; CALCIUM; EXPRESSION; IDENTIFICATION; SYNAPTOTAGMIN	alpha -Synuclein is a protein normally involved in presynaptic vesicle homeostasis. It participates in the development of Parkinson's disease, in which the nerve cell lesions, Lewy bodies, accumulate alpha -synuclein filaments. The synaptic neurotransmitter release is primarily dependent on Ca2+-regulated processes. A microdialysis technique was applied showing that alpha -synuclein binds Ca2+ with an IC,, of about 2-300 muM and in a reaction uninhibited by a 50 fold excess of Mg2+. The Ca2+-binding site consists of a novel C-terminally localized acidic 32-amino acid domain also present in the homologue beta -synuclein, as shown by Ca2+ binding to truncated recombinant and synthetic alpha -synuclein peptides. Ca2+ binding affects the functional properties of alpha -synuclein, First, the ligand binding of I-125-labeled bovine microtubule-associated protein 1A is stimulated by Ca2+ ions in the 1-500 muM. range and is dependent on an intact Ca2+ binding site in alpha -synuclein. Second, the Ca2+ binding stimulates the proportion of I-125-alpha -synuclein-containing oligomers, This suggests that Ca2+ ions may both participate in normal alpha -synuclein functions in the nerve terminal and exercise pathological effects involved in the formation of Lewy bodies.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark	Aarhus University	Jensen, PH (corresponding author), Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark.	phj@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Jensen, Poul Henning/0000-0002-4439-9020				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Bayer TA, 1999, NEUROREPORT, V10, P2799, DOI 10.1097/00001756-199909090-00019; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P22; Buchman VL, 1998, NAT NEUROSCI, V1, P101, DOI 10.1038/349; Caillard O, 2000, P NATL ACAD SCI USA, V97, P13372, DOI 10.1073/pnas.230362997; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fink JK, 1996, GENOMICS, V35, P577, DOI 10.1006/geno.1996.0400; Fukuda M, 2000, J BIOL CHEM, V275, P28180; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Goda Y, 1997, CURR OPIN CELL BIOL, V9, P513, DOI 10.1016/S0955-0674(97)80027-0; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hsu LJ, 1998, J NEUROCHEM, V71, P338; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1999, EUR J NEUROSCI, V11, P3369, DOI 10.1046/j.1460-9568.1999.00754.x; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; KRAGHHANSEN U, 1993, CLIN CHEM, V39, P202; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; NIXON RA, 1990, J CELL BIOL, V110, P437, DOI 10.1083/jcb.110.2.437; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; Petersen K, 1999, NEUROSCIENCE, V91, P651, DOI 10.1016/S0306-4522(98)00596-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Vorum H, 1996, ELECTROPHORESIS, V17, P1787, DOI 10.1002/elps.1150171118; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	56	119	121	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22680	22684		10.1074/jbc.M101181200	http://dx.doi.org/10.1074/jbc.M101181200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312271	hybrid			2022-12-27	WOS:000169412700095
J	Stivala, LA; Savio, M; Carafoli, F; Perucca, P; Bianchi, L; Maga, G; Forti, L; Pagnoni, UM; Albini, A; Prosperi, E; Vannini, V				Stivala, LA; Savio, M; Carafoli, F; Perucca, P; Bianchi, L; Maga, G; Forti, L; Pagnoni, UM; Albini, A; Prosperi, E; Vannini, V			Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; DNA-POLYMERASE; POLYPHENOLIC COMPOUND; PLATELET-AGGREGATION; PHENOLIC-COMPOUNDS; TRANS-RESVERATROL; VITIS-VINIFERA; GRAPE BERRIES; RED WINE; CANCER	Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a natural phytoalexin found in grapes and wine, which shows antioxidant and antiproliferative activities. In this study we have investigated whether these properties are dependent on similar or different structural determinants of the molecule. To this purpose, resveratrol derivatives, in which all or each single hydroxylic function were selectively substituted with methyl groups, were synthesized. Analogues with the stilbenic double bond reduced or with the stereoisomery modified were also investigated. The antioxidant activity of these compounds was evaluated by measuring the inhibition of citronellal thermo-oxidation, or the reduction of 2,2 diphenyl-1-picrylhydrazyl radical. In addition, the protection against lipid peroxidation was determined in rat liver microsomes, and in human primary cell cultures. The antiproliferative activity was evaluated by a clonogenic assay, and by analysis of cell cycle progression and DNA synthesis. The results showed that the hydroxyl group in 4' position is not the sole determinant for antioxidant activity. In contrast, the presence of 4'-OH together with stereoisomery in the trans conformation (4'-hydroxystyryl moiety) was absolutely required for inhibition of cell proliferation. Enzymatic assays in vitro demonstrated that inhibition of DNA synthesis was induced by a direct interaction of resveratrol with DNA polymerases alpha and delta.	Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen C Golgi, I-27100 Pavia, Italy; CNR, Ctr Studio Istochim, I-27100 Pavia, Italy; CNR, IGBE, I-27100 Pavia, Italy; Univ Modena, Dipartimento Chim, I-41100 Modena, Italy	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Universita di Modena e Reggio Emilia	Stivala, LA (corresponding author), Univ Pavia, Dipartimento Med Sperimentale, Sez Patol Gen C Golgi, Piazza Botta 10, I-27100 Pavia, Italy.	l.stivala@botta.unipv.it	Prosperi, Ennio/A-3439-2014; Forti, Luca/AAY-9976-2021; Luca, Forti/C-9876-2015; Maga, Giovanni/C-5409-2009	Prosperi, Ennio/0000-0001-5391-5157; Forti, Luca/0000-0002-5662-7756; Luca, Forti/0000-0002-5662-7756; Maga, Giovanni/0000-0001-8092-1552; Albini, Adriana/0000-0002-9624-5103; ALBINI, ANGELO/0000-0003-4036-4290				ARICHI H, 1982, CHEM PHARM BULL, V30, P1766; Babich H, 2000, TOXICOL LETT, V114, P143, DOI 10.1016/S0378-4274(99)00288-X; Belguendouz L, 1997, BIOCHEM PHARMACOL, V53, P1347, DOI 10.1016/S0006-2952(96)00820-9; Bertelli AAE, 1996, DRUG EXP CLIN RES, V22, P61; Bocco A, 1998, SCI ALIMENT, V18, P13; BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25; Carbo N, 1999, BIOCHEM BIOPH RES CO, V254, P739, DOI 10.1006/bbrc.1998.9916; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Goldberg DM, 1996, ANAL CHEM, V68, P1688, DOI 10.1021/ac951083i; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; HAIN R, 1990, PLANT MOL BIOL, V15, P325, DOI 10.1007/BF00036918; Hsieh TC, 1999, INT J ONCOL, V15, P245; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jang DS, 1999, BIOCHEM PHARMACOL, V57, P705, DOI 10.1016/S0006-2952(98)00350-5; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; JEANDET P, 1991, AM J ENOL VITICULT, V42, P41; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kerry NL, 1997, ATHEROSCLEROSIS, V135, P93, DOI 10.1016/S0021-9150(97)00156-1; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; KURECHI T, 1980, CHEM PHARM BULL, V28, P2089; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; Liu M, 1999, CARCINOGENESIS, V20, P1869, DOI 10.1093/carcin/20.9.1869; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Orsini F, 1997, CARBOHYD RES, V301, P95, DOI 10.1016/S0008-6215(97)00087-6; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; PEZET R, 1988, PLANT PHYSIOL BIOCH, V26, P603; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; PROSPERI E, 1994, EXP CELL RES, V215, P257, DOI 10.1006/excr.1994.1341; Rotondo S, 1998, BRIT J PHARMACOL, V123, P1691, DOI 10.1038/sj.bjp.0701784; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Stivala LA, 2000, EUR J BIOCHEM, V267, P2290, DOI 10.1046/j.1432-1327.2000.01236.x; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Tadolini B, 2000, FREE RADICAL RES, V33, P105, DOI 10.1080/10715760000300661; WEISER T, 1991, J BIOL CHEM, V266, P10420; YAGI K, 1976, BIOCHEM MED METAB B, V15, P212, DOI 10.1016/0006-2944(76)90049-1; Zi XL, 1998, CANCER RES, V58, P1920; Zou JG, 1999, INT J ONCOL, V15, P647	52	406	427	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22586	22594		10.1074/jbc.M101846200	http://dx.doi.org/10.1074/jbc.M101846200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11316812	hybrid			2022-12-27	WOS:000169412700083
J	Sumi, T; Matsumoto, K; Shibuya, A; Nakamura, T				Sumi, T; Matsumoto, K; Shibuya, A; Nakamura, T			Activation of LIM kinases by myotonic dystrophy kinase-related Cdc42-binding kinase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN CYTOSKELETAL DYNAMICS; CONTAINING PROTEIN-KINASE; ZINC-FINGER; COFILIN PHOSPHORYLATION; GENOMIC ORGANIZATION; CELL MOTILITY; CDNA CLONING; FAMILY; MOTIF; RHO	LIM kinases (LIMK1 and LIMK2) regulate actin cytoskeletal reorganization through cofilin phosphorylation downstream of distinct Rho family GTPases. Pak1 and ROCK, respectively, activate LIMK1 and LIMK2 downstream of Rac and Rho; however, an effector protein kinase for LIMKs downstream of Cdc42 remains to be defined. We now report evidence that LIMK1 and LIMK2 activities toward cofilin phosphorylation are stimulated in cells by the co-expression of myotonic dystrophy kinase-related Cdc42-binding kinase alpha (MRCK alpha), an effector protein kinase of Cdc42. In vitro, MRCK alpha phosphorylated the protein kinase domain of LIM kinases, and the site in LIMK2 phosphorylated by MRCK alpha proved to be threonine 505 within the activation segment. Expression of MRCK alpha induced phosphorylation of actin depolymerizing factor (ADF)/cofilin in cells, whereas MRCK alpha -induced ADF/cofilin phosphorylation was inhibited by the co expression with the protein kinase-deficient form of LIM kinases. These results indicate that MRCK alpha phosphorylates and activates LIM kinases downstream of Cdc42, which in turn regulates the actin cytoskeletal reorganization through the phosphorylation and inactivation of ADF/cofilin.	Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, Suita, Osaka 5650871, Japan	Osaka University	Nakamura, T (corresponding author), Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Course Adv Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bamburg JR, 1999, TRENDS CELL BIOL, V9, P364, DOI 10.1016/S0962-8924(99)01619-0; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Carlier MF, 1999, J BIOL CHEM, V274, P33827, DOI 10.1074/jbc.274.48.33827; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ikebe C, 1997, GENOMICS, V46, P504, DOI 10.1006/geno.1997.5060; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Koshimizu U, 1997, BIOCHEM BIOPH RES CO, V241, P243, DOI 10.1006/bbrc.1997.7795; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIZUNO K, 1994, ONCOGENE, V9, P1605; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; NUNOUE K, 1995, ONCOGENE, V11, P701; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; OHASHI K, 2000, J BIOL CHEM, V249, P138; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sumi T, 2001, J BIOL CHEM, V276, P670, DOI 10.1074/jbc.M007074200; Takahashi T, 1997, DEV DYNAM, V209, P196, DOI 10.1002/(SICI)1097-0177(199706)209:2<196::AID-AJA5>3.0.CO;2-D; Takahashi T, 2001, DEV BIOL, V229, P554, DOI 10.1006/dbio.2000.9999; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	29	73	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23092	23096		10.1074/jbc.C100196200	http://dx.doi.org/10.1074/jbc.C100196200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11340065	hybrid			2022-12-27	WOS:000169412700147
J	Planque, N; Leconte, L; Coquelle, FM; Martin, P; Saule, S				Planque, N; Leconte, L; Coquelle, FM; Martin, P; Saule, S			Specific Pax-6/microphthalmia transcription factor interactions involve their DNA-binding domains and inhibit transcriptional properties of both proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA GENE-PRODUCT; RETINAL-PIGMENT EPITHELIUM; PAX6 PAIRED DOMAIN; WAARDENBURG-SYNDROME; NEURAL RETINA; IN-VITRO; EXPRESSION; MITF; HELIX; HOMEODOMAIN	Pax-6 and microphthalmia transcription factor (Mitf) are required for proper eye development. Pax-6, expressed in both the neuroretina and pigmented retina, has two DNA-binding domains: the paired domain and the homeodomain. Mice homozygous for Pax-6 mutations are anophthalmic. Mitf, a basic helix-loop-helix leucine zipper (b-HLH-LZ) transcription factor associated with the onset and maintenance of pigmentation, identifies the retinal pigmented epithelium during eye development. Loss of Mitf function results in the formation of an ectopic neuroretina at the expense of the dorsal retinal pigmented epithelium. In the present study, we investigated the interaction between Pax-6 and Mitf. In transient transfection-expression experiments, we found that transactivating effects of Pax-6 and Mitf on their respective target promoters were strongly inhibited by co-transfection of both transcription factors. This repression was due to direct protein/protein interactions involving both Pax-6 DNA-binding domains and the Mitf b-HLH-LZ domain. These results suggest that Pax-6/Mitf interactions may be critical for retinal pigmented epithelium development.	Inst Curie Sect Rech, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Saule, S (corresponding author), Inst Curie Sect Rech, CNRS, UMR 146, Ctr Univ Batiment 110, F-91405 Orsay, France.	Simon.Saule@curie.u-psud.fr		COQUELLE, Frederic/0000-0002-5483-8787				AGATA K, 1993, DEVELOPMENT, V118, P1025; Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BOISSY RE, 1993, J SUBMICR CYTOL PATH, V25, P319; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chow RL, 1999, DEVELOPMENT, V126, P4213; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GLASER T, 1995, MOL GENETICS OCULAR, P55; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Lam PYP, 1999, MOL CELL BIOL, V19, P594; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTIN P, 1992, ONCOGENE, V7, P1721; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Mochii M, 1998, DEV BIOL, V196, P145, DOI 10.1006/dbio.1998.8864; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Okada T S, 1980, Curr Top Dev Biol, V16, P349; PARK CM, 1989, DEV BIOL, V134, P201, DOI 10.1016/0012-1606(89)90089-4; PITTACK C, 1991, DEVELOPMENT, V113, P577; Planque N, 1999, CELL GROWTH DIFFER, V10, P525; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Singh S, 2000, J BIOL CHEM, V275, P17306, DOI 10.1074/jbc.M000359200; Singh S, 2001, HUM MOL GENET, V10, P911, DOI 10.1093/hmg/10.9.911; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; Takebayashi K, 1996, MOL CELL BIOL, V16, P1203; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Torres MA, 1996, DEVELOPMENT, V122, P3381; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Xu HE, 1999, GENE DEV, V13, P1263, DOI 10.1101/gad.13.10.1263; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123	54	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29330	29337		10.1074/jbc.M101812200	http://dx.doi.org/10.1074/jbc.M101812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11350962	hybrid			2022-12-27	WOS:000170346000093
J	Cuevas, BD; Lu, YL; Mao, ML; Zhang, JY; LaPushin, R; Siminovitch, K; Mills, GB				Cuevas, BD; Lu, YL; Mao, ML; Zhang, JY; LaPushin, R; Siminovitch, K; Mills, GB			Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; FACTOR-RECEPTOR; CELL-SURVIVAL; PROTEIN; BINDING; KINASE; SH2; PROLIFERATION; ASSOCIATION; ACTIVATION	Under resting conditions, the p85 regulatory subunit of phosphatidylinositol S-kinase (PI3K) serves to both stabilize and inactivate the p110 catalytic subunit. The inhibitory activity of p85 is relieved by occupancy of the NH2-terminal SH2 domain of p85 by phosphorylated tyrosine. Src family kinases phosphorylate tyrosine 688 in p85, a process that we have shown to be reversed by the activity of the p85-associated SH2 domain-containing phosphatase SHP1. We demonstrate that phosphorylation of the downstream PI3K target Akt is increased in cells lacking SHP1, implicating phosphorylation of p85 in the regulation of PI3K activity. Furthermore, the in vitro specific activity of PI3K associated with tyrosine-phosphorylated p85 is higher than that associated with nonphosphorylated p85, Expression of wild-type p85 inhibits PI3K enzyme activity as indicated by PI3K-dependent Akt phosphorylation. The inhibitory activity of p85 is accentuated by mutation of tyrosine 688 to alanine and reversed by mutation of tyrosine 688 to aspartic acid, changes that block and mimic tyrosine phosphorylation, respectively. Strikingly, mutation of tyrosine 688 to aspartic acid completely reverses the inhibitory activity of p85 on cell viability and activation of the downstream targets Akt and NF kappaB, indicative of the physiological relevance of p85 phosphorylation, Tyrosine phosphorylation of Tyr(688) or mutation of tyrosine 688 to aspartic acid is sufficient to allow binding to the NH2-terminal SH2 domain of p85. Thus an intramolecular interaction between phosphorylated Tyr(688) and the NH2-terminal SH2 domain of p85 can relieve the inhibitory activity of p85 on p110. Taken together, the data indicate that phosphorylation of Tyr(688) in p85 leads to a novel mechanism of PI3K regulation.	Univ Texas, MD Anderson Canc Ctr, Div Med, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Toronto, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X5, Canada	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University of Toronto	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Med, Dept Mol Therapeut, 1515 Holcombe Blvd,Box 317, Houston, TX 77030 USA.		Siminovitch, Katherine/K-1475-2013		NATIONAL CANCER INSTITUTE [R01CA074247, P01CA064602, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [CA64602, CA74247, CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; delPeso L, 1997, SCIENCE, V278, P687; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; HE TC, 1993, BLOOD, V82, P3530; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Martinez-Lorenzo MJ, 2000, INT J BIOCHEM CELL B, V32, P435, DOI 10.1016/S1357-2725(99)00142-9; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	24	192	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27455	27461		10.1074/jbc.M100556200	http://dx.doi.org/10.1074/jbc.M100556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11337495	hybrid			2022-12-27	WOS:000169966900096
J	Horer, S; Stoop, J; Mooibroek, H; Baumann, U; Sassoon, J				Horer, S; Stoop, J; Mooibroek, H; Baumann, U; Sassoon, J			The crystallographic structure of the mannitol 2-dehydrogenase NADP(+) binary complex from Agaricus bisporus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 17-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; COENZYME SPECIFICITY; ANGSTROM RESOLUTION; COMMON MUSHROOM; REDUCTASE; BINDING; METABOLISM	Mannitol, an acyclic six-carbon polyol, is one of the most abundant sugar alcohols occurring in nature, In the button mushroom, Agaricus bisporus, it is synthesized from fructose by the enzyme mannitol a dehydrogenase (MtDH; EC 1.1.1.138) using NADPH as a cofactor. Mannitol serves as the main storage carbon (up to 50% of the fruit body dry weight) and plays a critical role in growth, fruit body development, osmoregulation, and salt tolerance. Furthermore, mannitol dehydrogenases are being evaluated for commercial mannitol production as alternatives to the less efficient chemical reduction of fructose, Given the importance of mannitol metabolism and mannitol dehydrogenases, MtDH was cloned into the pET28 expression system and overexpressed in Escherichia coli, Kinetic and physicochemical properties of the recombinant enzyme are indistinguishable hom the natural enzyme. The crystal structure of its binary complex with NADP was solved at 1.5-Angstrom resolution and refined to an R value of 19.3%. It shows MtDH to be a tetramer and a member of the short chain dehydrogenase/reductase family of enzymes. The catalytic residues forming the so-called catalytic triad can be assigned to Ser(149), Tyr(169), and Lys(173).	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; DuPont Crop Genet, Wilmington, DE 19880 USA; Univ Wageningen & Res Ctr, Dept Bioconvers, Agrotechnol Res Inst, ATO BV, NL-6700 AA Wageningen, Netherlands	University of Bern; DuPont; Wageningen University & Research	Baumann, U (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	ulrich.baumann@ibc.unibe.ch; sassoon@ibc.unibe.ch	Baumann, Ulrich/B-1220-2013					Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; DUTSCH GA, 1972, PHYTOCHEMISTRY, V11, P2677, DOI 10.1016/S0031-9422(00)86496-1; Evans W, 1997, CHEM BRIT, V33, P22; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; HAMMOND JBW, 1975, J SCI FOOD AGR, V26, P835, DOI 10.1002/jsfa.2740260615; Hery S, 1998, J MOL BIOL, V279, P303, DOI 10.1006/jmbi.1998.1754; HOLTZ RB, 1971, J AGR FOOD CHEM, V19, P1272, DOI 10.1021/jf60178a052; Hulsmeyer M, 1998, PROTEIN SCI, V7, P1286; IUPAC-IUB Joint Commission on Biochemical Nomeclature (JCBN), 1983, EUR J BIOCHEM, V131, P9, DOI DOI 10.1021/IC2011716; JENNINGS DH, 1984, ADV MICROB PHYSIOL, V25, P149; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KLEYWEGT GJ, 1996, CCP4 ESF EACBM NEWSL, V32, P32; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; LESLIE AGW, 1996, PROTEIN CRYSTALLOGR, V32, P7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mazza C, 1998, J BIOL CHEM, V273, P8145, DOI 10.1074/jbc.273.14.8145; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOOIBROEK H, 1996, PROGR TRANSFORMATION; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; OPPENHEIMER NJ, 1992, MECH NAD DEPENDENT E, V20; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RAST D, 1965, PLANTA, V64, P81, DOI 10.1007/BF00518625; ROSSMANN MG, 1975, EVOLUTIONARY STRUCTU; RUFFNER HP, 1978, PHYTOCHEMISTRY, V17, P865, DOI 10.1016/S0031-9422(00)88635-5; Sassoon J, 2001, ACTA CRYSTALLOGR D, V57, P711, DOI 10.1107/S0907444901002542; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; STOOP JMH, 1994, PLANT PHYSIOL, V106, P503, DOI 10.1104/pp.106.2.503; Stoop JMH, 1996, TRENDS PLANT SCI, V1, P139, DOI 10.1016/S1360-1385(96)80048-3; Stoop JMH, 1998, APPL ENVIRON MICROB, V64, P4689; SU Y, 1993, J BIOL CHEM, V268, P26836; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; vandeRhee MD, 1996, CURR GENET, V30, P166, DOI 10.1007/s002940050116; vandeRhee MD, 1996, MOL GEN GENET, V250, P252, DOI 10.1007/BF02174382; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yamamoto K, 2001, J BIOCHEM, V129, P303, DOI 10.1093/oxfordjournals.jbchem.a002858; Yamashita A, 1999, BIOCHEMISTRY-US, V38, P7630, DOI 10.1021/bi9825044	53	53	56	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27555	27561		10.1074/jbc.M102850200	http://dx.doi.org/10.1074/jbc.M102850200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335726	hybrid			2022-12-27	WOS:000169966900108
J	D'Amico, S; Gerday, C; Feller, G				D'Amico, S; Gerday, C; Feller, G			Structural determinants of cold adaptation and stability in a large protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOPLANCTIS ALPHA-AMYLASE; ALTEROMONAS-HALOPLANCTIS; DIRECTED EVOLUTION; CONFORMATIONAL FLEXIBILITY; DEHYDROGENASE; ENZYME; DENATURATION; TEMPERATURE; ENVIRONMENTS; DYNAMICS	The heat-labile alpha -amylase from an antarctic bacterium is the largest known protein that unfolds reversibly according to a two-state transition as shown by differential scanning calorimetry, Mutants of this enzyme were produced, carrying additional weak interactions found in thermostable alpha -amylases, It is shown that single amino acid side chain substitutions can significantly modify the melting point T-m, the calorimetric enthalpy DeltaH(cal) the cooperativity and reversibility of unfolding, the thermal inactivation rate constant, and the kinetic parameters k(cat) and K-m. The correlation between thermal inactivation and unfolding reversibility displayed by the mutants also shows that stabilizing interactions increase the frequency of side reactions during refolding, leading to intramolecular mismatches or aggregations typical of large proteins. Although all mutations were located far from the active site, their overall trend is to decrease both k(cat) and K-m by rigidifying the molecule and to protect mutants against thermal inactivation. The effects of these mutations indicate that the cold-adapted alpha -amylase has lost a large number of weak interactions during evolution to reach the required conformational plasticity for catalysis at low temperatures, thereby producing an enzyme close to the lowest stability allowing maintenance of the native conformation.	Univ Liege, Inst Chem B6, Biochem Lab, B-4000 Liege, Belgium	University of Liege	Feller, G (corresponding author), Univ Liege, Inst Chem B6, Biochem Lab, B-4000 Liege, Belgium.	gfeller@ulg.ac.be						Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Cherry JR, 1999, NAT BIOTECHNOL, V17, P379, DOI 10.1038/7939; D'Amico S, 2000, GENE, V253, P95, DOI 10.1016/S0378-1119(00)00229-8; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Feller G, 1996, J BIOL CHEM, V271, P23836, DOI 10.1074/jbc.271.39.23836; Feller G, 1998, APPL ENVIRON MICROB, V64, P1163; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; FUKADA H, 1987, BIOCHEMISTRY-US, V26, P4063, DOI 10.1021/bi00387a048; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; Jaenicke R, 1999, PROG BIOPHYS MOL BIO, V71, P155, DOI 10.1016/S0079-6107(98)00032-7; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Lebbink JHG, 2000, BIOCHEMISTRY-US, V39, P3656, DOI 10.1021/bi991483q; Lonhienne T, 2001, BBA-PROTEIN STRUCT M, V1545, P349, DOI 10.1016/S0167-4838(00)00296-X; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Merz A, 2000, BIOCHEMISTRY-US, V39, P880, DOI 10.1021/bi992333i; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Pappenberger G, 1997, J MOL BIOL, V274, P676, DOI 10.1006/jmbi.1997.1421; Petrounia IP, 2000, CURR OPIN BIOTECH, V11, P325, DOI 10.1016/S0958-1669(00)00107-5; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Privalov Peter L., 1992, P83; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Roovers H, 2001, J BACTERIOL, V183, P1101, DOI 10.1128/JB.183.3.1101-1105.2001; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; Strop P, 2000, BIOCHEMISTRY-US, V39, P1251, DOI 10.1021/bi992257j; VARLEY PG, 1991, J MOL BIOL, V220, P531, DOI 10.1016/0022-2836(91)90028-5; Vetriani C, 1998, P NATL ACAD SCI USA, V95, P12300, DOI 10.1073/pnas.95.21.12300; Wintrode PL, 2000, J BIOL CHEM, V275, P31635, DOI 10.1074/jbc.M004503200; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	41	100	104	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25791	25796		10.1074/jbc.M102741200	http://dx.doi.org/10.1074/jbc.M102741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11325973	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000169823300022
J	Dupont, J; Fernandez, AM; Glackin, CA; Helman, L; LeRoith, D				Dupont, J; Fernandez, AM; Glackin, CA; Helman, L; LeRoith, D			Insulin-like growth factor 1 (IGF-1)-induced Twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; TYROSINE KINASE-ACTIVITY; BHLH PROTEIN TWIST; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; INHIBITS APOPTOSIS; CELL-DEATH; ANNEXIN-V; ACTIVATION; DIFFERENTIATION	In this study we investigated the molecular mechanisms whereby insulin-like growth factor 1 (IGF-1) induced Twist gene expression and the role of Twist in the anti-apoptotic actions of the IGF-1 receptor. In NIH-3T3 fibroblasts overexpressing the human IGF-1 receptor (NWTb3), treatment with IGF-1 (10(-8) M) for 1 and 4 h increased the level of Twist mRNA as well as protein by 3-fold. In contrast, insulin at physiological concentrations did not stimulate Twist expression in NIH-3T3 fibroblasts overexpressing the human insulin receptor. The IGF-1 effect was specific for the IGF-1 receptor since, in cells overexpressing a dominant negative IGF-1 receptor, IGF-1 failed to increase Twist expression. Preincubation with the ERK1/2 inhibitor U0126 or expression of a dominant negative MEK-1 abolished the effect of IGF-1 on Twist mRNA expression in NWTb3 cells, suggesting that Twist induction by IGF-1 occurs via the mitogen-activated protein kinase signaling pathway. In vivo, IGF-1 injection increased the mRNA level of Twist in mouse skeletal muscle, the major site of Twist expression. Finally, using an antisense strategy, we demonstrated that a reduction of 40% in Twist expression decreased significantly the ability of IGF-1 to rescue NWTb3 cells from etoposide-induced apoptosis, Taken together, these results define Twist as an important factor involved in the anti-apoptotic actions of the IGF-1 receptor.	NIDDK, Clin Endocrinol Branch, Sect Mol & Cell Physiol, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City of Hope; Beckman Research Institute of City of Hope	LeRoith, D (corresponding author), NIDDK, Clin Endocrinol Branch, Sect Mol & Cell Physiol, NIH, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.	derek@helix.nih.gov		Fernandez, Ana M./0000-0001-5160-3854				Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; Bourez RLJH, 1997, J CRANIOFAC SURG, V8, P441, DOI 10.1097/00001665-199711000-00002; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DAmbrosio C, 1997, CANCER RES, V57, P3264; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiCola G, 1997, J CLIN INVEST, V99, P2538, DOI 10.1172/JCI119438; Dunn SE, 1997, CANCER RES, V57, P2687; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Harrrison M, 1998, FEBS LETT, V435, P207, DOI 10.1016/S0014-5793(98)01051-5; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Hsing AY, 1996, CANCER RES, V56, P5146; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; KATO H, 1993, J BIOL CHEM, V268, P2655; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leshem Y, 2000, J CELL PHYSIOL, V184, P101, DOI 10.1002/(SICI)1097-4652(200007)184:1<101::AID-JCP11>3.0.CO;2-D; LEVYTOLEDANO R, 1993, BIOCHIM BIOPHYS ACTA, V1220, P1, DOI 10.1016/0167-4889(93)90090-C; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V273, P322, DOI 10.1006/bbrc.2000.2934; Mooney A, 1997, J IMMUNOL, V159, P3949; MURRAY SS, 1992, J BONE MINER RES, V7, P1131; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Parrizas M, 1997, J BIOL CHEM, V272, P154; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; ROHWEDEL J, 1995, EXP CELL RES, V220, P92, DOI 10.1006/excr.1995.1295; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SELL C, 1995, CANCER RES, V55, P303; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang SM, 1997, GENE, V187, P83, DOI 10.1016/S0378-1119(96)00727-5; Winnay JN, 2000, J BIOL CHEM, V275, P10545, DOI 10.1074/jbc.275.14.10545; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001	56	85	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26699	26707		10.1074/jbc.M102664200	http://dx.doi.org/10.1074/jbc.M102664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11323435	Green Submitted, hybrid			2022-12-27	WOS:000169823300137
J	Kimura, M; Mizukami, Y; Miura, T; Fujimoto, K; Kobayashi, S; Matsuzaki, M				Kimura, M; Mizukami, Y; Miura, T; Fujimoto, K; Kobayashi, S; Matsuzaki, M			Orphan G protein-coupled receptor, GPR41, induces apoptosis via a p53/bax pathway during ischemic hypoxia and reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; TUMOR-SUPPRESSOR P53; INTERLEUKIN-8 RECEPTOR; NUCLEAR TRANSLOCATION; KINASE ACTIVATION; MOLECULAR-CLONING; LEUKOTRIENE B-4; AMINO-TERMINUS; HEART-FAILURE; GROWTH-FACTOR	Orphan receptors that couple to G protein without known ligands are considered to relate directly to drug discovery, Here, we examine the expression of various orphan receptors in H9c2 cells during ischemic hypoxia and reoxygenation. Among orphan receptors examined, the level of G protein-coupled receptor 41 (GPR41) mRNA increases significantly, with a peak at 2 h after reoxygenation, and recovers to the control level by 3 h after reoxygenation. The level of glyceraldehyde-3-phosphate dehydrogenase mRNA used as an internal control remains almost constant. The levels of c-fos and c-jun mRNA increase significantly with ischemic hypoxia and reoxygenation. The transfection of GPR41 into H9c2 cells results in a significant decrease in cell number, with DNA fragmentation observed by in vitro and in situ assay. The amount of p53 protein increases significantly in the nuclei of cells expressing GPR41, accompanying an increase in the transcriptional activity of p53. Consistent with the activation of p53, the level of bat mRNA is significantly increased, which leads to an increase in Bax protein. Furthermore, the expression of a deletion mutant of a GPR41, which lacks the G protein binding site and shows an attenuation of intracellular phosphorylation signals to H9c2 cells, inhibits cell death and the increase in p53 protein within 24 h after reoxygenation, These observations demonstrate that GPR41 is a novel receptor that activates p53 leading to apoptosis during reoxygenation after ischemic hypoxia in H9c2 cells. We have designated GPR41 as the hypoxia-induced apoptosis receptor, HIA-R.	Yamaguchi Univ, Sch Med, Dept Physiol 1, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Internal Med 2, Ube, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University	Mizukami, Y (corresponding author), Yamaguchi Univ, Sch Med, Dept Physiol 1, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	mizukami@po.cc.yamaguchi-u.ac.jp	Kobayashi, Sei/E-7175-2010	Mizukami, Yoichi/0000-0002-3290-0754				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; Bonini JA, 1997, BIOCHEM BIOPH RES CO, V234, P190, DOI 10.1006/bbrc.1997.6591; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cheng W, 1996, EXP CELL RES, V226, P316, DOI 10.1006/excr.1996.0232; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Dobrzynski E, 2000, HYPERTENSION, V36, P995, DOI 10.1161/01.HYP.36.6.995; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Fujimoto K, 2001, BBA-GENE STRUCT EXPR, V1518, P173, DOI 10.1016/S0167-4781(00)00309-2; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Hagan JJ, 1999, P NATL ACAD SCI USA, V96, P10911, DOI 10.1073/pnas.96.19.10911; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; Kobayashi S, 1999, J BIOL CHEM, V274, P20358, DOI 10.1074/jbc.274.29.20358; Ladoux A, 2000, J BIOL CHEM, V275, P39914, DOI 10.1074/jbc.M006512200; Landau E, 2000, J BIOL CHEM, V275, P2281, DOI 10.1074/jbc.275.4.2281; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; Lund PE, 2000, J BIOL CHEM, V275, P30806, DOI 10.1074/jbc.M002603200; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; Mizukami Y, 1997, BIOCHEM J, V323, P785, DOI 10.1042/bj3230785; Mizukami Y, 2000, J BIOL CHEM, V275, P19921, DOI 10.1074/jbc.M907901199; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Noiri E, 2000, P NATL ACAD SCI USA, V97, P823, DOI 10.1073/pnas.97.2.823; Oie E, 2000, CIRCULATION, V101, P415; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Ono K, 1997, CIRCULATION, V95, P2552, DOI 10.1161/01.CIR.95.11.2552; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Terui Y, 1998, BLOOD, V92, P2672, DOI 10.1182/blood.V92.8.2672.420k40_2672_2680; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; Webster KA, 1999, J CLIN INVEST, V104, P239; Xie W, 1997, J BIOL CHEM, V272, P24948, DOI 10.1074/jbc.272.40.24948; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Ziesche R, 1996, P NATL ACAD SCI USA, V93, P12478, DOI 10.1073/pnas.93.22.12478	62	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26453	26460		10.1074/jbc.M101289200	http://dx.doi.org/10.1074/jbc.M101289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335718	hybrid			2022-12-27	WOS:000169823300107
J	Nakajima, J; Tanaka, Y; Yamazaki, M; Saito, K				Nakajima, J; Tanaka, Y; Yamazaki, M; Saito, K			Reaction mechanism from leucoanthocyanidin to anthocyanidin 3-glucoside, a key reaction for coloring in anthocyanin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETUNIA-HYBRIDA; UDP-GLUCOSE; FLAVANONE 3-BETA-HYDROXYLASE; BIOCHEMICAL-CHARACTERIZATION; MOLECULAR-CLONING; ANTIRRHINUM-MAJUS; FLAVONOL SYNTHASE; GENES; EXPRESSION; ENZYMES	In the conversion from colorless leucoanthocyanidin to colored anthocyanidin 5-glucoside, at least two enzymes, anthocyanidin synthase (ANS) and UDP-glucose: flavonoid 3-O-glucosyltransferase (3-GT), are postulated to be involved. Despite the importance of this reaction sequence for coloring in anthocyanin biosynthesis, the biochemical reaction mechanism has not been clarified, and the possible involvement of a dehydratase has not been excluded. Here we show that recombinant ANSs from several model plant species, snapdragon, petunia, torenia, and maize, catalyze the formation of anthocyanidin in vitro through a 2-oxoglutarate-dependent oxidation of leucoanthocyanidin, Crude extracts of Escherichia coli, expressing recombinant ANSs from these plant species, and purified recombinant enzymes of petunia and maize catalyzed the formation of anthocyanidin in the presence of ferrous ion, 8-oxoglutarate, and ascorbate, The in vitro formation of colored cyanidin 5-glucoside from leucocyanidin, via a cyanidin intermediate, was demonstrated using petunia ANS and 3-GT, The entire reaction sequence did not require any additional dehydratase but was dependent on moderate acidic pH conditions following the enzymatic steps. The present study indicated that the in vivo cytosolic reaction sequence involves an ANS-catalyzed 8-oxogiutarate-dependent conversion of leucoanthocyanidin (flavan3,4-cis-diol) to 3-flaven-2,3-diol (pseudobase), most probably through 2,3-desaturation and isomerization, followed by glucosylation at the C-3 position by 3-GT.	Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Inage Ku, Chiba 2638522, Japan; Suntory Ltd, Inst Fundamental Res, Mishima, Osaka 6188503, Japan	Chiba University; Suntory Holdings Ltd	Saito, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol, Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.	ksaito@p.chiba-u.ac.jp	Yamazaki, Mami/A-9050-2010; Saito, Kazuki/D-2670-2009	Yamazaki, Mami/0000-0001-6157-5287; Saito, Kazuki/0000-0001-6310-5342				AKHTAR M, 1991, NAT PROD REP, V8, P527, DOI 10.1039/np9910800527; ATTWOOD MR, 1983, J CHEM SOC PERK T 1, P2229, DOI 10.1039/p19830002229; BALDWIN JE, 1987, J CHEM SOC CHEM COMM, P1654, DOI 10.1039/c39870001654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V282, P152, DOI 10.1016/0003-9861(90)90099-K; BRITSCH L, 1990, ARCH BIOCHEM BIOPHYS, V276, P348, DOI 10.1016/0003-9861(90)90731-D; BRITSCH L, 1992, J BIOL CHEM, V267, P5380; BROUILLARD R, 1990, CAN J CHEM, V68, P755, DOI 10.1139/v90-119; Burbulis IE, 1999, P NATL ACAD SCI USA, V96, P12929, DOI 10.1073/pnas.96.22.12929; DAVIES KM, 1993, PLANT PHYSIOL, V103, P1015, DOI 10.1104/pp.103.3.1015; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; DOONER HK, 1977, P NATL ACAD SCI USA, V74, P5623, DOI 10.1073/pnas.74.12.5623; Ebel J., 1982, FLAVONOIDS ADV RES, P641; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Ford CM, 1998, J BIOL CHEM, V273, P9224, DOI 10.1074/jbc.273.15.9224; HELLER W, 1988, FLAVONOIDS ADV RES 1, P399; HELLER W, 1986, FLAVONOIDS ADV RES S, P499; HOLTON TA, 1993, PLANT J, V4, P1003, DOI 10.1046/j.1365-313X.1993.04061003.x; HOLTON TA, 1995, PLANT CELL, V7, P1071, DOI 10.1105/tpc.7.7.1071; KAMSTEEG J, 1978, BIOCHEM GENET, V16, P1045, DOI 10.1007/BF00484525; KHO KFF, 1978, Z PFLANZENPHYSIOL, V88, P449, DOI 10.1016/S0044-328X(78)80261-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN C, 1991, PLANT J, V1, P37, DOI 10.1111/j.1365-313X.1991.00037.x; Martin C, 1992, MOL BIOL FLOWERS, P219; MENSSEN A, 1990, EMBO J, V9, P3051, DOI 10.1002/j.1460-2075.1990.tb07501.x; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; NAKAJIMA J, 2000, PLANT BIOTECHNOL-NAR, V17, P331; Nakanishi K., 1999, COMPREHENSIVE NATURA, V1, P713; Pelletier MK, 1997, PLANT PHYSIOL, V113, P1437, DOI 10.1104/pp.113.4.1437; Prescott AG, 1996, ANNU REV PLANT PHYS, V47, P245, DOI 10.1146/annurev.arplant.47.1.245; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; REDDY GM, 1962, SCIENCE, V138, P149, DOI 10.1126/science.138.3537.149; Rosati C, 1999, PLANT SCI, V149, P73, DOI 10.1016/S0168-9452(99)00146-6; RUHNAU B, 1988, PHYTOCHEMISTRY, V27, P1035, DOI 10.1016/0031-9422(88)80268-1; Saito K, 1999, PLANT J, V17, P181, DOI 10.1046/j.1365-313X.1999.00365.x; SPARVOLI F, 1994, PLANT MOL BIOL, V24, P743, DOI 10.1007/BF00029856; STAFFORD HA, 1985, PHYTOCHEMISTRY, V24, P333; STAFFORD HA, 1984, PLANT PHYSIOL, V76, P184, DOI 10.1104/pp.76.1.184; STEAHELIN LA, 2000, BIOCH MOL BIOL PLANT, P2; Tanaka Y, 1996, PLANT CELL PHYSIOL, V37, P711, DOI 10.1093/oxfordjournals.pcp.a029004; Tanaka Y, 1998, PLANT CELL PHYSIOL, V39, P1119, DOI 10.1093/oxfordjournals.pcp.a029312; WEISS D, 1993, PLANT MOL BIOL, V22, P893, DOI 10.1007/BF00027374	42	110	139	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25797	25803		10.1074/jbc.M100744200	http://dx.doi.org/10.1074/jbc.M100744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316805	hybrid			2022-12-27	WOS:000169823300023
J	Briggs, SD; Scholtz, B; Jacque, JM; Swingler, S; Stevenson, M; Smithgall, TE				Briggs, SD; Scholtz, B; Jacque, JM; Swingler, S; Stevenson, M; Smithgall, TE			HIV-1 Nef promotes survival of myeloid cells by a stat3-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; COLONY-STIMULATING FACTOR; SH3 DOMAIN; IMMUNODEFICIENCY-VIRUS; STAT3 ACTIVATION; GENE HCK; FIBROBLAST TRANSFORMATION; SRC ONCOPROTEIN; IN-VIVO; BINDING	Human immunodeficiency virus Nef is a small myristylated protein that plays a critical role in AIDS progression. Nef binds with high affinity to the SH3 domain of the myeloid-restricted tyrosine kinase Hck in vitro, identifying this Src-related kinase as a possible cellular target for Nef in macrophages. Here we show that Nef activates endogenous Hck in the granulocyte-macrophage colony-stimulating factor-dependent myeloid cell line, TF-1. Unexpectedly, Nef induced cytokine-independent TF-1 cell outgrowth and constitutive activation of the Stat3 transcription factor. Induction of survival required the Nef SH3 binding and membrane-targeting motifs and was blocked by dominant-negative Stat3 mutants. Nef also stimulated Stat3 activation in primary human macrophages, providing evidence for Stat3 as a Nef effector in a target cell for human immunodeficiency virus.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu	Jacque, Jean-Marc/B-6875-2008	Briggs, Scott D/0000-0003-2852-3594; Scholtz, Beata/0000-0002-2737-5027	NCI NIH HHS [R01 CA081398, CA81398] Funding Source: Medline; NCRR NIH HHS [RR11589, R01 RR011589] Funding Source: Medline; NHLBI NIH HHS [R01 HL057880] Funding Source: Medline; NIAID NIH HHS [R01 AI032890, R01 AI049152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR011589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alexander L, 1997, J VIROL, V71, P6094, DOI 10.1128/JVI.71.8.6094-6099.1997; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Arold S, 1998, BIOCHEMISTRY-US, V37, P14683, DOI 10.1021/bi980989q; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Balter M, 1996, SCIENCE, V274, P1464, DOI 10.1126/science.274.5292.1464; BOULET I, 1992, ONCOGENE, V7, P703; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Briggs SD, 2000, BIOCHEMISTRY-US, V39, P489, DOI 10.1021/bi992504j; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Hirsch VM, 1998, NAT MED, V4, P1401, DOI 10.1038/3992; HITT M, 1995, METH MOL G, V7, P13; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KALTER DC, 1991, J IMMUNOL, V146, P298; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; LINNEKIN D, 1994, BLOOD, V84, P94, DOI 10.1182/blood.V84.1.94.bloodjournal84194; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; Rajotte D, 1996, BLOOD, V88, P2906, DOI 10.1182/blood.V88.8.2906.bloodjournal8882906; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; Stevenson M, 1996, NAT STRUCT BIOL, V3, P303, DOI 10.1038/nsb0496-303; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TORIGOE T, 1992, BLOOD, V80, P617; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wei S, 1996, J IMMUNOL, V157, P5155; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	65	71	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25605	25611		10.1074/jbc.M103244200	http://dx.doi.org/10.1074/jbc.M103244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328823	hybrid, Green Accepted			2022-12-27	WOS:000169800700152
J	Jiang, QJ; Taupenot, L; Mahata, SK; Mahata, M; O'Connor, DT; Miles, LA; Parmer, RJ				Jiang, QJ; Taupenot, L; Mahata, SK; Mahata, M; O'Connor, DT; Miles, LA; Parmer, RJ			Proteolytic cleavage of chromogranin A (CgA) by plasmin - Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; PARATHYROID CELL SECRETION; N-TERMINAL FRAGMENT; PHEOCHROMOCYTOMA CELLS; RECOMBINANT PROTEINS; MOLECULAR-CLONING; MESSENGER-RNA; A FRAGMENT; PEPTIDE; DESORPTION	Chromogranin A (CgA), the major soluble protein in catecholamine storage vesicles, serves as a prohormone that is cleaved into bioactive peptides that inhibit catecholamine release, providing an autocrine, negative feedback mechanism for regulating catecholamine responses during stress. However, the proteases responsible for the processing of CgA and release of bioactive peptides have not been established. Recently, we found that chromaffin cells express components of the plasmin(ogen) system, including tissue plasminogen activator, which is targeted to catecholamine storage vesicles and released with CgA and catecholamines in response to sympathoadrenal stimulation, and high affinity cell surface receptors for plasminogen, to promote plasminogen activation at the cell surface. In the present study, we investigated processing of CgA by plasmin and sought to identify specific bioactive CgA peptides produced by plasmin proteolysis, Highly purified human CgA (hCgA) was produced by expression in Escherichia coli and purification using metal affinity chromatography, hCgA was digested with plasmin, Matrix-assisted laser desorption/ionization mass spectrometry identified a major peptide produced with a mass/charge ratio (m/z) of 1546, corresponding uniquely to hCgA-(360-373), the identity of which was confirmed by reverse phase high pressure liquid chromatography and amino-terminal microsequencing, hCgA-(360-373) was selectively liberated by plasmin from hCgA at early time points and was stable even after prolonged exposure to plasmin, The corresponding synthetic peptide markedly inhibited nicotine-induced catecholamine release from pheochromocytoma cells. These results identify plasmin as a protease, present in the local environment of the chromaffin cell, that selectively cleaves CgA to generate a bioactive fragment, hCgA-(360-373), that inhibits nicotinic-mediated catecholamine release. These results suggest that the plasminogen/plasmin system through its interaction with CgA may play a major role in catecholaminergic function and suggest a specific mechanism as well as a discrete CgA peptide through which this effect is mediated.	Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Dept Vet Affairs Med Ctr, San Diego, CA 92161 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute	Parmer, RJ (corresponding author), Univ Calif San Diego, Dept Med, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.		Mahata, Sushil/AAF-8781-2021	Taupenot, Laurent/0000-0003-2316-3825	NHLBI NIH HHS [HL-07261, HL-38272, HL-50398, HL-58120] Funding Source: Medline; NIDDK NIH HHS [DK-07671] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038272, R01HL050398, P01HL058120, R29HL038272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BILLECI TM, 1993, ANAL CHEM, V65, P1709, DOI 10.1021/ac00061a013; COLLEN D, 1975, THROMB DIATH HAEMOST, V34, P403, DOI 10.1055/s-0038-1651399; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; Hervio LS, 2000, CHEM BIOL, V7, P443, DOI 10.1016/S1074-5521(00)00125-3; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; Kriwacki RW, 1996, J AM CHEM SOC, V118, P5320, DOI 10.1021/ja960752m; LI KW, 1994, J BIOL CHEM, V269, P30288; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MILES LA, 1985, J BIOL CHEM, V260, P4303; OCONNOR DT, 1984, T ASSOC AM PHYSICIAN, V97, P242; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PARMER RJ, 1989, HYPERTENSION, V14, P435, DOI 10.1161/01.HYP.14.4.435; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; Siuzdak G., 1996, MASS SPECTROMETRY BI; STULTS JT, 1995, CURR OPIN STRUC BIOL, V5, P691, DOI 10.1016/0959-440X(95)80063-8; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taylor JA, 1996, RAPID COMMUN MASS SP, V10, P679, DOI 10.1002/(SICI)1097-0231(199604)10:6<679::AID-RCM528>3.0.CO;2-Q; TSARBOPOULOS A, 1994, ANAL CHEM, V66, P2062, DOI 10.1021/ac00085a022; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; WEINSTEI.MJ, 1972, BIOCHIM BIOPHYS ACTA, V258, P577, DOI 10.1016/0005-2744(72)90250-1; WIGHTMAN RM, 1995, 8 INT S CHROM CELL S, V25, P66; WINKLER H, 1976, NEUROSCIENCE, V1, P65, DOI 10.1016/0306-4522(76)90001-4; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130	41	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25022	25029		10.1074/jbc.M101545200	http://dx.doi.org/10.1074/jbc.M101545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342539	hybrid			2022-12-27	WOS:000169800700079
J	Kang, Q; Cao, Y; Zolkiewska, A				Kang, Q; Cao, Y; Zolkiewska, A			Direct interaction between the cytoplasmic tail of ADAM 12 and the Src homology 3 domain of p85 alpha activates phosphatidylinositol 3-kinase in C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-II; CYSTEINE-RICH DOMAIN; MELTRIN-ALPHA; PHOSPHOINOSITIDE 3-KINASES; SIGNALING PATHWAYS; MYOBLAST FUSION; MUSCLE-CELLS; DIFFERENTIATION; MYOGENESIS; BINDING	ADAM 12, a member of the ADAM family of transmembrane metalloprotease-disintegrins, has been implicated previously in the differentiation of skeletal myoblasts. In the present study, we show that the cytoplasmic tail of mouse ADAM 12 interacts in vitro and in vivo with the Src homology 3 domain of the p85 alpha regulatory subunit of phosphatidylinositol (PI) 3-kinase, By site-directed mutagenesis, we have identified three p85 alpha -binding sites in ADAM 12 involving PXXP motifs located at amino acids 825-828, 833-836, and 884-887, Using green fluorescent protein (GFP)-pleckstrin homology (PH) domain fusion protein as a probe for PI 3-kinase lipid products, we have further demonstrated that expression of ADAM 12 in C2C12 cells resulted in translocation of c;FP-PH to the plasma membrane. This suggests that transmembrane ADAM 12, by providing docking sites for the Src homology 3 domain of p85 alpha, activates PI 3-kinase by mediating its recruitment to the membrane. Because PI 3-kinase is critical for terminal differentiation of myoblasts, and because expression of ADAM 12 is up-regulated at the onset of the differentiation process, ADAM 12-mediated activation may constitute one of the regulatory mechanisms for PI I-kinase during myoblast differentiation.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Zolkiewska, A (corresponding author), Kansas State Univ, Dept Biochem, 104 Willard Hall, Manhattan, KS 66506 USA.	zolkiea@ksu.edu			NIAMS NIH HHS [AR 45787] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045787] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Bornemann A, 2000, J MUSCLE RES CELL M, V21, P475, DOI 10.1023/A:1005657607591; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Schlondorff J, 1999, J CELL SCI, V112, P3603; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	37	39	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24466	24472		10.1074/jbc.M101162200	http://dx.doi.org/10.1074/jbc.M101162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313349	hybrid			2022-12-27	WOS:000169800700008
J	Benson, MA; Newey, SE; Martin-Rendon, E; Hawkes, R; Blake, DJ				Benson, MA; Newey, SE; Martin-Rendon, E; Hawkes, R; Blake, DJ			Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; NITRIC-OXIDE SYNTHASE; ALPHA-DYSTROBREVIN; BETA-DYSTROBREVIN; SYNTROPHIN; TORPEDO; LOCALIZATION; SARCOLEMMA; COMPLEX; BINDING	The dystrophin-associated protein complex (DPC) is required for the maintenance of muscle integrity during the mechanical stresses of contraction and relaxation. In addition to providing a membrane scaffold, members of the DPC such as the alpha -dystrobrevin protein family are thought to play an important role in intracellular signal transduction. To gain additional insights into the function of the DPC, we performed a yeast two-hybrid screen for dystrobrevin-interacting proteins. Here we describe the identification of a dysbindin, a novel dystrobrevin-binding protein. Dysbindin is an evolutionary conserved 40-kDa coiled-coil-containing protein that binds to alpha- and beta -dystrobrevin in muscle and brain. Dystrophin and alpha -dystrobrevin are co-immunoprecipitated with dysbindin, indicating that dysbindin is DPC-associated in muscle. Dysbindin co-localizes with alpha -dystrobrevin at the sarcolemma and is up-regulated in dystrophin-deficient muscle. In the brain, dysbindin is found primarily in axon bundles and especially in certain axon terminals, notably messy fiber synaptic terminals in the cerebellum and hippocampus. These findings have implications for the molecular pathology of Duchenne muscular dystrophy and may provide an alternative route for anchoring dystrobrevin and the DPC to the muscle membrane.	Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Calgary, Fac Med, Dept Cell Biol & Anat & Genes, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dev Res Grp, Calgary, AB T2N 4N1, Canada	University of Oxford; University of Oxford; University of Calgary; University of Calgary		dblake@enterprise.molbiol.ox.ac.uk	Hawkes, Richard/F-7971-2011	Benson, Matthew/0000-0003-4459-0439				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Armstrong CL, 2000, J COMP NEUROL, V416, P383, DOI 10.1002/(SICI)1096-9861(20000117)416:3<383::AID-CNE9>3.0.CO;2-M; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; Blake DJ, 1998, P NATL ACAD SCI USA, V95, P241, DOI 10.1073/pnas.95.1.241; Blake DJ, 1999, J CELL BIOL, V147, P645, DOI 10.1083/jcb.147.3.645; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BLAKE DJ, 1995, P NATL ACAD SCI USA, V92, P3697, DOI 10.1073/pnas.92.9.3697; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; Blake DJ, 2000, TRENDS NEUROSCI, V23, P92, DOI 10.1016/S0166-2236(99)01510-6; Blank M, 1999, EUR J NEUROSCI, V11, P2121, DOI 10.1046/j.1460-9568.1999.00636.x; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399; Crosbie RH, 2000, HUM MOL GENET, V9, P2019, DOI 10.1093/hmg/9.13.2019; DWYER TM, 1995, FEBS LETT, V375, P91, DOI 10.1016/0014-5793(95)01176-F; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Gee SH, 1998, J NEUROSCI, V18, P128; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Jaarsma D, 1997, PROG BRAIN RES, V114, P67; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; Knuesel I, 2000, J COMP NEUROL, V422, P594, DOI 10.1002/1096-9861(20000710)422:4<594::AID-CNE8>3.0.CO;2-Q; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; Michalak M, 1997, CURR OPIN NEUROL, V10, P436, DOI 10.1097/00019052-199710000-00014; Nawrotzki R, 1998, J CELL SCI, V111, P2595; Newey SE, 2000, CURR BIOL, V10, P1295, DOI 10.1016/S0960-9822(00)00760-0; Newey SE, 2001, J BIOL CHEM, V276, P6645, DOI 10.1074/jbc.M008305200; NGUYEN TM, 1992, BIOCHEM J, V288, P663, DOI 10.1042/bj2880663; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Peters MF, 1998, J CELL BIOL, V142, P1269, DOI 10.1083/jcb.142.5.1269; Peters MF, 1997, J BIOL CHEM, V272, P31561, DOI 10.1074/jbc.272.50.31561; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; SadouletPuccio HM, 1997, P NATL ACAD SCI USA, V94, P12413, DOI 10.1073/pnas.94.23.12413; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; SCHOFIELD JN, 1994, HUM MOL GENET, V3, P1309; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; UEDA H, 1995, INVEST OPHTH VIS SCI, V36, P2318; Ueda H, 2000, NEUROSCI LETT, V283, P121, DOI 10.1016/S0304-3940(00)00925-3; Vainzof M, 1996, HUM MOL GENET, V5, P1963, DOI 10.1093/hmg/5.12.1963; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R	52	256	270	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24232	24241		10.1074/jbc.M010418200	http://dx.doi.org/10.1074/jbc.M010418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316798	hybrid			2022-12-27	WOS:000169531100132
J	Bregoli, L; Baldassare, JJ; Raben, DM				Bregoli, L; Baldassare, JJ; Raben, DM			Nuclear diacylglycerol kinase-theta is activated in response to alpha-thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; RAT-LIVER NUCLEI; SWISS 3T3 CELLS; PHOSPHOLIPASE-D; LYMPHOCYTE-PROLIFERATION; INDUCED TRANSLOCATION; CULTURED FIBROBLASTS; SIGNAL-TRANSDUCTION; CALCIUM-BINDING; GROWTH-FACTOR	Currently, there is substantial evidence that nuclear lipid metabolism plays a critical role in a number of signal transduction cascades. Previous work from our laboratory showed that stimulation of quiescent fibroblasts with Lu-thrombin leads to the production of two lipid second messengers in the nucleus: an increase in nuclear diacylglycerol mass and an activation of phospholipase D, which catalyzes the hydrolysis of phosphatidylcholine to generate phosphatidic acid. Diacylglycerol kinase (DGK) catalyzes the conversion of diacylglycerol to phosphatidic acid, making it an attractive candidate for a signal transduction component. There is substantial evidence that this activity is indeed regulated in a number of signaling cascades (reviewed by van Blitterswijk, W.J., and Houssa, B. (1999) Chem. Phys. Lipids 98, 95-108). In this report, we show that the addition of cr-thrombin to quiescent IIC9 fibroblasts results in an increase in nuclear DGK activity. The examination of nuclei isolated from quiescent IIC9 cells indicates that DGK-theta and DGK-delta are both present. We took advantage of the previous observations that phosphatidylserine inhibits DGK-delta (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and Kanoh, H. (1996) J. Biol. Chem. 271, 8394-8401), and constitutively active RhoA inhibits DGK-theta (reviewed by Houssa, B., de Widt, J., Kranenburg, O., Moolenaar, W. H., and van Blitterswijk, W. J. (1999) J. Biol Chem. 274, 6820-6822) to identify the activity induced by Lv-thrombin. Constitutively active RhoA inhibited the nuclear stimulated activity, whereas phosphatidylserine did not have an inhibitory effect. In addition, a monoclonal anti-DGK-theta antibody inhibited the alpha -thrombin-stimulated nuclear activity in vitro. These results demonstrate that DGK-theta is the isoform responsive to alpha -thrombin stimulation. Western blot and immunofluorescence microscopy analyses showed that cr-thrombin induced the translocation of DGK-theta to the nucleus, implicating that this translocation is at least partly responsible for the increased nuclear activity. Taken together, these data are the first to demonstrate an agonist-induced activity of nuclear DGK-theta activity and a nuclear localization of DGK-delta.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	Johns Hopkins University; Saint Louis University	Raben, DM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.			Bregoli, Lisa/0000-0001-9376-1914	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059251] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM59251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSSEL C, 1992, CELL IMMUNOL, V139, P333, DOI 10.1016/0008-8749(92)90075-Z; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; BROCK TG, 1994, J BIOL CHEM, V269, P22059; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P526, DOI 10.1021/bi00168a018; JIMENEZ B, 1988, BIOCHEM BIOPH RES CO, V150, P118, DOI 10.1016/0006-291X(88)90494-9; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KATO H, 1988, BIOCHEM BIOPH RES CO, V154, P959, DOI 10.1016/0006-291X(88)90233-1; KATO M, 1989, FEBS LETT, V247, P247, DOI 10.1016/0014-5793(89)81345-6; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Liu ZT, 2001, J BIOL CHEM, V276, P5900, DOI 10.1074/jbc.M007311200; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MARONEY AC, 1989, J CELL BIOCHEM, V40, P165, DOI 10.1002/jcb.240400205; Martelli AM, 2000, CANCER RES, V60, P815; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; Nobe K, 1997, BIOCHEM PHARMACOL, V53, P1683, DOI 10.1016/S0006-2952(97)82454-9; NOBE K, 1995, BIOCHEM PHARMACOL, V50, P591, DOI 10.1016/0006-2952(95)00184-2; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; OHANIAN J, 1994, BIOCHEM J, V300, P51, DOI 10.1042/bj3000051; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PREVIATI M, 1994, CELL SIGNAL, V6, P393, DOI 10.1016/0898-6568(94)90086-8; PUNNONEN K, 1992, J INVEST DERMATOL, V99, P221, DOI 10.1111/1523-1747.ep12650445; Raben DM, 2000, ADV ENZYME REGUL, V40, P97, DOI 10.1016/S0065-2571(99)00023-0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; SAKANE F, 1991, J BIOL CHEM, V266, P7096; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; SMITH CD, 1983, J BIOL CHEM, V258, P9368; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; VANDERKLIS FRM, 1993, INT J BIOCHEM, V25, P575, DOI 10.1016/0020-711X(93)90666-3; Wada I, 1996, FEBS LETT, V393, P48, DOI 10.1016/0014-5793(96)00857-5; Walker AJ, 2001, BIOCHEM J, V353, P129, DOI 10.1042/bj3530129; WANG YL, 1993, J BIOL CHEM, V268, P5899; WRIGHT TM, 1988, J BIOL CHEM, V263, P9374	49	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23288	23295		10.1074/jbc.M101501200	http://dx.doi.org/10.1074/jbc.M101501200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309392	hybrid			2022-12-27	WOS:000169531100012
J	Craddock, BL; Hobbs, J; Edmead, CE; Welham, MJ				Craddock, BL; Hobbs, J; Edmead, CE; Welham, MJ			Phosphoinositide 3-kinase-dependent regulation of interleukin-3-induced proliferation - Involvement of mitogen-activated protein kinases, SHP2 and Gab2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; COLONY-STIMULATING FACTOR; CELL-CYCLE PROGRESSION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; T-CELL; NUCLEAR TRANSLOCATION; LYSOPHOSPHATIDIC-ACID; SIGNAL-TRANSDUCTION	We have demonstrated previously that class I,phosphoinositide 3-kinases play a major role in regulation of interleukin-3 (IL)-3-dependent proliferation. Investigations into the downstream targets involved have identified the MAPK cascade as a target. Expression of Delta p85 and incubation with LY294002 both inhibited IL-S-induced activation of Mek, Erk1, and Erk2, This was most pronounced during the initial phase of Erk activation. The Mek inhibitor, PD98059, blocked IL-3-driven proliferation, an effect enhanced by Delta p85 expression, suggesting that inhibition of Mek and Erks by Delta p85 contributes to the decrease in IL-3-induced proliferation in these cells but that additional pathways may also be involved. To investigate the mechanism leading to decreased activation of Erks, me investigated effects on SHP2 and Gab2, both implicated in IL-3 regulation of Erk activation. Expression of Delta p85 led to a reduction in SHP2 tyrosine phosphorylation and its ability to interact with Grb2 and Gab2 but increased overall tyrosine phosphorylation of Gab2. LY294002 did not perturb SHP2 interactions, potentially related to differences in the effects of these inhibitors on levels of phosphoinositides. These results imply that the regulation of Erks by class I, phosphoinositide 3-kinase may contribute to IL-3-driven proliferation and that both SHP2 and Gab2 are possibly involved in this regulation.	Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	University of Bath	Welham, MJ (corresponding author), Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England.	M.J.Welham@bath.ac.uk						Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Bacqueville D, 1998, BIOCHEM BIOPH RES CO, V244, P630, DOI 10.1006/bbrc.1997.7885; Bavelloni A, 2000, CELL DEATH DIFFER, V7, P112, DOI 10.1038/sj.cdd.4400591; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; FERBY IM, 1994, J BIOL CHEM, V269, P30485; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hinton HJ, 1999, J IMMUNOL, V162, P7002; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; IZOH M, 2000, MOL CELL BIOL, V20, P3695; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1995, BLOOD, V85, P343; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; WARD SG, 2000, METHODS MOL BIOL; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	75	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24274	24283		10.1074/jbc.M009098200	http://dx.doi.org/10.1074/jbc.M009098200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11335710	hybrid			2022-12-27	WOS:000169531100137
J	Cunnick, JM; Mei, L; Doupnik, CA; Wu, J				Cunnick, JM; Mei, L; Doupnik, CA; Wu, J			Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; TANDEM SH2 DOMAINS; PHOSPHATASE SH-PTP2; DOCKING PROTEIN; GRB2-ASSOCIATED BINDER-1; PHOSPHORYLATION SITES; ADAPTER PROTEIN; EGF-RECEPTOR; INSULIN	A major Grb2-associated binder-1 (Gab1) binding partner in epidermal growth factor (EGF)-stimulated cells is protein-tyrosine phosphatase (PTPase) SHP2, which contains tandem SH2 domains. The SHP2 PTPase activity is required for activation of the extracellular signal-regulated kinase (ERK) subfamily of mitogen-activated protein (MAP) kinase by EGF, To investigate the mechanism by which Gab1 and SHP2 mediate ERK activation, me characterized the Gab1-SHP2 interaction. We found that both Tyr-627 and Tyr-659 of Gab1 were required for SHP2 binding to Gab1 and for ERK2 activation by EGF, Far Western blot analysis suggested that the tandem SH2 domains of SHP2 bind to Gab1 in a specific orientation, in which the N-SH2 domain binds to phosphotyrosine (Tyr(P))-627 and the C-SH2 domain binds to Tyr(P)-659, When assayed with peptide substrates, SHP2 PTPase was activated by a bisphosphopeptide containing both Tyr(P)-627 and Tyr(P)-659, but not by monophosphopeptides containing Tyr(P)-627 or Tyr(P)-659 or a mixture of these monophosphopeptides. These results suggest that Tyr(P)-627 and Tyr(P)-659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) that binds and activates SHP2, Remarkably while a constitutively active SHPB (SHP2 DeltaN) could not rescue the defect of a SHP2-binding defective Gab1 (Gab1FF) in ERK2 activation, expression of a Gab1FF-SHP2 DeltaN chimera resulted in constitutive activation of ERK2 in transfected cells. Thus, physical association of activated SHPB with Gab1 is necessary and sufficient to mediate the ERK mitogen-activated protein kinase activation. Phosphopeptides derived from Gab1 were dephosphorylated by active SHP2 in vitro. Consistently, substrate-trapping experiments with a SHPB catalytic inactive mutant suggested that Gab1 was a SRPB PTPase substrate in the cells. Therefore, Gab1 not only is a SHPB activator but also is a target of its PTPase.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 3E, Tampa, FL 33612 USA; Univ S Florida, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Immunol & Med Microbiol, Tampa, FL 33612 USA; Univ S Florida, Dept Physiol & Biophys, Tampa, FL 33612 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Alabama System; University of Alabama Birmingham	Wu, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, MRC 3E, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Doupnik, Craig A/I-3617-2012; Wu, Jie/R-2404-2019; Mei, Lin/G-8755-2012; Cunnick, Jess/F-1715-2018	Doupnik, Craig A/0000-0002-7314-0747; Wu, Jie/0000-0002-2864-1606; 	NCI NIH HHS [R29 CA077467, CA77467] Funding Source: Medline; NINDS NIH HHS [NS40480, NS34062] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA077467, R01CA077467, R29CA077467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062, R01NS040480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HASEGAWA H, 1982, ANAL BIOCHEM, V120, P360, DOI 10.1016/0003-2697(82)90358-X; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; MEI L, 1994, J BIOL CHEM, V269, P12254; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	34	128	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24380	24387		10.1074/jbc.M010275200	http://dx.doi.org/10.1074/jbc.M010275200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323411	hybrid			2022-12-27	WOS:000169531100152
J	Diamond, TL; Kimata, J; Kim, B				Diamond, TL; Kimata, J; Kim, B			Identification of a simian immunodeficiency virus reverse transcriptase variant with enhanced replicational fidelity in the late stage of viral infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMICS IN-VIVO; GENETIC-VARIATION; ERROR SPECIFICITY; ESCHERICHIA-COLI; DRUG-RESISTANCE; DNA-SYNTHESIS; MUTATION-RATE; TYPE-1; HIV-1; POLYMERASE	Genomic hypermutation of human and simian immunodeficiency viruses (HIV and SIV) enables these viruses to adapt and escape from various types of antiviral selection by altering the molecular properties of viral gene products. In this study, we examined whether the biochemical and catalytic properties of SIV DNA polymerases (reverse transcriptases; RT) can change during the course of viral infection. For this test, we analyzed RTs obtained from two SIV clones, SIVMNE CL8 and SIVMNE 170. SIVMNE 170 was isolated during the late symptomatic phase of infection with the parental strain, SIVMNE CL8, We found these two RTs have identical DNA polymerase specific activities and kinetics with three different DNA and RNA templates. In addition, the processivity of these two SIV RT proteins mere also similar. However, as demonstrated by a misincorporation assay, the SIVMNE 170 RT showed much higher fidelity than SIVMNE CL8, The fidelity difference between these two SIV RTs was also confirmed by a steady state kinetic fidelity assay. These findings suggest that the fidelity of lentiviral RTs may change during the course of viral infection, possibly in response to alterations of host anti-viral immune capability. In addition, our sequence analysis of these two RT genes proposes possible structural strategies that the virus may employ to alter RT fidelity.	Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14672 USA; SW Fdn Biomed Res, Dept Virol & Immunol, San Antonio, TX 78245 USA	University of Rochester; Texas Biomedical Research Institute	Kim, B (corresponding author), Univ Rochester, Med Ctr, Dept Microbiol & Immunol, 601 Elmwood Ave,Box 672, Rochester, NY 14672 USA.			Kimata, Jason/0000-0002-0504-0090	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI047725, R01AI047725] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055500] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI047725, AI 47725] Funding Source: Medline; NIGMS NIH HHS [GM55500] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BATTULA N, 1974, J BIOL CHEM, V249, P4086; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Cherry E, 1997, ANTIMICROB AGENTS CH, V41, P2763, DOI 10.1128/AAC.41.12.2763; Cheynier R, 1997, AIDS RES HUM RETROV, V13, P985, DOI 10.1089/aid.1997.13.985; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; COFFIN JM, 1992, CURR TOP MICROBIOL I, V176, P156; Douglas NW, 1997, J MOL BIOL, V273, P122, DOI 10.1006/jmbi.1997.1277; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; GOUDSMIT J, 1991, FASEB J, V5, P2427, DOI 10.1096/fasebj.5.10.2065891; Hirsch VM, 1999, NAT MED, V5, P488, DOI 10.1038/8369; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; Kim B, 1997, METHODS, V12, P318, DOI 10.1006/meth.1997.0485; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; Kimata JT, 1997, J VIROL, V71, P7629, DOI 10.1128/JVI.71.10.7629-7639.1997; Kimata JT, 1999, NAT MED, V5, P535, DOI 10.1038/8414; Kimata JT, 1999, J VIROL, V73, P1655, DOI 10.1128/JVI.73.2.1655-1660.1999; KIRCHHOFF F, 1994, J VIROL, V68, P3682, DOI 10.1128/JVI.68.6.3682-3692.1994; Mansky LM, 2000, J VIROL, V74, P9532, DOI 10.1128/JVI.74.20.9532-9539.2000; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; Quinones-Mateu ME, 1998, J VIROL, V72, P9002; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; Rezende LF, 1998, J VIROL, V72, P2890, DOI 10.1128/JVI.72.4.2890-2895.1998; RUDENSEY LM, 1995, VIROLOGY, V207, P528, DOI 10.1006/viro.1995.1113; Shahs FS, 2000, J BIOL CHEM, V275, P27037; SHIODA T, 1994, J VIROL, V68, P7689, DOI 10.1128/JVI.68.12.7689-7696.1994; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; Vartanian JP, 1997, J MOL BIOL, V270, P139, DOI 10.1006/jmbi.1997.1104; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; Weiss KK, 2000, BIOCHEMISTRY-US, V39, P10684, DOI 10.1021/bi000788y; WILLIAMS KJ, 1992, CURR TOP MICROBIOL, V176, P165; Zhang LQ, 1997, AIDS RES HUM RETROV, V13, P1357, DOI 10.1089/aid.1997.13.1357	40	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23624	23631		10.1074/jbc.M102496200	http://dx.doi.org/10.1074/jbc.M102496200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11325971	hybrid			2022-12-27	WOS:000169531100054
J	Gentil, BJ; Delphin, C; Mbele, GO; Deloulme, JC; Ferro, M; Garin, J; Baudier, J				Gentil, BJ; Delphin, C; Mbele, GO; Deloulme, JC; Ferro, M; Garin, J; Baudier, J			The giant protein AHNAK is a specific target for the calcium- and zinc-binding S100B protein - Potential implications for Ca2+ homeostasis regulation by S100B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GENE AHNAK; YEAST 2-HYBRID SYSTEM; DESMOYOKIN/AHNAK PROTEIN; ALZHEIMER-DISEASE; S100-BETA PROTEIN; PLASMA-MEMBRANE; DNA-BINDING; KINASE-C; IN-VIVO; P53	Transformation of rat embryo fibroblast clone 6 cells by ras and temperature sensitive p53val(135) is reverted by ectopic expression of the calcium- and zinc-binding protein S100B. In an attempt to define the molecular basis of the S100B action, we have identified the giant phosphoprotein AHNAK as the major and most specific Ca2+ dependent S100B target protein in rat embryo fibroblast cells. We next characterized AHNAK as a major Ca2+-dependent S100B target protein in the rat glial C6 and human U-87MG astrocytoma cell lines. AHNAK binds to S100B-Sepharose beads and is also recovered in anti-S100B immunoprecipitates in a strict Ca2+- and Zn2+-dependent manner. Using truncated AHNAK fragments, we demonstrated that the domains of AHNAK responsible for interaction with S100B correspond to repeated motifs that characterize the AHNAK molecule. These motifs show no binding to calmodulin or to S100A6 and S100A11, We also provide evidence that the binding of 2 Zn2+ equivalents/mol S100B enhances Ca2+-dependent S100B-AHNAK interaction and that the effect of Zn2+. relies on Zn2+-dependent regulation of S100B affinity for Ca2+. Taking into consideration that AHNAK is a protein implicated in calcium flux regulation, we propose that the S100B-AHNAK interaction may participate in the S100B-mediated regulation of cellular Ca2+ homeostasis.	Ctr Etud Nucl Grenoble, Dept Biol Mol & Struct, INSERM EPI 0104, F-38054 Grenoble 9, France; CEN Grenoble, Lab Chim Prot DBMS CP, F-38054 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA	Baudier, J (corresponding author), Ctr Etud Nucl Grenoble, Dept Biol Mol & Struct, INSERM EPI 0104, EPI-0104,17 Rue Martyrs, F-38054 Grenoble 9, France.		GENTIL, Benoit/B-9459-2012; Baudier, Jacques/O-2183-2016; FERRO, Myriam/O-6588-2014; Deloulme, Jean Christophe/P-6858-2017; Christian, Delphin/P-9284-2017	FERRO, Myriam/0000-0002-4222-6847; Deloulme, Jean Christophe/0000-0002-2234-5865; jacques, baudier/0000-0001-8427-4444; Christian, Delphin/0000-0003-3240-8695; GENTIL, Benoit/0000-0003-2022-1890				ALLORE R, 1988, SCIENCE, V239, P1311, DOI 10.1126/science.2964086; Barber KR, 1999, J BIOL CHEM, V274, P1502, DOI 10.1074/jbc.274.3.1502; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BAUDIER J, 1986, BIOCHEMISTRY-US, V25, P6934, DOI 10.1021/bi00370a029; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; COCHRAN AJ, 1983, MELANOMA RES, V53, P325; Deloulme JC, 2000, J BIOL CHEM, V275, P35302, DOI 10.1074/jbc.M003943200; Delphin C, 1999, J BIOL CHEM, V274, P10539, DOI 10.1074/jbc.274.15.10539; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FUJI T, 1990, J BIOCHEM-TOKYO, V107, P133, DOI 10.1093/oxfordjournals.jbchem.a122996; GANNON JV, 1991, NATURE, V349, P802; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Heierhorst J, 1997, EUR J BIOCHEM, V249, P127, DOI 10.1111/j.1432-1033.1997.00127.x; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; Maler L, 1999, J BIOMOL NMR, V13, P233, DOI 10.1023/A:1008315517955; MARSHAK DR, 1981, P NATL ACAD SCI USA, V11, P6793; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; Pozdnyakov N, 1997, BIOCHEMISTRY-US, V36, P14159, DOI 10.1021/bi971792l; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Schafer BW, 2000, J BIOL CHEM, V275, P30623, DOI 10.1074/jbc.M002260200; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; Scotto C, 1999, MOL CELL BIOL, V19, P7168; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHENG JG, 1994, J NEUROSCI RES, V39, P398, DOI 10.1002/jnr.490390406; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; STANLEY LC, 1994, J NEUROPATH EXP NEUR, V53, P231, DOI 10.1097/00005072-199405000-00003; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tsoporis JN, 1998, J CLIN INVEST, V102, P1609, DOI 10.1172/JCI3077; Tsoporis JN, 1997, J BIOL CHEM, V272, P31915, DOI 10.1074/jbc.272.50.31915; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; Yang Q, 1999, EXP CELL RES, V246, P501, DOI 10.1006/excr.1998.4314; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	45	85	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23253	23261		10.1074/jbc.M010655200	http://dx.doi.org/10.1074/jbc.M010655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312263	hybrid			2022-12-27	WOS:000169531100007
J	Qi, MS; Ikematsu, S; Maeda, N; Ichihara-Tanaka, K; Sakuma, S; Noda, M; Muramatsu, T; Kadomatsu, K				Qi, MS; Ikematsu, S; Maeda, N; Ichihara-Tanaka, K; Sakuma, S; Noda, M; Muramatsu, T; Kadomatsu, K			Haptotactic migration induced by midkine - Involvement of protein-tyrosine phosphatase xi, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULE HB-GAM; CHONDROITIN SULFATE PROTEOGLYCAN; GROWTH-DIFFERENTIATION FACTOR; ACID-RESPONSIVE GENE; NEURITE OUTGROWTH; CELL-MIGRATION; ZETA/RPTP-BETA; SIGNALING PATHWAY; CARCINOMA-CELLS; BINDING	Midkine, a heparin-binding growth factor, plays a critical role in cell migration causing suppression of neointima formation in midkine-deficient mice. Here we have determined the molecules essential for midkine-induced migration. Midkine induced haptotaxis of osteoblast-like cells, which was abrogated by the soluble form of midkine or pleiotrophin, a midkine-homologous protein. Chondroitin sulfate B, E, chondroitinase ABC, B, and orthovanadate, an inhibitor of protein-tyrosine phosphatase, suppressed the migration. Supporting these data, the cells examined expressed PTP zeta, a receptor-type protein-tyrosine phosphatase that exhibits high affinity to both midkine and pleiotrophin and harbors chondroitin sulfate chains. Furthermore, strong synergism between midkine and platelet-derived growth factor in migration was detected. The use of specific inhibitors demonstrated that mitogen-activated protein (MAP) kinase and protein-tyrosine phosphatase were involved in midkine-induced haptotaxis but not PDGF-induced chemotaxis, whereas phosphatidylinositol 3 (PI3)-kinase and protein kinase C were involved in both functions. Midkine activated both PI3-kinase and MAP kinases, the latter activation was blocked by a PI3-kinase inhibitor. Midkine further recruited PTP zeta and PI3-kinase. These results indicate that PTP zeta and concerted signaling involving PI3-kinase and MAP kinase are required for midkine-induced migration and demonstrate for the first time the synergism between midkine and platelet-derived growth factor in cell migration.	Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Nagoya, Aichi 4668550, Japan; Meiji Milk Prod Co Ltd, Pharmaceut Dev Dept, Odawara, Kanagawa 2500862, Japan; Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan	Nagoya University; Meiji Holdings Co., Ltd.; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Kadomatsu, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Kadomatsu, Kenji/G-8083-2012; Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X				ANDREW JG, 1995, BONE, V16, P455; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Choudhuri R, 1997, CANCER RES, V57, P1814; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HIYAMA K, 1975, J BIOL CHEM, V250, P1824; Horiba M, 2000, J CLIN INVEST, V105, P489, DOI 10.1172/JCI7208; Imai S, 1998, J CELL BIOL, V143, P1113, DOI 10.1083/jcb.143.4.1113; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Iwashita N, 1999, BURNS, V25, P119, DOI 10.1016/S0305-4179(98)00120-X; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 1997, BRIT J CANCER, V75, P354, DOI 10.1038/bjc.1997.58; Kaneda N, 1996, J BIOCHEM-TOKYO, V119, P1150; Kaneda N, 1996, BIOCHEM BIOPH RES CO, V220, P108, DOI 10.1006/bbrc.1996.0365; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; Kurosawa N, 2000, EUR J BIOCHEM, V267, P344, DOI 10.1046/j.1432-1327.2000.01005.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MICHELACCI YM, 1975, BIOCHEM J, V151, P121, DOI 10.1042/bj1510121; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; Nakanishi T, 1997, J BIOCHEM-TOKYO, V121, P197; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; Nishiwaki T, 1998, J BIOCHEM-TOKYO, V123, P458; Obama H, 1998, ANTICANCER RES, V18, P145; Ohta S, 1999, J BONE MINER RES, V14, P1132, DOI 10.1359/jbmr.1999.14.7.1132; Rameshwar P, 1997, J IMMUNOL, V158, P3417; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; Revest JM, 1999, EUR J NEUROSCI, V11, P1134, DOI 10.1046/j.1460-9568.1999.00521.x; Rigot V, 1998, J CELL SCI, V111, P3119; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Sumi Y, 2000, J BIOCHEM-TOKYO, V127, P247, DOI 10.1093/oxfordjournals.jbchem.a022601; Takada T, 1997, J BIOCHEM-TOKYO, V122, P453; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUKAMOTO T, 1991, BIOCHEM BIOPH RES CO, V175, P745, DOI 10.1016/0006-291X(91)91629-Q; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693; YOSHIDA Y, 1995, DEV BRAIN RES, V85, P25, DOI 10.1016/0165-3806(94)00183-Z; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	60	132	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15868	15875		10.1074/jbc.M005911200	http://dx.doi.org/10.1074/jbc.M005911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340082	hybrid			2022-12-27	WOS:000168623100041
J	Rappsilber, J; Ajuh, P; Lamond, AI; Mann, M				Rappsilber, J; Ajuh, P; Lamond, AI; Mann, M			SPF30 is an essential human splicing factor required for assembly of the U4/U5/U6 tri-small nuclear ribonucleoprotein into the spliceosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; DISEASE GENE-PRODUCT; MASS-SPECTROMETRY; U2 SNRNP; POLYACRYLAMIDE GELS; SEQUENCE DATABASES; COILED BODIES; U4/U6 SNRNP; BRANCH SITE; 2'-OME RNA	Spliceosome assembly involves the sequential recruitment of small nuclear ribonucleoproteins (snRNPs) onto a pre-mRNA substrate. Although several non-snRNP proteins function during the binding of U1 and U2 snRNP's, little is known about the subsequent binding of the U4/U5/U6 tri-snRNP. A recent proteomic analysis of the human spliceosome identified SPF30 (Neubauer, G., King, A., Rappsilber, J., Calvio, C., Watson, M., Ajuh, P., Sleeman, J., Lamond, A., and Mann, M. (1998) Nat. Genet. 20, 46-50), a homolog of the survival of motor neurons (SMN) protein, as a spliceosome factor. We show here that SPF30 is a nuclear protein that associates with both U4/U5/U6 and U2 snRNP components. In the absence of SPF30, the preformed tri-snRNP fails to assemble into the spliceosome. Mass spectrometric analysis shows that a recombinant glutathione S-transferase-SPF30 fusion protein associates with complexes containing core Sm and U4/U5/U6 tri-snRNP proteins when added to HeLa nuclear extract, most strongly to U4/U6-90. The data indicate that SPF30 is an essential human splicing factor that may act to dock the U4/U5/U6 tri-snRNP to the A complex during spliceosome assembly or, alternatively, may act as a late assembly factor in both the tri-snRNP and the A-complex.	Univ So Denmark, Prot Interact Lab, DK-5230 Odense M, Denmark; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	University of Southern Denmark; European Molecular Biology Laboratory (EMBL); University of Dundee	Mann, M (corresponding author), Univ So Denmark, Prot Interact Lab, Campusvej 55, DK-5230 Odense M, Denmark.	mann@bmb.sdu.dk	Mann, Matthias/A-3454-2013; Rappsilber, Juri/B-7265-2015; Rappsilber, Juri/ABF-3328-2020	Mann, Matthias/0000-0003-1292-4799; Rappsilber, Juri/0000-0001-5999-1310; Lamond, Angus/0000-0001-6204-6045				ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; Arning S, 1996, RNA, V2, P794; Ayadi L, 1997, RNA, V3, P197; BACH M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P139, DOI 10.1016/0167-4781(91)90164-H; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BARABINO SML, 1990, CELL, V63, P293, DOI 10.1016/0092-8674(90)90162-8; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; Bertrandy S, 1999, HUM MOL GENET, V8, P775, DOI 10.1093/hmg/8.5.775; BLANTON S, 1992, MOL CELL BIOL, V12, P3939, DOI 10.1128/MCB.12.9.3939; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; Bohmann K, 1995, J CELL SCI, P107; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; Fetzer S, 1997, RNA, V3, P344; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FU XD, 1995, RNA, V1, P663; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; Gee S, 1997, P NATL ACAD SCI USA, V94, P11803, DOI 10.1073/pnas.94.22.11803; Gottschalk A, 1999, EMBO J, V18, P4535, DOI 10.1093/emboj/18.16.4535; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; HABETS WJ, 1989, J IMMUNOL, V143, P2560; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAMER A, 1991, EMBO J, V10, P1503, DOI 10.1002/j.1460-2075.1991.tb07670.x; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kuster B, 2001, PROTEOMICS, V1, P641; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, HUM MOL GENET, V7, P1269, DOI 10.1093/hmg/7.8.1269; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; Lygerou Z, 1999, MOL CELL BIOL, V19, P2008; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Meister G, 2001, EMBO J, V20, P2304, DOI 10.1093/emboj/20.9.2304; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Nishikimi A, 1999, BBA-PROTEIN STRUCT M, V1435, P147, DOI 10.1016/S0167-4838(99)00203-4; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; ROSCIGNO RF, 1995, RNA, V1, P692; RYDER U, 1990, NUCLEIC ACIDS RES, V18, P7373, DOI 10.1093/nar/18.24.7373; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shichijo S, 1998, J EXP MED, V187, P277, DOI 10.1084/jem.187.3.277; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; Talbot K, 1998, HUM MOL GENET, V7, P2149, DOI 10.1093/hmg/7.13.2149; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	74	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31142	31150		10.1074/jbc.M103620200	http://dx.doi.org/10.1074/jbc.M103620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11331295	hybrid			2022-12-27	WOS:000170472900073
J	Langland, G; Kordich, J; Creaney, J; Goss, KH; Lillard-Wetherell, K; Bebenek, K; Kunkel, TA; Groden, J				Langland, G; Kordich, J; Creaney, J; Goss, KH; Lillard-Wetherell, K; Bebenek, K; Kunkel, TA; Groden, J			The Bloom's syndrome protein (BLM) interacts with MLH1 but is not required for DNA mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; SACCHAROMYCES-CEREVISIAE; HOLLIDAY JUNCTIONS; TOPOISOMERASE-III; HELICASE ACTIVITY; SYNDROME CELLS; REPLICATION; RECOMBINATION; ASSOCIATION	Bloom's syndrome (BS) is a rare autosomal recessive disorder characterized by pre- and postnatal growth deficiency, immunodeficiency, and a tremendous predisposition to a wide variety of cancers. Cells from BS individuals are characterized by a high incidence of chromosomal gaps and breaks, elevated sister chromatid exchange, quadriradial formations, and locus-specific mutations. BS is the consequence of mutations that lead to loss of function of BLM, a gene encoding a helicase with homology to the RecQ helicase family. To delineate the role of BLM in DNA replication, recombination, and repair we used a yeast two-hybrid screen to identify potential protein partners of the BLM helicase. The C terminus of BLM interacts directly with MLH1 in the yeast-two hybrid assay; far Western analysis and co-immunoprecipitations confirmed the interaction. Cell extracts deficient in BLM were competent for DNA mismatch repair. These data suggest that the BLM helicase and MLH1 function together in replication, recombination, or DNA repair events independent of single base mismatch repair.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Cincinnati, OH 45267 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	University System of Ohio; University of Cincinnati; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Groden, J (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.		Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788; Goss, Kathleen/0000-0002-7379-5639	NCI NIH HHS [CA59268-06A1, CA63507] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063507, R29CA063507, T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, Z01ES065089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Chakraverty RK, 1999, BIOESSAYS, V21, P286; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, J CELL SCI, V113, P2641; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GERMAN J, 1995, DERMATOL CLIN, V13, P7, DOI 10.1016/S0733-8635(18)30101-3; GRODEN J, 1990, P NATL ACAD SCI USA, V87, P4315, DOI 10.1073/pnas.87.11.4315; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Johnson FB, 2000, CANCER RES, V60, P1162; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; LONN U, 1990, CANCER RES, V50, P3141; Marsischky GT, 1999, J BIOL CHEM, V274, P7200, DOI 10.1074/jbc.274.11.7200; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Watt PM, 1996, GENETICS, V144, P935; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	29	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30031	30035		10.1074/jbc.M009664200	http://dx.doi.org/10.1074/jbc.M009664200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11325959	hybrid			2022-12-27	WOS:000170558000057
J	Lin, JQ; Hutchinson, L; Gaston, SM; Raab, G; Freeman, MR				Lin, JQ; Hutchinson, L; Gaston, SM; Raab, G; Freeman, MR			BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor - A unique role for proHB-EGF in cell survival regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; APOPTOTIC PROTEIN BAG-1; DEATH ACTIVITY; EXPRESSION; ALPHA; PROLIFERATION; ACTIVATION; CLONING; RAP46; BCL-2	Several cell functions related to growth and survival regulation have been attributed specifically to the membrane form of heparin-binding EGF-like growth factor (proHB-EGF), rather than to the diffusible, processed HB-EGF isoform. These findings suggest the existence of a functional binding partner specifically for the membrane form of the growth factor. In this study we have identified the prosurvival cochaperone, BAG-1, as a protein that interacts with the cytoplasmic tail domain of proHB-EGF. Interaction between BAG-1 and the 24-amino acid proHB-EGF cytoplasmic tail was initially identified in a yeast two-hybrid screen and was confirmed in mammalian cells. The proHB-EGF tail bound BAG-1 in an hsp70-independent manner and within a 97-amino acid segment that includes the ubiquitin homology domain in BAG-1 but does not include the hsp70 binding site. Effects of BAG-1 and proHB-EGF co-expression were demonstrated in cell adhesion and cell survival assays and in quantitative assays of regulated secretion of soluble HB-EGF. Because the BAG-1 binding site is not present on the mature, diffusible form of the growth factor, these findings suggest a new mechanism by which proHB-EGF, in isolation from the diffusible form, can mediate cell signaling events. In addition, because effects of BAG-1 on regulated secretion of soluble I-IB-EGF were also identified, this interaction has the potential to alter the signaling capabilities of both the membrane-anchored and the diffusible forms of the growth factor.	Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Urol, Boston, MA 02115 USA; Childrens Hosp, Surg Res Lab, Boston, MA 02115 USA; Childrens Hosp, Urol Lab, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Freeman, MR (corresponding author), Enders Res Labs, Rm 1161,300 Longwood Ave, Boston, MA 02115 USA.		Gaston, Sandra/AAN-4088-2021		NATIONAL CANCER INSTITUTE [R01CA077386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057691, R01DK047556] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77386] Funding Source: Medline; NIDDK NIH HHS [R01 DK47556, R01 DK57691] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Lin JQ, 1999, CANCER RES, V59, P2891; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Naishiro Y, 1999, ONCOGENE, V18, P3244, DOI 10.1038/sj.onc.1202661; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Raab G, 1996, DEVELOPMENT, V122, P637; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Takemura T, 1997, J BIOL CHEM, V272, P31036, DOI 10.1074/jbc.272.49.31036; Takemura T, 1999, KIDNEY INT, V55, P71, DOI 10.1046/j.1523-1755.1999.00259.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang JY, 1998, J BIOL CHEM, V273, P20525, DOI 10.1074/jbc.273.32.20525; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	29	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30127	30132		10.1074/jbc.M010237200	http://dx.doi.org/10.1074/jbc.M010237200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11340068	hybrid			2022-12-27	WOS:000170558000071
J	Denk, A; Goebeler, M; Schmid, S; Berberich, I; Ritz, O; Lindemann, D; Ludwig, S; Wirth, T				Denk, A; Goebeler, M; Schmid, S; Berberich, I; Ritz, O; Lindemann, D; Ludwig, S; Wirth, T			Activation of NF-kappa B via the I kappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; E-SELECTIN; IKK-ALPHA; TRANSCRIPTIONAL ACTIVATION; BETA; A20; INHIBITION; PHOSPHORYLATION; EPSILON; ADHESION	Activation of the transcription factor NF-kappaB is necessary for full expression of tumor necrosis factor alpha (TNF-alpha)-inducible endothelial chemokines and adhesion molecules. However, a detailed analysis regarding contribution of the different NF-kappaB upstream components to endothelial activation has not been performed yet. We employed a retroviral infection approach to stably express transdominant (TD) mutants of I kappaB alpha, I kappaB beta, or I kappaB epsilon and dominant negative (dn) versions of I kappaB kinases (IKK) 1 or 2 as well as a constitutively active version of IKK2 in human endothelial cells. TD I kappaB alpha, I kappaB beta, and I kappaB epsilon were not degraded upon TNF-alpha exposure, and each prevented NF-kappaB activation. These TD I kappaB mutants almost completely inhibited the induction of monocyte chemoattractant protein-1, interleukin-8, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression by TNF-alpha, whereas interferon-gamma -mediated up-regulation of intercellular adhesion molecule-1 and HLA-DR was not affected. Expression of dn IKK2 completely blocked TNF-alpha -induced up-regulation, whereas dn IKK1 showed a partial inhibition of expression of these molecules. Importantly, expression of constitutively active IKK2 was sufficient to drive full expression of all chemokines and adhesion molecules in the absence of cytokine. We conclude that the IKK/I kappaB/NF-kappaB pathway is crucial and sufficient for proinflammatory activation of endothelium.	Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Wuerzburg Univ, Dept Dermatol, D-97078 Wuerzburg, Germany; Wuerzburg Univ, Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wuerzburg, Germany; Wuerzburg Univ, Inst Virol & Immunol, D-97078 Wuerzburg, Germany	Ulm University; University of Wurzburg; University of Wurzburg; University of Wurzburg	Wirth, T (corresponding author), Univ Ulm, Dept Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany.		Goebeler, Matthias/F-7118-2013; Lindemann, Dirk/H-5857-2013; Goebeler, Matthias/P-3612-2019; Wirth, Thomas/X-7172-2019	Lindemann, Dirk/0000-0002-0320-4223; Ludwig, Stephan/0000-0003-4490-3052				Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; CHEN CC, 1995, J IMMUNOL, V155, P3538; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Ebnet K, 1999, HISTOCHEM CELL BIOL, V112, P1, DOI 10.1007/s004180050387; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Goodman DJ, 1996, TRANSPLANTATION, V62, P967, DOI 10.1097/00007890-199610150-00016; Grignani F, 1998, CANCER RES, V58, P14; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; LEMBECHER T, 1993, NATURE, V365, P767; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Min W, 1997, J IMMUNOL, V159, P3508; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; VANHUIJSDUIJNEN RH, 1993, NUCLEIC ACIDS RES, V21, P3711, DOI 10.1093/nar/21.16.3711; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	43	174	183	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28451	28458		10.1074/jbc.M102698200	http://dx.doi.org/10.1074/jbc.M102698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11337506	hybrid			2022-12-27	WOS:000170093400094
J	Neufeld, EB; Remaley, AT; Demosky, SJ; Stonik, JA; Cooney, AM; Comly, M; Dwyer, NK; Zhang, M; Blanchette-Mackie, J; Santamarina-Fojo, S; Brewer, HB				Neufeld, EB; Remaley, AT; Demosky, SJ; Stonik, JA; Cooney, AM; Comly, M; Dwyer, NK; Zhang, M; Blanchette-Mackie, J; Santamarina-Fojo, S; Brewer, HB			Cellular localization and trafficking of the human ABCA1 transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; CHOLESTEROL EFFLUX; PLASMA-MEMBRANE; BREFELDIN-A; CELLS; REMOVAL; FIBROBLASTS	ABCA1, the ATP-binding cassette protein,mutated in Tangier disease, mediates the efflux of,excess cellular sterol to apoA-I and thereby the formation of high density lipoprotein. The intracellular localization and trafficking of ABCA1 was examined in stably and transiently transfected HeLa cells expressing a functional human ABCA1-green fluorescent protein (GFP) fusion protein. The fluorescent chimeric ABCA1 transporter was found to reside on the cell surface and on intracellular vesicles that include a novel subset of early endosomes, as well as late endosomes and lysosomes, Studies of the localization and trafficking of ABCA1-GFP in the presence of brefeldin A or monensin, agents known to block intracellular vesicular trafficking as well as apoA-I-mediated cellular lipid efflux, showed that: (i) ABCA1 functions in lipid efflux at the cell surface, and (ii) delivery of ABCA1 to lysosomes for degradation may serve as a mechanism to modulate its surface expression. Time-lapse fluorescence microscopy revealed that ABCA1-GFP-containing early endosomes undergo fusion, fission,: and tubulation and transiently interact with one another, late endocytic vesicles, and the cell surface, These studies establish a complex intracellular trafficking pathway for human ABCA1 that may play important roles in modulating ABCA1 transporter activity and cellular cholesterol homeostasis.	NHLBI, NIH, Bethesda, MD 20892 USA; NIDDK, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Neufeld, EB (corresponding author), NHLBI, NIH, 10-7N115,10 Ctr Dr, Bethesda, MD 20892 USA.		Neufeld, Edward/R-3819-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, ZIADK060003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Assmann G, 2001, METABOLIC MOL BASES, P2937; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GHOSH RN, 1994, J CELL SCI, V107, P2177; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Heeren J, 1999, J CELL SCI, V112, P349; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; LISCUM L, 1989, J BIOL CHEM, V264, P11796; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mendez AJ, 1997, J LIPID RES, V38, P1807; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Zhang F, 2000, J BIOL CHEM, V275, P23287, DOI 10.1074/jbc.M001819200; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200; Zhou CJ, 2001, J NEUROSCI, V21, P849, DOI 10.1523/JNEUROSCI.21-03-00849.2001	36	269	272	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27584	27590		10.1074/jbc.M103264200	http://dx.doi.org/10.1074/jbc.M103264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11349133	hybrid			2022-12-27	WOS:000169966900112
J	Burchett, SA; Scott, A; Errede, B; Dohlman, HG				Burchett, SA; Scott, A; Errede, B; Dohlman, HG			Identification of novel pheromone-response regulators through systematic overexpression of 120 protein kinases in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; SACCHAROMYCES-CEREVISIAE; MATING PHEROMONE; FEEDBACK PHOSPHORYLATION; MUTATIONAL ANALYSIS; INVASIVE GROWTH; FACTOR RECEPTOR; TRANSCRIPTION; STE12	Protein kinases are well known to transmit and regulate signaling pathways. To identify additional regulators of the pheromone signaling apparatus in yeast, we evaluated an array of 120 likely protein kinases encoded by the yeast genome. Each kinase was fused to glutathione S-transferase, overexpressed, and tested for changes in pheromone responsiveness in vivo, As expected, several known components of the pathway (YCK1, STE7 STE11, FUS3, and KSS1) impaired the growth arrest response. Seven other kinases also interfered with pheromone-induced growth arrest; in rank order they are as follows: YKL116c (renamed PRR1) = YDL214c (renamed PRR2) > YJL141c (YAK1, SRA1) > YNR047w = YCR091w (KIN82) = YIL095w (PRK1) > YCL024w (KCC4). Inhibition of pheromone signaling by PRR1, but not PRR2, required the glutathione S-transferase moiety, Both kinases inhibited gene transcription after stimulation with pheromone, a constitutively active kinase mutant STE11-4, or overexpression of the transcription factor STE12. Neither protein altered the ability of the mitogen-activated protein kinase (MAPK) Fus3 to feedback phosphorylate a known substrate, the MAPK kinase Ste7, These results reveal two new components of the pheromone-signaling cascade in yeast, each acting at a point downstream of the MAPK.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, New Haven, CT 06536 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Yale University; University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pharmacol, 295 Congress Ave,Rm 436,POB 9812, New Haven, CT 06536 USA.	henrik.dohlman@yale.edu		Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039852, R01GM059167, R29GM055316, R01GM055316] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39852, GM55316, R01 GM059167, R01 GM055316, GM59167] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; Baur M, 1997, MOL CELL BIOL, V17, P4330, DOI 10.1128/MCB.17.8.4330; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dohlman HG, 1998, SEMIN CELL DEV BIOL, V9, P135, DOI 10.1006/scdb.1998.0218; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Farley FW, 1999, GENETICS, V151, P1425; Feng Y, 2000, MOL CELL BIOL, V20, P5350, DOI 10.1128/MCB.20.14.5350-5359.2000; Feng Y, 2000, MOL CELL BIOL, V20, P563, DOI 10.1128/MCB.20.2.563-574.2000; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Haynes PA, 2000, YEAST, V17, P81, DOI 10.1002/1097-0061(20000630)17:2<81::AID-YEA22>3.3.CO;2-Q; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Inouye C, 1997, GENETICS, V147, P479; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Mitchell DA, 2001, MOL CELL BIOL, V21, P488, DOI 10.1128/MCB.21.2.488-500.2001; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Olson KA, 2000, MOL CELL BIOL, V20, P4199, DOI 10.1128/MCB.20.12.4199-4209.2000; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PRINTEN JA, 1994, GENETICS, V138, P609; SENGUPTA P, 1990, MOL CELL BIOL, V10, P6809, DOI 10.1128/MCB.10.12.6809; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; SONG OK, 1991, GENE DEV, V5, P741, DOI 10.1101/gad.5.5.741; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yesilaltay A, 2000, MOL BIOL CELL, V11, P2873, DOI 10.1091/mbc.11.9.2873; YUAN YLO, 1993, GENE DEV, V7, P1584, DOI 10.1101/gad.7.8.1584; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	66	14	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26472	26478		10.1074/jbc.M103436200	http://dx.doi.org/10.1074/jbc.M103436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337509	hybrid, Green Published			2022-12-27	WOS:000169823300109
J	Raman, CS; Li, HY; Martasek, P; Babu, BR; Griffith, OW; Masters, BSS; Poulos, TL				Raman, CS; Li, HY; Martasek, P; Babu, BR; Griffith, OW; Masters, BSS; Poulos, TL			Implications for isoform-selective inhibitor design derived from the binding mode of bulky isothioureas to the heme domain of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; POTENT; PTERIN; MECHANISM; PARADIGM; CYCLASE; OXYGEN; SYSTEM; ENZYME; DIMER	Nitric oxide produced by nitric-oxide synthase (NOS) is not only involved in a wide range of physiological functions but also in a variety of pathological conditions, Isoform-selective NOS inhibitors are highly desirable to regulate the NO production of one isoform beneficial to normal physiological functions from. the uncontrolled NO production of another isoform that accompanies certain pathological states. Crystal structures of the heme domain of the three NOS isoforms have revealed a very high degree of similarity in the immediate vicinity of the heme active site illustrating the challenge of isoform-selective inhibitor design, Isothioureas are potent NOS inhibitors, and the structures of the endothelial NOS heme domain complexed with isothioureas bearing small S-alkyl substituents have been determined (Li, H,, Raman, C,S,, Martasek, P,, Kral, V., Masters, B.S.S., and Poulos, T.L. (2000) J. Inorg. Biochem, 81, 133-139), In the present communication, the binding mode of larger bisisothioureas complexed to the endothelial NOS heme domain has been determined, These structures afford a structural rationale for the known inhibitory activities, In addition, these structures provide clues on how to exploit the longer inhibitor substituents that extend out of the active site pocket for isoform-selective inhibitor design.	Univ Calif Irvine, Dept Molec Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Program Macromol Struct, Irvine, CA 92697 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Texas System; University of Texas Health San Antonio; Medical College of Wisconsin	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Molec Biol & Biochem, Irvine, CA 92697 USA.		Martásek, Pavel/G-6622-2017	Martásek, Pavel/0000-0001-6165-4444; Raman, C. S./0000-0002-1036-3193	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419, R01GM057353] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48423] Funding Source: Medline; NIGMS NIH HHS [GM52419, GM 57353] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babu BR, 1998, CURR OPIN CHEM BIOL, V2, P491, DOI 10.1016/S1367-5931(98)80125-7; Babu BR, 1999, J BIOL CHEM, V274, P25218, DOI 10.1074/jbc.274.36.25218; BABU BR, 1999, 6 INT M BIOL NITR OX, P145; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Collins JL, 1998, J MED CHEM, V41, P2858, DOI 10.1021/jm980072p; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Huang H, 1999, J MED CHEM, V42, P3147, DOI 10.1021/jm990111c; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Li HY, 2000, J INORG BIOCHEM, V81, P133, DOI 10.1016/S0162-0134(00)00099-4; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MAYER B, 1989, BIOCHEM BIOPH RES CO, V164, P678, DOI 10.1016/0006-291X(89)91513-1; Mayer B, 1998, N-S ARCH PHARMACOL, V358, P127, DOI 10.1007/PL00005233; MONCADA S, 1991, PHARMACOL REV, V43, P109; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Reif DW, 2000, FREE RADICAL BIO MED, V28, P1470, DOI 10.1016/S0891-5849(00)00250-1; Shearer BG, 1997, J MED CHEM, V40, P1901, DOI 10.1021/jm960785c; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Zhang ZG, 1996, J CEREBR BLOOD F MET, V16, P599, DOI 10.1097/00004647-199607000-00009	31	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26486	26491		10.1074/jbc.M102255200	http://dx.doi.org/10.1074/jbc.M102255200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331290	hybrid			2022-12-27	WOS:000169823300111
J	Qu, W; Bradbury, JA; Tsao, CC; Maronpot, R; Harry, GJ; Parker, CE; Davis, LS; Breyer, MD; Waalkes, MP; Falck, JR; Chen, JY; Rosenberg, RL; Zeldin, DC				Qu, W; Bradbury, JA; Tsao, CC; Maronpot, R; Harry, GJ; Parker, CE; Davis, LS; Breyer, MD; Waalkes, MP; Falck, JR; Chen, JY; Rosenberg, RL; Zeldin, DC			Cytochrome P450CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; ARTERIAL SMOOTH-MUSCLE; RAT-BRAIN; EPOXYEICOSATRIENOIC ACIDS; MOLECULAR-CLONING; CDNA CLONING; 5,6-EPOXYEICOSATRIENOIC ACID; MONOOXYGENASE ACTIVITIES; MULTIPLE FORMS; MESSENGER-RNA	A cDNA encoding a new cytochrome P450 was isolated from a mouse brain library. Sequence analysis reveals that this 1,958-base pair cDNA encodes a 57-58-kDa 502-amino acid polypeptide that is 70-91% identical to CYP2J subfamily P450s and is designated CYP2J9. Recombinant CYP2J9 was co-expressed with NADPH-cytochrome P450 oxidoreductase (CYPOR) in Sf9 cells using a baculovirus system. Microsomes of CYP2J9/CYPOR-transfected cells metabolize arachidonic acid to 19-hydroxyeicosatetraenoic acid (HETE) thus CYP2J9 is enzymologically distinct from other P450s. Northern analysis reveals that CYP2J9 transcripts are present at high levels in mouse brain. Mouse brain microsomes biosynthesize 19-HETE. RNA polymerase chain reaction analysis demonstrates that CYP2J9 mRNAs are widely distributed in brain and most abundant in the cerebellum. Immunoblotting using an antibody raised against human CYP2J2 that cross-reacts with CYP2J9 detects a 56-kDa protein band that is expressed in cerebellum and other brain segments and is regulated during postnatal development. In situ hybridization of mouse brain sections with a CYP2J9-specific riboprobe and immunohistochemical staining with the anti-human CYP2J2 IgG reveals abundant CYP2J9 mRNA and protein in cerebellar Purkinje cells. Importantly, 19-HETE inhibits the activity of recombinant P/Q-type Ca2+ channels that are known to be expressed preferentially in cerebellar Purkinje cells and are involved in triggering neurotransmitter release. Based on these data, we conclude that CYP2J9 is a developmentally regulated P450 that is abundant in brain, localized to cerebellar Purkinje cells, and active in the biosynthesis of 19-HETE, an eicosanoid that inhibits activity of P/Q-type Ca2+ channels. We postulate that CYP2J9 arachidonic acid products play important functional roles in the brain.	NIEHS, Pulm Pathobiol Lab, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; NIEHS, Inorgan Carcinogensis Sect, NCI, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of North Carolina; University of North Carolina Chapel Hill	Zeldin, DC (corresponding author), NIEHS, Pulm Pathobiol Lab, Div Intramural Res, NIH, Bldg 101,Rm D236,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Harry, Gaylia Jean/AAC-1171-2022; Zeldin, Darryl C/Y-7091-2018	Harry, Gaylia Jean/0000-0002-0829-7318; Zeldin, Darryl C/0000-0002-2087-7307; Breyer, Matthew/0000-0003-1880-371X; Falck, John/0000-0002-9219-7845	NHLBI NIH HHS [HL49449] Funding Source: Medline; NIDDK NIH HHS [P01-DK38226] Funding Source: Medline; NIGMS NIH HHS [GM-31278] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES021164, Z01ES025041, Z01ES050106, Z01ES021164, Z01ES025034, ZIAES025043, ZIAES025034, ZIAES025041, Z01ES025044, Z01ES025043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkayed NJ, 1996, STROKE, V27, P971, DOI 10.1161/01.STR.27.5.971; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Bhagwat SV, 2000, BIOCHEM PHARMACOL, V59, P573, DOI 10.1016/S0006-2952(99)00362-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREYER MD, 1993, KIDNEY INT, V44, P1372, DOI 10.1038/ki.1993.391; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Carroll MA, 1996, AM J PHYSIOL-REG I, V271, pR863, DOI 10.1152/ajpregu.1996.271.4.R863; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; Chen JY, 1999, MOL PHARMACOL, V55, P288, DOI 10.1124/mol.55.2.288; CLARE RA, 1991, J CHROMATOGR-BIOMED, V562, P237, DOI 10.1016/0378-4347(91)80581-V; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; ESCALANTE B, 1993, J CARDIOVASC PHARM, V22, pS106, DOI 10.1097/00005344-199322002-00034; ESCALANTE B, 1993, EUR J PHARMACOL, V235, P1, DOI 10.1016/0014-2999(93)90812-V; FALCK JR, 1983, BIOCHEM BIOPH RES CO, V114, P743, DOI 10.1016/0006-291X(83)90843-4; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; Gebremedhin D, 1998, J PHYSIOL-LONDON, V507, P771, DOI 10.1111/j.1469-7793.1998.771bs.x; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; Harder DR, 1998, STROKE, V29, P229, DOI 10.1161/01.STR.29.1.229; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Hua JY, 1995, TOXICOLOGY, V104, P83, DOI 10.1016/0300-483X(95)03143-4; JUNIER MP, 1990, ENDOCRINOLOGY, V126, P1534, DOI 10.1210/endo-126-3-1534; Kawashima H, 1995, BIOCHEM BIOPH RES CO, V217, P1137, DOI 10.1006/bbrc.1995.2887; Kawashima H, 1996, J BIOL CHEM, V271, P28176, DOI 10.1074/jbc.271.45.28176; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; KOMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P721, DOI 10.1006/bbrc.1993.2309; LAETHEM RM, 1992, J PHARMACOL EXP THER, V262, P433; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; LEE CA, 1995, ARCH BIOCHEM BIOPHYS, V319, P157, DOI 10.1006/abbi.1995.1278; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Luo G, 1998, ARCH BIOCHEM BIOPHYS, V357, P45, DOI 10.1006/abbi.1998.0806; Ma JX, 1999, J BIOL CHEM, V274, P17777, DOI 10.1074/jbc.274.25.17777; MANNA S, 1983, TETRAHEDRON LETT, V24, P33, DOI 10.1016/S0040-4039(00)81319-2; McFadyen MCE, 1998, BIOCHEM PHARMACOL, V55, P825, DOI 10.1016/S0006-2952(97)00516-9; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; NASLUND BMA, 1988, MOL PHARMACOL, V33, P31; NEGROVILAR A, 1985, ENDOCRINOLOGY, V116, P2663, DOI 10.1210/endo-116-6-2663; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Nguyen X, 1999, AM J PHYSIOL-REG I, V276, pR1691; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; NORRIS PJ, 1994, NEUROSCIENCE, V61, P331, DOI 10.1016/0306-4522(94)90235-6; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OLIW EH, 1990, J CHROMATOGR-BIOMED, V526, P525, DOI 10.1016/S0378-4347(00)82534-7; OMURA T, 1964, J BIOL CHEM, V239, P2370; Petratos S, 2000, DEV BRAIN RES, V123, P81, DOI 10.1016/S0165-3806(00)00076-6; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; Riedl AG, 2000, SYNAPSE, V38, P392, DOI 10.1002/1098-2396(20001215)38:4<392::AID-SYN4>3.0.CO;2-Z; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; SAKAIRI Y, 1995, AM J PHYSIOL-RENAL, V268, pF931, DOI 10.1152/ajprenal.1995.268.5.F931; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scarborough PE, 1999, DRUG METAB REV, V31, P205, DOI 10.1081/DMR-100101915; Schilter B, 2000, J PHARMACOL EXP THER, V294, P916; SMITH SJ, 1985, P NATL ACAD SCI USA, V82, P622, DOI 10.1073/pnas.82.2.622; SNYDER GD, 1983, P NATL ACAD SCI-BIOL, V80, P3504, DOI 10.1073/pnas.80.11.3504; SNYDER GD, 1989, AM J PHYSIOL, V265, pE221; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; Thompson CM, 2000, J PHARMACOL EXP THER, V294, P1120; Tirumalai PS, 1998, BIOCHEM PHARMACOL, V56, P371, DOI 10.1016/S0006-2952(98)00036-7; Upadhya SC, 2000, ARCH BIOCHEM BIOPHYS, V373, P23, DOI 10.1006/abbi.1999.1477; WARNER M, 1993, J STEROID BIOCHEM, V47, P191, DOI 10.1016/0960-0760(93)90074-7; White JA, 2000, P NATL ACAD SCI USA, V97, P6403, DOI 10.1073/pnas.120161397; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; Zhang QY, 1997, ARCH BIOCHEM BIOPHYS, V340, P270, DOI 10.1006/abbi.1997.9922; ZOU A, 2000, AM J PHYSIOL, V278, pL335; Zou AP, 1996, AM J PHYSIOL-RENAL, V270, pF822, DOI 10.1152/ajprenal.1996.270.5.F822; Zou AP, 1996, AM J PHYSIOL-REG I, V270, pR228, DOI 10.1152/ajpregu.1996.270.1.R228	77	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25467	25479		10.1074/jbc.M100545200	http://dx.doi.org/10.1074/jbc.M100545200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328810	hybrid			2022-12-27	WOS:000169800700137
J	Shafirovich, V; Dourandin, A; Huang, WD; Geacintov, NE				Shafirovich, V; Dourandin, A; Huang, WD; Geacintov, NE			The carbonate radical is a site-selective oxidizing agent of guanine in double-stranded oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER FLASH-PHOTOLYSIS; AQUEOUS-SOLUTION; ELECTRON-TRANSFER; NITRIC-OXIDE; EPR-DETECTION; CU,ZN-SUPEROXIDE DISMUTASE; 2-PHOTON PHOTOIONIZATION; TYROSINE NITRATION; REACTIVE OXYGEN; RATE CONSTANTS	The carbonate radical anion (CO3.-) is believed to be an important intermediate oxidant derived from the oxidation of bicarbonate anions and nitrosoperoxocarboxylate anions (formed in the reaction of CO2 with ONOO-) in cellular environments. Employing nanosecond laser flash photolysis methods, we show that the CO3.- anion can selectively oxidize guanines in the self-complementary oligonucleotide duplex d(AACGCGAATTCGCGTT) dissolved in air-equilibrated aqueous buffer solution (pH 7.5), In these time-resolved transient absorbance experiments, the CO3.- radicals are generated by one-electron oxidation of the bicarbonate anions (HCO3-) with sulfate radical anions (SO4.-) that, in turn, are derived from the photodissociation of persulfate anions (S2O82-) initiated by 308-nm XeCl excimer laser pulse excitation. The kinetics of the CO3.- anion and neutral guanine radicals, G(-H)(.), arising from the rapid deprotonation of the guanine radical cation, are monitored via their transient absorption spectra (characteristic maxims at 600 and 315 nm, respectively) on time scales of microseconds to seconds. The bimolecular rate constant of oxidation of guanine in this oligonucleotide duplex by CO3.- is (1.9 +/- 0.2) x 10(7) M-1 s(-1). The decay of the CO3.- anions and the formation of G(-H)(.) radicals are correlated with one another on the millisecond time scale, whereas the neutral guanine radicals decay on time scales of seconds. Alkali-labile guanine lesions are produced and are revealed by treatment of the irradiated oligonucleotides in hot piperidine solution. The DNA fragments thus formed are identified by a standard polyacrylamide gel electrophoresis assay, showing that strand cleavage occurs at the guanine sites only, The biological implications of these oxidative processes are discussed.	NYU, Dept Chem, New York, NY 10003 USA; NYU, Radiat & Solid State Lab, New York, NY 10003 USA	New York University; New York University	Shafirovich, V (corresponding author), NYU, Dept Chem, 31 Washington Pl, New York, NY 10003 USA.							ADAMS GE, 1972, RADIAT RES, V49, P278, DOI 10.2307/3573266; ALSHEIKHLY M, 1994, RADIAT PHYS CHEM, V44, P297, DOI 10.1016/0969-806X(94)90007-8; ALTMAN P, 1971, BLOOD OTHER BODY FLU; BACHLER V, 1992, RADIAT PHYS CHEM, V40, P59; BAVERSTOCK K, 1974, INT J RADIAT BIOL, V26, P39, DOI 10.1080/09553007414550921; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; BIELSKI BHJ, 1978, PHOTOCHEM PHOTOBIOL, V28, P645, DOI 10.1111/j.1751-1097.1978.tb06986.x; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; CANDEIAS LP, 1989, J AM CHEM SOC, V111, P1094, DOI 10.1021/ja00185a046; Candeias LP, 2000, CHEM-EUR J, V6, P475, DOI 10.1002/(SICI)1521-3765(20000204)6:3<475::AID-CHEM475>3.0.CO;2-E; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Czapski G, 1999, J PHYS CHEM A, V103, P3447, DOI 10.1021/jp984769y; DOGLIOTTI L, 1967, J PHYS CHEM-US, V71, P2511, DOI 10.1021/j100867a019; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; Epperlein MM, 1998, J AM SOC NEPHROL, V9, P457; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Goldstein S, 1999, J AM CHEM SOC, V121, P2444, DOI 10.1021/ja9822254; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; HILDENBRAND K, 1990, FREE RADICAL RES COM, V11, P195, DOI 10.3109/10715769009088916; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; HUIE RE, 1991, RADIAT PHYS CHEM, V38, P477; HUIE RE, 1990, J PHYS CHEM-US, V94, P8561, DOI 10.1021/j100386a015; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Ivanov KL, 2000, J PHOTOCH PHOTOBIO A, V133, P99, DOI 10.1016/S1010-6030(00)00218-5; JONSSON M, 1995, J CHEM SOC PERK T 2, P67, DOI 10.1039/p29950000067; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Kuzmin VA, 2000, PHYS CHEM CHEM PHYS, V2, P1531, DOI 10.1039/b000212g; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LILIE J, 1978, RADIAT PHYS CHEM, V11, P225, DOI 10.1016/0146-5724(78)90101-2; Lymar SV, 2000, RADIAT PHYS CHEM, V59, P387, DOI 10.1016/S0969-806X(00)00277-2; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; LYMAR SV, 1995, CHEM RES TOXICOL, V8, P833, DOI 10.1021/tx00048a003; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MCELROY WJ, 1990, J PHYS CHEM-US, V94, P2435, DOI 10.1021/j100369a044; Merenyi G, 1997, CHEM RES TOXICOL, V10, P1216, DOI 10.1021/tx970101j; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; NETA P, 1988, J PHYS CHEM REF DATA, V17, P1027, DOI 10.1063/1.555808; ONEILL P, 1987, INT J RADIAT BIOL, V52, P577, DOI 10.1080/09553008714552071; PATEL DJ, 1982, SCIENCE, V216, P581, DOI 10.1126/science.6280281; PATEL DJ, 1982, BIOCHEMISTRY-US, V21, P428, DOI 10.1021/bi00532a002; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Schiemann O, 2000, J PHYS CHEM B, V104, P7214, DOI 10.1021/jp000725p; SCHINDLER S, 1993, INORG CHEM, V32, P4200, DOI 10.1021/ic00072a009; Shafirovich V, 2000, J CHEM SOC PERK T 2, P271, DOI 10.1039/a907995e; Shafirovich V, 2000, PHYS CHEM CHEM PHYS, V2, P4399, DOI 10.1039/b004896h; Shafirovich V, 1999, J PHYS CHEM B, V103, P10924, DOI 10.1021/jp992002f; Shafirovich V, 2001, CHEM RES TOXICOL, V14, P233, DOI 10.1021/tx000204t; Shafirovich V, 2001, J PHYS CHEM B, V105, P586, DOI 10.1021/jp0029055; SHAFIROVICH VY, 1995, J AM CHEM SOC, V117, P4920, DOI 10.1021/ja00122a024; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Steenken S, 2000, J AM CHEM SOC, V122, P2373, DOI 10.1021/ja993508e; Tien M, 1999, P NATL ACAD SCI USA, V96, P7809, DOI 10.1073/pnas.96.14.7809; Tretyakova NY, 2000, CHEM RES TOXICOL, V13, P658, DOI 10.1021/tx000083x; Tretyakova NY, 2000, MUTAT RES-FUND MOL M, V447, P287, DOI 10.1016/S0027-5107(99)00221-3; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; WEAST RC, 1984, CRC HDB CHEM PHYSICS, pD167; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; WOLCOTT RG, 1994, J BIOL CHEM, V269, P9721; Yermilov V, 1996, FEBS LETT, V399, P67, DOI 10.1016/S0014-5793(96)01288-4; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038	74	125	127	0	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24621	24626		10.1074/jbc.M101131200	http://dx.doi.org/10.1074/jbc.M101131200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320091	hybrid			2022-12-27	WOS:000169800700029
J	Wintjens, R; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Buee, L; Lippens, G; Landrieu, I				Wintjens, R; Wieruszeski, JM; Drobecq, H; Rousselot-Pailley, P; Buee, L; Lippens, G; Landrieu, I			H-1 NMR study on the binding of Pin1 Trp-Trp domain with phosphothreonine peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE PIN1; WW DOMAIN; REGULATORY MECHANISM; STRUCTURAL-ANALYSIS; LIGAND-BINDING; TAU-PROTEINS; BETA-SHEET; PHOSPHORYLATION; PROLINE; RECOGNITION	The recent crystal structure of Pin1 protein bound to a doubly phosphorylated peptide from the C-terminal domain of RNA polymerase II revealed that binding interactions between Pin1 and its substrate take place through its Trp-Trp (WW) domain at the level of the loop Ser(11)-Arg(12) and the aromatic pair Tyr(18)-Trp(29), and showed a trans conformation for both pSer-Pro peptide bonds. However, the orientation of the ligand in the aromatic recognition groove still could be sequence-specific, as previously observed in SH3 domains complexed by peptide ligands or for different class of WW domains (Zarrinpar, A, and Lim, W, A (2000) Nat, Struct, Riot, 7, 611-613), Because the bound peptide conformation could also differ as observed for peptide ligands bound to the 14-3-3 domain, ligand orientation and conformation for two other biologically relevant monophosphate substrates, one derived from the Cdc25 phosphatase of Xenopus laevis (EQPLpTPVTDL) and another from the human tau protein (KVSVVRpTPPKSPS) in complex with the WW domain are here studied by solution NMR methods. First, the proton resonance perturbations on the WW domain upon complexation with both peptide ligands were determined to be essentially located in the positively charged beta -hairpin Ser(11)-Gly(15) and around the aromatic Trp(29). Dissociation equilibrium constants of 117 and 230 muM for Cdc25 and tau peptides, respectively, were found. Several intermolecular nuclear Overhauser effects between WW domain and substrates were obtained from a ligand-saturated solution and were used to determine the structures of the complexes in solution. We found a similar N to C orientation as the one observed in the crystal complex structure of Pin1 and a trans conformation for the pThr-Pro peptidic bond in both peptide ligands, thereby indicating a unique binding scheme for the Pin1 WW domain to its multiple substrates.	Inst Pasteur Lille, Inst Biol Lille, CNRS UMR 8525, F-59021 Lille, France; Unite INSERM 422, F-59045 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Institut National de la Sante et de la Recherche Medicale (Inserm)	Landrieu, I (corresponding author), Inst Pasteur Lille, Inst Biol Lille, CNRS UMR 8525, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.		BUEE, Luc/B-3126-2010; Landrieu, Isabelle/AAF-8495-2019; Rousselot-Pailley, Pierre/E-4151-2015	BUEE, Luc/0000-0002-6261-4230; Landrieu, Isabelle/0000-0002-4883-2637; Drobecq, Herve/0000-0002-4081-1575; Lippens, Guy/0000-0002-8236-0901				BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BAX A, 1985, J MAGN RESON, V53, P521; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brunger A. T, 1993, XPLOR MANUAL VERSION; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Crane JC, 2000, J MOL BIOL, V298, P283, DOI 10.1006/jmbi.2000.3665; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; Daly NL, 2000, BIOCHEMISTRY-US, V39, P9039, DOI 10.1021/bi0004807; Delacourte A, 1997, INT REV CYTOL, V171, P167; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Fletcher R, 1980, PRACTICAL METHODS OP, V1; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAPLAN JI, 1995, ENCY NUCL MAGNETIC R, V2, P1247; Karaiskou A, 1999, J CELL SCI, V112, P3747; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Landrieu I, 2001, J BIOL CHEM, V276, P1434, DOI 10.1074/jbc.M006420200; Landrieu I, 2000, J BIOL CHEM, V275, P10577, DOI 10.1074/jbc.275.14.10577; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, NATURE, V399, P784; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MAPLE JR, 1988, P NATL ACAD SCI USA, V85, P5350, DOI 10.1073/pnas.85.15.5350; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Shoemaker BA, 2000, P NATL ACAD SCI USA, V97, P8868, DOI 10.1073/pnas.160259697; Staub O, 1996, STRUCTURE, V4, P495, DOI 10.1016/S0969-2126(96)00054-8; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; WILLIAMSON MP, 1995, J MOL BIOL, V247, P541, DOI 10.1006/jmbi.1995.0160; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P130; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	47	112	117	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25150	25156		10.1074/jbc.M010327200	http://dx.doi.org/10.1074/jbc.M010327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313338	hybrid			2022-12-27	WOS:000169800700097
J	Yao, XY; Rubenstein, PA				Yao, XY; Rubenstein, PA			F-actin-like ATPase activity in a polymerization-defective mutant yeast actin (V266G/L267G)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERELY DECREASED HYDROPHOBICITY; FILAMENT; STABILITY; DYNAMICS	Polymerization increases a low level G-actin ATPase activity yielding ADP-P-i F-actin and then ADP F-actin following release of P-i. By monitoring P-i release, we explored the relationship between the ATPase activity and polymerization characteristics of a mutant yeast actin, GG. In this mutant, two hydrophobic residues at the tip of a proposed hydrophobic plug between actin subdomains 3 and 4, Val(266) and Leu(267), were mutated to Gly. Although GG-actin does not polymerize by itself in vitro, GG cells are viable. We show that GG-actin ATPase activity increases under normal polymerization conditions, although stable filaments do not form. A plot of P-i release rate versus actin concentration yields an apparent critical concentration, like that seen for actin polymerization, of similar to8 muM for Mg2+ GG-actin and 11 muM for Ca2+ GG-actin, In contrast to WT-actin, P-i release from GG-actin is cold-sensitive, reflecting the temperature sensitivity associated with mutations that decrease hydrophobicity in this region. Thus, under polymerization conditions, GG-actin exhibits a continuous F-actin-like ATPase activity resulting from the temperature-sensitive formation of unstable cycling F-actin oligomers, Tropomyosin limits the extent and rate of this activity and restores polymerization by capturing and stabilizing these oligomers rather than enhancing filament nucleation.	Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Rubenstein, PA (corresponding author), Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA.	peter-rubenstein@uiowa.edu		Rubenstein, Peter/0000-0003-1225-4414	NIGMS NIH HHS [GM-33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; Cheng DM, 1999, J BIOL CHEM, V274, P35873, DOI 10.1074/jbc.274.50.35873; COOK RK, 1992, J BIOL CHEM, V267, P9430; HESTERKAMP T, 1993, EUR J BIOCHEM, V218, P507, DOI 10.1111/j.1432-1033.1993.tb18403.x; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Kuang B, 1997, J BIOL CHEM, V272, P1237, DOI 10.1074/jbc.272.2.1237; Kuang B, 1997, J BIOL CHEM, V272, P4412, DOI 10.1074/jbc.272.7.4412; Melki R, 1996, BIOCHEMISTRY-US, V35, P12038, DOI 10.1021/bi961325o; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Pollard TD, 2001, J CELL SCI, V114, P3; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RICH SA, 1976, J MOL BIOL, V104, P777, DOI 10.1016/0022-2836(76)90181-9; SELDEN LA, 1983, BIOCHEM BIOPH RES CO, V116, P478, DOI 10.1016/0006-291X(83)90548-X; SHU WP, 1992, BIOCHEM J, V283, P567, DOI 10.1042/bj2830567; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; Wen KK, 2000, BIOCHEMISTRY-US, V39, P8638, DOI 10.1021/bi000241j; Wen KK, 2000, J BIOL CHEM, V275, P40594, DOI 10.1074/jbc.M007201200; Yao XY, 1999, J BIOL CHEM, V274, P37443, DOI 10.1074/jbc.274.52.37443	23	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25598	25604		10.1074/jbc.M011797200	http://dx.doi.org/10.1074/jbc.M011797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328808	hybrid			2022-12-27	WOS:000169800700151
J	Caldwell, SR; Hill, KJ; Cooper, AA				Caldwell, SR; Hill, KJ; Cooper, AA			Degradation of endoplasmic reticulum (ER) quality control substrates requires transport between the ER and Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN-RESPONSE; COPII-COATED VESICLES; DI-LYSINE MOTIF; TRANSCRIPTION FACTOR; TRANSMEMBRANE PROTEIN; MEMBRANE GLYCOPROTEIN; PROTEASOME; COMPONENT; PATHWAY; COMPLEX	Endoplasmic reticulum (ER) quality control (ERQC) components retain and degrade misfolded proteins, and our results have found that the degradation of the soluble ERQC substrates CPY* and PrA* but not membrane spanning ERQC substrates requires transport between the ER and Golgi. Stabilization of these misfolded soluble proteins was seen in cells lacking Erv29p, a probable Golgi localized protein that cycles through the ER by means of a di-lysine ER retrieval motif (KKKIY). Cells lacking Erv29p also displayed severely retarded ER exit kinetics for a subset of correctly folded proteins. We suggest that Erv29p is likely involved in cargo loading of a subset of proteins, including soluble misfolded proteins, into vesicles for ER exit. The stabilization of soluble ERQC substrates in both erv29 Delta cells and sec mutants blocked in either ER exit (sec12) or vesicle delivery to the Golgi (sec18) suggests that ER-Golgi transport is required for ERQC and reveals a new aspect of the degradative mechanism.	Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Cooper, AA (corresponding author), Univ Missouri, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64110 USA.	coopera@umkc.edu		Cooper, Antony/0000-0002-6027-2353	NIGMS NIH HHS [GM55848] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055848] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Belden WJ, 1996, J BIOL CHEM, V271, P26939, DOI 10.1074/jbc.271.43.26939; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BONIFACINO JS, 1994, MODERN CELL BIOL CEL; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brigance WT, 2000, MOL BIOL CELL, V11, P171, DOI 10.1091/mbc.11.1.171; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEONORA FC, 2000, J BIOL CHEM, V275, P8382; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mori K, 2000, P NATL ACAD SCI USA, V97, P4660, DOI 10.1073/pnas.050010197; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1991, METHOD ENZYMOL, V194, P195; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Springer S, 2000, P NATL ACAD SCI USA, V97, P4034, DOI 10.1073/pnas.070044097; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198	54	139	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23296	23303		10.1074/jbc.M102962200	http://dx.doi.org/10.1074/jbc.M102962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316816	hybrid			2022-12-27	WOS:000169531100013
J	Friedhoff, P; Lurz, R; Luder, G; Pingoud, A				Friedhoff, P; Lurz, R; Luder, G; Pingoud, A			Sau3AI, a monomeric type II restriction endonuclease that dimerizes on the DNA and thereby induces DNA loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SEQUENCE ALIGNMENT; 2 RECOGNITION SITES; ESCHERICHIA-COLI; MISMATCH REPAIR; HOMING ENDONUCLEASE; CRYSTAL-STRUCTURE; STRUCTURE PREDICTION; PI-SCEI; PROTEIN; CLEAVAGE	Here, we report that Sau3AI, an unusually large type II restriction enzyme with sequence homology to the mismatch repair protein MutH, is a monomeric enzyme as shown by gel filtration and ultracentrifugation. Structural similarities in the N- and C-terminal halves of the protein suggest that Sau3AI is a pseudo-dimer, i.e. a polypeptide with two similar domains. Since Sau3AI dis plays a nonlinear dependence of cleavage activity on enzyme concentration and a strong preference for substrates with two recognition sites over those with only one, it is likely that the functionally active form of Sau3AI is a dimer of a pseudo-dimer. Indeed, electron microscopy studies demonstrate that two distant recognition sites are brought together through DNA looping induced by the simultaneous binding of two Sau3AI molecules to the DNA. We suggest that the dimeric form of Sau3AI supplies two DNA-binding sites, one that is associated with the catalytic center and one that serves as an effector site.	Univ Giessen, Inst Biochem FB8, D-35392 Giessen, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Justus Liebig University Giessen; Max Planck Society	Pingoud, A (corresponding author), Univ Giessen, Inst Biochem FB8, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	Alfred.M.Pingoud@chemie.bio.uni-giessen.de	Friedhoff, Peter/G-7905-2012	Friedhoff, Peter/0000-0003-1946-1117				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; Bilcock DT, 1999, MOL MICROBIOL, V31, P1243, DOI 10.1046/j.1365-2958.1999.01266.x; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; Bron S, 1980, Methods Enzymol, V65, P112; Bujnicki JM, 2001, PROTEIN SCI, V10, P352, DOI 10.1110/ps.40501; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Fischer D, 2000, Pac Symp Biocomput, P119; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Hadden JM, 2001, NAT STRUCT BIOL, V8, P62; Halford SE, 2000, NAT STRUCT BIOL, V7, P705, DOI 10.1038/78911; Halford SE, 1999, BIOCHEM SOC T, V27, P696, DOI 10.1042/bst0270696; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hickman AB, 2000, MOL CELL, V5, P1025, DOI 10.1016/S1097-2765(00)80267-1; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; KARPLUS K, 1999, PROTEINS STRUCT FU S, V3, P121; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, GENE, V157, P165, DOI 10.1016/0378-1119(95)00699-7; KUPPER D, 1995, GENE, V157, P97, DOI 10.1016/0378-1119(95)00700-G; Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mucke M, 2000, J BIOL CHEM, V275, P30631, DOI 10.1074/jbc.M003904200; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PETRAUSKENE OV, 1994, BIOCHEM BIOPH RES CO, V198, P885, DOI 10.1006/bbrc.1994.1126; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; PINGOUD A, 2001, IN PRESS NUCL ACIDS; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Roberts R, 1993, NUCLEASES, P35; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; SPIESS E, 1988, METHOD MICROBIOL, V20, P293, DOI 10.1016/S0580-9517(08)70057-6; Stahl F, 1998, BIOL CHEM, V379, P467, DOI 10.1515/bchm.1998.379.4-5.467; SYDDALL R, 1985, BIOCHIM BIOPHYS ACTA, V825, P236, DOI 10.1016/0167-4781(85)90108-3; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564; Weigel C, 1997, EMBO J, V16, P6574, DOI 10.1093/emboj/16.21.6574; WELSH KM, 1987, J BIOL CHEM, V262, P15624; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123; Wentzell LM, 1998, J MOL BIOL, V281, P433, DOI 10.1006/jmbi.1998.1967; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6	59	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23581	23588		10.1074/jbc.M101694200	http://dx.doi.org/10.1074/jbc.M101694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316811	hybrid			2022-12-27	WOS:000169531100049
J	Jiang, SW; Dong, MQ; Trujillo, MA; Miller, LJ; Eberhardt, NL				Jiang, SW; Dong, MQ; Trujillo, MA; Miller, LJ; Eberhardt, NL			DNA binding of TEA/ATTS domain factors is regulated by protein kinase C phosphorylation in human choriocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; SOMATOMAMMOTROPIN GENE ENHANCER; HEAVY-CHAIN PROMOTER; PHORBOL ESTER; CARDIAC MYOCYTES; TRANSCRIPTION FACTOR; SV40 ENHANCER; EXPRESSION; ACTIVATION; ELEMENTS	Transcription enhancer factor 1 (TEF-1) controls the expression of a diverse set of genes. Previous studies implicated protein kinase C (PKC)-mediated signal transduction in modulating TEF function. We demonstrate that in human choriocarcinoma BeWo cells, the PKC activator 12-O-tetradecanoyl phorbol 13-acetate and PHC inhibitor bisindolylmaleimide reciprocally down- and up-regulate, respectively, TEF-mediated GGAATG core enhancer activity. In vitro TEF-1 phosphorylation with several PKC isozymes and phosphoamino acid analysis confirmed that TEF-1 is a potential PKC substrate. TEF-1(.)DNA complexes formed by BeWo nuclear extracts are supershifted by phosphoserine- and phosphothreonine- but not phosphotyrosine-specific antibodies, indicating that TEF-1 is phosphorylated in vivo at serine and threonine residues. The TEF-1 phosphorylation domain was localized to the third alpha -helix of the DNA binding domain and adjacent hinge region by phosphopeptide analysis. TEF-1 phosphorylation significantly reduced its DNA binding activity both in vitro and in vivo, providing a possible mechanism for the inhibitory action of PKC. Finally, BeWo cells contained abundant levels of gamma and delta PKC isoforms, and their overexpression resulted in even greater inhibition of GGAATG core enhancer activity after 12-O-tetradecanoyl phorbol 13-acetate treatment. These data strongly suggest that PKC-mediated phosphorylation is a key factor controlling TEF function.	Mayo Clin, Dept Med, Div Endocrinol, Rochester, MN 55905 USA; Mayo Clin, Dept Biochem & Mol Biol, Div Endocrinol, Rochester, MN 55905 USA; Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Jiang, SW (corresponding author), St Marys Hosp, Mayo Clin, Rochester, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bamberger AM, 1997, ENDOCRINE, V6, P111, DOI 10.1007/BF02738953; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Cabell CH, 1996, P ASSOC AM PHYSICIAN, V108, P37; CARTER AN, 1997, CURRENT PROTOCOLS MO; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; COURAGE C, 1995, BRIT J CANCER, V71, P697, DOI 10.1038/bjc.1995.137; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; Gupta MP, 2000, NUCLEIC ACIDS RES, V28, P3168, DOI 10.1093/nar/28.16.3168; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Jacquemin P, 1997, J BIOL CHEM, V272, P12928, DOI 10.1074/jbc.272.20.12928; Jiang SW, 1999, MOL ENDOCRINOL, V13, P879, DOI 10.1210/me.13.6.879; Jiang SW, 2000, DNA CELL BIOL, V19, P507, DOI 10.1089/10445490050128430; JIANG SW, 1995, NUCLEIC ACIDS RES, V23, P3607, DOI 10.1093/nar/23.17.3607; Jiang SW, 1996, J BIOL CHEM, V271, P9510, DOI 10.1074/jbc.271.16.9510; JIANG SW, 1995, J BIOL CHEM, V270, P13906, DOI 10.1074/jbc.270.23.13906; JIANG SW, 1994, J BIOL CHEM, V269, P10384; Jiang SW, 2000, BIOCHEMISTRY-US, V39, P3505, DOI 10.1021/bi991048w; Kaneko KJ, 1998, DEV GENET, V22, P43, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;43::AID-DVG5&gt;3.0.CO;2-7; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KARIYA K, 1994, J BIOL CHEM, V269, P3775; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; Larkin SB, 1996, MOL CELL BIOL, V16, P3742; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mochly-Rosen D, 1998, FASEB J, V12, P35; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; Ruzycky AL, 1996, PLACENTA, V17, P461, DOI 10.1016/S0143-4004(96)90028-4; SchmitzPeiffer C, 1996, BIOCHEM J, V320, P207, DOI 10.1042/bj3200207; TERTRINCLARY C, 1991, ANN ENDOCRINOL-PARIS, V52, P327; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; Ueyama T, 2000, J BIOL CHEM, V275, P17476, DOI 10.1074/jbc.M001970200; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727	46	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23464	23470		10.1074/jbc.M010934200	http://dx.doi.org/10.1074/jbc.M010934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313339	hybrid			2022-12-27	WOS:000169531100033
J	Kim, M; Spelta, V; Sim, J; North, RA; Surprenant, A				Kim, M; Spelta, V; Sim, J; North, RA; Surprenant, A			Differential assembly of rat purinergic P2X(7) receptor in immune cells of the brain and periphery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-LYMPHOCYTES; GATED ION-CHANNEL; MICROGLIAL CELLS; XENOPUS OOCYTES; PURINOCEPTORS; EXPRESSION; SUBUNITS; RELEASE	ATP-gated P2X(7) purinoceptors are found in most immune cells of the periphery and the brain where their activation leads to multiple downstream events such as cell permeabilization, apoptosis, and/or cytokine release. P2X(7) receptors do not form heteromeric receptors with any of the other six P2X subunits, and it is not known what type of homomeric assemblies the P2X(7) subunit makes. We constructed and purified an ectodomain protein of the rat P2X(7) receptor (amino acids 60-323) and used this to generate a monoclonal antibody (Ab) with which to probe P2X(7) receptors in central and peripheral immune cells. In HEK cells expressing rat P2X(7) receptors, the Ab increased the maximum current evoked by BzATP by 3-8-fold with a 5-fold leftward shift in EC50 concentration. This Ab recognized only a nondenatured, multimeric form of the receptor on blue native-PAGE but did not recognize the denatured form on SDS-PAGE. A C-terminaI polyclonal P2X(7) Ab recognized both monomeric subunits on SDS-PAGE and a multimeric complex on blue native-PAGE in this heterologous expression system. With Western blotting using these two Abs, native P2X(7) receptors in peritoneal macrophage and bone marrow cells are shown to exist as a strongly bound multimeric complex, whereas P2X(7) receptors in brain glia and/or astrocytes appear to form only as monomeric subunits.	Univ Sheffield, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Surprenant, A (corresponding author), Univ Sheffield, Inst Mol Physiol, Alfred Denny Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		North, Richard/GQA-6156-2022					Boucsein C, 2000, EUR J NEUROSCI, V12, P2049, DOI 10.1046/j.1460-9568.2000.00100.x; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BUTTNER C, 2000, PUR 2000 INT S NUCL; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Di Virgilio F, 1999, PROG BRAIN RES, V120, P355; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Gudipaty L, 2001, AM J PHYSIOL-CELL PH, V280, pC943, DOI 10.1152/ajpcell.2001.280.4.C943; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Inoue K, 1998, BRIT J PHARMACOL, V123, P1304, DOI 10.1038/sj.bjp.0701732; KENNENMANN H, 1999, ADV NEUROL, V79, P565; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; Klapperstuck M, 2000, BBA-BIOMEMBRANES, V1467, P444, DOI 10.1016/S0005-2736(00)00245-5; MacKenzie AB, 1999, ANN NY ACAD SCI, V868, P716, DOI 10.1111/j.1749-6632.1999.tb11351.x; Markwardt E, 1999, PROG BRAIN RES, V120, P345; Markwardt F, 1997, J PHYSIOL-LONDON, V498, P143, DOI 10.1113/jphysiol.1997.sp021847; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Pannicke T, 2000, J NEUROSCI, V20, P5965, DOI 10.1523/JNEUROSCI.20-16-05965.2000; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1998, FEBS LETT, V425, P19, DOI 10.1016/S0014-5793(98)00179-3; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x	34	93	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23262	23267		10.1074/jbc.M102253200	http://dx.doi.org/10.1074/jbc.M102253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313357	hybrid			2022-12-27	WOS:000169531100008
J	Smart, DE; Vincent, KJ; Arthur, MJP; Eiekelberg, O; Castellazzi, M; Mann, J; Mann, DA				Smart, DE; Vincent, KJ; Arthur, MJP; Eiekelberg, O; Castellazzi, M; Mann, J; Mann, DA			JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; MESSENGER-RNA; LIVER-INJURY; C-FOS; EXPRESSION; PROMOTER; AP-1; INDUCTION; PROTEIN-1; FIBROSIS	Activation of hepatic stellate cells (HSCs) to a myofibroblast-like phenotype is the pivotal event in hepatic wound healing and fibrosis. Rat HSCs activated in vitro express JunD, Fra2, and FosB as the predominant AP-1 DNA-binding proteins, and all three associate with an AP-I sequence that is essential for activity of the tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter. In this study, we used expression vectors for wild-type, dominant-negative, and forced homodimeric (Jun/eb1 chimeric factors) forms of JunD and other Fos and Jun proteins to determine the requirement for JunD in the transcriptional regulation of the TIMP-1 and interleukin-6 (IL-6) genes. JunD activity was required for TIMP-1 gene promoter activity, whereas overexpression of Fra2 or FosB caused a repression of promoter activity. The ability of homodimeric JunD/eb1 to elevate TIMP-1 promoter activity supports a role for JunD homodimers as the major AP-1-dependent transactivators of the TIMP-1 gene. IL-6 promoter activity was induced upon activation of HSCs and also required JunD activity; however, expression of JunD/eb1 homodimers resulted in transcriptional repression, Mutagenesis of the IL-6 promoter showed that an AP-1 DNA-binding site previously reported to be an activator of transcription in fibroblasts functions as a suppressor of promoter activity in HSCs, We conclude that JunD activates IL-6 gene transcription as a heterodimer and operates at an alternative DNA-binding site in the promoter. The relevance of these findings to events occurring in the injured Liver was addressed by showing that AP-I DNA-binding complexes are induced during HSC activation and contain JunD as the predominant Jun family protein. JunD is therefore an important transcriptional regulator of genes responsive to Jun homo- and heterodimers in activated HSCs.	Univ Southampton, Southampton Gen Hosp, Liver Grp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Ecole Normale Super Lyon, Unite Virol Humaine, INSERM U 412, F-69364 Lyon 07, France	University of Southampton; Yale University; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mann, DA (corresponding author), Univ Southampton, Southampton Gen Hosp, Liver Grp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England.	dam2@soton.ac.uk		smart, David/0000-0002-1411-723X; Mann, Derek/0000-0003-0950-243X				ARMENDARIZBORUNDA J, 1994, BIOCHEM J, V304, P817, DOI 10.1042/bj3040817; Arthur MJP, 1998, J GASTROEN HEPATOL, V13, pS33; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; CHEN A, 1999, J BIOL CHEM, V271, P25994; Chen AP, 2000, MOL CELL BIOL, V20, P2818, DOI 10.1128/MCB.20.8.2818-2826.2000; CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Knittel T, 1999, AM J PATHOL, V155, P1841, DOI 10.1016/S0002-9440(10)65502-2; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; SONOBE MH, 1995, ONCOGENE, V10, P689; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TANABE O, 1988, J IMMUNOL, V141, P3875; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; TIGGELMAN AMB, 1995, J HEPATOL, V23, P295, DOI 10.1016/0168-8278(95)80474-9; Toda K, 2000, J GASTROENTEROL, V35, P214, DOI 10.1007/s005350050333; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Weiner JK, 1998, J BIOL CHEM, V273, P15913, DOI 10.1074/jbc.273.26.15913; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	41	80	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24414	24421		10.1074/jbc.M101840200	http://dx.doi.org/10.1074/jbc.M101840200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11337499	hybrid			2022-12-27	WOS:000169531100157
J	Stephen, AG; Raval-Fernandes, S; Huynh, T; Torres, M; Kickhoefer, VA; Rome, LH				Stephen, AG; Raval-Fernandes, S; Huynh, T; Torres, M; Kickhoefer, VA; Rome, LH			Assembly of vault-like particles in insect cells expressing only the major vault protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-LIKE PARTICLES; RIBONUCLEOPROTEIN-PARTICLES; SMALL RNA; RESISTANCE; POLYMERASE; DISRUPTION; COMPLEX; CONTAIN	Vaults are the largest (13 megadalton) cytoplasmic ribonucleoprotein particles known to exist in eukaryotic cells. They have a unique barrel-shaped structure with 8-fold symmetry. Although the precise function of vaults is unknown, their wide distribution and highly conserved morphology in eukaryotes suggests that their function is essential and that their structure must be important for their function. The 100-kDa major vault protein (MVP) constitutes similar to 75% of the particle mass and is predicted to form the central barrel portion of the vault. To gain insight into the mechanisms for vault assembly, we have expressed rat MVP in the Sf9 insect cell line using a baculovirus vector. Our results show that the expression of the rat MVP alone can direct the formation of particles that have biochemical characteristics similar to endogenous rat vaults and display the distinct vault-like morphology when negatively stained and examined by electron microscopy. These particles are the first example of a single protein polymerizing into a non-spherically, non-cylindrically symmetrical structure. Understanding vault assembly will enable us to design agents that disrupt vault formation and hence aid in elucidating vault function in vivo.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; NCI, Frederick Canc Res & Dev Ctr, SAIC Frederick, Frederick, MD 21702 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Rome, LH (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, 33-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Stephen, Andrew/W-2636-2019; Rome, Leonard H/E-8786-2016	Stephen, Andrew/0000-0002-8259-621X; Rome, Leonard H/0000-0002-1236-2063; Kickhoefer, Valerie/0000-0002-0048-0580	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038097] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38097] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHUGANI DC, 1993, J CELL SCI, V106, P23; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; Herrmann C, 1999, J CELL BIOL, V144, P1163, DOI 10.1083/jcb.144.6.1163; Izquierdo MA, 1998, CYTOTECHNOLOGY, V27, P137, DOI 10.1023/A:1008004502861; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1994, GENE, V151, P257, DOI 10.1016/0378-1119(94)90667-X; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157; KIRNBAUER R, 1993, J VIROL, V67, P6929, DOI 10.1128/JVI.67.12.6929-6936.1993; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kong LB, 2000, RNA, V6, P890, DOI 10.1017/S1355838200000157; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Li TC, 1997, J VIROL, V71, P7207, DOI 10.1128/JVI.71.10.7207-7213.1997; Roy P, 1997, GENE, V190, P119, DOI 10.1016/S0378-1119(96)00619-1; Siva AC, 2001, INT J CANCER, V92, P195, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VASU SK, 1993, J BIOL CHEM, V268, P15356; Wang MY, 2000, BIOTECHNOL BIOENG, V67, P104, DOI 10.1002/(SICI)1097-0290(20000105)67:1&lt;104::AID-BIT12&gt;3.0.CO;2-I	23	107	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23217	23220		10.1074/jbc.C100226200	http://dx.doi.org/10.1074/jbc.C100226200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11349122	hybrid			2022-12-27	WOS:000169531100002
J	Wu, HJ; Lima, WF; Crooke, ST				Wu, HJ; Lima, WF; Crooke, ST			Investigating the structure of human RNase H1 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; BINDING; PURIFICATION; SUBUNIT; SPECIFICITY; EXPRESSION; RESOLUTION; ENZYME	In this study we examine for the first time the roles of the various domains of human RNase H1 by site-directed mutagenesis. The carboxyl terminus of human RNase H1 is highly conserved with Escherichia coli RNase H1 and contains the amino acid residues of the putative catalytic site and basic substrate binding do. main of the E. coli RNase enzyme. The amino terminus of human RNase H1 contains a structure consistent with a double-strand RNA (dsRNA) binding motif that is separated from the conserved E. coli RNase H1 region by a Ga-amino acid sequence. These studies showed that although the conserved amino acid residues of the putative catalytic site and basic substrate-binding domain are required for RNase H activity, deletion of either the catalytic site or the basic substrate-binding domain did not ablate binding to the heteroduplex substrate. Deletion of the region between the dsRNA-binding domain and the conserved E. coli RNase H1 domain resulted in a significant loss in the RNase H activity. Furthermore, the binding affinity of this deletion mutant for the heteroduplex substrate was similar to2-fold tighter than the wildtype enzyme suggesting that this central ga-amino acid region does not contribute to the binding affinity of the enzyme for the substrate. The dsRNA-binding domain was not required for RNase H activity, as the dsRNA-deletion mutants exhibited catalytic rates similar to2-fold faster than the rate observed for wild-type enzyme. Comparison of the dissociation constant of human RNase H1 and the dsRNA-deletion mutant for the heteroduplex substrate indicates that the deletion of this region resulted in a 5-fold loss in binding affinity. Finally, comparison of the cleavage patterns exhibited by the mutant proteins with the cleavage pattern for the wild-type enzyme indicates that the dsRNA-binding domain is responsible for the observed strong positional preference for cleavage exhibited by human RNase H1.	ISIS Pharmaceut, Dept Biol Mol & Struct, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Lima, WF (corresponding author), ISIS Pharmaceut, Dept Biol Mol & Struct, 2292 Faraday Ave, Carlsbad, CA 92008 USA.	wlima@isisph.com						Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAMARA RA, 1997, J BIOL CHEM, V272, P4647; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; BUSEN W, 1977, EUR J BIOCHEM, V74, P203, DOI 10.1111/j.1432-1033.1977.tb11382.x; BUSEN W, 1980, J BIOL CHEM, V255, P9434; Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497; CERRITELLI SM, 1995, RNA, V1, P246; Crouch R. J., 1982, NUCLEASES, P211; Dabora JM, 1996, BIOCHEMISTRY-US, V35, P11951, DOI 10.1021/bi9611671; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P392; EDER PS, 1993, BIOCHIMIE, V75, P123, DOI 10.1016/0300-9084(93)90033-O; EDER PS, 1991, J BIOL CHEM, V266, P6472; FRANK P, 1994, NUCLEIC ACIDS RES, V22, P5247, DOI 10.1093/nar/22.24.5247; Frank P, 1998, P NATL ACAD SCI USA, V95, P12872, DOI 10.1073/pnas.95.22.12872; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; ITAYA M, 1991, NUCLEIC ACIDS RES, V19, P4443, DOI 10.1093/nar/19.16.4443; ITAYA M, 1991, MOL GEN GENET, V227, P438, DOI 10.1007/BF00273935; KANAYA S, 1992, J BIOL CHEM, V267, P10184; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lima WF, 1997, BIOCHEMISTRY-US, V36, P390, DOI 10.1021/bi962230p; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; RONG YW, 1990, BIOCHEMISTRY-US, V29, P383, DOI 10.1021/bi00454a012; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scaringe SA, 1998, J AM CHEM SOC, V120, P11820, DOI 10.1021/ja980730v; STEIN H, 1969, SCIENCE, V166, P393, DOI 10.1126/science.166.3903.393; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 1998, ANTISENSE NUCLEIC A, V8, P53, DOI 10.1089/oli.1.1998.8.53; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	34	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23547	23553		10.1074/jbc.M009676200	http://dx.doi.org/10.1074/jbc.M009676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319219	hybrid			2022-12-27	WOS:000169531100045
J	Srinivas, V; Leshchinsky, I; Sang, N; King, MP; Minchenko, A; Caro, J				Srinivas, V; Leshchinsky, I; Sang, N; King, MP; Minchenko, A; Caro, J			Oxygen sensing and HIF-1 activation does not require an active mitochondrial respiratory chain electron-transfer pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; DEGRADATION DOMAIN; HYPOXIA; ERYTHROPOIETIN; CELLS; MECHANISM; HIF-1-ALPHA; INDUCTION; ALPHA	Hypoxia induces the stabilization and transcriptional activation of the hypoxia-inducible factor 1 alpha (HIF-1 alpha) protein, the regulatory member of the HIF-1 complex, The molecular mechanisms that are responsible for oxygen sensing and the downstream pathways utilized by the hypoxic signal are still poorly understood, One hypothesis for oxygen sensing has postulated that reactive oxygen species generated at mitochondrial complex III are the initiators of the hypoxic signal. Here we find that mitochondrial DNA-less (rho degrees) cells have a normal response to hypoxia, measured at the level of HIF-1 alpha protein stabilization, nuclear translocation, and its transcriptional activation activity. Furthermore, overexpression of catalase, either in the mitochondria or in the cytosol, fails to modify the hypoxia response indicating that hydrogen peroxide is not a signaling molecule in the hypoxic signaling cascade that culminates with HIF-1 activation.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Srinivas, V (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, Dept Med, 1015 Walnut St, Philadelphia, PA 19107 USA.		Minchenko, Oleksandr/AAV-5742-2020	Minchenko, Oleksandr/0000-0002-7093-5173	NATIONAL CANCER INSTITUTE [K01CA098809, R01CA089212] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1 CA89212-02, K01 CA098809, R01 CA089212] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKER H, 1994, ANN NY ACAD SCI, V718, P1; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Horiguchi H, 2000, BBA-MOL CELL RES, V1495, P231, DOI 10.1016/S0167-4889(99)00169-X; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Liu ZD, 2001, BIOCHEM PHARMACOL, V61, P285, DOI 10.1016/S0006-2952(00)00551-7; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MINCHENKO A, 1994, LAB INVEST, V71, P374; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Srinivas V, 1998, J BIOL CHEM, V273, P18019, DOI 10.1074/jbc.273.29.18019; Srinivas V, 1999, J BIOL CHEM, V274, P1180; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2000, J EXP BIOL, V203, P1253	26	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					21995	21998		10.1074/jbc.C100177200	http://dx.doi.org/10.1074/jbc.C100177200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11342528	Green Accepted, hybrid			2022-12-27	WOS:000169412700002
J	Xu, Y; Potapova, O; Leschziner, AE; Grindley, NDF; Joyce, CM				Xu, Y; Potapova, O; Leschziner, AE; Grindley, NDF; Joyce, CM			Contacts between the 5 ' nuclease of DNA polymerase I and its DNA substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FLAP ENDONUCLEASE-1; BACTERIOPHAGE-T4 RNASE-H; SINGLE-STRANDED-DNA; CALF RTH-1 NUCLEASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; 5'-NUCLEASE DOMAIN; KLENOW FRAGMENT; EXONUCLEASE; REPLICATION	The 5 ' nuclease of DNA polymerase I (Pol I) of Escherichia coli is a member of an important class of prokaryotic and eukaryotic nucleases, involved in DNA replication and repair, with specificity for the junction between single-stranded and duplex DNA. We have investigated the interaction of the 5 ' nuclease domain with DNA substrates from the standpoint of both the protein and the DNA. Phosphate ethylation interference showed that the nuclease binds to the nucleotides immediately surrounding the cleavage site and also contacts the complementary strand one-half turn away, indicating that contacts are made to one face only of the duplex portion of the DNA substrate. Phosphodiester contacts were investigated further using DNA substrates carrying unique methylphosphonate substitutions, together with mutations in the 5 ' nuclease. These experiments suggested that two highly conserved basic residues, Lys(78) and Arg(81), are close to the phosphodiester immediately 5 ' to the cleavage site, while a third highly conserved residue, Arg(20), may interact with the phosphodiester 3 ' to the cleavage site. Our results provide strong support for a DNA binding model proposed for the related exonuclease from bacteriophage T5, in which the conserved basic residues mentioned above define the two ends of a helical arch that forms part of the single-stranded DNA-binding region. The nine highly conserved carboxylates in the active site region appear to play a relatively minor role in substrate binding, although they are crucial for catalysis. In addition to binding the DNA backbone around the cleavage point, the 5 ' nuclease also has a binding site for one or two frayed bases at the 3 ' end of an upstream primer strand. In agreement with work in related systems, 5 ' nuclease cleavage is blocked by duplex DNA in the 5 ' tag, but the enzyme is quite tolerant of abasic DNA or polarity reversal within the 5 ' tail.	Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, New Haven, CT 06520 USA	Yale University	Joyce, CM (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, Bass Ctr Mol & Struct Biol, 266 Whitney Ave,POB 208114, New Haven, CT 06520 USA.	catherine.joyce@yale.edu		Leschziner, Andres/0000-0002-7732-7023	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019025, R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-19025, GM-28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28523, DOI 10.1074/jbc.272.45.28523; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; GUTMAN PD, 1993, NUCLEIC ACIDS RES, V21, P4406, DOI 10.1093/nar/21.18.4406; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kornberg A., 1992, DNA REPLICATION; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LONGLEY MJ, 1990, NUCLEIC ACIDS RES, V18, P7317, DOI 10.1093/nar/18.24.7317; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MERKENS LS, 1995, BBA-GENE STRUCT EXPR, V1264, P243, DOI 10.1016/0167-4781(95)00153-8; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Pickering TJ, 1999, NUCLEIC ACIDS RES, V27, P730, DOI 10.1093/nar/27.3.730; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Riggs MG, 1996, BBA-GENE STRUCT EXPR, V1307, P178, DOI 10.1016/0167-4781(96)00051-6; RIMPHANITCHAYAK.V, 1991, LAB GUIDE IN VITRO S, V5, P111; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Sayers JR, 1998, NAT STRUCT BIOL, V5, P668, DOI 10.1038/1358; Setlow P, 1974, Methods Enzymol, V29, P3; Shafritz KM, 1998, NUCLEIC ACIDS RES, V26, P2593, DOI 10.1093/nar/26.11.2593; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199	52	30	32	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30167	30177		10.1074/jbc.M100985200	http://dx.doi.org/10.1074/jbc.M100985200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11349126	hybrid			2022-12-27	WOS:000170558000076
J	Kappes, F; Burger, K; Baack, M; Fackelmayer, FO; Gruss, C				Kappes, F; Burger, K; Baack, M; Fackelmayer, FO; Gruss, C			Subcellular localization of the human proto-oncogene protein DEK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACUTE MYELOID-LEUKEMIA; A SAF-A; DNA-REPLICATION; HISTONE H1; CHROMATIN; TRANSCRIPTION; ONCOPROTEIN; BINDING	Recent data revealed that DEK associates with splicing complexes through interactions mediated by serine/arginine-repeat proteins. However, the DEK protein has also been shown to change the topology of DNA in chromatin in vitro, This could indicate that the DEK protein resides on cellular chromatin, To investigate the in vivo localization of DEK, we performed cell fractionation studies, immunolabeling, and micrococcal nuclease digestion analysis. Most of the DEK protein was found to be released by DNase treatment of nuclei, and only a small amount by treatment with RNase, Furthermore, micrococcal nuclease digestion of nuclei followed by glycerol gradient sedimentation revealed that DEK cosedimentates with oligonucleosomes, clearly demonstrating that DEK is associated with chromatin in vivo. Additional chromatin fractionation studies, based on the different accessibilities to micrococcal nuclease, showed that DEK is associated both with extended, genetically active and more densely organized, inactive chromatin, We found no significant change in the amount and localization of DEK in cells that synchronously traversed the cell cycle. In summary these data demonstrate that the major portion of DEK is associated with chromatin in vivo and suggest that it might play a role in chromatin architecture.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Gruss, C (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	claudia.gruss@uni-konstanz.de	Ferdinand, Kappes/H-4445-2014	Ferdinand, Kappes/0000-0002-0369-0065				ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Alexiadis V, 2000, GENE DEV, V14, P1308; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; BLENCOWE BJ, 1995, RNA, V1, P852; CLARK RJ, 1971, NATURE-NEW BIOL, V229, P101, DOI 10.1038/newbio229101a0; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dong XW, 1998, ARTHRITIS RHEUM-US, V41, P1505, DOI 10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO;2-N; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fu GK, 1997, P NATL ACAD SCI USA, V94, P1811, DOI 10.1073/pnas.94.5.1811; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HALMER L, 1995, NUCLEIC ACIDS RES, V23, P773, DOI 10.1093/nar/23.5.773; Johnson R. T., 1993, CELL CYCLE PRACTICAL, P1; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Kipp M, 2000, J BIOL CHEM, V275, P5031, DOI 10.1074/jbc.275.7.5031; KLEMPNAUER KH, 1980, J MOL BIOL, V136, P359, DOI 10.1016/0022-2836(80)90395-2; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Krude T, 1996, J CELL SCI, V109, P309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; McGarvey T, 2000, J CELL BIOL, V150, P309, DOI 10.1083/jcb.150.2.309; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Richter A, 1998, BIOL CHEM, V379, P1181; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; ROSE SM, 1984, J BIOL CHEM, V259, P8534; SZER IS, 1994, J RHEUMATOL, V21, P2136; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wichmann I, 2000, CLIN EXP IMMUNOL, V119, P530, DOI 10.1046/j.1365-2249.2000.01154.x; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761	38	83	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26317	26323		10.1074/jbc.M100162200	http://dx.doi.org/10.1074/jbc.M100162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333257	hybrid			2022-12-27	WOS:000169823300090
J	Kodama, E; Baba, T; Yokosawa, H; Sawada, H				Kodama, E; Baba, T; Yokosawa, H; Sawada, H			cDNA cloning and functional analysis of ascidian sperm proacrosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACROSIN-LIKE ENZYME; ZONA-PELLUCIDA; HALOCYNTHIA-RORETZI; CUB DOMAIN; FERTILIZATION; PROTEINS; SEQUENCE; IDENTIFICATION; SPERMADHESINS; PARTICIPATION	cDNA cloning and functional analysis of proacrosin from the ascidian Halocynthia roretzi were undertaken. The isolated cDNA of the ascidian preproacrosin consists of 2367 nucleotides, and an open reading frame encodes 505 amino acids, which corresponds to the molecular mass of 55,003 De. The mRNA of proacrosin was found to be specifically expressed in the gonad by Northern blotting and in the spermatocytes or spermatids by in situ hybridization, The amino acid sequences around His(76), Asp(132), and Ser(227), which make up a catalytic triad, showed high homology to those of the trypsin family. Ascidian acrosin has paired basic residues (Lys(56)-His(57)) in the N-terminal region, which is one of the most characteristic features of mammalian acrosin, This region seems to play a key role in the binding of (pro)acrosin to the vitelline coat, because the peptide containing the paired basic residues, but not the peptide substituted with Ale, was capable of binding to the vitelline coat. Unlike mammalian proacrosin, ascidian proacrosin contains two CUB domains in the C-terminal region, in which CUB domain 1 seems to be involved in its binding to the vitelline coat. Four components of the vitelline coat that are capable of binding to CUB domain 1 in proacrosin were identified. In response to sperm activation, acrosin was released from sperm into the surrounding seawater, suggesting that ascidian acrosin plays a key role in sperm penetration through the coat. These results indicate that ascidian sperm contains a mammalian acrosin homologue, a multi-functional protein working in fertilization.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	Hokkaido University; University of Tsukuba	Sawada, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Sapporo, Hokkaido 0600812, Japan.							Adham IM, 1997, MOL REPROD DEV, V46, P370, DOI 10.1002/(SICI)1098-2795(199703)46:3&lt;370::AID-MRD16&gt;3.0.CO;2-2; BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1994, J BIOL CHEM, V269, P31845; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; CALVETE JJ, 1993, FEBS LETT, V334, P37, DOI 10.1016/0014-5793(93)81675-P; CLAVETE JJ, 1995, FEBS LETT, V365, P179; DELGADILLOREYNOSO MG, 1989, J MOL EVOL, V29, P314, DOI 10.1007/BF02103619; DOSTALOVA Z, 1994, BIOL CHEM H-S, V375, P457, DOI 10.1515/bchm3.1994.375.7.457; HOSHI M, 1981, DEV BIOL, V86, P117, DOI 10.1016/0012-1606(81)90322-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT CC, 1979, DEV BIOL, V69, P296, DOI 10.1016/0012-1606(79)90293-8; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MULLERESTERL W, 1981, METHOD ENZYMOL, V80, P621; OLAND R, 1986, ADV EXP MED BIOL, V205, P131; Richardson RT, 1996, J BIOL CHEM, V271, P24069, DOI 10.1074/jbc.271.39.24207; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Sambrook J., 2002, MOL CLONING LAB MANU; Sawada H, 1996, BIOCHEM BIOPH RES CO, V222, P499, DOI 10.1006/bbrc.1996.0773; SAWADA H, 1984, J BIOL CHEM, V259, P2900; SAWADA H, 1982, GAMETE RES, V5, P291, DOI 10.1002/mrd.1120050309; SAWADA H, 1984, DEV BIOL, V105, P246, DOI 10.1016/0012-1606(84)90281-1; Topfer-Petersen E, 1996, J Reprod Fertil Suppl, V50, P55; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; URCH UA, 1991, DEVELOPMENT, V111, P1165; URCH UA, 1985, J EXP ZOOL, V233, P479, DOI 10.1002/jez.1402330317; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470	28	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24594	24600		10.1074/jbc.M011370200	http://dx.doi.org/10.1074/jbc.M011370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313341	hybrid			2022-12-27	WOS:000169800700025
J	van Roosmalen, ML; Jongbloed, JDH; Dubois, JYF; Venema, G; Bron, S; van Dijl, JM				van Roosmalen, ML; Jongbloed, JDH; Dubois, JYF; Venema, G; Bron, S; van Dijl, JM			Distinction between major and minor Bacillus signal peptidases based on phylogenetic and structural criteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPORALLY CONTROLLED EXPRESSION; MULTIPLE SEQUENCE ALIGNMENT; SUBTILIS; IDENTIFICATION; SECRETION; SIPS; MECHANISM; PROTEINS; CLEAVAGE; SITE	The processing of secretory preproteins by signal peptidases (SPases) is essential for cell viability. As previously shown for Bacillus subtilis, only certain SPases of organisms containing multiple paralogous SPases are essential. This allows a distinction between SPases that are of major and minor importance for cell viability. Notably, the functional difference between major and minor SPases is not reflected clearly in sequence alignments. Here, we have successfully used molecular phylogeny to predict major and minor SPases, The results were verified with SPases from various bacilli, As predicted, the latter enzymes behaved as major or minor SPases when expressed in B. subtilis. Strikingly, molecular modeling indicated that the active site geometry is not a critical parameter for the classification of major and minor Bacillus SPases, Even though the substrate binding site of the minor SPase SipV is smaller than that of other known SPases, SipV could be converted into a major SPase without changing this site. Instead, replacement of amino-terminal residues of SipV with corresponding residues of the major SPase SipS was sufficient for conversion of SipV into a major SPase, This suggests that differences between major and minor SPases are based on activities other than substrate cleavage site selection.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	J.M.VAN.DIJL@FARM.RUG.NL	van Dijl, Jan Maarten/G-1205-2013					Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; BRON S, 1972, MUTAT RES, V15, P395, DOI 10.1016/0027-5107(72)90004-8; Carlos JL, 2000, J BIOL CHEM, V275, P38813, DOI 10.1074/jbc.M007093200; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; HOANG V, 1995, BBA-MOL CELL RES, V1269, P64, DOI 10.1016/0167-4889(95)00101-W; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; Paetzel M, 2000, PHARMACOL THERAPEUT, V87, P27, DOI 10.1016/S0163-7258(00)00064-4; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Stover AG, 1999, J BACTERIOL, V181, P7065; Stover AG, 1999, J BACTERIOL, V181, P1664; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tjalsma H, 1999, J BACTERIOL, V181, P2448, DOI 10.1128/JB.181.8.2448-2454.1999; Tjalsma H, 2000, J BIOL CHEM, V275, P25102, DOI 10.1074/jbc.M002676200; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; van Roosmalen ML, 2001, MICROBIOL-UK, V147, P909, DOI 10.1099/00221287-147-4-909; van Roosmalen ML, 2000, J BACTERIOL, V182, P5765, DOI 10.1128/JB.182.20.5765-5770.2000; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	28	12	12	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25230	25235		10.1074/jbc.M102099200	http://dx.doi.org/10.1074/jbc.M102099200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309398	hybrid			2022-12-27	WOS:000169800700107
J	Knight, JS; Cotter, MA; Robertson, ES				Knight, JS; Cotter, MA; Robertson, ES			The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus transactivates the telomerase reverse transcriptase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAVITY-BASED LYMPHOMA; EPSTEIN-BARR-VIRUS; HTERT GENE PROMOTER; DNA-SEQUENCES; C-MYC; CELL-LINES; MAMMALIAN TELOMERASE; ENDOTHELIAL-CELLS; RNA COMPONENT; ACTIVATION	Telomerase is a multi-subunit ribonucleoprotein holoenzyme that stabilizes telomere length through the addition of new repeat sequence to the ends of chromosomes. Telomerase reverse transcriptase is the subunit of this complex responsible for the enzymatic activity of telomerase. Expression of the reverse transcriptase is regulated at the level of transcription through the action of transcription factors that target its promoter. Most Kaposi's sarcoma tumor cells are latently infected with the Kaposi's sarcoma-associated herpesvirus, and the constitutive expression of a viral-encoded latency-associated nuclear antigen has been shown to be important for the maintenance of the viral episome. The proliferative nature of Kaposi's sarcoma suggests that this antigen may also play a critical role in viral-mediated oncogenesis. In this study telomerase reverse transcriptase promoter elements cloned into a luciferase reporter plasmid were analyzed to determine the ability of the latency associated nuclear antigen to regulate transcription. The latency associated nuclear antigen transactivated the fall-length promoter in 293T, 293, and BJAB cell. lines. Furthermore, truncation promoter studies implicated sequence from -130 to +5 in viral mediated activation. This region contains five Spl transcription factor-binding sites. Electrophoretic mobility shift assays indicated that the latency-associated nuclear antigen targets and affects the Sp1-DNA complex in the context of BJAB nuclear extracts.	Univ Michigan, Med Ctr, Sch Med, Med Scientist Training Program, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Cell & Mol Biol Grad Program, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Comprehens Canc & Geriatr Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Robertson, ES (corresponding author), Univ Michigan, Med Ctr, Sch Med, Med Scientist Training Program, CCGC 3217, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [T32 GM07863] Funding Source: Medline; PHS HHS [C072150-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIELLO L, 1979, VIROLOGY, V94, P460, DOI 10.1016/0042-6822(79)90476-8; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; BATSCHE E, 1994, ONCOGENE, V9, P2235; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Callahan J, 1999, VIROLOGY, V262, P18, DOI 10.1006/viro.1999.9876; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; CLEMENTS GB, 1975, INT J CANCER, V16, P125, DOI 10.1002/ijc.2910160114; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; DIGIOVANNA JJ, 1981, AM J MED, V71, P779, DOI 10.1016/0002-9343(81)90364-8; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Foreman KE, 1997, NEW ENGL J MED, V336, P163, DOI 10.1056/NEJM199701163360302; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Gao SJ, 1999, J INFECT DIS, V180, P1466, DOI 10.1086/315098; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Gunes C, 2000, CANCER RES, V60, P2116; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Horikawa I, 1999, CANCER RES, V59, P826; Ito H, 1998, CLIN CANCER RES, V4, P1603; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; KATZ MH, 1994, J INFECT DIS, V170, P198, DOI 10.1093/infdis/170.1.198; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, INT J CANCER, V80, P804; Lim C, 2000, J GEN VIROL, V81, P2645, DOI 10.1099/0022-1317-81-11-2645; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; Nakabayashi K, 1997, EXP CELL RES, V235, P345, DOI 10.1006/excr.1997.3678; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NAMBA M, 1985, INT J CANCER, V35, P275, DOI 10.1002/ijc.2910350221; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Renne R, 1998, J VIROL, V72, P5182, DOI 10.1128/JVI.72.6.5182-5188.1998; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 1998, CANCER RES, V58, P1558; TAPPERO JW, 1993, J AM ACAD DERMATOL, V28, P371, DOI 10.1016/0190-9622(93)70057-Z; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010	68	94	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22971	22978		10.1074/jbc.M101890200	http://dx.doi.org/10.1074/jbc.M101890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11313352	hybrid			2022-12-27	WOS:000169412700132
J	Vatamaniuk, OK; Bucher, EA; Ward, JT; Rea, PA				Vatamaniuk, OK; Bucher, EA; Ward, JT; Rea, PA			A new pathway for heavy metal detoxification in animals - Phytochelatin synthase is required for cadmium tolerance in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS; YEAST; GLUTATHIONE; RESISTANCE; PROTEIN; GENES	Increasing emissions of heavy metals such as cadmium, mercury, and arsenic into the environment pose an acute problem for all organisms. Considerations of the biochemical basis of heavy metal detoxification in animals have focused exclusively on two classes of peptides, the thiol tripeptide, glutathione (GSH, gamma -Glu Cys-Gly), and a diverse family of cysteine-rich low molecular weight proteins, the metallothioneins. Plants and some fungi, however, not only deploy GSH and metallothioneins for metal detoxification but also synthesize another class of heavy metal binding peptides termed phytochelatins (PCs) from GSH. Here we show that PC-mediated heavy metal detoxification is not restricted to plants and some fungi but extends to animals by demonstrating that the ce-pcs-l gene of the nematode worm Caenorhabditis elegans encodes a functional PC synthase whose activity is critical for heavy metal tolerance in the intact organism.	Univ Penn, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Rea, PA (corresponding author), Univ Penn, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu			NHLBI NIH HHS [R01-HL 59680-0] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059680] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Broeks A, 1996, EMBO J, V15, P6132, DOI 10.1002/j.1460-2075.1996.tb01001.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; Costa Max, 1998, Science Progress, V81, P329; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GIEST RD, 1991, YEAST, V7, P253; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HONG L, 2001, IN PRESS J CELL BIOL; Hu H, 2000, PRIMARY CARE, V27, P983, DOI 10.1016/S0095-4543(05)70185-8; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; Koga M, 2000, EMBO J, V19, P5148, DOI 10.1093/emboj/19.19.5148; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; Mello C, 1995, METHOD CELL BIOL, V48, P451; NORTHROPCLEWES CA, 1998, BR MED B, V56, P193; PARISH RW, 1975, ARCH MICROBIOL, V105, P187, DOI 10.1007/BF00447136; Sambrook J, 1989, MOL CLONING; Svoboda P, 2000, DEVELOPMENT, V127, P4147; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110	23	161	170	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20817	20820		10.1074/jbc.C100152200	http://dx.doi.org/10.1074/jbc.C100152200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11313333	hybrid			2022-12-27	WOS:000169297900004
J	Adam, L; Vadlamudi, RK; McCrea, P; Kumar, R				Adam, L; Vadlamudi, RK; McCrea, P; Kumar, R			Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta-catenin nuclear signaling in breast cancer cells by modulating the intercellular stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; N-TERMINAL PLECKSTRIN; PROTEIN-KINASE-C; BETA-CATENIN; GROWTH-FACTOR; EPITHELIAL-CELLS; ALPHA-CATENIN; E-CADHERIN; TYROSINE PHOSPHORYLATION	Heregulin-beta1 (HRG) promotes motility, scattering, and invasiveness of breast cancer cells. Tiam1, a newly identified guanine nucleotide exchange factor, has been shown to inhibit or promote cell migration in a cell type-dependent manner. In this study, we identified Tiam1 as a target of HRG signaling. HRG stimulation of breast cancer epithelial cells induced the phosphorylation and redistribution of Tiam1 to the membrane ruffles and the loosening of intercellular junctions. In addition, HRG-mediated scattering of breast epithelial cells was accompanied by stimulation of tyrosine phosphorylation and redistribution of beta -catenin from the cell junctions to the cytosol and, finally, entry into the nucleus. Decompaction of breast cancer epithelial cells by HRG was accompanied by a transient physical association of the tyrosine-phosphorylated beta -catenin with the activated human epidermal growth factor receptor 2 and subsequent nuclear translocation of beta -catenin, as well as beta -catenin-dependent transactivation of T-cell factor-lymphoid enhancer factor-1. All of these HRG-induced phenotypic changes were regulated in a phosphatidylinositol-3 kinase-sensitive manner. HRG-induced cellular ruffles, loss of intercellular adhesiveness, and increased cell migration could be mimicked by overexpression of a fully functional Tiam1 construct. Furthermore, ectopic expression of Tiam1 or of an active beta -catenin mutant led to potentiation of the beta -catenin-dependent T-cell factor-lymphoid enhancer factor-1 transactivation and invasiveness of HRG-treated cells. We also found preliminary evidence suggesting a close correlation between the status of Tiam1 expression and invasiveness of human breast tumor cells with the degree of progression of breast tumors. Together, these findings suggest that HRG regulate Tiam1 activation and lymphoid enhancer factor/beta -catenin nuclear signaling via phosphatidylinositol-3 kinase in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr 108, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA65746, CA16672, CA80066] Funding Source: Medline; NIGMS NIH HHS [R01 GM052112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA080066, U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Baeckstrom D, 2000, INT J ONCOL, V16, P1081; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fleming IN, 1998, FEBS LETT, V429, P229, DOI 10.1016/S0014-5793(98)00566-3; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER BM, 1997, CURR BIOL, V7, P443; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kumar R, 2000, J CLIN LIGAND ASSAY, V23, P233; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nieset JE, 1997, J CELL SCI, V110, P1013; Orsulic S, 1999, J CELL SCI, V112, P1237; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SINKOVICS JG, 1988, CRC CR REV IMMUNOL, V8, P217; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Takahashi K, 1997, ONCOGENE, V15, P71, DOI 10.1038/sj.onc.1201160; Vadlamudi R, 1999, CANCER RES, V59, P2843; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3	52	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28443	28450		10.1074/jbc.M009769200	http://dx.doi.org/10.1074/jbc.M009769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11328805	hybrid			2022-12-27	WOS:000170093400093
J	Matter, ML; Ruoslahti, E				Matter, ML; Ruoslahti, E			A signaling pathway from the alpha(5)beta 1 and alpha(v)beta(3) integrins that elevates bcl-2 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; NF-KAPPA-B; PROTEIN-KINASE; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; FIBRONECTIN RECEPTOR; TYROSINE PHOSPHORYLATION; TRANSDUCTION PATHWAY; MEDIATED ACTIVATION; MAP KINASE	Integrin-mediated cell adhesion is necessary for the survival of many cell types, and loss of adhesion causes apoptosis. We have previously shown that the alpha (5)beta (1) integrin supports cell survival on fibronectin and increases Bcl-2 protein expression. Here we show that bcl-2 transcription is elevated in cells that attach to fibronectin through alpha (v)beta (1) or to vitronectin through alpha (v)beta (1) but is not elevated in cells attaching through the alpha (v)beta (1) integrin. Bcl-2 protein expression and protection from apoptosis under serum-free conditions correlated with bcl-2 transcription. This integrin-mediated regulation of bcl-2 is She- and FAK-dependent, and activation of Ras by FAK is required. Furthermore, Ras mediates this up-regulation of bcl-2 by activating the phosphatidylinositol 3-kinase-AKT pathway. Mitogen-activated protein kinase did not appear to be necessary for the activation of bcl-2 transcription. Therefore, our work characterizes the pathway that mediates the effect of integrins on bcl-2 transcription and cell survival.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 90237 USA.		Matter, Michelle/GSN-9703-2022	Matter, Michelle/0000-0002-5988-9663	NATIONAL CANCER INSTITUTE [T32CA009579, R01CA079984, R01CA074238] Funding Source: NIH RePORTER; NCI NIH HHS [CA79984, CA74238, CA09579] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, NATURE, V396, P416, DOI 10.1038/24743; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Harigai M, 1996, ONCOGENE, V12, P1369; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matter ML, 1998, J CELL BIOL, V141, P1019, DOI 10.1083/jcb.141.4.1019; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; REY I, 1994, ONCOGENE, V9, P685; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	48	197	222	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27757	27763		10.1074/jbc.M102014200	http://dx.doi.org/10.1074/jbc.M102014200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11333270	hybrid			2022-12-27	WOS:000170093400004
J	Ikuta, M; Kamata, K; Fukasawa, K; Honma, T; Machida, T; Hirai, H; Suzuki-Takahashi, I; Hayama, T; Nishimura, S				Ikuta, M; Kamata, K; Fukasawa, K; Honma, T; Machida, T; Hirai, H; Suzuki-Takahashi, I; Hayama, T; Nishimura, S			Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CRYSTAL-STRUCTURES; CDC2 KINASE; GENE; COMPLEX; CANCER; G1; PHOSPHORYLATION; FLAVOPIRIDOL; SPECIFICITY	Genetic alteration of one or more components of the P16(INK4A)-CDK4,6/cyclin D-retinoblastoma pathway is found in more than half of all human cancers. Therefore, CDR4 is an attractive target, for the development of a novel anticancer agent. However, it is difficult to make CDK4-specific inhibitors that do not possess activity for other kinases, especially CDK2, because the CDH family has high structural homology, The three-dimensional structure of CDK2, particularly that bound with the inhibitor, has provided useful information for the synthesis of CDK2-specific inhibitors. The same approach used to make CDK4-specific inhibitors was hindered by the failure to obtain a crystal structure of CDK4, To overcome this problem, we synthesized a CDK4 mimic CDK2 protein in which the ATP binding pocket of CDK2 was replaced with that of CDK4, This CDK4 mimic CDK2 was crystallized both in the free and inhibitor-bound form. The structural information thus obtained was found to be useful for synthesis of a CDK4-specific inhibitor that does not, have substantial CDK2 activity. Namely, the data suggest that CDK4 has additional space that will accommodate a large substituent such as the CDK4 selective inhibitor. Inhibitors designed to bind into this large cavity should be selective for CDK4 without having substantial CDK2 activity. This design principle was confirmed in the x-ray crystal structure of the CDK4 mimic CDK2 with a new CDK4 selective inhibitor bound.	Merck Res Labs, Banyu Tsukuba Res Inst, Tsuchiura, Ibaraki 3002611, Japan	Merck & Company	Nishimura, S (corresponding author), Merck Res Labs, Banyu Tsukuba Res Inst, Okubo 3, Tsuchiura, Ibaraki 3002611, Japan.							BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carlson BA, 1996, CANCER RES, V56, P2973; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIGASHI H, 1995, BIOCHEM BIOPH RES CO, V216, P520, DOI 10.1006/bbrc.1995.2653; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; LESLIE AGW, 1990, CRYSTALLOGRAPHIC COM, P50; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	41	99	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27548	27554		10.1074/jbc.M102060200	http://dx.doi.org/10.1074/jbc.M102060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335721	hybrid			2022-12-27	WOS:000169966900107
J	Adimoolam, S; Lin, CX; Ford, JM				Adimoolam, S; Lin, CX; Ford, JM			The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; P53 TUMOR-SUPPRESSOR; HUMAN CANCER-CELLS; XERODERMA-PIGMENTOSUM; HUMAN FIBROBLASTS; IN-VITRO; PREFERENTIALLY AFFECTS; NONTRANSCRIBED STRAND; GENE; DAMAGE	The p53 tumor suppressor gene is a transcriptional activator involved in cell cycle regulation, apoptosis, and DNA repair. We have shown that p53 is required for efficient nucleotide excision repair of UV-induced DNA photoproducts from global genomic DNA but has no effect on transcription-coupled repair. In order to evaluate whether p53 influences repair indirectly through cell cycle arrest following DNA damage or plays a direct role, we examined repair in vivo in human cells genetically altered to disrupt or regulate the function of p53 and p21, Both primary human fibroblasts and HCT116 colon carcinoma cells wild type for p53 but in which the p21 gene was inactivated through targeted homologous recombination showed no decrease in global repair of W photoproducts, Human bladder carcinoma cells mutant for p53 and containing a tetracycline-regulated p21 cDNA showed no significant enhancement of repair upon induction of p21 expression. All of the cell lines, including the mismatch repair-deficient, MLH1 mutant HCT116 cells, were proficient for transcription-coupled repair. Clonogenic survival of HCT116 cells following W irradiation showed no dependence on p21, Therefore, our results indicate that p53-dependent nucleotide excision repair does not require the function of the p21 gene product and is independent of p53-regulated cell cycle checkpoints.	Stanford Univ, Sch Med, Dept Med, Div Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Div Oncol, Stanford, CA 94305 USA	Stanford University; Stanford University	Ford, JM (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Oncol, 1115 CCSR Bldg, Stanford, CA 94305 USA.	jmf@stanford.edu		Ford, James/0000-0002-2513-7025	NATIONAL CANCER INSTITUTE [R01CA083889] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83889] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Balajee AS, 1998, MUTAT RES-DNA REPAIR, V409, P135, DOI 10.1016/S0921-8777(98)00051-2; Bowman KK, 2000, MOL CARCINOGEN, V29, P17, DOI 10.1002/1098-2744(200009)29:1<17::AID-MC3>3.3.CO;2-5; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; El-Mahdy MA, 2000, MUTAT RES-DNA REPAIR, V459, P135, DOI 10.1016/S0921-8777(99)00066-X; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1997, CURR TOP MICROBIOL, V221, P47; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORD JM, 2000, P AM ASSOC CANC RES, V41, P1131; FOX M, 1981, DNA REPAIR, P523; Ganesan AK, 1999, MUTAT RES-DNA REPAIR, V433, P117, DOI 10.1016/S0921-8777(98)00070-6; HARPER JW, 1993, CELL, V75, P805; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leadon SA, 1997, CANCER RES, V57, P3784; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LOMMEL L, 1995, MUTAT RES-DNA REPAIR, V336, P181, DOI 10.1016/0921-8777(94)00055-B; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Shivji MKK, 1998, ONCOGENE, V17, P2827, DOI 10.1038/sj.onc.1202352; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Spivak Graciela, 1995, Methods (Orlando), V7, P147, DOI 10.1006/meth.1995.1021; Stewart ZA, 1999, CANCER RES, V59, P3831; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492	52	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25813	25822		10.1074/jbc.M102240200	http://dx.doi.org/10.1074/jbc.M102240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331289	hybrid			2022-12-27	WOS:000169823300025
J	Braun, P; Ockhuijsen, C; Eppens, E; Koster, M; Bitter, W; Tommassen, J				Braun, P; Ockhuijsen, C; Eppens, E; Koster, M; Bitter, W; Tommassen, J			Maturation of Pseudomonas aeruginosa elastase - Formation of the disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; GRAM-NEGATIVE BACTERIA; ACTIVE-SITE HIS-223; SECRETION; PROPEPTIDE; CLONING; MUTANTS; BINDING; GENES; TRANSLOCATION	Elastase of Pseudomonas aeruginosa is synthesized as a preproenzyme. After propeptide-mediated folding in the periplasm, the proenzyme is autoproteolytically processed, prior to translocation of both the mature enzyme and the propeptide across the outer membrane. The formation of the two disulfide bonds present in the mature enzyme was examined by studying the expression of the wild-type enzyme and of alanine for cysteine mutant derivatives in the authentic host and in dsb mutants of Escherichia coli. It appeared that the two disulfide bonds are formed successively. First, DsbA catalyzes the formation of the disulfide bond between Cys-270 and Cys-297 within the proenzyme, This step is essential for the subsequent autoproteolytic processing to occur, The second disulfide bond between Cys-30 and Cys-57 is formed more slowly and appears to be formed after processing of the proenzyme, and its formation is catalyzed by DsbA as well. This second disulfide bond appeared to be required for the full proteolytic activity of the enzyme and contributes to its stability.	Univ Utrecht, Dept Mol & Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	Tommassen, J (corresponding author), Univ Utrecht, Dept Mol & Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	j.p.m.tommassen@bio.uu.nl	Bitter, W/CAJ-5778-2022; Bitter, Wilbert/AAA-6872-2019; Bitter, Wilbert/ABG-3726-2020; Koster, Margot/D-1261-2011; Tommassen, Jan/I-1690-2016	Bitter, Wilbert/0000-0001-8347-6511; Tommassen, Jan/0000-0001-7633-4945; Braun, Peter/0000-0002-9870-465X				BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; Braun P, 2000, MICROBIOL-UK, V146, P2565, DOI 10.1099/00221287-146-10-2565; Braun P, 1998, J BACTERIOL, V180, P3467, DOI 10.1128/JB.180.13.3467-3469.1998; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; DEGROOT A, 1991, MOL GEN GENET, V229, P278, DOI 10.1007/BF00272167; Eppens EF, 1997, EMBO J, V16, P4295, DOI 10.1093/emboj/16.14.4295; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FILLOUX A, 1987, FEMS MICROBIOL LETT, V40, P159; Filloux A, 1998, FEMS MICROBIOL REV, V22, P177, DOI 10.1016/S0168-6445(98)00013-8; Folders J, 2000, J BACTERIOL, V182, P1257, DOI 10.1128/JB.182.5.1257-1263.2000; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GUZZO J, 1990, J BACTERIOL, V172, P942, DOI 10.1128/jb.172.2.942-948.1990; HAAS D, 1976, MOL GEN GENET, V144, P243, DOI 10.1007/BF00341722; HARDIE KR, 1995, MOL MICROBIOL, V17, P1035, DOI 10.1111/j.1365-2958.1995.mmi_17061035.x; HEKSTRA D, 1993, J BACTERIOL, V175, P6546, DOI 10.1128/jb.175.20.6546-6552.1993; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; KANIGA K, 1991, GENE, V109, P137, DOI 10.1016/0378-1119(91)90599-7; KESSLER E, 1988, J BACTERIOL, V170, P5241, DOI 10.1128/jb.170.11.5241-5247.1988; Kessler E, 1998, J BIOL CHEM, V273, P30225, DOI 10.1074/jbc.273.46.30225; KESSLER E, 1994, J BIOL CHEM, V269, P22726; KING EO, 1954, J LAB CLIN MED, V44, P301; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MCIVER K, 1991, J BACTERIOL, V173, P7781, DOI 10.1128/jb.173.24.7781-7789.1991; McIver KS, 1995, MOL MICROBIOL, V18, P877, DOI 10.1111/j.1365-2958.1995.18050877.x; MCIVER KS, 1993, J BACTERIOL, V175, P4008, DOI 10.1128/JB.175.13.4008-4015.1993; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAD PA, 1987, J BACTERIOL, V169, P2691, DOI 10.1128/jb.169.6.2691-2696.1987; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TOMMASSEN J, 1992, FEMS MICROBIOL LETT, V103, P73; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; Wilhelm S, 1999, J BACTERIOL, V181, P6977, DOI 10.1128/JB.181.22.6977-6986.1999; WRETLIND B, 1984, J BACTERIOL, V158, P801, DOI 10.1128/JB.158.3.801-808.1984; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	43	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26030	26035		10.1074/jbc.M007122200	http://dx.doi.org/10.1074/jbc.M007122200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11350952	hybrid			2022-12-27	WOS:000169823300053
J	Gargalovic, P; Dory, L				Gargalovic, P; Dory, L			Caveolin-1 and caveolin-2 expression in mouse macrophages - High density lipoprotein 3-stimulated secretion and a lack of significant subcellular co-localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; APOLIPOPROTEIN-E; GOLGI-COMPLEX; IN-VIVO; CHOLESTEROL TRANSPORT; PROTEIN CAVEOLIN; BINDING PROTEIN; GENE FAMILY; IDENTIFICATION; CELLS	Evidence for caveolin expression in macrophages is scarce and conflicting. We therefore examined caveolin-1 and caveolin-2 expression in resident and thioglycollate-elicited mouse peritoneal macrophages (tg-MPM) and in the J774 mouse macrophage cell line by RT-PCR, ribonuclease protection assay, immunoblotting, and immunofluorescence. We found that relative to 3T3 cells, resident MPM and tg-MPM express low amounts of caveolin-1 (45 and 15% of those in 3T3 fibroblasts, respectively), while J774.A1 cells do not express any. Caveolin-2, on the other hand, is expressed in all cells examined, with highest expression in tg-MPM and the lowest in J774 cells. The relative levels of caveolin expression in the various cells correspond well with their respective mRNA levels, as measured by ribonuclease protection assay. Caveolin-1, present primarily on the cell surface, does not co-localize significantly with caveolin-2, which is present primarily in the Golgi compartment in all macrophages studied. Loading of tg-MPM with cholesterol or variations in unesterified cholesterol content appear to have little effect on the level of caveolin-1 or -2 expression or their distribution. Stimulation of cholesterol efflux by HDL, leads to caveolin-1 and caveolin-2 secretion to the cell culture medium, a process not detected in the absence of HDL,, The lack of significant co-localization of the two caveolin isoforms in primary macrophages and their secretion in the presence of HDL, provides an interesting and physiologically relevant model system to study additional aspects of caveolin function.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA	University of North Texas System; University of North Texas Health Science Center	Dory, L (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.				NHLBI NIH HHS [HL 45513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAM R, 1989, BIOCHIM BIOPHYS ACTA, V1004, P292, DOI 10.1016/0005-2760(89)90076-3; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DENG JT, 1995, J LIPID RES, V36, P2129; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; DORY L, 1991, J LIPID RES, V32, P783; DORY L, 1989, J LIPID RES, V30, P809; Fielding CJ, 1997, J LIPID RES, V38, P1503; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Hailstones D, 1998, J LIPID RES, V39, P369; HO MK, 1982, J IMMUNOL, V128, P1221; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lei MG, 2000, INFECT IMMUN, V68, P5084, DOI 10.1128/IAI.68.9.5084-5089.2000; Li SW, 1996, J BIOL CHEM, V271, P3863; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Matveev S, 1999, J LIPID RES, V40, P1647; Mora R, 1999, J BIOL CHEM, V274, P25708, DOI 10.1074/jbc.274.36.25708; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Sengelov H, 1998, J LEUKOCYTE BIOL, V63, P563, DOI 10.1002/jlb.63.5.563; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; TAKEMURA R, 1984, AM J PHYSIOL, V246, P1; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; van Reyk DM, 1999, J LEUKOCYTE BIOL, V66, P557, DOI 10.1002/jlb.66.4.557	42	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26164	26170		10.1074/jbc.M011291200	http://dx.doi.org/10.1074/jbc.M011291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316799	hybrid			2022-12-27	WOS:000169823300071
J	Jang, GF; Kuksa, V; Filipek, S; Bartl, F; Ritter, E; Gelb, MH; Hofmann, KP; Palczewski, K				Jang, GF; Kuksa, V; Filipek, S; Bartl, F; Ritter, E; Gelb, MH; Hofmann, KP; Palczewski, K			Mechanism of rhodopsin activation as examined with ring-constrained retinal analogs and the crystal structure of the ground state protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-STABLE RHODOPSIN; BETA-IONONE RING; VISUAL PIGMENT; TRANSDUCIN ACTIVATION; BOVINE RHODOPSIN; 9-METHYL GROUP; BINDING-SITE; CHROMOPHORE; SPECTROSCOPY; FTIR	The guanine nucleotide-binding protein (G-protein)coupled receptor superfamily (GPCR) is comprised of a large group of membrane proteins involved in a wide range of physiological signaling processes. The functional switch from a quiescent to an active conformation is at the heart of GPCR action. The GPCR rhodopsin has been studied extensively because of its key role in scotopic vision. The ground state chromophore, Il-cis-retinal, holds the transmembrane region of the protein in the inactive conformation, Light induces cis-trans isomerization and rhodopsin activation. Here we show that rhodopsin regenerated with a ring-constrained 11-cis-retinal analog undergoes photoisomerization; however, it remains marginally active because isomerization occurs without the chromophore-induced conformational change of the opsin moiety, Modeling the locked chromophore analogs in the active site of rhodopsin suggests that the beta -ionone ring rotates but is largely confined within the binding site of the natural Il-cis-retinal chromophore, This constraint is a result of the geometry of the stable 11-cis-locked configuration of the chromophore analogs. These results suggest that the native chromophore cis-trans isomerization is merely a mechanism for repositioning of the beta -ionone ring which ultimately leads to helix movements and determines receptor activation.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Warsaw, Dept Chem, PL-02093 Warsaw, Poland; Humboldt Univ, Univ Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Warsaw; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.		Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858; gelb, michael/0000-0001-7000-5219	NEI NIH HHS [R01 EY009339] Funding Source: Medline; NIEHS NIH HHS [ES09339] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKITA A, 1980, J AM CHEM SOC, V102, P6372; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; GANTER UM, 1989, BIOCHEMISTRY-US, V28, P5954, DOI 10.1021/bi00440a036; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Grobner G, 2000, NATURE, V405, P810, DOI 10.1038/35015604; Han M, 1997, P NATL ACAD SCI USA, V94, P13442, DOI 10.1073/pnas.94.25.13442; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HUANG MJ, 1994, J AM CHEM SOC, V116, P2515; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P6257, DOI 10.1021/bi9519359; ITO M, 1992, PHOTOCHEM PHOTOBIOL, V56, P915, DOI 10.1111/j.1751-1097.1992.tb09713.x; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; Jang GF, 2000, J BIOL CHEM, V275, P28128; KHORANA HG, 1999, J BIOMOL STRUCT DES, V1, P1; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; LIU RSH, 1988, J AM CHEM SOC, V110, P8617, DOI 10.1021/ja00234a007; MAPLE JR, 1994, J COMPUT CHEM, V15, P162, DOI 10.1002/jcc.540150207; MATSUMOTO H, 1975, NATURE, V258, P523, DOI 10.1038/258523a0; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rao VR, 1996, ANNU REV BIOPH BIOM, V25, P287; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SHEVES M, 1986, J AM CHEM SOC, V108, P6440, DOI 10.1021/ja00280a081; SHICHIDA Y, 1988, BIOCHEMISTRY-US, V27, P6495, DOI 10.1021/bi00417a044; TELLER DC, 2001, IN PRESS BIOCHEMISTR; VANDERSTEEN R, 1989, RECL TRAV CHIM PAY B, V108, P20; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0; ZANKEL T, 1990, J AM CHEM SOC, V112, P5387, DOI 10.1021/ja00169a077; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	38	52	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26148	26153		10.1074/jbc.M102212200	http://dx.doi.org/10.1074/jbc.M102212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316815	Green Accepted, hybrid			2022-12-27	WOS:000169823300069
J	Lai, A; Sarcevic, B; Prall, OWJ; Sutherland, RL				Lai, A; Sarcevic, B; Prall, OWJ; Sutherland, RL			Insulin/Insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; ALPHA GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; MITOGENIC STIMULATION; CARCINOMA CELLS; CDK INHIBITORS; KINASE; PROLIFERATION; COMPLEX	Estrogens and insulin/insulin-like growth factor-I (IGF-I) are potent mitogens for breast epithelial cells and, when co-administered, induce synergistic stimulation of cell proliferation. To investigate the molecular basis of this effect, a MCF-7 breast cancer cell model was established where serum deprivation and concurrent treatment with the pure estrogen antagonist, ICI 182780, inhibited growth factor and estrogen action and arrested cells in G(0)/G(1) phase. Subsequent stimulation with insulin or IGF-I alone failed to induce significant S-phase entry. However, these treatments increased cy. clin D1, cyclin E, and p21 gene expression and induced the formation of active Cdk4 complexes but resulted in only minor increases in cyclin E-Cdk2 activity, likely due to recruitment of the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/Cip1) into these complexes. Treatment with estradiol alone resulted in a greater increase in cyclin D1 gene expression but markedly decreased p21 expression, with a concurrent increase in Cdk4 and Cdk2 activity and subsequent synchronous entry of cells into S phase. Go-administration of insulin/ IGF-I and estrogen induced synergistic stimulation of S-phase entry coincident with synergistic: activation of high molecular mass (similar to 350 kDa) cyclin E-Cdk2 complexes lacking p21, To determine if the ability of estrogen to deplete p21 was central to these effects, cells stimulated with insulin and estradiol were infected with an adenovirus expressing p21, Induction of p21 to levels equivalent to those following treatment with insulin alone markedly inhibited the synergism between estradiol and insulin on S-phase entry. Thus the ability of estradiol to antagonize the insulin-induced increase in p21 gene expression, with consequent activation of cy. clin E-Cdk2, is a central component of the synergistic stimulation of breast epithelial cell proliferation induced by simultaneous activation of the estrogen and insulin/IGF-I signaling pathways.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St,Darlinghurst, Sydney, NSW 2010, Australia.		Sutherland, Robert L/A-8378-2008	Sarcevic, Boris/0000-0002-8063-1050				ADAMO M, 1992, BIOFACTORS, V3, P151; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; Altucci L, 1996, ONCOGENE, V12, P2315; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Daws MR, 1996, ENDOCRINOLOGY, V137, P1177, DOI 10.1210/en.137.4.1177; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; FALCKPEDERSEN E, 1998, CELLS LAB MANUAL; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Guvakova MA, 1997, CANCER RES, V57, P2606; HARLOW E, 1988, ANTIBODIES LAB MANUA, P526; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 1997, J ENDOCRINOL, V152, P39, DOI 10.1677/joe.0.1520039; Lukas J, 1996, MOL CELL BIOL, V16, P6917; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; MILAZZO G, 1992, J CLIN INVEST, V89, P899, DOI 10.1172/JCI115670; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nicholson RI, 1996, ANN NY ACAD SCI, V784, P325, DOI 10.1111/j.1749-6632.1996.tb16247.x; OSBORNE CK, 1976, P NATL ACAD SCI USA, V73, P4536, DOI 10.1073/pnas.73.12.4536; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STEWART AJ, 1992, BRIT J CANCER, V66, P640, DOI 10.1038/bjc.1992.330; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; Thornton JM, 1992, SEED SCI RES, V2, P41, DOI 10.1017/S0960258500001094; VANDERBURG B, 1990, CANCER RES, V50, P7770; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	56	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25823	25833		10.1074/jbc.M100925200	http://dx.doi.org/10.1074/jbc.M100925200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337496	hybrid			2022-12-27	WOS:000169823300026
J	Mitrovic, AD; Plesko, F; Vandenberg, RJ				Mitrovic, AD; Plesko, F; Vandenberg, RJ			Zn2+ inhibits the anion conductance of the glutamate transporter EAAT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL GLIAL-CELLS; RAT-BRAIN; CHLORIDE CHANNEL; ZINC; NEURONS; EXPRESSION; ASPARTATE; SUBTYPES; CURRENTS; AFFINITY	Glutamate transport by the excitatory amino acid transporters (EAATs) is coupled to the co-transport of 3 Na+ ions and 1 H+ and the counter-transport of 1 K+ ion, which ensures that extracellular glutamate concentrations are maintained in the submicromolar range. In addition to the coupled ion fluxes, glutamate transport activates an uncoupled anion conductance that does not influence the rate or direction of transport but may have the capacity to influence the excitability of the cell. Free Zn2+ ions are often co-localized with glutamate in the central nervous system and have the capacity to modulate the dynamics of excitatory neurotransmission. In this study we demonstrate that Zn2+ ions inhibit the uncoupled anion conductance and also reduce the affinity of L-aspartate for EAAT4. The molecular basis for this effect was investigated using site-directed mutagenesis. Two histidine residues in the extracellular loop between transmembrane domains three and four of EAAT4 appear to confer Zn2+ inhibition of the anion conductance.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Sydney	Vandenberg, RJ (corresponding author), Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@pharmacol.usyd.edu.au	Vandenberg, Robert John/E-6018-2016	Vandenberg, Robert John/0000-0003-1523-4814				ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Billups B, 1996, J NEUROSCI, V16, P6722; BUSSELBERG D, 1994, J NEUROPHYSIOL, V71, P1491, DOI 10.1152/jn.1994.71.4.1491; DAWSON RMC, 1986, DATA BIOCH RES, P76; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Lehre KP, 1998, J NEUROSCI, V18, P8751, DOI 10.1523/jneurosci.18-21-08751.1998; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Marie H, 1999, J PHYSIOL-LONDON, V520, P393, DOI 10.1111/j.1469-7793.1999.00393.x; MILEDI R, 1989, J PHYSIOL-LONDON, V417, P173, DOI 10.1113/jphysiol.1989.sp017796; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; REGAN L, 1995, TRENDS BIOCHEM SCI, V20, P280, DOI 10.1016/S0968-0004(00)89044-1; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; Spiridon M, 1998, J PHYSIOL-LONDON, V506, P363, DOI 10.1111/j.1469-7793.1998.363bw.x; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Vandenberg RJ, 1997, MOL PHARMACOL, V51, P809, DOI 10.1124/mol.51.5.809; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26071	26076		10.1074/jbc.M011318200	http://dx.doi.org/10.1074/jbc.M011318200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352900	hybrid			2022-12-27	WOS:000169823300059
J	Takei, K; Sakakibara, H; Sugiyama, T				Takei, K; Sakakibara, H; Sugiyama, T			Identification of genes encoding adenylate isopentenyltransferase, a cytokinin biosynthesis enzyme, in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; PROTEIN; DNA; EXPRESSION; BINDING	The initial step in the de novo biosynthesis of cytokinin in higher plants is the formation of isopentenyladenosine 5 ' -monophosphate (iPMP) from AMP and dimethylallylpyrophosphate (DMAPP), which is catalyzed by adenylate isopentenyltransferase (IPT). Although cytokinin is an essential hormone for growth and development, the nature of the enzyme for its biosynthesis in higher plants has not been identified. Herein, we describe the molecular cloning and biochemical identification of IPTs from Arabidopsis thaliana. Eight cDNAs encoding putative IPT, designated as AtIPT1 to AtIPT8, were picked up from A. thaliana, The Escherichia coli transformants expressing the recombinant proteins excreted cytokinin species into the culture medium except for that expressing AtIPT2 that is a putative tRNA IPT. A purified recombinant AtIPT1 catalyzed the formation of iPMP from DMAPP and AMP. These results indicate that the small multigene family contains both types of isopentenyltransferase, which could synthesize cytokinin and mature tRNA.	RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Wako, Saitama 3510198, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Biol Mech & Funct, Nagoya, Aichi 4648601, Japan	RIKEN; Nagoya University	Sakakibara, H (corresponding author), RIKEN, Inst Phys & Chem Res, Plant Sci Ctr, Hirosawa 2-1, Wako, Saitama 3510198, Japan.		Sakakibara, Hitoshi/A-6040-2010; Ding, Cheng-Qiang/B-6287-2011	Sakakibara, Hitoshi/0000-0001-5449-6492; 				AKIYOSHI DE, 1984, P NATL ACAD SCI-BIOL, V81, P5994, DOI 10.1073/pnas.81.19.5994; Astot C, 2000, P NATL ACAD SCI USA, V97, P14778, DOI 10.1073/pnas.260504097; BARTZ JK, 1972, BIOCHIMIE, V54, P31, DOI 10.1016/S0300-9084(72)80035-X; BLACKWELL JR, 1994, PHYTOCHEMISTRY, V35, P339, DOI 10.1016/S0031-9422(00)94760-5; BLACKWELL JR, 1993, PHYTOCHEMISTRY, V34, P1477, DOI 10.1016/S0031-9422(00)90831-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAILLET J, 1988, J BACTERIOL, V170, P4147, DOI 10.1128/jb.170.9.4147-4152.1988; CHEN CM, 1979, FEBS LETT, V107, P15, DOI 10.1016/0014-5793(79)80452-4; CHEN CM, 1994, CYTOKININS CHEM ACTI, P81; CHONG S, 1995, BIOCHEMISTRY-US, V34, P3695; CRESPI M, 1992, EMBO J, V11, P795, DOI 10.1002/j.1460-2075.1992.tb05116.x; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; Feldman L. J., 1975, The development and function of roots (Third Cabot Symposium)., P55; FUJIWARA T, 1992, PLANT PHYSIOL, V99, P263, DOI 10.1104/pp.99.1.263; Golovko A, 2000, GENE, V258, P85, DOI 10.1016/S0378-1119(00)00421-2; HOLTZ J, 1978, H-S Z PHYSIOL CHEM, V359, P89; HOLTZ J, 1975, H-S Z PHYSIOL CHEM, V356, P1459; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; KLAMBT D, 1992, PHYSIOLOGY AND BIOCHEMISTRY OF CYTOKININS IN PLANTS, P25; KLINE KL, 1969, BIOCHEMISTRY-US, V8, P4361; KODA Y, 1980, PHYSIOL PLANTARUM, V49, P193, DOI 10.1111/j.1399-3054.1980.tb02651.x; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; LICHTER A, 1995, J BACTERIOL, V177, P4457, DOI 10.1128/jb.177.15.4457-4465.1995; MASUI Y, 1983, EXPT MANIPULATION GE, P15; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; Mok MC., 1994, CYTOKININS CHEM ACTI, P155, DOI DOI 10.1201/9781351071284; POWELL GK, 1986, NUCLEIC ACIDS RES, V14, P2555, DOI 10.1093/nar/14.6.2555; ROSENBAUM N, 1972, J BIOL CHEM, V247, P5675; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shudo K., 1994, CYTOKININS CHEM ACTI, P35; Suzuki K, 1998, BBA-GENE STRUCT EXPR, V1396, P1, DOI 10.1016/S0167-4781(97)00182-6; Suzuki T, 2001, PLANT CELL PHYSIOL, V42, P107, DOI 10.1093/pcp/pce037; SWAMINATHAN S, 1977, BIOCHEMISTRY-US, V16, P1355, DOI 10.1021/bi00626a018; Takei K, 2001, PLANT CELL PHYSIOL, V42, P85, DOI 10.1093/pcp/pce009; WADSWORTH GJ, 1988, ANAL BIOCHEM, V172, P279, DOI 10.1016/0003-2697(88)90443-5	38	334	388	3	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26405	26410		10.1074/jbc.M102130200	http://dx.doi.org/10.1074/jbc.M102130200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313355	hybrid			2022-12-27	WOS:000169823300101
J	Yang, JQ; Kawai, Y; Hanson, RW; Arinze, IJ				Yang, JQ; Kawai, Y; Hanson, RW; Arinze, IJ			Sodium butyrate induces transcription from the G alpha(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITORS; LLC-PK1 RENAL-CELLS; CHAIN FATTY-ACIDS; RNA-POLYMERASE-II; EMBRYONAL CARCINOMA-CELLS; HUMAN K562 CELLS; PROTEIN-KINASE; ALPHA-SUBUNIT; MAP KINASE; PROTOONCOGENE TRANSCRIPTION	Sodium butyrate, an erythroid differentiation inducer and a histone deacetylase inhibitor, increases G alpha (i2), levels in differentiating K562 cells, Here we show that sodium butyrate induces Gal, gene transcription via sequences at -50/-36 and -92/-85 in the G alpha (i), gene promoter. Both sequences contain core sequence motif for Spl binding; electrophoretic mobility shift as well as supershift assays confirmed binding to Spl, Transcription from the G alpha (i2) gene promoter was also activated by two other histone deacetylase inhibitors, trichostatin A and Helminthsporium carbonium toxin (HC toxin), which also induce erythroblastic differentiation in K562 cells. However, hydroxyurea, a potent erythroid differentiation inducer in these cells, did not activate transcription from this gene promoter, indicating that promoter activation is inducer-specific, Mutations within the Spl sites at -50/-36 and -92/-85 in the Gai, gene promoter substantially decreased transcriptional activation by sodium butyrate, trichostatin A, or HC toxin, Transfection with constitutively activated ERKs indicated that this promoter can be activated through the MEK-ERK signal transduction pathway. Inhibition of the MEK-ERK pathway with U0126 or reduction in the expression of endogenous ERK with an antisense oligonucleotide to ERK significantly inhibited sodium butyrate- and HC toxin-induced transcription but had no effect on trichostatin A-induced transcription, Inhibition of the JNK and p38 MAPKs, using selective inhibitors, had no effect on sodium butyrate-induced transcription. In cells in which sodium butyrate induction of promoter activation had been inhibited by various concentrations of U0126, constitutively activated ERK2 reversed this inhibition. These results show that the MEK-ERK signal transduction pathway is important in butyrate signaling, which eventually converges in the cell nucleus.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Meharry Medical College; Case Western Reserve University	Arinze, IJ (corresponding author), Meharry Med Coll, Dept Biochem, 1005 David B Todd Jr Blvd, Nashville, TN 37208 USA.	i.arinze@worldnet.att.net			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25541] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADUNYAH SE, 1995, BBA-GENE STRUCT EXPR, V1263, P123; Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Benvenuto G, 1996, MOL CELL BIOL, V16, P2736; BIRREN BW, 1986, NUCLEIC ACIDS RES, V14, P853, DOI 10.1093/nar/14.2.853; BROSCH G, 1995, PLANT CELL, V7, P1941, DOI 10.1105/tpc.7.11.1941; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CONSTANTOULAKIS P, 1989, BLOOD, V74, P1963; Courilleau D, 2000, J BIOL CHEM, V275, P17344, DOI 10.1074/jbc.M000887200; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Davis MG, 2000, BIOCHEM J, V346, P455, DOI 10.1042/0264-6021:3460455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOVER GJ, 1986, BLOOD, V67, P735; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Eschenhagen T, 1996, BASIC RES CARDIOL, V91, P41, DOI 10.1007/BF00795361; Espinos E, 1998, MOL BRAIN RES, V56, P118, DOI 10.1016/S0169-328X(98)00036-9; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; HEERDT BG, 1994, CANCER RES, V54, P3288; HERUTH DP, 1993, J BIOL CHEM, V268, P20466; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; Janson W, 1997, ONCOGENE, V15, P1395, DOI 10.1038/sj.onc.1201304; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Khanna-Gupta A, 2000, BLOOD, V95, P3734; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LAZAR MA, 1990, J BIOL CHEM, V265, P17474; LE HB, 1994, DNA CELL BIOL, V13, P473, DOI 10.1089/dna.1994.13.473; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Lu Y, 1999, BBA-GENE STRUCT EXPR, V1444, P85, DOI 10.1016/S0167-4781(98)00257-7; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; McBain JA, 1997, BIOCHEM PHARMACOL, V53, P1357, DOI 10.1016/S0006-2952(96)00904-5; McCaffrey PG, 1997, BLOOD, V90, P2075, DOI 10.1182/blood.V90.5.2075; MERCHANT JL, 1995, J BIOL CHEM, V270, P6314, DOI 10.1074/jbc.270.11.6314; Merchiers P, 1999, FEBS LETT, V456, P149, DOI 10.1016/S0014-5793(99)00942-4; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Naar AM, 1998, COLD SPRING HARB SYM, V63, P189, DOI 10.1101/sqb.1998.63.189; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Netzker R, 1999, BBA-GENE STRUCT EXPR, V1444, P231, DOI 10.1016/S0167-4781(98)00281-4; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; RIUS C, 1990, EXP CELL RES, V188, P129, DOI 10.1016/0014-4827(90)90287-K; Rivero JA, 1996, BIOCHEM BIOPH RES CO, V224, P796, DOI 10.1006/bbrc.1996.1102; ROEDIGER WEW, 1980, LANCET, V2, P712; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHEPPACH W, 1992, JPEN-PARENTER ENTER, V16, P43, DOI 10.1177/014860719201600143; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	77	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25742	25752		10.1074/jbc.M102821200	http://dx.doi.org/10.1074/jbc.M102821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337508	hybrid			2022-12-27	WOS:000169823300016
J	Blobe, GC; Schiemann, WP; Pepin, MC; Beauchemin, M; Moustakas, A; Lodish, HF; O'Connor-McCourt, MD				Blobe, GC; Schiemann, WP; Pepin, MC; Beauchemin, M; Moustakas, A; Lodish, HF; O'Connor-McCourt, MD			Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; GENE-EXPRESSION; LIGAND-BINDING; I RECEPTOR; BETAGLYCAN; ENDOGLIN; COMPLEX; FORM; RESPONSIVENESS; PATHWAY	Transforming growth factor beta (TGF-beta) signals through three high affinity cell surface receptors, TGF-beta type I, type II, and type III receptors, The type III receptor, also known as betaglycan, binds to the type II receptor and is thought to act solely by "presenting" the TGF-beta ligand to the type II receptor. The short cytoplasmic domain of the type III receptor is thought to have no role in TGF-beta signaling because deletion of this domain has no effect on association with the type II receptor, or with the presentation role of the type III receptor. Here we demonstrate that the cytoplasmic domains of the type III and type II receptors interact specifically in a manner dependent on the kinase activity of the type II receptor and the ability of the type II receptor to autophosphorylate, This interaction results in the phosphorylation of the cytoplasmic domain of the type III receptor by the type II receptor, The type III receptor with the cytoplasmic domain deleted is able to bind TGF-beta, to bind the type II receptor, and to enhance TGF-beta binding to the type II receptor but is unable to enhance TGF-beta signaling, determining that the cytoplasmic domain is essential for some functions of the type III receptor. The type III receptor functions by selectively binding the autophosphorylated type II receptor via its cytoplasmic domain, thus promoting the preferential formation of a complex between the autophosphorylated type II receptor and the type I receptor and then dissociating from this active signaling complex. These studies, for the first time, elucidate important functional roles of the cytoplasmic domain of the type III receptor and demonstrate that these roles are essential for regulating TGF-beta signaling.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Biotechnol Res Inst, Cell Surface Recognot Grp, Montreal, PQ H4P 2R2, Canada; Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Massachusetts General Hospital; National Research Council Canada; Ludwig Institute for Cancer Research	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 2631, Durham, NC 27710 USA.		Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NCI NIH HHS [CA63260, CA73161-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA073161, R01CA063260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fink SP, 2001, CANCER RES, V61, P256; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LIN HY, 1994, CELL MOL BIOL, V40, P337; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; MORELLO JP, 1995, J CELL PHYSIOL, V165, P201, DOI 10.1002/jcp.1041650123; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; PEPIN MC, 1994, P NATL ACAD SCI USA, V91, P6997, DOI 10.1073/pnas.91.15.6997; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; SANKAR S, 1995, J BIOL CHEM, V270, P13567, DOI 10.1074/jbc.270.22.13567; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	30	104	118	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24627	24637		10.1074/jbc.M100188200	http://dx.doi.org/10.1074/jbc.M100188200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323414	hybrid			2022-12-27	WOS:000169800700030
J	Detich, N; Ramchandani, S; Szyf, M				Detich, N; Ramchandani, S; Szyf, M			A conserved 3 '-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; A+U-RICH ELEMENTS; DEPENDENT REGULATION; CYTOSINE-DNA; CELL-CYCLE; SERUM STIMULATION; SIGNALING PATHWAY; BINDING PROTEIN; COLON-CANCER	Ectopic expression of DNA methyltransferase 1 (DNMT1) has been proposed to play an important role in cancer. dnmt1 mRNA is undetectable in growth-arrested cells but is induced upon entrance into the S phase of the cell cycle, and until now, the mechanisms responsible for this regulation were unknown. In this report, we demonstrate that the 3 ' -untranslated region (3 ' -UTR) of the dnmt1 mRNA can confer a growth-dependent regulation on its own message as well as a heterologous beta -globin mRNA Our results indicate that a 54-nucleotide highly conserved element within the 3 ' -UTR is necessary and sufficient to mediate this regulation. Cell-free mRNA decay experiments demonstrate that this element increases mRNA turnover rates and does so to a greater extent in the presence of extracts prepared from arrested cells. A specific RNA-protein complex is formed with the 3 ' -UTR only in growth-arrested cells, and a UV cross-linking analysis revealed a 40-kDa protein (p40), the binding of which is dramatically increased in growth-arrested cells and is inversely correlated with dnmt1 mRNA levels as cells are induced into the cell cycle. Although ectopic expression of human DNMT1 lacking the 3 ' -UTR can transform NIH-3T3 cells, inclusion of the 3 ' -UTR prevents transformation. These results support the hypothesis that deregulated expression of DNMT1 with the cell cycle is important for cellular transformation.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; Atasoy U, 1998, J CELL SCI, V111, P3145; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Baker DM, 2000, J BIOL CHEM, V275, P19985, DOI 10.1074/jbc.M002351200; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Buzby JS, 1996, BLOOD, V88, P2889, DOI 10.1182/blood.V88.8.2889.bloodjournal8882889; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; De Marzo AM, 1999, CANCER RES, V59, P3855; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Eads CA, 1999, CANCER RES, V59, P2302; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heaton JH, 2001, J BIOL CHEM, V276, P3341, DOI 10.1074/jbc.M006538200; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Jurgens B, 1996, CANCER RES, V56, P5698; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Kessler O, 1996, MOL CELL BIOL, V16, P4426; Knox JD, 2000, J BIOL CHEM, V275, P17986, DOI 10.1074/jbc.C900894199; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Liu YL, 1996, NUCLEIC ACIDS RES, V24, P2718, DOI 10.1093/nar/24.14.2718; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Maity A, 1997, CELL GROWTH DIFFER, V8, P311; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Melamed M. R., 1990, FLOW CYTOMETRY SORTI; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nass SJ, 1999, ONCOGENE, V18, P7453, DOI 10.1038/sj.onc.1203138; Noe V, 1999, J BIOL CHEM, V274, P27807, DOI 10.1074/jbc.274.39.27807; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Pande A, 1996, J BIOL CHEM, V271, P8493, DOI 10.1074/jbc.271.14.8493; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Scheper W, 1996, BIOCHEM J, V318, P195, DOI 10.1042/bj3180195; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; Staton JM, 2000, J MOL ENDOCRINOL, V25, P17, DOI 10.1677/jme.0.0250017; SURDEJ P, 1994, ANNU REV GENET, V28, P263; SZYF M, 1985, J BIOL CHEM, V260, P8653; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1984, P NATL ACAD SCI-BIOL, V81, P3278, DOI 10.1073/pnas.81.11.3278; Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5; Szyf M, 2000, ANN NY ACAD SCI, V910, P156; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; TEUBNER B, 1995, J CELL PHYSIOL, V165, P284, DOI 10.1002/jcp.1041650209; Tholanikunnel BG, 1999, BIOCHEMISTRY-US, V38, P15564, DOI 10.1021/bi9913348; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Wu J C, 1985, Prog Clin Biol Res, V198, P119; Wu JJ, 1996, CANCER RES, V56, P616; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zhou QM, 1998, MOL CELL BIOL, V18, P815, DOI 10.1128/MCB.18.2.815	84	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24881	24890		10.1074/jbc.M103056200	http://dx.doi.org/10.1074/jbc.M103056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335728	hybrid			2022-12-27	WOS:000169800700061
J	Genetta, T; Morisaki, H; Morisaki, T; Holmes, EW				Genetta, T; Morisaki, H; Morisaki, T; Holmes, EW			A novel bipartite intronic splicing enhancer promotes the inclusion of a mini-exon in the AMP deaminase 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR-2; TRACT BINDING-PROTEIN; ALTERNATIVE EXON; SKELETAL-MUSCLE; RNA; EXPRESSION; RECOGNITION; ELEMENT; SITE; IDENTIFICATION	Alternative splicing of the 12-base exon 2 of the adenosine monophosphate deaminase (AMPD) gene is subject to regulation by both cis- and trans-regulatory signals. The extent of exon 2 inclusion is stage- and cell type-specific and is subject to the physiological state of the cell. In adult skeletal muscle, a cell type that regulates the activity of this allosteric enzyme at several levels, the exon S-plus form of AMPD, predominates. We have performed a systematic analysis of the cis-acting regulatory sequences that reside in the intron immediately downstream of this mini-exon. A complex element comprising sequences that enhance exon 2 inclusion and sequences that counteract this effect resides in the middle of this intron. We demonstrate that the enhancing component is bipartite, with more than a kilobase of sequence separating the two functional sites. The presence of even minimal levels the mini-exon in the fully processed AMPD mRNA requires both of these sites, neither of which appears in any other published splicing enhancer. An RNA binding activity derived from a muscle cell line requires both of the enhancing sites. Mutations in either of the sites that eliminate exon 2 inclusion abrogate this binding activity.	Univ Calif San Diego, Sch Med, Off Dean, La Jolla, CA 92093 USA; Childrens Hosp Philadelphia, Joseph P Stokes Res Inst, Philadelphia, PA 19104 USA; Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 5650871, Japan	University of California System; University of California San Diego; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Cerebral & Cardiovascular Center - Japan	Holmes, EW (corresponding author), Univ Calif San Diego, Sch Med, Off Dean, Rm 1313 Basic Sci Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.		Holmes, Edward/GVR-9499-2022		NIDDK NIH HHS [DK12314] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; ASHBY B, 1979, J CELL BIOL, V81, P361, DOI 10.1083/jcb.81.2.361; ASHBY B, 1977, J BIOL CHEM, V252, P1869; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BLACK DL, 1995, RNA, V1, P763; Carlo T, 2000, MOL CELL BIOL, V20, P3988, DOI 10.1128/MCB.20.11.3988-3995.2000; Carlo T, 1996, RNA, V2, P342; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; Dirksen WP, 2000, J BIOL CHEM, V275, P29170, DOI 10.1074/jbc.M001126200; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Guo NH, 2000, J BIOL CHEM, V275, P33641, DOI 10.1074/jbc.M005597200; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; HERTEL KJ, 1998, CELL, V98, P449; HISATOME I, 1998, AM J PHYSIOL, V275, P870; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; HUH GS, 1993, MOL CELL BIOL, V13, P5301, DOI 10.1128/MCB.13.9.5301; KORETZ JF, 1980, P NATL ACAD SCI-BIOL, V77, P7186, DOI 10.1073/pnas.77.12.7186; Lim LP, 1998, MOL CELL BIOL, V18, P3900, DOI 10.1128/MCB.18.7.3900; Loh E, 1999, CIRCULATION, V99, P1422, DOI 10.1161/01.CIR.99.11.1422; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; MARQUETANT R, 1989, BIOCHEMISTRY-US, V28, P8744, DOI 10.1021/bi00448a010; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MINEO I, 1991, MOL CELL BIOL, V11, P5356, DOI 10.1128/MCB.11.10.5356; MINEO I, 1990, MOL CELL BIOL, V10, P5271, DOI 10.1128/MCB.10.10.5271; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; MORISAKI H, 1993, J CLIN INVEST, V91, P2275, DOI 10.1172/JCI116455; Morisaki H, 2000, GENE, V246, P365, DOI 10.1016/S0378-1119(00)00078-0; MORISAKI T, 1992, P NATL ACAD SCI USA, V89, P6457, DOI 10.1073/pnas.89.14.6457; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; Ryan KJ, 2000, J BIOL CHEM, V275, P20618, DOI 10.1074/jbc.M909977199; Sabina R.L., 1990, METABOLIC BASIS INHE, V2, P1769; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; STERNER DA, 1993, MOL CELL BIOL, V13, P2677, DOI 10.1128/MCB.13.5.2677; WHEELER TJ, 1979, J BIOL CHEM, V254, P8994; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	49	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25589	25597		10.1074/jbc.M011637200	http://dx.doi.org/10.1074/jbc.M011637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331279	hybrid			2022-12-27	WOS:000169800700150
J	Lin, YC; Hsu, CL; Shih, JW; Lin, JJ				Lin, YC; Hsu, CL; Shih, JW; Lin, JJ			Specific binding of single-stranded telomeric DNA by Cdc13p of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYTRICHA MACRONUCLEAR DNA; REPLICATION ORIGIN; IN-VITRO; INITIATOR PROTEIN; HUMAN-CHROMOSOMES; EST1 PROTEIN; 3' TERMINUS; YEAST; END; MAINTENANCE	Cdc13p is a single strand telomere-binding protein of Saccharomyces cerevisiae; its telomere-binding region is within amino acids 451-693, Cdc13(451-693)p, In this study, we used purified Cdc13p and Cdc13(451-693)p to characterize their telomere binding activity, We found that the binding specificity of single-stranded TC,, DNA by these two proteins is similar. However, the affinity of Cdc13(451-693)p to DNA was slightly lower than that of Cdc13p, The binding of telomeric DNA by these two proteins was disrupted at NaCl concentrations higher than 0.3 M, indicating that electrostatic interaction contributed significantly to the binding process. Because both proteins bound to strand TG,, DNA positioned at the 3 ' end, the 5 ' end, or in the middle of the oligonucleotide substrates, our results indicated that the location of TG,, in single-stranded DNA does not appear to be important for Cdc13p binding. Moreover, using DNase I footprint analysis, the structure of the telomeric DNA complexes of Cdc13p and Cdc13(451693)p was analyzed. The DNase I footprints of these two proteins to three different telomeric DNA substrates were virtually identical, indicating that the telomere contact region of Cdc13p is within Cdc13(451-693)p, Together, the binding properties of Cdcl3p and its binding domain support the theory that the specific binding of Cdcl3p to telomeres is an important feature of telomeres that regulate telomerase access and/or differentiate natural telomeres from broken ends.	Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lin, JJ (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Shih Pai, Taipei 112, Taiwan.	jjlin@ym.edu.tw	Lin, Jing-Jer/G-8068-2015; Shih, Jing-Wen/J-4555-2017	Shih, Jing-Wen/0000-0002-0417-9015; LIN, JING-JER/0000-0001-8250-7398				Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Hughes TR, 2000, P NATL ACAD SCI USA, V97, P6457, DOI 10.1073/pnas.97.12.6457; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LIN JJ, 1993, BIOESSAYS, V15, P555, DOI 10.1002/bies.950150809; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MUKHERJEE S, 1985, CELL, V43, P189, DOI 10.1016/0092-8674(85)90023-6; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; Qi HY, 2000, GENE DEV, V14, P1777; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SHUEY DJ, 1986, NATURE, V323, P459, DOI 10.1038/323459a0; Steiner BR, 1996, P NATL ACAD SCI USA, V93, P2817, DOI 10.1073/pnas.93.7.2817; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Wang MJ, 2000, NUCLEIC ACIDS RES, V28, P4733, DOI 10.1093/nar/28.23.4733; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x	48	18	18	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24588	24593		10.1074/jbc.M101642200	http://dx.doi.org/10.1074/jbc.M101642200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309395	hybrid			2022-12-27	WOS:000169800700024
J	Robin, MA; Anandatheerthavarada, HK; Fang, JK; Cudic, M; Otvos, L; Avadhani, NG				Robin, MA; Anandatheerthavarada, HK; Fang, JK; Cudic, M; Otvos, L; Avadhani, NG			Mitochondrial targeted cytochrome p450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; BETA-NAPHTHOFLAVONE; ENDOPLASMIC-RETICULUM; FORMS; PURIFICATION; METABOLISM; SYSTEM; PHOSPHORYLATION; ACTIVATION; FERREDOXIN	Hepatic mitochondria contain an inducible cytochrome P450, referred to as P450 MT5, which cross-reacts with antibodies to microsomal cytochrome P450 2E1, In the present study, we purified, partially sequenced, and determined enzymatic properties of the rat liver mitochondrial form, The mitochondrial cytochrome P450 2E1 was purified from pyrazole-induced rat livers using a combination of hydrophobic and ion-exchange chromatography. Mass spectrometry analysis of tryptic fragments of the purified protein further ascertained its identity, N-terminal sequencing of the purified protein showed that its N terminus is identical to that of the microsomal cytochrome P450 2E1, In reconstitution experiments, the mitochondrial cytochrome P450 2E1 displayed the same catalytic activity as the microsomal counterpart, although the activity of the mitochondrial enzyme was supported exclusively by adrenodoxin and adrenodoxin reductase, Mass spectrometry analysis of tryptic fragments and also immunoblot analysis of proteins with anti-serine phosphate antibody demonstrated that the mitochondrial cytochrome P450 2E1 is phosphorylated at a higher level compared with the microsomal counterpart. A different conformational state of the mitochondrial targeted cytochrome P450 2E1 (P450 MT5) is likely to be responsible for its observed preference for adrenodoxin and adrenodoxin reductase electron transfer proteins.	Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; The Wistar Institute	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Biol Anim, 3800 Spruce St, Philadelphia, PA 19104 USA.				NIGMS NIH HHS [GM 34883] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Anandatheerthavarada HK, 2001, EMBO J, V20, P2394, DOI 10.1093/emboj/20.10.2394; Anandatheerthavarada HK, 1997, ARCH BIOCHEM BIOPHYS, V339, P136, DOI 10.1006/abbi.1996.9855; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; BHAT NK, 1982, BIOCHEMISTRY-US, V21, P2452, DOI 10.1021/bi00539a026; Boopathi E, 2000, J BIOL CHEM, V275, P34415, DOI 10.1074/jbc.M004431200; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; Fataccioli V, 1999, HEPATOLOGY, V29, P14, DOI 10.1002/hep.510290106; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; KOCH JA, 1991, METHOD ENZYMOL, V206, P305; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEPER J, 1990, HEPATOLOGY, V11, P850, DOI 10.1002/hep.1840110521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUBARA T, 1976, ANAL BIOCHEM, V75, P596, DOI 10.1016/0003-2697(76)90114-7; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1988, J BIOL CHEM, V263, P6038; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; NIRANJAN BG, 1984, J BIOL CHEM, V259, P2495; OMURA T, 1991, METHOD ENZYMOL, V206, P75; RAZA H, 1988, J BIOL CHEM, V263, P9533; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; Robin MA, 2000, J PHARMACOL EXP THER, V294, P1063; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; SHAYIQ RM, 1991, METHOD ENZYMOL, V206, P587; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Tanaka E, 2000, J CLIN PHARM THER, V25, P165; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TU YY, 1983, CANCER RES, V43, P623; Von Wachenfeldt Claes, 1995, P183	41	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24680	24689		10.1074/jbc.M100363200	http://dx.doi.org/10.1074/jbc.M100363200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325963	hybrid			2022-12-27	WOS:000169800700037
J	Xu, T; Forgac, M				Xu, T; Forgac, M			Microtubules are involved in glucose-dependent dissociation of the yeast vacuolar [H+]-ATPase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; V-ATPASE; PROTON TRANSPORT; SUBUNIT; DOMAIN; INHIBITION; MECHANISM; SYNTHASES; CATALYSIS; PROTEIN	The vacuolar [H+]-ATPases (V-ATPases) are composed of a peripheral V-1 domain and a membrane-embedded V-0 domain. Reversible dissociation of the V-1 and V-0 domains has been observed in both yeast and insects and has been suggested to represent a general regulatory mechanism for controlling V-ATPase activity in vivo. in yeast, dissociation of the V-ATPase is triggered by glucose depletion, but the signaling pathways that connect V-ATPase dissociation and glucose metabolism have not been identified. We have found that nocodazole, an agent that disrupts microtubules, partially blocked dissociation of the V-ATPase in response to glucose depletion in yeast. By contrast, latrunculin, an agent that disrupts actin filaments, had no effect on glucose-dependent dissociation of the V-ATPase complex. Neither nocodazole nor latrunculin blocked reassembly of the V-ATPase upon re-addition of glucose to the medium. The effect of nocodazole appears to be specifically through disruption of microtubules since glucose-dependent dissociation of the V-ATPase was not blocked by nocodazole in yeast strains bearing a mutation in tubulin that renders it resistant to nocodazole. Because nocodazole has been shown to arrest cells in the G(2) phase of the cell cycle, it was of interest to determine whether nocodazole exerted its effect on dissociation of the V-ATPase through cell cycle arrest. Glucose-dependent dissociation of the V-ATPase was examined in four yeast strains bearing temperature-sensitive mutations that arrest cells in different stages of the cell cycle. Because dissociation of the V-ATPase occurred normally at both the permissive and restrictive temperatures in these mutants, the results suggest that in vivo dissociation is not dependent upon cell cycle phase.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34478, R01 GM034478, R37 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALISON EM, 1991, METHOD ENZYMOL, V194, P729; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Brown D, 2000, J EXP BIOL, V203, P137; BROWN D, 1991, KIDNEY INT, V40, pS79; Capaldi RA, 2000, J EXP BIOL, V203, P29; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; Fillingame RH, 2000, J EXP BIOL, V203, P9; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forgac M, 1998, FEBS LETT, V440, P258, DOI 10.1016/S0014-5793(98)01425-2; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; GUTHRIE BA, 1988, J CELL BIOL, V107, P115, DOI 10.1083/jcb.107.1.115; HASEK J, 1986, EUR J CELL BIOL, V41, P150; Kane PM, 1999, J BIOENERG BIOMEMBR, V31, P49, DOI 10.1023/A:1005444513542; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; Meaden PG, 1999, YEAST, V15, P1211, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1211::AID-YEA448>3.0.CO;2-H; Moriyama Y, 1996, BIOL CHEM H-S, V377, P155; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; Richards KL, 2000, MOL BIOL CELL, V11, P1887, DOI 10.1091/mbc.11.5.1887; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SOLOMON F, 1992, P197; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TEICHERT U, 1989, J BIOL CHEM, V264, P16037; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEINERT TA, 1993, GENETICS, V134, P63; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	50	57	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24855	24861		10.1074/jbc.M100637200	http://dx.doi.org/10.1074/jbc.M100637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331282	hybrid			2022-12-27	WOS:000169800700058
J	Azizan, A; Holaday, N; Neame, PJ				Azizan, A; Holaday, N; Neame, PJ			Post-translational processing of bovine chondromodulin-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-MODULATING FACTOR; PSEUDOMONAS EXOTOXIN-A; MOLECULAR-CLONING; GENE-EXPRESSION; CARTILAGE; CELLS; FURIN	Chondromodulin-I (ChM-I) is a small. glycoprotein that is abundant in fetal cartilage. Mature chondromodulin-I is processed from a larger precursor form, presumably at a proteolytic site RERR-ELVR. The precursor, mature chondromodulin-I and two processed products, the remnant left after removal of mature chondromodulin-I and a smaller, unglycosylated form, were identified using antipeptide antisera. The products of chondromodulin-I precursor processing were seen in cultured chondrocytes, a stable long-term culture chondrosarcoma cell line, as well as Chinese hamster ovary (CHO) cells transfected with an expression plasmid that contained cDNA coding for the chondromodulin-I precursor, Pulse-chase analysis allowed a processing pathway to be analyzed for chonaromodulin-I. To further dissect the processing events, three constructs that express recombinant wild-type or mutant chondromodulin-I were transfected into CHO cells. We showed that chondromodulin-I is cleaved intracellularly at the predicted cleavage site, and that the mature glycopeptide is rapidly secreted immediately after processing. The chondromodulin-1 precursor has a short half-life and is not readily apparent in tissue samples, suggesting that chondromodulin is not a member of the juxtacrine family of growth factors, despite some similarities, The smaller unglycosylated form of chondromodulin-I was only observed in cartilage and not in short-term cultures or transfected cells, suggesting an extracellular processing event. No processing occurred when the precursor cleavage site was mutated to RERQ-SLVR or when precursor chondromodulin-I was expressed in the furin-deficient CHO cell line, suggesting the involvement of furin in processing.	Shriners Hosp Children, Ctr Res Skeletal Dev & Pediat Orthoped, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Neame, PJ (corresponding author), Shriners Hosp Children, Ctr Res Skeletal Dev & Pediat Orthoped, 12502 N Pine Dr, Tampa, FL 33612 USA.		Azizan, Azliyati/A-6774-2009					Azizan A, 2000, MATRIX BIOL, V19, P521, DOI 10.1016/S0945-053X(00)00110-4; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Brandau O, 2001, DEV DYNAM, V221, P72, DOI 10.1002/dvdy.1126; Dietz UH, 1999, DEV DYNAM, V216, P233, DOI 10.1002/(SICI)1097-0177(199911)216:3<233::AID-DVDY2>3.0.CO;2-G; Hering Thomas M., 1999, Frontiers in Bioscience, V4, pd743, DOI 10.2741/Hering; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; Hiraki Y, 1999, EUR J BIOCHEM, V260, P869, DOI 10.1046/j.1432-1327.1999.00227.x; Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419; Hiraki Y, 2000, PEDIATR NEPHROL, V14, P602, DOI 10.1007/s004670000339; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KUCHARSKA A, 1990, J ORTHOPAED RES, P781; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NEAME PJ, 1990, J BIOL CHEM, V265, P9628; Neame PJ, 1999, CELL MOL LIFE SCI, V55, P1327, DOI 10.1007/s000180050373; Shukunami C, 1999, INT J DEV BIOL, V43, P39; Shukunami C, 1999, FEBS LETT, V456, P165, DOI 10.1016/S0014-5793(99)00931-X; Shukunami C, 2001, BIOCHEM BIOPH RES CO, V280, P1323, DOI 10.1006/bbrc.2001.4271; Suzuki F, 1999, BIOCHEM BIOPH RES CO, V259, P1, DOI 10.1006/bbrc.1999.0610; Yamana K, 2001, BIOCHEM BIOPH RES CO, V280, P1101, DOI 10.1006/bbrc.2000.4245	21	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23632	23638		10.1074/jbc.M009967200	http://dx.doi.org/10.1074/jbc.M009967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323410	hybrid			2022-12-27	WOS:000169531100055
J	Ghosh, I; Sun, L; Xu, MQ				Ghosh, I; Sun, L; Xu, MQ			Zinc inhibition of protein trans-splicing and identification of regions essential for splicing and association of a split intein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERBICIDE SULFOMETURON METHYL; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; ACETOLACTATE SYNTHASE; BRANCHED INTERMEDIATE; HOMING ENDONUCLEASE; CATALYTIC SUBUNIT; DNAE GENE	Two important aspects of protein splicing were investigated by employing the trans-splicing intein from the dnaE gene of Synechocystis sp. PCC6803. First, we demonstrated that both protein splicing and cleavage at the N-terminal splice junction were inhibited in the; presence of zinc ion. The trans-splicing reaction was partially blocked at a concentration of 1-10 muM Zn2+ and completely inhibited at 100 muM Zn2+; the inhibition by zinc was reversed in the presence of ethylenediaminetetraacetic acid. We propose that inactivation of Cys(160) at the C-terminal splice junction by the chelation of zinc affects both the N-S acyl rearrangement and the transesterification steps in the splicing pathway. Furthermore, in vivo and in vitro assays were established for the determination of intein residues and regions required for splicing or association between the N- and C-terminal intein halves. N-terminal truncation of the intein C-terminal segment inhibited both splicing and association activities, suggesting this region is crucial for the formation of an interface between the two intein halves. The replacement of conserved residues in blocks B and F with alanine abolished splicing but allowed for association. This is the first evidence showing that the conserved residues in block F are required for protein splicing.	New England Biolabs Inc, Beverly, MA 01915 USA		Xu, MQ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.							Chen LX, 2001, GENE, V263, P39, DOI 10.1016/S0378-1119(00)00568-0; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; DAILEY FE, 1986, J BACTERIOL, V165, P453, DOI 10.1128/jb.165.2.453-460.1986; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Gorbalenya AE, 1998, NUCLEIC ACIDS RES, V26, P1741, DOI 10.1093/nar/26.7.1741; GUAN C, 1988, GENE, V67, P21; Hill CM, 1998, BIOCHEM J, V335, P653, DOI 10.1042/bj3350653; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; Kawasaki M, 1997, J BIOL CHEM, V272, P15668, DOI 10.1074/jbc.272.25.15668; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; LAROSSA RA, 1984, J BIOL CHEM, V259, P8753; Martin DD, 2001, BIOCHEMISTRY-US, V40, P1393, DOI 10.1021/bi001786g; Mills KV, 2001, J BIOL CHEM, V276, P10832, DOI 10.1074/jbc.M011149200; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, CURR OPIN CHEM BIOL, V1, P292, DOI 10.1016/S1367-5931(97)80065-8; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Shingledecker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P138, DOI 10.1006/abbi.1999.1645; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun L, 2001, APPL ENVIRON MICROB, V67, P1025, DOI 10.1128/AEM.67.3.1025-1029.2001; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; YADAV N, 1986, P NATL ACAD SCI USA, V83, P4418, DOI 10.1073/pnas.83.12.4418	35	52	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24051	24058		10.1074/jbc.M011049200	http://dx.doi.org/10.1074/jbc.M011049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11331276	hybrid			2022-12-27	WOS:000169531100110
J	Lyons, PD; Dunty, JM; Schaefer, EM; Schaller, MD				Lyons, PD; Dunty, JM; Schaefer, EM; Schaller, MD			Inhibition of the catalytic activity of cell adhesion kinase beta by protein-tyrosine phosphatase-PEST-mediated dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION; PTP-PEST; SUBSTRATE RECOGNITION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; PROLINE-RICH; SH3 DOMAIN; PHOSPHORYLATION; PAXILLIN; MIGRATION	Protein-tyrosine phosphatase (PTP)-PEST is a cytoplasmic tyrosine phosphatase that can bind and dephosphorylate the focal adhesion-associated proteins p130(CAS) and paxillin. Focal adhesion kinase (FAK) and cell adhesion kinase beta (CAK beta)/PYK2/CADTK/RAFTK are protein-tyrosine kinases that can colocalize with, bind to, and induce tyrosine phosphorylation of p130(CAS) and paxillin, Thus, we considered the possibility that these kinases might be substrates for PTP-PEST. Using a combination of substrate-trapping assays and overexpression of PTP-PEST in mammalian cells, CAK beta was found to be a substrate for PTP-PEST. Both the major autophosphorylation site of CAK beta (Tyr(402)) and activation loop tyrosine residues, Tyr(579) and Tyr(580), were targeted for dephosphorylation by PTP-PEST. Dephosphorylation of CAK beta by PTP-PEST dramatically inhibited CAK beta kinase activity. In contrast, FAK was a poor substrate for PTP-PEST, and treatment with PTP-PEST had no effect on FAK kinase activity. Tyrosine phosphorylation of paxillin, which is greatly enhanced by CAK beta overexpression, was dramatically reduced upon coexpression of PTP-PEST. Finally, endogenous PTP-PEST and endogenous CAK beta were found to localize to similar cellular compartments in epithelial and smooth muscle cells. These results suggest that CAK beta is a substrate of PTP-PEST and that FAK is a poor PTP-PEST substrate. Further, PTP-PEST can negatively regulate CAK beta signaling by inhibiting the catalytic activity of the kinase.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Biosource Int, Hopkinton, MA 01748 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Schaller, MD (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 534 Taylor Hall,CB7090, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057943] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57943] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreev J, 1999, MOL CELL BIOL, V19, P2338; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Astier A, 1997, J BIOL CHEM, V272, P228; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Baldari CT, 1999, BIOL CHEM, V380, P129, DOI 10.1515/BC.1999.020; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHAREST A, 1995, GENOMICS, V28, P501, DOI 10.1006/geno.1995.1181; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; Cloutier JF, 1999, J EXP MED, V189, P111, DOI 10.1084/jem.189.1.111; Cooley MA, 2000, MOL BIOL CELL, V11, P3247, DOI 10.1091/mbc.11.9.3247; Cote JF, 1999, J BIOL CHEM, V274, P20550, DOI 10.1074/jbc.274.29.20550; Davidson D, 1997, J BIOL CHEM, V272, P23455, DOI 10.1074/jbc.272.37.23455; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lev S, 1999, MOL CELL BIOL, V19, P2278; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROGERS SW, 1986, BIOMED BIOCHIM ACTA, V45, P1611; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; YANG Q, 1993, J BIOL CHEM, V268, P6622; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	62	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24422	24431		10.1074/jbc.M011080200	http://dx.doi.org/10.1074/jbc.M011080200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11337490	hybrid, Green Published			2022-12-27	WOS:000169531100158
J	Musial, A; Eissa, NT				Musial, A; Eissa, NT			Inducible nitric-oxide synthase is regulated by the proteasome degradation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTION; INHIBITORS; CALMODULIN; MECHANISMS; REQUIRES; SUBUNIT; RELEASE; CLONING; DOMAIN	Inducible nitric-oxide synthase (iNOS) is responsible for nitric oxide (NO) synthesis from L-arginine in response to inflammatory mediators. To determine the degradation pathway of iNOS, human epithelial kidney HEK293 cells with stable expression of human iNOS were incubated in the presence of various degradation pathway inhibitors. Treatment with the proteasomal inhibitors lactacystin, MG132, and N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal resulted in the accumulation of iNOS, indicating that these inhibitors blocked its degradation. Moreover proteasomal inhibition blocked iNOS degradation in a dose- and time-dependent manner as well as when NO synthesis was inhibited by N-omega-nitro-L-arginine methyl ester. Furthermore, proteasomal inhibition blocked the degradation of an iNOS splice variant that lacked the capacity to dimerize and of an iNOS mutant that lacks L-arginine binding ability, suggesting that iNOS is targeted by proteasomes, notwithstanding its capacity to produce NO, dimerize, or bind the substrate. In contrast to proteasomal inhibitors, the calpain inhibitor calpastatin and the lysosomal inhibitors transepoxysuccinyl-L-leucylamido-4-guanidino butane, leupeptin, pepstatin-A chloroquine, and NH4Cl did not lead to significant accumulation of iNOS. Interestingly, when cytokines were used to induce iNOS in RT4 human epithelial cells, the effect of proteasomal inhibition was dichotomous. Lactacystin added prior to cytokine stimulation prevented iNOS induction by blocking the degradation of the NF-KB inhibitor I kappaB-alpha, thus preventing activation of NF-kappaB. In contrast, lactacystin added 48 h after iNOS induction led to the accumulation of iNOS. Similarly in murine macrophage cell line RAW 264.7, lactacystin blocked iNOS degradation when added 48 h after MOS induction by Lipopolysaccharide. These data identify the proteasome as the primary degradation pathway for iNOS.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Eissa, NT (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,FBRN-B567, Houston, TX 77030 USA.	teissa@bcm.tmc.edu						ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Eissa NT, 1998, P NATL ACAD SCI USA, V95, P7625, DOI 10.1073/pnas.95.13.7625; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Eissa NT, 2001, AM J RESP CELL MOL, V24, P616, DOI 10.1165/ajrcmb.24.5.4324; Felley-Bosco E, 2000, P NATL ACAD SCI USA, V97, P14334, DOI 10.1073/pnas.250406797; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Konur A, 1996, J IMMUNOL, V157, P2109; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; NAKANE M, 1995, MOL PHARMACOL, V47, P831; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Noguchi S, 2000, J BIOL CHEM, V275, P2376, DOI 10.1074/jbc.275.4.2376; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; Vodovotz Y, 1996, J EXP MED, V184, P1425, DOI 10.1084/jem.184.4.1425; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	32	131	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24268	24273		10.1074/jbc.M100725200	http://dx.doi.org/10.1074/jbc.M100725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312270	hybrid			2022-12-27	WOS:000169531100136
J	Pacek, M; Konopa, G; Konieczny, I				Pacek, M; Konopa, G; Konieczny, I			DnaA box sequences as the site for helicase delivery during plasmid RK2 replication initiation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTANTLY RELATED BACTERIA; HOST-RANGE; CHROMOSOMAL REPLICATION; BACILLUS-SUBTILIS; NUCLEOTIDE-SEQUENCE; PROTEIN COMPLEX; GENE-PRODUCT; ORIGIN; BINDING; REGION	DnaA box sequences are a common motif present within the replication origin region of a diverse group of bacteria and prokaryotic extrachromosomal genetic elements. Although the origin opening caused by binding of the host DnaA protein has been shown to be critical for the loading of the DnaB helicase, to date there has been no direct evidence presented for the formation of the DnaB complex at the DnacA box site. For these studies, we used the replication origin of plasmid RK2 (oriV), containing a cluster of four DnaA boxes that bind DnaA proteins isolated from different bacterial species (Caspi, R., Helinski, D. R., Pacek, M,, and Konieczny, I. (2000) J. Biol. Chem. 275, 18454-18461). Size exclusion chromatography, surface plasmon resonance, and electron microscopy experiments demonstrated that the DnaB helicase is delivered to the DnaA box region, which is localized similar to 200 base pairs upstream hom the region of Origin opening and a potential site for helicase entry. The DnaABC complex was formed on both double-stranded superhelical and linear RK2 templates. A strict DnaA box sequence requirement for stable formation of that nucleoprotein structure was confirmed. In addition, our experiments provide evidence for interaction between the plasmid initiation protein TrfA and the DnaABC prepriming complex, formed at DnaA box region. This interaction is facilitated via direct contact between TrfA and DnaB proteins.	Univ Gdansk, Dept Mol & Cellular Biol, Fac Biotechnol, PL-80822 Gdansk, Poland; Univ Gdansk, Fac Biol, Dept Mol Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; University of Gdansk	Konieczny, I (corresponding author), Univ Gdansk, Dept Mol & Cellular Biol, Fac Biotechnol, 24 Kladki, PL-80822 Gdansk, Poland.			Konieczny, Igor/0000-0002-1588-5601				ABELES AL, 1990, J BACTERIOL, V172, P4386, DOI 10.1128/jb.172.8.4386-4391.1990; ABELES AL, 1984, J MOL BIOL, V173, P307, DOI 10.1016/0022-2836(84)90123-2; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Caspi R, 2000, J BIOL CHEM, V275, P18454, DOI 10.1074/jbc.M000552200; COWAN P, 1982, PLASMID, V8, P164, DOI 10.1016/0147-619X(82)90054-3; CROSS MA, 1986, PLASMID, V15, P132, DOI 10.1016/0147-619X(86)90049-1; Datta HJ, 1999, P NATL ACAD SCI USA, V96, P73, DOI 10.1073/pnas.96.1.73; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; Doran KS, 1999, MOL MICROBIOL, V33, P490, DOI 10.1046/j.1365-2958.1999.01491.x; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; FUJITA MQ, 1989, MOL GEN GENET, V215, P381, DOI 10.1007/BF00427033; FUKUOKA T, 1990, J BIOCHEM-TOKYO, V107, P732, DOI 10.1093/oxfordjournals.jbchem.a123117; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HELINSKI DR, 1996, ESCHERICHIA COLI SAL, V2, P2295; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Kornberg A., 1992, DNA REPLICATION; Krause M, 1997, J MOL BIOL, V274, P365, DOI 10.1006/jmbi.1997.1404; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lu YB, 1998, EMBO J, V17, P5192, DOI 10.1093/emboj/17.17.5192; Majka J, 1997, J BACTERIOL, V179, P2426, DOI 10.1128/jb.179.7.2426-2432.1997; Majka J, 1999, EUR J BIOCHEM, V260, P325, DOI 10.1046/j.1432-1327.1999.00168.x; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1987, P NATL ACAD SCI USA, V84, P4781, DOI 10.1073/pnas.84.14.4781; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MUROTSU T, 1981, GENE, V15, P257, DOI 10.1016/0378-1119(81)90135-9; NIETO C, 1992, J MOL BIOL, V223, P415, DOI 10.1016/0022-2836(92)90661-3; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PERRI S, 1991, J BIOL CHEM, V266, P12536; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; STALKER DM, 1979, P NATL ACAD SCI USA, V76, P1150, DOI 10.1073/pnas.76.3.1150; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; VOCKE C, 1983, CELL, V35, P495, DOI 10.1016/0092-8674(83)90183-6; VOCKE C, 1983, P NATL ACAD SCI-BIOL, V80, P6557, DOI 10.1073/pnas.80.21.6557; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YEE TW, 1990, P NATL ACAD SCI USA, V87, P1278, DOI 10.1073/pnas.87.4.1278; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	56	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23639	23644		10.1074/jbc.M100255200	http://dx.doi.org/10.1074/jbc.M100255200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316803	hybrid			2022-12-27	WOS:000169531100056
J	Cebrian, C; Areste, C; Nicolas, A; Olive, P; Carceller, A; Piulats, J; Meseguer, A				Cebrian, C; Areste, C; Nicolas, A; Olive, P; Carceller, A; Piulats, J; Meseguer, A			Kidney androgen-regulated protein interacts with cyclophilin B and reduces cyclosporine A-mediated toxicity in proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA; GENE-EXPRESSION; MOUSE KIDNEY; CALCINEURIN-BINDING; THYROID-HORMONE; NEPHROTOXICITY; MECHANISMS; SEQUENCE; LINES	The gene for kidney androgen-regulated protein (KAP) is the most abundant and specific gene expressed in mouse kidney proximal tubule cells, where it is tightly regulated by steroid and thyroid hormones in different tubule segments. Despite the cell-specific expression, strict regulatory mechanisms, and relative abundance, nothing is known of the function of its encoded protein, which does not exhibit known structural or functional domains, or homologies with other sequences in the data bases. We raised monoclonal antibodies against KAP, which specifically recognize a protein with an apparent molecular mass of 20 kDa in crude kidney homogenates, the distribution and regulation of which parallel that of its m-RNA. To gain insight into its function, we performed a yeast two hybrid screen and determined that KAP specifically interacts with cyclophilin B. Furthermore, cyclosporine A (CsA)-treated mice exhibited a significant decrease in KAP levels, and tetracycline-controlled overexpression of KAP in stably transfected proximal tubule cells significantly decreased the toxic effects of CsA. Taken together, these results indicate a functional relationship among KAP-, cyclophilin B-, and CsA-mediated nephrotoxicity and suggest an important role of KAP in renal physiology, providing new data on the molecular mechanisms implied in the toxic effects of CsA.	Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona 08035, Spain; Merck Farma & Quim SA, Lab Bioinvest, Barcelona 08010, Spain	Hospital Universitari Vall d'Hebron	Meseguer, A (corresponding author), Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Pg Vall dHebron 119-129,Plta 14, Barcelona 08035, Spain.	meseguer@hg.vhebron.es	Cebrian, Cristina/ABE-1974-2021; Navarro, Anna Meseguer/M-2222-2014; Cebrian, Cristina/E-2185-2012	Navarro, Anna Meseguer/0000-0003-3833-2249; Cebrian, Cristina/0000-0002-1297-6591				Ader JL, 1998, CURR OPIN NEPHROL HY, V7, P539, DOI 10.1097/00041552-199809000-00009; ANDERSON R, 1994, TOXICOL APPL PHARM, V125, P176, DOI 10.1006/taap.1994.1062; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BENNETT WM, 1994, MINER ELECTROL METAB, V20, P214; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Buetler TM, 2000, TRENDS PHARMACOL SCI, V21, P288, DOI 10.1016/S0165-6147(00)01508-X; CARTIER N, 1993, J CELL SCI, V104, P695; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Mattos AM, 2000, AM J KIDNEY DIS, V35, P333, DOI 10.1016/S0272-6386(00)70348-9; Denys A, 1998, TRANSPLANTATION, V65, P1076, DOI 10.1097/00007890-199804270-00012; El-Meanawy MA, 2000, AM J PHYSIOL-RENAL, V279, pF383, DOI 10.1152/ajprenal.2000.279.2.F383; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; Healy E., 1994, British Journal of Pharmacology, V112, p142P; HEALY E, 1995, J AM SOC NEPHROL, V6, P999; Healy E, 1998, KIDNEY INT, V54, P1955, DOI 10.1046/j.1523-1755.1998.00202.x; Kainer DB, 2000, HYPERTENSION, V35, P958, DOI 10.1161/01.HYP.35.4.958; KASIK JW, 1993, MOL CELL ENDOCRINOL, V90, P239, DOI 10.1016/0303-7207(93)90157-F; KOPP JB, 1990, J AM SOC NEPHROL, V1, P162; LACAVE R, 1993, J CELL SCI, V104, P705; Lally C, 1999, KIDNEY INT, V56, P1254, DOI 10.1046/j.1523-1755.1999.00696.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Melia MJ, 1998, ENDOCRINOLOGY, V139, P688, DOI 10.1210/en.139.2.688; MESEGUER A, 1987, MOL ENDOCRINOL, V1, P535, DOI 10.1210/mend-1-8-535; MESEGUER A, 1989, MOL ENDOCRINOL, V3, P962, DOI 10.1210/mend-3-6-962; MESEGUER A, 1990, MOL ENDOCRINOL, V4, P1240, DOI 10.1210/mend-4-8-1240; MESEGUER A, 1992, MOL CELL ENDOCRINOL, V89, P153, DOI 10.1016/0303-7207(92)90221-Q; MIHATSCH MJ, 1986, CLIN NEPHROL, V25, pS2; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; OTSUKA M, 1994, KIDNEY INT, V45, P1340, DOI 10.1038/ki.1994.175; Ouar Z, 1998, KIDNEY INT, V53, P59, DOI 10.1046/j.1523-1755.1998.00721.x; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; Ruhlmann A, 1997, IMMUNOBIOLOGY, V198, P192; Runic R, 1996, ENDOCRINOLOGY, V137, P729, DOI 10.1210/en.137.2.729; SCHNEIDER H, 1994, BIOCHEMISTRY-US, V33, P8218, DOI 10.1021/bi00193a007; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shihab FS, 1996, KIDNEY INT, V49, P1141, DOI 10.1038/ki.1996.165; Shihab FS, 1997, KIDNEY INT, V52, P660, DOI 10.1038/ki.1997.380; Shihab FS, 1999, KIDNEY INT, V56, P2147, DOI 10.1046/j.1523-1755.1999.00794.x; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; SOLE E, 1994, ENDOCRINOLOGY, V135, P2120, DOI 10.1210/en.135.5.2120; Sole E, 1996, MOL CELL ENDOCRINOL, V119, P147, DOI 10.1016/0303-7207(96)03603-9; SUZUKI S, 1987, TRANSPLANTATION, V44, P363, DOI 10.1097/00007890-198709000-00008; Takenaka M, 1998, KIDNEY INT, V53, P562, DOI 10.1046/j.1523-1755.1998.00808.x; TAKESHI F, 1997, SEMIN NEPHROL, V17, P34; TOOLE JJ, 1979, CELL, V17, P441, DOI 10.1016/0092-8674(79)90170-3; Virlon B, 1999, P NATL ACAD SCI USA, V96, P15286, DOI 10.1073/pnas.96.26.15286; VONWILLEBRAND E, 1983, LANCET, V2, P189; Wang L, 2000, KIDNEY INT, V58, P528, DOI 10.1046/j.1523-1755.2000.00199.x; WOLF G, 1995, TRANSPLANTATION, V60, P237, DOI 10.1097/00007890-199508000-00005; Zhang H, 1999, KIDNEY INT, V56, P549, DOI 10.1046/j.1523-1755.1999.00561.x	57	21	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29410	29419		10.1074/jbc.M102916200	http://dx.doi.org/10.1074/jbc.M102916200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11323438	hybrid			2022-12-27	WOS:000170346000103
J	Engelmann, K; Baldus, SE; Hanisch, FG				Engelmann, K; Baldus, SE; Hanisch, FG			Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; MOLECULAR-CLONING; ANTIGEN; CDNA; ANTIBODIES; INDUCTION; PEPTIDE; CELLS	This study shows for the first time that the tandemly repeated icosapeptide of human MUC1 underlies a genetic sequence polymorphism at three positions (underlined): P (TD) under bar RPAPGSTAP (P) under bar AHGVTSA. The concerted replacement DT --> ES (sequence variation 1) and the single replacements P -->Q (sequence variation 2), P -->A (sequence variation 3), and P -->T (sequence variation 4) were identified by sequencing of polymerase chain reaction products and studied by minisatellite variant repeat analysis for their incidence and topology in the 5` and 3' peripheral regions of the variable number of tandem repeats domain. Minisatellite variant repeat analyses were performed with 27 individual samples of genomic DNA from human cells and tissues covering 30-60% of the domain. Within the peripheral regions, sequence variations 1-4 occur at high incidence and show a nearly constant repeat topology in all individual normal and tumor samples. Also, individuals who were non-Caucasian or of different ethnic background were found to have the same set of replacements with identical topology. The repeat variant 1 replacing the established tumor target motif DTR with ESR was found in all individuals and appears predominantly in repeat clusters (diads and triads). The largely constant topology of variant repeats is interpreted by the assumption that the variable number of tandem repeats domain has evolved as a recent expansion of sequence variable super-repeats.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Inst Pathol, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Hanisch, FG (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.							Agrawal B, 1996, J IMMUNOL, V157, P2089; Apostolopoulos V, 1997, J IMMUNOL, V159, P5211; APOSTOLOPOULOS V, 1995, J IMMUNOL, V155, P5089; Conway K, 1996, CANCER RES, V56, P4773; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; HANISCH FG, 2001, IN PRESS GLYCOBIOLOG; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; JEROME KR, 1991, CANCER RES, V51, P2908; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Muller S, 1999, J BIOL CHEM, V274, P18165, DOI 10.1074/jbc.274.26.18165; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price MR, 1998, TUMOR BIOL, V19, P1, DOI 10.1159/000056500; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; TONDINI C, 1988, CANCER RES, V48, P4107; von Mensdorff-Pouilly S, 2000, INT J CANCER, V86, P702, DOI 10.1002/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1; vonMensdorffPouilly S, 1996, EUR J CANCER, V32A, P1325, DOI 10.1016/0959-8049(96)00048-2; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	22	38	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27764	27769		10.1074/jbc.M103187200	http://dx.doi.org/10.1074/jbc.M103187200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350974	hybrid			2022-12-27	WOS:000170093400005
J	Avison, MB; Horton, RE; Walsh, TR; Bennett, PM				Avison, MB; Horton, RE; Walsh, TR; Bennett, PM			Escherichia coli CreBC is a global regulator of gene expression that responds to growth in minimal media	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE REGULON; BETA-LACTAMASES; AEROMONAS-SOBRIA; PHOM; IDENTIFICATION; SEQUENCE; CLONING; KINASE; PHOSPHOTRANSACETYLASE; NUCLEOTIDE	We have identified nine genes, the expression of which are regulated by the CreEC two-component system: the first members of the cre regulon. They are divided into eight transcriptional units, each having a promoter-proximal TTCACnnnnnnTTCAC "cre-tag" motif. The cre regulon genes are: the ackA/pta operon, the products of which collectively catalyze the conversion of acetyl-CoA into acetate and ATP; talA, which encodes an enzyme involved in the mobilization of glyceraldehyde-3-phosphate into the pentose phosphate pathway; radC, which encodes a RecG-like DNA recombination/repair function; malE, which is the first gene in the malEFG maltose transporter operon; trgB, which encodes an ADP-ribose pyrophosphorylase; and three other genes, creD, yidS and yieI, the products of which have not been assigned a function. Expression of each of these cre regulon genes is induced via CreBC during growth in minimal media, with the exception of malE, which is more tightly repressed. The diverse functions encoded by the cre regulon suggest that CreBC is a global regulator that sits right at the heart of metabolic control in Escherichia coli.	Univ Bristol, Bristol Ctr Antimicrobial Res & Evaluat, Dept Pathol & Microbiol, Sch Med Sci, Bristol BS8 1TD, Avon, England	University of Bristol	Avison, MB (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	Matthewb.Avison@bris.ac.uk	Walsh, Timothy R/F-6519-2010	Walsh, Timothy/0000-0003-4315-4096; Avison, Matthew/0000-0003-1454-8440				Alksne LE, 1997, J BACTERIOL, V179, P2006, DOI 10.1128/jb.179.6.2006-2013.1997; AMEMURA M, 1986, J BACTERIOL, V168, P294, DOI 10.1128/jb.168.1.294-302.1986; AMEMURA M, 1990, J BACTERIOL, V172, P6300, DOI 10.1128/jb.172.11.6300-6307.1990; Avison MB, 2000, J ANTIMICROB CHEMOTH, V46, P695, DOI 10.1093/jac/46.5.695; Avison MB, 2000, J ANTIMICROB CHEMOTH, V46, P879, DOI 10.1093/jac/46.6.879; AVISON MB, 1999, 39 INT C ANT AG CHEM, P88; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BUXTON RS, 1973, MOL GEN GENET, V127, P69, DOI 10.1007/BF00267784; Chang DE, 1999, J BACTERIOL, V181, P6656, DOI 10.1128/JB.181.21.6656-6663.1999; DRURY LS, 1988, MOL MICROBIOL, V2, P109, DOI 10.1111/j.1365-2958.1988.tb00012.x; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; FELZENSZWALB I, 1992, MUTAT RES, V273, P263, DOI 10.1016/0921-8777(92)90088-K; FELZENSZWALB I, 1984, RADIAT RES, V97, P615, DOI 10.2307/3576153; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; KAKUDA H, 1994, J BIOCHEM-TOKYO, V116, P916, DOI 10.1093/oxfordjournals.jbchem.a124616; Lombardo MJ, 2000, J BACTERIOL, V182, P6287, DOI 10.1128/JB.182.22.6287-6291.2000; LOW KB, 1972, BACTERIOL REV, V36, P587, DOI 10.1128/MMBR.36.4.587-607.1972; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MAKINO K, 1984, MOL GEN GENET, V195, P381, DOI 10.1007/BF00341438; Makino K, 1996, J MOL BIOL, V259, P15, DOI 10.1006/jmbi.1996.0298; NIUMSUP P, 1997, 37 INT C ANT AG CHEM, P79; Okamura H, 2000, J MOL BIOL, V295, P1225, DOI 10.1006/jmbi.1999.3379; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RASMUSSEN BA, 1994, ANTIMICROB AGENTS CH, V38, P2078, DOI 10.1128/AAC.38.9.2078; Richet E, 1996, J MOL BIOL, V264, P852, DOI 10.1006/jmbi.1996.0682; SAMBROOK J, 1989, MOL CLONING LABORATO, V1, P53; Saveson CJ, 1999, GENETICS, V152, P5; Sprenger GA, 1995, ARCH MICROBIOL, V164, P324, DOI 10.1007/BF02529978; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Walsh TR, 1998, ANTIMICROB AGENTS CH, V42, P436; WALSH TR, 1995, J ANTIMICROB CHEMOTH, V36, P41, DOI 10.1093/jac/36.1.41; Wanner B.L., 1996, E COLI SALMONELLA CE, V1, P1357; WANNER BL, 1992, J BACTERIOL, V174, P2124, DOI 10.1128/JB.174.7.2124-2130.1992; WANNER BL, 1987, J BACTERIOL, V169, P900, DOI 10.1128/jb.169.2.900-903.1987; WANNER BL, 1980, GENETICS, V96, P353	35	76	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26955	26961		10.1074/jbc.M011186200	http://dx.doi.org/10.1074/jbc.M011186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350954	hybrid			2022-12-27	WOS:000169966900031
J	Park, AR; Cho, SK; Yun, UJ; Jin, MY; Lee, SH; Sachetto-Martins, G; Park, OK				Park, AR; Cho, SK; Yun, UJ; Jin, MY; Lee, SH; Sachetto-Martins, G; Park, OK			Interaction of the arabidopsis receptor protein kinase Wak1 with a glycine-rich protein, AtGRP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; OXIDATIVE BURST; CROSS-LINKING; GENE; EXPRESSION; CLAVATA3; TRANSDUCTION; SIGNALOSOME; RESISTANCE; PATHWAYS	The Arabidopsis wall-associated receptor kinase, Wak1, is a member of the Wak family (Wak1-5) that links the plasma membrane to the extracellular matrix, By the yeast two-hybrid screen, we found that a glycine-rich extracellular protein, AtGRP-3, binds to the extracellular domain of Wak1, Further in vitro binding studies indicated that AtGRP-3 is the only isoform among the six tested AtGRPs that specifically interacts with Waks, and the cysteine-rich carboxyl terminus of AtGRP-3 is essential for its binding to Wak1, We also show that Wak1 and AtGRP-3 form a complex with a molecular size of similar to 500 kDa in vivo in conjunction with the kinase-associated protein phosphatase, KAPP, that has been shown to interact with a number of plant receptor-like kinases, Binding of AtGRP-3 to Wak1 is shown to be crucial for the integrity of the complex. Wak1 and AtGRP-3 are both induced by salicylic acid treatment. Moreover, exogenously added AtGRP-3 up-regulates the expression of Wak1, AtGRP-3, and PR-1 (for (p) under bar athogenesis-(r) under bar elated) in protoplasts. Taken together, our data suggest that AtGRP-3 regulates Wak1 function through binding to the cell wall domain of Wak1 and that the interaction of Wak1 with AtGRP-3 occurs in a pathogenesis-related process in planta.	Kumho Life & Environm Sci Lab, Puk Gu, Kwangju 500480, South Korea; Univ Fed Rio de Janeiro, Dept Genet, BR-21941970 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Park, OK (corresponding author), Kumho Life & Environm Sci Lab, Puk Gu, 1 Oryong Dong, Kwangju 500480, South Korea.	omkim@hotmail.com	Sachetto-Martins, Gilberto/AAT-4095-2021; Sachetto-Martins, Gilberto/AAN-6328-2020					Abel S, 1998, METH MOL B, V82, P209; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; Brady JD, 1997, PLANT PHYSIOL, V115, P87, DOI 10.1104/pp.115.1.87; Braun DM, 1997, PLANT J, V12, P83, DOI 10.1046/j.1365-313X.1997.12010083.x; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; BRISSON LF, 1994, PLANT CELL, V6, P1703, DOI 10.1105/tpc.6.12.1703; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Cosgrove DJ, 1997, ANNU REV CELL DEV BI, V13, P171, DOI 10.1146/annurev.cellbio.13.1.171; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; DEOLIVEIRA DE, 1993, PLANT J, V3, P495, DOI 10.1046/j.1365-313X.1993.03040495.x; Domingo C, 1999, PLANT J, V20, P563, DOI 10.1046/j.1365-313X.1999.00631.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Friedrich L, 1995, PLANT MOL BIOL, V29, P959, DOI 10.1007/BF00014969; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; He ZH, 1996, J BIOL CHEM, V271, P19789, DOI 10.1074/jbc.271.33.19789; He ZH, 2000, SCIENCE, V288, P2360, DOI 10.1126/science.288.5475.2360; He ZH, 1998, PLANT J, V14, P55, DOI 10.1046/j.1365-313X.1998.00092.x; He ZH, 1999, PLANT MOL BIOL, V39, P1189, DOI 10.1023/A:1006197318246; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; KELLER B, 1993, PLANT PHYSIOL, V101, P1127, DOI 10.1104/pp.101.4.1127; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; Kohorn BD, 1999, TRENDS CELL BIOL, V9, P381, DOI 10.1016/S0962-8924(99)01643-8; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lease K, 1998, CURR OPIN PLANT BIOL, V1, P388, DOI 10.1016/S1369-5266(98)80261-6; Li JM, 1997, CELL, V90, P929, DOI 10.1016/S0092-8674(00)80357-8; LINTHORST HJM, 1990, PLANT MOL BIOL, V15, P521, DOI 10.1007/BF00019172; McCubbin AG, 2000, ANNU REV CELL DEV BI, V16, P333, DOI 10.1146/annurev.cellbio.16.1.333; MUDD JB, 1997, PLANT RESPONSE AIR P, P267; Pennell R, 1998, CURR OPIN PLANT BIOL, V1, P504, DOI 10.1016/S1369-5266(98)80043-5; Penninckx IAMA, 1996, PLANT CELL, V8, P2309, DOI 10.1105/tpc.8.12.2309; PRASAD TK, 1994, PLANT CELL, V6, P65, DOI 10.1105/tpc.6.1.65; QUIGLEY F, 1991, PLANT MOL BIOL, V17, P949, DOI 10.1007/BF00037079; Sachetto-Martins G, 2000, BBA-GENE STRUCT EXPR, V1492, P1, DOI 10.1016/S0167-4781(00)00064-6; SANDAL NN, 1992, PLANT MOL BIOL, V18, P607, DOI 10.1007/BF00040679; SHOWALTER AM, 1993, PLANT CELL, V5, P9, DOI 10.1105/tpc.5.1.9; Smith HB, 1999, PLANT CELL, V11, P299; Streuli C, 1999, CURR OPIN CELL BIOL, V11, P634, DOI 10.1016/S0955-0674(99)00026-5; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; Trotochaud AE, 2000, SCIENCE, V289, P613, DOI 10.1126/science.289.5479.613; Trotochaud AE, 1999, PLANT CELL, V11, P393, DOI 10.1105/tpc.11.3.393; VANHUIJSDUIJNEN RA, 1988, EMBO J, V5, P2057; VANNOCKER S, 1993, PLANT MOL BIOL, V21, P695, DOI 10.1007/BF00014552; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wojtaszek P, 1997, BIOCHEM J, V322, P681, DOI 10.1042/bj3220681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	49	34	37	0	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26688	26693		10.1074/jbc.M101283200	http://dx.doi.org/10.1074/jbc.M101283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335717	hybrid			2022-12-27	WOS:000169823300135
J	Chatterji, A; Beachy, RN; Fauquet, CM				Chatterji, A; Beachy, RN; Fauquet, CM			Expression of the oligomerization domain of the replication-associated protein (Rep) of Tomato leaf curl New Delhi virus interferes with DNA accumulation of heterologous geminiviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RESISTANCE; ORIGIN; IDENTIFICATION; ORGANIZATION; INFECTIVITY; SEQUENCES; CLEAVAGE; GENOME	The minimal DNA binding domain of the replication-associated protein (Rep) of Tomato leaf curl New Delhi virus was determined by electrophoretic mobility gel shift analysis and co-purification assays. DNA binding activity maps to amino acids 1-160 (Rep-(1-160)) of the Rep protein and overlaps with the protein oligomerization domain. Transient expression of Rep protein (Rep(1-160)) was found to inhibit homologous viral DNA accumulation by 70-86% in tobacco protoplasts and in Nicotiana benthamiana plants. The results obtained showed that expression of N-terminal sequences of Rep protein could efficiently interfere with DNA binding and oligomerization activities during virus infection. Surprisingly, this protein reduced accumulation of the African cassava mosaic virus, Pepper huasteco yellow vein virus and Potato yellow mosaic virus by 22-48%, electrophoretic mobility shift assays and co-purification studies showed that Rep-(1-160) did not bind with high affinity in vitro to the corresponding common region sequences of heterologous geminiviruses. However, Rep-(1-160) formed oligomers with the Rep proteins of the other geminiviruses. These data suggest that the regulation of virus accumulation may involve binding of the Rep to target DNA sequences and to the other Rep molecules during virus replication.	Univ Missouri, Int Lab Trop Agr Biotechnol, Donald Danforth Plant Sci Ctr, CME, St Louis, MO 63121 USA	Donald Danforth Plant Science Center; University of Missouri System; University of Missouri Saint Louis	Fauquet, CM (corresponding author), Univ Missouri, Int Lab Trop Agr Biotechnol, Donald Danforth Plant Sci Ctr, CME, 8001 Nat Bridge Rd,M308, St Louis, MO 63121 USA.	iltab@danforthcenter.org						ARGUELLOASTORGA GR, 1994, VIROLOGY, V203, P90, DOI 10.1006/viro.1994.1458; Bendahmane M, 1997, PLANT MOL BIOL, V33, P351, DOI 10.1023/A:1005715805000; BonillaRamirez GM, 1997, J GEN VIROL, V78, P947, DOI 10.1099/0022-1317-78-4-947; Brown J. K., 1994, FAO (Food and Agriculture Organization of the United Nations) Plant Protection Bulletin, V42, P3; Chatterji A, 1999, J VIROL, V73, P5481, DOI 10.1128/JVI.73.7.5481-5489.1999; Chatterji A, 2000, VIROLOGY, V273, P341, DOI 10.1006/viro.2000.0434; DAY AG, 1991, P NATL ACAD SCI USA, V88, P6721, DOI 10.1073/pnas.88.15.6721; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; DESBIEZ C, 1995, P NATL ACAD SCI USA, V92, P5640, DOI 10.1073/pnas.92.12.5640; EAGLE PA, 1994, PLANT CELL, V6, P1157, DOI 10.1105/tpc.6.8.1157; Fauquet CM, 2000, ARCH VIROL, V145, P1743, DOI 10.1007/s007050070089; FONTES EPB, 1994, J BIOL CHEM, V269, P8459; FONTES EPB, 1994, PLANT CELL, V6, P405, DOI 10.1105/tpc.6.3.405; FRISCHMUTH T, 1991, VIROLOGY, V183, P539, DOI 10.1016/0042-6822(91)90982-H; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HEYRAUD F, 1993, EMBO J, V12, P4445, DOI 10.1002/j.1460-2075.1993.tb06130.x; HEYRAUDNITSCHKE F, 1995, NUCLEIC ACIDS RES, V23, P910, DOI 10.1093/nar/23.6.910; Hong YG, 1996, MOL PLANT MICROBE IN, V9, P219, DOI 10.1094/MPMI-9-0219; HONG YG, 1995, J GEN VIROL, V76, P2415, DOI 10.1099/0022-1317-76-10-2415; JUPIN I, 1995, FEBS LETT, V362, P116, DOI 10.1016/0014-5793(95)00221-T; LAUFS J, 1995, P NATL ACAD SCI USA, V92, P3879, DOI 10.1073/pnas.92.9.3879; Noris E, 1996, VIROLOGY, V224, P130, DOI 10.1006/viro.1996.0514; Orozco BM, 1997, J BIOL CHEM, V272, P9840; PADIDAM M, 1995, J GEN VIROL, V76, P25, DOI 10.1099/0022-1317-76-1-25; SAUNDERS K, 1991, NUCLEIC ACIDS RES, V19, P2325, DOI 10.1093/nar/19.9.2325; Settlage SB, 1996, J VIROL, V70, P6790, DOI 10.1128/JVI.70.10.6790-6795.1996; STANLEY J, 1983, NATURE, V305, P643, DOI 10.1038/305643a0; STANLEY J, 1990, P NATL ACAD SCI USA, V87, P6291, DOI 10.1073/pnas.87.16.6291; STENGER DC, 1991, P NATL ACAD SCI USA, V88, P8029, DOI 10.1073/pnas.88.18.8029; SUNTER G, 1993, VIROLOGY, V195, P275, DOI 10.1006/viro.1993.1374; Umaharan P, 1998, PHYTOPATHOLOGY, V88, P1262, DOI 10.1094/PHYTO.1998.88.12.1262; Verdaguer B, 1998, PLANT MOL BIOL, V37, P1055, DOI 10.1023/A:1006004819398; WATANABE Y, 1987, FEBS LETT, V219, P65, DOI 10.1016/0014-5793(87)81191-2; [No title captured]	34	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25631	25638		10.1074/jbc.M100030200	http://dx.doi.org/10.1074/jbc.M100030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342533	hybrid			2022-12-27	WOS:000169800700155
J	de Meis, L				de Meis, L			Uncoupled ATPase activity and heat production by the sarcoplasmic reticulum Ca2+-ATPase - Regulation by ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; ENERGY INTERCONVERSION; ADENOSINE-TRIPHOSPHATE; CA2+ TRANSPORT; HYDROLYSIS; EFFLUX; COLD; THERMOGENESIS; EXPRESSION; RABBIT	Sarcoplasmic reticulum vesicles of rabbit skeletal muscle accumulate Ca2+ at the expense of ATP hydrolysis, The heat released during the hydrolysis of each ATP molecule varies depending on whether or not a Ca2+ gradient is formed across the vesicle membrane. After Ca2+ accumulation, a part of the Ca2+-ATPase activity is not coupled with Ca2+ transport (Yu, X,, and Inesi, G, (1995) J, Biol, Chem. 270, 4361-4367), I now show that both the heat produced during substrate hydrolysis and the uncoupled ATPase activity vary depending on the ADP/ATP ratio in the medium. With a low ratio, the Ca2+ transport is exothermic, and the formation of the gradient increases the amount of heat produced during the hydrolysis of each ATP molecule cleaved. With a high ADP/ATP ratio, the Ca2+ transport is endothermic, and formation of a gradient increased the amount of heat absorbed from the medium. Heat is absorbed from the medium when the Ca2+ efflux is coupled with the synthesis of ATP (5.7 kcal/mol of ATP), When there is no ATP synthesis, the Ca2+ efflux is exothermic (14-16 kcal/Ca2+ mol). It is concluded that in the presence of a low ADP concentration the uncoupled ATPase activity is the dominant route of heat production, With a high ADP/ATP ratio, the uncoupled ATPase activity is abolished, and the Ca2+ transport is endothermic, The possible correlation of these findings with thermogenesis and anoxia is discussed.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@bioqmed.ufjr.br						BIANCO AC, 1987, AM J PHYSIOL, V253, pE255, DOI 10.1152/ajpendo.1987.253.3.E255; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BUSTO R, 1987, J CEREB BLOOD FLOW M, V7, P129; CHIESI M, 1979, J BIOL CHEM, V254, P370; CHINET A, 1992, J PHYSIOL-LONDON, V455, P663, DOI 10.1113/jphysiol.1992.sp019321; DAGLORIA M, 1976, J BIOL CHEM, V251, P3629; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 1974, Biochemistry, V13, P5032, DOI 10.1021/bi00721a026; de Meis L, 1998, BIOCHEM BIOPH RES CO, V243, P598, DOI 10.1006/bbrc.1997.8028; De Meis L, 2000, AN ACAD BRAS CIENC, V72, P365, DOI 10.1590/S0001-37652000000300010; de Meis L, 2000, BIOCHEM BIOPH RES CO, V276, P35, DOI 10.1006/bbrc.2000.3418; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, SARCOPLASMIC RETICUL, V2; DIETRICH DLL, 1993, CIRC RES, V73, P1177, DOI 10.1161/01.RES.73.6.1177; DUMONTEIL E, 1993, AM J PHYSIOL, V265, pC507, DOI 10.1152/ajpcell.1993.265.2.C507; DUMONTEIL E, 1995, AM J PHYSIOL-CELL PH, V269, pC955, DOI 10.1152/ajpcell.1995.269.4.C955; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; GOULD GW, 1987, BIOCHIM BIOPHYS ACTA, V904, P45, DOI 10.1016/0005-2736(87)90085-X; Hamalainen N, 1997, J MUSCLE RES CELL M, V18, P545, DOI 10.1023/A:1018663218477; HASSELBACH W, 1964, PROG BIOPHYS MOL BIO, V14, P167, DOI 10.1016/S0079-6107(64)80006-7; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; Klingenspor M, 1996, BIOCHEM J, V316, P607, DOI 10.1042/bj3160607; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MAKINOSE M, 1971, FEBS LETT, V12, P269, DOI 10.1016/0014-5793(71)80195-3; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; MONTEROLOMELI M, 1992, J BIOL CHEM, V267, P1829; MOTTA HG, 1980, ARCH BIOCHEM BIOPHYS, V203, P395; Ramos RCS, 1999, J NEUROCHEM, V72, P81, DOI 10.1046/j.1471-4159.1999.0720081.x; ROMERO PJ, 1989, J BIOL CHEM, V264, P7869; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; Simonides WS, 1996, J BIOL CHEM, V271, P32048, DOI 10.1074/jbc.271.50.32048; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SORENSON MM, 1986, J MEMBRANE BIOL, V90, P219, DOI 10.1007/BF01870128; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; VanderLinden CG, 1996, AM J PHYSIOL-CELL PH, V271, pC1908, DOI 10.1152/ajpcell.1996.271.6.C1908; WOOD HG, 1966, J BIOL CHEM, V241, P5692; WOOD SC, 1991, ANNU REV PHYSIOL, V53, P71, DOI 10.1146/annurev.physiol.53.1.71; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	57	85	86	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25078	25087		10.1074/jbc.M103318200	http://dx.doi.org/10.1074/jbc.M103318200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342561	hybrid			2022-12-27	WOS:000169800700087
J	Hansen, CH; Du, LC; Naur, P; Olsen, CE; Axelsen, KB; Hick, AJ; Pickett, JA; Halkier, BA				Hansen, CH; Du, LC; Naur, P; Olsen, CE; Axelsen, KB; Hick, AJ; Pickett, JA; Halkier, BA			CYP83B1 is the oxime-metabolizing enzyme in the glucosinolate pathway in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGENIC GLUCOSIDE DHURRIN; ESCHERICHIA-COLI; CYTOCHROME P450S; SORGHUM-BICOLOR; BIOSYNTHESIS; EXPRESSION; L.; BENZYLGLUCOSINOLATE; TRYPTOPHAN; CONVERSION	CYP83B1 from Arabidopsis thaliana has been identified as the oxime-metabolizing enzyme in the biosynthetic pathway of glucosinolates. Biosynthetically active microsomes isolated from Sinapis alba converted p-hydroxyphenylacetaldoxime and cysteine into S-alkylated p-hydroxyphenylacetothiohydroximate, S-(p-hydroxyphenylacetohydroximoyl)-L-cysteine, the next proposed intermediate in the glucosinolate pathway. The production was shown to be dependent on a cytochrome P450 monooxygenase. We searched the genome of A. thaliana for homologues of CYP71E1 (P450ox), the only known oxime-metabolizing enzyme in the biosynthetic pathway of the evolutionarily related cyanogenic glucosides, By a combined use of bioinformatics, published expression data, and knock-out phenotypes, we identified the cytochrome P450 CYP83B1 as the oxime-metabolizing enzyme in the glucosinolate pathway as evidenced by characterization of the recombinant protein expressed in Escherichia coli, The data are consistent with the hypothesis that the oxime-metabolizing enzyme in the cyanogenic pathway (P450ox) was mutated into a "P450mox" that converted oximes into toxic compounds that the plant detoxified into glucosinolates.	Royal Vet & Agr Univ, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Royal Vet & Agr Univ, Ctr Mol Plant Physiol, DK-1871 Frederiksberg C, Denmark; Swiss Inst Bioinformat, SwissProt Grp, CH-1211 Geneva 4, Switzerland; IACR Rothamsted, Harpenden AL5 2JQ, Herts, England	University of Copenhagen; University of Copenhagen; University of Copenhagen; Swiss Institute of Bioinformatics; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Halkier, BA (corresponding author), Royal Vet & Agr Univ, Plant Biochem Lab, Thrvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.		Olsen, Carl E/H-3031-2014; Halkier, Barbara A/H-3196-2014; Axelsen, Kristian B/F-3449-2015	Olsen, Carl E/0000-0002-2275-0596; Halkier, Barbara A/0000-0002-3742-702X; Axelsen, Kristian B/0000-0003-3889-2879				Bak S, 1999, PLANT J, V20, P663, DOI 10.1046/j.1365-313X.1999.00642.x; Bak S, 2001, PLANT CELL, V13, P101, DOI 10.1105/tpc.13.1.101; Bak S, 1998, PLANT MOL BIOL, V36, P393, DOI 10.1023/A:1005915507497; Barlier I, 2000, P NATL ACAD SCI USA, V97, P14819, DOI 10.1073/pnas.260502697; Barnes HJ, 1996, METHOD ENZYMOL, V272, P3, DOI 10.1016/S0076-6879(96)72003-7; Du LC, 1995, P NATL ACAD SCI USA, V92, P12505, DOI 10.1073/pnas.92.26.12505; Ettlinger M.G., 1968, RECENT ADV PHYTOCHEM, V1, P59; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Halkier BA, 1999, NATURALLY OCCURRING GLYCOSIDES, P193; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; Hansen CH, 2001, J BIOL CHEM, V276, P11078, DOI 10.1074/jbc.M010123200; Hull AK, 2000, P NATL ACAD SCI USA, V97, P2379, DOI 10.1073/pnas.040569997; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Jones PR, 2000, RECENT ADV PHYTOCHEM, V34, P191, DOI 10.1016/S0079-9920(00)80008-8; Kahn RA, 1997, PLANT PHYSIOL, V115, P1661, DOI 10.1104/pp.115.4.1661; Kiddle GA, 1999, PLANT CELL ENVIRON, V22, P433, DOI 10.1046/j.1365-3040.1999.00416.x; MATSUO M, 1972, PHYTOCHEMISTRY, V11, P697, DOI 10.1016/0031-9422(72)80034-7; Mikkelsen MD, 2000, J BIOL CHEM, V275, P33712, DOI 10.1074/jbc.M001667200; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MITZUTANI M, 1998, PLANT MOL BIOL, V37, P39; Reintanz B, 2001, PLANT CELL, V13, P351, DOI 10.1105/tpc.13.2.351; Rodman J.E., 1981, PHYTOCHEMISTRY ANGIO, P43; RODMAN JE, 1991, SYST BOT, V16, P598, DOI 10.2307/2418864; Rodman JE, 1998, AM J BOT, V85, P997, DOI 10.2307/2446366; SCHWIMMER S, 1960, BIOCHIM BIOPHYS ACTA, V42, P316, DOI 10.1016/0006-3002(60)90795-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WETTER LR, 1968, CAN J BIOCHEM CELL B, V46, P931, DOI 10.1139/o68-139; Winkler RG, 1998, PLANT PHYSIOL, V118, P743, DOI 10.1104/pp.118.3.743; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659	30	126	134	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24790	24796		10.1074/jbc.M102637200	http://dx.doi.org/10.1074/jbc.M102637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333274	Green Published, hybrid			2022-12-27	WOS:000169800700051
J	Jones, LC; Whitlock, JP				Jones, LC; Whitlock, JP			Dioxin-inducible transactivation in a chromosomal setting - Analysis of the acidic domain of the Ah receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; STRUCTURAL ELEMENTS; PAS SUPERFAMILY; ALPHA-HELIX; IN-VIVO; PROTEIN; IDENTIFICATION; CLONING; BINDING; CBP	We analyzed the transactivation function of the acidic segment of the Ah receptor (amino acids 515-583) by reconstituting AhR-defective mouse hepatoma cells with mutants. Our data reveal that both hydrophobic and acidic residues are important for transactivation and that these residues are clustered in two regions of the acidic segment of AhR. Both regions are crucial for function, because disruption of either one substantially impairs transactivation of the chromosomal CYP1A1 target gene. Neither region contains an amino acid motif that resembles those reported for other acidic activation domains. Furthermore, proline substitutions in both regions do not impair transactivation in vivo, a finding that implies that cu-helix formation is not required for function.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol & Oncol, Los Angeles, CA 90048 USA	Stanford University; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Whitlock, JP (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	jpwhit@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA053887, R35CA053887] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53887] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Hi R, 1999, J BIOL CHEM, V274, P35152, DOI 10.1074/jbc.274.49.35152; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; Ko HP, 1997, MOL CELL BIOL, V17, P3497, DOI 10.1128/MCB.17.7.3497; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; LI H, 1994, J BIOL CHEM, V269, P28098; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Radhakrishnan I, 1999, J MOL BIOL, V287, P859, DOI 10.1006/jmbi.1999.2658; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCAMMELL JG, 1995, MOL BRAIN RES, V33, P326, DOI 10.1016/0169-328X(95)00161-K; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWIFT S, 1999, CURR PROTOCOL IMMU S, V31; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103	49	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25037	25042		10.1074/jbc.M102910200	http://dx.doi.org/10.1074/jbc.M102910200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350970	hybrid			2022-12-27	WOS:000169800700081
J	Ogretmen, B; Schady, D; Usta, J; Wood, R; Kraveka, JM; Luberto, C; Birbes, H; Hannun, YA; Obeid, LM				Ogretmen, B; Schady, D; Usta, J; Wood, R; Kraveka, JM; Luberto, C; Birbes, H; Hannun, YA; Obeid, LM			Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; GLUCOSYLCERAMIDE SYNTHASE; REVERSE-TRANSCRIPTASE; TUMOR-CELLS; EXPRESSION; APOPTOSIS; PROLIFERATION; PATHWAY; CANCER; GROWTH	This study was designed to analyze whether ceramide, a bioeffector of growth suppression, plays a role in the regulation of telomerase activity in A549 cells. Telomerase activity was inhibited significantly by exogenous C-6-ceramide, but not by the biologically inactive analog dihydro-C-6-ceramide, in a time- and dose-dependent manner, with 85% inhibition produced by 20 muM C-6-ceramide at 24 h, Moreover, analysis of phosphatidylserine translocation from the inner to the outer plasma membrane by flow cytometry and of poly(ADP-ribose) polymerase degradation by Western blotting showed that ceramide treatment (20 muM for 24 h) had no apoptotic effects. Trypan blue exclusion, [H-3]thymidine incorporation, and cell cycle analyses, coupled with clonogenic cell survival assay on soft agar, showed that ceramide treatment with a 20 muM concentration at 24 h resulted in the cell cycle arrest of the majority of the cell population at G(0)/G(1) with no detectable cell death, These results suggest that the inhibition of telomerase by ceramide is not a consequence of cell death but is correlated with growth arrest. Next, to determine the role of endogenous ceramide in telomerase modulation, A549 cells were transiently transfected with an expression vector containing the full-length bacterial sphingomyelinase cDNA (b-SMase). The overexpression of b-SMase, but not exogenously applied purified b-SMase enzyme, resulted in significantly decreased telomerase activity compared with controls, showing that the increased endogenous ceramide is sufficient for telomerase inhibition. Moreover, treatment of A549 cells with daunorubicin at 1 muM for 6 h resulted in the inhibition of telomerase, which correlated with the elevation of endogenous ceramide levels and growth arrest. Finally, stable overexpression of human glucosylceramide synthase, which attenuates ceramide levels by converting ceramide to glucosylceramide, prevented the inhibitory effects of C-6-ceramide and daunorubicin on telomerase, Therefore, these results provide novel data showing for the first time that ceramide is a candidate upstream regulator of telomerase.	Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charleston, SC 29425 USA; Amer Univ Beirut, Dept Biochem, Beirut, Lebanon	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Medical University of South Carolina; American University of Beirut	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, POB 250779, Charleston, SC 29425 USA.	obeidl@musc.edu		obeid, lina/0000-0002-0734-0847	NCI NIH HHS [CA87584] Funding Source: Medline; NIA NIH HHS [AG16583, AG12467] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R55AG012467, R01AG016583, R29AG012467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama M, 1999, CANCER LETT, V142, P23, DOI 10.1016/S0304-3835(99)00109-3; Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Connor CE, 2001, CYTOMETRY, V43, P164, DOI 10.1002/1097-0320(20010301)43:3<164::AID-CYTO1044>3.0.CO;2-O; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Faraoni I, 1997, CLIN CANCER RES, V3, P579; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hisatake J, 1999, CANCER RES, V59, P4023; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johnson VL, 1999, EXP CELL RES, V251, P175, DOI 10.1006/excr.1999.4557; Katakura Y, 1997, BIOCHEM BIOPH RES CO, V237, P313, DOI 10.1006/bbrc.1997.7104; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lee JY, 1998, BIOCHEM J, V334, P457, DOI 10.1042/bj3340457; Li J, 1999, FASEB J, V13, pA1420; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Marchetti A, 1999, CLIN CANCER RES, V5, P2077; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Ogretmen B, 1998, CANCER CHEMOTH PHARM, V42, P441, DOI 10.1007/s002800050843; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Park KH, 1998, INT J ONCOL, V13, P489; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Plo I, 1999, FEBS LETT, V452, P150, DOI 10.1016/S0014-5793(99)00631-6; RAO J, 1992, ANAL BIOCHEM, V207, P186, DOI 10.1016/0003-2697(92)90521-8; Sarvesvaran J, 1999, CARCINOGENESIS, V20, P1649, DOI 10.1093/carcin/20.8.1649; Schmelz EM, 1998, NUTRITION, V14, P717, DOI 10.1016/S0899-9007(98)00052-5; Schmelz EM, 1999, CANCER RES, V59, P5768; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shiratsuchi M, 1999, LEUKEMIA LYMPHOMA, V34, P349, DOI 10.3109/10428199909050960; Taga S, 1999, ANN SURG, V230, P715, DOI 10.1097/00000658-199911000-00015; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Ulaner GA, 1998, CANCER RES, V58, P4168; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Zhang JD, 1999, J CELL BIOL, V145, P99, DOI 10.1083/jcb.145.1.99; Zhang P, 1997, J BIOL CHEM, V272, P9609	56	95	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24901	24910		10.1074/jbc.M100314200	http://dx.doi.org/10.1074/jbc.M100314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335714	hybrid			2022-12-27	WOS:000169800700063
J	Schick, BP; Petrushina, I; Brodbeck, KC; Castronuevo, P				Schick, BP; Petrushina, I; Brodbeck, KC; Castronuevo, P			Promoter regulatory elements and DNase I-hypersensitive sites involved in serglycin proteoglycan gene expression in human erythroleukemia, CHRF 288-11, and HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULE PROTEOGLYCANS; ENDOTHELIAL GROWTH-FACTOR; GLYCOPROTEIN-IIB GENE; MEGAKARYOCYTE-SPECIFIC EXPRESSION; TISSUE-SPECIFIC EXPRESSION; CAMP RESPONSE ELEMENT; CIS-ACTING ELEMENTS; CORE PROTEIN GENE; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION	We have compared regulation of the serglycin gene in human erythroleukemia (HEL) and CHRF 288-11 cells, which have megakaryocytic characteristics, with promyelocytic HL-60 cells, Deletion constructs were prepared from the region -1123/+42 to -20/+42, and putative regulatory sites were mutated. In all three cell lines, the two major regulatory elements for constitutive expression were the (-80)ets site and the cyclic AMP response element (CRE) half-site at -70, A protein from HEL and CHRF, but not HL60, nuclear extracts bound to the (-80)ets site. Another protein from ah three cell lines bound to the (-70)CRE. Phorbol 12-myristate 15-acetate (PMA) and dibutyryl cyclic AMP (dbcAMP) increased expression of the reporter in HEL cells 2.5-3- and 4.5-fold, respectively, from all constructs except those with (-70)CRE mutations. PMA virtually eliminated expression of serglycin mRNA and promoter constructs, but dbcAMP increased expression in HL-60 cells. The effects of PMA and dbcAMP on promoter expression correlated with mRNA expression, The strengths of two DNase hypersensitive sites in the 5 ' -flanking region and the first intron in all three cells correlated with relative endogenous serglycin mRNA expression, An additional DNase I-hypersensitive site in HL60 DNA in the first intron may be related to the high serglycin expression in HL60 relative to HEL or CHRF cells.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, Philadelphia, PA 19107 USA	Jefferson University	Schick, BP (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Jefferson Med Coll, 1015 Walnut St, Philadelphia, PA 19107 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007821, R01HL029282] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07821, HL-29282] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLIEL PM, 1988, FEBS LETT, V236, P123, DOI 10.1016/0014-5793(88)80298-9; ANGERTH T, 1990, GENE, V93, P235, DOI 10.1016/0378-1119(90)90230-O; Asundi VK, 1998, GENE, V206, P255, DOI 10.1016/S0378-1119(97)00594-5; AVRAHAM S, 1992, J BIOL CHEM, V267, P610; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; BARBER AJ, 1972, BIOCHIM BIOPHYS ACTA, V286, P312, DOI 10.1016/0304-4165(72)90267-X; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; BLOCK KL, 1994, BLOOD, V84, P3385; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRENNAN MJ, 1983, CANCER RES, V43, P4302; CHURCH DJ, 1994, BIOCHEM J, V303, P217, DOI 10.1042/bj3030217; Cook DM, 1996, ONCOGENE, V13, P1789; Deere M, 1999, GENOME RES, V9, P449; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; EISMAN R, 1990, BLOOD, V76, P336; Eklund KK, 1997, J IMMUNOL, V158, P4373; ELLIOTT JF, 1993, MOL IMMUNOL, V30, P749, DOI 10.1016/0161-5890(93)90146-3; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; FUGMAN DA, 1990, BLOOD, V75, P1252; GROVER A, 1987, DIFFERENTIATION, V36, P138, DOI 10.1111/j.1432-0436.1987.tb00188.x; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; Ho HCK, 2001, BIOL REPROD, V64, P1667, DOI 10.1095/biolreprod64.6.1667; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; HUMPHRIES DE, 1992, J BIOL CHEM, V267, P13558; Ikeda T, 1996, GROWTH FACTORS, V13, P151, DOI 10.3109/08977199609003217; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; JUCKER M, 1992, ONCOGENE, V7, P943; Kim JS, 1997, MOL BRAIN RES, V51, P154, DOI 10.1016/S0169-328X(97)00227-1; Ko CW, 1996, MOL CELL BIOCHEM, V162, P65; Kolset SO, 1996, J LEUKOCYTE BIOL, V59, P545, DOI 10.1002/jlb.59.4.545; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Kulseth MA, 1999, BBA-GEN SUBJECTS, V1428, P225, DOI 10.1016/S0304-4165(99)00096-3; KUNKEL GR, 1981, NUCLEIC ACIDS RES, V9, P6869, DOI 10.1093/nar/9.24.6869; KURAMOCHI S, 1990, EUR J BIOCHEM, V193, P163, DOI 10.1111/j.1432-1033.1990.tb19318.x; LASKIN JD, 1991, LEUK RE, V15, P5515; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lok CN, 2000, J BIOL CHEM, V275, P24185, DOI 10.1074/jbc.M000944200; Lowe GN, 1996, ENDOCRINOLOGY, V137, P2208, DOI 10.1210/en.137.6.2208; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; MAILLET P, 1992, LEUKEMIA, V6, P1143; MARLEY PD, 1993, EUR J PHARM-MOLEC PH, V244, P7, DOI 10.1016/0922-4106(93)90053-C; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NASO MF, 1994, J BIOL CHEM, V269, P32999; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; OPREY J, 1994, MOL CELL BIOL, V14, P851; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; RAYGALLET D, 1995, ONCOGENE, V11, P303; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Sali A., 1993, J BIOL CHEM, V268, P9203; SCHICK BP, 1995, J CELL PHYSIOL, V165, P96, DOI 10.1002/jcp.1041650113; SCHICK BP, 1988, J BIOL CHEM, V263, P1052; SCHICK BP, 1993, LEUKEMIA, V7, P1955; SCHICK BP, 1991, ARTERIOSCLER THROMB, V11, P191, DOI 10.1161/01.ATV.11.1.191; SCHICK BP, 1992, BIOCHEM J, V282, P651, DOI 10.1042/bj2820651; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Schick BP, 1997, J CELL PHYSIOL, V172, P87, DOI 10.1002/(SICI)1097-4652(199707)172:1<87::AID-JCP10>3.0.CO;2-L; SCHICK PK, 1989, BLOOD, V73, P1801; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Shimura H, 1998, MOL ENDOCRINOL, V12, P1473, DOI 10.1210/me.12.10.1473; SPROTT SC, 1991, INT J BIOCHEM, V23, P713, DOI 10.1016/0020-711X(91)90042-L; STELLRECHT CM, 1991, DIFFERENTIATION, V48, P127, DOI 10.1111/j.1432-0436.1991.tb00251.x; STELLRECHT CMM, 1993, J BIOL CHEM, V268, P4078; Stevens R. L., 2000, PROTEOGLYCANS STRUCT, P177; ToyamaSorimachi N, 1997, J BIOL CHEM, V272, P26714, DOI 10.1074/jbc.272.42.26714; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Tsuzuki S, 1997, J BIOCHEM-TOKYO, V122, P17; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; Ungefroren H, 1997, BIOCHEM BIOPH RES CO, V235, P413, DOI 10.1006/bbrc.1997.6801; UZAN G, 1991, J BIOL CHEM, V266, P8932; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WHYZMUZIS CA, 1993, BIOCHEM BIOPH RES CO, V194, P118, DOI 10.1006/bbrc.1993.1793; WOLLBERG P, 1994, J BIOL CHEM, V269, P19719	98	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24726	24735		10.1074/jbc.M102958200	http://dx.doi.org/10.1074/jbc.M102958200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333275	hybrid			2022-12-27	WOS:000169800700043
J	Shetty, S; Idell, S				Shetty, S; Idell, S			Urokinase induces expression of its own receptor in Beas2B lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITORS; RNA BINDING-PROTEIN; POSTTRANSCRIPTIONAL REGULATION; MESOTHELIOMA CELLS; MESSENGER-RNA; TUMOR INVASION; BREAST-CANCER; U-PA; METASTASIS; CARCINOMA	Interaction between the urokinase-type plasminogen activator (uPA) and its receptor (uPAR) localizes cellular proteolysis and promotes cellular proliferation and migration. The interaction between uPA and uPAR at the surface of epithelial cells thereby contributes to the pathogenesis of lung inflammation and neoplasia. In this study, we sought to determine if uPA itself alters uPAR expression by lung epithelial cells. uPA enhanced uPAR expression as well as I-125-UpA binding in Beas2B lung epithelial cells in a time- and concentration-dependent manner. The uPA-mediated induction of uPAR is not accomplished through its receptor and requires enzymatic activity. The low molecular weight fragment of uPA, lacking the receptor binding domain, was as potent as intact two-chain uPA in inducing expression of uPAR at the cell surface. Plasmin, the end product of plasminogen activation, did not alter uPA-mediated uPAR expression. Induction of uPAR by uPA represents a novel pathway by which epithelial cells can regulate uPAR-dependent cellular responses that may contribute to stromal remodeling in lung injury or neoplasia.	Univ Texas Hlth Ctr, Dept Med Specialties, Lab C6, Tyler, TX 75708 USA		Shetty, S (corresponding author), Univ Texas Hlth Ctr, Dept Med Specialties, Lab C6, BIomed Res Bldg,11937 US Highway 271, Tyler, TX 75708 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062453] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-62453-01] Funding Source: Medline; PHS HHS [R01 45018-06] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHBAROU A, 1994, CANCER RES, V54, P2372; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BAHUSLAV J, 1995, J EXP MED, V181, P1381; Bhat GJ, 1999, AM J PHYSIOL-LUNG C, V277, pL301, DOI 10.1152/ajplung.1999.277.2.L301; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BOYD D, 1988, CANCER RES, V48, P3112; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CHAPMAN HA, 1988, CHEST, V93, P1256, DOI 10.1378/chest.93.6.1256; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1983, CANCER METAST REV, V2, P41, DOI 10.1007/BF00046905; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; GROSS TJ, 1991, AM J PHYSIOL, V260, pL286, DOI 10.1152/ajplung.1991.260.4.L286; GROSS TJ, 1990, AM J RESP CELL MOL, V3, P449, DOI 10.1165/ajrcmb/3.5.449; HOLLAS W, 1992, THROMB HAEMOSTASIS, V68, P662; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; IDELL S, 1992, AM J RESP CELL MOL, V7, P414, DOI 10.1165/ajrcmb/7.4.414; IDELL S, 1994, AM J PHYSIOL-LUNG C, V267, pL693, DOI 10.1152/ajplung.1994.267.6.L693; Idell S, 1994, New Horiz, V2, P566; Idell S, 1995, PULMONARY FIBROSIS, P743; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; JIANG Y, 1996, BLOOD, V19, P2775; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LIOTTA LA, 1991, CANCER INVEST, V9, P543, DOI 10.3109/07357909109018952; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MITSUBAYASHI S, 1987, UROL RES, V15, P335; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Shetty S, 1998, ARCH BIOCHEM BIOPHYS, V356, P265, DOI 10.1006/abbi.1998.0789; Shetty S, 1999, MOL CELL BIOCHEM, V199, P189, DOI 10.1023/A:1006914800447; Shetty S, 1998, AM J PHYSIOL-LUNG C, V274, pL871, DOI 10.1152/ajplung.1998.274.6.L871; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; SHETTY S, 1995, ANTISENSE RES DEV, V5, P307, DOI 10.1089/ard.1995.5.307; SHETTY S, 1995, AM J PHYSIOL, V268, P972; SPRENGERS ED, 1987, BLOOD, V69, P381; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Xing RH, 1997, CANCER RES, V57, P3585	48	42	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24549	24556		10.1074/jbc.M101605200	http://dx.doi.org/10.1074/jbc.M101605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342540	hybrid			2022-12-27	WOS:000169800700019
J	Sun, Y; Savanenin, A; Reddy, PH; Liu, YF				Sun, Y; Savanenin, A; Reddy, PH; Liu, YF			Polyglutamine-expanded Huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE MUTATION; PROTEIN; PSD-95; MICE; ACTIVATION; LOCALIZATION; EXPRESSION; PLASTICITY; APOPTOSIS; LENGTH	increased glutamate-mediated excitotoxicity seems to play an important role in the pathogenesis of Huntington's disease (Tabrizi, S, J., Cleeter, M, W,, Xuereb, J,, Taaman, J. W., Cooper, J. M., and Schapira, A. H. (1999) Ann, Neurol, 45, 25-32), However, how polyglutamine expansion in huntingtin promotes glutamate-mediated excitotoxicity remains a mystery. In this study we provide evidence that (i) normal huntingtin is associated with N-methyl-D-aspartate (NMDA) and kainate receptors via postsynaptic density 95 (PSD-95), (ii) the SH3 domain of PSD-95 mediates its binding to huntingtin, and (iii) polyglutamine expansion interferes with the ability of huntingtin to interact with PSD-95, The expression of polyglutamine-expanded huntingtin causes sensitization of NMDA receptors and promotes neuronal apoptosis induced by glutamate, The addition of the NMDA receptor antagonist significantly attenuates neuronal toxicity induced by glutamate and polyglutamine-expanded huntingtin, The overexpression of normal huntingtin significantly inhibits neuronal toxicity mediated by NMDA or kainate receptors, Our results demonstrate that polyglutamine expansion impairs the ability of huntingtin to bind PSD-95 and inhibits glutamate-mediated excitotoxicity, These changes may be essential for the pathogenesis of Huntington's disease.	Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA; Oregon Hlth Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA	Northeastern University; Oregon Health & Science University	Liu, YF (corresponding author), Boston Univ, Dept Pharmacol, 715 Albany St, Boston, MA 02118 USA.							BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chen Q, 1996, BRAIN RES, V743, P346, DOI 10.1016/S0006-8993(96)01098-0; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HARPER PS, 1996, HUNTINGTONS DIS, V31; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207; Levine MS, 1999, J NEUROSCI RES, V58, P515, DOI 10.1002/(SICI)1097-4547(19991115)58:4<515::AID-JNR5>3.0.CO;2-F; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Liu YF, 1997, J BIOL CHEM, V272, P8121, DOI 10.1074/jbc.272.13.8121; Liu YF, 2000, J BIOL CHEM, V275, P19035, DOI 10.1074/jbc.C000180200; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; Murphy KPSJ, 2000, J NEUROSCI, V20, P5115; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Savinainen A, 2001, J BIOL CHEM, V276, P11382, DOI 10.1074/jbc.M100190200; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; Tabrizi SJ, 1999, ANN NEUROL, V45, P25, DOI 10.1002/1531-8249(199901)45:1<25::AID-ART6>3.0.CO;2-E; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Usdin MT, 1999, HUM MOL GENET, V8, P839, DOI 10.1093/hmg/8.5.839; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0	30	218	226	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24713	24718		10.1074/jbc.M103501200	http://dx.doi.org/10.1074/jbc.M103501200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319238	hybrid			2022-12-27	WOS:000169800700041
J	Wang, HY; Maechler, P; Ritz-Laser, B; Hagenfeldt, KA; Ishihara, H; Philippe, J; Wollheim, CB				Wang, HY; Maechler, P; Ritz-Laser, B; Hagenfeldt, KA; Ishihara, H; Philippe, J; Wollheim, CB			Pdx1 level defines pancreatic gene expression pattern and cell lineage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE; BETA-CELLS; TRANSCRIPTIONAL ACTIVATION; ISLET CELLS; ALPHA-CELL; HOMEODOMAIN; PROTEIN; PAX4; REPRESSION; REVEALS	The absence of Pdx1 and the expression of brain-4 distinguish alpha -cells from other pancreatic endocrine cell lineages. To define the transcription factor responsible for pancreatic cell differentiation, we employed the reverse tetracycline-dependent transactivator system in INS-I cell-derived subclones INSr alpha beta and INSr beta to achieve tightly controlled and conditional expression of wild type Pdx1 or its dominant-negative mutant, as well as brain-4, INSr alpha beta cells express not only insulin but also glucagon and brain-4, while INSr beta cells express only insulin. Overexpression of Pdx1 eliminated glucagon mRNA and protein in INSr alpha beta cells and promoted the expression of beta -cell-specific genes in INSr beta cells. Induction of dominant-negative Pdx1 in INSr alpha beta cells resulted in differentiation of insulin-producing beta -cells into glucagon-containing alpha -cells without altering brain4 expression. Loss of Pdx1 function alone in INSr beta cells, which do not express endogenous brain-4 and glucagon, was also sufficient to abolish the expression of genes restricted to beta -cells and to cause alpha -cell differentiation. in contrast, induction of brain-4 in INSr beta cells initiated detectable expression of glucagon but did not affect beta -cell-specific gene expression. In conclusion, Pdx1 confers the expression of pancreatic beta -cell-specific genes, such as genes encoding insulin, islet amyloid polypeptide, Glut2, and Nkx6.1. Pdx1 defines pancreatic cell lineage differentiation. Loss of Pdx1 function rather than expression of brain4 is a prerequisite for alpha -cell differentiation.	Univ Geneva, Ctr Med, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland; Univ Geneva, Ctr Med, Dept Internal Med, Diabet Unit, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Wollheim, CB (corresponding author), Ctr Med Univ Geneva, Dept Med Interne, Div Biochim Clin & Diabetol Expt, CH-1211 Geneva 4, Switzerland.	Haiyan.Wang@medicine.unige.ch; Claes.Wollheim@medicine.unige.ch		Maechler, Pierre/0000-0002-2005-1433				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hessabi B, 1999, EUR J BIOCHEM, V263, P170, DOI 10.1046/j.1432-1327.1999.00481.x; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Larsson LI, 1996, MECH DEVELOP, V60, P175, DOI 10.1016/S0925-4773(96)00609-0; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; MADSEN OD, 1993, ENDOCRINOLOGY, V133, P2022, DOI 10.1210/en.133.5.2022; MADSEN OD, 1988, P NATL ACAD SCI USA, V85, P6652, DOI 10.1073/pnas.85.18.6652; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Offield MF, 1996, DEVELOPMENT, V122, P983; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Rafiq I, 2000, J BIOL CHEM, V275, P15977, DOI 10.1074/jbc.275.21.15977; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Seijffers R, 1999, ENDOCRINOLOGY, V140, P3311, DOI 10.1210/en.140.7.3311; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; TRIMBLE ER, 1982, J CLIN INVEST, V69, P405, DOI 10.1172/JCI110464; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang HY, 2000, EMBO J, V19, P4257, DOI 10.1093/emboj/19.16.4257; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200	57	150	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25279	25286		10.1074/jbc.M101233200	http://dx.doi.org/10.1074/jbc.M101233200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309388	Green Published, hybrid			2022-12-27	WOS:000169800700113
J	Spodsberg, N; Jacob, R; Alfalah, M; Zimmer, KP; Naim, HY				Spodsberg, N; Jacob, R; Alfalah, M; Zimmer, KP; Naim, HY			Molecular basis of aberrant apical protein transport in an intestinal enzyme disorder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE DEFICIENCY; LACTASE-PHLORHIZIN HYDROLASE; INTRACELLULAR-TRANSPORT; VIRUS HEMAGGLUTININ; GLYCOSYLATION SITES; EPITHELIAL-CELLS; PLASMA-MEMBRANE; SORTING SIGNALS; O-GLYCOSYLATION; CLEAVAGE	The impaired sorting profile to the apical membrane of human intestinal sucrase-isomaltase is the underlying cause in the pathogenesis of a novel phenotype of intestinal congenital sucrase-isomaltase deficiency. Molecular characterization of this novel phenotype reveals a point mutation in the coding region of the sucrase-isomaltase (SI) gene that results in an amino acid substitution of a glutamine by arginine at residue 117 of the isomaltase subunit. This substitution is located in a domain revealing features of a trefoil motif or a P-dornain in immediate vicinity of the heavily O-glycosylated stalk domain. Expression of the mutant SI phenotype in epithelial Madin-Darby canine kidney cells reveals a randomly targeted SI protein to the apical and basolateral membranes confirming an exclusive role of the Q117R mutation in generating this phenotype. Unlike wild type SI, the mutant protein is completely extractable with Triton X-100 despite the presence of O-glycans that serve in the wild type protein as an apical sorting signal and are required for the association of SI with detergent-insoluble lipid microdomains. Obviously the O-glycans are not adequately recognized in the context of the mutant SI, most likely due to altered folding of the P-domain that ultimately affects the access of the O-glycans to a putative sorting element.	Sch Vet Med, Dept Physiol Chem, D-30559 Hannover, Germany; Univ Munster, Childrens Hosp, D-41489 Munster, Germany	University of Veterinary Medicine Hannover, Foundation; University of Munster	Naim, HY (corresponding author), Sch Vet Med, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011; Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020; Al Falah, Dr. Marwan/C-6281-2011					Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; CHANTRET I, 1992, BIOCHEM J, V285, P915, DOI 10.1042/bj2850915; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 2000, J CLIN INVEST, V106, P281, DOI 10.1172/JCI9677; Jacob R, 2000, J BIOL CHEM, V275, P10630, DOI 10.1074/jbc.275.14.10630; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD ML, 1987, NEW ENGL J MED, V316, P438, DOI 10.1056/NEJM198702193160804; MATLIN K, 1983, J CELL BIOL, V97, P627, DOI 10.1083/jcb.97.3.627; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; Nichols BL, 1998, J BIOL CHEM, V273, P3076, DOI 10.1074/jbc.273.5.3076; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; Ouwendijk J, 1998, BBA-MOL BASIS DIS, V1406, P299, DOI 10.1016/S0925-4439(98)00016-7; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; TREEM WR, 1995, J PEDIATR GASTR NUTR, V21, P1, DOI 10.1097/00005176-199507000-00001; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; Wilson PD, 1997, AM J PHYSIOL-RENAL, V272, pF434, DOI 10.1152/ajprenal.1997.272.4.F434	33	28	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23506	23510		10.1074/jbc.C100219200	http://dx.doi.org/10.1074/jbc.C100219200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11340066	hybrid			2022-12-27	WOS:000169531100039
J	Yam, A; Hyun, T; Li, WQ				Yam, A; Hyun, T; Li, WQ			Characterization of insulin-like growth factor I (IGF-I) receptor mutants for their effects on IGF-I- and interleukin 4-mediated DNA synthesis of 32D cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; TRANSFORMING ACTIVITIES; TUMOR-GROWTH; MITOGENESIS; SUBSTRATE-1; MUTATIONS; DIFFERENTIATION; PROLIFERATION; ACTIVATION; STATS	Recently we demonstrated that overexpression of the wild type insulin-like growth factor I receptor (IGF-IRWT) in 32D myeloid progenitor cells led to cell proliferation in response to interleukin 4 (IL-4) as well as insulin-like growth factor I (IGF-I) in the absence of insulin receptor substrate expression (Soon, L,, Flechner, L., Gutkind, J, S., Wang, L, H,, Baserga, R,, Pierce, J, H,, and Li, W. (1999)Mol. Cell. Biol. 19, 3816-3828), To understand the structural importance of insulin-like growth factor I receptor (IGF-IR) in mediating IL-4- and IGF-I-induced DNA synthesis, we transfected various mutants of IGF-IR to 32D cells. Our results show that most mutants, including Y1250F, Y1251F, Y1250F/Y1251F, S1280A/S1281A/S1282A/S1283A, Y1316F, and 1245d, still retained mitogenic response toward IGF-I or IL-4. However, the Y950F, Y1131F, and Y1135F mutants were not able to respond to either ligand, The H1293F/K1294R and 1293d mutants reduced response toward IGF-I but not to IL-4, Phosphorylation of She was greatly reduced in those three mutants that lost mitogenic response. The MAPK activity was much lower in Y1131F and Y1135F mutants, indicating the importance of the Shc/MAPK pathway in IGF-I-induced mitogenesis. Importantly, the synergistic effect of these two factors on DNA synthesis was not affected in cells expressing most of the mutants, even in those three that had lower mitogenic response toward a single ligand, These results suggest that an unidentified pathway(s) may be induced upon co-addition of IGF-I and IL-4 that sustains the intact mitogenesis.	Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, WQ (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Canc Ctr, New Res Bldg,E407,3970 Reservoir Rd, Washington, DC 20007 USA.			Hyun, Teresa/0000-0002-9350-2733	NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [2P30-CA-51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; BASERGA R, 1995, CANCER RES, V55, P249; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; Hongo A, 1996, ONCOGENE, V12, P1231; Ihle JN, 1998, CANCER J SCI AM, V4, pS84; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; LI SW, 1994, J BIOL CHEM, V269, P32558; Li WQ, 2000, CANCER RES, V60, P3909; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Soon L, 1999, MOL CELL BIOL, V19, P3816; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423	27	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24409	24413		10.1074/jbc.M102358200	http://dx.doi.org/10.1074/jbc.M102358200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323432	hybrid			2022-12-27	WOS:000169531100156
J	Zeng, HY; Moise, L; Grant, MA; Hawrot, E				Zeng, HY; Moise, L; Grant, MA; Hawrot, E			The solution structure of the complex formed between alpha-bungarotoxin and an 18-mer cognate peptide derived from the alpha 1 subunit of the nicotinic acetylcholine receptor from Torpedo californica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 3-DIMENSIONAL SOLUTION STRUCTURE; QUANTITATIVE J-CORRELATION; BINDING-SITE; NMR-SPECTROSCOPY; LONG NEUROTOXIN; AMINO-ACIDS; J-COUPLINGS; PROTON NMR; SENSITIVITY	The region encompassing residues 181-98 on the alpha1 subunit of the muscle-type nicotinic acetylcholine receptor forms a major determinant for the binding of cu neurotoxins. We have prepared an N-15-enriched (18)-amino acid peptide corresponding to the sequence in this region to facilitate structural elucidation by multidimensional NMR. Our aim was to determine the structural basis for the high affinity, stoichiometric complex formed between this cognate peptide and cu-bungarotoxin, a long cu-neurotoxin. Resonances in the complex were assigned through heteronuclear and homonuclear NMR experiments, and the resulting interproton distance constraints were used to generate ensemble structures of the complex. Thr(8), Pro(10), Lys(38), Val(39), Val(40), and pro(69) in alpha -bungarotoxin and Tyr(189), Tyr(190), Thr(191), Cys(192), Asp(195), and Thr(196) in the peptide participate in major intermolecular contacts. A comparison of the free and bound Lu-bungarotoxin structures reveals significant conformational rearrangements in flexible regions of alpha -bungarotoxin, mainly loops I, II, and the C-terminal tail. Furthermore, several of the calculated structures suggest that cation-pi interactions may be involved in binding. The root mean square deviation of the polypeptide backbone in the complex is 2.07 Angstrom. This structure provides, to date, the highest resolution description of the contacts between a prototypic alpha -neurotoxin and its cognate recognition sequence.	Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University	Hawrot, E (corresponding author), Brown Univ, Sch Med, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.	Edward_Hawrot@brown.edu	Moise, Lenny/AAE-7448-2019	Moise, Lenny/0000-0002-4410-865X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034348] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08240] Funding Source: Medline; NIGMS NIH HHS [GM32629] Funding Source: Medline; NINDS NIH HHS [NS34348] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BASUS VJ, 1988, BIOCHEMISTRY-US, V27, P2763, DOI 10.1021/bi00408a016; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1994, METHOD ENZYMOL, V239, P79; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Connolly PJ, 1996, BIOCHEMISTRY-US, V35, P418, DOI 10.1021/bi9520287; DAVIS AL, 1992, J MAGN RESON, V98, P207, DOI 10.1016/0022-2364(92)90126-R; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GENTILE LN, 1995, ANN NY ACAD SCI, V757, P222, DOI 10.1111/j.1749-6632.1995.tb17479.x; GODDARD TD, 2000, SPARKY 3 95; Goldenberg DP, 2001, PROTEIN SCI, V10, P538, DOI 10.1110/ps.30701; Grutter T, 2000, BIOCHEMISTRY-US, V39, P3034, DOI 10.1021/bi992393o; KACHALSKY SG, 1995, P NATL ACAD SCI USA, V92, P10801, DOI 10.1073/pnas.92.23.10801; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KULIOPULOS A, 1994, J AM CHEM SOC, V116, P4599, DOI 10.1021/ja00090a008; LABHARDT AM, 1988, EUR J BIOCHEM, V177, P295, DOI 10.1111/j.1432-1033.1988.tb14376.x; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; Malany S, 2000, BIOCHEMISTRY-US, V39, P15388, DOI 10.1021/bi001825o; Michalet S, 2000, J BIOL CHEM, V275, P25608, DOI 10.1074/jbc.M002362200; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PEARCE SFA, 1990, P ROY SOC B-BIOL SCI, V241, P207, DOI 10.1098/rspb.1990.0087; Peng SS, 1997, J BIOL CHEM, V272, P7817, DOI 10.1074/jbc.272.12.7817; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rolz C, 2001, BIOPHYS CHEM, V89, P119, DOI 10.1016/S0301-4622(00)00222-2; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scherf T, 1997, P NATL ACAD SCI USA, V94, P6059, DOI 10.1073/pnas.94.12.6059; SCHLEUCHER J, 1993, ANGEW CHEM INT EDIT, V32, P1489, DOI 10.1002/anie.199314891; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Spura A, 2000, J BIOL CHEM, V275, P22452, DOI 10.1074/jbc.M001283200; Thompson GS, 2000, PROTEIN SCI, V9, P846, DOI 10.1110/ps.9.5.846; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1994, J BIOMOL NMR, V4, P193; WILSON PT, 1988, MOL PHARMACOL, V34, P643; WILSON PT, 1985, P NATL ACAD SCI USA, V82, P8790, DOI 10.1073/pnas.82.24.8790; WU SH, 1983, ARCH BIOCHEM BIOPHYS, V227, P111, DOI 10.1016/0003-9861(83)90353-3; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	51	41	43	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22930	22940		10.1074/jbc.M102300200	http://dx.doi.org/10.1074/jbc.M102300200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312275	hybrid			2022-12-27	WOS:000169412700127
J	Assarsson, M; Andersson, ME; Hogbom, M; Persson, BO; Sahlin, M; Barra, AL; Sjoberg, BM; Nordlund, P; Graslund, A				Assarsson, M; Andersson, ME; Hogbom, M; Persson, BO; Sahlin, M; Barra, AL; Sjoberg, BM; Nordlund, P; Graslund, A			Restoring proper radical generation by azide binding to the iron site of the E238A mutant R2 protein of ribonucleotide reductase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSYL RADICAL-DIIRON(III) COFACTOR; CRYSTAL-STRUCTURE; EPR SPECTROSCOPY; STRUCTURAL BASIS; FE2+ REACTION; MECHANISM; SUBUNIT; MOUSE; IDENTIFICATION; ACTIVATION	The enzyme activity of Escherichia coli ribonucleotide reductase requires the presence of a stable tyrosyl free radical and diiron center in its smaller R2 component. The iron/radical site is formed in a reconstitution reaction between ferrous iron and molecular oxygen in the protein. The reaction is known to proceed via a paramagnetic intermediate X, formally a Fe-III-Fe-IV state. me have used 9.6 GHz and 285 GHz EPR to investigate intermediates in the reconstitution reaction in the iron ligand mutant R2 E238A with or without azide, formate, or acetate present. Paramagnetic intermediates, i.e. a long-living X-like intermediate and a transient tyrosyl radical, were observed only with azide and under none of the other conditions, A crystal structure of the mutant protein R2 E238A/Y122F with a diferrous iron site complexed with azide was determined. Azide was found to be a bridging ligand and the absent Glu-238 ligand was compensated for by azide and an extra coordination from Glu-204, A general scheme for the reconstitution reaction is presented based on EPR and structure results. This indicates that tyrosyl radical generation requires a specific ligand coordination with 4-coordinate Fe1 and 6-coordinate Fe2 after oxygen binding to the diferrous site.	Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Stockholm Univ, Dept Mol Biol, S-10691 Stockholm, Sweden; Stockholm Univ, Dept Funct Genom, S-10691 Stockholm, Sweden; MPI, CNRS, High Field Magnet Lab, F-38042 Grenoble, France	Stockholm University; Stockholm University; Stockholm University; Centre National de la Recherche Scientifique (CNRS)	Graslund, A (corresponding author), Stockholm Univ, Dept Biophys, S-10691 Stockholm, Sweden.	astrid@biophys.su.se		Sjoberg, Britt-Marie/0000-0001-5953-3360; Hogbom, Martin/0000-0001-5574-9383				ABERG A, 1993, BIOCHEMISTRY-US, V34, P14093; Andersson ME, 1999, J AM CHEM SOC, V121, P2346, DOI 10.1021/ja982280c; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARRA AL, 1990, CHEM PHYS LETT, V165, P107, DOI 10.1016/0009-2614(90)87019-N; BOLLINGER JM, 1991, J AM CHEM SOC, V113, P6289, DOI 10.1021/ja00016a066; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burdi D, 1998, J AM CHEM SOC, V120, P12910, DOI 10.1021/ja9824270; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Hagadorn JR, 1998, J AM CHEM SOC, V120, P13531, DOI 10.1021/ja983333t; LING JS, 1994, J BIOL CHEM, V269, P5595; Logan DT, 1998, BIOCHEMISTRY-US, V37, P10798, DOI 10.1021/bi9806403; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; Moenne-Loccoz P, 1998, BIOCHEMISTRY-US, V37, P14659, DOI 10.1021/bi981838q; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; ORMO M, 1995, J BIOL CHEM, V270, P6570, DOI 10.1074/jbc.270.12.6570; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK WAR; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1986, J MAGN RESON, V67, P135, DOI 10.1016/0022-2364(86)90417-8; Schmidt PP, 1998, J BIOL CHEM, V273, P21463, DOI 10.1074/jbc.273.34.21463; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; Willems JP, 1997, J AM CHEM SOC, V119, P9816, DOI 10.1021/ja9709942	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26852	26859		10.1074/jbc.M008190200	http://dx.doi.org/10.1074/jbc.M008190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328804	hybrid			2022-12-27	WOS:000169966900018
J	Han, MH; Han, DKM; Aebersold, RH; Glomset, JA				Han, MH; Han, DKM; Aebersold, RH; Glomset, JA			Effects of protein kinase CK2, extracellular signal-regulated kinase 2, and protein phosphatase 2A on a phosphatidic acid-preferring phospholipase A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; MASS-SPECTROMETRY; IDENTIFICATION; A(2); A(1); CELLS; ATP	A soluble, phosphatidic acid-preferring phospholipase A1, expressed in mature bovine testes but not in newborn calf testes, may contribute to the formation or function of sperm. Here we incubated a recombinant preparation of the phospholipase in vitro with several enzymes including protein kinase CK2 (CK2), extracellular signal-regulated kinase 2 (ERK2), and protein phosphatase 2A (PP2A) to identify effects that might be of regulatory importance in vivo. Major findings were that 1) CK2 phosphorylated the phospholipase on serines 93, 105, and 716; 2) ERK2 phosphorylated the enzyme on serine 730; 3) there was cross-antagonism between the reactions that phosphorylated serines 716 and 730; 4) PP2A selectively hydrolyzed phosphate groups that were esterified to serines 716 and 730; 5) CK2 alpha formed a stable, MgATP/MgGTP-dependent complex with the phospholipase by a novel mechanism; and 6) the complex showed reduced phospholipase activity and resembled a complex identified in homogenates of macaque testis. These results provide the first available information about the effects of reactions of phosphorylation and dephosphorylation on the behavior of the phospholipase, shed Light on properties of CK2 alpha that may be required for the formation of complexes with its substrates, and raise the possibility that a complex containing CK2 alpha and the phospholipase may play a special biological role in the testis.	Univ Washington, Howard Hughes Med Inst, Res Labs, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA; Inst Syst Biol, Seattle, WA 98105 USA; Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Institute for Systems Biology (ISB); University of Connecticut	Glomset, JA (corresponding author), Univ Washington, Howard Hughes Med Inst, Res Labs, Box 357370, Seattle, WA 98195 USA.	jglomset@u.washington.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823, P51RR000166] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166, RR 11823] Funding Source: Medline; PHS HHS [A1 34339] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AHNERTHILGER G, 1993, NEUROSCIENCE, V53, P547, DOI 10.1016/0306-4522(93)90219-6; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Braun RE, 2000, INT J ANDROL, V23, P92, DOI 10.1046/j.1365-2605.2000.00027.x; Bunt G, 2000, BIOCHEMISTRY-US, V39, P7847, DOI 10.1021/bi992725p; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Haynes PA, 1998, ELECTROPHORESIS, V19, P939, DOI 10.1002/elps.1150190609; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; Higgs HN, 1998, J BIOL CHEM, V273, P5468, DOI 10.1074/jbc.273.10.5468; Higgs HN, 1996, J BIOL CHEM, V271, P10874, DOI 10.1074/jbc.271.18.10874; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin QS, 2000, BIOCHEMISTRY-US, V39, P9335, DOI 10.1021/bi000017u; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Luconi M, 1998, BIOL REPROD, V58, P1476, DOI 10.1095/biolreprod58.6.1476; Mudgal P, 1998, MOL REPROD DEV, V50, P178, DOI 10.1002/(SICI)1098-2795(199806)50:2&lt;178::AID-MRD8&gt;3.0.CO;2-H; Niefind K, 1999, NAT STRUCT BIOL, V6, P1100, DOI 10.1038/70033; Oko R, 1998, ANDROLOGIA, V30, P193; OKO RJ, 1991, ANN NY ACAD SCI, V637, P203, DOI 10.1111/j.1749-6632.1991.tb27311.x; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Wang Z, 2000, BIOCHEMISTRY-US, V39, P11114, DOI 10.1021/bi0006767; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	26	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27698	27708		10.1074/jbc.M101983200	http://dx.doi.org/10.1074/jbc.M101983200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11328814	hybrid			2022-12-27	WOS:000169966900127
J	Omori, K; Idei, A; Akatsuka, H				Omori, K; Idei, A; Akatsuka, H			Serratia ATP-binding cassette protein exporter, Lip, recognizes a protein region upstream of the C terminus for specific secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL ABC-TRANSPORTERS; OUTER-MEMBRANE COMPONENT; ESCHERICHIA-COLI; ERWINIA-CHRYSANTHEMI; PSEUDOMONAS-AERUGINOSA; EXTRACELLULAR LIPASE; CRYSTAL-STRUCTURE; SIGNAL PEPTIDE; AMINO-ACIDS; MARCESCENS	Serratia marcescens ATP-binding cassette (ABC) exporter, the Lip system, secretes lipase (LipA(SM)), metalloproteases, and a cell surface layer protein homologue but not a heme acquisition protein, HasA (HasA(SM)). Secretion of HasA(SM) is limited to the Has(SM) system. However, HasA proteins from Pseudomonas fluorescens (HasA(PF)) and Pseudomonas aeruginosa were exported through the Lip and Has(SM) systems. To investigate the specificity in Lip exporter-mediated secretion, secretion analysis was performed using chimeras containing the HasA(PF), and HasA(SM) sequences. The segment Val-Ala-Leu (designated R1 to R3 sites), which is present close to the C terminus of HasA(PF) but not HasA(SM), was revealed to be involved in the substrate specificity of the Lip exporter. Introduction of amino acid substitutions into the R1-R5 region demonstrated that R1, R3, R4, and R5 sites require some specific amino acid residues for Lip mediated secretion. The amino acid sequence of the region was conserved considerably among the proteins secreted by the Lip exporter, On the contrary, the region was not related to HasA secretion through the Has(SM) system. Interestingly, a typical C-terminal motif, so far regarded as a secretion signal, was not necessary for secretion through either the Lip or the Has(SM) exporter. In LipA(SM) secretion via the Lip system, the typical C-terminal motif was not essential either, but the presence of a sequence similar to Val-Ala-Leu and its location from the C terminus greatly affect the secretion level. Secretion analyses using hybrid exporters and competitors exhibited that the R1-R5 region was recognized by an ABC protein of the Lip exporter, LipB, and that the mutations aborting Lip-mediated secretion in the region resulted in a loss of the affinity to LipB. Thus, a determinant within the secretory protein for Lip-mediated secretion was fully defined.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Toda, Saitama 3358505, Japan; Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation	Omori, K (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, 2-50 Kawagishi-2-Chome, Toda, Saitama 3358505, Japan.							Akatsuka H, 1996, J FERMENT BIOENG, V81, P115, DOI 10.1016/0922-338X(96)87587-8; AKATSUKA H, 1995, J BACTERIOL, V177, P6381, DOI 10.1128/jb.177.22.6381-6389.1995; AKATSUKA H, 1994, J BACTERIOL, V176, P1949, DOI 10.1128/jb.176.7.1949-1956.1994; Akatsuka H, 1997, J BACTERIOL, V179, P4754, DOI 10.1128/jb.179.15.4754-4760.1997; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Binet R, 1996, MOL MICROBIOL, V22, P265, DOI 10.1046/j.1365-2958.1996.00103.x; Binet R, 1997, GENE, V192, P7, DOI 10.1016/S0378-1119(96)00829-3; BINET R, 1995, EMBO J, V14, P2298, DOI 10.1002/j.1460-2075.1995.tb07224.x; Duong F, 1996, MOL MICROBIOL, V21, P459, DOI 10.1111/j.1365-2958.1996.tb02555.x; GHIGO JM, 1994, J BIOL CHEM, V269, P8979; Idei A, 1999, J BACTERIOL, V181, P7545, DOI 10.1128/JB.181.24.7545-7551.1999; Izadi-Pruneyre N, 1999, EUR J BIOCHEM, V261, P562, DOI 10.1046/j.1432-1327.1999.00305.x; JARCHAU T, 1994, MOL GEN GENET, V245, P53, DOI 10.1007/BF00279750; Kawai E, 1998, MOL MICROBIOL, V27, P941, DOI 10.1046/j.1365-2958.1998.00739.x; KENNY B, 1992, MOL MICROBIOL, V6, P1477, DOI 10.1111/j.1365-2958.1992.tb00868.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Koronakis V, 1997, MOL MICROBIOL, V23, P617, DOI 10.1046/j.1365-2958.1997.d01-1880.x; LETOFFE S, 1993, J BACTERIOL, V175, P7321; LETOFFE S, 1994, J BACTERIOL, V176, P5372; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; LETOFFE S, 1994, P NATL ACAD SCI USA, V91, P9876, DOI 10.1073/pnas.91.21.9876; Letoffe S, 1998, MOL MICROBIOL, V28, P1223, DOI 10.1046/j.1365-2958.1998.00885.x; MACKMAN N, 1986, CURR TOP MICROBIOL, V125, P159; MATSUMAE H, 1993, J FERMENT BIOENG, V75, P93, DOI 10.1016/0922-338X(93)90216-U; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Sakurai N, 1996, LETT APPL MICROBIOL, V23, P23, DOI 10.1111/j.1472-765X.1996.tb00021.x; Sambrook J., 2002, MOL CLONING LAB MANU; TAKAGI T, 1985, J BIOTECHNOL, V3, P59, DOI 10.1016/0168-1656(85)90007-0; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WANDERSMAN C, 1987, J BACTERIOL, V169, P5046, DOI 10.1128/jb.169.11.5046-5053.1987; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3; ZHANG F, 1993, P NATL ACAD SCI USA, V90, P4211, DOI 10.1073/pnas.90.9.4211	33	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27111	27119		10.1074/jbc.M101410200	http://dx.doi.org/10.1074/jbc.M101410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335719	hybrid			2022-12-27	WOS:000169966900052
J	Sakamoto, N; Larson, JE; Iyer, RR; Montermini, L; Pandolfo, M; Wells, RD				Sakamoto, N; Larson, JE; Iyer, RR; Montermini, L; Pandolfo, M; Wells, RD			GGA center dot TCC-interrupted triplets in long GAA center dot TTC repeats inhibit the formation of tripler and sticky DNA structures, alleviate transcription inhibition, and reduce genetic instabilities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICHS-ATAXIA; SUPERCOILED PLASMIDS; MISMATCH REPAIR; EXPANSION; SEQUENCES; REPLICATION; LENGTH; DETERMINES; STABILITY; FRATAXIN	Large expansions of GAA.TTC repeats in the first intron of the frataxin (X25) gene are the principal mutation responsible for Friedreich's ataxia (FRDA). Sticky DNA, based on R.R.Y triplexes, was found at the expanded GAA.TTC repeats from FRDA patients. The (GAAGGA.TCCTTC)(65) repeat occurs in the same frataxin locus but is nonpathogenic and does not form sticky DNA. To elucidate the behavior of sticky DNA, we introduced various extents of GGA.TCC interruptions into the long GAA.TTC repeat, More than 20% of GGA.TCC interruptions abolished the formation of sticky DNA. However, the GAA.TTC repeats with less than 11% of GGA.TCC interruptions formed triplexes and/or sticky DNA similar to the uninterrupted repeat sequence. These triplexes showed different P1 nuclease sensitivities, and the GGA.TCC interruptions were slightly more sensitive than the surrounding GAA.TTC repeats. Furthermore, genetic instability investigations in Escherichia coli revealed that a small number (4%) of interruptions substantially stabilized the long GAA.TTC tracts. Furthermore, the greater the extent of interruptions of the GAA.TTC repeats, the less inhibition of in vitro transcription was observed, as expected, based on the capacity of interruptions to inhibit the formation of sticky DNA We propose that the interruptions introduce base mismatches into the R.R.Y triplex, which explains the observed chemical and biological properties.	Texas A&M Univ Syst, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr,Hlth Sci Ctr, Houston, TX 77030 USA; Ctr Hosp Univ Montreal, Montreal, PQ H2L 4M1, Canada	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Universite de Montreal	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Texas Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	Pandolfo, Massimo/B-2853-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554, R01NS034192] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS34192, NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cossee M, 1997, P NATL ACAD SCI USA, V94, P7452, DOI 10.1073/pnas.94.14.7452; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; Epplen C, 1997, HUM GENET, V99, P834, DOI 10.1007/s004390050458; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; Iyer RR, 1999, J BIOL CHEM, V274, P3865, DOI 10.1074/jbc.274.6.3865; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Moseley ML, 1998, NEUROLOGY, V51, P1666, DOI 10.1212/WNL.51.6.1666; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Parniewski P, 2000, J MOL BIOL, V299, P865, DOI 10.1006/jmbi.2000.3796; RICH A, 1961, J MOL BIOL, V3, P71, DOI 10.1016/S0022-2836(61)80009-0; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307	31	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27178	27187		10.1074/jbc.M101852200	http://dx.doi.org/10.1074/jbc.M101852200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11325966	hybrid			2022-12-27	WOS:000169966900061
J	Schuringa, JJ; Dekker, LV; Vellenga, E; Kruijer, W				Schuringa, JJ; Dekker, LV; Vellenga, E; Kruijer, W			Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase C delta is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR APRF; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; TYROSINE; PATHWAYS; IDENTIFICATION; ASSOCIATION; BINDING; FAMILY	Activation of signal transducer and activator of transcription 3 (STAT3) by interleukin-6 (IL-6) involves phosphorylation of Tyr-705 and Ser-727, both of which are critical for STAT3 transactivation. Here, we demonstrate that IL-6 activates Rac-1 and SEK-1/MKK-4 of the stress-activated protein kinase pathway, as well as protein kinase C delta (PKC delta), as indicated by PKC delta Thr-505 phosphorylation, However, JNK-1, the end point kinase of the stress-activated protein kinase pathway signal transduction cascade, is not activated by IL-6, PKC delta was found to be associated with SEK-1/MKK-4 in unstimulated HepG2 cells but rapidly dissociates from SEK-1/ MKK-4 upon IL-6 stimulation to become associated with STAT3, Inhibition of PKC delta using rottlerin (6 muM) or by overexpression of dominant negative PKC delta demonstrates that PKC delta kinase activity is required for STAT3 Ser-727 phosphorylation and transactivation but not for STAT3 Tyr-705 phosphorylation or nuclear import. PKC delta signals downstream of Rac-1 and SEK-1/MKK-4, because enhanced STAT3 transactivation induced by overexpression of constitutive active RacV12 was strongly abrogated by rottlerin, whereas IL-B-induced SEK-1/MKK-4 Thr-223 phosphorylation was not affected under these conditions. Studying the kinetics of STAT3 and PKC delta phosphorylation in cytoplasmic and nuclear fractions revealed that STAT3 Tyr-705 phosphorylation and nuclear translocation precedes PKC delta Thr-505 and STAT3 Ser-727 phosphorylation. Furthermore, the IL-6-induced PKC delta Thr-505 and STATE Ser-727 phosphorylation were only observed in nuclear fractions of HepG2 cells, These results demonstrate that IL-6-induced STAT3 transactivation involves the sequential activation of Rac-1 and SEK-1/MKK-4, which leads to nuclear translocation of PKC delta by release from a SEK-1/MKK-4-containing complex. Our results further indicate that PKC delta -mediated STAT3 Ser-727 phosphorylation is mainly a nuclear event.	Ctr Biol, Dept Genet, NL-9751 NN Haren, Netherlands; Univ Groningen Hosp, Dept Hematol, NL-9700 RB Groningen, Netherlands; UCL, Dept Med, Rayne Inst, London WC1E 6JJ, England	University of Groningen; University of London; King's College London; University College London	Kruijer, W (corresponding author), Ctr Biol, Dept Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.	W.Kruijer@biol.rug.nl	Dekker, Lodewijk/J-6934-2013	Dekker, Lodewijk/0000-0001-5247-3297				Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Saharinen P, 1997, BLOOD, V90, P4341; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schuringa JJ, 2000, BLOOD, V95, P3765, DOI 10.1182/blood.V95.12.3765; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	35	66	68	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27709	27715		10.1074/jbc.M009821200	http://dx.doi.org/10.1074/jbc.M009821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335711	hybrid			2022-12-27	WOS:000169966900128
J	Suzuki, T; Hiroki, A; Watanabe, T; Yamashita, T; Takei, I; Umezawa, K				Suzuki, T; Hiroki, A; Watanabe, T; Yamashita, T; Takei, I; Umezawa, K			Potentiation of insulin-related signal transduction by a novel protein-tyrosine phosphatase inhibitor, Et-3,4-dephostatin, on cultured 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORT; DEPENDENT DIABETES-MELLITUS; PANCREATIC BETA-CELLS; HUMAN SKELETAL-MUSCLE; GROWTH-FACTOR-I; HYPOGLYCEMIC AGENT; NEGATIVE REGULATOR; RECEPTOR KINASE; GENE-EXPRESSION; C-CBL	We previously isolated dephostatin from Streptomyces as a novel inhibitor of CD45-associated protein-tyrosine phosphatase. We prepared Et-3,4-dephostatin as a stable analogue and found it to inhibit PTP-1B and SHPTP-1 protein-tyrosine phosphatases selectively but not to inhibit CD45 and leukocyte common antigen-related phosphatase ones effectively. Et-3,4-dephostatin increased the tyrosine phosphorylation of the insulin receptor and insulin receptor substrate-1 with or without insulin in differentiated 3T3-L1 mouse adipocytes. The increase of tyrosine phosphorylation by Et-3,4-dephostatin was more prominent in 6-h than in 30-min incubation. It also increased phosphorylation and activation of Akt with or without insulin. Et-3,4-dephostatin also enhanced translocation of glucose transporter 4 from the cytoplasm to the membrane and 2-deoxy-glucose transport. Et-3,4-dephostatin-induced glucose uptake was inhibited by SB203580, a p38 inhibitor, but not by PD98059, a MEK inhibitor, or by cycloheximide as insulin-induced uptake. Interestingly, although LY294002, a phosphatidylinositol 3-kinase inhibitor, inhibited the insulin-induced glucose uptake completely, it only partially inhibited the Et-3,4-dephostatin-induced uptake. It also blocked insulin-induced glucose transporter 4 translocation but not the Et-3,4-dephostatin-induced one. The increase in c-Cbl tyrosine phosphorylation caused by Et-3,4 dephostatin was stronger than that in insulin receptor phosphorylation, These observations indicate that a phosphatidylinositol 3-kinase-independent pathway involving c-Cbl is more important in Et-3,4-dephostatin-induced glucose uptake than in insulin-induced uptake, Et-3,4-dephostatin showed an in vivo antidiabetic effect in terms of reducing the high blood glucose level in KK-A(y) mice after oral administration. Thus, Et-3,4-dephostatin potentiated insulin-related signal transductions in cultured mouse adipocytes and showed an antidiabetic effect in mice.	Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Yokohama, Kanagawa 2230061, Japan; Inst Microbial Chem, Shinagawa Ku, Tokyo 1410021, Japan; Kaneka Corp, Takasago, Hyogo 6768688, Japan; Keio Univ, Sch Med, Clin Lab Internal Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Kaneka Corporation; Keio University	Umezawa, K (corresponding author), Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2230061, Japan.							ABEL ED, 1995, CURR OPIN ENDOCRINOL, V2, P313; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; Asano T, 2000, J BIOL CHEM, V275, P17671, DOI 10.1074/jbc.M910391199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Donthi RV, 2000, CARDIOVASC DRUG THER, V14, P463, DOI 10.1023/A:1007876703644; Efanova IB, 1998, J BIOL CHEM, V273, P33501, DOI 10.1074/jbc.273.50.33501; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FANTUS IG, 1994, DIABETES, V43, P375, DOI 10.2337/diabetes.43.3.375; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujitani S, 1996, METABOLISM, V45, P184, DOI 10.1016/S0026-0495(96)90051-7; Fujiwara S, 1997, BIOCHEM BIOPH RES CO, V238, P213, DOI 10.1006/bbrc.1997.7174; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; HARUTA T, 1995, J BIOL CHEM, V270, P27991; IMOTO M, 1993, J ANTIBIOT, V46, P1342, DOI 10.7164/antibiotics.46.1342; Kayali AG, 1998, J BIOL CHEM, V273, P13808, DOI 10.1074/jbc.273.22.13808; KENNER KA, 1993, J BIOL CHEM, V268, P25455; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; MIMURA K, 1994, DIABETIC MED, V11, P685, DOI 10.1111/j.1464-5491.1994.tb00333.x; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; Nishimura M, 1969, EXP ANIMALS, V18, P147, DOI DOI 10.1538/EXPANIM1957.18.4_147; OBERMAIERKUSSER B, 1989, J BIOL CHEM, V264, P9497; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; RIVON V, 1997, BIOCHEM J, V324, P839; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; Schoonjans K, 1996, J LIPID RES, V37, P907; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Watanabe T, 1995, J ANTIBIOT, V48, P1460, DOI 10.7164/antibiotics.48.1460; Watanabe T, 2000, TETRAHEDRON, V56, P741, DOI 10.1016/S0040-4020(99)01058-3; WHITE MF, 1994, J BIOL CHEM, V269, P1	42	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27511	27518		10.1074/jbc.M011726200	http://dx.doi.org/10.1074/jbc.M011726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342532	hybrid			2022-12-27	WOS:000169966900102
J	Warnick, CT; Dabbas, B; Ford, CD; Strait, KA				Warnick, CT; Dabbas, B; Ford, CD; Strait, KA			Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; TRANSCRIPTIONAL ACTIVATION; TUMOR-CELLS; BINDING; FAMILY; P73; HETERODIMER; PROTEIN; MEMBER; LINES	Defects in the human MSH2 mismatch repair system have been implicated in cellular mutagenesis, tumorigenesis, and chemotherapeutic resistance. The current studies characterized the 5' upstream proximal promoter region of the hMSH2 gene using transient transfection of A2780 ovarian cancer cells. Serial deletions of a 1.88-kb fragment of the proximal promoter region of the hMSH2 gene revealed that promoter activity was restricted to the first -281 bp. Targeted deletions within this -281 bp region coupled with specific sequence mutagenesis identified a response element for the p53 tumor suppressor protein located between -242 and -222 bp, The -242 hMSH2 p53 element is configured as a direct tandem repeat palindrome with 80% homology to the p53 consensus binding sequence. Co-transfection of an hMSH2 reporter and p53 expression vector into the p53-null cell line SK-OV-3 produced 10-fold enhanced transcription, which was lost when the -242 to -222 p53 binding site was mutated. These results clearly demonstrate the presence of a previously unidentified p53 response element in the hMSH2 proximal promoter. Its location at -242 bp upstream of the start site of transcription is distinct from two previously reported p53 sites at -447 and -416, which transactivate in Saos-2 cells (Scherer, S. J., Maier, S. M., Seifert, M., Hanselmann, R. G., Zang, K. D., Muller-Hermelink, H. K., Angel, P., Welter, C., and Schartl, M. (2000) J. Biol. Chem. 275, 37469-37473). Finally, in sharp contrast to their activity in Saos-2 cells, deletion of the -447 and -416 sites in A2780 cells had no effect on hMSH2 promoter activity. Thus, it appears that p53 regulates hMSH2 expression through multiple cell type-specific DNA response elements.	Latter Day St Hosp, Dept Med, Canc Res Lab, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Dept Pathol, Canc Res Lab, Salt Lake City, UT 84143 USA		Strait, KA (corresponding author), Latter Day St Hosp, Dept Med, Canc Res Lab, 325 8th Ave, Salt Lake City, UT 84143 USA.							Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; CARSON DA, 1995, LANCET, V346, P1009, DOI 10.1016/S0140-6736(95)91693-8; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; delaChapelle A, 1995, ANNU REV GENET, V29, P329, DOI 10.1146/annurev.ge.29.120195.001553; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fujita M, 1995, INT J CANCER, V64, P361, DOI 10.1002/ijc.2910640602; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Li GM, 1999, ONCOL RES, V11, P393; MARKS JR, 1991, CANCER RES, V51, P2979; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; RUTTENBERG DH, 1999, J BIOL CHEM, V274, P33747; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SHEEHY G, 1986, J HISTOTECHNOL, V9, P134; Umar A, 1997, CANCER RES, V57, P3949; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; YAGINUMA Y, 1992, CANCER RES, V52, P4196; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	37	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27363	27370		10.1074/jbc.M103088200	http://dx.doi.org/10.1074/jbc.M103088200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350971	hybrid			2022-12-27	WOS:000169966900084
J	Zhang, T; Hong, WJ				Zhang, T; Hong, WJ			Ykt6 forms a SNARE complex with syntaxin 5, GS28, and Bet1 and participates in a late stage in endoplasmic reticulum-Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TRANSPORT; MEMBRANE-FUSION; INTERMEDIATE COMPARTMENT; SECRETORY PATHWAY; PRENYLATED SNARE; CIS-GOLGI; APPARATUS; ER; VESICLES; YEAST	The yeast SNARE Ykt6p has been implicated in several trafficking steps, including vesicular transport from the endoplasmic reticulum (ER) to the Golgi, intra-Golgi transport, and homotypic vacuole fusion. The functional role of its mammalian homologue (Ykt6) has not been established. Using antibodies specific for mammalian Ykt6, it is revealed that it is found mainly in Golgi-enriched membranes. Three SNAREs, syntaxin 5, GS28, and Bet1, are specifically associated with Ykt6 as revealed by co-immunoprecipitation, suggesting that these four SNAREs form a SNARE complex. Double labeling of Ykt6 and the Golgi marker mannosidase II or the ER-Golgi recycling marker KDEL receptor suggests that Ykt6 is primarily associated with the Golgi apparatus. Unlike the KDEL receptor, Ykt6 does not cycle back to the peripheral ER exit sites. Antibodies against Ykt6 inhibit in vitro ER-Golgi transport of vesicular stomatitis virus envelope glycoprotein (VSVG) only when they are added before the EGTA-sensitive stage. ER-Golgi transport of VSVG in vitro is also inhibited by recombinant Ykt6. In the presence of antibodies against Ykt6, VSVG accumulates in peri-Golgi vesicular structures and is prevented from entering the mannosidase II compartment, suggesting that Ykt6 functions at a late stage in ER-Golgi transport. Golgi apparatus marked by mannosidase II is fragmented into vesicular structures in cells microinjected with Ykt6 antibodies. It is concluded that Ykt6 functions in a late step of ER-Golgi transport, and this role may be important for the integrity of the Golgi complex.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hong, WJ (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010					ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Catchpoole DR, 1999, DNA CELL BIOL, V18, P141, DOI 10.1089/104454999315529; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hauri HP, 2000, J CELL SCI, V113, P587; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HAY JC, 1997, CELL, V89, P147; HONG W, 1996, PROTEIN TRAFFICKING; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz L, 1998, EMBO J, V17, P6200, DOI 10.1093/emboj/17.21.6200; Love HD, 1998, J CELL BIOL, V140, P541, DOI 10.1083/jcb.140.3.541; Lowe SL, 1996, J CELL SCI, V109, P209; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; McNew JA, 1998, FEBS LETT, V435, P89, DOI 10.1016/S0014-5793(98)01044-8; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Mironov A, 1998, FASEB J, V12, P249; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nichols BJ, 1998, BBA-MOL CELL RES, V1404, P9, DOI 10.1016/S0167-4889(98)00044-5; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RICHARD CL, 2000, ANNU REV CELL DEV BI, V16, P19; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stephens DJ, 2001, J CELL SCI, V114, P1053; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TANG BL, 1995, EUR J CELL BIOL, V68, P199; Tsui MMK, 2001, MOL BIOL CELL, V12, P521, DOI 10.1091/mbc.12.3.521; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Xu Y, 1998, J BIOL CHEM, V273, P21783, DOI 10.1074/jbc.273.34.21783; Yang W, 1998, MOL BIOL CELL, V9, P191, DOI 10.1091/mbc.9.1.191; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	64	97	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27480	27487		10.1074/jbc.M102786200	http://dx.doi.org/10.1074/jbc.M102786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11323436	hybrid			2022-12-27	WOS:000169966900099
J	Carlson, TR; Feng, YZ; Maisonpierre, PC; Mrksich, M; Morla, AO				Carlson, TR; Feng, YZ; Maisonpierre, PC; Mrksich, M; Morla, AO			Direct cell adhesion to the angiopoietins mediated by integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; OVEREXPRESSING ANGIOPOIETIN-1; FIBRONECTIN RECEPTOR; ENDOTHELIAL-CELLS; GROWTH-FACTORS; TIE2 RECEPTOR; IN-VITRO; ANGIOGENESIS; SURFACE; VITRONECTIN	Genetic ablation of angiopoietin-1 (Ang-l) or of its cognate receptor, Tie2, disrupts angiogenesis in mouse embryos. The endothelial cells in growing blood vessels of Ang-l knockout mice have a rounded appearance and are poorly associated with one another and their underlying basement membranes (Dumont, D. J., Gradwohl, G., Fong, G. H., purl, M. C., Gertsenstein, M., Auerbach, A, and Breitman, M. L. (1994) Genes Dev. 8, 1897-1909; Sate, T. N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and Qin, Y. (1995) Nature 376, 70-74; Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sate, T. N., and Yancopoulos, G. D. (1996) Cell 87, 1171-1180). It is therefore possible that Ang-l regulates endothelial cell adhesion. In this study we asked whether Ang-l might act as a direct substrate for cell adhesion. Human umbilical vein endothelial cells (HUVECs) plated for a brief period on different substrates were found to adhere and spread well on Ang-l. Similar results were seen on angiopoietin-2 (Ang-2)-coated surfaces, although cells did not spread well on Ang-2. Ang-l, but not Ang-2, supported HUVEC migration, and this was independent of growth factor activity. When the same experiments were done with fibroblasts that either lacked, or stably expressed, Tie2, results similar to those with HUVECs were seen, suggesting that adhesion to the angiopoietins was independent of Tie2 and not limited to endothelial cells. Interestingly, when integrin-blocking agents were included in these assays, adhesion to either angiopoietin was significantly reduced. Moreover, Chinese hamster ovary-B2 cells lacking the a, integrin subunit did not adhere to Ang-l, but they did adhere to Ang-8. Stable expression of the human a, integrin subunit in these cells rescued adhesion to Ang-l and promoted an increase in adhesion to Ang-a, We also found that Ang-l and Ang-8 bind rather selectively to vitronectin. These results suggest that, beyond their role in modulating Tie2 signaling, Ang-l and Ang-2 can directly support cell adhesion mediated by integrins.	Univ Chicago, Dept Pathol, Comm Canc Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Chicago; University of Chicago; University of Chicago; Regeneron	Morla, AO (corresponding author), Univ Chicago, Dept Pathol, Comm Canc Biol, MC 1089,5841 S Maryland Ave, Chicago, IL 60637 USA.		Mrksich, Milan/G-2469-2011	Mrksich, Milan/0000-0002-4964-796X	NHLBI NIH HHS [R01 HL-59962] Funding Source: Medline; NIGMS NIH HHS [R01 GM-54621] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059962] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; ASCH E, 1990, J CLIN INVEST, V85, P1372, DOI 10.1172/JCI114581; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Beckner ME, 1999, CANCER INVEST, V17, P594, DOI 10.3109/07357909909032845; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHRZANOWSKAWODNICKA M, 1994, J CELL SCI, V107, P3643; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Huang XL, 1999, BIOCHEM BIOPH RES CO, V264, P133, DOI 10.1006/bbrc.1999.1472; Jain RK, 2000, NAT MED, V6, P131, DOI 10.1038/72212; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Nishimura M, 1999, FEBS LETT, V448, P254, DOI 10.1016/S0014-5793(99)00381-6; Norde W, 1998, BIOTECHNOL APPL BIOC, V28, P133; Norde W, 2000, J BIOTECHNOL, V79, P259, DOI 10.1016/S0168-1656(00)00242-X; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	46	209	219	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26516	26525		10.1074/jbc.M100282200	http://dx.doi.org/10.1074/jbc.M100282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346644	hybrid			2022-12-27	WOS:000169823300115
J	Chipuk, JE; Bhat, M; Hsing, AY; Ma, JJ; Danielpour, D				Chipuk, JE; Bhat, M; Hsing, AY; Ma, JJ; Danielpour, D			Bcl-xL, blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; RAT VENTRAL PROSTATE; HUMAN HEPATOMA-CELLS; TGF-BETA; IMMUNOHISTOCHEMICAL ANALYSIS; ANIMAL DEVELOPMENT; CANCER CELLS; BCL-X(L); DEATH; EXPRESSION	The mechanism by which transforming growth factor-pi (TGF-beta1) induces apoptosis of prostate epithelial cells was studied in the NRP-154 rat prostate epithelial cell line. TGF-beta1 down-regulates expression of Bcl-xL and poly(ADP-ribosyl)polymerase (PARP), promotes cytochrome c release, up-regulates expression of latent caspase-3, and activates caspases 3 and 9, We tested the role of Bcl-xL in this cascade by stably overexpressing Bcl-xL to prevent loss by TGF-beta1, Clones overexpressing Bcl-xL are resistant to TGF-beta1 with respect to induction of apoptosis, cytochrome c release, activation of caspases 9 and 3, and cleavage of PARP; yet they remain sensitive to TGF-beta1 by cell cycle arrest, induction of both fibronectin and latent caspase-3 expression, and loss of PARP expression, We show that Bcl-xL associates with Apaf-1 in NRP-154 cells; but this association does not inhibit the activation of caspases 9 and 3 by cytochrome c, Together, our data suggest that TGF-beta1 induces apoptosis through loss of Bcl-xL, leading to cytochrome c release and the subsequent activation of caspases 9 and 3, Moreover, our data demonstrate that the antiapoptotic effect of Bcl-xL occurs by inhibition of mitochondrial cytochrome c release and not through antagonizing Apaf-1-dependent processing of caspases 9 and 3.	Case Western Reserve Univ, Ireland Canc Ctr, Dept Pharmacol, Res Labs,Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Dept Physiol & Biophys, Res Labs,Univ Hosp Cleveland, Cleveland, OH 44106 USA; NCI, Lab Cell Regualt & Carcinogensis, NIH, Bethesda, MD 20892 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Danielpour, D (corresponding author), Case Western Reserve Univ, Ireland Canc Ctr, Dept Pharmacol, Res Labs, Samuel Gerber Bldg,Suite 200,Lab 3,11001 Cedar Rd, Cleveland, OH 44106 USA.	dxd49@po.cwru.edu		Chipuk, Jerry Edward/0000-0002-1337-842X	NCI NIH HHS [1R01-CA30369-01, P30CA43703] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Axmann A, 1998, BIOCHEM BIOPH RES CO, V249, P456, DOI 10.1006/bbrc.1998.9188; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; Brodin G, 1999, CANCER RES, V59, P2731; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Buchmann A, 1999, CELL DEATH DIFFER, V6, P190, DOI 10.1038/sj.cdd.4400475; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Carthy CM, 1999, LAB INVEST, V79, P953; Chao DT, 1997, INT IMMUNOL, V9, P1375, DOI 10.1093/intimm/9.9.1375; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 1999, J CELL SCI, V112, P169; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Freathy C, 2000, HEPATOLOGY, V32, P750, DOI 10.1053/jhep.2000.18329; Gao CL, 2000, INT J CANCER, V88, P191, DOI 10.1002/1097-0215(20001015)88:2<191::AID-IJC7>3.3.CO;2-1; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guo YP, 1999, CANCER RES, V59, P1366; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; HARTLEYASP B, 1982, J UROLOGY, V127, P818, DOI 10.1016/S0022-5347(17)54057-4; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsing AY, 1996, CANCER RES, V56, P5146; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hung WC, 1998, CELL SIGNAL, V10, P511, DOI 10.1016/S0898-6568(97)00189-7; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; Kokontis J, 1991, Receptor, V1, P271; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Lam M, 1998, J BIOL CHEM, V273, P17307, DOI 10.1074/jbc.273.28.17307; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marcelli M, 2000, PROSTATE, V42, P260, DOI 10.1002/(SICI)1097-0045(20000301)42:4<260::AID-PROS3>3.0.CO;2-0; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; Massague J, 2000, GENE DEV, V14, P627; MICKEY DD, 1977, CANCER RES, V37, P4049; Milligan CE, 1997, BRIT MED BULL, V53, P570; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; Nunez G, 1996, ADV EXP MED BIOL, V406, P75; Ohta S, 1997, BIOCHEM J, V324, P777, DOI 10.1042/bj3240777; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pollard M, 1998, PROSTATE, V37, P1, DOI 10.1002/(SICI)1097-0045(19980915)37:1<1::AID-PROS1>3.0.CO;2-L; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SCHUURMANS ALG, 1991, J STEROID BIOCHEM, V40, P193, DOI 10.1016/0960-0760(91)90182-5; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; SPORN MB, 1991, CIBA F SYMP, V157, P1; Takahashi N, 2000, PROSTATE, V44, P328, DOI 10.1002/1097-0045(20000901)44:4<328::AID-PROS10>3.0.CO;2-8; Tang BW, 1999, CANCER RES, V59, P4834; Tang DG, 1998, CANCER RES, V58, P3466; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tu HC, 1996, INT J CANCER, V69, P357, DOI 10.1002/(SICI)1097-0215(19961021)69:5<357::AID-IJC1>3.0.CO;2-4; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zhang HC, 1996, PROSTATE, V29, P69	89	87	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26614	26621		10.1074/jbc.M100913200	http://dx.doi.org/10.1074/jbc.M100913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11320089	hybrid			2022-12-27	WOS:000169823300126
J	Mitsutake, S; Tani, M; Okino, N; Mori, K; Ichinose, S; Omori, A; Iida, H; Nakamura, T; Ito, M				Mitsutake, S; Tani, M; Okino, N; Mori, K; Ichinose, S; Omori, A; Iida, H; Nakamura, T; Ito, M			Purification, characterization, molecular cloning, and subcellular distribution of neutral ceramidase of rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR PROLIFERATION; ALKALINE CERAMIDASE; ACID CERAMIDASE; SPHINGOSINE; SPHINGOSINE-1-PHOSPHATE; CHOLESTEROL; PROTEINS; EXPRESSION; COMPLEX; ANTIGEN	Previously, we reported two types of neutral ceramidase in mice, one solubilized by freeze-thawing and one not. The former was purified as a 94-kDa protein from mouse liver, and cloned (Tani, M., Okino, N., Mori, K., Tanigawa, T., Izu, H., and Ito, M. (2000) J. Biol. Chem, 275, 11229-11234), In this paper, we describe the purification, molecular cloning, and subcellular distribution of a 112-kDa membrane-bound neutral ceramidase of rat kidney, which was completely insoluble by freeze-thawing. The open reading frame of the enzyme encoded a polypeptide of 761 amino acids having nine putative N-glycosylation sites and one possible transmembrane domain. In the ceramidase overexpressing HEK293 cells, 133-kDa (Golgi-form) and 113-kDa (endoplasmic reticulum-form) Myc-tagged ceramidases were detected, whereas these two proteins were converted to a 87-kDa protein concomitantly with loss of activity when expressed in the presence of tunicamycin, indicating that the N-glycosylation process is indispensable for the expression of the enzyme activity. Immunohistochemical analysis clearly showed that the ceramidase was mainly localized at the apical membrane of proximal tubules, distal tubules, and collecting ducts in rat kidney, while in liver the enzyme was distributed with endosome-like organelles in hepatocytes. Interestingly, the kidney ceramidase was found to be enriched in the raft microdomains with cholesterol and GM1 ganglioside.	Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Appl Genet & Pest Management, Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1948511, Japan	Kyushu University; Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Mitsutake, Susumu/A-4082-2012; Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818; Tani, Motohiro/0000-0003-4316-8260				Aguilar RC, 2001, J BIOL CHEM, V276, P13145, DOI 10.1074/jbc.M010591200; ANI M, 2000, J BIOL CHEM, V275, P11229; BENDALL DS, 1960, BIOCHEM J, V74, P444, DOI 10.1042/bj0740444; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; GAMBLE W, 1978, J LIPID RES, V19, P1068; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; Hatt PD, 1997, EUR J BIOCHEM, V246, P336, DOI 10.1111/j.1432-1033.1997.00336.x; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Ito M, 2000, METHOD ENZYMOL, V311, P682; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NEWMAN LS, 1995, CELL, V82, P773, DOI 10.1016/0092-8674(95)90474-3; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHTA H, 1995, CANCER RES, V55, P691; OKAZAKI T, 1990, J BIOL CHEM, V265, P3125; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Sambrook H., 1989, MOL CLONING LAB MANU; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SUGITA M, 1972, SCIENCE, V178, P1100, DOI 10.1126/science.178.4065.1100; SYMONS LJ, 1987, ANAL BIOCHEM, V164, P382, DOI 10.1016/0003-2697(87)90508-2; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; YADA Y, 1995, J BIOL CHEM, V270, P12677, DOI 10.1074/jbc.270.21.12677; ZHANG H, 1990, J BIOL CHEM, V265, P76	48	90	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26249	26259		10.1074/jbc.M102233200	http://dx.doi.org/10.1074/jbc.M102233200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11328816	hybrid			2022-12-27	WOS:000169823300082
J	MacDonald, NJ; Shivers, WY; Narum, DL; Plum, SM; Wingard, JN; Fuhrmann, SR; Liang, H; Holland-Linn, J; Chen, DHT; Sim, BKL				MacDonald, NJ; Shivers, WY; Narum, DL; Plum, SM; Wingard, JN; Fuhrmann, SR; Liang, H; Holland-Linn, J; Chen, DHT; Sim, BKL			Endostatin binds tropomyosin - A potential modulator of the antitumor activity of endostatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; ANGIOGENESIS INHIBITOR; KINETIC-ANALYSIS; GROWTH-FACTOR; AFFINITY; FIBRONECTIN; CD2	The mechanism of action of Endostatin, an endogenous inhibitor of angiogenesis and tumor growth, remains unknown. We utilized phage-display technology to identify polypeptides that mimic the binding domains of proteins with which Endostatin interacts. A conformed peptide (E37) was identified that shares an epitope with human tropomyosin implicating tropomyosin as an Endostatin-binding protein. We show that recombinant human Endostatin binds tropomyosin in vitro and to tropomyosin-associated microfilaments in a variety of endothelial cell types. The most compelling evidence that tropomyosin modulates the activity of Endostatin was demonstrated when E37 blocked greater than 84% of the tumor-growth inhibitory activity of Endostatin in the B16-BL6 metastatic melanoma model. We conclude that the E37 peptide mimics the Endostatinbinding epitope of tropomyosin and blocks the antitumor activity of Endostatin by competing for Endostatin binding. We postulate that the Endostatin interaction with tropomyosin results in disruption of microfilament integrity leading to inhibition of cell motility, induction of apoptosis, and ultimately inhibition of tumor growth.	EntreMed Inc, Rockville, MD 20850 USA		Sim, BKL (corresponding author), EntreMed Inc, 9640 Med Ctr Dr, Rockville, MD 20850 USA.	kims@entremed.com		Narum, David/0000-0003-3041-5402				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Berger AC, 2000, J SURG RES, V91, P26, DOI 10.1006/jsre.2000.5890; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bloch W, 2000, FASEB J, V14, P2373; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; DeMeester SL, 1998, SURGERY, V124, P362, DOI 10.1016/S0039-6060(98)70142-4; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Huang S, 1998, MOL BIOL CELL, V9, P3179, DOI 10.1091/mbc.9.11.3179; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; Kesari KV, 1999, CLIN EXP IMMUNOL, V118, P219; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Moses MA, 1999, P NATL ACAD SCI USA, V96, P2645, DOI 10.1073/pnas.96.6.2645; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Pourati J, 1998, AM J PHYSIOL-CELL PH, V274, pC1283, DOI 10.1152/ajpcell.1998.274.5.C1283; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shuster CB, 1998, MICROCIRCULATION, V5, P239; Silkowski H, 1997, EUR BIOPHYS J BIOPHY, V25, P455, DOI 10.1007/s002490050060; Sim B K, 1999, Angiogenesis, V3, P41, DOI 10.1023/A:1009058931769; Sim BKL, 2000, CANCER METAST REV, V19, P181, DOI 10.1023/A:1026551202548; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x	32	113	139	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25190	25196		10.1074/jbc.M100743200	http://dx.doi.org/10.1074/jbc.M100743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335715	hybrid			2022-12-27	WOS:000169800700102
J	Haghighi, K; Schmidt, AG; Hoit, B; Brittsan, AG; Yatani, A; Lester, JW; Zhai, J; Kimura, Y; Dorn, GW; MacLennan, DH; Kranias, EG				Haghighi, K; Schmidt, AG; Hoit, B; Brittsan, AG; Yatani, A; Lester, JW; Zhai, J; Kimura, Y; Dorn, GW; MacLennan, DH; Kranias, EG			Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR FUNCTION; HEART-FAILURE; GENDER-DIFFERENCES; AORTIC-STENOSIS; CA2+ CHANNELS; CALCIUM; CA2+-ATPASE; GENE; PHOSPHORYLATION; HYPERTROPHY	To determine whether selective impairment of cardiac sarcoplasmic reticulum (SR) Ca2+ transport may drive the progressive functional deterioration leading to heart failure, transgenic mice, overexpressing a phospholamban Val(49) --> Gly mutant (2-fold), which is a superinhibitor of SR Ca2+-ATPase affinity for Ca2+, were generated, and their cardiac phenotype was examined longitudinally. At 3 months of age, the increased EC50 level of SR Ca2+ uptake for Ca2+ (0.67 +/- 0.09 mum) resulted in significantly higher depression of cardiomyocyte rates of shortening (57%), relengthening (31%), and prolongation of the Ca2+ signal decay time (165%) than overexpression (2-fold) of wild type phospholamban (68%, 64%, and 125%, respectively), compared with controls (100%). Echocardiography also revealed significantly depressed function and impaired beta -adrenergic responses in mutant hearts. The depressed contractile parameters were associated with left ventricular remodeling, recapitulation of fetal gene expression, and hypertrophy, which progressed to dilated cardiomyopathy with interstitial tissue fibrosis and death by 6 months in males. Females also had ventricular hypertrophy at 3 months but exhibited normal systolic function up to 12 months of age. These results suggest a causal relationship between defective SR Ca2+ cycling and cardiac remodeling leading to heart failure, with a gender-dependent influence on the time course of these alterations.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Div Cardiol, Cincinnati, OH 45267 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University System of Ohio; University of Cincinnati; Case Western Reserve University; University of Toronto	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Div Cardiol, 231 A Sabin Way, Cincinnati, OH 45267 USA.	Litsa.Kranias@uc.edu			NHLBI NIH HHS [HL-64018, HL-26057, HL52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL026057, R01HL064018, R01HL026057, P50HL052318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams KF, 1999, CIRCULATION, V99, P1816, DOI 10.1161/01.CIR.99.14.1816; Bristow MR, 1998, LANCET, V352, P8; BUTTRICK P, 1992, CIRCULATION, V86, P1336, DOI 10.1161/01.CIR.86.4.1336; Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chu GX, 1996, CIRC RES, V79, P1064, DOI 10.1161/01.RES.79.6.1064; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DONNER R, 1983, AM J CARDIOL, V51, P946, DOI 10.1016/S0002-9149(83)80171-4; FELDMAN AM, 1993, CIRC RES, V73, P184, DOI 10.1161/01.RES.73.1.184; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; GROSSMAN W, 1980, AM J MED, V69, P576, DOI 10.1016/0002-9343(80)90471-4; Hasenfuss G, 1998, CARDIOVASC RES, V39, P60, DOI 10.1016/S0008-6363(98)00110-2; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; Houser SR, 2000, J MOL CELL CARDIOL, V32, P1595, DOI 10.1006/jmcc.2000.1206; JONES LR, 1993, J BIOL CHEM, V268, P11486; Ju YK, 1999, J PHYSIOL-LONDON, V516, P793, DOI 10.1111/j.1469-7793.1999.0793u.x; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kadokami T, 2000, J CLIN INVEST, V106, P589, DOI 10.1172/JCI9307; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; KOENIG H, 1982, CIRC RES, V50, P782, DOI 10.1161/01.RES.50.6.782; Koss KL, 1997, BASIC RES CARDIOL, V92, P17, DOI 10.1007/BF00794064; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Lorell BH, 2000, CIRCULATION, V102, P470; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Masaki H, 1997, AM J PHYSIOL-HEART C, V272, pH606, DOI 10.1152/ajpheart.1997.272.2.H606; MEYER M, 1995, CIRCULATION, V92, P778, DOI 10.1161/01.CIR.92.4.778; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; SCHAIBLE TF, 1984, CIRC RES, V54, P38, DOI 10.1161/01.RES.54.1.38; Schmidt U, 1999, AM J PHYSIOL-HEART C, V277, pH474, DOI 10.1152/ajpheart.1999.277.2.H474; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; Tada M, 1998, ANN NY ACAD SCI, V853, P116, DOI 10.1111/j.1749-6632.1998.tb08261.x; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; Weinberg EO, 1997, CIRCULATION, V95, P1592; Weinberg EO, 1999, J AM COLL CARDIOL, V34, P264, DOI 10.1016/S0735-1097(99)00165-5; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	44	94	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24145	24152		10.1074/jbc.M102403200	http://dx.doi.org/10.1074/jbc.M102403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328820	hybrid			2022-12-27	WOS:000169531100122
J	Yu, ZB; Lai, CM; Maoui, M; Banville, D; Shen, SH				Yu, ZB; Lai, CM; Maoui, M; Banville, D; Shen, SH			Identification and characterization of S2V, a novel putative siglec that contains two V set Ig-like domains and recruits protein-tyrosine phosphatases SHPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-SITE; HEMATOPOIETIC-CELL PHOSPHATASE; MYELIN-ASSOCIATED GLYCOPROTEIN; INHIBITORY RECEPTOR; SH2 DOMAIN; MOLECULAR-CLONING; SIALOADHESIN; ACTIVATION; MEMBER; CD33	We describe the molecular cloning and characterization of S2V, a novel sialic acid binding immunoglobulin-like lectin. The cDNA of S2V encodes a type 1 transmembrane protein with four extracellular immunoglobulin-like (Pg-like) domains and a cytoplasmic tail bearing a typical immunoreceptor tyrosine-based inhibitory motif (ITIM) and an ITIM-like motif. A unique feature of S2V is the presence of two V-set Ig-like domains responsible for the binding to sialic acid, whereas all other known siglecs possess only one. S2V is predominantly expressed in macrophage. In vivo S2V was tyrosine-phosphorylated. when co-expressed with exogenous c-Src kinase. Upon tyrosine phosphorylation, S2V recruits both Src homology 2 (SK2) domain-containing protein-tyrosine phosphatases SHP-1 and SHP-2, two important inhibitory regulators of immunoreceptor signal transduction. These findings suggest that S2V is involved in the negative regulation of the signaling in macrophage by functioning as an inhibitory receptor. When expressed in COS-7 cells, S2V was able to mediate sialic acid-dependent binding to human red blood cells, suggesting that S2V may function through cell-cell interaction.	Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, Montreal, PQ H4P 2R2, Canada; Univ Montreal, Dept Pathol & Microbiol, St Hyacinthe, PQ J2S 7C6, Canada	National Research Council Canada; Universite de Montreal	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Pharmaceut Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	shi.shen@nrc.ca						Angata T, 2000, J BIOL CHEM, V275, P22127, DOI 10.1074/jbc.M002775200; Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; Bakker ABH, 2000, HUM IMMUNOL, V61, P18, DOI 10.1016/S0198-8859(99)00160-3; Blery M, 2000, HUM IMMUNOL, V61, P51, DOI 10.1016/S0198-8859(99)00157-3; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; Bruhns P, 1999, J IMMUNOL, V162, P3168; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Falco M, 1999, J EXP MED, V190, P793, DOI 10.1084/jem.190.6.793; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Keegan K, 1996, ONCOGENE, V12, P1537; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Paul SP, 2000, BLOOD, V96, P483; POWELL LD, 1995, J BIOL CHEM, V270, P14234; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SIMMONS D, 1988, J IMMUNOL, V141, P2797; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Tangye SG, 1999, J IMMUNOL, V162, P6981; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; Ulyanova T, 1999, EUR J IMMUNOL, V29, P3440, DOI 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.3.CO;2-3; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Yu ZB, 2001, BIOCHEM J, V353, P483, DOI 10.1042/0264-6021:3530483; Zhang JQ, 2000, J BIOL CHEM, V275, P22121, DOI 10.1074/jbc.M002788200; Zhang JY, 1999, J IMMUNOL, V162, P6359	50	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23816	23824		10.1074/jbc.M102394200	http://dx.doi.org/10.1074/jbc.M102394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328818	hybrid			2022-12-27	WOS:000169531100080
J	Sanchez-Fernandez, R; Davies, TGE; Coleman, JOD; Rea, PA				Sanchez-Fernandez, R; Davies, TGE; Coleman, JOD; Rea, PA			The Arabidopsis thaliana ABC protein superfamily, a complete inventory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; P-GLYCOPROTEIN; GENE-PRODUCT; RESISTANCE; ENCODES; TRANSLOCASE; SENSITIVITY; CONJUGATE; PEPTIDES; PATHWAY	We describe the first complete inventory of ATP-binding cassette (ABC) proteins from a multicellular organism, the model plant Arabidopsis thaliana. By the application of several search criteria, Arabidopsis was found to contain a total of 129 open reading frames (ORFs) capable of encoding ABC proteins, of which 103 possessed contiguous transmembrane spans and were identified as putative intrinsic membrane proteins. Fifty-two of the putative intrinsic membrane proteins contained at least two transmembrane domains (TMDs) and two nucleotide-binding folds (NBFs) and could be classified as belonging to one of five subfamilies of full-molecule transporters. The other 51 putative membrane proteins, all of which were half-molecule transporters, fell into five subfamilies. Of the remaining ORFs identified, all of which encoded proteins lacking TMDs, 11 could be classified into three subfamilies. There were no obvious homologs in other organisms for 15 of the ORFs which encoded a heterogeneous group of non-intrinsic ABC proteins (NA-Ps). Unrooted phylogenetic analyses substantiated the subfamily designations. Notable features of the Arabidopsis ABC superfamily was the presence of a large yeast-Eke PDR subfamily, and the absence of genes encoding bona fide cystic fibrosis transmembrane conductance regulator (CFTR), sulfonylurea receptor (SUR), and heavy metal tolerance factor 1 (HMT1) homologs. Arabidopsis was unusual in its large allocation of ORFs (a minimum of 0.5%) to members of the ABC protein superfamily.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA; IACR Rothamsted, Harpenden AL5 2JQ, Herts, England	University of Pennsylvania; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Rea, PA (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.	parea@sas.upenn.edu	Davies, Thomas G. Emyr/C-2795-2017; Davies, Thomas/D-6091-2011	Davies, Thomas G. Emyr/0000-0002-9452-2947; 				Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Babiychuk E, 1997, P NATL ACAD SCI USA, V94, P12722, DOI 10.1073/pnas.94.23.12722; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BALZI E, 1994, J BIOL CHEM, V269, P2206; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Costanzo MC, 2000, NUCLEIC ACIDS RES, V28, P73, DOI 10.1093/nar/28.1.73; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DAVIES TGE, 1996, GENE, V199, P195; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; DUDLER R, 1992, J BIOL CHEM, V267, P5882; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAO Z, 2000, CANCER RES, V60, P4779; Henikoff S, 1997, SCIENCE, V278, P609, DOI 10.1126/science.278.5338.609; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Jasinski M, 2001, PLANT CELL, V13, P1095, DOI 10.1105/tpc.13.5.1095; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liu GS, 2001, J BIOL CHEM, V276, P8648, DOI 10.1074/jbc.M009690200; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; Lu YP, 1998, PLANT CELL, V10, P267, DOI 10.1105/tpc.10.2.267; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; Martinoia E., 2000, VACUOLAR COMPARTMENT, P221; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Mitsuhashi N, 2000, J BIOL CHEM, V275, P17536, DOI 10.1074/jbc.275.23.17536; Moller SG, 2001, GENE DEV, V15, P90, DOI 10.1101/gad.850101; MOSSER J, 1994, HUM MOL GENET, V3, P265, DOI 10.1093/hmg/3.2.265; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; OSRAM JF, 2000, BIOCHIM BIOPHYS ACTA, V1529, P321; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; Rea PA, 1999, J EXP BOT, V50, P895, DOI 10.1093/jexbot/50.suppl_1.895; Rea PA, 1998, ANNU REV PLANT PHYS, V49, P727, DOI 10.1146/annurev.arplant.49.1.727; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SALT DE, 1995, PLANT PHYSIOL, V107, P1293, DOI 10.1104/pp.107.4.1293; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Sidler M, 1998, PLANT CELL, V10, P1623, DOI 10.1105/tpc.10.10.1623; Smart CC, 1996, J BIOL CHEM, V271, P19351, DOI 10.1074/jbc.271.32.19351; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tommasini R, 1998, PLANT J, V13, P773, DOI 10.1046/j.1365-313X.1998.00076.x; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VOGELILANGE R, 1990, PLANT PHYSIOL, V92, P1086, DOI 10.1104/pp.92.4.1086; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240; Wink M, 1997, ADV BOT RES, V25, P141, DOI 10.1016/S0065-2296(08)60151-2	61	378	427	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30231	30244		10.1074/jbc.M103104200	http://dx.doi.org/10.1074/jbc.M103104200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11346655	hybrid			2022-12-27	WOS:000170558000084
J	de Jager, T; Pelzer, T; Muller-Botz, S; Imam, A; Muck, J; Neyses, L				de Jager, T; Pelzer, T; Muller-Botz, S; Imam, A; Muck, J; Neyses, L			Mechanisms of estrogen receptor action in the myocardium - Rapid gene activation via the ERK1/2 pathway and serum response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CARDIAC-HYPERTROPHY; CORONARY HEART-DISEASE; PROTEIN-KINASE PATHWAY; IMMEDIATE-EARLY GENES; TRANSCRIPTION FACTORS; EGR-1 TRANSCRIPTION; RAT CARDIOMYOCYTES; ENDOTHELIAL-CELLS; ER-ALPHA; C-FOS	We have previously shown that the myocardium is a target tissue for estrogen. Here, we have identified rapid non-nuclear estrogen effects on the expression of the early growth response gene-1 (Egr-1) in cardiomyocytes. Egr-1 mRNA and protein were rapidly and strongly induced by estrogen in an estrogen receptor-dependent manner via the extracellular signal-regulated kinase, ERK1/2. A promoter analysis study of a 1.2-kilobase Egr-1 promoter fragment revealed that the serum response elements (SREs) but not the estrogen response elements or AP-1 sites are responsible for Egr-1 induction by estrogen, identifying a novel mechanism of estrogen receptor-dependent gene activation in the myocardium. Both estrogen receptor-alpha and -beta induced the Egr-1 promoter via the SREs as well as an artificial promoter consisting of only five SREs in cardiomyocytes. Electrophoretic mobility shift assays showed that a protein complex containing serum response factor or an antigenically related protein was recruited to the SREs by estrogen treatment of primary cardiomyocytes. The recruitment of the protein complex was inhibited by the specific estrogen receptor antagonist ICI 182,780 as well as the MEK inhibitor PD 98059. Taken together, these results identify SREs as important promoter control elements for an estrogen receptor-dependent mechanism of gene activation in the myocardium.	Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany	University of Wurzburg	Neyses, L (corresponding author), Univ Wurzburg, Dept Med, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Neyses, Ludwig/AGY-7446-2022					Aumais JP, 1996, J BIOL CHEM, V271, P12568, DOI 10.1074/jbc.271.21.12568; Bernal-Mizrachi E, 2000, J BIOL CHEM, V275, P25681, DOI 10.1074/jbc.M003424200; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grohe C, 1997, FEBS LETT, V416, P107, DOI 10.1016/S0014-5793(97)01179-4; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; Hammes A, 1998, CIRC RES, V83, P877; Herrington DM, 1999, ANN INTERN MED, V131, P463, DOI 10.7326/0003-4819-131-6-199909210-00012; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Karas RH, 1995, FEBS LETT, V377, P103, DOI 10.1016/0014-5793(95)01293-1; Kim HP, 1999, BIOCHEM BIOPH RES CO, V263, P257; Kohout TA, 1996, CIRC RES, V78, P971, DOI 10.1161/01.RES.78.6.971; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Ling Y, 1998, J BIOL CHEM, V273, P10506, DOI 10.1074/jbc.273.17.10506; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; McCaffrey TA, 2000, J CLIN INVEST, V105, P653, DOI 10.1172/JCI8592; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NEYSES L, 1993, J HYPERTENS, V11, P927, DOI 10.1097/00004872-199309000-00006; Nuedling S, 1999, FEBS LETT, V454, P271, DOI 10.1016/S0014-5793(99)00816-9; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PELZER T, 1999, SCI C MOL CELL INT P; Pratt MAC, 1998, MOL CELL BIOCHEM, V189, P119, DOI 10.1023/A:1006827015320; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Russell KS, 2000, P NATL ACAD SCI USA, V97, P5930, DOI 10.1073/pnas.97.11.5930; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Saadane N, 2000, AM J PHYSIOL-HEART C, V278, pH796, DOI 10.1152/ajpheart.2000.278.3.H796; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; Shamim A, 1999, MOL CELL BIOCHEM, V195, P11, DOI 10.1023/A:1006887307568; Singer CA, 1999, J NEUROSCI, V19, P2455; Watters JJ, 2000, MOL ENDOCRINOL, V14, P1872, DOI 10.1210/me.14.11.1872; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Zhang Z, 1998, AM J PHYSIOL-CELL PH, V275, pC1104, DOI 10.1152/ajpcell.1998.275.4.C1104	41	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27873	27880		10.1074/jbc.M010984200	http://dx.doi.org/10.1074/jbc.M010984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11335712	hybrid			2022-12-27	WOS:000170093400019
J	Bouly, M; Masson, D; Gross, B; Jiang, XC; Fievet, C; Castro, G; Tall, AR; Fruchart, JC; Staels, B; Lagrost, L; Luc, G				Bouly, M; Masson, D; Gross, B; Jiang, XC; Fievet, C; Castro, G; Tall, AR; Fruchart, JC; Staels, B; Lagrost, L; Luc, G			Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; APOLIPOPROTEIN-A-I; ADENOVIRUS-MEDIATED OVEREXPRESSION; TISSUE-SELECTIVE MANNER; ESTER TRANSFER PROTEIN; HUMAN-PLASMA; TRANSGENIC MICE; HEPATIC LIPASE; PARTICLE-SIZE; HDL LEVELS	Fibrate treatment in mice is known to modulate high density lipoprotein (HDL) metabolism by regulating apolipoprotein (apo)AI and apoAII gene expression. In addition to alterations in plasma HDL levels, fibrates induce the emergence of large, cholesteryl ester-rich HDL in treated transgenic mice expressing human apoAI (HuAITg), The mechanisms of these changes may not be restricted to the modulation of apolipoprotein gene expression, and the aim of the present study was to determine whether the expression of factors known to affect HDL metabolism (ie. phospholipid transfer protein (PLTP), lecithin:cholesterol acyltransferase, and hepatic lipase) are modified in fenofibrate-treated mice. Significant rises in plasma PLTP activity were observed after 2 weeks of fenofibrate treatment in both wild-type and HuAITg mice. Simultaneously, hepatic PLTP mRNA levels increased in a dose-dependent fashion. In contrast to PLTP, lecithin: cholesterol acyltransferase mRNA levels in HuAITg mice were not significantly modified by fenofibrate despite a significant decrease in plasma cholesterol esterification activity, Fenofibrate did not induce any change in hepatic lipase activity. Fenofibrate significantly increased HDL size, an effect that was more pronounced in HuAITg mice than in wild-type mice, This effect in wild-type mice was completely abolished in PLTP-deficient mice. Finally, fenofibrate treatment did not influence PLTP activity or hepatic mRNA in peroxisome proliferator-activated receptor-alpha -deficient mice. It is concluded that 1) fenofibrate treatment increases plasma phospholipid transfer activity as the result of up-regulation of PLTP gene expression through a peroxisome proliferator-activated receptor-alpha -dependent mechanism, and 2) increased plasma PLTP levels account for the marked enlargement of HDL in fenofibrate-treated mice.	Inst Pasteur, INSERM U545, Dept Atherosclerosis, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Hop Bocage, INSERM U498, Lab Lipoprot Biochem, Dijon, France; Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University	Luc, G (corresponding author), Inst Pasteur, INSERM U545, Dept Atherosclerosis, 1 Rue Prof Calmette, F-59019 Lille, France.		MASSON, David/AAC-8896-2022; MASSON, David/R-4557-2017; Masson, David/R-6633-2019; Staels, Bart/N-9497-2016; Tall, Alan/AAT-8528-2021	MASSON, David/0000-0003-1692-0699; MASSON, David/0000-0003-1692-0699; Staels, Bart/0000-0002-3784-1503; GROSS, BARBARA/0000-0001-5566-0004				Albers JJ, 1996, INT J CLIN LAB RES, V26, P262, DOI 10.1007/BF02602960; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; Albers JJ, 1999, J LIPID RES, V40, P295; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; CHEN CH, 1982, J LIPID RES, V23, P680; CHEUNG MC, 1991, J LIPID RES, V32, P383; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P166; DAERR WH, 1982, BIOCHIM BIOPHYS ACTA, V710, P128, DOI 10.1016/0005-2760(82)90142-4; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DECKELBAUM RJ, 1982, J BIOL CHEM, V257, P6509; Ehnholm S, 1998, J LIPID RES, V39, P1248; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Francone OL, 1996, J LIPID RES, V37, P1268; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HENDERSON AD, 1993, CLIN CHEM, V39, P218; HOPKINS GJ, 1985, J LIPID RES, V26, P218; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MarquesVidal P, 1997, ATHEROSCLEROSIS, V133, P87, DOI 10.1016/S0021-9150(97)00120-2; NEWNHAM HH, 1990, ATHEROSCLEROSIS, V82, P167, DOI 10.1016/0021-9150(90)90037-J; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SALTER AM, 1987, BIOCHEM J, V247, P79, DOI 10.1042/bj2470079; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SHEPHERD J, 1994, ATHEROSCLEROSIS, V110, pS55, DOI 10.1016/0021-9150(94)05380-2; SPEIJER H, 1991, ATHEROSCLEROSIS, V90, P159, DOI 10.1016/0021-9150(91)90110-O; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; STAELS B, 1992, J LIPID RES, V33, P727; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TU AY, 1993, J BIOL CHEM, V268, P23098; vonEckardstein A, 1996, BBA-LIPID LIPID MET, V1301, P255, DOI 10.1016/0005-2760(96)00050-1; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118	37	77	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25841	25847		10.1074/jbc.M101160200	http://dx.doi.org/10.1074/jbc.M101160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342537				2022-12-27	WOS:000169823300028
J	Collins, TJ; Lipp, P; Berridge, MJ; Bootman, MD				Collins, TJ; Lipp, P; Berridge, MJ; Bootman, MD			Mitochondrial Ca2+ uptake depends on the spatial and temporal profile of cytosolic Ca2+ signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; RELEASE; TRANSPORT; STORE; HOMEOSTASIS; MECHANISM; FEEDBACK; CELLS; WAVES	Using confocal imaging of Rhod-2-loaded HeLa cells, we examined the ability of mitochondria to sequester Ca2+ signals arising from different sources. Mitochondrial Ca2+ (Ca-mit(2+)) uptake was stimulated by inositol 1,4,5-trisphosphate (InsP(3))-evoked Ca2+ release, capacitative Ca2+ entry, and Ca2+ leaking from the endoplasmic reticulum, For each Ca2+ source, the relationship between cytosolic Ca2+ (Ca-cyt(2+)) concentration and Ca-mit(2+) was complex. With Ca-cyt(2+) < 300 nM, a slow and persistent Ca-mit(2+) uptake was observed. If Ca-cyt(2+) increased above similar to 400 nM, Ca-mit(2+) uptake accelerated sharply. For equivalent Ca-mit(2+) increases, the rate of Ca-mit(2+) rise was greater with InsP(3)-evoked Ca2+ signals than any other source. Spatial variation of the Ca-mit(2+) response was observed within individual cells. Both the fraction of responsive mitochondria and the amplitude of the Ca-mit(2+) response were graded in direct proportion to stimulus concentration. Trains of repetitive Ca2+ oscillations did not maintain elevated Ca-mit(2+) levels. Only low frequency Ca2+ transients (<1/15 min) evoked repetitive Ca-mit(2+) signals. Our data indicate that there is a lag between Ca-cyt(2+) and Ca-mit(2+) increases but that mitochondria will accumulate calcium when it is elevated over basal levels regardless of its source. Furthermore, in addition to the characteristics of Ca2+ signals, Ca2+ uniporter desensitization and proximity of mitochondria to InsP(3) receptors modulate mitochondrial Ca2+ responses.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Cambridge	Lipp, P (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	peter.lipp@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451				Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Bootman M, 1997, J PHYSIOL-LONDON, V499, P307, DOI 10.1113/jphysiol.1997.sp021928; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; Breitbart H, 1996, BBA-MOL CELL RES, V1312, P79, DOI 10.1016/0167-4889(96)00022-5; Chow S, 1996, CYTOMETRY, V24, P360; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Colegrove SL, 2000, J GEN PHYSIOL, V115, P371, DOI 10.1085/jgp.115.3.371; Collins TJ, 2000, BIOCHEM J, V347, P593, DOI 10.1042/0264-6021:3470593; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; Drummond RM, 1996, PFLUG ARCH EUR J PHY, V431, P473, DOI 10.1007/s004240050025; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; GUNTER TE, 1994, J BIOENERG BIOMEMBR, V26, P465, DOI 10.1007/BF00762731; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LEISEY JR, 1993, AM J PHYSIOL, V265, pH1203; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; Pacher P, 2001, BIOPHYS J, V80, p236A; Racay P, 1996, GEN PHYSIOL BIOPHYS, V15, P193; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; Sheppard CA, 1997, J NEUROCHEM, V68, P2317; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TOVEY SC, 1998, J PHYSL, V509, P200; WHITE RJ, 1995, J NEUROSCI, V15, P1318	47	158	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26411	26420		10.1074/jbc.M101101200	http://dx.doi.org/10.1074/jbc.M101101200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333261	hybrid			2022-12-27	WOS:000169823300102
J	Han, H; Wang, HZ; Long, H; Nattel, S; Wang, ZG				Han, H; Wang, HZ; Long, H; Nattel, S; Wang, ZG			Oxidative preconditioning and apoptosis in L-cells - Roles of protein kinase B and mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; SMOOTH-MUSCLE CELLS; N-TERMINAL KINASE; CARDIOMYOCYTE APOPTOSIS; SIGNALING PATHWAYS; HYDROGEN-PEROXIDE; MAP KINASE; KAPPA-B; STRESS; SURVIVAL	Oxidative stress can cause significant cell death by apoptosis, We performed studies in L-cells to explore whether prior exposure to oxidative stress ("oxidative preconditioning") can protect the cell against the apoptotic consequences of subsequent oxidative insults and to establish the mediators in the preconditioning signaling cascade. Cells were preconditioned with three 5-min exposures to H2O2, followed by 10-h recovery and subsequent exposure to 600 muM H2O2 for 10 h. A Single 10-h exposure to H2O2 induced substantial apoptotic cell death (similar to 90%), as determined by enzyme-linked immunosorbent assay, TUNEL (terminal deoxyribonucleotide transferase-mediated dUTP nick end labeling), and Annexin V methods, but apoptosis was largely prevented in preconditioned cells. The degree of cytoprotection depended on the strength of preconditioning or H(2)O2 concentration (20 similar to 600 muM), Transient increases in mitogen-activated protein kinase (MAPK), p38, and JNK/SAPK activities and sustained protein kinase B (Akt) activation, accompanied by drastically reduced caspase 3 activity, were seen after preconditioning, The expression levels of these kinases were unaltered. Inhibitors of p38 (SB203580) and phosphoinositide 5-kinase (PI3K, LY294002) pathways abolished the protection provided by preconditioning, We conclude that oxidative preconditioning protects cells against apoptosis and that this effect involves MAPK and PI3K/Akt pathways. This system may be important in regulating apoptotic cell death in development and disease states.	Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3A 2T5, Canada	Universite de Montreal; Universite de Montreal; McGill University	Wang, ZG (corresponding author), Montreal Heart Inst, Res Ctr, 5000 Belanger E, Montreal, PQ H1T 1C8, Canada.		wang, zhiguo/AAN-4182-2021; Wang, Zhiguo/GRS-4339-2022; Han, Ho Jae/M-1476-2016	Wang, Zhiguo/0000-0002-0811-2045; Han, Ho Jae/0000-0002-0657-1766; Nattel, Stanley/0000-0002-5565-3311				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P1019, DOI 10.1006/jmcc.1998.0666; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DEFILY DV, 1993, AM J PHYSIOL, V265, pH700, DOI 10.1152/ajpheart.1993.265.2.H700; DEZEEUW S, 1999, ANN NY ACAD SCI, V874, P179; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Islam CF, 1997, BRIT J UROL, V79, P842, DOI 10.1046/j.1464-410X.1997.00209.x; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Konishi H, 1999, BIOCHEM BIOPH RES CO, V264, P840, DOI 10.1006/bbrc.1999.1579; Li PF, 1997, CIRCULATION, V96, P3602; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Maulik N, 1999, FEBS LETT, V443, P331, DOI 10.1016/S0014-5793(98)01719-0; Maulik N, 1998, MOL CELL BIOCHEM, V186, P139, DOI 10.1023/A:1006883717174; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; PANCY CY, 1997, AM J PHYSIOL, V273, pR887; PANG CY, 1995, CARDIOVASC RES, V29, P782, DOI 10.1016/S0008-6363(96)88613-5; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peralta C, 1996, BIOCHEM BIOPH RES CO, V229, P264, DOI 10.1006/bbrc.1996.1790; Ping PP, 2000, CIRC RES, V86, P921, DOI 10.1161/01.RES.86.9.921; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Shirai T, 1998, J THORAC CARDIOV SUR, V115, P210, DOI 10.1016/S0022-5223(98)70459-3; STEVENSON MA, 1994, CANCER RES, V54, P12; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Takeshima S, 1997, ACTA PHYSIOL SCAND, V161, P263, DOI 10.1046/j.1365-201X.1997.00218.x; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Valen G, 1998, FREE RADICAL RES, V29, P235, DOI 10.1080/10715769800300271; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Verdouw PD, 1996, ANN NY ACAD SCI, V793, P27, DOI 10.1111/j.1749-6632.1996.tb33502.x; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	45	70	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26357	26364		10.1074/jbc.M011136200	http://dx.doi.org/10.1074/jbc.M011136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331278	hybrid			2022-12-27	WOS:000169823300095
J	Kovalovich, K; Li, W; DeAngelis, R; Greenbaum, LE; Ciliberto, G; Taub, R				Kovalovich, K; Li, W; DeAngelis, R; Greenbaum, LE; Ciliberto, G; Taub, R			Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; CARBON-TETRACHLORIDE; MOUSE HEPATOCYTES; FACTOR RECEPTOR; DEFICIENT MICE; LIVER-INJURY; RAT-LIVER; ACTIVATION	Previous studies showed that following acute carbon tetrachloride (CCl4) treatment, interleukin-6 null (IL6-/-) mice develop increased hepatocellular injury, defective regeneration, delayed wound healing, and increased hepatocyte apoptosis, Pretreatment with IL-6 prior to CCl4 reduces injury, hepatocyte apoptosis, and accelerates regeneration in both IL-6-/- and +/+ livers. To demonstrate whether IL-6 can prevent liver injury that involves direct stimulation of hepatocyte apoptosis, IL-6-/- and +/+ mice were treated with the Fas agonist, Jo-2 mAb. At low Fas agonist doses, IL-6+/+ mice developed mild hepatic injury and survived, whereas IL-6-/-mice developed severe apoptotic hepatitis within 12 h and died. Pretreatment with IL-6 improved survival in IL-6-/- mice and reduced injury in both IL-6-/- and +/+ livers. The direct anti-apoptotic effects of IL-6 were demonstrated in vitro as IL-6 decreased Fas-mediated apoptosis in both IL-6-/- and +/+ primary hepatocyte cultures, and suggested that IL-6-/- hepatocytes have a pre-existing defect in anti-apoptotic pathways. After Fas activation, IL-6-/- livers demonstrated evidence of both proximal and distal alterations in the apoptotic pathways including elevated caspase 8 and 3 activation-associated fragments, and loss of cytochrome c staining. IL-6-/- livers had reduced pre-existing protein expression of the anti-apoptotic factors Bcl-2 and Bcl-xL as well as more rapid degradation of FLIP following Fas treatment that appeared to be post-transcriptionally regulated. FLIP is a crucial proximal inhibitor of caspase 8 activation in Fas, tumor necrosis factor, and DR3/DR4-mediated apoptosis, and Bcl-2 and Bcl-xL more downstream anti-apoptotic regulators. IL-6 may function as a critical anti-apoptotic factor in the liver by its ability to establish and maintain an adequate level of FLIP and downstream anti-apoptotic factors.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; IRBM, I-00040 Pomezia, Italy	University of Pennsylvania; University of Pennsylvania; Merck & Company	Taub, R (corresponding author), Univ Penn, Sch Med, Dept Genet, 705A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	taubra@mail.med.upenn.edu	Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605	NIDDK NIH HHS [1 F32 DK09732-01, 1 K08 DK 02667-01, DK 49629, P30 DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009732, R01DK049629, K08DK002667, P30DK050306] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BERGER ML, 1986, HEPATOLOGY, V6, P36, DOI 10.1002/hep.1840060108; BLUETHMANN H, 1994, J LEUKOCYTE BIOL, V56, P565, DOI 10.1002/jlb.56.5.565; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kao CY, 1996, BIOCHEM BIOPH RES CO, V222, P64, DOI 10.1006/bbrc.1996.0698; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Redondo C, 1996, J CLIN INVEST, V98, P1245, DOI 10.1172/JCI118908; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Shi JL, 1998, AM J PATHOL, V153, P515, DOI 10.1016/S0002-9440(10)65594-0; SLATER TF, 1966, NATURE, V209, P36, DOI 10.1038/209036a0; TAUB R, 1987, J BIOL CHEM, V262, P10893; Tokushige K, 2000, AM J GASTROENTEROL, V95, P2040; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	41	233	245	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26605	26613		10.1074/jbc.M100740200	http://dx.doi.org/10.1074/jbc.M100740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11349125	hybrid			2022-12-27	WOS:000169823300125
J	Vashee, S; Simancek, P; Challberg, MD; Kelly, TJ				Vashee, S; Simancek, P; Challberg, MD; Kelly, TJ			Assembly of the human origin recognition complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; FISSION YEAST; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOME-REPLICATION; DROSOPHILA HOMOLOG; ORC1 HOMOLOG; IDENTIFICATION; PROTEINS; XENOPUS	The six-subunit origin recognition complex (ORC) was originally identified in the yeast Saccharomyces cerevisiae, Yeast ORC binds specifically to origins of replication and serves as a platform for the assembly of additional initiation factors, such as Cdc6 and the Mcm proteins. Human homologues of all six ORC subunits have been identified by sequence similarity to their yeast counterparts, but little is known about the biochemical characteristics of human ORC (HsORC), We have extracted HsORC from HeLa cell chromatin and probed its subunit composition using specific antibodies. The endogenous HsORC, identified in these experiments, contained homologues of Orc1-Orc5 but lacked a putative homologue of Orc6, By expressing HsORC subunits in insect cells using the baculovirus system, we were able to identify a complex containing all six subunits, To explore the subunit-subunit interactions that are required for the assembly of HsORC, we carried out extensive co-immunoprecipitation experiments with recombinant ORC subunits expressed in different combinations. These studies revealed the following binary interactions: HsOrc2-HsOrc3, HsOrc2-HsOrc4, HsOrc3-HsOrc4, HsOrc2-HsOrc6, and HsOrc3-HsOrc6. HsOrc5 did not form stable binary complexes with any other HsORC subunit but interacted with sub-complexes containing any two of subunits HsOrc2, HsOrc3, or HsOrc4, Complex formation by HsOrc1 required the presence of HsOrc2, HsOrc3, HsOrc4, and HsOrc5 subunits, These results suggest that the subunits HsOrc2, HsOrc3, and HsOrc4 form a core upon which the ordered assembly of HsOrc5 and HsOrc1 takes place. The characterization of HsORC should facilitate the identification of human origins of DNA replication.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kelly, TJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.	tkelly@jhmi.edu			NCI NIH HHS [CA40414] Funding Source: Medline; NIGMS NIH HHS [GM19675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040414, R01CA040414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CURR OPIN GENET DEV, V5, P162, DOI 10.1016/0959-437X(95)80003-4; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, V1, P41; Carpenter PB, 1998, J BIOL CHEM, V273, P24891, DOI 10.1074/jbc.273.38.24891; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; Chesnokov I, 1999, GENE DEV, V13, P1289, DOI 10.1101/gad.13.10.1289; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; Dhar SK, 2000, J BIOL CHEM, V275, P34983, DOI 10.1074/jbc.M006069200; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dubey DD, 1996, CURR BIOL, V6, P467, DOI 10.1016/S0960-9822(02)00514-6; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kornberg A., 1992, DNA REPLICATION; Kreitz S, 2001, J BIOL CHEM, V276, P6337, DOI 10.1074/jbc.M009473200; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MAUNDRELL K, 1988, EMBO J, V7, P2203, DOI 10.1002/j.1460-2075.1988.tb03059.x; Moon KY, 1999, P NATL ACAD SCI USA, V96, P12367, DOI 10.1073/pnas.96.22.12367; Natale DA, 2000, EMBO J, V19, P2728, DOI 10.1093/emboj/19.11.2728; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; Quintana DG, 1998, J BIOL CHEM, V273, P27137, DOI 10.1074/jbc.273.42.27137; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tatsumi Y, 2000, J BIOL CHEM, V275, P5904, DOI 10.1074/jbc.275.8.5904; Thome KC, 2000, J BIOL CHEM, V275, P35233, DOI 10.1074/jbc.M005765200; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0	45	120	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26666	26673		10.1074/jbc.M102493200	http://dx.doi.org/10.1074/jbc.M102493200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11323433	hybrid			2022-12-27	WOS:000169823300132
J	Gaur, D; Swaminathan, S; Batra, JK				Gaur, D; Swaminathan, S; Batra, JK			Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor - Generation of inhibitor-resistant cytotoxic variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; BOVINE SEMINAL RIBONUCLEASE; AMINO-ACID-SEQUENCE; CATALYTIC PROPERTIES; CRYSTAL-STRUCTURE; CATIONIC PROTEIN; RESOLUTION; ANGIOGENIN; MECHANISM; COMPLEX	Mammalian ribonucleases interact very strongly with the intracellular ribonuclease inhibitor (RI), Eukaryotic cells exposed to mammalian ribonucleases are protected from their cytotoxic action by the intracellular inhibition of ribonucleases by RI. Human pancreatic ribonuclease (HPR) is structurally and functionally very similar to bovine RNase A and interacts with human RI with a high affinity. In the current study, we have investigated the involvement of Lys-7, Gln-11, Asn-71, Asn-88, Gly-89, Ser-90, and Glu-111 in HPR in its interaction with human ribonuclease inhibitor. These contact residues were mutated either individually or in combination to generate mutants K7A, Q11A, N71A, E111A, N88R, G89R, S90R, K7A/E111A, Q11A/E111A, N71A/E111A, K7A/ N71A/E111A, Q11A/N71A/E111A, and K7A/Q11A/N71A/ E111A. Out of these, eight mutants, K7A, Q11A, N71A, S90R, E111A, Q11A/E111A, N71A/E111A, and K7A/N71A/ E111A, showed an ability to evade RI more than the wild type HPR, with the triple mutant K7A/N71A/E111A having the maximum RI resistance. As a result, these variants exhibited higher cytotoxic activity than wild type HPR, The mutation of Gly-89 in HPR produced no change in the sensitivity of HPR for RI, whereas it has been reported that mutating the equivalent residue Gly-88 in RNase A yielded a variant with increased RI resistance and cytotoxicity, Hence, despite its considerable homology with RNase A, HPR shows differences in its interaction with RI. We demonstrate that interaction between human pancreatic ribonuclease and RI can be disrupted by mutating residues that are involved in HPR-RI binding. The inhibitor-resistant cytotoxic HPR mutants should be useful in developing therapeutic molecules.	Natl Inst Immunol, Immunochem Lab, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Batra, JK (corresponding author), Natl Inst Immunol, Immunochem Lab, Aruna Asaf Ali Rd, New Delhi 110067, India.		Batra, Janendra/GWQ-8031-2022	Batra, Janendra/0000-0003-2206-3398				ARDELT W, 1991, J BIOL CHEM, V266, P245; Bal HP, 1997, EUR J BIOCHEM, V245, P465, DOI 10.1111/j.1432-1033.1997.t01-1-00465.x; BARDON A, 1976, BIOCHIM BIOPHYS ACTA, V438, P461, DOI 10.1016/0005-2744(76)90262-X; Beintema J.J., 1997, RIBONUCLEASES STRUCT, P245; BEINTEMA JJ, 1984, ANAL BIOCHEM, V136, P48, DOI 10.1016/0003-2697(84)90306-3; BOIX E, 1994, J BIOL CHEM, V269, P2529; BOND MD, 1988, ANAL BIOCHEM, V173, P166, DOI 10.1016/0003-2697(88)90174-1; BOQUE L, 1994, J BIOL CHEM, V269, P19707; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; Chen CZ, 1997, P NATL ACAD SCI USA, V94, P1761, DOI 10.1073/pnas.94.5.1761; Chen CZ, 1999, BIOCHEMISTRY-US, V38, P9273, DOI 10.1021/bi990762a; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; Domachowske JB, 1997, J LEUKOCYTE BIOL, V62, P363, DOI 10.1002/jlb.62.3.363; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; Hofsteenge J., 1997, RIBONUCLEASES STRUCT, P621, DOI [10.1016/b978-012588945-2/50020-0, DOI 10.1016/B978-012588945-2/50020-0]; KAWANOMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P335, DOI 10.1016/0167-4781(92)90513-Y; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACCETTI P, 1992, CANCER RES, V52, P4582; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LEHRER RI, 1989, J IMMUNOL, V142, P4428; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; NEWTON DL, 1994, J NEUROSCI, V14, P538; NITTA K, 1994, CANCER RES, V54, P920; Papageorgiou AC, 1997, EMBO J, V16, P5162, DOI 10.1093/emboj/16.17.5162; PAVLOVSKY AG, 1978, FEBS LETT, V92, P258, DOI 10.1016/0014-5793(78)80766-2; Pous J, 2000, J MOL BIOL, V303, P49, DOI 10.1006/jmbi.2000.4506; RICHARDSON RM, 1990, BIOCHEM J, V267, P593, DOI 10.1042/bj2670593; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; SENO M, 1994, BBA-GENE STRUCT EXPR, V1218, P466, DOI 10.1016/0167-4781(94)90208-9; SHAPIRO R, 2000, J MOL BIOL, V362, P487; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; SORRENTINO S, 1994, ARCH BIOCHEM BIOPHYS, V312, P340, DOI 10.1006/abbi.1994.1318; VESCIA S, 1980, CANCER RES, V40, P3740; WEICKMANN JL, 1981, BIOCHEMISTRY-US, V20, P1272, DOI 10.1021/bi00508a035; WITZEL H, 1962, BIOCHEM BIOPH RES CO, V7, P295, DOI 10.1016/0006-291X(62)90194-8; WU YN, 1993, J BIOL CHEM, V268, P10686; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	48	47	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24978	24984		10.1074/jbc.M102440200	http://dx.doi.org/10.1074/jbc.M102440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342552	hybrid			2022-12-27	WOS:000169800700073
J	Yamagishi, SI; Edelstein, D; Du, XL; Kaneda, Y; Guzman, M; Brownlee, M				Yamagishi, SI; Edelstein, D; Du, XL; Kaneda, Y; Guzman, M; Brownlee, M			Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; NECROSIS-FACTOR-ALPHA; INSULIN-RESISTANCE; CYTOSKELETAL COMPONENTS; DIABETES-MELLITUS; VASCULAR-DISEASE; OBESE GENE; ATHEROSCLEROSIS; GLUCOSE; MICE	Leptin, a circulating hormone secreted mainly from adipose tissues, is involved in the control of body weight. The plasma concentrations are correlated with body mass index, and are reported to be high in patients with insulin resistance, which is one of the major risk factors for cardiovascular disease. However, the direct effect of leptin on vascular wall cells is not fully understood. In this study, we investigated the effects of leptin on reactive oxygen species (ROS) generation and expression of monocyte chemoattractant protein-1 (MCP-1) in bovine aortic endothelial cells (BAEC). We found that leptin increases ROS generation in BAEC in a dose-dependent manner and that its effects are additive with those of glucose. Rotenone, thenoyltrifluoroacetone (TTEA), carbonyl cyanide m-chlorophenylhydrazone (CCCP), Mn(III)tetrakis (4-benzoic acid) porphyrin (MnTBAP), uncoupling protein-1 (UCP1) HVJ-liposomes, or manganese superoxide dismutase (MnSOD) HVJ-liposomes completely prevented the effect of leptin, suggesting that ROS arise from mitochondrial electron transport. Leptin increased fatty acid orridation by stimulating the activity of carnitine palmitoyltransferase-1 (CPT-1) and inhibiting that of acetyl-CoA carboxylase (ACC), pace-setting enzymes for fatty acid oxidation and synthesis, respectively. Leptin-induced ROS generation, CPT-1 activation, ACC inhibition, and MCP-1 overproduction were found to be completely prevented by either genistein, a tyrosine kinase inhibitor, H-89, a protein kinase A (PKA) inhibitor, or tetradecylglycidate, a CPT-1 inhibitor. Leptin activated PKA, and the effects of leptin were inhibited by the cAMP antagonist Rp-cAMPS, These results suggest that leptin induces ROS generation by increasing fatty acid oxidation via PKA activation, which may play an important role in the progression of atherosclerosis in insulin-resistant obese diabetic patients.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res, Bronx, NY 10461 USA; Osaka Univ, Sch Med, Div Gene Therapy Sci, Suita, Osaka 5050871, Japan; Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, Madrid 28040, Spain	Yeshiva University; Albert Einstein College of Medicine; Osaka University; Complutense University of Madrid	Brownlee, M (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Guzman, Manuel/0000-0001-7475-118X				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; BIJLEVELD C, 1987, BIOCHIM BIOPHYS ACTA, V918, P273; Blazquez C, 1998, J NEUROCHEM, V71, P1597; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; Crandall DL, 1999, J CLIN ENDOCR METAB, V84, P3222, DOI 10.1210/jc.84.9.3222; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Guzman M, 2000, TRENDS ENDOCRIN MET, V11, P49, DOI 10.1016/S1043-2760(99)00223-4; GUZMAN M, 1992, BIOCHEM J, V287, P487, DOI 10.1042/bj2870487; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; KAISER N, 1993, DIABETES, V42, P80, DOI 10.2337/diabetes.42.1.80; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Nyholm B, 1997, EUR J ENDOCRINOL, V136, P173, DOI 10.1530/eje.0.1360173; Panahloo A, 1996, CORONARY ARTERY DIS, V7, P723, DOI 10.1097/00019501-199610000-00005; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rudberg S, 1998, HORM RES, V50, P297, DOI 10.1159/000023294; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Saeki Y, 1998, GENE THER, V5, P1031, DOI 10.1038/sj.gt.3300711; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; Velasco G, 1998, J BIOL CHEM, V273, P21497, DOI 10.1074/jbc.273.34.21497; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1	33	501	546	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25096	25100		10.1074/jbc.M007383200	http://dx.doi.org/10.1074/jbc.M007383200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342529	hybrid			2022-12-27	WOS:000169800700089
J	Zhang, XA; Bontrager, AL; Hemler, ME				Zhang, XA; Bontrager, AL; Hemler, ME			Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PHC to specific beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; BINDING PROTEINS; TM4SF PROTEINS; CROSS-LINKING; GROWTH-FACTOR; CDNA CLONE; RECEPTOR; ADHESION; COMPLEXES; MOLECULES	Translocation of conventional protein kinases C (PKCs) to the plasma membrane leads to their specific association with transmembrane-4 superfamily (TM4SF; tetraspanin) proteins (CD9, CD53, CD81, CD82, and CD151), as demonstrated by reciprocal co-immunoprecipitation and covalent cross-linking experiments. Although formation and maintenance of TM4SF-PKC complexes are not dependent on integrins, TM4SF proteins can act as linker molecules, recruiting PKC into proximity with specific integrins. Previous studies showed that the extracellular large loop of TM4SF proteins determines integrin associations. In contrast, specificity for PKC association probably resides within cytoplasmic tails or the first two transmembrane domains of TM4SF proteins, as seen from studies with chimeric CD9 molecules, Consistent with a TM4SF linker function, only those integrins (alpha (3)beta (1), alpha (6)beta (1), and a chimeric "X3TC5" alpha (3) mutant) that associated strongly with tetraspanins were found in association with PKC, We propose that PKC-TM4SF-integrin structures represent a novel type of signaling complex. The simultaneous binding of TM4SF proteins to the extracellular domains of the integrin alpha (3) subunit and to intracellular PKC helps to explain why the integrin alpha (3) extracellular domain is needed for both intracellular PKC recruitment and PKC-dependent phosphorylation of the alpha (3) integrin cytoplasmic tail.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Hemler, ME (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Rm D-1430,44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA86712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; AMIOT M, 1995, LEUKOCYTE TYPING, V5, P556; Bazzoni G, 1998, J BIOL CHEM, V273, P6670, DOI 10.1074/jbc.273.12.6670; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; CARMO AM, 1995, EUR J IMMUNOL, V25, P2090, DOI 10.1002/eji.1830250743; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; CHUN JS, 1993, MOL BIOL CELL, V3, P1863; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DUMONT JA, 1994, BIOCHEM BIOPH RES CO, V204, P264, DOI 10.1006/bbrc.1994.2454; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EMI N, 1993, IMMUNOGENETICS, V37, P193; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HEMLER ME, 1983, J IMMUNOL, V131, P334; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Kitadokoro K, 2001, EMBO J, V20, P12, DOI 10.1093/emboj/20.1.12; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Liu SC, 2000, J CELL SCI, V113, P3563; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MANGER B, 1987, J IMMUNOL, V139, P2755; Mannion BA, 1996, J IMMUNOL, V157, P2039; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mochly-Rosen D, 1998, FASEB J, V12, P35; Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; Pujades C, 1996, BIOCHEM J, V313, P899, DOI 10.1042/bj3130899; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SEEHAFER JG, 1991, BIOCHEM BIOPH RES CO, V179, P401, DOI 10.1016/0006-291X(91)91384-O; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SHIMIZU Y, 1992, J EXP MED, V175, P577, DOI 10.1084/jem.175.2.577; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WOODS A, 1992, J CELL SCI, V101, P277; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Yauch RL, 2000, J BIOL CHEM, V275, P9230, DOI 10.1074/jbc.275.13.9230; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	68	286	306	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25005	25013		10.1074/jbc.M102156200	http://dx.doi.org/10.1074/jbc.M102156200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325968	hybrid			2022-12-27	WOS:000169800700077
J	Jacquelin, B; Rozenshteyn, D; Kanaji, S; Koziol, JA; Nurden, AT; Kunicki, TJ				Jacquelin, B; Rozenshteyn, D; Kanaji, S; Koziol, JA; Nurden, AT; Kunicki, TJ			Characterization of inherited differences in transcription of the human integrin alpha(2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN RECEPTOR; REGULATORY ELEMENTS; YOUNGER PATIENTS; CODING SEQUENCE; PROMOTER; EXPRESSION; BINDING; SP1; POLYMORPHISMS; PROTEIN	Inherited, single-base substitutions are found at only two positions, C-52T and C(-92)G, within the proximal 5 ' -regulatory region (within -1096 to +48) of the human integrin alpha (2) gene. We recently reported that the T-52 substitution results in decreased binding of transcription factor Spl to adjacent binding sites, decreased transcription of the alpha (2) gene, and reduced densities of platelet alpha (2)beta (1). In this study, we identify an additional Sp1-binding site at position -107 to -99 and show that the adjacent dimorphic sequence C(-92)G also influences the rate of gene transcription. In the erythroleukemia cell line Dami, transfected promoter-luciferase constructs bearing the G(-92) sequence exhibit roughly a 3-fold decrease in activity relative to the C-92 constructs. In transfected CHRF-288-11 megakaryocytic cells, the corresponding activity decreases by 5-fold. DNase I footprinting of the promoter region with Dami nuclear extracts showed a protected segment at -107 to -99 that can be deprotected by coincubation with molar excess of a consensus Sp1 oligonucleotide, Gel mobility shift assays and supershift assays with specific antibodies indicate that Sp1 binds to this region of the cu, gene promoter. Mutation of the Sp1 binding element within -107 to -99 in constructs containing either (C-92 or G(-92) abolishes basal promoter activity and eliminates the binding of Sp. The G(-92) sequence has a gene frequency of 0.15 in a typical Caucasian population, and the presence of this allele correlates with reduced densities of platelet alpha (1)beta (2). The combined substitution G(-92)/T-52 has an additive influence on gene transcription, resulting in an 8-fold decrease in transfected Dami cells or a 20 fold decrease in transfected CRRF-288-11 cells. In summary, the natural dimorphism C(-92)G within the proximal 5 ' -regulatory region of the human integrin alpha (2) gene contributes to the regulation of integrin alpha (2)beta (1) expression on megakaryocytes and blood platelets and must thereby modulate collagen-related platelet function in vivo.	Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Hop Cardiol, CNRS, UMR 5533, F-33604 Pessac, France	Scripps Research Institute; Scripps Research Institute; Centre National de la Recherche Scientifique (CNRS); CHU Bordeaux	Kunicki, TJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, 10550 N Torrey Pines Rd,Maildrop MEM150, La Jolla, CA 92037 USA.			JACQUELIN, Beatrice/0000-0002-1896-5092	NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NHLBI NIH HHS [HL54203, HL46979] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054203, R01HL046979] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Brunekreef GA, 1997, EXP EYE RES, V64, P295, DOI 10.1006/exer.1996.0289; Carlsson LE, 1999, BLOOD, V93, P3583, DOI 10.1182/blood.V93.11.3583.410k34_3583_3586; Corral J, 1999, THROMB HAEMOSTASIS, V81, P951, DOI 10.1055/s-0037-1614605; Corral J, 1999, TRANSFUSION, V39, P372, DOI 10.1046/j.1537-2995.1999.39499235668.x; Di Paola J, 1999, BLOOD, V93, P3578, DOI 10.1182/blood.V93.11.3578.410k18_3578_3582; FUGMAN DA, 1990, BLOOD, V75, P1252; Jacquelin B, 2001, BLOOD, V97, P1721, DOI 10.1182/blood.V97.6.1721; JASPERS M, 1991, SOMAT CELL MOLEC GEN, V17, P505, DOI 10.1007/BF01233174; Kim S, 1999, MOL VIS, V5, pU1; Kritzik M, 1998, BLOOD, V92, P2382, DOI 10.1182/blood.V92.7.2382; Kunicki TJ, 1997, BLOOD, V89, P1939, DOI 10.1182/blood.V89.6.1939; KUNICKI TJ, 1993, BLOOD, V82, P2693; Matsubara Y, 2000, BLOOD, V95, P1560, DOI 10.1182/blood.V95.5.1560.005k43_1560_1564; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Noti JD, 1996, MOL CELL BIOL, V16, P2940; RANEY AK, 1989, J VIROL, V63, P3919, DOI 10.1128/JVI.63.9.3919-3925.1989; ROEST M, 2000, BLOOD, V101, P67; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santoso S, 1999, BLOOD, V93, P2449, DOI 10.1182/blood.V93.8.2449.408k34_2449_2453; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Wang ZY, 1999, BLOOD, V93, P4208, DOI 10.1182/blood.V93.12.4208.412k17_4208_4221; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; YE J, 1966, MOL CELL BIOL, V16, P6178; Ye JP, 1996, MOL CELL BIOL, V16, P157; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689; ZUTTER MM, 1994, J BIOL CHEM, V269, P463; ZUTTER MM, 1990, AM J PATHOL, V137, P113; ZUTTER MM, 1995, BLOOD, V86, P3006; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	36	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23518	23524		10.1074/jbc.M102019200	http://dx.doi.org/10.1074/jbc.M102019200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313353	hybrid			2022-12-27	WOS:000169531100041
J	Maroto, R; Hamill, OP				Maroto, R; Hamill, OP			Brefeldin a block of integrin-dependent mechanosensitive ATP release from Xenopus oocytes reveals a novel mechanism of mechanotransduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CFTR; GOLGI; CELLS; TRANSPORT; PROTEINS; MICROTUBULES; TRAFFICKING; INHIBITION; ACTIVATION	Many animal cells release ATP into the extracellular medium, and often this release is mechanosensitive, However, the mechanisms underlying this release are not well understood. Using the luciferin-luciferase bi. oluminescent assay we demonstrate that a Xenopus oocyte releases ATP at a basal rate similar to0.01 fmol/s, and gentle mechanical stimulation can increase this to 50 fmol/s. Brefeldin A, nocodazole, and progesterone-induced-maturation block basal and mechanosensitive ATP release. These treatments share the common feature of disrupting the Golgi complex and vesicle trafficking to the cell surface and thereby block protein secretion and membrane protein insertion. We propose that ATP release occurs when protein transport vesicles enriched in ATP fuse with the plasma membrane. Collagenase, integrin-binding peptides, and cytochalasin D also block ATP release, indicating that extracellular, membrane and cytoskeletal elements are involved in the release process. Elevation of intracellular Ca2+ does not evoke ATP release but potentiates mechanosensitive ATP release. Our study indicates a novel mechanism of mechanotransduction that would allow cells to regulate membrane trafficking and protein transport/secretion in response to mechanical loading.	Univ Texas, Med Branch, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston	Hamill, OP (corresponding author), Univ Texas, Med Branch, 301 Univ Blvd, Galveston, TX 77550 USA.	ohamill@utmb.edu						ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; Bodas E, 2000, J BIOL CHEM, V275, P20268, DOI 10.1074/jbc.M000894200; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Cantiello HF, 1998, AM J PHYSIOL-CELL PH, V274, pC799, DOI 10.1152/ajpcell.1998.274.3.C799; Chen BM, 1997, J NEUROSCI, V17, P904; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; DHO S, 1993, BIOCHIM BIOPHYS ACTA, V1225, P78, DOI 10.1016/0925-4439(93)90125-K; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Fisher RS, 1996, AM J PHYSIOL-CELL PH, V270, pC138, DOI 10.1152/ajpcell.1996.270.1.C138; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Grygorczyk R, 1997, AM J PHYSIOL-CELL PH, V272, pC1058; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; HAMILL OP, 1992, P NATL ACAD SCI USA, V89, P7462, DOI 10.1073/pnas.89.16.7462; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; LUNDIN A, 1976, ANAL BIOCHEM, V75, P611, DOI 10.1016/0003-2697(76)90116-0; Maroto R, 2000, J PHYSIOL-LONDON, V527, p45P; Mayerhofer A, 1998, P NATL ACAD SCI USA, V95, P10990, DOI 10.1073/pnas.95.18.10990; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; Nakamura F, 1996, P NATL ACAD SCI USA, V93, P10465, DOI 10.1073/pnas.93.19.10465; PEREZSAMARTIN AL, 2000, J PHYSL, P721; Peters KW, 1999, AM J PHYSIOL-CELL PH, V277, pC174, DOI 10.1152/ajpcell.1999.277.1.C174; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; Roman RM, 1999, AM J PHYSIOL-GASTR L, V277, pG1222, DOI 10.1152/ajpgi.1999.277.6.G1222; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Samartsev VN, 1997, FEBS LETT, V412, P179, DOI 10.1016/S0014-5793(97)00667-4; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Takahashi A, 1996, AM J PHYSIOL-CELL PH, V271, pC1887, DOI 10.1152/ajpcell.1996.271.6.C1887; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; VERREY F, 1995, J MEMBRANE BIOL, V145, P193; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Xu J, 1996, J CELL SCI, V109, P1605; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; Zhang Y, 1998, J PHYSIOL-LONDON, V508, P763, DOI 10.1111/j.1469-7793.1998.763bp.x; Zhang Y, 2000, J PHYSIOL-LONDON, V523, P83, DOI 10.1111/j.1469-7793.2000.t01-2-00083.x; ZHANG Y, 2000, J PHYSL, P117; ZHANG Y, 2000, J PHYSL, P101; ZIGANSHIN AU, 1995, PFLUG ARCH EUR J PHY, V429, P412, DOI 10.1007/BF00374157	57	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23867	23872		10.1074/jbc.M101500200	http://dx.doi.org/10.1074/jbc.M101500200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320093	hybrid			2022-12-27	WOS:000169531100086
J	Parada, Y; Banerji, L; Glassford, J; Lea, NC; Collado, M; Rivas, C; Lewis, JL; Gordon, MY; Thomas, NSB; Lam, EWF				Parada, Y; Banerji, L; Glassford, J; Lea, NC; Collado, M; Rivas, C; Lewis, JL; Gordon, MY; Thomas, NSB; Lam, EWF			BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27(Kip1) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; IN-VIVO; PROTEIN; ONCOGENE; INHIBITOR; G1; TRANSFORMATION; TRANSCRIPTION; FAMILY; GROWTH	Although it is evident that BGR-ABL can rescue cytokine-deprived hematopoietic progenitor cells from cell cycle arrest and apoptosis, the exact mechanism of action of BCR/ABL and interleukin (IL)-3 to promote proliferation and survival has not been established. Using the pro-B cell line BaF3 and a BaF3 cell line stably overexpressing BCR-ABL (BaF3-p210), we investigated the proliferative signals derived from BCR-ABL and IL-3, The results indicate that both IL-3 and BCR-ABE target the expression of cyclin Ds and down-regulation of p27(Kip1) mediate pRB-related pocket protein phosphorylation, E2F activation, and thus S phase progression. These findings were further confirmed in a BaF3 cell line (TonB.210) where the BCR-ABL expression is inducible by doxycyclin and by using the drug STI571 to inactivate BCR-ABL activity in BaF3-p210. To establish the functional significance of cyclin D2 and p27(Kip1) expression in response to IL-3 and BCR-ABL expression, me studied the effects of ectopic expression of cyclin D2 and p27(Kip1) On cell proliferation and survival. Our results demonstrate that both cyclin D2 and p27(Kip1) have a role in BaF3 cell proliferation and survival, as ectopic expression of cyclin D2 is sufficient to abolish the cell cycle arrest and apoptosis induced by IL-3 withdrawal or by BCR-ABL inactivation, while overexpression of p27(Kip1) can cause cell cycle arrest and apoptosis in the BaF3 cells. Furthermore, our data also suggest that cyclin D2 functions upstream of p27(Kip1), cyclin E, and cyclin D3, and therefore, plays an essential part in integrating the signals from IL-3 and BCR-ABL with the pRB/ESF pathway.	Hammersmith Hosp, Imperial Coll, Sch Med, CRC Labs, London W12 0NN, England; Hammersmith Hosp, Imperial Coll, Sch Med, Sect Canc Cell Biol, London W12 0NN, England; Ludwig Inst Canc Res, London W2 1PG, England; St Marys Hosp, Sch Med, Imperial Coll, Sect Virol & Cell Biol, London W2 1PG, England; Imperial Coll, Sch Med, Dept Haematol, Royal Postgrad Med Sch,LRF Ctr Adult Leukaemia, London W12 0NN, England; Guys Kings St Thomas Sch Med, Rayne Inst, Dept Haematol Med, London SE5 9NU, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Imperial College London; University of London; King's College London	Lam, EWF (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, CRC Labs, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Collado, Manuel/K-8140-2014; Lam, Eric W-F/AAW-8566-2020; Rivas, Carmen/L-3162-2017; Rivas, Carmen/AAB-6278-2019	Collado, Manuel/0000-0002-0330-0880; Lam, Eric W-F/0000-0003-1274-3576; Rivas, Carmen/0000-0002-0518-7199; Rivas, Carmen/0000-0002-0518-7199				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BEDI A, 1994, BLOOD, V83, P2038; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Buchdunger E, 1996, CANCER RES, V56, P100; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eder M, 1997, STEM CELLS, V15, P327, DOI 10.1002/stem.150327; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gordon MY, 1999, LEUKEMIA, V13, pS65, DOI 10.1038/sj.leu.2401281; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kato Jun-ya, 1999, Frontiers in Bioscience, V4, pd787, DOI 10.2741/Kato; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; KONOPKA JB, 1986, P NATL ACAD SCI USA, V83, P4049, DOI 10.1073/pnas.83.11.4049; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Maguer-Satta V, 1998, ONCOGENE, V16, P237, DOI 10.1038/sj.onc.1201533; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; ROSENBERG N, 1990, CANCER CELL-MON REV, V2, P284; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiotsu Y, 2000, BLOOD, V96, P2284, DOI 10.1182/blood.V96.6.2284; STRIFE A, 1988, CANCER RES, V48, P1035; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	58	97	101	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23572	23580		10.1074/jbc.M101885200	http://dx.doi.org/10.1074/jbc.M101885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323429	hybrid			2022-12-27	WOS:000169531100048
J	Govaerts, C; Lefort, A; Costagliola, S; Wodak, SJ; Ballesteros, JA; Van Sande, J; Pardo, L; Vassart, G				Govaerts, C; Lefort, A; Costagliola, S; Wodak, SJ; Ballesteros, JA; Van Sande, J; Pardo, L; Vassart, G			A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LEUCINE-RICH REPEATS; HYPERFUNCTIONING THYROID ADENOMAS; FOLLICLE-STIMULATING-HORMONE; SOMATIC MUTATIONS; GERMLINE MUTATIONS; MOLECULAR-CLONING; TSH RECEPTOR; DEVELOPMENTAL REGULATION; DROSOPHILA-MELANOGASTER	The thyrotropin (TSH) receptor is an interesting model to study G protein-coupled receptor activation as many point mutations can significantly increase its ba sal activity. Here, we identified a molecular interaction between Asp(633) in transmembrane helix 6 (TM6) and Asn(674) in TM7 of the TSHr that is crucial to maintain the inactive state through conformational constraint of the Asn. We show that these residues are perfectly conserved in the glycohormone receptor family, except in one case, where they are exchanged, suggesting a direct interaction. Molecular modeling of the TSHr, based on the high resolution structure of rhodopsin, strongly favors this hypothesis. Our approach combining site-directed mutagenesis with molecular modeling shows that mutations disrupting this interaction, like the D633A mutation in TM6, lead to high constitutive activation. The strongly activating N674D (TM7) mutation, which in our modeling breaks the TM6-TM7 link, is reverted to wild type-like behavior by an additional D633N mutation (TM6), which would restore this link. Moreover, we show that the Asn of TM7 (conserved in most G protein-coupled receptors) is mandatory for ligand-induced cAMP accumulation, suggesting an active role of this residue in activation. In the TSHr, the conformation of this Asn residue of TM7 would be constrained, in the inactive state, by its Asp partner in TM6.	Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Univ Autonoma Barcelona, Fac Med, Lab Med Computac, Unitat Bioestadist, Bellaterra 08193, Spain; Free Univ Brussels, Serv Conformat Macromol Biol, B-1050 Brussels, Belgium; Novasite Pharmaceut Inc, San Diego, CA 92121 USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Autonomous University of Barcelona; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vassart, G (corresponding author), Free Univ Brussels, IRIBHN, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.		costagliola, sabine/D-4864-2012	wodak, shoshana/0000-0002-0701-6545; Pardo, Leonardo/0000-0003-1778-7420				Angelova K, 2000, MOL ENDOCRINOL, V14, P459, DOI 10.1210/me.14.4.459; Aqvist J, 2000, NATURE, V404, P881, DOI 10.1038/35009114; AQVIST J, 2000, NATURE, V20, P404; ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; CASE DA, 1997, AMBERS5; CHAN T, 1992, J BIOL CHEM, V267, P9478; Chelvanayagam G, 1997, PROTEIN ENG, V10, P307, DOI 10.1093/protein/10.4.307; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Costagliola S, 1998, FEBS LETT, V436, P427, DOI 10.1016/S0014-5793(98)01177-6; Costagliola S, 1998, J IMMUNOL, V160, P1458; Da Costa CR, 1998, J BIOL CHEM, V273, P11874, DOI 10.1074/jbc.273.19.11874; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; Donnelly D, 1999, BIOCHEM J, V339, P55, DOI 10.1042/0264-6021:3390055; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; Eriksen KK, 2000, GENOME RES, V10, P924, DOI 10.1101/gr.10.7.924; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Fahmy K, 2000, BIOCHEMISTRY-US, V39, P10607, DOI 10.1021/bi000912d; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Ghanouni P, 2000, J BIOL CHEM, V275, P3121, DOI 10.1074/jbc.275.5.3121; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; Hauser F, 1997, J BIOL CHEM, V272, P1002, DOI 10.1074/jbc.272.2.1002; Horn F, 1998, NUCLEIC ACIDS RES, V26, P275, DOI 10.1093/nar/26.1.275; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MCGREGOR MJ, 1987, J MOL BIOL, V20, P198; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; NOTHACKER HP, 1993, BIOCHEM BIOPH RES CO, V197, P1062, DOI 10.1006/bbrc.1993.2586; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Perlman JH, 1997, J BIOL CHEM, V272, P11937, DOI 10.1074/jbc.272.18.11937; RATH P, 1993, BIOCHEMISTRY-US, V32, P10277, DOI 10.1021/bi00090a001; Refetoff S, 2001, METABOLIC MOL BASES, P4029; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; VANSANDE J, 1995, EUR J BIOCHEM, V229, P338; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	64	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22991	22999		10.1074/jbc.M102244200	http://dx.doi.org/10.1074/jbc.M102244200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312274	hybrid			2022-12-27	WOS:000169412700135
J	Klein, RC; Prorok, M; Galdzicki, Z; Castellino, FJ				Klein, RC; Prorok, M; Galdzicki, Z; Castellino, FJ			The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; 3 DIFFERENT SUBUNITS; NMDA-RECEPTOR; IN-VITRO; MOLECULAR CHARACTERIZATION; HIPPOCAMPAL-NEURONS; MAMMALIAN-CELLS; ZINC INHIBITION; RAT-BRAIN; BINDING	Whole cell voltage clamp recordings mere performed to assess the ability of conantokin-G: (con-G), conantokin-T (con-T), and a 17-residue truncated form of conantokin-R (con-R[1-17]) to inhibit N-methyl-n-aspartate (NMDA)evoked currents in human embryonic kidney 293 cells transiently expressing various combinations of NR1a, NR1b, NR2A, and NR2B receptor subunits. Con-T and conR[1-17] attenuated ion currents in cells expressing NR1a/ NR2A or NR1a/NR2B, Con-G,did not affect NMDA-evoked ionic currents in cells expressing NR1a/NR2A, but it showed inhibitory activity in cells expressing NR1a/NR2B receptors and the triheteromeric combination of NR1a/ NR2A/NR2B. An Ala-rich con-G analog, con-G[Q6G/gamma 7K/ N8A/gamma 10A/gamma 14A/K15A/S16A/N17A] (Ala/con-G, where gamma is Gla), in which all nonessential amino acids were altered to Ala residues, manifested subunit specificity similar to that of con-G, suggesting that the replaced residues are not responsible for selectivity in the con-G framework. A sarcosine-containing con-T truncation analog, con-T[1-9/ G1Src/Q6G], inhibited currents in NR1a/NR2A and NR1a/ NR2B receptors, eliminating residues 10-21 as mediators of the broad subunit selectivity of con-T, In contrast to the null effects of con-G and Ala/con-G at a NR1a/NR2A-containing receptor, some inhibition (similar to 40%) of NMDA-evoked currents was effected by these peptides in cells expressing NR1b/NR2A. This finding suggests that the presence of exon 5 in NR1b plays a role in the activity of the conantokins, Analysis of various conantokin analogs demonstrated that Leu(5) of con-G is an important determinant of conantokin selectivity, Taken as a whole, these results suggest that the important molecular determinants on conantokins responsible for NMDA receptor activity and specificity are discretely housed in specific residues of these peptides, thus allowing molecular manipulation of the NMDA receptor inhibitory properties of the conantokins.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	University of Notre Dame; University of Notre Dame; Uniformed Services University of the Health Sciences - USA	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, 229 Nieuwland Sci Hall, Notre Dame, IN 46556 USA.				NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams AC, 2000, EUR J PHARMACOL, V404, P303, DOI 10.1016/S0014-2999(00)00640-3; Blandl T, 1998, FEBS LETT, V435, P257, DOI 10.1016/S0014-5793(98)01077-1; Blandl T, 2000, FEBS LETT, V470, P139, DOI 10.1016/S0014-5793(00)01309-0; Blandl T, 2001, J BIOL CHEM, V276, P7391, DOI 10.1074/jbc.M006648200; BULLER AL, 1994, J NEUROSCI, V14, P5471; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen NS, 1997, MOL PHARMACOL, V51, P1015, DOI 10.1124/mol.51.6.1015; COLPITTS TL, 1993, INT J PEPT PROT RES, V41, P567; Donevan SD, 2000, MOL PHARMACOL, V58, P614, DOI 10.1124/mol.58.3.614; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; HAACK JA, 1990, J BIOL CHEM, V265, P6025; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kendrick SJ, 1996, J NEUROCHEM, V67, P608; Klein RC, 1999, NEUROSCI LETT, V273, P171, DOI 10.1016/S0304-3940(99)00649-7; Klein RC, 1999, NEUROPHARMACOLOGY, V38, P1819, DOI 10.1016/S0028-3908(99)00065-9; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laurie DJ, 1997, MOL BRAIN RES, V51, P23, DOI 10.1016/S0169-328X(97)00206-4; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; PRIESTLEY T, 1995, MOL PHARMACOL, V48, P841; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; Prorok M, 1996, INT J PEPT PROT RES, V48, P281; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; SKOLNICK P, 1994, PHARM TOXICOLOGY BAS, P155; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Sun LX, 1998, FEBS LETT, V441, P392, DOI 10.1016/S0014-5793(98)01590-7; Tovar KR, 1999, J NEUROSCI, V19, P4180; Traynelis SF, 1998, J NEUROSCI, V18, P6163; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; Warder SE, 1998, J BIOL CHEM, V273, P7512, DOI 10.1074/jbc.273.13.7512; Warder SE, 2001, J NEUROCHEM, V77, P812, DOI 10.1046/j.1471-4159.2001.00281.x; White HS, 2000, J PHARMACOL EXP THER, V292, P425; Williams AJ, 2000, J PHARMACOL EXP THER, V294, P378	41	52	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26860	26867		10.1074/jbc.M102428200	http://dx.doi.org/10.1074/jbc.M102428200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335724	hybrid			2022-12-27	WOS:000169966900019
J	Ohndorf, UM; Steegborn, C; Knijff, R; Sondermann, P				Ohndorf, UM; Steegborn, C; Knijff, R; Sondermann, P			Contributions of the individual domains in human La protein to its RNA 3 '-end binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTS; TERMINATION FACTOR LA; CRYSTAL-STRUCTURE; AUTOANTIGEN-LA; RECOGNITION MOTIFS; MESSENGER-RNA; SEX-LETHAL; SS-B; ANGSTROM RESOLUTION; NUCLEAR ANTIGEN	The autoantigen La regulates the maturation of RNA polymerase III transcripts by binding to their poly(U) termination signal, The modular protein harbors a N-terminal RNA recognition motif (RRM), RRM1, and in the C-terminal domain, a second, atypical RRM2, in addition to a phosphorylation site, and a putative nucleotide binding site. This study presents a detailed investigation into the RNA 3'-end binding properties of La by using binding titration and competition assays with subsequent gel mobility shift analysis. Two truncation mutants containing one (La-RRM1) or both(La-RRM1-RRM2) RNA-binding domains were constructed, overexpressed, and purified. A K-d value of 25 +/- 10 nM for La binding to a nonameric RNA ligand with the oligouridylate recognition sequence was obtained, discriminating with a specificity ratio of similar to 100 for this probe over a RNA ligand with a 3'-poly(A) stretch. The N-terminal La-RRM1 region was identified as the major contributor of these properties to La, manifested in a 5-fold lower K-d of 5 +/-3 nM and a slightly increased specificity ratio of 120 for the RNA ligand, The atypical RRM2 in the C-terminal domain of La has an unprecedented negative effect on 3'-end RNA recognition, as indicated by a higher Ltd value of 90 +/- 10 nM for the La-RRM1-RRM2 mutant but comparable specificity. Thus the C-terminal regions beyond RRM2 positively modulate the RNA binding affinity of La. Negative regulation, however, occurs through Ser(366) phosphorylation decreasing the binding affinity by 2-fold. ATP had no influence on RNA complex formation. The functional implications of these findings for the mechanism of action of La are discussed.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Planegg, Germany	Max Planck Society	Ohndorf, UM (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Planegg, Germany.							Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; BACHMANN M, 1990, CELL, V60, P85, DOI 10.1016/0092-8674(90)90718-T; BACHMANN M, 1986, BIOL CHEM H-S, V367, P671, DOI 10.1515/bchm3.1986.367.2.671; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; CHAMBERS JC, 1988, J BIOL CHEM, V263, P18043; CHAN EKL, 1989, J AUTOIMMUN, V2, P321, DOI 10.1016/0896-8411(89)90159-5; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Craig AWB, 1997, MOL CELL BIOL, V17, P163, DOI 10.1128/MCB.17.1.163; Crowder SM, 1999, P NATL ACAD SCI USA, V96, P4892, DOI 10.1073/pnas.96.9.4892; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Huhn P, 1997, NUCLEIC ACIDS RES, V25, P410, DOI 10.1093/nar/25.2.410; Intine RVA, 2000, MOL CELL, V6, P339, DOI 10.1016/S1097-2765(00)00034-4; James MC, 1999, EUR J BIOCHEM, V266, P151, DOI 10.1046/j.1432-1327.1999.00839.x; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; MATHEWS MB, 1984, MOL CELL BIOL, V4, P1134, DOI 10.1128/MCB.4.6.1134; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; PFEIFLE J, 1987, BIOCHIM BIOPHYS ACTA, V928, P217, DOI 10.1016/0167-4889(87)90124-8; PIZER LI, 1983, MOL CELL BIOL, V3, P1235, DOI 10.1128/MCB.3.7.1235; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PRUIJN GJM, 1995, EUR J BIOCHEM, V232, P611, DOI 10.1111/j.1432-1033.1995.tb20851.x; PRUIJN GJM, 1991, NUCLEIC ACIDS RES, V19, P5173, DOI 10.1093/nar/19.19.5173; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Rosenblum JS, 1998, J CELL BIOL, V143, P887, DOI 10.1083/jcb.143.4.887; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; Scofield RH, 1999, MOL IMMUNOL, V36, P1093, DOI 10.1016/S0161-5890(99)00095-4; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Simons FHM, 1996, EXP CELL RES, V224, P224, DOI 10.1006/excr.1996.0132; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; TOPFER F, 1993, J IMMUNOL, V150, P3091; VANVENROOIJ WJ, 1993, MOL BIOL REP, V18, P113, DOI 10.1007/BF00986765; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	53	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27188	27196		10.1074/jbc.M102891200	http://dx.doi.org/10.1074/jbc.M102891200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342556	hybrid			2022-12-27	WOS:000169966900062
J	Sung, JY; Kim, J; Paik, SR; Park, JH; Ahn, YS; Chung, KC				Sung, JY; Kim, J; Paik, SR; Park, JH; Ahn, YS; Chung, KC			Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; SPORADIC PARKINSONS-DISEASE; AMYLOID PRECURSOR PROTEIN; MULTIPLE SYSTEM ATROPHY; ALZHEIMERS-DISEASE; LEWY BODIES; CEREBROSPINAL-FLUID; NACP/ALPHA-SYNUCLEIN; PRESYNAPTIC PROTEIN; MEMBRANE-FUSION	The presynaptic alpha -synuclein is a prime suspect for contributing to Lewy pathology and clinical aspects of diseases, including Parkinson's disease, dementia with Lewy bodies, and a Lewy body variant of Alzheimer's disease. Here we examined the pathogenic mechanism of neuronal cell death induced by alpha -synuclein. The exogenous addition of alpha -synuclein caused a marked decrease of cell viability in primary and immortalized neuronal cells. The neuronal cell death appeared to be correlated with the Rab5A-specific endocytosis of alpha -synuclein that subsequently caused the formation of Lewy body-like intracytoplasmic inclusions. This was further supported by the fact that the expression of GTPase-deficient Rab5A resulted in a significant decrease of its cytotoxicity as a result of incomplete endocytosis of alpha -synuclein.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Res Inst, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Inha Univ, Dept Biochem, Coll Med, Inchon 402751, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Inha University	Chung, KC (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Shinchon Dong 134, Seoul 120752, South Korea.			Kim, Jongsun/0000-0002-3149-669X; Park, Jeon Han/0000-0001-9604-3205				Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Arima K, 1999, BRAIN RES, V843, P53, DOI 10.1016/S0006-8993(99)01848-X; Arima K, 2000, ACTA NEUROPATHOL, V100, P115, DOI 10.1007/s004010050002; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; Chung KC, 2000, J NEUROCHEM, V75, P9, DOI 10.1046/j.1471-4159.2000.0750009.x; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; DICARLO V, 1993, CAN J NEUROL SCI S, V4, pS80; DICARLO V, 2000, ABSTR SOC NEUROSCI, V26, P1547; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; Gai WP, 1995, BRAIN, V118, P1447, DOI 10.1093/brain/118.6.1447; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Ho SL, 1998, MOVEMENT DISORD, V13, P970, DOI 10.1002/mds.870130619; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Ikin AF, 1996, J BIOL CHEM, V271, P31783, DOI 10.1074/jbc.271.50.31783; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Kim HJ, 1999, NEUROREPORT, V10, P1427, DOI 10.1097/00001756-199905140-00008; Kim J, 1997, MOL CELLS, V7, P78; Ko LW, 2000, J NEUROCHEM, V75, P2546, DOI 10.1046/j.1471-4159.2000.0752546.x; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Lin JJ, 1999, EUR NEUROL, V42, P217, DOI 10.1159/000008110; Lin X, 1999, NEURON, V24, P499, DOI 10.1016/S0896-6273(00)81104-6; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; Martins VR, 1997, NAT MED, V3, P1376, DOI 10.1038/nm1297-1376; Masliah E, 1996, AM J PATHOL, V148, P201; McLean PJ, 2000, J NEURAL TRANSM-SUPP, P53; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Nakamura S, 2000, CLIN NEUROPATHOL, V19, P51; Neve RL, 1998, J NEUROSCI, V18, P7757; NISHIMURA M, 1994, BRAIN RES, V634, P339, DOI 10.1016/0006-8993(94)91940-2; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Troncoso JC, 1998, ANN NEUROL, V43, P673, DOI 10.1002/ana.410430519; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Vaughan J, 1998, ANN NEUROL, V44, P270, DOI 10.1002/ana.410440221; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang WW, 1998, ARCH NEUROL-CHICAGO, V55, P1521, DOI 10.1001/archneur.55.12.1521; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	62	154	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27441	27448		10.1074/jbc.M101318200	http://dx.doi.org/10.1074/jbc.M101318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11316809	hybrid			2022-12-27	WOS:000169966900094
J	Burtelow, MA; Roos-Mattjus, PMK; Rauen, M; Babendure, JR; Karnitz, LM				Burtelow, MA; Roos-Mattjus, PMK; Rauen, M; Babendure, JR; Karnitz, LM			Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9-1-1) DNA damage responsive checkpoint complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); REPLICATION-FACTOR-C; HUMAN HOMOLOG; SACCHAROMYCES-CEREVISIAE; STRUCTURAL HOMOLOG; CELLULAR-RESPONSE; PROTEIN COMPLEX; CONTROL GENE; KINASE; HUS1	DNA damage activates cell cycle checkpoint signaling pathways that coordinate cell cycle arrest and DNA repair. Three of the proteins involved in checkpoint signaling, Rad1, Hus1, and Rad9, have been shown to interact by immunoprecipitation and yeast two-hybrid studies. However, it is not known how these proteins interact and assemble into a complex. In the present study we demonstrated that in human cells all the hRad9 and hHus1 and approximately one-half of the cellular pool of hRad1 interacted as a stable, biochemically discrete complex, with an apparent molecular mass of 160 kDa. This complex was reconstituted by co-expression of all three recombinant proteins in a heterologous system, and the reconstituted complex exhibited identical chromatographic behavior as the endogenous complex. Interaction studies using differentially tagged proteins demonstrated that the proteins did not self-multimerize. Rather, each protein had a binding site for the other two partners, with the N terminus of hRad9 interacting with hRad1, the N terminus of hRad1 interacting with hHus1, and the N terminus of hHus1 interacting with the C terminus of hRad9's predicted PCNA-like region. Collectively, these analyses suggest a model of how these three proteins assemble to form a functional checkpoint complex, which we dubbed the 9-1-1 complex.	Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Guggenheim 13, Rochester, MN 55905 USA.			Roos-Mattjus, Pia/0000-0002-7187-2012	NATIONAL CANCER INSTITUTE [R01CA084321, R56CA084321] Funding Source: NIH RePORTER; NCI NIH HHS [CA-84321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 1999, CANCER RES, V59, P2023; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Cai RL, 2000, J BIOL CHEM, V275, P27909; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dahlen M, 1998, MOL BIOL CELL, V9, P611, DOI 10.1091/mbc.9.3.611; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; THELEN MP, 1994, J BIOL CHEM, V269, P747; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Weiss RS, 2000, GENE DEV, V14, P1886	41	117	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25903	25909		10.1074/jbc.M102946200	http://dx.doi.org/10.1074/jbc.M102946200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340080	hybrid			2022-12-27	WOS:000169823300037
J	Cottet, S; Dupraz, P; Hamburger, F; Dolci, W; Jaquet, M; Thorens, B				Cottet, S; Dupraz, P; Hamburger, F; Dolci, W; Jaquet, M; Thorens, B			SOCS-1 protein prevents Janus kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE PRODUCTION; RAT PANCREATIC-ISLETS; IFN-GAMMA; IN-VIVO; DIABETES-MELLITUS; TYROSINE PHOSPHORYLATION; LENTIVIRAL VECTOR; INDUCIBLE GENE; FATTY-ACIDS	In the pathogenesis of type I diabetes mellitus, activated leukocytes infiltrate pancreatic islets and induce beta cell dysfunction and destruction. Interferon (IFN)-gamma, tumor necrosis factor-ru and interleukin (IL)-1 beta play important, although not completely defined, roles in these mechanisms, Here, using the highly differentiated beta Tc-Tet insulin-secreting cell line, we showed that IFN-gamma dose- and time-dependently suppressed insulin synthesis and glucose-stimulated secretion. As described previously IFN-gamma, in combination with IL-1 beta, also induces inducible NO synthase expression and apoptosis (Dupraz, P,, Cottet, S,, Hamburger, F., Dolci, W,, Felley-Bosco, E,, and Thorens, B, (2000) J, Biol. Chem. 275, 37672-37678), To assess the role of the Janus kinase/signal transducer and activator of transcription (STAT) pathway in IFN-gamma intracellular signaling, we stably overexpressed SOCS-1 (suppressor of cytokine signaling-1) in the beta cell line. We demonstrated that SOCS-1 suppressed cytokine-induced STAT-1 phosphorylation and increased cellular accumulation, This was accompanied by a suppression of the effect of IFN-gamma on: (i) reduction in insulin promoter-luciferase reporter gene transcription, (ii) decrease in insulin mRNA and peptide content, and (iii) suppression of glucose-stimulated insulin secretion, Furthermore, SOCS-1 also suppressed the cellular effects that require the combined presence of IL-1 beta and IFN-gamma:: induction of nitric oxide production and apoptosis, Together our data demonstrate that IFN-gamma is responsible for the cytokine-induced defect in insulin gene expression and secretion and that this effect can be completely blocked by constitutive inhibition of the Janus kinase/STAT pathway.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Thorens, B (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, 27 Rue Bugnon, CH-1005 Lausanne, Switzerland.							Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Baldeon ME, 1997, DIABETES, V46, P770, DOI 10.2337/diabetes.46.5.770; CAMPBELL IL, 1990, MOL BIOL MED, V7, P299; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dunger A, 1996, DIABETES, V45, P183, DOI 10.2337/diabetes.45.2.183; Dupraz P, 1999, GENE THER, V6, P1160, DOI 10.1038/sj.gt.3300922; Dupraz P, 2000, J BIOL CHEM, V275, P37672, DOI 10.1074/jbc.M005150200; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Gremlich S, 1997, J BIOL CHEM, V272, P3216, DOI 10.1074/jbc.272.6.3216; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Guillam MT, 1997, NAT GENET, V17, P327, DOI 10.1038/ng1197-327; Heitmeier MR, 1999, J BIOL CHEM, V274, P29266, DOI 10.1074/jbc.274.41.29266; Hultgren B, 1996, DIABETES, V45, P812, DOI 10.2337/diabetes.45.6.812; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Kallmann BA, 1997, DIABETES, V46, P237, DOI 10.2337/diabetes.46.2.237; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OLSON LK, 1993, J CLIN INVEST, V92, P514, DOI 10.1172/JCI116596; RABINOVITCH A, 1994, DIABETOLOGIA, V37, P733, DOI 10.1007/BF00404328; RABINOVITCH A, 1994, J CLIN ENDOCR METAB, V79, P1058, DOI 10.1210/jc.79.4.1058; Rabinovitch A, 1998, DIABETES METAB REV, V14, P129, DOI 10.1002/(SICI)1099-0895(199806)14:2<129::AID-DMR208>3.3.CO;2-M; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; RAGO R, 1990, ANAL BIOCHEM, V191, P31; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STERNESJO J, 1995, AUTOIMMUNITY, V20, P185, DOI 10.3109/08916939508993349; SUAREZPINZON WL, 1994, ENDOCRINOLOGY, V134, P1006, DOI 10.1210/en.134.3.1006; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Thomas HE, 1998, J CLIN INVEST, V102, P1249, DOI 10.1172/JCI2899; vonHerrath MG, 1997, J EXP MED, V185, P531, DOI 10.1084/jem.185.3.531; Wang B, 1997, P NATL ACAD SCI USA, V94, P13844, DOI 10.1073/pnas.94.25.13844; Wilson SB, 1998, NATURE, V391, P177, DOI 10.1038/34419; YAGI N, 1995, DIABETES, V44, P744, DOI 10.2337/diabetes.44.7.744; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999; Zumsteg U, 2000, DIABETES, V49, P39, DOI 10.2337/diabetes.49.1.39	55	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25862	25870		10.1074/jbc.M103235200	http://dx.doi.org/10.1074/jbc.M103235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342558	hybrid			2022-12-27	WOS:000169823300031
J	Atshaves, BP; Storey, SM; McIntosh, AL; Petrescu, AD; Lyuksyutova, OI; Greenberg, AS; Schroeder, F				Atshaves, BP; Storey, SM; McIntosh, AL; Petrescu, AD; Lyuksyutova, OI; Greenberg, AS; Schroeder, F			Sterol carrier protein-2 expression modulates protein and lipid composition of lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-CELL FIBROBLASTS; DIFFERENTIATION-RELATED PROTEIN; FATTY ACYL-COENZYME; CHOLESTEROL TRANSPORT; MEMBRANE-STRUCTURE; STORAGE DISEASE; BINDING SITE; IN-VIVO; ACID; STEROIDOGENESIS	Despite the critical role lipid droplets play in maintaining energy reserves and lipid stores for the cell, little is known about the regulation of the lipid or protein components within the lipid droplet. Although immunofluorescence of intact cells as well as Western analysis of isolated lipid droplets revealed that sterol carrier protein-2 (SCP-S) was not associated with lipid droplets, SCP-S expression significantly altered the structure of the lipid droplet. First, the targeting of fatty acid and cholesterol to the lipid droplets was significantly decreased. Second, the content of several proteins important for lipid droplet function was differentially increased (perilipin A), reduced severalfold (adipose differentiation-related protein (ADRP), vimentin), or almost completely eliminated (hormone-sensitive lipase and proteins > 93 kDa) in the isolated lipid droplet. Third, the distribution of lipids within the lipid droplets was significantly altered. Double labeling of cells with 12-(N-methyl)-N-[(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-octadecanoic acid (NBD-stearic acid) and antisera to ADRP showed that 70, 24, and 13% of lipid droplets contained ADRP, NBD-stearic acid, or both, respectively. SCP-2 expression decreased the level of ADRP in the lipid droplet but increased the proportion wherein ADRP and NBD-stearic acid colocalized by 3-fold. SCP-S expression also decreased the lipid droplet fatty acid and cholesterol mass (nmol/mg protein) by 5.2-and 6.6-fold, respectively. Finally, SCP-2 expression selectively altered the pattern of esterified fatty acids in favor of polyunsaturated fatty acids within the lipid droplet. Displacement studies showed differential binding affinity of ADRP for cholesterol and fatty acids. These data suggested that SCP-2 and ADRP play a significant role in regulating fatty acid and cholesterol targeting to lipid droplets as well as in determining their lipid and protein components.	Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Tufts Univ, Program Obes Metab, JM USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Texas A&M University System; Texas A&M University College Station; Tufts University; United States Department of Agriculture (USDA)	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, TVMC, College Stn, TX 77843 USA.	Fschroeder@cvm.tamu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41406] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 2000, J BIOL CHEM, V275, P36852, DOI 10.1074/jbc.M003434200; Atshaves BP, 1998, AM J PHYSIOL-CELL PH, V274, pC633, DOI 10.1152/ajpcell.1998.274.3.C633; Avdulov NA, 1999, BBA-MOL CELL BIOL L, V1437, P37, DOI 10.1016/S0005-2760(98)00178-7; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CHANDERBHAN RF, 1986, ENDOCR RES, V12, P351, DOI 10.3109/07435808609035445; Chanderbhan RF, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P197; Chao H, 1999, BBA-MOL CELL BIOL L, V1439, P371, DOI 10.1016/S1388-1981(99)00109-2; Choi YS, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P109; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; EDELSTEIN RA, 1988, AM J GASTROENTEROL, V83, P687; Fielding CJ, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P273; Fong TH, 1997, J CELL BIOCHEM, V65, P67; Fong TH, 1996, J CELL BIOCHEM, V63, P366, DOI 10.1002/(SICI)1097-4644(19961201)63:3<366::AID-JCB12>3.0.CO;2-F; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Fuchs M, 1997, FASEB J, V11, pA1060; Fuchs M, 1998, BIOCHEM J, V336, P33, DOI 10.1042/bj3360033; GADELLA TWJ, 1991, BIOCHIM BIOPHYS ACTA, V1070, P237, DOI 10.1016/0005-2736(91)90170-D; GADELLA TWJ, 1994, EUR J BIOCHEM, V220, P1019, DOI 10.1111/j.1432-1033.1994.tb18707.x; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; GALLEGOS AM, 2001, IN PRESS PROG LIPID; GALLEGOS AM, 2001, IN PRESS BIOCHEMISTR; GALLEGOS AM, 2001, IN PRSS CHEM PHYS LI; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HIGUCHI K, 1970, J CELL PHYSIOL, V75, P65, DOI 10.1002/jcp.1040750108; Huang H, 1999, BIOCHEMISTRY-US, V38, P13231, DOI 10.1021/bi990870x; Huang H, 1999, BIOCHEM J, V344, P593, DOI 10.1042/0264-6021:3440593; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; INCERPI S, 1992, ARCH BIOCHEM BIOPHYS, V298, P35, DOI 10.1016/0003-9861(92)90090-J; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; Leonard AN, 1998, J LIPID RES, V39, P1981; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MARZO A, 1971, CLIN CHEM, V17, P145; McArthur MJ, 1999, J LIPID RES, V40, P1371; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; MENDISHANDAGAMA SMLC, 1995, TISSUE CELL, V27, P483, DOI 10.1016/S0040-8166(05)80056-4; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG237, DOI 10.1152/ajpgi.1998.275.2.G237; Murphy EJ, 2000, J LIPID RES, V41, P788; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; MyersPayne SC, 1996, J NEUROCHEM, V66, P313; NAGY L, 1990, ENDOCRINOLOGY, V126, P2267, DOI 10.1210/endo-126-5-2267; NICHOLS JW, 1987, J BIOL CHEM, V262, P14172; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681; Schoer JK, 2000, BIOCHEMISTRY-US, V39, P7662, DOI 10.1021/bi992686h; Schroeder F, 1996, P SOC EXP BIOL MED, V213, P150, DOI 10.3181/00379727-213-44047; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; SCHROEDER F, 2001, IN PRESS EXP BIOL ME; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Serrero G, 2000, BBA-MOL CELL BIOL L, V1488, P245, DOI 10.1016/S1388-1981(00)00128-1; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; SOKOL J, 1988, J BIOL CHEM, V263, P3411; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Sparrow CP, 1999, J LIPID RES, V40, P1747; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; Starodub O, 2000, AM J PHYSIOL-CELL PH, V279, pC1259, DOI 10.1152/ajpcell.2000.279.4.C1259; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; Stolowich NJ, 1997, BIOCHEMISTRY-US, V36, P1719, DOI 10.1021/bi962317a; Wang SM, 1997, J CELL BIOCHEM, V67, P84, DOI 10.1002/(SICI)1097-4644(19971001)67:1<84::AID-JCB9>3.0.CO;2-S; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463; YEAGLE PL, 1988, BIOL CHOLESTEROL, P121; ZANLUNGO S, 2000, GASTROENTEROLOGY, V118, P135	82	64	67	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25324	25335		10.1074/jbc.M100560200	http://dx.doi.org/10.1074/jbc.M100560200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333258	hybrid			2022-12-27	WOS:000169800700119
J	Domino, SE; Zhang, L; Lowe, JB				Domino, SE; Zhang, L; Lowe, JB			Molecular cloning, genomic mapping, and expression of two secretor blood group alpha(1,2)fucosyltransferase genes differentially regulated in mouse uterine epithelium and gastrointestinal tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; HEPARIN HEPARAN-SULFATE; EARLY-PREGNANCY; DEVELOPMENTAL REGULATION; CHROMOSOMAL ASSIGNMENT; CARBOHYDRATE ANTIGENS; HORMONAL-CONTROL; MENSTRUAL-CYCLE; BINDING-SITES; ATTACHMENT	Fucosylated oligosaccharides have been proposed to be involved in multiple cell-cell interactions, including mouse blastocyst adhesion and intestine-microbe interactions. To begin to define the regulation and function of terminal alpha (1,2)fucosylated carbohydrates in these and other tissues, we isolated and characterized a 85-kilobase (kb) genomic region of mouse chromosome 7, 23.2 centimorgans analogous to human chromosome 19q13.3 that encodes three alpha (1,2) fucosyltransferases. Gene-specific DNA probes from the open reading frames of the mouse fucosyltransferase genes corresponding to human FUT1, FUT2, and SEC1 demonstrate distinct tissue-specific expression patterns by Northern blot analyses. Flow cytometry profiles of cultured cells transfected with DNA segments containing the open reading frames of the mouse genes confirm that, each encodes an alpha (1,2)fucosyltransferase. In uterus and colon, a 3.3-kb FUT2 mRNA represents the major fucosyltransferase gene expressed. Steady-state FUT2 mRNA levels are cyclically regulated during the estrus cycle, increasing 10-fold from early diestrus to a relative maximum in proestrus. In contrast, SEC1 and FUT1 do not show prominently regulated expression in uterus, FUT2 expression localizes to luminal uterine epithelium by in situ hybridization, implying that this gene determines expression of cell surface Fuc alpha1 --> 2Gal beta epitopes proposed to mediate blastocyst adhesion.	Univ Michigan, Dept Obstet & Gynecol, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Domino, SE (corresponding author), Univ Michigan, Dept Obstet & Gynecol, Sch Med, 6428 Med Sci Bldg 1,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	sedomino@med.umich.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001195] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932] Funding Source: Medline; NICHD NIH HHS [K08 HD01195] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMANT DR, 1986, DEV BIOL, V116, P519, DOI 10.1016/0012-1606(86)90152-1; ARMANT DR, 1986, P NATL ACAD SCI USA, V83, P6751, DOI 10.1073/pnas.83.18.6751; BARBIAZ BS, 1988, BIOL REPROD, V39, P699; BENNETT G, 1978, AM J ANAT, V152, P223, DOI 10.1002/aja.1001520205; BIOL MC, 1992, BIOCHIM BIOPHYS ACTA, V1133, P206, DOI 10.1016/0167-4889(92)90070-R; BLOCH KD, 1987, CURRENT PROTOCOLS MO; BROWN T, 1993, CURRENT PROTOCOLS MO; Brown T., 1997, CURRENT PROTOCOLS MO; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; CARSON DD, 1994, INT J BIOCHEM, V26, P1269, DOI 10.1016/0020-711X(94)90096-5; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CHAVEZ DJ, 1985, BIOL REPROD, V32, P1135, DOI 10.1095/biolreprod32.5.1135; CLARK MA, 1995, CELL TISSUE RES, V282, P455, DOI 10.1007/BF00318877; CROSS JC, 1994, SCIENCE, V266, P1508, DOI 10.1126/science.7985020; DAS SK, 1994, DEVELOPMENT, V120, P1071; Domino SE, 1997, BIOCHEM J, V327, P105, DOI 10.1042/bj3270105; DUTT A, 1987, DEV BIOL, V119, P27, DOI 10.1016/0012-1606(87)90203-X; DUTT A, 1988, J BIOL CHEM, V263, P2270; Enders AC, 1976, J REPROD FERTIL    S, V25, P1; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; FARACH MC, 1987, DEV BIOL, V123, P401, DOI 10.1016/0012-1606(87)90398-8; FARR AG, 1985, J IMMUNOL, V134, P2971; FEINBERG RF, 1991, AM J PATHOL, V138, P537; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; HAGOPIAN A, 1968, ARCH BIOCHEM BIOPHYS, V128, P422, DOI 10.1016/0003-9861(68)90048-9; HARPER MJK, 1992, BAILLIERE CLIN OB GY, V6, P351, DOI 10.1016/S0950-3552(05)80092-6; Hitoshi S, 1996, J BIOL CHEM, V271, P16975, DOI 10.1074/jbc.271.28.16975; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; Hokke CH, 1998, GLYCOBIOLOGY, V8, P393, DOI 10.1093/glycob/8.4.393; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KIMBER SJ, 1988, J REPROD IMMUNOL, V12, P297, DOI 10.1016/0165-0378(88)90015-0; KIMBER SJ, 1990, J REPROD FERTIL, V89, P13, DOI 10.1530/jrf.0.0890013; KIMBER SJ, 1995, J REPROD FERTIL, V103, P75; KLIMAN HJ, 1995, AM J PATHOL, V146, P166; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LENOIR D, 1995, BBA-BIOMEMBRANES, V1234, P29, DOI 10.1016/0005-2736(94)00254-M; LESSEY BA, 1994, FERTIL STERIL, V62, P497; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; LINDENBERG S, 1988, J REPROD FERTIL, V83, P149; LINDENBERG S, 1990, J REPROD FERTIL, V89, P431, DOI 10.1530/jrf.0.0890431; NELSON JF, 1982, BIOL REPROD, V27, P327, DOI 10.1095/biolreprod27.2.327; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; ROY MJ, 1987, CELL TISSUE RES, V248, P483, DOI 10.1007/BF00216473; RUGGIEROLOPEZ D, 1991, BIOCHEM J, V279, P801, DOI 10.1042/bj2790801; SADLER JE, 1984, BIOL CARBOHYDRATES, P200; Sidhu SS, 1999, BIOL REPROD, V60, P147, DOI 10.1095/biolreprod60.1.147; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; SURVEYOR GA, 1995, ENDOCRINOLOGY, V136, P3639, DOI 10.1210/en.136.8.3639; SUTHERLAND AE, 1988, J CELL BIOL, V106, P1331, DOI 10.1083/jcb.106.4.1331; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; SVALANDER PC, 1990, J REPROD FERTIL, V88, P213; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; WHITE S, 1994, BIOL REPROD, V50, P73, DOI 10.1095/biolreprod50.1.73; WILSON O, 1990, J CELL PHYSIOL, V143, P60, DOI 10.1002/jcp.1041430108; YAMAGATA T, 1991, BIOCHEM BIOPH RES CO, V181, P1004, DOI 10.1016/0006-291X(91)92036-J	60	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23748	23756		10.1074/jbc.M100735200	http://dx.doi.org/10.1074/jbc.M100735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323419	hybrid			2022-12-27	WOS:000169531100071
J	Tiffany, HL; Lavigne, MC; Cui, YH; Wang, JM; Leto, TL; Gao, JL; Murphy, PM				Tiffany, HL; Lavigne, MC; Cui, YH; Wang, JM; Leto, TL; Gao, JL; Murphy, PM			Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; SCAVENGER RECEPTOR; MICROGLIAL CELLS; HUMAN MONOCYTE; INTERFERON-GAMMA; GENE-CLUSTER; MOUSE; NEUROTOXICITY	Amyloid-beta, the pathologic protein in Alzheimer's disease, induces chemotaxis and production of reactive oxygen species in phagocytic cells, but mechanisms have not been fully defined. Here me provide three lines of evidence that the phagocyte G protein-coupled receptor (N-formylpeptide receptor 2 (FPR2)) mediates these amyloid-beta -dependent functions in phagocytic cells. First, transfection of FPR2, but not related receptors, including the other known N-formylpeptide receptor FPR, reconstituted amyloid-beta -dependent chemotaxis and calcium flux in HEK 293 cells. Second, amyloid-beta induced both calcium flux and chemotaxis in mouse neutrophils (which express endogenous FPR2) with similar potency as in FPR2-transfected HEK 293 cells, This activity could be specifically desensitized in both cell types by preincubation with a specific FPR2 agonist, which desensitizes the receptor, or with pertussis toxin, which uncouples it from G(i)-dependent signaling. Third, specific and reciprocal desensitization of superoxide production was observed when N-formylpeptides and amyloid-beta were used to sequentially stimulate neutrophils from FPR -/- mice, which express FPR2 normally. Potential biological relevance of these results to the neuroinflamma. tion associated with Alzheimer's disease was suggested by two additional findings: first, FPR2 mRNA could be detected by PCR in mouse brain; second, induction of FPR2 expression correlated with induction of calcium flux and chemotaxis by amyloid-beta in the mouse microglial cell line N9, Further, in sequential stimulation experiments with N9 cells, N-formylpeptides and amyloid-beta were able to reciprocally cross-desensitize each other. Amyloid-beta was also a specific agonist at the human counterpart of FPR2, the FPR-like 1 receptor. These results suggest a unified signaling mechanism for linking amyloid-beta to phagocyte chemotaxis and oxidant stress in the brain.	NIAID, Mol Signaling Sect, NIH, Bethesda, MD 20892 USA; NIAID, Genet Immunotherapy Sect, Host Def Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Murphy, PM (corresponding author), NIAID, Mol Signaling Sect, NIH, Bldg 10,Rm 11N113, Bethesda, MD 20892 USA.		Gao, Ji-Liang/Y-4397-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614, ZIAAI000614, ZIAAI000615, Z01AI000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Antic A, 2000, EXP NEUROL, V161, P96, DOI 10.1006/exnr.1999.7265; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T; Bonaiuto C, 1997, J NEUROIMMUNOL, V77, P51, DOI 10.1016/S0165-5728(97)00054-4; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; Cotter RL, 1999, J LEUKOCYTE BIOL, V65, P416, DOI 10.1002/jlb.65.4.416; Cowburn RF, 1997, NEUROCHEM RES, V22, P1437, DOI 10.1023/A:1021942109490; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; DURSTIN M, 1994, BIOCHEM BIOPH RES CO, V201, P174, DOI 10.1006/bbrc.1994.1685; ElKhoury J, 1996, NATURE, V382, P716; Ferrari D, 1996, J IMMUNOL, V156, P1531; Fiala M, 1998, MOL MED, V4, P480, DOI 10.1007/BF03401753; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Flynn BL, 1999, ANN PHARMACOTHER, V33, P840, DOI 10.1345/aph.17093; GAO JL, 1993, J BIOL CHEM, V268, P25395; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hartt JK, 2000, BIOCHEM BIOPH RES CO, V272, P699, DOI 10.1006/bbrc.2000.2846; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Liang TS, 2000, BIOCHEM BIOPH RES CO, V270, P331, DOI 10.1006/bbrc.2000.2416; Liu Y, 1997, BIOCHEM BIOPH RES CO, V237, P37, DOI 10.1006/bbrc.1997.7068; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; Lorton D, 1997, MECH AGEING DEV, V94, P199, DOI 10.1016/S0047-6374(96)01847-7; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; McDonald DR, 1997, J NEUROSCI, V17, P2284; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; ROGERS J, 1996, NEUROBIOL AGING, V17, P661; SABO S, 1995, NEUROSCI LETT, V184, P25, DOI 10.1016/0304-3940(94)11159-G; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; Schulz JG, 1998, EUR J NEUROSCI, V10, P2085, DOI 10.1046/j.1460-9568.1998.00220.x; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Su SB, 1999, J IMMUNOL, V162, P5924; Sutton E. T., 1999, Journal of Submicroscopic Cytology and Pathology, V31, P313; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; TAKENOUCHI T, 1995, PEPTIDES, V16, P1019, DOI 10.1016/0196-9781(95)00084-W; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Van Muiswinkel FL, 1999, J NEUROIMMUNOL, V96, P121, DOI 10.1016/S0165-5728(99)00019-3; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y	62	132	136	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23645	23652		10.1074/jbc.M101031200	http://dx.doi.org/10.1074/jbc.M101031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316806	hybrid			2022-12-27	WOS:000169531100057
J	Glazner, GW; Camandola, S; Geiger, JD; Mattson, MP				Glazner, GW; Camandola, S; Geiger, JD; Mattson, MP			Endoplasmic reticulum D-myo-inositol 1,4,5-trisphosphate-sensitive stores regulate nuclear factor-kappa B binding activity in a calcium-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; BACKPROPAGATING ACTION-POTENTIALS; HIPPOCAMPAL SYNAPTIC PLASTICITY; TRANSCRIPTION FACTOR; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; INTRACELLULAR CALCIUM; PHOSPHATE FORMATION; CEREBRAL-ISCHEMIA	The transcription factor nuclear factor-kappaB (NF-kappaB) plays critical roles in neuronal survival and plasticity and in activation of immune responses. The activation of NF-kappaB has been closely associated with changes in intracellular calcium levels, but the relationship be tween the two remains unclear. Here we report that inhibition of endoplasmic reticulum (ER) D-myo-inositol 1,4,5-trisphosphate (IP3)-gated calcium release caused decreased basal NF-kappaB DNA-binding activity in cultured rat cortical neurons. Activation of NF-kappaB in response to tumor necrosis factor-alpha and glutamate was completely abolished when IP3 receptors were blocked, and NF-kappaB activation in response to depletion of ER calcium by thapsigargin treatment was also decreased by IP3 receptor blockade, We further investigated the relationship between IP3 receptor activation and NF-kappaB activity using a cell-free system. Microsomes enriched in the ER were isolated from adult rat cerebral cortex, resuspended, and treated with agents that induce or inhibit ER calcium release, They were then recentrifuged, and the supernatant was added to cytoplasmic extract isolated from the same source tissue. We found that microsomes released an NF-kappaB stimulating signal in response to activation of IP3 receptors or inhibition of the ER Ca2+-ATPase, but not in response to ryanodine. Studies of intact cells and cell-free preparations indicated that the signal released from the ER was not calcium and was heat- and trypsin sensitive. Our data suggest that activation of IP3 receptors is required for a major component of both constitutive and inducible NF-kappaB binding activity in neurons and that decreasing ER intraluminal calcium levels triggers release of a diffusible NF-kappaB-activating signal from the ER.	NIA, Neurosci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Univ Manitoba, Fac Med, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Manitoba; Johns Hopkins University	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, NIH, GRC 4F02,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Mattson, Mark P/F-6038-2012		NINDS NIH HHS [NS39184] Funding Source: Medline; NINR NIH HHS [NRSA467305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000313, Z01AG000313, Z01AG000312, ZIAAG000314, Z01AG000314, ZIAAG000312] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Albensi BC, 2000, SYNAPSE, V35, P151; AMRANI Y, 1995, BRIT J PHARMACOL, V114, P4, DOI 10.1111/j.1476-5381.1995.tb14896.x; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barger SW, 1996, MOL BRAIN RES, V40, P116; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BOUCHELOUCHE PN, 1990, CELL SIGNAL, V2, P479; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Chan SL, 2000, J BIOL CHEM, V275, P18195, DOI 10.1074/jbc.M000040200; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DELRIO E, 1994, J NEUROCHEM, V63, P535; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Glazner GW, 2000, J NEUROSCI, V20, P3641, DOI 10.1523/JNEUROSCI.20-10-03641.2000; Glazner GW, 2000, J NEUROCHEM, V75, P101, DOI 10.1046/j.1471-4159.2000.0750101.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Guerrini L, 1997, J NEUROSCI, V17, P6057; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Harris KM, 1999, P NATL ACAD SCI USA, V96, P12213, DOI 10.1073/pnas.96.22.12213; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Huang EP, 1998, ESSAYS BIOCHEM, V33, P165, DOI 10.1042/bse0330165; HUGHES AR, 1990, ENVIRON HEALTH PERSP, V84, P141, DOI 10.2307/3430715; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Kanno T, 1996, J IMMUNOL, V157, P5277; Kato BM, 1999, J NEUROPHYSIOL, V81, P1587, DOI 10.1152/jn.1999.81.4.1587; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Lazaar AL, 1998, J IMMUNOL, V161, P3120; Liu HN, 1997, EUR J PHARMACOL, V338, P277, DOI 10.1016/S0014-2999(97)81931-0; Liu JSH, 2000, J NEUROSCI, V20, P5292, DOI 10.1523/JNEUROSCI.20-14-05292.2000; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MAY W, 1998, BRAIN RES, V797, P243; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; Nakamura T, 2000, J NEUROSCI, V20, P8365, DOI 10.1523/JNEUROSCI.20-22-08365.2000; Nakamura T, 1999, NEURON, V24, P727, DOI 10.1016/S0896-6273(00)81125-3; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; Quinlan KL, 1999, J IMMUNOL, V163, P5656; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; RECASENS M, 1995, ANN NY ACAD SCI, V757, P418, DOI 10.1111/j.1749-6632.1995.tb17501.x; Reyes M, 1996, J NEUROSCI, V16, P5951; Rong YQ, 1996, J NEUROCHEM, V67, P662; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SEI Y, 1995, IMMUNOL LETT, V45, P75, DOI 10.1016/0165-2478(94)00250-U; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; Shatrov VA, 1997, BIOCHEM BIOPH RES CO, V234, P121, DOI 10.1006/bbrc.1997.6598; STEVENS CF, 1994, NEURON, V13, P769, DOI 10.1016/0896-6273(94)90244-5; SWINGLER S, 1992, AIDS RES HUM RETROV, V8, P487, DOI 10.1089/aid.1992.8.487; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; Yao CJ, 1999, J NEUROCHEM, V73, P457, DOI 10.1046/j.1471-4159.1999.0730457.x; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	82	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22461	22467		10.1074/jbc.M101315200	http://dx.doi.org/10.1074/jbc.M101315200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309390	hybrid			2022-12-27	WOS:000169412700066
J	Dreier, B; Beerli, RR; Segal, DJ; Flippin, JD; Barbas, CF				Dreier, B; Beerli, RR; Segal, DJ; Flippin, JD; Barbas, CF			Development of zinc finger domains for recognition of the 5 '-ANN-3 ' family of DNA sequences and their use in the construction of artificial transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLING GENE-EXPRESSION; CRYSTAL-STRUCTURE; PHAGE DISPLAY; FACTOR IIIA; FACTOR SP1; PROTEIN; COMPLEX; ACTIVATION; AFFINITY; DESIGN	In previous studies we have developed Cys(2)-His(2) zinc finger domains that specifically recognized each of the 16 5'-GNN-3' DNA target sequences and could be used to assemble six-finger proteins that bind 18-base pair DNA sequences (Beerli, R. R., Dreier, B., and Barbas, C. F., III (2000) Proc. Nad. Acad. Sci. U. S. A. 97,1495-1500). Such proteins provide the basis for the construction of artificial transcription factors to study gene/function relationships in the post-genomic era. Central to the universal application of this approach is the development of zinc finger domains that specifically recognize each of the 64 possible DNA triplets. Here we describe the construction of a novel phage display library that enables the selection of zinc finger domains recognizing the 5' ANN-3' family of DNA sequences. Library selections provided domains that in most cases showed binding specificity for the 3-base pair target site that they were selected to bind. These zinc finger domains were used to construct 6-finger proteins that specifically bound their 18-base pair target site with affinities in the pm to low nm range. When fused to regulatory domains, these proteins containing various numbers of 5'-ANN-3' domains were capable of specific transcriptional regulation of a reporter gene and the endogenous human ERBB-2 and ERBB-3 genes. These results suggest that modular DNA recognition by zinc finger domains is not limited to the 5'-GNN-3' family of DNA sequences and can be extended to the 5'-ANN-3' family. The domains characterized in this work provide for the rapid construction of artificial transcription factors, thereby greatly increasing the number of sequences and genes that can be targeted by DNA-binding proteins built from pre-defined zinc finger domains.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Barbas, CF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, BCC-515,N Torrey Pines Rd, La Jolla, CA 92037 USA.	carlos@scripps.edu	Segal, David/V-9126-2019; Segal, David/B-6646-2013	Segal, David/0000-0001-8962-3105; Segal, David/0000-0001-8962-3105	NCI NIH HHS [CA86258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Beerli RR, 2000, J BIOL CHEM, V275, P32617, DOI 10.1074/jbc.M005108200; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; Corbi N, 1997, FEBS LETT, V417, P71, DOI 10.1016/S0014-5793(97)01257-X; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; Elrod-Erickson M, 1998, STRUCTURE, V6, P451, DOI 10.1016/S0969-2126(98)00047-1; ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; Gogos JA, 1996, P NATL ACAD SCI USA, V93, P2159, DOI 10.1073/pnas.93.5.2159; Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; Houbaviy HB, 1996, P NATL ACAD SCI USA, V93, P13577, DOI 10.1073/pnas.93.24.13577; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Isalan M, 1998, BIOCHEMISTRY-US, V37, P12026, DOI 10.1021/bi981358z; Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617; Jamieson AC, 1996, P NATL ACAD SCI USA, V93, P12834, DOI 10.1073/pnas.93.23.12834; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Pabo CO, 2000, J MOL BIOL, V301, P597, DOI 10.1006/jmbi.2000.3918; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	45	228	288	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29466	29478		10.1074/jbc.M102604200	http://dx.doi.org/10.1074/jbc.M102604200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11340073	hybrid			2022-12-27	WOS:000170346000109
J	Aoyama, K; Nagata, M; Oshima, K; Matsuda, T; Aoki, N				Aoyama, K; Nagata, M; Oshima, K; Matsuda, T; Aoki, N			Molecular cloning and characterization of a novel dual specificity phosphatase, LMW-DSP2, that lacks the Cdc25 homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; IMMEDIATE-EARLY GENE; MAP KINASE; NEURONAL DIFFERENTIATION; HEAT-SHOCK; IN-VIVO; ACTIVATION; CASCADES; ERK2; DEPHOSPHORYLATES	A novel dual specificity phosphatase (DSP) designated LMW-DSP2 was cloned with a combination of reverse transcription-polymerase chain reaction and cDNA library screening strategies. The LMW-DSP2 open reading frame of 194 amino acids contained a single DSP catalytic domain but lacked the cdc25 homology domain, which is conserved in most known DSPs. Northern blot and reverse transcription-polymerase chain reaction analyses revealed that LMW-DSP2 was specifically expressed in testis. Recombinant LMW-DSP2 protein exhibited phosphatase activity toward an artificial low molecular weight substrate para-nitrophenyl phosphate, and the activity was inhibited completely by sodium orthovanadate but not sodium fluoride, pyrophosphate, and okadaic acid. The substitution of critical amino acid residues, aspartic acid and cysteine, resulted in a dramatic reduction of phosphatase activity. Transient transfection of LMW-DSP2 in COS7 cells resulted in the expression of a 21-kDa protein, and the phosphatase was shown to be distributed in both the cytosol and the nucleus, LMW-DSP2 dephosphorylated and deactivated p38, to a higher extent, and stress-activated protein kinase (SAPK)/c-Jun N-tenninal kinase (JNK), but not extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases, in transfected COS7 cells and in vitro. Interestingly, mutation in a conserved docking motif of p38 and SAPK/JNK as well as in a cluster of aspartic acids of LMW-DSP2 did not affect the deactivation of the mitogen-activated protein kinases by LMW-DSP2. Furthermore, the binding between LMW-DSP2 and p38 and SAPK/JNK was also not disrupted by such mutations. Among the DSPs lacking the cdc25 homology domain, LMW-DSP2 is the first one that dephosphorylates and deactivates p38 and SAPK/JNK.	Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Aoki, N (corresponding author), Nagoya Univ, Dept Appl Mol Biosci, Grad Sch Bioagr Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1993, ONCOGENE, V8, P2015; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Aoyama K, 1999, BIOCHEM BIOPH RES CO, V266, P523, DOI 10.1006/bbrc.1999.1845; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dowd S, 1998, J CELL SCI, V111, P3389; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; King AG, 1995, ONCOGENE, V11, P2553; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nakamura K, 1999, BIOCHEM J, V344, P819, DOI 10.1042/0264-6021:3440819; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Ohsugi M, 1997, J BIOL CHEM, V272, P33092, DOI 10.1074/jbc.272.52.33092; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V194, P930, DOI 10.1006/bbrc.1993.1910; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0	46	36	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27575	27583		10.1074/jbc.M100408200	http://dx.doi.org/10.1074/jbc.M100408200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346645	hybrid, Green Published			2022-12-27	WOS:000169966900111
J	Boren, J; Lookene, A; Makoveichuk, E; Xiang, SQ; Gustafsson, M; Liu, HQ; Talmud, P; Olivecrona, G				Boren, J; Lookene, A; Makoveichuk, E; Xiang, SQ; Gustafsson, M; Liu, HQ; Talmud, P; Olivecrona, G			Binding of low density lipoproteins to lipoprotein lipase is dependent on lipids but not on apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TO-RETENTION HYPOTHESIS; N-TERMINAL 17-PERCENT; HEPARAN-SULFATE; EXPRESSION; SURFACE; INCREASES; PLASMA; LDL; ATHEROSCLEROSIS; PROTEOGLYCANS	Lipoprotein lipase (LPL) efficiently mediates the binding of lipoprotein particles to lipoprotein receptors and to proteoglycans at cell surfaces and in the extracellular matrix. It has been proposed that LPL increases the retention of atherogenic Lipoproteins in the vessel wall and mediates the uptake of lipoproteins in cells, thereby promoting lipid accumulation and plaque formation. We investigated the interaction between LPL and low density lipoproteins (LDLs) with special reference to the protein-protein interaction between LPL and apolipoprotein B (apoB). Chemical modification of lysines and arginines in apoB or mutation of its main proteoglycan binding site did not abolish the interaction of LDL with LPL as shown by surface plasmon resonance (SPR) and by experiments with THP-I macrophages. Recombinant LDL with either apoB100 or apoB48 bound with similar affinity. In contrast, partial delipidation of LDL markedly decreased binding to LPL. In cell culture experiments, phosphatidylcholine-containing liposomes competed efficiently with LDL for binding to LPL. Each LDL particle bound several (up to 15) LPL dimers as determined by SPR and by experiments with THP-I macrophages. A recombinant NH2-terminal fragment of apoB (apoB17) bound with low affinity to LPL as shown by SPR, but this interaction was completely abolished by partial delipidation of apoB17. me conclude that the LPL-apoB interaction is not significant in brid,bing LDL to cell surfaces and matrix components; the main interaction is between LPL and the LDL lipids.	Gothenburg Univ, Wallenberg Lab, S-41345 Gothenburg, Sweden; Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden; NICPB, EE-12618 Tallinn, Estonia; UCL, Rayne Inst, Dept Med, Div Cardiovasc Genet, London WC1E 6JJ, England	University of Gothenburg; Umea University; National Institute of Chemical Physics & Biophysics (NICPB); University of London; King's College London; University College London	Boren, J (corresponding author), Sahlgrens Univ Hosp, Wallenberg Lab, S-41545 Gothenburg, Sweden.	jan.boren@wlab.wall.gu.se	Talmud, Philippa J/C-4402-2008	Talmud, Philippa/0000-0002-5560-1933				AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Beisiegel U, 1996, ATHEROSCLEROSIS, V124, P1, DOI 10.1016/0021-9150(95)05792-7; BENGTSSON G, 1980, EUR J BIOCHEM, V106, P549, DOI 10.1111/j.1432-1033.1980.tb04602.x; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Boren J, 1996, GENOME RES, V6, P1123, DOI 10.1101/gr.6.11.1123; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BOREN J, 1992, J BIOL CHEM, V267, P9858; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; Choi SY, 1997, J LIPID RES, V38, P77; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; Clee SM, 2000, J LIPID RES, V41, P521; EDWARDS IJ, 1993, J LIPID RES, V34, P1155; ELOVSON J, 1988, J LIPID RES, V29, P1461; ESTERBAUER H, 1987, J LIPID RES, V28, P495; Gaus K, 1999, J COLLOID INTERF SCI, V217, P111, DOI 10.1006/jcis.1999.6333; Goldberg IJ, 1996, J LIPID RES, V37, P693; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HELMKAMP RW, 1967, INT J APPL RADIAT IS, V18, P747, DOI 10.1016/0020-708X(67)90012-9; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Herscovitz H, 2001, J LIPID RES, V42, P51; Hussain MM, 2000, J BIOL CHEM, V275, P29324, DOI 10.1074/jbc.M005317200; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; MacPhee CE, 1997, J LIPID RES, V38, P1649; Makoveichuk E, 1998, BIOCHEM BIOPH RES CO, V252, P703, DOI 10.1006/bbrc.1998.9596; Mann WA, 1999, ATHEROSCLEROSIS, V145, P61, DOI 10.1016/S0021-9150(99)00015-5; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; McNamara JR, 1996, J LIPID RES, V37, P1924; Mead JR, 1999, FEBS LETT, V462, P1, DOI 10.1016/S0014-5793(99)01495-7; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Olin KL, 1999, J BIOL CHEM, V274, P34629, DOI 10.1074/jbc.274.49.34629; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Olivecrona T, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P223; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; Pang L, 1996, J BIOL CHEM, V271, P19518, DOI 10.1074/jbc.271.32.19518; Pentikainen MO, 2000, J BIOL CHEM, V275, P5694, DOI 10.1074/jbc.275.8.5694; Podrez EA, 2000, J LIPID RES, V41, P1455; RENIER G, 1993, ARTERIOSCLER THROMB, V13, P190, DOI 10.1161/01.ATV.13.2.190; SAXENA U, 1995, ARTERIOSCL THROM VAS, V15, P1240, DOI 10.1161/01.ATV.15.8.1240; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; Semenkovich CF, 1998, J LIPID RES, V39, P1141; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; WALLINDER L, 1984, BIOCHIM BIOPHYS ACTA, V795, P513, DOI 10.1016/0005-2760(84)90181-4; Wang XS, 2000, ATHEROSCLEROSIS, V150, P357, DOI 10.1016/S0021-9150(99)00413-X; Weinberg RB, 2000, J LIPID RES, V41, P1419; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P10143, DOI 10.1073/pnas.88.22.10143; YOUNG SG, 1986, P NATL ACAD SCI USA, V83, P1101, DOI 10.1073/pnas.83.4.1101; Zechner R, 1997, CURR OPIN LIPIDOL, V8, P77, DOI 10.1097/00041433-199704000-00005	61	40	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26916	26922		10.1074/jbc.M011090200	http://dx.doi.org/10.1074/jbc.M011090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11331277	hybrid			2022-12-27	WOS:000169966900026
J	Persad, S; Attwell, S; Gray, V; Mawji, N; Deng, JT; Leung, D; Yan, J; Sanghera, J; Walsh, MP; Dedhar, S				Persad, S; Attwell, S; Gray, V; Mawji, N; Deng, JT; Leung, D; Yan, J; Sanghera, J; Walsh, MP; Dedhar, S			Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase - Critical roles for kinase activity and amino acids arginine 211 and serine 343	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PHOSPHOINOSITIDE-3-OH KINASE; EXTRACELLULAR-MATRIX; ILK; ACTIVATION; APOPTOSIS; ADHESION; PDK1; PATHWAYS; DOMAIN	Protein kinase B (PKB/Akt) is a regulator of cell survival and apoptosis. To become fully activated, PKB/Akt requires phosphorylation at two sites, threonine 308 and serine 473, in a phoshpatidylinositol (PI) 3-kinase-dependent manner. The kinase responsible for phosphorylation of threonine 308 is the PI 3-kinase-dependent kinase-1 (PDK-1), whereas phosphorylation of serine 473 has been suggested to be regulated by PKB/Akt autophosphorylation in a PDK-1-dependent manner. However, the integrin-linked kinase (ILK) has also been shown to regulate phosphorylation of serine 473 in a PI 3-kinase-dependent manner. Whether ILK phosphorylates this site directly or functions as an adapter molecule has been debated. We now show by in-gel kinase assay and matrix-assisted laser desorption-ionization time-of-flight mass spectrometry that biochemically purified ILK can phosphorylate PKB/Akt directly. Co-immunoprecipitation analysis of cell extracts demonstrates that ILK can complex with PKB/Akt as well as PDK-1 and that ILK can disrupt PDK-1/PKB association. The amino acid residue serine 343 of ILK within the activation loop is required for kinase activity as well as for its interaction with PKB/Akt. Mutational analysis of ILK further shows a crucial role for arginine 211 of ILK within the phosphoinositide phospholipid binding domain in the regulation of PKB- serine 473 phosphorylation. A highly selective small molecule inhibitor of ILK activity also inhibits the ability of ILK to phosphorylate PKB/Akt in vitro and in intact cells. These data demonstrate that ILK is an important upstream kinase for the regulation of PKB/Akt.	Vancouver Hosp, British Columbia Canc Agcy, Hlth Sci Ctr, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ Calgary, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Canadian Inst Hlth, Res Grp Regulat Vasc Contractil, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Kinetek Pharmaceut Inc, Vancouver, BC V6P 6P2, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	British Columbia Cancer Agency; University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Calgary; University of British Columbia	Dedhar, S (corresponding author), Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.			Dedhar, Shoukat/0000-0003-4355-1657				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; KHAWJA A, 1997, EMBO J, V16, P2783; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	33	406	432	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27462	27469		10.1074/jbc.M102940200	http://dx.doi.org/10.1074/jbc.M102940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313365	hybrid			2022-12-27	WOS:000169966900097
J	Shen, YL; Musti, K; Hiramoto, M; Kikuchi, H; Kawarabayashi, Y; Matsui, I				Shen, YL; Musti, K; Hiramoto, M; Kikuchi, H; Kawarabayashi, Y; Matsui, I			Invariant Asp-1122 and Asp-1124 are essential residues for polymerization catalysis of family D DNA polymerase from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTHERMOPHILIC ARCHAEON; REPLICATION; COMPILATION; ALIGNMENT; FURIOSUS; ENZYMES; ALPHA	Family D DNA polymerase has recently been found in the Euryarchaeota subdomain of Archaea. Its genes are adjacent to several other genes related to DNA replication, repair, and recombination in the genome, suggesting that this enzyme may be the major DNA replicase in Euryarchaeota. Although it, possesses strong polymerization and proofreading activities, the motifs common to other DNA polymerase families are absent in its sequences. Here we report the mapping of the catalytic residues in a family D DNA polymerase from Pyrococcus horikoshii. Site-directed alanine mutants for 28 conserved aspartic acid or glutamic acid residues mere screened for polymerization and 3'-5' exonuclease activities. We identified the invariant aspartates Asp-1122 and Asp-1124 within the most conserved motif as the catalytic residues involved in DNA polymerization. Alanine mutation at either site caused a loss of polymerization activity, whereas the conserved mutants, D1122E, D1124N, and D1124E, had slightly reduced polymerization activity. We also found that the 3'-5' exonuclease activity remains in D1122A and D1124A, indicating that the catalytic residues of DNA polymerization are different from those of the 3'-5' exonuclease activity. Furthermore me determined the molecular mass of the recombinant enzyme by gel filtration and proposed a heterotetrameric structure for this enzyme.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Minist Int Trade & Ind, Natl Inst Technol & Evaluat, Shibuya Ku, Tokyo 150, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan.							Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; Gangurde R, 2000, J BIOL CHEM, V275, P19685, DOI 10.1074/jbc.M002307200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Imamura M, 1995, BIOL PHARM BULL, V18, P1647; Ishino Y, 1998, J BACTERIOL, V180, P2232, DOI 10.1128/JB.180.8.2232-2236.1998; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	20	44	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27376	27383		10.1074/jbc.M011762200	http://dx.doi.org/10.1074/jbc.M011762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11319225	hybrid			2022-12-27	WOS:000169966900086
J	Hartness, ME; Lewis, A; Searle, GJ; O'Kelly, I; Peers, C; Kemp, PJ				Hartness, ME; Lewis, A; Searle, GJ; O'Kelly, I; Peers, C; Kemp, PJ			Combined antisense and pharmacological approaches implicate hTASK as an airway O-2 sensing K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; NADPH-OXIDASE; CHEMORECEPTOR CELLS; ION CHANNELS; RAT; ACID; PH; EXPRESSION; MODULATION; HYPOXIA	Neuroepithelial bodies act as airway oxygen sensors. The lung carcinoma line H146 is an established model for neuroepithelial body cells. Although O-2 sensing in both cells is via NADPH oxidase H2O2/free radical production and acute hypoxia promotes K+ channel closure and cell depolarization, the identity of the K+ channel is still controversial. However, recent data point toward the involvement of a member of the tandem P domain family of K+ channels. Reverse transcription-polymerase chain reaction screening indicates that all known channels other than hTWIK1 and hTRAAK are expressed in H146 cells. Our detailed pharmacological characterization of the O-2-sensitive K+ current described herein is compatible with the involvement of hTASK1 or hTASK3 (pH dependence, tetraethylammonium and dithiothreitol insensitivity, blockade by arachidonic acid, and halothane activation). Furthermore, we have used antisense oligodeoxynucleotides directed against hTASK1 and hTASK3 to suppress almost completely the hTASK1 protein and show that these cells no longer respond to acute hypoxia; this behavior was not mirrored in liposome-only or missense-treated cells. Finally, we have used Zn2+ treatment as a maneuver able to discriminate between these two homologues of hTASK and show that the most likely candidate channel for O-2 sensing in these cells is hTASK3.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Cardiovasc Res Inst, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Kemp, PJ (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Med & Dent Bldg, Leeds LS2 9JT, W Yorkshire, England.	p.z.kemp@leeds.ac.uk	Hartness, Matthew/ABE-6961-2021; Kemp, Paul/A-4634-2010	Kemp, Paul/0000-0003-2773-973X; Peers, Chris/0000-0002-8354-346X				Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Conforti L, 2000, J PHYSIOL-LONDON, V524, P783, DOI 10.1111/j.1469-7793.2000.00783.x; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Fu XW, 1999, J PHYSIOL-LONDON, V514, P139, DOI 10.1111/j.1469-7793.1999.139af.x; GAZDAR AF, 1988, CANCER RES, V48, P4078; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; LAUWERYNS JM, 1973, Z ZELLFORSCH MIK ANA, V145, P521, DOI 10.1007/BF00306722; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; LESAGE F, 2000, AM J PHYSL, V793; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; LopezBarneo J, 1996, TRENDS NEUROSCI, V19, P435; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Meadows HJ, 2001, NEUROPHARMACOLOGY, V40, P551, DOI 10.1016/S0028-3908(00)00189-1; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Mojet MH, 1997, J PHYSIOL-LONDON, V504, P175, DOI 10.1111/j.1469-7793.1997.175bf.x; NECKERS L, 1993, AM J PHYSIOL, V265, pL1, DOI 10.1152/ajplung.1993.265.1.L1; O'Kelly I, 1998, AM J PHYSIOL-LUNG C, V275, pL709, DOI 10.1152/ajplung.1998.275.4.L709; O'Kelly I, 1999, AM J PHYSIOL-LUNG C, V276, pL96, DOI 10.1152/ajplung.1999.276.1.L96; O'Kelly I, 2000, J BIOL CHEM, V275, P7684, DOI 10.1074/jbc.275.11.7684; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Peers C, 1997, TRENDS PHARMACOL SCI, V18, P405; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Rashid AJ, 2001, J NEUROSCI, V21, P125, DOI 10.1523/JNEUROSCI.21-01-00125.2001; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Rudy B, 1999, ANN NY ACAD SCI, V868, P304, DOI 10.1111/j.1749-6632.1999.tb11295.x; Rychkov GY, 1997, J PHYSIOL-LONDON, V501, P355, DOI 10.1111/j.1469-7793.1997.355bn.x; Stengl M, 1998, J PHYSIOL-LONDON, V511, P827, DOI 10.1111/j.1469-7793.1998.827bg.x; Wang DS, 1996, P NATL ACAD SCI USA, V93, P13182, DOI 10.1073/pnas.93.23.13182; Youngson C, 1997, MICROSC RES TECHNIQ, V37, P101, DOI 10.1002/(SICI)1097-0029(19970401)37:1<101::AID-JEMT10>3.3.CO;2-S; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0	39	96	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26499	26508		10.1074/jbc.M010357200	http://dx.doi.org/10.1074/jbc.M010357200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344164	hybrid			2022-12-27	WOS:000169823300113
J	Tedford, HW; Fletcher, JI; King, GF				Tedford, HW; Fletcher, JI; King, GF			Functional significance of the beta-hairpin in the insecticidal neurotoxin omega-atracotoxin-Hv1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; IMPROVED BACULOVIRUS INSECTICIDE; ESCHERICHIA-COLI CYTOPLASM; PROGRAM; RESISTANCE; CONOTOXINS; EXPRESSION; MUTATIONS; PATHWAYS; PROTEINS	omega -Atracotoxin-Hv1a is an insect-specific neurotoxin whose phylogenetic specificity derives from its ability to antagonize insect, but not vertebrate, voltage-gated calcium channels. In order to help understand its mechanism of action and to enhance its utility as a lead compound for insecticide development, we used a combination of protein engineering and site-directed mutagenesis to probe the toxin for key functional regions. First, we constructed a Hairpinless mutant in which the C-terminal beta -hairpin, which is highly conserved in this family of neurotoxins, was excised without affecting the fold of the residual disulfide-rich core of the toxin. The Hairpinless mutant was devoid of insecticidal activity, indicating the functional importance of the hairpin. We subsequently developed a highly efficient system for production of recombinant toxin and then probed the hairpin for key functional residues using alanine-scanning mutagenesis followed by a second round of mutagenesis based on initial "hits" from the alanine scan. This revealed that two spatially proximal residues, Asn(27) and Arg(35), form a contiguous molecular surface that is essential for toxin activity. We propose that this surface of the beta -hairpin is a key site for interaction of the toxin with insect calcium channels.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Melbourne, Sch Biochem & Mol Biol, Melbourne, Vic 3010, Australia	University of Connecticut; University of Melbourne	King, GF (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, MC3305,263 Farmington Ave, Farmington, CT 06032 USA.		Fletcher, Jamie/V-4667-2019; King, Glenn F/J-5059-2012	King, Glenn F/0000-0002-2308-2200; Fletcher, Jamie/0000-0003-2949-9469				ATKINSON RK, 1993, Patent No. 9300039; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Billeter M, 1995, J BIOMOL NMR, V5, P1; Bonning BC, 1996, ANNU REV ENTOMOL, V41, P191, DOI 10.1146/annurev.en.41.010196.001203; BRUNGER AT, 1992, XPLOR VERSION 3 1; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; CORY JS, 1994, NATURE, V370, P138, DOI 10.1038/370138a0; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; Feyereisen R, 1995, TOXICOL LETT, V82-3, P83, DOI 10.1016/0378-4274(95)03470-6; ffrench-Constant RH, 1998, PHILOS T R SOC B, V353, P1685, DOI 10.1098/rstb.1998.0319; Fletcher JI, 1997, NAT STRUCT BIOL, V4, P559, DOI 10.1038/nsb0797-559; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Miller MK, 2000, TOXICON, V38, P409, DOI 10.1016/S0041-0101(99)00171-3; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; OERKE EC, 1994, CROP PRODUCTION CROP, P72; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; RILEY LG, 1994, EUR J BIOCHEM, V219, P877, DOI 10.1111/j.1432-1033.1994.tb18569.x; Shelton AM, 2000, NAT BIOTECHNOL, V18, P339, DOI 10.1038/73804; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STEWART LMD, 1991, NATURE, V352, P85, DOI 10.1038/352085a0; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TREACY MF, 1999, BIOPESTICIDES USES D, P321; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wang XH, 1999, EUR J BIOCHEM, V264, P488, DOI 10.1046/j.1432-1327.1999.00646.x; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2; Wuthrich K., 1986, NMR PROTEIN NUCL ACI; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	41	61	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26568	26576		10.1074/jbc.M102199200	http://dx.doi.org/10.1074/jbc.M102199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313356	hybrid			2022-12-27	WOS:000169823300121
J	Yoo, JY; Wang, WL; Desiderio, S; Nathans, D				Yoo, JY; Wang, WL; Desiderio, S; Nathans, D			Synergistic activity of STAT3 and c-Jun at a specific array of DNA elements in the alpha(2)-macroglobulin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-2-MACROGLOBULIN GENE; INTERLEUKIN-6 RESPONSIVE ELEMENT; INTERFERON-BETA ENHANCEOSOME; SIGNAL-TRANSDUCTION PATHWAY; EPIDERMAL GROWTH-FACTOR; ACUTE-PHASE RESPONSE; TRANSCRIPTIONAL ACTIVATION; REACTIVE PROTEIN; TYROSINE PHOSPHORYLATION; RECEPTOR	The transcriptional activity of natural promoters is sensitive to the precise spatial arrangement of DNA elements and their incorporation into higher order DNA-protein complexes. STAT3 and c-Jun form a specific ternary complex in vitro with a synthetic DNA element containing AP1 and SIE sites. These associations are critical for synergistic activation of transcription from a synthetic promoter by STAT3 and c-Jun. Expression of the acute phase protein alpha (2)-macroglobulin is induced in vivo by interleukin-6 (IL-6)-related cytokines; we demonstrate that coordinate interactions among STAT3, c-Jun, and a specific array of DNA elements contribute to activation of the alpha (2)-macroglobulin promoter in response to IL-6 family members. At least five promoter elements are involved in activation: two AP1 sites at -113 to -107 and -152 to -140, an acute phase response element (APRE (SIE)) at -171 to -163, and two AT-rich regions at -143 to -138 and -128 to -123. Synergism between STAT3 or STAT3-C and c-Jun is impaired by mutation of the APRE (SIE) or either AP1 site, as well as by mutations that alter the AT-rich regions or their phasing. Mutations of STAT3 previously shown to disrupt physical and functional interactions with c-Jun do not impair synergy between STAT3-C and c-Jun at the alpha2-macroglobulin promoter in HepG2 cells, suggesting that STAT3-C and STAT3 differ with respect to their precise contacts with c-Jun.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Desiderio, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CARRERA P, 1994, NUCLEIC ACIDS RES, V22, P3671, DOI 10.1093/nar/22.18.3671; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; Kasutani K, 1998, TOXICOL APPL PHARM, V151, P143, DOI 10.1006/taap.1998.8452; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Kophengnavong T, 1999, MOL CELL BIOL, V19, P3039; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Park OK, 1996, P NATL ACAD SCI USA, V93, P13704, DOI 10.1073/pnas.93.24.13704; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; TSUCHIYA Y, 1987, GENE, V57, P73; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHANG DX, 1995, BIOCHEM J, V310, P143, DOI 10.1042/bj3100143; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26421	26429		10.1074/jbc.M009935200	http://dx.doi.org/10.1074/jbc.M009935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319221	hybrid			2022-12-27	WOS:000169823300103
J	Ii, M; Mihara, K				Ii, M; Mihara, K			Insertion of mitochondrial DNA-encoded F1F0-ATPase subunit 8 across the mitochondrial inner membrane in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PF3 COAT PROTEIN; SACCHAROMYCES-CEREVISIAE; THYLAKOID MEMBRANE; ESCHERICHIA-COLI; PLASMA-MEMBRANE; ATP SYNTHASE; MESSENGER-RNAS; NUCLEAR GENE; M13 PROCOAT; C-TERMINI	Cytochrome oxidase subunits I, II, and III, the mitochondrial DNA-encoded proteins, are inserted across the inner membrane by the Oxa1p-containing translocator in a membrane potential-dependent manner. Oxa1p is also involved in the insertion of the cytoplasmically synthesized precursor of Oxa1p itself into the inner membrane from the matrix via the conservative sorting pathway. The mechanism of insertion of the other mitochondrially synthesized proteins, however, is unexplored, The insertion of the mitochondrial DNA-encoded subunit 8 of F1F0-ATPase (Su8) across the inner membrane was analyzed in vitro using the inverted inner membrane vesicles and the Escherichia coli lysate-synthesized substrate. This assay revealed that the N-terminal segment of Su8 inserted across the membrane to the intermembrane space and assumed the correct trans-cia topology depending on the mitochondrial matrix fraction. This translocation reaction was similar to those of Sec-independent, direct insertion pathways of E, coli and chloroplast thylakoid membranes. (i) It required neither nucleotide triphosphates nor membrane potential, and hydrophobic forces drove the process. (ii) It did not require protease-sensitive membrane components facing the matrix space. (iii) It could be inserted across liposomes in the correct topology in a matrix fraction-dependent manner. Thus, a novel mechanism conserved in bacteria and chloroplasts also functions in the insertion of Su8 across the mitochondrial inner membrane.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan	Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8120054, Japan.	mihara@cell.med.kyushu-u.ac.jp						Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GELLER BL, 1985, J BIOL CHEM, V260, P3281; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; HEKMAN C, 1991, J BIOL CHEM, V266, P13564; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; Ishihara N, 1998, J BIOCHEM-TOKYO, V123, P722; JASCUR T, 1991, METHOD CELL BIOL, V34, P359; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; KUHN A, 1987, SCIENCE, V238, P1413, DOI 10.1126/science.3317833; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; ODA T, 1989, BIOCHEM BIOPH RES CO, V165, P449, DOI 10.1016/0006-291X(89)91091-7; Rassow J, 1999, J MOL BIOL, V286, P105, DOI 10.1006/jmbi.1998.2455; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WELTER C, 1989, GENE, V83, P169, DOI 10.1016/0378-1119(89)90415-0; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YAMANE K, 1987, J BIOL CHEM, V262, P2358	43	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24704	24712		10.1074/jbc.M102584200	http://dx.doi.org/10.1074/jbc.M102584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320097	hybrid			2022-12-27	WOS:000169800700040
J	Kakio, A; Nishimoto, S; Yanagisawa, K; Kozutsumi, Y; Matsuzaki, K				Kakio, A; Nishimoto, S; Yanagisawa, K; Kozutsumi, Y; Matsuzaki, K			Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; SYNAPTIC PLASMA-MEMBRANES; A-BETA; PRECURSOR PROTEIN; FIBRIL FORMATION; DISEASE; PEPTIDE; BINDING; AGGREGATION; VESICLES	GM1 ganglioside-bound amyloid beta -protein (GM1/A beta), found in brains exhibiting early pathological changes of Alzheimer's disease (AD) including diffuse plaques, has been suggested to be involved in the initiation of amyloid fibril formation in vivo by acting as a seed. To elucidate the molecular mechanism underlying GM1/A beta formation, the effects of lipid composition on the binding of A beta to GM1-containing lipid bilayers were examined in detail using fluorescent dye-labeled human A beta-(1-40). Increases in not only GM1 but also cholesterol contents in the lipid bilayers facilitated the binding of A beta to the membranes by altering the binding capacity but not the binding affinity. An increase in membrane-bound A beta concentration triggered its conformational transition from helix-rich to beta -sheet-rich structures. Excimer formation of fluorescent dye-labeled GM1 suggested that A beta recognizes a GM1 "cluster" in membranes, the formation of which is facilitated by cholesterol, The results of the present study strongly suggested that increases in intramembrane cholesterol content, which are likely to occur during aging, appear to be a risk factor for amyloid fibril formation.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Engn, Dept Energy & Hydrocarbon Chem, Sakyo Ku, Kyoto 6068501, Japan; Natl Inst Longev Sci, Dept Dementia Res, Morioka, Obu 4748522, Japan; RIKEN, Glycochain Express Lab, Suprabiomol Syst Res, Frontier Res Syst, Wako, Saitama 3510198, Japan	Kyoto University; Kyoto University; RIKEN	Matsuzaki, K (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan.							Avdulov NA, 1997, J NEUROCHEM, V69, P1746; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Brown RE, 1998, J CELL SCI, V111, P1; BURDICK D, 1992, J BIOL CHEM, V267, P546; CERNY S, 1983, CHEM PHYSICS SOLID S, V2, P1; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; EPAND RM, 1983, BIOCHEMISTRY-US, V22, P5074, DOI 10.1021/bi00291a005; Esler WP, 2000, BIOCHEMISTRY-US, V39, P6288, DOI 10.1021/bi992933h; Ferraretto A, 1997, BIOCHEMISTRY-US, V36, P9232, DOI 10.1021/bi970428j; FORSTER T, 1969, ANGEW CHEM INT EDIT, V8, P333, DOI 10.1002/anie.196903331; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Igbavboa U, 1996, J NEUROCHEM, V66, P1717; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P112; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Matsuzaki K, 1999, BIOCHEMISTRY-US, V38, P4137, DOI 10.1021/bi982345o; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; MCDANIEL R, 1985, BIOCHIM BIOPHYS ACTA, V819, P153, DOI 10.1016/0005-2736(85)90169-5; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; SCHWARZ G, 1989, BIOCHIMIE, V71, P1, DOI 10.1016/0300-9084(89)90125-9; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Takakuwa T, 1985, ANAL SCI, V1, P215, DOI DOI 10.2116/ANALSCI.1.215; Terzi E, 1997, BIOCHEMISTRY-US, V36, P14845, DOI 10.1021/bi971843e; THOMPSON TE, 1985, BIOCHIM BIOPHYS ACTA, V817, P229, DOI 10.1016/0005-2736(85)90024-0; Tseng BP, 1999, BIOCHEMISTRY-US, V38, P10424, DOI 10.1021/bi990718v; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wieprecht T, 1999, BIOCHEMISTRY-US, V38, P10377, DOI 10.1021/bi990913+; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P442, DOI 10.1021/bi992146k; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; Yanagisawa K, 1997, FEBS LETT, V420, P43, DOI 10.1016/S0014-5793(97)01484-1; Yanagisawa K, 1998, NEUROBIOL AGING, V19, pS65, DOI 10.1016/S0197-4580(98)00032-3	47	324	337	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24985	24990		10.1074/jbc.M100252200	http://dx.doi.org/10.1074/jbc.M100252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342534	hybrid			2022-12-27	WOS:000169800700074
J	Parfenyev, AN; Salminen, A; Halonen, P; Hachimori, A; Baykov, AA; Lahti, R				Parfenyev, AN; Salminen, A; Halonen, P; Hachimori, A; Baykov, AA; Lahti, R			Quaternary structure and metal ion requirement of family II pyrophosphatases from Bacillus subtilis, Streptococcus gordonii, and Streptococcus mutans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; ESCHERICHIA-COLI; MANGANESE; SUBSTITUTIONS; ENCODES; ENZYME; FORMS	Pyrophosphatase (PPase) from Bacillus subtilis has recently been found to be the first example of a family II soluble PPase with a unique requirement for Mn2+. In the present work, we cloned and overexpressed in Escherichia coli putative genes for two more family II PPases (from Streptococcus mutans and Streptococcus gordonii), isolated the recombinant proteins, and showed them to be highly specific and active PPases (catalytic constants of 1700-3300 s(-1) at 25 degreesC in comparison with 200-400 s(-1) for family I). All three family II PPases were found to be dimeric manganese metalloenzymes, dissociating into much less active monomers upon removal of Mn2+. The dimers were found to have one high affinity manganese-specific site (K-d of 0.2-3 nM for Mn2+ and 10-80 muM for Mg2+) and two or three moderate affinity sites (K-d, similar to 1 mM for both cations) per subunit, Mn2+ binding to the high affinity site, which occurs with a half-time of less than 10 s at 1.5 mM Mn2+, dramatically shifts the monomer <----> dimer equilibrium in the direction of the dimer, further activates the dimer, and allows substantial activity (60-180 s(-1)) against calcium pyrophosphate, a potent inhibitor of family I PPases.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Turku Univ, Dept Biochem, FIN-20500 Turku, Finland; Shinshu Univ, Fac Text Sci & Technol, Inst High Polymer Res, Ueda, Nagano 3868856, Japan	Lomonosov Moscow State University; Lomonosov Moscow State University; Finland National Institute for Health & Welfare; University of Turku; Shinshu University	Baykov, AA (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.		Baykov, Alexander/AAH-5301-2021; Baykov, Alexander A/C-7981-2012	Baykov, Alexander/0000-0002-2495-8200				AVAEVA SM, 2000, BIOKHIMIYA, V65, P442; Baykov A A, 1999, Prog Mol Subcell Biol, V23, P127; BAYKOV AA, 1981, ANAL BIOCHEM, V116, P1, DOI 10.1016/0003-2697(81)90313-4; Baykov AA, 1995, J BIOL CHEM, V270, P30804, DOI 10.1074/jbc.270.51.30804; BEIGHTON D, 1980, MICROBIOS, V28, P149; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARNEY J, 1951, J BACTERIOL, V62, P145, DOI 10.1128/JB.62.2.145-148.1951; CHEN J, 1990, J BACTERIOL, V172, P5686, DOI 10.1128/jb.172.10.5686-5689.1990; CHERNYAK BY, 1982, ANAL BIOCHEM, V123, P101; CHERVENKA CH, 1972, METHODS ANAL ULTRACE, P23; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; GLASS RL, 1973, ARCH ORAL BIOL, V18, P1099, DOI 10.1016/0003-9969(73)90083-6; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; KAPYLA J, 1995, BIOCHEMISTRY-US, V34, P792, DOI 10.1021/bi00003a012; Kornberg A., 1962, HORIZONS BIOCH, P251; Kuhn NJ, 1998, ARCH BIOCHEM BIOPHYS, V354, P47, DOI 10.1006/abbi.1998.0629; Kuhn NJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P292, DOI 10.1006/abbi.2000.1860; KURGANOV BI, 1982, ALLOSTERIC ENZYMES K, P151; KURILOVA SA, 1984, BIOORG KHIM+, V10, P1153; LOESCHE WJ, 1986, MICROBIOL REV, V50, P353, DOI 10.1128/MMBR.50.4.353-380.1986; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; MARTIN ME, 1986, J BIOL CHEM, V261, P9361; Merckel MC, 2001, STRUCTURE, V9, P289, DOI 10.1016/S0969-2126(01)00587-1; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MOE OA, 1972, J BIOL CHEM, V247, P7315; Salminen A, 1999, J BIOL CHEM, V274, P33898, DOI 10.1074/jbc.274.48.33898; Sambrook J., 2002, MOL CLONING LAB MANU; Shintani T, 1998, FEBS LETT, V439, P263, DOI 10.1016/S0014-5793(98)01381-7; TONO H, 1967, J BIOL CHEM, V242, P2375; TONO H, 1967, J BACTERIOL, V93, P1819, DOI 10.1128/JB.93.6.1819-1824.1967; USHIRO I, 1991, J DENT RES, V70, P1422, DOI 10.1177/00220345910700110501; Velichko IS, 1998, BIOCHEMISTRY-US, V37, P734, DOI 10.1021/bi9714823; Young TW, 1998, MICROBIOL-SGM, V144, P2563, DOI 10.1099/00221287-144-9-2563	37	60	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24511	24518		10.1074/jbc.M101829200	http://dx.doi.org/10.1074/jbc.M101829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342544	hybrid			2022-12-27	WOS:000169800700014
J	Ramulu, P; Nathans, J				Ramulu, P; Nathans, J			Cellular and subcellular localization, N-terminal acylation, and calcium binding of Caenorhabditis elegans protein phosphatase with EF-hands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-MODULATED PALMITOYLATION; NUCLEOTIDE-GATED CHANNEL; BETA-ADRENERGIC-RECEPTOR; FATTY-ACID ACYLATION; RETINAL-DEGENERATION; BETA-2-ADRENERGIC RECEPTOR; PHOTOEXCITED RHODOPSIN; SENSORY NEURONS; 48-KDA PROTEIN; AMINO-TERMINUS	The RdgC/PPEF family of serine/threonine protein phosphatases is distinguished by the presence of C-terminal EF-hands and neuron-specific expression, including frequent expression in primary sensory neurons. Here we report that the sole Caenorhabditis elegans PPEF (CePPEF) homolog is also highly expressed in primary sensory neurons and is not found outside the nervous system. Neurons expressing CePPEF include the ciliary chemosensory neurons AWE and AWC; and within these neurons, CePPEF is highly enriched in the sensory cilia. In transgenic C, elegans and in transfected 293 cells, CePPEF is membrane-associated, and the N terminus of CePPEF is necessary and sufficient for this membrane association. [H-3]Myristate and [H-3]palmitate labeling studies in 293 cells demonstrated that this association was mediated by myristoylation at Gly(2) and palmitoylation at Cys(3). Introducing the G2A or C3S mutation into CePPEF greatly reduced membrane association in 293 cells and in transgenic nematodes. A recombinant C-terminal fragment of CePPEF containing two putative EF-hands bound between one and two Ca2+ ions/protein, and mutation of residues presumed to ligand calcium in the two putative EF-hands led to diminished calcium binding. These results establish the first direct evidence for fatty acylation and calcium binding of a PPEF family member and demonstrate a remarkable conservation of sensory neuron expression among the members of this distinctive family of protein phosphatases.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CARON MG, 1976, J BIOL CHEM, V251, P2374; CELIO MR, 1996, GUIDEBOOK CALCIUMBIN; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; Colbert HA, 1997, J NEUROSCI, V17, P8259; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GREENLEE DV, 1979, BIOCHEM BIOPH RES CO, V88, P380, DOI 10.1016/0006-291X(79)92059-X; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P305; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; L'Etoile ND, 2000, NEURON, V25, P575, DOI 10.1016/S0896-6273(00)81061-2; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; Montini E, 1997, HUM MOL GENET, V6, P1137, DOI 10.1093/hmg/6.7.1137; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SELINGER Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P283, DOI 10.1016/0167-4889(93)90084-3; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Sherman PM, 1997, P NATL ACAD SCI USA, V94, P11639, DOI 10.1073/pnas.94.21.11639; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Vinos J, 1997, SCIENCE, V277, P687, DOI 10.1126/science.277.5326.687; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WARE RW, 1975, J COMP NEUROL, V162, P71, DOI 10.1002/cne.901620106; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YANG SD, 1988, J BIOL CHEM, V263, P8856; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	63	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25127	25135		10.1074/jbc.M011712200	http://dx.doi.org/10.1074/jbc.M011712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312268	hybrid			2022-12-27	WOS:000169800700094
J	Tanha, J; Xu, P; Chen, ZG; Ni, F; Kaplan, H; Narang, SA; MacKenzie, CR				Tanha, J; Xu, P; Chen, ZG; Ni, F; Kaplan, H; Narang, SA; MacKenzie, CR			Optimal design features of camelized human single-domain antibody libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ANTIBODIES; IMPROVED CARBOHYDRATE-BINDING; SMALL RECOGNITION UNITS; PHAGE DISPLAY LIBRARY; B O-ANTIGEN; V-H DOMAIN; ESCHERICHIA-COLI; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY	We have constructed a human V-H library based on a camelized V-H sequence, The library was constructed with complete randomization of 19 of the 23 CDR3 residues and was penned against two monoclonal antibody targets to generate V-H sequences for determination of the antigen contact residue positions. Furthermore, the feasibility and desirability of introducing a disulfide bridge between CDR1 and CDR3 was investigated. Sequences derived from the library showed a bias toward the use of C-terminal CDR3 residues as antigen contact residues. Mass spectrometric analyses indicated that CDR1-CDR3 disulfide formation was universal. However, surface plasmon resonance and NMR data showed that the CDR3 constraint imposed by the disulfide bridge was not always desirable. Very high yields of soluble protein products and lack of protein aggregation, as demonstrated by the quality of the H-1-N-15 HSQC spectra, indicated that the V-H sequence for library construction was a good choice. These results should be useful in the design of V-H libraries with optimal features.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Viventia Biotech Inc, Winnipeg, MB R3T 3Z1, Canada	National Research Council Canada; National Research Council Canada	MacKenzie, CR (corresponding author), Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.	roger.mackenzie@nrc.ca	Ni, Feng/AAN-6388-2020					ANAND NN, 1991, GENE, V100, P39, DOI 10.1016/0378-1119(91)90347-E; ANAND NN, 1991, J BIOL CHEM, V266, P21874; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; CONSTANTINE KL, 1993, J BIOMOL NMR, V3, P41; CONSTANTINE KL, 1992, BIOCHEMISTRY-US, V31, P5033, DOI 10.1021/bi00136a017; DAN MD, 1995, J NEUROSURG, V82, P475, DOI 10.3171/jns.1995.82.3.0475; Davies J, 1996, PROTEIN ENG, V9, P531, DOI 10.1093/protein/9.6.531; DAVIES J, 1994, FEBS LETT, V339, P285, DOI 10.1016/0014-5793(94)80432-X; DAVIES J, 1995, BIO-TECHNOL, V13, P475, DOI 10.1038/nbt0595-475; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; DENG SJ, 1994, J BIOL CHEM, V269, P9533; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harrison JL, 1996, METHOD ENZYMOL, V267, P83; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kabat EA, 1991, SEQUENCES PROTEINS I; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; MACKENZIE CR, 1994, BIO-TECHNOL, V12, P390, DOI 10.1038/nbt0494-390; MacKenzie R, 1998, J IMMUNOL METHODS, V220, P39, DOI 10.1016/S0022-1759(98)00143-4; MICELI RM, 1994, J IMMUNOL METHODS, V167, P279, DOI 10.1016/0022-1759(94)90097-3; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Reiter Y, 1999, J MOL BIOL, V290, P685, DOI 10.1006/jmbi.1999.2923; Riechmann L, 1996, J MOL BIOL, V259, P957, DOI 10.1006/jmbi.1996.0373; RIECHMANN L, 1995, J BIOMOL NMR, V6, P141, DOI 10.1007/BF00211778; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheriff S, 1996, NAT STRUCT BIOL, V3, P733, DOI 10.1038/nsb0996-733; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SLATTER M, 1999, PROGR NMR SPECTROSC, V34, P93; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Voordijk S, 2000, J MOL BIOL, V300, P963, DOI 10.1006/jmbi.2000.3890; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; [No title captured]	40	59	96	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24774	24780		10.1074/jbc.M100770200	http://dx.doi.org/10.1074/jbc.M100770200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335716	hybrid			2022-12-27	WOS:000169800700049
J	Zhang, Y; Guan, R; Jiang, J; Kopchick, JJ; Black, RA; Baumann, G; Frank, SJ				Zhang, Y; Guan, R; Jiang, J; Kopchick, JJ; Black, RA; Baumann, G; Frank, SJ			Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; BINDING PROTEIN GENERATION; JAK2 TYROSINE KINASE; EXTRACELLULAR DOMAIN; CYTOPLASMIC DOMAIN; GROUP INACTIVATION; DISULFIDE LINKAGE; INSULIN-RECEPTOR; IM-9 LYMPHOCYTES; HUMAN-SERUM	Growth hormone (GH) initiates its cellular action by properly dimerizing GH receptor (GHR). A substantial fraction of circulating GH is complexed with a high-affinity GH-binding protein (GHBP) that in many species can be generated by GHR proteolysis and shedding of the receptor's ligand-binding extracellular domain. We previously showed that this proteolysis 1) can be acutely promoted by the phorbol ester phorbol 12-myristate 13-acetate (PMA), 2) requires a metalloprotease activity, 3) generates both shed GHBP and a membrane-associated GHR transmembrane/cytoplasmic domain remnant, and 4) results in down-regulation of GHR abundance and GH signaling. Using cell culture model systems, we now explore the effects of GH treatment on inducible GHR proteolysis and GHBP shedding. In human IM-9 lymphocytes, which endogenously express GHRs, and in Chinese hamster ovary cells heterologously expressing wild-type or cytoplasmic domain internal deletion mutant rabbit GHRs, brief exposure to GH inhibited PIMA-induced GHR proteolysis (receptor loss and remnant accumulation) by 60-93%. PMA-induced shedding of GHBP from Chinese hamster ovary transfectants was also inhibited by 70% in the presence of GH. The capacity of GH to inhibit inducible GHR cleavage did not rely on JAK2-dependent GH signaling, as evidenced by its continued protection in JAK2-deficient gamma 2A rabbit GHR cells. The GH concentration dependence for inhibition of PMA-induced GHR proteolysis paralleled that for its promotion of receptor dimerization las monitored by formation of GHR disulfide linkage. Unlike GH, the GH antagonist, G120K, which binds to but fails to properly dimerize GHRs, alone did not protect against PMA-induced GHR proteolysis; G120K did, however, antagonize the protective effect of GH. Our data suggest that GH inhibits PMA-induced GHR proteolysis and GHBP shedding by inducing GHR dimerization and that this effect does not appear to be related to GH site 1 binding, GHR internalization, or GHR signaling. The implications of these findings with regard to GH signaling and GHR down-regulation are discussed.	Univ Alabama, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL 35294 USA; Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA; Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA; Northwestern Univ, Sch Med, Dept Med, Ctr Endocrinol Metab & Mol Med, Chicago, IL 60611 USA; Vet Adm Chicago Hlth Syst, Lakeside Div, Chicago, IL 60611 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); University System of Ohio; Ohio University; University System of Ohio; Ohio University; Northwestern University	Frank, SJ (corresponding author), Univ Alabama, Dept Med, Div Endocrinol & Metab, 1530 3rd Ave,S,BDB 861, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R29DK046395, R01DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46395] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alele J, 1998, ENDOCRINOLOGY, V139, P1927, DOI 10.1210/en.139.4.1927; ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Amit T, 1996, ENDOCRINOLOGY, V137, P3986, DOI 10.1210/en.137.9.3986; AMIT T, 1992, HORM RES, V37, P205, DOI 10.1159/000182313; Amit T, 2000, J CLIN ENDOCR METAB, V85, P927, DOI 10.1210/jc.85.3.927; Amit T, 1999, ENDOCRINOLOGY, V140, P266, DOI 10.1210/en.140.1.266; Barnard R, 1997, J ENDOCRINOL, V153, P1, DOI 10.1677/joe.0.1530001; BAUMANN G, 1994, J ENDOCRINOL, V141, P1, DOI 10.1677/joe.0.1410001; BAUMANN G, 1989, METABOLISM, V38, P683, DOI 10.1016/0026-0495(89)90108-X; BAUMANN G, 1987, J CLIN ENDOCR METAB, V64, P657, DOI 10.1210/jcem-64-4-657; BAUMANN G, 1988, ENDOCRINOLOGY, V122, P976, DOI 10.1210/endo-122-3-976; Baumann G., 1999, GROWTH HORMONE, P37; BAUMANN G, 1989, ADV GROWTH HORMONE G, P69; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; Bick T, 1996, ENDOCRINOLOGY, V137, P3977, DOI 10.1210/en.137.9.3977; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Clark RG, 1996, ENDOCRINOLOGY, V137, P4308, DOI 10.1210/en.137.10.4308; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Dastot F, 1996, P NATL ACAD SCI USA, V93, P10723, DOI 10.1073/pnas.93.20.10723; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Flyvbjerg A, 1999, DIABETES, V48, P377, DOI 10.2337/diabetes.48.2.377; Frank SJ, 1999, ADV MOL CELL ENDOCR, V3, P1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; HARRISON SM, 1995, ENDOCRINOLOGY, V136, P651, DOI 10.1210/en.136.2.651; HERINGTON AC, 1986, BIOCHEM BIOPH RES CO, V139, P150, DOI 10.1016/S0006-291X(86)80092-4; Hermansson M, 1997, J CLIN ENDOCR METAB, V82, P421, DOI 10.1210/jc.82.2.421; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KNUTSON VP, 1995, J BIOL CHEM, V270, P24972, DOI 10.1074/jbc.270.42.24972; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; KRATZSCH J, 1995, EUR J ENDOCRINOL, V132, P306, DOI 10.1530/eje.0.1320306; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; LIM L, 1990, ENDOCRINOLOGY, V127, P1287, DOI 10.1210/endo-127-3-1287; MANNOR DA, 1991, J CLIN ENDOCR METAB, V73, P30, DOI 10.1210/jcem-73-1-30; MARTHA PM, 1991, J CLIN ENDOCR METAB, V73, P175, DOI 10.1210/jcem-73-1-175; MASSA G, 1993, ACTA ENDOCRINOL-COP, V129, P559, DOI 10.1530/acta.0.1290559; MCGUFFIN W L JR, 1976, Endocrinology, V98, P1401; MERCADO M, 1993, J CLIN ENDOCR METAB, V76, P1291, DOI 10.1210/jc.76.5.1291; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLIS PE, 1995, MOL CELL ENDOCRINOL, V111, P181, DOI 10.1016/0303-7207(95)03567-Q; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ross RJM, 1997, MOL ENDOCRINOL, V11, P265, DOI 10.1210/me.11.3.265; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SAITO Y, 1995, J BIOCHEM, V118, P521, DOI 10.1093/oxfordjournals.jbchem.a124939; Singh R, 1997, J CLIN INVEST, V100, P419, DOI 10.1172/JCI119549; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; Zhang Y, 1999, J BIOL CHEM, V274, P33072, DOI 10.1074/jbc.274.46.33072; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200	63	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24565	24573		10.1074/jbc.M101281200	http://dx.doi.org/10.1074/jbc.M101281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309389	hybrid			2022-12-27	WOS:000169800700021
J	Andersen, JP; Sorensen, TLM; Povlsen, K; Vilsen, B				Andersen, JP; Sorensen, TLM; Povlsen, K; Vilsen, B			Importance of transmembrane segment M3 of the sarcoplasmic reticulum Ca2+-ATPase for control of the gateway to the Ca2+ sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; ADENOSINE-TRIPHOSPHATASE; STALK SEGMENT; CALCIUM-PUMP; AMINO-ACIDS; ATPASE; THAPSIGARGIN; TRANSPORT; DISSOCIATION; MECHANISM	The specific functional roles of various parts of the third transmembrane segment (M3) of the sarcoplasmic reticulum Ca2+-ATPase were examined by functionally characterizing a series of mutants with multiple or single substitutions of M3 residues. Steady-state and transient kinetic measurements, assisted by computer simulation of the time and Ca2+ dependences of the phosphorylation level, were used to study the partial reaction steps of the enzyme cycle, including the binding and dissociation of Ca2+ at the high affinity cytoplasmically facing sites. The mutation Lys-Leu-Asp-Glu(255) --> Glu-ne-Glu-Ris resulted in a conspicuous increase in the rate of Ca2+ dissociation as well as a displacement of the major conformational equilibria of the phosphoenzyme and dephosphoenzyme forms. The point mutant Phe(256) --> Ala also showed an increased rate of Ca2+ dissociation, whereas a conspicuous decrease both in the rate of Ca2+ dissociation and in the rate of Ca2+ binding was found for the mutant Gly-Glu-Gln-Leu(260) --> Ile-His-Leu-Ile. These findings suggest that the NH2-terminal half of M3 is involved in control of the gateway to the Ca2+ sites. The main effect of two mutations to the COOH-terminal half of M3, Ser-Lys-Val-Ile-Ser(265) --> Thr-Gly-Val-Ala-Val and Leu-Ile-Cys-Val-Ala-Val-Trp-Leu-Ile(274) --> Phe-Leu-Gly-Val-Ser-Phe-Phe-Ile-Leu, was a block of the dephosphorylation.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Andersen, JP (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk	Sørensen, Thomas Lykke-Møller/AAA-7052-2020	Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300; Sorensen, Thomas Lykke-Moller/0000-0003-3873-3499				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FORGE V, 1993, J BIOL CHEM, V268, P10953; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1988, METHOD ENZYMOL, V157, P154; INESI G, 1994, J MEMBRANE BIOL, V141, P1; LUND S, 1988, J BIOL CHEM, V263, P1654; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1991, J BIOL CHEM, V266, P16157; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Yu MH, 1999, ARCH BIOCHEM BIOPHYS, V362, P225, DOI 10.1006/abbi.1998.1049; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	28	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23312	23321		10.1074/jbc.M102384200	http://dx.doi.org/10.1074/jbc.M102384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319233	hybrid			2022-12-27	WOS:000169531100015
J	Gong, XS; Chung, S; Fernandez-Velasco, JG				Gong, XS; Chung, S; Fernandez-Velasco, JG			Electron transfer and stability of the cytochrome b(6)f complex in a small domain deletion mutant of cytochrome f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASTOCYANIN IN-VITRO; CHLAMYDOMONAS-REINHARDTII; BC(1) COMPLEX; CRYSTAL-STRUCTURE; REDOX REACTIONS; GREEN-ALGA; BF COMPLEX; VIVO; MITOCHONDRIA; CHLOROPLASTS	The lumen segment of cytochrome f consists of a small and a large domain. The role of the small domain in the biogenesis and stability of the cytochrome b(6)f complex and electron transfer through the cytochrome b(6)f complex was studied with a small domain deletion mutant in Chlamydomonas reinhardtii. The mutant is able to grow photoautotrophically but with a slower rate than the wild type strain. The heme group is covalently attached to the polypeptide, and the visible absorption spectrum of the mutant protein is identical to that of the native protein. The kinetics of electron transfer in the mutant were measured by flash kinetic spectroscopy, Our results show that the rate for the oxidation of cytochrome f was unchanged (t(1/2) = similar to 100 mus), but the half-time for the reduction of cytochrome fis increased (t(1/2) = 32 ms; for wild type, t(1/2) = 2.1 ms). Cytochrome b(6) reduction was slower than that of the wild type by a factor of approximately 2 (t(1/2) = 8.6 ms; for wild type, t(1/2) = 4.7 ms); the slow phase of the electrochromic band shift also displayed a slower kinetics (t(1/2) = 5.5 ms; for wild type, t(1/2) = 2.7 ms). The stability of the cytochrome b(6)f complex in the mutant was examined by following the kinetics of the degradation of the individual subunits after inhibiting protein synthesis in the chloroplast. The results indicate that the cytochrome b(6)f complex in the small domain deletion mutant is less stable than in the wild type. We conclude that the small domain is not essential for the biogenesis of cytochrome f and the cytochrome b(6f) complex. However, it does have a role in electron transfer through the cytochrome b(6)f complex and contributes to the stability of the complex.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Gong, XS (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, 111 Koshland Hall, Berkeley, CA 94720 USA.	xsg20@nature.berkeley.edu		Chung, Susana/0000-0003-2729-1808	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020571] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20571] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baymann F, 1999, J BIOL CHEM, V274, P22957, DOI 10.1074/jbc.274.33.22957; Berthold D. A., 1993, Plant Molecular Biology Reporter, V11, P338, DOI 10.1007/BF02905336; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BERTSCH J, 1991, PLANT MOL BIOL, V17, P131, DOI 10.1007/BF00036814; Bron P, 1999, J MOL BIOL, V287, P117, DOI 10.1006/jmbi.1999.2604; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; Carrell CJ, 1999, BIOCHEMISTRY-US, V38, P9590, DOI 10.1021/bi9903190; Chain RK, 1995, PHOTOSYNTH RES, V46, P419, DOI 10.1007/BF00032296; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; Ejdeback M, 2000, BIOCHEMISTRY-US, V39, P5022, DOI 10.1021/bi992757c; Gong XS, 2000, EUR J BIOCHEM, V267, P1732, DOI 10.1046/j.1432-1327.2000.01168.x; Gong XS, 2000, EUR J BIOCHEM, V267, P3461, DOI 10.1046/j.1432-1327.2000.01366.x; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; GRAY JC, 1992, PHOTOSYNTH RES, V34, P359, DOI 10.1007/BF00029811; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; Hippler M, 1998, BBA-BIOENERGETICS, V1367, P1, DOI 10.1016/S0005-2728(98)00136-4; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jamshidi A, 2000, BIOPHYS J, V78, p133A; JOLIOT P, 1986, BIOCHIM BIOPHYS ACTA, V849, P211, DOI 10.1016/0005-2728(86)90027-7; Joliot P, 1998, BIOCHEMISTRY-US, V37, P10404, DOI 10.1021/bi980546m; JONES RW, 1985, PHOTOBIOCH PHOTOBIOP, V9, P119; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURAS R, 1995, BIOCHEMISTRY-US, V34, P7468, DOI 10.1021/bi00022a021; KURAS R, 1995, J BIOL CHEM, V270, P27797, DOI 10.1074/jbc.270.46.27797; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; Majeran W, 2000, PLANT CELL, V12, P137; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; MATSUMOTO T, 1991, PLANT CELL PHYSIOL, V32, P863; Mosser G, 1997, J BIOL CHEM, V272, P20263, DOI 10.1074/jbc.272.32.20263; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pearson DC, 1996, BIOPHYS J, V71, P64, DOI 10.1016/S0006-3495(96)79236-6; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Ponamarev MV, 1998, BIOCHEMISTRY-US, V37, P17199, DOI 10.1021/bi981814j; ROBERTSON DE, 1988, BIOCHIM BIOPHYS ACTA, V935, P273, DOI 10.1016/0005-2728(88)90223-X; SELAK MA, 1982, FEBS LETT, V150, P286, DOI 10.1016/0014-5793(82)80753-9; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Soriano GM, 1999, J BIOENERG BIOMEMBR, V31, P201, DOI 10.1023/A:1005463527752; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Soriano GM, 1997, BIOPHYS J, V73, P3265, DOI 10.1016/S0006-3495(97)78351-6; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xie ZY, 1998, BBA-BIOENERGETICS, V1365, P309, DOI 10.1016/S0005-2728(98)00085-1; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhou JH, 1996, J BIOL CHEM, V271, P6225, DOI 10.1074/jbc.271.11.6225	52	14	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24365	24371		10.1074/jbc.M010721200	http://dx.doi.org/10.1074/jbc.M010721200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320082	hybrid			2022-12-27	WOS:000169531100150
J	Kashani-Poor, N; Zwicker, M; Kerscher, S; Brandt, U				Kashani-Poor, N; Zwicker, M; Kerscher, S; Brandt, U			A central functional role for the 49-kDa subunit within the catalytic core of mitochondrial complex I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; QUINONE OXIDOREDUCTASE; NICKEL HYDROGENASES; BINDING	We have analyzed a series of eleven mutations in the 49-kDa protein of mitochondrial complex I (NADH:ubiquinone oxidoreductase) from Yarrowia lipolytica to identify functionally important domains in this central subunit. The mutations were selected based on sequence homology with the large subunit of [NiFe] hydrogenases, None of the mutations affected assembly of complex I, all decreased or abolished ubiquinone reductase activity. Several mutants exhibited decreased sensitivities toward ubiquinone-analogous inhibitors. Unexpectedly, seven mutations affected the properties of iron-sulfur cluster N2, a prosthetic group not located in the 49-kDa subunit, In three of these mutants cluster N2 was not detectable by electron-paramagnetic resonance spectroscopy. The fact that the small subunit of hydrogenase is homologous to the PSST subunit of complex I proposed to host cluster N2 offers a straightforward explanation for the observed, unforeseen effects on this iron-sulfur cluster. We propose that the fold around the hydrogen reactive site of [NiFe] hydrogenase is conserved in the 49-kDa subunit of complex I and has become part of the inhibitor and ubiquinone binding region. We discuss that the fourth ligand of iron-sulfur cluster N2 missing in the PSST subunit may be provided by the 49-kDa subunit.	Univ Frankfurt Klinikum, Inst Biochem 1, ZBC, Dept Biochem 1, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Brandt, U (corresponding author), Univ Frankfurt Klinikum, Inst Biochem 1, ZBC, Dept Biochem 1, Theodor Stern Kai 7,Haus 25B, D-60590 Frankfurt, Germany.	brandt@zbc.klinik.uni-frankfurt.de	Brandt, Ulrich/C-4406-2008; Brandt, Ulrich/GLV-1242-2022	Brandt, Ulrich/0000-0003-1869-6811; Brandt, Ulrich/0000-0003-1869-6811				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Barth G, 1996, NONCONVENTIONAL YEAS, P313, DOI [DOI 10.1007/978-3-642-79856-6_10, 10.1007/978-3-642-79856-6_10]; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Brandt U, 1998, BBA-BIOENERGETICS, V1364, P85; Chevallet M, 1997, EUR J BIOCHEM, V250, P451, DOI 10.1111/j.1432-1033.1997.0451a.x; Darrouzet E, 1998, FEBS LETT, V431, P34, DOI 10.1016/S0014-5793(98)00719-4; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Friedrich T, 1998, BBA-BIOENERGETICS, V1365, P215, DOI 10.1016/S0005-2728(98)00070-X; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; Kerscher S, 2001, J BIOENERG BIOMEMBR, V33, P187, DOI 10.1023/A:1010726818165; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kunkel A, 1998, EUR J BIOCHEM, V252, P467, DOI 10.1046/j.1432-1327.1998.2520467.x; Lancaster CRD, 1999, BIOCHEM SOC T, V27, P591, DOI 10.1042/bst0270591; Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHNISHI T, 1993, J BIOENERG BIOMEMBR, V25, P325, DOI 10.1007/BF00762457; Prieur I, 2001, BBA-BIOENERGETICS, V1504, P173, DOI 10.1016/S0005-2728(01)00158-X; Rich P, 1999, BIOCHEM SOC T, V27, P561, DOI 10.1042/bst0270561; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schuler F, 1999, P NATL ACAD SCI USA, V96, P4149, DOI 10.1073/pnas.96.7.4149; SLED VD, 1993, BIOCHIM BIOPHYS ACTA, V1141, P262, DOI 10.1016/0005-2728(93)90051-G; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482	29	114	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24082	24087		10.1074/jbc.M102296200	http://dx.doi.org/10.1074/jbc.M102296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11342550	hybrid			2022-12-27	WOS:000169531100114
J	Kuge, O; Yamakawa, Y; Nishijima, M				Kuge, O; Yamakawa, Y; Nishijima, M			Enhancement of transport-dependent decarboxylation of phosphatidylserine by S100B protein in permeabilized Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; MITOCHONDRIA-ASSOCIATED MEMBRANES; AMINO-ACID-SEQUENCE; BIOSYNTHETIC DEFECT; GENE-PRODUCT; CHO-K1 CELLS; ANIMAL-CELLS; SYNTHASE-I; TRANSLOCATION; MUTANT	Phosphatidylethanolamine synthesis through the phosphatidylserine (PtdSer) decarboxylation pathway requires PtdSer transport from the endoplasmic reticulum or mitochondrial-associated membrane to the mitochondrial inner membrane in mammalian cells. The transport-dependent PtdSer decarboxylation in permeabilized Chinese hamster ovary (CHO) cells was enhanced by cytosolic factors from bovine brain. A cytosolic protein factor exhibiting this enhancing activity was purified, and its amino acid sequence was partially determined. The sequence was identical to part of the amino acid sequence of an EF-hand type calcium-binding protein, S100B. A His(6)-tagged recombinant CHO S100B protein was able to remarkably enhance the transport-dependent PtdSer decarboxylation in permeabilized CHO cells. Under the standard assay conditions for PtdSer decarboxylase, the recombinant S100B protein did not stimulate PtdSer decarboxylase activity and exhibited no PtdSer decarboxylase activity. These results implicated the S100B protein in the transport of PtdSer to the mitochondrial inner membrane.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Kuge, O (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.			Kuge, Osamu/0000-0003-4962-3519				BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P811; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; ISOBE T, 1978, EUR J BIOCHEM, V89, P379, DOI 10.1111/j.1432-1033.1978.tb12539.x; KUGE O, 1986, J BIOL CHEM, V261, P5790; Kuge O, 1996, BIOCHEM J, V319, P33, DOI 10.1042/bj3190033; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; KUGE O, 1991, J BIOL CHEM, V266, P6370; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHGGER H, 1987, ANAL BIOCHEM, V166, P368; Shiao YJ, 1998, BIOCHEM J, V331, P217, DOI 10.1042/bj3310217; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1991, J BIOL CHEM, V266, P12185; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	28	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23700	23706		10.1074/jbc.M101911200	http://dx.doi.org/10.1074/jbc.M101911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320095	hybrid			2022-12-27	WOS:000169531100064
J	Panda, K; Ghosh, S; Stuehr, DJ				Panda, K; Ghosh, S; Stuehr, DJ			Calmodulin activates intersubunit electron transfer in the neuronal nitric-oxide synthase dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; L-ARGININE; SUBUNIT DIMERIZATION; BINDING; HEME; DOMAIN; TETRAHYDROBIOPTERIN; REVEALS; SITE; OXYGENASE	Neuronal nitric oxide synthase (nNOS) is composed of an oxygenase domain that binds heme, (6R)-tetrahydrobiopterin, and Arg, coupled to a reductase domain that binds FAD, FMN, and NADPH. Activity requires dimeric interaction between two oxygenase domains and calmodulin binding between the reductase and oxygenase domains, which triggers electron transfer between flavin and heme groups. We constructed four different nNOS heterodimers to determine the path of calmodulin-induced electron transfer in a nNOS dimer, A predominantly monomeric mutant of rat nNOS (G671A) and its Arg binding mutant (G671A/E592A) were used as full-length subunits, along with oxygenase domain partners that either did or did not contain the E592A mutation. The E592A mutation prevented Arg binding to the oxygenase domain in which it was present. It also prevented NO synthesis when it was located in the oxygenase domain adjacent to the full-length subunit, However, it had no effect when present in the full-length subunit (i.e. the subunit containing the reductase domain). The active heterodimer (G671A/E592A full-length subunit plus wild type oxygenase domain subunit) showed remarkable similarity with wild type homodimeric nNOS in its catalytic responses to five different forms and chimeras of calmodulin, This reveals an active involvement of calmodulin in supporting transelectron transfer between flavin and heme groups on adjacent subunits in nNOS, In summary, we propose that calmodulin functions to properly align adjacent reductase and the oxygenase domains in a nNOS dimer for electron transfer between them, leading to NO synthesis by the heme.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave,Immunol NB-3, Cleveland, OH 44195 USA.	stuehrd@ccf.org	Panda, Koustubh/E-5273-2017	Panda, Koustubh/0000-0002-4783-2221; Ghosh, Sanjay/0000-0001-8624-1494	NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Noble MA, 1999, BIOCHEMISTRY-US, V38, P16413, DOI 10.1021/bi992150w; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P7160; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	54	108	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23349	23356		10.1074/jbc.M100687200	http://dx.doi.org/10.1074/jbc.M100687200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11325964	hybrid			2022-12-27	WOS:000169531100019
J	Smith, KM; Van Etten, RA				Smith, KM; Van Etten, RA			Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; CELLULAR-RESPONSE; BINDING DOMAIN; GENE-PRODUCT; IN-VITRO; PROTEIN; MUTATION; BCR	c-Abl is a non-receptor tyrosine kinase that is activated in human leukemias by the fusion of Bcr or Tel sequences to the Abl NH, terminus. Although Bcr and Tel have little in common, both contain oligomerization domains. To determine whether oligomerization alone is sufficient to activate c-Abl, we have generated and characterized an Abl protein that can be activated selectively with the chemical inducer of dimerization, AP1510. Mutant Abl proteins with one (c4F1) or two (c4F2) copies of the AP1510 binding motif (FKBP) transformed NIH 3T3 cells in a ligand-dependent manner with the c4F2 protein 60-fold more potent than c4F1, Both chimeric proteins exhibited ligand-dependent dimerization in vivo, suggesting that the increased transformation efficiency of the c4F2 mutant reflects more effective dimerization rather than formation of higher order oligomers. In the absence of ligand, c4F2-expresssing fibroblasts morphologically reverted and arrested in G(1) In Ba/F3 cells, the c4F2 chimera exhibited Ligand-dependent kinase activation, transformation to interleukin S-independent growth, and relocalization of the fusion protein from nucleus to cytoplasm. These results demonstrate that dimerization alone is sufficient to activate the Abl kinase and provide a method to regulate conditionally c-Abl activity that will be useful for studying the normal physiological role of c-Abl and the mechanism of transformation and leukemogenesis.	Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Smith, KM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.	vanetten@cbr.med.harvard.edu		Smith, Kristen/0000-0003-0960-0937	NATIONAL CANCER INSTITUTE [R01CA072465] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623] Funding Source: NIH RePORTER; NCI NIH HHS [CA72465] Funding Source: Medline; NHLBI NIH HHS [T32-HL07623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Belshaw PJ, 1996, P NATL ACAD SCI USA, V93, P4604, DOI 10.1073/pnas.93.10.4604; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; BRASHER BB, 2001, IN PRESS ONCOGENE; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gong JG, 1999, NATURE, V399, P806; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LI WJ, 1988, ONCOGENE, V2, P559; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Okuda K, 1997, J CLIN INVEST, V100, P1708, DOI 10.1172/JCI119695; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VANETTEN RA, 1995, ONCOGENE, V10, P1977; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	53	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24372	24379		10.1074/jbc.M100786200	http://dx.doi.org/10.1074/jbc.M100786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320088	Green Published, hybrid			2022-12-27	WOS:000169531100151
J	Friedrich, U; Nicolaes, GAF; Villoutreix, BO; Dahlback, B				Friedrich, U; Nicolaes, GAF; Villoutreix, BO; Dahlback, B			Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND CLEAVAGES; BLOOD-COAGULATION; FACTOR VA(R506Q); FACTOR XA; INACTIVATION; INHIBITION; THROMBIN; COMPLEX; SITES; LOOP	Proteolytic inactivation of activated factor V (FVa) by activated protein C (APC) is a key reaction in the regulation of hemostasis. We now demonstrate the importance of a positive cluster in loop 37 of the serine protease (SP) domain of APC for the degradation of FVa. Lysine residues in APC at positions 37, 38, and 39 form a secondary binding site for FVa, which is important for cleavage of FVa at Arg-506 while having no effect on Arg-306 cleavage, In contrast, topological neighbors Lys-62, Lys-63, and Arg-74 in APC appear of minor importance in FVa degradation. This demonstrates that secondary binding exosites of APC specifically guide the proteolytic action of APC, resulting in a more favorable degradation of the 506-507 peptide bond as compared with the 306-307 bond.	Univ Lund, Wallenberg Lab, MAS, Dept Clin Chem, SE-20502 Malmo, Sweden; Univ Paris 05, INSERM, U428, F-75006 Paris, France	Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Univ Lund, Wallenberg Lab, MAS, Dept Clin Chem, SE-20502 Malmo, Sweden.		Villoutreix, Bruno/I-4565-2015; Nicolaes, Gerry A.F./A-8421-2016	Villoutreix, Bruno/0000-0002-6456-7730; Nicolaes, Gerry A.F./0000-0002-2482-0412; Dahlback, Bjorn/0000-0003-1546-0328				Cleland W W, 1979, Methods Enzymol, V63, P103; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; Esmon CT, 1997, THROMB HAEMOSTASIS, V78, P70; FRIEDRICH U, 2001, IN PRESS J BIOL CHEM; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gale AJ, 2000, BLOOD, V96, P585; Gerlitz B, 1996, J BIOL CHEM, V271, P22285, DOI 10.1074/jbc.271.37.22285; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; Knobe KE, 1999, PROTEINS, V35, P218, DOI 10.1002/(SICI)1097-0134(19990501)35:2<218::AID-PROT8>3.0.CO;2-2; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MESTERS RM, 1993, PROTEIN SCI, V2, P1482, DOI 10.1002/pro.5560020912; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Shen L, 1999, THROMB HAEMOSTASIS, V82, P72, DOI 10.1055/s-0037-1614632; Shen L, 2000, BIOCHEMISTRY-US, V39, P2853, DOI 10.1021/bi992357p; Shen L, 1999, THROMB HAEMOSTASIS, V82, P1078, DOI 10.1055/s-0037-1614332; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607; Villoutreix BO, 2001, J COMPUT AID MOL DES, V15, P13, DOI 10.1023/A:1011158717139; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	24	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23105	23108		10.1074/jbc.M103138200	http://dx.doi.org/10.1074/jbc.M103138200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309403	hybrid			2022-12-27	WOS:000169412700149
J	Mehta, D; Rahman, A; Malik, AB				Mehta, D; Rahman, A; Malik, AB			Protein kinase C-alpha signals Rho-guanine nucleotide dissociation inhibitor phosphorylation and Rho activation and regulates the endothelial cell barrier function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; THROMBIN RECEPTOR; FAMILY GTPASES; PERMEABILITY; DYSFUNCTION; ADHESION; CYTOSKELETON; INCREASE; PEPTIDE; CDC42HS	The Rho-GDP guanine nucleotide dissociation inhibitor (GDI) complexes with the GDP-bound form of Rho and inhibits its activation. We investigated the role of protein kinase C (PKC) isozymes in the mechanism of Rho activation and in signaling the loss of endothelial barrier function. Thrombin and phorbol la-myristate 13-acetate induced rapid phosphorylation of GDI and the activation of Rho-A in human umbilical venular endothelial cells. Inhibition of PKC by chelerythrine chloride abrogated the thrombin-induced GDI phosphorylation and Rho activation. Depletion of PKC prevented the thrombin-induced GDI phosphorylation and Rho activation, thereby indicating that these events occurred downstream of phorbol ester-sensitive PKC isozyme activation. The depletion of PKC or inhibition of Rho by C3 toxin also prevented the thrombin-induced decrease in transendothelial electrical resistance (a measure of increased transendothelial permeability), thus indicating that PKC-induced barrier dysfunction was mediated through Rho-dependent pathway. Using inhibitors and dominant-negative mutants, we found that Rho activation was regulated by PKC-alpha. Moreover, the stimulation of human umbilical venular endothelial cells with thrombin induced rapid association of PKC-alpha with Rho, Activated PKC-alpha but not PKC-epsilon induced marked phosphorylation of GDI in vitro. Taken together, these results indicate that PKC-alpha is critical in regulating GDI phosphorylation, Rho activation, and in signaling Rho-dependent endothelial barrier dysfunction.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mehta, D (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.	dmehta@uic.edu		Malik, Asrar/0000-0002-8205-7128	NHLBI NIH HHS [HL46350, HL45638, HL27016] Funding Source: Medline; NIGMS NIH HHS [R01 GM058531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046350, R01HL045638, R01HL027016, R37HL027016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Aschner JL, 1997, J CELL PHYSIOL, V173, P387, DOI 10.1002/(SICI)1097-4652(199712)173:3<387::AID-JCP11>3.0.CO;2-9; Bourmeyster N, 1996, BIOCHEM BIOPH RES CO, V218, P54, DOI 10.1006/bbrc.1996.0011; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Gao BC, 2000, J CELL SCI, V113, P247; GARCIA JGN, 1995, BLOOD COAGUL FIBRIN, V6, P609, DOI 10.1097/00001721-199510000-00001; GARCIA JGN, 1993, J CELL PHYSIOL, V156, P541, DOI 10.1002/jcp.1041560313; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1999, AM J PHYSIOL-LUNG C, V276, pL989, DOI 10.1152/ajplung.1999.276.6.L989; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hippenstiel S, 1998, BIOCHEM BIOPH RES CO, V245, P830, DOI 10.1006/bbrc.1998.8525; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; LUM H, 1993, J CELL BIOL, V120, P1491, DOI 10.1083/jcb.120.6.1491; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; Meacci E, 2000, FEBS LETT, V482, P97, DOI 10.1016/S0014-5793(00)02039-1; MORII N, 1995, METHOD ENZYMOL, V256, P196; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PATTERSON CE, 1994, MICROVASC RES, V48, P212, DOI 10.1006/mvre.1994.1050; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; QIAO RL, 1995, AM J PHYSIOL-CELL PH, V269, pC110, DOI 10.1152/ajpcell.1995.269.1.C110; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vuong PT, 1998, J CELL PHYSIOL, V175, P379, DOI 10.1002/(SICI)1097-4652(199806)175:3<379::AID-JCP16>3.3.CO;2-T; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116	50	215	220	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22614	22620		10.1074/jbc.M101927200	http://dx.doi.org/10.1074/jbc.M101927200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309397	hybrid			2022-12-27	WOS:000169412700087
J	Affourtit, C; Krab, K; Leach, GR; Whitehouse, DG; Moore, AL				Affourtit, C; Krab, K; Leach, GR; Whitehouse, DG; Moore, AL			New insights into the regulation of plant succinate dehydrogenase - On the role of the protonmotive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MATRIX; ALTERNATIVE OXIDASE; ELECTRON-TRANSPORT; LIGHT-SCATTERING; ADENYLATE KINASE; QUINONE POOL; MEMBRANE; CONTRACTION; RESPIRATION; CARRIER	Regulation of succinate dehydrogenase was investigated using tightly coupled potato tuber mitochondria in a novel fashion by simultaneously measuring the oxygen uptake rate and the ubiquinone (Q) reduction level. We found that the activation level of the enzyme is unambiguously reflected by the kinetic dependence of the succinate oxidation rate upon the Q-redox poise. Kinetic results indicated that succinate dehydrogenase is activated by both ATP (K-1/2 similar to 3 mum) and ADP. The carboxyatractyloside insensitivity of these stimulatory effects indicated that they occur at the cytoplasmic side of the mitochondrial inner membrane. Importantly, our novel approach revealed that the enzyme is also activated by oligomycin (K-1/2 similar to 16 nm). Time-resolved kinetic measurements of succinate dehydrogenase activation by succinate furthermore revealed that the activity of the enzyme is negatively affected by potassium. The succinate-induced activation (+/-K+) is prevented by the presence of an uncoupler. Together these results demonstrate that in vitro activity of succinate dehydrogenase is modulated by the protonmotive force. We speculate that the widely recognized activation of the enzyme by adenine nucleotides in plants is mediated in this manner. A mechanism that could account for such regulation is suggested and ramifications for its in vivo relevance are discussed.	Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England; Free Univ Amsterdam, Fac Biol, BioCtr Amsterdam, Dept Mol Cell Physiol, NL-1081 HV Amsterdam, Netherlands	University of Sussex; University of Amsterdam; Vrije Universiteit Amsterdam	Affourtit, C (corresponding author), Univ Sussex, Sch Biol Sci, Dept Biochem, Brighton BN1 9QG, E Sussex, England.	C.Affourtit@sussex.ac.uk	Affourtit, Charles/I-3958-2019	Affourtit, Charles/0000-0003-1776-9943				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1977, J BIOL CHEM, V252, P1582; ACKRELL BAC, 1977, J BIOL CHEM, V252, P6963; ACKRELL BAC, 1974, J BIOL CHEM, V249, P2021; ACKRELL BAC, 1977, FEBS LETT, V75, P249, DOI 10.1016/0014-5793(77)80097-5; ACKRELL BAC, 1975, J BIOL CHEM, V250, P7114; Affourtit C, 1999, J BIOL CHEM, V274, P6212, DOI 10.1074/jbc.274.10.6212; AFFOURTIT C, 2001, BIOCHIM BIOPHYS ACTA, V1504, P59; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; Casolo V, 1998, PLANT SCI, V136, P149, DOI 10.1016/S0168-9452(98)00114-9; DOUCE R, 1986, BIOCHIM BIOPHYS ACTA, V850, P64, DOI 10.1016/0005-2728(86)90009-5; DRANSFIELD DT, 1993, AM J PHYSIOL, V264, pC663, DOI 10.1152/ajpcell.1993.264.3.C663; FRICAUD AC, 1992, BIOCHIM BIOPHYS ACTA, V1099, P253, DOI 10.1016/0005-2728(92)90035-Z; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GUTMAN, 1971, BIOCHEMISTRY-US, V10, P4763, DOI 10.1021/bi00801a025; GUTMAN M, 1971, BIOCHEM BIOPH RES CO, V42, P1016, DOI 10.1016/0006-291X(71)90005-2; GUTMAN M, 1971, BIOCHEMISTRY-US, V10, P2726; Heldt HW, 1987, BIOCH PLANTS, V12, P49; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; KEARNEY EB, 1972, BIOCHEM BIOPH RES CO, V49, P1115, DOI 10.1016/0006-291X(72)90328-2; KEARNEY EB, 1974, J BIOL CHEM, V249, P2016; KEARNEY EB, 1972, BIOCHEM BIOPH RES CO, V46, P531, DOI 10.1016/S0006-291X(72)80171-2; KEARNEY EB, 1957, J BIOL CHEM, V229, P363; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KRAB K, 1995, J BIOENERG BIOMEMBR, V27, P387, DOI 10.1007/BF02110001; Krab K, 2000, EUR J BIOCHEM, V267, P869, DOI 10.1046/j.1432-1327.2000.01065.x; KRAB K, 1995, BIOCHEM SOC T, V23, pS289, DOI 10.1042/bst023289s; Leach GR, 1996, BIOCHEM J, V317, P313, DOI 10.1042/bj3170313; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1982, PLANT PHYSIOL, V70, P1271, DOI 10.1104/pp.70.5.1271; OESTREIC.G, 1973, PLANT PHYSIOL, V52, P622, DOI 10.1104/pp.52.6.622; Pastore D, 1999, J BIOL CHEM, V274, P26683, DOI 10.1074/jbc.274.38.26683; RUSTIN P, 1991, BIOCHEM J, V274, P249, DOI 10.1042/bj2740249; SINGER TP, 1973, PLANT PHYSIOL, V52, P616, DOI 10.1104/pp.52.6.616; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VANDENBERGEN CWM, 1994, EUR J BIOCHEM, V226, P1071; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; WHITEHOUSE DG, 1989, PLANT PHYSIOL, V91, P487, DOI 10.1104/pp.91.2.487	40	38	44	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					32567	32574		10.1074/jbc.M103111200	http://dx.doi.org/10.1074/jbc.M103111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11350973	hybrid, Green Published			2022-12-27	WOS:000170746000027
J	Andrews, RK; Gardiner, EE; Asazuma, N; Berlanga, O; Tulasne, D; Nieswandt, B; Smith, AI; Berndt, MC; Watson, SP				Andrews, RK; Gardiner, EE; Asazuma, N; Berlanga, O; Tulasne, D; Nieswandt, B; Smith, AI; Berndt, MC; Watson, SP			A novel viper venom metalloproteinase, alborhagin, is an agonist at the platelet collagen receptor GPVI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; BOTHROPS-JARARACA VENOM; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-VI; GAMMA-CHAIN; TRIMERESURUS-ALBOLABRIS; PHOSPHOLIPASE C-GAMMA-2; IB; ACTIVATION; PROTEINS	The interaction of platelet membrane glycoprotein VI (GPVI) with collagen can initiate (patho)physiological thrombus formation. The viper venom C-type lectin family proteins convulxin and alboaggregin-A activate platelets by interacting with GPVI. In this study, we isolated from white-lipped tree viper (Trimeresurus albolabris) venom, alborhagin, which is functionally related to convulxin because it activates platelets but is structurally different and related to venom metalloproteinases. Alborhagin-induced platelet aggregation (EC50, <7.5 <mu>g/ml) was inhibitable by an anti-alpha IIb beta3 antibody, CRC64, and the Src family kinase inhibitor PP1, suggesting that alborhagin activates platelets, leading to alpha IIb,beta3-dependent aggregation. Additional evidence suggested that, like convulxin, alborhagin activated platelets by a mechanism involving GPVI. First, alborhagin- and convulxin-treated platelets showed a similar tyrosine phosphorylation pattern, including a similar level of phospholipase C gamma2 phosphorylation. Second, alborhagin induced GPVI-dependent responses in GPVI-transfected K562 and Jurkat cells. Third, alborhagin-dependent aggregation of mouse platelets was inhibited by the anti-GPVI monoclonal antibody JAQ1. Alborhagin had minimal effect on convulxin binding to GPVI-expressing cells, indicating that these venom proteins may recognize distinct binding sites. Characterization of alborhagin as a GPVI agonist that is structurally distinct from convulxin demonstrates the versatility of snake venom toxins and provides a novel probe for GPVI-dependent platelet activation.	Baker Med Res Inst, Hazel & Pip Appel Vasc Biol Lab, Melbourne, Vic 8008, Australia; Baker Med Res Inst, Peptide Biol Lab, Melbourne, Vic 8008, Australia; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Witten Herdecke, Ferdinand Sauerbruch Klinikum Wuppertal, D-42117 Wuppertal, Germany	Baker Heart and Diabetes Institute; Baker Heart and Diabetes Institute; University of Oxford; Witten Herdecke University	Andrews, RK (corresponding author), Baker Med Res Inst, Hazel & Pip Appel Vasc Biol Lab, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	rkandrews@hotmail.com	Gardiner, Elizabeth/P-8716-2019; Tulasne, David/AAR-5287-2020; Tulasne, David/A-8705-2008; Gardiner, Elizabeth/E-7774-2011; Berndt, Michael C/D-5580-2012; Watson, Stephen P/Q-6292-2016	Gardiner, Elizabeth/0000-0001-9453-9688; Tulasne, David/0000-0002-6764-7242; Watson, Stephen P/0000-0002-7846-7423; Smith, Ian/0000-0002-4143-2892				Andrews RK, 1996, BIOCHEMISTRY-US, V35, P12629, DOI 10.1021/bi960704e; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Andrews RK, 2000, TOXICON, V38, P775, DOI 10.1016/S0041-0101(99)00187-7; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Asazuma N, 2001, BLOOD, V97, P3989, DOI 10.1182/blood.V97.12.3989; Berlanga O, 2000, BLOOD, V96, P2740; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; Hers I, 2000, EUR J BIOCHEM, V267, P2088, DOI 10.1046/j.1432-1327.2000.01214.x; Ichinohe T, 1997, J BIOL CHEM, V272, P63; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jeon OH, 1999, EUR J BIOCHEM, V263, P526, DOI 10.1046/j.1432-1327.1999.00525.x; KHASPEKOVA SG, 1993, BRIT J HAEMATOL, V85, P332, DOI 10.1111/j.1365-2141.1993.tb03175.x; KINI RM, 1992, TOXICON, V30, P265, DOI 10.1016/0041-0101(92)90869-7; Kini RM, 1996, TOXICON, V34, P1287, DOI 10.1016/S0041-0101(96)00107-9; Kowalska MA, 1998, THROMB HAEMOSTASIS, V79, P609; KROLL MH, 1993, J BIOL CHEM, V268, P3520; Kulkarni S, 2000, J CLIN INVEST, V105, P783, DOI 10.1172/JCI7569; Leduc M, 1998, BIOCHEM J, V333, P389, DOI 10.1042/bj3330389; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Navdaev A, 2001, BLOOD, V97, P2333, DOI 10.1182/blood.V97.8.2333; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Pasquet JM, 1999, BIOCHEM J, V342, P171, DOI 10.1042/0264-6021:3420171; PENG ML, 1992, THROMB HAEMOSTASIS, V67, P702; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHOLEY JM, 1980, NATURE, V287, P233, DOI 10.1038/287233a0; Schulte V, 2001, J BIOL CHEM, V276, P364, DOI 10.1074/jbc.M007536200; TAKEYA H, 1990, J BIOL CHEM, V265, P16068; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; Ward CM, 1996, TOXICON, V34, P1203, DOI 10.1016/0041-0101(96)00115-8; Watson SP, 1999, THROMB HAEMOSTASIS, V82, P365; WEISS HJ, 1995, THROMB HAEMOSTASIS, V74, P117	41	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28092	28097		10.1074/jbc.M011352200	http://dx.doi.org/10.1074/jbc.M011352200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11344165	hybrid			2022-12-27	WOS:000170093400047
J	Lian, GW; Ding, L; Chen, M; Liu, Z; Zhao, DQ; Ni, JZ				Lian, GW; Ding, L; Chen, M; Liu, Z; Zhao, DQ; Ni, JZ			Preparation and properties of a selenium-containing catalytic antibody as type I deiodinase mimic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; IODOTHYRONINE DEIODINASE; PARTIAL-PURIFICATION; 5'-DEIODINASE; MICROSOMES; THYROXINE; ENZYME; KIDNEY	Conversion of thyroxine (T-4) to 3,5,3'-triiodothyronine is an essential first step in controlling thyroid hormone action. Type I deiodinase (DI) can catalyze the conversion to produce the bulk of serum 3,5,3'-triiodothyronine. Acting as a mimic of DI, a selenium-containing catalytic antibody (Se-4C5) prepared by converting the serine residues of monoclonal antibody 4C5 raised against T4 into selenocysteines, can catalyze the deiodination of T4 with dithiothreitol (DTT) as cosubstrate. The mimic enzyme Se-4C5 exhibited a much greater deiodinase activity than model compound ebselen and another selenium-containing antibody Se-Hp4 against GSH. The coupling of selenocysteine with the combining pocket of antibody 4C5 endowed Se-4C5 with enzymatic activity. To probe the catalytic mechanism of the catalytic antibody, detailed kinetic studies were carried out in this paper. Investigations into the deiodinative reaction revealed the relationship between the initial velocity and substrate concentration. The characteristic parallel Dalziel plots demonstrated that Se-4C5-catalyzed reaction mechanism was ping-pong one, involving at least one covalent enzyme intermediate. The kinetic properties of the catalytic antibody were similar to those of DI, with K-m values for T-4 and DTT of approximately 0.8 muM and 1.8 muM, respectively, and a V-m value of 270 pmol per mg of protein per min. The activity could be sensitively inhibited by 6-propyl-2-thiouracil (PTU) with a K-i value of similar to 120 muM at 2.0 muM T-4 concentration. The PTU inhibition was progressively alleviated with the increasing concentration of added DTT, revealing that PTU was a competitive inhibitor for DTT.	Changchun Univ Agr & Anim Husb Sci, Inst Mil Vet Sci, Changchun 130021, Peoples R China; Chinese Acad Sci, Changchun Inst Appl Chem, Lab Rare Earth Chem & Phys, Changchun 130022, Peoples R China	Jilin University; Chinese Academy of Sciences; Changchun Institute of Applied Chemistry, CAS	Ding, L (corresponding author), Chinese Acad Sci, Changchun Inst Appl Chem, Lab Rare Earth Chem & Phys, Changchun 130022, Peoples R China.		Chen, Mo/E-8234-2010					AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BELL IM, 1993, BIOCHEMISTRY-US, V32, P3754, DOI 10.1021/bi00065a030; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; CAVALLINI D, 1966, NATURE, V212, P294, DOI 10.1038/212294a0; CHIU D, 1977, ARCH BIOCHEM BIOPHYS, V184, P209, DOI 10.1016/0003-9861(77)90344-7; Ding L, 1998, BIOCHEM J, V332, P251, DOI 10.1042/bj3320251; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GOSWAMI A, 1984, J CLIN INVEST, V74, P2097, DOI 10.1172/JCI111634; GOSWAMI A, 1990, BIOCHEM BIOPH RES CO, V173, P6, DOI 10.1016/S0006-291X(05)81013-7; HUMMEL BCW, 1985, BIOCHIM BIOPHYS ACTA, V841, P173, DOI 10.1016/0304-4165(85)90019-4; JANGHORBANI M, 1989, ANAL CHEM, V61, P701, DOI 10.1021/ac00182a013; KLAYMAN DL, 1973, J AM CHEM SOC, V95, P197, DOI 10.1021/ja00782a034; KOELER G, 1975, NATURE, V256, P495; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEONARD JL, 1978, ENDOCRINOLOGY, V103, P2137, DOI 10.1210/endo-103-6-2137; Leonard JL, 1986, THYROID HORMONE META, P189; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LOWERY OH, 1951, J BIOL CHEM, V193, P265; MOL JA, 1988, MOL CELL ENDOCRINOL, V55, P159, DOI 10.1016/0303-7207(88)90130-X; MPOKO CN, 1985, CLIN CHIM ACTA, V146, P215, DOI 10.1016/0009-8981(85)90061-0; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; Schultz PG, 1998, P NATL ACAD SCI USA, V95, P14590, DOI 10.1073/pnas.95.25.14590; VISSER TJ, 1975, BIOCHEM J, V150, P489, DOI 10.1042/bj1500489; WENDEL A, 1975, BIOCHIM BIOPHYS ACTA, V377, P211, DOI 10.1016/0005-2744(75)90303-4; Wentworth P, 1998, CURR OPIN CHEM BIOL, V2, P138, DOI 10.1016/S1367-5931(98)80046-X	28	15	18	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28037	28041		10.1074/jbc.M101942200	http://dx.doi.org/10.1074/jbc.M101942200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350963	hybrid			2022-12-27	WOS:000170093400040
J	Strang, C; Cushman, SJ; DeRubeis, D; Peterson, D; Pfaffinger, PJ				Strang, C; Cushman, SJ; DeRubeis, D; Peterson, D; Pfaffinger, PJ			A central role for the T1 domain in voltage-gated potassium channel formation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; TETRAMERIZATION DOMAIN; CRYSTAL-STRUCTURE; MEMBRANE-PROTEIN; SUBUNIT; EXPRESSION; INTERFACE; COMPLEX; BRAIN	To interpret the recent atomic structures of the Kv (voltage-dependent potassium) channel T1 domain in a functional context, we must understand both how the T1 domain is integrated into the full-length functional channel protein and what functional roles the T1 domain governs. The T1 domain clearly plays a role in restricting Kv channel subunit heteromultimerization. However, the importance of T1 tetramerization for the assembly and retention of quarternary structure within full-length channels has remained controversial. Here we describe a set of mutations that disrupt both T1 assembly and the formation of functional channels and show that these mutations produce elevated levels of the subunit monomer that becomes subject to degradation within the cell. In addition, our experiments reveal that the T1 domain lends stability to the full-length channel structure, because channels lacking the T1 containing N terminus are more easily denatured to monomers. The integration of the T1 domain ultrastructure into the full-length channel was probed by proteolytic mapping with immobilized trypsin. Trypsin cleavage yields an N-terminal fragment that is further digested to a tetrameric domain, which remains reactive with antisera to T1, and that is similar in size to the T1 domain used for crystallographic studies. The trypsin-sensitive linkages retaining the T1 domain are cleaved somewhat slowly over hours. Therefore, they seem to be intermediate in trypsin resistance between the rapidly cleaved extracellular linker between the first and second transmembrane domains, and the highly resistant T1 core, and are likely to be partially structured or contain dynamic structure. Our experiments suggest that tetrameric atomic models obtained for the T1 domain do reflect a structure that the T1 domain sequence forms early in channel assembly to drive subunit protein tetramerization and that this structure is retained as an integrated stabilizing structural element within the full-length functional channel.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Pfaffinger, PJ (corresponding author), Baylor Coll Med, Div Neurosci, S613,1 Baylor Plaza, Houston, TX 77030 USA.	ppfaff@cns.neusc.bcm.tmc.edu						AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Biggin PC, 2000, CURR OPIN STRUC BIOL, V10, P456, DOI 10.1016/S0959-440X(00)00114-7; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Choe S, 1999, TRENDS BIOCHEM SCI, V24, P345, DOI 10.1016/S0968-0004(99)01440-1; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Diedrich G, 2001, J IMMUNOL, V166, P1703, DOI 10.4049/jimmunol.166.3.1703; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; Kobertz WR, 1999, NAT STRUCT BIOL, V6, P1122; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; PFAFFINGER PJ, 1991, J NEUROSCI, V11, P918; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Schulteis CT, 1998, J BIOL CHEM, V273, P26210, DOI 10.1074/jbc.273.40.26210; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; TU L, 2000, BIOCHEMISTRY-US, V398, P24; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797	40	39	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28493	28502		10.1074/jbc.M010540200	http://dx.doi.org/10.1074/jbc.M010540200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11312262	hybrid			2022-12-27	WOS:000170093400100
J	Castric, P; Cassels, FJ; Carlson, RW				Castric, P; Cassels, FJ; Carlson, RW			Structural characterization of the Pseudomonas aeruginosa 1244 pilin glycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; CAMPYLOBACTER FLAGELLIN; NEISSERIA-MENINGITIDIS; STREPTOCOCCUS-SANGUIS; MENINGOCOCCAL PILIN; TWITCHING MOTILITY; SOMATIC ANTIGENS; GLYCOSYLATION; GLYCOPROTEIN; GENE	An antigenic similarity between lipopolysaccharide (LPS) and glycosylated pilin of Pseudomonas aeruginosa 1244 was noted. We purified a glycan-containing molecule from proteolytically digested pill and showed it to be composed of three sugars and serine. This glycan competed with pure pill and LPS for reaction with an LPS-specific monoclonal antibody, which also inhibited twitching motility by P. aeruginosa bearing glycosylated pill. One-dimensional NMR analysis of the glycan indicated the sugars to be 5N beta OHC(4)7NfmPse, Xyl, and FucNAc. The complete proton assignments of these sugars as well as the serine residue were determined by COSY and TOCSY. Electrospray ionization mass spectrometry (MS) determined the mass of this molecule to be 771.5. The ROESY NMR spectrum, tandem MS/MS analysis, and methylation analysis provided information on linkage and the sequence of oligosaccharide components. These data indicated that the molecule had the following structure: alpha -5N beta OHC(4)7NFmPse-(2 -->4)-beta -Xyl-(1 -->3)-beta -FucNAc-(1 -->3)-beta -Ser.	Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA; Walter Reed Army Med Ctr, Dept Enter Infect, Washington, DC 20307 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	Duquesne University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University System of Georgia; University of Georgia	Castric, P (corresponding author), Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI043317] Funding Source: NIH RePORTER; NIAID NIH HHS [R15 AI43317] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGYAL SJ, 1979, CARBOHYD RES, V77, P37, DOI 10.1016/S0008-6215(00)83791-X; BOCK K, 1994, J BIOL CHEM, V269, P7137; BODEY GP, 1983, REV INFECT DIS, V5, P279; BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022; Brimer CD, 1998, J BACTERIOL, V180, P3209, DOI 10.1128/JB.180.12.3209-3217.1998; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; CASSELS FJ, 1989, J BACTERIOL, V171, P4019, DOI 10.1128/jb.171.7.4019-4025.1989; CASTRIC P, 1995, MICROBIOL-UK, V141, P1247, DOI 10.1099/13500872-141-5-1247; CASTRIC PA, 1994, INFECT IMMUN, V62, P371, DOI 10.1128/IAI.62.2.371-376.1994; CASTRIC PA, 1969, J BIOL CHEM, V244, P4089; CASTRIC PA, 1989, MOL GEN GENET, V216, P75, DOI 10.1007/BF00332233; Comolli JC, 1999, INFECT IMMUN, V67, P3625, DOI 10.1128/IAI.67.7.3625-3630.1999; CROSS AS, 1993, J INFECT DIS, V167, P112, DOI 10.1093/infdis/167.1.112; Davey ME, 2000, MICROBIOL MOL BIOL R, V64, P847, DOI 10.1128/MMBR.64.4.847-867.2000; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; FROST LS, 1977, J BACTERIOL, V131, P259, DOI 10.1128/JB.131.1.259-269.1977; GHEBREGZABHER M, 1976, J CHROMATOGR, V127, P133, DOI 10.1016/S0021-9673(00)80168-5; Hahn HP, 1997, GENE, V192, P99, DOI 10.1016/S0378-1119(97)00116-9; HAMADEH RM, 1995, INFECT IMMUN, V63, P4900, DOI 10.1128/IAI.63.12.4900-4906.1995; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; IRVIN RT, 1990, MICROBIAL CELL SURFA, P137; Kang PJ, 1997, MOL MICROBIOL, V24, P1249; KNIREL YA, 1990, CRIT REV MICROBIOL, V17, P273, DOI 10.3109/10408419009105729; KNIREL YA, 1987, EUR J BIOCHEM, V163, P639, DOI 10.1111/j.1432-1033.1987.tb10913.x; Lanyi B., 1978, METHOD MICROBIOL, V10, P93; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; LEE KK, 1994, MOL MICROBIOL, V11, P705, DOI 10.1111/j.1365-2958.1994.tb00348.x; LIU PV, 1983, INT J SYST BACTERIOL, V33, P256, DOI 10.1099/00207713-33-2-256; LOGAN SM, 1989, J BACTERIOL, V171, P3031, DOI 10.1128/jb.171.6.3031-3038.1989; Marceau M, 1998, MOL MICROBIOL, V27, P705, DOI 10.1046/j.1365-2958.1998.00706.x; MCMICHAEL JC, 1992, J GEN MICROBIOL, V138, P2687, DOI 10.1099/00221287-138-12-2687; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; PARANCHYCH W, 1988, ADV MICROB PHYSIOL, V29, P53, DOI 10.1016/S0065-2911(08)60346-X; PARANCHYCH W, 1979, CAN J MICROBIOL, V25, P1175, DOI 10.1139/m79-182; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAMPHAL R, 1991, INFECT IMMUN, V59, P1307, DOI 10.1128/IAI.59.4.1307-1311.1991; Sadoff J C, 1985, Antibiot Chemother (1971), V36, P134; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; Stimson E, 1996, BIOCHEM J, V316, P29, DOI 10.1042/bj3160029; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; VIRJI M, 1993, MOL MICROBIOL, V10, P1013, DOI 10.1111/j.1365-2958.1993.tb00972.x; WIELAND F, 1985, J BIOL CHEM, V260, P5180; WIELAND F, 1983, P NATL ACAD SCI-BIOL, V80, P5470, DOI 10.1073/pnas.80.18.5470; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	49	158	169	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26479	26485		10.1074/jbc.M102685200	http://dx.doi.org/10.1074/jbc.M102685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342554	hybrid			2022-12-27	WOS:000169823300110
J	Desmyter, A; Decanniere, K; Muyldermans, S; Wyns, L				Desmyter, A; Decanniere, K; Muyldermans, S; Wyns, L			Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANONICAL STRUCTURES; CRYSTAL-STRUCTURE; VH DOMAINS; CONFORMATIONS; FRAGMENTS; SEQUENCES; SELECTION; PROGRAM; CRYSTALLOGRAPHY; IMMUNOGLOBULINS	Detailed knowledge on antibody-antigen recognition is scarce given the unlimited antibody specificities of which only few have been investigated at an atomic level. We report the crystal structures of an antibody fragment derived from a camel heavy chain antibody against carbonic anhydrase, free and in complex with antigen. Surprisingly, this single-domain antibody interacts with nanomolar affinity with the antigen through its third hypervariable loop (19 amino acids long), providing a flat interacting surface of 620 Angstrom (2). For the first time, a single-domain antibody is observed with its first hypervariable loop adopting a type-1 canonical structure. The second hypervariable loop, of unique size due to a somatic mutation, reveals a regular p-turn, The third hypervariable loop covers the remaining hypervariable loops and the side of the domain that normally interacts with the variable domain of the light chain, Specific amino acid substitutions and reoriented side chains reshape this side of the domain and increase its hydrophilicity, Of interest is the substitution of the conserved Trp-103 by Arg because it opens new perspectives to 'humanize' a camel variable domain of heavy chain of heavy chain antibody (VHH) or to 'camelize' a human or a mouse variable domain of heavy chain of conventional antibody (VH).	Free Univ Brussels VIB, Dept Ultrastruct, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Desmyter, A (corresponding author), Free Univ Brussels VIB, Dept Ultrastruct, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	aldesmtr@vub.ac.be	Muyldermans, Serge/AAC-7374-2019; Muyldermans, Serge V/C-6418-2016	Muyldermans, Serge/0000-0002-3678-3575; Muyldermans, Serge V/0000-0002-3678-3575				AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger A. T., 1992, SYSTEM XRAY CRYSTALL; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; Chothia C, 1998, J MOL BIOL, V278, P457, DOI 10.1006/jmbi.1998.1653; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; Davies J, 1996, PROTEIN ENG, V9, P531, DOI 10.1093/protein/9.6.531; DAVIES J, 1995, BIO-TECHNOL, V13, P475, DOI 10.1038/nbt0595-475; Decanniere K, 1999, STRUCTURE, V7, P361, DOI 10.1016/S0969-2126(99)80049-5; Decanniere K, 2000, J MOL BIOL, V300, P83, DOI 10.1006/jmbi.2000.3839; Desmyter A, 1996, NAT STRUCT BIOL, V3, P803, DOI 10.1038/nsb0996-803; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; Frenken LGJ, 2000, J BIOTECHNOL, V78, P11, DOI 10.1016/S0168-1656(99)00228-X; Ghahroudi MA, 1997, FEBS LETT, V414, P521, DOI 10.1016/S0014-5793(97)01062-4; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Hubbard SJ, 1993, NACCESS COMPUTER PRO; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; KABAT EA, 1991, J IMMUNOL, V147, P1709; Kabat EA, 1991, US PUBLIC HLTH SERVI; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Muyldermans S, 1999, J MOL RECOGNIT, V12, P131, DOI 10.1002/(SICI)1099-1352(199903/04)12:2<131::AID-JMR454>3.0.CO;2-M; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK, P107; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Riechmann L, 1996, J MOL BIOL, V259, P957, DOI 10.1006/jmbi.1996.0373; Riechmann L, 1999, J IMMUNOL METHODS, V231, P25, DOI 10.1016/S0022-1759(99)00138-6; Schaffitzel C, 1999, J IMMUNOL METHODS, V231, P119, DOI 10.1016/S0022-1759(99)00149-0; Sheriff S, 1996, NAT STRUCT BIOL, V3, P733, DOI 10.1038/nsb0996-733; Shirai H, 1999, FEBS LETT, V455, P188, DOI 10.1016/S0014-5793(99)00821-2; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; Spinelli S, 1996, NAT STRUCT BIOL, V3, P752, DOI 10.1038/nsb0996-752; Spinelli S, 2000, BIOCHEMISTRY-US, V39, P1217, DOI 10.1021/bi991830w; Transue TR, 1998, PROTEINS, V32, P515, DOI 10.1002/(SICI)1097-0134(19980901)32:4<515::AID-PROT9>3.0.CO;2-E; van der Linden R, 2000, J IMMUNOL METHODS, V240, P185, DOI 10.1016/S0022-1759(00)00188-5; van der Linden RHJ, 1999, BBA-PROTEIN STRUCT M, V1431, P37, DOI 10.1016/S0167-4838(99)00030-8; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6	50	126	231	10	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26285	26290		10.1074/jbc.M102107200	http://dx.doi.org/10.1074/jbc.M102107200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342547	hybrid			2022-12-27	WOS:000169823300086
J	Hirota, K; Murata, M; Itoh, T; Yodoi, J; Fukuda, K				Hirota, K; Murata, M; Itoh, T; Yodoi, J; Fukuda, K			Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EGF RECEPTOR; HYDROGEN-PEROXIDE; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; KINASE-ALPHA; THIOREDOXIN; APOPTOSIS	Cross-communication between different signaling systems allows the integration of the great diversity of stimuli that a cell receives under varying physiological situations. In this paper we have explored the possibility that tumor necrosis factor (TNF) receptor signal cross-talks with epidermal growth factor (EGF) receptor signal on the nuclear factor-kappaB (NF-kappaB) activation pathway. We have demonstrated that overexpression of the EGF receptor (EGFR) in NIH3T3 cells significantly enhances TNF-induced NF-kappaB-dependent luciferase activity even without EGF, that EGF treatment has a synergistic effect on the induction of the reporter activity, and that this enhancement is suppressed by AG1478, EGFR-specific tyrosine kinase inhibitor. We also have shown that TNF induces tyrosine phosphorylation and internalization of the overexpressed EGFR in NIH3T3 cells and the endogenously expressed EGFR in A431 cells and that the transactivation by TNF is suppressed by N-acetyl-L-cysteine or overexpression of an endogenous reducing molecule, thioredoxin, but not by phosphatidylinositol 3-kinase inhibitors and protein kinase C inhibitor. Taken together, this evidence strongly suggests that EGFR transactivation by TNF, which is regulated in a redox-dependent manner, is playing a pivotal role in TNF-induced NF-kappaB activation.	Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Integrat Brain Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Hirota, K (corresponding author), Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.		Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; Kamata H, 2000, EUR J BIOCHEM, V267, P1933, DOI 10.1046/j.1432-1327.2000.01194.x; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Ozes ON, 1999, NATURE, V401, P82; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; SULCINER DJ, 1996, MOL CELL BIOL, V16, P7155; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takeuchi J, 2000, ANTIOXID REDOX SIGN, V2, P83, DOI 10.1089/ars.2000.2.1-83; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	49	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25953	25958		10.1074/jbc.M011021200	http://dx.doi.org/10.1074/jbc.M011021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337489	hybrid			2022-12-27	WOS:000169823300043
J	Ma, R; Pluznick, J; Kudlacek, P; Sansom, SC				Ma, R; Pluznick, J; Kudlacek, P; Sansom, SC			Protein kinase C activates store-operated Ca2+ channels in human glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; SMOOTH-MUSCLE; INTRACELLULAR CA2+; SIGNALING COMPLEX; HUMAN-NEUTROPHILS; XENOPUS OOCYTES; T-LYMPHOCYTES; TRP; DEPLETION; INFLUX	Store-operated Ca2+ channels (SOC) are expressed in cultured human mesangial cells and activated by epidermal growth factor through a pathway involving protein kinase C (PKC), We used fura-2 fluorescence and patch clamp experiments to determine the role of PKC in mediating the activation of SOC after depletion of internal stores by thapsigargin, The measurements of intracellular Ca2+ concentration ([Ca2+],) revealed that the thapsigargin-induced Ca2+ entry pathway was abolished by calphostin C, a protein kinase C inhibitor, The PKC activator, phorbol 12-myristate 13-acetate (PMA), promoted a Ca2+ influx that was significantly attenuated by calphostin C and La3+ but not by diltiazem, Neither PMA nor calphostin C altered the thapsigargin-induced initial transient rise in [Ca2+](i-). In cell-attached patch clamp experiments, the thapsigargin-induced activation of SOC was potentiated by PMA and abolished by both calphostin C and staurosporine. However, SOC was unaffected by thapsigargin when clamping [Ca2+](i) with 1,2-bis (o-Aminophenoxy)ethane-N,N,N ' ,N ' tetraacetic acid tetra(acetoxymethyl)ester. In the absence of thapsigargin, PMA and phorbol 12, 13-didecanoate evoked a significant increase in NP, of SOC, whereas calphostin C did not affect base-line channel activity, In inside-out patches, SOC activity ran down immediately upon excision but was reactivated significantly after adding the catalytic subunit of 0.1 unit/ml of PKC plus 100 mum ATP, Neither ATP alone nor ATP with heat-inactivated PKC rescued a rundown of SOC, Metavanadate, a general protein phosphatase inhibitor, also enhanced SOC activity in inside-out patches. Bath [Ca2+] did not significantly affect the channel activity in inside-out patch, These results indicate that the depletion of Ca2+ stores activates SOC by PRC-mediated phosphorylation of the channel proteins or a membrane-associated complex.	Univ Nebraska, Med Ctr, Dept Physiol & Biophys, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Sansom, SC (corresponding author), Univ Nebraska, Med Ctr, Dept Physiol & Biophys, 984575 Nebraska Med Ctr, Omaha, NE 68198 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049561] Funding Source: NIH RePORTER; NHLBI NIH HHS [1T32HL07888] Funding Source: Medline; NIDDK NIH HHS [DK-49561] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; Bonev AD, 1996, J GEN PHYSIOL, V108, P315, DOI 10.1085/jgp.108.4.315; Camello C, 1999, J PHYSIOL-LONDON, V516, P399, DOI 10.1111/j.1469-7793.1999.0399v.x; CARMINES PK, 1993, AM J PHYSIOL, V265, pF677, DOI 10.1152/ajprenal.1993.265.5.F677; Chang EY, 1997, J IMMUNOL, V159, P2624; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kondo I, 2000, JPN J PHARMACOL, V82, P210, DOI 10.1254/jjp.82.210; Kwak YG, 1999, J BIOL CHEM, V274, P25355, DOI 10.1074/jbc.274.36.25355; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; Leinweber B, 2000, J BIOL CHEM, V275, P40329, DOI 10.1074/jbc.M008257200; Lo CF, 1999, ANN NY ACAD SCI, V868, P431, DOI 10.1111/j.1749-6632.1999.tb11307.x; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; Ma R, 2001, J AM SOC NEPHROL, V12, P47, DOI 10.1681/ASN.V12147; Ma R, 2000, AM J PHYSIOL-RENAL, V278, pF954, DOI 10.1152/ajprenal.2000.278.6.F954; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; Mene P, 1996, J AM SOC NEPHROL, V7, P983; MENE P, 1994, KIDNEY INT, V46, P122, DOI 10.1038/ki.1994.251; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MONTERO M, 1993, J BIOL CHEM, V268, P13055; Nagahama T, 2000, KIDNEY INT, V57, P215, DOI 10.1046/j.1523-1755.2000.00822.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okoro EO, 1999, J PHARM PHARMACOL, V51, P953, DOI 10.1211/0022357991773221; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; Pfaff IL, 1999, J AM SOC NEPHROL, V10, P1861; Putney JW, 1999, BIOESSAYS, V21, P38; Ribeiro CMP, 2000, CELL CALCIUM, V27, P175, DOI 10.1054/ceca.2000.0108; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; Schubert R, 1999, AM J PHYSIOL-CELL PH, V276, pC648, DOI 10.1152/ajpcell.1999.276.3.C648; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1993, BIOCHEM J, V290, P443; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Yamazaki J, 1999, BIOPHYS J, V76, P1972, DOI 10.1016/S0006-3495(99)77356-X; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; Yoshiji H, 1999, CANCER RES, V59, P4413; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	50	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25759	25765		10.1074/jbc.M011241200	http://dx.doi.org/10.1074/jbc.M011241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11352899	hybrid			2022-12-27	WOS:000169823300018
J	Warny, M; Aboudola, S; Robson, SC; Sevigny, J; Communi, D; Soltoff, SP; Kelly, CP				Warny, M; Aboudola, S; Robson, SC; Sevigny, J; Communi, D; Soltoff, SP; Kelly, CP			P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHOKINASE; PERITONEAL-MACROPHAGES; PURINERGIC RECEPTOR; IL-1-BETA RELEASE; ATP; ACTIVATION; EXPRESSION; IDENTIFICATION; CELLS; MODULATION	Extracellular nucleotides are autocrine and paracrine cellular mediators that signal through P2 nucleotide receptors. Monocytic cells express several P2Y receptors but the role of these G protein-coupled receptors in monocytes is not known. Here, we present evidence that P2Y(6) regulates chemokine production and release in monocytes, We find that UDP, a selective P2Y(6) agonist, stimulates interleukin (IL)-8 release in human THP-1 monocytic cells whereas other nucleotides are relatively inactive. P2 receptor antagonists or P2Y(6) antisense oligonucleotides inhibit IL-8 release induced by UDP, Furthermore, UDP specifically activated IL-8 production in astrocytoma 1321N1 cells transfected with human P2Y(6). Since lipopolysaccharide has been suggested to activate P2 receptors via nucleotide release, we tested whether IL-8 production stimulated by lipopolysaccharide might result from P2Y(6) activation. P2 antagonists or apyrase, an enzyme which hydrolyzes nucleotides including UDP, inhibit IL-8 production induced by lipopolysaccharide but not by other stimuli. Furthermore, IL-8 gene expression activated by lipopolysaccharide is enhanced by P2Y(6) overexpression and inhibited by P2Y(6) antisense oligonucleotides. Thus, UDP activates IL-8 production via P2Y(6) in monocytic cells. Furthermore, lipopolysaccharide mediates IL-8 production at least in part by autocrine P2Y(6) activation. These findings indicate a novel role for P2Y(6) in innate immune defenses.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Signal Transduct Div, Boston, MA 02215 USA; Free Univ Brussels, Sch Med, Inst Interdisciplinary Res, B-1070 Brussels, Belgium	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Warny, M (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Dana Bldg,Rm 501,330 Brookline Ave, Boston, MA 02215 USA.	mwarny@caregroup.harvard.edu	Sevigny, Jean/E-8039-2012; Robson, Simon C./AAA-8537-2021; Sévigny, Jean/AGH-9323-2022	Sevigny, Jean/0000-0003-2922-1600; Sévigny, Jean/0000-0003-2922-1600	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057307, R01HL063972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058858, R21DK054290] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL63972, R01HL57307] Funding Source: Medline; NIDDK NIH HHS [R01DK54290, R01DK58858] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuebor MN, 1999, J IMMUNOL, V162, P1685; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Balboa MA, 1999, J BIOL CHEM, V274, P36764, DOI 10.1074/jbc.274.51.36764; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Beigi RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/jimmunol.165.12.7189; Berchtold S, 1999, FEBS LETT, V458, P424, DOI 10.1016/S0014-5793(99)01197-7; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1998, P2 NUCLEOTIDE RECEPT, P3; Chen BC, 1998, J BIOL CHEM, V273, P29754, DOI 10.1074/jbc.273.45.29754; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Clifford EE, 1997, AM J PHYSIOL-CELL PH, V273, pC973, DOI 10.1152/ajpcell.1997.273.3.C973; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Evans RJ, 1998, P2 NUCLEOTIDE RECEPT, P43; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Grahames CBA, 1999, BRIT J PHARMACOL, V127, P1915, DOI 10.1038/sj.bjp.0702732; HARDEN TK, 1998, P2 NUCLEOTIDE RECEPT, P109; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Imai M, 2000, BIOCHEM BIOPH RES CO, V270, P272, DOI 10.1006/bbrc.2000.2410; Jin JG, 1998, BRIT J PHARMACOL, V123, P789, DOI 10.1038/sj.bjp.0701665; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; ROBSON SC, 2001, IN PRESS DRUG DEV RE; Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Somers GR, 1998, LAB INVEST, V78, P1375; Sperlagh B, 1998, NEUROCHEM INT, V33, P209, DOI 10.1016/S0197-0186(98)00025-4; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Warny M, 2000, J CLIN INVEST, V105, P1147, DOI 10.1172/JCI7545; WARNY M, 2000, AM J PHYSIOL, V276, pC717; WERNER A, 1991, J CHROMATOGR, V553, P205, DOI 10.1016/S0021-9673(01)88490-9; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	41	122	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26051	26056		10.1074/jbc.M102568200	http://dx.doi.org/10.1074/jbc.M102568200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11349132	hybrid			2022-12-27	WOS:000169823300056
J	Ahmed, Z; Ravandi, A; Maguire, GF; Emili, A; Draganov, D; La Du, BN; Kuksis, A; Connelly, PW				Ahmed, Z; Ravandi, A; Maguire, GF; Emili, A; Draganov, D; La Du, BN; Kuksis, A; Connelly, PW			Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; LIPID-PEROXIDATION; LDL OXIDATION; NITRIC-OXIDE; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; ALPHA-TOCOPHEROL; HUMAN-PLASMA; HYDROPEROXIDES; SUPEROXIDE	High density lipoprotein (HDL) is rich in polyunsaturated phospholipids that are sensitive to oxidation, However, the effect of apolipoprotein A-I and paraoxonase-l (PON-1) on phosphatidylcholine oxidation products has not been identified. We subjected native HDL, trypsinized HDL, and HDL lipid suspensions to oxidation by the peroxynitrite donor, 3-morpholinosydnonimine. HDL had a basal level of phosphatidylcholine mono- and di-hydroperoxides that increased to a greater extent in HDL, compared with either trypsinized HDL or HDL lipid alone. Phosphatidylcholine core aldehydes, which were present in small amounts, increased 10-fold during oxidation of native HDL, compared with trypsinized HDL (p = 0,004), and I-fold compared with HDL lipid suspensions (p = 0,0021), In addition, the content of lysophosphatidylcholine increased 300% during oxidation of native HDL, but only 80 and 25%, respectively, during oxidation of trypsinized HDL and HDL lipid suspensions. Phosphatidylcholine isoprostanes accumulated in comparable amounts during the oxidation of all three preparations. Incubation of apolipoprotein A-I with 1 -palmitoyl-2-linoleoyl glycerophosphocholine proteoliposomes in the presence of S-morpholinosyd-nonimine or apoAI with phosphatidylcholine hydroperoxides resulted in a significant increase in phosphatidyicholine core aldehydes with no formation of lysophosphatidylcholine. We propose that apolipoprotein A-I catalyzes a one-electron oxidation of alkoxyl radicals. Purified PON-1 hydrolyzed phosphatidylcholine core aldehydes to lysophosphatidylcholine. We conclude that, upon HDL oxidation with peroxynitrite, apolipoprotein AI increases the formation of phosphatidylcholine core aldehydes that are subsequently hydrolyzed by PON1.	Univ Toronto, St Michaels Hosp, J Alick Little Lipid Res Lab, Toronto, ON M5B 1A6, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5B 1A6, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5B 1A6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5B 1A6, Canada; Univ Toronto, Dept Med, Toronto, ON M5B 1A6, Canada; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Michigan System; University of Michigan	Connelly, PW (corresponding author), Univ Toronto, St Michaels Hosp, J Alick Little Lipid Res Lab, 38 Shuter St,Rm 1004 WA, Toronto, ON M5B 1A6, Canada.		Ravandi, Amir/O-7552-2019; Connelly, Philip W/B-7583-2012	Connelly, Philip W/0000-0001-7244-6843				[Anonymous], LIPID OXIDATION; Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Aviram M, 1999, FREE RADICAL BIO MED, V26, P892, DOI 10.1016/S0891-5849(98)00272-X; Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bergt C, 2000, BIOCHEM J, V346, P345, DOI 10.1042/0264-6021:3460345; Bonnefont-Rousselot D, 1999, CLIN CHEM LAB MED, V37, P939, DOI 10.1515/CCLM.1999.139; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; CHEN CH, 1982, J LIPID RES, V23, P680; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Christen S, 1997, P NATL ACAD SCI USA, V94, P3217, DOI 10.1073/pnas.94.7.3217; Connelly PW, 1996, METHOD ENZYMOL, V263, P188; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; ECKERSON HW, 1983, AM J HUM GENET, V35, P1126; Francis GA, 2000, BBA-MOL CELL BIOL L, V1483, P217, DOI 10.1016/S1388-1981(99)00181-X; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Gardner HW, 1996, LIPIDS, V31, P1023, DOI 10.1007/BF02522458; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786; Hall LM, 1998, ANAL BIOCHEM, V258, P184, DOI 10.1006/abio.1998.2602; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; KAMIDO H, 1995, J LIPID RES, V36, P1876; Kanazawa K, 1998, BBA-LIPID LIPID MET, V1393, P336, DOI 10.1016/S0005-2760(98)00088-5; Khovidhunkit W, 2000, J INFECT DIS, V181, pS462, DOI 10.1086/315611; KUO CL, 1995, DRUG METAB DISPOS, V23, P935; La Du BN, 1999, CHEM-BIOL INTERACT, V119, P379, DOI 10.1016/S0009-2797(99)00049-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laplaud PM, 1998, CLIN CHEM LAB MED, V36, P431, DOI 10.1515/CCLM.1998.073; Lee C, 1999, ARTERIOSCL THROM VAS, V19, P1437, DOI 10.1161/01.ATV.19.6.1437; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; Mackness MI, 2000, CURR OPIN LIPIDOL, V11, P383, DOI 10.1097/00041433-200008000-00007; Macphee CH, 1999, BIOCHEM J, V338, P479, DOI 10.1042/0264-6021:3380479; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mashima R, 1998, J LIPID RES, V39, P1133; Pannala AS, 1998, FEBS LETT, V423, P297, DOI 10.1016/S0014-5793(98)00108-2; Patel RP, 1997, BIOCHEM J, V322, P425, DOI 10.1042/bj3220425; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RAVANDI A, 1995, J BIOCHEM BIOPH METH, V30, P271, DOI 10.1016/0165-022X(95)00015-7; Ravandi A, 1997, LIPIDS, V32, P989, DOI 10.1007/s11745-997-0129-6; Ravandi A, 1996, FEBS LETT, V381, P77, DOI 10.1016/0014-5793(96)00064-6; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Ronson RS, 1999, CARDIOVASC RES, V44, P47, DOI 10.1016/S0008-6363(99)00184-4; SHAIKH NA, 1994, ANAL BIOCHEM, V216, P313, DOI 10.1006/abio.1994.1047; SorciThomas MG, 1996, J LIPID RES, V37, P673; STAFFORINI DM, 1989, P NATL ACAD SCI USA, V86, P2393, DOI 10.1073/pnas.86.7.2393; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Thomas SR, 2000, FREE RADICAL BIO MED, V28, P1795, DOI 10.1016/S0891-5849(00)00236-7; Thomas SR, 1998, CHEM RES TOXICOL, V11, P484, DOI 10.1021/tx970173a; VanLenten BJ, 1995, J CLIN INVEST, V96, P2758, DOI 10.1172/JCI118345; VERDERY RB, 1974, BIOCHEM BIOPH RES CO, V57, P1271, DOI 10.1016/0006-291X(74)90833-X; Whitman SC, 1998, J LIPID RES, V39, P1008	58	101	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24473	24481		10.1074/jbc.M010459200	http://dx.doi.org/10.1074/jbc.M010459200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320081	hybrid			2022-12-27	WOS:000169800700009
J	Carvalho, J; Bertram, PG; Wente, SR; Zheng, XFS				Carvalho, J; Bertram, PG; Wente, SR; Zheng, XFS			Phosphorylation regulates the interaction between Gln3p and the nuclear import factor Srp1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; PORE COMPLEX; NUCLEOCYTOPLASMIC TRANSPORT; RAPAMYCIN TOR; PROTEIN; YEAST; CRM1; IDENTIFICATION	Gln3p is a GATA-type transcription activator of nitrogen catabolite repressible (NCR) genes. Gln3p was recently found to be hyperphosphorylated in a TOR-dependent manner and resides in the cytoplasm in high quality nitrogen. In contrast, during nitrogen starvation or rapamycin treatment, Gln3p becomes rapidly dephosphorylated and accumulates in the nucleus, thereby activating nitrogen catabolite repression genes. However, a detailed mechanistic understanding is lacking for the regulation of Gln3p nucleocytoplasmic distribution, In this study, we applied a functional genomics approach to identify the nuclear transport factors for Gln3p, We found that yeast karyopherin alpha /Srp1p and Crm1p are required for the nuclear import and export of Gln3p, respectively. Similarly, the Ran GTPase pathway is also involved in the nuclear translocation of Gln3p, Finally, we show that Srp1p preferentially interacts with the hypophosphorylated versus the hyperphosphorylated Gln3p. These findings define a possible mechanism for regulated nucleocytoplasmic transport of Gln3p by phosphorylation in vivo.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8069,1030 CSRBNT,660 S Euclid Ave, St Louis, MO 63110 USA.	zheng@pathology.wustl.edu						Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LANFORD RE, 1985, VIROLOGY, V147, P72, DOI 10.1016/0042-6822(85)90228-4; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAN R, 1994, J BIOL CHEM, V269, P32027; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	69	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25359	25365		10.1074/jbc.M103050200	http://dx.doi.org/10.1074/jbc.M103050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331291	hybrid			2022-12-27	WOS:000169800700123
J	Kingan, TG; Cardullo, RA; Adams, ME				Kingan, TG; Cardullo, RA; Adams, ME			Signal transduction in eclosion hormone-induced secretion of ecdysis-triggering hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MANDUCA-SEXTA; NERVOUS-SYSTEM; NITRIC-OXIDE; CALYCULIN-A; BEHAVIORAL SEQUENCE; ENDOCRINE SYSTEM; CHROMAFFIN CELLS; INSECT ECDYSIS; CA2+ STORES	Inks cells of insect epitracheal glands (EGs) secrete preecdysis and ecdysis-triggering hormones (PETH and ETH) at the end of each developmental stage. Both peptides act in the central nervous system to evoke the ecdysis behavioral sequence, a stereotype behavior during which old cuticle is shed. Secretion of ETH is stimulated by a brain neuropeptide, eclosion hormone (EH), EH evokes accumulation of cGMP followed by release of ETH from Inks cells, and exogenous cGMP evokes secretion of ETH, The secretory responses to EH and cGMP are inhibited by the broad-spectrum kinase inhibitor staurosporine, and the response to EH is potentiated by the phosphatase inhibitor calyculin A Staurosporine did not inhibit EH-evoked accumulation of cGMP, Changes in cytoplasmic Ca2+ in Inks cells during EH signaling were monitored via fluorescence ratioing with fura-2-loaded EGs. Cytoplasmic Ca2+ increases within 30-120 s after addition of EH to EGs, and it remains elevated for at least 10 min, corresponding with the time course of secretion. Secretion is increased in dose-dependent manner by the Ca2+-ATPase inhibitor thapsigargin, a treatment that does not elevate glandular cGMP above basal levels. The secretory response to EH is partially inhibited in glands loaded with EGTA, while cGMP levels are unaffected. These findings suggest that EH activates second messenger cascades leading to cGMP accumulation and Ca2+ mobilization and/or influx and that both pathways are required for a full secretory response, cGMP activates a staurosporine-inhibitable protein kinase, We propose that Ca2+ acts vis a parallel cascade with a time course that is similar to that for cGMP activation of a cGMP-dependent protein kinase.	Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biol, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California Riverside	Kingan, TG (corresponding author), Univ Calif Riverside, Dept Entomol, 5419 Boyce Hall, Riverside, CA 92521 USA.		Adams, Michael/ABF-6728-2020; Cardullo, Richard/GVT-2950-2022	Adams, Michael/0000-0003-0519-6113; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040555, R01AI040555] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40555] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTT E, 1994, EUR J PHARM-MOLEC PH, V269, P265, DOI 10.1016/0922-4106(94)90095-7; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P451, DOI 10.1111/j.1476-5381.1968.tb08474.x; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Ewer J, 1997, J EXP BIOL, V200, P869; Gammie SC, 1999, J EXP BIOL, V202, P343; GUTIERREZ LM, 1995, EUR J CELL BIOL, V68, P88; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; HEWES RS, 1991, J COMP PHYSIOL A, V168, P697; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KATO Y, 1986, J AM CHEM SOC, V108, P2780, DOI 10.1021/ja00270a061; Kingan TG, 1997, J EXP BIOL, V200, P3245; Klein C, 1999, J INSECT PHYSIOL, V45, P65, DOI 10.1016/S0022-1910(98)00085-7; KNIGHT DE, 1989, TRENDS NEUROSCI, V12, P451, DOI 10.1016/0166-2236(89)90095-7; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Morgan A, 1997, SEMIN CELL DEV BIOL, V8, P141, DOI 10.1006/scdb.1996.0133; MORTON DB, 1985, J COMP PHYSIOL A, V157, P423, DOI 10.1007/BF00615142; MORTON DB, 1986, NATURE, V323, P264, DOI 10.1038/323264a0; Morton DB, 1995, J COMP PHYSIOL B, V165, P417, DOI 10.1007/BF00261295; Morton DB, 1997, ANN NY ACAD SCI, V814, P40, DOI 10.1111/j.1749-6632.1997.tb46143.x; NAKAZAWA M, 1994, EUR J PHARMACOL, V253, P179; Nighorn A, 1999, J BIOL CHEM, V274, P2525, DOI 10.1074/jbc.274.4.2525; Novicki A, 1996, J EXP BIOL, V199, P1757; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; SHIBANAKA Y, 1993, EUR J BIOCHEM, V211, P427, DOI 10.1111/j.1432-1033.1993.tb17567.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRIFARO JM, 1992, EUR J PHARM-MOLEC PH, V225, P83, DOI 10.1016/0922-4106(92)90088-D; TRUMAN JW, 1981, NATURE, V291, P70, DOI 10.1038/291070a0; TRUMAN JW, 1980, J EXP BIOL, V88, P327; TRUMAN JW, 1989, J EXP BIOL, V147, P457; TRUMAN JW, 1979, J EXP BIOL, V84, P201; VITALE ML, 1992, NEUROSCIENCE, V51, P463, DOI 10.1016/0306-4522(92)90330-5; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WEEKS JC, 1984, J COMP PHYSIOL, V155, P407, DOI 10.1007/BF00610594; XU X, 1994, J BIOL CHEM, V269, P12645; Zitnan D, 2000, J EXP BIOL, V203, P1329; Zitnan D, 1999, NEURON, V23, P523, DOI 10.1016/S0896-6273(00)80805-3; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	44	24	24	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25136	25142		10.1074/jbc.M102421200	http://dx.doi.org/10.1074/jbc.M102421200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313360	hybrid			2022-12-27	WOS:000169800700095
J	Schwartz, SH; Qin, XQ; Zeevaart, JAD				Schwartz, SH; Qin, XQ; Zeevaart, JAD			Characterization of a novel carotenoid cleavage dioxygenase from plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; PSEUDOMONAS-PAUCIMOBILIS TMY1009; BETA-CAROTENE; ARABIDOPSIS-THALIANA; PHASEOLUS-VULGARIS; OXIDATIVE CLEAVAGE; GROWTH INHIBITOR; PROVITAMIN-A; VITAMIN-A; IDENTIFICATION	The plant hormone abscisic acid is derived from the oxidative cleavage of a carotenoid precursor. Enzymes that catalyze this carotenoid cleavage reaction, nine-cis epoxy-carotenoid dioxygenases, have been identified in several plant species. Similar proteins, whose functions are not yet known, are present in diverse organisms, A putative cleavage enzyme from Arabidopsis thaliana contains several highly conserved motifs found in other carotenoid cleavage enzymes. However, the overall homology with known abscisic acid biosynthetic enzymes is low. To determine the biochemical function of this protein, it was expressed in Escherichia coli and used for in vitro assays. The recombinant protein was able to cleave a variety of carotenoids at the 9-10 and 9'-10' positions. In most instances, the enzyme cleaves the substrate symmetrically to produce a C-14 dialdehyde and two C-13 products, which vary depending on the carotenoid substrate. Based upon sequence similarity, orthologs of this gene are present throughout the plant kingdom. A similar protein in beans catalyzes the same reaction in vitro. The characterization of these activities offers the potential to synthesize a variety of interesting, natural products and is the first step in determining the function of this gene family in plants.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Zeevaart, JAD (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.	zeevaart@msu.edu		Schwartz, Steve/0000-0002-5982-8553				Burbidge A, 1999, PLANT J, V17, P427, DOI 10.1046/j.1365-313X.1999.00386.x; BURDEN RS, 1972, PHYTOCHEMISTRY, V11, P2295, DOI 10.1016/S0031-9422(00)88393-4; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; DONALDSON JMI, 1990, J ECON ENTOMOL, V83, P1298, DOI 10.1093/jee/83.4.1298; EISNER T, 1966, SCIENCE, V153, P1341, DOI 10.1126/science.153.3742.1341; EUGSTER CH, 1991, ANGEW CHEM INT EDIT, V30, P654, DOI 10.1002/anie.199106541; Iuchi S, 2000, PLANT PHYSIOL, V123, P553, DOI 10.1104/pp.123.2.553; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P931, DOI 10.1271/bbb.57.931; KATONOGUCHI H, 1992, PHYSIOL PLANTARUM, V86, P583, DOI 10.1111/j.1399-3054.1992.tb02173.x; KATONOGUCHI H, 1993, PHYTOCHEMISTRY, V33, P553, DOI 10.1016/0031-9422(93)85447-Y; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; MARKIFISCHER E, 1988, HELV CHIM ACTA, V71, P1491, DOI 10.1002/hlca.19880710613; MEINWALD J, 1968, TETRAHEDRON LETT, P2959; MOLNAR P, 1979, ACTA CHIM HUNG, V99, P155; Neill SJ, 1998, J EXP BOT, V49, P1893, DOI 10.1093/jexbot/49.328.1893; Olson JA, 1995, FASEB J, V9, P1547, DOI 10.1096/fasebj.9.15.8529833; OLSON JA, 1989, J NUTR, V119, P105, DOI 10.1093/jn/119.1.105; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Sun ZR, 1996, J BIOL CHEM, V271, P24349, DOI 10.1074/jbc.271.40.24349; Tan BC, 1997, P NATL ACAD SCI USA, V94, P12235, DOI 10.1073/pnas.94.22.12235; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; WALHBERG I, 1998, CAROTENOIDS, V3, P195; Walter MH, 2000, PLANT J, V21, P571, DOI 10.1046/j.1365-313x.2000.00708.x; Williams RN, 2000, J ECON ENTOMOL, V93, P1480, DOI 10.1603/0022-0493-93.5.1480; Winterhalter P, 2000, FOOD REV INT, V16, P39, DOI 10.1081/FRI-100100281; WINTERHALTER P, 1992, ACS SYM SER, V490, P98; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439	31	258	285	1	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25208	25211		10.1074/jbc.M102146200	http://dx.doi.org/10.1074/jbc.M102146200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316814	hybrid			2022-12-27	WOS:000169800700104
J	Waugh, DJJ; Gaivin, RJ; Zuscik, MJ; Gonzalez-Cabrera, P; Ross, SA; Yun, J; Perez, DM				Waugh, DJJ; Gaivin, RJ; Zuscik, MJ; Gonzalez-Cabrera, P; Ross, SA; Yun, J; Perez, DM			Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha(1)-adrenergic receptor antagonist binding - Imidazoline agonists bind like antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PROTEIN-COUPLED RECEPTOR; EXTRACELLULAR LOOP; BETA(2)-ADRENERGIC RECEPTOR; IDENTIFICATION; SUBTYPE; ACTIVATION; RESIDUES; SELECTIVITY; AFFINITY	Although agonist binding in adrenergic receptors is fairly well understood and involves residues located in transmembrane domains 3 through 6, there are few residues reported that are involved in antagonist binding. In fact, a major docking site for antagonists has never been reported in any G-protein coupled receptor. It has been speculated that antagonist binding is quite diverse depending upon the chemical structure of the antagonist, which can be quite different from agonists, We now report the identification of two phenylalanine residues in transmembrane domain 7 of the alpha (1a)-adrenergic receptor (Phe-312 and Phe-308) that are a major site of antagonist affinity. Mutation of either Phe-308 or Phe-312 resulted in significant losses of affinity (4-1200-fold) for the antagonists prazosin, WB4101, BMY7378, (+) niguldipine, and 5-methylurapidil, with no changes in affinity for phenethylamine-type agonists such as epinephrine, methoxamine, or phenylephrine, Interestingly, both residues are involved in the binding of all imidazoline-type agonists such as oxymetazoline, cirazoline, and clonidine, confirming previous evidence that this class of ligand binds differently than phenethylamine-type agonists and may be more antagonist-like, which may explain their partial agonist properties. In modeling these interactions with previous mutagenesis studies and using the current backbone structure of rhodopsin, we conclude that antagonist binding is docked higher in the pocket closer to the extracellular surface than agonist binding and appears skewed toward transmembrane domain 7.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Perez, DM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, NB5,9500 Euclid Ave, Cleveland, OH 44195 USA.			Zuscik, Michael/0000-0003-0461-8708; WAUGH, DAVID/0000-0002-4022-3765	NHLBI NIH HHS [R01 HL61438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; DIXON RAF, 1989, PROTEINS, V6, P267, DOI 10.1002/prot.340060309; GUAN XM, 1992, MOL PHARMACOL, V41, P695; Guarino RD, 1996, CELL SIGNAL, V8, P323, DOI 10.1016/0898-6568(96)00066-6; Hamaguchi N, 1996, BIOCHEMISTRY-US, V35, P14312, DOI 10.1021/bi961024e; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; LI X, 1996, EUR J PHARMACOL, V300, P1; MARULLO S, 1990, EMBO J, V9, P1471, DOI 10.1002/j.1460-2075.1990.tb08264.x; MINNEMAN KP, 1994, MOL PHARMACOL, V46, P929; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; RUFFOLO RR, 1977, J PHARM PHARMACOL, V29, P378, DOI 10.1111/j.2042-7158.1977.tb11344.x; RUFFOLO RR, 1983, EUR J PHARMACOL, V86, P471, DOI 10.1016/0014-2999(83)90199-1; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4383; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; Waugh DJJ, 2000, J BIOL CHEM, V275, P11698, DOI 10.1074/jbc.275.16.11698; Wurch T, 1998, MOL PHARMACOL, V54, P1088, DOI 10.1124/mol.54.6.1088; Zhao MM, 1996, MOL PHARMACOL, V50, P1118; Zhao MM, 1998, MOL PHARMACOL, V53, P524, DOI 10.1124/mol.53.3.524	25	52	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25366	25371		10.1074/jbc.M103152200	http://dx.doi.org/10.1074/jbc.M103152200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331292	Green Published, hybrid			2022-12-27	WOS:000169800700124
J	Falls, LA; Furie, BC; Jacobs, M; Furie, B; Rigby, AC				Falls, LA; Furie, BC; Jacobs, M; Furie, B; Rigby, AC			The omega-loop region of the human prothrombin gamma-carboxyglutamic acid domain penetrates anionic phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FACTOR-VIII; VITAMIN-K; COAGULATION-FACTOR; BINDING-PROPERTIES; GLA DOMAIN; C2 DOMAIN; PARALLAX ANALYSIS; RICH DOMAIN; PROTEIN-C; FACTOR-VA	The hydrophobic omega -loop within the prothrombin gamma -carboxyglutamic acid-rich (Gla) domain is important in membrane binding. The role of this region in membrane binding was investigated using a synthetic peptide, PT-(1-46)F4W, which includes the N-terminal 46 residues of human prothrombin with Phe-4 replaced by Trp providing a fluorescent probe. PT-(1-46)F4W and PT-(1-46) bind calcium ions and phospholipid membranes, and inhibit the prothrombinase complex. PT-(1-46)F4W, but not PT-(1-46), exhibits a blue shift (5 nm) and red-edge excitation shift (28 nm) in the presence of phosphatidylserine (PS)-containing vesicles, suggesting Trp ii is located within the motionally restricted membrane interfacial region, PS-containing vesicles protect PT-(1-46)F4W, but not PT-(1-46), fluorescence from potassium iodide-induced quenching. Stern-Volmer analysis of the quenching of PT-(1-46)F4W in the presence and absence of 80% phosphatidylcholine/20% PS vesicles suggested that Trp-4 is positioned within the membrane and protected from aqueous quenching agents whereas Trp-41 remains solvent-accessible in the presence of PS-containing vesicles, Fluorescence quenching of membrane-bound PT-(1-46)F4W is optimal with 7- and 10-doxyl-labeled lipids, indicating that Trp-4 is inserted 5 to 7 Angstrom into the bilayer, This report demonstrates that the omega -loop region of prothrombin specifically interacts with PS-containing membranes within the interfacial membrane region.	Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Rigby, AC (corresponding author), Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis Res, POB 15732, Boston, MA 02215 USA.	arigby@caregroup.harvard.edu			NHLBI NIH HHS [HL42443, HL10328, HL18834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018834, R01HL018834, P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5322, DOI 10.1021/bi00138a011; ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; ASHCROFT RG, 1981, BIOCHIM BIOPHYS ACTA, V643, P191, DOI 10.1016/0005-2736(81)90232-7; ASUNCIONPUNZALAN E, 1995, BIOCHEMISTRY-US, V34, P11460, DOI 10.1021/bi00036a019; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; CHATTOPADHYAY A, 1991, BIOCHEMISTRY-US, V30, P7159, DOI 10.1021/bi00243a017; Chattopadhyay A, 1997, BIOPHYS J, V73, P839, DOI 10.1016/S0006-3495(97)78116-5; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; Cheng CH, 2000, FASEB J, V14, pA110; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEMCHENKO AP, 1986, ESSAYS BIOCHEM, V22, P120; Falls LA, 2000, BIOCHEMISTRY-US, V39, P13216, DOI 10.1021/bi0009789; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Ghosh AK, 1997, BIOCHEMISTRY-US, V36, P14291, DOI 10.1021/bi971933j; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; JACOBS M, 1994, J BIOL CHEM, V269, P25494; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LENTZ BR, 1985, BIOCHEMISTRY-US, V24, P6997, DOI 10.1021/bi00345a037; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MacPhee CE, 1999, BIOCHEMISTRY-US, V38, P10878, DOI 10.1021/bi990726b; MANN KG, 1990, BLOOD, V76, P1; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; McGee MP, 1999, BBA-MOL BASIS DIS, V1453, P239, DOI 10.1016/S0925-4439(98)00108-2; McGee MP, 1998, BIOCHEM J, V330, P533; MORRIS SJ, 1985, BIOCHIM BIOPHYS ACTA, V818, P365, DOI 10.1016/0005-2736(85)90011-2; MUKHERJEE S, 1994, BIOCHEMISTRY-US, V33, P5089, DOI 10.1021/bi00183a012; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; Nicolaes GAF, 2000, BLOOD COAGUL FIBRIN, V11, P89, DOI 10.1097/00001721-200011010-00010; PEROCHON E, 1992, BIOCHEMISTRY-US, V31, P7672, DOI 10.1021/bi00148a031; PETERSEN TE, 1980, FEBS LETT, V114, P278, DOI 10.1016/0014-5793(80)81133-1; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; Ren JH, 1999, BIOCHEMISTRY-US, V38, P5905, DOI 10.1021/bi982942a; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; Smeets EF, 1996, THROMB RES, V81, P419, DOI 10.1016/0049-3848(96)00014-X; Smirnov MD, 1999, BIOCHEMISTRY-US, V38, P3591, DOI 10.1021/bi982538b; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; Wang SX, 1999, BIOCHEMISTRY-US, V38, P9477, DOI 10.1021/bi990084s; WEBER DJ, 1992, J BIOL CHEM, V267, P4564; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; ZHANG L, 1994, J BIOL CHEM, V269, P3590	64	52	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23895	23902		10.1074/jbc.M008332200	http://dx.doi.org/10.1074/jbc.M008332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11312259	hybrid			2022-12-27	WOS:000169531100090
J	Lee, K; Cohen, SN				Lee, K; Cohen, SN			Effects of 3 ' terminus modifications on mRNA functional decay during in vitro protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; RIBONUCLEASE-E; POLYNUCLEOTIDE PHOSPHORYLASE; ANTISENSE RNAI; CELL-DIVISION; DEGRADATION; TRANSCRIPTION; TRANSLATION; POLYMERASE; INITIATION	The pcnB gene, which encodes the principal poly(A) polymerase of Escherichia coli, promotes 3'-polyadenylation and chemical decay of mRNA. However, there is no evidence that pcnB-mediated mRNA destabilization decreases protein synthesis, suggesting that polyadenylation may enhance translational efficiency. Using in vitro translation by E, coli cell extracts and toeprinting analysis of transcripts encoded by the chloramphenicol acetyltransferase (CAT) and p-galactosidase genes to investigate this notion, we found no effect of poly(A) tails on protein synthesis. However, we observed that 3'-polyguanylation delayed the chemical decay of CAT mRNA and, even more dramatically, increased the ability of CAT mRNA to produce enzymatically active full-length protein in 30 S E. coli cell fractions, This resulted from interference with the primary mechanism for inactivation of CAT transcript function in cell extracts, which occurred by 3'-exonucleolytic degradation rather than endonucleolytic fragmentation by RNase E, Using bacteriophage T7 RNA polymerase to install poly(G) tails on mRNAs transcribed from polymerase chain reaction-generated DNA templates, we observed sharply increased synthesis of active proteins in vitro in coupled transcription/translation reactions. The ability of poly(G) tails to functionally stabilize transcripts from polymerase chain reaction-generated templates allows proteins encoded by translational open reading frames on genomic DNA or cDNA to be synthesized directly and efficiently in vitro.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Ctr Med, Dept Genet, Room M322, Stanford, CA 94305 USA.	sncohen@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054158] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; Blum E, 1999, J BIOL CHEM, V274, P4009, DOI 10.1074/jbc.274.7.4009; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CALOGERO RA, 1988, P NATL ACAD SCI USA, V85, P6427, DOI 10.1073/pnas.85.17.6427; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; Coburn GA, 1996, J BIOL CHEM, V271, P15776, DOI 10.1074/jbc.271.26.15776; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DREYFUS M, 1988, J MOL BIOL, V204, P79, DOI 10.1016/0022-2836(88)90601-8; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; Hagege JM, 1997, MOL MICROBIOL, V25, P1077, DOI 10.1046/j.1365-2958.1997.5311904.x; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; IOST I, 1992, J BACTERIOL, V174, P619, DOI 10.1128/jb.174.2.619-622.1992; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; Jones GH, 1996, J BACTERIOL, V178, P4281, DOI 10.1128/jb.178.14.4281-4288.1996; Kalapos MP, 1997, BIOCHIMIE, V79, P493, DOI 10.1016/S0300-9084(97)82741-1; Kim DM, 2000, BIOTECHNOL PROGR, V16, P385, DOI 10.1021/bp000031y; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Lisitsky I, 1999, EUR J BIOCHEM, V261, P468, DOI 10.1046/j.1432-1327.1999.00285.x; MCCARTHY JEG, 1994, TRENDS GENET, V10, P402, DOI 10.1016/0168-9525(94)90057-4; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MEACOCK PA, 1980, CELL, V20, P529, DOI 10.1016/0092-8674(80)90639-X; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Moll I, 1998, FEBS LETT, V436, P213, DOI 10.1016/S0014-5793(98)01131-4; NEVIN DE, 1991, FEBS LETT, V291, P259, DOI 10.1016/0014-5793(91)81297-L; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; RINGQUIST S, 1993, BIOCHEMISTRY-US, V32, P10254, DOI 10.1021/bi00089a048; Sarkar N, 1997, ANNU REV BIOCHEM, V66, P173, DOI 10.1146/annurev.biochem.66.1.173; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; STENT GS, 1966, PROC R SOC SER B-BIO, V164, P181, DOI 10.1098/rspb.1966.0022; Szalewska-Palasz A, 1998, FEBS LETT, V432, P70, DOI 10.1016/S0014-5793(98)00834-5; TAL M, 1972, BIOCHIM BIOPHYS ACTA, V281, P381, DOI 10.1016/0005-2787(72)90452-2; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	48	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23268	23274		10.1074/jbc.M102408200	http://dx.doi.org/10.1074/jbc.M102408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309400	hybrid			2022-12-27	WOS:000169531100009
J	Suenaga, H; Goto, M; Furukawa, K				Suenaga, H; Goto, M; Furukawa, K			Emergence of multifunctional oxygenase activities by random priming recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCHLORINATED BIPHENYL DEGRADATION; PSEUDOMONAS-PSEUDOALCALIGENES KF707; SITE-DIRECTED MUTAGENESIS; SP STRAIN LB400; NAPHTHALENE DIOXYGENASE; CHLORINE SUBSTITUTION; SUBSTRATE-SPECIFICITY; TOLUENE DIOXYGENASE; ALPHA-SUBUNIT; AMINO-ACIDS	Biphenyl dioxygenase (Bph Dox) is responsible for the initial dioxygenation of biphenyl, The large subunit (BphA1) of Bph Dox plays a crucial role in determination of substrate specificity of biphenyl-related compounds including polychlorinated biphenyls (PCBs), Functional evolution of Bph Dox of Pseudomonas pseudoalcaligenes KF707 was accomplished by random priming recombination of the bphA1 gene, involving two rounds of in vitro recombination and mutation followed by selection for increased activity in vivo. Evolved Bph Dox acquired novel and multifunctional degradation capabilities not only for PCBs but also for dibenzofuran, dibenzo-p-dioxin, dibenzothiophene, and fluorene, the compounds scarcely attacked by the original KF707 Bph Dox. The modes of oxygenation were angular and lateral dioxygenation for dibenzofuran and dibenzo-p-dioxin, sulfoxidation for dibenzothiophene, and mono-oxygenation for fluorene, These enzymes also exhibited enhanced degradation abilities for PCB congeners, retaining 2,3-dioxygenase activity and gaining 3,4-dioxygenase activity, depending on the chlorine substitution of PCB congeners. Further mutation analysis revealed that the amino acid at position 376 in BphA1 is significantly involved in the acquisition of multifunctional oxygenase activities and mode of oxygenation.	Kyushu Univ, Appl Microbiol Lab, Grad Sch Bioresource & Bioenvironm Sci, Fukuoka 8128581, Japan	Kyushu University	Furukawa, K (corresponding author), Kyushu Univ, Appl Microbiol Lab, Grad Sch Bioresource & Bioenvironm Sci, Hakozaki 6-10-1, Fukuoka 8128581, Japan.		KENSUKE, FURUKAWA/R-3105-2019					BEDARD DL, 1990, MICROBIAL ECOL, V20, P87, DOI 10.1007/BF02543870; BEDARD DL, 1986, APPL ENVIRON MICROB, V51, P761, DOI 10.1128/AEM.51.4.761-768.1986; Beil S, 1997, EUR J BIOCHEM, V247, P190, DOI 10.1111/j.1432-1033.1997.00190.x; BUNZ PV, 1993, J BACTERIOL, V175, P6467; CERNIGLIA CE, 1979, BIOCHEM J, V180, P175, DOI 10.1042/bj1800175; CHUNG SY, 1994, BIOSCI BIOTECH BIOCH, V58, P2111, DOI 10.1271/bbb.58.2111; ERICKSON BD, 1993, APPL ENVIRON MICROB, V59, P3858, DOI 10.1128/AEM.59.11.3858-3862.1993; FURUKAWA K, 1986, J BACTERIOL, V166, P392, DOI 10.1128/jb.166.2.392-398.1986; FURUKAWA K, 1993, J BACTERIOL, V175, P5224, DOI 10.1128/JB.175.16.5224-5232.1993; FURUKAWA K, 1979, APPL ENVIRON MICROB, V38, P301, DOI 10.1128/AEM.38.2.301-310.1979; FURUKAWA K, 1982, BIODEGRADATION DETOX, P33; Furukawa Kensuke, 1994, Biodegradation, V5, P289, DOI 10.1007/BF00696466; GIBSON DT, 1995, J BACTERIOL, V177, P2615, DOI 10.1128/jb.177.10.2615-2621.1995; GIBSON DT, 1993, J BACTERIOL, V175, P4561, DOI 10.1128/JB.175.14.4561-4564.1993; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; HIROSE J, 1994, GENE, V138, P27; Jiang HY, 1996, J BACTERIOL, V178, P3133, DOI 10.1128/jb.178.11.3133-3139.1996; Kauppi B, 1998, STRUCTURE, V6, P571, DOI 10.1016/S0969-2126(98)00059-8; Kimura N, 1997, J BACTERIOL, V179, P3936, DOI 10.1128/jb.179.12.3936-3943.1997; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; MASAI E, 1995, APPL ENVIRON MICROB, V61, P2079, DOI 10.1128/AEM.61.6.2079-2085.1995; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; MONDELLO FJ, 1989, J BACTERIOL, V171, P1725, DOI 10.1128/jb.171.3.1725-1732.1989; Nojiri H, 1999, J BACTERIOL, V181, P3105, DOI 10.1128/JB.181.10.3105-3113.1999; Parales RE, 2000, J BACTERIOL, V182, P5495, DOI 10.1128/JB.182.19.5495-5504.2000; Parales RE, 2000, J BACTERIOL, V182, P1641, DOI 10.1128/JB.182.6.1641-1649.2000; Resnick SM, 1996, APPL ENVIRON MICROB, V62, P4073, DOI 10.1128/AEM.62.11.4073-4080.1996; SATO S, 1997, J BACTERIOL, V179, P1850; SHAO Z, 1998, NUCLEIC ACIDS RES, V26, P381; SIMON MJ, 1993, GENE, V127, P31, DOI 10.1016/0378-1119(93)90613-8; Suenaga H, 1999, J BIOSCI BIOENG, V87, P430, DOI 10.1016/S1389-1723(99)80090-5; Sylvestre Michel, 1994, P47; TAIRA K, 1992, J BIOL CHEM, V267, P4844; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; WACKETT LP, 1988, BIOCHEMISTRY-US, V27, P1360, DOI 10.1021/bi00404a041; WITTICH RM, 1992, APPL ENVIRON MICROB, V58, P1005, DOI 10.1128/AEM.58.3.1005-1010.1992	37	42	47	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22500	22506		10.1074/jbc.M101323200	http://dx.doi.org/10.1074/jbc.M101323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312272	hybrid			2022-12-27	WOS:000169412700071
J	Drain, J; Bishop, JR; Hajduk, SL				Drain, J; Bishop, JR; Hajduk, SL			Haptoglobin-related protein mediates trypanosome lytic factor binding to trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; NORMAL HUMAN SERUM; BRUCEI-BRUCEI; AFRICAN TRYPANOSOMES; RECEPTOR; LYSIS; IDENTIFICATION; ENDOCYTOSIS; COMPLEX; FORMS	Trypanosome lytic factor (TLF-1) is an unusual high density lipoprotein (HDL) found inhuman serum that is toxic to Trypanosoma brucei bruce! and may be critical in preventing human infections by this parasite. TLF-1 is composed of four major apolipoproteins: apolipoprotein AI, apolipoprotein AII, paraoxonase, and the primate-specific haptoglobin-related protein (Hpr). Hpr is greater than 90% homologous to haptoglobin (Hp), an abundant acute phase serum protein. Killing of trypanosomes by TLF-1 requires cell sin-face binding, endocytosis, and subsequent lysosomal targeting. Low temperature binding studies reveal two receptors for TLF-1: one that is high affinity/low capacity (K-d similar to 12 nM, 350 receptors per cell) and another that binds with low affinity/ high capacity (K-d similar to 1 muM, 60,000 receptors per cell). The low affinity binding is competed by nonlytic human HDL and is likely to be apolipoprotein Al-mediated. Purified human Hpr and human Hp bind to trypanosomes, are internalized, and are targeted to the lysosome. Furthermore,. Hpr shows competition for TLF-1 binding, and a monoclonal antibody against Hpr prevents both TLF-1 uptake and trypanosome killing. Based on these results, we propose that Hpr mediates the high affinity binding of TLF-1 to T. b. brucei through a haptoglobin-like receptor.	Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Hajduk, SL (corresponding author), Univ Alabama, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027316] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27316] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; Dobryszycka W, 1997, EUR J CLIN CHEM CLIN, V35, P647; GILLETT MPT, 1992, BIOCHIM BIOPHYS ACTA, V1123, P239, DOI 10.1016/0005-2760(92)90002-D; GRAB DJ, 1993, EUR J CELL BIOL, V62, P114; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HAJDUK SL, 1992, PARASITOL TODAY, V8, P95, DOI 10.1016/0169-4758(92)90247-Y; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; KIMURA H, 1975, J BIOCHEM-TOKYO, V77, P909, DOI 10.1093/oxfordjournals.jbchem.a130814; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; Lee MGS, 1999, MOL BIOCHEM PARASIT, V100, P153, DOI 10.1016/S0166-6851(99)00009-2; LORENZ P, 1994, T ROY SOC TROP MED H, V88, P487, DOI 10.1016/0035-9203(94)90443-X; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MCEVOY SM, 1988, J BIOL CHEM, V263, P15740; Miller YI, 1997, BIOCHEMISTRY-US, V36, P12189, DOI 10.1021/bi970258a; Muranjan M, 1998, J BIOL CHEM, V273, P3884, DOI 10.1074/jbc.273.7.3884; OKUDA M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P143, DOI 10.1016/0167-4889(92)90249-B; Raper J, 1996, J EXP MED, V183, P1023, DOI 10.1084/jem.183.3.1023; Raper J, 1996, MOL BIOCHEM PARASIT, V76, P337, DOI 10.1016/0166-6851(95)02551-0; Sambrook J., 2002, MOL CLONING LAB MANU; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; SHIMAMURA M, 2001, IN PRESS MOL BIOCH P; SMITH AB, 1995, P NATL ACAD SCI USA, V92, P10262, DOI 10.1073/pnas.92.22.10262; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; VADIVELOO PK, 1992, BIOCHEM J, V284, P145, DOI 10.1042/bj2840145	30	77	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30254	30260		10.1074/jbc.M010198200	http://dx.doi.org/10.1074/jbc.M010198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11352898	hybrid			2022-12-27	WOS:000170558000086
J	Okuyama, H; Shimahara, Y; Kawada, N; Seki, S; Kristensen, DB; Yoshizato, K; Uyama, N; Yamaoka, Y				Okuyama, H; Shimahara, Y; Kawada, N; Seki, S; Kristensen, DB; Yoshizato, K; Uyama, N; Yamaoka, Y			Regulation of cell growth by redox-mediated extracellular proteolysis of platelet-derived growth factor receptor ss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STELLATE CELLS; ACTIVATION; PROTEINS	Redox-regulated processes are important elements in various cellular functions. Reducing agents, such as N-acetyl-L-cysteine- (NAC), are known to regulate signal transduction and cell growth through their radical scavenging action. However, recent studies have shown that reactive oxygen species are not always involved in ligand-stimulated intracellular signaling. Here, we report a novel mechanism by which NAC blocks platelet-derived growth factor (PDGF)-induced signaling pathways in hepatic stellate cells, a fibrogenic player in the liver. Unlike in vascular smooth muscle cells, we found that reducing agents, including NAC, triggered extracellular proteolysis of PDGF receptor-beta, leading to desensitization of hepatic stellate cells toward PDGF-BB. This effect was mediated by secreted mature cathepsin B. In addition, type II transforming growth factor-beta receptor was also down-regulated. Furthermore, these events seemed to cause a dramatic improvement of rat liver fibrosis. These results indicated that redox processes impact the cell's response to growth factors by regulating the turnover of growth factor receptors and that "redox therapy" is promising for fibrosis-related disease.	Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Sakyo Ku, Kyoto 6068397, Japan; Osaka City Univ, Grad Sch Med, Dept Hepatol, Abeno Ku, Osaka 5458585, Japan; Japan Sci & Technol Corp, Reg Sci Promoter Program, Hiroshima Proteome Lab, Hiroshima 7390046, Japan; JST, Hiroshima Prefecture Collaborat Reg Ent Advanceme, Hiroshima Tissue Regenerat Project, Hiroshima 7390046, Japan; Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Hiroshima 7398526, Japan	Kyoto University; Osaka Metropolitan University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Hiroshima University	Okuyama, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Surg Gastroenterol, Sakyo Ku, Kyoto 6068397, Japan.	yokuyama@f8.dion.ne.jp	kawada, norifumi/AAS-1367-2020					Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; George J, 1999, P NATL ACAD SCI USA, V96, P12719, DOI 10.1073/pnas.96.22.12719; HILL PA, 1994, J CELL BIOCHEM, V56, P118, DOI 10.1002/jcb.240560116; KASAI Y, 1988, P NATL ACAD SCI USA, V85, P146; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; KAWADA N, 1993, EUR J BIOCHEM, V213, P815, DOI 10.1111/j.1432-1033.1993.tb17824.x; KELLY GS, 1997, ALT MED REV, V3, P114; Kirschke H, 1998, LYSOSOMAL CYSTEINE P; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LAUTERBURG BH, 1983, J CLIN INVEST, V71, P980, DOI 10.1172/JCI110853; Leto G, 1997, ONCOLOGY, V54, P79; Li D, 1999, J GASTROEN HEPATOL, V14, P618, DOI 10.1046/j.1440-1746.1999.01928.x; MORI S, 1993, J BIOL CHEM, V268, P577; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; NISHIMURA Y, 1990, ACTA HISTOCHEM CYTOC, V23, P53, DOI 10.1267/ahc.23.53; OKAMOTO T, 1999, OXIDAT STRESS DIS, V3, P261; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SASADA T, 1999, OXIDAT STRESS DIS, V3, P1; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F	27	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28274	28280		10.1074/jbc.M102995200	http://dx.doi.org/10.1074/jbc.M102995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11346654	hybrid, Green Submitted			2022-12-27	WOS:000170093400072
J	Dmitriev, OY; Fillingame, RH				Dmitriev, OY; Fillingame, RH			Structure of Ala(20) -> Prs/Pro(64) -> Ala substituted subunit c of Escherichia coli ATP synthase in which the essential proline is switched between transmembrane helices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING H+ TRANSPORT; CROSS-LINKING; PROTON TRANSLOCATION; MEMBRANE DOMAIN; ALPHA-HELIX; POLAR LOOP; F-0; OLIGOMER; EPSILON; F0F1	The structure of the A20P/P64A mutated subunit c of Escherichia coli ATP synthase, in which the essential proline has been switched from residue 64 of the second transmembrane helix (TMH) to residue 20 of the first TMH, has been solved by N-15,H-1 MMR in a monophasic chloroform/methanol/water (4:4:1) solvent mixture. The cA20P/P64A mutant grows as well as wild type, and the F0F1 complex is fully functional in ATPase-coupled H+ pumping. Residues 20 and 64 lie directly opposite to each other in the hairpin-like structure of wild type subunit c, and the prolinyl 64 residue is thought to induce a slight bend in TMH-2 such that it wraps around a more straightened TMH-1. In solution, the A20P/P64A substituted subunit c also forms a hairpin of two alpha -helices, with residues 41-45 forming a connecting loop as in the case of the wild type protein, but, in this case, Pro(20) induces a bend in TMH-1, which then packs against a more straightened TMH-2. The essential prolinyl residue, whether at position 64 or 20, lies close to the aspartyl 61 H+ binding site. The prolinyl residue may introduce structural flexibility in this region of the protein, which may be necessary for the proposed movement of the alpha -helical segments during the course of the H+ pumping catalytic cycle.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Fillingame, RH (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	rhfillin@facstaff.wisc.edu	Dmitriev, Oleg/AAB-7830-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008438, S10RR002781, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023105, R01GM023105] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02301, RR08438, RR02781] Funding Source: Medline; NIGMS NIH HHS [GM23105] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Altendorf K, 2000, J EXP BIOL, V203, P19; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BAX A, 1994, METHOD ENZYMOL, V239, P79; Biggin PC, 1997, BIOPHYS J, V72, P627, DOI 10.1016/S0006-3495(97)78701-0; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Capaldi RA, 2000, J EXP BIOL, V203, P29; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1999, SCIENCE, V286, P1687, DOI 10.1126/science.286.5445.1687; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 2000, J EXP BIOL, V203, P9; FILLINGAME RH, 1975, J BACTERIOL, V124, P870, DOI 10.1128/JB.124.2.870-883.1975; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FIMMEL AL, 1983, BIOCHEM J, V213, P451, DOI 10.1042/bj2130451; FRAGA D, 1990, THESIS U WISCONSIN M; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 2000, J BIOL CHEM, V275, P11355, DOI 10.1074/jbc.275.15.11355; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; MOSHER ME, 1985, J BIOL CHEM, V260, P4807; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SANKARARAMAKRISHNAN R, 1993, PROTEINS, V15, P26, DOI 10.1002/prot.340150105; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; VIK SB, 1994, J BIOL CHEM, V269, P30364; WARREN WS, 1993, SCIENCE, V262, P2005, DOI 10.1126/science.8266096; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; Woolf TB, 1997, BIOPHYS J, V73, P2376, DOI 10.1016/S0006-3495(97)78267-5; YUN RH, 1991, PROTEINS, V10, P219, DOI 10.1002/prot.340100306; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	56	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27449	27454		10.1074/jbc.M100762200	http://dx.doi.org/10.1074/jbc.M100762200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11331283	hybrid			2022-12-27	WOS:000169966900095
J	Stuible, HP; Kombrink, E				Stuible, HP; Kombrink, E			Identification of the substrate specificity-conferring amino acid residues of 4-coumarate : coenzyme A ligase allows the rational design of mutant enzymes with new catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-FORMING ENZYMES; CELL-SUSPENSION CULTURES; COA LIGASE; PEPTIDE SYNTHETASES; PARA-COUMARATE; ISOENZYMES; BIOSYNTHESIS; EXPRESSION; BINDING; DOMAINS	4-Coumarate:coenzyme A ligases (4CLs) generally use, in addition to coumarate, caffeate and ferulate as their main substrates, However, the recently cloned Arabidopsis thaliana isoform At4CL2 is exceptional because it has no appreciable activity with ferulate, On the basis of information obtained from the crystal structure of the phenylalanine-activating domain of gramicidin S-synthetase, 10 amino acid residues were identified that may form the substrate binding pocket of 4CL, Among these amino acids, representing the putative "substrate specificity motif," only one residue, Met(293), was not con served in At4CL2, compared with At4CL1 and At4CL3, two isoforms using ferulate, Substitution of Met(293) or Lys(320), another residue of the putative substrate specificity motif, which in the predicted three-dimensional structure is located in close proximity to Met(293), by smaller amino acids converted At4CL2 to an enzyme capable of using ferulate. The activity with caffeate was not or only moderately affected. Conversely, substitution of Met(293) by bulky aromatic amino acids increased the apparent affinity (K-m) for caffeate up to 10-fold, whereas single substitutions of Val(294) did not affect substrate use, The results support our structural assumptions and suggest that the amino acid residues 293 and 320 of At4CL2 directly interact with the 3-methoxy group of the phenolic substrate and therefore allow a first insight into the structural principles determining substrate specificity of 4CL.	Max Planck Inst Zuchtungsforsch, Biochem Abt, D-50829 Cologne, Germany	Max Planck Society	Kombrink, E (corresponding author), Max Planck Inst Zuchtungsforsch, Biochem Abt, Carl von Linne Weg 10, D-50829 Cologne, Germany.							BECKERANDRE M, 1991, J BIOL CHEM, V266, P8551; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Challis GL, 2000, CHEM BIOL, V7, P211, DOI 10.1016/S1074-5521(00)00091-0; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dixon RA, 1999, TRENDS PLANT SCI, V4, P394, DOI 10.1016/S1360-1385(99)01471-5; Ehlting J, 1999, PLANT J, V19, P9, DOI 10.1046/j.1365-313X.1999.00491.x; FULDA M, 1994, MOL GEN GENET, V242, P241, DOI 10.1007/BF00280412; GRAND C, 1983, PLANTA, V158, P225, DOI 10.1007/BF01075258; Hu WJ, 1998, P NATL ACAD SCI USA, V95, P5407, DOI 10.1073/pnas.95.9.5407; Kajita S, 1997, PLANT PHYSIOL, V114, P871, DOI 10.1104/pp.114.3.871; KNOBLOCH KH, 1977, ARCH BIOCHEM BIOPHYS, V184, P237, DOI 10.1016/0003-9861(77)90347-2; KNOBLOCH KH, 1975, EUR J BIOCHEM, V52, P311, DOI 10.1111/j.1432-1033.1975.tb03999.x; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; Lee D, 1997, PLANT CELL, V9, P1985, DOI 10.1105/tpc.9.11.1985; RANJEVA R, 1976, BIOCHIMIE, V58, P1255, DOI 10.1016/S0300-9084(76)80125-3; Sambrook J., 2002, MOL CLONING LAB MANU; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; Stuible HP, 2000, FEBS LETT, V467, P117, DOI 10.1016/S0014-5793(00)01133-9; von Dohren H, 1999, CHEM BIOL, V6, pR273, DOI 10.1016/S1074-5521(00)80014-9; WALLIS PJ, 1977, PHYTOCHEMISTRY, V16, P1891, DOI 10.1016/0031-9422(77)80090-3; Weisshaar B, 1998, CURR OPIN PLANT BIOL, V1, P251, DOI 10.1016/S1369-5266(98)80113-1	25	59	81	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26893	26897		10.1074/jbc.M100355200	http://dx.doi.org/10.1074/jbc.M100355200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11323416	hybrid			2022-12-27	WOS:000169966900023
J	Zeng, HY; Dvorak, HF; Mukhopadhyay, D				Zeng, HY; Dvorak, HF; Mukhopadhyay, D			Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; TUMOR-CELLS; ANGIOGENESIS; FLT-1; EXPRESSION; 3-KINASE; KDR; IDENTIFICATION	Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) achieves its multiple functions by activating two receptor tyrosine kinases, Flt-1 (VEGF receptor-1) and KDR (VEGF receptor-2), both of which are selectively expressed on primary vascular endothelium. To dissect the respective signaling pathways and biological functions mediated by these receptors in primary endothelial cells with these two receptors intact, we developed a chimeric receptor system in which the N terminus of the epidermal growth factor receptor was fused to the transmembrane domain and intracellular domain of KDR (EGDR) and Flt-1 (EGLT). We observed that KDR, but not Flt-1, was responsible for VPF/VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation and migration. Moreover, Flt-1 showed an inhibitory effect on KDR-mediated proliferation, but not migration. We also demonstrated that the inhibitory function of Flt-1 was mediated through the phosphatidylinositol 3-kinase (PI-3K)-dependent pathway because inhibitors of PI-3K as well as a dominant negative mutant of p85 (PI-3K subunit) reversed the inhibition, whereas a constitutively activated mutant of p110 introduced the inhibition to HUVEC-EGDR. We also observed that, in VPF/VEGF-stimulated HUVECs, the Flt-1/EGLT-mediated down-modulation of KDR/EGDR signaling was at or before intracellular Ca2+ mobilization, but after KDR/EGDR phosphorylation. By mutational analysis, we further identified that the tyrosine 794 residue of Flt-1 was essential for its antiproliferative effect. Taken together, these studies contribute significantly to our understanding of the signaling pathways and biological functions triggered by KDR and Flt-1 and describe a unique mechanism in which PI-3K acts as a mediator of antiproliferation in primary vascular endothelium.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN270H,330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA050453, R01CA078383, R29CA078383] Funding Source: NIH RePORTER; NCI NIH HHS [CA50453, CA78383] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEZRA M, 1993, BLOOD, V81, P3324; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; BROCK TA, 1991, AM J PATHOL, V138, P213; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dvorak H.F., 1984, DEV ONCOL, V22, P96; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1979, J IMMUNOL, V122, P166; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	39	245	268	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26969	26979		10.1074/jbc.M103213200	http://dx.doi.org/10.1074/jbc.M103213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350975	hybrid			2022-12-27	WOS:000169966900033
J	Kline, JB; Clevenger, CV				Kline, JB; Clevenger, CV			Identification and characterization of the prolactin-binding protein in human serum and milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; PLASMA-MEMBRANE GLYCOPROTEINS; GH-BINDING; (GH)-BINDING PROTEIN; LACTOGENIC HORMONES; EXTRACELLULAR DOMAIN; ESCHERICHIA-COLI; SINGLE-GENE; EXPRESSION; RAT	The actions of prolactin (PRL) are mediated by its receptor, a member of the superfamily of single transmembrane cytokine receptors, High affinity binding proteins for the closely related growth hormone have been found in the sera of several species including humans and are generated by alternative splicing or proteolysis of the growth hormone receptor extracellular domain (ECD), In contrast, no conclusive evidence has been presented that an analogous prolactin-binding protein (PRLBP) is expressed in human serum. Using both monoclonal and polyclonal antibodies generated against hPRL and the ECD of the human prolactin receptor, co-immunoprecipitation analyses of human serum identified a 32-kDa hPRLBP capable of binding both hPRL and human growth hormone. A measurable fraction of circulating PRL (36%) was associated with the hPRLBP, Despite well documented sex differences in serum hPRL levels, there were no significant differences in the levels of hPRLBP found in the sera of normal adult males and females (15.3 +/- 1.3 ng/ml versus 13.4 +/- 0.8 ng/ml, respectively (mean +/- S,E,)). Immunoprecipitation studies also detected the PRLBP in human milk albeit at lower concentrations than found in sera. Deglycosylation did not alter its electrophoretic mobility, indicating an absence of carbohydrate moieties and suggesting that the hPRLBP spans most of the PRLR ECD, a result confirmed by limited proteolysis and mass spectrometry. The potential function of this serum chaperone was assessed in vitro by the addition of recombinant hPRLBP to the culture medium of the PRL-dependent Nb2 T-cell line. These studies revealed that the hPRLBP antagonizes PRL action, inhibiting PRL-driven growth in a dose-dependent manner.	Univ Penn, Med Ctr, Dept Pathol & Lab Med, Stellar Chance Labs 513, Philadelphia, PA 19104 USA	University of Pennsylvania	Clevenger, CV (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Stellar Chance Labs 513, 422 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA069294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009727] Funding Source: NIH RePORTER; NCI NIH HHS [2R01 CA69294] Funding Source: Medline; NIDDK NIH HHS [1F32 DK09727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amit T, 1997, MOL CELL ENDOCRINOL, V130, P167, DOI 10.1016/S0303-7207(97)00088-9; Barnard R, 1997, J ENDOCRINOL, V153, P1, DOI 10.1677/joe.0.1530001; BAUMANN G, 1986, J CLIN ENDOCR METAB, V62, P134, DOI 10.1210/jcem-62-1-134; BAUMANN G, 1987, J CLIN ENDOCR METAB, V64, P657, DOI 10.1210/jcem-64-4-657; BAUMANN G, 1988, ENDOCRINOLOGY, V122, P976, DOI 10.1210/endo-122-3-976; BAUMANN G, 1990, J CLIN ENDOCR METAB, V71, P470, DOI 10.1210/jcem-71-2-470; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; Buteau H, 1998, MOL ENDOCRINOL, V12, P544, DOI 10.1210/me.12.4.544; CARMIGNAC DF, 1992, J ENDOCRINOL, V135, P447, DOI 10.1677/joe.0.1350447; Clark RG, 1996, ENDOCRINOLOGY, V137, P4308, DOI 10.1210/en.137.10.4308; DORATO A, 1992, ENDOCRINOLOGY, V131, P1734, DOI 10.1210/en.131.4.1734; EDENS A, 1994, ENDOCRINOLOGY, V135, P2802, DOI 10.1210/en.135.6.2802; FRASER IS, 1989, J CLIN ENDOCR METAB, V69, P585, DOI 10.1210/jcem-69-3-585; GARGOSKY SE, 1995, ENDOCRINE, V3, P813, DOI 10.1007/BF02935686; Gertler A, 1996, J BIOL CHEM, V271, P24482, DOI 10.1074/jbc.271.40.24482; HERINGTON AC, 1986, J CLIN INVEST, V77, P1817, DOI 10.1172/JCI112507; IINO T, 1986, J GEN VIROL, V67, P1373, DOI 10.1099/0022-1317-67-7-1373; Leav I, 1999, AM J PATHOL, V154, P863, DOI 10.1016/S0002-9440(10)65333-3; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIM L, 1990, ENDOCRINOLOGY, V127, P1287, DOI 10.1210/endo-127-3-1287; MANNOR DA, 1991, J CLIN ENDOCR METAB, V73, P30, DOI 10.1210/jcem-73-1-30; MERCADO M, 1994, J CLIN ENDOCR METAB, V79, P1637, DOI 10.1210/jc.79.6.1637; PEETERS S, 1977, ENDOCRINOLOGY, V101, P1164, DOI 10.1210/endo-101-4-1164; Rycyzyn MA, 2000, MOL ENDOCRINOL, V14, P1175, DOI 10.1210/me.14.8.1175; SAITO Y, 1995, J BIOCHEM, V118, P521, DOI 10.1093/oxfordjournals.jbchem.a124939; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SOTIROPOULOS A, 1993, ENDOCRINOLOGY, V132, P1863, DOI 10.1210/en.132.4.1863; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TALAMANTES F, 1994, P SOC EXP BIOL MED, V206, P254; TAR A, 1990, J CLIN ENDOCR METAB, V71, P1202, DOI 10.1210/jcem-71-5-1202; TAUBER R, 1989, EUR J BIOCHEM, V186, P55, DOI 10.1111/j.1432-1033.1989.tb15177.x; TAUBER R, 1983, P NATL ACAD SCI-BIOL, V80, P4026, DOI 10.1073/pnas.80.13.4026; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; TRIVEDI B, 1988, ENDOCRINOLOGY, V123, P2201, DOI 10.1210/endo-123-5-2201; WALKER AM, 1992, J PSYCHIATR NEUROSCI, V17, P61; WALKER AM, 1995, P NATL ACAD SCI USA, V92, P3278, DOI 10.1073/pnas.92.8.3278; WATERS MJ, 1980, ENDOCRINOLOGY, V107, P816, DOI 10.1210/endo-107-3-816; YMER SI, 1985, MOL CELL ENDOCRINOL, V41, P153, DOI 10.1016/0303-7207(85)90018-8; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZHANG FP, 1995, J ENDOCRINOL, V147, P497, DOI 10.1677/joe.0.1470497	42	59	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24760	24766		10.1074/jbc.M011786200	http://dx.doi.org/10.1074/jbc.M011786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337493	hybrid			2022-12-27	WOS:000169800700047
J	Ma, XR; Karra, S; Guo, W; Lindner, DJ; Hu, JD; Angell, JE; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV				Ma, XR; Karra, S; Guo, W; Lindner, DJ; Hu, JD; Angell, JE; Hofmann, ER; Reddy, SPM; Kalvakolanu, DV			Regulation of interferon and retinoic acid-induced cell death activation through thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT PROTEIN-KINASE; INDUCED APOPTOSIS; MOLECULAR-CLONING; REDOX REGULATION; CYTOCHROME-C; VITAMIN-A; GROWTH; RECEPTOR; EXPRESSION	Interferons (IFNs) and retinoids are potent biological response modifiers. The IFN-beta and all-trans-retinoic acid combination, but not these single agents individually, induces death in several tumor cell lines. To elucidate the molecular basis for these actions, we have employed an antisense knockout approach to identify the gene products that mediate cell death and isolated several genes associated with retinoid-IFN-induced mortality (GRIMs), One of the GRIM cDNAs, GRIM-12, was identical to human thioredoxin reductase (TR). To define the functional relevance of TR to cell death and to define its mechanism of death-modulating functions, we generated mutants of TR and studied their influence on the IFN/RA-induced death regulatory functions of caspases, Wild-type TR activates cell death that was inhibited in the presence of caspase inhibitors or catalytically inactive caspases, A mutant TR, lacking the active site cysteines, inhibits the cell death induced by caspase 8. IFN/all-trans-retinoic acid-induced cytochrome c release from the mitochondrion was promoted in the presence of wild type and was inhibited in the presence of mutant TR, We find that TR modulates the activity of caspase 8 to promote death. This effect is in part caused by the stimulation of death receptor gene expression. These studies identify a new mechanism of cell death regulation by the IFN/all-trans-retinoic acid combination involving redox enzymes.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol,Mol & Cellular Biol Prog, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		NCI NIH HHS [CA 78282, CA 71401] Funding Source: Medline; NHLBI NIH HHS [HL-58122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078282, R01CA071401] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058122, R01HL058122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Casso D, 1996, MOL GEN GENET, V252, P518, DOI 10.1007/BF02172398; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gallegos A, 1996, CANCER RES, V56, P5765; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HARTMAN H, 1993, P NATL ACAD SCI USA, V90, P2271, DOI 10.1073/pnas.90.6.2271; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; IRMIER M, 1997, NATURE, V388, P190; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUBARTELLI A, 1995, CANCER RES, V55, P675; SALZ HK, 1994, GENETICS, V136, P1075; Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 2000, CLIN CANCER RES, V6, P1563; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Ueda S, 1998, J IMMUNOL, V161, P6689; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang ZG, 1998, SCIENCE, V279, P1547; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xiao WH, 1997, J BIOL CHEM, V272, P9742, DOI 10.1074/jbc.272.15.9742; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	77	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24843	24854		10.1074/jbc.M100380200	http://dx.doi.org/10.1074/jbc.M100380200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331281	hybrid			2022-12-27	WOS:000169800700057
J	Nomura, M; Kaji, A; Ma, WY; Zhong, SP; Liu, GM; Bowden, CT; Miyamoto, K; Dong, ZG				Nomura, M; Kaji, A; Ma, WY; Zhong, SP; Liu, GM; Bowden, CT; Miyamoto, K; Dong, ZG			Mitogen and stress-activated protein kinase 1 mediates activation of Akt by ultraviolet B irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; GLYCOGEN-SYNTHASE KINASE-3; SERINE THREONINE KINASES; TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; P38 MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELL-SURVIVAL; GROWTH-FACTOR	In this study, we investigated the mechanism by which UVB irradiation activates Akt (also known as protein kinase B (PKB)) in mouse epidermal JB6 cells. Treatment with a phosphatidylinositol 3-kinase inhibitor, LY 294002, or expression of a dominant negative mutant of p85 (regulatory component of phosphatidylinositol 3-kinase) inhibited UVB-induced Akt activation. Interestingly, Akt activation by UVB was attenuated by treatment with PD 98059, a specific mitogen-activated protein kinase/extracellular signal-regulated protein kinase (Erk) kinase 1 inhibitor, or SE 202190, a specific p38 kinase inhibitor. Furthermore, the expression of a dominant negative mutant of Erk2 or p38 kinase, but not that of c-dun N-terminal kinase 1 (JNK1), blocked UVB-induced Akt activation. The expression of a dominant negative mutant of p85 or treatment with LY 294002 also inhibited UVB-induced Erk phosphorylation. The UVB-activated mitogen-activated protein kinase members, which were immunoprecipitated from cells exposed to UVB, did not phosphorylate Akt, Instead, Akt was phosphorylated at both threonine 308 and serine 473 and activated by UVB-activated mitogen- and stress-activated protein kinase 1 (Msk1). The expression of a Msk1 C-terminal kinase-dead mutant inhibited UVB-induced phosphorylation and activation of Akt. These data thus suggested that UVB-induced Akt activation was mediated through Msk1, which is a downstream kinase of the Erk and p38 kinase signaling pathways.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85721 USA; Kanazawa Univ, Hosp Pharm, Kanazawa, Ishikawa 9200934, Japan	University of Minnesota System; Arizona Center Cancer Care; University of Arizona; Kanazawa University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@smig.net			NCI NIH HHS [CA27502, CA74916, CA81064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027502, R29CA074916, R01CA081064, R37CA081064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cadet J, 1997, BIOL CHEM, V378, P1275; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Davies MA, 1999, CANCER RES, V59, P2551; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Kabuyama Y, 1998, FEBS LETT, V441, P297, DOI 10.1016/S0014-5793(98)01565-8; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEY RD, 1993, P NATL ACAD SCI USA, V90, P4337, DOI 10.1073/pnas.90.10.4337; Li DM, 1997, CANCER RES, V57, P2124; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Matsuda N, 2000, PHOTOCHEM PHOTOBIOL, V72, P334, DOI 10.1562/0031-8655(2000)072<0334:DAOEAJ>2.0.CO;2; MATSUI MS, 1995, PHOTOCARCINOGENESIS, P21; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Nomura T, 1997, CANCER RES, V57, P2081; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Scheid MP, 1996, J BIOL CHEM, V271, P18134, DOI 10.1074/jbc.271.30.18134; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tyrrell R M, 1996, EXS, V77, P255; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	80	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25558	25567		10.1074/jbc.M101164200	http://dx.doi.org/10.1074/jbc.M101164200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350959	hybrid			2022-12-27	WOS:000169800700147
J	Wong, GE; Zhu, XL; Prater, CE; Oh, E; Evans, JP				Wong, GE; Zhu, XL; Prater, CE; Oh, E; Evans, JP			Analysis of fertilin alpha (ADAM1)-mediated sperm-egg cell adhesion during fertilization and identification of an adhesion-mediating sequence in the disintegrin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; IN-VITRO FERTILIZATION; INTEGRIN ALPHA-6-BETA-1; POTENTIAL ROLE; ADAM 2; HUMAN FIBRONECTIN; SURFACE PROTEIN; MOUSE EGGS; BINDING; BETA	Fertilin alpha (also known as ADAM1) is a member of the ADAM ((A) under bar (d) under bar isintegrin and (A) under bar (m) under bar etalloprotease domain) family of proteins. In this study, we examine the mechanism of mouse fertilin alpha 's in adhesion of sperm to the egg plasma membrane during fertilization. We find that recombinant forms of fertilin alpha corresponding to either the disintegrin-like domain or the cysteine-rich domain and the EGF-like repeat can perturb sperm-egg binding, suggesting that both of these domains can participate in fertilin alpha -mediated adhesion events. In further examination of the fertilin alpha disintegrin-like domain, we find that a subdomain of disintegrin-like domain with the sequence DLEECDCG outside the putative disintegrin loop but with homology to the fertilin beta disintegrin loop can inhibit the binding of both sperm and recombinant fertilin a to eggs, suggesting that this is an adhesion-mediating motif of the fertilin a disintegrin-like domain. This sequence also inhibits the binding of recombinant fertilin p to eggs and thus is the first peptide sequence found to block two different sperm ligands, Finally, a monoclonal antibody to the tetraspanin protein CD9, KMC.8, inhibited the binding of recombinant fertilin a to eggs in one type of binding assay, suggesting that, under certain conditions, fertilin a may interact with a KMC.8-sensitive binding site on the egg plasma membrane.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Div Reprod Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Evans, JP (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Div Reprod Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.	jpevans@jhsph.edu		Prater, Chrissy/0000-0002-4247-2351	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD037696, R01HD037696] Funding Source: NIH RePORTER; NCI NIH HHS [CA09110] Funding Source: Medline; NICHD NIH HHS [R29 HD037696-04, R29 HD037696, HD 37696, HD07276] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; AOTA S, 1994, J BIOL CHEM, V269, P24756; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Chen MS, 1999, P NATL ACAD SCI USA, V96, P11830, DOI 10.1073/pnas.96.21.11830; Chen MS, 1999, J CELL BIOL, V144, P549, DOI 10.1083/jcb.144.3.549; Cho CH, 2000, DEV BIOL, V222, P289, DOI 10.1006/dbio.2000.9703; Dustin ML, 1998, CELL ADHES COMMUN, V6, P255, DOI 10.3109/15419069809004481; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Evans Janice P., 1999, Frontiers in Bioscience, V4, pD114, DOI 10.2741/Evans; Evans JP, 1997, DEV BIOL, V187, P94, DOI 10.1006/dbio.1997.8612; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; Evans JP, 1998, BIOL REPROD, V59, P145, DOI 10.1095/biolreprod59.1.145; Hardy CM, 1997, BIOL REPROD, V57, P879, DOI 10.1095/biolreprod57.4.879; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Jia LG, 2000, ARCH BIOCHEM BIOPHYS, V373, P281, DOI 10.1006/abbi.1999.1517; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Linder B, 1997, DEV GROWTH DIFFER, V39, P243; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; MARDON HJ, 1994, FEBS LETT, V340, P197, DOI 10.1016/0014-5793(94)80137-1; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Pyluck A, 1997, BIOORG MED CHEM LETT, V7, P1053, DOI 10.1016/S0960-894X(97)00160-1; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Redkar AA, 1999, J ANDROL, V20, P500; Schlondorff J, 1999, J CELL SCI, V112, P3603; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Waters SI, 1997, BIOL REPROD, V56, P1245, DOI 10.1095/biolreprod56.5.1245; Whitten WK, 1971, ADV BIOSCI, V6, P129, DOI DOI 10.1016/B978-0-08-017571-3.50013-9; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhu XL, 2000, J BIOL CHEM, V275, P7677, DOI 10.1074/jbc.275.11.7677	40	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24937	24945		10.1074/jbc.M101637200	http://dx.doi.org/10.1074/jbc.M101637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342541	hybrid			2022-12-27	WOS:000169800700068
J	Zhong, Q; Kolls, JK; Schwarzenberger, P				Zhong, Q; Kolls, JK; Schwarzenberger, P			Retrovirus molecular conjugates - A novel, high transduction efficiency, potentially safety-improved, gene transfer system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; GEL-ELECTROPHORESIS; TERMINAL FRAGMENTS; TARGET-CELLS; DNA LENGTH; VECTORS; THERAPY; RECEPTOR; FIBRONECTIN; PROGENITOR	Two significant barriers limit the use of amphotropic retrovirus for human gene transfer protocols: 1) low transduction efficiency in cells with low receptor expression and 2) safety concerns originating from the risk of formation and propagation of replication competent virus in vivo. In principle, if ecotropic retrovirus, which is incapable of infecting human cells, could be transiently modified to effectively transduce human cells, this safety risk could be alleviated. Here we demonstrate that formation of amphotropic retrovirus polylysine molecular conjugates (aMMLV-PL) enhanced gene transfer up to 10-fold in a variety of human cell lines over the equivalent of unconjugated vector (aMMLV). The polylysine modification and formation of ecotropic retrovirus molecular conjugates (eMMLV-PL) permitted effective and stable transduction of different human cell lines as well as primary human bone marrow stroma cells at frequencies of greater than 80%. It is conceivable that this novel ecotropic-based conjugate retrovirus vector could also potentially provide enhanced safety characteristics not only over amphotropic retrovirus vectors but also over genetically tropism-modified recombinant ecotropic vectors. In contrast to genetic modifications, physical or chemical modifications are not propagated. Thus, formation of replication competent eMMLV from conjugates would be self-limited and would not result in virus propagation in humans.	Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, New Orleans, LA 70122 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med, New Orleans, LA 70122 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70122 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Schwarzenberger, P (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, 533 Bolivar St,Rm 611, New Orleans, LA 70122 USA.	pschwa1@lsuhsc.edu	Kolls, Jay/AAH-1829-2019; Schwarzenberger, Paul/AAZ-2174-2021	Kolls, Jay/0000-0001-5151-6304; 	NCI NIH HHS [R01 CA81125-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKATSUKA Y, 1994, INT J HEMATOL, V60, P251; Asada K, 1998, J BIOCHEM-TOKYO, V123, P1041; Avalosse Bernard, 1995, Current Opinion in Oncology, V7, P94; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Chen L, 1996, J CLIN INVEST, V98, P2539, DOI 10.1172/JCI119072; CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; CORNETTA K, 1989, J VIROL METHODS, V23, P187, DOI 10.1016/0166-0934(89)90132-8; CROOKS GM, 1993, BLOOD, V82, P3290; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; ELDER JK, 1983, ANAL BIOCHEM, V128, P227, DOI 10.1016/0003-2697(83)90369-X; EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fielding AK, 1998, BLOOD, V91, P1802, DOI 10.1182/blood.V91.5.1802.1802_1802_1809; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HADDADA H, 1995, CURR TOP MICROBIOL, V199, P297; HANANIA EG, 1995, AM J MED, V99, P537, DOI 10.1016/S0002-9343(99)80232-0; Jenks S, 1997, J NATL CANCER I, V89, P1182; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; KIERNEY PC, 1987, BLOOD, V70, P1418; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; MacNeill EC, 1999, J VIROL, V73, P3960, DOI 10.1128/JVI.73.5.3960-3967.1999; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1990, BLOOD, V76, P271; Moritz T, 1996, BLOOD, V88, P855, DOI 10.1182/blood.V88.3.855.bloodjournal883855; NEDA H, 1991, J BIOL CHEM, V266, P14143; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; Sambrook J, 1989, MOL CLONING; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; Schwarzenberger P, 1997, J VIROL, V71, P8563, DOI 10.1128/JVI.71.11.8563-8571.1997; Schwarzenberger P, 1996, BLOOD, V87, P472, DOI 10.1182/blood.V87.2.472.bloodjournal872472; SKUTELSKY E, 1976, J CELL BIOL, V71, P232, DOI 10.1083/jcb.71.1.232; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; THOMA SJ, 1994, BLOOD, V83, P2103; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; Wickham TJ, 1996, NAT BIOTECHNOL, V14, P1570, DOI 10.1038/nbt1196-1570; YEE JK, 1994, METHOD CELL BIOL, V43, P99	41	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24601	24607		10.1074/jbc.M010318200	http://dx.doi.org/10.1074/jbc.M010318200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11313337	hybrid			2022-12-27	WOS:000169800700026
J	Zhu, Z; Ma, B; Homer, RJ; Zheng, T; Elias, JA				Zhu, Z; Ma, B; Homer, RJ; Zheng, T; Elias, JA			Use of the tetracycline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LUNG INJURY; GENE-EXPRESSION; MAMMALIAN-CELLS; EUKARYOTIC CELLS; REGULATED SYSTEM; GROWTH-FACTOR; MURINE LUNG; IL-13; INTERLEUKIN-13; INFLAMMATION	The doxycycline-inducible reverse tetracycline transactivator (rtTA) is frequently used to overexpress transgenes in a temporally regulated fashion in vivo, These systems are, however, often limited by the levels of transgene expression in the absence of dox administration. The tetracycline-controlled transcriptional silencer (tTS), a fusion protein containing the tet repressor and the KRAB-AB domain of the kid-1 transcriptional repressor, is inhibited by doxycycline, We hypothesized that tTS would tighten control of transgene expression in rtTA-based systems. To test this hypothesis we generated mice in which the CC10 promoter targeted tTS to the lung, bred these mice with CC10-rtTA-interleukin 13 (IL-13) mice in which IL-13 was overexpressed in an inducible lung-specific fashion, and compared the IL-13 production and phenotypes of parental mice and the triple transgenic CC10-rtTA/tTS-IL-13 progeny of these crosses. In the CC10-rtTA-IL-13 mice, IL-13, mucus metaplasia, inflammation, alveolar enlargement, and enhanced lung volumes were noted at base line and increased greatly after doxycycline administration. In the triple transgenic tTS animals, IL-13 and the IL-13-induced phenotype could not be appreciated without doxycycline. In contrast, tTS did not alter the induction of IL-13 or the generation of the IL-13 phenotype by doxycycline, Thus, tTS effectively eliminated the baseline leak without altering the inducibility of rtTA-regulated transgenes in vivo. Optimal "off/on" regulation of transgene expression can be accomplished with the combined use of tTS and rtTA.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Vet Affairs Connecticut Hlth Care Syst, Pathol & Lab Med Serv, West Haven, CT 06516 USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 333 Cedar St,105 LCI, New Haven, CT 06520 USA.	jack.elias@yale.edu	homer, robert/P-3884-2019	homer, robert/0000-0002-2055-5885	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056389, R01HL061904, R01HL064242, P50HL056389] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64242, HL-61904, HL-56389] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Cohn L, 1999, J IMMUNOL, V162, P6178; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; Forster K, 1999, NUCLEIC ACIDS RES, V27, P708, DOI 10.1093/nar/27.2.708; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gallia GL, 1998, ONCOGENE, V16, P1879, DOI 10.1038/sj.onc.1201706; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HOGAN B, 1986, MANIPULATING MOUSE E; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; SCHILZ R, 1996, AIRWAYS SMOOTH MUSCL, P241; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	34	104	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25222	25229		10.1074/jbc.M101512200	http://dx.doi.org/10.1074/jbc.M101512200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331286	hybrid			2022-12-27	WOS:000169800700106
J	Coon, SL; Weller, JL; Korf, HW; Namboodiri, MAA; Rollag, M; Klein, DC				Coon, SL; Weller, JL; Korf, HW; Namboodiri, MAA; Rollag, M; Klein, DC			cAMP regulation of arylalkylamine N-acetyltransferase (AANAT, EC 2.3.1.87) - A new cell line (1E7) provides evidence of intracellular AANAT activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELATONIN RHYTHM ENZYME; PINEAL-GLAND; PROTEASOMAL PROTEOLYSIS; ANGSTROM RESOLUTION; DISULFIDE EXCHANGE; NOCTURNAL INCREASE; PROTEIN THIOL; CYCLIC-AMP; EXPRESSION; INHIBITION	Arylalkylamine N-acetyltransferase (serotonin N-acetyltransferase, AANAT, EC 2.3.1.87) is the penultimate enzyme in melatonin synthesis. As described here, a cell line (1E7) expressing human AANAT (hAANAT) has been developed to study the human enzyme. 1E7 hAANAT is detectable in immunoblots as a 23-kDa band and is immunocytochemically visualized in the cytoplasm. The specific concentration of hAANAT in homogenates is comparable to that of the night rat pineal gland. Kinetics of AANAT extracted from 1E7 cells are the same as those of bacterially expressed hAANAT; both preparations of hAANAT are equally sensitive to the inhibitor CoA-S-N-acetyltryptamine. Studies of cAMP regulation indicate that treatment with forskolin, dibutyryl cAMP, isobutylmethylxanthine, or isoproterenol activate cellular hAANAT within intact 1E7 cells similar to8-fold without markedly increasing the abundance of AANAT protein or the activity of AANAT in broken cell preparations; and, that forskolin, isobutylmethylxanthine and isoproterenol elevate cyclic AMP production. These observations extend our understanding of cAMP regulation of AANAT activity, because it is currently thought that this only involves changes in the steady-state levels of AANAT protein. This previously unrecognized switching mechanism could function physiologically to control melatonin production without changing AANAT protein levels.	NICHD, Dev Neurobiol Lab, Sect Neuroendocrinol, NIH, Bethesda, MD 20892 USA; Univ Frankfurt, Inst Anat 2, D-60590 Frankfurt, Germany; Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Goethe University Frankfurt; Uniformed Services University of the Health Sciences - USA	Klein, DC (corresponding author), NICHD, Dev Neurobiol Lab, Sect Neuroendocrinol, NIH, Bldg 49,Rm 6A-80, Bethesda, MD 20892 USA.		Korf, Horst/ACX-9860-2022	Korf, Horst/0000-0002-5051-0303; Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000095, ZIAHD000095] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arent J., 1995, MELATONIN MAMMALIAN; Bernard M, 1997, J NEUROCHEM, V68, P213; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; Coon SL, 1996, GENOMICS, V34, P76, DOI 10.1006/geno.1996.0243; Coon SL, 1999, J BIOL CHEM, V274, P9076, DOI 10.1074/jbc.274.13.9076; DAVIS S E, 1980, Journal of Immunoassay, V1, P15, DOI 10.1080/01971528008055773; Dixon M, 1964, ENZYMES, P54; Falcon J, 2001, ENDOCRINOLOGY, V142, P1804, DOI 10.1210/en.142.5.1804; Ferry G, 2000, J BIOL CHEM, V275, P8794, DOI 10.1074/jbc.275.12.8794; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P161; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; GRACE MS, 1991, BRAIN RES, V559, P56, DOI 10.1016/0006-8993(91)90286-5; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Iuvone P. Michael, 1995, P25; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1969, ANAL BIOCHEM, V31, P480, DOI 10.1016/0003-2697(69)90290-5; KLEIN DC, 1982, TRENDS BIOCHEM SCI, V7, P98, DOI 10.1016/0968-0004(82)90156-6; KLEIN DC, 1972, THYROID BIOGENIC AMI, P550; KLEIN DC, 1998, HDB BEHAV STATE CONT, V4, P45; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAMBOODIRI MAA, 1985, J NEUROCHEM, V45, P832, DOI 10.1111/j.1471-4159.1985.tb04069.x; NAMBOODIRI MAA, 1981, SCIENCE, V213, P571, DOI 10.1126/science.7017937; NAMBOODIRI MAA, 1980, J BIOL CHEM, V255, P6032; NAMBOODIRI MAA, 1984, J COMP BIOCH B, V80, P731; PERLOW MJ, 1980, BRAIN RES, V182, P211, DOI 10.1016/0006-8993(80)90848-3; PIERCE ME, 1989, J NEUROCHEM, V53, P307, DOI 10.1111/j.1471-4159.1989.tb07330.x; REPPERT SM, 1979, ENDOCRINOLOGY, V104, P295, DOI 10.1210/endo-104-2-295; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Schomerus C, 2000, J NEUROCHEM, V75, P2123, DOI 10.1046/j.1471-4159.2000.0752123.x; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; THIBAULT C, 1993, J NEUROCHEM, V61, P332, DOI 10.1111/j.1471-4159.1993.tb03572.x; VATSIS KP, 1995, PHARMACOGENETICS, V5, P1, DOI 10.1097/00008571-199502000-00001; Yanez J, 1996, GEN COMP ENDOCR, V101, P165, DOI 10.1006/gcen.1996.0018; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zatz M, 2000, J NEUROCHEM, V74, P2315, DOI 10.1046/j.1471-4159.2000.0742315.x; Zhan-Poe XY, 1999, J PINEAL RES, V27, P49, DOI 10.1111/j.1600-079X.1999.tb00596.x	40	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24097	24107		10.1074/jbc.M011298200	http://dx.doi.org/10.1074/jbc.M011298200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313340	hybrid			2022-12-27	WOS:000169531100116
J	Mukherjee, K; Parashuraman, S; Raje, M; Mukhopadhyay, A				Mukherjee, K; Parashuraman, S; Raje, M; Mukhopadhyay, A			SopE acts as an Rab5-specific nucleotide exchange factor and recruits non-prenylated Rab5 on Salmonella-containing phagosomes to promote fusion with early endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; MEMBRANE ASSOCIATION; PROTEINS; TRANSPORT; GTPASES; TRAFFICKING; CYSTEINES; UNIQUE; DOMAIN	Rab-GTPase regulates the fusion between two specific vesicles. It is well documented that, for their biological function, Rab proteins need to be prenylated for attachment to the vesicle membrane. In contrast, we showed in the present investigation that SopE, a type III secretory protein of Salmonella, translocates onto Salmonella-containing phagosomes (LSP) and mediates the recruitment of non-prenylated RabB (Rab5:Delta C4) on LSP in GTP form. Simultaneously, SopE present in infected cell cytosol acts as an RabB specific exchange factor and converts the inactive Rab-GDP to the G;TP form. The non-prenylated Rab5 subsequently promoted efficient fusion of LSP with early endosomes. This is the first demonstration that a prenylation-deficient Rab protein retains biological activity and can promote vesicle fusion, if it is recruited on the membrane by some other method.	Natl Inst Immunol, Cell Biol Lab, New Delhi 110067, India; Inst Microbial Technol, Chandigarh 160036, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Mukhopadhyay, A (corresponding author), Natl Inst Immunol, Cell Biol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	amitabha@nii.res.in	Mukhopadhyay, Asok/C-4051-2009; Parashuraman, Seetharaman/P-3389-2014; parashuraman, seetharaman/ABE-2639-2020	Parashuraman, Seetharaman/0000-0001-5113-4592; parashuraman, seetharaman/0000-0001-5113-4592				Alory C, 2000, J CELL BIOL, V150, P89, DOI 10.1083/jcb.150.1.89; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Funato K, 1997, J BIOL CHEM, V272, P16147, DOI 10.1074/jbc.272.26.16147; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Garcia-del Portillo F, 1999, TRENDS MICROBIOL, V7, P467, DOI 10.1016/S0966-842X(99)01618-2; GARCIADELPORTILLO F, 1995, TRENDS MICROBIOL, V3, P373, DOI 10.1016/S0966-842X(00)88982-9; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gromov P, 1998, ELECTROPHORESIS, V19, P1803, DOI 10.1002/elps.1150191043; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hashim S, 2000, J BIOL CHEM, V275, P16281, DOI 10.1074/jbc.275.21.16281; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; Knight JB, 2000, ENDOCRINOLOGY, V141, P208, DOI 10.1210/en.141.1.208; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; Lobell RB, 1998, ADV IMMUNOL, V68, P145, DOI 10.1016/S0065-2776(08)60559-3; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Mukherjee K, 2000, J CELL BIOL, V148, P741, DOI 10.1083/jcb.148.4.741; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; Mukhopadhyay A, 1997, J BIOL CHEM, V272, P13055, DOI 10.1074/jbc.272.20.13055; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; Robinson LJ, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P248; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Seabra MC, 1998, CELL SIGNAL, V10, P167, DOI 10.1016/S0898-6568(97)00120-4; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092; ZIEGLER K, 1981, J IMMUNOL, V127, P1869	40	60	60	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23607	23615		10.1074/jbc.M101034200	http://dx.doi.org/10.1074/jbc.M101034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316807	hybrid			2022-12-27	WOS:000169531100052
J	Papineni, RVL; Sanchez, JU; Baksi, K; Willcockson, IU; Pedersen, SE				Papineni, RVL; Sanchez, JU; Baksi, K; Willcockson, IU; Pedersen, SE			Site-specific charge interactions of alpha-conotoxin MI with the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; SUBUNIT INTERFACES; ESCHERICHIA-COLI; LIGAND-BINDING; MOLECULAR DISSECTION; HIGH-AFFINITY; GI; DETERMINANTS; FUSION; IDENTIFICATION	We have tested the importance of charge interactions for cy-conotoxin MI binding to the nicotinic acetylcholine receptor (AChR). Ionic residues on alpha -conotoxin MI were altered by site-directed mutagenesis or by chemical modification. In physiological buffer, removal of charges at the N terminus, His-5, and Lys-10 had small (2-4-fold) effects on binding affinity to the mouse muscle AChR and the Torpedo AChR, It was also demonstrated that conotoxin had no effect on the conformational equilibrium of either receptor, as assessed by the effects of the noncompetitive antagonist proadifen on conotoxin binding and, conversely, the effect of conotoxin on the affinity of phencyclidine, proadifen, and ethidium. Conotoxin displayed higher binding affinity in low ionic strength buffer; neutralization of Lys-10 and the N terminus by acetylation blocked this affinity shift at the alpha delta site but not at the alpha gamma site, It is concluded that Ctx residues Lys-10 and the N terminal interact with oppositely charged receptor residues only at the alpha delta site, and the two sites have distinct arrangements of charged residues. Ethidium fluorescence experiments demonstrated that conotoxin is formally competitive with a small cholinergic ligand, tetramethylammonium, Thus, alpha -conotoxin MI appears to interact with the portion of the binding site responsible for stabilizing agonist cations but does not do so with a cationic residue and is, consequently, incapable of inducing a conformational change.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Cent Caribe, Dept Anat & Cell Biol, Bayamon, PR 00960 USA	Baylor College of Medicine	Pedersen, SE (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.	pedersen@bcm.tmc.edu		Pedersen, Steen E./0000-0001-8755-8899	NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003035] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035212] Funding Source: NIH RePORTER; NCRR NIH HHS [2G12RR3035] Funding Source: Medline; NHLBI NIH HHS [T32-HL07676] Funding Source: Medline; NINDS NIH HHS [NS35212] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARRANTES FJ, 1998, NICOTINIC ACETYLCHOL, P1; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; Bren N, 2000, J BIOL CHEM, V275, P12692, DOI 10.1074/jbc.275.17.12692; Chiara DC, 1999, BIOCHEMISTRY-US, V38, P6689, DOI 10.1021/bi9901735; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; GRAY WR, 1983, J BIOL CHEM, V258, P2247; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; Groebe DR, 1997, BIOCHEMISTRY-US, V36, P6469, DOI 10.1021/bi970195w; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; GUND TM, 1991, METHOD ENZYMOL, V203, P677; Hann RM, 1997, BIOCHEMISTRY-US, V36, P9051, DOI 10.1021/bi970807c; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; HASHIMOTO K, 1985, EUR J PHARMACOL, V118, P351, DOI 10.1016/0014-2999(85)90147-5; HERZ JM, 1987, J BIOL CHEM, V262, P7238; JENTOFT N, 1983, METHOD ENZYMOL, V91, P570; KELLERMANN OK, 1982, METHOD ENZYMOL, V90, P459; Lurtz MM, 1999, MOL PHARMACOL, V55, P159, DOI 10.1124/mol.55.1.159; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; McIntosh JM, 1999, ANNU REV BIOCHEM, V68, P59, DOI 10.1146/annurev.biochem.68.1.59; Means G.E., 1971, CHEM MODIFICATION PR, P214; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MYERS RA, 1989, THESIS U UTAH; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NISHIUCHI Y, 1982, FEBS LETT, V148, P260, DOI 10.1016/0014-5793(82)80820-X; Papineni RVL, 1997, J BIOL CHEM, V272, P24891, DOI 10.1074/jbc.272.40.24891; Pedersen S, 1995, Telemed J, V1, P47, DOI 10.1089/tmj.1.1995.1.47; Pedersen S E, 1999, Methods Enzymol, V294, P117; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; Prince RJ, 1999, J BIOL CHEM, V274, P19623, DOI 10.1074/jbc.274.28.19623; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Song XZ, 2000, BIOPHYS J, V78, P1324, DOI 10.1016/S0006-3495(00)76687-2; Sugiyama N, 1998, MOL PHARMACOL, V53, P787, DOI 10.1124/mol.53.4.787; Sugiyama N, 1996, J BIOL CHEM, V271, P26575, DOI 10.1074/jbc.271.43.26575; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; WEBER M, 1974, MOL PHARMACOL, V10, P1; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	44	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23589	23598		10.1074/jbc.M102350200	http://dx.doi.org/10.1074/jbc.M102350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323431	hybrid			2022-12-27	WOS:000169531100050
J	Roux, PP; Bhakar, AL; Kennedy, TE; Barker, PA				Roux, PP; Bhakar, AL; Kennedy, TE; Barker, PA			The p75 neurotrophin receptor activates Akt (protein kinase B) through a phosphatidylinositol 3-kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NF-KAPPA-B; ZINC-FINGER PROTEIN; CELL-DEATH; SIGNAL-TRANSDUCTION; NEURONAL APOPTOSIS; FACTOR-BINDING; SPHINGOMYELIN HYDROLYSIS; INTRACELLULAR DOMAIN; SURVIVAL SIGNALS	The Akt kinase plays a crucial role in supporting Trk-dependent cell survival, whereas the p75 neurotrophin receptor (p75NTR) facilitates cellular apoptosis. The precise mechanism that p75NTR uses to promote cell death is not certain, but one possibility is that p75NTR-dependent ceramide accumulation inhibits phosphatidylinositol 3-kinase mediated Akt activation. To test this hypothesis, we developed a system for examining p75NTR-dependent apoptosis and determined the effect of p75NTR on Akt activation. Surprisingly, p75NTR increased, rather than decreased, Akt phosphorylation in a variety of cell types, including human Niemann-Pick fibroblasts, which lack acidic sphingomyelinase activity. The p75NTR expression level required to elicit Akt phosphorylation was much lower than that required to activate the JNK pathway or to mediate apoptosis. Fire show that p75NTR dependent Akt phosphorylation was independent of TrkA signaling, required active phosphatidylinositol 3-kinase, and was associated with increased tyrosine phosphorylation of p85 and She and with reduced cytosolic tyrosine phosphatase activity. Finally, we show that p75NTR expression increased sur vival in cells exposed to staurosporine or subjected to serum withdrawal. These findings indicate that p75NTR facilitates cell survival through novel signaling cascades that result in Akt activation.	McGill Univ, Ctr Neuronal Survival, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Barker, PA (corresponding author), McGill Univ, Ctr Neuronal Survival, Montreal Neurol Inst, 3801 Univ Ave, Montreal, PQ H3A 2B4, Canada.		Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250				Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Blochl A, 1996, J BIOL CHEM, V271, P21100; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Brann AB, 1999, J NEUROSCI, V19, P8199; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Cochran B H, 1993, NIDA Res Monogr, V125, P3; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Frade JM, 2000, J CELL SCI, V113, P1139; Frade JM, 1999, DEVELOPMENT, V126, P683; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1996, NATURE, V383, P166; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GROB PM, 1985, J BIOL CHEM, V260, P8044; Gu CH, 1999, J NEUROSCI, V19, P3043; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Majdan M, 1997, J NEUROSCI, V17, P6988; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Ozes ON, 1999, NATURE, V401, P82; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rabizadeh S, 1999, CELL DEATH DIFFER, V6, P1222, DOI 10.1038/sj.cdd.4400614; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Verheij M, 1998, ACTA ONCOL, V37, P575, DOI 10.1080/028418698430287; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	67	122	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23097	23104		10.1074/jbc.M011520200	http://dx.doi.org/10.1074/jbc.M011520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312266	hybrid			2022-12-27	WOS:000169412700148
J	Pesesse, X; Dewaste, V; De Smedt, F; Laffargue, M; Giuriato, S; Moreau, C; Payrastre, B; Erneux, C				Pesesse, X; Dewaste, V; De Smedt, F; Laffargue, M; Giuriato, S; Moreau, C; Payrastre, B; Erneux, C			The Src homology 2 domain containing inositol 5-phosphatase SHIP2 is recruited to the epidermal growth factor (EGF) receptor and dephosphorylates phosphatidylinositol 3,4,5-trisphosphate in EGF-stimulated COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; SH2 DOMAIN; POLYPHOSPHATE 5-PHOSPHATASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; PHOSPHATASE SHIP; SIGNALING PATHWAY; MOLECULAR-CLONING; ACTIVATION; ASSOCIATION	The lipid phosphatase SHIP2 (Src homology 2 domain containing inositol 5-phosphatase 2) has been shown to be expressed in nonhemopoietic and hemopoietic cells. It has been implicated in signaling events initiated by several extracellular signals, such as epidermal growth factor (EGF) and insulin. In COS-7 cells, SHIP2 was tyrosine-phosphorylated at least at two separated tyrosine phosphorylation sites in response to EGF. SHIP2 was coimmunoprecipitated with the EGF receptor (EGFR) and also with the adaptor protein Shc. A C-terminal truncated form of SHIP2 that lacks the 366 last amino acids, referred to as tSHIP2, was also precipitated with the EGFR when transfected in COS-7 cells. The Src homology 2 domain of SHIP2 was unable to precipitate the EGFR in EGF-stimulated cells. Moreover, when transfected in COS-7 cells, it could not be detected in immunoprecipitates of the EGFR When the His-tagged. full-length enzyme was expressed in COS-7 cells and stained with anti-His(6) monoclonal antibody, a signal was observed at plasma membranes in EGF-stimulated cells that colocalize with the EGFR by double staining. Upon stimulation by EGF, phosphatidylinositol 3,4,5-trisphosphate and protein kinase B activity were decreased in SHIP2-transfected COS-7 cells as compared with the vector alone. SHIP2 appears therefore in a tyrosine-phosphorylated complex with at least two other proteins, the EGFR and Shc.	Free Univ Brussels, Interdisciplinary Res Inst, B-1070 Brussels, Belgium; Hop Purpan, INSERM, U326, F-31059 Toulouse, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pesesse, X (corresponding author), Free Univ Brussels, Interdisciplinary Res Inst, Campus Erasme,Bldg C,808 Route Lennik, B-1070 Brussels, Belgium.	xpesesse@ulb.ac.be	Giuriato, Sylvie/A-9113-2010; Laffargue, Muriel/AAE-7849-2021	Giuriato, Sylvie/0000-0003-3274-3397; Laffargue, Muriel/0000-0003-1833-639X; , Bernard/0000-0002-8693-0190				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Brauweiler AM, 2000, IMMUNOL REV, V176, P69; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Bruyns C, 1999, BIOL CHEM, V380, P969, DOI 10.1515/BC.1999.120; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Coffer PJ, 1998, BIOCHEM J, V335, P1; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Dixon JE, 1996, RECENT PROG HORM RES, V51, P405; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GIURIATO S, 2001, J BIOL CHEM, V282, P839; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Harmer SL, 1999, J BIOL CHEM, V274, P12183, DOI 10.1074/jbc.274.17.12183; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Ishihara H, 1999, BIOCHEM BIOPH RES CO, V260, P265, DOI 10.1006/bbrc.1999.0888; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kudo M, 2000, MOL BRAIN RES, V75, P172, DOI 10.1016/S0169-328X(99)00311-3; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu Q, 1997, GENOMICS, V39, P109, DOI 10.1006/geno.1996.4374; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Muraille E, 2000, IMMUNOL LETT, V72, P7, DOI 10.1016/S0165-2478(00)00162-0; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Poe JC, 2000, J BIOL CHEM, V275, P17420, DOI 10.1074/jbc.M001892200; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rohrschneider LR, 2000, GENE DEV, V14, P505; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Schurmans S, 1999, GENOMICS, V62, P260, DOI 10.1006/geno.1999.5995; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	57	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28348	28355		10.1074/jbc.M103537200	http://dx.doi.org/10.1074/jbc.M103537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11349134	hybrid			2022-12-27	WOS:000170093400081
J	Hall, BE; Yang, SS; Boriack-Sjodin, PA; Kuriyan, J; Bar-Sagi, D				Hall, BE; Yang, SS; Boriack-Sjodin, PA; Kuriyan, J; Bar-Sagi, D			Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FACTOR CDC25(MM); HOMOLOGY DOMAIN; ARF GTPASE; IN-VIVO; ACTIVATION; RESIDUES; PROTEINS; GRB2; IDENTIFICATION	Ras GTPases function as binary switches in signaling pathways controlling cell growth and differentiation. The guanine nucleotide exchange factor Sos mediates the activation of Ras in response to extracellular signals. We have previously solved the crystal structure of nucleotide-free Ras in complex with the catalytic domain of Sos (Boriack-Sjodin, P.A., Margarit, S.M., Bar-Sagi, D., and Kuriyan, J. (1998) Nature 394, 337-343), The structure demonstrates that Sos induces conformational changes in two loop regions of Ras known as switch 1 and switch 2, In this study, we have employed site-directed mutagenesis to investigate the functional significance of the conformational changes for the catalytic function of Sos. Switch 2 of Ras is held in a very tight embrace by Sos, with almost every external side chain coordinated by Sos. Mutagenesis of contact residues at the switch 2-Sos interface shows that only a small set of side chains affect binding, with the most important contact being mediated by tyrosine 64, which is buried in a hydrophobic pocket of Sos in the Ras Sos complex. Substitutions of Ras and Sos side chains that are inserted into the Mg2+- and nucleotide phosphate-binding site of switch 2 (Ras Ala(59) and Sos Leu(938) and Glu(942)) have no effect on the catalytic function of Sos. These results indicate that the interaction of Sos with switch 2 is necessary for tight binding, but is not the critical driving force for GDP displacement. The structural distortion of switch 1 induced by Sos is mediated by a small number of specific contacts between highly conserved residues on both Ras and Sos. Mutations of a subset of these residues (Ras Tyr(32) and Tyr(40)) result in an increase in the intrinsic rate of nucleotide dissociation from Ras and impair the binding of Ras to Sos. Based on this analysis, me propose that the interactions of Sos with the snitch 1 and switch 2 regions of Ras have distinct functional consequences: the interaction with switch 2 mediates the anchoring of Ras to Sos, whereas the interaction with switch 1 leads to disruption of the nucleotide-binding site and GDP dissociation.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Mol Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Mol & Cellular Biol, Stony Brook, NY 11794 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Life Sci Bldg, Stony Brook, NY 11794 USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CHARDIN P, 1994, CYTOGENET CELL GENET, V66, P68, DOI 10.1159/000133667; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; HOWE LR, 1993, ONCOGENE, V8, P2583; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Jefferson AB, 1998, ONCOGENE, V16, P2303, DOI 10.1038/sj.onc.1201891; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; Kim JH, 1998, ONCOGENE, V16, P2597, DOI 10.1038/sj.onc.1201822; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200	47	99	101	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27629	27637		10.1074/jbc.M101727200	http://dx.doi.org/10.1074/jbc.M101727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11333268	hybrid			2022-12-27	WOS:000169966900118
J	Komori, K; Ishino, Y				Komori, K; Ishino, Y			Replication protein A in Pyrococcus furiosus is involved in homologous DNA recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; STRAND EXCHANGE; FUNCTIONAL DOMAINS; CRYSTAL-STRUCTURE; POLYMERASE-ALPHA; RAD52 PROTEIN; SUBUNIT; IDENTIFICATION; COMPLEX; RPA	Single-stranded DNA-binding protein in Bacteria and replication protein A (RPA) in Eukarya play crucial roles in DNA replication, repair, and recombination processes. We identified an RPA complex from the hyperthermophilic archaeon, Pyrococcus furiosus. Unlike the single-peptide RPAs from the methanogenic archaea, Methanococcus jannaschii and Methanothermobacter thermoautotrophicus, P, furiosus RPA (PfuRPA) exists as a stable hetero-oligomeric complex consisting of three subunits, RPA41, RPA14, and RPA32, The amino acid sequence of RPA41 has some similarity to those of the eukaryotic RPA70 subunit and the M. jannaschii RPA, On the other hand, RPA14 and RPA32 do not share homology with any known open reading frames from Bacteria and Eukarya, However, six of eight archaea, whose total genome sequences have been published, have the open reading frame homologous to RPA32. The PfuRPA complex, but not each subunit alone, specifically bound to a single-stranded DNA and clearly enhanced the efficiency of an in vitro strand-exchange reaction by the P, furiosus RadA protein. Moreover, immunoprecipitation analyses showed that PfuRPA interacts with the recombination proteins, RadA and Hjc, as well as replication proteins, DNA polymerases, primase, proliferating cell nuclear antigen, and replication factor C in P, furiosus cells. These results indicate that PfuRPA plays important roles in the homologous DNA recombination in P. furiousus.	Biomol Engn Res Inst, Dept Biol Mol, Suita, Osaka 5650874, Japan		Ishino, Y (corresponding author), Biomol Engn Res Inst, Dept Biol Mol, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	ishino@beri.co.jp		Ishino, Yoshizumi/0000-0001-9419-0826				Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Bocquier AA, 2001, CURR BIOL, V11, P452, DOI 10.1016/S0960-9822(01)00119-1; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Chedin F, 1998, TRENDS BIOCHEM SCI, V23, P273, DOI 10.1016/S0968-0004(98)01243-2; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; Gupta RC, 1998, P NATL ACAD SCI USA, V95, P9843, DOI 10.1073/pnas.95.17.9843; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; Kelly TJ, 1998, P NATL ACAD SCI USA, V95, P14634, DOI 10.1073/pnas.95.25.14634; Kelman Z, 1999, J BIOL CHEM, V274, P28751, DOI 10.1074/jbc.274.40.28751; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kil YV, 2000, J BACTERIOL, V182, P130, DOI 10.1128/JB.182.1.130-134.2000; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Komori K, 2000, J BIOL CHEM, V275, P33791, DOI 10.1074/jbc.M004556200; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; Komori K, 1999, P NATL ACAD SCI USA, V96, P8873, DOI 10.1073/pnas.96.16.8873; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Spies M, 2000, EUR J BIOCHEM, V267, P1125, DOI 10.1046/j.1432-1327.2000.01108.x; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; UEMORI T, 1993, NUCLEIC ACIDS RES, V21, P259, DOI 10.1093/nar/21.2.259; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	55	73	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25654	25660		10.1074/jbc.M102423200	http://dx.doi.org/10.1074/jbc.M102423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342551	hybrid			2022-12-27	WOS:000169823300005
J	Macia, E; Chabre, M; Franco, M				Macia, E; Chabre, M; Franco, M			Specificities for the small G proteins ARF1 and ARF6 of the guanine nucleotide exchange factors ARNO and EFA6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PLASMA-MEMBRANE; SEC7 DOMAIN; ACTIN CYTOSKELETON; CHROMAFFIN CELLS; BINDING; MYRISTOYLATION; CYTOHESIN-1; ACTIVATION; EXPRESSION	ARF1 and ARF6 are distant members of the ADP-ribosylation factor (ARF) small G-protein subfamily. Their distinct cellular functions must result from specificity of interaction with different effecters and regulators, including guanine nucleotide exchange factors (GEFs), ARF nucleotide-binding site opener (ARNO), and EFA6 are analogous ARF-GEFs, both comprising a catalytic "Sec7" domain and a pleckstrin homology domain. In vivo ARNO, like ARF1, is mostly cytosolic, with minor localizations at the Golgi and plasma membrane; EFA6, like ARF6, is restricted to the plasma membrane. However, depending on conditions, ARNO appears active on ARF6 as well as on ARF1, Here we analyze the origin of these ARF-GEF selectivities. In vitro, in the presence of phospholipid membranes, ARNO activates ARF1 preferentially and ARF6 slightly, whereas EFA6 activates ARF6 exclusively; the stimulation efficiency of EFA6 on ARF6 is comparable with that of ARNO on ARF1, These selectivities are determined by the GEFs Sec7 domains alone, without the pleckstrin homology and N-terminal domains, and by the ARF core domains, without the myristoylated N-terminal helix; they are not modified upon permutation between ARF1 and ARF6 of the few amino acids that differ within the switch regions. Thus selectivity for ARF1 or ARF6 must depend on subtle folding differences between the ARFs switch regions that interact with the Sec7 domains.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Franco, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, 660 Route des Lucioles, F-06560 Valbonne, France.	franco@ipmc.cnrs.fr	Macia, Eric/AAW-2964-2021; Franco, Michel/ABH-4993-2020; FRANCO, michel/AAA-9735-2021	Franco, Michel/0000-0003-1853-8661; macia, eric/0000-0003-3686-2000				Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chavrier P, 2001, METHOD ENZYMOL, V329, P272; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; KAHN RA, 1986, J BIOL CHEM, V261, P7906; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Knorr T, 2000, EUR J BIOCHEM, V267, P3784, DOI 10.1046/j.1432-1327.2000.01416.x; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Lee SY, 2000, J CELL SCI, V113, P1883; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Menetrey J, 2000, NAT STRUCT BIOL, V7, P466; Monier S, 1998, J CELL SCI, V111, P3427; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	41	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24925	24930		10.1074/jbc.M103284200	http://dx.doi.org/10.1074/jbc.M103284200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342560	hybrid			2022-12-27	WOS:000169800700066
J	Raharjo, SB; Emoto, N; Ikeda, K; Sato, R; Yokoyama, M; Matsuo, M				Raharjo, SB; Emoto, N; Ikeda, K; Sato, R; Yokoyama, M; Matsuo, M			Alternative splicing regulates the endoplasmic reticulum localization or secretion of soluble secreted endopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; II MEMBRANE-PROTEINS; NEUTRAL ENDOPEPTIDASE-24.11; MOLECULAR-IDENTIFICATION; CLEAVAGE-SECRETION; GENE-EXPRESSION; GROWTH-FACTOR; CELL-SURFACE; TRANSMEMBRANE; RETENTION	A subfamily of zinc metalloproteases, represented by Neutral endopeptidase (EC 3.4.24.11) and endothelin-converting enzyme, is involved in the metabolism of a variety of biologically active peptides. Recently, we cloned and characterized a novel member of this metalloprotease family termed soluble secreted endopeptidase (SEP), which hydrolyzes many vasoactive peptides, Here we report that alternative splicing of the mouse SEP gene generates two polypeptides, SEPDelta and SEP. After synthesis, both isoforms are inserted into the endoplasmic reticulum (ER) as type II membrane proteins. SEPDelta then becomes an ER resident, whereas SEP, which differs by only the presence of 23 residues at the beginning of its luminal domain, is proteolytically cleaved by membrane secretase(s) in the ER and transported into the extracellular compartment. An analysis of the chimeric proteins between SEP Delta and bovine endothelin-converting enzyme-1b (bECE-1b) demonstrated that the retention of SEPDelta in the ER is mediated by the luminal domain. In addition, the dissection of the chimeric bECE-1b/SEP insertion showed that its insertion domain is obviously responsible for its secretion. A series of mutagenesis in this region revealed that the minimal requirement for cleavage was found to be a WDERTVV motif. Our results suggest that the unique subcellular localization and secretion of SEP proteins provide a novel model of protein trafficking within the secretory pathway.	Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Div Mol Med, Int Ctr Med Res, Kobe, Hyogo 6500017, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan	Kobe University; Kobe University; University of Tokyo	Emoto, N (corresponding author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med, 7-5-1 Kusunoki,Chuo, Kobe, Hyogo 6500017, Japan.			Emoto, Noriaki/0000-0001-6673-2616; ikeda, Koji/0000-0002-9972-7255; raharjo, sunu budhi/0000-0001-5749-8231				Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; CHEN CY, 1992, J IMMUNOL, V148, P2817; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; Deng P, 1996, J BIOL CHEM, V271, P16338, DOI 10.1074/jbc.271.27.16338; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Fu J, 2000, J BIOL CHEM, V275, P3984, DOI 10.1074/jbc.275.6.3984; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; HANLEY JM, 1983, J BIOL CHEM, V258, P7858; Honsho M, 1998, J BIOL CHEM, V273, P20860, DOI 10.1074/jbc.273.33.20860; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; Lee S, 1999, BLOOD, V94, P1440, DOI 10.1182/blood.V94.4.1440.416k01_1440_1450; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Mottola G, 2000, J BIOL CHEM, V275, P24070, DOI 10.1074/jbc.M910400199; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sato K, 1997, P NATL ACAD SCI USA, V94, P9693, DOI 10.1073/pnas.94.18.9693; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Szczesna-Skorupa E, 2000, ARCH BIOCHEM BIOPHYS, V374, P128, DOI 10.1006/abbi.1999.1628; Tang BL, 1997, EUR J CELL BIOL, V73, P98; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 2000, BIOCHEM SOC T, V28, P426, DOI 10.1042/0300-5127:0280426; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	38	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25612	25620		10.1074/jbc.M101703200	http://dx.doi.org/10.1074/jbc.M101703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342542	hybrid			2022-12-27	WOS:000169800700153
J	Battaglia, E; Gollan, J				Battaglia, E; Gollan, J			A unique multifunctional transporter translocates estradiol-17 beta-glucuronide in rat liver microsomal vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONIC ACID; MULTIDRUG-RESISTANCE PROTEIN; ENDOPLASMIC-RETICULUM; GLUCURONOSYLTRANSFERASE ACTIVITY; GLUCOSE-TRANSPORT; SUBSTRATE; MEMBRANE; LOCALIZATION; GLUTATHIONE; CARRIER	A wide array of drugs, xenobiotics, and endogenous compounds undergo detoxification by conjugation with glucuronic acid in the Liver via the action of UDP-glucuronosyl-transferases. The mechanism whereby glucuronides, generated by this enzyme system in the lumen of the endoplasmic reticulum (ER), are exported to the cytosol prior to excretion is unknown. We examined this process in purified rat liver microsomes using a rapid filtration technique and [H-3]estradiol-17 beta -D-glucuronide ([H-3]E(2)17 betaG) as model substrate. Time-dependent uptake of intact [H-3]E(2)17 betaG was observed and shrinkage of ER vesicles by raffinose lowered the steady-state level of [H-3]E(2)17 betaG accumulation. In addition, rapid efflux of [H-3]E(21)7 betaG fi om rat liver microsomal vesicles suggested that the transport process is bidirectional. Microsomal uptake was saturable with an apparent K-m and V-max of 3.29 +/- 0.58 muM and 0.19 +/- 0.02 nmol(.)min(-1) mg protein(-1), respectively. Transport of [H-3]E(2)17 betaG was inhibited by the anion transport inhibitors 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid and probenecid. Specificity of the transport process was investigated by studying the cis-inhibitory effect of anionic metabolites, as well as substrates of the plasma membrane multidrug resistance-associated proteins on the uptake of [H-3]E(2)17 betaG. Collectively, these data are indicative of a novel multifunctional and bidirectional protein carrier for E(2)17 betaG and other anionic compounds in the hepatic ER This intracellular membrane transporter may contribute to the phenomenon of multidrug resistance.	UFR Sci Fondamentales & Appl, Lab Ingn Mol & Biochim Pharmacol, F-57070 Metz, France; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; Univ Adelaide, Royal Adelaide Hosp, Dept Med, Adelaide, SA 5000, Australia	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Royal Adelaide Hospital; University of Adelaide	Battaglia, E (corresponding author), UFR Sci Fondamentales & Appl, Lab Ingn Mol & Biochim Pharmacol, Campus Bridoux P7,Rue Claude Bernard, F-57070 Metz, France.	battaglia@sciences.univ-metz.fr			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036887] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-36887] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 1999, J BIOL CHEM, V274, P17159, DOI 10.1074/jbc.274.24.17159; ARION WJ, 1989, METHOD ENZYMOL, V174, P58; Banhegyi G, 1998, ARCH BIOCHEM BIOPHYS, V359, P133, DOI 10.1006/abbi.1998.0888; Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; BANHEGYI G, 1993, FEBS LETT, V328, P149, DOI 10.1016/0014-5793(93)80983-2; Banhegyi G, 1996, BIOCHEM J, V315, P171, DOI 10.1042/bj3150171; BATTAGLIA E, 1994, ARCH BIOCHEM BIOPHYS, V309, P266, DOI 10.1006/abbi.1994.1112; Battaglia E, 1997, DRUG METAB DISPOS, V25, P406; Battaglia E, 1996, BBA-BIOMEMBRANES, V1283, P223, DOI 10.1016/0005-2736(96)00098-3; Battaglia E, 1998, BIOCHEMISTRY-US, V37, P258, DOI 10.1021/bi9716332; BATTAGLIA E, 1999, HEPATOLOGY, V30; BERG CL, 1995, GASTROENTEROLOGY, V108, P183, DOI 10.1016/0016-5085(95)90023-3; BLAIR JNR, 1988, BIOCHIM BIOPHYS ACTA, V964, P161, DOI 10.1016/0304-4165(88)90162-6; BOSSUYT X, 1994, BIOCHEM J, V302, P261, DOI 10.1042/bj3020261; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; CRAWFORD JM, 1992, J BIOL CHEM, V267, P16943; Cui YH, 1999, MOL PHARMACOL, V55, P929; DUTTON GJ, 1966, GLUCURONIC ACID FREE, P464; Eckhardt U, 1999, AM J PHYSIOL-GASTR L, V276, pG1037, DOI 10.1152/ajpgi.1999.276.4.G1037; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; HAUSER SC, 1988, BIOCHIM BIOPHYS ACTA, V967, P149, DOI 10.1016/0304-4165(88)90004-9; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Huang LY, 2000, HEPATOLOGY, V32, P66, DOI 10.1053/jhep.2000.8263; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF326, DOI 10.1152/ajprenal.1996.270.2.F326; Keppler D, 1997, FASEB J, V11, P509, DOI 10.1096/fasebj.11.7.9212074; Keppler D, 1997, BIOL CHEM, V378, P787; Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; LILLY LB, 1995, AM J PHYSIOL-GASTR L, V268, pG1017, DOI 10.1152/ajpgi.1995.268.6.G1017; Little JM, 1997, DRUG METAB DISPOS, V25, P5; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; Morikawa A, 2000, PHARM RES-DORDR, V17, P546, DOI 10.1023/A:1026412915168; Nardai G, 2001, J BIOL CHEM, V276, P8825, DOI 10.1074/jbc.M010563200; RADOMINSKA A, 1993, J BIOL CHEM, V268, P15127; RADOMINSKA A, 1994, BBA-BIOMEMBRANES, V1195, P63, DOI 10.1016/0005-2736(94)90010-8; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; STDENIS JF, 1995, J BIOL CHEM, V270, P21092, DOI 10.1074/jbc.270.36.21092; SUGAWARA I, 1995, INT J CANCER, V64, P322, DOI 10.1002/ijc.2910640507; VORE M, 1983, LIFE SCI, V32, P2989, DOI 10.1016/0024-3205(83)90650-1; WADDELL ID, 1995, MOL MEMBR BIOL, V12, P283, DOI 10.3109/09687689509072429; WHITING JF, 1993, J BIOL CHEM, V268, P23197; Zucker SD, 1999, J BIOL CHEM, V274, P10852, DOI 10.1074/jbc.274.16.10852	52	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23492	23498		10.1074/jbc.M102494200	http://dx.doi.org/10.1074/jbc.M102494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313362	hybrid			2022-12-27	WOS:000169531100037
J	Ehses, JA; Lee, SST; Pederson, RA; McIntosh, CHS				Ehses, JA; Lee, SST; Pederson, RA; McIntosh, CHS			A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling - Evidence for the involvement of phospholipase A, in GIP-stimulated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; RAT PANCREATIC-ISLETS; BETA-GAMMA-SUBUNITS; ARACHIDONIC-ACID; PROTEIN-KINASE; CYCLIC-AMP; FUNCTIONAL EXPRESSION; LIGAND-BINDING; A(2); CELLS	The hormone glucose-dependent insulinotropic polypeptide (GIP) is an important regulator of insulin secretion. GIP has been shown to increase adenylyl cyclase activity, elevate intracellular Ca2+ levels, and stimulate a mitogen-activated protein kinase pathway in the pancreatic beta -cell. In the current study we demon strate a role for arachidonic acid in GIP-mediated signal transduction. Static incubations revealed that both GIP (100 nM) and ATP (5 muM) significantly increased [H-3] arachidonic acid ([H-3]AA) efflux from transfected Chinese hamster ovary K1 cells expressing the GIP receptor (basal, 128 +/- 11 cpm/well; GIP, 212 +/- 32 cpm/well; ATP, 263 +/- 35 cpm/well; n = 4; p < 0.05). In addition, GIP receptors were shown for the first time to be capable of functionally coupling to AA production through G beta gamma dimers in Chinese hamster ovary K1 cells. In a beta -cell model (beta TC-3), GIP was found to elicit [H-3]AA release, independent of glucose, in a concentration-dependent manner (EC50 value of 1.4 +/- 0.62 nM; n = 3). Although GIP did not potentiate insulin release under extracellular Ca2+-free conditions, it was still capable of elevating intracellular cAMP and stimulating [H-3]AA release. Our data suggest that cAMP is the proximal signaling intermediate responsible for GIP-stimulated AA release. Finally, stimulation of GIP-mediated AA production was shown to be mediated via a Ca2+-independent phospholipase A(2). Arachidonic acid is therefore a new component of GIP-mediated signal transduction in the beta -cell.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	McIntosh, CHS (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintoch@interchange.ubc.ca	Ehses, Jan/AAK-1635-2020	Ehses, Jan/0000-0001-9066-7607				AMIRANOFF B, 1984, BIOCHEM BIOPH RES CO, V123, P671, DOI 10.1016/0006-291X(84)90281-X; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Bymaster FP, 1999, CELL SIGNAL, V11, P405, DOI 10.1016/S0898-6568(99)00006-6; CATALAND S, 1974, J CLIN ENDOCR METAB, V39, P223, DOI 10.1210/jcem-39-2-223; Chen M, 1996, ENDOCRINOLOGY, V137, P2901, DOI 10.1210/en.137.7.2901; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DICKERSON CD, 1995, EXP CELL RES, V216, P46, DOI 10.1006/excr.1995.1006; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FALKO JM, 1975, J CLIN ENDOCR METAB, V41, P260, DOI 10.1210/jcem-41-2-260; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GREMLICH S, 1995, DIABETES, V44, P1202, DOI 10.2337/diabetes.44.10.1202; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; Hinke SA, 2000, J ENDOCRINOL, V165, P281, DOI 10.1677/joe.0.1650281; Holst JJ, 1997, DIABETOLOGIA, V40, P984, DOI 10.1007/s001250050779; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kubota A, 1997, BIOCHEM BIOPH RES CO, V235, P171, DOI 10.1006/bbrc.1997.6743; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; LOWETH AC, 1995, MOL CELL ENDOCRINOL, V112, P177, DOI 10.1016/0303-7207(95)03595-X; LU M, 1993, ENDOCRINOLOGY, V132, P94, DOI 10.1210/en.132.1.94; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; McIntosh CHS, 1996, ACTA PHYSIOL SCAND, V157, P361, DOI 10.1046/j.1365-201X.1996.44267000.x; MCINTOSH CHS, 1981, CAN J PHYSIOL PHARM, V59, P468, DOI 10.1139/y81-069; McIntosh CHS, 1999, ENDOCRINOLOGY, V140, P398, DOI 10.1210/en.140.1.398; METZ SA, 1988, DIABETES, V37, P1453, DOI 10.2337/diabetes.37.11.1453; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; NAUCK M, 1986, DIABETOLOGIA, V29, P46, DOI 10.1007/BF02427280; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Owada S, 1999, J BIOL CHEM, V274, P2000, DOI 10.1074/jbc.274.4.2000; PEDERSON RA, 1975, DIABETES, V24, P1050, DOI 10.2337/diabetes.24.12.1050; PEDERSON RA, 1978, ENDOCRINOLOGY, V103, P610, DOI 10.1210/endo-103-2-610; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1998, BBA-LIPID LIPID MET, V1390, P301, DOI 10.1016/S0005-2760(97)00189-6; Ramanadham S, 1997, BBA-LIPID LIPID MET, V1344, P153, DOI 10.1016/S0005-2760(96)00139-7; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Sauvadet A, 1997, J BIOL CHEM, V272, P12437, DOI 10.1074/jbc.272.19.12437; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; SIEGEL EG, 1985, DIABETOLOGIA, V28, P857, DOI 10.1007/BF00291078; Simonsson E, 2000, BIOCHEM BIOPH RES CO, V269, P242, DOI 10.1006/bbrc.2000.2248; Simonsson E, 2000, INT J PANCREATOL, V27, P1, DOI 10.1385/IJGC:27:1:01; Simonsson E, 1998, DIABETES, V47, P1436, DOI 10.2337/diabetes.47.9.1436; Straub SG, 1996, BIOCHEM BIOPH RES CO, V224, P369, DOI 10.1006/bbrc.1996.1035; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; TURK J, 1993, DIABETES, V42, P367, DOI 10.2337/diabetes.42.3.367; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WAHL MA, 1992, MOL CELL ENDOCRINOL, V90, P117, DOI 10.1016/0303-7207(92)90109-J; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Zhang H, 1998, FEBS LETT, V424, P202, DOI 10.1016/S0014-5793(98)00176-8	57	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23667	23673		10.1074/jbc.M103023200	http://dx.doi.org/10.1074/jbc.M103023200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323439	hybrid			2022-12-27	WOS:000169531100060
J	Lechner, PS; Croniger, CM; Hakimi, P; Millward, C; Fekter, C; Yun, JS; Hanson, RW				Lechner, PS; Croniger, CM; Hakimi, P; Millward, C; Fekter, C; Yun, JS; Hanson, RW			The use of transgenic mice to analyze the role of accessory factor two in the regulation of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE UNIT; TISSUE-SPECIFIC EXPRESSION; GROWTH-HORMONE GENE; BINDING PROTEIN-1; PEPCK GENE; INSULIN; INDUCTION; PROMOTER; IDENTIFICATION; METABOLISM	The regulation of transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) (PEPCK-C) (4.1.1.32) during diabetes is a complex process that involves a number of regulatory elements in the PEPCK-C gene promoter. The accessory factor 2 (AF2)-binding region that is contained within the glucocorticoid regulatory unit of the PEPCK C gene promoter (-451 to -353) has been implicated in the action of both insulin and glucocorticoids on PEPCK-C gene transcription. To determine the role of AF2 in these processes, we have generated a mouse model bearing a transgene that contains the PEPCK-C gene promoter with a mutation in the AF2-binding region. This promoter is linked to the structural gene for human growth hormone that is biologically inactive (AF2-2000/hGx). In the absence of the AF2 regulatory element, the transcription of the transgene in the liver is not induced by diabetes but is inhibited by the administration of insulin. There is also a marked reduction in the response of the AF2-2000/hGx gene in the kidney to the administration of glucocorticoids. The AF2-2000/hGx gene in the liver responds normally to a high carbohydrate diet with a marked decrease in gene transcription. This suggests that insulin is not exerting its usual negative effect on the PEPCK-C gene promoter through the AF2 site. In contrast, the response of this transgene to a high fat/ carbohydrate free diet is severely blunted. Our results support a role for the AF2 site in the PEPCK-C gene promoter in the effect of glucocorticoids, but not insulin, on PEPCK C gene transcription in the liver.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Ohio Univ, Edison Anim Biotechnol Ctr, Athens, OH 45107 USA	Case Western Reserve University; Ohio University	Hanson, RW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	rwh@po.cwru.edu	Hakimi, Parvin/AAB-1643-2021		NIDDK NIH HHS [DK-07319, DK-22451] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLARD FJ, 1967, BIOCHEM J, V104, P866, DOI 10.1042/bj1040866; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; GIRARD JR, 1973, J CLIN INVEST, V52, P3190, DOI 10.1172/JCI107519; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRANNER DK, 1992, DIABETES CARE, V15, P369, DOI 10.2337/diacare.15.3.369; GUNN JM, 1975, BIOCHEM J, V150, P195, DOI 10.1042/bj1500195; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HANSON RW, 1993, ADV ENZYMOL RAMB, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; OBERBAUMER I, 1992, NUCLEIC ACIDS RES, V20, P671; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PATEL YM, 1994, J BIOL CHEM, V269, P5619; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880	37	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22675	22679		10.1074/jbc.M102422200	http://dx.doi.org/10.1074/jbc.M102422200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11309401	hybrid			2022-12-27	WOS:000169412700094
J	Mani, SS; Batni, S; Whitaker, L; Chen, SM; Engbretson, G; Knox, BE				Mani, SS; Batni, S; Whitaker, L; Chen, SM; Engbretson, G; Knox, BE			Xenopus rhodopsin promoter - Identification of immediate upstream sequences necessary for high level, rod-specific transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; LEUCINE-ZIPPER; HOMEODOMAIN PROTEIN; TRANSGENIC MICE; CELL-CULTURES; FACTOR NRL; PHOTORECEPTOR; RETINA; ELEMENT; SITES	To understand the mechanisms that control the cell-specific visual pigment gene transcription, the Xenopus rhodopsin 5' regulatory region has been characterized in vivo using transient transfection of Xenopus embryos and transgenesis. The principal control sequences were located within -233/+41, a region with significant conservation with mammalian rhodopsin genes. DNase footprinting indicated seven distinct regions that contain potential cis-acting elements. Sequences near the initiation site (-45/+41, basal region) were essential, but not sufficient, for rod-specific transcription. Two negative regulatory regions were found, one between -233 to -202, with no apparent similarity to known elements, and a second Ret-l-like CAAT (-136/-122) motif. Deletion of either sequence led to a 2-3-fold increase in expression levels, without a change in rod specificity. Sequences between -170 to -146, which contain an E-box motif, were necessary for high level expression in transgenic tadpoles but not in transient transfections. Sequences between -84 and -58, which contained an NRE-like consensus were found to be necessary for high level expression in both assays. Although expression levels were modulated by various proximal sequences in the rhodopsin promoter, none of the tested sequences were found to be necessary for rod specificity. Promoter constructs with a consensus BAT-1 sequence in conjunction with an NRE-like element upstream of the basal promoter directed low level green fluorescent protein expression in the central nervous system in transgenic tadpoles. These results suggest that rod cell-specific expression of rhodopsin is controlled by redundant elements in the proximal promoter.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Ophthalmol, Syracuse, NY 13210 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA; Syracuse Univ, Dept Bioengn & Neurosci, Syracuse, NY 13244 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Washington University (WUSTL); Syracuse University	Knox, BE (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL EYE INSTITUTE [R01EY012975, R01EY011256, R01EY009409, R55EY009409, R01EY012543, R56EY000667, R01EY000667] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012543, EY12975, EY00667, EY09409, EY11256] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad I, 1995, Brain Res Dev Brain Res, V90, P184; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; Batni S, 2000, METHOD ENZYMOL, V316, P50; Bingham PM, 1997, CELL, V90, P385, DOI 10.1016/S0092-8674(00)80496-1; Boatright JH, 1997, EXP EYE RES, V64, P269, DOI 10.1006/exer.1996.0222; Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; Chau KY, 2000, J NEUROSCI, V20, P7317; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; DOWLING JE, 1987, RETINA APPROACHABLE, P12; GOURAS P, 1994, VISUAL NEUROSCI, V11, P1227, DOI 10.1017/S0952523800007021; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kimura A, 2000, J BIOL CHEM, V275, P1152, DOI 10.1074/jbc.275.2.1152; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; KUMAR R, 1995, MOL GENETICS OCULAR, P139; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Martinez JA, 1998, BIOCHEM BIOPH RES CO, V250, P175, DOI 10.1006/bbrc.1998.9261; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P162; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PERRON M, 1999, CELL LINEAGE FATE DE, P353, DOI DOI 10.1016/B978-012505255-9/50024-9; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SAMBROOK J, 1992, MOL CLONING LAB MANU; SAXEN LAURI, 1954, ANN ACAD SCI FENNICAE SER A, V23, P1; SOKAL RR, 1995, BIOMETRY, P229; STIEMKE MM, 1994, DEV BIOL, V162, P169, DOI 10.1006/dbio.1994.1076; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Tomic-Canic M, 1996, Methods Mol Biol, V57, P259; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WOODFORD BJ, 1994, EXP EYE RES, V58, P631, DOI 10.1006/exer.1994.1058; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Yokoyama S, 1996, GENES CELLS, V1, P787, DOI 10.1046/j.1365-2443.1996.d01-273.x; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	47	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 28	2001	276	39					36557	36565		10.1074/jbc.M101685200	http://dx.doi.org/10.1074/jbc.M101685200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	475XF	11333267	hybrid			2022-12-27	WOS:000171194500069
J	Gizard, F; Lavallee, B; DeWitte, F; Hum, DW				Gizard, F; Lavallee, B; DeWitte, F; Hum, DW			A novel zinc finger protein TReP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SIDE-CHAIN CLEAVAGE; STEROIDOGENIC FACTOR-I; NUCLEAR RECEPTOR COACTIVATORS; AUG INITIATOR CODON; BOVINE LUTEAL CELLS; DNA-BINDING DOMAIN; ADRENAL Y1 CELLS; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; TRANSLATIONAL CONTROL	The human CYP11A1 gene is expressed specifically in steroidogenic tissues and encodes cytochrome P450sec, which catalyzes the first step in steroid synthesis. A region of the 5 ' -flanking DNA of the gene from nucleotides -155 to -131 (-155/-131) is shown to activate transcription in steroidogenic human placental JEG-3 (1) and adrenal NCI-H295 cells. Using this region of the gene as probe, a cDNA clone of 4.4 kilobase pairs was isolated by screening JEG-3 cell and human placental cDNA expression libraries. The open reading frame encodes three zinc fingers of the C2H2 subtype, and separate regions rich in glutamate, proline, and glutamine, which are indicative of a DNA-binding protein involved in gene transcription. Expression of the cDNA in vitro and in HeLa cells yields a protein of 132 kDa, which concurs with the predicted size. Northern blot analysis demonstrate expression of two TReP-132 transcripts of 4.4 and 7.5 kilobase pairs in the thymus, adrenal cortex, and testis; and expression is also found in the steroidogenic JEG-3, NCI-H295, and MCF-7 cell lines. Immunocytochemistry analysis demonstrates localization of the HA-tagged TReP-132 protein in the nucleus. The expression of exogenous TReP-132 in HeLa cells was demonstrated to interact with the -155/-131 region in bandshift analysis. Transfection of the cDNA in placental JEG-3 and adrenal NCI-H295 cells increases expression of a reporter construct controlled by the P450sec gene 5 ' -flanking region from nucleotides -1676 to +49. Moreover, a chimeric protein generated by fusion of TReP-132 with the Gal4 DNA-binding domain was able to significantly increase promoter activity of a reporter construct via Gal4-binding sites upstream of the E1b minimal promoter. Coexpression of CREB-binding protein (CBP)/p300 with TReP-132 has an additive effect on promoter activity, and the proteins were demonstrated to interact physically. Thus, these results together indicate the isolation of a novel zinc-finger transcriptional regulating protein of 132 kDa (TReP-132) involved in the regulation of P450sec gene expression.	Genfit, F-59120 Loos, France; Univ Laval, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1K 7P4, Canada	Laval University	Hum, DW (corresponding author), Genfit, Parc Eurasante,885 Ave Eugene Avinee, F-59120 Loos, France.	dean.hum@genfit.com						ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CAO JH, 1994, VIROLOGY, V205, P151, DOI 10.1006/viro.1994.1630; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chau YM, 1997, BIOL REPROD, V57, P765, DOI 10.1095/biolreprod57.4.765; CHEN CT, 1995, DNA CELL BIOL, V14, P803, DOI 10.1089/dna.1995.14.803; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; Chou SJ, 1996, J BIOL CHEM, V271, P22125, DOI 10.1074/jbc.271.36.22125; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; CONLEY AJ, 1994, J MOL ENDOCRINOL, V12, P155, DOI 10.1677/jme.0.0120155; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; Crawford PA, 1997, MOL CELL BIOL, V17, P3997, DOI 10.1128/MCB.17.7.3997; Durocher F, 1998, PHARMACOGENETICS, V8, P49, DOI 10.1097/00008571-199802000-00007; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; GUO IC, 1994, J BIOL CHEM, V269, P6362; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HANUKOGLU I, 1989, FOLLICULAR DEV OVULA, P233; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HONDA S, 1993, J BIOL CHEM, V268, P7494; Huang NW, 2000, J BIOL CHEM, V275, P2852, DOI 10.1074/jbc.275.4.2852; HUM DW, 1988, J BIOL CHEM, V263, P15946; HUM DW, 1993, ENDOCRINOLOGY, V132, P546, DOI 10.1210/en.132.2.546; HUM DW, 1995, DNA CELL BIOL, V14, P451, DOI 10.1089/dna.1995.14.451; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; INOUE H, 1988, EUR J BIOCHEM, V171, P435, DOI 10.1111/j.1432-1033.1988.tb13808.x; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Juengel JL, 1998, ENDOCRINE, V9, P227, DOI 10.1385/ENDO:9:3:227; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Liu Z, 1997, MOL ENDOCRINOL, V11, P127, DOI 10.1210/me.11.2.127; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mamluk R, 1999, BIOL REPROD, V60, P628, DOI 10.1095/biolreprod60.3.628; MATHENY C, 1994, J BIOL CHEM, V269, P8176; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Mesiano S, 1996, J CLIN ENDOCR METAB, V81, P340, DOI 10.1210/jc.81.1.340; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Montminy M, 1997, NATURE, V387, P654, DOI 10.1038/42594; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MORRIS JF, 1991, ONCOGENE, V6, P2339; ONATE SA, 1995, SCIENCE, V270, P1354; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Pedone PV, 1996, P NATL ACAD SCI USA, V93, P2822, DOI 10.1073/pnas.93.7.2822; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Radtke F, 1996, BIOL CHEM H-S, V377, P47, DOI 10.1515/bchm3.1996.377.1.47; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; Sandhoff TW, 1998, ENDOCRINOLOGY, V139, P4820, DOI 10.1210/en.139.12.4820; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; SIMPSON ER, 1990, MOL CELL ENDOCRINOL, V70, pC25, DOI 10.1016/0303-7207(90)90151-W; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; STROMSTEDT M, 1995, MOL BRAIN RES, V34, P75, DOI 10.1016/0169-328X(95)00140-N; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1994, MOL CELL BIOL, V14, P6046, DOI 10.1128/MCB.14.9.6046; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; Waterman MR, 1996, ENDOCR RES, V22, P615, DOI 10.1080/07435809609043755; Waterman MR, 1986, CYTOCHROME P450 STRU, P345; Westin S, 2000, ADV PHARMACOL, V47, P89; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	101	40	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 7	2001	276	36					33881	33892		10.1074/jbc.M100113200	http://dx.doi.org/10.1074/jbc.M100113200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471CP	11349124	hybrid			2022-12-27	WOS:000170910200081
J	Zhu, QZ; Yao, JH; Wani, G; Wani, MA; Wani, AA				Zhu, QZ; Yao, JH; Wani, G; Wani, MA; Wani, AA			Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; DNA-REPAIR; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVITY; IN-VIVO; PROTEIN; E1A; PROTEASOME; STABILIZATION; ACCUMULATION	Turnover of the p53 tumor suppressor protein is mediated by Mdm2 through the ubiquitin proteolysis pathway. p300, a co-activator for p53, also participates in this process by complexing with Mdm2. We now report that the mutant Mdm2, defective in p53 binding, does not promote p53 ubiquitination and degradation in vivo or inhibit p53 transcriptional activation. By contrast, the mutant Mdm2, defective in p300 binding, still retains its activity to promote p53 ubiquitination and to inhibit p53 transcriptional activation but fails in promoting p53 degradation. We also show that both wild-type Mdm2 and the mutant Mdm2, defective in p300 binding, can promote the ubiquitination of cancer-derived p53 mutants, but only wild-type Mdm2 can cause their degradation. Furthermore, adenoviral oncoprotein, 12S.E.1A, but not its deletion mutant that lacks p300 binding, was shown to decrease in vivo ubiquitination of mutant p53. Taken together, these results provide genetic evidence that p300 plays a pivotal role in the regulation of Mdm2-mediated p53 turnover by integrating the cellular ubiquitination and proteolytic processes.	Mol Carcinogenesis Lab, Columbus, OH 43210 USA; James Canc Hosp, Dept Radiol, Columbus, OH 43210 USA; James Canc Hosp, Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University	Wani, AA (corresponding author), Mol Carcinogenesis Lab, 103 Wiseman Hall,400 W 12th Ave, Columbus, OH 43210 USA.	wani.2@osu.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002388] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES2388] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Nakajima T, 1998, J BIOL CHEM, V273, P20036, DOI 10.1074/jbc.273.32.20036; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; Wani MA, 2000, CANCER RES, V60, P2273; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492; Zhu QZ, 2001, CANCER RES, V61, P64	48	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					29695	29701		10.1074/jbc.M102634200	http://dx.doi.org/10.1074/jbc.M102634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11340074	hybrid			2022-12-27	WOS:000170558000015
J	Kilic, G; Doctor, RB; Fitz, JG				Kilic, G; Doctor, RB; Fitz, JG			Insulin stimulates membrane conductance in a liver cell line - Evidence for insertion of ion channels through a phosphoinositide 3-kinase-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; FROG NEUROMUSCULAR-JUNCTION; PATCH-CLAMP TECHNIQUES; MOTOR-NERVE TERMINALS; PHOSPHATIDYLINOSITOL 3-KINASE; INTRACELLULAR CALCIUM; HEPATOCYTE COUPLETS; SECRETORY PROTEINS; PLASMA-MEMBRANE; APICAL DOMAIN	Activation of insulin receptors stimulates a rapid increase in the ion permeability of liver cells. To evaluate whether this response involves insertion of ion channels,plasma membrane turnover was measured in a model liver cell line using the fluorescent membrane marker FM1-43. Under basal conditions, the rate of constitutive membrane turnover was similar to2%min(-1) and balanced exocytosis and endocytosis maintainer; the total cell membrane area constant. Exposure to insulin stimulated a transient increase in membrane turnover of up to 10-fold above constitutive rates. The response was concentration-dependent (0.001-10 muM). Insulin also caused a parallel increase in membrane conductance as measured by whole-cell patch clamp recording due to opening of Cl-- and K+-selective ion channels. The insulin-stimulated membrane turnover did not appear to involve the constitutive recycling compartments, suggesting that a distinct pool of vesicles may be involved. The effects of insulin on membrane turnover and membrane conductance were inhibited by blockers of phosphoinositide 3-kinase LY294002 and wortmannin or by disrupting microtubule assembly with nocodazole. Taken together, these findings indicate that insulin stimulates recruitment of new membranes through phosphoinositide 3-kinase-dependent mechanisms. Thus, regulated insertion of a separate population of ion channel-containing vesicles may represent one mechanism for mediating the changes in membrane conductance that are essential for the cellular response to insulin.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kilic, G (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Campus Box B158,Rm 6416,4200 E 9th Ave, Denver, CO 80262 USA.	gordan.kilic@uchsc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046082, R01DK046082, R01DK043278] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43278, DK46082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; BARNARD GF, 1984, J CLIN INVEST, V74, P173, DOI 10.1172/JCI111399; Benzeroual K, 1997, AM J PHYSIOL-GASTR L, V272, pG1425, DOI 10.1152/ajpgi.1997.272.6.G1425; Benzeroual K, 2000, BBA-MOL CELL RES, V1495, P14, DOI 10.1016/S0167-4889(99)00147-0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; BRUCK R, 1993, AM J PHYSIOL, V265, pG347, DOI 10.1152/ajpgi.1993.265.2.G347; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Graf J, 1996, J HEPATOL, V24, P53; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; HALLBRUCKER C, 1991, PFLUG ARCH EUR J PHY, V418, P519, DOI 10.1007/BF00497781; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamm-Alvarez SF, 1998, PHYSIOL REV, V78, P1109, DOI 10.1152/physrev.1998.78.4.1109; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Harvey J, 2000, J BIOL CHEM, V275, P4660, DOI 10.1074/jbc.275.7.4660; HEATON JH, 1984, J BIOL CHEM, V259, P2396; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Kavalali ET, 1999, P NATL ACAD SCI USA, V96, P12893, DOI 10.1073/pnas.96.22.12893; KELLY KL, 1992, J BIOL CHEM, V267, P3423; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Mathe L, 2000, CAN J GASTROENTEROL, V14, P389, DOI 10.1155/2000/574820; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Roelofsen H, 1998, J CELL SCI, V111, P1137; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Ryan TA, 1997, NATURE, V388, P478, DOI 10.1038/41335; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SAUCAN L, 1992, HEPATOLOGY, V15, P714, DOI 10.1002/hep.1840150427; SCHARSCHMIDT BF, 1986, P NATL ACAD SCI USA, V83, P9488, DOI 10.1073/pnas.83.24.9488; Shimoni Y, 1999, J PHYSIOL-LONDON, V514, P735, DOI 10.1111/j.1469-7793.1999.735ad.x; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; Terzic A, 1996, J PHYSIOL-LONDON, V492, P395, DOI 10.1113/jphysiol.1996.sp021316; THOMSEN OO, 1983, AM J PHYSIOL, V245, pG59, DOI 10.1152/ajpgi.1983.245.1.G59; THOMSEN OO, 1982, SCAND J GASTROENTERO, V17, P687, DOI 10.3109/00365528209181080; THOMSEN OO, 1982, SCAND J GASTROENTERO, V17, P297; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Wu LG, 1996, NEURON, V17, P769, DOI 10.1016/S0896-6273(00)80208-1	49	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26762	26768		10.1074/jbc.M100992200	http://dx.doi.org/10.1074/jbc.M100992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11349127	hybrid			2022-12-27	WOS:000169966900006
J	Tsukihashi, Y; Kawaichi, M; Kokubo, T				Tsukihashi, Y; Kawaichi, M; Kokubo, T			Requirement for yeast TAF145 function in transcriptional activation of the RPS5 promoter that depends on both core promoter structure and upstream activating sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA BOX-BINDING; IN-VIVO; TFIID COMPLEX; ACETYLTRANSFERASE ACTIVITY; COACTIVATOR REQUIREMENTS; SACCHAROMYCES-CEREVISIAE; TAF(II)250 SUBUNIT; CYCLIN GENES; DNA	The general transcription factor TFIID has been shown to be involved in both core promoter recognition and the transcriptional activation of eukaryotic genes. We recently isolated TAF145 (one of TFIID subunits) temperature-sensitive mutants in yeast, in which transcription of the TUB2 gene is impaired at restrictive temperatures due to a defect in core promoter recognition. Here, we show in these mutants that the transcription of the RPS5 gene is impaired, mostly due to a defect in transcriptional activation rather than to a defect in core promoter recognition, although the latter is slightly affected as well. Surprisingly, the RPS5 core promoter can be activated by various activation domains fused to a GAL4 DNA binding domain, but not by the original upstream activating sequence (UAS) of the RPS5 gene. In addition, a heterologous CYC1 core promoter can be activated by RPS5-UAS at normal levels even in these mutants. These observations indicate that a distinct combination of core promoters and activators may exploit alternative activation pathways that vary in their requirement for TAF145 function. In addition, a particular function of TAF145 that is deleted in our mutants appears to be involved in both core promoter recognition and transcriptional activation.	Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan	Nara Institute of Science & Technology	Kokubo, T (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Div Mol & Cellular Biol, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	kokubo@tsurumi.yohohama-cu.ac.jp						Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen Z, 2000, MOL CELL BIOL, V20, P5064, DOI 10.1128/MCB.20.14.5064-5076.2000; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Graham IR, 1999, MOL CELL BIOL, V19, P7481; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Lascaris RF, 1999, BIOINFORMATICS, V15, P267, DOI 10.1093/bioinformatics/15.4.267; Lee DK, 1999, GENE DEV, V13, P2934, DOI 10.1101/gad.13.22.2934; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Li B, 2000, EMBO J, V19, P4091, DOI 10.1093/emboj/19.15.4091; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Lieberman PM, 1997, MOL CELL BIOL, V17, P6624, DOI 10.1128/MCB.17.11.6624; LUNDBLACK V, 1998, CURRENT PROTOCOLS MO, V2; Luo X, 1996, MOL CELL BIOL, V16, P1367; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Sakurai H, 1999, BIOCHEM BIOPH RES CO, V261, P734, DOI 10.1006/bbrc.1999.1113; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tsukihashi Y, 2000, MOL CELL BIOL, V20, P2385, DOI 10.1128/MCB.20.7.2385-2399.2000; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Weissman JDJ, 2000, J BIOL CHEM, V275, P10160, DOI 10.1074/jbc.275.14.10160; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; Xiao WM, 1997, J VIROL, V71, P1757, DOI 10.1128/JVI.71.3.1757-1765.1997	61	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25715	25726		10.1074/jbc.M102416200	http://dx.doi.org/10.1074/jbc.M102416200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337503	hybrid			2022-12-27	WOS:000169823300013
J	Abdel-Ghany, M; Cheng, HC; Elble, RC; Pauli, BU				Abdel-Ghany, M; Cheng, HC; Elble, RC; Pauli, BU			The breast cancer beta(4) integrin and endothelial human CLCA2 mediate lung metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DIPEPTIDYL PEPTIDASE IV; CARCINOMA CELL-LINES; MATRIX METALLOPROTEINASES; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; MAMMALIAN HEPARANASE; CYSTIC-FIBROSIS; TUMOR INVASION; E-CADHERIN	Adhesion of blood-borne cancer cells to the endothelium is a critical determinant of organ-specific metastasis. Here we show that colonization of the lungs by human breast cancer cells is correlated with cell surface expression of the alpha (6)beta (4) integrin and adhesion to human CLCA2 (hCLCA2), a Ca2+-sensitive chloride channel protein that is expressed on the endothelial cell luminal surface of pulmonary arteries, arterioles, and venules, Tumor cell adhesion to endothelial hCLCA2 is mediated by the beta (4) integrin, establishing for the first time a cell-cell adhesion property for this integrin that involves an entirely new adhesion partner. This adhesion is augmented by an increased surface expression of the alpha (6)beta (4) integrin in breast cancer cells selected in vivo for enhanced lung colonization but abolished by the specific cleavage of the beta (4) integrin with matrilysin. beta (4) integrin/hCLCA2 adhesion-blocking antibodies directed against either of the two interacting adhesion molecules inhibit lung colonization, while overexpression of the beta (4) integrin in a model murine tumor cell line of modest lung colonization potential significantly increases the lung metastatic performance. Our data clearly show that the beta (4)/hCLCA2 adhesion is critical for lung metastasis, yet expression of the beta (4) integrin in many benign breast tumors shows that this integrin is insufficient to bestow metastatic competence on cells that lack invasiveness and other established properties of metastatic cells.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Pauli, BU (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.	bup1@cornell.edu			NATIONAL CANCER INSTITUTE [R01CA047668, R01CA071626] Funding Source: NIH RePORTER; NCI NIH HHS [CA71626, CA47668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 1998, INVAS METAST, V18, P35, DOI 10.1159/000024497; ABDELGHANY M, 1987, P NATL ACAD SCI USA, V84, P8888, DOI 10.1073/pnas.84.24.8888; AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bohm JP, 2000, J PATHOL, V192, P321; Cheng HC, 1998, J BIOL CHEM, V273, P24207, DOI 10.1074/jbc.273.37.24207; Cimino L, 1997, CANCER DETECT PREV, V21, P158; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Dans M, 2001, J BIOL CHEM, V276, P1494, DOI 10.1074/jbc.M008663200; Donovan D, 1997, ANN SURG ONCOL, V4, P621, DOI 10.1007/BF02303745; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; FALCIONI R, 1986, CANCER RES, V46, P5772; Fidler IJ, 2000, CANCER J, V6, pS134; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; Goetz DJ, 1996, INT J CANCER, V65, P192, DOI 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Jones JL, 1997, EXP CELL RES, V235, P325, DOI 10.1006/excr.1997.3662; Kebers F, 1998, EXP CELL RES, V240, P197, DOI 10.1006/excr.1998.3935; KEMPERMAN H, 1993, CANCER RES, V53, P3611; Lee-Huang S, 2000, ANTICANCER RES, V20, P653; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Maguire PD, 2000, ONCOLOGY-BASEL, V59, P139, DOI 10.1159/000012151; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Martin DK, 1996, MICROVASC RES, V52, P200, DOI 10.1006/mvre.1996.0058; Mbalaviele G, 1996, CANCER RES, V56, P4063; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PAULI BU, 1988, LAB INVEST, V58, P379; Pauli BU, 2000, CLIN EXP PHARMACOL P, V27, P901, DOI 10.1046/j.1440-1681.2000.03358.x; PAULI BU, 1997, ENCY CANC, V1, P464; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PERROTTI D, 1990, ANTICANCER RES, V10, P1587; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pier GB, 1998, NATURE, V393, P79, DOI 10.1038/30006; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; Pulyaeva H, 1997, CLIN EXP METASTAS, V15, P111, DOI 10.1023/A:1018444609098; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Roetger A, 1998, AM J PATHOL, V153, P1797, DOI 10.1016/S0002-9440(10)65694-5; ROSSEN K, 1994, ACTA DERM-VENEREOL, V74, P101; Russell RL, 1997, CANCER, V79, P1158, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1158::AID-CNCR14>3.0.CO;2-Z; Shain KH, 2000, CURR OPIN ONCOL, V12, P557, DOI 10.1097/00001622-200011000-00008; Shaw LM, 1996, CANCER RES, V56, P959; SOULE HD, 1990, CANCER RES, V50, P6075; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Taverna D, 1998, CANCER RES, V58, P848; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Walsh MD, 1999, BREAST CANCER RES TR, V58, P255; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; Yip D, 1999, INVEST NEW DRUG, V17, P387, DOI 10.1023/A:1006386406584; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZHU DZ, 1993, INT J CANCER, V53, P628; ZHU DZ, 1991, J HISTOCHEM CYTOCHEM, V39, P1137, DOI 10.1177/39.8.1856462; ZHU DZ, 1992, J CLIN INVEST, V89, P1718, DOI 10.1172/JCI115773; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	76	107	117	4	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25438	25446		10.1074/jbc.M100478200	http://dx.doi.org/10.1074/jbc.M100478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320086	hybrid			2022-12-27	WOS:000169800700134
J	LeGros, L; Halim, AB; Chamberlin, ME; Geller, A; Kotb, M				LeGros, L; Halim, AB; Chamberlin, ME; Geller, A; Kotb, M			Regulation of the human MAT2B gene encoding the regulatory beta subunit of methionine adenosyltransferase, MAT II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; HUMAN-ERYTHROCYTES; HUMAN-LYMPHOCYTES; EXPRESSION; TRANSCRIPTION; ACTIVATION; ISOZYMES; CLONING; CELLS	Methionine adenosyltransferase (MAT) catalyzes the biosynthesis of S-adenosylmethionine (AdoMet), a key molecule in transmethylation reactions and polyamine biosynthesis, The MAT II isozyme consists of a catalytic alpha2 and a regulatory beta subunit. Down-regulation of the MAT II beta subunit expression causes a 6-10-fold increase in intracellular AdoMet levels. To understand the mechanism by which the beta subunit expression is regulated, we cloned the MAT2B gene, determined its organization, characterized its 5 ' -flanking sequences, and elucidated the in vitro and in vivo regulation of its promoter. Transcription of the MAT2B gene initiates at position -203 relative to the translation start site, Promoter deletion analysis defined a minimal promoter between positions +52 and +93 base pairs, a GC-rich region, Inclusion of the sequences between -4 and +52 enhanced promoter activity; this was primarily because of an Sp1 recognition site at +9/+15, The inclusion of sequences up to position -115 provided full activity; this was attributed to a TATA at -32, The Sp1 site at position +9 was key for the formation of protein DNA complexes. Mutation of both the Sp1 site at +9 and the TATA at -32 reduced promoter activity to its minimal level. Supershift assays showed no effect of the anti-Spl antibody on complex formation, whereas the anti-Sp3 antibody had a strong effect on protein DNA complex formation, suggesting that Sp3 is one of the main factors binding to this Sp1 site. Chromatin immunoprecipitation assays supported the involvement of both Sp1 and Sp3 in complexes formed on the MAT2B promoter. The data show that the 5 ' -untranslated sequences play an important role in regulating the MAT2B gene and identifies the Sp1 site at +9 as a potential target for modulating MAT2B expression, a process that can have a major effect on intracellular AdoMet levels.	Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA; Vet Affairs Med Ctr, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Kotb, M (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Surg, 956 Court Ave,Suite A-202, Memphis, TN 38163 USA.				NIGMS NIH HHS [GM-54892-09] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CANTONI GL, 1953, J BIOL CHEM, V204, P403; DELAROSA J, 1992, J BIOL CHEM, V267, P10699; DELAROSA J, 1995, J BIOL CHEM, V270, P21860; DELAROSA J, 1992, CANCER RES, V52, P3361; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; Gil B, 1996, HEPATOLOGY, V24, P876; Halim AB, 1999, J BIOL CHEM, V274, P29720, DOI 10.1074/jbc.274.42.29720; Halim AB, 2001, J BIOL CHEM, V276, P9784, DOI 10.1074/jbc.M002347200; Hiroki T, 1997, EUR J BIOCHEM, V250, P653, DOI 10.1111/j.1432-1033.1997.00653.x; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KOTB M, 1985, J BIOL CHEM, V260, P3923; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1039, P253, DOI 10.1016/0167-4838(90)90193-J; KOTB M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P137, DOI 10.1016/0167-4838(90)90068-Q; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; LANGKAMPHENKEN B, 1994, BBA-GEN SUBJECTS, V1201, P397, DOI 10.1016/0304-4165(94)90068-X; LeGros HL, 1997, J BIOL CHEM, V272, P16040, DOI 10.1074/jbc.272.25.16040; LeGros HL, 2000, J BIOL CHEM, V275, P2359, DOI 10.1074/jbc.275.4.2359; LIAU MC, 1979, CANCER RES, V39, P162; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1973, ADENOSYLTRANSFERASES, P121; Mudd SH, 1995, DISORDERS TRANSSULFU; ODEN KL, 1983, BIOCHEMISTRY-US, V22, P2978, DOI 10.1021/bi00281a030; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; PAJARES MA, 1992, FEBS LETT, V309, P1, DOI 10.1016/0014-5793(92)80726-W; PISSOWOTZKI K, 1991, MOL GEN GENET, V231, P113, DOI 10.1007/BF00293829; SAKATA SF, 1993, J BIOL CHEM, V268, P13978; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; SUMA Y, 1986, J BIOCHEM, V100, P67, DOI 10.1093/oxfordjournals.jbchem.a121707; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; UBAGAI T, 1995, J CLIN INVEST, V96, P1943, DOI 10.1172/JCI118240; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09; Yang Y, 2000, J BIOL CHEM, V275, P38863, DOI 10.1074/jbc.M007906200	40	43	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24918	24924		10.1074/jbc.M102816200	http://dx.doi.org/10.1074/jbc.M102816200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337507	hybrid			2022-12-27	WOS:000169800700065
J	Tomita, K; Saijo, K; Yamasaki, S; Iida, T; Nakatsu, F; Arase, H; Ohno, H; Shirasawa, T; Kuriyama, T; O'Shea, JJ; Saito, T				Tomita, K; Saijo, K; Yamasaki, S; Iida, T; Nakatsu, F; Arase, H; Ohno, H; Shirasawa, T; Kuriyama, T; O'Shea, JJ; Saito, T			Cytokine-independent Jak3 activation upon T cell receptor (TCR) stimulation through direct association of Jak3 and the TCR complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING JAK3; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; GAMMA-CHAIN; IL-2 RECEPTOR; LYMPHOID DEVELOPMENT; INTERFERON-ALPHA; GENETIC-EVIDENCE; CD3 COMPLEX; INTERLEUKIN-2	Jak3 is responsible for growth signals by various cytokines such as interleukin (IL)-2, IL-4, and IL-7 through association with the common gamma chain (gammac) in lymphocytes. We found that T cells from Jak3-deficient mice exhibit impairment of not only cytokine signaling but also early activation signals and that Jak3 is phosphorylated upon T cell receptor (TCR) stimulation. TCR-mediated phosphorylation of Jak3 is independent of IL-2 receptor/gammac but is dependent on Lck and ZAP-70. Jak3 was found to be assembled with the TCR complex, particularly through direct association with CD3 zeta via its JH4 region, which is a different region from that for gammac association. These results suggest that Jak3 plays a role not only in cell growth but also in T cell activation and represents cross-talk of a signaling molecule between TCR and growth signals.	Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608790, Japan; Tokyo Metropolitan Inst Gerontol, Dept Neurophysiol, Itabashi Ku, Tokyo 1730015, Japan; Chiba Univ, Sch Med, Inst Pulm Canc Res, Dept Internal Med,Chuo Ku, Chiba 2608790, Japan; NIAMS, Lymphocyte Cell Biol Sect, NIH, Bethesda, MD 20892 USA	Chiba University; Tokyo Metropolitan Institute of Gerontology; Chiba University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Saito, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, 1-8-1 Inohana, Chiba 2608790, Japan.		Saito, Takashi/C-9684-2009; Ohno, Hiroshi/L-7899-2014; Arase, Hisashi/C-8442-2009	Saito, Takashi/0000-0001-9495-3547; Ohno, Hiroshi/0000-0001-8776-9661; Arase, Hisashi/0000-0002-1153-3166	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Malaviya R, 1999, J BIOL CHEM, V274, P27028, DOI 10.1074/jbc.274.38.27028; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; Miyatake S, 1997, EUR J IMMUNOL, V27, P1816, DOI 10.1002/eji.1830270733; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Nakano H, 1996, J BIOL CHEM, V271, P6483, DOI 10.1074/jbc.271.11.6483; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Saijo K, 1997, J EXP MED, V185, P351, DOI 10.1084/jem.185.2.351; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Takase K, 1997, J IMMUNOL, V159, P741; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; Thomis DC, 1997, J IMMUNOL, V159, P4708; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; Viola A, 1997, J EXP MED, V186, P1775, DOI 10.1084/jem.186.10.1775; Wakizaka K, 1998, EUR J IMMUNOL, V28, P636, DOI 10.1002/(SICI)1521-4141(199802)28:02<636::AID-IMMU636>3.0.CO;2-A; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Welte T, 1999, SCIENCE, V283, P222, DOI 10.1126/science.283.5399.222; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	42	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25378	25385		10.1074/jbc.M011363200	http://dx.doi.org/10.1074/jbc.M011363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11349123	hybrid			2022-12-27	WOS:000169800700126
J	Weisman, R; Finkelstein, S; Choder, M				Weisman, R; Finkelstein, S; Choder, M			Rapamycin blocks sexual development in fission yeast through inhibition of the cellular function of an FKBP12 homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR FUNCTION; CIS-TRANS-ISOMERASES; TGF-BETA FAMILY; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CYCLOPHILIN-A; FK506-BINDING PROTEIN; TRANSCRIPTION FACTOR; PROLYL ISOMERASE	FKBP12 is a ubiquitous and a highly conserved prolyl isomerase that binds the immunosuppressive drugs FK506 and rapamycin, Members of the FKBP12 family have been implicated in many processes that include intracellular protein folding, transport, and assembly. In the budding yeast Saccharomyces cerevisiae and in human T cells, rapamycin forms a complex with FKBP12 that inhibits cell cycle progression by inhibition of the TOR kinases, We reported previously that rapamycin does not inhibit the vegetative growth of the fission yeast Schizosaccharomyces pombe; however, it specifically inhibits its sexual development. Here we show that disruption of the S, pombe FKBP12 homolog, fkh1(+), at its chromosomal locus results in a mating-deficient phenotype that is highly similar to that obtained by treatment of wild type cells with rapamycin, A screen for fkh1 mutants that can confer rapamycin resistance identified five amino acids in Fkh1 that are critical for the effect of rapamycin in S, pombe, All five amino acids are located in the putative rapamycin binding pocket. Together, our findings indicate that Fkh1 has an important role in sexual development and serves as the target for rapamycin action in S. pombe.	Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Weisman, R (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ronitt@post.tau.ac.il	weisman, ronit/D-3741-2016; weisman, ronit/R-6969-2016					Alarcon CM, 1997, MOL CELL BIOL, V17, P5968, DOI 10.1128/MCB.17.10.5968; ATKISON P, 1995, LANCET, V345, P894, DOI 10.1016/S0140-6736(95)90011-X; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Cardenas ME, 1999, CLIN MICROBIOL REV, V12, P583, DOI 10.1128/CMR.12.4.583; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; Cardenas ME, 1998, TRENDS BIOTECHNOL, V16, P427, DOI 10.1016/S0167-7799(98)01239-6; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Davey J, 1998, YEAST, V14, P1529, DOI 10.1002/(SICI)1097-0061(199812)14:16<1529::AID-YEA357>3.0.CO;2-0; DEMARTIN R, 1990, NUCLEIC ACIDS RES, V18, P4917, DOI 10.1093/nar/18.16.4917; DEVOTI J, 1991, EMBO J, V10, P3759, DOI 10.1002/j.1460-2075.1991.tb04945.x; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; Dolinski KJ, 1999, GENETICS, V151, P935; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Himukai R, 1999, J BIOCHEM, V126, P879, DOI 10.1093/oxfordjournals.jbchem.a022530; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kunz J, 2000, MOL MICROBIOL, V37, P1480, DOI 10.1046/j.1365-2958.2000.02105.x; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MOCHIZUKI N, 1992, MOL GEN GENET, V233, P17, DOI 10.1007/BF00587556; MORENO S, 1991, METHOD ENZYMOL, V194, P795; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Snaith HA, 1999, GENETICS, V152, P839; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Weisman R, 1996, EMBO J, V15, P447, DOI 10.1002/j.1460-2075.1996.tb00377.x; Weisman R, 2001, J BIOL CHEM, V276, P7027, DOI 10.1074/jbc.M010446200; Weisman R, 1997, J BACTERIOL, V179, P6325, DOI 10.1128/jb.179.20.6325-6334.1997; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Yao DY, 2000, J BIOL CHEM, V275, P13149, DOI 10.1074/jbc.275.17.13149; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	68	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24736	24742		10.1074/jbc.M102090200	http://dx.doi.org/10.1074/jbc.M102090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335722	hybrid			2022-12-27	WOS:000169800700044
J	Yang, QH; Zhu, Z; Dong, MQ; Ling, S; Wu, CL; Li, L				Yang, QH; Zhu, Z; Dong, MQ; Ling, S; Wu, CL; Li, L			Binding of ATP to the fructose-2,6-bisphosphatase domain of chicken liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase leads to activation of its 6-phosphofructo-2-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-LIVER; BIFUNCTIONAL ENZYME; 2-KINASE DOMAIN; CRYSTAL-STRUCTURE; FRUCTOSE 6-PHOSPHATE,2-KINASE; ESCHERICHIA-COLI; BASIC RESIDUES; MECHANISM; 2,6-BISPHOSPHATASE	To understand the mechanism by which the activity of the 6-phosphofructo-2-kinase (6PF-2K) of chicken liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase is stimulated by its substrate ATP, we studied two mutants of the enzyme. Mutation of either Arg-279, the penultimate basic residue within the Walker A nucleotide-binding fold in the bisphosphatase domain, or Arg-359 to Ala eliminated the activation of the chicken 6PF-2K by ATP, Binding analysis by fluorescence spectroscopy using 2 ' (3 ')-O-(N-methylanthraniloyl)-ATP revealed that the kinase domains of these two mutants, unlike that of the wild type enzyme, showed no cooperativity in ATP binding and that the mutant enzymes possess only the high affinity ATP binding site, suggesting that the ATP binding site on the bisphosphatase domain represents the low affinity site. This conclusion was supported by the result that the affinity of ATP for the isolated bisphosphatase domain is similar to that for the low affinity site in the wild type enzyme. In addition, we found that the 6PP-2K of a chimeric enzyme, in which the last 25 residues of chicken enzyme were replaced with those of the rat enzyme, could not be activated by ATP, despite the fact that the ATP-binding properties of this chimeric enzyme were not different from those of the wild type chicken enzyme, These results demonstrate that activation of the chicken 6PF-2K by ATP may result from allosteric binding of ATP to the bisphosphatase domain where residues Arg-279 and Arg-359 are critically involved and require specific C-terminal sequences.	Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, L (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.							ABE Y, 1995, BIOCHEMISTRY-US, V34, P2553, DOI 10.1021/bi00008a020; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; Bertrand L, 1997, BIOCHEM J, V321, P623, DOI 10.1042/bj3210623; Bertrand L, 1997, BIOCHEM J, V321, P615, DOI 10.1042/bj3210615; ELMAGHRABI MR, 1986, P NATL ACAD SCI USA, V83, P5005, DOI 10.1073/pnas.83.14.5005; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; KURLAND IJ, 1995, PROTEIN SCI, V4, P1023, DOI 10.1002/pro.5560040601; Kurland IJ, 2000, BIOCHEM J, V347, P459, DOI 10.1042/0264-6021:3470459; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; LEE YH, 1994, J BIOL CHEM, V269, P11002; Li L, 1997, BIOCHEM J, V328, P751, DOI 10.1042/bj3280751; LI L, 1992, J BIOL CHEM, V267, P4386; LI L, 1991, SCI CHINA SER B, V34, P916; LI L, 1995, BIOCHEM BIOPH RES CO, V209, P883, DOI 10.1006/bbrc.1995.1581; LI L, 1993, BIOCHEM BIOPH RES CO, V190, P397, DOI 10.1006/bbrc.1993.1061; LI L, 1992, J BIOL CHEM, V267, P21588; LIN K, 1994, J BIOL CHEM, V269, P16953; MAPES JP, 1978, ARCH BIOCHEM BIOPHYS, V190, P193; Mizuguchi H, 1997, BIOCHEMISTRY-US, V36, P8775, DOI 10.1021/bi970639o; Okar DA, 2000, BIOCHEMISTRY-US, V39, P9754, DOI 10.1021/bi000815k; PEARCE J, 1977, INT J BIOCHEM, V8, P260; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; RIDER MH, 1994, BIOCHEM J, V300, P111, DOI 10.1042/bj3000111; ROUSSEAU GG, 1993, PROG NUCLEIC ACID RE, V45, P99, DOI 10.1016/S0079-6603(08)60868-5; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Uyeda K, 1997, J BIOL CHEM, V272, P7867, DOI 10.1074/jbc.272.12.7867; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; Vertommen D, 1996, J BIOL CHEM, V271, P17875, DOI 10.1074/jbc.271.30.17875; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang ZX, 1996, FEBS LETT, V388, P73, DOI 10.1016/0014-5793(96)00498-X; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Wu RF, 1999, ARCH BIOCHEM BIOPHYS, V371, P15, DOI 10.1006/abbi.1999.1430; Yang QH, 1997, PROTEIN EXPRES PURIF, V10, P320, DOI 10.1006/prep.1997.0749; Yuen MH, 1999, J BIOL CHEM, V274, P2176, DOI 10.1074/jbc.274.4.2176; Zhu Z, 2000, BIOL CHEM, V381, P1195, DOI 10.1515/BC.2000.147	36	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24608	24613		10.1074/jbc.M102366200	http://dx.doi.org/10.1074/jbc.M102366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325970	hybrid			2022-12-27	WOS:000169800700027
J	Lim, SE; Copeland, WC				Lim, SE; Copeland, WC			Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTI-HIV DEOXYNUCLEOTIDES; MITOCHONDRIAL-DNA; REVERSE-TRANSCRIPTASE; EXONUCLEASE ACTIVITY; NUCLEOSIDE ANALOGS; (-)-2'-DEOXY-3'-THIACYTIDINE 3TC; INTRACELLULAR PHOSPHORYLATION; SUBSTRATE-SPECIFICITY; INSERTION FIDELITY	Mitochondrial toxicity can result hom antiviral nucleotide analog therapy used to control human immunodeficiency virus type 1 infection. We evaluated the ability of such analogs to inhibit DNA synthesis by the human mitochondrial DNA polymerase (pol gamma) by comparing the insertion and exonucleolytic removal of six antiviral nucleotide analogs. Apparent steady-state K-m and k(cat) values for insertion of 2 ' ,3 ' -dideoxy-TTP (ddTTP), 3 ' -azido-TTP (AZT-TP), 2 ' ,3 ' -dideoxy-TTP (dd-TTP), 2 ' ,3 ' -didehydro-TTP (D4T-TP), (-)-2 ' ,3 ' -dideoxy-3 ' -thiacytidine (3TC-TP), and carbocyclic 2 ' ,3 ' -didehydro-ddGTP (CBV-TP) indicated incorporation of all six analogs, albeit with varying efficiencies. Dideoxynucleotides and D4T-TP were utilized by pol gamma in vitro as efficiently as natural deoxynucleotides, whereas AZT-TP, 3TC-TP, and CBV-TP were only moderate inhibitors of DNA chain elongation. Inefficient excision of dideoxynucleotides, D4T, AZT, and CBV from DNA predicts persistence in vivo following successful incorporation. In contrast, removal of 3'-terminal 3TC residues was 50% as efficient as natural 3 ' termini. Finally, me observed inhibition of exonuclease activity by concentrations of AZT-monophosphate known to occur in cells. Thus, although their greatest inhibitory effects are through incorporation and chain termination, persistence of these analogs in DNA and inhibition of exonucleolytic proofreading may also contribute to mitochondrial toxicity.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065080, ZIAES065080, ZIAES065078, Z01ES065078] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agarwal RP, 1997, MUTAT RES-GEN TOX EN, V390, P223, DOI 10.1016/S1383-5718(97)00014-4; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; Ayers KM, 1996, FUND APPL TOXICOL, V32, P148, DOI 10.1006/faat.1996.0118; BEBENEK K, 1993, MOL PHARMACOL, V43, P57; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bialkowska A, 2000, CARCINOGENESIS, V21, P1059, DOI 10.1093/carcin/21.5.1059; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; Bridges EG, 1996, BIOCHEM PHARMACOL, V51, P731, DOI 10.1016/0006-2952(96)00056-1; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; BRIDGES EG, 1993, BIOCHEM PHARMACOL, V45, P1571, DOI 10.1016/0006-2952(93)90296-9; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CID MG, 1994, MUTAT RES, V321, P113, DOI 10.1016/0165-1218(94)90127-9; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; GRAY NM, 1995, BIOCHEM PHARMACOL, V50, P1043, DOI 10.1016/0006-2952(95)96620-A; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1990, J BIOL CHEM, V265, P11914; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; KAGUNI LS, 1988, CANCER CELL, V6, P425; Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288; LEWIS W, 1994, CIRC RES, V74, P344, DOI 10.1161/01.RES.74.2.344; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; MEDINA DJ, 1994, ANTIMICROB AGENTS CH, V38, P1824, DOI 10.1128/AAC.38.8.1824; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Meng QX, 2000, MUTAGENESIS, V15, P405, DOI 10.1093/mutage/15.5.405; Meng QX, 2000, TOXICOL SCI, V54, P322, DOI 10.1093/toxsci/54.2.322; NICKEL W, 1992, J BIOL CHEM, V267, P848; Olivero OA, 1999, AIDS, V13, P919, DOI 10.1097/00002030-199905280-00007; OLSON MW, 1992, J BIOL CHEM, V267, P23136; *PAN CLIN PRACT TR, 2001, GUID US ANT AG HIV I; Parker WB, 1997, ANTIVIR RES, V34, P131, DOI 10.1016/S0166-3542(97)01033-4; PARKER WB, 1991, J BIOL CHEM, V266, P1754; PETERS BS, 1993, Q J MED, V86, P5; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Sussman HE, 1999, MUTAT RES-FUND MOL M, V429, P249, DOI 10.1016/S0027-5107(99)00111-6; Szabados E, 1999, FREE RADICAL BIO MED, V26, P309, DOI 10.1016/S0891-5849(98)00199-3; UNAIDS/World Health Organization, 2000, AIDS EP UPD, P1; WALLACE DC, 1992, J INHERIT METAB DIS, V15, P472, DOI 10.1007/BF01799605; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Wang HY, 1996, BBA-MOL BASIS DIS, V1316, P51, DOI 10.1016/0925-4439(96)00015-4; YARCHOAN R, 1988, LANCET, V1, P76; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333; Zhu CY, 2000, J BIOL CHEM, V275, P26727	61	186	192	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23616	23623		10.1074/jbc.M101114200	http://dx.doi.org/10.1074/jbc.M101114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319228	hybrid			2022-12-27	WOS:000169531100053
J	Moreno, CS; Lane, WS; Pallas, DC				Moreno, CS; Lane, WS; Pallas, DC			A mammalian homolog of yeast MOB1 is both a member and a putative substrate of striatin family-protein phosphatase 2A complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; DUPLICATION GENE MPS1; RHO-ASSOCIATED KINASE; OKADAIC ACID; NUCLEAR AUTOANTIGEN; CATALYTIC SUBUNIT; CDC2 KINASE; PHOSPHORYLATION; MITOSIS; VIMENTIN	Striatin and S/G(2) nuclear autoantigen (SG2NA) are related proteins that contain membrane binding domains and associate with protein phosphatase 2A (PP2A) and many additional proteins that may be PP2A regulatory targets. Here we identify a major member of these complexes as class II mMOB1, a mammalian homolog of the yeast protein MOB1, and show that its phosphorylation appears to be regulated by PP2A. Yeast MOB1 is critical for cytoskeletal reorganization during cytokinesis and exit from mitosis. We show that mMOB1 associated with PP2A is not detectably phosphorylated in asynchronous murine fibroblasts. However, treatment with the PP2A inhibitor okadaic acid induces phosphorylation of PP2A-associated mMOB1 on serine. Moreover, specific inhibition of PP2A also results in hyperphosphorylation of striatin, SG2NA, and three unidentified proteins, suggesting that these proteins may also be regulated by PP2A. Indirect immunofluorescence produced highly similar staining patterns for striatin, SG2NA, and mMOB1, with the highest concentrations for each protein adjacent to the nuclear membrane. We also present evidence that these complexes may interact with each other. These data are consistent with a model in which PP2A may regulate mMOB1, striatin, and SG2NA to modulate changes in the cytoskeleton or interactions between the cytoskeleton and membrane structures.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	Emory University; Emory University; Harvard University	Pallas, DC (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	dpallas@emory.edu	Moreno, Carlos S/B-3863-2009	Moreno, Carlos S/0000-0002-5582-0028	NATIONAL CANCER INSTITUTE [R01CA057327] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA057327, CA57327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 1997, J BIOCHEM, V122, P409; Baillat G, 2001, MOL BIOL CELL, V12, P663, DOI 10.1091/mbc.12.3.663; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Castets F, 2000, J BIOL CHEM, V275, P19970, DOI 10.1074/jbc.M909782199; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Cheng S, 2000, CELL MOTIL CYTOSKEL, V47, P337, DOI 10.1002/1097-0169(200012)47:4<337::AID-CM7>3.3.CO;2-2; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Frenz LM, 2000, J CELL SCI, V113, P3399; Giasson BI, 1997, J NEUROBIOL, V32, P193, DOI 10.1002/(SICI)1097-4695(199702)32:2<193::AID-NEU4>3.0.CO;2-3; Goto H, 1998, J BIOL CHEM, V273, P11728, DOI 10.1074/jbc.273.19.11728; Gowdy PM, 1998, J CELL SCI, V111, P3401; Hou MC, 2000, CURR BIOL, V10, P619, DOI 10.1016/S0960-9822(00)00492-9; Hoyt MA, 2000, CELL, V102, P267, DOI 10.1016/S0092-8674(00)00031-3; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MURO Y, 1995, BIOCHEM BIOPH RES CO, V207, P1029, DOI 10.1006/bbrc.1995.1288; Nakamura Y, 2000, GENES CELLS, V5, P823, DOI 10.1046/j.1365-2443.2000.00372.x; Nakayama T, 1999, J NEUROBIOL, V41, P326, DOI 10.1002/(SICI)1097-4695(19991115)41:3<326::AID-NEU2>3.0.CO;2-W; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PALLAS D, 1982, CELL, V30, P407, DOI 10.1016/0092-8674(82)90238-0; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Salimova E, 2000, J CELL SCI, V113, P1695; Salin P, 1998, J COMP NEUROL, V397, P41; Schutz AR, 1998, MOL BIOL CELL, V9, P759, DOI 10.1091/mbc.9.4.759; Schutz AR, 1997, J CELL BIOL, V136, P969, DOI 10.1083/jcb.136.5.969; TEMELES GL, 1994, MOL REPROD DEV, V37, P121, DOI 10.1002/mrd.1080370202; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; VANDRE DD, 1992, J CELL SCI, V101, P79; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Yasui Y, 1998, J CELL BIOL, V143, P1249, DOI 10.1083/jcb.143.5.1249; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185	43	73	77	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24253	24260		10.1074/jbc.M102398200	http://dx.doi.org/10.1074/jbc.M102398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319234	Green Accepted, hybrid			2022-12-27	WOS:000169531100134
J	Giampuzzi, M; Botti, G; Cilli, M; Gusmano, R; Borel, A; Sommer, P; Di Donato, A				Giampuzzi, M; Botti, G; Cilli, M; Gusmano, R; Borel, A; Sommer, P; Di Donato, A			Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of Ras proto-oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; RECEPTOR EXPRESSION; BETA-SUBUNITS; MESSENGER-RNA; UP-REGULATION; I RECEPTOR; H-RAS; GENE; INSULIN	Several investigations have suggested a putative tumor suppressor role for lysyl oxidase because it is downregulated in many human and oncogene-induced tumors. To address this issue we down-regulated the enzyme in normal rat kidney fibroblasts by stable transfection of its cDNA in an antisense orientation. The selected clones revealed an absence of lysyl oxidase and dramatic phenotypic changes, interpretable as signs of transformation. The antisense lysyl oxidase clones showed, indeed, loose attachment to the plate and anchorage-independent growth and were highly tumorigenic in nude mice. Moreover, we found an impaired response of the PDGF and IGF-1 receptors to their ligands. In particular, the transformed cells showed a down-regulation of both PDGF receptors and expressed the 105-kDa isoform of the IGF-1 beta receptor, which was not present in the normal control cells. The lack of response to PDGF-BB has been described as a feature of many ras-transformed phenotypes. Therefore, we looked at the status of the p21(ras). Indeed, we found a significantly higher level of active p21(ras) both during steady-state growth and prolonged starvation. Our data reveal new evidence for a tumor suppressor activity of lysyl oxidase, highlighting its particular role in controlling Ras activation and growth factor dependence.	Ist Giannina Gaslini, Dept Nephrol, I-16147 Genoa, Italy; Ist Nazl Ric Canc, I-16136 Genoa, Italy; CNRS, UPR 412, Inst Biol & Chim Prot, F-69367 Lyon, France	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; Centre National de la Recherche Scientifique (CNRS)	Di Donato, A (corresponding author), Ist Giannina Gaslini, Dept Nephrol, Largo G Gaslini 5, I-16147 Genoa, Italy.			Cilli, Michele/0000-0003-4083-8986				BARENTON B, 1993, ENDOCRINOLOGY, V133, P651, DOI 10.1210/en.133.2.651; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; CARNERO A, 1994, ONCOGENE, V9, P1387; CHANOKI M, 1995, BRIT J DERMATOL, V133, P710; CONTENTE S, 1993, GENOMICS, V16, P395, DOI 10.1006/geno.1993.1202; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; Decitre M, 1998, LAB INVEST, V78, P143; Di Donato A, 1997, FEBS LETT, V419, P63, DOI 10.1016/S0014-5793(97)01420-8; DiDonato A, 1997, NEPHRON, V76, P192, DOI 10.1159/000190168; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GAROFALO RS, 1989, MOL CELL BIOL, V9, P2806, DOI 10.1128/MCB.9.7.2806; Garrouste FL, 1997, ENDOCRINOLOGY, V138, P2021, DOI 10.1210/en.138.5.2021; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; HAINAUT P, 1991, BIOCHEM J, V273, P673, DOI 10.1042/bj2730673; HAJNAL A, 1993, CANCER RES, V53, P4670; HAMALAINEN ER, 1995, J BIOL CHEM, V270, P21590, DOI 10.1074/jbc.270.37.21590; Jourdan-Le Saux C, 1999, J BIOL CHEM, V274, P12939; JOURDANLESAUX C, 1994, BIOCHEM BIOPH RES CO, V199, P587, DOI 10.1006/bbrc.1994.1269; KAGAN HM, 1991, AM J RESP CELL MOL B, V5, P296; KELLERER M, 1990, J BIOL CHEM, V265, P9340; KENYON K, 1993, J BIOL CHEM, V268, P18435; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li WD, 1997, P NATL ACAD SCI USA, V94, P12817, DOI 10.1073/pnas.94.24.12817; MOSS AM, 1993, BIOCHEM J, V294, P685, DOI 10.1042/bj2940685; MURAWAKI Y, 1991, HEPATOLOGY, V14, P1167, DOI 10.1002/hep.1840140635; Nellaiappan K, 2000, J CELL BIOCHEM, V79, P576, DOI 10.1002/1097-4644(20001215)79:4<576::AID-JCB60>3.0.CO;2-A; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; Perez-Juste G, 1999, ONCOGENE, V18, P5393, DOI 10.1038/sj.onc.1202906; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; RAKE JB, 1991, J BIOL CHEM, V266, P5348; Rice PL, 1999, MOL CARCINOGEN, V25, P285, DOI 10.1002/(SICI)1098-2744(199908)25:4<285::AID-MC7>3.0.CO;2-F; RILEY DJ, 1982, AM REV RESPIR DIS, V125, P67; Saito H, 1997, J BIOL CHEM, V272, P8157, DOI 10.1074/jbc.272.13.8157; Scotlandi K, 1996, CANCER RES, V56, P4570; SIEGEL RC, 1978, P NATL ACAD SCI USA, V75, P2945, DOI 10.1073/pnas.75.6.2945; SOMMER P, 1993, LAB INVEST, V69, P460; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626	40	64	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29226	29232		10.1074/jbc.M101695200	http://dx.doi.org/10.1074/jbc.M101695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11323426	hybrid			2022-12-27	WOS:000170346000080
J	Preiss, S; Argentaro, A; Clayton, A; John, A; Jans, DA; Ogata, T; Nagai, T; Barroso, I; Schafer, AJ; Harley, VR				Preiss, S; Argentaro, A; Clayton, A; John, A; Jans, DA; Ogata, T; Nagai, T; Barroso, I; Schafer, AJ; Harley, VR			Compound effects of point mutations causing campomelic dysplasia/autosomal sex reversal upon SOX9 structure, nuclear transport, DNA binding, and transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AROMATIC AROMATIC INTERACTIONS; CHONDROCYTE-SPECIFIC ENHANCER; TESTIS-DETERMINING GENES; II COLLAGEN GENE; SRY-RELATED GENE; HMG BOX; PROTEIN STABILITY; SIDE-CHAINS; DYSPLASIA; DOMAIN	Human mutations in the transcription factor SOX9 cause campomelic dysplasia/autosomal sex reversal. Here we identify and characterize two novel heterozygous mutations, F154L and A158T, that substitute conserved "hydrophobic core" amino acids of the high mobility group domain at positions thought to stabilize SOX9 conformation. Circular dichroism studies indicated that. both mutations disrupt alpha -helicity within their high mobility group domain, whereas tertiary structure is essentially maintained as judged by fluorescence spectroscopy. In cultured cells, strictly nuclear localization was observed for wild type SOX9 and the F154L mutant; however, the A158T mutant showed a 2-fold reduction in nuclear import efficiency. Importin-beta was demonstrated to be the nuclear transport receptor recognized by SOX9, with both mutant proteins binding importin-beta with wild type affinity. Whereas DNA bending was unaffected, DNA binding was drastically reduced in both mutants (to 5% of wild type activity in F154L, 17% in A158T). Despite this large effect, transcriptional activation in cultured cells was only reduced to 26% in F154L and 62% in A158T of wild type activity, suggesting that a small loss of SOX9 transactivation activity could be sufficient to disrupt proper regulation of target genes during bone and testis formation. Thus, clinically relevant mutations of SOX9 affect protein structure leading to compound effects of reduced nuclear import and reduced DNA binding, the net effect being loss of transcriptional activation.	Monash Med Ctr, Prince Henrys Inst, Melbourne, Vic 3168, Australia; Univ Melbourne, Dept Genet, Parkville, Vic 3052, Australia; Univ Melbourne, Howard Florey Inst, Parkville, Vic 3052, Australia; Max Planck Inst Biophys Chem, Dept Mol Biol, D-37077 Gottingen, Germany; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT, Australia; Tokyo Elect Power Co Hosp, Dept Paediat, Tokyo 1600016, Japan; Keio Univ, Sch Med, Tokyo 1600016, Japan; Dokkyo Univ, Sch Med, Dept Paediat, Koshigaya 3438555, Japan; Incyte Genom, Cambridge CB4 0WA, England	Monash University; Prince Henry's Institute of Medical Research; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Max Planck Society; Australian National University; John Curtin School of Medical Research; Tokyo Electric Power Company; Keio University; Dokkyo Medical University; Incyte	Harley, VR (corresponding author), Monash Med Ctr, Prince Henrys Inst, Melbourne, Vic 3168, Australia.	vincent.harley@med.monash.edu.au	Harley, Vincent/B-8092-2018	Harley, Vincent/0000-0002-2405-1262; Jans, David/0000-0001-5115-4745; Barroso, Ines/0000-0001-5800-4520; Ogata, Tsutomu/0000-0001-7178-9991				Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Cameron FJ, 1997, HUM MUTAT, V9, P388; Clayton AHA, 1999, BIOPHYS J, V76, P3235, DOI 10.1016/S0006-3495(99)77475-8; Crane-Robinson C, 1998, J MOL BIOL, V281, P705, DOI 10.1006/jmbi.1998.1895; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; de Santa Barbara P, 2000, DEV DYNAM, V217, P293, DOI 10.1002/(SICI)1097-0177(200003)217:3<293::AID-DVDY7>3.0.CO;2-P; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; Foster JW, 1996, ACTA PAEDIATR JAPON, V38, P405; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; Hageman RM, 1998, HUM MUTAT, pS112; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Harley VR, 1996, FEBS LETT, V391, P24, DOI 10.1016/0014-5793(96)00694-1; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; JAGER RJ, 1992, HUM GENET, V90, P350; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JASANOFF A, 1992, J MOL BIOL, V225, P1035, DOI 10.1016/0022-2836(92)90103-Q; Kent J, 1996, DEVELOPMENT, V122, P2813; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; KWOK C, 1995, AM J HUM GENET, V57, P1028; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LYNCH SA, 1993, J MED GENET, V30, P683, DOI 10.1136/jmg.30.8.683; McDowall S, 1999, J BIOL CHEM, V274, P24023, DOI 10.1074/jbc.274.34.24023; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Meyer J, 1997, HUM MOL GENET, V6, P91, DOI 10.1093/hmg/6.1.91; Nanda V, 2000, PROTEINS, V40, P112, DOI 10.1002/(SICI)1097-0134(20000701)40:1<112::AID-PROT130>3.0.CO;2-C; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; PADMANABHAN S, 1994, PROTEIN SCI, V3, P1992, DOI 10.1002/pro.5560031111; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; SCHAFER AJ, 2001, CAMPOMELIC DYSPLASIA; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Vijayakumar M, 1999, PROTEINS, V34, P497, DOI 10.1002/(SICI)1097-0134(19990301)34:4<497::AID-PROT9>3.3.CO;2-7; Vlassi M, 1999, J MOL BIOL, V285, P817, DOI 10.1006/jmbi.1998.2342; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; ZENG YT, 1993, J MED GENET, V30, P655, DOI 10.1136/jmg.30.8.655; Zhao Q, 1997, DEV DYNAM, V209, P377, DOI 10.1002/(SICI)1097-0177(199708)209:4<377::AID-AJA5>3.0.CO;2-F	52	75	79	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27864	27872		10.1074/jbc.M101278200	http://dx.doi.org/10.1074/jbc.M101278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11323423	hybrid			2022-12-27	WOS:000170093400018
J	Wang, XT; McCullough, KD; Wang, XJ; Carpenter, G; Holbrook, NJ				Wang, XT; McCullough, KD; Wang, XJ; Carpenter, G; Holbrook, NJ			Oxidative stress-induced phospholipase C-gamma l activation enhances cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; FACTOR RECEPTOR; HYDROGEN-PEROXIDE; PROTEIN-KINASE; SIGNALING PATHWAYS; INDUCED APOPTOSIS; PHOSPHORYLATION; SRC; C-GAMMA-1	Phospholipase C-gamma1 (PLC-gamma1) is rapidly activated in response to growth factor stimulation and plays an important role in regulating cell proliferation and differentiation through the generation of the second messengers diacylglycerol and inositol 1,4,5-trisphosphate, leading to the activation of protein kinase C (PKC) and increased levels of intracellular calcium, respectively. Given the existing overlap between signaling pathways that are activated in response to oxidant injury and those involved in responding to proliferative stimuli, we investigated the role of PLC-gamma1 during the cellular response to oxidative stress. Treatment of normal mouse embryonic fibroblasts (MEF) with H2O2 resulted in time- and concentration-dependent tyrosine phosphorylation of PLC-gamma1. Phosphorylation could be blocked by pharmacological inhibitors of Src family tyrosine kinases or the epidermal growth factor receptor tyrosine kinase, but not by inhibitors of the platelet-derived growth factor receptor or phosphatidylinositol 3-kinase. To investigate the physiologic relevance of H2O2-induced tyrosine phosphorylation of PLC-gamma1, we compared survival of normal MEF and PLC-gamma1-deficient MEF following exposure to H2O2. Treatment of PLC-gamma1-deficient MEF with H2O2 resulted in rapid cell death, whereas normal MEF were resistant to the stress. Pretreatment of normal MEF with a selective pharmacological inhibitor of PLC-gamma1, or inhibitors of inositol trisphosphate receptors and PKC, increased their sensitivity to H2O2, whereas treatment of PLC-gamma1-deficient MEF with agents capable of directly activating PKC and enhancing calcium mobilization significantly improved their survival. Finally, reconstitution of PLC-gamma1 protein expression in PLC-gamma1-deficient MEF restored cell survival following H2O2 treatment. These findings suggest an important protective function for PLC-gamma1 activation during the cellular response to oxidative stress.	NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Vanderbilt University; Vanderbilt University	Holbrook, NJ (corresponding author), NIA, Cell Stress & Aging Sect, Cellular & Mol Biol Lab, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [CA75195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; BLAKE RA, 1993, BIOCHEM J, V290, P471, DOI 10.1042/bj2900471; Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Khare S, 1997, J CLIN INVEST, V99, P1831, DOI 10.1172/JCI119350; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lee YH, 1999, BBA-MOL CELL BIOL L, V1440, P235, DOI 10.1016/S1388-1981(99)00128-6; Lee YH, 2000, LIFE SCI, V67, P827, DOI 10.1016/S0024-3205(00)00677-9; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; Liao HJ, 2001, J BIOL CHEM, V276, P8627, DOI 10.1074/jbc.C100030200; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rao GN, 1996, ONCOGENE, V13, P713; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zanella CL, 1996, CANCER RES, V56, P5334	40	126	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28364	28371		10.1074/jbc.M102693200	http://dx.doi.org/10.1074/jbc.M102693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350969	hybrid			2022-12-27	WOS:000170093400083
J	Asami, T; Mizutani, M; Fujioka, S; Goda, H; Min, YK; Shimada, Y; Nakano, T; Takatsuto, S; Matsuyama, T; Nagata, N; Sakata, K; Yoshida, S				Asami, T; Mizutani, M; Fujioka, S; Goda, H; Min, YK; Shimada, Y; Nakano, T; Takatsuto, S; Matsuyama, T; Nagata, N; Sakata, K; Yoshida, S			Selective interaction of triazole derivatives with DWF4, a cytochrome P450 monooxygenase of the brassinosteroid biosynthetic pathway, correlates with brassinosteroid deficiency in Planta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; EXPRESSION; GENE; INHIBITORS; ELONGATION; REDUCTASE; MUTANTS; GROWTH; FACKEL	Brassinazole, a synthetic chemical developed in our laboratory, is a triazole-type brassinosteroid biosynthesis inhibitor that induces dwarfism in various plant species. The target sites of brassinazole were investigated by chemical analyses of endogenous brassinosteroids (BRs) in brassinazole-treated Catharanthus roseus cells. The levels of castasterone and brassinolide in brassinazole-treated plant cells were less than 6% of the levels in untreated cells. In contrast, campestanol and 6-oxocampestanol levels were increased, and levels of BR intermediates with hydroxy groups on the side chains were reduced, suggesting that brassinazole treatment reduced BR levels by inhibiting the hydroxylation of the C-22 position. DWF4, which is an Arabidopsis thaliana cytochrome P450 isolated as a putative steroid 22-hydroxylase, was expressed in Escherichia coli, and the binding affinity of brassinazole and its derivatives to the recombinant DWF4 were analyzed. Among several triazole derivatives, brassinazole had both the highest binding affinity to DWF4 and the highest growth inhibitory activity. The binding affinity and the activity for inhibiting hypocotyl growth were well correlated among the derivatives. In brassinazole-treated A. thaliana, the CPD gene involved in BR biosynthesis was induced within 3 h, most likely because of feedback activation caused by the reduced levels of active BRs, These results indicate that brassinazole inhibits the hydroxylation of the C-22 position of the side chain in BRs by direct binding to DWF4 and that DWF4 catalyzes this hydroxylation reaction.	RIKEN, Wako, Saitama 3510198, Japan; Kyoto Univ, Chem Res Inst, Uji, Kyoto 6110011, Japan; Joetsu Univ Educ, Dept Chem, Niigata 9438512, Japan; RIKEN, Plant Sci Ctr, Wako, Saitama 3510198, Japan	RIKEN; Kyoto University; Joetsu University Education; RIKEN	Asami, T (corresponding author), RIKEN, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Shimada, Yukihisa/D-8879-2016; Nakano, Takeshi/E-9171-2013	Shimada, Yukihisa/0000-0001-7497-9408; Nakano, Takeshi/0000-0002-3188-7770; Matsuyama, Tomoki/0000-0002-4473-7720				Asami T, 1999, TRENDS PLANT SCI, V4, P348, DOI 10.1016/S1360-1385(99)01456-9; Asami T, 2000, PLANT PHYSIOL, V123, P93, DOI 10.1104/pp.123.1.93; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Bishop GJ, 1999, P NATL ACAD SCI USA, V96, P1761, DOI 10.1073/pnas.96.4.1761; Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; Choe SW, 1999, PLANT CELL, V11, P207, DOI 10.1105/tpc.11.2.207; Choe SW, 1998, PLANT CELL, V10, P231, DOI 10.1105/tpc.10.2.231; Clouse SD, 1996, PLANT PHYSIOL, V111, P671, DOI 10.1104/pp.111.3.671; Clouse SD, 1998, ANNU REV PLANT PHYS, V49, P427, DOI 10.1146/annurev.arplant.49.1.427; Hedden P, 1997, ANNU REV PLANT PHYS, V48, P431, DOI 10.1146/annurev.arplant.48.1.431; Jang JC, 2000, GENE DEV, V14, P1485; KAWAKAMI N, 1988, PLANT CELL PHYSIOL, V29, P33; Mathur J, 1998, PLANT J, V14, P593, DOI 10.1046/j.1365-313X.1998.00158.x; Min YK, 1999, BIOORG MED CHEM LETT, V9, P425, DOI 10.1016/S0960-894X(99)00008-6; Mizutani M, 1998, PLANT PHYSIOL, V116, P357, DOI 10.1104/pp.116.1.357; Mizutani M, 1997, PLANT PHYSIOL, V113, P755, DOI 10.1104/pp.113.3.755; Noguchi T, 2000, PLANT PHYSIOL, V124, P201, DOI 10.1104/pp.124.1.201; Noguchi T, 1999, PLANT PHYSIOL, V121, P743, DOI 10.1104/pp.121.3.743; Parikh A, 1997, NAT BIOTECHNOL, V15, P784, DOI 10.1038/nbt0897-784; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Sambrook J., 2002, MOL CLONING LAB MANU; Schrick K, 2000, GENE DEV, V14, P1471; Szekeres M, 1996, CELL, V85, P171, DOI 10.1016/S0092-8674(00)81094-6; Yamamuro C, 2000, PLANT CELL, V12, P1591, DOI 10.1105/tpc.12.9.1591; YOKOTA T, 1991, GIBBERELLINS, P339; Yokota T, 1997, TRENDS PLANT SCI, V2, P137, DOI 10.1016/S1360-1385(97)01017-0	26	131	139	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25687	25691		10.1074/jbc.M103524200	http://dx.doi.org/10.1074/jbc.M103524200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319239	hybrid			2022-12-27	WOS:000169823300009
J	Ngo, TH; Hoylaerts, MF; Knockaert, I; Brouwers, E; Declerck, PJ				Ngo, TH; Hoylaerts, MF; Knockaert, I; Brouwers, E; Declerck, PJ			Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; CELL-ADHESION; BIOLOGICAL SAMPLES; BINDING DOMAIN; VITRONECTIN; PAI-1; MIGRATION; TYPE-1; PURIFICATION; LOCALIZATION	The serpin plasminogen activator inhibitor-1 (PAI-1) has a dual function: 1) it plays an important role as a direct inhibitor of the plasminogen activation system, and 2) its interaction with the adhesive glycoprotein vitronectin suggests a role in tissue remodeling and metastasis, independent from its proteinase inhibitory properties. Unique to this serpin is the close association between its conformational and functional properties. Indeed, PAI-1 can occur in an active and a latent conformation, but both functions are exclusively present in the active conformation. We report here the epitope localization and functional effects of a monoclonal antibody (MA-124K1) that inhibits rat PAI-1 activity and simultaneously increases the binding of inactive PAI-1 to vitronectin (the affinity constant of PAI-1 for vitronectin is 2 x 10(7) M-1 in the absence of MA-124K1 and 160 x 10(7) M-1 in the presence of MA-124K1). To the best of our knowledge, this is the first monoclonal antibody dissociating the proteinase inhibitory properties from the vitronectin binding properties in PAI-1. Mutation of Glu(212) and/or Glu(220) in rat PAI-1 to Ala results in a strongly reduced affinity or absence of binding to MA-124K1. The three-dimensional structure of PAI-1 reveals that these residues constitute a conformational epitope close to the reactive-site loop and compatible with the effect of MA-124K1 on the inhibitory properties of PAI-1, However, the vitronectin binding site is localized at the opposite site of the molecule, indicating that the effect of MA-124K1 involves an allosteric modulation of the vitronectin binding site. Cell culture experiments revealed a significant reduction of cell attachment and migration in the presence of MA-124K1, providing evidence for the functional relevance of this antibody-mediated up-regulation of the vitronectin binding properties of PAI-1. In conclusion, a novel mechanism for interference with PAI-1 functions has been identified and is of importance in the modulation of cell migration and related events (e.g, tumor metastasis).	Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharmaceut Sci, B-3000 Louvain, Belgium; Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	KU Leuven; Universite Catholique Louvain	Declerck, PJ (corresponding author), Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharmaceut Sci, Van Evenstr 4, B-3000 Louvain, Belgium.	paul.declerck@farm.kuleuven.ac.be	Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105; Hoylaerts, Marc/0000-0002-6474-3933				Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bijnens AP, 2000, J BIOL CHEM, V275, P6375, DOI 10.1074/jbc.275.9.6375; Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350; Bijnens AP, 2001, THROMB HAEMOSTASIS, V85, P866; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; Debrock S, 1998, THROMB HAEMOSTASIS, V79, P597; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DECLERCK PJ, 1994, J INTERN MED, V236, P425, DOI 10.1111/j.1365-2796.1994.tb00820.x; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 1999, THROMB HAEMOSTASIS, V82, P1510; Ngo TH, 1998, FIBRINOLYSIS PROTEOL, V12, P335, DOI 10.1016/S0268-9499(98)80390-1; Ngo TH, 1998, THROMB HAEMOSTASIS, V79, P808, DOI 10.1055/s-0037-1615069; Ngo TH, 1997, FIBRINOLYSIS PROTEOL, V11, P37, DOI 10.1016/S0268-9499(97)80007-0; Oosterhof GON, 1997, EUR UROL, V32, P91, DOI 10.1159/000480887; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Sugiura Y, 1999, CANCER RES, V59, P1327; VANMEIJER M, 1994, FEBS LETT, V352, P342, DOI 10.1016/0014-5793(94)00990-2; Wiman B, 1999, SCAND J CLIN LAB INV, V59, P23; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	36	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26243	26248		10.1074/jbc.M008241200	http://dx.doi.org/10.1074/jbc.M008241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342530	hybrid			2022-12-27	WOS:000169823300081
J	Quan, TH; He, TY; Voorhees, JJ; Fisher, GJ				Quan, TH; He, TY; Voorhees, JJ; Fisher, GJ			Ultraviolet irradiation blocks cellular responses to transforming growth factor-beta by down-regulating its Type-II receptor and inducing Smad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; SIGNAL-TRANSDUCTION; HUMAN SKIN; COMPLEX-FORMATION; TYROSINE KINASES; BINDING-PROTEINS; RETINOIC ACID; PROMOTER; ACTIVATION; CELLS	Transforming growth factor-beta (TGF-beta) is a multi-functional cytokine that regulates cell growth and differentiation. Cellular responses to TGF-beta are mediated through its cell surface receptor complex, which activates transcription factors Smad2 and Smad3. Here we report that UV irradiation of mink lung epithelial cells causes near complete inhibition of TFG-beta -induced Smad2/3-mediated gene expression. UV irradiation inhibited TGF-P-induced phosphorylation of Smad2 and subsequent nuclear translocation and DNA binding of Smad2/3. Specific cell surface binding of TGF-beta was substantially reduced after UV irradiation. This loss of TGF-beta binding resulted from W-induced down-regulation of TGF-beta type II receptor (T beta RII) mRNA and protein. UV irradiation significantly inhibited T beta RII promoter reporter constructs, indicating that UV reduction of T beta RII expression involved transcriptional repression. In contrast to its effects on T beta RII, W irradiation rapidly induced Smad7 mRNA and protein. Smad7 is known to antagonize activation of Smad2/3 and thereby block TGF-beta -dependent gene expression. UV irradiation stimulated Smad7 promoter reporter constructs, indicating that increased Smad7 expression resulted, at least in part, from increased transcription. Overexpression of Smad7 protein to the level induced by W irradiation inhibited TGF-beta -induced gene expression 30%, Maintaining T beta RII levels by overexpression of T beta RII prevented UV inhibition of TGF-beta responsiveness. Taken together, these data indicate that UV irradiation blocks cellular responsiveness to TGF-beta through two mechanisms that impair TGF-beta receptor function. The primary mechanism is down-regulation of T beta RII, and the secondary mechanism is induction of Smad7.	Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fisher, GJ (corresponding author), Univ Michigan, Sch Med, Dept Dermatol, 1150 W Med Ctr Dr,Med Sci 1,Rm 6447, Ann Arbor, MI 48109 USA.		Voorhees, John/AAM-9966-2020	Voorhees, John/0000-0003-1856-785X; Quan, Taihao/0000-0002-0954-5109				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Barr RM, 1999, J INVEST DERMATOL, V112, P692, DOI 10.1046/j.1523-1747.1999.00570.x; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bitzer M, 2000, GENE DEV, V14, P187; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1994, J BIOL CHEM, V269, P22868; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COFFER PJ, 1995, ONCOGENE, V11, P561; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DEVOS S, 1994, J INVEST DERMATOL, V103, P92, DOI 10.1111/1523-1747.ep12391818; DUMONT N, 1995, MOL CELL ENDOCRINOL, V111, P57, DOI 10.1016/0303-7207(95)03548-L; Fisher G J, 1998, J Investig Dermatol Symp Proc, V3, P61; Fisher GJ, 2000, J CLIN INVEST, V106, P663, DOI 10.1172/JCI9362; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kondo Seijo, 1995, Journal of Dermatology (Tokyo), V22, P888; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; MARKOWITZ S, 2000, BIOCHIM BIOPHYS ACTA, V1470, P13; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MILLER JH, 1972, EXPRESSION MOL GENET; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Quan TH, 1999, J BIOL CHEM, V274, P28566, DOI 10.1074/jbc.274.40.28566; Riggins GJ, 1997, CANCER RES, V57, P2578; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHWARTZ E, 1989, J INVEST DERMATOL, V93, P142, DOI 10.1111/1523-1747.ep12277386; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; Takashima Akira, 1995, Journal of Dermatology (Tokyo), V22, P876; Tam BYY, 1998, J CELL PHYSIOL, V176, P553, DOI 10.1002/(SICI)1097-4652(199809)176:3<553::AID-JCP12>3.3.CO;2-A; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wells RG, 1997, J BIOL CHEM, V272, P11444; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Yu YS, 1996, BIOCHEM BIOPH RES CO, V225, P302, DOI 10.1006/bbrc.1996.1170; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZHAO J, 1995, CANCER RES, V55, P6181; Zhao Y, 1999, MOL CELL ENDOCRINOL, V150, P91, DOI 10.1016/S0303-7207(99)00021-0	72	130	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26349	26356		10.1074/jbc.M010835200	http://dx.doi.org/10.1074/jbc.M010835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11320083	hybrid			2022-12-27	WOS:000169823300094
J	Shimizu, K; Chiba, S; Saito, T; Kumano, K; Takahashi, T; Hirai, H				Shimizu, K; Chiba, S; Saito, T; Kumano, K; Takahashi, T; Hirai, H			Manic fringe and lunatic fringe modify different sites of the Notch2 extracellular region, resulting in different signaling modulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL ECTODERMAL RIDGE; HUMAN JAGGED1; LIGAND; HOMOLOG; GENE; EXPRESSION; DELTA; SERRATE; GLYCOSYLTRANSFERASE; MUTATIONS	Three mammalian fringe proteins are implicated in controlling Notch activation by Delta/Serrate/Lag2 ligands during tissue boundary formation, It was proved recently that they are glycosyltransferases that initiate elongation of O-linked fucose residues attached to epidermal growth factor-like sequence repeats in the extracellular domain of Notch molecules. Here we demonstrate the existence of functional diversity among the mammalian fringe proteins. Although both manic fringe (mFng) and lunatic fringe (1Fng) decreased the binding of Jagged1 to Notch2 and not that of Delta1, the decrease by mFng was greater in degree than that by 1Fng, We also found that both fringe proteins reduced Jagged1-triggered Notch2 signaling, whereas neither affected Delta1-triggered Notch2 signaling. However, the decrease in Jagged1-triggered Notch2 signaling by mFng was again greater than that by 1Fng, Furthermore, we observed that each fringe protein acted on a different site of the extracellular region of Notch2, Taking these findings together, we propose that the difference in modulatory function of multiple fringe proteins may result from the distinct amino acid sequence specificity targeted by these glycosyltransferases.	Tokyo Univ Hosp, Grad Sch Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, Tokyo 1138655, Japan; Tokyo Univ Hosp, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo	Hirai, H (corresponding author), Tokyo Univ Hosp, Grad Sch Med, Dept Cell Therapy & Transplantat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hhirai-tky@umin.ac.jp		Takahashi, Tokiharu/0000-0002-5785-8660				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Cohen B, 1997, NAT GENET, V16, P283, DOI 10.1038/ng0797-283; de Celis JF, 2000, DEVELOPMENT, V127, P1291; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Evrard YA, 1998, NATURE, V394, P377, DOI 10.1038/28632; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Johnston SH, 1997, DEVELOPMENT, V124, P2245; Ju BG, 2000, NATURE, V405, P191, DOI 10.1038/35012090; Klein T, 1998, DEVELOPMENT, V125, P2951; Klueg KM, 1999, J CELL SCI, V112, P3289; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rauskolb C, 1999, NATURE, V401, P476, DOI 10.1038/46786; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; Shawber C, 1996, DEV BIOL, V180, P370, DOI 10.1006/dbio.1996.0310; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Shutter JR, 2000, GENE DEV, V14, P1313; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Valsecchi V, 1997, MECH DEVELOP, V69, P203, DOI 10.1016/S0925-4773(97)00146-9; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8; Zhang NA, 1998, NATURE, V394, P374, DOI 10.1038/28625	38	95	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25753	25758		10.1074/jbc.M103473200	http://dx.doi.org/10.1074/jbc.M103473200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346656	hybrid			2022-12-27	WOS:000169823300017
J	Ghanouni, P; Gryczynski, Z; Steenhuis, JJ; Lee, TW; Farrens, DL; Lakowicz, JR; Kobilka, BK				Ghanouni, P; Gryczynski, Z; Steenhuis, JJ; Lee, TW; Farrens, DL; Lakowicz, JR; Kobilka, BK			Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta(2) adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; PROTON TRANSLOCATION; CYTOPLASMIC DOMAINS; REQUIREMENT; ACTIVATION; RHODOPSIN; BINDING; STATE	G protein-coupled receptors represent the largest class of drug discovery targets, Drugs that activate G protein-coupled receptors are classified as either agonists or partial agonists, To study the mechanism whereby these different classes of activating ligands modulate receptor function, we directly monitored ligand-induced conformational changes in the G protein-coupling domain of the P, adrenergic receptor. Fluorescence lifetime analysis of a reporter fluorophore covalently attached to this domain revealed that, in the absence of ligands, this domain oscillates around a single detectable conformation. Binding to an antagonist does not change this conformation but does reduce the flexibility of the domain. However, when the P, adrenergic receptor is bound to a full agonist, the G protein coupling domain exists in two distinct conformations. Moreover, the conformations induced by a full agonist can be distinguished from those induced by partial agonists. These results provide new insight into the structural consequence of antagonist binding and the basis of agonism and partial agonism.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Ctr Fluorescence Spect, Baltimore, MD 21201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; University System of Maryland; University of Maryland Baltimore; Oregon Health & Science University	Kobilka, BK (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.	kobilka@cmgm.stanford.edu		Kobilka, Brian/0000-0001-5958-3990				ARNIS S, 1994, J BIOL CHEM, V269, P23879; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Freire E, 2000, P NATL ACAD SCI USA, V97, P11680, DOI 10.1073/pnas.97.22.11680; GETHER U, 1995, J BIOL CHEM, V270, P28268; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; GRATTON E, 1989, FLUORESCENT BIOMOLEC, P17; HOSHI T, 1994, J GEN PHYSIOL, V103, P249, DOI 10.1085/jgp.103.2.249; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; LACZKO G, 1990, REV SCI INSTRUM, V61, P2331, DOI 10.1063/1.1141360; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perez DM, 1996, MOL PHARMACOL, V49, P112; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; Selley DE, 1997, MOL PHARMACOL, V51, P87, DOI 10.1124/mol.51.1.87; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; TOTA MR, 1990, MOL PHARMACOL, V37, P996; Tucek S, 1997, TRENDS PHARMACOL SCI, V18, P414	26	315	334	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24433	24436		10.1074/jbc.C100162200	http://dx.doi.org/10.1074/jbc.C100162200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320077	hybrid			2022-12-27	WOS:000169800700001
J	Hall, JA; Maloney, PC				Hall, JA; Maloney, PC			Transmembrane segment 11 of UhpT, the sugar phosphate carrier of Escherichia coli, is an alpha-helix that carries determinants of substrate selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAHELICAL SALT BRIDGE; LACTOSE PERMEASE; TRANSLOCATION PATHWAY; STREPTOCOCCUS-LACTIS; MELIBIOSE CARRIER; TRANSPORT SYSTEM; ANION-EXCHANGE; SITE; BINDING; IDENTIFICATION	In Escherichia coli, transport of hexose 6-phosphates is mediated by the P-i-linked antiport carrier, UhpT, a member of the major facilitator superfamily, We showed earlier that Lys(391), a member of an intrahelical salt bridge (Asp(388)/Lys(391)) in the eleventh transmembrane segment (TM11) of this transporter, can function as a determinant of substrate selectivity (Hall, J, A., Fann, M.-C., and Maloney, P. C. (1999) J. Biol. Chem. 274, 6148-6153), Here, we examine in detail the role of TM11 in setting substrate preference. Derivatives having an uncompensated cationic charge at either position 388 or 391 (the D388C, D388V, or D388K/K391C variants) are gain-of-function mutants in which phosphoenolpyruvate, not sugar g-phosphate, is the preferred organic substrate. By contrast, when an uncompensated anionic charge is placed at position 388 (K391C), we observed behavior consistent with an increased preference for monovalent rather than divalent sugar 6-phosphate. Because positions 388 and 391 lie deep within the UhpT hydrophobic sector, these findings suggested that an extended length of TM11 may be accessible to external substrates and probes. To explore this issue, we used a panel of TM11 single cysteine variants to examine the transport of glucose 6-phosphate in the presence and absence of the membrane-impermeant, thiol-reactive agent p-chloromercuribenzosulfonate (PCMBS). Accessibility to PCMBS, together with the pattern of substrate protection against PCMBS inhibition, leads us to conclude that TM11 spans the membrane as an a-helix, with approximately two-thirds of its surface lining a substrate translocation pathway. We suggest that this feature is a general property of carrier proteins in the major facilitator superfamily and that for this reason residues in TM11 will serve to carry determinants of substrate selectivity.	Johns Hopkins Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Maloney, PC (corresponding author), Johns Hopkins Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIGMS NIH HHS [F32 GM19421, GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019421, R01GM024195, R56GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1986, P NATL ACAD SCI USA, V83, P280, DOI 10.1073/pnas.83.2.280; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EVANS PR, 1981, PHILOS T ROY SOC B, V293, P53, DOI 10.1098/rstb.1981.0059; Fann MC, 1998, J MEMBRANE BIOL, V164, P187, DOI 10.1007/s002329900404; Fann MC, 1998, J BIOL CHEM, V273, P33735, DOI 10.1074/jbc.273.50.33735; Franco PJ, 1999, J BACTERIOL, V181, P6377, DOI 10.1128/JB.181.20.6377-6386.1999; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; FRILLINGOS S, 1995, BIOCHEMISTRY-US, V34, P9368, DOI 10.1021/bi00029a012; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; Fu DX, 2001, J BIOL CHEM, V276, P8753, DOI 10.1074/jbc.M008417200; Fu DX, 1997, J BIOL CHEM, V272, P2129; GOSWITZ VC, 1995, PROTEIN SCI, V4, P534; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; Hall JA, 1999, J BIOL CHEM, V274, P6148, DOI 10.1074/jbc.274.10.6148; HARLOW E, 1988, ANTIBODIES LAB MANUA, P486; HE MM, 1995, BIOCHEMISTRY-US, V34, P15661, DOI 10.1021/bi00048a009; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; JOHANSON RA, 1985, J BIOL CHEM, V260, P1465; KABACK HR, 1994, J EXP BIOL, V196, P183; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KYTE J, 1995, STRUCTURE PROTEIN CH, P59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JI, 1996, BBA-BIOMEMBRANES, V1278, P111, DOI 10.1016/0005-2736(95)00209-X; LEUCKE H, 1990, NATURE, V347, P402; LODI PJ, 1994, BIOCHEMISTRY-US, V33, P2809, DOI 10.1021/bi00176a009; LUNDQVIST T, 1989, J BIOL CHEM, V264, P7078; MALONEY PC, 1990, MICROBIOL REV, V54, P1; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MALONEY PC, 1984, J BACTERIOL, V158, P238, DOI 10.1128/JB.158.1.238-245.1984; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; Matsuzaki S, 1999, BBA-BIOMEMBRANES, V1420, P63, DOI 10.1016/S0005-2736(99)00087-5; Miller J. H., 1972, EXPT MOL GENETICS, P431; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Paulsen IT, 1998, J MOL BIOL, V277, P573, DOI 10.1006/jmbi.1998.1609; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; Quiocho FA, 1997, STRUCTURE, V5, P997, DOI 10.1016/S0969-2126(97)00253-0; Rosenberg H., 1987, ION TRANSPORT PROKAR, P205; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SKARZYNSKI T, 1987, J MOL BIOL, V193, P171, DOI 10.1016/0022-2836(87)90635-8; Someya Y, 2000, J BIOL CHEM, V275, P210, DOI 10.1074/jbc.275.1.210; SONNA LA, 1988, J BIOL CHEM, V263, P6625; Varela MF, 1996, BBA-BIOENERGETICS, V1276, P21, DOI 10.1016/0005-2728(96)00030-8; Varela MF, 1997, J BACTERIOL, V179, P5570, DOI 10.1128/jb.179.17.5570-5573.1997; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; Voss J, 1997, BIOCHEMISTRY-US, V36, P15055, DOI 10.1021/bi971726j; Voss J, 1996, BIOCHEMISTRY-US, V35, P12915, DOI 10.1021/bi9608774; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WESTON LA, 1987, J BACTERIOL, V169, P3546, DOI 10.1128/jb.169.8.3546-3555.1987; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	59	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25107	25113		10.1074/jbc.M102017200	http://dx.doi.org/10.1074/jbc.M102017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11349129	hybrid			2022-12-27	WOS:000169800700091
J	Szilagyi, L; Kenesi, E; Katona, G; Kaslik, G; Juhasz, G; Graf, L				Szilagyi, L; Kenesi, E; Katona, G; Kaslik, G; Juhasz, G; Graf, L			Comparative in vitro studies on native and recombinant human cationic trypsins - Cathepsin B is a possible pathological activator of trypsinogen in pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY PANCREATITIS; MUTATIONS; ZYMOGEN; CANCER; GENE	Hereditary pancreatitis, an autosomal dominant disease is believed to be caused by mutation in the human trypsinogen gene. The role of mutations has been investigated by in vitro studies using recombinant rat and human trypsinogen (TG), In this study we compare the enzymatic properties and inhibition by human pancreatic secretory trypsin inhibitor (hPSTI) of the native, postsynthetically modified and recombinant cationic trypsin, and found these values practically identical, We also determined the autolytic stability of recombinant wild type (Hu1Asn21) and pancreatitis-associated (Hu1Ile21) trypsin, Both forms were equally stable. Similarly, we found no difference in the rate of activation of the two zymogens by human cationic and anionic trypsin. Mesotrypsin did not activate either form. The rate of autocatalytic activation of Hu1Asn21 TG and Hu1Ile21 TG was also identical at pH 8 both in the presence and absence of Ca2+. At pH 5 Hu1Ile21 TG autoactivated about twice as fast as HulAsn21 TG, The presence of physiological amount of hPSTI completely prevented autoactivation of both zymogens at pH 8 and at pH 5 as well. Cathepsin B readily activated both zymogens although Hu1Ile21 TG was activated about 2.5-3 times as fast as Hu1Asn21 TG, The presence of hPSTI did not prevent the activation of zymogens by cathepsin B, Our results underlie the central role of cathepsin B in the development of different forms of pancreatitis.	Eotvos Lorand Univ, Dept Biochem, H-1088 Budapest, Hungary; Hungarian Acad Sci, Biotechnol Res Grp, H-1088 Budapest, Hungary; Eotvos Lorand Univ, Dept Physiol, H-1088 Budapest, Hungary	Eotvos Lorand University; Hungarian Academy of Sciences; Eotvos Lorand University	Szilagyi, L (corresponding author), Eotvos Lorand Univ, Dept Biochem, H-1088 Budapest, Hungary.	szilagyi@cerberus.elte.hu	Katona, Gergely/B-3491-2008; Juhász, Gábor/I-7781-2017	Katona, Gergely/0000-0002-2031-8716; Juhász, Gábor/0000-0002-0849-6931				BRODRICK JW, 1978, J BIOL CHEM, V253, P2732; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; Coleman P L, 1976, Methods Enzymol, V45, P12; COLOMB E, 1978, BIOCHIM BIOPHYS ACTA, V525, P186, DOI 10.1016/0005-2744(78)90213-9; Dang Q, 1997, TRENDS BIOCHEM SCI, V22, P317, DOI 10.1016/S0968-0004(97)01062-1; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; FEINSTEIN G, 1974, EUR J BIOCHEM, V43, P569, DOI 10.1111/j.1432-1033.1974.tb03444.x; FIGARELLA C, 1988, BIOL CHEM H-S, V369, P293; FRIEDEN C, 1980, BIOCHEMISTRY-US, V19, P5303, DOI 10.1021/bi00564a024; Gaboriaud C, 1996, J MOL BIOL, V259, P995, DOI 10.1006/jmbi.1996.0376; Gorry MC, 1997, GASTROENTEROLOGY, V113, P1063, DOI 10.1053/gast.1997.v113.pm9322498; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; Graf R, 2000, PANCREAS, V21, P181, DOI 10.1097/00006676-200008000-00012; GUYCROTTE O, 1984, BIOCHEM BIOPH RES CO, V125, P516, DOI 10.1016/0006-291X(84)90570-9; KOIKE H, 1982, AM J PHYSIOL, V242, pG297, DOI 10.1152/ajpgi.1982.242.4.G297; Nishimori I, 1999, GUT, V44, P259, DOI 10.1136/gut.44.2.259; Nyaruhucha CNM, 1997, J BIOL CHEM, V272, P10573; Ohta T, 1998, INT J MOL MED, V1, P689; ORSINI G, 1978, J BIOL CHEM, V253, P3453; RINDERKNECHT H, 1979, GUT, V20, P886, DOI 10.1136/gut.20.10.886; RINDERKNECHT H, 1984, GASTROENTEROLOGY, V86, P681; Rinderknecht Heinrich, 1993, P219; Sahin-Toth M, 1999, BIOCHEM BIOPH RES CO, V264, P505, DOI 10.1006/bbrc.1999.1565; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; Sahin-Toth M, 1999, J BIOL CHEM, V274, P29699, DOI 10.1074/jbc.274.42.29699; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHMIDT K, 2001, J BIOL CHEM     0110; STEER ML, 1984, DIGEST DIS SCI, V29, P934, DOI 10.1007/BF01312483; Teich N, 2000, GASTROENTEROLOGY, V119, P461, DOI 10.1053/gast.2000.9312; TOOZE J, 1991, EUR J CELL BIOL, V56, P187; Varallyay E, 1998, BIOCHEM BIOPH RES CO, V243, P56, DOI 10.1006/bbrc.1997.8058; WATANABE O, 1984, AM J PHYSIOL, V246, pG457, DOI 10.1152/ajpgi.1984.246.4.G457; Whitcomb DC, 1999, GUT, V45, P317, DOI 10.1136/gut.45.3.317; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141	35	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24574	24580		10.1074/jbc.M011374200	http://dx.doi.org/10.1074/jbc.M011374200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312265	hybrid			2022-12-27	WOS:000169800700022
J	Zauberman, A; Lapter, S; Zipori, D				Zauberman, A; Lapter, S; Zipori, D			Smad proteins suppress CCAAT/enhancer-binding protein (C/EBP) beta- and STAT3-mediated transcriptional activation of the haptoglobin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; TUMOR-SUPPRESSOR; ACTIVIN-A; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; SKI ONCOPROTEIN; RESTRICTIN-P; CELL-GROWTH; RECEPTOR	Activin A, a member of the transforming growth factor beta (TGF beta) superfamily, blocks interleukin (IL)-6 biological functions. The molecular basis of the influence of this TGF beta signaling on the IL-6 receptor triggered cascade is unknown. We studied IL-g-induced secretion of the acute phase protein haptoglobin by hepatoma cells. Overexpression of the C/EBP beta gene, a downstream effector in the IL-6 pathway, activated transcription from the haptoglobin promoter. This was abolished by either a constitutively active form of activin A type IB receptor (CAactRIB) or by a combination of Smad3 and Smad4, Similarly, Smads abolished transcriptional activation by co-stimulation with IL-6 and STAT3. The transcription co-activator p300 partially overcame the suppressive effect of Smads. Electrophoretic mobility shift assays indicated that C/EBP beta binding to haptoglobin promoter DNA was reduced by over-expression of CAactRIB and Smad4. We thus show that Smad proteins operate as transcription inhibitors on target genes of the IL-6 induced pathway. The effect of Smads is exerted on components of the transcription activation complex and may also involve interference with DNA binding. This study thus depicts molecular sites of interaction between the TGF beta superfamily and the IL-6 signaling cascades.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zipori, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; Boudreau F, 1998, DNA CELL BIOL, V17, P669, DOI 10.1089/dna.1998.17.669; BRETON J, 1995, EUR J BIOCHEM, V227, P573, DOI 10.1111/j.1432-1033.1995.tb20427.x; Bright JJ, 1998, J IMMUNOL, V161, P1772; BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KISHIMOTO T, 1992, INT J IMMUNOPHARMACO, V14, P431; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Sternberg D, 1995, GROWTH FACTORS, V12, P277, DOI 10.3109/08977199509028966; Sudarshan C, 1999, J IMMUNOL, V162, P2974; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; WANG L, 1995, J BIOL CHEM, V270, P23159, DOI 10.1074/jbc.270.39.23159; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yu SJ, 1999, BIOCHEM BIOPH RES CO, V259, P544, DOI 10.1006/bbrc.1999.0808; Zauberman A, 1997, ONCOGENE, V15, P1705, DOI 10.1038/sj.onc.1201348; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZIPORI D, 1986, P NATL ACAD SCI USA, V83, P4547, DOI 10.1073/pnas.83.12.4547	52	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24719	24725		10.1074/jbc.M005813200	http://dx.doi.org/10.1074/jbc.M005813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11331273	hybrid			2022-12-27	WOS:000169800700042
J	Craggs, G; Kellie, S				Craggs, G; Kellie, S			A functional nuclear localization sequence in the C-terminal domain of SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; HEMATOPOIETIC-CELL PHOSPHATASE; SIGNAL-TRANSDUCTION; SH2 DOMAIN; CRYSTAL-STRUCTURE; ANTIGEN RECEPTOR; ASSOCIATION; KINASE; INACTIVATION; PTP1C	The Src homology 2 domain-containing protein tyrosine phosphatases SHP-1 and SHP-2 play an important role in many intracellular signaling pathways. Both SHP-1 and SHP-2 have been shown to interact with a diverse range of cytosolic and membrane-bound signaling proteins. Generally, SHP-1 and SHP-2 perform opposing roles in signaling processes; SHP-1 acts as a negative regulator of transduction in hemopoietic cells, whereas SHP-2 acts as a positive regulator. Intriguingly, SHP-1 has been proposed to play a positive regulating role in non-hemopoietic cells, although the mechanisms for this are not understood. Here we show that green fluorescent protein-tagged SHP-1 is unexpectedly localized within the nucleus of transfected HEK293 cells. In contrast, the highly related SHP-2 protein is more abundant within the cytoplasm of transfected cells. In accordance with this, endogenous SHP-1 is localized within the nucleus of several other nonhemopoietic cell types, whereas SHP-2 is distributed throughout the cytoplasm. In contrast, SHP-1 is confined to the cytoplasm of hemopoietic cells, with very little nuclear SHP-1 evident. Using chimeric SHP proteins and mutagenesis studies, the nuclear localization signal of SHP-1 was identified within the C-terminal domain of SHP-1 and found to consist of a short cluster of basic amino acids (KRK), Although the KRK motif resembles half of a bipartite nuclear localization signal, it appears to function independently and is absolutely required for nuclear import. Our findings show that SHP-1 and SHP-2 are distinctly localized within nonhemopoietic cells, with the localization of SHP-1 differing dramatically between nonhemopoietic and hemopoietic cell lineages. This implies that SHP-1 nuclear import is a tightly regulated process and indicates that SHP-1 may possess novel nuclear targets.	Yamanouchi Res Inst, Oxford OX4 4SX, England		Craggs, G (corresponding author), Yamanouchi Res Inst, Littlemore Pk, Oxford OX4 4SX, England.		Kellie, Stuart/A-6036-2010	Kellie, Stuart/0000-0002-8163-1474				Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Erlich H.A., 1989, PCR TECHNOLOGY; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Jin YJ, 1999, J BIOL CHEM, V274, P28301, DOI 10.1074/jbc.274.40.28301; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	34	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23719	23725		10.1074/jbc.M102846200	http://dx.doi.org/10.1074/jbc.M102846200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323437	hybrid			2022-12-27	WOS:000169531100067
J	Feng, JY; Johnson, AA; Johnson, KA; Anderson, KS				Feng, JY; Johnson, AA; Johnson, KA; Anderson, KS			Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-GAMMA; IMMUNODEFICIENCY-VIRUS INFECTION; HIV-1 REVERSE-TRANSCRIPTASE; CHRONIC HEPATITIS-B; PHARMACOKINETIC PROPERTIES; (-)-2'-DEOXY-3'-THIACYTIDINE 3TC; SUBSTRATE-SPECIFICITY; NUCLEOSIDE ANALOGS; FIALURIDINE FIAU; SUBUNIT	Several of the nucleoside analogs used in the treatment of AIDS exhibit a delayed clinical toxicity limiting their usefulness. The toxicity of nucleoside analogs may be related to their effects on the human mitochondrial DNA polymerase (Pol gamma), the polymerase responsible for mitochondrial DNA replication. Among the AIDS drugs approved by the FDA for clinical use, two are modified cytosine analogs, Zalcitabine (2 ' ,3 ' -dideoxycytidine (ddC)) and Lamivudine (beta -D-(+)-2 ' ,3 ' -dideoxy-3 ' -thiacytidine ((-)3TC])). (-)3TC is the only analog containing an unnatural L(-) nucleoside configuration and is well tolerated by patients even after long term administration. In cell culture (-)3TC is less toxic than its D(+) isomer, (+)3TC, containing the natural nucleoside configuration, and both are considerably less toxic than ddC. We have investigated the mechanistic basis for the differential toxicity of these three cytosine analogs by comparing the effects of dideoxy-CTP), (+)3TC-triphosphate (TP), and (-)3TC-TP on the polymerase and exonuclease activities of recombinant human Pol gamma. This analysis reveals that Pol gamma incorporates (-)3TC-triphosphate 16-fold less efficiently than the corresponding (+)isomer and 1140-fold less efficiently than dideoxy-CTP, showing a good correlation between incorporation rate and toxicity. The rates of excision of the incorporated analogs from the chain-terminated 3 ' -end of the DNA primer by the 3 ' -5 ' -exonuclease activity of Pol gamma were similar (0.01 s(-1)) for both 3TC analogs. In marked contrast, the rate of exonuclease removal of a ddC chain-terminated DNA occurs at least 2 orders of magnitude slower, suggesting that the failure of the exonuclease to remove ddC may play a major role in its greater toxicity. This study demonstrates that direct analysis of the mitochondrial DNA polymerase structure/function relationships may provide valuable insights leading to the design of less toxic inhibitors.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	Yale University; University of Texas System; University of Texas Austin	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.	karen.anderson@yale.edu			NIGMS NIH HHS [GM49551, GM44613] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551, R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adkins JC, 1997, DRUGS, V53, P1054, DOI 10.2165/00003495-199753060-00009; Barile M, 1998, GEN PHARMACOL, V31, P531, DOI 10.1016/S0306-3623(98)00041-X; Beach JW, 1998, CLIN THER, V20, P2; Benbrik E, 1997, J NEUROL SCI, V149, P19, DOI 10.1016/S0022-510X(97)05376-8; CAMMACK N, 1992, BIOCHEM PHARMACOL, V43, P2059, DOI 10.1016/0006-2952(92)90162-C; CHANG CN, 1992, J BIOL CHEM, V267, P22414; CHANG CN, 1992, J BIOL CHEM, V267, P13938; CHEN CH, 1989, J BIOL CHEM, V264, P11934; CHEN CH, 1991, MOL PHARMACOL, V39, P625; Colacino JM, 1996, ANTIVIR RES, V29, P125, DOI 10.1016/0166-3542(95)00836-5; DUBINSKY RM, 1989, MUSCLE NERVE, V12, P856, DOI 10.1002/mus.880121012; ERIKSSON S, 1995, J BIOL CHEM, V270, P18929, DOI 10.1074/jbc.270.32.18929; FAULDS D, 1992, DRUGS, V44, P94, DOI 10.2165/00003495-199244010-00008; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; FRICK LW, 1988, BIOCHEM BIOPH RES CO, V154, P124, DOI 10.1016/0006-291X(88)90659-6; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; GRAY H, 1992, J BIOL CHEM, V267, P5835; GRAY NM, 1995, BIOCHEM PHARMACOL, V50, P1043, DOI 10.1016/0006-2952(95)96620-A; HALL ET, 1994, J BIOL CHEM, V269, P14355; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HITCHCOCK M J M, 1991, Antiviral Chemistry and Chemotherapy, V2, P125; Honkoop P, 1997, DRUG SAFETY, V17, P1, DOI 10.2165/00002018-199717010-00001; Honkoop P, 1997, HEPATOLOGY, V26, P211; Horn DM, 1997, ANTIVIR RES, V34, P71, DOI 10.1016/S0166-3542(96)01027-3; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; Kewn S, 1997, BIOCHEM PHARMACOL, V54, P589, DOI 10.1016/S0006-2952(97)00189-5; KUKHANOVA M, 1995, J BIOL CHEM, V270, P23055, DOI 10.1074/jbc.270.39.23055; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MEDINA DJ, 1994, ANTIMICROB AGENTS CH, V38, P1824, DOI 10.1128/AAC.38.8.1824; Notermans DW, 1996, DRUG SAFETY, V15, P176, DOI 10.2165/00002018-199615030-00003; OLSON MW, 1992, J BIOL CHEM, V267, P23136; PARKER WB, 1994, J NIH RES, V6, P57; PEZESHKPOUR G, 1987, J NEUROL SCI, V77, P285, DOI 10.1016/0022-510X(87)90129-8; Simon DK, 1999, ANNU REV MED, V50, P111; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; WHITTINGTON R, 1992, DRUGS, V44, P656, DOI 10.2165/00003495-199244040-00009; WILDE MI, 1993, DRUGS, V46, P515, DOI 10.2165/00003495-199346030-00010	45	107	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23832	23837		10.1074/jbc.M101156200	http://dx.doi.org/10.1074/jbc.M101156200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328813	hybrid			2022-12-27	WOS:000169531100082
J	Friedrich, U; Blom, AM; Dahlback, B; Villoutreix, BO				Friedrich, U; Blom, AM; Dahlback, B; Villoutreix, BO			Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR-V; BLOOD-COAGULATION; MAST-CELLS; DOMAIN; IDENTIFICATION; INHIBITOR; THROMBIN; ALPHA-1-ANTITRYPSIN; STIMULATION	Human activated protein C (APC) is a key component of a natural anticoagulant system that regulates blood coagulation, rn vivo, the catalytic activity of APC is regulated by two serpins, alpha1-antitrypsin and the protein C inhibitor (PCI), the inhibition by the latter being stimulated by heparin, We have identified a heparin-binding site in the serine protease domain of APC and characterized the energetic basis of the interaction with heparin. According to the counter-ion condensation theory, the binding of heparin to APC is 66% ionic in nature and comprises four to six net; ionic interactions. To localize the heparin-binding site, five recombinant APC variants containing amino acid exchanges in loops 37, 60, and 70 (chymotrypsinogen numbering) were created. As demonstrated by surface plasmon resonance, reduction of the electropositive character of loops 37 and 60 resulted in complete loss of heparin binding. The functional consequence was loss in heparin-induced stimulation of APC inhibition by PCI, whereas the PCI-induced APC inhibition in the absence of heparin was enhanced. Presumably, the former observations were due to the inability of heparin to bridge some APC mutants to PCI, whereas the increased inhibition of certain APC variants by PCI in the absence of heparin was due to reduced repulsion between the enzymes and the serpin. The heparin-binding site of APC was also shown to interact with heparan sulfate, albeit with lower affinity. In conclusion, we have characterized and spatially localized the functionally important heparin/heparan sulfate-binding site of APC.	Univ Lund, MAS, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Paris 05, INSERM U428, F-75006 Paris, France	Lund University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dahlback, B (corresponding author), Univ Lund, MAS, Wallenberg Lab, Dept Clin Chem, S-20502 Malmo, Sweden.		Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009; Villoutreix, Bruno/I-4565-2015	Blom, Anna/0000-0002-1348-1734; Villoutreix, Bruno/0000-0002-6456-7730; Dahlback, Bjorn/0000-0003-1546-0328				Aznar J, 1996, THROMB HAEMOSTASIS, V76, P983; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Cleland W W, 1979, Methods Enzymol, V63, P103; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; Esmon CT, 1997, THROMB HAEMOSTASIS, V78, P70; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; FISHER CL, 1994, PROTEIN SCI, V3, P588; FRIEDRICH U, 1994, THROMB HAEMOSTASIS, V72, P567; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Hari SP, 2000, BIOCHEMISTRY-US, V39, P3763, DOI 10.1021/bi9926734; HEEB MJ, 1988, J BIOL CHEM, V263, P11613; HERMANS JM, 1993, BIOCHEM J, V295, P239, DOI 10.1042/bj2950239; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; Montserret R, 1999, BIOCHEMISTRY-US, V38, P6479, DOI 10.1021/bi9900222; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; Neese LL, 1998, ARCH BIOCHEM BIOPHYS, V355, P101, DOI 10.1006/abbi.1998.0716; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Rosing J, 1997, THROMB HAEMOSTASIS, V78, P427; SALI A, 1993, J BIOL CHEM, V268, P9023; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; Shen L, 1999, THROMB HAEMOSTASIS, V82, P72, DOI 10.1055/s-0037-1614632; Shen L, 2000, BIOCHEMISTRY-US, V39, P2853, DOI 10.1021/bi992357p; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; WACEY AI, 1993, BRIT J HAEMATOL, V84, P290, DOI 10.1111/j.1365-2141.1993.tb03067.x; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641; [No title captured]	37	52	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24122	24128		10.1074/jbc.M011567200	http://dx.doi.org/10.1074/jbc.M011567200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316800	hybrid			2022-12-27	WOS:000169531100119
J	Glading, A; Uberall, F; Keyse, SM; Lauffenburger, DA; Wells, A				Glading, A; Uberall, F; Keyse, SM; Lauffenburger, DA; Wells, A			Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; PROTEIN-KINASE; SELECTIVE LOCALIZATION; CELL-MIGRATION; CLEAVAGE; MOTILITY; CALCIUM; PATHWAY; TALIN; INTERNALIZATION	Localization of signaling is critical in directing cellular outcomes, especially in pleiotropic signaling pathways. The extracellular signal-regulated kinase (ERK)/ microtubule-associated protein kinase, which promotes cell migration, proliferation, and differentiation is found in the nucleus and throughout the cytoplasm. Recently, it has been shown that nuclear translocation of ERK is required for transcriptional changes and cell proliferation. However, the cellular consequences, of cytoplasmic signaling have not been defined. We explored whether cytoplasmic, specifically membrane-proximal, ERK signaling is involved in growth factor-induced cell motility, We previously have demonstrated that increased M-calpain activity downstream of epidermal growth factor receptor (EGFR)-mediated ERK activation is necessary for epidermal growth factor (EGF)induced motility. Calpain isoforms also have been found in nuclear, cytosolic, and plasma membrane-associated compartments in a variety of cell types. We now employ cell engineering approaches to control localization of the upstream EGFR and ERK activities to examine the spatial effect of upstream signal locale on downstream calpain activity. With differential ligand-induced internalization and trafficking-restricted receptor variants, we find that calpain activity is triggered only by plasma membrane-restricted activated EGFR, not by internalized (although still active) EGFR. Cells transfected with membrane-targeted ERK1 and ERK2, which sequester endogenous ERKs, exhibited normal EGF-induced calpain activity. Transfection of an inactive ERK phosphatase (MKP-3/Pyst1) that sequesters ERK in the cytoplasm prevented calpain activation as well as deadhesion. These data strongly suggest that EGF-induced calpain activity can be enhanced near sites of membrane-proximal EGFR-mediated ERK signaling, providing insights about how calpain activity might be regu lated and targeted to enhance its effects on adhesion-related substrates.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Ninewells Hosp, Biomed Res Ctr, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Innsbruck; University of Dundee; Massachusetts Institute of Technology (MIT)	Wells, A (corresponding author), Univ Pittsburgh, Dept Pathol, 713 Scaife Hall, Pittsburgh, PA 15261 USA.	wellsa@msx.upmc.edu	Keyse, Stephen M./B-9575-2009; Glading, Angela/AAI-3455-2020	Keyse, Stephen M./0000-0002-5150-8221; Wells, Alan/0000-0002-1637-8150; Glading, Angela/0000-0002-1830-6601	NCI NIH HHS [CA69213] Funding Source: Medline; NIGMS NIH HHS [GM54739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIYOSHI H, 1993, BIOCHEM MOL BIOL INT, V30, P63; Ariyoshi H, 1998, ARTERIOSCL THROM VAS, V18, P493, DOI 10.1161/01.ATV.18.3.493; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hochholdinger F, 1999, MOL CELL BIOL, V19, P8052; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; KITAHARA A, 1985, FEBS LETT, V184, P120, DOI 10.1016/0014-5793(85)80666-9; KITAHARA A, 1986, J CLIN ENDOCR METAB, V63, P343, DOI 10.1210/jcem-63-2-343; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUBOKI M, 1987, BIOCHIM BIOPHYS ACTA, V929, P164, DOI 10.1016/0167-4889(87)90172-8; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; MUGURUMA M, 1995, J BIOCHEM-TOKYO, V117, P1036, DOI 10.1093/oxfordjournals.jbchem.a124803; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; PONTREMOLI S, 1985, BIOCHEM BIOPH RES CO, V128, P331, DOI 10.1016/0006-291X(85)91683-3; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; POTTS AJ, 1994, EXP CELL RES, V212, P2, DOI 10.1006/excr.1994.1111; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; Santella L, 1998, CELL CALCIUM, V23, P123, DOI 10.1016/S0143-4160(98)90110-5; Shiraha H, 1999, J CELL BIOL, V146, P243; TOMPA P, 1995, ANAL BIOCHEM, V228, P287, DOI 10.1006/abio.1995.1352; TRANQUI L, 1995, EXP CELL RES, V217, P149, DOI 10.1006/excr.1995.1074; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; Xie H, 1998, J CELL SCI, V111, P615; YOSHIMURA N, 1984, J BIOL CHEM, V259, P9847; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	43	177	183	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23341	23348		10.1074/jbc.M008847200	http://dx.doi.org/10.1074/jbc.M008847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319218				2022-12-27	WOS:000169531100018
J	Bernard, D; Quatannens, B; Vandenbunder, B; Abbadie, C				Bernard, D; Quatannens, B; Vandenbunder, B; Abbadie, C			Rel/NF-kappa B transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; INDUCED CELL-DEATH; TRANSFORMED KERATINOCYTES; CD95-INDUCED APOPTOSIS; EMBRYONIC LETHALITY; LIVER DEGENERATION; DEFICIENT MICE; JNK ACTIVATION; T-LYMPHOCYTES; FAS-LIGAND	Rel/nuclear factor (NF)-kappaB transcription factors play a major role in the regulation of programmed cell death. A few anti-apoptotic Rel/NF-kappaB target genes have been characterized; they act either downstream in the apoptotic pathway or upstream, for example at the tumor necrosis factor (TNF) receptor Level. We found using DNA arrays, reverse transcription-polymerase chain reaction, and immunofluorescence that Rel/NF-kappaB factors up-regulate DcR1, a receptor for TNF-related apoptosis-inducing ligand (TRAIL), a cytokine of the TNF family that induces apoptosis in tumor cells. Four related receptors bind TRAIL, two death receptors (DR4 and DR5) that signal apoptosis and two decoy receptors (DcR1 and DcR2) that act as dominant negative inhibitors of TRAIL-mediated apoptosis. DcR1 is devoid of an intracellular domain and is anchored at the cell surface membrane by a glycophospholipid. Our results indicate that overexpression of cRel or activation of endogenous Rel/NF-kappaB factors by TNF alpha in HeLa cells up-regulates DcR1 without changing the expression of DcR2, DR4, and DR5 and makes cells resistant against TRAIL-induced apoptosis. This resistance is a consequence of DcR1 upregulation,,because it was abolished when DcR1 was removed from the cell surface by a phosphatidylinositol phospholipase C. Therefore, Rel/NF-kappaB transcription factors could regulate the sensitivity of cells to TRAIL, by: controlling the ratio of TRAIL-decoy to -death receptors.	Univ Lille 2, CNRS,FRE 2353, IPL, Inst Biol Lille, F-59021 Lille, France; Univ Lille 2, CNRS,Unite Mixte Rech 8526, Inst Pasteur Lille, Inst Biol Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Abbadie, C (corresponding author), Univ Lille 2, CNRS,FRE 2353, IPL, Inst Biol Lille, 1 Rue Calmette,BP 447, F-59021 Lille, France.		ABBADIE, Corinne/F-4949-2018; Bernard, David/D-6265-2018	ABBADIE, Corinne/0000-0002-8174-2393; Bernard, David/0000-0002-1557-2074				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernard D, 2001, CANCER RES, V61, P2656; BROWNELL E, 1989, ONCOGENE, V4, P935; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Foo SY, 1999, TRENDS GENET, V15, P229; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; HUGUET C, 1997, CELL DEATH DIFFER, V4, P1; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leverkus M, 2000, CANCER RES, V60, P553; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1999, RECENT PROG HORM RES, V54, P225; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Rudolph D, 2000, GENE DEV, V14, P854; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; VAN AD, 1996, SCIENCE, V274, P787; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zhang XD, 2000, FEBS LETT, V482, P193, DOI 10.1016/S0014-5793(00)02042-1; Zhang XD, 1999, CANCER RES, V59, P2747; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	59	107	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27322	27328		10.1074/jbc.M011183200	http://dx.doi.org/10.1074/jbc.M011183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350953	hybrid			2022-12-27	WOS:000169966900079
J	Christenson, LK; Stouffer, RL; Strauss, JF				Christenson, LK; Stouffer, RL; Strauss, JF			Quantitative analysis of the hormone-induced hyperacetylation of histone H3 associated with the steroidogenic acute regulatory protein gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; PERI-OVULATORY INTERVAL; MACAQUE GRANULOSA-CELLS; LEYDIG TUMOR-CELLS; BINDING-PROTEIN; STAR GENE; FACTOR-I; TRANSCRIPTIONAL REGULATION; RAPID ACCUMULATION; CORPUS-LUTEUM	Transcriptional regulation of steroidogenic acute regulatory protein (StAR) determines adrenal and gonadal cell steroidogenesis. Chromatin immunoprecipitation assays were combined with quantitative real-time polymerase chain reaction to assess histone acetylation associated with the StAR promoter. MA-10 cells treated with 8-bromo-cAMP had increased acetylated histone H3 associated with the proximal (but not distal) StAR promoter, nascent StAR transcripts, and progesterone production within 15 min, whereas StAR mRNA increased at 30 min. At 360 min, steroidogenesis remained elevated, but mRNA, nascent RNA, and StAR promoter-associated H3 acetylation all declined. StAR promoter-associated H4 acetylation was unchanged by 8-bromo-cAMP treatment of MA-10 cells. In vivo analysis of macaque and human granulosa cells showed that luteinization was associated with increased StAR promoter-associated H3 acetylation. We conclude that acetylation of H3 (but not H4) associated with the proximal promoter is associated with StAR gene transcription, that chromatin modification occurs in discrete regions of the promoter, that the initial steroidogenic response to 8-bromo-cAMP occurs prior to increased StAR mRNA accumulation, and that MA-10 cell StAR gene transcription and promoter-associated H3 acetylation are biphasic during a 6-h treatment period. The union of the chromatin immunoprecipitation assay with quantitative real-time polymerase chain reaction described and validated here should enhance the analysis of gene expression.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Oregon Reg Primate Res Ctr, Div Reprod Sci, Beaverton, OR 97006 USA	University of Pennsylvania; Pennsylvania Medicine; Oregon Health & Science University; Oregon National Primate Research Center	Christenson, LK (corresponding author), Univ Penn, Ctr Res Reprod & Womens Hlth, 1349 Biomed Res Bldg II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	lchriste@mail.med.upenn.edu	Christenson, Lane K/G-6435-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD020869] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD018185] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00163] Funding Source: Medline; NICHD NIH HHS [HD20869, HD06274, U54 HD18185] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		*APPL BIOS, 1997, APPL BIOS B, V2; Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; Bauer MP, 2000, MOL CELL ENDOCRINOL, V168, P119, DOI 10.1016/S0303-7207(00)00316-6; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Chaffin CL, 1999, HUM REPROD, V14, P642, DOI 10.1093/humrep/14.3.642; Chaffin CL, 2000, MOL HUM REPROD, V6, P11, DOI 10.1093/molehr/6.1.11; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Christenson LK, 1997, J CLIN ENDOCR METAB, V82, P2135, DOI 10.1210/jc.82.7.2135; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Christenson LK, 2001, ENDOCRINOLOGY, V142, P28, DOI 10.1210/endo.142.1.7867; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Clark BJ, 1997, ENDOCRINOLOGY, V138, P4893, DOI 10.1210/en.138.11.4893; CLARK BJ, 1995, MOL ENDOCRINOL, V9, P1346, DOI 10.1210/me.9.10.1346; Davie JR, 1999, J CELL BIOCHEM, P141; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hazzard TM, 1999, MOL HUM REPROD, V5, P1115, DOI 10.1093/molehr/5.12.1115; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LaVoie HA, 1999, ENDOCRINOLOGY, V140, P146, DOI 10.1210/en.140.1.146; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MCALLISTER JM, 1994, J CLIN ENDOCR METAB, V79, P106, DOI 10.1210/jc.79.1.106; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PON LA, 1988, ENDOCRINOLOGY, V123, P1942, DOI 10.1210/endo-123-4-1942; PON LA, 1986, J BIOL CHEM, V261, P3309; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; Reinhart AJ, 1999, MOL CELL ENDOCRINOL, V151, P161, DOI 10.1016/S0303-7207(98)00257-3; Reinhart AJ, 1999, MOL ENDOCRINOL, V13, P729, DOI 10.1210/me.13.5.729; Rust W, 1998, J MOL ENDOCRINOL, V21, P189, DOI 10.1677/jme.0.0210189; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; Sugawara T, 1997, BIOCHEMISTRY-US, V36, P7249, DOI 10.1021/bi9628984; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; Wooton-Kee CR, 2000, ENDOCRINOLOGY, V141, P1345, DOI 10.1210/en.141.4.1345; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899	46	78	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27392	27399		10.1074/jbc.M101650200	http://dx.doi.org/10.1074/jbc.M101650200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346648	hybrid			2022-12-27	WOS:000169966900088
J	Cammarano, MS; Minden, A				Cammarano, MS; Minden, A			Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; C-JUN; RAS TRANSFORMATION; PROTEIN-KINASE; CELLULAR-TRANSFORMATION; CYCLIN D1; TRANSCRIPTIONAL ACTIVITY; FOCAL COMPLEXES; FAMILY GTPASES; TAX PROTEIN	Dbl is a guanine nucleotide exchange factor that activates the Rho family GTPases Cdc42, Rac, and Rho, Dbl and all three GTPases are strong activators of transcription factor NF kappaB, which has been shown to have an important role in Dbl-induced oncogenic transformation, Here we show that although Dbl activation of NF kappaB requires Cdc42, Rac, and Rho, the different GTPases activate NF kappaB by different mechanisms. Whereas Rac stimulates the activity of the I kappaB kinase IKK beta, Cdc42 and Rho activate NF kappaB without activating either IKK alpha or IKK beta, Like Dbl, Rac activation of IKK beta is mediated by the serine/threonine kinases NIK but not MEKK. This differs from Rac activation of the JNK pathway, which was previously shown to be mediated by MEKK, The pathway leading from Rho and Cdc42 to NF kappaB is more elusive, but our results suggest that it involves an IKK alpha /IKK beta -independent mechanism. Finally, we show that the signaling enzymes that mediate NF kappaB activation by Dbl and the Rho GTPases are also necessary for malignant transformation induced by oncogenic Dbl.	Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci MC 2460, New York, NY 10027 USA	Columbia University	Minden, A (corresponding author), Columbia Univ, Sherman Fairchild Ctr, Dept Biol Sci MC 2460, Rm 813,1212 Amsterdam Ave, New York, NY 10027 USA.				NATIONAL CANCER INSTITUTE [R01CA076342] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76342] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baichwal V. R., 1997, CURR BIOL, V7, P94; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dutartre H, 1996, J CELL SCI, V109, P367; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HART MJ, 1994, J BIOL CHEM, V269, P62; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VAN AD, 1996, SCIENCE, V274, P787; VAN AL, 1997, GENE DEV, V11, P2295; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	70	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25876	25882		10.1074/jbc.M011345200	http://dx.doi.org/10.1074/jbc.M011345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337492	hybrid			2022-12-27	WOS:000169823300033
J	Yarnell, AT; Oh, S; Reinberg, D; Lippard, SJ				Yarnell, AT; Oh, S; Reinberg, D; Lippard, SJ			Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; YEAST PROTEIN; LARGE SUBUNIT; TRANSCRIPTION; ADDUCTS; BINDING; REPAIR; CDC68; RECOGNITION; POB3	The structure-specific recognition protein SSRP1, initially isolated from expression screening of a human B-cell cDNA library for proteins that bind to cisplatin (cis-diamminedichloroplatinum(II))-modified DNA, contains a single DNA-binding high mobility group (HMG) domain. Human SSRP1 purifies as a heterodimer of SSRP1 and Spt16 (FACT) that alleviates the nucleosomal block to transcription elongation by RNAPII in vitro. The affinity and specificity of FACT, SSRP1, and the isolated HMG domain of SSRP1 for cisplatin-damaged DNA were investigated by gel mobility shift assays, FACT exhibits both affinity and specificity for DNA damaged globally with cisplatin compared with unmodified DNA or DNA damaged globally with the clinically ineffective trans-DDP isomer, FACT binds the major 1,2-d(GpG) intrastrand cisplatin adduct, but its isolated SSRP1 subunit fails to form discrete, high affinity complexes with cisplatin-modified DNA under similar conditions. These results suggest that Spt16 primes SSRP1 for cisplatin-damaged DNA recognition by unveiling its HMG domain, As expected, the isolated HMG domain of SSRP1 is sufficient for specific binding to cisplatin-damaged DNA and binds the major cisplatin 1,1-d(GpG) intrastrand cross-link, The affinity and specificity of FACT for cisplatin-modified DNA as well as its importance for transcription of chromatin, suggests that the interaction of FACT and cisplatin-damaged DNA may be crucial to the anticancer mechanism of cisplatin.	MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Div Nucleic Acids Enzymol,Dept Biochem, Piscataway, NJ 08854 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lippard, SJ (corresponding author), MIT, Dept Chem, Rm 18-590, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu		Reinberg, Danny/0000-0003-4288-2016	NATIONAL CANCER INSTITUTE [R01CA034992, R37CA034992] Funding Source: NIH RePORTER; NCI NIH HHS [CA34992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILLINGS PC, 1992, BIOCHEM BIOPH RES CO, V188, P1286, DOI 10.1016/0006-291X(92)91371-V; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1993, NUCLEIC ACIDS RES, V21, P1643, DOI 10.1093/nar/21.7.1643; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; Evans DRH, 1998, GENETICS, V150, P1393; FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025; Fleck O, 1998, J BIOL CHEM, V273, P30398, DOI 10.1074/jbc.273.46.30398; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jordan P, 1998, NUCLEIC ACIDS RES, V26, P2831, DOI 10.1093/nar/26.12.2831; LEPRE CA, 1990, NUCLEIC ACIDS MOL BI, P9, DOI DOI 10.1007/978-3-642-84150-7_2; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; McANulty MM, 1996, BIOCHEMISTRY-US, V35, P6089, DOI 10.1021/bi952877u; McANulty MM, 1996, MUTAT RES-DNA REPAIR, V362, P75, DOI 10.1016/0921-8777(95)00037-2; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Pil P., 1997, ENCY CANC, P392; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Sandman KE, 1999, CHEM BIOL, V6, P541, DOI 10.1016/S1074-5521(99)80086-6; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; Trimmer EE, 1998, BIOCHEMISTRY-US, V37, P352, DOI 10.1021/bi971675q; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553; Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h	46	83	89	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25736	25741		10.1074/jbc.M101208200	http://dx.doi.org/10.1074/jbc.M101208200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344167	hybrid			2022-12-27	WOS:000169823300015
J	Kawada, N; Kristensen, DB; Asahina, K; Nakatani, K; Minamiyama, Y; Seki, S; Yoshizato, K				Kawada, N; Kristensen, DB; Asahina, K; Nakatani, K; Minamiyama, Y; Seki, S; Yoshizato, K			Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMOBILIZED PH GRADIENTS; IN-VIVO; 2-DIMENSIONAL ELECTROPHORESIS; SAMPLE APPLICATION; MASS-SPECTROMETRY; TISSUE INHIBITOR; OXIDATIVE STRESS; UP-REGULATION; EXPRESSION; LIVER	A proteome approach for the molecular analysis of the activation of rat stellate cell, a liver-specific pericyte, led to the discovery of a novel protein named STAP (stellate cell activation-associated protein). We cloned STAP cDNA, STAP is a cytoplasmic protein with molecular weight of 21,496 and shows about 40% amino acid sequence homology with myoglobin, STAP was dramatically induced in in vivo activated stellate cells isolated from fibrotic liver and in stellate cells undergoing in vitro activation during primary culture. This induction was seen together with that of other activation-associated molecules, such as smooth muscle alpha -actin, PDGF receptor-beta, and neural cell adhesion molecule. The expression of STAP protein and mRNA was augmented time dependently in thioacetamide-induced fibrotic liver. Immunoelectron microscopy and proteome analysis detected STAP in stellate cells but not in other hepatic constituent cells. Biochemical characterization of recombinant rat STAP revealed that STAP is a heme protein exhibiting peroxidase activity toward hydrogen peroxide and linoleic acid hydroperoxide. These results indicate that STAP is a novel endogenous peroxidase catabolizing hydrogen peroxide and lipid hydroperoxides, both of which have been reported to trigger stellate cell activation and consequently promote progression of liver fibrosis, STAP could thus play a role as an antifibrotic scavenger of peroxides in the liver.	Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Dev Biol Lab, Higashihiroshima 7398526, Japan; Japan Sci & Technol Corp, Hiroshima Tissue Regenerat Project, Hiroshima Prefecture Collaborat Reg Ent Advancemen, Hiroshima 7390046, Japan; Hiroshima Technol Org, Reg Sci Program, Hiroshima Proteome Lab, Hiroshima 7390046, Japan; Osaka City Univ, Sch Med, Grad Sch Med, Dept Hepatol, Osaka 5458585, Japan	Hiroshima University; Japan Science & Technology Agency (JST); Osaka Metropolitan University	Yoshizato, K (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Biol Sci, Dev Biol Lab, 1-3-1 Kagamiyama, Higashihiroshima 7398526, Japan.		kawada, norifumi/AAS-1367-2020; Asahina, Kinji/X-8794-2019	Asahina, Kinji/0000-0003-0398-8395				Asahina K, 1999, MATRIX BIOL, V18, P89, DOI 10.1016/S0945-053X(99)00005-0; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; Eaton W A, 1981, Methods Enzymol, V76, P175; Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7, DOI 10.1152/ajpgi.2000.279.1.G7; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118; Gressner AM, 1998, CELL TISSUE RES, V292, P447, DOI 10.1007/s004410051073; Hellerbrand C, 1996, HEPATOLOGY, V24, P670; Ikeda K, 1998, AM J PATHOL, V153, P1695, DOI 10.1016/S0002-9440(10)65683-0; Kawada N, 1997, HISTOL HISTOPATHOL, V12, P1069; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; KAWAMOTO S, 1977, ARCH MICROBIOL, V112, P1, DOI 10.1007/BF00446647; KHARASCH ED, 1985, J BIOL CHEM, V260, P645; Knittel T, 1996, AM J PATHOL, V149, P449; Kristensen DB, 2000, ELECTROPHORESIS, V21, P430, DOI 10.1002/(SICI)1522-2683(20000101)21:2<430::AID-ELPS430>3.3.CO;2-S; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Lang A, 2000, AM J PHYSIOL-GASTR L, V279, pG1333, DOI 10.1152/ajpgi.2000.279.6.G1333; Maher JJ, 1997, BIOCHEM PHARMACOL, V53, P637, DOI 10.1016/S0006-2952(96)00865-9; Marra F, 1998, AM J PATHOL, V152, P423; Nagy NE, 1997, J LIPID RES, V38, P645; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Pinzani M, 1999, SEMIN LIVER DIS, V19, P397, DOI 10.1055/s-2007-1007128; Pinzani M, 1996, GASTROENTEROLOGY, V110, P534, DOI 10.1053/gast.1996.v110.pm8566602; PINZANI M, 1995, HEPATOLOGY, V22, P997; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; RAMADORI G, 1990, CELL PATHOL INCL MOL, V59, P349; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Reichard JF, 2000, BBA-MOL CELL BIOL L, V1487, P222, DOI 10.1016/S1388-1981(00)00095-0; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Roepstorff P, 1997, CURR OPIN BIOTECH, V8, P6, DOI 10.1016/S0958-1669(97)80151-6; Sanchez JC, 1997, ELECTROPHORESIS, V18, P324, DOI 10.1002/elps.1150180305; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Shao R, 1999, J BIOL CHEM, V274, P3228, DOI 10.1074/jbc.274.5.3228; SHEA SM, 1968, AM J PATHOL, V52, P55; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; TAKAICHI S, 1981, J BIOCHEM-TOKYO, V89, P1513, DOI 10.1093/oxfordjournals.jbchem.a133344; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; Wang SC, 1998, J BIOL CHEM, V273, P302, DOI 10.1074/jbc.273.1.302; Whalen R, 1999, HEPATOLOGY, V30, P927, DOI 10.1002/hep.510300404; Yates JR, 1998, J MASS SPECTROM, V33, P1	42	281	309	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25318	25323		10.1074/jbc.M102630200	http://dx.doi.org/10.1074/jbc.M102630200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320098	hybrid			2022-12-27	WOS:000169800700118
J	Macdonald, JR; Bachinger, HP				Macdonald, JR; Bachinger, HP			HSP47 binds cooperatively to triple helical type I collagen but has little effect on the thermal stability or rate of refolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOLECULAR CHAPERONE HSP47; ENDOPLASMIC-RETICULUM; PROCOLLAGEN; REQUIREMENTS; PURIFICATION; GLYCOPROTEIN; RECOGNITION; EXPRESSION; SECRETION	HSP47, a collagen-specific molecular chaperone, interacts with unfolded and folded procollagens. Binding of chicken HSP47 to native bovine type I collagen was studied by fluorescence quenching and cooperative binding with a collagen concentration at half saturation (K-half) of 1.4 x 10(-7) M, and a Hill coefficient of 4.3 was observed. Similar results are observed for the binding of mouse HSP47 recombinantly expressed in Escherichia coli, Chicken HSP47 binds equally well to native type II and type III procollagen without the carboxyl-terminal propeptide (pN type III collagen), but binding to triple helical collagen-like peptides is much weaker. Weak binding occurred to both hydroxylated and nonhydroxylated collagen-like peptides, and a significant chain length dependence was observed. Binding of HSP47 to native type I collagen had no effect on the thermal stability of the triple helix. Refolding of type I collagen in the presence of HSP47 showed minor changes, but these are probably not biologically significant. Binding of HSP47 to bovine pN type III collagen has only minor effects on the thermal stability of the triple helix and does not influence the refolding kinetics of the triple helix.	Shriners Hosp Children, Res Unit, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Children, Res Unit, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	hpb@shcc.org		Macdonald, Randy/0000-0001-7203-1234				BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; HIRAYOSHI K, 1991, MOL CELL BIOL, V11, P4036, DOI 10.1128/MCB.11.8.4036; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; KAMBE K, 1994, J HISTOCHEM CYTOCHEM, V42, P833, DOI 10.1177/42.7.8014466; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2000, J BIOL CHEM, V275, P27957; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAGATA K, 1988, BIOCHEM BIOPH RES CO, V153, P428, DOI 10.1016/S0006-291X(88)81242-7; Nagata K, 1998, MATRIX BIOL, V16, P379, DOI 10.1016/S0945-053X(98)90011-7; NATSUME T, 1994, J BIOL CHEM, V269, P31224; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; Tanaka Y, 1996, EXP EYE RES, V63, P383, DOI 10.1006/exer.1996.0128; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Thomson CA, 2000, BIOCHEM J, V349, P877, DOI 10.1042/bj3490877; Tomita M, 1999, J BIOCHEM, V126, P1118, DOI 10.1093/oxfordjournals.jbchem.a022557; VAILLANCOURT JP, 1991, BIOCHEM J, V274, P793, DOI 10.1042/bj2740793	21	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25399	25403		10.1074/jbc.M102471200	http://dx.doi.org/10.1074/jbc.M102471200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333272	hybrid			2022-12-27	WOS:000169800700129
J	Morrison, BH; Bauer, JA; Kalvakolanu, DV; Lindner, DJ				Morrison, BH; Bauer, JA; Kalvakolanu, DV; Lindner, DJ			Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE HEMATOPOIETIC-CELLS; HUMAN-LEUKOCYTE INTERFERONS; DIPHOSPHOINOSITOL PENTAKISPHOSPHATE; PROTEIN-KINASE; INTERLEUKIN-6 SUPPRESS; IN-VITRO; EXPRESSION; IDENTIFICATION; RECOMBINANT; ALPHA	Interferons (IFNs) regulate the expression of genes that mediate their antiviral, antitumor, and immunomodulatory actions. We have previously shown that IFN-beta suppresses growth of human ovarian carcinoma xenografts in vivo and induces apoptosis of ovarian carcinoma cells in vitro. To investigate mechanisms of IFN-beta -induced apoptosis we employed an antisense technical knockout approach to identify gene products that mediate cell death and have isolated several regulators of interferon-induced death (RIDs). In this investigation, we have characterized one of the RIDs, RID-2. Sequence analysis revealed that RID-2 was identical to human inositol hexakisphosphate kinase 2 (IP6K2). IP6K2 is post-transcriptionally induced by IFN-beta in ovarian carcinoma cells. A mutant IP6K2 with substitutions in the putative inositol phosphate binding domain abrogates IFN-beta -induced apoptosis. These studies identify a novel function for IP6K2 in cell growth regulation and apoptosis.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Ctr Canc Drug Dev & Discovery,Taussig Canc Ctr, Cleveland, OH 44195 USA	University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation	Lindner, DJ (corresponding author), 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.		Lindner, Daniel/ABB-5440-2020	Bauer, Joseph/0000-0003-4972-6008	NCI NIH HHS [CA78282, CA71401, R01 CA095020-01A1, R01 CA078282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095020, R01CA078282, R01CA071401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; Blackshaw S, 2000, FASEB J, V14, P1375, DOI 10.1096/fj.14.10.1375; DAMELL JE, 1997, SCIENCE, V277, P1630; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; GREINER JW, 1987, SCIENCE, V235, P895, DOI 10.1126/science.3580039; GREINER JW, 1984, CANCER RES, V44, P3208; GRESSER I, 1969, P NATL ACAD SCI USA, V63, P51, DOI 10.1073/pnas.63.1.51; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; Kalvakolanu DV, 2000, HISTOL HISTOPATHOL, V15, P523, DOI 10.14670/HH-15.523; Kinoshita S, 1998, PHARMACEUT RES, V15, P1851, DOI 10.1023/A:1011953906065; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; ORTALDO JR, 1983, J BIOL CHEM, V258, P5011; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Samuel CE, 1997, INT J HEMATOL, V65, P227; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Vyas P, 2000, P NATL ACAD SCI USA, V97, P13696, DOI 10.1073/pnas.250476397; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAGINUMA Y, 1992, CANCER RES, V52, P4196	37	123	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24965	24970		10.1074/jbc.M101161200	http://dx.doi.org/10.1074/jbc.M101161200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337497	Green Accepted, hybrid			2022-12-27	WOS:000169800700071
J	Yoo, MH; Woo, CH; You, HJ; Cho, SH; Kim, BC; Choi, JE; Chun, JS; Jhun, BH; Kim, TS; Kim, JH				Yoo, MH; Woo, CH; You, HJ; Cho, SH; Kim, BC; Choi, JE; Chun, JS; Jhun, BH; Kim, TS; Kim, JH			Role of the cytosolic phospholipase A(2)-linked cascade in signaling by an oncogenic, constitutively active Ha-Ras isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; TERNARY COMPLEX-FORMATION; ARACHIDONIC-ACID RELEASE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; ANNEXIN-I; ACTIVATION; A(2); PHOSPHORYLATION; GROWTH	Activation of Res signaling by growth factors has been associated with gene regulation and cell proliferation. Here we characterize the contributory role of cytosolic phospholipase A(2) in the oncogenic Ha-Ras(V12) signaling pathway leading to activation of c-fos serum response element (SRE) and transformation in Rat-a fibroblasts. Using a c-fos SRE-luciferase reporter gene, we showed that the transactivation of SRE by Ha-Ras(V12) is mainly via a Rac-linked cascade, although the Raf-mitogen-activated protein kinase cascade is required for full activation. In addition, Ha-Ras(V12)-induced DNA synthesis was significantly attenuated by microinjection of recombinant Rac(N17), a dominant negative mutant of Rad. To identify the mediators downstream of Rac in the Ha-Ras(V12) signaling, we investigated the involvement of cytosolic phospholipase A(2). Oncogenic Ha-Ras(V12)-induced SRE activation was significantly inhibited by either pretreatment with mepacrine, a phospholipase A(2) inhibitor, or cotransfection with the antisense oligonucleotide of cytosolic phospholipase A(2). We also found cytosolic phospholipase A(2) to be situated downstream of Ha-Ras(V12) in a signal pathway leading to transformation. Together, these results are indicative of mediatory roles of Rac and cytosolic phospholipase A(2) in the signaling pathway by which Ha-Ras(V12) transactivates c-fos SRE and transformation. Our findings point to cytosolic phospholipase A(2) as a novel potential target for suppressing oncogenic Ha-Ras(V12) signaling in the cell.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwang Ju 500712, South Korea; Chonnam Natl Univ, Coll Pharm, Kwang Ju 500757, South Korea; Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea	Gwangju Institute of Science & Technology (GIST); Chonnam National University; Pusan National University	Kim, JH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Kwang Ju 500712, South Korea.	jkim@eunhasu.kjist.ac.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kim BC, 1997, BIOCHEM J, V326, P333, DOI 10.1042/bj3260333; Kim BC, 1997, FEBS LETT, V407, P7, DOI 10.1016/S0014-5793(97)00289-5; Kim BC, 1998, BIOCHEM J, V330, P1009, DOI 10.1042/bj3301009; Kim JH, 1997, FEBS LETT, V406, P93, DOI 10.1016/S0014-5793(97)00249-4; KIM JH, 1994, J BIOL CHEM, V269, P13740; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUMAR CC, 1992, CANCER RES, V52, P6877; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVERS SL, 1996, SIGNAL TRANSDUCTION, P143; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Oh J, 2000, FEBS LETT, V477, P244, DOI 10.1016/S0014-5793(00)01812-3; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; QUI RG, 1995, NATURE, V374, P457; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WARNER LC, 1993, ONCOGENE, V8, P3249; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Woo CH, 2000, BIOCHEM BIOPH RES CO, V268, P231, DOI 10.1006/bbrc.2000.2102; Woo CH, 2000, BIOCHEM J, V348, P525, DOI 10.1042/0264-6021:3480525; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	49	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24645	24653		10.1074/jbc.M101975200	http://dx.doi.org/10.1074/jbc.M101975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323430	hybrid			2022-12-27	WOS:000169800700032
J	Bungert, S; Molday, LL; Molday, RS				Bungert, S; Molday, LL; Molday, RS			Membrane topology of the ATP binding cassette transporter ABCR and its relationship to ABC1 and related ABCA transporters - Identification of N-linked glycosylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STARGARDT MACULAR DYSTROPHY; DISEASE GENE ABCR; HUMAN P-GLYCOPROTEIN; ROD OUTER SEGMENTS; RETINITIS-PIGMENTOSA; RIM PROTEIN; TANGIER-DISEASE; DISK MEMBRANES; MUTATIONS; DEGENERATION	ABCR is a member of the ABCA subclass of ATP binding cassette transporters that is responsible for Stargardt macular disease and implicated in retinal transport across photoreceptor disc membranes. It consists of a single polypeptide chain arranged in two tandem halves, each having a multi-spanning membrane domain followed by a nucleotide binding domain. To delineate between several proposed membrane topological models, we have identified the exocytoplasmic (extracellular/lumen) N-linked glycosylation sites on ABCR, Using trypsin digestion, site-directed mutagenesis, concanavalin A binding, and endoglycosidase digestion, we show that ABCR contains eight glycosylation sites. Four sites reside in a 600-amino acid exocytoplasmic domain of the N-terminal half between the first transmembrane segment H1 and the first multi-spanning membrane domain, and four sites are in a 275-amino acid domain of the C half between transmembrane segment H7 and the second multi-spanning membrane domain. This leads to a model in which each half has a transmembrane segment followed by a large exocytoplasmic domain, a multi-spanning membrane domain, and a nucleotide binding domain. Other ABCA transporters, including ABC1 linked to Tangier disease, are proposed to have a similar membrane topology based on sequence similarity to ABCR. Studies also suggest that the N and C halves of ABCR are linked through disulfide bonds.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.				NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahn J, 2000, J BIOL CHEM, V275, P20399, DOI 10.1074/jbc.M000555200; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Klevering BJ, 1999, BRIT J OPHTHALMOL, V83, P914, DOI 10.1136/bjo.83.8.914; Klugbauer N, 1996, FEBS LETT, V391, P61, DOI 10.1016/0014-5793(96)00700-4; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 1999, BIOCHEMISTRY-US, V38, P5124, DOI 10.1021/bi982525y; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323; Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; MOLDAY RS, 1979, J BIOL CHEM, V254, P4653; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; Pullinger CR, 2000, BIOCHEM BIOPH RES CO, V271, P451, DOI 10.1006/bbrc.2000.2652; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; Souied EH, 1999, INVEST OPHTH VIS SCI, V40, P2740; Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Zhao LX, 2000, BIOCHEM J, V350, P865, DOI 10.1042/0264-6021:3500865	41	115	125	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23539	23546		10.1074/jbc.M101902200	http://dx.doi.org/10.1074/jbc.M101902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320094	hybrid			2022-12-27	WOS:000169531100044
J	Lee, SH; Hannink, M				Lee, SH; Hannink, M			The N-terminal nuclear export sequence of I kappa B alpha is required for RanGTP-dependent binding to CRM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REL PROTEINS; SIGNAL; TRANSPORT; LOCALIZATION; ACTIVATION; RANGAP1; PATHWAY; COMPLEX; IMPORT	Nuclear export of I kappaB alpha is mediated by the CRM1 nuclear export receptor. However, the identity of the nuclear export sequences NES(s) in I kappaB alpha that are responsible for binding of I kappaB alpha to CRM1 is controversial. Both a N-terminal NES-like region (amino acids 45-54) and a C-terminal NES-like region (amino acids 265-280) have, in a number of reports from different laboratories, been implicated in CRM1-dependent nuclear export of I kappaB alpha. We now demonstrate that the N-terminal NES-like region, but not the C-terminal NES-like region, is required for RanGTP-dependent binding of I kappaB alpha to CRM1. I kappaB alpha is a relatively weak substrate for CRM1, with an affinity for CRM1 that is 100 fold less than the minute virus of mice NS2 protein, a high affinity cargo protein for CRM1, We also demonstrate that I kappaB alpha functions as a physical adaptor between CRM1 and NF kappaB/Rel proteins. Both free I kappaB alpha and Rel-associated I kappaB alpha have comparable affinities for CRM1, suggesting that CRM1 does not discriminate between free I kappaB alpha and Rel-associated I kappaB alpha. Nuclear export of c-Rel by I kappaB alpha requires the N-terminal NES-like sequence of I kappaB alpha but is not affected by alanine substitutions within the C-terminal NES-like sequence of I kappaB alpha. In contrast, nuclear export of the v-Rel oncoprotein by I kappaB alpha is disrupted by alanine substitutions within either the N-terminal or the C-terminal NES-like sequences. However, alanine substitutions within the C-terminal NES-like sequence significantly reduce the affinity of I kappaB alpha for v-Rel, suggesting that loss of export function for this mutant is secondary to reduced association between I kappaB alpha and v-Rel, Taken together, our results demonstrate that the N-terminal NES-like sequence in I kappaB alpha is required for RanGTP-dependent binding of both free I kappaB alpha and NF kappaB/Rel-associated I kappaB alpha proteins to CRM1.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia	Hannink, M (corresponding author), Univ Missouri, Dept Biochem, Columbia, MO 65212 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059213] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM59213] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREZANASEISDEDO.F, 1997, J CELL SCI, V110, P369; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; Askjaer P, 1999, MOL CELL BIOL, V19, P6276; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Paraskeva E, 1999, J CELL BIOL, V145, P255, DOI 10.1083/jcb.145.2.255; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Sambrook J, 1989, MOL CLOINING LAB MAN; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000	25	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23599	23606		10.1074/jbc.M011197200	http://dx.doi.org/10.1074/jbc.M011197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319224	hybrid			2022-12-27	WOS:000169531100051
J	Rajamohan, F; Mao, C; Uckun, FM				Rajamohan, F; Mao, C; Uckun, FM			Binding interactions between the active center cleft of recombinant pokeweed antiviral protein and the alpha-sarcin/ricin stem loop of ribosomal RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTALLOGRAPHIC ANALYSIS; PHYTOLACCA-AMERICANA; SUBSTRATE-ANALOGS; STRUCTURAL BASIS; N-GLYCOSIDASE; A-CHAIN; RICIN; PURIFICATION; INACTIVATION; RESOLUTION	Pokeweed antiviral protein (PAP) is a ribosome-inactivating protein that catalytically cleaves a specific adenine base from the highly conserved alpha -sarcin/ricin loop of the large ribosomal RNA, thereby inhibiting protein synthesis at the elongation step. Recently, we discovered that alanine substitutions of the active center cleft residues significantly impair the depurinating and ribosome inhibitory activity of PAP, Here we employed site-directed mutagenesis combined with standard filter binding assays, equilibrium binding assays with Scatchard analyses, and surface plasmon resonance technology to elucidate the putative role of the PAP active center cleft in the binding of PAP to the alpha -sarcin/ricin stem loop of rRNk Our findings presented herein provide experimental evidence that besides the catalytic site, the active center cleft also participates in the binding of PAP to the target tetraloop structure of rRNA These results extend our recent modeling studies, which predicted that the residues of the active center cleft could, via electrostatic interactions, contribute to both the correct orientation and stable binding of the substrate RNA molecules in PAP active site pocket. The insights gained from this study also explain why and how the conserved charged and polar side chains located at the active center cleft of PAP and certain catalytic site residues, that do not directly participate in the catalytic deadenylation of ribosomal RNA, play a critical role in the catalytic removal of the adenine base from target rRNA substrates by affecting the binding interactions between PAP and rRNA.	Parker Hughes Canc Ctr, Biotherapy Program, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Prod Engn, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Virol, St Paul, MN 55113 USA		Rajamohan, F (corresponding author), Parker Hughes Inst, 2657 Patton Rd, Roseville, MN 55113 USA.	frajamohan@ih.org; fatih_uckun@ih.org		Uckun, Fatih M./0000-0001-9334-183X				AGO H, 1994, EUR J BIOCHEM, V225, P369, DOI 10.1111/j.1432-1033.1994.00369.x; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BRAVI G, 1995, J MOL GRAPHICS, V13, P83, DOI 10.1016/0263-7855(94)00014-J; DALLAL JA, 1978, FEBS LETT, V89, P257, DOI 10.1016/0014-5793(78)80230-0; ENDO Y, 1988, J BIOL CHEM, V263, P8735; FRANKEL A, 1990, MOL CELL BIOL, V10, P6257, DOI 10.1128/MCB.10.12.6257; GESSNER SL, 1980, J BIOL CHEM, V255, P3251; Gu YJ, 2000, PROTEINS, V39, P37, DOI 10.1002/(SICI)1097-0134(20000401)39:1<37::AID-PROT4>3.3.CO;2-7; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; IRVIN JD, 1980, ARCH BIOCHEM BIOPHYS, V200, P418, DOI 10.1016/0003-9861(80)90372-0; IRVIN JD, 1975, ARCH BIOCHEM BIOPHYS, V169, P522, DOI 10.1016/0003-9861(75)90195-2; IRVIN JD, 1992, PHARMACOL THERAPEUT, V55, P279, DOI 10.1016/0163-7258(92)90053-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurinov IV, 1999, PROTEIN SCI, V8, P2399; Kurinov IV, 1999, PROTEIN SCI, V8, P1765, DOI 10.1110/ps.8.9.1765; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MONZINGO AF, 1993, J MOL BIOL, V233, P705, DOI 10.1006/jmbi.1993.1547; *MSI, 1991, INS US GUID; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; OBRIG TG, 1973, ARCH BIOCHEM BIOPHYS, V155, P278, DOI 10.1016/0003-9861(73)90116-1; Rajamohan F, 1999, PROTEIN EXPRES PURIF, V16, P359, DOI 10.1006/prep.1999.1084; Rajamohan F, 2000, J BIOL CHEM, V275, P3382, DOI 10.1074/jbc.275.5.3382; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; UCHIUMI T, 1995, J BIOL CHEM, V270, P29889; UCKUN FM, 1989, BLOOD, V73, P533	29	18	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24075	24081		10.1074/jbc.M011406200	http://dx.doi.org/10.1074/jbc.M011406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313342	hybrid			2022-12-27	WOS:000169531100113
J	Smaili, SS; Stellato, KA; Burnett, P; Thomas, AP; Gaspers, LD				Smaili, SS; Stellato, KA; Burnett, P; Thomas, AP; Gaspers, LD			Cyclosporin A inhibits inositol 1,4,5-trisphosphate-dependent Ca2+ signals by enhancing Ca2+ uptake into the endoplasmic reticulum and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; RAT-LIVER MITOCHONDRIA; ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOSOLIC CALCIUM OSCILLATIONS; CELL-DEATH; DIFFERENTIAL MODULATION; BINDING-PROTEIN; GENE-EXPRESSION; CYCLOPHILIN-D; RECEPTOR	Cytosolic Ca2+ ([Ca2+](i)) oscillations may be generated by the inositol 1,4,5-trisphosphate receptor (IP3R) driven through cycles of activation/inactivation by local Ca2+. feedback. Consequently, modulation of the local Ca2+ gradients influences IP3R excitability as well as the duration and amplitude of the [Ca2+](i) oscillations. In the present work, we demonstrate that the immunosuppressant cyclosporin A (CSA) reduces the frequency of IP3-dependent [Ca2+](i) oscillations in intact hepatocytes, apparently by altering the local Ca2+ gradients. Permeabilized cell experiments demonstrated that CSA lowers the apparent IF, sensitivity for Ca2+ release from intracellular stores. These effects on IP3-dependent [Ca2+](i) signals could not be attributed to changes in calcineurin activity, altered ryanodine receptor function, or impaired Ca2+ fluxes across the plasma membrane. However, CSA enhanced the removal of cytosolic Ca2+ by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA), lowering basal and interspike [Ca2+](i). In addition, CSA stimulated a stable rise in the mitochondrial membrane potential (Delta psi (m)), presumably by inhibiting the mitochondrial permeability transition pore, and this was associated with increased Ca2+ uptake and retention by the mitochondria during a rise in [Ca2+](i). We suggest that CSA suppresses local Ca2+ feedback by enhancing mitochondrial and endoplasmic reticulum Ca2+ uptake, these actions of CSA underlie the lower IP3 sensitivity found in permeabilized cells and the impaired IP3-dependent [Ca2+](i) signals in intact cells. Thus, CSA binding proteins (cyclophilins) appear to fine tune agonist-induced [Ca2+](i) signals, which, in turn, may adjust the output of downstream Ca2+-sensitive pathways.	New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA; Univ Fed Sao Paulo, Dept Farmacol, UNIFESP EPM, BR-04044 Sao Paulo, Brazil	Rutgers State University New Brunswick; Rutgers State University Medical Center; Universidade Federal de Sao Paulo (UNIFESP)	Gaspers, LD (corresponding author), New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave,Univ Hts, Newark, NJ 07103 USA.		Smaili, Soraya/AAH-2129-2019; Gaspers, Lawrence/W-8766-2019; Thomas, Andrew/C-6755-2013	Smaili, Soraya/0000-0001-5844-1368; Gaspers, Lawrence/0000-0002-5620-3283; Thomas, Andrew/0000-0002-9026-7467	NIDDK NIH HHS [DK38422] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038422, R29DK038422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULD RA, 1992, AM J PHYSIOL, V262, pH1699, DOI 10.1152/ajpheart.1992.262.6.H1699; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Budd SL, 1996, J NEUROCHEM, V67, P2282; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Fall CP, 1999, BBA-BIOENERGETICS, V1410, P77, DOI 10.1016/S0005-2728(98)00177-7; FLIRI H, 1993, ANN NY ACAD SCI, V696, P47; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GREGORY RB, 1991, BIOCHIM BIOPHYS ACTA, V1098, P61; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; GUNTER KK, 1991, J BIOL CHEM, V266, P21640; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hajnoczky G, 1997, EMBO J, V16, P3533, DOI 10.1093/emboj/16.12.3533; HOEK JB, 1995, BBA-MOL BASIS DIS, V1271, P93, DOI 10.1016/0925-4439(95)00015-V; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; JUNG DW, 1995, J BIOL CHEM, V270, P672, DOI 10.1074/jbc.270.2.672; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; KRONER H, 1986, ARCH BIOCHEM BIOPHYS, V251, P525, DOI 10.1016/0003-9861(86)90360-7; KRONER H, 1986, BIOL CHEM H-S, V367, P483, DOI 10.1515/bchm3.1986.367.1.483; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Morgan AJ, 1999, METH MOL B, V114, P93; NATHANSON MH, 1994, GASTROENTEROLOGY, V106, P1349, DOI 10.1016/0016-5085(94)90030-2; NICCHITTA CV, 1985, J BIOL CHEM, V260, P3613; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Ramesh V, 1998, ANN NY ACAD SCI, V853, P341, DOI 10.1111/j.1749-6632.1998.tb08295.x; Reddy PA, 1999, INT J BIOL MACROMOL, V25, P345, DOI 10.1016/S0141-8130(99)00053-7; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Robb-Gaspers LD, 1998, BBA-BIOENERGETICS, V1366, P17, DOI 10.1016/S0005-2728(98)00118-2; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SCHREIER MH, 1993, TRANSPLANT P, V25, P502; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; Smaili SS, 1999, CELL CALCIUM, V26, P121, DOI 10.1054/ceca.1999.0061; Smaili SS, 2000, J BIOENERG BIOMEMBR, V32, P35, DOI 10.1023/A:1005508311495; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	71	51	52	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23329	23340		10.1074/jbc.M100989200	http://dx.doi.org/10.1074/jbc.M100989200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323421	hybrid			2022-12-27	WOS:000169531100017
J	Denning, G; Jamieson, L; Maquat, LE; Thompson, EA; Fields, AP				Denning, G; Jamieson, L; Maquat, LE; Thompson, EA; Fields, AP			Cloning of a novel phosphatidylinositol kinase-related kinase - Characterization of the human SMG-1 RNA surveillance protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; MESSENGER-RNA; PHOSPHOINOSITIDE 3-KINASE; MAMMALIAN TARGET; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; CAENORHABDITIS-ELEGANS; G(1) PROGRESSION; MEDIATED DECAY; HUMAN HOMOLOG; UPF1 PROTEIN	We have cloned and characterized a new member of the phosphatidylinositol kinase (PIK)-related kinase family. This gene, which we term human SMG-1 (hSMG- 1), is orthologous to Caenorhabditis elegans SMG-1, a protein that functions in nonsense-mediated mRNA decay (NMD). cDNA sequencing revealed that hSMG-1 encodes a protein of 3031 amino acids containing a conserved kinase domain, a C-terminal domain unique to the PIK-related kinases and an FKBP12-rapamycin binding-like domain similar to that found in the PIK-related kinase mTOR. Immunopurified FLAG-tagged hSMG-1 exhibits protein kinase activity as measured by autophosphorylation and phosphorylation of the generic PIK-related kinase substrate PHAS-1. hSMG-1 kinase activity is inhibited by high nanomolar concentrations of wortmannin (IC50 = 105 nM) but is not inhibited by a FISBP12-rapamycin complex. Mutation of conserved residues within the kinase domain of hSMG-1 abolishes both autophosphorylation and substrate phosphorylation, demonstrating that hSMG-1 exhibits intrinsic protein kinase activity. hSMG-1 phosphorylates purified hUpf1 protein, a phosphoprotein that plays a critical role in NMD, at sites that are also phosphorylated in whole cells. Eased on these data, we conclude that hSMG-1 is the human orthologue to C. elegans SMG-1. Our data indicate that hSMG-1 may function in NMD by directly phosphorylating hUpf1 protein at physiologically relevant sites.	Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Rochester	Fields, AP (corresponding author), Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	afields@utmb.edu		Maquat, Lynne/0000-0002-2789-2075	NCI NIH HHS [R01 CA56869] Funding Source: Medline; NIDDK NIH HHS [DK33938] Funding Source: Medline; NIGMS NIH HHS [GM59614] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Bentley NJ, 1997, BIOL CHEM, V378, P1267; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Cutler NS, 1999, MOL CELL ENDOCRINOL, V155, P135, DOI 10.1016/S0303-7207(99)00121-5; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Ishikawa K, 1997, DNA Res, V4, P307, DOI 10.1093/dnares/4.5.307; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; Lew JE, 1998, MOL CELL BIOL, V18, P6121, DOI 10.1128/MCB.18.10.6121; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; MAQUAT LE, 1995, RNA, V1, P453; Mitrovich QM, 2000, GENE DEV, V14, P2173, DOI 10.1101/gad.819900; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Page MF, 1999, MOL CELL BIOL, V19, P5943; Pal M, 2001, RNA, V7, P5, DOI 10.1017/S1355838201000127; Perlick HA, 1996, P NATL ACAD SCI USA, V93, P10928, DOI 10.1073/pnas.93.20.10928; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	42	122	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22709	22714		10.1074/jbc.C100144200	http://dx.doi.org/10.1074/jbc.C100144200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11331269	hybrid			2022-12-27	WOS:000169412700098
J	Burke, B; Lipman, RSA; Shiba, K; Musier-Forsyth, K; Hou, YM				Burke, B; Lipman, RSA; Shiba, K; Musier-Forsyth, K; Hou, YM			Divergent adaptation of tRNA recognition by Methanococcus jannaschii prolyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACCEPTOR STEM; AMINOACYLATION; TRNA(PRO); EVOLUTION; COMPLEX; GENOME; CODE	Analysis of prolyl-tRNA synthetase (ProRS) across all three taxonomic domains (Eubacteria, Eucarya, and Archaea) reveals that the sequences are divided into two distinct groups. Recent studies show that Escherichia coti ProRS, a member of the "prokaryotic-like" group, recognizes specific tRNA bases at both the acceptor and anticodon ends, whereas human ProRS, a member of the "eukaryotic-like" group, recognizes nucleotide bases primarily in the anticodon, The archaeal Methanococcus jannaschii ProRS is a member of the eukaryotic-like group, although its tRNA(Pro) possesses prokaryotic features in the acceptor stem, We show here that, in some respects, recognition of tRNA(Pro) by M. jannaschii ProRS parallels that of human, with a strong emphasis on the anticodon and only weak recognition of the acceptor stem. However, our data also indicate differences in the details of the anticodon recognition between these two eukaryotic-like synthetases. Although the human enzyme places a stronger emphasis on G35, the M. jannaschii enzyme places a stronger emphasis on G36, a feature that is shared by E. coli ProRS. These results, interpreted in the context of an extensive sequence alignment., provide evidence of divergent adaptation by M. jannaschii ProRS; recognition of the tRNA acceptor end is eukaryotic-like, whereas the details of the anticodon recognition are prokaryotic-like, This divergence may be a reflection of the unusual dual function of this enzyme, which catalyzes specific aminoacylation with proline as well as with cysteine.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 170, Japan	University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; Japanese Foundation for Cancer Research	Hou, YM (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	Ya-Ming.Hou@mail.tju.edu	Shiba, Kiyotaka/I-9588-2014	Shiba, Kiyotaka/0000-0001-6459-0204; Hou, Ya-Ming/0000-0001-6546-2597	NIGMS NIH HHS [GM49928, GM56662] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049928, R01GM056662, R55GM049928, R29GM049928] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Bunjun S, 2000, P NATL ACAD SCI USA, V97, P12997, DOI 10.1073/pnas.230444397; Burke B, 2000, BIOCHEMISTRY-US, V39, P15540, DOI 10.1021/bi001835p; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Chihade JW, 1998, BIOCHEMISTRY-US, V37, P9193, DOI 10.1021/bi9804636; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4; HIPPS D, 1995, P NATL ACAD SCI USA, V92, P5550, DOI 10.1073/pnas.92.12.5550; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; QUINN CL, 1995, BIOCHEMISTRY-US, V34, P12489, DOI 10.1021/bi00039a001; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; SHIBA K, 1995, BIOCHEMISTRY-US, V34, P10340, DOI 10.1021/bi00033a004; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Steer BA, 1999, BIOCHEMISTRY-US, V38, P4965, DOI 10.1021/bi990038s; Stehlin C, 1998, BIOCHEMISTRY-US, V37, P8605, DOI 10.1021/bi980364s; Wakasugi K, 1998, EMBO J, V17, P297, DOI 10.1093/emboj/17.1.297; Yaremchuk A, 2000, EMBO J, V19, P4745, DOI 10.1093/emboj/19.17.4745	25	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20286	20291		10.1074/jbc.M100456200	http://dx.doi.org/10.1074/jbc.M100456200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11342535	hybrid			2022-12-27	WOS:000169135100084
J	Pang, TX; Su, XH; Wakabayashi, S; Shigekawa, R				Pang, TX; Su, XH; Wakabayashi, S; Shigekawa, R			Calcineurin homologous protein as an essential cofactor for Na+/H+ exchangers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-BINDING PROTEIN; MOLECULAR-CLONING; IDENTIFICATION; DOMAIN; GROWTH; NHE1; PH; EXPRESSION; INHIBITION; ANTIPORTER	The Na+/H+ exchangers (NHEs) comprise a family of transporters that catalyze cell functions such as regulation of the pH and volume of a cell and epithelial absorption of Na+ and bicarbonate. Ubiquitous calcineurin B homologous protein (CHP or p22) is co-localized and co-immunoprecipitated with expressed NHE1, NHE2, or NHE3 independently of its myristoylation and Ca2+ binding, and its binding site was identified as the jux-tamembrane region within the carboxyl-terminal cytoplasmic domain of exchangers. CHP binding-defective mutations of NHE1-3 or CHP depletion by injection of the competitive CHP-binding region of NHE1 into Xeno-pus oocytes resulted in a dramatic reduction (> 90%) in the Na+/H+ exchange activity. The data suggest that CHP serves as an essential cofactor, which supports the physiological activity of NHE family members.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Suita, Osaka 5658565, Japan	National Cerebral & Cardiovascular Center - Japan	Wakabayashi, S (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5-7-1, Suita, Osaka 5658565, Japan.							Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; Baird NR, 1999, J BIOL CHEM, V274, P4377, DOI 10.1074/jbc.274.7.4377; Barroso MR, 1996, J BIOL CHEM, V271, P10183, DOI 10.1074/jbc.271.17.10183; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Busch S, 1997, BBA-BIOMEMBRANES, V1325, P13, DOI 10.1016/S0005-2736(97)00011-4; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; Cox GA, 1997, CELL, V91, P139, DOI 10.1016/S0092-8674(01)80016-7; Ikeda T, 1997, J BIOCHEM-TOKYO, V121, P295; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Timm S, 1999, MOL BIOL CELL, V10, P3473, DOI 10.1091/mbc.10.10.3473; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WATANABE Y, 1995, J BIOL CHEM, V270, P456, DOI 10.1074/jbc.270.1.456; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	26	146	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17367	17372		10.1074/jbc.M100296200	http://dx.doi.org/10.1074/jbc.M100296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350981	hybrid			2022-12-27	WOS:000168730400103
J	Soler, C; Valdes, R; Garcia-Manteiga, J; Xaus, J; Comalada, M; Casado, FJ; Modolell, M; Nicholson, B; MacLeod, C; Felipe, A; Celada, A; Pastor-Anglada, M				Soler, C; Valdes, R; Garcia-Manteiga, J; Xaus, J; Comalada, M; Casado, FJ; Modolell, M; Nicholson, B; MacLeod, C; Felipe, A; Celada, A; Pastor-Anglada, M			Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; ADENOSINE-INDUCED APOPTOSIS; MOLECULAR-BIOLOGY; TNF-ALPHA; SYNTHASE EXPRESSION; EXTRACELLULAR ATP; IFN-GAMMA; RECEPTOR; HL-60; INDUCTION	In murine bone marrow macrophages, lipopolysaccharide (LPS) induces apoptosis through the autocrine production of tumor necrosis factor-alpha (TNF-alpha), as demonstrated by the fact that macrophages from TNF-alpha receptor I knock-out mice did not undergo early apoptosis. In these conditions LPS up-regulated the two concentrative high affinity nucleoside transporters here shown to be expressed in murine bone marrow macrophages, concentrative nucleoside transporter (CNT) 1 and 2, in a rapid manner that is nevertheless consistent with the de novo synthesis of carrier proteins. This effect was not dependent on the presence of macrophage colony-stimulating factor, although LPS blocked the macrophage colony-stimulating factor-mediated up-regulation of the equilibrative nucleoside transport system es. TNF-alpha mimicked the regulatory response of nucleoside transporters triggered by LPS, but macrophages isolated from TNF-alpha receptor I knock-out mice similarly up-regulated nucleoside transport after LPS treatment. Although NO is produced by macrophages after LPS treatment, NO is not involved in these regulatory responses because LPS up-regulated CNT1 and CNT2 transport activity and expression in macrophages from inducible nitric oxide synthase and cationic amino acid transporter (CAT) 2 knock-out mice, both of which lack inducible nitric oxide synthesis. These data indicate that the early proapoptotic responses of macrophages, involving the up-regulation of CNT transporters, follow redundant regulatory pathways in which TNF-alpha- dependent- and -independent mechanisms are involved. These observations also support a role for CNT transporters in determining extracellular nucleoside availability and modulating macrophage apoptosis.	Univ Barcelona, Dept Bioquim & Biol Mol, Regulat Transport Syst Grp, Fac Biol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Fisiol Biol Macrofag, E-08028 Barcelona, Spain; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	University of Barcelona; University of Barcelona; Max Planck Society; University of California System; University of California San Diego; University of California System; University of California San Diego	Pastor-Anglada, M (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Regulat Transport Syst Grp, Fac Biol, Diagonal 645, E-08028 Barcelona, Spain.	mpastor@porthos.bio.ub.es	Felipe, Antonio/M-8297-2015; Soler, Concepció/L-1185-2014; Manteiga, Jose Manuel Garcia/AAN-1954-2020; Celada, Antonio/I-1714-2016	Felipe, Antonio/0000-0002-7294-6431; Soler, Concepció/0000-0001-6502-5012; Manteiga, Jose Manuel Garcia/0000-0002-5481-040X; Casado Merediz, Francisco Javier/0000-0003-0192-841X; Celada, Antonio/0000-0003-3883-2171	NATIONAL CANCER INSTITUTE [R01CA081376] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINA JE, 1993, J IMMUNOL, V150, P5080; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Cass C E, 1999, Pharm Biotechnol, V12, P313; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Dawicki DD, 1997, AM J PHYSIOL-LUNG C, V273, pL485, DOI 10.1152/ajplung.1997.273.2.L485; del Santo B, 1998, HEPATOLOGY, V28, P1504, DOI 10.1002/hep.510280609; Denlinger LC, 1996, J BIOL CHEM, V271, P337, DOI 10.1074/jbc.271.1.337; Dragan Y, 2000, HEPATOLOGY, V32, P239, DOI 10.1053/jhep.2000.9546; Dresser MJ, 2000, DRUG METAB DISPOS, V28, P1135; Ferrari D, 1997, J IMMUNOL, V159, P1451; GREENBLATT MS, 1992, BLOOD, V80, P1339; Hasko G, 2000, BRIT J PHARMACOL, V129, P909, DOI 10.1038/sj.bjp.0703134; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Humphreys BD, 1996, J IMMUNOL, V157, P5627; Kim KT, 1998, J CANCER RES CLIN, V124, P471, DOI 10.1007/s004320050201; LEIST M, 1995, J IMMUNOL, V154, P1307; Mata JF, 2001, MOL PHARMACOL, V59, P1542, DOI 10.1124/mol.59.6.1542; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Pastor-Anglada M, 1998, BIOCHEM CELL BIOL, V76, P771, DOI 10.1139/bcb-76-5-771; Pastor-Anglada M, 1998, TRENDS PHARMACOL SCI, V19, P424, DOI 10.1016/S0165-6147(98)01253-X; Pastor-Anglada M, 2001, MOL MEMBR BIOL, V18, P81, DOI 10.1080/096876800110033783; Pastor-Anglada M, 2001, DRUG DEVELOP RES, V52, P431, DOI 10.1002/ddr.1144; Peyot ML, 2000, CIRC RES, V86, P76, DOI 10.1161/01.RES.86.1.76; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SALKOWSKI CA, 1995, J IMMUNOL, V155, P3168; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; Soler C, 2000, J LEUKOCYTE BIOL, V67, P345, DOI 10.1002/jlb.67.3.345; SOLER C, 2001, IN PRESS FASEB J; Sperlagh B, 1998, NEUROCHEM INT, V33, P209, DOI 10.1016/S0197-0186(98)00025-4; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; WAKADE TD, 1995, J PHYSIOL-LONDON, V488, P123, DOI 10.1113/jphysiol.1995.sp020951; Wang J, 1997, PHARM RES-DORDR, V14, P1524, DOI 10.1023/A:1012113931332; Xaus J, 2000, BLOOD, V95, P3823; Xaus J, 1999, J IMMUNOL, V162, P3607	44	67	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 10	2001	276	32					30043	30049		10.1074/jbc.M101807200	http://dx.doi.org/10.1074/jbc.M101807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	464XE	11346649	hybrid, Green Published			2022-12-27	WOS:000170558000059
J	Sakurai, K; Katoh, M; Fujimoto, Y				Sakurai, K; Katoh, M; Fujimoto, Y			Alloxan-induced mitochondrial permeability transition triggered by calcium, thiol oxidation, and matrix ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDES; APOPTOSIS; MEMBRANE; TRANSPORT; RELEASE; PORE; MECHANISMS; REDUCTION; INDUCTION; CELLS	In addition to their critical function in energy metabolism, mitochondria contain a permeability transition pore, which is regulated by adenine nucleotides. We investigated conditions required for ATP to induce a permeability transition in mammalian mitochondria. Mitochondrial smelling associated,with mitochondria permeability transition (MPT) was initiated by adding succinate to a rat liver mitochondrial suspension containing alloxan, a diabetogenic agent. If alloxan was added immediately with or 5 min after adding succinate, MPT was strikingly decreased, MPT induced by alloxan was inhibited by EGTA and several agents causing thiol oxidation, suggesting that alloxan leads to permeability transition through a mechanism dependent on Ca2+ uptake and sulfhydryl oxidation; Antimycin A and cyanide, inhibitors of electron transfer, carbonyl cyanide m-chlorophenylhydrazone, and oligomycin all-inhibited MPT. During incubation with succinate, alloxan depleted ATP in mitochondria after an initial transient increase. However, in a mitochondrial suspension containing EGTA, ATP significantly increased in the presence of alloxan to a level greater than that of the control, These results suggest the involvement of energized transport of Ca2+ in the MPT initiation, Addition of exogenous ATP, however, did not trigger MPT in the presence of alloxan and had no effect on MPT induced by alloxan. We conclude that alloxan-induced MPT requires mitochondrial energization, oxidation of protein thiols, and matrix ATP to promote energized uptake of Ca2+.	Hokkaido Coll Pharm, Dept Biochem, Otaru, Hokkaido 0470264, Japan		Sakurai, K (corresponding author), Hokkaido Coll Pharm, Dept Biochem, 7-1 Katsuraoka Cho, Otaru, Hokkaido 0470264, Japan.	ks51@hokuyakudai.ac.jp						ASIMAKIS GK, 1981, AM J PHYSIOL, V241, pH672, DOI 10.1152/ajpheart.1981.241.5.H672; AUSTIN J, 1984, J BIOL CHEM, V259, P154; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BOQUIST L, 1984, DIABETOLOGIA, V27, P379, DOI 10.1007/BF00304854; Bortner CD, 1999, J BIOL CHEM, V274, P21953, DOI 10.1074/jbc.274.31.21953; Constantini P., 1996, J BIOL CHEM, V271, P6746; CROMPTON M, 1990, INTRACELLULAR CALCIU, P183; Eguchi Y, 1997, CANCER RES, V57, P1835; FARBER JL, 1982, LAB INVEST, V47, P114; FREI B, 1985, J BIOL CHEM, V260, P7394; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kowaltowski AJ, 1997, BBA-BIOENERGETICS, V1318, P395, DOI 10.1016/S0005-2728(96)00111-9; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; MALAISSE WJ, 1982, BIOCHEM PHARMACOL, V31, P3527, DOI 10.1016/0006-2952(82)90571-8; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; Novgorodov SA, 1996, J BIOENERG BIOMEMBR, V28, P139, DOI 10.1007/BF02110644; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RIGOBELLO MP, 1995, ARCH BIOCHEM BIOPHYS, V319, P225, DOI 10.1006/abbi.1995.1286; Rodriguez-Zavala JS, 1998, J BIOL CHEM, V273, P7850, DOI 10.1074/jbc.273.14.7850; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; Sakurai K, 2000, FREE RADICAL BIO MED, V28, P273, DOI 10.1016/S0891-5849(99)00236-1; SAKURAI K, 1990, CHEM PHARM BULL, V38, P993; SanchezAlcazar JA, 1997, J BIOL CHEM, V272, P30167, DOI 10.1074/jbc.272.48.30167; Schweizer M, 1996, BIOCHEMISTRY-US, V35, P4524, DOI 10.1021/bi952708+; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; SKREDE S, 1968, BIOCHEM J, V108, P693, DOI 10.1042/bj1080693; SUSIN SA, 1998, BIOCHIM BIOPHYS ACTA, V1633, P151; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZARATTI M, 1995, BIOCHIM BIOPHYS ACTA, V1241, P139	42	20	20	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26942	26946		10.1074/jbc.M102029200	http://dx.doi.org/10.1074/jbc.M102029200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342546	hybrid			2022-12-27	WOS:000169966900029
J	Borges, K; Dingledine, R				Borges, K; Dingledine, R			Functional organization of the GluR1 glutamate receptor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC EXPRESSION; VENTRAL TEGMENTAL AREA; MESSENGER-RNA; CORE PROMOTER; IN-VITRO; GENE; AMPA; ACID; TRANSCRIPTION; INCREASES	The GluR1 glutamate receptor subunit is expressed in most brain areas and plays a major role in excitatory synaptic transmission. We cloned and sequenced 5 kilobase pairs of the rat GluR1 promoter and identified multiple transcriptional start sites between -295 and -202 (relative to the first ATG). Similar to other glutamate receptor subunit promoters, the GluR1 promoter lacks TATA and CAAT elements in that region but binds Spl proteins at two sites. Promoter activity of GluR1 fragments cloned into pGL3 was assessed by immunocytochemistry and by measuring luciferase activity after transfection into primary cultures of rat cortical neurons and glia. GluR1 promoter activity was stronger in neurons, with neuronal specificity appearing to reside mainly within the neuronal expression-enhancing regions, -1395 to -743 and -253 to -48. The latter region contains 4 sites that bound recombinant cAMP-response element-binding proteins and a glial silencing region between -253 and -202. In both neurons and dia, promoter activity was increased by a 64-base pair GA repeat upstream of the initiation sites and reduced by a 57-base pair region that contained an N box. In contrast to the GluR2 promoter the regulatory regions are mainly located outside of the GluR1 initiation region.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Emory University	Borges, K (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	kborges@pharm.emory.edu	dingledine, Ray/F-5173-2011; Borges, Karin/B-4276-2011	Borges, Karin/0000-0001-7448-0770; Dingledine, Ray/0000-0001-7128-4520				Abbott KL, 2000, J MOL CELL CARDIOL, V32, P391, DOI 10.1006/jmcc.1999.1085; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; Cammarota M, 1998, EUR J NEUROSCI, V10, P2669, DOI 10.1046/j.1460-9568.1998.t01-1-00254.x; Carlton SM, 1998, NEUROSCI LETT, V242, P21, DOI 10.1016/S0304-3940(98)00036-6; CHENG B, 1995, J NEUROCHEM, V65, P2525; Chew LJ, 1997, J NEUROSCI, V17, P227, DOI 10.1523/JNEUROSCI.17-01-00227.1997; CHIN LS, 1994, J BIOL CHEM, V269, P18507; Churchill L, 1999, J NEUROCHEM, V72, P2397, DOI 10.1046/j.1471-4159.1999.0722397.x; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; Dingledine R, 1999, PHARMACOL REV, V51, P7; EGGEN BJL, 1994, MOL BRAIN RES, V23, P221, DOI 10.1016/0169-328X(94)90229-1; Fitzgerald LW, 1996, J NEUROSCI, V16, P274; FITZGERALD LW, 1995, J NEUROSCI, V15, P2453, DOI 10.1523/JNEUROSCI.15-03-02453.1995; Gallo V, 2000, TRENDS PHARMACOL SCI, V21, P252, DOI 10.1016/S0165-6147(00)01494-2; GARCIALADONA FJ, 1994, MOL BRAIN RES, V21, P75, DOI 10.1016/0169-328X(94)90380-8; Gecz J, 1999, GENOMICS, V62, P356, DOI 10.1006/geno.1999.6032; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LUEDERS KK, 1982, NUCLEIC ACIDS RES, V10, P7715, DOI 10.1093/nar/10.23.7715; Mathern GW, 1998, J NEUROPATH EXP NEUR, V57, P615, DOI 10.1097/00005072-199806000-00008; Myers SJ, 1998, J NEUROSCI, V18, P6723; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; MYERS SJ, 1998, SOC NEUR ABSTR, V23, P923; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; Naylor P, 1996, MOL BRAIN RES, V35, P349, DOI 10.1016/0169-328X(95)00264-S; NEDIVI E, 1992, J NEUROSCI, V12, P691; Ohtsuka T, 1999, EMBO J, V18, P2196, DOI 10.1093/emboj/18.8.2196; PELLEGRINIGIAMPIETRO DE, 1992, NEUROSCI LETT, V144, P65, DOI 10.1016/0304-3940(92)90717-L; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; SUCHER NJ, 1993, J BIOL CHEM, V268, P22299; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; Weber JRM, 1998, J NEUROSCI, V18, P5264, DOI 10.1523/JNEUROSCI.18-14-05264.1998; Weber JRM, 1997, J NEUROSCI, V17, P7583; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; Yaworsky PJ, 1997, J BIOL CHEM, V272, P25112, DOI 10.1074/jbc.272.40.25112; Yeo J F, 1997, Int J Neurosci, V90, P9; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; Zilles K, 1999, NEUROSCIENCE, V94, P1051, DOI 10.1016/S0306-4522(99)00392-9	44	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25929	25938		10.1074/jbc.M009105200	http://dx.doi.org/10.1074/jbc.M009105200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340067	hybrid			2022-12-27	WOS:000169823300040
J	Chen, CB; Wallis, R				Chen, CB; Wallis, R			Stoichiometry of complexes between mannose-binding protein and its associated serine proteases - Defining functional units for complement activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RA-REACTIVE FACTOR; CLASSICAL PATHWAY; IMMUNE-SYSTEM; LECTIN; MANNAN; SERUM; EQUILIBRIUM; COMPONENT; ZYMOSAN; C1S	Serum mannose-binding protein (MBP) initiates the lectin branch of the complement cascade by binding to sugars on the surfaces of microorganisms and activating two MBP-associated serine proteases (MASP-1 and MASP-2). Rat serum MBP consists of oligomers containing up to four copies of a subunit that is composed of three identical polypeptide chains. Biophysical analysis of intact and truncated MASPs indicates that each MASP is a homodimer that is stabilized through interactions involving an N-terminal CUB domain. The binding sites for MBP are formed from the three N-terminal MASP domains, in which two CUB modules interact with MBP. Each MASP dimer contains binding sites for two MBP subunits. Both sites must be occupied by subunits from a single MBP oligomer to form a stable complex. Thus, the smallest functional unit for complement activation consists of MBP dimers bound to MASP-1 or MASP-2 homodimers. Trimers and tetramers of MBP form complexes containing up to two MASPs. The results reveal how MASP-1 and MASP-2 can function independently to activate the complement cascade.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Wallis, R (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.			Wallis, Russell/0000-0002-8705-5295				Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Endo Y, 1998, J IMMUNOL, V161, P4924; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; LU J, 1990, J IMMUNOL, V144, P2287; Minton AP, 1997, PROG COLL POL SCI S, V107, P11; REID KBM, 1983, BIOCHEM SOC T, V11, P1; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stover CM, 1999, J IMMUNOL, V163, P6848; Stover CM, 1999, J IMMUNOL, V162, P3481; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TAKADA F, 1993, BIOCHEM BIOPH RES CO, V196, P1003, DOI 10.1006/bbrc.1993.2349; Takahashi M, 1999, INT IMMUNOL, V11, P859, DOI 10.1093/intimm/11.5.859; TAKAYAMA Y, 1994, J IMMUNOL, V152, P2308; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Thielens NM, 2001, J IMMUNOL, V166, P5068, DOI 10.4049/jimmunol.166.8.5068; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1997, BIOCHEM J, V325, P391, DOI 10.1042/bj3250391; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414	32	88	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25894	25902		10.1074/jbc.M103539200	http://dx.doi.org/10.1074/jbc.M103539200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337510	hybrid			2022-12-27	WOS:000169823300036
J	Milisav, I; Moro, F; Neupert, W; Brunner, M				Milisav, I; Moro, F; Neupert, W; Brunner, M			Modular structure of the TIM23 preprotein translocase of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; INNER MEMBRANE; INTERMEMBRANE SPACE; CARRIER PROTEINS; MATRIX HSP70; COMPLEX; SYSTEM; HSP70-TIM44; MACHINERY; TRANSPORT	The TIM23 complex mediates import into mitochondria of nuclear encoded preproteins with a matrix-targeting signal. It is composed of the integral membrane proteins Tim17 and Tim23 and the peripheral membrane protein Tim44, which recruits mitochondrial Hsp70 to the sites of protein import. We have analyzed the functions of these constituents using a combined genetic and biochemical approach. Depletion of either Tim17 or Tim23 led to loss of import competence of mitochondria and to a reduction in the number of preprotein-conducting channels. Upon depletion of Tim44, mitochondria also lost their ability to import proteins but maintained normal numbers of import channels. In the absence of Tim44 precursor protein was specifically recognized. The presequence was translocated in a Delta psi -dependent manner across the inner membrane and cleaved by matrix-processing peptidase, However, the preprotein did not move further into the matrix but rather underwent retrograde sliding out of the TIM23 complex. Thus, the TIM23 complex is composed of functionally independent modules. Tim17 and Tim23 are necessary for initiating translocation, whereas Tim44 and mitochondrial Hsp70 are indispensable for complete transport of preproteins and for unfolding of folded domains of preproteins.	Univ Munich, Inst Phys Chem, D-80336 Munich, Germany	University of Munich	Brunner, M (corresponding author), Univ Munich, Inst Phys Chem, Goethestr 33, D-80336 Munich, Germany.		Moro Pérez, Fernando/P-3891-2015	Moro Pérez, Fernando/0000-0002-3568-3388; Brunner, Michael/0000-0001-9798-3047				Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; Bomer U, 1998, EMBO J, V17, P4226, DOI 10.1093/emboj/17.15.4226; Creighton T. E., 1996, PROTEINS STRUCTURES; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; HOVLAND P, 1989, GENE, V83, P57, DOI 10.1016/0378-1119(89)90403-4; Kaldi K, 1998, EMBO J, V17, P1569, DOI 10.1093/emboj/17.6.1569; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PFANNER N, 1997, CURR BIOL, V7, P100; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Ryan MT, 2000, INT J BIOCHEM CELL B, V32, P13, DOI 10.1016/S1357-2725(99)00114-4; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Sirrenberg C, 1997, J BIOL CHEM, V272, P29963, DOI 10.1074/jbc.272.47.29963; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x	35	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25856	25861		10.1074/jbc.M102132200	http://dx.doi.org/10.1074/jbc.M102132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344168	hybrid			2022-12-27	WOS:000169823300030
J	Mouchantaf, R; Kumar, U; Sulea, T; Patel, YC				Mouchantaf, R; Kumar, U; Sulea, T; Patel, YC			A conserved alpha-helix at the amino terminus of prosomatostatin serves as a sorting signal for the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROHORMONE CONVERTASE PC2; CARBOXYPEPTIDASE-E; CHROMOGRANIN-B; CPE(FAT)/CPE(FAT) MICE; VESICLE BIOGENESIS; HORMONE STORAGE; DISULFIDE BOND; GROWTH-HORMONE; CPE(FAT) MICE	Mammalian prosomatostatin (PSST) contains the bioactive peptides SST-14 and SST-28 at the COOH-terminal end of the molecule and a putative sorting signal in the propeptide segment for targeting the precursor to the regulated secretory pathway. The NH2-terminal segment of PSST consists of an amphipathic cu-helix, which has been totally conserved throughout vertebrate evolution. We have analyzed the PSST-(3-15) region for sorting function by alanine scanning and deletional mutagenesis, Mutants created were stably expressed in AtT-SO cells. Regulated secretion was studied by analyzing basal and stimulated release of SST-14 LI and by immunocytochemistry for staining of SST-14 LI in punctate granules. Deletion of the PSST-(3-15) segment blocked regulated secretion and rerouted PSST for constitutive secretion as unprocessed precursor. Alanine scanning mutagenesis identified the region Pro(5)-Gln(12) as being important in precursor targeting, with Leu(7) and Leu(11) being critical. Molecular modeling demonstrated that these two residues are located in close proximity on a hydrophobic surface of the alpha -helix. Disruption of the alpha -helix did not impair the ability of PSST to be processed at the COOH terminus to SST-14 and SST-28. Processing, however, was shifted to the early compartments of the secretory pathway rather than storage granules and was relatively inefficient.	McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Neurol & Neurosurg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Pharmacol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Therapeut, Montreal, PQ H3A 1A1, Canada; Montreal Neurol Inst, Montreal, PQ H3A 1A1, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; National Research Council Canada	Patel, YC (corresponding author), McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada.							Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; BENOIT R, 1987, SCIENCE, V238, P1126, DOI 10.1126/science.2891188; BENOIT R, 1990, METABOLISM, V39, P22, DOI 10.1016/0026-0495(90)90202-N; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CASTLE AM, 1995, J CELL SCI, V108, P3827; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; Dhanvantari S, 2000, J BIOL CHEM, V275, P29887, DOI 10.1074/jbc.M005364200; GALANOPOULOU AS, 1993, J BIOL CHEM, V268, P6041; GALANOPOULOU AS, 1995, BIOCHEM J, V309, P33, DOI 10.1042/bj3090033; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HALBAN PA, 1994, BIOCHEM J, V299, P1; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Irminger JC, 1997, J BIOL CHEM, V272, P27532, DOI 10.1074/jbc.272.44.27532; Jutras I, 2000, J BIOL CHEM, V275, P40337, DOI 10.1074/jbc.M004757200; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; Kumar U, 1999, DIABETES, V48, P77, DOI 10.2337/diabetes.48.1.77; Lee MS, 2001, J BIOL CHEM, V276, P715, DOI 10.1074/jbc.M008530200; LEPAGELEZIN A, 1991, J BIOL CHEM, V266, P1679; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOUCHANTAF R, 2000, P ANN M SOC NEUR NEW, P27; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Normant E, 1998, ENDOCRINOLOGY, V139, P2137, DOI 10.1210/en.139.4.2137; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PATEL YC, 1988, J BIOL CHEM, V263, P745; Patel YC, 1997, MOL CELL ENDOCRINOL, V131, P183, DOI 10.1016/S0303-7207(97)00107-X; RAVAZZOLA M, 1989, J CLIN INVEST, V83, P362, DOI 10.1172/JCI113892; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHMIDT WK, 1994, J BIOL CHEM, V269, P27115; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SEVARINO KA, 1991, J BIOL CHEM, V266, P18507; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; Zhang CF, 1999, MOL ENDOCRINOL, V13, P527, DOI 10.1210/me.13.4.527	52	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26308	26316		10.1074/jbc.M102514200	http://dx.doi.org/10.1074/jbc.M102514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11309402	hybrid			2022-12-27	WOS:000169823300089
J	Uchiyama, M; Griffiths, D; Arai, K; Masai, H				Uchiyama, M; Griffiths, D; Arai, K; Masai, H			Essential role of Sna41/Cdc45 in loading of DNA polymerase alpha onto minichromosome maintenance proteins in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION ORIGINS; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MCM PROTEIN; BUDDING YEAST; COMPLEX; CDC45P; GENE	Assembly of replication complexes at the replication origins is strictly regulated. Cdc45p is known to be a part of the active replication complexes. In Xenopus egg extracts, Cdc45p was shown to be required for loading of DNA polymerase alpha onto chromatin. The fission yeast cdc45 homologue was identified as a suppressor for nda8 and named snag41. Nevertheless, it is not known how Cdc45p facilitates loading of DNA polymerase ru onto chromatin, particularly to prereplicative complexes. To gain novel insight into the function of this protein in fission yeast, we characterized the fission yeast Cdc45 homologue, Sna41p, We have constructed C-terminally epitope-tagged Sna41p and Pol alphap and replaced the endogenous genes with the corresponding tagged genes. Analyses of protein-protein interactions in vivo by the use of these tagged strains revealed the following: Sna41p interacts with Pol alphap throughout the cell cycle, whereas it interacts with Mis5p/Mcm6p in the chromatin fractions at the G(1)-S boundary through S phase. In an initiation-defective sna41 mutant, sna41(goal), interaction of Pol alphap with Mis5p is not observed, although Pol alphap loading onto the chromatin that occurs before G, START is not affected. These results show that fission yeast Sna41p facilitates the loading of Pol alphap onto minichromosome maintenance proteins. Our results are consistent with a model in which loading of Pol alphap onto replication origins occurs through two steps, namely, loading onto chromatin at preSTART and association with prereplicative complexes at G(1)-S through Sna41p, which interacts with minichromosome maintenance proteins in a cell cycle-dependent manner.	CREST, Tokyo 1088639, Japan; Imperial Canc Res Fund, London WC2A 3PX, England; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan	Japan Science & Technology Agency (JST); Cancer Research UK; University of Tokyo	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 113, Japan.							Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Brown GW, 1997, P NATL ACAD SCI USA, V94, P6142, DOI 10.1073/pnas.94.12.6142; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Chuang RY, 1999, P NATL ACAD SCI USA, V96, P2656, DOI 10.1073/pnas.96.6.2656; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; FOIANI M, 1995, MOL CELL BIOL, V15, P883; FRANCESCONI S, 1993, NUCLEIC ACIDS RES, V21, P3821, DOI 10.1093/nar/21.16.3821; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; Griffiths DJF, 2001, MOL BIOL CELL, V12, P115, DOI 10.1091/mbc.12.1.115; HAGAN IM, 1988, J CELL SCI, V89, P343; Hopwood B, 1996, P NATL ACAD SCI USA, V93, P12309, DOI 10.1073/pnas.93.22.12309; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kukimoto I, 1999, EUR J BIOCHEM, V265, P936, DOI 10.1046/j.1432-1327.1999.00791.x; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; Miyake S, 1998, GENES CELLS, V3, P157, DOI 10.1046/j.1365-2443.1998.00177.x; Mizuno T, 1998, MOL CELL BIOL, V18, P3552, DOI 10.1128/MCB.18.6.3552; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Newlon CS, 1997, CELL, V91, P717, DOI 10.1016/S0092-8674(00)80459-6; Ogawa Y, 1999, MOL CELL BIOL, V19, P7228; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Okishio N, 1996, J CELL SCI, V109, P319; Okuno Y, 1997, NUCLEIC ACIDS RES, V25, P530, DOI 10.1093/nar/25.3.530; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; Sherman DA, 1998, MOL BIOL CELL, V9, P1833, DOI 10.1091/mbc.9.7.1833; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Takeda T, 1999, MOL CELL BIOL, V19, P5535; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; UCHIYAMA M, 2001, IN PRESS MOL GEN GEN; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; WANG TSF, 1996, DNA REPLICATION EUKA, P461; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	49	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26189	26196		10.1074/jbc.M100007200	http://dx.doi.org/10.1074/jbc.M100007200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11344166	hybrid			2022-12-27	WOS:000169823300074
J	Marc, F; Weigel, P; Legrain, C; Glansdorff, N; Sakanyan, V				Marc, F; Weigel, P; Legrain, C; Glansdorff, N; Sakanyan, V			An invariant threonine is involved in self-catalyzed cleavage of the precursor protein for ornithine acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; SITE-DIRECTED MUTAGENESIS; BACILLUS-STEAROTHERMOPHILUS; SACCHAROMYCES-CEREVISIAE; ARGININE-BIOSYNTHESIS; INTRAMOLECULAR PROTEOLYSIS; CRYSTAL-STRUCTURE; ACETYL CYCLE; MECHANISM; ENZYME	In Bacillus stearothermophilus ornithine acetyltransferase is a bifunctional enzyme, catalyzing the first and the fifth steps of arginine biosynthesis; it follows a ping-pong kinetic mechanism. A single chain precursor protein is cleaved between the alanine and threonine residues in a highly conserved ATML sequence leading to the formation of alpha and beta subunits that assemble into a heterotetrameric 2 alpha2 beta molecule. The beta subunit has been shown to form an acetylated intermediate in the course of the transacetylation reaction. The present data show that the precursor protein synthesized in vitro or in vivo undergoes a self-catalyzed cleavage involving an invariant threonine (Thr-197). Using site-directed mutagenesis T197G, T197S, and T197C derivatives have been generated. The T197G substitution abolishes both precursor protein cleavage and catalytic activity, whereas T197S and T197C substitutions reduce precursor cleavage and catalytic activity in the order Thr-197 (wild type) --> Ser-197 --> Cys-197. A mechanism is proposed in which Thr-197 plays a crucial role in the autoproteolytic cleavage of ornithine acetyltransferase.	Univ Nantes, Fac Sci & Tech, FRE CNRS 2230 Biocatalyse, Biotechnol Lab, F-44322 Nantes 3, France; Jean Marie Wiame Inst Microbiol Res, B-1070 Brussels, Belgium; Free Univ Brussels, Lab Genet & Microbiol, B-1070 Brussels, Belgium; Flanders Interuniv Inst Biotechnol, Dept Microbiol, B-1070 Brussels, Belgium	Nantes Universite; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Sakanyan, V (corresponding author), Univ Nantes, Fac Sci & Tech, FRE CNRS 2230 Biocatalyse, Biotechnol Lab, F-44322 Nantes 3, France.			Sakanyan, Vehary/0000-0002-0513-8434				Abadjieva A, 2000, J BIOL CHEM, V275, P11361, DOI 10.1074/jbc.275.15.11361; ARONSON NN, 1996, GLYCOBIOLOGY, P699; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HZ, 1983, METHOD ENZYMOL, V101, P674; Crabeel M, 1997, EUR J BIOCHEM, V250, P232, DOI 10.1111/j.1432-1033.1997.0232a.x; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Grahame DA, 1996, J BIOL CHEM, V271, P8352, DOI 10.1074/jbc.271.14.8352; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Guo HC, 1998, J BIOL CHEM, V273, P20205, DOI 10.1074/jbc.273.32.20205; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Karaivanova IM, 1999, J MOL BIOL, V291, P843, DOI 10.1006/jmbi.1999.3016; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Li X, 1995, P NATL ACAD SCI USA, V92, P12357, DOI 10.1073/pnas.92.26.12357; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LIU YS, 1995, EUR J BIOCHEM, V228, P291, DOI 10.1111/j.1432-1033.1995.tb20262.x; Marc F, 2000, EUR J BIOCHEM, V267, P5217, DOI 10.1046/j.1432-1327.2000.01593.x; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; SAKANYAN V, 1992, J GEN MICROBIOL, V138, P125, DOI 10.1099/00221287-138-1-125; SAKANYAN V, 1993, J GEN MICROBIOL, V139, P393, DOI 10.1099/00221287-139-3-393; Sakanyan V, 1996, MICROBIOL-SGM, V142, P99, DOI 10.1099/13500872-142-1-99; SAKANYAN VA, 1990, GENETIKA+, V26, P1915; Savchenko A, 1998, GENE, V212, P167, DOI 10.1016/S0378-1119(98)00174-7; Sinclair JC, 2000, NAT STRUCT BIOL, V7, P560; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	30	19	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25404	25410		10.1074/jbc.M100392200	http://dx.doi.org/10.1074/jbc.M100392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320085	hybrid			2022-12-27	WOS:000169800700130
J	O'Flaherty, JT; Chadwell, BA; Kearns, MW; Sergeant, S; Daniel, LW				O'Flaherty, JT; Chadwell, BA; Kearns, MW; Sergeant, S; Daniel, LW			Protein kinases C translocation responses to low concentrations of arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; DIBUTYRATE BINDING-SITES; HUMAN NEUTROPHILS; PHORBOL ESTERS; NADPH OXIDASE; OLEIC-ACID; ACTIVATION; CELLS; ISOFORMS; PHOSPHORYLATION	Arachidonic acid (AA) directly activates protein kinases C (PKC) and may thereby serve as a regulatory signal during cell stimulation. The effect, however, requires a greater than or equal to 20 muM concentration of the fatty acid. We find that human polymorphonuclear neutrophils (PMN) equilibrated with a ligand for the diacylglycerol receptor on PKC, [H-3]phorbol dibutyrate (PDB), increased binding of [3H]PDB within 15 s of exposure to greater than or equal to 10-30 nM Ak Other unsaturated fatty acids, but not a saturated fatty acid, likewise stimulated PDB binding. These responses, similar to those caused by chemotactic factors, resulted from a rise in the number of diacylglycerol receptors that were plasma membrane-associated and therefore accessible to PDB. Unlike chemotactic factors, however, AA was fully active on cells overloaded with Ca2+ chelators, The major metabolites of AA made by PMN, leukotriene B-4 and 5-hydroxyicosatetraenoate, did not mimic Ak and an AA antimetabolite did not block responses to Ak AA also induced PMN to translocate cytosolic PKC alpha, beta (II), and delta to membranes. This response paralleled PDB binding with respect to dose requirements, time, Ca2+-independence, resistance to an AA antimetabolite, and induction by another unsaturated fatty acid but not by a saturated fatty acid. Finally, HEK 293 cells transfected with vectors encoding PKC beta (1) or PKC delta fused to the reporter enhanced green fluorescent protein (EGFP) were studied, AA caused EGFP-PKC beta translocation from cytosol to plasma membrane at greater than or equal to0.5 muM, and EGFP-PKC delta translocation from cytosol to nuclear and, to a lesser extent, plasma membrane at as little as 30 nM. We conclude that AA induces PKC translocations to specific membrane targets at concentrations 2-4 orders of magnitude below those activating the enzymes. These responses, at least as they occur in PMN, do not require changes in cell Ca2+ or oxygenation of the fatty acid. AA seems more suited for signaling the movement than activation of PKC.	Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	O'Flaherty, JT (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27156 USA.	joflaher@wfubmc.edu			NHLBI NIH HHS [1RO1 HL56710] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056710] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Barry OP, 1997, J CLIN INVEST, V99, P2118, DOI 10.1172/JCI119385; Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; BROWN JH, 1990, SYM SOC EXP BIOL, V44, P147; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; COMBADIERE C, 1993, BIOCHEM J, V289, P695, DOI 10.1042/bj2890695; DANG PMC, 1995, BIOCHEM BIOPH RES CO, V212, P664, DOI 10.1006/bbrc.1995.2020; Daniele JJ, 1999, PROSTAG OTH LIPID M, V57, P341, DOI 10.1016/S0090-6980(98)00084-7; Dekker LV, 2000, BIOCHEM J, V347, P285, DOI 10.1042/0264-6021:3470285; DIAZGUERRA MJM, 1991, J BIOL CHEM, V266, P23568; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Hii CST, 1999, ADV EXP MED BIOL, V469, P365; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Huang XP, 1997, J CELL SCI, V110, P1625; Huang ZH, 1997, BIOCHEM J, V325, P553, DOI 10.1042/bj3250553; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kent JD, 1996, J IMMUNOL, V157, P4641; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Lu Y, 1999, CELL SIGNAL, V11, P275, DOI 10.1016/S0898-6568(98)00061-8; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mochly-Rosen D, 1998, FASEB J, V12, P35; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Nixon JB, 1999, J IMMUNOL, V163, P4574; Nowicki S, 2000, AM J PHYSIOL-CELL PH, V279, pC1812, DOI 10.1152/ajpcell.2000.279.6.C1812; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P21619; OFLAHERTY JT, 1990, J BIOL CHEM, V265, P9146; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Padma M, 1999, PROSTAG LEUKOTR ESS, V60, P55, DOI 10.1054/plef.1998.0008; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Raeder EMB, 1999, BLOOD, V93, P686, DOI 10.1182/blood.V93.2.686.402k27_686_693; RAIS S, 1994, BIOCHEM PHARMACOL, V47, P1797, DOI 10.1016/0006-2952(94)90308-5; Reeves EP, 1999, BIOCHEM J, V344, P859, DOI 10.1042/0264-6021:3440859; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069; SASAKI Y, 1993, FEBS LETT, V320, P47, DOI 10.1016/0014-5793(93)81655-J; Sergeant S, 1997, J IMMUNOL, V159, P2877; Shirai Y, 1998, JPN J PHARMACOL, V78, P411, DOI 10.1254/jjp.78.411; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; SZAMEL M, 1989, J IMMUNOL, V143, P2806; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; WOLF M, 1985, J BIOL CHEM, V260, P5718; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989	68	62	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24743	24750		10.1074/jbc.M101093200	http://dx.doi.org/10.1074/jbc.M101093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328812	hybrid			2022-12-27	WOS:000169800700045
J	Song, LN; Huse, B; Rusconi, S; Simons, SS				Song, LN; Huse, B; Rusconi, S; Simons, SS			Transactivation specificity of glucocorticoid versus progesterone receptors - Role of functionally different interactions of transcription factors with amino- and carboxyl-terminal receptor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TUMOR VIRUS PROMOTER; PARTIAL AGONIST ACTIVITY; HUMAN ESTROGEN-RECEPTOR; BREAST-CANCER CELLS; NUCLEAR RECEPTOR; ANDROGEN RECEPTOR; GENE-EXPRESSION; DNA-BINDING; STEROID-RECEPTORS	A major unanswered question of glucocorticoid and progesterone action is how different whole cell responses arise when both of the cognate receptors can bind to, and activate, the same hormone response elements. We have documented previously that the EC,, of agonist complexes, and the partial agonist activity of antagonist complexes, of both glucocorticoid receptors (GRs) and progesterone receptors (PRs) are modulated by increased amounts of homologous receptor and of coregulators. We now ask whether these components can differentially alter GR and PR transcriptional properties. To remove possible cell-specific differences, we have examined both receptors in the common environment of a line of mouse mammary adenocarcinoma (1470.2) cells, In order to segregate the responses that might be due to unequal nucleosome reorganization by the two receptors from those reflecting interactions with other components, we chose a transiently transfected reporter containing a simple glucocorticoid response element (i.e. GREtkLUC), No significant differences are found with elevated levels of either receptor. However, major, qualitative differences are seen with the corepressors SMRT and NCoR, which afford opposite responses with GR and PR. Studies with chimeric GR/PR receptors indicate that no one segment of PR or G;R is responsible for these properties and that the composite response likely involves interactions with both the amino and carboxyl termini of receptors, Collectively, the data suggest that GR and PR induction of responsive genes in a given cell can be differentially controlled, in part, by unequal interactions of multiple receptor domains with assorted nuclear cofactors.	NIDDK, Steroid Hormones Sect, LMCB, NIH, Bethesda, MD 20892 USA; Univ Fribourg, CH-1700 Fribourg, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Fribourg	Simons, SS (corresponding author), NIDDK, Steroid Hormones Sect, LMCB, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK057800, Z01DK057800] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alen P, 1999, MOL CELL BIOL, V19, P6085; Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Auger AP, 2000, P NATL ACAD SCI USA, V97, P7551, DOI 10.1073/pnas.97.13.7551; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Endoh H, 1999, MOL CELL BIOL, V19, P5363; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Giannoukos G, 2001, MOL ENDOCRINOL, V15, P255, DOI 10.1210/me.15.2.255; Glass CK, 2000, GENE DEV, V14, P121; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Kaul S, 2000, MOL ENDOCRINOL, V14, P1010, DOI 10.1210/me.14.7.1010; Kinyamu HK, 2000, J BIOL CHEM, V275, P20061, DOI 10.1074/jbc.M001142200; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; Lambert JR, 1998, J BIOL CHEM, V273, P32708, DOI 10.1074/jbc.273.49.32708; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Li DS, 1999, MOL CELL BIOL, V19, P7191; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Massaad C, 2000, BIOCHEM J, V350, P123, DOI 10.1042/0264-6021:3500123; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; MYMRYK JS, 1995, GENE DEV, V9, P1366, DOI 10.1101/gad.9.11.1366; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; RICOUSSE SL, 1996, P NATL ACAD SCI USA, V93, P5072; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Sarlis NJ, 1999, J STEROID BIOCHEM, V68, P89, DOI 10.1016/S0960-0760(99)00021-7; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shim WS, 1999, P NATL ACAD SCI USA, V96, P208, DOI 10.1073/pnas.96.1.208; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; Smith CL, 2000, MOL ENDOCRINOL, V14, P956, DOI 10.1210/me.14.7.956; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Thackray VG, 1998, J STEROID BIOCHEM, V66, P171, DOI 10.1016/S0960-0760(98)00044-2; Thackray VG, 2000, ENDOCRINOLOGY, V141, P3912, DOI 10.1210/en.141.10.3912; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; Yang ZH, 1999, J BIOL CHEM, V274, P37131, DOI 10.1074/jbc.274.52.37131; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	89	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24806	24816		10.1074/jbc.M102610200	http://dx.doi.org/10.1074/jbc.M102610200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333273	hybrid, Green Submitted			2022-12-27	WOS:000169800700053
J	Wang, X; Li, MX; Spyracopoulos, L; Beier, N; Chandra, M; Solaro, RJ; Sykes, BD				Wang, X; Li, MX; Spyracopoulos, L; Beier, N; Chandra, M; Solaro, RJ; Sykes, BD			Structure of the C-domain of human cardiac troponin C in complex with the Ca2+ sensitizing drug EMD 57033	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I INHIBITORY PEPTIDE; N-TERMINAL DOMAIN; PULSED-FIELD GRADIENT; REGULATORY DOMAIN; SKELETAL-MUSCLE; CALCIUM SENSITIZATION; RESONANCE ASSIGNMENTS; IMPROVED SENSITIVITY; STUNNED MYOCARDIUM; CRYSTAL-STRUCTURE	Ca2+ binding to cardiac troponin C (cTnC) triggers contraction in heart muscle. In heart failure, myofilaments response to Ca2+ are often altered and compounds that sensitize the myofilaments to Ca2+ possess therapeutic value in this syndrome. One of the most potent and selective Ca2+ sensitizers is the thiadiazinone derivative EMD 57033, which increases myocardial contractile function both in vivo and in vitro and interacts with cTnC in vitro. We have determined the NMR structure of the 1:1 complex between Ca2+-saturated C-domain of human cTnC (cCTnC) and EMD 57033. Favorable hydrophobic interactions between the drug and the protein position EMD 57033 in the hydrophobic cleft of the protein. The drug molecule is orientated such that the chiral group of EMD 57033 fits deep in the hydrophobic pocket and makes several key contacts with the protein. This stereospecific interaction explains why the (-)-enantiomer of EMD 57033 is inactive. Titrations of the cCTnC EMD 57033 complex with two regions of cardiac troponin I (CTnI(34-71) and cTnI(128-147)) reveal that the drug does not share a common binding epitope with cTnI(128-147) but is completely displaced by cTnI(34-71). These results have important implications for elucidating the mechanism of the Ca2+ sensitizing effect of EMD 57033 in cardiac muscle contraction.	Univ Alberta, Dept Biochem, Grp Prot Struct & Funct, CIHR, Edmonton, AB T6G 2H7, Canada; Merck KGaA, Pharmaceut Res Dept, D-64271 Darmstadt, Germany; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Alberta; Merck KGaA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Sykes, BD (corresponding author), Univ Alberta, Dept Biochem, Grp Prot Struct & Funct, CIHR, Edmonton, AB T6G 2H7, Canada.							ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CAMPBELL AP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P35, DOI 10.1016/0167-4838(92)90036-D; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; Chandra M, 1997, BIOCHEMISTRY-US, V36, P13305, DOI 10.1021/bi9710129; de Zeeuw S, 2000, EUR J PHARMACOL, V403, P99, DOI 10.1016/S0014-2999(00)00513-6; de Zeeuw S, 2000, BRIT J PHARMACOL, V129, P1413, DOI 10.1038/sj.bjp.0703231; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ENDOH M, 1995, GEN PHARMACOL, V26, P1, DOI 10.1016/0306-3623(94)00144-C; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Filatov VL, 1999, BIOCHEMISTRY-MOSCOW+, V64, P969; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; GROSS T, 1993, J MOL CELL CARDIOL, V25, P239, DOI 10.1006/jmcc.1993.1030; Haeusler G, 1997, J CARDIOVASC PHARM, V29, P647, DOI 10.1097/00005344-199705000-00013; Hernandez G, 1999, BIOCHEMISTRY-US, V38, P6911, DOI 10.1021/bi990150q; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOWARTH JW, 1995, PROTEIN SCI, V4, P671; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kleerekoper Q, 1999, J BIOL CHEM, V274, P23932, DOI 10.1074/jbc.274.34.23932; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; LAN JQ, 1989, BIOCHEMISTRY-US, V28, P7380, DOI 10.1021/bi00444a035; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li MX, 2000, BIOCHEMISTRY-US, V39, P8782, DOI 10.1021/bi000473i; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; LI MX, 1995, BIOCHEMISTRY-US, V34, P8330, DOI 10.1021/bi00026a014; Li Y, 2000, P NATL ACAD SCI USA, V97, P5140, DOI 10.1073/pnas.090098997; LUES I, 1993, J CARDIOVASC PHARM, V21, P883, DOI 10.1097/00005344-199306000-00006; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; McKay RT, 2000, BIOCHEMISTRY-US, V39, P12731, DOI 10.1021/bi001240u; McKay RT, 1997, J BIOL CHEM, V272, P28494, DOI 10.1074/jbc.272.45.28494; McKay RT, 1998, BIOCHEMISTRY-US, V37, P12419, DOI 10.1021/bi9809019; Mercier P, 2000, BIOCHEMISTRY-US, V39, P2902, DOI 10.1021/bi992579n; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NGAI SM, 1994, J BIOL CHEM, V269, P2165; NGAI SM, 1992, J BIOL CHEM, V267, P15715; Nicholls A., 1992, GRASP GRAPHICAL REPR; NielsenKudsk JE, 1995, J CARDIOVASC PHARM, V26, pS77; Ogura K, 1996, J BIOMOL NMR, V8, P492, DOI 10.1007/BF00228150; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Senzaki H, 2000, CIRCULATION, V101, P1040, DOI 10.1161/01.CIR.101.9.1040; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SOLARO RJ, 1993, CIRC RES, V73, P981, DOI 10.1161/01.RES.73.6.981; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; SORSA T, 2000, J BIOL CHEM, V11, P11; Spyracopoulos L, 1997, BIOCHEMISTRY-US, V36, P12138, DOI 10.1021/bi971223d; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tsutsui H, 2001, J CARDIOVASC PHARM, V37, P16, DOI 10.1097/00005344-200101000-00003; Tung CS, 2000, PROTEIN SCI, V9, P1312; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; Varro A, 1995, J CARDIOVASC PHARM, V26, pS32; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; VENTURA C, 1992, CIRC RES, V70, P1081, DOI 10.1161/01.RES.70.6.1081; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	65	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25456	25466		10.1074/jbc.M102418200	http://dx.doi.org/10.1074/jbc.M102418200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320096	hybrid			2022-12-27	WOS:000169800700136
J	Ammendola, A; Geiselhoringer, A; Hofmann, F; Schlossmann, J				Ammendola, A; Geiselhoringer, A; Hofmann, F; Schlossmann, J			Molecular determinants of the interaction between the inositol 1,4,5-trisphosphate receptor-associated cGMP kinase substrate (IRAG) and cGMP kinase I beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; VASCULAR SMOOTH-MUSCLE; PHOSPHORYLATION SITES; VIVO PHOSPHORYLATION; MYOSIN PHOSPHATASE; NITRIC-OXIDE; CA2+ RELEASE; CELLS; CAMP; INHIBITION	Cyclic GMP-dependent protein kinase I (cGKI) affects the inositol 1,4,5-trisphosphate (InsP(3))-dependent release of intracellular calcium by phosphorylation of IRAG (inositol 1,4,5-trisphophate receptor-associated cGMP kinase substrate). IRAG is present in a macromolecular complex with the InsP(3) receptor type I (InsP(3)RI) and cGKI beta. The specificity of the interaction between these three proteins was investigated by using the yeast two-hybrid system and by co-precipitation of expressed proteins. The amino terminal region containing the leucine zipper (amino acids 1-53) of cGKI beta but not that of cGKI alpha or cGKZII interacted with the sequence between amino acids 152 and 184 of IRAG in vitro and in vivo most likely through electrostatic interaction. cGKT beta did not interact with the InsP(3)RI, but co-precipitated the InsP(3)RI in the presence of IRAG indicating that IRAG bound to the InsP(3)RI and to cGKI beta. cGKI beta phosphorylated up to four serines in IRAG. Mutation of these four serines to alanine showed that cGKI beta -dependent phosphorylation of Ser(696) is necessary to decrease calcium release from InsP(3)-sensitive stores. These results show that cGMP induced reduction of cytosolic calcium concentrations requires cGKI beta and phosphorylation of Ser(696) of IRAG.	Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	Technical University of Munich	Schlossmann, J (corresponding author), Tech Univ Munich, Inst Pharmakol & Toxikol, Biedersteiner Str 29, D-80802 Munich, Germany.		Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839				Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; BUTT E, 1994, J BIOL CHEM, V269, P14509; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Endo S, 1999, P NATL ACAD SCI USA, V96, P2467, DOI 10.1073/pnas.96.5.2467; FELBEL J, 1988, J BIOL CHEM, V263, P16764; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hall KU, 1999, J BIOL CHEM, V274, P3485, DOI 10.1074/jbc.274.6.3485; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann F, 2000, J CELL SCI, V113, P1671; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LINCOLN TM, 1990, AM J PHYSIOL, V258, P399; MacDonald JA, 2000, FEBS LETT, V479, P83, DOI 10.1016/S0014-5793(00)01884-6; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Moore DD, 1995, GLOB MOB SURV; Murthy KS, 1998, J BIOL CHEM, V273, P34519, DOI 10.1074/jbc.273.51.34519; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; Tertyshnikova X, 1998, J PHYSIOL-LONDON, V512, P89, DOI 10.1111/j.1469-7793.1998.089bf.x; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Wyatt TA, 1998, AM J PHYSIOL-HEART C, V274, pH448, DOI 10.1152/ajpheart.1998.274.2.H448; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; Yuasa K, 2000, J BIOL CHEM, V275, P4897, DOI 10.1074/jbc.275.7.4897	45	107	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24153	24159		10.1074/jbc.M101530200	http://dx.doi.org/10.1074/jbc.M101530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11309393	hybrid			2022-12-27	WOS:000169531100123
J	Wang, YT; Yin, LY; Hillgartner, FB				Wang, YT; Yin, LY; Hillgartner, FB			The homeodomain proteins PBX and MEIS1 are accessory factors that enhance thyroid hormone regulation of the malic enzyme gene in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; CHICK-EMBRYO HEPATOCYTES; TRANSCRIPTIONAL CONTROL; RESPONSE ELEMENTS; RECEPTOR-ALPHA; HOMEOBOX GENES; HOX PROTEINS; EXPRESSION; TRIIODOTHYRONINE; DOMAIN	Triiodothyronine (T3) stimulates a robust increase (40-fold) in transcription of the malic enzyme gene in chick embryo hepatocytes. Previous work has shown that optimal T3 regulation of malic enzyme transcription is dependent on the presence of an accessory element (designated as region E) that immediately flanks a cluster of five T3 response elements in the malic enzyme gene. Here, we have analyzed the binding of nuclear proteins to region E and investigated the mechanism by which region E enhances T3 responsiveness. In nuclear extracts hom hepatocytes, region E binds heterodimeric complexes consisting of the homeodomain proteins PBX and MEIS1, Region E contains four consecutive PBX/MEIS1 half-sites, PBX-MEIS1 heterodimers bind the first and second half-sites, the third and fourth half-sites, and the first and fourth half-sites. The configuration conferring the greatest increase in T3 responsiveness consists of the first and fourth half-sites that are separated by 7 nucleotides. Stimulation of T3 response element functions by region E does not require the presence of additional melic enzyme sequences. In pull-down experiments, PBX1a and PBX1b specifically bind the nuclear T3 receptor-or, and this interaction is enhanced by the presence of T3, A T3 receptor-ct region containing the DNA binding domain plus nanking sequences famine acids 21-157) is necessary and sufficient for binding to PBX1a and PBX1b, These results indicate that PBX-MEIS1 complexes interact with nuclear T3 receptors to enhance T3 regulation of malic enzyme transcription in hepatocytes.	W Virginia Univ, Dept Biochem, Sch Med, Morgantown, WV 26506 USA	West Virginia University	Hillgartner, FB (corresponding author), W Virginia Univ, Dept Biochem, Sch Med, POB 9142, Morgantown, WV 26506 USA.	fbhillgartner@hsc.wvu.edu						Abramovich C, 2000, J BIOL CHEM, V275, P26172, DOI 10.1074/jbc.M001323200; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; Fang XX, 1998, ARCH BIOCHEM BIOPHYS, V349, P138, DOI 10.1006/abbi.1997.0406; Fang XX, 2000, MOL CELL ENDOCRINOL, V164, P41, DOI 10.1016/S0303-7207(00)00238-0; Ferretti E, 2000, DEVELOPMENT, V127, P155; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; Glass CK, 2000, GENE DEV, V14, P121; Gonzalez-Manchon C, 1999, GENE, V226, P111, DOI 10.1016/S0378-1119(98)00543-5; GOODRIDG.AG, 1973, J BIOL CHEM, V248, P1924; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; GOODRIDGE AG, 1968, BIOCHEM J, V108, P667, DOI 10.1042/bj1080667; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Herzig S, 2000, J BIOL CHEM, V275, P27989; HILLGARTNER FB, 1992, J BIOL CHEM, V267, P12299; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LU QA, 1995, MOL CELL BIOL, V15, P3786; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MA XJ, 1990, J BIOL CHEM, V265, P18435; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Moore DD, 1995, GLOB MOB SURV; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Ogo A, 1997, ARCH BIOCHEM BIOPHYS, V348, P226, DOI 10.1006/abbi.1997.0372; Ogo A, 1997, ARCH BIOCHEM BIOPHYS, V338, P193, DOI 10.1006/abbi.1996.9838; ONATE SA, 1995, SCIENCE, V270, P1354; Palomino T, 1998, FASEB J, V12, P1201, DOI 10.1096/fasebj.12.12.1201; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Popperl H, 2000, MOL CELL, V6, P255, DOI 10.1016/S1097-2765(00)00027-7; RONCERO C, 1992, J BIOL CHEM, V267, P14918; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JE, 1997, GENOMICS, V43, P99, DOI 10.1006/geno.1997.4766; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Thurmond DC, 1998, J BIOL CHEM, V273, P1613, DOI 10.1074/jbc.273.3.1613; Toresson H, 2000, MECH DEVELOP, V94, P183, DOI 10.1016/S0925-4773(00)00324-5; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; Yeagley D, 2000, J BIOL CHEM, V275, P17814, DOI 10.1074/jbc.M909842199; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	65	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23838	23848		10.1074/jbc.M102166200	http://dx.doi.org/10.1074/jbc.M102166200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11331288	hybrid, Green Published			2022-12-27	WOS:000169531100083
J	Abe, M; Nishida, I; Minemura, M; Qadota, H; Seyama, Y; Watanabe, T; Ohya, Y				Abe, M; Nishida, I; Minemura, M; Qadota, H; Seyama, Y; Watanabe, T; Ohya, Y			Yeast 1,3-beta-glucan synthase activity is inhibited by phytosphingosine localized to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ELONGATION; SACCHAROMYCES-CEREVISIAE; 1,3-BETA-D-GLUCAN SYNTHASE; SECRETORY PATHWAY; MEMBRANE-PROTEIN; PLASMA-MEMBRANES; OUTER-MEMBRANE; GENE ENCODES; IN-VITRO; TRANSPORT	1,3-beta -D-Glucan, a major filamentous component of the cell wall in the budding yeast Saccharomyces cerevisiae, is synthesized by 1,3-beta -glucan synthase (GS), Although a yeast gene whose product is required for GS activity in vitro, GNS1, was isolated and characterized, its role in GS function has remained unknown. In the current study we show that Delta gns1 cells accumulate a non-competitive and non-proteinous inhibitor(s) in the membrane fraction. Investigations of inhibitory activity on GS revealed that the inhibitor(s) is mainly present in the sphingolipid fraction. It is shown that Delta gns1 cells contain phytosphingosine (PHS), an intermediate in the sphingolipid biosynthesis, 30-fold more than wild-type cells do. The membrane fraction isolated from Delta sur2 cells contains an increased amount of dihydrosphingosine (DRS) and also exhibits reduced GS activity. Among constituents of the sphingolipid fraction, PHS and DHS show striking inhibition in a non-competitive manner. The intracellular level of DHS is much lower than that of PHS in wild-type cells, suggesting that PHS is the primary inhibitor of GS in vivo. The localization of PHS to the endoplasmic reticulum in wild-type cells coincides with that of the inhibitor(s) in Delta gns1 cells. Taken together, our results indicate that PHS is a potent inhibitor of yeast GS in vivo.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Biol Sci, Grad Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Physiol Chem & Metab, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Nippon Roche Res Ctr, Dept Mycol, Kanagawa 2478530, Japan; Japan Sci & Technol Corp, Unit Proc & Combined Circuit, PRESTO, Osaka 5650082, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Roche Holding; Japan Science & Technology Agency (JST)	Ohya, Y (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bunkyo Ku, Tokyo 1130033, Japan.	ohya@k.u-tokyo.ac.jp	Nishida, Ikuo/W-8007-2019; Abe, Mitsuhiro/C-3602-2017; Nishida, Ikuo/E-3339-2010	Nishida, Ikuo/0000-0002-9669-4005				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BANDLOW W, 1972, BIOCHIM BIOPHYS ACTA, V282, P105, DOI 10.1016/0005-2736(72)90315-X; BASCO RD, 1994, BIOCHEM J, V304, P917, DOI 10.1042/bj3040917; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHU FK, 1983, ARCH BIOCHEM BIOPHYS, V223, P543, DOI 10.1016/0003-9861(83)90619-7; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; ESMON PC, 1987, J BIOL CHEM, V263, P8832; Gennis R, 1989, BIOMEMBRANES MOL STR, P199; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Grote E, 2000, MOL BIOL CELL, V11, P4051, DOI 10.1091/mbc.11.12.4051; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; HURT EC, 1988, EUR J CELL BIOL, V46, P554; Inoue SB, 1999, J BIOL CHEM, V274, P38119, DOI 10.1074/jbc.274.53.38119; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; Panaretou B, 1996, Methods Mol Biol, V53, P117; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; Robertson J, 1999, J VAC SCI TECHNOL B, V17, P659, DOI 10.1116/1.590613; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Sakumoto NM, 1999, YEAST, V15, P1669, DOI 10.1002/(SICI)1097-0061(199911)15:15<1669::AID-YEA480>3.0.CO;2-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO K, 1995, MOL BIOL CELL, V6, P1459, DOI 10.1091/mbc.6.11.1459; SCHATZ G, 1964, BIOCHIM BIOPHYS ACTA, V81, P448, DOI 10.1016/0926-6569(64)90130-0; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smits GJ, 1999, CURR OPIN MICROBIOL, V2, P348; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TAKITA Y, 1995, MOL GEN GENET, V246, P269, DOI 10.1007/BF00288599; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; Wolff AM, 1996, YEAST, V12, P823, DOI 10.1002/(SICI)1097-0061(199607)12:9<823::AID-YEA975>3.0.CO;2-J; YOSHIHISA T, 1988, J BIOL CHEM, V263, P5158	57	24	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26923	26930		10.1074/jbc.M102179200	http://dx.doi.org/10.1074/jbc.M102179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11337502	hybrid			2022-12-27	WOS:000169966900027
J	Benndorf, R; Sun, XK; Gilmont, RR; Biedermann, KJ; Molloy, MP; Goodmurphy, CW; Cheng, H; Andrews, PC; Welsh, MJ				Benndorf, R; Sun, XK; Gilmont, RR; Biedermann, KJ; Molloy, MP; Goodmurphy, CW; Cheng, H; Andrews, PC; Welsh, MJ			HSP22, a new member of the small heat shock protein superfamily, interacts with mimic of phosphorylated HSP27 ((3D)HSP27)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; SMALL STRESS PROTEIN; ACTIN POLYMERIZATION; INTRACELLULAR-LOCALIZATION; SERTOLI CELLS; IN-VIVO; KINASE; IDENTIFICATION; MUSCLE; RAT	Most of the members of the superfamily of mammalian small heat shock or stress proteins are abundant in muscles where they play a role in muscle function and maintenance of muscle integrity. One member of this protein superfamily, human HSP27, is rapidly phosphorylated on three serine residues (Ser(15), Ser(78), and Ser(82)) during cellular response to a number of extracellular factors. To understand better the role of HSP27, we performed a yeast two-hybrid screen of a human heart cDNA library for HSP27-interacting proteins. By using the triple aspartate mutant, a mimic of phosphorylated HSP27, as 'bait" construct, a protein with a molecular mass of 21.6 kDa was identified as an HSP27-binding protein. Sequence analysis revealed that this new protein shares an overall sequence identity of 33% with human HSP27. This protein also contains the alpha -crystallin domain in its C-terminal half, a hallmark of the superfamily of small stress proteins. Thus, the new protein itself is a member of this protein superfamily, and consequently we designated it HSP22. According to the two-hybrid data, HSP22 interacts preferentially with the triple aspartate form of HSP27 as compared with wild-type HSP27. HSP22 is expressed predominantly in muscles. In vitro, HSP22 is phosphorylated by protein kinase C (at residues Ser(14) and Thr(63)) and by p44 mitogen-activated protein kinase (at residues Ser(27) and Thr(87)) but not by MAPKAPK-2.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Plast & Reconstruct Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Benndorf, R (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, 1335 Catherine St, Ann Arbor, MI 48109 USA.	rbenndo@umich.edu	Goodmurphy, Craig/AAO-8264-2021; Welsh, Michael/B-1968-2008	Goodmurphy, Craig/0000-0002-7778-1998; Molloy, Mark/0000-0003-4679-5868; Andrews, Philip/0000-0001-6843-5420	NCI NIH HHS [R01CA77078-01] Funding Source: Medline; NHGRI NIH HHS [R01HG01709-01] Funding Source: Medline; NIEHS NIH HHS [ES06265] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077078] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006265] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Benndorf R, 2000, METH MOL B, V99, P431; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BITAR KN, 1991, BIOCHEM BIOPH RES CO, V181, P1192, DOI 10.1016/0006-291X(91)92065-R; Boelens WC, 1998, BBA-PROTEIN STRUCT M, V1388, P513, DOI 10.1016/S0167-4838(98)00215-5; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Davidson SM, 2000, DEV BIOL, V218, P146, DOI 10.1006/dbio.1999.9596; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Eaton P, 2000, J MOL CELL CARDIOL, V32, P961, DOI 10.1006/jmcc.2000.1136; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Golenhofen N, 1999, J MOL CELL CARDIOL, V31, P569, DOI 10.1006/jmcc.1998.0892; Hawkins J, 2000, ARCH BIOCHEM BIOPHYS, V382, P310, DOI 10.1006/abbi.2000.2005; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; Jansen G, 1996, NAT GENET, V13, P316, DOI 10.1038/ng0796-316; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1994, J BIOL CHEM, V269, P15302; KATO K, 1992, J BIOL CHEM, V267, P7718; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Krief S, 1999, J BIOL CHEM, V274, P36592, DOI 10.1074/jbc.274.51.36592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Liu CH, 2000, J BIOL CHEM, V275, P18724, DOI 10.1074/jbc.M001981200; Liu CH, 1999, BIOCHEM BIOPH RES CO, V255, P256, DOI 10.1006/bbrc.1999.0174; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P121, DOI 10.1007/BF00221053; Lutsch G, 1997, CIRCULATION, V96, P3466; Martin JL, 1997, CIRCULATION, V96, P4343; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; PITTENGER GL, 1992, ENDOCRINOLOGY, V130, P3207, DOI 10.1210/en.130.6.3207; Preville X, 1998, J CELL BIOCHEM, V69, P436, DOI 10.1002/(SICI)1097-4644(19980615)69:4<436::AID-JCB5>3.0.CO;2-O; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Sakamoto K, 2000, BIOCHEM BIOPH RES CO, V269, P137, DOI 10.1006/bbrc.2000.2233; Schafer C, 1999, AM J PHYSIOL-CELL PH, V277, pC1032; Schneider GB, 1998, J CELL PHYSIOL, V177, P575, DOI 10.1002/(SICI)1097-4652(199812)177:4<575::AID-JCP8>3.0.CO;2-1; Smith CC, 2000, J BIOL CHEM, V275, P25690, DOI 10.1074/jbc.M002140200; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; VOORTER CEM, 1989, FEBS LETT, V259, P50; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x; Wieske M, 2001, EUR J BIOCHEM, V268, P2083, DOI 10.1046/j.1432-1327.2001.02082.x; Yamboliev IA, 2000, AM J PHYSIOL-HEART C, V278, pH1899, DOI 10.1152/ajpheart.2000.278.6.H1899; Yoshida K, 1999, CELL STRUCT FUNCT, V24, P181, DOI 10.1247/csf.24.181; Zavialov A, 1998, INT J BIOL MACROMOL, V22, P163, DOI 10.1016/S0141-8130(98)00014-2; ZHU Y, 1994, J BIOL CHEM, V269, P22379	63	96	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26753	26761		10.1074/jbc.M103001200	http://dx.doi.org/10.1074/jbc.M103001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342557	hybrid			2022-12-27	WOS:000169966900005
J	Butscher, WG; Haggerty, CM; Chaudhry, S; Gardner, K				Butscher, WG; Haggerty, CM; Chaudhry, S; Gardner, K			Targeting of p300 to the interleukin-2 promoter via CREB-Rel cross-talk during mitogen and oncogenic molecular signaling in activated T-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITOUS TRANSCRIPTION FACTORS; CYTOKINE GENE-EXPRESSION; DNA-BINDING ACTIVITY; LEUKEMIA-VIRUS; I TAX; COACTIVATOR CBP; IL-2 GENE; PROTEIN; RECEPTOR	In this report, we explore the mechanisms of targeting of p300 to the interleukin-2 (IL-2) promoter in response to mitogenic and oncogenic molecular signals. Recruitment of p300 by cAMP-responsive element-binding protein-Rel cross-talk at the composite CD28 response element (CD28RE)-TRE element of the IL-2 promoter is essential for promoter inducibility during T-cell activation, and CD28RE-TRE is the exclusive target of the human T-cell lymphotropic virus type I oncoprotein Tax. The intrinsic histone acetyltransferase activity of p300 is dispensable for activation of the IL-2 promoter, and the N-terminal 743 residues contain the minimal structural requirements for synergistic transactivation of the CD28RE-TRE, the IL-2 promoter, and endogenous IL-2 gene expression. Mutational analysis of p300 reveals differential structural requirements for the N-terminal p300 module by individual cis-elements within the IL-2 promoter. These findings provide evidence that p300 assembles at the IL-2 promoter to form an enhanceosome-like signal transduction target that is centrally integrated at the CD28RE-TRE element of the IL-2 promoter through specific protein module-targeted associations in activated T-cells.	NCI, Ctr Adv Technol, Pathol Lab, NIH, Bethesda, MD 20892 USA; Howard Univ, Coll Med, Dept Microbiol, Washington, DC 20059 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard University	Gardner, K (corresponding author), NCI, Ctr Adv Technol, Pathol Lab, NIH, Rm 134C,8717 Grovemont Circle, Bethesda, MD 20892 USA.			Haggerty, Cynthia/0000-0002-6019-2724				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; AVOTS A, 1995, IMMUNOBIOLOGY, V193, P254, DOI 10.1016/S0171-2985(11)80551-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Eckner R, 1996, BIOL CHEM, V377, P685; GARDNER K, 1994, J BIOL CHEM, V269, P32963; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Glass CK, 2000, GENE DEV, V14, P121; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HENTSCH B, 1992, NUCLEIC ACIDS RES, V20, P2657, DOI 10.1093/nar/20.11.2657; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KANNO T, 1995, J BIOL CHEM, V270, P11745, DOI 10.1074/jbc.270.20.11745; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; MANGER B, 1987, J IMMUNOL, V139, P2755; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MUNOZ E, 1995, IMMUNOBIOLOGY, V193, P128, DOI 10.1016/S0171-2985(11)80535-8; PETRAK D, 1994, J IMMUNOL, V153, P2046; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RISSE G, 1990, ENVIRON HEALTH PERSP, V88, P133; Semmes OJ, 1996, J BIOL CHEM, V271, P9730, DOI 10.1074/jbc.271.16.9730; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Van Orden K, 1999, ONCOGENE, V18, P3766, DOI 10.1038/sj.onc.1202703; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; Yasui H, 1997, J BIOL CHEM, V272, P28762, DOI 10.1074/jbc.272.45.28762; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	49	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27647	27656		10.1074/jbc.M009614200	http://dx.doi.org/10.1074/jbc.M009614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313336	hybrid			2022-12-27	WOS:000169966900120
J	Gwizdek, C; Bertrand, E; Dargemont, C; Lefebvre, JC; Blanchard, JM; Singer, RH; Doglio, A				Gwizdek, C; Bertrand, E; Dargemont, C; Lefebvre, JC; Blanchard, JM; Singer, RH; Doglio, A			Terminal minihelix, a novel RNA motif that directs polymerase III transcripts to the cell cytoplasm - Terminal minihelix and RNA export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-ASSOCIATED RNA; ADENOVIRUS VA RNA1; PRE-MESSENGER-RNA; NUCLEAR EXPORT; NUCLEOCYTOPLASMIC TRANSPORT; SACCHAROMYCES-CEREVISIAE; RO RIBONUCLEOPROTEINS; XENOPUS-LAEVIS; PROTEINS; LOCALIZATION	Determining the cia-acting elements controlling nuclear export of RNA is critical, because they specify which RNA will be selected for transport. We have characterized the nuclear export motif of the adenoviral VA1 RNA a small cytoplasmic RNA transcribed by RNA polymerase III. Using a large panel of VA1 mutants in both transfected COS cells and injected Xenopus oocytes, we showed that the terminal stem of VA1 is necessary and sufficient for its export. Surprisingly, we found that the nucleotide sequence within the terminal stem is not important. Rather, the salient features of this motif are its length and its relative position within the RNA. Such stems thus define a novel and degenerate cytoplasmic localization motif that we termed the minihelix, This motif is found in a variety of polymerase III transcripts, and cross-competition analysis in Xenopus oocytes revealed that export of one such RNA, like hY1 RNA, is specifically competed by VA1 or artificial minihelix, Taken together these results show that the minihelix defines a new cia-acting export element and that this motif could be exported via a novel and specific nuclear export pathway.	Fac Med Nice, Virol Lab U526, F-06107 Nice 2, France; Inst Genet Mol Montpellier, F-34293 Montpellier, France; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA; Inst Jacques Monod, Lab Transport Nucleocytoplasm, F-75251 Paris 5, France	UDICE-French Research Universities; Universite Cote d'Azur; Universite de Montpellier; Yeshiva University; Albert Einstein College of Medicine; UDICE-French Research Universities; Universite Paris Cite	Doglio, A (corresponding author), Fac Med Nice, Virol Lab U526, Ave Valombrose, F-06107 Nice 2, France.		DOGLIO, Alain/ABF-2581-2020	bertrand, edouard/0000-0002-9642-7994; DOGLIO, Alain/0000-0002-5456-5598	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057071] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57071, GM54887] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; Barcellini-Couget S, 1998, ANTISENSE NUCLEIC A, V8, P379, DOI 10.1089/oli.1.1998.8.379; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; Bertrand E, 1997, RNA, V3, P75; BHAT RA, 1983, MOL CELL BIOL, V3, P1996, DOI 10.1128/MCB.3.11.1996; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; CAGNON L, 1995, J ACQ IMMUN DEF SYND, V9, P349; Chen XG, 2000, GENE DEV, V14, P777; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Grosshans H, 2000, J STRUCT BIOL, V129, P288, DOI 10.1006/jsbi.2000.4226; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMM J, 1989, EMBO J, V8, P4179, DOI 10.1002/j.1460-2075.1989.tb08603.x; HAMM J, 1990, METHOD ENZYMOL, V181, P273; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; HOWE JG, 1988, J VIROL, V62, P2790, DOI 10.1128/JVI.62.8.2790-2798.1988; Izaurralde E, 1998, RNA, V4, P351; IZAURRALDE E, 1997, EMBO J, V16; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KHANNAGUPTA A, 1989, P NATL ACAD SCI USA, V86, P1791, DOI 10.1073/pnas.86.6.1791; Kim J, 1996, BIOCHEMISTRY-US, V35, P13753, DOI 10.1021/bi960913z; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; Lipowsky G, 1999, RNA, V5, P539, DOI 10.1017/S1355838299982134; Ma YL, 1996, J VIROL, V70, P5083, DOI 10.1128/JVI.70.8.5083-5099.1996; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATTAJ IW, 1998, CURR BIOL, V67, P265; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MELLITS KH, 1988, EMBO J, V7, P2849, DOI 10.1002/j.1460-2075.1988.tb03141.x; MELLITS KH, 1992, J VIROL, V66, P2369, DOI 10.1128/JVI.66.4.2369-2377.1992; MELLITS KH, 1990, CELL, V61, P843, DOI 10.1016/0092-8674(90)90194-J; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; OBRIEN CA, 1993, P NATL ACAD SCI USA, V90, P7250, DOI 10.1073/pnas.90.15.7250; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PEERY T, 1993, J VIROL, V67, P3534, DOI 10.1128/JVI.67.6.3534-3543.1993; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROE BA, 1975, BIOCHEM BIOPH RES CO, V66, P1097, DOI 10.1016/0006-291X(75)90470-2; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Sarkar S, 1998, MOL BIOL CELL, V9, P3041, DOI 10.1091/mbc.9.11.3041; SCHMIDTZACHMANN MS, 1993, CELL, V74, P493, DOI 10.1016/0092-8674(93)80051-F; SCHWEMMLE M, 1992, P NATL ACAD SCI USA, V89, P10292, DOI 10.1073/pnas.89.21.10292; Simons FHM, 1996, RNA, V2, P264; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Terns MP, 1998, METHOD CELL BIOL, V53, P559; VANGELDER CWG, 1994, NUCLEIC ACIDS RES, V22, P2498, DOI 10.1093/nar/22.13.2498; VANHORN DJ, 1995, RNA, V1, P293; WICKENS MP, 1983, J MOL BIOL, V163, P1, DOI 10.1016/0022-2836(83)90027-X; ZACHARIAS M, 1995, J MOL BIOL, V247, P486, DOI 10.1006/jmbi.1995.0155; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; Zuker M, 1998, RNA, V4, P669, DOI 10.1017/S1355838298980116	54	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25910	25918		10.1074/jbc.M100493200	http://dx.doi.org/10.1074/jbc.M100493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11342536	hybrid, Green Published			2022-12-27	WOS:000169823300038
J	Oelmann, S; Stanley, P; Gerardy-Schahn, R				Oelmann, S; Stanley, P; Gerardy-Schahn, R			Point mutations identified in Lec8 Chinese hamster ovary glycosylation mutants that inactivate both the UDP-galactose and CMP-sialic acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-MANNOSE TRANSPORTER; NUCLEOTIDE SUGAR TRANSPORTERS; CELL-ADHESION MOLECULE; EXPRESSION CLONING; GOLGI; DEFICIENT; BIOSYNTHESIS; PROTEIN; TRANSLOCATION; PURIFICATION	Nucleotide-sugar transporters (NSTs) are critical components of glycosylation pathways in eukaryotes, The identification of structural elements that are involved in NST functions provides an important task. Chinese hamster ovary glycosylation mutants defective in nucleotide-sugar transport provide access to inactive transporters that can define such structure/function relationships. In this study, we have cloned the hamster UDP-galactose transporter (UGT) and identified defects in UGT gene transcripts from nine independent Chinese hamster ovary mutants that belong to the Lec8 complementation group. Reverse transcription polymerase chain reaction with primers that span the UGT open reading frame showed that three Lec8 mutants express a full-length open reading frame, while six Lec8 mutants predominantly express truncated UGT gene transcripts. Sequencing identified different single or triplet nucleotide changes in full-length UGT transcripts from three of the mutants. These mutations translate into three different amino acid changes at positions that are highly conserved in all the known mammalian NSTs. Transfection of a cDNA encoding either of the mutations Delta serine 213 or G281D failed to correct the UDP-galactose transport defect in Lec8 transfectants. Most importantly, introducing these same mutations into the homologous region of the murine CMP-sialic acid transporter caused inactivation of this transporter. Thus, identifying point mutations that inactivate UGT in Lec8 mutants resulted in the discovery of amino acids that are critical to the activity of both UGT and CST, the two most divergent mammalian NSTs.	Hannover Med Sch, Inst Physiol Chem, D-30625 Hannover, Germany; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Hannover Medical School; Yeshiva University; Albert Einstein College of Medicine	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Physiol Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy-schahn.rita@mh-hannover.de		Stanley, Pamela/0000-0001-5704-3747	NATIONAL CANCER INSTITUTE [R01CA036434] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 36434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe M, 1999, FEBS LETT, V458, P309, DOI 10.1016/S0014-5793(99)01177-1; Aoki K, 1999, J BIOCHEM, V126, P940, DOI 10.1093/oxfordjournals.jbchem.a022538; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; Cacan R, 1998, BIOCHIMIE, V80, P59, DOI 10.1016/S0300-9084(98)80057-6; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Gao XD, 2001, J BIOL CHEM, V276, P4424, DOI 10.1074/jbc.M009114200; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; GERARDYSCHAHN R, 1994, INT J CANCER, P38; GERARDYSCHAHN R, 2000, OLIGOSACCHARIDES CHE, V2, P19; HARA T, 1989, J BIOCHEM-TOKYO, V106, P236, DOI 10.1093/oxfordjournals.jbchem.a122838; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 1999, J BIOCHEM, V126, P1107, DOI 10.1093/oxfordjournals.jbchem.a022556; Kawakita M, 1998, J BIOCHEM, V123, P777; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; PELS RW, 1995, BIOCHEM J, V305, P865; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; Puglielli L, 1999, J BIOL CHEM, V274, P4474, DOI 10.1074/jbc.274.7.4474; ROTH J, 1997, GOLGI APPARATUS, P131; Segawa H, 1999, FEBS LETT, V451, P295, DOI 10.1016/S0014-5793(99)00596-7; STANLEY P, 1991, Glycobiology, V1, P307, DOI 10.1093/glycob/1.3.307; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; Takegawa K, 1996, BIOSCI BIOTECH BIOCH, V60, P1156; Toma L, 1996, J BIOL CHEM, V271, P3897; Yoshioka S, 1997, J BIOCHEM, V122, P691	49	76	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26291	26300		10.1074/jbc.M011124200	http://dx.doi.org/10.1074/jbc.M011124200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11319223	hybrid			2022-12-27	WOS:000169823300087
J	Vaughan, PS; Leszyk, JD; Vaughan, KT				Vaughan, PS; Leszyk, JD; Vaughan, KT			Cytoplasmic dynein intermediate chain phosphorylation regulates binding to dynactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN; TRANSPORT; COMPLEX; SUBUNIT; IDENTIFICATION; MICROTUBULES; PROTEINS; LOCALIZATION; HOMOLOGY; SPECTRIN	Previously, we identified dynactin as a cargo receptor or adaptor for cytoplasmic dynein, mediated by an interaction between the dynein intermediate chain and p150(Glued), To test phosphorylation as a potential regulatory mechanism for this interaction, we analyzed cytoplasmic dynein by two-dimensional gel analysis and detected two intermediate chain variants, one of which was eliminated by phosphatase treatment. Overlay assays demonstrated that p150(Glued) bound dephosphorylated but not phosphorylated intermediate chains, We then subjected the purified cytoplasmic dynein intermediate chain to mass spectrometry and identified a single phosphorylated tryptic fragment corresponding to the p150(Glued)-binding domain. Fragmentation and retention time analysis mapped the phosphorylation site to serine 84. Site-directed mutants designed to mimic the dephosphorylated or phosphorylated intermediate chain disrupted both in vitro phosphorylation and in vivo phosphorylation of transfected proteins. Mutants mimicking the dephosphorylated form bound p150Glued in vitro and overexpression perturbed transport of dynein-dependent membranes. Mutants mimicking the phosphorylated form displayed diminished p150(Glued) binding in vitro and did not disrupt dynein-mediated transport when expressed in vivo. These findings represent the first mapping of an intermediate chain phosphorylation site and suggest that this phosphorylation plays an important role in regulating the binding of cytoplasmic dynein to dynactin.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Massachusetts, Sch Med, Dept Biochem, Worcester, MA 01605 USA	University of Notre Dame; University of Massachusetts System; University of Massachusetts Worcester	Vaughan, KT (corresponding author), Univ Notre Dame, Dept Biol Sci, POB 369, Notre Dame, IN 46556 USA.	vaughan.4@nd.edu						ALLAN V, 1995, J CELL BIOL, V128, P879, DOI 10.1083/jcb.128.5.879; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Annan RS, 2001, ANAL CHEM, V73, P393, DOI 10.1021/ac001130t; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Bowman AB, 1999, J CELL BIOL, V146, P165; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; CARTER AN, 1997, CURRENT PROTOCOLS MO; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; Dell KR, 2000, TRAFFIC, V1, P38, DOI 10.1034/j.1600-0854.2000.010107.x; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; Huang CYF, 1999, J BIOL CHEM, V274, P14262, DOI 10.1074/jbc.274.20.14262; HUGHES SM, 1995, J CELL SCI, V108, P17; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kumar S, 2000, J BIOL CHEM, V275, P31798, DOI 10.1074/jbc.M000449200; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1992, J CELL SCI, V101, P125; Lo KWH, 2001, J BIOL CHEM, V276, P14059, DOI 10.1074/jbc.M010320200; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; PASCHAL BM, 1992, J CELL BIOL, V118, P1133, DOI 10.1083/jcb.118.5.1133; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Reese EL, 2000, J CELL BIOL, V151, P155, DOI 10.1083/jcb.151.1.155; Reilein AR, 1998, J CELL BIOL, V142, P803, DOI 10.1083/jcb.142.3.803; Rogers SL, 1997, P NATL ACAD SCI USA, V94, P3720, DOI 10.1073/pnas.94.8.3720; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; Steffen W, 1996, J STRUCT BIOL, V117, P227, DOI 10.1006/jsbi.1996.0087; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; Tynan SH, 2000, J BIOL CHEM, V275, P32769, DOI 10.1074/jbc.M001537200; Tynan SH, 2000, J BIOL CHEM, V275, P32763, DOI 10.1074/jbc.M001536200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; WILKERSON CG, 1995, J CELL BIOL, V129, P169, DOI 10.1083/jcb.129.1.169; Yano H, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0003.2001; Young A, 2000, MOL BIOL CELL, V11, P2047, DOI 10.1091/mbc.11.6.2047	50	102	106	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26171	26179		10.1074/jbc.M102649200	http://dx.doi.org/10.1074/jbc.M102649200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340075	hybrid			2022-12-27	WOS:000169823300072
J	Berry, FB; Miura, Y; Mihara, K; Kaspar, P; Sakata, N; Hashimoto-Tamaoki, T; Tamaoki, T				Berry, FB; Miura, Y; Mihara, K; Kaspar, P; Sakata, N; Hashimoto-Tamaoki, T; Tamaoki, T			Positive and negative regulation of myogenic differentiation of C2C12 cells by isoforms of the multiple homeodomain zinc finger transcription factor ATBF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; ENHANCER-BINDING PROTEIN; LOOP-HELIX PROTEINS; MUSCLE DIFFERENTIATION; GENE-EXPRESSION; DNA-BINDING; NEURONAL DIFFERENTIATION; DROSOPHILA ZFH-1; SKELETAL-MUSCLE; MRF4 PROMOTER	The ATBF1 gene encodes two protein isoforms, the 404-kDa ATBF1-A, possessing four homeodomains and 23 zinc fingers, and the 306-kDa ATBF1-B, lacking a 920-amino acid N-terminal region of ATBF1-A which contains 5 zinc fingers. ln vitro, ATBF1-A was expressed in proliferating C2C12 myoblasts, but its expression levels decreased upon induction of myogenic differentiation in low serum medium. Forced expression of ATBF1-A in C2C12 cells resulted in repression of MyoD and myogenin expression and elevation of Id3 and cyclin D1 expression, leading to inhibition of myogenic differentiation in low serum. In contrast, transfection of C2C12 cells with the ATBF1-B isoform led to an acceleration of myogenic differentiation, as indicated by an earlier onset of myosin heavy chain expression and formation of a higher percentage of multinucleated myotubes. The fourth homeodomain of ATBF1-A bound to an AT-rich element adjacent to the El E-box of the muscle regulatory factor 4 promoter mediating transcriptional repression. The ATBF1-A-specific N-terminal region possesses general transcription repressor activity. These results suggest that ATBF1-A plays a role in the maintenance of the undifferentiated myoblast state, and its down-regulation is a prerequisite to initiate terminal differentiation of C2C12 cells.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Nagoya City Univ, Fac Med, Dept Bioregulat Res, Nagoya, Aichi 4678601, Japan; Showa Pharmaceut Univ, Dept Biochem, Tokyo 1948543, Japan; Hyogo Coll Med, Dept Genet, Nishinomiya, Hyogo 6638501, Japan	University of Calgary; Nagoya City University; Showa Pharmaceutical University; Hyogo College of Medicine	Berry, FB (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.		Kaspar, Petr/G-5864-2014; Sakata, Nobuo/L-9753-2015; Kaspar, Petr/J-1705-2014	Sakata, Nobuo/0000-0001-9967-8409; 				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen JCJ, 1999, CELL TISSUE RES, V296, P213, DOI 10.1007/s004410051282; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HASHIMOTO T, 1992, MECH DEVELOP, V39, P125, DOI 10.1016/0925-4773(92)90031-E; IDO A, 1994, DEV BIOL, V163, P184, DOI 10.1006/dbio.1994.1134; IKEDA K, 1995, EUR J BIOCHEM, V233, P73, DOI 10.1111/j.1432-1033.1995.073_1.x; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; Kataoka H, 2000, BIOCHEM BIOPH RES CO, V267, P91, DOI 10.1006/bbrc.1999.1911; KOSTICH WA, 1995, DEV DYNAM, V202, P145, DOI 10.1002/aja.1002020206; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lemercier C, 1997, DEV BIOL, V182, P101, DOI 10.1006/dbio.1996.8454; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; LUNDELL MJ, 1992, DEV BIOL, V154, P84, DOI 10.1016/0012-1606(92)90050-Q; MADDEN SL, 1993, ONCOGENE, V8, P1713; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P515, DOI 10.1007/BF02255842; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; Olson EN, 1998, DEV BIOL, V202, P153, DOI 10.1006/dbio.1998.9020; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; Postigo AA, 1999, MOL CELL BIOL, V19, P7255; Postigo AA, 1997, EMBO J, V16, P3935, DOI 10.1093/emboj/16.13.3935; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Tsai RYL, 1998, MOL CELL BIOL, V18, P6447, DOI 10.1128/MCB.18.11.6447; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walsh K, 1997, Prog Cell Cycle Res, V3, P53; Watanabe M, 1996, MOL BRAIN RES, V42, P344, DOI 10.1016/S0169-328X(96)00204-5; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; YASUDA H, 1994, MOL CELL BIOL, V14, P1395, DOI 10.1128/MCB.14.2.1395; Yoshida S, 1996, J CELL BIOL, V132, P181, DOI 10.1083/jcb.132.1.181; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	64	61	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25057	25065		10.1074/jbc.M010378200	http://dx.doi.org/10.1074/jbc.M010378200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312261	hybrid			2022-12-27	WOS:000169800700084
J	Choi, KS; Fitzpatrick, SL; Filipenko, NR; Fogg, DK; Kassam, G; Magliocco, AM; Waisman, DM				Choi, KS; Fitzpatrick, SL; Filipenko, NR; Fogg, DK; Kassam, G; Magliocco, AM; Waisman, DM			Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RECEPTOR; EXTRACELLULAR-MATRIX; T-PA; TETRAMER; ACTIVATOR; BINDING; SYSTEM; SURFACE; ENHANCEMENT; MECHANISMS	In a previous report we showed that plasmin-dependent lysis of a fibrin polymer, produced from purified components, was totally blocked if annexin II heterotetramer (AIIt) was present during fibrin polymer formation. Here, we show that AIIt inhibits fibrin clot lysis by stimulation of plasmin autodegradation, which results in a loss of plasmin activity. Furthermore, the C-terminal lysine residues of its pll subunit play an essential role in the inhibition of fibrin clot lysis by AIIt, We also found that AIIt binds to fibrin with a K-d of 436 nM and a stoichiometry of about 0.28 mol of AIIt/mol of fibrin monomer. The binding of AIIt to fibrin was not dependent on the C-terminal lysines of the p11 subunit, Furthermore, in the presence of plasminogen, the binding of AIIt to fibrin was increased to about 1.3 mol of AIIt/mol of fibrin monomer, suggesting that AIIt and plasminogen do not compete for identical sites on fibrin. Immunohistochemical identification of p36 and p11 subunits of AIIt in a pathological clot provides important evidence for its role as a physiological fibrinolytic regulator. These results suggest that AIIt may play a key role in the regulation of plasmin activity on the fibrin clot surface.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pathol, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@acs.ucalgary.ca	Magliocco, Anthony M/E-5723-2010	Waisman, David/0000-0002-5097-9662				Borza DB, 1997, J BIOL CHEM, V272, P5718, DOI 10.1074/jbc.272.9.5718; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; Choi KS, 1998, BIOCHEMISTRY-US, V37, P648, DOI 10.1021/bi971005k; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; DRAPIER JC, 1979, BIOCHIMIE, V61, P463, DOI 10.1016/S0300-9084(79)80202-3; Filipenko NR, 2001, J BIOL CHEM, V276, P3718; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Hajjar K A, 1995, Curr Opin Hematol, V2, P345; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1997, ANN NY ACAD SCI, V811, P337, DOI 10.1111/j.1749-6632.1997.tb52013.x; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; HUSAIN SS, 1991, ARCH BIOCHEM BIOPHYS, V285, P373, DOI 10.1016/0003-9861(91)90375-S; JESPERSEN J, 1986, THROMB RES, V41, P395, DOI 10.1016/0049-3848(86)90250-1; JOST M, 1994, BIOCHEM J, V298, P553, DOI 10.1042/bj2980553; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1997, J BIOL CHEM, V272, P15093, DOI 10.1074/jbc.272.24.15093; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P387; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MAGNUSSON S, 1996, PROTEOLYSIS PHYSIOLO, P203; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MOSER TL, 1993, J BIOL CHEM, V268, P18917; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; MUSIAL J, 1986, PROSTAGLANDINS, V31, P61, DOI 10.1016/0090-6980(86)90225-X; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Olman MA, 1999, BLOOD, V94, P2029, DOI 10.1182/blood.V94.6.2029.418k25_2029_2038; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; STUMP DC, 1988, ANN EMERG MED, V17, P1138, DOI 10.1016/S0196-0644(88)80059-3; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; SUENSON E, 1990, J BIOL CHEM, V265, P22228; TAKADA A, 1988, Haemostasis, V18, P25; TRACY PB, 1988, SEMIN THROMB HEMOST, V14, P227, DOI 10.1055/s-2007-1002782; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	47	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25212	25221		10.1074/jbc.M101426200	http://dx.doi.org/10.1074/jbc.M101426200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319229	hybrid			2022-12-27	WOS:000169800700105
J	Lively, TN; Ferguson, HA; Galasinski, SK; Seto, AC; Goodrich, JK				Lively, TN; Ferguson, HA; Galasinski, SK; Seto, AC; Goodrich, JK			c-Jun binds the N terminus of human TAF(II)250 to derepress RNA polymerase II transcription in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BOX-BINDING; DNA-BINDING; MEDIATED TRANSCRIPTION; PROMOTER SELECTIVITY; ACTIVATION DOMAIN; LACKING TAF(II)S; COMPLEX; PROTEIN; TFIIA; YEAST	c-Jun is an oncoprotein that activates transcription of many genes involved in cell growth and proliferation. We studied the mechanism of transcriptional activation by human c-Jun in a human RNA polymerase II transcription system composed of highly purified recombinant and native transcription factors. Transcriptional activation by c-Jun depends on the TATA-binding protein (TBP)-associated factor (TAF) subunits of transcription factor IID (TFIID), Protein-protein interaction assays revealed that c-Jun binds with high specificity to the largest subunit of human TFIID, TAF(II)250, The region of TAF(II)250 bound by c-Jun lies in the N-terminal 163 amino acids. This same region of TAF(II)250 binds to TBP and represses its interaction with TATA boxes, thereby decreasing DNA binding by TFIID. We hypothesized that c-Jun is capable of derepressing the effect of the TAF(II)250 N terminus on TFIID-driven transcription. In support of this hypothesis, we found that c-Jun increased levels of TFIID-driven transcription in vitro when added at high concentrations to a DNA template lacking activator protein 1 (AP-1) sites. Moreover, c-Jun blocked the repression of TBP DNA binding caused by the N terminus of TAF(II)250. In addition to revealing a mechanism by which c-Jun activates transcription, our studies provide the first evidence that an activator can bind directly to the N terminus of TAF(II)250 to derepress RNA polymerase II transcription in vitro.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Goodrich, JK (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135, R01GM055235] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55235, T32 GM07135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CAREY MF, 1995, CURR BIOL, V5, P1003, DOI 10.1016/S0960-9822(95)00201-6; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Galasinski SK, 2000, MOL CELL BIOL, V20, P1923, DOI 10.1128/MCB.20.6.1923-1930.2000; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kotani T, 1998, J BIOL CHEM, V273, P32254, DOI 10.1074/jbc.273.48.32254; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478	46	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25582	25588		10.1074/jbc.M100278200	http://dx.doi.org/10.1074/jbc.M100278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316804	hybrid			2022-12-27	WOS:000169800700149
J	Wolf, I; Rubinfeld, H; Yoon, S; Marmor, G; Hanoch, T; Seger, R				Wolf, I; Rubinfeld, H; Yoon, S; Marmor, G; Hanoch, T; Seger, R			RETRACTED: Involvement of the activation loop of ERK in the detachment from cytosolic anchoring (Retracted article. See vol. 292, pg. 8853, 2017)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							NUCLEAR EXPORT SIGNAL; PROTEIN MAP KINASE; GROWTH-FACTOR; NUCLEOCYTOPLASMIC TRANSPORT; ACTIVE-TRANSPORT; TRANSLOCATION; CASCADE; PHOSPHORYLATION; IDENTIFICATION; LOCALIZATION	The Extracellular signal-regulated kinases (ERKs) are translocated into the nucleus in response to mitogenic stimulation. The mechanism of translocation and the residues in ERKs that govern this process are not clear as yet. Here we studied the involvement of residues in the activation loop of ERK2 in determining its subcellular localization. Substitution of residues in the activation loop to alanines indicated that residues 173-181 do not play a significant role in the phosphorylation and activation of ERK2. However, residues 176-181 are responsible for the detachment of ERK2 from MEK1 upon mitogenic stimulation. This dissociation can be mimicked by substitution of residues 176-178 to alanines and is prevented by deletion of these residues or by substitution of residues 179-181 to alanines. On the other hand, residues 176-181, as well as residues essential for ERK2 dimerization, do not play a role in the shuttle of ERK2 through nuclear pores. Thus, phosphorylation-induced conformational rearrangement of residues in the activation loop of ERK2 plays a major role in the control of subcellular localization of this protein.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Seger, R (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	rony.seger@weizmann.ac.il						Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Ferrell JE, 1998, TRENDS BIOCHEM SCI, V23, P461, DOI 10.1016/S0968-0004(98)01316-4; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0	34	74	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24490	24497		10.1074/jbc.M103352200	http://dx.doi.org/10.1074/jbc.M103352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11328824	hybrid, Green Published			2022-12-27	WOS:000169800700011
J	Pincas, H; Laverriere, JN; Counis, R				Pincas, H; Laverriere, JN; Counis, R			Pituitary adenylate cyclase-activating polypeptide and cyclic adenosine 3 ',5 '-monophosphate stimulate the promoter activity of the rat gonadotropin-releasing hormone receptor gene via a bipartite response element in gonadotrope-derived cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; SIGNAL-TRANSDUCTION PATHWAYS; MESSENGER RIBONUCLEIC-ACIDS; PROTEIN-KINASE-C; TRANSCRIPTIONAL ACTIVATION; 5'-FLANKING REGION; ALPHA-T3-1 CELLS; RNA LEVELS; EXPRESSION; GNRH	Specific type I receptors for pituitary adenylate cyclase-activating polypeptide (PACAP) are present in gonadotrope cells of the anterior pituitary gland. By transient transfection of mouse gonadotrope-derived alpha T3-1 cells, which are direct targets for PACAP and express gonadotropin-releasing hormone receptor (GnRH-R), a marker of the gonadotrope lineage, we provide the first evidence that PACAP stimulates rat GnRH-R gene promoter activity. The EC50 of this stimulation is compatible with a mediation via activation of the cyclic AMP-dependent signaling pathway and, consistently, co-transfection of an expression vector expressing the protein kinase A inhibitor causes reduction in PACAP as well as cholera toxin-stimulated promoter activity. Deletion and mutational analyses indicate that PACAP activation necessitates a bipartite response element that consists of a first region (-272/-237) termed PACAP response element (PARE) I that includes a steroidogenic factor-1 (SF-1)-binding site and a second region (-136/-101) referred to as PARE II that contains an imperfect cyclic AMP response element. Gel shift experiments indicate the specific binding of the SF-1 and a potential SF-1-interacting factor to PARE I while a protein inununologically related to the cyclic AMP response element-binding protein interacts with PARE II. These findings suggest that PACAP might regulate the GnRH-R gene at the transcriptional level, providing novel insights into the regulation of pituitary-specific genes by hypothalamic hypophysiotropic signals.	Univ Paris 06, CNRS, ESA 7080, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Counis, R (corresponding author), Univ Paris 06, CNRS, ESA 7080, Case 244, F-75252 Paris 05, France.	Raymond.Counis@snv.jussieu.fr	Laverriere, Jean-Noel/L-3286-2017	Laverriere, Jean-Noel/0000-0003-0442-1358				Alarid ET, 1996, DEVELOPMENT, V122, P3319; ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attardi B, 1998, MOL CELL ENDOCRINOL, V137, P97, DOI 10.1016/S0303-7207(98)00006-9; BAUERDANTOIN AC, 1993, ENDOCRINOLOGY, V133, P1911, DOI 10.1210/en.133.4.1911; Burrin JM, 1998, ENDOCRINOLOGY, V139, P1731, DOI 10.1210/en.139.4.1731; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Cheng KW, 2000, ENDOCRINOLOGY, V141, P3611, DOI 10.1210/en.141.10.3611; CLAY CM, 1995, ENDOCRINE, V3, P615, DOI 10.1007/BF02953028; Crawford PA, 1997, MOL ENDOCRINOL, V11, P1626, DOI 10.1210/me.11.11.1626; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; Duval DL, 1999, ENDOCRINOLOGY, V140, P1949, DOI 10.1210/en.140.4.1949; Duval DL, 1997, MOL ENDOCRINOL, V11, P1814, DOI 10.1210/me.11.12.1814; FAN NC, 1995, MOL CELL ENDOCRINOL, V107, pR1, DOI 10.1016/0303-7207(94)03460-B; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HART GR, 1992, J ENDOCRINOL, V134, P33, DOI 10.1677/joe.0.1340033; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; ISHIZAKA K, 1993, ENDOCRINOLOGY, V133, P2040, DOI 10.1210/en.133.5.2040; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Ito M, 1998, MOL ENDOCRINOL, V12, P290, DOI 10.1210/me.12.2.290; KAISER UB, 1993, ENDOCRINOLOGY, V133, P931, DOI 10.1210/en.133.2.931; LERRANT Y, 1995, ENDOCRINOLOGY, V136, P2803, DOI 10.1210/en.136.7.2803; Lin XW, 1998, ENDOCRINOLOGY, V139, P3896, DOI 10.1210/en.139.9.3896; Lin XW, 1999, ENDOCRINOLOGY, V140, P358, DOI 10.1210/en.140.1.358; Lopez D, 1999, ENDOCRINOLOGY, V140, P3034, DOI 10.1210/en.140.7.3034; Maya-Nunez G, 1999, ENDOCRINOLOGY, V140, P3452, DOI 10.1210/en.140.8.3452; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Naville D, 1999, BIOCHEM BIOPH RES CO, V255, P28, DOI 10.1006/bbrc.1998.9891; Ngan ESW, 1999, ENDOCRINOLOGY, V140, P2452, DOI 10.1210/endo.140.6.6759; Norwitz ER, 1999, J BIOL CHEM, V274, P867, DOI 10.1074/jbc.274.2.867; OSUGA Y, 1992, ENDOCRINOL JAPON, V39, P153; Pincas H, 2001, MOL ENDOCRINOL, V15, P319, DOI 10.1210/me.15.2.319; Pincas H, 1998, MOL CELL ENDOCRINOL, V144, P95, DOI 10.1016/S0303-7207(98)00149-X; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; Reinhart J, 1997, MOL CELL ENDOCRINOL, V130, P1, DOI 10.1016/S0303-7207(97)00064-6; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; TSUJII T, 1994, ENDOCRINOLOGY, V135, P826, DOI 10.1210/en.135.3.826; TSUJII T, 1995, MOL CELL ENDOCRINOL, V113, P123, DOI 10.1016/0303-7207(95)03613-C; VANPATTEN SM, 1992, MOL ENDOCRINOL, V6, P2114, DOI 10.1210/me.6.12.2114; VAUDRY D, 2000, PHARMACOL REV, V52, P296; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; Winters SJ, 1997, ENDOCRINOLOGY, V138, P4324, DOI 10.1210/en.138.10.4324; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	44	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23562	23571		10.1074/jbc.M100563200	http://dx.doi.org/10.1074/jbc.M100563200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320087	hybrid			2022-12-27	WOS:000169531100047
J	Tsuji, S; Uehori, J; Matsumoto, M; Suzuki, Y; Matsuhisa, A; Toyoshima, K; Seya, T				Tsuji, S; Uehori, J; Matsumoto, M; Suzuki, Y; Matsuhisa, A; Toyoshima, K; Seya, T			Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEREGRINA HUMORAL LECTIN; MANNOSE-BINDING PROTEIN; C-TYPE LECTIN; XENOPUS-LAEVIS; SERINE-PROTEASE; ASIALOGLYCOPROTEIN RECEPTOR; LEISHMANIA-MAJOR; CLONING; CDNA; EXPRESSION	Galactofuranosyl residues are present in various microorganisms but not in mammals, In this study, we identified a human lectin binding to galactofuranosyl residues and named this protein human intelectin (hIntL). The mature hIntL was a secretory glycoprotein consisting of 295 amino acids and N-linked oligosaccharides, and its basic structural unit was a 120-kDa homotrimer in which 40-kDa polypeptides mere bridged by disulfide bonds. The hIntL gene was spilt into 8 exons on chromosome 1q21.3, and hIntL mRNA was expressed in the heart, small intestine, colon, and thymus, hIntL showed high levels of homology with mouse intelectin, Xenopus laevis cortical granule lectin/oocyte lectin, lamprey serum lectin, and ascidian galactose-specific lectin, These homologues commonly contained no carbohydrate recognition domain, which is a characteristic of C-type lectins, although some of them have been reported as Ca2+-dependent lectins. Recombinant hIntL revealed affinities to D-pentoses and a D-galactofuranosyl residue in the presence of Ca2+, and recognized the bacterial arabinogalactan of Nocardia containing D-galactofuranosyl residues. These results suggested that hIntL is a new type lectin recognizing galactofuranose, and that hIntL plays a role in the recognition of bacteria-specific components in the host.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan; Osaka Prefectural Inst Publ Hlth, Higashinari Ku, Osaka 5370025, Japan; Fuso Pharmaceut Ind Ltd, Ctr Res & Dev, Joto Ku, Osaka 5368523, Japan; Org Pharmaceut Safety & Res, Tokyo 1000013, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Prefectural Institute of Public Health; Fuso Pharmaceutical Industries, Ltd.	Seya, T (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan.		Suzuki, Yasuhiko/F-6890-2012; Seya, Tsukasa/A-4336-2012					Abe Y, 1999, EUR J BIOCHEM, V261, P33, DOI 10.1046/j.1432-1327.1999.00238.x; ABEYGUNAWARDANA C, 1991, BIOCHEMISTRY-US, V30, P8568, DOI 10.1021/bi00099a012; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DELEDERKREMER RM, 1995, GLYCOBIOLOGY, V5, P547, DOI 10.1093/glycob/5.6.547; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; GERTON GL, 1986, DEV BIOL, V116, P1, DOI 10.1016/0012-1606(86)90036-9; Inoue N, 2001, J IMMUNOL, V166, P424, DOI 10.4049/jimmunol.166.1.424; IZUMI S, 1987, CANCER RES, V47, P1785; IZUMI S, 1986, CANCER RES, V46, P1960; KOMANO H, 1985, DEV COMP IMMUNOL, V9, P31, DOI 10.1016/0145-305X(85)90057-6; Komiya T, 1998, BIOCHEM BIOPH RES CO, V251, P759, DOI 10.1006/bbrc.1998.9513; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; Lee JK, 1997, GLYCOBIOLOGY, V7, P367, DOI 10.1093/glycob/7.3.367; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; Naik UP, 2001, J CELL SCI, V114, P539; NISHIHARA T, 1986, BIOCHEMISTRY-US, V25, P6013, DOI 10.1021/bi00368a027; NOTERMANS S, 1988, MOL IMMUNOL, V25, P975, DOI 10.1016/0161-5890(88)90003-X; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; OZAKI K, 1992, J BIOL CHEM, V267, P9229; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Quill TA, 1996, ARCH BIOCHEM BIOPHYS, V333, P326, DOI 10.1006/abbi.1996.0398; ROBERSON MM, 1983, J CELL BIOL, V97, P1875, DOI 10.1083/jcb.97.6.1875; ROBERSON MM, 1982, J BIOL CHEM, V257, P7520; Sandrin MS, 1996, IMMUNOGENETICS, V43, P13; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; STAUNTON DE, 1989, J EXP MED, V169, P1087, DOI 10.1084/jem.169.3.1087; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; SUPER M, 1989, LANCET, V2, P1236; Suzuki E, 1997, GLYCOBIOLOGY, V7, P463, DOI 10.1093/glycob/7.4.463; Suzuki N, 1996, J IMMUNOL, V156, P128; TAKAHASHI H, 1985, J BIOL CHEM, V260, P2228; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; WARR GA, 1980, BIOCHEM BIOPH RES CO, V93, P737, DOI 10.1016/0006-291X(80)91139-0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G	41	276	299	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23456	23463		10.1074/jbc.M103162200	http://dx.doi.org/10.1074/jbc.M103162200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313366	hybrid			2022-12-27	WOS:000169531100032
J	Wang, Q; Ko, KS; Kapus, A; McCulloch, CAG; Ellen, RP				Wang, Q; Ko, KS; Kapus, A; McCulloch, CAG; Ellen, RP			A spirochete surface protein uncouples store-operated calcium channels in fibroblasts - A novel cytotoxic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; TREPONEMA-DENTICOLA; GINGIVAL FIBROBLASTS; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; HUMAN PLATELETS; ACTIN CYTOSKELETON; ESCHERICHIA-COLI; OUTER SHEATH; ION CHANNELS	The cytotoxicity of infectious agents can be mediated by disruption of calcium signaling in target cells. Outer membrane proteins of the spirochete Treponema denticola, a periodontal pathogen, inhibit agonist induced Ca2+ release from internal stores in gingival fibroblasts, but the mechanism is not defined. We determined here that the major surface protein (Msp) of T. denticola perturbs calcium signaling in human fibroblasts by uncoupling store-operated channels. Msp localized in complexes on the cell surface. Ratio fluorimetry showed that in cells loaded with fura-2 or fura-C18, Msp induced cytoplasmic and near-plasma membrane Ca2+ transients, respectively. Increased conductance was confirmed by fluorescence quenching of fura-2-loaded cells with Mn2+ after Msp treatment. Calcium entry was blocked with anti-Msp antibodies and inhibited by chelating external Ca2+ with EGTA. Msp pretreatment reduced the amplitude of [Ca2+](i) transients upon challenge with ATP or thapsigargin. In experiments using cells loaded with mag-fura-a to report endoplasmic reticulum Ca2+, Msp reduced Ca2+ efflux from endoplasmic reticulum stores when ATP was used as an agonist. Msp alone did not induce Ca2+ release from these stores. Msp inhibited store-operated influx of extracellular calcium following intracellular Ca2+ depletion by thapsigargin and also promoted the assembly of subcortical actin filaments. This actin assembly was blocked by chelating intracellular Ca2+ with 1,2 bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester. The reduced amplitude of agonist-induced transients and inhibition of store-operated Ca2+ entry due to Msp were reversed by latrunculin B, an inhibitor of actin filament assembly. Thus, Msp retards Ca2+ release from endoplasmic reticulum stores, and it inhibits subsequent Ca2+ influx by uncoupling store-operated channels. Actin filament rearrangement coincident with conformational uncoupling of store operated calcium fluxes is a novel mechanism by which surface proteins and toxins of pathogenic microorganisms may damage host cells.	Univ Toronto, Fac Dent, Dent Res Inst, Toronto, ON M5G 1G6, Canada; Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Periodontal Physiol, Toronto, ON M5G 1G6, Canada; Univ Toronto, Dept Surg, Toronto, ON M5G 1G6, Canada; Toronto Gen Hosp, Div Surg, Toronto, ON M5G 1G6, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Ellen, RP (corresponding author), Univ Toronto, Fac Dent, Dent Res Inst, 124 Edward St, Toronto, ON M5G 1G6, Canada.							Arora PD, 2000, J BIOL CHEM, V275, P35432, DOI 10.1074/jbc.M003221200; BAEHNI PC, 1992, INFECT IMMUN, V60, P3360, DOI 10.1128/IAI.60.8.3360-3368.1992; BALDWIN TJ, 1991, INFECT IMMUN, V59, P1599, DOI 10.1128/IAI.59.5.1599-1604.1991; Battikhi T, 1999, INFECT IMMUN, V67, P1220, DOI 10.1128/IAI.67.3.1220-1226.1999; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; BIBBY KJ, 1994, AM J PHYSIOL, V266, pC1639, DOI 10.1152/ajpcell.1994.266.6.C1639; Buommino E, 1999, INFECT IMMUN, V67, P4794, DOI 10.1128/IAI.67.9.4794-4800.1999; DAWSON JR, 1990, INFECT IMMUN, V58, P3924, DOI 10.1128/IAI.58.12.3924-3928.1990; DEFILIPPO AB, 1995, ARCH ORAL BIOL, V40, P199, DOI 10.1016/0003-9969(95)98809-D; DYTOC M, 1994, GASTROENTEROLOGY, V106, P1150, DOI 10.1016/0016-5085(94)90004-3; EGLI C, 1993, INFECT IMMUN, V61, P1694, DOI 10.1128/IAI.61.5.1694-1699.1993; Ellen RP, 1999, MICROBES INFECT, V1, P621, DOI 10.1016/S1286-4579(99)80062-8; Ellen RP, 2000, J MOL MICROB BIOTECH, V2, P581; ELLEN RP, 1994, INFECT IMMUN, V62, P3033, DOI 10.1128/IAI.62.7.3033-3037.1994; ETTER EF, 1994, J BIOL CHEM, V269, P10141; Fenno JC, 1996, J BACTERIOL, V178, P2489, DOI 10.1128/jb.178.9.2489-2497.1996; Fenno JC, 1997, J BACTERIOL, V179, P1082, DOI 10.1128/jb.179.4.1082-1089.1997; Fenno JC, 1998, INFECT IMMUN, V66, P1869, DOI 10.1128/IAI.66.5.1869-1877.1998; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAAPASALO M, 1992, INFECT IMMUN, V60, P2058, DOI 10.1128/IAI.60.5.2058-2065.1992; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Izutsu KT, 1996, FEMS MICROBIOL LETT, V144, P145, DOI 10.1111/j.1574-6968.1996.tb08521.x; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kallstrom H, 1998, J BIOL CHEM, V273, P21777, DOI 10.1074/jbc.273.34.21777; Ko KSC, 1998, INFECT IMMUN, V66, P703, DOI 10.1128/IAI.66.2.703-709.1998; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; KULKARNI GV, 1994, J CELL SCI, V107, P1169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mathers DA, 1996, INFECT IMMUN, V64, P2904, DOI 10.1128/IAI.64.8.2904-2910.1996; McCloskey MA, 2000, J CELL BIOL, V148, P137, DOI 10.1083/jcb.148.1.137; Muller A, 1999, EMBO J, V18, P339, DOI 10.1093/emboj/18.2.339; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PENDER N, 1991, J CELL SCI, V100, P187; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Rosado JA, 2000, BIOCHEM J, V347, P183, DOI 10.1042/0264-6021:3470183; Rosado JA, 2000, J BIOL CHEM, V275, P9110, DOI 10.1074/jbc.275.13.9110; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCOPES RK, 1997, CURRENT PROTOCOLS MO, V2; Seidl J, 1999, CYTOMETRY, V36, P102, DOI 10.1002/(SICI)1097-0320(19990601)36:2<102::AID-CYTO3>3.0.CO;2-D; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; UITTO VJ, 1995, INFECT IMMUN, V63, P3401, DOI 10.1128/IAI.63.9.3401-3410.1995; Yang PF, 1998, INFECT IMMUN, V66, P696, DOI 10.1128/IAI.66.2.696-702.1998	51	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23056	23064		10.1074/jbc.M011735200	http://dx.doi.org/10.1074/jbc.M011735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312269	hybrid			2022-12-27	WOS:000169412700143
J	Seno, K; Kishimoto, M; Abe, M; Higuchi, Y; Mieda, M; Owada, Y; Yoshiyama, W; Liu, H; Hayashi, F				Seno, K; Kishimoto, M; Abe, M; Higuchi, Y; Mieda, M; Owada, Y; Yoshiyama, W; Liu, H; Hayashi, F			Light- and guanosine 5 '-3-O-(thio)triphosphate-sensitive localization of a G protein and its effector on detergent-resistant membrane rafts in rod photoreceptor outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP PHOSPHODIESTERASE; GAMMA-SUBUNIT; ALPHA-SUBUNIT; TRANSDUCIN; DOMAIN; CYSTEINE; BINDING	Detergent-resistant membrane microdomains in the plasma membrane, known as lipid rafts, have been implicated in various cellular processes. We report here that a low-density Triton X-100-insoluble membrane (detergent-resistant membrane; DRM) fraction is present in bovine rod photoreceptor outer segments (ROS), In dark-adapted ROS, transducin and most of cGMP-phosphodiesterase (PDE) were detergent-soluble. When ROS membranes were exposed to light, however, a large portion of transducin localized in the DRM fraction. Furthermore, on addition of guanosine 5'-3-O-(thio)triphosphate (GTP gammaS) to light-bleached ROS, transducin became detergent-soluble again. PDE was not recruited to the DRM fraction after light stimulus alone, but simultaneous stimulation by light and GTP gammaS induced a massive translocation of all PDE subunits to the DRM, A cholesterol-removing reagent, methyl-beta -cyclodextrin, selectively but partially solubilized PDE from the DRM, suggesting that cholesterol contributes, at least in part, to the association of PDE with the DRM, By contrast, transducin was not extracted by the depletion of cholesterol, These data suggest that transducin and PDE are likely to perform their functions in phototransduction by changing their localization between two distinct lipid phases, rafts and surrounding fluid membrane, on disc membranes in an activation-dependent manner.	Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Grad Sch Sci & Technol, Nada Ku, Kobe, Hyogo 657, Japan	Kobe University; Kobe University	Hayashi, F (corresponding author), Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe, Hyogo 657, Japan.	fhayashi@kobe-u.ac.jp						ANANT JS, 1992, J BIOL CHEM, V267, P687; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4746, DOI 10.1073/pnas.88.11.4746; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Liu W, 1998, J BIOL CHEM, V273, P34284, DOI 10.1074/jbc.273.51.34284; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Maekawa S, 1999, J BIOL CHEM, V274, P21369, DOI 10.1074/jbc.274.30.21369; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Skiba NP, 2000, J BIOL CHEM, V275, P32716, DOI 10.1074/jbc.C000413200; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690	23	94	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20813	20816		10.1074/jbc.C100032200	http://dx.doi.org/10.1074/jbc.C100032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11319214	hybrid			2022-12-27	WOS:000169297900003
J	Kumar, S; Bharti, A; Mishra, NC; Raina, D; Kharbanda, S; Saxena, S; Kufe, D				Kumar, S; Bharti, A; Mishra, NC; Raina, D; Kharbanda, S; Saxena, S; Kufe, D			Targeting of the c-Ab1 tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; C-ABL; APOPTOTIC RESPONSE; DNA; GENERATION; NUCLEAR; P73	The ubiquitously expressed c-Abl tyrosine kinase is activated in the response of cells to genotoxic and oxidative stress. The present study demonstrates that reactive oxygen species (ROS) induce targeting of c-Abl to mitochondria. We show that ROS-induced localization of c-Abl to mitochondria is dependent on activation of protein kinase C (PKC)S and the c-Abl kinase function. Targeting of c-Abl to mitochondria is associated with ROS-induced loss of mitochondrial transmembrane potential. The results also demonstrate that c-Abl is necessary for ROS-induced depletion of ATP and the activation of a necrosis-like cell death. These findings indicate that the c-Abl kinase targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Lovelace Resp Res Inst, Albuquerque, NM 87115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Lovelace Respiratory Research Institute	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; Gong JG, 1999, NATURE, V399, P806; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li TK, 1999, GENE DEV, V13, P1553, DOI 10.1101/gad.13.12.1553; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nicotera P, 1998, TOXICOL LETT, V103, P139; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	28	93	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17281	17285		10.1074/jbc.M101414200	http://dx.doi.org/10.1074/jbc.M101414200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350980	hybrid			2022-12-27	WOS:000168730400091
J	Harris, MB; Ju, H; Venema, VJ; Liang, HY; Zou, R; Michell, BJ; Chen, ZP; Kemp, BE; Venema, RC				Harris, MB; Ju, H; Venema, VJ; Liang, HY; Zou, R; Michell, BJ; Chen, ZP; Kemp, BE; Venema, RC			Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CYCLOSPORINE-A; AKT; PATHWAY; HYPERTENSION; PROSTACYCLIN; INHIBITOR; LY294002	Endothelial nitric-oxide synthase (eNOS) is phosphorylated at Ser-1179 (bovine sequence) by Akt after growth factor or shear stress stimulation of endothelial cells, resulting in increased eNOS activity. Purified eNOS is also phosphorylated at Thr-497 by purified AMP-activated protein kinase, resulting in decreased eNOS activity, We investigated whether bradykinin (BK) stimulation of bovine aortic endothelial cells (BAECs) regulates eNOS through Akt activation and Ser-1179 or Thr-497 phosphorylation. Akt is transiently activated in BK-stimulated BAECs. Activation is blocked completely by wortmannin and LY294002, inhibitors of phosphatidylinositol 3-kinase, suggesting that Akt activation occurs downstream from phosphatidylinositol 3-kinase, BK stimulates a transient phosphorylation of eNOS at Ser-1179 that is correlated temporally with a transient dephosphorylation of eNOS at Thr-497. Phosphorylation at Ser-1179, but not dephosphorylation at Thr-497, is blocked by wortmannin and LY294002. BK also stimulates a transient nitric oxide (NO) release from BAECs with a time-course similar to Ser-1179 phosphorylation and Thr-497 dephosphorylation, NO release is not altered by wortmannin. BK-stimulated dephosphorylation of Thr-497 and NO release are blocked by the calcineurin inhibitor, cyclosporin A. These data suggest that BK activation of eNOS in BAECs primarily involves deinhibition of the enzyme through calcineurin-mediated dephosphorylation at Thr-497.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; St. Vincent's Institute of Medical Research	Venema, RC (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.		Harris, M. Brennan/F-7772-2015; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Harris, M. Brennan/0000-0002-2908-1647; Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062152, R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62152, HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Coffer PJ, 1998, BIOCHEM J, V335, P1; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; HAMILTON DV, 1982, TRANSPLANT P, V14, P597; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Oriji GK, 1998, HYPERTENSION, V32, P849, DOI 10.1161/01.HYP.32.5.849; PAPAPETROPOULOS A, 1997, J CLIN INVEST, V100, P313; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; SCOTTBURDEN T, 1993, CIRCULATION, V87, P51; SUDHIR K, 1994, CIRCULATION, V90, P3018, DOI 10.1161/01.CIR.90.6.3018; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	32	347	357	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16587	16591		10.1074/jbc.M100229200	http://dx.doi.org/10.1074/jbc.M100229200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340086	hybrid			2022-12-27	WOS:000168623100136
J	Zhuge, Y; Xu, JH				Zhuge, Y; Xu, JH			Rad mediates type I collagen-dependent MMP-2 activation - Role in cell invasion across collagen barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; GELATINASE-A; TISSUE INHIBITOR; PROGELATINASE-A; EXTRACELLULAR-MATRIX; TUMOR PROGRESSION; INTERSTITIAL COLLAGENASE; NORMAL FIBROBLASTS; ENDOTHELIAL-CELLS; BREAST-CARCINOMA	Cell migration and proteolysis are two essential processes during tumor invasion and metastasis. Matrix metalloproteinase (MMP)-2 (type IV collagenase; gelatinase A), is implicated in tumor metastasis as well as in primary tumor growth. The Rho family of small GTPases regulates the dynamics of actin cytoskeleton associated with cell motility. In this report, we provide evidence that Rac1, one member of Rho-related small GTPases, is a mediator of MMP-2 activation in HT1080 fibrosarcoma cells cultured in three-dimensional collagen gel (3D-col) and that MMP-2 activation is required for Rac1-promoted cell invasion through collagen barrier. Stable expression of dominant negative (Rac1V12N17) and constitutively active Rac1 (Rac1V12), respectively, in HT1080 cells demonstrates that Rac1 promoted cell invasiveness across type I collagen and collagen-dependent MMP-2 activation. Active Rac1 is sufficient to induce MMP-2 activation in cells cultured in fibrin gel, an extracellular matrix component that does not support MMP-2 activation. The Rac1-dependent MMP-2 activation occurred in a cell-associated fashion and required MMP activities. Because the cell membrane-mediated MMP-2 activation requires MT1-MMP and low amount of issue inhibitor of matrix metalloproteinase-2 (TIMP-2), their expression was examined. Rac1 modulated MT1-MMP mRNA level and the accumulation of a 43-kDa form of MT1-MMP protein, in correlation with MMP-2 activation profile. However, TIMP-2 expression was independent of Rac1 activity. The coordinate modulation of MMP-2 activity and MT1-MMP expression/processing by Rac1 is consistent with cell collagenolytic activity. The C-terminal hemopexin-like domain of MMP-2, which interferes with the cell membrane activation of MMP-2, reduced Rac1-promoted cell invasiveness as monitored by collagen invasion assay. These results suggest that collagen-dependent MMP-2 activation and MT1-MMP expression/processing contribute to Rac-promoted tumor cell invasion through interstitial collagen barrier.	SUNY Stony Brook, Sch Med, Dept Dermatol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Xu, JH (corresponding author), SUNY Stony Brook, Sch Med, Dept Dermatol, Stony Brook, NY 11794 USA.				NIAMS NIH HHS [5K01AR02036, 1RO1AR4657101] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002036, R01AR046571] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALBINI A, 1987, CANCER RES, V47, P3239; ANGLIKER H, 1993, BIOCHEM J, V293, P75, DOI 10.1042/bj2930075; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 1998, CANCER RES, V58, P3743; Ellerbroek SM, 1999, CANCER RES, V59, P1635; EMONARD HP, 1992, CANCER RES, V52, P5845; Friedl P, 1997, CANCER RES, V57, P2061; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 1997, LAB INVEST, V76, P651; Gogly B, 1998, ANAL BIOCHEM, V255, P211, DOI 10.1006/abio.1997.2318; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HUHTALA P, 1990, GENOMICS, V6, P554, DOI 10.1016/0888-7543(90)90486-E; Imai K, 1996, CANCER RES, V56, P2707; Imren S, 1996, CANCER RES, V56, P2891; Itoh T, 1998, CANCER RES, V58, P1048; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kubota S, 1997, INT J CANCER, V70, P106; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; LEVY AT, 1991, CANCER RES, V51, P439; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONSKY WL, 1993, CANCER RES, V53, P3159; MOOKHTIAR KA, 1986, ANAL BIOCHEM, V158, P322, DOI 10.1016/0003-2697(86)90557-9; MORTON DL, 1997, CANC MED, P2467; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rajavashisth TB, 1999, J BIOL CHEM, V274, P11924, DOI 10.1074/jbc.274.17.11924; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Seltzer JL, 1999, J INVEST DERMATOL, V112, P993, DOI 10.1046/j.1523-1747.1999.00616.x; Stanton H, 1998, J CELL SCI, V111, P2789; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Xu JH, 1996, J CELL BIOL, V134, P1301, DOI 10.1083/jcb.134.5.1301	79	155	166	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16248	16256		10.1074/jbc.M010190200	http://dx.doi.org/10.1074/jbc.M010190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340084	hybrid			2022-12-27	WOS:000168623100091
J	Mukhopadhyay, D; Sundereshan, S; Rao, C; Karande, AA				Mukhopadhyay, D; Sundereshan, S; Rao, C; Karande, AA			Placental protein 14 induces apoptosis in T cells but not in monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGESTAGEN-ASSOCIATED PROTEIN; BETA-LACTOGLOBULIN HOMOLOG; ENDOMETRIAL PROTEIN; MENSTRUAL-CYCLE; CASPASE FAMILY; LUTEAL-PHASE; SERUM LEVELS; SEQUENCE; PP14; IDENTIFICATION	Substantial evidence exists in literature to suggest that placental protein 14 (PP14) (recently renamed glycodelin A), exhibits immunosuppressive properties and is an indispensable macromolecule in the maternal system for the establishment, maintenance, and progression of pregnancy. Though there are several reports substantiating the above, the mechanism of its action at the molecular level has not been elucidated as yet. In this paper we provide data that suggest that amniotic fluid PP14 and recombinant PP14 expressed in Pichia pastoris induce apoptosis in human peripheral blood lymphocytes upon activation, independent of monocytes. That PP14 has a direct apoptotic action on T cells but not on monocytes was also demonstrated by utilizing human cell lines. PP14 was shown to induce apoptosis in the human T cell lines, Jurkat and MOLT-4 cells, but not in the human monocytic cell line, U937.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India; Raos Matern Hosp, Bangalore 560044, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Karande, AA (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	anjali@biochem.iisc.ernet.in	Karande, Anjali/C-4880-2009					Bohn H, 1982, Placenta Suppl, V4, P67; BOLTON AE, 1987, LANCET, V1, P593; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Bulmer J, 1987, IMMUNOREGULATION FET, P111; CHECK JH, 1993, INT J FERTIL, V38, P34; Dutta B, 1998, PROTEIN EXPRES PURIF, V14, P327, DOI 10.1006/prep.1998.0961; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HUHTALA ML, 1987, ENDOCRINOLOGY, V120, P2620, DOI 10.1210/endo-120-6-2620; JOSHI SG, 1983, J STEROID BIOCHEM, V19, P751, DOI 10.1016/0022-4731(83)90007-9; JOSHI SG, 1981, J CLIN ENDOCR METAB, V52, P1185, DOI 10.1210/jcem-52-6-1185; JULKUNEN M, 1986, FERTIL STERIL, V45, P47; JULKUNEN M, 1986, ENDOCRINOLOGY, V118, P1782, DOI 10.1210/endo-118-5-1782; JULKUNEN M, 1990, MOL ENDOCRINOL, V4, P700, DOI 10.1210/mend-4-5-700; JULKUNEN M, 1985, BRIT J OBSTET GYNAEC, V92, P1145, DOI 10.1111/j.1471-0528.1985.tb03027.x; Karri T, 2000, HISTOCHEM J, V32, P711, DOI 10.1023/A:1004144909714; KROEMER G, 1997, IMMUNOLOGY METHODS M, P1121; Lalitkumar PGL, 1998, HUM REPROD, V13, P3478, DOI 10.1093/humrep/13.12.3478; MACKENNA A, 1993, FERTIL STERIL, V59, P577; Miller RE, 1998, FEBS LETT, V436, P455, DOI 10.1016/S0014-5793(98)01184-3; OEHNINGER S, 1995, FERTIL STERIL, V63, P377; OKAMOTO N, 1991, AM J REPROD IMMUNOL, V26, P137, DOI 10.1111/j.1600-0897.1991.tb00713.x; POCKLEY AG, 1990, IMMUNOLOGY, V69, P277; Rachmilewitz J, 1999, CELL IMMUNOL, V191, P26, DOI 10.1006/cimm.1998.1408; REDDY BMMMK, 1992, MOL IMMUNOL, V29, P511, DOI 10.1016/0161-5890(92)90008-L; Seppala M, 1997, CLIN ENDOCRINOL, V46, P381, DOI 10.1046/j.1365-2265.1997.1510943.x; SEPPALA M, 1991, BAILLIERE CLIN OB GY, V5, P61, DOI 10.1016/S0950-3552(05)80070-7; SEPPO A, 1998, CELLS LAB MANUAL, V1, P335; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomczak S, 1996, ARCH GYNECOL OBSTET, V258, P165, DOI 10.1007/s004040050120; TULPPALA M, 1995, FERTIL STERIL, V63, P792, DOI 10.1016/S0015-0282(16)57483-4; VAISSE C, 1990, DNA CELL BIOL, V9, P401, DOI 10.1089/dna.1990.9.401; WAITES GT, 1990, HUM REPROD, V5, P487, DOI 10.1093/oxfordjournals.humrep.a137130; Westergaard LG, 1998, HUM REPROD, V13, P2612, DOI 10.1093/humrep/13.9.2612	35	62	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28268	28273		10.1074/jbc.M010487200	http://dx.doi.org/10.1074/jbc.M010487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11325960	hybrid			2022-12-27	WOS:000170093400071
J	Rozanov, DV; Deryugina, EI; Ratnikov, BI; Monosov, EZ; Marchenko, GN; Quigley, JP; Strongin, AY				Rozanov, DV; Deryugina, EI; Ratnikov, BI; Monosov, EZ; Marchenko, GN; Quigley, JP; Strongin, AY			Mutation analysis of membrane type-1 matrix metalloproteinase (MT1-MMP) - The role of the cytoplasmic tail Cys(574), the active site Glu(240), and furin cleavage motifs in oligomerization, processing, and self-proteolysis of MT1-MMP expressed in breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; 1-MATRIX METALLOPROTEINASE; GELATINASE-A; INTEGRIN ALPHA-V-BETA-3; EXTRACELLULAR-MATRIX; EFFICIENT ACTIVATION; COLLAGEN MATRIX; IV COLLAGENASE; PRO-GELATINASE; PROGELATINASE	Membrane type-1 matrix metalloproteinase (MT1-MMP) is a key enzyme in the activation pathway of matrix prometalloproteinase-2 (pro-MMP-8). Both activation and autocatalytic maturation of pro-MMP-2 in trans suggest that MT1-MMP should exist as oligomers on the cell surface. To better understand the functions of MT1-MIMP, we designed mutants with substitutions in the active site (E240A), the cytoplasmic tail (C574A), and the RRXR furin cleavage motifs (R89A, ARAA, and R89A/ ARAA) of the enzyme. The mutants were expressed in MCF7 breast carcinoma cells that are deficient in both MMP-2 and MT1-MMP, Our results supported the existence of MT1-MMP oligomers and demonstrated that a disulfide bridge involving the Cys(574) Of the enzyme's cytoplasmic tail covalently links MT1-MMP monomers on the MCF7 cell surface, The presence of MT1-MMP oligomers also was shown for the enzyme naturally expressed in HT1080 fibrosarcoma cells. The single (R89A and ARAA) and double (RS9A/ARAA) furin cleavage site mutants of MT1-MMP were processed in MCF7 cells into the mature proteinase capable of activating pro-MMP-2 and stimulating cell locomotion. This suggested that furin cleavage is not a prerequisite for the conversion of pro-MT1-MMP into the functionally active enzyme. A hydroxamate class inhibitor (GM6001, or Ilomastat) blocked activation of MT1-MIMP in MCF7 cells but not in HT1080 cells. This implied that a matrixin-like proteinase sensitive to hydroxamates could be involved in a furin-independent, alternative pathway of MT1-MMP activation in breast carcinoma cells. The expression of the wild type MT1-MMP enhanced cell invasion and migration, indicating a direct involvement of this enzyme in cell locomotion. In contrast, both the C574A and E240A mutations render MT1-MMP inefficient in stimulating cell migration and invasion, In addition, the C574A mutation negatively affected cell adhesion, thereby indicating critical interactions involving the cytosolic part of MT1-MMP and the intracellular milieu.	Burnham Inst, La Jolla, CA 92037 USA; Scripps Res Inst, Vasc Biol Dept, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Scripps Research Institute	Strongin, AY (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NCI NIH HHS [CA77470, CA83017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao J, 2000, J BIOL CHEM, V275, P29648, DOI 10.1074/jbc.M001920200; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Deryugina EI, 1998, CANCER RES, V58, P3743; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Kazes I, 2000, BLOOD, V96, P3064, DOI 10.1182/blood.V96.9.3064.h8003064_3064_3069; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kurschat P, 1999, J BIOL CHEM, V274, P21056, DOI 10.1074/jbc.274.30.21056; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Llano E, 1999, CANCER RES, V59, P2570; Maquoi E, 2000, J BIOL CHEM, V275, P11368, DOI 10.1074/jbc.275.15.11368; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Quaranta V, 2000, J CELL BIOL, V149, P1167, DOI 10.1083/jcb.149.6.1167; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, BRIT J CANCER, V80, P1137, DOI 10.1038/sj.bjc.6690477; Sato T, 1999, ANN NY ACAD SCI, V878, P713, DOI 10.1111/j.1749-6632.1999.tb07770.x; Sato T, 1997, J CELL SCI, V110, P589; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; Stanton H, 1998, J CELL SCI, V111, P2789; Steele DL, 2000, PROTEIN ENG, V13, P397, DOI 10.1093/protein/13.6.397; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Urena JM, 1999, J CELL SCI, V112, P773; Valtanen H, 2000, PROTEIN EXPRES PURIF, V19, P66, DOI 10.1006/prep.2000.1216; Velasco G, 2000, CANCER RES, V60, P877; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	63	145	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25705	25714		10.1074/jbc.M007921200	http://dx.doi.org/10.1074/jbc.M007921200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335709	hybrid			2022-12-27	WOS:000169823300012
J	Schwanbeck, R; Gymnopoulos, M; Petry, I; Piekielko, A; Szewczuk, Z; Heyduk, T; Zechel, K; Wisniewski, JR				Schwanbeck, R; Gymnopoulos, M; Petry, I; Piekielko, A; Szewczuk, Z; Heyduk, T; Zechel, K; Wisniewski, JR			Consecutive steps of phosphorylation affect conformation and DNA binding of the Chironomus high mobility group A protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; 4-WAY JUNCTION DNA; CASEIN KINASE-II; HMG-I; REGIONS FLANKING; BOX DOMAIN; I/Y; IDENTIFICATION; PROMOTER; ACRYLODAN	The high mobility group (HMG) proteins of the AT-hook family (HMGA) lie downstream in regulatory networks with protein kinase CI Cdc2 kinase, MAP kinase, and casein kinase 2 (CK2) as final effecters. In the cells of the midge Chironomus, almost all of the HMGA protein (cHMGA) is phosphorylated by CK2 at two adjacent sites. 40% of the protein population is additionally modified by MAP kinase, Using spectroscopic and protein footprinting techniques, we analyzed how individual and consecutive steps of phosphorylation change the conformation of an HMGA protein and affect its contacts with poly(dA-dT). poly(dA-dT) and a fragment of the interferon-beta promoter. We demonstrate that phosphorylation of cHMGA by CK2 alters its conformation and modulates its DNA binding properties such that a subsequent phosphorylation by Cdc2 kinase changes the organization of the protein-DNA complex. In contrast, consecutive phosphorylation by MAP kinase, which results in a dramatic change in cHMGA conformation, has no direct effect on the complex. Because the phosphorylation of the HMGA proteins attenuates binding affinity and reduces the extent of contacts between the DNA and protein, it is likely that this process mirrors the dynamics and diversity of regulatory processes in chromatin.	Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany; Uniwersytet Wroclawski, Wydziat Chem, PL-50388 Wroclaw, Poland; St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Max Planck Inst Biophys Chem, Dept Biochem, D-37077 Gottingen, Germany; MDS Proteom AS, DK-5230 Odense M, Denmark	University of Gottingen; University of Wroclaw; Saint Louis University; Max Planck Society	Wisniewski, JR (corresponding author), MDS Proteom AS, Staermosegardsvej 6, DK-5230 Odense M, Denmark.		Schwanbeck, Ralf/A-2648-2008; Szewczuk, Zbigniew/A-2243-2013; Piekielko-Witkowska, Agnieszka/V-1011-2019; Petry-Podgorska, Inga/I-3886-2014	Schwanbeck, Ralf/0000-0003-0925-929X; Piekielko-Witkowska, Agnieszka/0000-0002-5348-0760; Szewczuk, Zbigniew/0000-0001-5884-9363				Amirand C, 1998, J CELL SCI, V111, P3551; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Badea M G, 1979, Methods Enzymol, V61, P378; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLAUS P, 1994, J BIOL CHEM, V269, P33042; Cmarik JL, 1998, ONCOGENE, V16, P3387, DOI 10.1038/sj.onc.1201888; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; EPPS DE, 1992, J BIOL CHEM, V267, P3129; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; Frank O, 1998, J BIOL CHEM, V273, P20015, DOI 10.1074/jbc.273.32.20015; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LEHRER SS, 1988, BIOCHEMISTRY-US, V27, P5899, DOI 10.1021/bi00416a012; Louie DF, 2000, PROTEIN SCI, V9, P170; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; Martelli AM, 1998, J HISTOCHEM CYTOCHEM, V46, P863, DOI 10.1177/002215549804600710; MEISNER H, 1995, PROTEIN KINASE FACTS, P240; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; Piekielko A, 2001, J BIOL CHEM, V276, P1984, DOI 10.1074/jbc.M004065200; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; REEVES R, 1990, J BIOL CHEM, V265, P8573; Renner U, 2000, BBA-GEN SUBJECTS, V1475, P99, DOI 10.1016/S0304-4165(00)00054-4; RODRIGUEZALFAGEME C, 1980, CHROMOSOMA, V78, P1; Schwanbeck R, 2000, J BIOL CHEM, V275, P1793, DOI 10.1074/jbc.275.3.1793; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; Schwanbeck R, 2000, BIOCHEMISTRY-US, V39, P14419, DOI 10.1021/bi0011274; Slama-Schwok A, 2000, BIOPHYS J, V78, P2543, DOI 10.1016/S0006-3495(00)76799-3; WANG DZ, 1995, J BIOL CHEM, V270, P22924, DOI 10.1074/jbc.270.39.22924; Wisniewski Jacek R., 1998, Zoologica Poloniae, V43, P5; Wisniewski JR, 1999, J BIOL CHEM, V274, P20116; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; WISNIEWSKI JR, 1994, EUR J BIOCHEM, V225, P687, DOI 10.1111/j.1432-1033.1994.00687.x; Wisniewski JR, 2000, INT J MOL MED, V6, P409; Xiao DM, 2000, J NEUROCHEM, V74, P392, DOI 10.1046/j.1471-4159.2000.0740392.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	52	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26012	26021		10.1074/jbc.M011053200	http://dx.doi.org/10.1074/jbc.M011053200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11335713	hybrid			2022-12-27	WOS:000169823300051
J	Douglas, DN; Dolinsky, VW; Lehner, R; Vance, DE				Douglas, DN; Dolinsky, VW; Lehner, R; Vance, DE			A role for sp1 in the transcriptional regulation of hepatic triacylglycerol hydrolase in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL ESTER HYDROLASE; MOLECULAR-CLONING; DEVELOPMENTAL EXPRESSION; BINDING-SITES; DNA-BINDING; IN-VIVO; PROMOTER; RAT; GENE; ACTIVATION	Microsomal triacylglycerol hydrolase (TGH) hydrolyzes stored triacylglycerol in cultured hepatoma cells (Lehner, R., and Vance, D, E, (1999) Biochem. J. 343, 1-10). We studied expression of TGH in murine liver and found both protein and mRNA increased dramatically at 27 days after birth. Nuclear run-on assays demonstrated that this was due to increased transcription. We cloned 542 base pairs upstream of the transcriptional start site of the murine TGH gene. Electrophoretic mobility shift assays demonstrated enhanced binding of hepatic nuclear proteins from 27-day-old mice to the murine TGH promoter, yielding three differentially migrating complexes. DNase I footprint analysis localized these complexes to two distinct regions: site A contains a putative Sp binding site, and site B contains a degenerate E box. We transfected primary murine hepatocytes with a series of 5 ' -deletion constructs upstream of the reporter luciferase cDNA Positive control elements were identified in a segment containing site A Competitive electrophoretic mobility shift assays and supershift assays demonstrated that site A binds Sp1 and Sp3. Transcriptional activation assays in Schneider SL-2 insect cells demonstrated that Spl is a potent activator of the TGH promoter. These experiments directly link increased TGH expression at the time of weaning to transcriptional regulation by Sp1.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pediat, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Canadian Inst Hlth Res, Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta; Institute for Work & Health; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.	dennis.vance@ualberta.ca		Lehner, Richard/0000-0002-6008-1805				Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; ALEXSON SEH, 1994, J BIOL CHEM, V269, P17118; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; Bratke J, 1999, BIOCHEM J, V339, P563, DOI 10.1042/0264-6021:3390563; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; COLEMAN RA, 1988, J LIPID RES, V29, P33; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOLINSKY VW, 2001, IN PRESS BIOCH BIOPH; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EPERON IC, 1994, RNA PROCESSING PRACT, V1, P57; Ghosh S, 1995, BBA-LIPID LIPID MET, V1259, P305, DOI 10.1016/0005-2760(95)00184-0; Ghosh S, 1998, AM J PHYSIOL-GASTR L, V274, pG662, DOI 10.1152/ajpgi.1998.274.4.G662; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JOHANSSON MBN, 1983, BIOL NEONATE, V44, P278, DOI 10.1159/000241728; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kumar AP, 1998, BIOCHEM BIOPH RES CO, V252, P517, DOI 10.1006/bbrc.1998.9676; Langmann T, 1997, BBA-GENE STRUCT EXPR, V1350, P65, DOI 10.1016/S0167-4781(96)00142-X; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; Natarajan R, 1999, J LIPID RES, V40, P2091; Natarajan R, 1998, BIOCHEM BIOPH RES CO, V243, P349, DOI 10.1006/bbrc.1997.8030; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PETERS J, 1978, BIOCHEM GENET, V16, P553, DOI 10.1007/BF00484219; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rolfe FG, 1997, J IMMUNOL METHODS, V202, P143, DOI 10.1016/S0022-1759(96)00245-1; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Satoh T, 1998, ANNU REV PHARMACOL, V38, P257, DOI 10.1146/annurev.pharmtox.38.1.257; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SPANOPOULOU E, 1991, MOL CELL BIOL, V11, P2216, DOI 10.1128/MCB.11.4.2216; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; YANG LY, 1995, J LIPID RES, V36, P125; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	51	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25621	25630		10.1074/jbc.M103874200	http://dx.doi.org/10.1074/jbc.M103874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337511	hybrid			2022-12-27	WOS:000169800700154
J	Harvey, NL; Daish, T; Mills, K; Dorstyn, L; Quinn, LM; Read, SH; Richardson, H; Kumar, S				Harvey, NL; Daish, T; Mills, K; Dorstyn, L; Quinn, LM; Read, SH; Richardson, H; Kumar, S			Characterization of the Drosophila caspase, DAMM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; STRUCTURAL BASIS; APOPTOTIC ACTIVITY; ACTIVATION; PROTEIN; DRONC; IDENTIFICATION; INHIBITION; EXPRESSION; PRODOMAIN	Caspases are main effecters of apoptosis in metazoans, Genome analysis indicates that there are seven caspases in Drosophila, six of which have been previously characterized. Here we describe the cloning and characterization of the last Drosophila caspase, DAMM. Similar to mammalian effector caspases, DAMM lacks a long prodomain, We show that the DAMM precursor, along with the caspases DRONC and DECAY, is partially processed in cells undergoing apoptosis, Recombinant DAMM produced in Escherichia coli shows significant catalytic activity on a pentapeptide caspase substrate. Low levels of damm mRNA are ubiquitously expressed in Drosophila embryos during early stages of development. Relatively high levels of damm mRNA are detected in larval salivary glands and midgut, and in adult egg chambers. Ectopic expression of DAMM in cultured cells induces apoptosis, and similarly, transgenic overexpression of DAMM, but not of a catalytically inactive DAMM mutant, in Drosophila results in a rough eye phenotype, We demonstrate that expression of the catalytically inactive DAMM mutant protein significantly suppresses the rough eye phenotype due to the overexpression of HID, suggesting that DAMM may be required in a hid-mediated cell death pathway.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia	Institute Medical & Veterinary Science Australia; Peter Maccallum Cancer Center	Kumar, S (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, POB 14,Rundle Mall,Frome Rd, Adelaide, SA 5000, Australia.	sharad-.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020; Richardson, Helena E/A-8080-2013; Dorstyn, Loretta/F-3673-2013	Kumar, Sharad/0000-0001-7126-9814; Richardson, Helena E/0000-0003-3852-4953; Dorstyn, Loretta/0000-0001-9886-0989; Quinn, Leonie/0000-0002-3911-6508; Harvey, Natasha/0000-0001-9839-8966				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chen P, 1996, J BIOL CHEM, V271, P25735, DOI 10.1074/jbc.271.42.25735; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Colussi PA, 2000, J CELL BIOL, V148, P703, DOI 10.1083/jcb.148.4.703; Colussi PA, 1998, J BIOL CHEM, V273, P26566, DOI 10.1074/jbc.273.41.26566; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1997, CELL DEATH DIFFER, V4, P570, DOI 10.1038/sj.cdd.4400281; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Doumanis J, 2001, CELL DEATH DIFFER, V8, P387, DOI 10.1038/sj.cdd.4400864; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HAY BA, 1994, DEVELOPMENT, V120, P2121; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jiang CG, 1997, DEVELOPMENT, V124, P4673; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kanuka H, 1999, P NATL ACAD SCI USA, V96, P145, DOI 10.1073/pnas.96.1.145; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Kumar S, 2000, CELL DEATH DIFFER, V7, P1039, DOI 10.1038/sj.cdd.4400756; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; NICHOLSON DW, 1999, CELL DEATH DIFFER, V6, P1551; Quinn LM, 2000, J BIOL CHEM, V275, P40416, DOI 10.1074/jbc.M002935200; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Talanian RV, 1997, J BIOL CHEM, V272, P9677; WOLFF T, 1991, DEVELOPMENT, V113, P825; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	48	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25342	25350		10.1074/jbc.M009444200	http://dx.doi.org/10.1074/jbc.M009444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337486	hybrid			2022-12-27	WOS:000169800700121
J	Jacob, KK; Stanley, FM				Jacob, KK; Stanley, FM			Elk-1, C/EBP alpha, and Pit-1 confer an insulin-responsive phenotype on prolactin promoter expression in Chinese hamster ovary cells and define the factors required for insulin-increased transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; GENE-EXPRESSION; REGULATORY ELEMENT; NUCLEAR-PROTEIN; THYROID-HORMONE; GROWTH-HORMONE; DNA-BINDING; DOMAIN; ETS; PHOSPHORYLATION	The transcription factor(s) that mediate insulin-increased gene transcription are not well defined. These studies use phenotypic conversion of Rat2 and Chinese hamster ovary (CHO) cells with transcription factors to identify components required for regulation of prolactin promoter activity and its control by insulin. The pituitary-derived GH4 cells contain all of the transcription factors required for insulin-increased prolactin-chloramphenicol acetyltransferase (CAT) expression while HeLa cells require only Pit-1, a pituitary-specific factor. However, Rate and CHO cells require additional factors. We had determined previously that the transcription factor that mediates insulin-increased prolactin gene expression was likely an Ets-related protein. Elk-1 and Sap-1 were the only Ets-related transcription factors tested as chimeras with LexA DNA-binding domain that were able to mediate insulin-increased expression of a LexA-CAT reporter plasmid, Elk-1 and Sap-1 are expressed in GH4 and HeLa cells but Rate and CHO cells express Sap-1, but not Elk-1, Expression of Elk-1 made Rats cells (but not CHO cells) insulin responsive. C/EBP alpha also binds to the prolactin promoter at a sequence overlapping the binding site for Elk-1, Expression of both C/EBP alpha and Pit-1 in CHO cells is required for high basal transcription of prolactin-CAT. Expression of Elk-1 converts CHO cells into a phenotype in which prolactin gene expression is increased by insulin treatment. Finally, antisense mediated reduction of Elk-1 in GH4 cells decreased insulin-increased prolactin gene expression and confirmed the requirement for Elk-1 for insulin-increased prolactin gene expression. Thus, both C/EBP alpha and Pit-1 were required for high basal transcription while insulin sensitivity required Elk-1.	NYU Med Ctr, Dept Med, Sch Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University	Stanley, FM (corresponding author), NYU Med Ctr, Dept Med, Sch Med, TH 450,550 1st Ave, New York, NY 10016 USA.			Stanley, Frederick/0000-0002-3684-2168	NIDDK NIH HHS [DK43365] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COFFER P, 1994, ONCOGENE, V9, P911; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Gille H, 1996, MOL CELL BIOL, V16, P1094; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jacob KK, 1999, ENDOCRINOLOGY, V140, P4542, DOI 10.1210/en.140.10.4542; JACOB KK, 1994, J BIOL CHEM, V269, P25515; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; Park EA, 1999, J BIOL CHEM, V274, P211, DOI 10.1074/jbc.274.1.211; PARK EA, 1993, J BIOL CHEM, V268, P613; Partridge M, 1996, ANTISENSE NUCLEIC A, V6, P169, DOI 10.1089/oli.1.1996.6.169; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; Stein CA, 1999, NAT BIOTECHNOL, V17, P209, DOI 10.1038/6909; TAE HJ, 1994, J BIOL CHEM, V269, P10475; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	34	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24931	24936		10.1074/jbc.M102826200	http://dx.doi.org/10.1074/jbc.M102826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340077	hybrid			2022-12-27	WOS:000169800700067
J	Zhou, TY; Chiang, CM				Zhou, TY; Chiang, CM			The intronless and TATA-less human TAF(II)55 gene contains a functional initiator and a downstream promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR AP-2; LONG TERMINAL REPEAT; BOX-BINDING PROTEIN; DNA-BINDING; MAMMALIAN-CELLS; CORE PROMOTERS; CHROMOSOMAL LOCALIZATION; DEPENDENT TRANSCRIPTION; TFIID SUBUNITS	Human TAF(II)55 (hTAF(II)55) is a component of the multisubunit general transcription factor TFIID and has been shown to mediate the functions of many transcriptional activators via direct protein-protein interactions. To uncover the regulatory properties of the general transcription machinery, we have isolated the hTAF(II)55 gene and dissected the regulatory elements and the core promoter responsible for hTAF(II)55 gene expression. Surprisingly, the hTAF(II)55 gene has a single uninterrupted open reading frame and is the only intronless general transcription factor identified so far. Its expression is driven by a TATA-less promoter that contains a functional initiator and a downstream promoter element, as illustrated by both transfection assays and mutational analyses. Moreover, this core promoter can mediate the activity of a transcriptional activator that is artificially recruited to the promoter in a heterologous context. Interestingly, in the promoter-proximal region there are multiple Sp1-binding sites juxtaposed to a single AP2-binding site, indicating that Sp1 and AP2 may regulate the core promoter activity of the hTAF(II)55 gene. These findings indicate that a combinatorial regulation of a general transcription factor-encoding gene can be conferred by both ubiquitous and cell type-specific transcriptional regulators.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Case Western Reserve University	Chiang, CM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.	c-chiang@biochemistry.cwru.edu			NCI NIH HHS [CA81017] Funding Source: Medline; NIGMS NIH HHS [GM59643] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059643] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; BOAM DSW, 1995, J BIOL CHEM, V270, P19487, DOI 10.1074/jbc.270.33.19487; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHALUT C, 1995, GENE, V161, P277, DOI 10.1016/0378-1119(95)00209-O; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIANG CM, 1991, J VIROL, V65, P3317, DOI 10.1128/JVI.65.6.3317-3329.1991; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Gentles AJ, 1999, TRENDS GENET, V15, P47, DOI 10.1016/S0168-9525(98)01648-5; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hou SY, 2000, MOL CELL BIOL, V20, P113, DOI 10.1128/MCB.20.1.113-125.2000; HUANG ZM, 1995, MOL CELL BIOL, V15, P3864; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; INOSTROZA JA, 1992, CELL, V70, P477; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; KEDES LH, 1979, ANNU REV BIOCHEM, V48, P837, DOI 10.1146/annurev.bi.48.070179.004201; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lavigne AC, 1996, J BIOL CHEM, V271, P19774, DOI 10.1074/jbc.271.33.19774; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; LEWIN B, 2000, GENES, V7, P37; Lewis BA, 2000, P NATL ACAD SCI USA, V97, P7172, DOI 10.1073/pnas.120181197; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Martinez E, 1998, MOL CELL BIOL, V18, P6571, DOI 10.1128/MCB.18.11.6571; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; NAGATA S, 1980, NATURE, V287, P401, DOI 10.1038/287401a0; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; Qureshi SA, 1998, MOL CELL, V1, P389, DOI 10.1016/S1097-2765(00)80039-8; Ren B, 1998, EMBO J, V17, P1076, DOI 10.1093/emboj/17.4.1076; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHEER E, 1995, GENOMICS, V29, P269, DOI 10.1006/geno.1995.1243; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; Shibuya T, 1999, GENETICS, V152, P869; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Trubetskoy AM, 1999, J VIROL, V73, P3477, DOI 10.1128/JVI.73.4.3477-3483.1999; vanderKnaap JA, 1997, P NATL ACAD SCI USA, V94, P11827, DOI 10.1073/pnas.94.22.11827; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Willy PJ, 2000, SCIENCE, V290, P982, DOI 10.1126/science.290.5493.982; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu SY, 1996, BIOTECHNIQUES, V21, P718; Wu SY, 1999, J BIOL CHEM, V274, P23480, DOI 10.1074/jbc.274.33.23480; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Zhang MQ, 1998, GENOME RES, V8, P319, DOI 10.1101/gr.8.3.319	82	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25503	25511		10.1074/jbc.M102875200	http://dx.doi.org/10.1074/jbc.M102875200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11340078	hybrid			2022-12-27	WOS:000169800700141
J	Dohadwala, M; Luo, J; Zhu, L; Lin, Y; Dougherty, GJ; Sharma, S; Huang, M; Pold, N; Batra, RK; Dubinett, SM				Dohadwala, M; Luo, J; Zhu, L; Lin, Y; Dougherty, GJ; Sharma, S; Huang, M; Pold, N; Batra, RK; Dubinett, SM			Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASED EXPRESSION; CARCINOMA CELLS; TUMOR INVASION; HUMAN PROSTATE; UP-REGULATION; TGF-BETA; IN-VIVO; APOPTOSIS; INHIBITION; GROWTH	Elevated tumor cyclooxygenase (COX-2) expression is associated with increased angiogenesis, tumor invasion, and suppression of host immunity. We have previously shown that genetic inhibition of tumor COX-2 expression reverses the immunosuppression induced by nonsmall cell lung cancer (NSCLC). To assess the impact of COX-2 expression in lung cancer invasiveness, NSCLC cell lines were transduced with a retroviral vector expressing the human COX-2 cDNA in the sense (COX-2-S) and antisense (COX-2-AS) orientations. COX-2-S clones expressed significantly more COX-2 protein, produced 10-fold more prostaglandin E-2, and demonstrated an enhanced invasive capacity compared with control vector-transduced or parental cells. CD44, the cell surface receptor for hyaluronate, was overexpressed in COX-2-S cells, and specific blockade of CD44 significantly decreased tumor cell invasion. In contrast, COX-2-AS clones had a very limited capacity for invasion and showed diminished expression of CD44. These findings suggest that a COX-2-mediated, CD44-dependent pathway is operative in NSCLC invasion. Because tumor COX-2 expression appears to have a multifaceted role in conferring the malignant phenotype, COX-2 may be an important target for gene or pharmacologic therapy in NSCLC.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Radiat Oncol, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Dubinett, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.			Batra, Raj K./0000-0002-1126-543X	NATIONAL CANCER INSTITUTE [R01CA078654, P50CA090388] Funding Source: NIH RePORTER; NCI NIH HHS [1P50 CA90388, R01 CA78654, R01 CA71817, P50 CA090388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achiwa H, 1999, CLIN CANCER RES, V5, P1001; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; Beck C, 2001, MICROSC RES TECHNIQ, V52, P387, DOI 10.1002/1097-0029(20010215)52:4<387::AID-JEMT1023>3.0.CO;2-W; Chan G, 1999, CANCER RES, V59, P991; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; Ding XZ, 2000, ANTICANCER RES, V20, P2625; DROLL A, 1995, J BIOL CHEM, V270, P11567, DOI 10.1074/jbc.270.19.11567; ENDO T, 1995, AM J RESP CELL MOL, V12, P358, DOI 10.1165/ajrcmb.12.3.7873203; Formby B, 1999, MOL CELL BIOCHEM, V202, P53, DOI 10.1023/A:1007081021483; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hida T, 1998, CANCER RES, V58, P3761; Hida T, 2000, CLIN CANCER RES, V6, P2006; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang M, 1998, CANCER RES, V58, P1208; Huang M, 1996, J IMMUNOL, V157, P5512; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; KOHN EC, 1995, CANCER RES, V55, P1856; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Leahy KM, 2000, CURR MED CHEM, V7, P1163, DOI 10.2174/0929867003374336; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Masferrer JL, 2000, CANCER RES, V60, P1306; Molina MA, 1999, CANCER RES, V59, P4356; Murata H, 1999, AM J GASTROENTEROL, V94, P451; Ochiai M, 1999, JPN J CANCER RES, V90, P1338, DOI 10.1111/j.1349-7006.1999.tb00717.x; PASS HI, 2000, LUNG CANC ETIOLOGY E, P367; Ramanathan RK, 1997, SEMIN ONCOL, V24, P440; Ryu HS, 2000, GYNECOL ONCOL, V76, P320, DOI 10.1006/gyno.1999.5690; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; Shah AH, 2000, PROSTATE, V45, P167, DOI 10.1002/1097-0045(20001001)45:2<167::AID-PROS11>3.0.CO;2-J; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Sun LK, 2001, KIDNEY INT, V59, P190, DOI 10.1046/j.1523-1755.2001.00479.x; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tanji N, 2000, ANTICANCER RES, V20, P2313; Tian B, 2000, EXP CELL RES, V257, P135, DOI 10.1006/excr.2000.4871; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Watkins DN, 1999, EUR RESPIR J, V14, P412, DOI 10.1034/j.1399-3003.1999.14b28.x; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wolff H, 1998, CANCER RES, V58, P4997; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163	50	195	211	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20809	20812		10.1074/jbc.C100140200	http://dx.doi.org/10.1074/jbc.C100140200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11320076	hybrid, Green Accepted			2022-12-27	WOS:000169297900002
J	Cabib, E; Roh, DH; Schmidt, M; Crotti, LB; Varma, A				Cabib, E; Roh, DH; Schmidt, M; Crotti, LB; Varma, A			The yeast cell wall and septum as paradigms of cell growth and morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GTP-BINDING PROTEIN; MAP KINASE PATHWAY; SACCHAROMYCES-CEREVISIAE; CHITIN SYNTHESIS; IDENTIFICATION; INTEGRITY; SYNTHASE; POLARIZATION; CHS3P; BIOSYNTHESIS		NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Cabib, E (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bldg 8,Rm 403, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK024945, Z01DK024945] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Cabib E, 1998, ANNU REV BIOCHEM, V67, P307, DOI 10.1146/annurev.biochem.67.1.307; CABIB E, 1992, J GEN MICROBIOL, V138, P97, DOI 10.1099/00221287-138-1-97; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CABIB E, 1996, MYCOTA, V3, P243; CHOI WJ, 1994, MOL CELL BIOL, V14, P7685, DOI 10.1128/MCB.14.12.7685; CHOI WJ, 1994, P NATL ACAD SCI USA, V91, P4727, DOI 10.1073/pnas.91.11.4727; Chuang JS, 1996, J CELL BIOL, V135, P597, DOI 10.1083/jcb.135.3.597; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; Cos T, 1998, EUR J BIOCHEM, V256, P419, DOI 10.1046/j.1432-1327.1998.2560419.x; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; DeMarini DJ, 1997, J CELL BIOL, V139, P75, DOI 10.1083/jcb.139.1.75; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Ford RA, 1996, MOL GEN GENET, V252, P420, DOI 10.1007/s004380050246; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Montijn RC, 1999, J BACTERIOL, V181, P7414, DOI 10.1128/JB.181.24.7414-7420.1999; Moukadiri I, 1999, J BACTERIOL, V181, P4741, DOI 10.1128/JB.181.16.4741-4745.1999; Mrsa V, 1997, YEAST, V13, P1145; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Pruyne D, 2000, J CELL SCI, V113, P365; Pruyne D, 2000, J CELL SCI, V113, P571; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Santos B, 1997, J CELL BIOL, V136, P95, DOI 10.1083/jcb.136.1.95; Shahinian S, 2000, MOL MICROBIOL, V35, P477, DOI 10.1046/j.1365-2958.2000.01713.x; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Trilla JA, 1997, YEAST, V13, P795, DOI 10.1002/(SICI)1097-0061(199707)13:9<795::AID-YEA139>3.3.CO;2-C; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; Yabe T, 1998, EUR J BIOCHEM, V258, P941, DOI 10.1046/j.1432-1327.1998.2580941.x; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Ziman M, 1998, MOL BIOL CELL, V9, P1565, DOI 10.1091/mbc.9.6.1565; Ziman M, 1996, MOL BIOL CELL, V7, P1909, DOI 10.1091/mbc.7.12.1909; ZLOTNIK H, 1984, J BACTERIOL, V159, P1018, DOI 10.1128/JB.159.3.1018-1026.1984	51	252	261	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19679	19682		10.1074/jbc.R000031200	http://dx.doi.org/10.1074/jbc.R000031200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11309404	hybrid			2022-12-27	WOS:000169135100001
J	Figueroa, C; Taylor, J; Vojtek, AB				Figueroa, C; Taylor, J; Vojtek, AB			Prenylated Rab acceptor protein is a receptor for prenylated small GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; PLASMA-MEMBRANE; TRANSFORMATION; IDENTIFICATION; LOCALIZATION; TRAFFICKING; ASSOCIATION; PATHWAY; CLONING; KINASE	Localization of Ras and Ras-like proteins to the correct subcellular compartment is essential for these proteins to mediate their biological effects. Many members of the Ras superfamily (Ha-Ras, N-Ras, TC21, and RhoA) are prenylated in the cytoplasm and then transit through the endomembrane system on their way to the plasma membrane. The proteins that aid in the trafficking of the small GTPases have not been well characterized. We report here that prenylated Rab acceptor protein (PRA1), which others previously identified as a prenylation-dependent receptor for Rab proteins, also interacts with Ha-Ras, RhoA, TC21, and Rap1a. The interaction of these small GTPases with PRA1 requires their post-translational modification by prenylation. The prenylation-dependent association of PRA1 with multiple GTPases is conserved in evolution; the yeast PRA1 protein associates with both Ha-Ras and RhoA. Earlier studies reported the presence of PRA1 in the Golgi, and we show here that PRA1 co-localizes with Ha-Ras and RhoA in the Golgi compartment. We suggest that PRA1 acts as an escort protein for small GTPases by binding to the hydrophobic isoprenoid moieties of the small GTPases and facilitates their trafficking through the endomembrane system.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Vojtek, AB (corresponding author), Univ Michigan, Dept Biol Chem, 3323 MSRB 3,Box 0606, Ann Arbor, MI 48109 USA.							ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Bartels DJ, 1999, MOL CELL BIOL, V19, P6775, DOI 10.1128/mcb.19.10.6775; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; Booden MA, 1999, J BIOL CHEM, V274, P1423, DOI 10.1074/jbc.274.3.1423; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; Graham SM, 1996, MOL CELL BIOL, V16, P6132; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P60; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; Magee T, 1999, CELL, V98, P9, DOI 10.1016/S0092-8674(00)80601-7; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; VOJTEK AB, 1993, J CELL SCI, V105, P777; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	33	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28219	28225		10.1074/jbc.M101763200	http://dx.doi.org/10.1074/jbc.M101763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11335720	hybrid			2022-12-27	WOS:000170093400065
J	Moritz, OL; Tam, BM; Papermaster, DS; Nakayama, T				Moritz, OL; Tam, BM; Papermaster, DS; Nakayama, T			A functional rhodopsin-green fluorescent protein fusion protein localizes correctly in transgenic Xenopus laevis retinal rods and is expressed in a time-dependent pattern	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; POSITION-EFFECT VARIEGATION; MATRIX-ATTACHMENT REGIONS; BOVINE RHODOPSIN; OUTER SEGMENT; DROSOPHILA-MELANOGASTER; CYTOPLASMIC TAIL; GENE; KINASE; HETEROCHROMATIN	To study rhodopsin biosynthesis and transport in vivo, we engineered a fusion protein (rho-GFP) of bovine rhodopsin (rho) and green fluorescent protein (GFP). rho-GFP expressed in COS-1 cells bound 11-cis retinal, generating a pigment with spectral properties of rhodopsin (A(max) at 500 nm) and GFP (A(max) at 488 nm). rho-GFP activated transducin at 50% of the wild-type activity, whereas phosphorylation of rho-GFP by rhodopsin kinase was 10% of wild-type levels. We expressed rho-GFP in the rod photoreceptors of Xenopus laevis using the X. laevis principal opsin promoter. Like rhodopsin, rho-GFP localized to rod outer segments, indicating that rho-GFP was recognized by membrane transport mechanisms. In contrast, a rho-GFP variant lacking the C-terminal outer segment localization signal distributed to both outer and inner segment membranes. Confocal microscopy of transgenic retinas revealed that transgene expression levels varied between cells, an effect that is probably analogous to position-effect variegation. Furthermore, rho-GFP concentrations varied along the length of individual rods, indicating that expression levels varied within single cells on a daily or hourly basis. These results have implications for transgenic models of retinal degeneration and mechanisms of position-effect variegation and demonstrate the utility of rho-GYP as a probe for rhodopsin transport and temporal regulation of promoter function.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06032 USA; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	University of Connecticut; Vertex Pharmaceuticals	Moritz, OL (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06032 USA.			Moritz, Orson L/0000-0002-6183-6499	NEI NIH HHS [EY-06891, EY-12421] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012421] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adler R., 1986, RETINA MODEL CELL BI, P297; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, P2; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; BESHARSE JC, 1977, J CELL BIOL, V75, P507, DOI 10.1083/jcb.75.2.507; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BROWN NG, 1992, EUR J BIOCHEM, V208, P659, DOI 10.1111/j.1432-1033.1992.tb17232.x; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Deretic D, 1998, P NATL ACAD SCI USA, V95, P10620, DOI 10.1073/pnas.95.18.10620; Deretic D, 1996, J BIOL CHEM, V271, P2279, DOI 10.1074/jbc.271.4.2279; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P588; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Green ES, 2000, INVEST OPHTH VIS SCI, V41, P1546; Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922; HAROSI FI, 1975, J GEN PHYSIOL, V66, P357, DOI 10.1085/jgp.66.3.357; KAPLAN MW, 1981, INVEST OPHTH VIS SCI, V21, P395; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LEIBMAN P, 1968, VISION RES, V8, P761; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; Moritz OL, 1999, INVEST OPHTH VIS SCI, V40, P3276; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; Namciu SJ, 1998, MOL CELL BIOL, V18, P2382, DOI 10.1128/MCB.18.4.2382; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPERMASTER DS, 1985, INVEST OPHTH VIS SCI, V26, P1386; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Piston DW, 1999, METHOD CELL BIOL, V58, P31; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Talbert PB, 2000, GENETICS, V154, P259; Tam BM, 2000, J CELL BIOL, V151, P1369, DOI 10.1083/jcb.151.7.1369; TOWNESANDERSON E, 1985, J CELL BIOL, V100, P175, DOI 10.1083/jcb.100.1.175; WEISS ER, 1995, BIOCHEM BIOPH RES CO, V216, P755, DOI 10.1006/bbrc.1995.2686; Yeagle P L, 1996, Mol Vis, V2, P12; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P9649, DOI 10.1021/bi970908a; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	55	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28242	28251		10.1074/jbc.M101476200	http://dx.doi.org/10.1074/jbc.M101476200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11350960	hybrid			2022-12-27	WOS:000170093400068
J	Briknarova, K; Gehrmann, M; Banyai, L; Tordai, H; Patthy, L; Llinas, M				Briknarova, K; Gehrmann, M; Banyai, L; Tordai, H; Patthy, L; Llinas, M			Gelatin-binding region of human matrix metalloproteinase-2 - Solution structure, dynamics, and function of the COL-23 two-domain construct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-BINDING; N-15 NMR; DISTANCE GEOMETRY; IV COLLAGENASE; TYPE-2 MODULE; II MODULE; FIBRONECTIN; SPECTROSCOPY; DOMAIN; PLASMINOGEN	Human matrix metalloproteinase-2 (MMP-2) contains an array of three fibronectin type II (FII) modules postulated to interact with gelatin (denatured collagen). Here, we verify that the NMR solution structure of the third FII repeat (COL-3) is similar to that of the second FII repeat (COL-2); characterize its ligand-binding properties; and derive dynamics properties and relative orientation in solution for the two domains of the COL-23 fragment, a construct comprising COL-2 and COL-3 in tandem, with each domain possessing a putative collagen-binding site. Interaction of the synthetic gelatin-like octadecapeptide (Pro-Pro-Gly)(6) (PPG6) with COL-3 is weaker than with COL-2. We found that a synthetic peptide comprising segment 33-42 (peptide 33-42) from the MMP-2 prodomain interacts with COL-3 and, albeit with lower affinity, with COL-2 in a way that mimics PPG6 binding. COL-3 strongly prefers peptide 33-42 over PPG6, which suggests that intramolecular interactions with the prodomain could modulate binding of pro-MMP-2 to its gelatin substrate. In COL-23, the two modules retain their structural individuality and tumble independently. Overall, the NMR data indicate that the relative orientation of the modules in COL-23 is not fixed in solution, that the modules do not interact with one another, and that COL-23 is rather flexible. The binding sites face opposite each other, and their responses to, and normalized affinities for, the longer ligand PPG12 are virtually identical to those of the individual domains for PPG6, thus precluding cooperativity, although they may interact simultaneously with multiple sites of the extracellular matrix.	Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	Carnegie Mellon University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Llinas, M (corresponding author), Carnegie Mellon Univ, Dept Chem, 4400 5th Ave, Pittsburgh, PA 15213 USA.	Ilinas+@andrew.cmu.edu	Patthy, Laszlo/Q-6058-2019; Patthy, Laszlo/A-2353-2013	Tordai, Hedvig/0000-0002-0875-5569	NHLBI NIH HHS [HL29409] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; An SSA, 1998, PROTEIN SCI, V7, P1960, DOI 10.1002/pro.5560070911; An SSA, 1998, PROTEIN SCI, V7, P1947, DOI 10.1002/pro.5560070910; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Briknarova K, 1999, STRUCTURE, V7, P1235, DOI 10.1016/S0969-2126(00)80057-X; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; Copie V, 1998, J MOL BIOL, V277, P663; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; DEMARCO A, 1977, J MAGN RESON, V26, P527, DOI 10.1016/0022-2364(77)90104-4; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Dux P, 1997, J BIOMOL NMR, V10, P301, DOI 10.1023/A:1018393225804; FRIEDRICHS MS, 1995, J BIOMOL NMR, V5, P147, DOI 10.1007/BF00208805; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KOBAYASHI Y, 1970, BIOPOLYMERS, V9, P415, DOI 10.1002/bip.1970.360090404; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; LUKACSOVICH T, 1987, J BACTERIOL, V169, P272, DOI 10.1128/jb.169.1.272-277.1987; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Martinez MJF, 1997, HELICOBACTER, V2, P36, DOI 10.1111/j.1523-5378.1997.tb00055.x; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MULLER L, 1979, J AM CHEM SOC, V101, P4481; MURPHY G, 1994, J BIOL CHEM, V269, P6632; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; RUCKER SP, 1989, MOL PHYS, V68, P509, DOI 10.1080/00268978900102331; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Smith SP, 2000, BIOCHEMISTRY-US, V39, P8374, DOI 10.1021/bi000427i; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STERNLICHT MD, 1999, GUIDEBOOK EXTRACELLU, P545; Sticht H, 1998, J MOL BIOL, V276, P177, DOI 10.1006/jmbi.1997.1528; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326; Tordai H, 1999, EUR J BIOCHEM, V259, P513, DOI 10.1046/j.1432-1327.1999.00070.x; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; VANZIJL PCM, 1995, J MAGN RESON SER A, V113, P265, DOI 10.1006/jmra.1995.1092; Yu AE, 1998, BIOL EXTRAC, P85; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	58	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27613	27621		10.1074/jbc.M101105200	http://dx.doi.org/10.1074/jbc.M101105200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11320090	hybrid			2022-12-27	WOS:000169966900116
J	Kim, JH; Shin, DY; Han, MH; Choi, MU				Kim, JH; Shin, DY; Han, MH; Choi, MU			Mutational and kinetic evaluation of conserved His-123 in dual specificity protein-tyrosine phosphatase vaccinia H1-related phosphatase - Participation of Tyr-78 and Thr-73 residues in tuning the orientation of His-123	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE STRUCTURES; CRYSTAL-STRUCTURE; CATALYZED REACTION; VHR; INTERMEDIATE; DEPHOSPHORYLATION; VISUALIZATION; TUNGSTATE; DOMAIN; PTP1	Active-site cysteine strategically positioned in the P-loop of protein-tyrosine phosphatases has been suggested to be further stabilized by hydrogen bonding arrays radiating out from the P-loop to neighboring residues. In this work, we investigated the structural, role of histidine array in HC(X)(5)RS motif of the (v) under bar accinia (H) under bar1-(r) under bar elated protein phosphatase (VHR), using site-directed mutagenesis in conjunction with an extensive kinetic analysis. Conserved His-123 was mutated along with neighboring residues Tyr-78 and Thr-73. The increased pK(alpha) values of active-site Cys-124 found in Y78F and T73A mutants (6.51 and 6.75, respectively) were comparable to those of H123A and H123F mutants. Kinetic evaluation of Y78F and T73A mutants further implicates that the mutations perturb the relative position of Cys-124 within the P-loop. These results imply that Tyr-78 and Thr-73 make up an essential part of the Hi-123 array and structurally tune the Cys-124 position. Tyr-78 of VHR turns out to be the invariant Tyr reported in several protein-tyrosine phosphatases by a structure-based sequence alignment, Therefore, orientation of the imidazole ring of His-123 by the invariant Tyr-78 is crucial for maintaining the proper position of Cys-124 in the P-loop.	Seoul Natl Univ, Sch Chem & Mol Engn, Seoul 151747, South Korea; Seoul Natl Univ, Ctr Mol Catalysis, Seoul 151747, South Korea; Korea Res Inst Biosci & Biotechnol, Mol Funct Prot Res Unit, Taejon 305333, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Choi, MU (corresponding author), Seoul Natl Univ, Sch Chem & Mol Engn, Seoul 151747, South Korea.							BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; CORMACK B, 1995, SHORT PROTOCOLS MOL; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Evans B, 1996, BIOCHEMISTRY-US, V35, P13609, DOI 10.1021/bi9605651; Fauman EB, 1996, J BIOL CHEM, V271, P18780, DOI 10.1074/jbc.271.31.18780; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; WALSH C, 1979, ENZYMATIC REACTIONS, P41; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; Zhao Y, 1996, BIOCHEMISTRY-US, V35, P11797, DOI 10.1021/bi960471r; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	34	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27568	27574		10.1074/jbc.M010526200	http://dx.doi.org/10.1074/jbc.M010526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11346639	hybrid			2022-12-27	WOS:000169966900110
J	Nakagawa, T; Bulger, M; Muramatsu, M; Ito, T				Nakagawa, T; Bulger, M; Muramatsu, M; Ito, T			Multistep chromatin assembly on supercoiled plasmid DNA by nucleosome assembly protein-1 and ATP-utilizing chromatin assembly and remodeling factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLATION; MAMMALIAN-CELLS; CORE PARTICLE; TRANSCRIPTION; BINDING; ISWI; INVITRO; COMPLEX; PURIFICATION; DISRUPTION	We examine in vitro nucleosome assembly by nucleosome assembly protein-1 (NAP-1) and ATP-utilizing chromatin assembly and remodeling factor (ACF). In contrast to previous studies that used relaxed, circular plasmids as templates, we have found that negatively supercoiled templates reveal the distinct roles of NAP-1 and ACF in histone deposition and the formation of an ordered nucleosomal array. NAP-1 can efficiently deposit histones onto supercoiled plasmids. Furthermore, NAP-1 exhibits a greater affinity for histones H2A-H2B than does naked DNA, but in the presence of H3-H4, H2A-H2B are transferred from NAP-1 to the plasmid templates. These observations underscore the importance of a high affinity between H2A-H2B and NAP-1 for ordered transfer of core histones onto DNA. In addition, recombinant ACF composed of imitation snitch and Acf1 can extend closely packed nucleosomes, which suggests that recombinant ACF can mobilize nucleosomes. In the assembly reaction with a supercoiled template, ACF need not be added simultaneously with MAP-1. Regularly spaced nucleosomes are generated even when recombinant ACF is added after core histones are transferred completely onto the DNA. Atomic force microscopy, however; suggests that NAP-1 alone fails to accomplish the formation of fine nucleosomal core particles, which are only formed in the presence of ACF. These results suggest a model for the ordered deposition of histones and the arrangement of nucleosomes during chromatin assembly in vivo.	Saitama Med Sch, Div Gene Struct & Funct, Res Ctr Genom Med, Moroyama, Saitama 3500495, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Saitama Medical University; Fred Hutchinson Cancer Center	Ito, T (corresponding author), Saitama Med Sch, Div Gene Struct & Funct, Res Ctr Genom Med, Moroyama, Saitama 3500495, Japan.	tito@saitama-med.ac.jp						Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LEUBA SH, 1994, P NATL ACAD SCI USA, V91, P11621, DOI 10.1073/pnas.91.24.11621; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McQuibban GA, 1998, J BIOL CHEM, V273, P6582, DOI 10.1074/jbc.273.11.6582; PFAFFLE P, 1990, J BIOL CHEM, V265, P16821; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; van Holde K.E., 1988, CHROMATIN; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wolffe A., 1998, CHROMATIN STRUCTURE; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	45	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27384	27391		10.1074/jbc.M101331200	http://dx.doi.org/10.1074/jbc.M101331200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11333264	hybrid			2022-12-27	WOS:000169966900087
J	Urban, G; Golden, T; Aragon, IV; Scammell, JG; Dean, NM; Honkanen, RE				Urban, G; Golden, T; Aragon, IV; Scammell, JG; Dean, NM; Honkanen, RE			Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; CYCLIN E-CDK2 ACTIVATION; C-MYC; CANCER-CELLS; PROTEIN-KINASE; SERINE/THREONINE PHOSPHATASE; ANTISENSE OLIGONUCLEOTIDES; ONCOGENE EXPRESSION; CATALYTIC SUBUNIT; MOLECULAR-CLONING	The proliferation of many estrogen receptor (ER)-positive breast cancer cells depends on estradiol, and tumors arising from these cells are often responsive initially to treatment with Selective ER modulators, which produce an antiestrogen effect. However, tumors that are refractory to the antiestrogenic effects of selective ER modulators often reemerge, and the prognosis for these patients is poor because of the lack of additional effective therapy, Accordingly, deciphering the cellular events associated with estrogen-dependent growth and the subsequent outgrowth of tumors with san estrogen-independent phenotype is of considerable interest. Here me show that the expression of PP5, an evolutionarily conserved Ser/Thr phosphatase that functions as an inhibitor of glucocorticoid- and p53-induced signaling cascades leading to growth suppression, is responsive to 17 beta -estradiol (E-2) in ER-positive human breast carcinoma cells (MCF-7). Northern analysis revealed that E-2-induced PP5 expression is blocked by treatment with tamoxifen, and a consensus ER recognition element was identified in the PP5 promoter, The PP5-ER recognition element associates with human ERs and confers E-2-induced transcriptional activation to reporter plasmids. The specific inhibition of PP5-expression ablates E-2-mediated proliferation in MCF-7 cells without having an apparent effect on E-2-induced expression of c-myc or cyclin DI. Thus, although critical for cell growth, PP5 likely acts either downstream or independently of c-Myc and Cyclin D1. To further characterize the role of PP5 in E-2-regulated growth control, we constructed stable MCF-7 cell lines in which the expression of PP5 was placed under the control of tetracycline-regulated transactivator and operator plasmids, Studies with these cells revealed that the constitutive overexpression of PP5 affords E-2-dependent MCF-7 cells with the ability to proliferate in E-2-depleted media. Together, these studies indicate that E-2-induced PP5 expression functions to enhance E-2-initiated signaling cascades leading to cell division and that aberrant PP5 expression may contribute to the development of MCF-7 cells with an estrogen-independent phenotype.	Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; Univ S Alabama, Dept Pharmacol & Comparat Med, Mobile, AL 36688 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	University of South Alabama; University of South Alabama; Isis Pharmaceuticals Inc	Honkanen, RE (corresponding author), Univ S Alabama, Dept Biochem, Mobile, AL 36688 USA.	honkanen@sungcg.usouthal.edu			NATIONAL CANCER INSTITUTE [R29CA060750, R01CA060750] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR013200] Funding Source: NIH RePORTER; NCI NIH HHS [CA60750] Funding Source: Medline; NCRR NIH HHS [RR13200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altucci L, 1996, ONCOGENE, V12, P2315; AMARA JF, 1983, ENDOCRINOLOGY, V112, P1141, DOI 10.1210/endo-112-3-1141; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; Bastians H, 1996, J CELL SCI, V109, P2865; BECKER W, 1994, J BIOL CHEM, V269, P22586; BINDAL RD, 1988, J MED CHEM, V31, P1978, DOI 10.1021/jm00118a020; Borthwick EB, 2001, FEBS LETT, V491, P279, DOI 10.1016/S0014-5793(01)02177-9; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; Driscoll MD, 1998, J BIOL CHEM, V273, P29321, DOI 10.1074/jbc.273.45.29321; DUBIK D, 1987, CANCER RES, V47, P6517; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; FOEKENS JA, 1995, J NATL CANCER I, V87, P751, DOI 10.1093/jnci/87.10.751; FOEKENS JA, 1994, BRIT J CANCER, V70, P1217, DOI 10.1038/bjc.1994.476; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Huang XZ, 1997, GENOMICS, V44, P336, DOI 10.1006/geno.1997.4891; *INT AG RES CANC, 1992, PUBL WHO, V120; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGE.BS, 1977, BREAST CANC RES TREA, V44, P23; LEUNG BS, 1987, J CELL BIOCHEM, V34, P213, DOI 10.1002/jcb.240340307; LIPPMAN M, 1976, CANCER RES, V36, P4595; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1882, DOI 10.1210/endo-120-5-1882; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NICHOLSON S, 1989, LANCET, V1, P182; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Osborne CK, 1996, SCI MED, V3, P32; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PTASHNE M, 1989, SCIENCE, V254, P371; RABIN DS, 1990, BIOL REPROD, V42, P74, DOI 10.1095/biolreprod42.1.74; RAVDIN PM, 1992, J CLIN ONCOL, V10, P1284, DOI 10.1200/JCO.1992.10.8.1284; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; SHERMAN CD, 1990, MANUAL CLIN ONCOLOGY, P253; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sinclair C, 1999, J BIOL CHEM, V274, P23666, DOI 10.1074/jbc.274.33.23666; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; SONG Q, 1993, GENE, V129, P291, DOI 10.1016/0378-1119(93)90282-8; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUTHERLAND RL, 1983, EUR J CANCER CLIN ON, V19, P307, DOI 10.1016/0277-5379(83)90127-X; WATSON PH, 1991, CANCER RES, V51, P3996; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	57	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27638	27646		10.1074/jbc.M103512200	http://dx.doi.org/10.1074/jbc.M103512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11331294	hybrid			2022-12-27	WOS:000169966900119
J	Marks, DL; Dominguez, M; Wu, KJ; Pagano, RE				Marks, DL; Dominguez, M; Wu, KJ; Pagano, RE			Identification of active site residues in glucosylceramide synthase - A nucleotide-binding/catalytic motif conserved with processive beta-glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-BUTYLDEOXYNOJIRIMYCIN; CRYSTAL-STRUCTURE; GLYCOSPHINGOLIPID BIOSYNTHESIS; LYSOSOMAL STORAGE; SEQUENCE-ANALYSIS; HIGHER-PLANTS; DISEASE MICE; INHIBITOR; GLUCOSYLTRANSFERASE; TOPOLOGY	Glucosylceramide synthase (GCS) transfers glucose from UDP-Glc to ceramide, catalyzing the first glycosylation step in the formation of higher order glycosphingolipids, The amino acid sequence of GCS was reported to be dissimilar from other proteins, with no identifiable functional domains. We previously identified His-193 of rat GCS as an important residue in UDP-Glc and GCS inhibitor binding; however, little else is known about the GCS active site. Here, we identify key residues of the GCS active site by performing biochemical and site-directed mutagenesis studies of rat GCS expressed in bacteria. First, we found that Cys-207 was the primary residue involved in GCS N-ethylmaleimide sensitivity. Next, we showed by multiple alignment that the region of GCS flanking His-193 and Cys-SO? (amino acids 89-278) contains a D1,D2,D3,(Q/R)XXRW motif found in the putative active site of processive beta -glycosyltransferases (e,g, cellulose, chitin, and hyaluronan syntheses). Site-directed mutagenesis studies demonstrated that most of the highly conserved residues were essential for GCS activity. We also note that GCS and processive beta -glycosyltransferases are topologically similar, possessing cytosolic active sites, with putative transmembrane domains immediately N-terminal to the conserved domain. These results provide the first extensive information on the GCS active site and show that GCS and processive beta -glycosyltransferases possess a conserved substrate-binding/catalytic domain.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Rochester, MN 55905 USA	Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, 200 1st St SW,Stabile 8, Rochester, MN 55905 USA.	Pagano.Richard@mayo.edu			NIGMS NIH HHS [GM22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942, R01GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe A, 2000, J CLIN INVEST, V105, P1563, DOI 10.1172/JCI9711; ABE A, 1995, J LIPID RES, V36, P611; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersson U, 2000, BIOCHEM PHARMACOL, V59, P821, DOI 10.1016/S0006-2952(99)00384-6; Barny MA, 1996, MOL MICROBIOL, V19, P443, DOI 10.1046/j.1365-2958.1996.382911.x; Blanton RL, 2000, P NATL ACAD SCI USA, V97, P2391, DOI 10.1073/pnas.040565697; Butters TD, 2000, CHEM REV, V100, P4683, DOI 10.1021/cr990292q; Campbell J A, 1998, BIOCHEM J, V329, P929; Charnock SJ, 1999, BIOCHEMISTRY-US, V38, P6380, DOI 10.1021/bi990270y; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; Cox T, 2000, LANCET, V355, P1481, DOI 10.1016/S0140-6736(00)02161-9; Delmer DP, 1999, ANNU REV PLANT PHYS, V50, P245, DOI 10.1146/annurev.arplant.50.1.245; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hakamori S, 1998, ACTA ANAT, V161, P79; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; IELPI L, 1990, J BIOL CHEM, V265, P2843; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Jeyakumar M, 1999, P NATL ACAD SCI USA, V96, P6388, DOI 10.1073/pnas.96.11.6388; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Keenleyside WJ, 1996, J BIOL CHEM, V271, P28581, DOI 10.1074/jbc.271.45.28581; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Llull D, 1999, J EXP MED, V190, P241, DOI 10.1084/jem.190.2.241; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; Marks DL, 2000, METHOD ENZYMOL, V311, P50; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; Paul P, 1996, J BIOL CHEM, V271, P2287, DOI 10.1074/jbc.271.4.2287; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Platt FM, 1997, SCIENCE, V276, P428, DOI 10.1126/science.276.5311.428; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Radin NS, 1999, BIOCHEM PHARMACOL, V57, P589; RADIN NS, 1994, MOL CHEM NEUROPATHOL, V21, P111, DOI 10.1007/BF02815346; Saxena IM, 1997, CELLULOSE, V4, P33, DOI 10.1023/A:1018411101036; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Stasinopoulos SJ, 1999, GLYCOBIOLOGY, V9, P31, DOI 10.1093/glycob/9.1.31; Tifft CJ, 2000, GLYCOBIOLOGY, V10, P1249, DOI 10.1093/glycob/10.12.1249; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; Wang-Gillam A, 2000, J BIOL CHEM, V275, P1433, DOI 10.1074/jbc.275.2.1433; Wu KJ, 1999, BIOCHEM J, V341, P395, DOI 10.1042/0264-6021:3410395	49	39	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26492	26498		10.1074/jbc.M102612200	http://dx.doi.org/10.1074/jbc.M102612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337504	hybrid			2022-12-27	WOS:000169823300112
J	Moller, T; Contos, JJ; Musante, DB; Chun, J; Ransom, BR				Moller, T; Contos, JJ; Musante, DB; Chun, J; Ransom, BR			Expression and function of lysophosphatidic acid receptors in cultured rodent microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; G-PROTEIN; SPHINGOSINE 1-PHOSPHATE; CALCIUM MOBILIZATION; MOLECULAR-CLONING; MOUSE-BRAIN; PROLIFERATION; ASTROCYTES; IDENTIFICATION; CONDUCTANCE	Microglia are the resident tissue macrophages of the central nervous system. They are rapidly activated by a variety of insults; and recently, receptors linked to cytoplasmic Ca2+ signals have been implicated in such events. One potential class of receptors are those recognizing lysophosphatidic acid (LPA). LPA is a phospholipid signaling molecule that has been shown to cause multiple cellular responses, including increases in cytoplasmic calcium. We examined whether any of the known LPA receptor genes (lp(A1)/Edg2, lp(A2)/Edg4, and lp(A3)/Edg7) are expressed by cultured mouse or rat microglia. Reverse transcriptase-polymerase chain reaction indicated that mouse microglia predominantly expressed the Ip,, gene, whereas rat microglia predominantly expressed Ip,, Although LPA induced increases in the cytoplasmic Ca2+ concentration in both microglial preparations, the responses differed substantially. The Ca2+ signal in rat microglia occurred primarily through Ca2+ influx via the plasma membrane, whereas the Ca2+ signal in mouse microglia was due to release from intracellular stores. Only at high concentrations was an additional influx component recruited. Additionally, LPA induced increased metabolic activity in mouse (but not rat) microglial cells, Our findings provide evidence for functional LPA receptors on microglia, Thus, LPA might play an important role as a mediator of microglial activation in response to central nervous system injury.	Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, San Diego, CA 92093 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Diego	Moller, T (corresponding author), Univ Washington, Sch Med, Dept Neurol, 1959 NE Pacific St,POB 356465, Seattle, WA 98195 USA.		Ransom, Bruce/ABE-4606-2021	Ransom, Bruce R./0000-0002-9658-0294	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015589] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15589] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Chun J, 1999, CRIT REV NEUROBIOL, V13, P151, DOI 10.1615/CritRevNeurobiol.v13.i2.20; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Contos JJA, 2000, GENOMICS, V64, P155, DOI 10.1006/geno.2000.6122; Dubin AE, 1999, J NEUROSCI, V19, P1371; DURIEUX ME, 1992, AM J PHYSIOL, V263, P896; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Ikeda H, 1998, BIOCHEM BIOPH RES CO, V248, P436, DOI 10.1006/bbrc.1998.8983; Im DS, 2000, MOL PHARMACOL, V57, P753, DOI 10.1124/mol.57.4.753; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Keller JN, 1997, J NEUROCHEM, V69, P1073; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Manning TJ, 1997, GLIA, V20, P163, DOI 10.1002/(SICI)1098-1136(199706)20:2<163::AID-GLIA8>3.0.CO;2-A; Manning TJ, 1998, J NEUROSCI RES, V53, P343, DOI 10.1002/(SICI)1097-4547(19980801)53:3<343::AID-JNR8>3.0.CO;2-A; Moller T, 2000, BRAIN RES, V853, P49, DOI 10.1016/S0006-8993(99)02244-1; Moller T, 1997, J NEUROSCI, V17, P615; MOLLER T, 1988, NEUROREPORT, V10, P2929; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Nietgen GW, 1997, ANESTHESIOLOGY, V86, P1112, DOI 10.1097/00000542-199705000-00015; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Repp H, 1998, N-S ARCH PHARMACOL, V358, P509, DOI 10.1007/PL00005286; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIGHI M, 1989, EUR J IMMUNOL, V19, P1443, DOI 10.1002/eji.1830190815; Rosskopf D, 1998, AM J PHYSIOL-CELL PH, V274, pC1573, DOI 10.1152/ajpcell.1998.274.6.C1573; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Saito S, 1997, NEUROSCI LETT, V229, P73, DOI 10.1016/S0304-3940(97)00397-2; Schulze C, 1997, J NEUROCHEM, V68, P991; SCHUMACHER KA, 1979, THROMB HAEMOSTASIS, V42, P631; Selmaj K, 1996, SPRINGER SEMIN IMMUN, V18, P57, DOI 10.1007/BF00792609; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048, DOI 10.1152/ajpheart.1995.268.5.H2048; TOKUMURA A, 1978, LIPIDS, V13, P572, DOI 10.1007/BF02533598; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WALZ W, 1993, J NEUROSCI, V13, P4403; Weiner JA, 1998, J COMP NEUROL, V398, P587	48	102	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25946	25952		10.1074/jbc.M102691200	http://dx.doi.org/10.1074/jbc.M102691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340076	hybrid			2022-12-27	WOS:000169823300042
J	Ghosh, A; Sarkar, SN; Rowe, TM; Sen, GC				Ghosh, A; Sarkar, SN; Rowe, TM; Sen, GC			A specific isozyme of 2 '-5 ' oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-ALPHA; 2-5A SYNTHETASE; CELL-DEATH; 2'-5'-OLIGOADENYLATE SYNTHETASES; CONSTITUTIVE EXPRESSION; APOPTOSIS; GROWTH; IDENTIFICATION; REGULATORS; SURVIVAL	2-5(A) synthetases are a family of interferon-induced enzymes that polymerize ATP into 2 ' -5 ' linked oligoadenylates that activate RNase L and cause mRNA degradation. Because they all can synthesize 2-5(A), the reason for the existence of so many synthetase isozymes is unclear. Here we report that the 9-2 isozyme of 2-5(A) synthetase has an additional activity: it promotes apoptosis in mammalian cells. The proapoptotic activity of 9-2 was isozyme-specific and enzyme activity-independent. The 9-2-expressing cells exhibited many properties of cells undergoing apoptosis, such as DNA fragmentation, caspase activation, and poly ADP-ribose polymerase and lamin B cleavage. The isozyme-specific carboxyl-terminal tail of the 9-2 protein was shown, by molecular modeling, to contain a Bcl-2 homology 3 (BH3) domain, suggesting that it may be able to interact with members of the Bcl-2 family that contain BH1 and BH2 domains. Co-immunoprecipitate assays and confocal microscopy showed that 9-2 can indeed interact with the anti-apoptotic proteins Bcl-2 and Bclx(L) in vivo and in vitro. Mutations in the BH3 domain that eliminated the 9-2-Bcl-2 amd 9-2-Bclx(L) interactions also eliminated the apoptotic activity of 9-2. Thus, we have identified an interferon-induced dual function protein of the Bcl-2 family that can synthesize 2-5(A) and promote cellular apoptosis independently. Moreover, the cellular abundance of this protein is regulated by alternative splicing; the other isozymes encoded by the same gene are not proapoptotic.	Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Dept Mol Biol NC20, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org	Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA062220, R01 CA068782, CA62220, CA68782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; ETIENNESMEKENS M, 1983, P NATL ACAD SCI-BIOL, V80, P4609, DOI 10.1073/pnas.80.15.4609; Ghosh A, 1997, J BIOL CHEM, V272, P15452, DOI 10.1074/jbc.272.24.15452; Ghosh A, 1997, J BIOL CHEM, V272, P33220, DOI 10.1074/jbc.272.52.33220; Ghosh A, 2000, VIROLOGY, V266, P319, DOI 10.1006/viro.1999.0085; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; Gibson L, 1996, ONCOGENE, V13, P665; ICHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117, DOI 10.1093/nar/14.24.10117; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KERR IM, 1987, J INTERFERON RES, V7, P505, DOI 10.1089/jir.1987.7.505; Luchetti F, 1998, HAEMATOLOGICA, V83, P974; MARIE I, 1992, J BIOL CHEM, V267, P9933; Otsuki T, 1998, BRIT J HAEMATOL, V103, P518, DOI 10.1046/j.1365-2141.1998.01000.x; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; REBOUILLAT D, 1999, J INTERFERON CYTOKIN, V19, P1917; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; Sarkar SN, 1999, J BIOL CHEM, V274, P25535, DOI 10.1074/jbc.274.36.25535; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SILVERMAN RH, 1997, GENE REGULATION, P295; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STARK GR, 1979, NATURE, V278, P471, DOI 10.1038/278471a0; VILCEK J, 1996, FIELDS VIROLOGY, P375	29	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25447	25455		10.1074/jbc.M100496200	http://dx.doi.org/10.1074/jbc.M100496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323417	hybrid			2022-12-27	WOS:000169800700135
J	Li, HT; Samouilov, A; Liu, XP; Zweier, JL				Li, HT; Samouilov, A; Liu, XP; Zweier, JL			Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrite reduction - Evaluation of its role in nitric oxide generation in anoxic tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; D-GLUCAMINE DITHIOCARBAMATE; O-2-DEPENDENT TYPES; DEHYDROGENASE; HEART; PEROXYNITRITE; PURIFICATION; INHIBITION; MECHANISM; PATHWAY	Xanthine oxidase (XO)-catalyzed nitrite reduction with nitric oxide (NO) production has been reported to occur under anaerobic conditions, but questions remain regarding the magnitude, kinetics, and biological importance of this process, To characterize this mechanism and its quantitative importance in biological systems, electron paramagnetic resonance spectroscopy, chemiluminescence NO analyzer, and NO electrode studies were performed. The XO reducing substrates xanthine, NADH, and 2,3-dihydroxybenz-aldehyde triggered nitrite reduction to NO, and the molybdenum-binding XO inhibitor oxypurinol inhibited this NO formation, indicating that nitrite reduction occurs at the molybdenum site. However, at higher xanthine concentrations, partial inhibition was seen, suggesting the formation of a substrate-bound reduced enzyme complex with xanthine blocking the molybdenum site. Studies of the pH dependence of NO formation indicated that XO-mediated nitrite reduction occurred via an acid-catalyzed mechanism, Nitrite and reducing substrate concentrations were important regulators of XO-catalyzed NO generation. The substrate dependence of anaerobic XO-catalyzed nitrite reduction followed Michaelis-Menten kinetics, enabling prediction of the magnitude of NO formation and delineation of the quantitative importance of this process in biological systems. It was determined that under conditions occurring during no-flow ischemia, myocardial XO and nitrite levels are sufficient to generate NO levels comparable to those produced from nitric oxide synthase, Thus, XO-catalyzed nitrite reduction can be an important source of NO generation under ischemic conditions.	Johns Hopkins Univ, Sch Med, Mol & Cellular Biophys Labs, Dept Med,Div Cardiol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Elect Paramagnet Resonance Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University	Zweier, JL (corresponding author), Johns Hopkins Asthma & Allergy Ctr, EPR Ctr, 5501 Hopkins Bayview Circle,Rm LA-14, Baltimore, MD 21224 USA.	jzweier@welch.jhu.edu	Liu, Xiaoping/A-4516-2008; Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011	Liu, Xiaoping/0000-0002-7516-382X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R29HL038324, P01HL065608, R01HL063744] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38324, HL63744, HL65608] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLISON RC, 1990, J APPL PHYSIOL, V69, P597, DOI 10.1152/jappl.1990.69.2.597; BATTELLI MG, 1973, BIOCHEM J, V131, P191, DOI 10.1042/bj1310191; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; Giraldez RR, 1997, J BIOL CHEM, V272, P21420, DOI 10.1074/jbc.272.34.21420; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Harris CM, 1997, J BIOL CHEM, V272, P8370, DOI 10.1074/jbc.272.13.8370; HILLE R, 1984, J BIOL CHEM, V259, P1570; HUNT J, 1992, J BIOL CHEM, V267, P21479; LANCASTER JR, 1992, J BIOL CHEM, V267, P10994; LANGREHR JM, 1993, TRANSPLANTATION, V55, P1205, DOI 10.1097/00007890-199306000-00001; Lee CI, 2000, J BIOL CHEM, V275, P9369, DOI 10.1074/jbc.275.13.9369; McCord J M, 1985, Adv Myocardiol, V5, P183; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; SAITO T, 1989, J BIOL CHEM, V264, P10015; SAITO T, 1989, J BIOL CHEM, V264, P15930; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Sarnesto A, 1996, LAB INVEST, V74, P48; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; Trujillo M, 1998, J BIOL CHEM, V273, P7828, DOI 10.1074/jbc.273.14.7828; Wang PH, 1996, J BIOL CHEM, V271, P29223, DOI 10.1074/jbc.271.46.29223; Xia M, 1999, J BIOL CHEM, V274, P3323, DOI 10.1074/jbc.274.6.3323; Xia Y, 2000, FREE RADICAL BIO MED, V29, P793, DOI 10.1016/S0891-5849(00)00427-5; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304	32	217	223	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24482	24489		10.1074/jbc.M011648200	http://dx.doi.org/10.1074/jbc.M011648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11312267	hybrid			2022-12-27	WOS:000169800700010
J	Tachibana, M; Sugimoto, K; Fukushima, T; Shinkai, Y				Tachibana, M; Sugimoto, K; Fukushima, T; Shinkai, Y			SET domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY GENE INDUCTION; DNA-BINDING PROTEIN; C CENP-C; CHROMOSOME CONDENSATION; CHROMATIN STRUCTURE; FISSION YEAST; CELL-CYCLE; PHOSPHORYLATION; HETEROCHROMATIN; DROSOPHILA	The covalent modification of histone tails has regulatory roles in various nuclear processes, such as control of transcription and mitotic chromosome condensation. Among the different groups of enzymes known to catalyze the covalent modification, the most recent additions are the histone methyltransferases (HMTases), whose functions are now being characterized. Here we show that a SET domain-containing protein, G9a, is a novel mammalian lysine-preferring HMTase. Like Suv39 h1, the first identified lysine-preferring mammalian HMTase, G9a transfers methyl groups to the lysine residues of histone H3, but with a 10-20-fold higher activity, It was reported that lysines 4, 9, and 27 in H3 are methylated in mammalian cells. G9a was able to add methyl groups to lysine 27 as well as 9 in H3, compared with Suv39 hi, which was only able to methylate lysine 9, Our data clearly demonstrated that G9a has an enzymatic nature distinct from Suv39 h1 and its homologue h2, Finally, fluorescent protein-labeled G9a was shown to be localized in the nucleus but not in the repressive chromatin domains of centromeric loci, in which Suv39 h1 family proteins were localized. This finding indicates that G9a may contribute to the organization of the higher order chromatin structure of non-centromeric loci.	Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan; Osaka Prefecture Univ, Dept Appl Biochem, Lab Appl Mol Biol, Sakai, Osaka 5998501, Japan; Nippon Med Sch, Dept Microbiol & Immunol, Bunkyo Ku, Tokyo 1138602, Japan	Kyoto University; Osaka Metropolitan University; Nippon Medical School	Shinkai, Y (corresponding author), Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan.	yshinkai@virus.kyoto-u.ac.jp	Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484; Tachibana, Makoto/0000-0001-7977-1120				Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Duerre John A., 1991, Critical Reviews in Oncogenesis, V2, P97; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000; MILNER CM, 1993, BIOCHEM J, V290, P811, DOI 10.1042/bj2900811; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Muro Y, 2000, CLIN EXP IMMUNOL, V120, P218, DOI 10.1046/j.1365-2249.2000.01189.x; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sugimoto K, 1996, J BIOCHEM, V120, P153; SUGIMOTO K, 1994, J BIOCHEM-TOKYO, V116, P877, DOI 10.1093/oxfordjournals.jbchem.a124610; SUGIMOTO K, 1992, J BIOCHEM, V111, P478, DOI 10.1093/oxfordjournals.jbchem.a123783; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; VONHOLT C, 1989, METHOD ENZYMOL, V170, P431; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Yamada T, 1999, J BIOCHEM, V125, P832, DOI 10.1093/oxfordjournals.jbchem.a022356; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592	43	606	628	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25309	25317		10.1074/jbc.M101914200	http://dx.doi.org/10.1074/jbc.M101914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316813	hybrid			2022-12-27	WOS:000169800700117
J	Whitaker, GB; Limberg, BJ; Rosenbaum, JS				Whitaker, GB; Limberg, BJ; Rosenbaum, JS			Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; 2 VEGF RECEPTORS; TYROSINE KINASE; CONE COLLAPSE; CONTAINING PROTEIN; FACTOR ISOFORMS; SEMAPHORIN-III; FLT-1 RECEPTOR; IN-VIVO; CELLS	The two most abundant secreted isoforms of vascular endothelial growth factor A (VEGF(165) and VEGF(121)) are formed as a result of differential splicing of the VEGF-A gene. VEGF(165) and VEGF(121) share similar affinities at the isolated VEGF receptor (VEGFR)-2 but have been previously demonstrated to have differential ability to activate VEGFR-2-mediated effects on endothelial cells. Herein we investigate whether the recently described VEGF(165) isoform-specific receptor neuropilin-1 (Npn-1) is responsible for the difference in potency observed for these ligands, We demonstrate that although VEGFR-2 and Npn-1 form a complex, this complex does not result in an increase in VEGF(165) binding affinity. Therefore, the differential activity of VEGF(165) and VEGF(121) cannot be explained by a differential binding affinity for the complex. Using an antagonist that competes for VEGF(165) binding at the VEGFR-2(.)Npn-1 complex, we observe specific antagonism of VEGF(165)-meditated phosphorylation of VEGFR-2 without affecting the VEGF(121) response. These data indicate that the formation of the complex is responsible for the increased potency of VEGF(165) versus VEGF(121). Taken together, these data suggest a receptor-clustering role for Npn-1, as opposed to Npn-1 behaving as an affinity-converting subunit.	Procter & Gamble Pharmacuet, Hlth Care Res Ctr, Dept Cardiovasc Res, Mason, OH 45040 USA	Procter & Gamble	Rosenbaum, JS (corresponding author), Procter & Gamble Pharmacuet, Hlth Care Res Ctr, Dept Cardiovasc Res, 8700 Mason Montgomery Rd, Mason, OH 45040 USA.							Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Cai HB, 1999, J NEUROSCI, V19, P6519; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; FERRARA N, 1995, NATURE, V121, P1089; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fong TAT, 1999, CANCER RES, V59, P99; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Horowitz JR, 1997, ARTERIOSCL THROM VAS, V17, P2793, DOI 10.1161/01.ATV.17.11.2793; Ikeda M, 2000, J PATHOL, V191, P426; Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649; Jin Z, 1997, J NEUROSCI, V17, P6256; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kiessling LL, 2000, CURR OPIN CHEM BIOL, V4, P696, DOI 10.1016/S1367-5931(00)00153-8; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; MACEWAN DJ, 1995, MOL PHARMACOL, V48, P316; Machein MR, 1999, HUM GENE THER, V10, P1117, DOI 10.1089/10430349950018111; Mak JCW, 2000, MOL PHARMACOL, V57, P857; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 2000, CANCER METAST REV, V19, P29, DOI 10.1023/A:1026579711033; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Ortega N, 1997, AM J PATHOL, V151, P1215; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PARK JE, 1994, J BIOL CHEM, V269, P25646; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tordjman R, 1999, BLOOD, V94, P2301, DOI 10.1182/blood.V94.7.2301.419k24_2301_2309; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wilson S, 1996, J PHARMACOL EXP THER, V279, P214; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Zhu ZP, 1999, INVEST NEW DRUG, V17, P195, DOI 10.1023/A:1006314501634	69	234	259	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25520	25531		10.1074/jbc.M102315200	http://dx.doi.org/10.1074/jbc.M102315200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333271	hybrid			2022-12-27	WOS:000169800700143
J	Deng, XM; Xiao, L; Lang, WH; Gao, FQ; Ruvolo, P; May, WS				Deng, XM; Xiao, L; Lang, WH; Gao, FQ; Ruvolo, P; May, WS			Novel role for JNK as a stress-activated Bcl2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; PROTEIN-KINASE; CELL-DEATH; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PHOSPHORYLATION; PATHWAY; MITOCHONDRIA; BCL-X(L); IDENTIFICATION	Interleukin (IL)-3-induced Bcl2 phosphorylation at Ser(70) may be required for its full and potent antiapoptotic activity. However, in the absence of IL-3, increased expression of Bcl2 can also prolong cell survival. To determine how Bcl2 may be functionally phosphorylated following IL-3 withdrawal, a stress-activated Bcl2 kinase (SAK) was sought. Results indicate that anisomycin, a potent activator of the stress kinase JNK/SAPK, can induce Bcl2 phosphorylation at Ser70 and that JNK1 can be latently activated following IL-3 withdrawal to mediate Bcl2 phosphorylation. JNK1 directly phosphorylates Bc12 in vitro, co-localizes with Bc12, and collaborates with Bcl-2 to mediate prolonged cell survival in the absence of IL-3 or following various stress applications. Dominant-negative (DN)-JNK1 can block both anisomycin and latent IL-3 withdrawal-induced Bc12 phosphorylation (> 90%) and potently enhances cell death. Furthermore, low dose okadaic acid (OA), a potent protein phosphatase 1 and 2A inhibitor, can activate the mito gen-activated protein kinases JNK1 and ERK1/2, but not p38 kinase, to induce Bcl2 phosphorylation and prolong cell survival in factor-deprived cells. Since PD98059, a specific MEK inhibitor, can only partially inhibit OA-induced Bc12 phosphorylation but completely blocks OA-induced Bc12 phosphorylation in cells expressing DN-JNK1, this supports the conclusion that OA may stimulate Bc12 phosphorylation via a mechanism involving both JNK1 and ERK1/2. Collectively, these findings indicate a novel role for JNK1 as a SAK, and may explain, at least in part, how functional phosphorylation of Bc12 can occur in the absence of growth factor.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	May, WS (corresponding author), Univ Florida, Shands Canc Ctr, 1600 SW Archer Rd,Med Sci Bldg,N505,POB 100232, Gainesville, FL 32610 USA.	smay@ufscc.ufl.edu			NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER; NCI NIH HHS [CA44649-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Andre N, 2000, CANCER RES, V60, P5349; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dixon SC, 1997, ANN PHARMACOTHER, V31, P76, DOI 10.1177/106002809703100113; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Krajewska M, 1997, CANCER RES, V57, P1605; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murata M, 1997, CELL MOL LIFE SCI, V53, P737, DOI 10.1007/s000180050093; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Shu JY, 1996, ONCOGENE, V13, P2421; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; TANG C, 1994, LEUKEMIA, V8, P1960; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yue TL, 1998, J MOL CELL CARDIOL, V30, P495, DOI 10.1006/jmcc.1997.0614; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	52	236	241	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23681	23688		10.1074/jbc.M100279200	http://dx.doi.org/10.1074/jbc.M100279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323415	hybrid			2022-12-27	WOS:000169531100062
J	Hallstrom, TC; Lambert, L; Schorling, S; Balzi, E; Goffeau, A; Moye-Rowley, WS				Hallstrom, TC; Lambert, L; Schorling, S; Balzi, E; Goffeau, A; Moye-Rowley, WS			Coordinate control of sphingolipid biosynthesis and multidrug resistance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; TRANSCRIPTIONAL CONTROL; OLIGOMYCIN RESISTANCE; STRESS-RESPONSE; YEAST; GENE; PROTEIN; PDR1; IDENTIFICATION; MUTANTS	Multiple or pleiotropic drug resistance often occurs in the yeast Saccharomyces cerevisiae through genetic activation of the Cys(6)-Zn(II) transcription factors Pdr1p and Pdr3p. Hyperactive alleles of these proteins cause overproduction of target genes that include drug efflux pumps, which in turn confer high level drug resistance. Here we provide evidence that both Pdr1p and Pdr3p act to regulate production of an enzyme involved in sphingolipid biosynthesis in S. cerevisiae. The last step in formation of the major sphingolipid in the yeast plasma membrane, mannosyldiinositol phosphorylceramide, is catalyzed by the product of the IPT1 gene, inositol phosphotransferase (Ipt1p), Transcription of the IPT1 gene is responsive to changes inactivity of Pdrlp and Pdr3p. A single Pdr1p/Pdr3p response element is present in the IPT1 promoter and is required for regulation by these factors. Loss of IPT1 has complex effects on drug resistance of the resulting strain, consistent with an important role for mannosyldiinositol phosphorylceramide in normal plasma membrane function. Direct assay for Lipid contents of cells demonstrates that changes in sphingolipid composition correlate with changes in the activity of Pdr3p. These data suggest that Pdr1p and Pdr3p may act to modulate the lipid composition of membranes in S. cerevisiae through activation of sphingolipid biosynthesis along with other target genes.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Max Planck Inst Biochem, Dept Membrane Biochem, D-82152 Martinsried, Germany; Univ Catholique Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	University of Iowa; Max Planck Society; Universite Catholique Louvain	Moye-Rowley, WS (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-612 Bowen Sci Bldg, Iowa City, IA 52242 USA.		Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BEELER T, 1994, J BIOL CHEM, V269, P7279; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4048; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; Dickson RC, 1997, J BIOL CHEM, V272, P29620, DOI 10.1074/jbc.272.47.29620; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUERINEAU M, 1974, BIOCHEM BIOPH RES CO, V61, P462, DOI 10.1016/0006-291X(74)90979-6; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hallstrom TC, 2000, J BIOL CHEM, V275, P37347, DOI 10.1074/jbc.M007338200; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; HANSON BA, 1980, J LIPID RES, V21, P309; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; LEPPERT G, 1990, GENETICS, V125, P13; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; NASS G, 1976, MOL GEN GENET, V147, P39, DOI 10.1007/BF00337933; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stock SD, 2000, ANTIMICROB AGENTS CH, V44, P1174, DOI 10.1128/AAC.44.5.1174-1180.2000; TAGUCHI N, 1994, MICROBIOL-SGM, V140, P353, DOI 10.1099/13500872-140-2-353; van den Hazel HB, 1999, J BIOL CHEM, V274, P1934, DOI 10.1074/jbc.274.4.1934; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3; Wu WI, 2000, J BIOL CHEM, V275, P14446, DOI 10.1074/jbc.275.19.14446; Yoshida S, 2000, MOL GEN GENET, V263, P877, DOI 10.1007/s004380000255; ZHAO C, 1994, J BIOL CHEM, V269, P21480	52	69	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23674	23680		10.1074/jbc.M101568200	http://dx.doi.org/10.1074/jbc.M101568200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323424	hybrid			2022-12-27	WOS:000169531100061
J	Hussain, I; Christie, G; Schneider, K; Moore, S; Dingwall, C				Hussain, I; Christie, G; Schneider, K; Moore, S; Dingwall, C			Prodomain processing of Asp1 (BACE2) is autocatalytic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE CLEAVAGE; ALZHEIMERS-DISEASE; GOLGI-COMPLEX; CELL-SURFACE; IDENTIFICATION; TRANSPORT; ENZYME; SITE; PURIFICATION	Generation of the amyloid peptide through proteolytic processing of the amyloid precursor protein by beta -and gamma -secretases is central to the etiology of Alzheimer's disease. The highly elusive beta -secretase was recently identified as a transmembrane aspartic proteinase, Asp2 (BACE). The Asp2 homolog Asp1 (BACE2/DRAP) has also been reported to exhibit beta -secretase cleavage of amyloid precursor protein. Most aspartic proteinases are generated as inactive proenzymes, requiring removal of the prodomain to generate active proteinase, Here we show that prodomain processing of Asp1 occurs between Leu(62) and Ala(63) and is autocatalytic. Asp1 cleaved a maltose-binding protein-Asp1 prodomain fusion protein and a synthetic peptide at this site. Mutation of one of the conserved catalytic aspartic acid residues in the active site of Asp1 to asparagine (D110N) abolished this cleavage. Mutation of P-1' and P-2' residues in the substrate to phenylalanine reduced cleavage at this site. Asp1 expressed in cells was the mature form, and prodomain processing occurred intramolecularly within the endoplasmic reticulum/early Golgi. Interestingly, a proportion of mature Asp1 was expressed on the cell surface. When full-length Asp1(D110N) was expressed in COS-7 cells, it was not processed, suggesting that no other proteinase can activate Asp1 in these cells.	GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Dept Computat & Struct Sci, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Dingwall, C (corresponding author), GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Colin_Dingwall@sbphrd.com	Schneider, Klaus/N-6604-2014	Schneider, Klaus/0000-0002-3068-8681				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Howlett DR, 2000, TRENDS NEUROSCI, V23, P565, DOI 10.1016/S0166-2236(00)01647-7; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROSA P, 1992, J BIOL CHEM, V267, P12227; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Saunders AJ, 1999, SCIENCE, V286; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 2000, SCIENCE, V289, P2296, DOI 10.1126/science.289.5488.2296; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	35	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23322	23328		10.1074/jbc.M101069200	http://dx.doi.org/10.1074/jbc.M101069200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11316808	hybrid			2022-12-27	WOS:000169531100016
J	Kanaoka, Y; Maekawa, A; Penrose, JF; Austen, KF; Lam, BK				Kanaoka, Y; Maekawa, A; Penrose, JF; Austen, KF; Lam, BK			Attenuated zymosan-induced peritoneal vascular permeability and IgE dependent passive cutaneous anaphylaxis in mice lacking leukotriene C-4 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE INFLAMMATORY RESPONSES; GLUTATHIONE S-TRANSFERASE; MAST-CELLS; MOLECULAR-CLONING; MEMBRANE-PROTEIN; DEFICIENT MICE; MOUSE EAR; PURIFICATION; METABOLISM; EXPRESSION	Leukotriene C-4 synthase (LTC4S), the terminal 5-lipoxygenase pathway enzyme that is responsible for the biosynthesis of cysteinyl leukotrienes, has been deleted by targeted gene disruption to define its tissue distribution and integrated pathway function in vitro and in vivo. The LTC4S (-/-) mice developed normally and were fertile. LTC4S activity, assessed by conjugation of leukotriene (LT) A(4) methyl ester with glutathione, was absent from tongue, spleen, and brain and greater than or equal to 90% reduced in lung, stomach, and colon of the LTC4S (-/-) mice. Bone marrow-derived mast cells (BMMC) from the LTC4S (-/-) mice provided no LTC, in response to IgE dependent activation. Exocytosis and the generation of prostaglandin D-2, LTB4, and 5-hydroxyeicosatetraenoic acid by BMMC from LTC4S (-/-) mice and LTC4S (+/+) mice were similar, whereas the degraded product of LTA(4), 6-trans-LTB4, was doubled in BMMC from LTC4S (-/-) mice because of lack of utilization. The zymosan elicited intraperitoneal extravasation of plasma protein and the IgE-mediated passive cutaneous anaphylaxis in the ear were significantly diminished in the LTC4S (-/-) mice. These observations indicate that LTC4S, but not microsomal or cytosolic glutathione S-transferases, is the major LTC4-producing enzyme in tissues and that its integrated function includes mediation of increased vascular permeability in either innate or adaptive immune host inflammatory responses.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Lam, BK (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Rm 628,1 Jimmy Fund Way, Boston, MA 02115 USA.				NHLBI NIH HHS [HL36110] Funding Source: Medline; NIAID NIH HHS [AI31599] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI031599, U01AI031599] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byrum RS, 1999, J IMMUNOL, V163, P6810; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CZOP JK, 1985, P NATL ACAD SCI USA, V82, P2751, DOI 10.1073/pnas.82.9.2751; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HSIEH FH, 2000, J EXP MED, V275, P30531; INAGAKI N, 1986, INT ARCH ALLER A IMM, V80, P285, DOI 10.1159/000234067; INAGAKI N, 1985, INT ARCH ALLER A IMM, V78, P113, DOI 10.1159/000233873; ISHIKAWA T, 1988, EUR J BIOCHEM, V176, P551, DOI 10.1111/j.1432-1033.1988.tb14313.x; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jakobsson PJ, 1997, J BIOL CHEM, V272, P22934, DOI 10.1074/jbc.272.36.22934; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; KOLLER M, 1985, BIOCHIM BIOPHYS ACTA, V833, P128, DOI 10.1016/0005-2760(85)90260-7; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; Lynch KR, 1999, NATURE, V399, P789; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; MIURA T, 1992, EUR J PHARMACOL, V221, P333; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PENROSE JF, 1992, P NATL ACAD SCI USA, V89, P11603, DOI 10.1073/pnas.89.23.11603; Penrose JF, 1997, EUR J BIOCHEM, V248, P807, DOI 10.1111/j.1432-1033.1997.00807.x; RAO TS, 1994, J PHARMACOL EXP THER, V269, P917; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; Scoggan KA, 1997, J BIOL CHEM, V272, P10182; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TSUCHIDA S, 1987, EUR J BIOCHEM, V170, P159, DOI 10.1111/j.1432-1033.1987.tb13681.x; URADE Y, 1990, J BIOL CHEM, V265, P371; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745	49	124	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22608	22613		10.1074/jbc.M103562200	http://dx.doi.org/10.1074/jbc.M103562200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11319240	hybrid			2022-12-27	WOS:000169412700086
J	Miranda, KC; Khromykh, T; Christy, P; Le, TL; Gottardi, CJ; Yap, AS; Stow, JL; Teasdale, RD				Miranda, KC; Khromykh, T; Christy, P; Le, TL; Gottardi, CJ; Yap, AS; Stow, JL; Teasdale, RD			A dileucine motif targets E-cadherin to the basolateral cell surface in Madin-Darby canine kidney and LLC-PK1 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; DI-LEUCINE MOTIF; MDCK CELLS; SORTING SIGNALS; ADHESION MOLECULE; STRUCTURAL REQUIREMENTS; CYTOPLASMIC DOMAIN; COMPLEX-FORMATION; CATENIN COMPLEX; PLASMA-MEMBRANE	E-cadherin is a major adherens junction protein of epithelial cells, with a central role in cell-cell adhesion and cell polarity. Newly synthesized E-cadherin is targeted to the basolateral cell surface, We analyzed targeting information in the cytoplasmic tail of E-cadherin by utilizing chimeras of E-cadherin fused to the ectodo- main of the interleukin-2 alpha (IL-2 alpha) receptor expressed in Madin-Darby canine kidney and LLC-PK1 epithelial cells, Chimeras containing the full-length or membrane-proximal half of the E-cadherin cytoplasmic tail were correctly targeted to the basolateral domain. Sequence analysis of the membrane-proximal tail region revealed the presence of a highly conserved dileucine motif, which was analyzed as a putative targeting signal by mutagenesis. Elimination of this motif resulted in the loss of Tac/E-cadherin basolateral localization, pinpointing this dileucine signal as being both necessary and sufficient for basolateral targeting of E-cadherin, Truncation mutants unable to bind beta -catenin were correctly targeted, showing, contrary to current understanding, that beta -catenin is not required for basolateral trafficking. Our results also provide evidence that dileucine mediated targeting is maintained in UC-PK, cells despite the altered polarity of basolateral proteins with tyrosine-based signals in this cell line, These results provide the first direct insights into how E-cadherin is targeted to the basolateral membrane.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Biochem, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Queensland; University of Queensland; University of Queensland; Memorial Sloan Kettering Cancer Center	Teasdale, RD (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Stow, Jennifer L/I-4723-2013; Khromykh, Tatiana/D-3952-2017; Yap, Alpha S./J-1554-2014; Teasdale, Rohan/AAD-6698-2019; Teasdale, Rohan D/B-2538-2009; Gottardi, Cara J./AAU-4691-2021	Stow, Jennifer L/0000-0002-5409-9101; Khromykh, Tatiana/0000-0001-6629-6885; Yap, Alpha S./0000-0002-1038-8956; Teasdale, Rohan/0000-0001-7455-5269; Teasdale, Rohan D/0000-0001-7455-5269; Gottardi, Cara J./0000-0003-0912-7617				Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Brown D, 1996, PHYSIOL REV, V76, P245, DOI 10.1152/physrev.1996.76.1.245; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; DEALMEIDA JB, 1991, AM J PHYSIOL, V260, pC691, DOI 10.1152/ajpcell.1991.260.4.C691; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Distel B, 1998, J BIOL CHEM, V273, P186, DOI 10.1074/jbc.273.1.186; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; El Nemer W, 1999, J BIOL CHEM, V274, P31903, DOI 10.1074/jbc.274.45.31903; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Huber O, 1999, J CELL SCI, V112, P4415; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lechner J, 1999, KIDNEY INT, V55, P2178, DOI 10.1046/j.1523-1755.1999.00487.x; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Polakis P, 2000, GENE DEV, V14, P1837; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V200, P1754, DOI 10.1006/bbrc.1994.1656; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sambrook J., 2002, MOL CLONING LAB MANU; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Simmen T, 1999, MOL CELL BIOL, V19, P3136; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simonsen A, 1998, EUR J CELL BIOL, V76, P25, DOI 10.1016/S0171-9335(98)80014-9; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanentzapf G, 2000, J CELL BIOL, V151, P891, DOI 10.1083/jcb.151.4.891; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	57	134	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22565	22572		10.1074/jbc.M101907200	http://dx.doi.org/10.1074/jbc.M101907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11312273	hybrid			2022-12-27	WOS:000169412700080
J	Singh, SK; Rozycki, J; Ortega, J; Ishikawa, T; Lo, J; Steven, AC; Maurizi, MR				Singh, SK; Rozycki, J; Ortega, J; Ishikawa, T; Lo, J; Steven, AC; Maurizi, MR			Functional domains of the ClpA and ClpX molecular chaperones identified by limited proteolysis and deletion analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; ATP-DEPENDENT PROTEASES; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ARCHAEAL CHAPERONIN; TERMINAL DOMAIN; DEGRADATION; THERMOSOME; TARGETS; COMPLEX	Escherichia coli ClpA and ClpX are ATP-dependent protein unfoldases that each interact with the protease, ClpP, to promote specific protein degradation. We have used limited proteolysis and deletion analysis to probe the conformations of ClpA and ClpX and their interactions with ClpP and substrates. ATP gammaS binding stabilized ClpA and ClpX such that that cleavage by lysylendopeptidase C occurred at only two sites. Both proteins were cleaved within in a loop preceding an a-helix-rich C-terminal domain. Although the loop varies in size and composition in Clp ATPases, cleavage occurred within and around a conserved triad, IG(FIL). Binding of ClpP blocked this cleavage, and prior cleavage at this site rendered both ClpA and ClpX defective in binding and activating ClpP, suggesting that this site is involved in interactions with ClpP. ClpA was also cut at a site near the junction of the two ATPase domains, whereas the second cleavage site in ClpX lay between its N-terminal and ATPase domains. ClpP did not block cleavage at these other sites. The N-terminal domain of ClpX dissociated upon cleavage, and the remaining ClpX DeltaN remained as a hexamer, associated with ClpP, and expressed ATPase, chaperone, and proteolytic activity. A truncated mutant of ClpA lacking its N-terminal 153 amino acids also formed a hexamer, associated with ClpP, and expressed these activities. We propose that the N-terminal domains of ClpX and ClpA lie on the outside ring surface of the holoenzyme complexes where they contribute to substrate binding or perform a gating function affecting substrate access to other binding sites and that a loop on the opposite face of the ATPase rings stabilizes interactions with ClpP and is involved in promoting ClpP proteolytic activity.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMS, Struct Biol Lab, NIH, Bethesda, MD 20892 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Massachusetts Institute of Technology (MIT)	Maurizi, MR (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,1B07, Bethesda, MD 20892 USA.	mmaulizi@helix.nih.gov	Ishikawa, Takashi/E-5023-2017	Ishikawa, Takashi/0000-0002-1976-7477				Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Carrascosa JL, 2001, MICRON, V32, P43, DOI 10.1016/S0968-4328(00)00027-5; CONWAY JF, 1993, J STRUCT BIOL, V111, P222, DOI 10.1006/jsbi.1993.1052; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Gottesman S, 1995, COLD SPRING HARB SYM, V60, P533, DOI 10.1101/SQB.1995.060.01.057; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Ishikawa T, 2000, NATURE, V408, P667, DOI 10.1038/35047165; ISHIKAWA T, 2001, IN PRESS P NATL ACAD, V98; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; May AP, 1999, NAT CELL BIOL, V1, P175, DOI 10.1038/11097; Neuwald AF, 1999, GENOME RES, V9, P27; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; PARK SK, 1993, J BIOL CHEM, V268, P20170; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schoehn G, 2000, J MOL BIOL, V301, P323, DOI 10.1006/jmbi.2000.3952; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Singh SK, 1999, BIOCHEMISTRY-US, V38, P14906, DOI 10.1021/bi991615f; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	41	107	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 3	2001	276	31					29420	29429		10.1074/jbc.M103489200	http://dx.doi.org/10.1074/jbc.M103489200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	461BX	11346657	hybrid			2022-12-27	WOS:000170346000104
J	Mao, CD; Hoang, P; DiCorleto, PE				Mao, CD; Hoang, P; DiCorleto, PE			Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; COLONY-STIMULATING FACTOR; LACKING FUNCTIONAL P53; BETA-CATENIN; VE-CADHERIN; IN-VIVO; MOLECULAR MECHANISM; NEURONAL APOPTOSIS; GROWTH-CONTROL; DNA-DAMAGE	Lithium affects development of various organisms and cell fate through the inhibition of glycogen synthase kinase-3 beta and induction of the Wnt/beta -catenin signaling pathway. In this study, we investigated the effects of lithium on primary bovine aortic endothelial cells (BAEC), Lithium treatment of BAEC induced beta -catenin stabilization but failed to activate the transcriptional activity of the beta -catenin/T-cell factor complex. Lithium caused a sustained G(2)/M cell cycle arrest without affecting cell viability. Reversibility of this cell cycle arrest occurred up to 3 days after treatment but was reduced thereafter. Lithium-treated BAEC exhibited a senescent-like morphology with an increase in cells positive for the senescence-associated-beta -galactosidase activity. Lithium also increased the expression of p21(CiP), a cyclin-dependent kinase inhibitor, both at the protein and RNA levels. No change in p21(Cip) mRNA stability was observed, whereas the transcriptional activity of a p21(Cip) promoter-luciferase construct containing p53 binding sites was increased after lithium treatment. Furthermore, lithium caused increased transcription of a reporter gene under the control of a promoter containing the p53 consensus binding sites both in transiently transfected BAEC and in a stably transfected fibroblast cell line. Lithium caused accumulation of p53 protein in BAEC without affecting p53 mRNA levels. Finally, upregulation of p21(Cip) in response to lithium did not occur in mouse embryonic fibroblasts that were null for p53 alleles, confirming the dependence on a p53 pathway for this lithium effect. These findings demonstrate for the first time that lithium induces also stabilization of the tumor suppressor p53 and reveal a new mechanism that may contribute to the neuroprotective effects of lithium.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Mao, CD (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL29582, HL34727] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034727, P01HL029582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Barker N, 2000, BIOESSAYS, V22, P961; Bazzoni G, 1999, CURR OPIN CELL BIOL, V11, P573, DOI 10.1016/S0955-0674(99)00023-X; Bijur GN, 2000, J BIOL CHEM, V275, P7583, DOI 10.1074/jbc.275.11.7583; Blankesteijn WM, 2000, AM J PATHOL, V157, P877, DOI 10.1016/S0002-9440(10)64601-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DAVIES JA, 1995, DEV BIOL, V167, P50, DOI 10.1006/dbio.1995.1006; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duplaa C, 1999, CIRC RES, V84, P1433; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615; Finch RA, 2000, BLOOD, V96, P2262; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Giles JJ, 1999, J ANAT, V194, P197, DOI 10.1046/j.1469-7580.1999.19420197.x; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; HAMMOND WP, 1982, BLOOD, V59, P179; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ikonomov OC, 1999, AM J PSYCHIAT, V156, P1506, DOI 10.1176/ajp.156.10.1506; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Ladislas R, 2000, Pathol Oncol Res, V6, P3; Logan CY, 1999, DEVELOPMENT, V126, P345; Lucas FR, 1998, J CELL SCI, V111, P1351; Mao C, 2000, ARTERIOSCL THROM VAS, V20, P43, DOI 10.1161/01.ATV.20.1.43; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matsushita H, 2000, CIRCULATION, V101, P1447, DOI 10.1161/01.CIR.101.12.1447; Mei JM, 2000, CANCER RES, V60, P3379; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Shimokawa H, 1999, J MOL CELL CARDIOL, V31, P23, DOI 10.1006/jmcc.1998.0841; Smits VAJ, 1999, FEBS LETT, V457, P23, DOI 10.1016/S0014-5793(99)01002-9; Staal FJT, 1999, INT IMMUNOL, V11, P317, DOI 10.1093/intimm/11.3.317; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Wei HF, 2000, EUR J PHARMACOL, V392, P117, DOI 10.1016/S0014-2999(00)00127-8; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Yonemitsu Y, 1998, CIRC RES, V82, P147; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	69	70	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26180	26188		10.1074/jbc.M101188200	http://dx.doi.org/10.1074/jbc.M101188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337498	hybrid			2022-12-27	WOS:000169823300073
J	McGuire, TF; Trump, DL; Johnson, CS				McGuire, TF; Trump, DL; Johnson, CS			Vitamin D-3-induced apoptosis of murine squamous cell carcinoma cells - Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; VITAMIN-D ANALOGS; 1,25-DIHYDROXYVITAMIN D-3; IN-VITRO; PROSTATE-CANCER; KINASE 1; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; JNK ACTIVATION; PROTEIN-KINASE; TUMOR-CELLS	Vitamin D-3 inhibits cell growth and induces apoptosis in several human cancer lines in vitro and in vivo. However, little is known about the molecular events involved in vitamin D-3-induced apoptosis, Here, we demonstrate that the growth-promoting/pro-survival signaling molecule mitogen-activated protein kinase kinase (MEK) is cleaved in a caspase-dependent manner in murine squamous cell carcinoma (SCC) cells induced to undergo apoptosis by treatment with vitamin D-3. Cleavage resulted in nearly complete loss of full-length MEK and ERK1/2 phosphorylation. ERK1/2 expression was affected only slightly. The phosphorylation and expression of Akt, a kinase regulating a second cell survival pathway, was also inhibited after treatment with vitamin D-3. However, the pro-apoptotic signaling molecule MEKK-1 was up-regulated in both apoptotic and non-apoptotic cells with greater induction and partial N-terminal proteolysis of MEKK-1 observed in apoptotic cells. In contrast to vitamin D-3, cisplatin and etoposide down-regulated Akt levels only modestly, did not promote significant loss of MEK expression, and did not up-regulate MEKK-1. We propose that vitamin D-3 induces apoptosis in SCC cells by a unique mechanism involving selective caspase-dependent MEK cleavage and up-regulation of MEKK-1, Additional evidence is provided that vitamin D-3-induced apoptosis may be mediated via p38 MAPK.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Urol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	McGuire, TF (corresponding author), Univ Pittsburgh, Inst Canc, W1002 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	mcguire@server.pharm.pitt.edu			NCI NIH HHS [CA-67267, CA-85142] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085142, R01CA067267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE E, 1981, P NATL ACAD SCI-BIOL, V78, P4990, DOI 10.1073/pnas.78.8.4990; Blanc C, 2000, CANCER RES, V60, P4386; Blutt SE, 2000, CANCER RES, V60, P779; Blutt SE, 2000, ENDOCRINOLOGY, V141, P10, DOI 10.1210/en.141.1.10; Blutt SE, 1999, P SOC EXP BIOL MED, V221, P89, DOI 10.1046/j.1525-1373.1999.d01-60.x; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHO YL, 1991, CANCER RES, V51, P2848; CHOUVET C, 1986, J STEROID BIOCHEM, V24, P373, DOI 10.1016/0022-4731(86)90085-3; Danielsson C, 1998, CELL DEATH DIFFER, V5, P946, DOI 10.1038/sj.cdd.4400437; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; DEL PL, 1997, SCIENCE, V278, P687; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Diaz GD, 2000, CANCER RES, V60, P2304; EISMAN JA, 1987, CANCER RES, V47, P21; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Evans SRT, 1999, INT J ONCOL, V14, P979; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fife RS, 1997, CANCER LETT, V120, P65, DOI 10.1016/S0304-3835(97)00298-X; Fioravanti L, 1998, ANTICANCER RES, V18, P1703; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gebauer G, 2000, INT J ONCOL, V16, P321; Getzenberg RH, 1997, UROLOGY, V50, P999, DOI 10.1016/S0090-4295(97)00408-1; Gross C, 1998, J UROLOGY, V159, P2035, DOI 10.1016/S0022-5347(01)63236-1; Hansen CM, 1997, BIOCHEM PHARMACOL, V54, P1173, DOI 10.1016/S0006-2952(97)00181-0; Hershberger PA, 1999, CANCER RES, V59, P2644; James SY, 1998, BRIT J PHARMACOL, V125, P953, DOI 10.1038/sj.bjp.0702103; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; JIANG HP, 1994, ONCOGENE, V9, P3397; Johnson CS, 2000, P AN M AM SOC CLIN, V19, P19; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Light BW, 1997, CANCER RES, V57, P3759; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mathiasen IS, 1999, CANCER RES, V59, P4848; McElwain Mariann C., 1995, Molecular and Cellular Differentiation, V3, P31; Narvaez CJ, 1997, ENDOCRINOLOGY, V138, P4690, DOI 10.1210/en.138.11.4690; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Opolski A, 2000, CURR PHARM DESIGN, V6, P755, DOI 10.2174/1381612003400407; Page C, 2000, ANTICANCER RES, V20, P407; Pirianov G, 1999, CELL DEATH DIFFER, V6, P890, DOI 10.1038/sj.cdd.4400563; Rozen F, 1999, INT J ONCOL, V15, P589; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; SimboliCampbell M, 1996, J STEROID BIOCHEM, V58, P367, DOI 10.1016/0960-0760(96)00055-6; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Sundaram S, 1999, RADIAT RES, V152, P479, DOI 10.2307/3580143; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TRUMP DL, 2000, P AN M AM SOC CLIN, V19, pA337; VanWeelden K, 1998, ENDOCRINOLOGY, V139, P2102, DOI 10.1210/en.139.4.2102; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Verlinden L, 2000, CANCER RES, V60, P2673; Wang Q, 2000, CANCER RES, V60, P2040; Welsh J, 1998, SUB CELL BIOCHEM, V30, P245; WELSH J, 1994, BIOCHEM CELL BIOL, V72, P537, DOI 10.1139/o94-072; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xie SP, 1999, EUR J CANCER, V35, P1717, DOI 10.1016/S0959-8049(99)00200-2; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yu H, 1999, J La State Med Soc, V151, P218; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	74	116	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26365	26373		10.1074/jbc.M010101200	http://dx.doi.org/10.1074/jbc.M010101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331275	hybrid			2022-12-27	WOS:000169823300096
J	Palmer, S; Brouillet, JP; Kilbey, A; Fulton, R; Walker, M; Crossley, M; Bartholomew, C				Palmer, S; Brouillet, JP; Kilbey, A; Fulton, R; Walker, M; Crossley, M; Bartholomew, C			Evi-1 transforming and repressor activities are mediated by CtBP Co-repressor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOCYTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; TERMINAL BINDING-PROTEIN; ZINC-FINGER PROTEIN; CELL-CYCLE CONTROL; TRANSCRIPTIONAL REPRESSION; MYELOID-LEUKEMIA; HISTONE DEACETYLASE; RAT1 FIBROBLASTS; DROSOPHILA CTBP	Ectopic production of the Evil transcriptional repressor zinc finger protein is seen in 4-6% of human acute myeloid leukemias. Overexpression also transforms Rat1 fibroblasts by an unknown mechanism, which is likely to be related to its role in leukemia and which depends upon its repressor activity. We show here that mutant murine Evi-1 proteins, lacking either the N-terminal zinc finger DNA binding domain or both DNA binding zinc finger clusters, function as dominant negative mutants by reverting the transformed phenotype of Evi-1 transformed Rat1 fibroblasts, The dominant negative activity of the non-DNA binding mutants suggests sequestration of transformation-specific cofactors and that recruitment of these cellular factors might mediate Evi-1 transforming activity. C-terminal binding protein (CtBP) co-repressor family proteins bind PLDLS-like motifs, We show that the murine Evi-1 repressor domain has two such sites, PFDLT (site a, amino acids 553-659) and PLDLS (site b, amino acids 584-599), which independently can bind CtBP family co-repressor proteins, with site b binding with higher affinity than site a. Functional analysis of specific CtBP binding mutants show site b is absolutely required to mediate both transformation of Rat1 fibroblasts and transcriptional repressor activity. This is the first demonstration that the biological activity of a mammalian cellular transcriptional repressor protein is mediated by CtBPs. Furthermore, it suggests that CtBP proteins are involved in the development of some acute leukemias and that blocking their ability to specifically interact with EVI1 might provide a target for the development of pharmacological therapeutic agents.	Glasgow Caledonian Univ, Sch Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland; CHU Arnaud Villeneuve, Lab Biol Cellulaire & Hormonale, F-34295 Montpellier 5, France; Univ Montpellier 1, INSERM U 540, Unite Endocrinol Mol & Cellulaire Canc, F-34090 Montpellier, France; Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow 961 1BD, Lanark, Scotland; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	Glasgow Caledonian University; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Beatson Institute; University of Sydney	Bartholomew, C (corresponding author), Glasgow Caledonian Univ, Sch Biol & Biomed Sci, City Campus,Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.		Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642				BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FICHELSON S, 1992, LEUKEMIA, V6, P93; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FUNABIKI T, 1994, ONCOGENE, V9, P1575; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; HORLEIN AJ, 1995, NATURE, V377, P395; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Kilbey A, 1998, ONCOGENE, V16, P2287, DOI 10.1038/sj.onc.1201732; Kilbey A, 1999, CELL GROWTH DIFFER, V10, P601; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; KUROKAWA M, 1995, ONCOGENE, V11, P833; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MITANI K, 1995, BRIT J HAEMATOL, V90, P711, DOI 10.1111/j.1365-2141.1995.tb05606.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Ogawa S, 1996, LEUKEMIA, V10, P788; Peeters P, 1997, CANCER RES, V57, P564; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Suzukawa K, 1997, GENOMICS, V42, P356, DOI 10.1006/geno.1997.4732; Suzukawa K, 1999, LEUKEMIA, V13, P1359, DOI 10.1038/sj.leu.2401483; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yufu Y, 1996, AM J HEMATOL, V53, P30, DOI 10.1002/(SICI)1096-8652(199609)53:1<30::AID-AJH6>3.0.CO;2-6	49	77	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25834	25840		10.1074/jbc.M102343200	http://dx.doi.org/10.1074/jbc.M102343200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11328817	Green Published, hybrid			2022-12-27	WOS:000169823300027
J	You, ZB; Ouyang, H; Lopatin, D; Polver, PJ; Wang, CY				You, ZB; Ouyang, H; Lopatin, D; Polver, PJ; Wang, CY			Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; SIGNAL-TRANSDUCTION; IMMUNE ESCAPE; ACTIVATION; FLICE; FAS; EXPRESSION; RECEPTORS; HOMOLOG; THERAPY	Activation of the transcription factor nuclear factor-kappaB (NF-kappaB) has been found to play an essential role in the inhibition of tumor necrosis factor (TNF)-mediated apoptosis, NF-kappaB regulates several antiapoptotic molecules including inhibitors of apoptosis, Bcl-2 family proteins (A1 and Bcl-X-L) and IEX-IL. Here we report that the expression of a small death effector domain (DEI)-containing protein, NDED (NF-kappaB-inducible DED-containing protein), depends on the activation of NF-kappaB, The inhibition of NF-kappaB by IKB alpha a natural inhibitor of NF-kappaB, suppressed NDED mRNA expression induced by TNF, The restoration of NDED in NF-kappaB null cells inhibited TNF-induced apoptosis, Intriguingly, unlike the caspase-8 inhibitor cellular FADD-like interleukin-1 beta converting enzyme-inhibitory protein (c-FLIP), NDED suppressed TNF-mediated apoptosis by inhibiting TNF-induced caspase-8 enzymatic activity but not the processing of caspase-8, Furthermore, NDED could not inhibit etoposide-mediated apoptosis that is independent of caspase-8 activation. Our results provide the first demonstration that NF-kappaB transcriptionally induces the DED-containing protein to suppress TNF-mediated apoptosis by inhibiting caspase-8 activity, which offers new insight into the antiapoptotic mechanism of NF-kappaB.	Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cardiol Restorat Sci & Endodont, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Minnesota, Sch Dent, Minneapolis, MN 55455 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	Wang, CY (corresponding author), Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013848, R01DE013788] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE13848, R01-DE13788] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Duckett CS, 1997, BBA-REV CANCER, V1332, pR45, DOI 10.1016/S0304-419X(97)00002-4; French LE, 1999, J EXP MED, V190, P891, DOI 10.1084/jem.190.7.891; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	48	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26398	26404		10.1074/jbc.M102464200	http://dx.doi.org/10.1074/jbc.M102464200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346652	hybrid			2022-12-27	WOS:000169823300100
J	Mayo, LD; Kessler, KM; Pincheira, R; Warren, RS; Donner, DB				Mayo, LD; Kessler, KM; Pincheira, R; Warren, RS; Donner, DB			Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS TRANSCRIPTION; PERMEABILITY FACTOR; RESPONSE ELEMENT; MAP KINASE; DEVELOPMENTAL EXPRESSION; IN-VIVO; PHOSPHORYLATION; VEGF; TRANSDUCTION; FLT-1	Vascular endothelial cell growth factor (VEGF) plays a crucial role in the development of the cardiovascular system and in promoting angiogenesis associated with physiological and pathological processes. Although a great deal is known of the cytoplasmic signaling pathways activated by VEGF, much less is known of the mechanisms through which VEGF communicates with the nucleus and alters the activity of transcription factors. Binding of VEGF to the KDR/Flk1 receptor tyrosine kinase induces phosphorylation of the CRE-binding protein (CREB) transcription factor on serine 133 and increases CREB DNA binding and transactivation. p38 MAPK/MSK-1 and protein kinase C/p90RSK pathways mediate CREB phosphorylation, Confocal microscopy shows that VEGF-induced phosphorylation of nuclear CREB is blocked by pharmacological inhibition of protein kinase C and p38 mitogen-activated protein kinase signaling. Thus, KDR/Flk1 uses multiple pathways to transmit signals into the nucleus where CREB becomes activated. These results suggest that CREB may play a role in alterations of gene expression important to angiogenesis.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; University of California System; University of California San Francisco	Donner, DB (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St, Indianapolis, IN 46202 USA.	ddonner@IUPUI.edu		Pincheira, Roxana/0000-0003-4277-5245	NCI NIH HHS [CA84018, CA73023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Ankoma-Sey V, 1998, ONCOGENE, V17, P115, DOI 10.1038/sj.onc.1201912; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blendy JA, 1998, J MOL MED-JMM, V76, P104, DOI 10.1007/s001090050197; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BREIER G, 1992, DEVELOPMENT, V114, P521; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM J, 1993, NATURE, V262, P841; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; PARK JE, 1994, J BIOL CHEM, V269, P25646; Parrizas M, 1997, J BIOL CHEM, V272, P154; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Strawn LM, 1996, CANCER RES, V56, P3540; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang DF, 2000, J BIOL CHEM, V275, P15905, DOI 10.1074/jbc.M001847200; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	71	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25184	25189		10.1074/jbc.M102932200	http://dx.doi.org/10.1074/jbc.M102932200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335727	hybrid			2022-12-27	WOS:000169800700101
J	Swertfeger, DK; Hui, DY				Swertfeger, DK; Hui, DY			Apolipoprotein E receptor binding Versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; LDL-RECEPTOR; MICE LACKING; LIPOPROTEIN-BINDING; PLASMA-LIPOPROTEINS; SYNTHETIC PEPTIDE; CYTOSOLIC ADAPTER; SURFACE RECEPTORS; APO-E; PROTEIN	This study showed that synthetic peptides containing either a single copy or tandem repeat of the receptor binding domain sequence of apolipoprotein (apo) E, or a peptide containing its C-terminal heparin binding domain, apoE-(211-243), were all effective inhibitors of platelet-derived growth factor (PDGF)-stimulated smooth muscle cell proliferation. In contrast, only the peptide containing a tandem repeating unit of the receptor binding domain sequence of apoE, apoE-(141-155)(2), was capable of inhibiting PDGF-directed smooth muscle cell migration. Peptide containing only a single unit of this sequence, apoE-(141-155), or the apoE-(211-243) peptide were ineffective in inhibiting PDGF-directed smooth muscle cell migration. Additional experiments showed that reductively methylated apoE, which is incapable of receptor binding yet retains its heparin binding capability, was equally effective as apoE in inhibiting PDGF-stimulated smooth muscle cell proliferation, However, reductively methylated apoE was unable to inhibit smooth muscle cell migration toward PDGF, Additionally, the receptor binding domain-specific apoE antibody 1D7 also mitigated the anti-migratory properties of apoE on smooth muscle cells, Finally, pretreatment of cells with heparinase failed to abolish apoE inhibition of smooth muscle cell migration. Taken together, these data documented that apoE inhibition of PDGF-stimulated smooth muscle cell proliferation is mediated by its binding to heparan sulfate proteoglycans, while its inhibition of cell migration is mediated through apoE binding to cell surface receptors.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.		Swertfeger, Debi/AAN-6490-2021	Swertfeger, Debi/0000-0002-0570-0271	NHLBI NIH HHS [HL61332] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061332] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1984, METHOD PHARMACOL, V5, P141; Couchman JR, 1996, J CELL BIOCHEM, V61, P578, DOI 10.1002/(SICI)1097-4644(19960616)61:4<578::AID-JCB11>3.0.CO;2-C; DYER CA, 1991, J BIOL CHEM, V266, P15009; DYER CA, 1988, J BIOL CHEM, V263, P10965; DYER CA, 1991, J BIOL CHEM, V266, P22803; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; HUI DY, 1984, J BIOL CHEM, V259, P860; HUI DY, 1981, J BIOL CHEM, V256, P5646; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Ishigami M, 2000, ARTERIOSCL THROM VAS, V20, P1020, DOI 10.1161/01.ATV.20.4.1020; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; JI ZS, 1993, J BIOL CHEM, V268, P10160; Koyama N, 1998, CIRC RES, V83, P305, DOI 10.1161/01.RES.83.3.305; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; MAHLEY RW, 1979, BIOCHIM BIOPHYS ACTA, V575, P81, DOI 10.1016/0005-2760(79)90133-4; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MIMURA Y, 1995, BIOL PHARM BULL, V18, P1203; Obunike JC, 2000, ARTERIOSCL THROM VAS, V20, P111, DOI 10.1161/01.ATV.20.1.111; Paka L, 1999, J BIOL CHEM, V274, P4816, DOI 10.1074/jbc.274.8.4816; Paka L, 1999, J BIOL CHEM, V274, P36403, DOI 10.1074/jbc.274.51.36403; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Riddell DR, 1997, J BIOL CHEM, V272, P89; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Swertfeger DK, 2001, FRONT BIOSCI-LANDMRK, V6, pD526, DOI 10.2741/Swertfeg; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Weiser MCM, 1996, MATRIX BIOL, V15, P331, DOI 10.1016/S0945-053X(96)90136-5; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; Yamamoto T, 1996, CURR OPIN LIPIDOL, V7, P298, DOI 10.1097/00041433-199610000-00007; YlaHerttuala S, 1996, CURR OPIN LIPIDOL, V7, P292, DOI 10.1097/00041433-199610000-00006; Zerbinatti CV, 1999, BIOL REPROD, V61, P665, DOI 10.1095/biolreprod61.3.665; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460; Zhu BH, 2000, AM J PATHOL, V157, P1839, DOI 10.1016/S0002-9440(10)64823-7	47	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25043	25048		10.1074/jbc.M102357200	http://dx.doi.org/10.1074/jbc.M102357200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350966	hybrid			2022-12-27	WOS:000169800700082
J	Vaidyanathan, VV; Puri, N; Roche, PA				Vaidyanathan, VV; Puri, N; Roche, PA			The last exon of SNAP-23 regulates granule exocytosis from mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-INDUCED TRANSLOCATION; SNARE COMPLEX; MEMBRANE-FUSION; CLOSTRIDIAL NEUROTOXINS; T-SNARE; SYNTAXIN; INHIBITION; PROTEINS; BINDING; RELEASE	SNAP-25 and its ubiquitous homolog SNAP-23 are members of the SNARE family of proteins that regulate membrane fusion during exocytosis, Although SNAP-23 has been shown to participate in a variety of intracellular transport processes, the structural domains of SNAP-23 that are required for its interaction with other SNAREs have not been determined. By employing deletion mutagenesis we found that deletion of the aminoterminal 18 amino acids of SNAP-23 (encoded in the first exon) dramatically inhibited binding of SNAP-23 to both the target SNARE syntaxin and the vesicle SNARE vesicle-associated membrane protein(VAMP). By contrast, deletion of the carboxyl-terminal 23 amino acids (encoded in the last exon) of SNAP-23 does not affect SNAP-23 binding to syntaxin but profoundly inhibits its binding to VAMP. To determine the functional relevance of the modular structure of SNAP-23, we overexpressed SNAP-23 in cells possessing the capacity to undergo regulated exocytosis. Expression of human SNAP-23 in a rat mast cell line significantly enhanced exocytosis, and this effect was not observed in transfectants expressing the carboxyl-terminal VAMP-binding mutant of SNAP-23. Despite considerable amino acid identity, we found that human SNAP-23 bound to SNAREs more efficiently than did rat SNAP-23, These data demonstrate that the introduction of a "better" SNARE binder into secretory cells augments exocytosis and defines the carboxyl terminus of SNAP-23 as an essential regulator of exocytosis in mast cells.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Roche, PA (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10,Rm 4B36, Bethesda, MD 20892 USA.			Roche, Paul/0000-0002-8949-9172				Anderson HA, 1998, J IMMUNOL, V160, P4850; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BLASI J, 1994, J PHYSIOLOGY-PARIS, V88, P235, DOI 10.1016/0928-4257(94)90086-8; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kawanishi M, 2000, J BIOL CHEM, V275, P8240, DOI 10.1074/jbc.275.11.8240; Leung SM, 1998, J BIOL CHEM, V273, P17732, DOI 10.1074/jbc.273.28.17732; LI H, 1994, GENE, V143, P303; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; St-Denis JF, 1999, BIOCHEM J, V338, P709, DOI 10.1042/0264-6021:3380709; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Vaidyanathan VV, 2000, GENE, V247, P181, DOI 10.1016/S0378-1119(00)00100-1; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Wang GY, 1997, J CELL SCI, V110, P505; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4	33	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25101	25106		10.1074/jbc.M103536200	http://dx.doi.org/10.1074/jbc.M103536200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11350976	hybrid			2022-12-27	WOS:000169800700090
J	Fortune, JM; Lavrukhin, OV; Gurnon, JR; Van Etten, JL; Lloyd, RS; Osheroff, N				Fortune, JM; Lavrukhin, OV; Gurnon, JR; Van Etten, JL; Lloyd, RS; Osheroff, N			Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWINE FEVER VIRUS; NUCLEAR-LOCALIZATION SIGNALS; HAIRPIN LOOP STRUCTURE; VACCINIA VIRUS; CIRCULAR PERMUTATION; ANTINEOPLASTIC DRUGS; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; TARGETED DRUGS; HYDRA-VIRIDIS	Chlorella virus PBCV-1 topoisomerase II is the only functional type II enzyme known to be encoded by a virus that infects eukaryotic cells. However, it has not been established whether the protein is expressed following viral infection or whether the enzyme has any catalytic features that distinguish it from cellular type II topoisomerases. Therefore, the present study characterized the physiological expression of PBCV-1 topoisomerase II and individual reaction steps catalyzed by the enzyme. Results indicate that the topoisomerase II gene is widely distributed among Chlorella viruses and that the protein is expressed 60-90 min after viral infection of algal cells. Furthermore, the enzyme has an extremely high DNA cleavage activity that sets it apart from all known eukaryotic type II topoisomerases. Levels of DNA scission generated by the viral enzyme are similar to 30 times greater than those observed with human topoisomerase II alpha, The high levels of cleavage are not due to inordinately tight enzyme-DNA binding or to impaired DNA religation, Thus, they most likely reflect an elevated forward rate of scission. The robust DNA cleavage activity of PBCV-1 topoisomerase II provides a unique tool for studying the catalytic functions of type II topoisomerases.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Hematol Oncol, Nashville, TN 37232 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Nebraska, Dept Plant Pathol, Lincoln, NE 68583 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Nebraska System; University of Nebraska Lincoln	Osheroff, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 654 Robinson Res Bldg, Nashville, TN 37232 USA.	osheron@ctrvax.vanderbilt.edu		Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944, R01GM032441] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05355] Funding Source: Medline; NIGMS NIH HHS [GM33944, GM32441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Baguley BC, 1998, BBA-GENE STRUCT EXPR, V1400, P213, DOI 10.1016/S0167-4781(98)00137-7; BAUER WR, 1977, P NATL ACAD SCI USA, V74, P1841, DOI 10.1073/pnas.74.5.1841; BAYLIS SA, 1992, J MOL BIOL, V228, P1003, DOI 10.1016/0022-2836(92)90887-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; Cowell IG, 1998, EXP CELL RES, V243, P232, DOI 10.1006/excr.1998.4150; DELIUS H, 1984, J VIROL, V49, P609, DOI 10.1128/JVI.49.2.609-614.1984; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Fortune JM, 1998, J BIOL CHEM, V273, P17643, DOI 10.1074/jbc.273.28.17643; GARCIABEATO R, 1992, VIROLOGY, V188, P938, DOI 10.1016/0042-6822(92)90558-7; GESHELIN P, 1974, J MOL BIOL, V88, P785, DOI 10.1016/0022-2836(74)90399-4; GONZALEZ A, 1986, NUCLEIC ACIDS RES, V14, P6835, DOI 10.1093/nar/14.17.6835; HALLIGAN BD, 1985, J BIOL CHEM, V260, P2475; Hammonds TR, 1997, J BIOL CHEM, V272, P32696, DOI 10.1074/jbc.272.51.32696; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Karakashian M. W, 1975, Symposia Soc exp Biol, VNo. 29, P145; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; Kingma PS, 1999, BIOCHEMISTRY-US, V38, P3457, DOI 10.1021/bi982855i; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1998, J BIOL CHEM, V273, P17999, DOI 10.1074/jbc.273.29.17999; KRAUZER KN, 1983, BACTERIOPHAGE T4, P90; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavrukhin OV, 2000, J BIOL CHEM, V275, P6915, DOI 10.1074/jbc.275.10.6915; Li Y, 1997, VIROLOGY, V237, P360, DOI 10.1006/viro.1997.8805; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Mao Y, 1999, BIOCHEMISTRY-US, V38, P10793, DOI 10.1021/bi9909804; Mirski SEL, 1997, EXP CELL RES, V237, P452, DOI 10.1006/excr.1997.3805; MIRSKI SEL, 1995, CANCER RES, V55, P2129; Mirski SEL, 1999, EXP CELL RES, V251, P329, DOI 10.1006/excr.1999.4587; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Muller K, 1999, VIRUS GENES, V18, P243, DOI 10.1023/A:1008072319875; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; ORTIN J, 1979, J VIROL, V31, P579; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; POMMIER Y, 1997, CANC THERAPEUTICS EX, V1, P153; REISSER W, 1992, ALGAE SYMBIOSIS; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1990, BIOCHEMISTRY-US, V29, P2511, DOI 10.1021/bi00462a012; ROHOZINSKI J, 1989, VIROLOGY, V168, P363, DOI 10.1016/0042-6822(89)90277-8; ROSS PM, 1989, BIOTECHNIQUES, V7, P680; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNITZLER P, 1987, VIROLOGY, V160, P66, DOI 10.1016/0042-6822(87)90045-6; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; SOLTAU JB, 1987, J GEN VIROL, V68, P2717, DOI 10.1099/0022-1317-68-10-2717; STETLER GL, 1979, P NATL ACAD SCI USA, V76, P3737, DOI 10.1073/pnas.76.8.3737; Sun LW, 1999, VIROLOGY, V263, P376, DOI 10.1006/viro.1999.9958; UDVARDY A, 1986, J MOL BIOL, V191, P231, DOI 10.1016/0022-2836(86)90260-3; Van Etten JL, 1999, ANNU REV MICROBIOL, V53, P447, DOI 10.1146/annurev.micro.53.1.447; VANETTEN JL, 1982, P NATL ACAD SCI-BIOL, V79, P3867; VANETTEN JL, 1981, VIROLOGY, V113, P704, DOI 10.1016/0042-6822(81)90199-9; VANETTEN JL, 1991, MICROBIOL REV, V55, P586, DOI 10.1128/MMBR.55.4.586-620.1991; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; Wessel I, 1997, CANCER RES, V57, P4451; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; ZHANG YP, 1994, VIROLOGY, V202, P1079, DOI 10.1006/viro.1994.1444	78	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24401	24408		10.1074/jbc.M101693200	http://dx.doi.org/10.1074/jbc.M101693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323425	hybrid			2022-12-27	WOS:000169531100155
J	Miyake, JH; Doung, XDT; Strauss, W; Moore, GL; Castellani, LW; Curtiss, LK; Taylor, JM; Davis, RA				Miyake, JH; Doung, XDT; Strauss, W; Moore, GL; Castellani, LW; Curtiss, LK; Taylor, JM; Davis, RA			Increased production of apolipoprotein B-containing lipoproteins in the absence of hyperlipidemia in transgenic mice expressing cholesterol 7 alpha-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; TRIGLYCERIDE TRANSFER PROTEIN; BILE-ACID BIOSYNTHESIS; LOW-DENSITY LIPOPROTEINS; RECEPTOR LXR-ALPHA; NUCLEAR RECEPTOR; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; OXYSTEROL 7-ALPHA-HYDROXYLASE; BINDING PROTEIN-1	The finding that expression of a cholesterol 7 alpha -hydroxylase (CYP7A1) transgene in cultured rat hepatoma cells caused a coordinate increase in lipogenesis and secretion of apoB-containing lipoproteins led to the hypothesis that hepatic production of apoB-containing lipoproteins may be linked to the expression of CYP7A1 (Wang, S.-L., Du, E., Martin, T. D., and Davis, R. A (1997) J. Biol. Chem. 272, 19351-19358). To examine this hypothesis in vivo, a transgene encoding CYP7A1 driven by the constitutive liver-specific enhancer of the human apoE gene was expressed in C56BL/6 mice. The expression of CYP7A1 mRNA (20-fold), protein (similar to 10-fold), and enzyme activity (5-fold) was markedly increased in transgenic mice compared with non-transgenic littermates, The bile acid pool of CYP7A1 transgenic mice was doubled mainly due to increased hydrophobic dihydroxy bile acids. In CYP7A1 transgenic mice, livers contained similar to3-fold more sterol response element-binding protein-2 mRNA. Hepatic expression of mRNAs encoding lipogenic enzymes (i.e. fatty-acid synthase, acetyl-CoA carboxylase, stearoyl-CoA desaturase, squalene synthase, farnesyl-pyrophosphate synthase, 3-hydroxy-3-methylglutaryl-CoA reductase, and low density lipoprotein receptor) as well as microsomal triglyceride transfer protein mere elevated similar to3-5-fold in transgenic mice. CYP7A1 transgenic mice also displayed a >2-fold increase in hepatic production and secretion of triglyceride-rich apoB-containing lipoproteins. Despite the increased hepatic secretion of apoB-containing lipoproteins in CYP7A1 mice, plasma levels of triglycerides and cholesterol were not significantly increased. These data suggest that the 5-fold increased expression of the low density lipoprotein receptor displayed by the livers of CYP7A1 transgenic mice was sufficient to compensate for the 2-fold increase production of apoB-containing lipoproteins. These findings emphasize the important homeostatic role that CYP7A1 plays in balancing the anabolic lipoprotein assembly/secretion pathway with the cholesterol catabolic bile acid synthetic pathway.	San Diego State Univ, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Scripps Res Inst, La Jolla, CA 92037 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	California State University System; San Diego State University; University of California System; University of California Los Angeles; Scripps Research Institute; University of California System; University of California San Francisco; The J David Gladstone Institutes	Davis, RA (corresponding author), San Diego State Univ, Mammalian Cell & Mol Biol Lab, Life Sci Bldg LS307,5500 Campanile Dr, San Diego, CA 92182 USA.	rdavis@sunstroke.sdsu.edu			NHLBI NIH HHS [HL57974, HL51648] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057974, R01HL051648] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEIS D, 1992, SEMIN LIVER DIS, V12, P397, DOI 10.1055/s-2008-1040409; ANGELIN B, 1978, J LIPID RES, V19, P1004; ANGELIN B, 1987, P NATL ACAD SCI USA, V84, P5434, DOI 10.1073/pnas.84.15.5434; BEIL U, 1982, METABOLISM, V31, P438, DOI 10.1016/0026-0495(82)90231-1; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOOGAERTS JR, 1984, AM J PHYSIOL, V246, pE77, DOI 10.1152/ajpendo.1984.246.1.E77; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CAMARRI E, 1978, BIOMED EXPRESS, V29, P193; Cavallo D, 1998, J BIOL CHEM, V273, P33397, DOI 10.1074/jbc.273.50.33397; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DAVIS RA, 1985, J BIOL CHEM, V260, P4137; DAVIS RA, 1989, J BIOL CHEM, V264, P8970; DeBose-Boyd RA, 2001, P NATL ACAD SCI USA, V98, P1477, DOI 10.1073/pnas.98.4.1477; del Castillo-Olivares A, 2000, J BIOL CHEM, V275, P17793, DOI 10.1074/jbc.M000996200; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; Duane WC, 1997, J LIPID RES, V38, P183; DUANE WC, 1995, J LIPID RES, V36, P96; Duane WC, 2000, J LIPID RES, V41, P1384; DUELAND S, 1993, J LIPID RES, V34, P923; EDWARDS PA, 1996, N COMP BIOC, V31, P341; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fleming JF, 1999, J BIOL CHEM, V274, P9509, DOI 10.1074/jbc.274.14.9509; FRIEDMAN M, 1965, ARCH INTERN MED, V116, P807, DOI 10.1001/archinte.116.6.807; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GOLDSTEIN JL, 1985, J CELL SCI, P131, DOI 10.1242/jcs.1985.Supplement_3.13; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; Havel RJ, 1997, P NUTR SOC, V56, P659, DOI 10.1079/PNS19970065; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Kim E, 1998, J LIPID RES, V39, P703; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; Liao W, 1999, BIOCHEMISTRY-US, V38, P7532, DOI 10.1021/bi9904196; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Miyake JH, 2000, J BIOL CHEM, V275, P21805, DOI 10.1074/jbc.C000275200; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Moore GL, 1997, BIOCHEM J, V324, P863, DOI 10.1042/bj3240863; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Powell-Braxton L, 1998, NAT MED, V4, P934, DOI 10.1038/nm0898-934; Qian XB, 1998, ARTERIOSCL THROM VAS, V18, P1013, DOI 10.1161/01.ATV.18.6.1013; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Schwarz M, 1998, J LIPID RES, V39, P1833; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Sehayek E, 1996, Z Gastroenterol, V34 Suppl 3, P110; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; TENG BB, 1994, J BIOL CHEM, V269, P29395; Tietge UJF, 1999, J LIPID RES, V40, P2134; Trawick JD, 1996, J LIPID RES, V37, P588; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Vega GL, 1998, AM J CARDIOL, V81, p36B, DOI 10.1016/S0002-9149(98)00036-8; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; Vlahcevic ZR, 2000, GASTROENTEROLOGY, V118, P599, DOI 10.1016/S0016-5085(00)70267-8; VLAHCEVIC ZR, 1992, SEMIN LIVER DIS, V12, P403, DOI 10.1055/s-2008-1040410; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; WETTERAU JR, 1992, SCIENCE, V258, P999; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	79	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23304	23311		10.1074/jbc.M101853200	http://dx.doi.org/10.1074/jbc.M101853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323427	hybrid			2022-12-27	WOS:000169531100014
J	Thulin, CD; Savage, JR; McLaughlin, JN; Truscott, SM; Old, WM; Ahn, NG; Resing, KA; Hamm, HE; Bitensky, MW; Willardson, BM				Thulin, CD; Savage, JR; McLaughlin, JN; Truscott, SM; Old, WM; Ahn, NG; Resing, KA; Hamm, HE; Bitensky, MW; Willardson, BM			Modulation of the G protein regulator phosducin by Ca2+/calmodulin-dependent protein kinase II phosphorylation and 14-3-3 protein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ROD OUTER SEGMENTS; IN-VIVO; SERINE PHOSPHORYLATION; PHOTORECEPTOR CELLS; CRYSTAL-STRUCTURE; RECEPTOR KINASE; ZETA-ISOFORM; RAT RETINA; LIGHT	Phototransduction is a canonical G protein-mediated cascade of retinal photoreceptor cells that transforms photons into neural responses. Phosducin (Pd) is a G beta gamma -binding protein that is highly expressed in photoreceptors. Pd is phosphorylated in dark-adapted retina and is dephosphorylated in response to light. Dephosphorylated Pd binds G beta gamma with high affinity and inhibits the interaction of G beta gamma with G alpha or Other effecters, whereas phosphorylated Pd does not. These results have led to the hypothesis that Pd down-regulates the light response. Consequently, it is important to understand the mechanisms of regulation of Pd phosphorylation. We have previously shown that phosphorylation of Pd by cAMP-dependent protein kinase moderately inhibits its association with G beta gamma. In this study, we report that Pd was rapidly phosphorylated by Ca2+/calmodulin-dependent kinase II, resulting in 100-fold greater inhibition of G beta gamma binding than cAMP-dependent protein kinase phosphorylation, Furthermore, Pd phosphorylation by Ca2+/calmodulin-dependent kinase II at Ser-54 and Ser-73 led to binding of the phosphoserine-binding protein 14-3-3. Importantly, in vivo decreases in Ca2+. concentration blocked the interaction of Pd with 14-3-3, indicating that Ca2+ controls the phosphorylation state of Ser-54 and Ser-73 in vivo. These results are consistent with a role for Pd in Ca2+-dependent light adaptation processes in photoreceptor cells and also suggest other possible physiological functions.	Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Brigham Young University; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Northwestern University; Boston University	Willardson, BM (corresponding author), Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA.	bmwillardson@chemdept.byu.edu	Hamm, Heidi E/G-2374-2014	OLD, WILLIAM/0000-0002-9499-8478; Willardson, Barry/0000-0002-8503-2268	NATIONAL EYE INSTITUTE [R01EY006062, R01EY012287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043768] Funding Source: NIH RePORTER; NEI NIH HHS [EY12287, EY06062] Funding Source: Medline; NIAMS NIH HHS [AR43768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BAUER PH, 1995, NATURE, V358, P732; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Boekhoff I, 1997, J BIOL CHEM, V272, P4606, DOI 10.1074/jbc.272.7.4606; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BRONSTEIN J, 1989, BRAIN RES, V495, P83, DOI 10.1016/0006-8993(89)91220-1; BRONSTEIN JM, 1988, J NEUROCHEM, V50, P1438, DOI 10.1111/j.1471-4159.1988.tb03028.x; Chen FY, 1997, BIOCHEM BIOPH RES CO, V233, P370, DOI 10.1006/bbrc.1997.6460; CHENG HC, 1986, J BIOL CHEM, V261, P989; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Colbran R J, 1990, Curr Top Cell Regul, V31, P181; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; Detwiler PB, 1996, CURR OPIN NEUROBIOL, V6, P440, DOI 10.1016/S0959-4388(96)80047-X; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GRAYKELLER MP, 1994, NEURON, V13, P849, DOI 10.1016/0896-6273(94)90251-8; HAMM H, 1990, J GEN PHYSIOL, V95, P545, DOI 10.1085/jgp.95.3.545; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; Hirooka K, 1997, VISION RES, V37, P2029, DOI 10.1016/S0042-6989(97)00175-2; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; Koulen P, 1999, P NATL ACAD SCI USA, V96, P9909, DOI 10.1073/pnas.96.17.9909; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KUO CH, 1989, NEUROSCI LETT, V103, P8, DOI 10.1016/0304-3940(89)90476-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; LEE RH, 1992, J BIOL CHEM, V267, P25104; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakano K, 2001, P NATL ACAD SCI USA, V98, P4693, DOI 10.1073/pnas.071067198; NEWTON AC, 1993, J BIOL CHEM, V268, P18181; NguyenLegros J, 1996, J NEUROCHEM, V67, P2514; PAGHROEHL K, 1995, J NEUROSCI, V15, P6475; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pootanakit K, 1999, VISUAL NEUROSCI, V16, P221, DOI 10.1017/S0952523899162035; REIG JA, 1990, J BIOL CHEM, V265, P5816; Rey HL, 1999, J NEUROCHEM, V72, P2345, DOI 10.1046/j.1471-4159.1999.0722345.x; ROSEBOOM PH, 1994, DNA CELL BIOL, V13, P629, DOI 10.1089/dna.1994.13.629; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Savage JR, 2000, J BIOL CHEM, V275, P30399, DOI 10.1074/jbc.M005120200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz K, 1996, J BIOL CHEM, V271, P22546, DOI 10.1074/jbc.271.37.22546; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; TERASHIMA T, 1994, BRAIN RES, V650, P133, DOI 10.1016/0006-8993(94)90215-1; THULIN CD, 1999, MOL VIS, V5, P40; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wehmeyer A, 1998, LIFE SCI, V62, pPL127, DOI 10.1016/S0024-3205(97)01190-9; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Wilkins JF, 1996, J BIOL CHEM, V271, P19232, DOI 10.1074/jbc.271.32.19232; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yoshida K, 1996, INVEST OPHTH VIS SCI, V37, P174; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhu X, 1998, Mol Vis, V4, P13	77	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23805	23815		10.1074/jbc.M101482200	http://dx.doi.org/10.1074/jbc.M101482200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11331285	hybrid			2022-12-27	WOS:000169531100079
J	Kubota, H; Ota, K; Sakaki, Y; Ito, T				Kubota, H; Ota, K; Sakaki, Y; Ito, T			Budding yeast GCN1 binds the GI domain to activate the eIF2 alpha kinase GCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; IMPRINTED GENE IMPACT; FACTOR 2-ALPHA KINASE; INITIATION FACTOR-II; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; TRANSFER-RNA; MAMMALIAN-CELLS; ALPHA-SUBUNIT	When starved for a single amino acid, the budding yeast Saccharomyces cerevisiae activates the eukaryotic initiation factor 2 alpha (eIF2 alpha) kinase GCN2 in a GCN1-dependent manner. Phosphorylated eIF2 alpha inhibits general translation but selectively derepresses the synthesis of the transcription factor GCN4, which leads to coordinated induction of genes involved in biosynthesis of various amino acids, a phenomenon called general control response. We recently demonstrated that this response requires binding of GCN1 to the GI domain occurring at the N terminus of GCN2 (Kubota, H,, Sakaki, Y., and Ito, T. (2000) J. Biol. Chem. 275, 20243-20246), Here we provide the first evidence for the involvement of GCN1-GCN2 interaction in activation of GCN2 per se. We identified a C-terminal segment of GCN1 sufficient to bind the GI domain and used a novel dual bait two-hybrid method to identify mutations rendering GCN1 incapable of interacting with GCN2, The yeast bearing such an allele, gcn1-F2291L, fails to display derepression of GCN4 translation and hence general control response, as does a GI domain mutant, gcn2-Y74A,, defective in association with GCN1. Furthermore, we demonstrated that phosphorylation of eIF2 alpha is impaired in both mutants. Since GCN2 is the sole eIF2 alpha kinase in yeast, these findings indicate a critical role of GCN1-GCN2 interaction in activation of the kinase in vivo.	Kanazawa Univ, Canc Res Inst, Div Genome Biol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	Kanazawa University; University of Tokyo	Ito, T (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genome Biol, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.			Ito, Takashi/0000-0001-6097-2803				Anderson J, 1998, GENE DEV, V12, P3650, DOI 10.1101/gad.12.23.3650; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; DEALDANA CRV, 1995, EMBO J, V14, P3148; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Garcia-Barrio M, 2000, EMBO J, V19, P1887, DOI 10.1093/emboj/19.8.1887; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hagiwara Y, 1997, P NATL ACAD SCI USA, V94, P9249, DOI 10.1073/pnas.94.17.9249; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HINNEBUSCH AG, 1997, J BIOL CHEM, V272, P2161; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Ito T, 1996, FEBS LETT, V385, P229, DOI 10.1016/0014-5793(96)00387-0; James P, 1996, GENETICS, V144, P1425; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kubota H, 2000, J BIOL CHEM, V275, P20243, DOI 10.1074/jbc.C000262200; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Okamura K, 2000, GENOME RES, V10, P1878, DOI 10.1101/gr.139200; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Qiu HF, 2000, MOL CELL BIOL, V20, P2505, DOI 10.1128/MCB.20.7.2505-2516.2000; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Sattlegger E, 2000, EMBO J, V19, P6622, DOI 10.1093/emboj/19.23.6622; SCHMITT ME, 1992, GENE DEV, V6, P1975, DOI 10.1101/gad.6.10.1975; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Tavernarakis N, 1996, GENE, V179, P271, DOI 10.1016/S0378-1119(96)00379-4; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Yamada Y, 1999, BIOCHEM BIOPH RES CO, V256, P162, DOI 10.1006/bbrc.1999.0297; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhu SH, 1998, J BIOL CHEM, V273, P1808, DOI 10.1074/jbc.273.3.1808	37	41	44	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17591	17596		10.1074/jbc.M011793200	http://dx.doi.org/10.1074/jbc.M011793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11350982	hybrid			2022-12-27	WOS:000168730400132
J	Johnson, RA; Ince, TA; Scotto, KW				Johnson, RA; Ince, TA; Scotto, KW			Transcriptional repression by p53 through direct binding a novel DNA element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; GENE-EXPRESSION; MDR1 GENE; NF-Y; DOWN-REGULATION; P-GLYCOPROTEIN; CANCER-CELLS; MUTANT P53; ACTIVATION	The tumor suppressor protein p53 has been well documented as a transcriptional activator involved in the regulation of a number of critical genes involved in the cell cycle, response to DNA damage, and apoptosis, Activation by p53 requires the interaction of the protein with a consensus binding site consisting of two half-sites, each comprising two copies of the sequence PuPuPuC(A/T) arranged head-to-head and separated by 0-13 base pairs. In addition to activation, p53 has been shown to be a potent repressor of transcription. Howl ever; the basis for p53-mediated repression is not well understood and has been proposed to occur indirectly through interactions with other promoter-bound transcription factors. In the present study, we show that p53 can repress transcription directly by binding to a novel head-to-tail (HT) site within the MDR1 promoter. A mutation that disrupted p53 binding to the MDR1 HT site blocked p53-mediated repression of the MDR1 promoter in transfection assays. Replacement of the HT site with a head-to-head (HH) site converted the activity of p53 from repression to activation, indicating that simple recruitment of p53 to the promoter is not sufficient for repression and that the orientation of the binding element determines the fate of p53-regulated promoters.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Scotto, KW (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave,W269, Philadelphia, PA 19111 USA.			Ince, Tan/0000-0003-0315-6425	NATIONAL CANCER INSTITUTE [R01CA057307, P01CA018856, P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748, R01-CA57307, P01-CA18856-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnstone RW, 2000, TRENDS BIOCHEM SCI, V25, P1, DOI 10.1016/S0968-0004(99)01493-0; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MORROW CS, 1994, J BIOL CHEM, V269, P10739; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAMPATH J, 2000, P AM ASSOC CANC RES, V41, P841; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; van Veen HW, 1998, ADV EXP MED BIOL, V456, P145; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Watanabe T, 2000, P NATL ACAD SCI USA, V97, P8490, DOI 10.1073/pnas.150104097; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	40	131	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27716	27720		10.1074/jbc.C100121200	http://dx.doi.org/10.1074/jbc.C100121200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350951	hybrid			2022-12-27	WOS:000169966900129
J	Tailor, CS; Marin, M; Nouri, A; Kavanaugh, MP; Kabat, D				Tailor, CS; Marin, M; Nouri, A; Kavanaugh, MP; Kabat, D			Truncated forms of the dual function human ASCT2 neutral amino acid transporter/retroviral receptor are translationally initiated at multiple alternative CUG and GUG codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTOR; MURINE LEUKEMIA-VIRUS; FIBROBLAST GROWTH-FACTOR; GLUTAMATE TRANSPORTER; MESSENGER-RNA; MAMMALIAN-CELLS; ENDOGENOUS RETROVIRUS; STRUCTURAL FEATURES; SINGLE-GENE; AUG	The sodium-dependent neutral amino acid transporter type 2 (ASCT2) was recently identified as a cell surface receptor for endogenously inherited retroviruses of cats, baboons, and humans as well as for horizontally transmitted type-D simian retroviruses. By functional cloning, we obtained 10 full-length 2.9-kilobase pair (kbp) cDNAs and two smaller identical 2.1-kbp cDNAs that conferred susceptibility to these viruses. Compared with the 2.9-kbp cDNA, the 2.1-kbp cDNA contains exonic deletions in its 3' noncoding region and a 627-bp 5' truncation that eliminates sequences encoding the amino-terminal portion of the full-length ASCT2 protein. Although expression of the truncated mRNA caused enhanced amino acid transport and viral receptor activities, the AUG codon nearest to its 5' end is flanked by nucleotides that are incompatible with translational initiation and the next in-frame AUG codon is far downstream toward the end of the protein coding sequence. Interestingly, the 5' region of the truncated ASCT2 mRNA contains a closely Linked series of CUG(Leu) and GUG(Val) codons in optimal consensus contexts for translational initiation. By deletion and site-directed mutagenesis, cell-free translation, and analyses of epitope-tagged ASCT2 proteins synthesized intracellularly, we determined that the truncated mRNA encodes multiple ASCT2 isoforms with distinct amino termini that are translationally initiated by a leaky scanning mechanism at these CUG and GUG codons, Although the full-length ASCT2 mRNA contains a 5'-situated AUG initiation codon, a significant degree of leaky scanning also occurred in its translation. ASCT2 isoforms with relatively short truncations were active in both amino acid transport and viral reception, whereas an isoform with a 79-amino acid truncation that lacked the first transmembrane sequence was active only in viral reception. We conclude that ASCT2 isoforms with truncated amino termini are synthesized in mammalian cells by a leaky scanning mechanism that employs multiple alternative CUG and GUG initiation codons.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Kabat, D (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd,Mail Code L224, Portland, OR 97201 USA.	kabat@ohsu.edu			NCI NIH HHS [CA25810, CA83835] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083835, R01CA025810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Arnaud E, 1999, MOL CELL BIOL, V19, P505; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Cunillera N, 1997, J BIOL CHEM, V272, P15381, DOI 10.1074/jbc.272.24.15381; DICKSON C, 1990, ENZYME, V44, P225, DOI 10.1159/000468760; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FALVEY E, 1995, EMBO J, V14, P4307, DOI 10.1002/j.1460-2075.1995.tb00105.x; Gammie AE, 1999, MOL CELL BIOL, V19, P817; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li J, 2000, BBA-BIOMEMBRANES, V1467, P338, DOI 10.1016/S0005-2736(00)00232-7; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; Marin M, 2000, J VIROL, V74, P8085, DOI 10.1128/JVI.74.17.8085-8093.2000; Matsumoto Y, 1999, TOHOKU J EXP MED, V187, P173, DOI 10.1620/tjem.187.173; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; PILLEMER EA, 1986, J VIROL, V57, P413, DOI 10.1128/JVI.57.2.413-421.1986; PRATS AC, 1989, J MOL BIOL, V205, P363, DOI 10.1016/0022-2836(89)90347-1; RajBhandary UL, 2000, P NATL ACAD SCI USA, V97, P1325, DOI 10.1073/pnas.040579197; Rasko JEJ, 1999, P NATL ACAD SCI USA, V96, P2129, DOI 10.1073/pnas.96.5.2129; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; Tailor CS, 1999, P NATL ACAD SCI USA, V96, P927, DOI 10.1073/pnas.96.3.927; Tailor CS, 1997, J VIROL, V71, P9383, DOI 10.1128/JVI.71.12.9383-9391.1997; Tailor CS, 1999, J VIROL, V73, P4470, DOI 10.1128/JVI.73.5.4470-4474.1999; TAIRA M, 1990, J BIOL CHEM, V265, P16491; TAKEUCHI Y, 1994, J VIROL, V68, P8001, DOI 10.1128/JVI.68.12.8001-8007.1994; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; Wimmer B, 1997, P NATL ACAD SCI USA, V94, P13624, DOI 10.1073/pnas.94.25.13624; Yang YL, 1999, NAT GENET, V21, P216, DOI 10.1038/6005; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	55	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27221	27230		10.1074/jbc.M100737200	http://dx.doi.org/10.1074/jbc.M100737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350958	Green Published, hybrid			2022-12-27	WOS:000169966900067
J	Wang, LK; Shuman, S				Wang, LK; Shuman, S			Domain structure and mutational analysis of T4 polynucleotide kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENYLATE KINASE; ESCHERICHIA-COLI; DNA HELICASE; LIGASE; GENE; 3'-PHOSPHATASE; POLYMERASE; RESOLUTION; MECHANISM	T4 polynucleotide kinase (Pnk) is the founding member of a family of 5'-kinase/3'-phosphatase enzymes that heal broken termini in RNA or DNA by converting 3'-PO4/5'-OH ends into 3'-OH/5'-PO4 ends, which are then suitable for sealing by RNA or DNA ligases. Here we employed site directed mutagenesis and biochemical methods to dissect the domain structure of the homotetrameric T4 Pnk protein and to localize essential constituents of the apparently separate active sites for the 5'-kinase and 3'-phosphatase activities. We characterized deletion mutants Pnk(42-301) and Pnk(1-181) which correspond to domains defined by proteolysis with chymotrypsin. Pnk(1-181) is a monomer with no 3'-phosphatase and low residual 5'-kinase activity, Pnk(42-301) is a dimer with no 5'-kinase and low residual 3'-phosphatase activity, Four classes of missense mutational effects were observed, (i) Mutations K15A, S16A, and D35A inactivated the 5'-kinase but did not affect the 3'-phosphatase or the tetrameric quaternary structure of T4 Pnk. 5'-kinase activity was ablated by the conservative mutations K15R, K15Q, and D35N; however, kinase activity was restored by the S16T change. (ii) Mutation D167A inactivated the 3'-phosphatase without affecting the 5'-kinase or tetramerization. (iii) Mutation D85A caused a severe decrement in 5'-kinase activity and only a modest effect on the 3'-phosphatase; the nearby N87A mutation resulted in a significantly reduced 3'-phosphatase activity and slightly reduced 5'-kinase activity. D85A and N87A both affected the quaternary structure, resulting in a mixed population of tetramer and dimer species, (iv) Alanine mutations at 11 other conserved positions had no significant effect on either 5'-kinase or 3'-phosphatase activity.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.							AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; BECKER A, 1967, J BIOL CHEM, V242, P936; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; Durantel D, 1998, J GEN VIROL, V79, P629, DOI 10.1099/0022-1317-79-3-629; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JARVEST RL, 1981, BIOCHEM J, V199, P273, DOI 10.1042/bj1990273; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; Karimi-Busheri F, 1999, J BIOL CHEM, V274, P24187, DOI 10.1074/jbc.274.34.24187; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1221, DOI 10.1021/bi00677a020; Martins A, 1999, J VIROL, V73, P1302, DOI 10.1128/JVI.73.2.1302-1308.1999; MIDGLEY CA, 1985, EMBO J, V4, P2695, DOI 10.1002/j.1460-2075.1985.tb03989.x; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2933; NOVOGRODSKY A, 1966, J BIOL CHEM, V241, P2923; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; RICHARDSON CC, 1965, P NATL ACAD SCI USA, V54, P158, DOI 10.1073/pnas.54.1.158; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P727, DOI 10.1093/nar/25.4.727; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; SOLTIS DA, 1982, J BIOL CHEM, V257, P1340; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; VANDESAN.JH, 1973, BIOCHEMISTRY-US, V12, P5050, DOI 10.1021/bi00749a004	28	116	118	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26868	26874		10.1074/jbc.M103663200	http://dx.doi.org/10.1074/jbc.M103663200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11335730	hybrid			2022-12-27	WOS:000169966900020
J	Fabrizi, C; Silei, V; Menegazzi, M; Salmona, M; Bugiani, O; Tagliavini, F; Suzuki, H; Lauro, GM				Fabrizi, C; Silei, V; Menegazzi, M; Salmona, M; Bugiani, O; Tagliavini, F; Suzuki, H; Lauro, GM			The stimulation of inducible nitric-oxide synthase by the prion protein fragment 106-126 in human microglia is tumor necrosis factor-alpha-dependent and involves p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-INFECTED MICE; FACTOR-KAPPA-B; CREUTZFELDT-JAKOB-DISEASE; EXPRESSION; CELLS; LIPOPOLYSACCHARIDE; PRP; RESIDUES-106-126; NEUROTOXICITY; MACROPHAGES	A synthetic peptide consisting of amino acid residues 106-126 of the human prion protein (PrP-(106-126)) has been previously demonstrated to be neurotoxic and to induce microglial activation. The present study investigated the expression of the inducible form of the nitric-oxide synthase (NOS-II) in human microglial cells treated with PrP-(106-126). Using reverse transcriptase-polymerase chain reaction, we found that PrP-(106-126) induces NOS-II gene expression after 24 h of treatment and that this effect is accompanied by a peak of nuclear factor kappa B (NF-KB) binding at 30 min as evaluated by electrophoretic mobility shift assay. Since our previous data demonstrated tumor necrosis factor-alpha (TNF-alpha) to be a potent inducer of NOS-II in these cells, we analyzed the expression of this cytokine in PrP-(106-126)treated microglia, PrP-(106-126) caused the release of TNF-alpha as detected by enzyme-linked immunosorbent assay, and a blocking antibody, anti-TNF-alpha, abolished NOS-II induction elicited by this peptide. Moreover, PrP-(106-126) activates p38 mitogen-activated protein kinase, and the inhibition of this pathway determines the ablation of NF-kappaB binding induced by this fragment peptide.	Univ Roma Tre, Dipartimento Biol, I-00146 Rome, Italy; Univ Verona, Sez Chim Biol, Dipartimento Sci Neurol, I-37134 Verona, Italy; Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy; Ist Nazl Neurol Carlo Besta, I-20133 Milan, Italy	Roma Tre University; University of Verona; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Neurologico Besta	Lauro, GM (corresponding author), Univ Roma Tre, Dipartimento Biol, Viale Marconi 446, I-00146 Rome, Italy.	lauro@uniroma3.it	fabrizi, cinzia/G-2379-2012; salmona, mario/ABI-4066-2020; salmona, mario/AAA-7116-2020; Tagliavini, Fabrizio/AAO-7891-2021; Menegazzi, Marta/AAE-7079-2019	salmona, mario/0000-0002-9098-9873; Tagliavini, Fabrizio/0000-0003-1039-7315; Menegazzi, Marta/0000-0003-1310-9227				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chen CC, 1999, MOL PHARMACOL, V55, P481; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; COLASANTI M, 1995, NEUROSCI LETT, V200, P144, DOI 10.1016/0304-3940(95)12101-9; Combs CK, 1999, J NEUROSCI, V19, P928; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; FORLONI G, 1994, EUR J NEUROSCI, V6, P1415, DOI 10.1111/j.1460-9568.1994.tb01003.x; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Hippenstiel S, 2000, BLOOD, V95, P3044; Jeon YJ, 2000, J PHARMACOL EXP THER, V294, P548; Ju WK, 1998, J NEUROVIROL, V4, P445; Keshet GI, 1999, J NEUROCHEM, V72, P1224, DOI 10.1046/j.1471-4159.1999.0721224.x; Kim JI, 1999, MOL BRAIN RES, V73, P17, DOI 10.1016/S0169-328X(99)00229-6; Lauro GM, 1995, INT J DEV NEUROSCI, V13, P739, DOI 10.1016/0736-5748(95)00059-3; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Muhleisen H, 1995, NEUROPATH APPL NEURO, V21, P505, DOI 10.1111/j.1365-2990.1995.tb01097.x; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ovadia H, 1996, J BIOL CHEM, V271, P16856, DOI 10.1074/jbc.271.28.16856; PRICHETT W, 1995, J INFLAMM, V45, P97; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; SELVAGGINI C, 1993, BIOCHEM BIOPH RES CO, V194, P1380, DOI 10.1006/bbrc.1993.1977; Sharief MK, 1999, NEUROLOGY, V52, P1289, DOI 10.1212/WNL.52.6.1289; Silei V, 1999, BRAIN RES, V818, P168, DOI 10.1016/S0006-8993(98)01272-4; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Williams A, 1997, EXP NEUROL, V144, P433, DOI 10.1006/exnr.1997.6424; Williams A, 1997, BRAIN RES, V754, P171, DOI 10.1016/S0006-8993(97)00067-X; Zielasek J, 1996, ADV NEUROIMMUNOL, V6, P191, DOI 10.1016/0960-5428(96)00017-4	38	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25692	25696		10.1074/jbc.M100133200	http://dx.doi.org/10.1074/jbc.M100133200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316802	hybrid			2022-12-27	WOS:000169823300010
J	Taniyama, Y; Sato, K; Sugawara, A; Uruno, A; Ikeda, Y; Kudo, M; Ito, S; Takeuchi, K				Taniyama, Y; Sato, K; Sugawara, A; Uruno, A; Ikeda, Y; Kudo, M; Ito, S; Takeuchi, K			Renal tubule-specific transcription and chromosomal localization of rat thiazide-sensitive Na-Cl cotransporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL CONVOLUTED TUBULE; SODIUM-CHLORIDE COTRANSPORTER; CELL-SPECIFIC ACTIVITY; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; GITELMANS-SYNDROME; MOLECULAR-CLONING; RECEPTOR DENSITY; DNA-BINDING; KIDNEY; EXPRESSION	The molecular mechanism underlying the renal expression localization of the thiazide-sensitive Na-CI cotransporter (TSC) gene was studied, The TSC gene was localized to chromosome 19p12-14, In cultured cells, tissue-specific transcription activity of the 5 ' -flanking region of the rat rTSC gene (5 ' FL/rTSC) was demonstrated, and the major promoter region was located between position -580 and -141. To further examine the tissue-specific transcription, transgenic rats harboring the 5 ' FL/rTSC fused upstream of the LacZ gene were generated. Immunohistochemical analysis clearly showed that LacZ gene expression was co-localized to distal convoluted tubules (DCT) with TSC, indicating that the 5 ' FL/rTSC regulates the renal tubule-specific TSC expression. Because a transcription factor, HFH-3 (hepatocyte nuclear factor-3/folk head homologue-3), had also been localized to DCT, a possible role of the putative cia-acting element (HPH-3/rTSC, -400/-387 position) for HFH-3 binding in the tissue-specific transcription was examined. Deletion and mutation analyses suggested that transcription of the HFH-3/rTSC was actually responsive to HFH-3, and electrophoretic mobility shift assay showed a direct binding of in vitro synthesized HFH-3 to the HFH-3/rTSC. In conclusion, the rTSC gene is localized to rat chromosome 19p12-24. The transcription regulatory region of the TSC gene confers DCT-specific gene expression, DCT-specific transcription factor HFH-3 may be involved in the renal tubule-specific transcription of TSC gene.	Tohoku Univ, Grad Sch Med, Mol Biol Unit,Dept Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, Sendai, Miyagi 9808574, Japan	Tohoku University	Takeuchi, K (corresponding author), Tohoku Univ, Grad Sch Med, Mol Biol Unit,Dept Med, Div Nephrol Endocrinol & Vasc Med,Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	kazut2i@mail.cc.tohoku.ac.jp	Uruno, Akira/U-1812-2019; Uruno, Akira/ABF-3988-2020; Ito, Sadayoshi/A-3933-2015	Sugawara, Akira/0000-0003-4511-8101; Ito, Sadayoshi/0000-0002-5092-3626				ADACHI S, 1994, J BIOL CHEM, V269, P17677; BACHMANN S, 1995, J CLIN INVEST, V96, P2510, DOI 10.1172/JCI118311; Blakely P, 1996, J AM SOC NEPHROL, V7, P1052; Bostonjoglo M, 1998, J AM SOC NEPHROL, V9, P1347; CHEN ZF, 1994, J AM SOC NEPHROL, V5, P1361; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Hilfiker H, 1998, AM J PHYSIOL-RENAL, V274, pF197, DOI 10.1152/ajprenal.1998.274.1.F197; Igarashi P, 1996, J BIOL CHEM, V271, P9666, DOI 10.1074/jbc.271.16.9666; Ikeda Y, 2000, J BIOL CHEM, V275, P33142, DOI 10.1074/jbc.M002319200; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kim GH, 1998, P NATL ACAD SCI USA, V95, P14552, DOI 10.1073/pnas.95.24.14552; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Levi M, 1996, J MEMBRANE BIOL, V154, P1, DOI 10.1007/s002329900127; Mastroianni N, 1996, GENOMICS, V35, P486, DOI 10.1006/geno.1996.0388; Obermuller N, 1995, AM J PHYSIOL-RENAL, V269, pF900, DOI 10.1152/ajprenal.1995.269.6.F900; Overdier DG, 1997, J BIOL CHEM, V272, P13725, DOI 10.1074/jbc.272.21.13725; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Pathak BG, 1996, GENOMICS, V33, P124, DOI 10.1006/geno.1996.0168; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Plotkin MD, 1996, KIDNEY INT, V50, P174, DOI 10.1038/ki.1996.300; Pollak MR, 1996, J AM SOC NEPHROL, V7, P2244; Sambrook J, 1989, MOL CLONING; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; SCHUNG J, 1997, CBILTR19971001V00 U; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Takahashi N, 1998, BIOCHEM BIOPH RES CO, V244, P489, DOI 10.1006/bbrc.1998.8283; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; Takeuchi K, 1996, J CLIN ENDOCR METAB, V81, P4496, DOI 10.1210/jc.81.12.4496; Takeuchi K, 1996, KIDNEY INT, pS183; TOKUNAGA K, 1987, CANCER RES, V47, P5616; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Uchida S, 1998, AM J PHYSIOL-RENAL, V274, pF602, DOI 10.1152/ajprenal.1998.274.3.F602; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Velazquez H, 1998, KIDNEY INT, V54, P464, DOI 10.1046/j.1523-1755.1998.00036.x; Velazquez H, 1996, AM J PHYSIOL-RENAL, V270, pF211, DOI 10.1152/ajprenal.1996.270.1.F211; Whyte DA, 1999, AM J PHYSIOL-RENAL, V277, pF587, DOI 10.1152/ajprenal.1999.277.4.F587	38	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26260	26268		10.1074/jbc.M101614200	http://dx.doi.org/10.1074/jbc.M101614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11313351	hybrid			2022-12-27	WOS:000169823300083
J	Eckman, EA; Reed, DK; Eckman, CB				Eckman, EA; Reed, DK; Eckman, CB			Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; MEMBRANE-BOUND METALLOPROTEASE; PRECURSOR PROTEIN; INTRACELLULAR COMPARTMENT; NEUTRAL ENDOPEPTIDASE; EXTRACELLULAR LEVELS; CEREBROSPINAL-FLUID; MOLECULAR-CLONING; BIG ENDOTHELIN-1; HUMAN TISSUES	Deposition of beta -amyloid (A beta) peptides in the brain is an early and invariant feature of all forms of Alzheimer's disease. As with any secreted protein, the extracellular concentration of A beta is determined not only by its production but also by its catabolism. A major focus of Alzheimer's research has been the elucidation of the mechanisms responsible for the generation of A beta, Much less, however, is known about the mechanisms responsible for A beta removal in the brain, In this report, we describe the identification of endothelin-converting enzyme-1 (ECE-1) as a novel A beta -degrading enzyme. We show that treatment of endogenous ECE-expressing cell lines with the metalloprotease inhibitor phosphoramidon causes a 2-3-fold elevation in extracellular A beta concentration that appears to be due to inhibition of intracellular A beta degradation. Furthermore, we show that overexpression of ECE-1 in Chinese hamster ovary cells, which lack endogenous ECE activity, reduces extracellular A beta concentration by up to 90% and that this effect is completely reversed by treatment of the cells with phosphoramidon. Finally, we show that recombinant soluble ECE-1 is capable of hydrolyzing synthetic A beta 40 and A beta 42 in vitro at multiple sites.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd,Birdsall Bldg,Rm 253, Jacksonville, FL 32224 USA.		Eckman, Elizabeth/AAL-7316-2021	Eckman, Elizabeth/0000-0002-5391-4960				Ahn K, 1998, ARCH BIOCHEM BIOPHYS, V359, P258, DOI 10.1006/abbi.1998.0913; Ahn K, 1998, BIOCHEM BIOPH RES CO, V243, P184, DOI 10.1006/bbrc.1998.8081; AHN K, 1995, LIFE SCI, V56, P2331, DOI 10.1016/0024-3205(95)00227-W; ANSORGE S, 1984, BIOMED BIOCHIM ACTA, V43, P39; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Azarani A, 1998, BIOCHEM J, V333, P439, DOI 10.1042/bj3330439; Backstrom JR, 1996, J NEUROSCI, V16, P7910; Barnes K, 1997, J NEUROCHEM, V68, P570; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Davenport AP, 1998, HISTOCHEM J, V30, P359, DOI 10.1023/A:1003236628701; ECKMAN CB, 1995, SOC NEUROSCIENCE; Emoto N, 1999, J BIOL CHEM, V274, P1509, DOI 10.1074/jbc.274.3.1509; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Fahnoe DC, 2000, J CARDIOVASC PHARM, V36, pS22, DOI 10.1097/00005344-200036051-00009; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Ghaddar G, 2000, BIOCHEM J, V347, P419, DOI 10.1042/0264-6021:3470419; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; Gray GA, 1996, PHARMACOL THERAPEUT, V72, P109, DOI 10.1016/S0163-7258(96)00101-5; GRONHAGENRISKA C, 1980, SCAND J CLIN LAB INV, V40, P711, DOI 10.3109/00365518009095586; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Hasegawa H, 1998, FEBS LETT, V428, P304, DOI 10.1016/S0014-5793(98)00554-7; Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Ikeda K, 1999, J BIOL CHEM, V274, P32469, DOI 10.1074/jbc.274.45.32469; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; Korth P, 1997, FEBS LETT, V417, P365, DOI 10.1016/S0014-5793(97)01323-9; KUKKOLA PJ, 1995, J CARDIOVASC PHARM, V26, pS65; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Parnot C, 1997, HYPERTENSION, V30, P837, DOI 10.1161/01.HYP.30.4.837; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245; Russell FD, 1999, CIRC RES, V84, P891; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; Soleilhac JM, 1996, EUR J CLIN INVEST, V26, P1011, DOI 10.1046/j.1365-2362.1996.2420580.x; SPILLANTINI MG, 1990, BIOCHEM PHARMACOL, V39, P1353, DOI 10.1016/0006-2952(90)90012-A; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takaki Y, 2000, J BIOCHEM-TOKYO, V128, P897, DOI 10.1093/oxfordjournals.jbchem.a022839; Tanja O, 2000, BIOCHEM BIOPH RES CO, V271, P565, DOI 10.1006/bbrc.2000.2664; Telemaque S, 1998, J CARDIOVASC PHARM, V31, pS548, DOI 10.1097/00005344-199800001-00158; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Turner AJ, 1996, BIOCHEM PHARMACOL, V51, P91, DOI 10.1016/0006-2952(95)02036-5; UMEZAWA S, 1972, Tetrahedron Letters, V1, P97; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Vekrellis K, 2000, J NEUROSCI, V20, P1657; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yamin R, 1999, J BIOL CHEM, V274, P18777, DOI 10.1074/jbc.274.26.18777; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yanagisawa H, 2000, J CLIN INVEST, V105, P1373, DOI 10.1172/JCI7447; YOSHIZAWA T, 1992, NEUROPEPTIDES, V22, P85, DOI 10.1016/0143-4179(92)90059-6	62	283	293	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24540	24548		10.1074/jbc.M007579200	http://dx.doi.org/10.1074/jbc.M007579200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11337485	hybrid			2022-12-27	WOS:000169800700018
J	Zhu, XJ; Kahn, RA				Zhu, XJ; Kahn, RA			The Escherichia coli heat labile toxin binds to Golgi membranes and alters golgi and cell morphologies using ADP-ribosylation factor-dependent processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; BREFELDIN-A; ADENYLATE-CYCLASE; RIBOSYLTRANSFERASE ACTIVITY; MUCOSAL ADJUVANTICITY; DOWNSTREAM EFFECTOR; NUCLEOTIDE-EXCHANGE; PROTEIN COFACTOR; PLASMA-MEMBRANE; PHOSPHOLIPASE-D	The fate of the catalytic subunit of the Escherichia coli heat labile toxin (LTA(1)) was studied after expression in mammalian cells to assess the requirement for ADP-ribosylation factor (ARF) binding to localization and toxicity and ability to compete with endogenous ARF effecters, A progression in LTA(1) localization from cytosol to binding Golgi stacks to condensation of Golgi membranes was found to correlate with the time and level of LTA(1) expression. At the highest levels of LTA(1) expression the staining of LTA and both extrinsic and lumenal Golgi markers all became diffuse, in a fashion reminiscent of the actions of brefeldin A. Thus, LTA(1) binds to the Golgi and can alter its morphology in two distinct ways. However, point mutants of LTA(1) that are defective in the ability to bind activated ARF were also unable to bind Golgi membranes or modify Golgi morphology. Co-expression of mutants of ARF3 that regained binding to these same mutant LTA(1) proteins restored the localization and activities of the toxin, Thus, binding to ARF is required both for the localization of the toxin to the Golgi and for effects on Golgi membranes. A correlation was also seen between the ability of LTA mutants to bind ARF and the increase in cellular cAMP levels. These results demonstrate the importance of ARF binding to the toxicity and cellular effects of the ADP-ribosylating bacterial toxin and reveal that mutants defective in binding ARF retain basal ADP-ribosylation activity but are the least toxic LTA(1) mutants yet described, making them the best candidates for development as mucosal adjuvants.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rkahn@emory.edu	Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				AMRTIN ME, 2000, J BIOL CHEM, V275, P19050; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Cheng E, 1999, VACCINE, V18, P38, DOI 10.1016/S0264-410X(99)00168-1; Cieplak W, 1995, J BIOL CHEM, V270, P30545, DOI 10.1074/jbc.270.51.30545; CLEMENTS JD, 1988, VACCINE, V6, P269, DOI 10.1016/0264-410X(88)90223-X; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ELSON CO, 1984, J IMMUNOL, V132, P2736; Freytag LC, 1999, CURR TOP MICROBIOL, V236, P215; GILL DM, 1980, J INFECT DIS, V141, P64, DOI 10.1093/infdis/141.1.64; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; GUERRANT RL, 1974, INFECT IMMUN, V10, P320, DOI 10.1128/IAI.10.2.320-327.1974; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kuai J, 2000, J BIOL CHEM, V275, P4022, DOI 10.1074/jbc.275.6.4022; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MERRITT EA, 1995, CURR OPIN STRUC BIOL, V5, P165, DOI 10.1016/0959-440X(95)80071-9; MOSS J, 1993, J BIOL CHEM, V268, P6383; MOSS J, 1977, J BIOL CHEM, V252, P2455; NASHAR TO, 1993, VACCINE, V11, P235, DOI 10.1016/0264-410X(93)90023-Q; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Rappuoli R, 1999, IMMUNOL TODAY, V20, P493, DOI 10.1016/S0167-5699(99)01523-6; Rodighiero C, 1999, J BIOL CHEM, V274, P3962, DOI 10.1074/jbc.274.7.3962; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; Snider DP, 1995, CRIT REV IMMUNOL, V15, P317, DOI 10.1615/CritRevImmunol.v15.i3-4.70; Stevens LA, 1999, INFECT IMMUN, V67, P259; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Williams NA, 1999, IMMUNOL TODAY, V20, P95, DOI 10.1016/S0167-5699(98)01397-8; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465; Zhu XJ, 2001, BIOCHEMISTRY-US, V40, P4560, DOI 10.1021/bi002628s	43	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25014	25021		10.1074/jbc.M100923200	http://dx.doi.org/10.1074/jbc.M100923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333260	hybrid			2022-12-27	WOS:000169800700078
J	Bain, DL; Franden, MA; McManaman, JL; Takimoto, GS; Horwitz, KB				Bain, DL; Franden, MA; McManaman, JL; Takimoto, GS; Horwitz, KB			The N-terminal region of human progesterone B-receptors - Biophysical and biochemical comparison to A-receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; MONOCLONAL-ANTIBODY; BINDING; PROTEINS; FORM; IDENTIFICATION; EQUILIBRIUM; SUPERFAMILY; ACTIVATION; PROMOTERS	To understand the basis for functional differences between the two human progesterone receptors (PR), we have carried out a detailed biochemical and biophysical analysis of the N-terminal region of each isoform, Extending our previous work on the A-isoform (Bain, D, L, Franden, M, A, McManaman, J, L,, Takimoto, G, S,, and Horwitz, R, B, (2000) J, Biol, Chem, 275, 7313-7320), here we present studies on the N-terminal region of the B isoform (NT-B) and compare its properties to its A-receptor counterpart (NT-A), As seen previously with NT-A, NT-B is quantitatively monomeric in solution, yet undergoes N-terminal-mediated assembly upon DNA binding. Limited proteolysis, microsequencing, and sedimentation analyses indicate that the B-isoform exists in a non-globular, extended conformation very similar to that of NT-A, Additionally, the 164 amino acids unique to the B-isoform (BUS) appear to be in a more extended conformation relative to sequences common to both receptors and do not exist as an independent structural domain. However, sedimentation studies of NT-A and NT-B show differences in the ensemble distribution of their conformational states. We hypothesize that isoform-specific functional differences are not due to structural differences, per se. Rather, the transcriptional element BUS, or possibly other transcription factors, causes a redistribution of the conformational ensemble by stabilizing a more functionally active set of conformations in NT-B.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bain, DL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, 4200 E 9th Ave,C-238, Denver, CO 80262 USA.	david.bain@uchsc.edu		Horwitz, Kathryn/0000-0001-7402-6455	NATIONAL CANCER INSTITUTE [R01CA026869, R37CA026869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER; NCI NIH HHS [CA26869] Funding Source: Medline; NIDDK NIH HHS [DK48238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; Barbar E, 1998, BIOCHEMISTRY-US, V37, P7822, DOI 10.1021/bi973102j; Beck CA, 1996, J BIOL CHEM, V271, P19546, DOI 10.1074/jbc.271.32.19546; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; Cohn E. J., 1943, PROTEINS AMINO ACIDS; Demeler B, 1997, BIOPHYS J, V72, P397, DOI 10.1016/S0006-3495(97)78680-6; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hovland AR, 1998, J BIOL CHEM, V273, P5455, DOI 10.1074/jbc.273.10.5455; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kumar S, 2000, PROTEIN SCI, V9, P10; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Luque I, 2000, PROTEINS, P63; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Milne JS, 1999, J MOL BIOL, V290, P811, DOI 10.1006/jmbi.1999.2924; PESSEN H, 1985, METHOD ENZYMOL, V117, P219; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SMITH DF, 1988, ENDOCRINOLOGY, V122, P2816, DOI 10.1210/endo-122-6-2816; TAKIMOTO GS, 1991, J STEROID BIOCHEM, V39, P687, DOI 10.1016/0960-0760(91)90368-F; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VANHOLDE KE, 1971, PHYSICAL BIOCH, P105; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	40	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23825	23831		10.1074/jbc.M102611200	http://dx.doi.org/10.1074/jbc.M102611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11328821	hybrid			2022-12-27	WOS:000169531100081
J	Chen, BS; Sun, ZW; Hampsey, M				Chen, BS; Sun, ZW; Hampsey, M			A Ga14-sigma(54) hybrid protein that functions as a potent activator of RNA polymerase II transcription in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; ESCHERICHIA-COLI; SAGA COMPLEX; ADA COMPLEX; SIGMA 54; PROMOTER; RECRUITMENT; COMPONENTS; INITIATION; SUBUNIT	The bacterial sigma (54) protein associates with core RNA polymerase to form a holoenzyme complex that renders cognate promoters enhancer-dependent. Although unusual in bacteria, enhancer-dependent transcription is the paradigm in eukaryotes. Here we report that a fragment of Escherichia coli sigma (54) encompassing amino acid residues 29-177 functions as a potent transcriptional activator in yeast when fused to a Gal4 DNA binding domain. Activation by Gal4-sigma (54) is TATA-dependent and requires the SAGA coactivator complex, suggesting that Gal4-sigma (54) functions by a normal mechanism of transcriptional activation. Surprisingly, deletion of the AHC1 gene, which encodes a polypeptide unique to the ADA coactivator complex, stimulates Gal4-sigma (54)-mediated activation and enhances the toxicity of Gal4-sigma (54). Accordingly, the SAGA and ADA complexes, both of which include Gcn5 as their histone acetyltransferase subunit, exert opposite effects on transcriptional activation by Gal4-sigma (54). Gal4-sigma (54) activation and toxicity are also dependent upon specific sigma (54) residues that are required for activator-responsive promoter melting by sigma (54) in bacteria, implying that activation is a consequence of sigma (54)-specific features rather than a structurally fortuitous polypeptide fragment. As such, Gal4-sigma (54) represents a novel tool with the potential to provide insight into the mechanism by which natural activators function in eukaryotic cells.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acids, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Hampsey, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acids, 675 Hoes Lane, Piscataway, NJ 08854 USA.	hampsemi@umdnj.edu	Chen, Bo-Shiun/H-4633-2012; Chen, Bo-Shiun/E-2736-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039484, R29GM039484] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39484] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Dudley AM, 1999, GENETICS, V151, P1365; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Gallegos MT, 1999, J MOL BIOL, V288, P539, DOI 10.1006/jmbi.1999.2704; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; Guo YL, 1997, J BACTERIOL, V179, P1239, DOI 10.1128/jb.179.4.1239-1245.1997; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; JAEHNING JA, 1991, SCIENCE, V253, P859, DOI 10.1126/science.1876846; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pappas DL, 2000, MOL CELL BIOL, V20, P8343, DOI 10.1128/MCB.20.22.8343-8351.2000; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; Roberts SM, 1997, GENETICS, V147, P451; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Syed A, 1998, J BACTERIOL, V180, P5619, DOI 10.1128/JB.180.21.5619-5625.1998; TINTUT Y, 1995, J BACTERIOL, V177, P5818, DOI 10.1128/jb.177.20.5818-5825.1995; Todone F, 2000, P NATL ACAD SCI USA, V97, P6306, DOI 10.1073/pnas.97.12.6306; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; Wu WH, 1999, P NATL ACAD SCI USA, V96, P2764, DOI 10.1073/pnas.96.6.2764; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Yee A, 2000, P NATL ACAD SCI USA, V97, P6311, DOI 10.1073/pnas.97.12.6311; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	50	5	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23881	23887		10.1074/jbc.M102893200	http://dx.doi.org/10.1074/jbc.M102893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313364	hybrid			2022-12-27	WOS:000169531100088
J	Gautam, A; Mulugu, S; Alexander, K; Bastia, D				Gautam, A; Mulugu, S; Alexander, K; Bastia, D			A single domain of the replication termination protein of Bacillus subtilis is involved in arresting both DnaB helicase and RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; ESCHERICHIA-COLI; POLAR CONTRAHELICASE; TRANSCRIPTION; IDENTIFICATION; TRANSLOCATION; MECHANISM; COMPLEX	The current models that have been proposed to explain the mechanism of replication termination are (i) passive arrest of a replication fork by the terminus (Ter) DNA-terminator protein complex that impedes the replication fork and the replicative helicase in a polar fashion and (ii) an active barrier model in which the Ter-terminator protein complex arrests a fork not only by DNA-protein interaction but also by mechanistically significant terminator protein-helicase interaction. Despite the existence of some evidence supporting in vitro interaction between the replication terminator protein (RTP) and DnaB helicase, there has been continuing debate in the literature questioning the validity of the protein-protein interaction model. The objective of the present work was two-fold: (i) to reexamine the question of RTP-DnaB interaction by additional techniques and different mutant forms of RTP, and (ii) to investigate if a common domain of RTP is involved in the arrest of both helicase and RNA polymerase, The results validate and confirm the RTP-DnaB interaction in vitro and suggest a critical role for this interaction in replication fork arrest. The results also show that the Tyr(33) residue of RTP plays a critical role both in the arrest of helicase and RNA polymerase.	Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA	Duke University; Duke University	Bastia, D (corresponding author), Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA.							Bastia D., 1996, DNA REPLICATION EUKA, P177; BUSSIERE DE, 1995, CELL, V80, P651; Bussiere DE, 1999, MOL MICROBIOL, V31, P1611, DOI 10.1046/j.1365-2958.1999.01287.x; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Duggin IG, 1999, J MOL BIOL, V286, P1325, DOI 10.1006/jmbi.1999.2553; Gautam A, 2001, J BIOL CHEM, V276, P8771, DOI 10.1074/jbc.M009538200; Hill AV, 1913, BIOCHEM J, V7, P471, DOI 10.1042/bj0070471; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; Manna AC, 1996, CELL, V87, P881, DOI 10.1016/S0092-8674(00)81995-9; Manna AC, 1996, P NATL ACAD SCI USA, V93, P3253, DOI 10.1073/pnas.93.8.3253; Mohanty BK, 2001, J BIOL CHEM, V276, P13160, DOI 10.1074/jbc.M010940200; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; Pai KS, 1996, EMBO J, V15, P3164, DOI 10.1002/j.1460-2075.1996.tb00679.x; Pai KS, 1996, P NATL ACAD SCI USA, V93, P10647, DOI 10.1073/pnas.93.20.10647; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Wake RG, 1997, STRUCTURE, V5, P1, DOI 10.1016/S0969-2126(97)00160-3; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445	26	13	13	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23471	23479		10.1074/jbc.M009537200	http://dx.doi.org/10.1074/jbc.M009537200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313334	hybrid			2022-12-27	WOS:000169531100034
J	Osyczka, A; Nagashima, KVP; Sogabe, S; Miki, K; Shimada, K; Matsuura, K				Osyczka, A; Nagashima, KVP; Sogabe, S; Miki, K; Shimada, K; Matsuura, K			Different mechanisms of the binding of soluble electron donors to the photosynthetic reaction center of Rubrivivax gelatinosus and Blastochloris viridis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; BOUND CYTOCHROME SUBUNIT; RHODOPSEUDOMONAS-VIRIDIS; RHODOFERAX FERMENTANS; INTERACTION SITE; PURPLE BACTERIA; HIPIP; KINETICS; C(8); PARTICIPATION	The tetraheme cytochrome subunits of the photosynthetic reaction centers (RCs) in two species of purple bacteria, Rubrivivax gelatinosus and Blastochloris (Rhodopseudomonas) viridis, were compared in terms of their capabilities to bind different electron-donor proteins. The wild-type RCs from both species and mutated forms of R gelatinosus Res (with amino acid substitutions introduced to the binding domain for electron-donor proteins) were tested for their reactivity with soluble cytochromes and high potential iron-sulfur protein. Cytochromes from both species mere good electron donors to the B. viridis RC and the R. gelatinosus RC, The reactivity in the R. gelatinosus RC showed a clear dependence on the polarity of the charges introduced to the binding domain, indicating the importance of the electrostatic interactions. In contrast, high potential iron-sulfur protein, presumed to operate according to the hydrophobic mechanism of binding, reacted significantly only with the R gelatinosus RC. Evolutionary substitution of amino acids in a region of the binding domain on the cytochrome subunit surface probably caused the change in the principal mode of protein-protein interactions in the electron-transfer chains.	Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo 1920397, Japan; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan	Tokyo Metropolitan University; Kyoto University	Osyczka, A (corresponding author), Univ Penn, Johson Res Fdn, Dept Biochem & Biophys, 242 Anat Chem Bldg, Philadelphia, PA 19104 USA.		Nagashima, Kenji V. P./M-2208-2017	Nagashima, Kenji V. P./0000-0002-4526-6625; Osyczka, Artur/0000-0002-1637-2365				AMBLER RP, 1991, BIOCHIM BIOPHYS ACTA, V1058, P42, DOI 10.1016/S0005-2728(05)80266-X; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; Hochkoeppler A, 1996, P NATL ACAD SCI USA, V93, P6998, DOI 10.1073/pnas.93.14.6998; HOCHKOEPPLER A, 1995, FEBS LETT, V357, P70, DOI 10.1016/0014-5793(94)01334-W; Hochkoeppler A, 1997, PHOTOSYNTH RES, V53, P13, DOI 10.1023/A:1005830003198; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; MATSUURA K, 1988, FEBS LETT, V237, P21, DOI 10.1016/0014-5793(88)80163-7; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; Menin L, 1997, BIOCHEMISTRY-US, V36, P12183, DOI 10.1021/bi971163b; Menin L, 1998, PHOTOSYNTH RES, V55, P343, DOI 10.1023/A:1005989900756; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4719, DOI 10.1021/bi00069a005; Meyer TE, 1995, ANOXYGENIC PHOTOSYNT, P725; NAGASHIMA KVP, 1994, J BIOL CHEM, V269, P2477; Nagashima KVP, 1998, PHOTOSYNTH RES, V55, P349, DOI 10.1023/A:1005912810674; Nogi T, 2000, P NATL ACAD SCI USA, V97, P13561, DOI 10.1073/pnas.240224997; Ortega JM, 1999, PHOTOSYNTH RES, V59, P147, DOI 10.1023/A:1006149621029; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P15779, DOI 10.1021/bi990907d; Osyczka A, 1999, BIOCHEMISTRY-US, V38, P2861, DOI 10.1021/bi982747w; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; Osyczka A, 1997, BBA-BIOENERGETICS, V1321, P93, DOI 10.1016/S0005-2728(97)00041-8; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Samyn B, 1996, EUR J BIOCHEM, V236, P689, DOI 10.1111/j.1432-1033.1996.00689.x; Santana M, 2001, J BACTERIOL, V183, P687, DOI 10.1128/JB.183.2.687-699.2001; SCHOEPP B, 1995, BIOCHEMISTRY-US, V34, P11736, DOI 10.1021/bi00037a010; Sigfridsson K, 1996, BIOCHEMISTRY-US, V35, P1249, DOI 10.1021/bi9520141; TIEDE DM, 1993, BIOCHEMISTRY-US, V32, P4515, DOI 10.1021/bi00068a006; VANDEKAMP M, 1990, EUR J BIOCHEM, V194, P109; [No title captured]	28	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24108	24112		10.1074/jbc.M101141200	http://dx.doi.org/10.1074/jbc.M101141200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313347	hybrid			2022-12-27	WOS:000169531100117
J	Sanders, CM; Stenlund, A				Sanders, CM; Stenlund, A			Mechanism and requirements for bovine papillomavirus, type 1, E1 initiator complex assembly promoted by the E2 transcription factor bound to distal sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; REPLICATION PROTEIN; ORIGIN; HELICASE; TRANSACTIVATOR; ROLES; ACTIVATION; ENHANCER; REVEALS; ATPASE	DNA replication of papillomavirus requires the viral initiator E1 and the transcription factor E2. Bovine papillomavirus, type 1 (BPV-1), E1, and E2 bind cooperatively as dimers to proximal sites in the viral replicator generating a sequence-specific E1E2-ori complex. This complex is critical for replication and can be converted to a multimeric E1-ori initiator complex by displacement of E2 in the presence of hydrolyzable ATP. However, E2 can function over extended distances, and E2 at a distal position 33 base pairs upstream of the E1-binding site also loads an E1 dimer onto ori. Under these conditions, neither displacement of E2 nor ATP hydrolysis are required for E1-ori formation, consistent with a need for ATP hydrolysis in E2 displacement from E1E2-ori. However, ATP is required for stabilization of the resulting E1 ori complex. These results indicate that BPV (with a proximal E2-binding site) and human papillomaviruses (with distal E2-binding sites) utilize the same general mechanism for E1 loading but suggest that E1E2-ori, which forms preferentially on ori, may perform an additional role in BPV replication.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stenlund, A (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	Stenlund@cshl.org			NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; Berg M, 1997, J VIROL, V71, P3853, DOI 10.1128/JVI.71.5.3853-3863.1997; Chen G, 2000, J VIROL, V74, P1506, DOI 10.1128/JVI.74.3.1506-1512.2000; Chen G, 1998, J VIROL, V72, P2567, DOI 10.1128/JVI.72.4.2567-2576.1998; Cleary MA, 1997, P NATL ACAD SCI USA, V94, P8450, DOI 10.1073/pnas.94.16.8450; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; Ferguson MK, 1996, J VIROL, V70, P4193, DOI 10.1128/JVI.70.7.4193-4199.1996; FRATTINI MG, 1994, P NATL ACAD SCI USA, V91, P12398, DOI 10.1073/pnas.91.26.12398; GILLETTE TG, 1994, P NATL ACAD SCI USA, V91, P8846, DOI 10.1073/pnas.91.19.8846; Gillette TG, 1998, J VIROL, V72, P5735, DOI 10.1128/JVI.72.7.5735-5744.1998; Gillitzer E, 2000, EMBO J, V19, P3069, DOI 10.1093/emboj/19.12.3069; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HOLT SE, 1994, J VIROL, V68, P1094, DOI 10.1128/JVI.68.2.1094-1102.1994; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LUSKY M, 1994, P NATL ACAD SCI USA, V91, P8895, DOI 10.1073/pnas.91.19.8895; MACPHERSON P, 1994, VIROLOGY, V204, P403, DOI 10.1006/viro.1994.1544; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; McShan GD, 1997, VIROLOGY, V237, P198, DOI 10.1006/viro.1997.8793; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Sanders CM, 1998, EMBO J, V17, P7044, DOI 10.1093/emboj/17.23.7044; Sanders CM, 2000, J BIOL CHEM, V275, P3522, DOI 10.1074/jbc.275.5.3522; SARAFI TR, 1995, VIROLOGY, V211, P385, DOI 10.1006/viro.1995.1421; Sedman J, 1998, J VIROL, V72, P6893, DOI 10.1128/JVI.72.8.6893-6897.1998; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STENLUND A, 1996, DNA REPLICATION EUKA, P679; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; Sun YN, 1996, VIROLOGY, V216, P219, DOI 10.1006/viro.1996.0050; SVERDRUP F, 1995, J VIROL, V69, P1319, DOI 10.1128/JVI.69.2.1319-1323.1995; SYRJANEN K, 1987, PAPILLOMAVIRUSES HUM, P69; THORNER LK, 1993, J VIROL, V67, P6000, DOI 10.1128/JVI.67.10.6000-6014.1993; USTAV E, 1993, P NATL ACAD SCI USA, V90, P898, DOI 10.1073/pnas.90.3.898; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; van der Vliet P.C., 1996, DNA REPLICATION EUKA, P87; Winokur PL, 1996, VIROLOGY, V221, P44, DOI 10.1006/viro.1996.0351; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	42	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23689	23699		10.1074/jbc.M101861200	http://dx.doi.org/10.1074/jbc.M101861200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323428	hybrid			2022-12-27	WOS:000169531100063
J	Feng, X; Jiang, Y; Meltzer, P; Yen, PM				Feng, X; Jiang, Y; Meltzer, P; Yen, PM			Transgenic targeting of a dominant negative corepressor to liver blocks basal repression by thyroid hormone receptor and increases cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; CANDIDATE PROTOONCOGENE BCL-3; TUMOR-NECROSIS-FACTOR; KAPPA-B PROTEIN; N-COR; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; CYCLE CONTROL; PARTIAL-HEPATECTOMY; REGENERATING LIVER	Unliganded thyroid hormone receptors (TRs) interact with corepressors and repress basal transcription of target genes in cotransfection and in vitro studies. Currently, little is known about the function of corepressors in vivo. We thus used a mouse albumin promoter to generate several transgenic mouse lines that overexpressed a dominant negative mutant corepressor, NCoRi, in liver. The transgenic mice had normal liver weight, appearance, and minimal changes in enzyme activity. To study the effects of NCoRi on transcription of hepatic target genes, we examined T-3-regulated gene expression of hypo- and hyperthyroid transgenic mice. In hypothyroid mice, hepatic expression of Spot 14, Bcl-3, glucose 6-phosphatase, and 5'-deiodinase mRNA was higher in transgenic mice than littermate controls whereas these genes were induced to similar levels in T-3-treated mice. Derepression was not observed for malic enzyme mRNA expression in hypothyroid mice. Thus, NCoRi selectively blocked basal transcription of several thyroid hormone-responsive genes but had no effect on ligand-mediated transcription. Additionally, compensatory increases in endogenous SMRT and NCoR mRNA were observed in hypothyroid transgenic mice, Interestingly, hepatocyte proliferation as detected by BrdUrd incorporation was increased in transgenic mice. The gene profile in transgenic mouse livers was studied by cDNA microarray, and several genes related to cell proliferation were induced, In summary, our studies show that NCoR plays important roles in mediating basal repression by TRs and may prevent cellular proliferation in vivo.	NIDDK, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, Bethesda, MD 20892 USA; NHRGI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Yen, PM (corresponding author), NIDDK, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, Bethesda, MD 20892 USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK055101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chin WW, 1996, ENDOCRINOLOGY, V137, P387, DOI 10.1210/en.137.2.387; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P710, DOI 10.1210/endo-129-2-710; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Feng X, 2000, MOL ENDOCRINOL, V14, P947, DOI 10.1210/me.14.7.947; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; GHAHARY A, 1992, HEPATOLOGY, V15, P1125, DOI 10.1002/hep.1840150625; GILLESPIEA JR, 2000, BIOCHIM BIOPHYS ACTA, V14, P1; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lazar MA, 1999, J INVEST MED, V47, P364; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Na SY, 1998, J BIOL CHEM, V273, P30933, DOI 10.1074/jbc.273.47.30933; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; Payraudeau V, 1998, MOL CELL ENDOCRINOL, V143, P107, DOI 10.1016/S0303-7207(98)00136-1; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rao G, 1996, ONCOGENE, V12, P1165; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Servillo G, 1997, ONCOGENE, V14, P1601, DOI 10.1038/sj.onc.1200996; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; Shibata H, 1997, MOL ENDOCRINOL, V11, P714, DOI 10.1210/me.11.6.714; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Snibson KJ, 1999, LIVER, V19, P242, DOI 10.1111/j.1478-3231.1999.tb00042.x; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; TABOR E, 1994, J MED VIROL, V42, P357, DOI 10.1002/jmv.1890420406; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	60	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15066	15072		10.1074/jbc.M011027200	http://dx.doi.org/10.1074/jbc.M011027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11328825	hybrid			2022-12-27	WOS:000168528800073
J	Mummidi, S; Catano, G; Lam, L; Hoefle, A; Telles, V; Begum, K; Jimenez, F; Ahuja, SS; Ahuja, SK				Mummidi, S; Catano, G; Lam, L; Hoefle, A; Telles, V; Begum, K; Jimenez, F; Ahuja, SS; Ahuja, SK			Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms - Inter-individual variation in expression of DC-SIGN transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; C-TYPE LECTIN; PRE-MESSENGER-RNA; TRANSLATIONAL CONTROL; T-CELLS; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; LIGAND-BINDING; ANTIGEN; HIV-1	Expression in dendritic cells (DCs) of DC-SIGN, a type II membrane protein with a C-type lectin ectodomain, is thought to play an important role in establishing the initial contact between DCs and resting T cells. DC-SIGN is also a unique type of human immunodeficiency virus-1 (HIV-1) attachment factor and promotes efficient infection in trans of cells that express CD4 and chemokine receptors. We have identified another gene, designated here as DC-SIGN2, that exhibits high sequence homology with DC-SIGN. Here we demonstrate that alternative splicing of DC-SIGN1 (original version) and DC-SIGN2 pre-mRNA generates a large repertoire of DC-SIGN-like transcripts that are predicted to encode membrane-associated and soluble isoforms. The range of DC-SIGN1 mRNA expression was significantly broader than previously reported and included THP-1 monocytic cells, placenta, and peripheral blood mononuclear cells (PBMCs), and there was cell maturation/activation-induced differences in mRNA expression levels. Immunostaining of term placenta with a DC-SIGN1-specific antiserum showed that DC-SIGN1 is expressed on endothelial cells and CC chemokine receptor 5 (CCR5)-positive macrophage-like cells in the villi. DC-SIGN2 mRNA expression was high in the placenta and not detectable in PBMCs. In DCs, the expression of DC-SIGN2 transcripts was significantly lower than that of DC-SIGN1. Notably, there was significant inter-individual heterogeneity in the repertoire of DC-SIGN1 and DC-SIGN2 transcripts expressed. The genes for DC-SIGN1, DC-SIGN2, and CD23, another Type II lectin, colocalize to an similar to 85 kilobase pair region on chromosome 19p13.3, forming a cluster of related genes that undergo highly complex alternative splicing events. The molecular diversity of DC-SIGN-1 and -2 is reminiscent of that observed for certain other adhesive cell surface proteins involved in cell-cell connectivity. The generation of this large collection of polymorphic cell surface and soluble variants that exhibit inter-individual variation in expression levels has important implications for the pathogenesis of HIV-1 infection, as well as for the molecular code required to establish complex interactions between antigen-presenting cells and T cells, i.e. the immunological synapse.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Nephrol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Ahuja, SK (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Infect Dis, Mail Code 7880, San Antonio, TX 78229 USA.	ahujas@uthscsa.edu	Mummidi, Srinivas/H-3335-2017; Mummidi, Srinivas/C-1004-2008; Catano, Gabriel/AAQ-5387-2020	Mummidi, Srinivas/0000-0002-4068-6380; Mummidi, Srinivas/0000-0002-4068-6380; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043279, R01AI046326, R21AI046326, R37AI046326] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43279, AI46326] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Ahuja SS, 1998, J IMMUNOL, V161, P868; Arinobu Y, 1999, CELL IMMUNOL, V191, P161, DOI 10.1006/cimm.1998.1431; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; Blauvelt A, 1997, J CLIN INVEST, V100, P2043, DOI 10.1172/JCI119737; Bloom TJ, 1996, P NATL ACAD SCI USA, V93, P14188, DOI 10.1073/pnas.93.24.14188; Bocek P, 1997, J IMMUNOL, V158, P3235; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Canque B, 1999, BLOOD, V93, P3866, DOI 10.1182/blood.V93.11.3866.411k43_3866_3875; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; CIAMARELLI A, 1994, J ACQ IMMUN DEF SYND, V7, P230; CLINTON M, 1989, BIOCHEM BIOPH RES CO, V158, P855, DOI 10.1016/0006-291X(89)92801-5; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; Corradi JP, 1997, J NEUROSCI, V17, P1406; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; de Melker AA, 1999, BIOESSAYS, V21, P499, DOI 10.1002/(SICI)1521-1878(199906)21:6<499::AID-BIES6>3.0.CO;2-D; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; Dietz AB, 2000, BIOCHEM BIOPH RES CO, V275, P731, DOI 10.1006/bbrc.2000.3372; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Fichter M, 1997, ONCOGENE, V14, P2817, DOI 10.1038/sj.onc.1201127; Frank I, 1999, J VIROL, V73, P3449, DOI 10.1128/JVI.73.4.3449-3454.1999; Garcia-Sanz JA, 1998, FASEB J, V12, P299, DOI 10.1096/fasebj.12.3.299; GarciaSanz JA, 1996, J EXP MED, V184, P159, DOI 10.1084/jem.184.1.159; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Gonzalez E, 1999, P NATL ACAD SCI USA, V96, P12004, DOI 10.1073/pnas.96.21.12004; GOODALL GJ, 1986, P NATL ACAD SCI USA, V83, P8926, DOI 10.1073/pnas.83.23.8926; GORDON J, 1994, IMMUNOL TODAY, V15, P411, DOI 10.1016/0167-5699(94)90270-4; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Hebert E, 2000, BIOSCIENCE REP, V20, P213, DOI 10.1023/A:1026484722248; HILL JR, 1993, J BIOL CHEM, V268, P726; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kacani L, 1998, J VIROL, V72, P6671, DOI 10.1128/JVI.72.8.6671-6677.1998; KIKUTANI H, 1989, CIBA F SYMP, V147, P23; Knight SC, 1997, ANNU REV IMMUNOL, V15, P593, DOI 10.1146/annurev.immunol.15.1.593; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Mangano A, 2001, J INFECT DIS, V183, P1574, DOI 10.1086/320705; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Marrack P, 2000, CURR OPIN IMMUNOL, V12, P206, DOI 10.1016/S0952-7915(99)00075-8; Metheny LJ, 1996, EXP CELL RES, V228, P44, DOI 10.1006/excr.1996.0297; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; Newell ML, 1998, AIDS, V12, P831, DOI 10.1097/00002030-199808000-00004; Pearson WR, 1997, GENOMICS, V46, P24, DOI 10.1006/geno.1997.4995; PINCHUK LM, 1994, IMMUNITY, V1, P317, DOI 10.1016/1074-7613(94)90083-3; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; RAO SM, 1993, J BIOL CHEM, V268, P22164; Roca X, 1998, AM J PATHOL, V153, P183, DOI 10.1016/S0002-9440(10)65559-9; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; Sancho D, 2000, J IMMUNOL, V165, P3868, DOI 10.4049/jimmunol.165.7.3868; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shapiro L, 1999, NEURON, V23, P427, DOI 10.1016/S0896-6273(00)80796-5; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; Steinman RM, 2000, CELL, V100, P491, DOI 10.1016/S0092-8674(00)80684-4; SUTER U, 1987, NUCLEIC ACIDS RES, V15, P7295, DOI 10.1093/nar/15.18.7295; Tone M, 2001, P NATL ACAD SCI USA, V98, P1751, DOI 10.1073/pnas.98.4.1751; Tsunetsugu-Yokota Y, 1997, VIROLOGY, V239, P259, DOI 10.1006/viro.1997.8895; TSUNETSUGUYOKOTA Y, 1995, J VIROL, V69, P4544, DOI 10.1128/JVI.69.7.4544-4547.1995; Tsytsikov VN, 1996, J BIOL CHEM, V271, P23055, DOI 10.1074/jbc.271.38.23055; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; van der Merwe PA, 2000, SEMIN IMMUNOL, V12, P5, DOI 10.1006/smim.2000.0203; Walker J, 2000, J IMMUNOL METHODS, V239, P167, DOI 10.1016/S0022-1759(00)00181-2; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Weissman D, 1997, CLIN MICROBIOL REV, V10, P358, DOI 10.1128/CMR.10.2.358; Williams SC, 1996, J MOL BIOL, V264, P220, DOI 10.1006/jmbi.1996.0636; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; YING, 1995, J IMMUNOL, V155, P1637; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; Yokoyama-Kobayashi M, 1999, GENE, V228, P161, DOI 10.1016/S0378-1119(99)00004-9; Yoshikawa T, 1999, MOL IMMUNOL, V36, P1223, DOI 10.1016/S0161-5890(99)00139-X; Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369	97	91	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 31	2001	276	35					33196	33212		10.1074/jbc.M009807200	http://dx.doi.org/10.1074/jbc.M009807200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	468EW	11337487	hybrid			2022-12-27	WOS:000170746000106
J	Cohen, S; Orian, A; Ciechanover, A				Cohen, S; Orian, A; Ciechanover, A			Processing of p105 is inhibited by docking of p50 active subunits to the ankyrin repeat domain, and inhibition is alleviated by signaling via the carboxyl-terminal phosphorylation/ubiquitin-ligase binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; GLYCINE-RICH REGION; PRECURSOR P105; NF-KAPPA-B1 PRECURSOR; CONJUGATING ENZYMES; 26S PROTEASOME; DEGRADATION; PROTEOLYSIS; GENERATION	Processing of the p105 precursor to generate the p50 subunit of the nuclear factor kappaB transcription factor is an exceptional case in which the ubiquitin system is involved in Limited processing rather than in complete destruction of the target substrate. A Gly-rich region "stop" signal in the middle of the molecule along with a neighboring downstream ubiquitination, and probably an E3 anchoring domain, have been demonstrated to be important for processing In addition, we have shown that I kappaB kinase-mediated phosphorylation of the C-terminal domain leads to recruitment of the SCFbeta -TrCP ubiquitin ligase with subsequent accelerated ubiquitination and processing/degradation of the precursor (Orian, A, Gonen, H., Bercovich, B,, Fajerman, I., Eytan, E., Israel, A, Mercurio, F,, Iwai, K, Schwartz, A. L., and Ciechanover, A. (2000) EMBO J. 19, 2580-2591), Here we show that processing of p105 molecules that contain more then four ankyrin repeats, but lack the C-terminal phosphorylation/ubiquitin ligase binding domain, is strongly inhibited by docked p50 subunits, Inhibition is caused by interference with the function of the proteasome, as conjugation is not affected. Inhibition is alleviated after I kappaB kinase phosphorylation of the C-terminal domain leads to accelerated, beta -TrCP-mediated ubiquitination and processing/degradation of p105. We suggest that under basal conditions, slow generation of p50 probably involves the mid molecule ubiquitination/E3 recognition motif. Following stimulation, the C-terminal domain is involved in rapid processing/degradation of p105 with release of a large amount of the stored subunits that now become transcriptionally active.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Lady Davis Carmel Med Ctr, Dept Internal Med A, IL-34362 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.		Ciechanover, Aaron J/C-9166-2017					ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Foo SY, 1999, TRENDS GENET, V15, P229; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; Harhaj EW, 1996, ONCOGENE, V12, P2385; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	34	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26769	26776		10.1074/jbc.M102448200	http://dx.doi.org/10.1074/jbc.M102448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11350967	hybrid			2022-12-27	WOS:000169966900007
J	Lin, E; Graziano, JH; Freyer, GA				Lin, E; Graziano, JH; Freyer, GA			Regulation of the 75-kDa subunit of mitochondrial complex I by iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; RESPONSIVE ELEMENT; PARKINSONS-DISEASE; TRANSLATIONAL REGULATION; TRANSFERRIN RECEPTOR; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; BINDING PROTEIN; CYTOSOLIC PROTEIN; FREE-RADICALS	Iron homeostasis is tightly regulated, as cells work to conserve this essential but potentially toxic metal, The translation of many iron proteins is controlled by the binding of two cytoplasmic proteins, iron regulatory protein 1 and 2 (IRP1 and IRP2) to stem loop structures, known as iron-responsive elements (IREs), found in the untranslated regions of their mRNAs. In short, when iron is depleted, IRP1 or IRP2 bind IREs; this decreases the synthesis of proteins involved in iron storage and mitochondrial metabolism (e.g. ferritin and mitochondrial aconitase) and increases the synthesis of those involved in iron uptake (e.g. transferrin receptor). It is likely that more iron containing proteins have IREs and that other IRPs may exist. One obvious place to search is in Complex I of the mitochondrial respiratory chain, which contains at least 6 iron-sulfur (Fe-S) subunits, Interestingly, in idiopathic Parkinson's disease, iron homeostasis is altered, and Complex I activity is diminished. These findings led us to investigate whether iron status affects the Fe-S subunits of Complex I. We found that the protein levels of the 75-kDa subunit of Complex I were modulated by levels of iron in the cell, whereas mRNA levels were minimally changed. Isolation of a clone of the 75-kDa Fe-S subunit with a more complete 5'-untranslated region sequence revealed a novel IRE-like stem loop sequence. RNA protein gel shift assays demonstrated that a specific cytoplasmic protein bound the novel IRE and that the binding of the protein was affected by iron status. Western blot analysis and supershift assays showed that this cytosolic protein is neither IRP1 nor IRP2. In addition, ferritin IRE was able to compete for binding with this putative IRP, These results suggest that the 75-kDa Fe-S subunit of mitochondrial Complex I may be regulated by a novel IRE-IRP system.	Columbia Univ, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University	Freyer, GA (corresponding author), Columbia Univ, Div Environm Hlth Sci, 722 W 168th St,PI Annex,Rm 114, New York, NY 10032 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032527] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES09089] Funding Source: Medline; NINDS NIH HHS [NS32527] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKRELL BAC, 1984, J BIOL CHEM, V259, P53; Allerson CR, 1999, J BIOL CHEM, V274, P26439, DOI 10.1074/jbc.274.37.26439; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; COOPER JM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P198, DOI 10.1016/S0005-2728(05)80019-2; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DAVIES KJA, 1982, AM J PHYSIOL, V242, pE418, DOI 10.1152/ajpendo.1982.242.6.E418; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HIRSCH EC, 1993, EUR NEUROL, V33, P52, DOI 10.1159/000118538; JAFFREY SR, 1993, NUCLEIC ACIDS RES, V21, P4627, DOI 10.1093/nar/21.19.4627; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kim HY, 1996, J BIOL CHEM, V271, P24226, DOI 10.1074/jbc.271.39.24226; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; Kohler SA, 1999, J BIOL CHEM, V274, P2401, DOI 10.1074/jbc.274.4.2401; LANGSTON JW, 1984, CAN J NEUROL SCI, V11, P160; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1983, NEW ENGL J MED, V309, P310; LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859; MAGUIRE JJ, 1982, BIOCHIM BIOPHYS ACTA, V679, P210, DOI 10.1016/0005-2728(82)90292-4; MANN VM, 1994, ANN NEUROL, V36, P876, DOI 10.1002/ana.410360612; McCord JM, 1998, SEMIN HEMATOL, V35, P5; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOCHIZUKI H, 1994, NEUROSCI LETT, V168, P251, DOI 10.1016/0304-3940(94)90462-6; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; PIETRANGELO A, 1991, HEPATOLOGY, V14, P1083, DOI 10.1002/hep.1840140623; PIETRANGELO A, 1990, HEPATOLOGY, V11, P798, DOI 10.1002/hep.1840110513; PILKINGTON SJ, 1993, BIOCHEM SOC T, V21, P26, DOI 10.1042/bst0210026; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SCHAPIRA AHV, 1993, ADV NEUROL, V60, P288; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Schapira AHV, 1996, CURR OPIN NEUROL, V9, P260, DOI 10.1097/00019052-199608000-00003; SCHAPIRA AHV, 1993, BIOCHEM SOC T, V21, P367, DOI 10.1042/bst0210367; SIERZPUTOWSKAGRACZ H, 1995, NUCLEIC ACIDS RES, V23, P146, DOI 10.1093/nar/23.1.146; SOFIC E, 1988, J NEURAL TRANSM, V74, P199, DOI 10.1007/BF01244786; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WHITE K, 1988, J BIOL CHEM, V263, P8938	51	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27685	27692		10.1074/jbc.M100941200	http://dx.doi.org/10.1074/jbc.M100941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313346	hybrid			2022-12-27	WOS:000169966900125
J	Settasatian, N; Duong, MN; Curtiss, LK; Ehnholm, C; Jauhiainen, M; Huuskonen, J; Rye, KA				Settasatian, N; Duong, MN; Curtiss, LK; Ehnholm, C; Jauhiainen, M; Huuskonen, J; Rye, KA			The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; ESTER TRANSFER PROTEIN; HUMAN-PLASMA; CHOLESTEROL ACYLTRANSFERASE; PARTICLE FUSION; CONVERSION; SIZE; HDL; PHOSPHATIDYLCHOLINE; PRECIPITATION	Phospholipid transfer protein (PLTP) remodels high density lipoproteins (HDL) into large and small particles. It also mediates the dissociation of lipid-poor or lipid-free apolipoprotein A-I (apoA-I) from HDL, Remodeling is enhanced markedly in triglyceride (TG)-enriched HDL (Rye, K.-A, Jauhiainen, M,, Barter, P, J,, and Ehnholm, C, (1998) J; Lipid. Res. 39, 613-622), This study defines the mechanism of the remodeling of HDL by PLTP and determines why it is enhanced in TG-enriched HDL, Homogeneous populations of spherical reconstituted HDL (rHDL) containing apoA-I and either cholesteryl esters only (CE-rHDL; diameter 9.3 nm) or CE and TG in their core (TG-rHDL; diameter 9.5 nm) were used. After 24 h of incubation with PLTP, all of the TG-rHDL, but only a proportion of the CE-rHDL, were converted into large (11.3-nm diameter) and small (7.7-nm diameter) particles. Only small particles were formed during the first 6 h of incubation of CE-rHDL with PLTP, The large particles and dissociated apoA-I were apparent after 12 h. In the case of TG-rHDL, small particles appeared after 1 h of incubation, while dissociated apoA-I and large particles were apparent at 3-h, The composition of the large particles indicated that they were derived from a fusion product. Spectroscopic studies indicated that the apoA-I in TG rHDL was less stable than the apoA-I in CE-rHDL, In conclusion, these results show that: (i) PLTP mediates rHDL fusion, (ii) the fusion product rearranges by two independent processes into small and large particles, and (iii) the more rapid remodeling of TG-rHDL by PLTP may be due to the destabilization of apoA-I.	Hanson Ctr, Lipid Res Lab, Adelaide, SA 5000, Australia; Univ Adelaide, Royal Adelaide Hosp, Dept Med, Adelaide, SA 5000, Australia; Scripps Res Inst, La Jolla, CA 92037 USA; Natl Publ Hlth Inst, Dept Biochem, FIN-00300 Helsinki, Finland; Royal Adelaide Hosp, Div Cardiovasc Serv, Adelaide, SA 5000, Australia	Royal Adelaide Hospital; University of Adelaide; Scripps Research Institute; Finland National Institute for Health & Welfare; Royal Adelaide Hospital	Rye, KA (corresponding author), Hanson Ctr, Lipid Res Lab, Level 1,Frome Rd, Adelaide, SA 5000, Australia.	karye@ozemail.com.au						Albers JJ, 1996, INT J CLIN LAB RES, V26, P262, DOI 10.1007/BF02602960; ALBERS JJ, 1995, BBA-LIPID LIPID MET, V1258, P27, DOI 10.1016/0005-2760(95)00091-P; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V8, P1; BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Cheung MC, 1996, BBA-LIPID LIPID MET, V1303, P103, DOI 10.1016/0005-2760(96)00082-3; Curtiss LK, 2000, BIOCHEMISTRY-US, V39, P5712, DOI 10.1021/bi992902m; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; ECKARDSTEIN A, 1996, BIOCHIM BIOPHYS ACTA, V1301, P255; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; HOPKINS GJ, 1982, METABOLISM, V31, P78, DOI 10.1016/0026-0495(82)90048-8; Huuskonen J, 1998, J LIPID RES, V39, P2021; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2000, BIOCHEMISTRY-US, V39, P16092, DOI 10.1021/bi0019287; Jauhiainen M, 1999, J LIPID RES, V40, P654; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Kawano K, 2000, J BIOL CHEM, V275, P29477, DOI 10.1074/jbc.M003523200; Korhonen A, 1998, BIOCHEM BIOPH RES CO, V249, P910, DOI 10.1006/bbrc.1998.9162; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029; LIANG HQ, 1994, J LIPID RES, V35, P1187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MAHADEVAN V, 1983, BIOCHIM BIOPHYS ACTA, V752, P89, DOI 10.1016/0005-2760(83)90236-9; MATZ CE, 1982, J BIOL CHEM, V257, P4535; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; Pace C N, 1986, Methods Enzymol, V131, P266; PIRAN U, 1979, J LIPID RES, V20, P1040; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; PUSSINEN P, 1995, J LIPID RES, V36, P975; RAJARAM OV, 1985, BIOCHIM BIOPHYS ACTA, V835, P41, DOI 10.1016/0005-2760(85)90028-1; Rao R, 1997, BIOCHEMISTRY-US, V36, P3645, DOI 10.1021/bi962776b; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Rye KA, 1998, J LIPID RES, V39, P613; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; RYE KA, 1992, J LIPID RES, V33, P215; SPARKS DL, 1995, J BIOL CHEM, V270, P26910, DOI 10.1074/jbc.270.45.26910; SPARKS DL, 1992, J LIPID RES, V33, P123; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; TOLLEFSON JH, 1988, J LIPID RES, V29, P1593; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; TU AY, 1993, J BIOL CHEM, V268, P23098; WARNICK GR, 1978, J LIPID RES, V19, P65; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	47	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26898	26905		10.1074/jbc.M010708200	http://dx.doi.org/10.1074/jbc.M010708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11325961	hybrid			2022-12-27	WOS:000169966900024
J	Hapke, S; Kessler, H; de Prada, NA; Benge, A; Schmitt, M; Lengyel, E; Reuning, U				Hapke, S; Kessler, H; de Prada, NA; Benge, A; Schmitt, M; Lengyel, E; Reuning, U			Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PLASMINOGEN-ACTIVATOR INHIBITOR-1; PHORBOL ESTER INDUCTION; P65 SUBUNIT; EXTRACELLULAR-MATRIX; VITRONECTIN RECEPTOR; GENE-EXPRESSION; ADHESION; BINDING; FIBRONECTIN	The urokinase type plasminogen activator (uPA), together with its receptor uPAR and the plasminogen activator inhibitor type-1 (PAI-1) plays a pivotal role during tumor invasion and metastasis. Integrins, via interaction with the extracellular matrix (ECM), control cell adhesion and motility, The two systems are functionally linked because uPAR and PAI-1 bind to the ECM component vitronectin (VN), Because integrin signaling alters gene expression patterns, we investigated whether the expression levels of uPA, uPAR, and PAI-1 are affected by ECM/integrin interactions. Expression of uPA, uPAR, and PAI-1 was significantly enhanced when human ovarian cancer cells (OV-MZ-6) were cultivated on fibronectin or collagen type , In contrast, VN induced down-regulation of uPA and uPAR while increasing PAI-1 by up to 4-fold. VN-dependent decrease of uPA protein was paralleled by a significant reduction of uPA promoter activity that was even more pronounced upon alpha (v)beta (3) overexpression and depended on the presence of intact Rel protein-binding sites. The activity of Rel transcription factors was also significantly reduced upon alpha (v)beta (3)-mediated cell adhesion to VN, The activity of the Rel-unresponsive PAI-1 promoter was up to 5-fold induced as a function of alpha (v)beta (3)/VN interaction. Thus, the balance between available concentrations of uPA, uPAR, PAI-1, and integrins in human ovarian cancer cells might provide a switch within the regulation of their invasive phenotype.	Tech Univ Munich, Klin Forschergrp, Frauenklin, Klinikum Rechts Isar, D-81675 Munich, Germany; Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Univ Calif San Francisco, Ctr Canc, Dept Obstet Gynecol & Reprod Sci, Canc Res Inst, San Francisco, CA 94143 USA	Technical University of Munich; Technical University of Munich; University of California System; University of California San Francisco	Reuning, U (corresponding author), Tech Univ Munich, Klin Forschergrp, Frauenklin, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany.	ute.reuning@lrz.tum.de	Kessler, Horst/C-1178-2010; Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507				AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Bearz A, 1998, BIOCHEM BIOPH RES CO, V243, P732, DOI 10.1006/bbrc.1997.8017; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; Bewsey KE, 1996, BBA-MOL BASIS DIS, V1317, P55, DOI 10.1016/0925-4439(96)00037-3; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; CARDARELLI PM, 1994, J BIOL CHEM, V269, P18668; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Carreiras F, 1999, GYNECOL ONCOL, V72, P312, DOI 10.1006/gyno.1998.5262; Carriero MV, 1999, CANCER RES, V59, P5307; CHUCHOLOWSKI N, 1992, BIOCHEM SOC T, V20, P208, DOI 10.1042/bst0200208; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; DENG G, 1995, THROMB HAEMOSTASIS, V74, P66; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRILLI M, 1993, INT REV CYTOL, V143, P1; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; GURRATH M, 1992, EUR J BIOCHEM, V210, P911, DOI 10.1111/j.1432-1033.1992.tb17495.x; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Lauffenburger DA, 1996, NATURE, V383, P390, DOI 10.1038/383390a0; Lengyel E, 1996, J CELL BIOCHEM, V61, P430, DOI 10.1002/(SICI)1097-4644(19960601)61:3<430::AID-JCB10>3.0.CO;2-N; Liapis H, 1997, HUM PATHOL, V28, P443, DOI 10.1016/S0046-8177(97)90033-2; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MOBUS V, 1992, INT J CANCER, V52, P76, DOI 10.1002/ijc.2910520115; Muehlenweg B, 2000, THROMB RES, V98, P73, DOI 10.1016/S0049-3848(99)00238-8; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; NOWLIN DM, 1993, J BIOL CHEM, V268, P20352; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PFAFF M, 1994, J BIOL CHEM, V269, P20233; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; REUNING U, 1995, NUCLEIC ACIDS RES, V23, P3887, DOI 10.1093/nar/23.19.3887; Reuning U, 1998, INT J ONCOL, V13, P893; Reuning U, 1999, EUR J BIOCHEM, V259, P143, DOI 10.1046/j.1432-1327.1999.00014.x; RICCIO A, 1988, NUCLEIC ACIDS RES, V16, P2805, DOI 10.1093/nar/16.7.2805; RICCIO A, 1985, NUCLEIC ACIDS RES, V13, P2759, DOI 10.1093/nar/13.8.2759; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SOKOLOSKI JA, 1993, BLOOD, V82, P625; STACK MS, 1993, CANCER RES, V53, P1998; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STREULI CH, 1990, J CELL BIOL, V110, P1405; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; Urtreger AJ, 1999, INT J CANCER, V82, P748, DOI 10.1002/(SICI)1097-0215(19990827)82:5<748::AID-IJC20>3.0.CO;2-R; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; Xue W, 1997, CANCER RES, V57, P1682; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	69	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26340	26348		10.1074/jbc.M100181200	http://dx.doi.org/10.1074/jbc.M100181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331280	hybrid			2022-12-27	WOS:000169823300093
J	Michelsen, KS; Aicher, A; Mohaupt, M; Hartung, T; Dimmeler, S; Kirschning, CJ; Schumann, RR				Michelsen, KS; Aicher, A; Mohaupt, M; Hartung, T; Dimmeler, S; Kirschning, CJ; Schumann, RR			The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCs) - Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; LIPOPOLYSACCHARIDE; IMMUNITY; CD14; ACTIVATION; RESPONSIVENESS; RECOGNITION; GENERATION; INDUCTION; MUTATIONS	Toll-like receptors (TLRs) have been found to be key elements in pathogen recognition by the host immune system. Dendritic cells (DCs) are crucial for both innate immune responses and initiation of acquired immunity, Here we focus on the potential involvement of TLR ligand interaction in DC maturation. TLR2 knockout mice and mice carrying a TLR4 mutation (C3H/HeJ) were investigated for DC maturation induced by peptidoglycan (PGN), lipopolysaccharide (LPS), or lipoteichoic acids (LTAs), All stimuli induced maturation of murine bone marrow-derived DCs in control mice. TLR2(-/-) mice lacked maturation upon stimulation with PGN, as assessed by expression of major histocompatibility complex class II, CD86, cytokine, and chemokine production, fluorescein isothiocyanate-dextran uptake, and mixed lymphocyte reactions, while being completely responsive to LPS. A similar lack of maturation was observed in C3H/HeJ mice upon stimulation with LPS, DC maturation induced by LTAs from two different types of bacteria was severely impaired in TLR2(-/-), whereas C3H/HeJ mice responded to LTAs in a manner similar to wild-type mice, We demonstrate that DC maturation is induced by stimuli from Gram-positive microorganisms, such as PGN and LTA, with similar efficiency as by LPS, Finally, we provide evidence that TLR2 and TLR4 interaction with the appropriate ligand is essential for bacteria-induced maturation of DCs.	Humboldt Univ, Univ Med Ctr Charite, Inst Mikrobiol & Hyg, D-10117 Berlin, Germany; Univ Frankfurt, Zentrum Inneren Med, D-60590 Frankfurt, Germany; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Goethe University Frankfurt; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Konstanz; Technical University of Munich	Schumann, RR (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Inst Mikrobiol & Hyg, Dorotheenstr 96, D-10117 Berlin, Germany.		Mohaupt, Markus/AAE-3368-2020; Aicher, Alexandra/GZK-8031-2022	Dimmeler, Stefanie/0000-0002-1045-2436; Aicher, Alexandra/0000-0002-8920-9577				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; FISCHER W, 1993, ANAL BIOCHEM, V208, P49, DOI 10.1006/abio.1993.1007; Hashimoto M, 2000, BIOCHEM BIOPH RES CO, V273, P164, DOI 10.1006/bbrc.2000.2921; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Mahnke K, 1997, ADV EXP MED BIOL, V417, P145; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 1999, J IMMUNOL, V163, P6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MORRISON DC, 1975, J BIOL CHEM, V250, P2911; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rescigno M, 1999, IMMUNOL TODAY, V20, P200, DOI 10.1016/S0167-5699(98)01427-3; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sousa CRE, 1999, CURR OPIN IMMUNOL, V11, P392, DOI 10.1016/S0952-7915(99)80066-1; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	34	230	238	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25680	25686		10.1074/jbc.M011615200	http://dx.doi.org/10.1074/jbc.M011615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11316801	hybrid			2022-12-27	WOS:000169823300008
J	Bell, M; Capone, R; Pashtan, I; Levitzki, A; Engelberg, D				Bell, M; Capone, R; Pashtan, I; Levitzki, A; Engelberg, D			Isolation of hyperactive mutants of the MAPK p38/Hog1 that are independent of MAPK kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; YEAST SACCHAROMYCES-CEREVISIAE; OF-FUNCTION MUTATION; PROTEIN-KINASE; MAMMALIAN-CELLS; DUAL PHOSPHORYLATION; STRESS-RESPONSE; DIFFERENTIATION; TRANSFORMATION; SPECIFICITY	Mitogen-activated protein kinases (MAPKs) play pivotal roles in growth, development, differentiation, and apoptosis, The exact role of a given MAPK in these processes is not fully understood. This question could be addressed using active forms of these enzymes that are independent of external stimulation and upstream regulation, Yet, such molecules are not available. MAPK activation requires dual phosphorylation, on neighboring Tyr and Thr residues, catalyzed by MAPK kinases (MAPKKs). It is not known how to force MAPK activation independent of MAPKK phosphorylation, Here we describe a series of nine hyperactive (catalytically and biologically), MAPKK-independent variants of the MAPK Hog1, Each of the active molecules contains just a single point mutation. Six mutations are in the conserved L16 domain of the protein. The active Hog1 mutants were obtained through a novel genetic screen that could be applied for isolation of active MAPKs of other families. Equivalent mutations, introduced to the human p38 alpha, rendered the enzyme active even when produced in Escherichia coli, showing that the mutations increased the intrinsic catalytic activity of p38, It implies that the activating mutations could be directly used for production of active forms of MAPKs from yeasts to humans and could open the way to revealing their biological functions.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.		Capone, Ricardo F/D-1943-2010	Capone, Ricardo F/0000-0002-7327-9837				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKENS M, 1997, SCIENCE, V277, P963; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang Y, 1997, J BIOL CHEM, V272, P11096; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SILHAVY TJ, 1984, COLD SPRING HARBOR L, P75; Stanhill A, 1999, MOL CELL BIOL, V19, P7529; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	46	65	71	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25351	25358		10.1074/jbc.M101818200	http://dx.doi.org/10.1074/jbc.M101818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11309396	hybrid			2022-12-27	WOS:000169800700122
J	Clark, PL; King, J				Clark, PL; King, J			A newly synthesized, ribosome-bound polypeptide chain adopts conformations dissimilar from early in vitro refolding intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-P22 TAILSPIKE PROTEIN; TAIL SPIKE ENDORHAMNOSIDASE; HEAD-BINDING DOMAIN; FOLDING IN-VIVO; MONOCLONAL-ANTIBODIES; MOLECULAR CHAPERONES; TRIGGER FACTOR; SALMONELLA PHAGE-P22; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE	Little is known about the conformations of newly synthesized polypeptide chains as they emerge from the large ribosomal subunit, or how these conformations compare with those populated immediately after dilution of polypeptide chains out of denaturant in vitro. Both in vivo and in vitro, partially folded intermediates of the tailspike protein from Salmonella typhimurium phage P22 can be trapped in the cold. A subset of monoclonal antibodies raised against tailspike recognize partially folded intermediates, whereas other antibodies recognize only later intermediates and/or the native state. We have used a pair of monoclonal antibodies to probe the conformational features of full-length, newly synthesized tailspike chains recovered on ribosomes from phage-infected cells. The antibody that recognizes early intermediates in vitro also recognizes the ribosome-bound intermediates. Surprisingly, the antibody that did not recognize early in vitro intermediates did recognize ribosome-bound tailspike chains translated in vivo, Thus, the newly synthesized, ribosome-bound tailspike chains display structured epitopes not detected upon dilution of tailspike chains from denaturant. As opposed to the random ensemble first populated when polypeptide chains are diluted out of denaturant, folding in vivo from the ribosome may begin with polypeptide conformations already directed toward the productive folding and assembly pathway.	MIT, Dept Biol 68 340D, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Clark, PL (corresponding author), MIT, Dept Biol 68 340D, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	plclark@mit.edu	Clark, Patricia/C-9850-2009	Clark, Patricia/0000-0001-5462-8248	NCRR NIH HHS [S10 RR05734] Funding Source: Medline; NIGMS NIH HHS [GM19715, GM17980] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017980, R37GM017980] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BAZINET C, 1988, BIOCHEMISTRY-US, V27, P1849, DOI 10.1021/bi00406a009; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; Betts SD, 1998, PROTEIN SCI, V7, P1516, DOI 10.1002/pro.5560070704; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; Caldas T, 2000, J BIOL CHEM, V275, P855, DOI 10.1074/jbc.275.2.855; CAMPBELL AM, 1996, ESCHERICHIA COLI SAL, P2325; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Fedorov AN, 1999, J MOL BIOL, V294, P579, DOI 10.1006/jmbi.1999.3281; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FRIGUET B, 1994, J BIOL CHEM, V269, P15945; FRIGUET B, 1990, J BIOL CHEM, V265, P10347; FRIGUET B, 1984, MOL IMMUNOL, V21, P673, DOI 10.1016/0161-5890(84)90053-1; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; Frydman J, 1999, NAT STRUCT BIOL, V6, P697, DOI 10.1038/10754; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; FULTON AB, 1993, J CELL SCI, V105, P867; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GORDON CL, 1994, J BIOL CHEM, V269, P27941; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; King J, 1986, Methods Enzymol, V131, P250; Komar AA, 1997, J BIOL CHEM, V272, P10646; Kreisberg JF, 2000, PROTEIN SCI, V9, P2338, DOI 10.1110/ps.9.12.2338; Kudlicki W, 1997, FOLD DES, V2, P101, DOI 10.1016/S1359-0278(97)00014-X; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Miller S, 1998, BIOCHEMISTRY-US, V37, P9160, DOI 10.1021/bi980190e; Neira JL, 1999, J MOL BIOL, V285, P1309, DOI 10.1006/jmbi.1998.2249; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Nicola AV, 1999, NAT CELL BIOL, V1, P341, DOI 10.1038/14032; Pal S, 1999, J BIOL CHEM, V274, P32771, DOI 10.1074/jbc.274.46.32771; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; SATHER SK, 1994, J BIOL CHEM, V269, P25268; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SHEA RG, 1977, THESIS MIT CAMBRIDGE; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Speed MA, 1997, PROTEIN SCI, V6, P99; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; SPEED MA, 1995, PROTEIN SCI, V4, P900; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; Steinbacher S, 1997, J MOL BIOL, V267, P865, DOI 10.1006/jmbi.1997.0922; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; YU MH, 1988, J BIOL CHEM, V263, P1424	64	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25411	25420		10.1074/jbc.M008490200	http://dx.doi.org/10.1074/jbc.M008490200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319217	hybrid			2022-12-27	WOS:000169800700131
J	Fukada, T; Tonks, NK				Fukada, T; Tonks, NK			The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-Abl oncoprotein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATA TRANSCRIPTION FACTORS; GROWTH-FACTOR-I; SACCHAROMYCES-CEREVISIAE; PHOSPHATASE 1B; INSULIN SENSITIVITY; NEGATIVE REGULATOR; SKELETAL-MUSCLE; GENE-EXPRESSION; BINDING MOTIF; ELEMENT STRE	Protein-tyrosine phosphatase 1B (PTP1B) is an important regulator of protein-tyrosine kinase-dependent signaling pathways. Changes in expression and activity of PTP1B have been associated with various human diseases; however, the mechanisms by which PTP1B expression is regulated have yet to be characterized. Previously, we have shown that the expression of PTP1B is enhanced by p210 Bcr-Ab1 and that PTP1B is a specific antagonist of transformation induced by this oncoprotein protein-tyrosine kinase, Here we have characterized the PTP1B promoter and demonstrate that a motif with features of a stress-response element acts as a (p) under bar 210 Bcr-Ab1-(r) under bar esponsive (s) under bar equence, termed PRS. We have shown that three C2H2 zinc finger proteins, namely Sp1, Sp3, and Egr-1, bind to PRS. Whereas binding of either Spl or Sp3 induced promoter function, Egr-1 repressed Sp3-mediated PTP1B promoter activation. The binding of Egr-1 to PRS is suppressed by p210 Bcr-Ab1 due to the inhibition of Egr-1 expression, resulting in the enhancement of PTP1B promoter activity. Our data indicate that Egr-1 and Sp family proteins play a reciprocal role in the control of expression from the PTP1B promoter.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Tonks, NK (corresponding author), Cold Spring Harbor Lab, Demerec Bldg,1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.				NATIONAL CANCER INSTITUTE [R37CA053840, P30CA045508, R01CA053840] Funding Source: NIH RePORTER; NCI NIH HHS [CA53840, P30 CA45508] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Ahmad F, 1997, J CLIN INVEST, V100, P449, DOI 10.1172/JCI119552; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Byon JCH, 1998, MOL CELL BIOCHEM, V182, P101, DOI 10.1023/A:1006868409841; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dadke SS, 2000, BIOCHEM BIOPH RES CO, V274, P583, DOI 10.1006/bbrc.2000.3188; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Forsell PKAL, 2000, GENE, V260, P145, DOI 10.1016/S0378-1119(00)00464-9; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; KENNER KA, 1993, J BIOL CHEM, V268, P25455; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1998, J MOL MED-JMM, V76, P613, DOI 10.1007/s001090050258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Moller N P, 2000, Curr Opin Drug Discov Devel, V3, P527; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; ZHAI YF, 1993, CANCER RES, V53, P2272	52	59	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25512	25519		10.1074/jbc.M101354200	http://dx.doi.org/10.1074/jbc.M101354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11316810	hybrid			2022-12-27	WOS:000169800700142
J	Gaudry, CA; Palka, HL; Dusek, RL; Huen, AC; Khandekar, MJ; Hudson, LG; Green, KJ				Gaudry, CA; Palka, HL; Dusek, RL; Huen, AC; Khandekar, MJ; Hudson, LG; Green, KJ			Tyrosine-phosphorylated plakoglobin is associated with desmogleins but not desmoplakin after epidermal growth factor receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADHERIN CATENIN COMPLEX; MEDIATED CELL-ADHESION; BETA-CATENIN; INTERMEDIATE-FILAMENTS; DESMOSOMAL CADHERINS; CYTOPLASMIC DOMAIN; ALPHA-CATENIN; IN-VITRO; BINDING; DISSOCIATION	Tyrosine phosphorylation of junctional components has been proposed as a mechanism for modulating cell-cell adhesion. Although a correlation exists between the tyrosine phosphorylation of the adherens junction protein beta -catenin and loss of classical cadherin-mediated adhesion, the effects of tyrosine phosphorylation on the function of the adherens junction and desmosome-associated protein plakoglobin is unknown. In the present study, we investigated the effects of epidermal growth factor receptor (EGFR) tyrosine kinase activation on the subcellular distribution of plakoglobin and its association with its junctional binding partners. Long term epidermal growth factor (EGF) treatment of A431 cells revealed a modest decrease in the cytoskeleton-associated pool of plakoglobin (Pg) and a corresponding increase in the cytosolic pool of Pg. After short term EGF treatment, plakoglobin was rapidly phosphorylated, and tyrosine-phosphorylated Pg was distributed predominantly in a membrane-associated Triton X-100-soluble pool, along with a co-precipitating high molecular weight tyrosine-phosphorylated protein identified as desmoglein 2, Analysis of deletion and point mutants defined the primary EGFR-dependent targets as one or more of three C-terminal tyrosine residues. Whereas phosphorylated Pg remained associated with the desmoglein tail after both short and long term EGFR activation, no phosphorylated Pg was found associated with the N-terminal Pg-binding domain (DPNTP) of the intermediate filament-associated protein, desmoplakin, Together these results are consistent with the possibility that EGF-dependent tyrosine phosphorylation of Pg may modulate cell-cell adhesion by compromising the link between desmosomal cadherins and the intermediate filament cytoskeleton.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Canc Ctr, Chicago, IL 60611 USA; Univ New Mexico, Hlth Sci Ctr, Coll Pharm, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol, Albuquerque, NM 87131 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Green, KJ (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	kgreen@nwu.edu			NATIONAL CANCER INSTITUTE [T32CA009560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042989, R01AR041836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09560-10] Funding Source: Medline; NIAMS NIH HHS [R01 AR42989, R01 AR41836] Funding Source: Medline; NIDCR NIH HHS [P01 DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABERLE H, 1994, J CELL SCI, V107, P3655; Adams CL, 1996, J CELL BIOL, V135, P1899, DOI 10.1083/jcb.135.6.1899; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Bornslaeger EA, 2001, J CELL SCI, V114, P727; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; GELDERLOOS JA, 1997, CYTOSKELETAL MEMBRAN, P12; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huen AC, 2000, MOL BIOL CELL, V11, p174A; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; KORMAN NJ, 1989, NEW ENGL J MED, V321, P631, DOI 10.1056/NEJM198909073211002; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1999, J BIOL CHEM, V274, P18145, DOI 10.1074/jbc.274.26.18145; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MENG JJ, 1995, MOL BIOL CELL, V6, P2186; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Ozawa M, 2001, J CELL SCI, V114, P503; Palka HL, 1997, J CELL SCI, V110, P2359; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rubenstein A, 1997, DEV GENET, V20, P91, DOI 10.1002/(SICI)1520-6408(1997)20:2<91::AID-DVG2>3.0.CO;2-3; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790	54	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24871	24880		10.1074/jbc.M102731200	http://dx.doi.org/10.1074/jbc.M102731200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335725	hybrid			2022-12-27	WOS:000169800700060
J	Kumar, R; Shieh, BH				Kumar, R; Shieh, BH			The second PDZ domain of INAD is a type I domain involved in binding to eye protein kinase C - Mutational analysis and naturally occurring variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA PHOTORECEPTORS; DIRECTED MUTAGENESIS; VISUAL TRANSDUCTION; TARGET PROTEINS; RECOGNITION; GENE; DNA; LOCALIZATION; DEACTIVATION; ASSOCIATION	INAD is a scaffolding protein containing five PSD95/ dlg/zonular occludens-1 (PDZ) domains that tether NORPA (phospholipase C beta (4)), the TRP calcium channel, and eye-PKC in Drosophila photoreceptors. We previously showed that eye-PKC interacted with the second PDZ domain (PDZ2) of INAD, Sequence comparison with a prototypical type I PDZ domain predicts that PDZ2 is the best candidate among the five PDZ domains to recognize eye-PKC that contains a type I PDZ ligand, Ile-Thr-Ile-Ile, at its carboxyl terminus. Replacement of Ile(-3) in eye-PKC with charged residues resulted in a drastic reduction of the PDZ2 interaction. Substitution of a conserved His with Arg at the second alpha -helix of PDZ2 led to a reduced binding; however, a Leu replacement resulted in an enhanced eye-PKC association. We isolated and sequenced the InaD gene. The coding sequence of InaD contains nine exons spanning 3 kilobases. Translation of coding sequences from three wildtype alleles revealed three SNPs affecting residues, 282, 319, and 333 of INAD, These polymorphisms are localized in PDZ2. Interestingly, we found two of three PDZ2 variants displayed a greater affinity for eye-PKC, In summary, we evaluated the molecular basis of the eye-PKC and PDZ2 association by mutational analysis and concluded that PDZ2 of INAD is a type I domain important for the eye-PKC interaction.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Shieh, BH (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	bih-hwa.shieh@mcmail.vanderbilt.edu			NEI NIH HHS [EY09743] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009743] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamski FM, 1998, J BIOL CHEM, V273, P17713, DOI 10.1074/jbc.273.28.17713; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MISMER D, 1989, GENETICS, V121, P77; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SMITH DB, 1988, MOL BIOCHEM PARASIT, V27, P249, DOI 10.1016/0166-6851(88)90044-8; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	32	9	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24971	24977		10.1074/jbc.M103570200	http://dx.doi.org/10.1074/jbc.M103570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342563	hybrid			2022-12-27	WOS:000169800700072
J	Lewin, TM; Kim, JH; Granger, DA; Vance, JE; Coleman, RA				Lewin, TM; Kim, JH; Granger, DA; Vance, JE; Coleman, RA			Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLATION; SN-GLYCEROL 3-PHOSPHATE; COENZYME-A SYNTHETASE; FATTY-ACID TRANSPORT; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; SELECTIVE CHANGES; PLASMA-MEMBRANE; LIPID-SYNTHESIS; EXPRESSION	Inhibition studies have suggested that acyl-CoA synthetase (ACS, EC 6.2.1.3) isoforms might regulate the use of acyl-CoAs by different metabolic pathways. In order to determine whether the subcellular locations differed for each of the three ACSs present in liver and whether these isoforms were regulated independently, non-cross-reacting peptide antibodies were raised against ACS1, ACS4, and ACS5, ACS1 was identified in endoplasmic reticulum, mitochondria-associated membrane (MAM), and cytosol, but not in mitochondria. ACS4 was present primarily in MAM, and the 76-kDa ACS5 protein was located in mitochondrial membrane, Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum. Troglitazone, a second ACS4 inhibitor, inhibited ACS activity < 10% in microsomes and mitochondria and 45% in MAM. Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria. ACS1, ACS4, and ACS5 were regulated independently by fasting and re-feeding. Fasting rats for 48 h resulted in a decrease in ACS4 protein, and an increase in ACS5, Refeeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies, These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis. Taken together, the data suggest that acyl-CoAs may be functionally channeled to specific metabolic pathways through different ACS isoforms in unique subcellular locations.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res, Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Alberta; Institute for Work & Health; University of Alberta	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NICHD NIH HHS [HD 56598, HD 08431] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; BANIS RJ, 1974, BIOCHIM BIOPHYS ACTA, V348, P210, DOI 10.1016/0005-2760(74)90232-X; Cao Y, 2000, FEBS LETT, V467, P263, DOI 10.1016/S0014-5793(00)01159-5; CHANG YY, 1967, J LIPID RES, V8, P447; COLEMAN RA, 1980, J BIOL CHEM, V255, P7681; COLEMAN RA, 1983, J BIOL CHEM, V258, P450; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; CUI Z, 1993, J BIOL CHEM, V268, P16655; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fleischer S, 1979, Methods Enzymol, V55, P32; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Gargiulo CE, 1999, J LIPID RES, V40, P881; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Igal RA, 1996, J BIOL CHEM, V271, P16644, DOI 10.1074/jbc.271.28.16644; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMIRYO T, 1979, P NATL ACAD SCI USA, V76, P4390, DOI 10.1073/pnas.76.9.4390; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; Kansara MS, 1996, AM J PHYSIOL-ENDOC M, V270, pE873, DOI 10.1152/ajpendo.1996.270.5.E873; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; Li JX, 1999, NEUROCHEM RES, V24, P739, DOI 10.1023/A:1020727429052; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V275, pE64, DOI 10.1152/ajpendo.1998.275.1.E64; MERRILL AH, 1982, J LIPID RES, V23, P1368; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; Muoio DM, 2000, AM J PHYSIOL-ENDOC M, V279, pE1366, DOI 10.1152/ajpendo.2000.279.6.E1366; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; Petersen KF, 2000, DIABETES, V49, P827, DOI 10.2337/diabetes.49.5.827; Piccini M, 1998, GENOMICS, V47, P350, DOI 10.1006/geno.1997.5104; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; Sleeman MW, 1998, J BIOL CHEM, V273, P3132, DOI 10.1074/jbc.273.6.3132; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VesLosada A, 1996, MOL CELL BIOCHEM, V159, P1; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	50	219	227	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24674	24679		10.1074/jbc.M102036200	http://dx.doi.org/10.1074/jbc.M102036200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319232	Green Published, hybrid			2022-12-27	WOS:000169800700036
J	Williams, DD; Price, NT; Loughlin, AJ; Proud, CG				Williams, DD; Price, NT; Loughlin, AJ; Proud, CG			Characterization of the mammalian initiation factor eIF2B complex as a GDP dissociation stimulator protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GTP-BINDING; FACTOR-II; TRANSLATIONAL CONTROL; RABBIT RETICULOCYTES; KINETIC MECHANISM; ALPHA-SUBUNIT; GAMMA-SUBUNIT; FACTOR EIF-2B; FACTOR 2B	Initiation factor eIF2B mediates a key regulatory step in the initiation of mRNA translation, i.e. the regeneration of active eIF2(.)GTP complexes. It is composed of five subunits, alpha-epsilon. The largest of these (E) displays catalytic activity in the absence of the others. The catalytic mechanism of eIF2B and the functions of the other subunits remain to be clarified. Here we show that, when present at similar concentrations to eIF2, mammalian eIF2B can mediate release of eIF2-bound GDP even in the absence of free nucleotide, indicating that it acts as a GDP dissociation stimulator protein. Consistent with this, addition of GDP to purified eIF2(.)eIF2B complexes causes them to dissociate. The alternative sequential mechanism would require that eIF2B epsilon itself bind GTP. However, we show that it is the beta -subunit of eIF2B that interacts with GTP, This indicates that binding of GTP to eIF2B is not an essential element of its mechanism. eIF2B preparations that lack the alpha -subunit display reduced activity compared with the holocomplex. Supplementation of such preparations with recombinant eIF2B alpha markedly enhances activity, indicating that eIF2B alpha is required for full activity of mammalian eIF2B.	Univ Dundee, Sch Life Sci, Div Mol Physiol, Inst Med Sci, Dundee DD1 5EH, Scotland; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Kent, Res Sch Biosci, Canterbury CT2 7NJ, Kent, England	University of Dundee; University of Bristol; University of Kent	Proud, CG (corresponding author), Univ Dundee, Sch Life Sci, Div Mol Physiol, Inst Med Sci, Dow St,Wellcome Trust Bioctr Complex, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk		Proud, Christopher/0000-0003-0704-6442; Loughlin, Alison/0000-0003-4769-3740				BOMMER U-A, 1988, Biochemistry International, V16, P549; BOMMER UA, 1989, FEBS LETT, V244, P323, DOI 10.1016/0014-5793(89)80555-1; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P4618, DOI 10.1128/MCB.13.8.4618; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; Craddock BL, 1996, BIOCHEM BIOPH RES CO, V220, P843, DOI 10.1006/bbrc.1996.0495; CRADDOCK BL, 1995, BIOCHEM J, V309, P1009, DOI 10.1042/bj3091009; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; FLOWERS KM, 1995, P NATL ACAD SCI USA, V92, P4274, DOI 10.1073/pnas.92.10.4274; FLOWERS KM, 1996, BIOCHIM BIOPHYS ACTA, V1317, P318; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; Hinnebusch AG, 2000, COLD SPRING HARBOR M, V39, P185; Hutchinson JP, 2000, BIOCHEMISTRY-US, V39, P11348, DOI 10.1021/bi0007573; HWANG YW, 1985, J BIOL CHEM, V260, P1498; KIMBALL SR, 1995, BIOCHEM BIOPH RES CO, V212, P1074, DOI 10.1006/bbrc.1995.2079; Kimball SR, 1998, J BIOL CHEM, V273, P12841, DOI 10.1074/jbc.273.21.12841; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Nika J, 2000, J BIOL CHEM, V275, P26011, DOI 10.1074/jbc.M003718200; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SINGH LP, 1995, BIOCHEM BIOPH RES CO, V212, P1007, DOI 10.1006/bbrc.1995.2070; SINGH LP, 1998, BIOCHEM BIOPH RES CO, V217, P616; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Webb BLJ, 1997, INT J BIOCHEM CELL B, V29, P1127, DOI 10.1016/S1357-2725(97)00039-3; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williams DD, 2001, J BIOL CHEM, V276, P3733, DOI 10.1074/jbc.M008041200	41	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24697	24703		10.1074/jbc.M011788200	http://dx.doi.org/10.1074/jbc.M011788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323413	hybrid			2022-12-27	WOS:000169800700039
J	D'Souza, SJA; Pajak, A; Balazsi, K; Dagnino, L				D'Souza, SJA; Pajak, A; Balazsi, K; Dagnino, L			Ca2+ and BMP-6 signaling regulate E2F during epidermal keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; CELL-CYCLE PROGRESSION; TRANSCRIPTION FACTORS; RETINOBLASTOMA FAMILY; EXPRESSION PATTERNS; HISTONE DEACETYLASE; TERMINAL REGION; DNA-BINDING; PROTEINS; GROWTH	The epidermis consists of a squamous epithelium continuously replenished by committed stem cells, which can either self-renew or differentiate. We demonstrated previously that E2F genes are differentially expressed in developing epidermis (Dagnino, L., Fry, C. J., Bartley, S. M., Farnham, P., Gallie, B. L., and Phillips, R. A. (1997) Cell Growth Differ. 8, 553-563). Thus, we hypothesized that various E2F proteins likely play distinct growth regulatory roles in the undifferentiated stem cells and in terminally differentiated keratinocytes. To further understand the function of E2F genes in epidermal morphogenesis, we have examined the expression, regulation, and protein-protein interactions of E2F factors in undifferentiated cultured murine primary keratinocytes or in cells induced to differentiate with Ca2+ or BMP-6 ((b) under bar one (m) under bar orphogenetic (p) under bar (p) under bar rotein (6) under bar). We find similar patterns of E2F regulation with both differentiating agents and demonstrate a switch in expression from E2F-1, -2, and -3 in undifferentiated, proliferating cells to E2F-5 in terminally differentiated keratinocytes. Inhibition of keratinocyte proliferation by transforming growth factor-beta did not enhance E2F-5 protein levels, suggesting that this response is specific to differentiation rather than reversible cell cycle withdrawal. E2F-5 up-regulation is also accompanied by formation of heteromeric nuclear complexes containing E2F5, p130, and histone deacetylase (HDAC) 1. Overexpression of E2F5 specifically inhibited DNA synthesis in undifferentiated keratinocytes in an HDAC-dependent manner, suggesting that E2F-5(.)p130(.)HDAC1 complexes are likely involved in the permanent withdrawal from the cell cycle of keratinocytes responding to differentiation stimuli.	Univ Western Ontario, Child Hlth Res Inst, Dept Paediat, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada; Ottawa Hosp, Inst Res, Ottawa, ON K1H 8L6, Canada; Univ Western Ontario, Chlid Hlth Res Inst, Dept Pharmacol Toxicol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Pharmacol & Toxicol, Med Sci Bldg, London, ON N6A 5C1, Canada.			Dagnino, Lina/0000-0003-1483-5159				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Advani SJ, 2000, J VIROL, V74, P7842, DOI 10.1128/JVI.74.17.7842-7850.2000; Alani RM, 1998, MOL CARCINOGEN, V23, P226, DOI 10.1002/(SICI)1098-2744(199812)23:4<226::AID-MC5>3.0.CO;2-N; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Callaghan DA, 1999, DEV BIOL, V207, P257, DOI 10.1006/dbio.1998.9162; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Guida P, 1999, BIOCHEM BIOPH RES CO, V258, P596, DOI 10.1006/bbrc.1999.0656; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; Hendrix SW, 1998, ARCH DERMATOL RES, V290, P420, DOI 10.1007/s004030050329; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HERTLE MD, 1991, DEVELOPMENT, V112, P193; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Magnaghi-Jaulin L, 2000, Prog Cell Cycle Res, V4, P41; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Martinez LA, 1999, ONCOGENE, V18, P397, DOI 10.1038/sj.onc.1202300; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; Muller H, 1997, MOL CELL BIOL, V17, P5508; Myster DL, 2000, DEVELOPMENT, V127, P3249; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Saunders NA, 1999, J INVEST DERMATOL, V112, P977, DOI 10.1046/j.1523-1747.1999.00611.x; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Stiegler P, 1998, CANCER RES, V58, P5049; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Tennenbaum T, 1996, CELL GROWTH DIFFER, V7, P615; Todd C, 1998, AM J PATHOL, V153, P39, DOI 10.1016/S0002-9440(10)65543-5; van der Sman J, 1999, J BIOL CHEM, V274, P12009, DOI 10.1074/jbc.274.17.12009; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZINKEL S, 1994, SEMIN CANCER BIOL, V5, P77	65	67	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23531	23538		10.1074/jbc.M100780200	http://dx.doi.org/10.1074/jbc.M100780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319226	hybrid			2022-12-27	WOS:000169531100043
J	Hakli, M; Karvonen, U; Janne, OA; Palvimo, JJ				Hakli, M; Karvonen, U; Janne, OA; Palvimo, JJ			The RING finger protein SNURF is a bifunctional protein possessing DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY JUNCTION DNA; IN-VITRO; IDENTIFICATION; RNF4; GENE; TRANSCRIPTION; HORMONE; HMG-1; COREGULATOR; COMPONENT	The small nuclear C3HC4 finger protein (SNURF), RNF4, acts as transcriptional coactivator for both steroid-dependent and -independent promoters such as those driven by androgen response elements and GC boxes, respectively. However, SNURF does not possess intrinsic transcription activation function, and the precise molecular mechanism of its action is unknown, We have studied herein the interaction of SNURF with DNA in vitro, SNURF binds to linear double-stranded DNA with no apparent sequence specificity in a cooperative fashion that is highly dependent on the length of the DNA fragment used. SNURF interacts efficiently with both supercoiled circular and four-way junction DNA, and importantly, it also recognizes nucleosomes. An intact RING structure of SNURF is not mandatory for DNA binding, whereas mutations of specific positively charged residues in the N terminus (amino acids 8-11) abolish DNA binding. Interestingly, the ability of SNURF to interact with DNA is associated with its capability to enhance transcription from promoters containing GC box elements. Because SNURF can interact with both DNA and protein (transcription) factors, it may promote assembly of nucleoprotein structures.	Univ Helsinki, Biomedicum Helsinki, Inst Biomed Physiol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Palvimo, JJ (corresponding author), Univ Helsinki, Biomedicum Helsinki, Inst Biomed Physiol, POB 63, FIN-00014 Helsinki, Finland.	jorma.palvimo@helsinki.fi		Palvimo, Jorma/0000-0003-2373-0578				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; BIANCHI ME, 1988, EMBO J, V7, P843, DOI 10.1002/j.1460-2075.1988.tb02883.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burden DA, 1999, J BIOL CHEM, V274, P5227, DOI 10.1074/jbc.274.8.5227; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 1999, MOL CELL BIOL, V19, P5237; BUTLER AP, 1985, J BIOL CHEM, V260, P613; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Duprez E, 1999, J CELL SCI, V112, P381; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Galili N, 2000, DEV DYNAM, V218, P102, DOI 10.1002/(SICI)1097-0177(200005)218:1<102::AID-DVDY9>3.3.CO;2-1; GOODWIN GH, 1977, FEBS LETT, V80, P413, DOI 10.1016/0014-5793(77)80488-2; Hill DA, 1999, NUCLEIC ACIDS RES, V27, P2135, DOI 10.1093/nar/27.10.2135; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; Li Q, 1997, METHODS, V12, P96, DOI 10.1006/meth.1997.0451; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Lyngso C, 2000, J BIOL CHEM, V275, P26144, DOI 10.1074/jbc.M003405200; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Nehls P, 1998, NUCLEIC ACIDS RES, V26, P1160, DOI 10.1093/nar/26.5.1160; Niessing D, 2000, MOL CELL, V5, P395, DOI 10.1016/S1097-2765(00)80434-7; PANYIM S, 1971, J BIOL CHEM, V246, P4206; Poukka H, 2000, J CELL SCI, V113, P2991; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Remboutsika E, 1999, J CELL SCI, V112, P1671; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; WEISSHART K, 1994, J BIOL CHEM, V269, P22788; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zhao T, 2000, J BIOL CHEM, V275, P28332; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	48	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23653	23660		10.1074/jbc.M009891200	http://dx.doi.org/10.1074/jbc.M009891200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11319220	hybrid			2022-12-27	WOS:000169531100058
J	Krupenko, SA; Vlasov, AP; Wagner, C				Krupenko, SA; Vlasov, AP; Wagner, C			On the role of conserved histidine 106 in 10-formyltetrahydrofolate dehydrogenase catalysis - Connection between hydrolase and dehydrogenase mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; DENOVO PURINE BIOSYNTHESIS; ESCHERICHIA-COLI; ACTIVE-SITE; ALDEHYDE DEHYDROGENASE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; METHIONYL-TRNA(F)(MET) FORMYLTRANSFERASE; DIENELACTONE HYDROLASE; FLUORESCENCE METHODS	The enzyme, 10-formyltetrahydrofolate dehydrogenase (FDH), converts 10-formyltetrahydrofolate (10-formyl-THF) to tetrahydrofolate in an NADP(+)-dependent dehydrogenase reaction or an NADP(+)-independent hydrolase reaction. The hydrolase reaction occurs in a 310-amino acid long amino-terminal domain of FDH (N-t-FDH), whereas the dehydrogenase reaction requires the full-length enzyme. The amino-terminal, domain of FDH shares some sequence identity with several other enzymes utilizing 10-formyl-THF as a substrate. These enzymes have two strictly conserved residues, aspartate and histidine, in the putative catalytic center. We have shown recently that the conserved aspartate is involved in FDH catalysis, In the present work we studied the role of the conserved histidine, His(106), in FDH function. Site-directed mutagenesis experiments showed that replacement of the histidine with alanine, asparagine, aspartate, glutamate, glutamine, or arginine in N-t-FDH resulted in expression of insoluble proteins. Replacement of the histidine with another positively charged residue, lysine, produced a soluble mutant with no hydrolase activity, The insoluble mutants refolded from inclusion bodies adopted a conformation inherent to the wild-type N-t-FDH, but they did not exhibit any hydrolase activity, Substitution of alanine for three non-conserved histidines located close to the conserved one did not reveal any significant changes in the hydrolase activity of N-t-FDH, Expressed full-length FDH with the substitution of lysine for the His(106) completely lost both the hydrolase and dehydrogenase activities. Thus, our study showed that His(106), besides being an important structural residue, is also directly involved in both the hydrolase and dehydrogenase mechanisms of FDH. Modeling of the putative hydrolase catalytic center/folate-binding site suggested that the catalytic residues, aspartate and histidine, are unlikely to be adjacent to the catalytic cysteine in the aldehyde dehydrogenase catalytic center. We hypothesize that 10-formyl-TRF dehydrogenase reaction is not an independent reaction but is a combination of hydrolase and aldehyde dehydrogenase reactions.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Res Serv, Nashville, TN 37212 USA	Medical University of South Carolina; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.				NIDDK NIH HHS [DK15289, DK53488] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015289, R37DK015289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; ALMASSY RJ, 1992, P NATL ACAD SCI USA, V89, P6114, DOI 10.1073/pnas.89.13.6114; BENKOVIC SJ, 1984, TRENDS BIOCHEM SCI, V9, P320, DOI 10.1016/0968-0004(84)90302-5; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; Blow DM, 1997, TRENDS BIOCHEM SCI, V22, P405, DOI 10.1016/S0968-0004(97)01115-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brayer GD, 2000, BIOCHEMISTRY-US, V39, P4778, DOI 10.1021/bi9921182; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEAH E, 1993, PROTEINS, V16, P64, DOI 10.1002/prot.340160108; CHEN P, 1992, J MOL BIOL, V227, P283, DOI 10.1016/0022-2836(92)90698-J; Cherbavaz DB, 2000, J MOL BIOL, V295, P377, DOI 10.1006/jmbi.1999.3195; CHOW SF, 1985, J BIOL CHEM, V260, P5516; Cobessi D, 2000, J MOL BIOL, V300, P141, DOI 10.1006/jmbi.2000.3824; COOK RJ, 1991, J BIOL CHEM, V266, P4965; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Eftink MR, 1997, METHOD ENZYMOL, V278, P258; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; FELDMAN RI, 1972, J BIOL CHEM, V247, P267; Goldenberg David P., 1992, P353; Greasley SE, 1999, BIOCHEMISTRY-US, V38, P16783, DOI 10.1021/bi991888a; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; INGLESE J, 1990, BIOCHEMISTRY-US, V29, P6678, DOI 10.1021/bi00480a018; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; KOHNO T, 1990, METHOD ENZYMOL, V185, P187; Krokan HE, 1997, BIOCHEM J, V325, P1; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; KRUPENKO SA, 1995, J BIOL CHEM, V270, P519, DOI 10.1074/jbc.270.2.519; Krupenko SA, 1998, PROTEIN EXPRES PURIF, V14, P146, DOI 10.1006/prep.1998.0937; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; Krupenko SA, 1999, J BIOL CHEM, V274, P35777, DOI 10.1074/jbc.274.50.35777; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; MEINNEL T, 1994, J BACTERIOL, V176, P7387, DOI 10.1128/JB.176.23.7387-7390.1994; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; NAGY PL, 1993, J BACTERIOL, V175, P7066, DOI 10.1128/jb.175.21.7066-7073.1993; NAGY PL, 1995, J BACTERIOL, V177, P1292, DOI 10.1128/jb.177.5.1292-1298.1995; Nixon AE, 1997, P NATL ACAD SCI USA, V94, P1069, DOI 10.1073/pnas.94.4.1069; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; SCHEIN CH, 1990, BIO-TECHNOL, V8, P308, DOI 10.1038/nbt0490-308; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; Schmitt E, 1996, EMBO J, V15, P4749, DOI 10.1002/j.1460-2075.1996.tb00852.x; Schultz LW, 1998, BIOCHEMISTRY-US, V37, P8886, DOI 10.1021/bi972766q; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Shim JH, 1998, BIOCHEMISTRY-US, V37, P8776, DOI 10.1021/bi980244k; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; SMITH JM, 1987, J BIOL CHEM, V262, P10565; STEBEN C, 1986, J BIOL CHEM, V261, P4629; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Su Y, 1998, J MOL BIOL, V281, P485, DOI 10.1006/jmbi.1998.1931; Wagner C, 1995, FOLATE HLTH DIS, P23; Wang S, 2000, BIOCHEMISTRY-US, V39, P1234, DOI 10.1021/bi991515+; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715; WHITEHEAD TR, 1988, J BACTERIOL, V170, P3255, DOI 10.1128/jb.170.7.3255-3261.1988; Yuan CH, 1999, BBA-MOL CELL BIOL L, V1441, P215, DOI 10.1016/S1388-1981(99)00156-0	74	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24030	24037		10.1074/jbc.M009257200	http://dx.doi.org/10.1074/jbc.M009257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11320079	hybrid			2022-12-27	WOS:000169531100107
J	Suzuki, A; Hiraoka, N; Suzuki, M; Angata, K; Misra, AK; McAuliffe, J; Hindsgaul, O; Fukuda, M				Suzuki, A; Hiraoka, N; Suzuki, M; Angata, K; Misra, AK; McAuliffe, J; Hindsgaul, O; Fukuda, M			Molecular cloning and expression of a novel human beta-Gal-3-O-sulfotransferase that acts preferentially on N-acetyllactosamine in N- and O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CORE 2; LINKED OLIGOSACCHARIDES; CARBOHYDRATE UNITS; HNK-1 SULFOTRANSFERASE; MUTANT DEFICIENT; L-SELECTIN; SULFATE; GALACTOSE; RESIDUES	A novel cDNA-encoding galactose 3-O-sulfotransferase was cloned by screening the expressed sequence tag data base using the previously cloned cDNA encoding a galactosyl ceramide 3-O-sulfotransferase, which we term Gal3ST-1, The newly isolated cDNA encodes a novel 3-O-sulfotransferase, termed Ga13ST-3, that acts exclusively on N-acetyllactosamine present in N-glycans and core2-branched O-glycans, These conclusions were confirmed by analyzing CD43 chimeric proteins in Chinese hamster ovary cells expressing corea beta1,6-N-acetylglucosaminyl-transferase. The acceptor specificity of Ga13ST-3 contrasts with that of the recently cloned galactose 3-O-sulfotransferase (Honke, It, Tsuda, M, Koyota, S,, Wada, P,, Iida-Tanaka N., Ishizuka, I., Nakayama, J,, and Taniguchi, N. (2001) J, Biol Chem 276, 267-274), which we term Ga13ST-2 in the present study because the latter enzyme can also act on core1 O-glycan and type 1 oligosaccharides, Gal beta1 --> 3GlcNAc. Moreover, Ga13ST-3 but not Ga13ST-2 can act on Gal beta1 -->4(sulfo -->6)GlcNAc, indicating that disulfated sulfo --> 3Gal beta1 -->4(sulfo -->6) GlcNAc -->R may be formed by Gal3ST-3 in combination with GlcNAc 6-O-sulfotransferase. Although both Ga13ST-2 and Ga13ST-3 do not act on galactosyl ceramide, Ga13ST-3 is only moderately more homologous to Ga13ST-2 (40.1%) than to Gal3ST-1 (38.0%) at the amino acid level, Northern blot analysis demonstrated that transcripts for Ga13ST-3 are predominantly expressed in the brain, kidney, and thyroid where the presence of 3 ' -sulfation of N-acetyllactosamine has been reported. These results indicate that the newly cloned Ga13ST-3 plays a critical role in 3 ' -sulfation of N-acetyllactosamine in both O- and N-glycans.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham.org	Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [R01CA048737, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; CAPON C, 1989, EUR J BIOCHEM, V182, P139, DOI 10.1111/j.1432-1033.1989.tb14810.x; Chandrasekaran EV, 1997, GLYCOBIOLOGY, V7, P753, DOI 10.1093/glycob/7.6.753; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Ding YL, 1998, BIOORG MED CHEM LETT, V8, P1903, DOI 10.1016/S0960-894X(98)00332-1; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; Edge ASB, 1997, ARCH BIOCHEM BIOPHYS, V343, P73, DOI 10.1006/abbi.1997.0143; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GREEN PJ, 1992, BIOCHEM BIOPH RES CO, V188, P244, DOI 10.1016/0006-291X(92)92376-9; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; HIRAOKA N, 2001, IN PRESS GLYCOBIOLOG; Honke K, 1997, J BIOL CHEM, V272, P4864, DOI 10.1074/jbc.272.8.4864; Honke K, 2001, J BIOL CHEM, V276, P267, DOI 10.1074/jbc.M005666200; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KATO Y, 1989, J BIOL CHEM, V264, P3364; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUHNS W, 1995, GLYCOBIOLOGY, V5, P689, DOI 10.1093/glycob/5.7.689; LAMBLIN G, 1991, BIOCHEM J, V275, P199, DOI 10.1042/bj2750199; LOGUIDICE JM, 1995, J BIOL CHEM, V270, P27544, DOI 10.1074/jbc.270.46.27544; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; Misra AK, 2000, BIOORG MED CHEM LETT, V10, P1505, DOI 10.1016/S0960-894X(00)00207-9; MISRA AK, 2001, IN PRESS BIOORG MED; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; SAWADA R, 1994, J BIOL CHEM, V269, P1425; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; Tsuboi S, 2000, ARCH BIOCHEM BIOPHYS, V374, P100, DOI 10.1006/abbi.1999.1614; Tsuiji H, 1998, BIOCHEM BIOPH RES CO, V253, P374, DOI 10.1006/bbrc.1998.9726; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Ujita M, 2000, J BIOL CHEM, V275, P15868, DOI 10.1074/jbc.M001034200; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; WAARD PD, 1991, J BIOL CHEM, V266, P4237; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	50	26	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24388	24395		10.1074/jbc.M103135200	http://dx.doi.org/10.1074/jbc.M103135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11323440	hybrid			2022-12-27	WOS:000169531100153
J	Dulin, NO; Niu, JX; Browning, DD; Ye, RD; Voyno-Yasenetskaya, T				Dulin, NO; Niu, JX; Browning, DD; Ye, RD; Voyno-Yasenetskaya, T			Cyclic AMP-independent activation of protein kinase A by vasoactive peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CAMP; INHIBITION; RECEPTOR; PHOSPHORYLATION; RELEASE; CASCADE; CYCLASE; CLONING; INFLUX	Protein kinase A (PKA) is an important effector enzyme commonly activated by cAMP. The present study focuses on our finding that the vasoactive peptide endothelin-l (ET1), whose signaling is not coupled to cAMP production, stimulates PKA in two independent cellular models. Using an in vivo assay for PKA activity, we found that ET1 stimulated PKA in HeLa cells overexpressing ET1 receptors and in aortic smooth muscle cells expressing endogenous levels of ET1 receptors, In these cell models, ET1 did not stimulate cAMP production, indicating a novel mechanism for PKA activation. The ET1-induced activation of PKA was found to be dependent on the degradation of inhibitor of kappaB, which was previously reported to bind and inhibit PIKA, ET1 potently stimulated the nuclear factor-kappaB pathway, and this effect was inhibited by overexpression of the inhibitor of kappaB dominant negative mutant (I kappaB alpham) and by treatment with the proteasome inhibitor MG-132. Importantly, I kappaB alpham and MG-132 had similar inhibitory effects on ET1-induced activation of PKA without affecting G(s)-mediated activation of PKA or ET1-induced phosphorylation of mitogen-activated protein kinase. Finally, another vasoactive peptide, angiotensin II, also stimulated PKA in a cAMP-independent manner in aortic smooth muscle cells. These findings suggest that cAMP-independent activation of PKA might be a general response to vasoactive peptides.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Dulin, NO (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, M-C 868,Med Sci Bldg,Rm E-407,835 S Wolcott Ave, Chicago, IL 60612 USA.	dulin@uic.edu	Ye, Richard/ABF-2413-2020; voyno-yasenetskaya, tatyana/A-3171-2008; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1991, BIOCHEM BIOPH RES CO, V180, P1265, DOI 10.1016/S0006-291X(05)81332-4; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; BUTT E, 1994, J BIOL CHEM, V269, P14509; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Dodge KL, 1998, ENDOCRINOLOGY, V139, P2265, DOI 10.1210/en.139.5.2265; El-Mowafy AM, 1998, BIOCHEM BIOPH RES CO, V251, P494, DOI 10.1006/bbrc.1998.9496; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; LIN WW, 1993, MOL PHARMACOL, V44, P158; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Mateo AO, 1997, PHARMACOL RES, V36, P339, DOI 10.1006/phrs.1997.0246; MURRAY KJ, 1990, PHARMACOL THERAPEUT, V47, P329, DOI 10.1016/0163-7258(90)90060-F; Orlov SN, 1996, HYPERTENSION, V27, P774, DOI 10.1161/01.HYP.27.3.774; Parris R J, 1997, Vasc Med, V2, P31; Rebsamen MC, 1997, AM J PHYSIOL-ENDOC M, V273, pE922, DOI 10.1152/ajpendo.1997.273.5.E922; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Wu-Wong JR, 1998, J CARDIOVASC PHARM, V31, pS185, DOI 10.1097/00005344-199800001-00053; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Yamboliev IA, 1998, PULM PHARMACOL THER, V11, P205, DOI 10.1006/pupt.1998.0139; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhu Y, 1997, AM J PHYSIOL-HEART C, V273, pH119, DOI 10.1152/ajpheart.1997.273.1.H119	37	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20827	20830		10.1074/jbc.C100195200	http://dx.doi.org/10.1074/jbc.C100195200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11331270	hybrid			2022-12-27	WOS:000169297900007
J	Riballo, E; Doherty, AJ; Dai, Y; Stiff, T; Oettinger, MA; Jeggo, PA; Kysela, B				Riballo, E; Doherty, AJ; Dai, Y; Stiff, T; Oettinger, MA; Jeggo, PA; Kysela, B			Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; V(D)J RECOMBINATION; CRYSTAL-STRUCTURE; REPAIR; FIBROBLASTS; GENES; CELLS; LINE	DNA ligase IV functions in DNA non-homologous end-joining, in V(D)J recombination, and during brain development. We previously reported a homozygous mutation (R278H) in DNA ligase IV in a developmentally normal leukemia patient who over-responded to radiotherapy. The impact of this hypomorphic mutation has been evaluated using cellular, biochemical, and structural approaches. Structural modeling using T7 DNA ligase predicts that the activity and conformational stability of the protein is likely to be impaired. We show that wild type DNA ligase IV-Xrcc4 is an efficient double-stranded ligase with distinct optimal requirements for adenylate complex formation versus rejoining. The mutation impairs the formation of an adenylate complex as well as reducing the rejoining activity. Additionally, it imparts temperature-sensitive activity to the protein consistent with the predictions of the structural modeling. At the cellular level, the mutation confers a unique V(D)J recombination phenotype affecting the fidelity of signal joint formation with little effect on the frequency of the reaction. These findings suggest that hypomorphic mutations in ligase IV may allow normal development but confer marked radiosensitivity.	Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; Univ Cambridge, Wellcome Trust Ctr Mol Mechanisms, Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	University of Sussex; University of Cambridge; University of Cambridge; Harvard University; Massachusetts General Hospital	Jeggo, PA (corresponding author), Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England.	p.a.jeggo@sussex.ac.uk; b.kysela@sussex.ac.uk		Doherty, Aidan/0000-0002-6370-1109				ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BADIE C, 1995, CANCER RES, V55, P1232; Badie C, 1997, CANCER RES, V57, P4600; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Gauss GH, 1998, EUR J IMMUNOL, V28, P351, DOI 10.1002/(SICI)1521-4141(199801)28:01<351::AID-IMMU351>3.0.CO;2-#; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; KYSELA BP, 1995, RADIAT RES, V144, P276, DOI 10.2307/3578946; Lee KJ, 2000, J BIOL CHEM, V275, P34787, DOI 10.1074/jbc.M004011200; Lehmann AR, 1998, BIOESSAYS, V20, P146, DOI 10.1002/(SICI)1521-1878(199802)20:2<146::AID-BIES7>3.3.CO;2-5; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PLOWMAN PN, 1990, BRIT J RADIOL, V63, P624, DOI 10.1259/0007-1285-63-752-624; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Shuman S, 1996, STRUCTURE, V4, P653, DOI 10.1016/S0969-2126(96)00070-6; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; YANG SW, 1992, J BIOL CHEM, V267, P8117	32	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31124	31132		10.1074/jbc.M103866200	http://dx.doi.org/10.1074/jbc.M103866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11349135	hybrid			2022-12-27	WOS:000170472900071
J	Paul, S; Tramontano, A; Gololobov, G; Zhou, YX; Taguchi, H; Karle, S; Nishiyama, Y; Planque, S; George, S				Paul, S; Tramontano, A; Gololobov, G; Zhou, YX; Taguchi, H; Karle, S; Nishiyama, Y; Planque, S; George, S			Phosphonate ester probes for proteolytic antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; BENCE-JONES PROTEINS; SITE-DIRECTED MUTAGENESIS; TRANSITION-STATE ANALOG; CATALYTIC ANTIBODIES; LIGHT-CHAIN; PHAGE DISPLAY; CRYSTAL-STRUCTURES; ACTIVE-SITE; ANTIGEN	The reactivity of phosphonate ester probes with several available proteolytic antibody (Ab) fragments was characterized. Irreversible, active site-directed inhibition of the peptidase activity was evident. Stable phosphonate diester-Ab adducts were resolved by column chromatography and denaturing electrophoresis. Biotinylated phosphonate esters were applied for chemical capture of phage particles displaying Fv and light chain repertoires. Selected Ab fragments displayed enriched catalytic activity inhibitable by the selection reagent. Somewhat unexpectedly, a phosphonate monoester also formed stable adducts with the Abs. Improved catalytic activity of phage Abs selected by monoester binding was evident. Turnover values (k(cat)) for a selected Fv construct and a light chain against their preferred model peptide substrates were 0.5 and 0.2 min(-1), respectively, and the corresponding Michaelis-Menten constants (K-m) were 10 and 8 mum. The covalent reactivity of Abs with phosphonate esters suggests their ability to recapitulate the catalytic mechanism utilized by classical serine proteases.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA	University of Texas System	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059746, R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046029, R01AI031268, R21AI031268] Funding Source: NIH RePORTER; NCI NIH HHS [CA80312] Funding Source: Medline; NHLBI NIH HHS [HL59746, HL44126] Funding Source: Medline; NIAID NIH HHS [AI31268, AI46029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANAND NN, 1991, J BIOL CHEM, V266, P21874; BALDWIN E, 1989, SCIENCE, V245, P1104, DOI 10.1126/science.2672338; BENCSURA A, 1995, BIOCHEMISTRY-US, V34, P8989, DOI 10.1021/bi00028a007; BONE R, 1991, BIOCHEMISTRY-US, V30, P2263, DOI 10.1021/bi00222a032; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; HAREL M, 1991, J MOL BIOL, V221, P909, DOI 10.1016/0022-2836(91)80183-U; Haux JE, 2000, CHEM RES TOXICOL, V13, P646, DOI 10.1021/tx000027w; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; KALAGA R, 1995, J IMMUNOL, V155, P2695; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Legendre D, 2000, J MOL BIOL, V296, P87, DOI 10.1006/jmbi.1999.3437; Li L, 1996, MOL IMMUNOL, V33, P593, DOI 10.1016/0161-5890(96)00021-1; LI L, 1995, J IMMUNOL, V154, P3328; Liu E, 1998, MOL IMMUNOL, V35, P1069, DOI 10.1016/S0161-5890(98)00089-3; MATSUURA K, 1994, BIOCHEM BIOPH RES CO, V204, P57, DOI 10.1006/bbrc.1994.2425; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; MCCAFFERTY J, 1994, APPL BIOCHEM BIOTECH, V47, P157, DOI 10.1007/BF02787932; MODY R, 1994, INT J PEPT PROT RES, V44, P441; NOSSAL GJV, 1995, ANNU REV IMMUNOL, V13, P1; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2000, APPL BIOCHEM BIOTECH, V83, P71, DOI 10.1385/ABAB:83:1-3:71; PAUL S, 1990, J BIOL CHEM, V265, P11910; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; RAHIL J, 1994, BIOCHEMISTRY-US, V33, P116, DOI 10.1021/bi00167a015; SAMPSON NS, 1991, BIOCHEMISTRY-US, V30, P2255, DOI 10.1021/bi00222a031; Schowen R., 1988, MECHANISTIC PRINCIPL, P119; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; SUN M, 1991, J BIOL CHEM, V266, P15571; Takahashi N, 2000, J IMMUNOL METHODS, V235, P113, DOI 10.1016/S0022-1759(99)00224-0; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; Thiagarajan P, 2000, BIOCHEMISTRY-US, V39, P6459, DOI 10.1021/bi992588w; TRAMONTANO A, 1986, P NATL ACAD SCI USA, V83, P6736, DOI 10.1073/pnas.83.18.6736; TRAMONTANO A, 1994, APPL BIOCHEM BIOTECH, V47, P257, DOI 10.1007/BF02787939; Tyutyulkova S, 1996, BBA-MOL BASIS DIS, V1316, P217, DOI 10.1016/0925-4439(96)00028-2; TYUTYULKOVA S, 1995, ANTIBODY ENG PROTOCO, P377; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; Wong L, 2000, BIOCHEMISTRY-US, V39, P5750, DOI 10.1021/bi992906r; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	45	61	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28314	28320		10.1074/jbc.M102530200	http://dx.doi.org/10.1074/jbc.M102530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11346653	hybrid			2022-12-27	WOS:000170093400077
J	Eleftheriou, A; Yoshida, M; Henderson, BR				Eleftheriou, A; Yoshida, M; Henderson, BR			Nuclear export of human beta-catenin can occur independent of CRM1 and the adenomatous polyposis coli tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; APC; CANCER; TRANSACTIVATION; LOCALIZATION; EXPRESSION; SIGNALS; IDENTIFICATION; ACTIVATION; TRANSPORT	beta -Catenin is a mediator of the Wnt-signaling pathway. In many cancers, beta -catenin is stabilized and accumulates in the nucleus where it associates with lymphoid-enhancing factor II T-cell transcription factors to activate genes involved in cell transformation. Previously, we showed that adenomatous polyposis coli (APC) protein can regulate beta -catenin localization by nuclear export. In this study, we used in vitro transport assays to test whether cellular beta -catenin can exit the nucleus independent of APC and the CRM1 export receptor, In digitonin-permeabilized SW480 (APC(mut/mut)) tumor cells, nuclear beta -catenin decreased > 60% in export reactions in the absence of exogenous factors, Under similar conditions, nuclear c-ABL was only exported after the addition of cytosolic extract, and the export was blocked by the CRM1-specific inhibitor, leptomycin B, The nuclear export of beta -catenin was not blocked by leptomycin B treatment, revealing a CRM1- and APC-independent pathway. The export of beta -catenin was sensitive to lower temperatures and the removal of ATP, indicating an active process. Ectopically expressed yellow fluorescent protein-beta -catenin also displayed CRM1-independent export. Conversely, the overexpression of the CRM1 transporter moderately stimulated export of nuclear beta -catenin, confirming that beta -catenin exits the nucleus by at least two distinct pathways. The shuttling ability of tumor cell beta -catenin has implications for its regulation and its role in transferring signals between the nucleus and plasma membrane.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	University of Sydney; Westmead Institute for Medical Research; University of Tokyo	Henderson, BR (corresponding author), Westmead Millennium Inst, WICR, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kongkanuntn R, 1999, ONCOGENE, V18, P7219, DOI 10.1038/sj.onc.1203181; Kose S, 1999, J BIOL CHEM, V274, P3946, DOI 10.1074/jbc.274.7.3946; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee SJ, 2000, J MOL BIOL, V302, P251, DOI 10.1006/jmbi.2000.4055; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakielny S, 1998, CURR BIOL, V8, P89, DOI 10.1016/S0960-9822(98)70039-9; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 2000, EMBO REP, V1, P519; Orsulic S, 1999, J CELL SCI, V112, P1237; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119	42	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					25883	25888		10.1074/jbc.M102656200	http://dx.doi.org/10.1074/jbc.M102656200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11337505	hybrid			2022-12-27	WOS:000169823300034
J	Rohatgi, R; Nollau, P; Ho, HYH; Kirschner, MW; Mayer, BJ				Rohatgi, R; Nollau, P; Ho, HYH; Kirschner, MW; Mayer, BJ			Nck and phosphatidylinositol 4,5-bisphosphate synergistically activate actin polymerization through the N-WASP-Arp2/3 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SH2/SH3 ADAPTER PROTEIN; SRC HOMOLOGY-3 DOMAINS; N-WASP; 3T3 FIBROBLASTS; ARP2/3 COMPLEX; KINASE PAK1; CDC42; FILOPODIA; SIGNALS	The Wiskott-Aldrich syndrome protein (WASP) and its relative neural WASP (N-WASP) regulate the nucleation of actin filaments through their interaction with the Arp2/3 complex and are regulated in turn by binding to GTP-bound Cdc42 and phosphatidylinositol 4,5-bisphosphate, The Nck Src homology (SH) 2/3 adaptor binds via its SH3 domains to a proline-rich region on WASP and N-WASP and has been implicated in recruitment of these proteins to sites of tyrosine phosphorylation. We show here that Nck SH3 domains dramatically stimulate the rate of nucleation of actin filaments by purified N-WASP in the presence of Arp2/3 in vitro. All three Nck SH3 domains are required for maximal activation, Nck-stimulated actin nucleation by N-WASP Arp2/3 complexes is further stimulated by phosphatidylinositol 4,5-bisphosphate, but not by GTP-Cdc42, suggesting that Nck and Cdc42 activate N-WASP by redundant mechanisms. These results suggest the existence of an Nck-dependent, Cdc42-independent mechanism to induce actin polymerization at tyrosine-phosphorylated Nck binding sites.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02116 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02116 USA.	marc@hms.harvard.edu			NCI NIH HHS [CA82258] Funding Source: Medline; NIGMS NIH HHS [GM26875] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; CARLIER MF, 1990, J BIOL CHEM, V275, P21969; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5	26	312	320	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26448	26452		10.1074/jbc.M103856200	http://dx.doi.org/10.1074/jbc.M103856200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340081	hybrid			2022-12-27	WOS:000169823300106
J	Sachdev, P; Jiang, YX; Li, WQ; Miki, T; Maruta, H; Nur-e-Kamal, MSA; Wang, LH				Sachdev, P; Jiang, YX; Li, WQ; Miki, T; Maruta, H; Nur-e-Kamal, MSA; Wang, LH			Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; V-SRC; CYTOSKELETAL REORGANIZATION; GUANOSINE TRIPHOSPHATASES; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; RAS TRANSFORMATION; CYCLE PROGRESSION	Insulin-like growth factor I receptor (IGFR) plays an important role in cell growth and transformation. We dissected the downstream signaling pathways of an oncogenic variant of IGFR, Gag-IGFR, called NM1, Loss of function mutants of NM1, Phe-1136 and dS2, that retain kinase activity but are attenuated in their transforming ability were used to identify signaling pathways that are important for transformation of NIH 3T3 cells. MAPK, phospholipase C gamma, and Stat3 were activated to the same extent by NM1 and its two mutants, suggesting that activation of these pathways, individually or in combination, was not sufficient for NM1-induced cell transformation. The mutant dS2 has decreased IRS-1 phosphorylation levels and IRS-l-associated phosphatidylinositol 3 ' -kinase activity, suggesting that this impairment may be in part responsible for the defectiveness of dS2, We show that Rho family members, RhoA, Rad, and Cdc42 are activated by NM1, and this activation, particularly RhoA and Cdc42, is attenuated in both mutants of NM1, Dominant negative mutants of Rho, Rac, and Cdc42 inhibited NM1-induced cell transformation, as measured by focus and colony forming ability. Dominant negative Rho most potently inhibited the focus forming activity, whereas Cdc42 was most effective in inhibiting the colony forming ability of NM1-expressing cells. Conversely, constitutively activated (ca) Rho is more effective than ca Rac or ca Cdc42 in rescuing the focus forming ability of the mutants. By contrast, ca Cdc42 is most effective in rescuing the colony forming ability of both mutants.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Brockton W Roxbury Vet Affairs Med Ctr, Dept Med, Bronx, NY 10468 USA; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Med & Dent New Jersey, RW Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research; Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.				NCI NIH HHS [CA55054] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Aplin AE, 1999, J CELL SCI, V112, P695; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Berfield AK, 1997, J HISTOCHEM CYTOCHEM, V45, P583, DOI 10.1177/002215549704500410; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hirai A, 1997, J BIOL CHEM, V272, P13; Ito T, 1996, MOL CELL BIOL, V16, P943; JIANG Y, 1996, J BIOL CHEM, V271, P60; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KALEBIC T, 1994, CANCER RES, V54, P5531; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim BS, 1998, J NEUROCHEM, V71, P1333; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LI SW, 1994, J BIOL CHEM, V269, P32558; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; Liu Delong, 1994, Journal of Biomedical Science, V1, P65, DOI 10.1007/BF02257980; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEJNE AM, 1997, EXP CELL RES, V234, P477; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, J CELL SCI S, V8, P35; Nur-E-Kamal MSA, 1999, ONCOGENE, V18, P7787; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pass HI, 1996, CANCER RES, V56, P4044; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P ANTL ACD SCI US, V92, P17811; Resnicoff M, 1998, ANN NY ACAD SCI, V842, P76, DOI 10.1111/j.1749-6632.1998.tb09634.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; SANCHEZMARGALET V, 1995, MOL ENDOCRINOL, V9, P435, DOI 10.1210/me.9.4.435; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Scrimgeour AG, 1997, ENDOCRINOLOGY, V138, P2552, DOI 10.1210/en.138.6.2552; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; YASHIRO T, 1989, ACTA ENDOCRINOL-COP, V121, P112, DOI 10.1530/acta.0.1210112; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	69	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26461	26471		10.1074/jbc.M010995200	http://dx.doi.org/10.1074/jbc.M010995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11346642	hybrid, Green Submitted			2022-12-27	WOS:000169823300108
J	Beckstead, MJ; Phelan, R; Mihic, SJ				Beckstead, MJ; Phelan, R; Mihic, SJ			Antagonism of inhalant and volatile anesthetic enhancement of glycine receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; GENERAL-ANESTHETICS; GABA(A) RECEPTORS; BINDING-SITES; AMINO-ACID; ALCOHOL; ISOFLURANE; HALOTHANE; MUTATIONS; CHANNELS	Recent studies suggest that alcohols, volatile anesthetics, and inhaled drugs of abuse, which enhance gamma -aminobutyric acid, type A, and glycine receptor-activated ion channel function, may share common or overlapping molecular sites of action on these receptors, To investigate this possibility, these compounds were applied singly and in combination to wild-type glycine cu, receptors expressed in Xenopus laevis oocytes, Data obtained from concentration-response curves of the volatile anesthetic enflurane constructed in the presence and absence of ethanol, chloroform, or toluene were consistent with competition for a common binding pocket on these receptors, A mutant glycine receptor, insensitive to the enhancing effects of ethanol but not anesthetics or inhalants, demonstrated antagonism of anesthetic and inhalent effects on this receptor. Although ethanol (25-200 mM) had no effect on its own in this receptor, it was able to inhibit reversibly the enhancing effect of enflurane, toluene, and chloroform in a concentration-dependent manner. These data suggest the existence of overlapping molecular sites of action for ethanol, inhalants, and volatile anesthetics on glycine receptors and illustrate the feasibility of pharmacological antagonism of the effects of volatile anesthetics.	Univ Texas, Neurobiol Sect, Austin, TX 78712 USA; Univ Texas, Waggoner Ctr Alcohol & Addict Res, Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Wake Forest University; Wake Forest Baptist Medical Center	Beckstead, MJ (corresponding author), Univ Texas, Neurobiol Sect, 2500 Speedway,MBB 1-148, Austin, TX 78712 USA.				NIAAA NIH HHS [F31 AA005605, AA11525] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F31AA005605, R01AA011525] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Beckstead MJ, 2000, MOL PHARMACOL, V57, P1199; BECKSTEAD MJ, 2000, ALCOHOL CLIN EXP RES, V24, P45; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; Eger EI, 1999, ANESTH ANALG, V88, P867, DOI 10.1097/00000539-199904000-00035; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GION H, 1971, ANESTHESIOLOGY, V35, P361, DOI 10.1097/00000542-197110000-00008; Krasowski MD, 2000, BRIT J PHARMACOL, V129, P731, DOI 10.1038/sj.bjp.0703087; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; Lopez MM, 1998, BIOPHYS J, V74, P974, DOI 10.1016/S0006-3495(98)74020-2; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; MIHIC SJ, 1994, J BIOL CHEM, V269, P32768; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Neumahr S, 2000, ANESTH ANALG, V90, P1184, DOI 10.1097/00000539-200005000-00035; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Wick MJ, 1998, P NATL ACAD SCI USA, V95, P6504, DOI 10.1073/pnas.95.11.6504; Yamakura T, 1999, J BIOL CHEM, V274, P23006, DOI 10.1074/jbc.274.33.23006	21	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24959	24964		10.1074/jbc.M011627200	http://dx.doi.org/10.1074/jbc.M011627200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11346643	hybrid			2022-12-27	WOS:000169800700070
J	Ebisu, K; Nagasawa, T; Watanabe, K; Kakinuma, K; Miyano, K; Tamura, M				Ebisu, K; Nagasawa, T; Watanabe, K; Kakinuma, K; Miyano, K; Tamura, M			Fused p47(phox) and p67(phox) truncations efficiently reconstitute NADPH oxidase with higher activity and stability than the individual components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; NEUTROPHIL PLASMA-MEMBRANE; SH3 DOMAIN INTERACTIONS; SRC HOMOLOGY-3 DOMAINS; 1-ETHYL-3-(3-DIMETHYLAMINOPROPYL) CARBODIIMIDE; PHOSPHATIDIC-ACID; ACTIVATION DOMAIN; ESCHERICHIA-COLI; REDUCTASE	Activation of the neutrophil NADPH oxidase occurs via assembly of the cytosolic regulatory proteins p47(phox), p67(phox), and Rac with the membrane-associated flavocytochrome b(558). Following cell-free activation, enzymatic activity is highly labile (Tamura, M,, Takeshita, M,, Curnutte, J. T,, Uhlinger, D, J,, and Lambeth, J, D, (1992) J, Biol, Chem, 267, 7529-7538), To try to stabilize the activity and investigate the nature of the complex, fusion proteins between p47N-(1-286) and p67N-(1-210) were constructed. In a cell-free system, a fusion protein, p67N-p47N, had an 8-fold higher efficiency and produced a higher activity than the individual proteins, and also resulted in an 8-fold improved efficiency for Rac and a lowered K, for NADPH, Of, generating activity was remarkably stabilized by using p67N-p47N, The cytosolic proteins fused in the opposite orientation, p47N-p67N, showed similar activity and stability as individual proteins, but with a 4-fold improved efficiency compared with the individual cytosolic factors. In the system efficiency for Rac and affinity for NADPH were also higher than those with the nonfused components. Interestingly, the p67N-p47N showed nearly full activation in the absence of an anionic amphifile in a cell-free system containing cytochrome b(558) relipidated with phosphatidylinositol- or phosphatidylserine-enriched phospholipid mixtures, From the results we consider multiple roles of anionic amphifiles in a cell-free activation, which could be substituted by our system. The fact that a fusion produces a more stable complex indicates that interactions among components determine the longevity of the complex. Based on the findings we propose a model for the topology among p47N, p67N, and cytochrome b(558) in the active complex.	Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan; Univ Tokyo, Fac Sci, Biophoton Informat Labs, MMBS, Kanagawa 2380225, Japan	Ehime University; University of Tokyo	Tamura, M (corresponding author), Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan.							ABO A, 1992, J BIOL CHEM, V267, P16767; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; Dang PMC, 1999, BIOCHEMISTRY-US, V38, P5746, DOI 10.1021/bi982750f; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Erickson RW, 1999, J BIOL CHEM, V274, P22243, DOI 10.1074/jbc.274.32.22243; FISHER CW, 1992, P NATL ACAD SCI USA, V89, P10817, DOI 10.1073/pnas.89.22.10817; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; FUJII H, 1992, BIOCHIM BIOPHYS ACTA, V1136, P239, DOI 10.1016/0167-4889(92)90112-O; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hata K, 1998, J BIOL CHEM, V273, P4232, DOI 10.1074/jbc.273.7.4232; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Ogata K, 1996, BIOCHEM J, V313, P549, DOI 10.1042/bj3130549; Palicz A, 2001, J BIOL CHEM, V276, P3090, DOI 10.1074/jbc.M007759200; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SAKAKI T, 1994, BIOCHEMISTRY-US, V33, P4933, DOI 10.1021/bi00182a023; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; STEIN JM, 1991, BIOCHEM J, V274, P381, DOI 10.1042/bj2740381; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; TAMURA M, 1992, J BIOL CHEM, V267, P7529; TAMURA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P23, DOI 10.1016/0003-9861(89)90345-7; TAMURA M, 1988, J BIOL CHEM, V263, P17621; TAMURA M, 1993, ARCH BIOCHEM BIOPHYS, V305, P477, DOI 10.1006/abbi.1993.1450; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7	42	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24498	24505		10.1074/jbc.M101122200	http://dx.doi.org/10.1074/jbc.M101122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333262	hybrid			2022-12-27	WOS:000169800700012
J	Kang, KH; Lee, KH; Kim, MY; Choi, KH				Kang, KH; Lee, KH; Kim, MY; Choi, KH			Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; PROTEASOME PATHWAY; ALPHA PROTEOLYSIS; HEPATOMA-CELLS; INHIBITION; ACTIVATION; PHOSPHORYLATION; DEGRADATION; TNF	The transcription factor nuclear factor KB (NF-KB) plays a crucial role in immune and inflammatory response, and protects cells from apoptosis, In this report, we investigate whether the NF-KB signaling pathway is blocked during apoptosis induced by 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone (NA), an analog of naphthoquinone, It is observed that NA triggers apoptotic cell death in HeLa cells and destroys resistance to apoptosis caused by tumor necrosis factor-alpha. Bata presented in this study establish that p65/Re1A, a subunit of NF-KB, is cleaved at Asp(97) by caspase-3 during apoptosis, Caspase-3-cleaved p65 loses transcriptional activity and potentiates NA-induced apoptosis, in contrast to an uncleavable mutant of p65, which protects the cell from apoptosis, Caspase-3, which is responsible for the cleavage of p65, is activated via the cytochrome c/caspase-9 signaling pathway rather than Fas/caspase-8 pathway during NA-induced apoptosis, Our results suggest that NA induces apoptosis by the negative regulation of cell survival through caspase-3-mediated cleavage of p65.	Chung Ang Univ, Coll Nat Sci, Dept Biol, Dongjak Ku, Seoul 156756, South Korea; Chung Ang Univ, Coll Pharm, Div Biochem, Seoul 156756, South Korea	Chung Ang University; Chung Ang University	Choi, KH (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Biol, Dongjak Ku, Seoul 156756, South Korea.							Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Ham SW, 1998, BIOORG MED CHEM LETT, V8, P2507, DOI 10.1016/S0960-894X(98)00411-9; Jeong SY, 1999, J BIOL CHEM, V274, P18981, DOI 10.1074/jbc.274.27.18981; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIKAWA Y, 1995, J BIOL CHEM, V270, P28304, DOI 10.1074/jbc.270.47.28304; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; PERERA CS, 1995, ARCH BIOCHEM BIOPHYS, V323, P471, DOI 10.1006/abbi.1995.0069; Ravi R, 1998, CANCER RES, V58, P882; Rheaume E, 1997, EMBO J, V16, P6346, DOI 10.1093/emboj/16.21.6346; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	32	70	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24638	24644		10.1074/jbc.M101291200	http://dx.doi.org/10.1074/jbc.M101291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11320092	hybrid			2022-12-27	WOS:000169800700031
J	Levi, S; Corsi, B; Bosisio, M; Invernizzi, R; Volz, A; Sanford, D; Arosio, P; Drysdale, J				Levi, S; Corsi, B; Bosisio, M; Invernizzi, R; Volz, A; Sanford, D; Arosio, P; Drysdale, J			A human mitochondrial ferritin encoded by an intronless gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-FERRITIN; OXIDATIVE STRESS; IRON-METABOLISM; MESSENGER-RNA; L CHAINS; CELLS; OVEREXPRESSION; IDENTIFICATION; EVOLUTION	Ferritin is a ubiquitous protein that plays a critical role in regulating intracellular iron homoeostasis by storing iron inside its multimeric shell. It also plays an important role in detoxifying potentially harmful free ferrous iron to the less soluble ferric iron by virtue of the ferroxidase activity of the H subunit. Although excess iron is stored primarily in cytoplasm, most of the metabolically active iron in cells is processed in mitochondria. Little is yet known of how these organelles regulate iron homeostasis and toxicity. Here we report an unusual intronless gene on chromosome 5q23.1 that encodes a 242-amino acid precursor of a ferritin II-like protein. This 30-kDa protein is targeted to mitochondria and processed to a 22-kDa subunit that assembles into typical ferritin shells and has ferroxidase activity. Immunohistochemical analysis showed that it accumulates in high amounts in iron-loaded mitochondria of erythroblasts of subjects with impaired heme synthesis. This new ferritin may play an important role in the regulation of mitochondrial iron homeostasis and heme synthesis.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Hosp San Raffaele, Ist Ricovera & Cura Carattera Sci, I-20132 Milan, Italy; Univ Brescia, Fac Med, I-25100 Brescia, Italy; Univ Pavia, Dept Internal Med & Med Therapy, I-27100 Pavia, Italy; Univ Klinikum Humbolt, Charite, Berlin, Germany	Tufts University; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Brescia; University of Pavia; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Drysdale, J (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.		arosio, paolo/S-3272-2019; levi, sonia/A-3161-2015; arosio, paolo/E-6817-2010	arosio, paolo/0000-0002-5343-8992; levi, sonia/0000-0002-5092-0847; 				Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; AROSIO P, 1978, J BIOL CHEM, V253, P4451; BESSIS MC, 1962, BLOOD, V14, P423; BOTTOMLEY SS, 1999, WINTROBES CLIN HEMAT, P1071; BOYD D, 1985, J BIOL CHEM, V260, P1755; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Cozzi A, 2000, J BIOL CHEM, V275, P25122, DOI 10.1074/jbc.M003797200; DRYSDALE JW, 1966, J BIOL CHEM, V241, P3630; DRYSDALE JW, 1970, BIOCHIM BIOPHYS ACTA, V207, P256, DOI 10.1016/0005-2795(70)90158-3; DUGAST IJ, 1990, GENOMICS, V6, P204, DOI 10.1016/0888-7543(90)90558-C; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; INVERNIZZI R, 1990, BRIT J HAEMATOL, V76, P427, DOI 10.1111/j.1365-2141.1990.tb06379.x; JAIN SK, 1985, J BIOL CHEM, V260, P1762; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; MAZUR A, 1950, J BIOL CHEM, V187, P473; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ponka P, 1997, BLOOD, V89, P1; Santambrogio P, 2000, PROTEIN EXPRES PURIF, V19, P212, DOI 10.1006/prep.2000.1212; VANIN EF, 1984, BIOCHIM BIOPHYS ACTA, V782, P231, DOI 10.1016/0167-4781(84)90057-5; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676	26	293	306	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24437	24440		10.1074/jbc.C100141200	http://dx.doi.org/10.1074/jbc.C100141200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323407	hybrid			2022-12-27	WOS:000169800700002
J	Nakamoto, H; Tanaka, N; Ishikawa, N				Nakamoto, H; Tanaka, N; Ishikawa, N			A novel heat shock protein plays an important role in thermal stress management in cyanobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS-SP PCC-6803; GROEL-LIKE GENE; BACILLUS-SUBTILIS; SYNECHOCOCCUS-VULCANUS; FUNCTIONAL-ANALYSIS; MOLECULAR-CLONING; PHOTOSYSTEM-I; OPERON; CHAPERONIN; SUBUNIT	A novel heat shock gene, orf7.5, which encodes a putative acidic polypeptide of 63 amino acids, was cloned from the cyanobacterium Synechococcus sp, PCC 7942, Northern blot analysis revealed the presence of 400- and 330-base orf7,5 mRNAs, which were barely detectable in the cells grown at 30 degreesC but increased transiently in response to heat shock at 40 or 45 degreesC, Primer extension analysis showed that the two mRNAs have different 5'-ends. Chloramphenicol enhanced the accumulation of the orf7,5 mRNA, whereas it inhibited the increase in the amount of the groESL mRNA To reveal the role of the orf7,5 gene in thermal stress management, we constructed a stable mutant in which a gene conferring resistance to an antibiotic was inserted into the coding region of the orf7,5 gene. The interruption led to a marked inhibition of growth at 45 degreesC and a decrease in the basal and acquired thermo-tolerances at 50 degreesC in the transformants, indicating that the gene plays a role in thermal stress management. The orf7,5 mutant could be complemented with a return to the wild type phenotype by a DNA fragment containing orf7,5 but not by mutated orf7,5s, in which a nonsense mutation was generated by introducing a frameshift or a point mutation within the orf7,5-coding region. Thus, thermo-tolerance requires an appropriate translation product, not simply a transcript. Accumulation of the groESL transcript in the orf7,5 mutant was strongly reduced, suggesting that the orf7.5 gene product controls the expression of the groESL operon.	Saitama Univ, Dept Biochem & Mol Biol, Urawa, Saitama 3388570, Japan	Saitama University	Nakamoto, H (corresponding author), Saitama Univ, Dept Biochem & Mol Biol, Urawa, Saitama 3388570, Japan.		Nakamoto, Hitoshi/H-5315-2012					BOREBRY G, 1985, J BACTERIOL, V161, P1125; CHITNIS PR, 1991, J BIOL CHEM, V266, P58; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; Eriksson MJ, 1996, J BACTERIOL, V178, P4839, DOI 10.1128/jb.178.16.4839-4846.1996; Furuki M, 1996, BBA-PROTEIN STRUCT M, V1294, P106, DOI 10.1016/0167-4838(96)00037-4; Glatz A, 1997, BIOCHEM BIOPH RES CO, V239, P291, DOI 10.1006/bbrc.1997.7463; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Lee SY, 1998, CURR MICROBIOL, V37, P403, DOI 10.1007/s002849900400; LEHEL C, 1993, J BIOL CHEM, V268, P1799; LEHEL C, 1992, PLANT MOL BIOL, V18, P327, DOI 10.1007/BF00034959; Mogk A, 1997, EMBO J, V16, P4579, DOI 10.1093/emboj/16.15.4579; Nakamoto H, 1999, PLANT CELL PHYSIOL, V40, P9, DOI 10.1093/oxfordjournals.pcp.a029479; Narberhaus F, 1999, MOL MICROBIOL, V31, P1, DOI 10.1046/j.1365-2958.1999.01166.x; REILLY P, 1988, J BIOL CHEM, V263, P17658; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Roy SK, 1998, J BACTERIOL, V180, P3997, DOI 10.1128/JB.180.15.3997-4001.1998; Sambrook J., 2002, MOL CLONING LAB MANU; SERVANT P, 1995, J BACTERIOL, V177, P2998, DOI 10.1128/jb.177.11.2998-3003.1995; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Tanaka N, 1999, FEBS LETT, V458, P117, DOI 10.1016/S0014-5793(99)01134-5; Tanaka N, 1997, BBA-PROTEIN STRUCT M, V1343, P335, DOI 10.1016/S0167-4838(97)00159-3; WEBB R, 1990, J BACTERIOL, V172, P5079, DOI 10.1128/jb.172.9.5079-5088.1990; Webb R., 1994, MOL BIOL CYANOBACTER, P751; YUAN G, 1995, J BACTERIOL, V177, P6462, DOI 10.1128/jb.177.22.6462-6468.1995; ZUBER U, 1994, J BACTERIOL, V176, P1359, DOI 10.1128/jb.176.5.1359-1363.1994	26	12	12	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25088	25095		10.1074/jbc.M101717200	http://dx.doi.org/10.1074/jbc.M101717200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342543	hybrid			2022-12-27	WOS:000169800700088
J	Ostrander, DB; Zhang, M; Mileykovskaya, E; Rho, M; Dowhan, W				Ostrander, DB; Zhang, M; Mileykovskaya, E; Rho, M; Dowhan, W			Lack of mitochondrial anionic phospholipids causes an inhibition of translation of protein components of the electron transport chain - A yeast genetic model system for the study of anionic phospholipid function in mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; ATP SYNTHASE; PEL1 GENE; RAT-HEART; PHOSPHATIDYLGLYCEROPHOSPHATE SYNTHASE; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; ESCHERICHIA-COLI; NUCLEAR GENES	Reduction of mitochondrial cardiolipin (CL) levels has been postulated to compromise directly the function of several essential enzymes and processes of the mitochondria. There is limited genetic evidence for the critical roles with which CL and its precursor phosphatidylglycerol (PG) have been associated. A null allele of the PGS1 gene from Saccharomyces cerevisiae, which encodes the enzyme responsible for the synthesis of the CL precursor PG phosphate, was created in a yeast strain in which PGS1 expression is exogenously regulated by doxycycline. The addition of increasing concentrations of doxycycline to the growth medium causes a proportional decrease to undetectable levels of PGSI transcript, PG phosphate synthase activity, and PG plus CL. The doubling time of this strain with increasing doxycycline increases to senescence in non-fermentable carbon sources or at high temperatures, conditions that do not support growth of the pgs1 Delta strain. Doxycycline addition also causes mitochondrial abnormalities as observed by fluorescence microscopy, Products of four mitochondrial encoded genes (COX1, COX2, COX3, and COB) and one nuclear encoded gene (COX4) associated with the mitochondrial inner membrane are not present when PGSI expression is fully repressed. No translation of these proteins can be detected in cells lacking the PGSI gene product, although transcription and splicing appear unaffected. Protein import of other nuclear encoded proteins remains unaffected. The remaining proteins encoded by mitochondrial DNA are expressed and translated normally. Thus, the molecular basis for the lack of mitochondrial function in pgs1 Delta cells is the failure to translate gene products essential to the electron transport chain.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA	University of Texas System	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	William.Dowhan@uth.tmc.edu	Zhang, Mei/G-8690-2014	Mileykovskaya, Eugenia/0000-0002-8775-4467	NHLBI NIH HHS [HL10304] Funding Source: Medline; NIGMS NIH HHS [GM56389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056389] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITCH DA, 1990, BIOCHIM BIOPHYS ACTA, V1020, P34, DOI 10.1016/0005-2728(90)90090-Q; Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; BELENDIUK G, 1978, J BIOL CHEM, V253, P4555; BEREITERHAHN J, 1976, BIOCHIM BIOPHYS ACTA, V423, P1, DOI 10.1016/0005-2728(76)90096-7; Beyer K, 1996, BIOCHEMISTRY-US, V35, P15784, DOI 10.1021/bi9610055; Bobyleva V, 1997, BIOCHEM MOL BIOL INT, V41, P469; Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; Chang SC, 1998, J BIOL CHEM, V273, P9829, DOI 10.1074/jbc.273.16.9829; Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Chen XJ, 2000, INT REV CYTOL, V194, P197; CHUPIN V, 1995, FEBS LETT, V373, P239, DOI 10.1016/0014-5793(95)01054-I; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; Dzugasova V, 1998, CURR GENET, V34, P297, DOI 10.1007/s002940050399; EBLE KS, 1990, J BIOL CHEM, V265, P19434; EILERS M, 1989, J BIOL CHEM, V264, P2945; FINE JB, 1982, J LIPID RES, V23, P660; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FUJIKI M, 1993, J BIOL CHEM, V268, P1914; GAIGG B, 1995, BBA-BIOMEMBRANES, V1234, P214, DOI 10.1016/0005-2736(94)00287-Y; GALLET PF, 1995, EUR J BIOCHEM, V228, P113, DOI 10.1111/j.1432-1033.1995.tb20238.x; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GOORMAGHTIGH E, 1982, BIOCHEM BIOPH RES CO, V104, P314, DOI 10.1016/0006-291X(82)91976-3; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; GREKSAK M, 1977, FOLIA MICROBIOL, V22, P30, DOI 10.1007/BF02876990; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOFFMANN B, 1994, J BIOL CHEM, V269, P1940; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kawasaki K, 1999, J BIOL CHEM, V274, P1828, DOI 10.1074/jbc.274.3.1828; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; KOVAC L, 1977, MOL CELL BIOCHEM, V14, P11, DOI 10.1007/BF01734158; Law R H, 1995, Methods Mol Biol, V37, P293; LEENHOUTS JM, 1993, FEBS LETT, V327, P172, DOI 10.1016/0014-5793(93)80164-P; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Ma BJ, 1999, J LIPID RES, V40, P1837; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; Ortiz A, 1999, BIOPHYS J, V77, P2003, DOI 10.1016/S0006-3495(99)77041-4; OSTRANDER DB, 1995, J BIOL CHEM, V270, P27045, DOI 10.1074/jbc.270.45.27045; Ostrander DB, 1997, YEAST, V13, P871, DOI 10.1002/(SICI)1097-0061(199707)13:9<871::AID-YEA127>3.0.CO;2-2; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; Paradies G, 1999, FEBS LETT, V454, P207, DOI 10.1016/S0014-5793(99)00809-1; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Sedlak E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIKORSKI RS, 1989, GENETICS, V122, P19; Stephens AN, 2000, EUR J BIOCHEM, V267, P6443, DOI 10.1046/j.1432-1327.2000.01733.x; SUBIK J, 1974, FEBS LETT, V42, P309, DOI 10.1016/0014-5793(74)80753-2; ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; XIA WM, 1995, P NATL ACAD SCI USA, V92, P783, DOI 10.1073/pnas.92.3.783; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	72	81	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25262	25272		10.1074/jbc.M103689200	http://dx.doi.org/10.1074/jbc.M103689200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11335731	hybrid			2022-12-27	WOS:000169800700111
J	Reinelt, S; Marti, M; Dedier, S; Reitinger, T; Folkers, G; de Castro, JAL; Rognan, D				Reinelt, S; Marti, M; Dedier, S; Reitinger, T; Folkers, G; de Castro, JAL; Rognan, D			beta-amino acid scan of a class I major histocompatibility complex-restricted alloreactive T-cell epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ANTIGEN; AUTOIMMUNE-DISEASE; 3-DIMENSIONAL STRUCTURE; NONNATURAL PEPTIDES; CTL CLONE; BINDING; MHC; HLA-B27; MOLECULES; ANALOGS	An HLA-B27-restricted self-octapeptide known to react with an alloreactive T-cell receptor has been modified by systematic substitution of a p-amino acid for the natural cy-amino acid residue, over the whole length of the parent epitope, All modified peptides were shown to bind to recombinant HLA-B*2705 and induce stable major histocompatibility complex-peptide complexes, but with some variation depending on the position of the beta -amino acid on the peptide sequence, Alteration of the natural peptide sequence at the two N-terminal positions (positions 1 and 2) decreases binding affinity and thermodynamic stability of the refolded complex, but all other positions (from position 3 to the C-terminal residue) were insensitive to the beta -amino acid substitution. All modified peptides were recognized by an alloreactive T-cell clone specific for the parent epitope with decreased efficiency, to an extent dependent of the position that was modified. Furthermore, the introduction of a single beta -amino acid at the first two positions of the modified peptide was shown to be sufficient to protect them against enzymatic cleavage. Thus, beta -amino acids represent new interesting templates for alteration of T-cell epitopes to design either synthetic vaccines of T-cell receptor antagonists.	CNRS, UMR 7081, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch, France; Swiss Fed Inst Technol, Dept Appl Biosci, CH-8057 Zurich, Switzerland; Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Centre National de la Recherche Scientifique (CNRS); Swiss Federal Institutes of Technology Domain; ETH Zurich; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Rognan, D (corresponding author), F Hoffman La Roche Ltd, Div Pharmaceut, CH-4070 Basel, Switzerland.		Martí, Mercè/I-2164-2015; Rognan, Didier/B-9939-2014	Martí, Mercè/0000-0002-1846-0043; Folkers, Gerd/0000-0002-3620-705X				Alvarez I, 2000, CURR OPIN RHEUMATOL, V12, P248, DOI 10.1097/00002281-200007000-00003; Ayyoub M, 1998, RAPID COMMUN MASS SP, V12, P557, DOI 10.1002/(SICI)1097-0231(19980515)12:9<557::AID-RCM199>3.3.CO;2-4; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; Dedier S, 2000, J BIOL CHEM, V275, P27055; Falcioni F, 1999, NAT BIOTECHNOL, V17, P562, DOI 10.1038/9865; Garcia-Peydro M, 2000, J IMMUNOL, V165, P5680, DOI 10.4049/jimmunol.165.10.5680; Garcia-Peydro M, 1999, J IMMUNOL, V163, P6060; Guichard G, 2000, J MED CHEM, V43, P3803, DOI 10.1021/jm000909s; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P643; ISHIOKA GY, 1994, J IMMUNOL, V152, P4311; Khare Sanjay D., 1998, Current Opinion in Rheumatology, V10, P282, DOI 10.1097/00002281-199807000-00002; Krebs S, 1998, J PEPT SCI, V4, P378, DOI 10.1002/(SICI)1099-1387(199809)4:6<378::AID-PSC157>3.0.CO;2-B; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; Ottenhoff THM, 1997, J IMMUNOL METHODS, V200, P89, DOI 10.1016/S0022-1759(96)00190-1; Paas-Rozner M, 2000, P NATL ACAD SCI USA, V97, P2168, DOI 10.1073/pnas.040554597; PACE NC, 1997, PROTEIN STRUCTURE PR, P299; Paradela A, 1998, J IMMUNOL, V161, P5481; Persidis A, 1999, NAT BIOTECHNOL, V17, P1038, DOI 10.1038/13748; Poenaru S, 1999, J MED CHEM, V42, P2318, DOI 10.1021/jm981123l; Reinelt S, 2001, J BIOL CHEM, V276, P18472, DOI 10.1074/jbc.M101282200; ROGNAN D, 1995, P NATL ACAD SCI USA, V92, P753, DOI 10.1073/pnas.92.3.753; Seebach D, 1997, CHEM COMMUN, P2015, DOI 10.1039/a704933a; Singer DS, 1997, CRIT REV IMMUNOL, V17, P463; Spack EG, 1997, CRIT REV IMMUNOL, V17, P529; Thurau SR, 1999, IMMUNOL LETT, V68, P205, DOI 10.1016/S0165-2478(99)00071-1; Toda M, 2000, EUR J IMMUNOL, V30, P403; vanderBurg SH, 1996, J IMMUNOL, V156, P3308	29	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24525	24530		10.1074/jbc.M102772200	http://dx.doi.org/10.1074/jbc.M102772200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342555	hybrid			2022-12-27	WOS:000169800700016
J	Urano, T; Ihara, H; Umemura, K; Suzuki, Y; Oike, M; Akita, S; Tsukamoto, Y; Suzuki, I; Takada, A				Urano, T; Ihara, H; Umemura, K; Suzuki, Y; Oike, M; Akita, S; Tsukamoto, Y; Suzuki, I; Takada, A			The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEGETABLE CHEESE NATTO; HUMAN-PLASMA; SERINE PROTEASES; STRUCTURAL BASIS; PAI-1 ACTIVITY; FACTOR XA; GENE; NATTOKINASE; NEUTRALIZATION; PURIFICATION	In this report, we demonstrate an interaction between subtilisin NAT (formerly designated BSP, or nattokinase), a profibrinolytic serine proteinase from Bacillus subtilis, and plasminogen activator inhibitor 1 (PAI-1), Subtilisin NAT was purified to homogeneity (molecular mass, 27.7 kDa) from a saline extract of B, subtilis (natto), Subtilisin NAT appeared to cleave active recombinant prokaryotic PAI-1 (rpPAI-1) into low molecular weight fragments. Matrix-assisted laser desorption/ionization in combination with time-of-flight mass spectroscopy and peptide sequence analysis revealed that rpPAI-1 was cleaved at its reactive site (P1-P1 ': Arg(346)-Met(347)), rpPAI-1 lost its specific activity after subtilisin NAT treatment in a dose-dependent manner (0.02-1.0 nM; half-maximal effect at similar to0.1 nM), Subtilisin NAT dose dependently (0.06-1 nM) enhanced tissue-type plasminogen activator-induced fibrin clot lysis both in the absence of rpPAI-1 (48 +/- 1.48 at 1 nM) and especially in the presence of rpPAI-1 (78 +/- 2.0% at 1 nM), The enhancement observed in the absence of PAI-1 seems to be induced through direct fibrin dissolution by subtilisin NAT, The stronger enhancement by subtilisin NAT of rpPAI-1-enriched fibrin clot lysis seems to involve the cleavage and inactivation of active rpPAI-1, This mechanism is suggested to be important for subtilisin NAT to potentiate fibrinolysis.	Hamamatsu Univ Sch Med, Dept Physiol, Hamamatsu, Shizuoka 4313192, Japan; Hamamatsu Univ Sch Med, Dept Pharmacol, Hamamatsu, Shizuoka 4313192, Japan; Cent Res Inst Mitsukan Grp Corp, Handa 4758585, Japan; Prefectural Univ Kumamoto, Fac Environm & Symbiot Sci, Kumamoto 8628502, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Urano, T (corresponding author), Hamamatsu Univ Sch Med, Dept Physiol, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	uranot@hama-med.ac.jp						ABE O, 1989, J BIOCHEM, V105, P66, DOI 10.1093/oxfordjournals.jbchem.a122621; AOKI N, 1995, MOL BASIS THROMBOSIS, P545; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; BERRETTINI M, 1989, J BIOL CHEM, V264, P11738; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ERICKSON LA, 1990, NATURE, V346, P74, DOI 10.1038/346074a0; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; FUJITA M, 1995, BIOL PHARM BULL, V18, P1387; FUJITA M, 1995, FIBRINOLYSIS, V9, P157, DOI 10.1016/S0268-9499(95)80005-0; FUJITA M, 1993, BIOCHEM BIOPH RES CO, V197, P1340, DOI 10.1006/bbrc.1993.2624; HAMSTEN A, 1987, LANCET, V2, P3; Humphries SE, 1997, THROMB HAEMOSTASIS, V78, P457; HUNTINGTON JA, 1995, PROTEIN SCI, V4, P613; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Komiyama T, 1996, PROTEIN SCI, V5, P874; KRESS LF, 1983, BIOCHIM BIOPHYS ACTA, V745, P113, DOI 10.1016/0167-4838(83)90039-0; KURIHARA M, 1972, J BIOL CHEM, V247, P5619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LEVIN EG, 1987, BLOOD, V70, P1090; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NAKAMURA T, 1992, BIOSCI BIOTECH BIOCH, V56, P1869, DOI 10.1271/bbb.56.1869; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OTTONELLO L, 1994, EUR J CLIN INVEST, V24, P42, DOI 10.1111/j.1365-2362.1994.tb02058.x; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Siezen RJ, 1997, PROTEIN SCI, V6, P501; STACK MS, 1995, MOL BASIS THROMBOSIS, P479; STAHL ML, 1984, J BACTERIOL, V158, P411, DOI 10.1128/JB.158.2.411-418.1984; SUENSON E, 1990, J BIOL CHEM, V265, P22228; SUMI H, 1987, EXPERIENTIA, V43, P1110, DOI 10.1007/BF01956052; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Urano T, 2000, SEMIN THROMB HEMOST, V26, P39, DOI 10.1055/s-2000-9801; Urano T, 1998, THROMB HAEMOSTASIS, V80, P161, DOI 10.1055/s-0037-1615156; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; Urano T, 1999, FIBRINOLYSIS PROTEOL, V13, P264, DOI 10.1054/fipr.2000.0041; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056	43	117	156	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24690	24696		10.1074/jbc.M101751200	http://dx.doi.org/10.1074/jbc.M101751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325965	hybrid			2022-12-27	WOS:000169800700038
J	Komuro, I; Keicho, N; Iwamoto, A; Akagawa, KS				Komuro, I; Keicho, N; Iwamoto, A; Akagawa, KS			Human alveolar macrophages and granulocyte-macrophage colony-stimulating factor-induced manocyte-derived macrophages are resistant to H2O2 via their high basal and inducible levels of catalase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; ADENOVIRUS-MEDIATED TRANSFER; HUMAN AIRWAY EPITHELIUM; HUMAN-BLOOD MONOCYTES; DEFICIENT MICE; PERITONEAL-MACROPHAGES; HYDROGEN-PEROXIDE; GENE-EXPRESSION; OXIDANT INJURY; GM-CSF	Human alveolar macrophages (A-M Phi) and macrophages (M Phi) generated from human monocytes under the influence of granulocyte-macrophage colony-stimulating factors (GM-M Phi) express high Levels of catalase activity and are highly resistant to H2O2. In contrast, M Phi generated from monocytes by macrophage colony-stimulating factors (M-M Phi) express low catalase activity and are about 50-fold more sensitive to H2O2 than GM-M Phi or A-M Phi. Both A-M Phi, and GM-M Phi, but not M-M Phi can induce catalase expression in both protein and mRNA levels when stimulated with H,OZ or zymosan. M-M Phi but not GM-M Phi, produce a Large amount of H2O2 in response to zymosan or heat-killed Staphylococcus aureus. These findings indicate that GM-M Phi, and A-M Phi but not M-X Phi are strong scavengers of H2O2 via the high basal level of catalase activity and a marked ability of catalase induction and that catalase activity of M Phi is regulated by colony-stimulating factors during differentiation.	Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Infect Dis,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Dept Resp Med, Bunkyo Ku, Tokyo 1138655, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo; University of Tokyo	Akagawa, KS (corresponding author), Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, Toyama 1-23-1, Tokyo 1628640, Japan.	akagawak@nih.go.jp	Keicho, Naoto/GQZ-0301-2022	Keicho, Naoto/0000-0001-8232-9448				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Akagawa K, 1994, Hum Cell, V7, P116; Akagawa K S, 1994, Nihon Saikingaku Zasshi, V49, P385; Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029; AKAGAWA KS, 1997, JPN J MED MYEOL, V38, P209; ANDREESEN R, 1990, J LEUKOCYTE BIOL, V47, P490, DOI 10.1002/jlb.47.6.490; BLUSSEVANOUDALBLAS A, 1979, J EXP MED, V149, P1504, DOI 10.1084/jem.149.6.1504; BRUMMER E, 1995, CLIN EXP IMMUNOL, V102, P65; BRUMMER E, 1989, J MED MICROBIOL, V28, P173, DOI 10.1099/00222615-28-3-173; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; DELAHARPE J, 1985, J IMMUNOL METHODS, V78, P323, DOI 10.1016/0022-1759(85)90089-4; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; DURAN HA, 1988, CELL MOL BIOL, V34, P507; ERZURUM SC, 1993, J APPL PHYSIOL, V75, P1256, DOI 10.1152/jappl.1993.75.3.1256; ERZURUM SC, 1993, NUCLEIC ACIDS RES, V21, P1607, DOI 10.1093/nar/21.7.1607; Goto H, 1996, BONE MARROW TRANSPL, V17, P855; Hashimoto S, 1997, BLOOD, V89, P315, DOI 10.1182/blood.V89.1.315.315_315_321; Heard SO, 1999, ANESTH ANALG, V89, P353, DOI 10.1097/00000539-199908000-00020; HIRATA T, 1986, J IMMUNOL, V136, P1339; Kazazi F, 1996, FREE RADICAL BIO MED, V20, P813, DOI 10.1016/0891-5849(95)02214-7; Keler T, 2000, J IMMUNOL, V164, P5746, DOI 10.4049/jimmunol.164.11.5746; KIETZMANN D, 1993, INTENS CARE MED, V19, P78, DOI 10.1007/BF01708366; Klebanoff SJ, 1999, BLOOD, V93, P350, DOI 10.1182/blood.V93.1.350.401k18_350_356; Klebanoff SJ, 1999, J INFECT DIS, V179, P653, DOI 10.1086/314644; Kurata Shun-ichi, 1999, Journal of Cellular Biochemistry, V76, P13; LeVine AM, 1999, J CLIN INVEST, V103, P563, DOI 10.1172/JCI5212; Marques LJ, 1997, AM J RESP CRIT CARE, V156, P1700, DOI 10.1164/ajrccm.156.5.9611052; MATSUDA S, 1995, AIDS RES HUM RETROV, V11, P1031, DOI 10.1089/aid.1995.11.1031; Metcalf D, 1998, LEUKEMIA, V12, P353, DOI 10.1038/sj.leu.2400926; Moriuchi M, 1998, J CLIN INVEST, V102, P1540, DOI 10.1172/JCI4151; NAKAGAWARA A, 1983, J IMMUNOL METHODS, V56, P261; NAKATA K, 1991, J IMMUNOL, V147, P1266; Nakata K, 1999, BLOOD, V93, P667, DOI 10.1182/blood.V93.2.667.402k25_667_673; NAKATA K, 1995, MOL MED, V1, P744, DOI 10.1007/BF03401889; Nishinakamura R, 1996, J EXP MED, V183, P2657, DOI 10.1084/jem.183.6.2657; PIETARINEN P, 1995, AM J RESP CELL MOL, V13, P434, DOI 10.1165/ajrcmb.13.4.7546773; RADZUN HJ, 1988, J LEUKOCYTE BIOL, V44, P198, DOI 10.1002/jlb.44.3.198; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; SATO K, 1992, MOL CELL BIOL, V12, P2525, DOI 10.1128/MCB.12.6.2525; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; THOMAS ED, 1976, SCIENCE, V192, P1016, DOI 10.1126/science.775638; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959; YOUNG DA, 1990, J IMMUNOL, V145, P607; ZEIDLER RB, 1987, INFLAMMATION, V11, P371, DOI 10.1007/BF00915841	47	41	42	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24360	24364		10.1074/jbc.M102081200	http://dx.doi.org/10.1074/jbc.M102081200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313354	hybrid			2022-12-27	WOS:000169531100149
J	Valgardsdottir, R; Brede, G; Eide, LG; Frengen, E; Prydz, H				Valgardsdottir, R; Brede, G; Eide, LG; Frengen, E; Prydz, H			Cloning and characterization of MDDX28, a putative DEAD-box helicase with mitochondrial and nuclear localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; RNA HELICASE; LCAT GENE; PROTEIN; EXPORT; SEQUENCE; SIGNAL; CRM1; INHIBITION; COMPLEX	A cDNA encoding a novel member of the helicase family, MMDX28, has been cloned from a human testis library. This apparently intronless gene was transcribed in all tissues studied. MDDX28 encodes a protein of 540 amino acids, with similar to 30% homology to other helicases over the core region, containing all the conserved DEAD-box helicase motifs. No homologue is known. MDDX28 has RNA and Mg2+-dependent ATPase activity. Subcellular localization studies of MDDX28 using oligo-clonal antibodies raised against the protein as well as its enhanced green fluorescence protein (EGFP) demonstrated that the protein is localized in the mitochondria and the nucleus. To our knowledge, MDDX28 is the first member of the RNA helicase described with this dual location. The nuclear localization of MDDX28 depended on active RNA polymerase II transcription, suggesting that the protein could be transported to and from the nucleus. This was confirmed further in an interspecies heterokaryon assay, in which MDDX28 was seen to translocate to the nucleus and mitochondria. The mitochondrial uptake of the MDDX28-EGFP-N1 fusion protein was inhibited by carbonyl cyanide p-(trichloro-methoxy)phenylhydrazone. Our results indicate that MDDX28 can be transported between the mitochondria and the nucleus.	Univ Oslo, Ctr Biotechnol, N-0317 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Univ Oslo, Ctr Biotechnol, POB 1125, N-0317 Oslo, Norway.			Frengen, Eirik/0000-0002-8387-2247				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frengen E, 2000, GENOMICS, V70, P273, DOI 10.1006/geno.2000.6389; Frengen E, 1997, CYTOGENET CELL GENET, V76, P53, DOI 10.1159/000134515; FRENGEN E, 1995, CYTOGENET CELL GENET, V68, P194, DOI 10.1159/000133912; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gagliardi D, 1999, FEBS LETT, V458, P337, DOI 10.1016/S0014-5793(99)01168-0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LARSEN F, 1992, GENET ANAL-BIOMOL E, V9, P80, DOI 10.1016/1050-3862(92)90002-M; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Missel A, 1997, MOL CELL BIOL, V17, P4895, DOI 10.1128/MCB.17.9.4895; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; OSEOGAWA K, 1999, CURRENT PROTOCOLS HU; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; Pugh GE, 1999, J MOL BIOL, V292, P771, DOI 10.1006/jmbi.1999.3112; Ruggiero FP, 1998, J HISTOCHEM CYTOCHEM, V46, P177, DOI 10.1177/002215549804600206; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; SUDO K, 1995, CYTOGENET CELL GENET, V71, P385, DOI 10.1159/000134145; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	31	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 24	2001	276	34					32056	32063		10.1074/jbc.M011629200	http://dx.doi.org/10.1074/jbc.M011629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	465WT	11350955	hybrid			2022-12-27	WOS:000170613500081
J	Olah, Z; Karai, L; Iadarola, MJ				Olah, Z; Karai, L; Iadarola, MJ			Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY NERVES MEDIATE; GATED NA+ CHANNEL; CAPSAICIN-RECEPTOR; ENDOPLASMIC-RETICULUM; INFLAMMATORY MEDIATORS; SUBSTANCE-P; RAT; CALCIUM; CANNABINOIDS; TRANSPORT	The vanilloid receptor type 1 (VR1) is a heat-activated ionophore preferentially expressed in nociceptive neurons of trigeminal and dorsal root ganglia (DRG). VR1, which binds and is activated by capsaicin and other vanilloid compounds, was noted to interact with the endocannabinoid anandamide (ANA) and certain inflammatory metabolites of arachidonic acid in a pH-dependent manner. At pH less than or equal to 6.5 ANA induced Ca-45(2+) uptake either in primary cultures of DRG neurons or cells ectopically expressing C-terminally tagged recombinant forms of VR1 with an EC50 = similar to 10 mum at PH 5.5. Capsazepine, a potent antagonist of vanilloids, inhibited ANA-induced Ca2+ transport in both cell systems. Vanilloids displaced [H-3]ANA in VRI-expressing cells, suggesting competition for binding to VR1. Ratiometric determination of intracellular free calcium and confocal imaging of the VR1-green fluorescent fusion protein revealed that, at low PH (less than or equal to 6.5), ANA could induce an elevation of intracellular free Ca2+ and consequent intracellular membrane changes in DRG neurons or transfected cells expressing VR1. These actions of ANA were similar to the effects determined previously for vanilloids. The ligand-induced changes in Ca2+ at PH less than or equal to 6.5 are consistent with the idea that ANA and other eicosanoids act as endogenous ligands of VR1 in a conditional fashion in vivo. The PH dependence suggests that tissue acidification in inflammation, ischemia, or traumatic injury can sensitize VR1 to eicosanoids and transduce pain from the periphery.	NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mechanisms Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Olah, Z (corresponding author), NIDCR, Neuronal Gene Express Unit, Pain & Neurosensory Mechanisms Branch, NIH, Bldg 49,Rm 1A19,49 Convent Dr,MSC-4410, Bethesda, MD 20892 USA.	zoltan.olah@nih.gov			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000688] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ballou LR, 2000, P NATL ACAD SCI USA, V97, P10272, DOI 10.1073/pnas.180319297; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Baumann TK, 2000, J NEUROSCI, V20; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Beltramo M, 1999, EUR J PHARMACOL, V364, P75, DOI 10.1016/S0014-2999(98)00821-8; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; Calignano A, 2000, NATURE, V408, P96, DOI 10.1038/35040576; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Costa B, 1999, BEHAV PHARMACOL, V10, P327, DOI 10.1097/00008877-199905000-00009; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Dedov VN, 2000, NEUROSCIENCE, V95, P183; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; Dirig DM, 1999, BRIT J PHARMACOL, V126, P1333, DOI 10.1038/sj.bjp.0702427; Dux M, 1999, CELL TISSUE RES, V296, P471, DOI 10.1007/s004410051307; Edgemond WS, 1998, MOL PHARMACOL, V54, P180, DOI 10.1124/mol.54.1.180; Grimaldi M, 1999, J BIOL CHEM, V274, P33557, DOI 10.1074/jbc.274.47.33557; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Jung J, 1999, J NEUROSCI, V19, P529; KESSLER W, 1992, EXP BRAIN RES, V91, P467; Kress M, 1996, NEUROSCI LETT, V211, P5, DOI 10.1016/0304-3940(96)12691-4; Kwak JY, 1998, NEUROSCIENCE, V86, P619, DOI 10.1016/S0306-4522(98)00012-8; Lopshire JC, 1998, J NEUROSCI, V18, P6081; Lopshire JC, 1997, J NEUROPHYSIOL, V78, P3154, DOI 10.1152/jn.1997.78.6.3154; LYNN B, 1991, TRENDS NEUROSCI, V14, P95, DOI 10.1016/0166-2236(91)90067-5; MARRIOTT D, 1991, ADV PROSTAG THROMB L, V21, P739; Martin WJ, 1999, PAIN, V82, P199, DOI 10.1016/S0304-3959(99)00045-7; Melck D, 1999, BIOCHEM BIOPH RES CO, V262, P275, DOI 10.1006/bbrc.1999.1105; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Noda K, 1997, BRAIN RES, V751, P348, DOI 10.1016/S0006-8993(97)00077-2; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; PETERSEN M, 1993, PAIN, V54, P37, DOI 10.1016/0304-3959(93)90097-9; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Ralevic V, 2000, BRIT J PHARMACOL, V130, P1483, DOI 10.1038/sj.bjp.0703456; Ribeiro CMP, 2000, CELL CALCIUM, V27, P175, DOI 10.1054/ceca.2000.0108; Richardson JD, 1998, PAIN, V75, P111, DOI 10.1016/S0304-3959(97)00213-3; Robertson JT, 1996, SPINE, V21, P1731, DOI 10.1097/00007632-199608010-00004; Simpson PB, 1998, BRAIN RES REV, V26, P72, DOI 10.1016/S0165-0173(97)00056-8; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smart D, 2000, TRENDS PHARMACOL SCI, V21, P134, DOI 10.1016/S0165-6147(00)01459-0; Sterner O, 1999, TRENDS PHARMACOL SCI, V20, P459, DOI 10.1016/S0165-6147(99)01393-0; STEVENS CR, 1991, ANN RHEUM DIS, V50, P124, DOI 10.1136/ard.50.2.124; Subramanian K, 1997, CELL, V89, P963, DOI 10.1016/S0092-8674(00)80281-0; Szolcsanyi J, 2000, TRENDS PHARMACOL SCI, V21, P41, DOI 10.1016/S0165-6147(99)01436-4; Terasaki M, 1996, DEV BIOL, V179, P320, DOI 10.1006/dbio.1996.0263; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Vyklicky L, 1998, J NEUROPHYSIOL, V79, P670, DOI 10.1152/jn.1998.79.2.670; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Welch JM, 2000, P NATL ACAD SCI USA, V97, P13889, DOI 10.1073/pnas.230146497; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761; Zygmunt PM, 2000, TRENDS PHARMACOL SCI, V21, P43, DOI 10.1016/S0165-6147(99)01430-3	60	109	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 17	2001	276	33					31163	31170		10.1074/jbc.M101607200	http://dx.doi.org/10.1074/jbc.M101607200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	463JG	11333266	hybrid			2022-12-27	WOS:000170472900076
J	Kharel, Y; Zhang, YW; Fujihashi, M; Miki, K; Koyama, T				Kharel, Y; Zhang, YW; Fujihashi, M; Miki, K; Koyama, T			Identification of significant residues for homoallylic substrate binding of Micrococcus luteus B-P 26 undecaprenyl diphosphate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-LENGTH DETERMINATION; SITE-DIRECTED MUTAGENESIS; MOLECULAR-CLONING; BACILLUS-STEAROTHERMOPHILUS; CONSERVED ASPARTATE; CRYSTAL-STRUCTURE; PRENYLTRANSFERASE; EXPRESSION; CONVERSION; MECHANISM	The primary structure of cis-prenyltransferase is totally different from those of trans-prenyltransferases (Shimizu, N., Koyama, T., and Ogura, H. (1998) J. Biol. Chem. 272, 19476-19481). To better understand the molecular mechanism of enzymatic cis-prenyl chain elongation, we selected seven charged residues in the conserved Region V and two of Phe-Ser motif in Region III of undecaprenyl diphosphate synthase of Micrococcus luteus B-P 26 for substitutions by site-directed mutagenesis and examined their effects on substrate binding and catalysis. Kinetic studies indicated that replacements of Arg-197 or Arg-203 with Ser, and Glu-216 with Gln resulted in 7-11-fold increases of K-m values for isopentenyl diphosphate and 18-1200-fold decreases of k(cat) values compared with those of the wild-type enzyme. In addition, two mutants with respect to the Phe-Ser motif in Region III, F73A and S74A, showed 16-32-fold larger K-m values for isopentenyl diphosphate and 12-16-fold lower k(cat) values than those of the wild-type. Furthermore, product analysis indicated that three mutants, F73A, S74A, and E216Q, yielded shorter chain prenyl diphosphates as their main products. These facts together with the protein structural analysis recently carried out (Fujihashi, M., Zhang, Y.-W., Higuchi, Y., Li, X.-Y., Koyama, T., and Miki, K. (2001) Proc. Nad. Acad. Sci. U.S.A. 98, 4337-4342) indicated that the diphosphate moiety of homoallylic substrate is electrostatically recognized by the three charged amino acids, Arg-197, Arg-203, and Glu-216, in Region V and the Phe-Ser motif in Region III, also indispensable for homoallylic substrate binding as well as catalytic function. It was suggested that the undecaprenyl diphosphate synthase takes a different mode for the binding of isopentenyl diphosphate from that of trans-prenyl chain elongating enzymes.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; RIKEN, Harima Inst, SPring 8, Mikazuki, Hyogo 6795148, Japan	Tohoku University; Kyoto University; Japan Synchrotron Radiation Research Institute; RIKEN	Koyama, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.	koyama@tagen.tohoku.ac.jp						Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; BABA T, 1980, ARCH BIOCHEM BIOPHYS, V200, P474, DOI 10.1016/0003-9861(80)90379-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN AJ, 1994, PROTEIN SCI, V3, P600; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398; JOLY A, 1993, J BIOL CHEM, V268, P26983; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KOYAMA T, 1985, METHOD ENZYMOL, V110, P153; Koyama T, 1999, BIOSCI BIOTECH BIOCH, V63, P1671, DOI 10.1271/bbb.63.1671; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura K, 1998, CHEM REV, V98, P1263, DOI 10.1021/cr9600464; Ogura K, 1997, Subcell Biochem, V28, P57; Oh SK, 2000, J BIOL CHEM, V275, P18482, DOI 10.1074/jbc.M002000200; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1997, J BIOL CHEM, V272, P5192, DOI 10.1074/jbc.272.8.5192; Ohnuma S, 1998, J BIOL CHEM, V273, P26705, DOI 10.1074/jbc.273.41.26705; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; POULTER CD, 1978, ACCOUNTS CHEM RES, V11, P307, DOI 10.1021/ar50128a004; Sacchettini JC, 1997, SCIENCE, V277, P1788, DOI 10.1126/science.277.5333.1788; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato M, 1999, MOL CELL BIOL, V19, P471; Schulbach MC, 2000, J BIOL CHEM, V275, P22876, DOI 10.1074/jbc.M003194200; Shimizu N, 1998, J BIOL CHEM, V273, P19476, DOI 10.1074/jbc.273.31.19476; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; Wang K, 1999, TRENDS BIOCHEM SCI, V24, P445, DOI 10.1016/S0968-0004(99)01464-4	34	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28459	28464		10.1074/jbc.M102057200	http://dx.doi.org/10.1074/jbc.M102057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11346651	hybrid			2022-12-27	WOS:000170093400095
J	Leng, Y; Chase, TN; Bennett, MC				Leng, Y; Chase, TN; Bennett, MC			Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PHOSPHOLIPASE D2; LEWY BODIES; PROTEIN; BINDING; ACTIVATION; PRECURSOR; COMPONENT	The close correspondence between the distribution of brain alpha -synuclein and that of muscarinic M-1 and M-3 receptors suggests a role for this protein in cholinergic transmission. We thus examined the effect of muscarinic stimulation on alpha -synuclein in SH-SY5Y, a human dopaminergic cell line that expresses this protein. Under basal conditions, alpha -synuclein was detected in all subcellular compartments isolated as follows: plasma membrane, cytoplasm, nucleus, and two vesicle fractions. The lipid fractions contained only a 45-kDa alpha -synuclein oligomer, whereas the cytoplasmic and nuclear fractions contained both the oligomer and the monomer. This finding suggests alpha -synuclein exists physiologically as a lipid-bound oligomer and a soluble monomer. Muscarinic stimulation by carbachol reduced the alpha -synuclein oligomer in plasma membrane over a 30-min period, with a concomitant increase of both the oligomer and the monomer in the cytoplasmic fraction. The oligomer was associated with a light vesicle fraction in cytoplasm that contains uncoated endocytotic vesicles. The carbachol-induced alteration of alpha -synuclein was blocked by atropine. Translocation of the alpha -synuclein oligomer in response to carbachol, stimulation corresponds closely with the time course of ligand-stimulated muscarinic receptor endocytosis. The data suggest that the muscarine receptor stimulated release of the alpha -synuclein oligomer from plasma membrane, and its subsequent association with the endocytotic vesicle fraction may have a role in muscarine receptor endocytosis. We propose that its function may be a transient release of membrane-bound phospholipase D-2 from alpha -synuclein inhibition, thus allowing this lipase to participate in muscarinic receptor endocytosis.	NINDS, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Chase, TN (corresponding author), NINDS, Expt Therapeut Branch, NIH, Bldg 10,Rm 5C-103, Bethesda, MD 20892 USA.	chaset@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002265] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baba M, 1998, AM J PATHOL, V152, P879; BAUMERT HG, 1989, METHOD ENZYMOL, V172, P584; BENNETT MC, 1999, NEUROSCIENCE, V25, P48; BIEDLER JL, 1978, CANCER RES, V38, P3751; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Fleischer S, 1974, Methods Enzymol, V31, P3; HATTORI H, 1985, J NEUROCHEM, V45, P1578, DOI 10.1111/j.1471-4159.1985.tb07229.x; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Klein J, 1996, PROG BRAIN RES, V109, P201; KLEIN J, 1995, J NEUROCHEM, V65, P1445; LEE HC, 1993, P NATL ACAD SCI USA, V90, P10086, DOI 10.1073/pnas.90.21.10086; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Marshansky V, 1997, ELECTROPHORESIS, V18, P2661, DOI 10.1002/elps.1150181423; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TROWBRIDGE IS, 1993, CURR BIOL, V3, P773, DOI 10.1016/0960-9822(93)90028-M; Tsuga H, 1998, J BIOCHEM-TOKYO, V124, P863, DOI 10.1093/oxfordjournals.jbchem.a022191; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van der Goot FG, 1997, ELECTROPHORESIS, V18, P2689, DOI 10.1002/elps.1150181426; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yokogawa T, 2000, FEBS LETT, V473, P222, DOI 10.1016/S0014-5793(00)01535-0; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zhou KM, 1998, J CELL SCI, V111, P283	42	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					28212	28218		10.1074/jbc.M011121200	http://dx.doi.org/10.1074/jbc.M011121200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11337491	hybrid			2022-12-27	WOS:000170093400064
J	Martinez-Julvez, M; Nogues, I; Faro, M; Hurley, JK; Brodie, TB; Mayoral, T; Sanz-Aparicio, J; Hermoso, JA; Stankovich, MT; Medina, M; Tollin, G; Gomez-Moreno, C				Martinez-Julvez, M; Nogues, I; Faro, M; Hurley, JK; Brodie, TB; Mayoral, T; Sanz-Aparicio, J; Hermoso, JA; Stankovich, MT; Medina, M; Tollin, G; Gomez-Moreno, C			Role of a cluster of hydrophobic residues near the FAD cofactor in Anabaena PCC 7119 ferredoxin-NADP(+) reductase for optimal complex formation and electron transfer to ferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; NADP+ REDUCTASE; PCC 7119; NADH-CYTOCHROME-B5 REDUCTASE; CHEMICAL-MODIFICATION; TRANSIENT KINETICS; SPINACH FERREDOXIN; NITRATE REDUCTASE; ESCHERICHIA-COLI	In the ferredoxin-NADP(+) reductase (FNR)/ferredoxin (Fd) system, an aromatic amino acid residue on the surface of Anabaena Fd, Phe-65, has been shown to be essential for the electron transfer (ET) reaction. We have investigated further the role of hydrophobic interactions in complex stabilization and ET between these proteins by replacing three hydrophobic residues, Leu-76, Leu-78, and Val-136, situated on the FNR surface in the vicinity of its FAD cofactor. Whereas neither the ability of FNR to accept electrons from NADPH nor its structure appears to be affected by the introduced mutations, different behaviors with Fd are observed. Thus, the ET interaction with Fd is almost completely lost upon introduction of negatively charged side chains. In contrast, only subtle changes are observed upon conservative replacement. Introduction of Ser residues produces relatively sizable alterations of the FAD redox potential, which can explain the modified behavior of these mutants. The introduction of bulky aromatic side chains appears to produce rearrangements of the side chains at the FNR/Fd interaction surface. Thus, subtle changes in the hydrophobic patch influence the rates of ET to and hom Fd by altering the binding constants and the FAD redox potentials, indicating that these residues are especially important in the binding and orientation of Fd for efficient ET. These results are consistent with the structure reported for the Anabaena FNR.Fd complex.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; CSIC, Grp Cristalog Macromol & Biol Estructural, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Zaragoza; University of Arizona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); University of Minnesota System; University of Minnesota Twin Cities	Gomez-Moreno, C (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	gomezm@posta.unizar.es	Nogues, Isabel/AAA-7499-2019; Sanz-Aparicio, Julia/F-6201-2013; Martinez-Julvez, Marta M/G-5392-2012; Martinez-Julvez, Marta/G-3839-2017; Gonzalez, Isabel Nogues/K-2118-2012; Medina, Milagros/F-8310-2012; Hermoso, Juan/J-3433-2012	Sanz-Aparicio, Julia/0000-0002-6849-8621; Martinez-Julvez, Marta M/0000-0001-9047-0046; Martinez-Julvez, Marta/0000-0001-9047-0046; Gonzalez, Isabel Nogues/0000-0002-7475-2411; Medina, Milagros/0000-0001-8743-0182; Hermoso, Juan/0000-0002-1862-8950	NIDDK NIH HHS [DK15057] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015057] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM J, 1986, J BACTERIOL, V168, P1265, DOI 10.1128/jb.168.3.1265-1271.1986; ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; Aliverti A, 1998, J BIOL CHEM, V273, P34008, DOI 10.1074/jbc.273.51.34008; AOKI H, 1994, PLANT PHYSIOL, V104, P1473, DOI 10.1104/pp.104.4.1473; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BATIE CJ, 1981, J BIOL CHEM, V256, P7756; BOHME H, 1989, PLANT MOL BIOL, V12, P667, DOI 10.1007/BF00044157; BOWSHER CG, 1996, PLANT PHYSIOL, V112, P861; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Deng Z, 1999, NAT STRUCT BIOL, V6, P847; Ejdeback M, 2000, BIOCHEMISTRY-US, V39, P5022, DOI 10.1021/bi992757c; FILLAT MF, 1990, NUCLEIC ACIDS RES, V18, P7161, DOI 10.1093/nar/18.23.7161; FOUST GP, 1969, J BIOL CHEM, V244, P964; Gong XS, 2000, EUR J BIOCHEM, V267, P1732, DOI 10.1046/j.1432-1327.2000.01168.x; HAJIREZAEI M, 1997, Y14032 DDBJGENBANKEB; HALL AV, 1994, J BIOL CHEM, V269, P33082; HURLEY JK, 1993, J AM CHEM SOC, V115, P11698, DOI 10.1021/ja00078a006; Hurley JK, 1997, BIOCHEMISTRY-US, V36, P11100, DOI 10.1021/bi9709001; Hurley JK, 1999, PROTEIN SCI, V8, P1614, DOI 10.1110/ps.8.8.1614; HURLEY JK, 1993, BIOCHEMISTRY-US, V32, P9346, DOI 10.1021/bi00087a013; HURLEY JK, 1994, ARCH BIOCHEM BIOPHYS, V312, P480, DOI 10.1006/abbi.1994.1335; Hurley JK, 1996, J AM CHEM SOC, V118, P5526, DOI 10.1021/ja953662a; Hurley JK, 1996, ARCH BIOCHEM BIOPHYS, V333, P243, DOI 10.1006/abbi.1996.0387; Hurley JK, 2000, BIOCHEMISTRY-US, V39, P13695, DOI 10.1021/bi001124r; HYDE GE, 1990, BIOCHEM BIOPH RES CO, V168, P1285, DOI 10.1016/0006-291X(90)91168-R; JELESAROV I, 1994, BIOCHEMISTRY-US, V33, P13321, DOI 10.1021/bi00249a019; JELESAROV I, 1993, EUR J BIOCHEM, V216, P57, DOI 10.1111/j.1432-1033.1993.tb18116.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMADA HO, 1998, PLANT PHYSIOL, V116, P1192; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LONG DM, 1992, PHYSIOL PLANTARUM, V85, P561, DOI 10.1111/j.1399-3054.1992.tb04755.x; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P13604, DOI 10.1021/bi9807411; Martinez-Julvez M, 1999, J BIOL INORG CHEM, V4, P568, DOI 10.1007/s007750050379; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P17680, DOI 10.1021/bi981718i; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; Mayoral T, 2000, PROTEINS, V38, P60, DOI 10.1002/(SICI)1097-0134(20000101)38:1<60::AID-PROT7>3.0.CO;2-B; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Medina M, 2001, J BIOL CHEM, V276, P11902, DOI 10.1074/jbc.M009287200; MEDINA M, 1992, FEBS LETT, V298, P25, DOI 10.1016/0014-5793(92)80014-8; MEDINA M, 1992, ARCH BIOCHEM BIOPHYS, V299, P281, DOI 10.1016/0003-9861(92)90276-3; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Morales R, 1999, BIOCHEMISTRY-US, V38, P15764, DOI 10.1021/bi991578s; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PRZYSIECKI CT, 1985, J BIOL CHEM, V260, P1452; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; SIMONDSEN RP, 1982, BIOCHEMISTRY-US, V21, P6366, DOI 10.1021/bi00268a008; SIMONDSEN RP, 1983, BIOCHEMISTRY-US, V22, P3008, DOI 10.1021/bi00281a034; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; TOLLIN G, 1995, J BIOENERG BIOMEMBR, V27, P303, DOI 10.1007/BF02110100; Tsai CJ, 1997, PROTEIN SCI, V6, P1426, DOI 10.1002/pro.5560060707; VANDEKAMP M, 1990, EUR J BIOCHEM, V194, P109; VANPOUDEROYEN G, 1994, EUR J BIOCHEM, V222, P583; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; YAO Y, 1984, J BIOCHEM-TOKYO, V95, P1513, DOI 10.1093/oxfordjournals.jbchem.a134759; YUBISUI T, 1984, J BIOCHEM-TOKYO, V96, P579, DOI 10.1093/oxfordjournals.jbchem.a134871; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035	70	36	38	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27498	27510		10.1074/jbc.M102112200	http://dx.doi.org/10.1074/jbc.M102112200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11342548	hybrid			2022-12-27	WOS:000169966900101
J	Ni, YS; McPhie, P; Deacon, A; Ealick, S; Coleman, WG				Ni, YS; McPhie, P; Deacon, A; Ealick, S; Coleman, WG			Evidence that NADP(+) is the physiological cofactor of ADP-L-glycero-D-mannoheptose 6-epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; DEPENDENT GLUTAMATE-DEHYDROGENASE; AMINO-ACID-SEQUENCE; COENZYME SPECIFICITY; NUCLEOTIDE-SEQUENCE; RFAD GENE; BINDING; PURIFICATION; PROTEINS	ADP-L-glycero-D-mannoheptose 6-epimerase is required for lipopolysaccharide inner core biosynthesis in several genera of Gram-negative bacteria. The enzyme contains both fingerprint sequences Gly-X-Gly-X-X-Gly and Gly-X-X-Gly-X-X-Gly near its N terminus, which is indicative of an ADP binding fold. Previous studies of this ADP-L-glycero-D-mannoheptose 6-epimerase (ADP-hep 6-epimerase) were consistent with an NAD(+) cofactor. However, the crystal structure of this ADP-hep 6-epimerase showed bound NADP (Deacon, A. M., Ni, Y. S., Coleman, W. G., Jr., and Ealick, S. E. (2000) Structure 5, 453-462). In present studies, apo-ADP-hep 6-epimerase was reconstituted with NAD(+), NADP(+), and FAD. In this report we provide data that shows NAD(+) and NADP(+) both restored enzymatic activity, but FAD could not. Furthermore, ADP-hep 6-epimerase exhibited a preference for binding of NADP(+) over NAD(+). The K-d value for NADP(+) was 26 muM whereas that for NAD(+) was 45 muM. Ultraviolet circular dichroism spectra showed that apo-ADP-hep 6-epimerase reconstituted with NADP(+) had more secondary structure than apo-ADP-hep 6-epimerase reconstituted with NAD(+). Perchloric acid extracts of the purified enzyme were assayed with NAD(+)-specific alcohol dehydrogenase and NADP(+)- specific isocitric dehydrogenase. A sample of the same perchloric acid extract was analyzed in chromatographic studies, which demonstrated that ADP-hep 6-epimerase binds NADP(+) in vivo. A structural comparison of ADP-hep 6-epimerase with UDP-galactose 4-epimerase, which utilizes an NAD(+) cofactor, has identified the regions of ADP-hep 6-epimerase, which defines its specificity for NADP(+).	NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; Stanford Univ, Stanford Linear Accelerator Ctr, Stanford, CA 94309 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Cornell University	Coleman, WG (corresponding author), NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK023330, Z01DK024942, ZIADK023330] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS GA, 1967, CAN J MICROBIOL, V13, P1605, DOI 10.1139/m67-210; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAUER AJ, 1992, PROTEIN-STRUCT FUNCT, V9, P135; Bellamacina CR, 1996, FASEB J, V10, P1257, DOI 10.1096/fasebj.10.11.8836039; COLEMAN WG, 1992, PSEUDOMONAS : MOLECULAR BIOLOGY AND BIOTECHNOLOGY, P161; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; Daussmann T, 1997, EUR J BIOCHEM, V248, P889, DOI 10.1111/j.1432-1033.1997.00889.x; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; DING L, 1994, J BIOL CHEM, V269, P24384; Ding L, 1999, ACTA CRYSTALLOGR D, V55, P685, DOI 10.1107/S0907444998014723; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LILLEY KS, 1991, BIOCHIM BIOPHYS ACTA, V1080, P191, DOI 10.1016/0167-4838(91)90001-G; MCPHERSON MJ, 1983, NUCLEIC ACIDS RES, V11, P5257, DOI 10.1093/nar/11.15.5257; MOYE WS, 1985, J BIOL CHEM, V260, P8502; PEGUES JC, 1990, J BACTERIOL, V172, P4652, DOI 10.1128/jb.172.8.4652-4660.1990; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	21	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27329	27334		10.1074/jbc.M102258200	http://dx.doi.org/10.1074/jbc.M102258200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11313358	hybrid			2022-12-27	WOS:000169966900080
J	Fairchild, TA; Fulton, D; Fontana, JT; Gratton, JP; McCabe, TJ; Sessa, WC				Fairchild, TA; Fulton, D; Fontana, JT; Gratton, JP; McCabe, TJ; Sessa, WC			Acidic hydrolysis as a mechanism for the cleavage of the Glu(298) -> Asp variant of human endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY DISEASE; MYOCARDIAL-INFARCTION; GENE POLYMORPHISM; PEPTIDE-BONDS; PALMITOYLATION; HYPERTENSION; ASSOCIATION; APOPTOSIS; SEVERITY; MUTATION	The 894G -->T polymorphism within exon 7 of the human endothelial nitric-oxide synthase (eNOS) gene codes for glutamate or aspartate, respectively, at residue 298 and has been associated with several diseases of cardiovascular origin. A recent report indicates that Asp(298)-eNOS (E298D) is cleaved intracellularly to 100- and 35-kDa fragments, suggesting a mechanism for reduced endothelial function. Here we have documented the precise cleavage site of the E298D variant as a unique aspartyl-prolyl (Asp(298)-Pro(299)) bond not seen in wild-type eNOS (Glu(298)). W, show that E298D-eNOS, as isolated from cells and in vitro, is susceptible to acidic hydrolysis, and the 100-kDa fragment can be generated ex vivo by increasing temperature at low pH, Importantly, cleavage of E298D was eliminated using a sample buffer system designed to limit acidic hydrolysis of Asp-Pro bonds. These results argue against intracellular processing of E298D-eNOS and suggest that previously described fragmentation of E298D could be a product of sample preparation. We also found that eNOS turnover, NO production, and the susceptibility to cellular stress were not different in cells expressing WT versus E298D-eNOS, Finally, enzyme activities were identical for the respective recombinant enzymes. Thus, intracellular cleavage mechanisms are unlikely to account for associations between the exon 7 polymorphism and cardiovascular diseases.	Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, New Haven, CT 06536 USA	Yale University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06536 USA.		Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Gratton, Jean-Philippe/0000-0001-9877-8520	NHLBI NIH HHS [R01 HL61371, R01 HL64793, T32HL10183, R01 HL57665] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R01HL061371, F32HL010183, R01HL064793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banasiak KJ, 1998, BRAIN RES, V797, P295, DOI 10.1016/S0006-8993(98)00286-8; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Cai H, 1999, J MOL MED, V77, P511, DOI 10.1007/s001099900020; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Hibi K, 1998, HYPERTENSION, V32, P521, DOI 10.1161/01.HYP.32.3.521; Hingorani AD, 1999, CIRCULATION, V100, P1515, DOI 10.1161/01.CIR.100.14.1515; Kato N, 1999, HYPERTENSION, V33, P933, DOI 10.1161/01.HYP.33.4.933; Lacolley P, 1998, J HYPERTENS, V16, P31, DOI 10.1097/00004872-199816010-00006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; MacLeod MJ, 1999, NEUROLOGY, V53, P418, DOI 10.1212/WNL.53.2.418; MARSDEN PA, 1993, J BIOL CHEM, V268, P14778; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Miyamoto Y, 1998, HYPERTENSION, V32, P3, DOI 10.1161/01.HYP.32.1.3; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nakayama M, 2000, AM J CARDIOL, V86, P628, DOI 10.1016/S0002-9149(00)01041-9; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Rudic RD, 1999, AM J HUM GENET, V64, P673, DOI 10.1086/302304; Tesauro M, 2000, P NATL ACAD SCI USA, V97, P2832, DOI 10.1073/pnas.97.6.2832; Wang XL, 2000, MOL GENET METAB, V70, P241, DOI 10.1006/mgme.2000.3033; Zanchi A, 2000, KIDNEY INT, V57, P405, DOI 10.1046/j.1523-1755.2000.00860.x	28	149	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26674	26679		10.1074/jbc.M103647200	http://dx.doi.org/10.1074/jbc.M103647200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11331296	hybrid			2022-12-27	WOS:000169823300133
J	Heaslet, HA; Royer, WE				Heaslet, HA; Royer, WE			Crystalline ligand transitions in Lamprey hemoglobin - Structural evidence for the regulation of oxygen affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PETROMYZON-MARINUS; CO; EQUILIBRIUM; MOLSCRIPT; BINDING; MODEL	The hemoglobins of the Sea Lamprey (Petromyzon marinus) exist in an equilibrium between low affinity oligomers, stabilized by proton binding, and higher affinity monomers, stabilized by oxygen binding, Recent crystallographic analysis revealed that dimerization is coupled with key changes at the ligand binding site with the distal histidine sterically restricting ligand binding in the deoxy dimer but with no significant structural rearrangements on the proximal side. These structural insights led to the hypothesis that oxygen affinity of lamprey hemoglobin is distally regulated. Here we present the 2.9-Angstrom crystal structure of deoxygenated lamprey hemoglobin in an orthorhombic crystal form along with the structure of these crystals exposed to carbon monoxide. The hexameric assemblage in this crystal form is very similar to those observed in the previous deoxy structure. Whereas the hydrogen bonding network and packing contacts formed in the dimeric interface of lamprey hemoglobin are largely unaffected by ligand binding, the binding of carbon monoxide induces the distal histidine to swing to positions that would preclude the formation of a stabilizing hydrogen bond with the bound ligand, These results suggest a dual role for the distal histidine and strongly support the hypothesis that ligand affinity in lamprey hemoglobin is distally regulated.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA; Clark Univ, Dept Chem, Worcester, MA 01610 USA	University of Massachusetts System; University of Massachusetts Worcester; Clark University	Royer, WE (corresponding author), BASF Biores Corp, 100 Res Dr, Worcester, MA 01604 USA.	William.Royer@umassmed.edu		Soutter, Holly/0000-0001-9448-4904	NIDDK NIH HHS [DK43323] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DOHI Y, 1973, J BIOL CHEM, V248, P2354; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Heaslet HA, 1999, STRUCT FOLD DES, V7, P517, DOI 10.1016/S0969-2126(99)80068-9; HENDRICK.WA, 1968, J MOL BIOL, V33, P829, DOI 10.1016/0022-2836(68)90322-7; HONZATKO RB, 1985, J MOL BIOL, V184, P147, DOI 10.1016/0022-2836(85)90049-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kachalova GS, 1999, SCIENCE, V284, P473, DOI 10.1126/science.284.5413.473; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pardanani A, 1997, J BIOL CHEM, V272, P13171, DOI 10.1074/jbc.272.20.13171; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Qiu Y, 2000, J BIOL CHEM, V275, P13517, DOI 10.1074/jbc.275.18.13517; RIGGS A, 1972, BIOL LAMPREYS, V2, P261; ROMO TD, 1995, PROTEINS, V22, P311, DOI 10.1002/prot.340220403; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6; WALD G, 1951, J GEN PHYSIOL, V35, P45, DOI 10.1085/jgp.35.1.45; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	31	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26230	26236		10.1074/jbc.M101391200	http://dx.doi.org/10.1074/jbc.M101391200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11340069	hybrid			2022-12-27	WOS:000169823300079
J	Nakatsuka, S; Hayashi, M; Muroyama, A; Otsuka, M; Kozaki, S; Yamada, H; Moriyama, Y				Nakatsuka, S; Hayashi, M; Muroyama, A; Otsuka, M; Kozaki, S; Yamada, H; Moriyama, Y			D-aspartate is stored in secretory granules and released through a Ca2+-dependent pathway in a subset of rat pheochromocytoma PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-SERINE; GLUTAMATE TRANSPORTER; NICOTINIC RECEPTORS; MELATONIN SYNTHESIS; ALPHA-LATROTOXIN; BRAIN; ACID; MICROVESICLES; LOCALIZATION; EXOCYTOSIS	D-Aspartate in mammalian neuronal and neuroendocrine cells is suggested to play a regulatory role(s) in the neuroendocrine function. Although D-aspartate is known to be released from neuroendocrine cells, the mechanism underlying the release is less understood. Rat pheochromocytoma PC12 cells contain an appreciable amount of D-aspartate (257 +/- 31 pmol/10(7) cells). Indirect immunofluorescence microscopy with specific antibodies against D-aspartate indicated that the amino acid is present within a particulate structure, which is co-localized with dopamine and chromogranin A, markers for secretory granules, but not with synaptophysin, a marker for synaptic-like microvesicles. After sucrose density gradient centrifugation of the postnuclear particulate fraction, about 80% of the D-aspartate was recovered in the secretory granule fraction. Upon the addition of KCI, an appreciable amount of D-aspartate (about 40 pmol/10(7) cells at 10 min) was released from cultured cells on incubation in the presence of Ca2+ in the medium. The addition of A23187 also triggered D-aspartate release. Botulinum neurotoxin type E inhibited about 40% of KCl- and Ca2+-dependent D-aspartate release followed by specific cleavage of 25-kDa synaptosomal-associated protein. alpha -latrotoxin increased the intracellular [Ca2+] and caused the Ca2+-dependent D-aspartate release. Bafilomycin Al dissipated the intracellular acidic regions and inhibited 40% of the Ca2+-dependent D-aspartate release. These properties are similar to those of the exocytosis of dopamine. Furthermore, digitonin-permeabilized cells took up radiolabeled D-aspartate depending on MgATP, which is sensitive to bafilomycin Al or 3,5-di-tert-butyl-4-hydroxybenzylidene-malononitrile. Taken together, these results strongly suggest that D-aspartate is stored in secretory granules and then secreted through a Ca2+-dependent exocytotic mechanism. Exocytosis of D-aspartate further supports the role(s) of D-aspartate as a chemical transmitter in neuroendocrine cells.	Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, Okayama 7008530, Japan; Osaka Prefecture Univ, Coll Agr, Dept Vet Sci, Osaka, Japan	Okayama University; Osaka Metropolitan University	Moriyama, Y (corresponding author), Okayama Univ, Fac Pharmaceut Sci, Dept Biochem, 3-1-1 Tsushima Naka, Okayama 7008530, Japan.	moriyama@pheasant.pharm.okayama-u.ac.jp	Yamada, Hiroshi/AGZ-4497-2022; YAMADA, Hiroshi/B-2251-2011	Yamada, Hiroshi/0000-0002-9328-3446; YAMADA, Hiroshi/0000-0002-9328-3446				Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; COUSIN MA, 1995, J NEUROCHEM, V64, P2097; D'Aniello A, 2000, FASEB J, V14, P699, DOI 10.1096/fasebj.14.5.699; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FELICE LJ, 1978, J NEUROCHEM, V31, P1461, DOI 10.1111/j.1471-4159.1978.tb06573.x; Hashimoto A, 1997, PROG NEUROBIOL, V52, P325, DOI 10.1016/S0301-0082(97)00019-1; HASHIMOTO A, 1992, J CHROMATOGR-BIOMED, V582, P41, DOI 10.1016/0378-4347(92)80300-F; HASHIMOTO A, 1993, J NEUROCHEM, V60, P783, DOI 10.1111/j.1471-4159.1993.tb03219.x; Hayashi T, 1998, J NEUROCHEM, V71, P356; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; IMAI K, 1995, BIOMED CHROMATOGR, V9, P106, DOI 10.1002/bmc.1130090211; Ishio S, 1998, NEUROSCI LETT, V249, P143, DOI 10.1016/S0304-3940(98)00414-5; KAMATA Y, 1993, BIOCHIM BIOPHYS ACTA, V1156, P213, DOI 10.1016/0304-4165(93)90138-X; Kera Y, 1996, COMP BIOCHEM PHYS B, V115, P121, DOI 10.1016/0305-0491(96)00089-2; Lee IS, 1999, BIOCHEM PHARMACOL, V58, P1017, DOI 10.1016/S0006-2952(99)00181-1; Lee JA, 1997, BIOCHEM BIOPH RES CO, V231, P505, DOI 10.1006/bbrc.1996.5902; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; Moriyama Y, 1998, NEUROSCI LETT, V248, P57, DOI 10.1016/S0304-3940(98)00308-5; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; MORIYAMA Y, 1995, J BIOL CHEM, V270, P22314, DOI 10.1074/jbc.270.38.22314; NAGATA Y, 1992, BIOCHIM BIOPHYS ACTA, V1115, P208, DOI 10.1016/0304-4165(92)90055-Y; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; NICHOLLS DG, 1989, J NEUROCHEM, V52, P331, DOI 10.1111/j.1471-4159.1989.tb09126.x; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHELL MJ, 1995, P NATL ACAD SCI USA, V92, P3948, DOI 10.1073/pnas.92.9.3948; Schell MJ, 1997, J NEUROSCI, V17, P1604; Schell MJ, 1997, P NATL ACAD SCI USA, V94, P2013, DOI 10.1073/pnas.94.5.2013; Schindelholz B, 2000, EUR J NEUROSCI, V12, P194, DOI 10.1046/j.1460-9568.2000.00913.x; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Taylor SC, 2000, J BIOL CHEM, V275, P26786; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; Washbourne P, 1999, J NEUROCHEM, V73, P2424, DOI 10.1046/j.1471-4159.1999.0732424.x; Wolosker H, 2000, NEUROSCIENCE, V100, P183, DOI 10.1016/S0306-4522(00)00321-3; Yamada H, 1996, J PINEAL RES, V21, P175, DOI 10.1111/j.1600-079X.1996.tb00285.x; Yamada H, 1997, J NEUROCHEM, V69, P1491; Yamada H, 1998, J NEUROSCI, V18, P4946; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	44	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26589	26596		10.1074/jbc.M011754200	http://dx.doi.org/10.1074/jbc.M011754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11333256	hybrid			2022-12-27	WOS:000169823300123
J	Gineitis, D; Treisman, R				Gineitis, D; Treisman, R			Differential usage of signal transduction pathways defines two types of serum response factor target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE KINASE; C-FOS PROMOTER; TERNARY COMPLEX FACTORS; ALPHA-ACTIN PROMOTER; GROWTH-FACTOR; RHO-PROTEINS; LYSOPHOSPHATIDIC ACID; TRANSCRIPTIONAL ACTIVATION; MYOGENIC DIFFERENTIATION; 3T3 CELLS	Activation of the transcription factor serum response factor (SRF) is dependent on Rho-controled changes in actin dynamics. We used pathway-specific inhibitors to compare the roles of actin dynamics, extracellular signal-regulated kinase (ERK) signaling, and phosphatidylinositol I-kinase in signaling either to SRF itself or to four cellular SRF target genes. Serum, lysophosphatidic acid, platelet-derived growth factor, and phorbol 12-myristate 13-acetate (PMA) each activated transcription of a stably integrated SRF reporter gene dependent on functional RhoA GTPase, Inhibition of mitogen-activated protein kinase-ERK kinase (MEK) signalling reduced activation of the SRF reporter by all stimuli by about 50%, except for PMA, which was effectively blocked. inhibition of phosphatidylinositol 3-kinase slightly reduced reporter activation by serum and lysophosphatidic acid but substantially inhibited activation by platelet-derived growth factor and PMA. Reporter induction by all stimuli was absolutely dependent on actin dynamics. Regulation of the SRF (srf) and vinculin (ucl) genes was similar to that of the SRF reporter gene; activation by all stimuli was Rho-dependent and required actin dynamics but was largely independent of MEK activity. In contrast, activation of fos and egr1 occurred independently of RhoA and actin polymerization but was almost completely dependent on MEK activation. These results show that at least two classes of SRF target genes can be distinguished on the basis of their relative sensitivity to RhoA-actin and MEK-ERK signaling pathways.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields,Rm 401, London WC2A 3PX, England.			Treisman, Richard/0000-0002-9658-0067				Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Barth H, 1998, INFECT IMMUN, V66, P1364, DOI 10.1128/IAI.66.4.1364-1369.1998; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Beltman J, 1999, J BIOL CHEM, V274, P3772, DOI 10.1074/jbc.274.6.3772; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hahn A, 2000, J BIOL CHEM, V275, P37429, DOI 10.1074/jbc.M000976200; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAN L, 1987, P NATL ACAD SCI USA, V84, P1182; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Reiser COA, 1998, BIOCHEM J, V330, P1107; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Spencer JA, 1999, MOL CELL BIOL, V19, P3977; Spencer JA, 1999, ONCOGENE, V18, P7319, DOI 10.1038/sj.onc.1203121; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang Y, 2000, ONCOGENE, V19, P1379, DOI 10.1038/sj.onc.1203443; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Wei L, 2000, AM J PHYSIOL-HEART C, V278, pH1736, DOI 10.1152/ajpheart.2000.278.6.H1736; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	60	173	177	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24531	24539		10.1074/jbc.M102678200	http://dx.doi.org/10.1074/jbc.M102678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11342553	hybrid			2022-12-27	WOS:000169800700017
J	Gusarova, V; Caplan, AJ; Brodsky, JL; Fisher, EA				Gusarova, V; Caplan, AJ; Brodsky, JL; Fisher, EA			Apoprotein B degradation is promoted by the molecular chaperones hsp90 and hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; RABBIT RETICULOCYTE LYSATE; LOW-DENSITY LIPOPROTEINS; AMINO-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; APOLIPOPROTEIN-B; IN-VITRO; INTRACELLULAR DEGRADATION; STEROID-RECEPTOR	Apoprotein B (apoB) is the major protein of liver-derived atherogenic lipoproteins, The net production of apoB can be regulated by presecretory degradation mediated by the ubiquitin-proteasome pathway and cytosolic hsp70. To further explore the mechanisms of apoB degradation, we have established a cell-free system in which degradation can be faithfully recapitulated. Human apoB48 synthesized in vitro was translocated into microsomes, glycosylated, and ubiquitinylated, Subsequent incubation with rat hepatic cytosol led to proteasome-mediated degradation. To explore whether hsp90 is required for apoB degradation, geldanamycin (GA) was added during the degradation assay. GA increased the recovery of microsomal apoB48 similar to3-fold and disrupted the interaction between hsp90 and apoB48, Confirming the hsp90 effect in the cell-free system, we also found that transfection of hsp90 cDNA into rat hepatoma cells enhanced apoB48 degradation. Finally, apoB48 degradation was reconstituted in vitro using cytosol prepared from wild type yeast. Notably, degradation was attenuated when apoB48-containing microsomes were incubated with cytosol supplemented with GA or with cytosol prepared from yeast strains with mutations in the homologues of mammalian hsp70 and hsp90. Overall, our data suggest that hsp90 facilitates the interaction between endoplasmic reticulum-associated apoB and components of the proteasomal pathway, perhaps in cooperation with hsp70.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem Mol Biol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Fisher, EA (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1269,1 Gustave Levy Pl, New York, NY 10029 USA.		Caplan, Avrom/GPT-0824-2022	Fisher, Edward/0000-0001-9802-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58541] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; Becker J, 1996, MOL CELL BIOL, V16, P4378; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chavany C, 1996, J BIOL CHEM, V271, P4974; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fliss AE, 2000, J STEROID BIOCHEM, V72, P223, DOI 10.1016/S0960-0760(00)00037-6; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fuller W, 2000, J BIOL CHEM, V275, P37462, DOI 10.1074/jbc.M006278200; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Goasduff T, 2000, ARCH BIOCHEM BIOPHYS, V379, P321, DOI 10.1006/abbi.2000.1870; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Nganga A, 2000, BIOCHEM J, V352, P865, DOI 10.1042/0264-6021:3520865; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Rusinol AE, 1997, J BIOL CHEM, V272, P8019, DOI 10.1074/jbc.272.12.8019; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Sakata N, 1999, BBA-MOL CELL BIOL L, V1437, P71, DOI 10.1016/S1388-1981(98)00006-7; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Shaeffer JR, 1996, BIOCHEMISTRY-US, V35, P10886, DOI 10.1021/bi9530705; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Thulasiraman V, 1996, BIOCHEMISTRY-US, V35, P13443, DOI 10.1021/bi9615396; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; WAGNER BJ, 1995, ARCH BIOCHEM BIOPHYS, V323, P455, DOI 10.1006/abbi.1995.0067; WANG H, 1997, CIRCULATION, V96, P1543; WHITE AL, 1992, J BIOL CHEM, V267, P15657; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wilson CM, 2000, J BIOL CHEM, V275, P21224, DOI 10.1074/jbc.M000567200; Wu XJ, 1997, J BIOL CHEM, V272, P11575; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	60	108	110	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24891	24900		10.1074/jbc.M100633200	http://dx.doi.org/10.1074/jbc.M100633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11333259	hybrid			2022-12-27	WOS:000169800700062
J	Kim, JH; Lewin, TM; Coleman, RA				Kim, JH; Lewin, TM; Coleman, RA			Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5 - Selective inhibition by triacsin C and thiazolidinediones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; FATTY-ACID; TRIACYLGLYCEROL SYNTHESIS; INSULIN-SENSITIVITY; LIVER; TROGLITAZONE; ENZYMES; ESTERS; CELLS; PPAR	Inhibition by triacsins and troglitazone of long chain fatty acid incorporation into cellular lipids suggests the existence of inhibitor-sensitive and -resistant acyl-CoA synthetases (ACS, EC 6.2.1.3) that are linked to specific metabolic pathways. In order to test this hypothesis, we cloned and purified rat ACS1, ACS4, and ACS5, the isoforms present in liver and fat cells, expressed the isoforms as ACS-Flag fusion proteins in Escherichia coli, and purified them by Flag affinity chromatography, The Flag epitope at the C terminus did not alter the kinetic properties of the enzyme. Purified ACS1-, 4-, and 8-Flag isoforms differed in their apparent K-m values for ATP, thermolability, pH optima, requirement for Triton X-100, and sensitivity to N-ethylmaleimide and phenylglyoxal, The ACS inhibitor triacsin C strongly inhibited ACS1 and ACS4, but not ACS5, The thiazolidinedione (TZD) insulin-sensitizing drugs and peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands, troglitazone, rosiglitazone, and pioglitazone, strongly and specifically inhibited only ACS(4), with an IC50 of less than 1.5 muM. Troglitazone exhibited a mixed type inhibition of ACS4. alpha -Tocopherol, whose ring structure forms the non-TZD portion of troglitazone, did not inhibit ACS4, indicating that the thiazolidine-2,4-dione moiety is the critical component for inhibition. A non-TZD PPAR gamma ligand, GW1929, which is 7-fold more potent than rosiglitazone, inhibited ACS1 and ACS4 poorly with an IC50 of greater than 50 muM, more than 100-fold higher than was required for rosiglitazone, thereby demonstrating the specificity of TZD inhibition. Further, the PPAR alpha ligands, clofibrate and GW4647, and various xenobiotic carboxylic acids known to be incorporated into complex lipids had no effect on ACS1, -4, or -5, These results, together with previous data showing that triacsin C and troglitazone strongly inhibit triacylglycerol synthesis compared with other metabolic pathways, suggest that ACS1 and ACS4 catalyze the synthesis of acyl-Coks used for triacylglycerol synthesis and that lack of inhibition of a metabolic pathway by triacsin C does not prove lack of acyl-CoA involvement. The results further suggest the possibility that the insulin-sensitizing effects of the thiazolidinedione drugs might be achieved, in part, through direct interaction with ACS4 in a PPAR gamma -independent manner.	Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Coleman, RA (corresponding author), Univ N Carolina, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056598] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08431] Funding Source: Medline; NIDDK NIH HHS [DK56598] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AAS M, 1971, BIOCHIM BIOPHYS ACTA, V239, P208, DOI 10.1016/0005-2760(71)90166-4; BANIS RJ, 1976, ANAL BIOCHEM, V73, P1, DOI 10.1016/0003-2697(76)90135-4; BERGE RK, 1987, ARCH BIOCHEM BIOPHYS, V252, P269, DOI 10.1016/0003-9861(87)90031-2; Brown KK, 1999, DIABETES, V48, P1415, DOI 10.2337/diabetes.48.7.1415; Burant CF, 1997, J CLIN INVEST, V100, P2900, DOI 10.1172/JCI119839; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Cho YY, 2000, BIOCHEM BIOPH RES CO, V274, P741, DOI 10.1006/bbrc.2000.3207; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; CUNNANE SC, 1988, LIPIDS, V23, P372, DOI 10.1007/BF02537353; DODDS PF, 1995, PROG LIPID RES, V34, P219, DOI 10.1016/0163-7827(95)00007-M; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fujino T, 1996, J BIOL CHEM, V271, P16748, DOI 10.1074/jbc.271.28.16748; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; Fukui Y, 2000, DIABETES, V49, P759, DOI 10.2337/diabetes.49.5.759; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Igal RA, 1997, BIOCHEM J, V324, P529, DOI 10.1042/bj3240529; Kang MJ, 1997, P NATL ACAD SCI USA, V94, P2880, DOI 10.1073/pnas.94.7.2880; KORNBERG A, 1953, J BIOL CHEM, V204, P329; LAWSON N, 1981, BIOCHEM J, V200, P285, DOI 10.1042/bj2000285; LEE MK, 1995, METABOLISM, V44, P1166, DOI 10.1016/0026-0495(95)90010-1; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; LIPPEL K, 1972, BIOCHIM BIOPHYS ACTA, V280, P531, DOI 10.1016/0005-2760(72)90132-4; LIPPEL K, 1971, BIOCHIM BIOPHYS ACTA, V239, P384, DOI 10.1016/0005-2760(71)90031-2; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Muoio DM, 2000, AM J PHYSIOL-ENDOC M, V279, pE1366, DOI 10.1152/ajpendo.2000.279.6.E1366; Oikawa E, 1998, J BIOCHEM, V124, P679, DOI 10.1093/oxfordjournals.jbchem.a022165; POLOKOFF MA, 1977, J BIOL CHEM, V252, P1161; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoonjans K, 1996, J LIPID RES, V37, P907; Segel IH, 1975, ENZYME KINETICS BEHA; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; Wang ZW, 1999, BIOCHEM BIOPH RES CO, V260, P653, DOI 10.1006/bbrc.1999.0918; Wu XJ, 1996, J LIPID RES, V37, P1198	40	171	178	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24667	24673		10.1074/jbc.M010793200	http://dx.doi.org/10.1074/jbc.M010793200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11319222	hybrid			2022-12-27	WOS:000169800700035
J	Sola, M; Kneussel, M; Heck, IS; Betz, H; Weissenhorn, W				Sola, M; Kneussel, M; Heck, IS; Betz, H; Weissenhorn, W			X-ray crystal structure of the trimeric N-terminal domain of gephyrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; RECEPTOR-BETA-SUBUNIT; GLYCINE RECEPTOR; ESCHERICHIA-COLI; PROTEIN GEPHYRIN; MOLYBDOPTERIN BIOSYNTHESIS; STRUCTURE REFINEMENT; SPLICE VARIANTS; SPINAL-CORD; IDENTIFICATION	Gephyrin is a ubiquitously expressed protein that, in the central nervous system, forms a submembraneous scaffold for anchoring inhibitory neurotransmitter receptors in the postsynaptic membrane. The N- and C-terminal domains of gephyrin are homologous to the Escherichia coli enzymes MogA and MoeA, respectively, both of which are involved in molybdenum cofactor biosynthesis. This enzymatic pathway is highly conserved from bacteria to mammals, as underlined by the ability of gephyrin to rescue molybdenum cofactor deficiencies in different organisms. Here we report the x-ray crystal structure of the N-terminal domain (amino acids 2-188) of rat gephyrin at 1.9-Angstrom resolution. Gephyrin-(2-188) forms trimers in solution, and a sequence motif thought to be involved in molybdopterin binding is highly conserved between gephyrin and the E, coli protein. The atomic structure of gephyrin-(2-188) resembles MogA, albeit with two major differences. The path of the C-terminal ends of gephyrin-(2-188) indicates that the central and C-terminal domains, absent in this structure, should follow a similar 3-fold arrangement as the N-terminal region. In addition, a central beta -hairpin loop found in MogA is lacking in gephyrin-(2-188). Despite these differences, both structures show a high degree of surface charge conservation, which is consistent with their common catalytic function.	European Mol Biol Lab, F-38042 Grenoble 9, France; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany; Univ Tubingen, Inst Plant Biochem, D-72076 Tubingen, Germany	European Molecular Biology Laboratory (EMBL); Max Planck Society; Eberhard Karls University of Tubingen	Weissenhorn, W (corresponding author), European Mol Biol Lab, 6 Rue Jules Horowitz, F-38042 Grenoble 9, France.			Kneussel, Matthias/0000-0003-4900-366X; Sola, Maria/0000-0002-0838-9706				ALTSCHULER RA, 1986, BRAIN RES, V369, P316, DOI 10.1016/0006-8993(86)90542-1; BROWN GK, 1989, NEUROLOGY, V39, P252; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CPP4, 1994, ACTA CRYSTALLOGR D, V50, P760; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; GRAHAM D, 1985, BIOCHEMISTRY-US, V24, P990, DOI 10.1021/bi00325a027; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; Kamdar KP, 1997, BIOCHEM SOC T, V25, P778, DOI 10.1042/bst0250778; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; LANGOSCH D, 1992, FEBS LETT, V298, P113, DOI 10.1016/0014-5793(92)80034-E; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; STALLMEYER B, 1995, PLANT J, V8, P751, DOI 10.1046/j.1365-313X.1995.08050751.x; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	45	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25294	25301		10.1074/jbc.M101923200	http://dx.doi.org/10.1074/jbc.M101923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11325967	hybrid			2022-12-27	WOS:000169800700115
J	Stam, JC; Geerts, WJC; Versteeg, HH; Verkleij, AJ; van Bergen, PMP				Stam, JC; Geerts, WJC; Versteeg, HH; Verkleij, AJ; van Bergen, PMP			The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FAMILY ADAPTER PROTEINS; FOCAL ADHESION KINASE; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; BREAST-CANCER; PC12 CELLS; APOPTOSIS; TRANSFORMATION	The v-Crk oncogene encodes an adaptor protein containing an SH2 domain and an SH3 domain. v-Crk-transformed fibroblast cells display enhanced tyrosine phosphorylation levels, and the v-Crk protein localizes in focal adhesions, suggesting that transformation may be due to enhanced focal complex signaling. Here we investigated the mechanism of transformation and found that v-Crk-transformed NIH 3T3 cells display growth rates and serum requirements similar to control cells. However, v-Crk enhanced survival in conditions of serum starvation, Both an intact SH2 and SH3 domain are required; moreover, SH2 mutants displayed dominant interfering properties, enhancing cell death. Using other cell death-inducing stimuli, it appeared that v-Crk in general inhibits apoptosis and enhances cell survival. In search of the signaling pathways involved, we found that v-Crk-transformed cells show constitutively higher levels of phospho-protein kinase B (PKB)/Akt and PKB/ Akt activity, especially in conditions of serum starvation, These data strongly suggest involvement of the phosphatidylinositol 5-kinase/PKB survival pathway in the v-Crk-induced protection against apoptosis, In accordance, inhibition of this pathway by wortmannin or LY924002 reduced protection against starvation-induced apoptosis. In addition to the phosphatidylinositol 5-kinase/PKB pathway, a MEK-dependent pathway and an unknown additional pathway are also implicated in resistance against apoptosis, Activation of survival pathways may be the most important function of v-Crk in its oncogenic properties.	Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands	Utrecht University	van Bergen, PMP (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Versteeg, Henri/G-1783-2018; Geerts, Willie J.C./B-7640-2011; van Bergen en Henegouwen, Paul/B-8870-2011	Versteeg, Henri/0000-0003-4294-175X; Geerts, Willie J.C./0000-0002-4530-7458; van Bergen en Henegouwen, Paul/0000-0001-6050-9042				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Glassman RH, 1997, CELL DEATH DIFFER, V4, P82, DOI 10.1038/sj.cdd.4400203; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nievers MG, 1997, J CELL SCI, V110, P389; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; TENHOEVE J, 1993, ONCOGENE, V8, P2469; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	42	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25176	25183		10.1074/jbc.M009825200	http://dx.doi.org/10.1074/jbc.M009825200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11323409	hybrid			2022-12-27	WOS:000169800700100
J	Barbero, P; Buell, E; Zulley, S; Pfeffer, SR				Barbero, P; Buell, E; Zulley, S; Pfeffer, SR			TIP47 is not a component of lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; CYTOPLASMIC DOMAIN; ENDOSOMES; TRAFFICKING; TAIL	TIP47 functions in the delivery of mannose 6-phosphate receptors from endosomes to the trans-Golgi network both in vitro and in, vivo, It binds directly and very specifically to the cytoplasmic domains of both the cation-independent and cation-dependent mannose 6-phosphate receptors, TIP47 is 43% identical to a Lipid droplet-associated protein named adipophilin; much of the identity resides near the N termini of these proteins. It was recently reported in this journal, in a study using antiserum from this laboratory, that TIP47 is a constituent of lipid droplets (Wolins, N, E,, Rubin, B,, and Brasaemle, D. L, (2001) J, BioL Chem, 278, 5101-5108). We show here that the findings of Wolins et al. were likely due to either a cross-reactive, unidentified protein in HeLa cells that is recognized by our antiserum and/or the fact that our serum also cross-reacts with the adipophilin protein itself, shown directly by expression of adipophilin in Escherichia coli, Using antibodies specific for residues 152-434 of TIP47, me show that TIP47 is not st constituent of lipid droplets.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 95307 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Sch Med, Dept Biochem, 279 Campus Dr, Stanford, CA 95307 USA.	pfeffer@cmgm.stanford.edu			NIDDK NIH HHS [DK37336] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; DUDEN R, 1991, CELL, V64, P9; Krise JP, 2000, J BIOL CHEM, V275, P25188, DOI 10.1074/jbc.M001138200; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	11	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24348	24351		10.1074/jbc.M102468200	http://dx.doi.org/10.1074/jbc.M102468200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313361	hybrid			2022-12-27	WOS:000169531100147
J	Gerber, J; Muhlenhoff, U; Hofhaus, G; Lill, R; Lisowsky, T				Gerber, J; Muhlenhoff, U; Hofhaus, G; Lill, R; Lisowsky, T			Yeast Erv2p is the first microsomal FAD-linked sulfhydryl oxidase of the Erv1p/Alrp protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; REGENERATION ALR GENE; ENDOPLASMIC-RETICULUM; LIVER-REGENERATION; EGG-WHITE; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL; TRANSFORMATION; EXPRESSION; AUGMENTOR	Saccharomyces cerevisiae Erv2p was identified previously as a distant homologue of Erv1p, an essential mitachondrial protein exhibiting sulfhydryl oxidase activity. Expression of the ERV2 (essential for respiration and vegetative growth 2) gene from a high-copy plasmid cannot substitute for the lack of ERV1, suggesting that the two proteins perform nonredundant functions. Here, we show that the deletion of the ERV2 gene or the depletion of Erv2p by regulated gene expression is not associated with any detectable growth defects. Erv2p is located in the microsomal fraction, distinguishing it from the mitochondrial Erv1p, Despite their distinct subcellular localization, the two proteins exhibit functional similarities. Both form dimers in vivo and in vitro, contain a conserved YPCXXC motif in their carboxyl-terminal part, bind flavin adenine dinucleotide (FAD) as a cofactor, and catalyze the formation of disulfide bonds in protein substrates. The catalytic activity, the ability to form dimers, and the binding of FAD are associated with the carboxyl-terminal domain of the protein. Our findings identify Erv2p as the first microsomal member of the Erv1p/Alrp protein family of FAD-linked sulfhydryl oxidases, We propose that Erv2p functions in the generation of microsomal disulfide bonds acting in parallel with Ero1p, the essential, FAD-dependent oxidase of protein disulfide isomerase.	Univ Dusseldorf, Inst Bot, D-40225 Dusseldorf, Germany; Univ Marburg, Inst Zytobiol, D-35033 Marburg, Germany; Univ Dusseldorf, Med Forschungszentrum, Inst Biochem & Biol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Philipps University Marburg; Heinrich Heine University Dusseldorf	Lisowsky, T (corresponding author), Univ Dusseldorf, Inst Bot, Univ Str 1, D-40225 Dusseldorf, Germany.	lisowsky@uni-duesseldorf.de		Lill, Roland/0000-0002-8345-6518				Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; DAUM G, 1982, J BIOL CHEM, V257, P3028; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Giorda R, 1996, MOL MED, V2, P97, DOI 10.1007/BF03402206; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HAGIYA M, 1994, P NATL ACAD SCI USA, V91, P8142, DOI 10.1073/pnas.91.17.8142; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Harlow E., 1988, ANTIBODIES LAB MANUA; Hofhaus G, 1999, EUR J CELL BIOL, V78, P349, DOI 10.1016/S0171-9335(99)80069-7; Hoober KL, 1999, BIOCHEMISTRY-US, V38, P3211, DOI 10.1021/bi9820816; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hoober KL, 1999, J BIOL CHEM, V274, P22147, DOI 10.1074/jbc.274.32.22147; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kispal G, 1996, J BIOL CHEM, V271, P24458, DOI 10.1074/jbc.271.40.24458; LISOWSKY T, 1995, GENOMICS, V29, P690, DOI 10.1006/geno.1995.9950; LISOWSKY T, 1992, MOL GEN GENET, V232, P58, DOI 10.1007/BF00299137; Lisowsky T, 2001, DIGEST LIVER DIS, V33, P173, DOI 10.1016/S1590-8658(01)80074-8; Polimeno L, 1999, ITAL J GASTROENTEROL, V31, P494; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Senkevich TG, 1997, VIROLOGY, V233, P19, DOI 10.1006/viro.1997.8607; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Stein G, 1998, YEAST, V14, P171, DOI 10.1002/(SICI)1097-0061(19980130)14:2<171::AID-YEA209>3.0.CO;2-U; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; Woycechowsky KJ, 2000, CURR OPIN CHEM BIOL, V4, P533, DOI 10.1016/S1367-5931(00)00128-9; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149	39	93	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23486	23491		10.1074/jbc.M100134200	http://dx.doi.org/10.1074/jbc.M100134200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313344	hybrid			2022-12-27	WOS:000169531100036
J	Schmidt, A; MacColl, R; Lindau-Shepard, B; Buckler, DR; Dias, JA				Schmidt, A; MacColl, R; Lindau-Shepard, B; Buckler, DR; Dias, JA			Hormone-induced conformational change of the purified soluble hormone binding domain of follitropin receptor complexed with single chain follitropin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; CHORIONIC-GONADOTROPIN RECEPTOR; PROTEIN SECONDARY STRUCTURE; AMINO-ACID-RESIDUES; EXTRACELLULAR DOMAIN; CIRCULAR-DICHROISM; LUTROPIN RECEPTOR; FSH RECEPTOR; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL-PROPERTIES	Human follicle-stimulating hormone receptor (hFSHR) belongs to family I of G protein-coupled receptors. FSHR extracellular domain (ECD) is predicted to have 8-9 alpha beta or leucine-rich repeat motif elements. The objective of this study was to identify elements of the FSHR ECD involved in ligand binding. Preincubation of recombinant hFSHR ECD with rabbit antisera raised against synthetic peptides of hFSHR ECD primary sequence abolished follitropin binding primarily in the region of amino acids 150-254. Accessibility of hFSHR ECD after hormone binding, captured by monoclonal antibodies against either ECD or FSH, was decreased for the region of amino acids 150-220 but additionally for amino acids 15-100. Thus, when hFSH bound first, accessibility of antibody binding was decreased to a much larger extent than if antibody was bound first. This suggestion of a conformational change upon binding was examined further. Circular dichroism spectra were recorded for purified single chain hFSH, hFSHR ECD, and hFSHR ECD-single chain hFSH complex. A spectral change indicated a small but consistent conformational change in the ECD FSH complex after hormone binding. Taken together, these data demonstrate that FSH binding requires elements within the leucine-rich repeat motifs that form a central region of hFSHR ECD, and a conformational change occurs upon hormone binding.	New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst Publ Hlth, Albany, NY 12208 USA; Ares Adv Technol, Randolph, MA 02368 USA	State University of New York (SUNY) System; Wadsworth Center	Dias, JA (corresponding author), New York State Dept Hlth, Wadsworth Ctr, David Axelrod Inst Publ Hlth, 120 New Scotland Ave, Albany, NY 12208 USA.	James.Dias@wadsworth.org		Dias, James A/0000-0002-9792-5469; Schmidt, Anja/0000-0002-2304-8774	NICHD NIH HHS [HD18407] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018407] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; BOZON V, 1995, J MOL ENDOCRINOL, V14, P277, DOI 10.1677/jme.0.0140277; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHAZENBALK GD, 1995, J BIOL CHEM, V270, P1543, DOI 10.1074/jbc.270.4.1543; CHEN WY, 1993, MOL CELL ENDOCRINOL, V91, P35, DOI 10.1016/0303-7207(93)90252-F; Clement-Collin V, 1999, EUR J BIOCHEM, V264, P358, DOI 10.1046/j.1432-1327.1999.00608.x; DATTATREYAMURTY B, 1993, ENDOCRINOLOGY, V133, P1593, DOI 10.1210/en.133.4.1593; DATTATREYAMURTY B, 1992, MOL CELL ENDOCRINOL, V87, P9, DOI 10.1016/0303-7207(92)90228-X; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Hong SH, 1999, MOL ENDOCRINOL, V13, P1285, DOI 10.1210/me.13.8.1285; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Lin SS, 1996, BIOCHEMISTRY-US, V35, P14445, DOI 10.1021/bi961619+; Lindau-Shepard B, 2001, J REPROD IMMUNOL, V49, P1, DOI 10.1016/S0165-0378(00)00079-6; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; Liu XX, 2000, ENDOCRINE, V13, P361, DOI 10.1385/ENDO:13:3:361; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MURPHY CI, 1993, PROTEIN EXPRES PURIF, V4, P349, DOI 10.1006/prep.1993.1046; Nechamen CA, 2000, MOL CELL ENDOCRINOL, V166, P101, DOI 10.1016/S0303-7207(00)00281-1; Pajot-Augy E, 1999, EUR J BIOCHEM, V260, P635, DOI 10.1046/j.1432-1327.1999.00241.x; Peterson AJ, 2000, MOL CELL ENDOCRINOL, V160, P203, DOI 10.1016/S0303-7207(99)00204-X; Possee RD., 1992, BACULOVIRUS EXPRESSI; Purohit S, 1997, BIOCHEMISTRY-US, V36, P12355, DOI 10.1021/bi970303e; REICHERT LE, 1989, BIOL REPROD, V40, P13, DOI 10.1095/biolreprod40.1.13; ROTH KE, 1995, MOL CELL ENDOCRINOL, V109, P143, DOI 10.1016/0303-7207(95)03494-R; Roth KE, 1996, BIOCHEMISTRY-US, V35, P7928, DOI 10.1021/bi952566j; Shao K, 1999, MOL CELL ENDOCRINOL, V150, P47, DOI 10.1016/S0303-7207(99)00026-X; SHARMA SC, 1995, MOL CELL ENDOCRINOL, V115, P87, DOI 10.1016/0303-7207(95)03673-U; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stevis PE, 1999, ENDOCRINE, V10, P153, DOI 10.1385/ENDO:10:2:153; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; Woo SB, 1998, PROTEIN SCI, V7, P1006; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722	49	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23373	23381		10.1074/jbc.M100057200	http://dx.doi.org/10.1074/jbc.M100057200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11313343	hybrid			2022-12-27	WOS:000169531100022
J	Erickson, RL; Hemati, N; Ross, SE; MacDougald, OA				Erickson, RL; Hemati, N; Ross, SE; MacDougald, OA			p300 Coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; RECEPTOR GAMMA-2 PROMOTER; ADIPOSE CELL LINE; ADIPOCYTE DIFFERENTIATION; C/EBP-ALPHA; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; MAMMALIAN-CELLS; PPAR-GAMMA; ACTIVATION	Despite the knowledge that CCAAT/enhancer-binding protein alpha (C/EBP alpha) plays an important role in preadipocyte differentiation, our understanding of how C/EBP alpha interacts with nuclear proteins to regulate transcription is limited. Based on the hypothesis that evolutionarily conserved regions are functionally important and likely to interact with coactivators, we compared the amino acid sequence of C/EBP alpha from different species (frog to human) and identified four highly conserved regions (CR1-CR4) within the transactivation domain. A series of amino-terminal truncations and internal deletion constructs were made creating forms of C/EBP alpha which lack single or multiple conserved regions. To determine which regions of the C/EBP alpha transactivation domain are important in its ability to induce spontaneous differentiation of 3T3-L1 preadipocytes, we infected preadipocytes with expression vectors encoding the C/EBP alpha conserved region mutants and observed their ability to induce differentiation. We found that CR2 fused to the DNA binding domain is able to induce spontaneous differentiation independent of the other conserved regions. However, CR2 was not necessary for the adipogenic action of C/EBP alpha because a combination of CR1 and CR3 can also induce adipogenesis. Because the transcriptional coactivator p300 participates in the signaling of many transcription factors to the basal transcriptional apparatus, we examined whether functional interaction exists between C/EBP alpha and p300. Cotransfection of p300 with p42C/EBP alpha results in a synergistic increase in leptin promoter activity, indicating that p300 acts as a transcriptional coactivator of C/EBP alpha. Analyses using C/EBP alpha conserved region mutants suggest that multiple regions (CR2 and CR3) of the C/EBP alpha transactivation domain functionally interact with p300.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 7744 Med Sci Bldg 2,1301 E Catherine, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Erickson, Robin/AAV-3405-2020	Erickson, Robin/0000-0002-3945-6158; MacDougald, Ormond/0000-0001-6907-7960	NIDDK NIH HHS [DK51563] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051563] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRASIER AR, 1995, CURRENT PROTOCOLS MO, V1; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Elberg G, 2000, J BIOL CHEM, V275, P27815; ERICKSON RL, 1999, ADIPOCYTE BIOL HORMO, P79; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Goodman RH, 2000, GENE DEV, V14, P1553; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1996, P NATL ACAD SCI USA, V93, P873, DOI 10.1073/pnas.93.2.873; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Morrison RF, 1999, J CELL BIOCHEM, P59; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Osada S, 1996, J BIOL CHEM, V271, P3891; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Pond CM, 1998, IMMUNOL LETT, V63, P159, DOI 10.1016/S0165-2478(98)00074-1; PREECE A, 1972, MANUAL HISTOGIC TECH; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wickelgren I, 1998, SCIENCE, V280, P1364, DOI 10.1126/science.280.5368.1364; Williams SC, 1997, GENE EXPRESSION, V6, P371; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	55	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16348	16355		10.1074/jbc.M100128200	http://dx.doi.org/10.1074/jbc.M100128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11340085	hybrid			2022-12-27	WOS:000168623100104
